PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Okiyama, K; Smith, DH; White, WF; McIntosh, TK				Okiyama, K; Smith, DH; White, WF; McIntosh, TK			Effects of the NMDA antagonist CP-98,113 on regional cerebral edema and cardiovascular, cognitive, and neurobehavioral function following experimental brain injury in the rat	BRAIN RESEARCH			English	Article						cerebral edema; fluid-percussion brain injury; ifenprodil; memory; neurologic motor function; NMDA receptor blocker	METHYL-D-ASPARTATE; RECEPTOR ANTAGONISTS; GLUTAMATE RELEASE; H-3 IFENPRODIL; BINDING; SL-82.0715; POLYAMINES; AGENTS; DAMAGE; ACID	The present study examined the effects of CP-98,113, an N-methyl-D-aspartate (NMDA) receptor blocker, on cardiovascular variables, neurobehavioral motor function, spatial memory deficits, and cerebral edema formation following lateral (parasagittal) fluid-percussion (EP) brain injury in the rat. In Study 1, we compared the cardiovascular effects of i.p. administration of CP-98,113 at 15 min postinjury at doses of 1 mg/kg, 2 mg/kg, 5 mg/kg, or 20 mg/kg (n = 8/dose). Animals receiving 1 mg/kg to 5 mg/kg CP-98,113 showed slight but nonsignificant decreases in blood pressure, while those receiving the highest dose (20 mg/kg) showed significant hypotension. Based upon those observations, the 5 mg/kg dose was chosen as the optimal dose for subsequent behavioral studies. In Study 2, 15 min following lateral FP brain injury of moderate severity (2.5 atm), animals randomly received either CP-98,113 (5 mg/kg, i.p., n = 23) followed by a 24-h subcutaneous infusion (1.5 mg kg(-1) h(-1)) by means of a miniature osmotic pump, or identical volume of vehicle (n = 24), and were evaluated for neurologic motor function (n = 11/drug vs. 11/vehicle), memory function, and cerebral edema (n = 12/drug vs. 13/vehicle). CP-98,113 (5 mg/kg) significantly attenuated neurologic motor dysfunction at 24 h (p < 0.01) and 2 weeks (p < 0.05) postinjury, reduced posttraumatic impairment in spatial memory observed at 48 h postinjury (p < 0.001), and significantly reduced focal brain edema in the cortex adjacent to the site of maximal injury at 48 h postinjury (injury penumbra) (p < 0.001). These results suggest that blockade of the NMDA receptor may attenuate the deleterious sequelae of traumatic brain injury. (C) 1998 Elsevier Science B.V.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Pfizer Inc, Cent Res, Groton, CT 06340 USA	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	mcintosh@eniac.seas.upenn.edu	smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R0I-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P0I-NS08803, R0I-NS26818] Funding Source: Medline		BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CARRON C, 1971, ARZNEI-FORSCHUNG, V21, P1992; CARTER CJ, 1990, J PHARMACOL EXP THER, V253, P475; CARTER CJ, 1992, MOL NEUROPHARMACOL, V2, P107; CHAN PH, 1990, ACT NEUR S, V51, P7; CHENARD BL, 1991, J MED CHEM, V34, P3085, DOI 10.1021/jm00114a018; CHOI DW, 1988, J NEUROSCI, V8, P185; COOK P, 1981, NEW ENGL J MED, V305, P1508; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DANA C, 1991, NEUROSCI LETT, V125, P45, DOI 10.1016/0304-3940(91)90127-F; DELAGE I, 1981, EUR NEUROL, V20, P258, DOI 10.1159/000115244; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P789; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; HARGREAVES RJ, 1991, J CEREB BLOOD FLO S2, V11, pS301; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HONDA H, 1987, ARCH INT PHARMACOD T, V285, P211; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1986, ASTROCYTES, V3, P129; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCGURK JF, 1990, P NATL ACAD SCI USA, V87, P9971, DOI 10.1073/pnas.87.24.9971; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MONAGHAN DT, 1985, J NEUROSCI, V5, P2909; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P316; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; RANSOM RW, 1988, J NEUROCHEM, V51, P830, DOI 10.1111/j.1471-4159.1988.tb01818.x; REYNOLDS IJ, 1989, MOL PHARMACOL, V36, P758; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SANGER DJ, 1991, PSYCHOPHARMACOLOGY, V104, P27, DOI 10.1007/BF02244550; SCHOEMAKER H, 1990, EUR J PHARMACOL, V183, P1670, DOI 10.1016/0014-2999(90)91963-C; SHALABY I A, 1990, Society for Neuroscience Abstracts, V16, P193; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SQUIRE LR, 1996, MEMORY BRAIN; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; YOUNG AR, 1981, J CEREBR BLOOD F MET, V1, P117, DOI 10.1038/jcbfm.1981.12; ZEEVALK GD, 1990, BRAIN RES, V522, P135, DOI 10.1016/0006-8993(90)91588-8	54	47	47	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 11	1998	792	2					291	298		10.1016/S0006-8993(98)00158-9			8	Neurosciences	Neurosciences & Neurology	ZU326	WOS:000074185500013	9593949				2021-06-18	
J	Kuether, TA; O'Neill, O; Nesbit, GM; Barnwell, SL				Kuether, TA; O'Neill, O; Nesbit, GM; Barnwell, SL			Endovascular treatment of traumatic dural sinus thrombosis: Case report	NEUROSURGERY			English	Article						dural sinus thrombosis; thrombolysis; trauma; urokinase	UROKINASE INFUSION; OCCLUSION	OBJECTIVE: Dural sinus thrombosis has rarely been associated with closed head injury. We present a unique case involving the use of endovascular thrombolysis in the treatment of traumatic dural sinus thrombosis, which has not been reported. CLINICAL PRESENTATION: A 20-year-old male patient suffered a severe closed head injury while skiing. He developed refractory elevated intracranial pressure requiring barbiturate coma. Angiography demonstrated thrombosis of the dominant right transverse and sigmoid sinuses, with partial thrombosis of the superior sagittal sinus. Urokinase was administered via a microcatheter within the thrombus as a bolus of 250,000 units and then as a continuous infusion of 60,000 to 100,000 units per hour for 48 hours. The patient was maintained in a barbiturate coma and heparinized. Serial angiography was performed to assess the sinus patency and efficacy of thrombolysis. RESULTS: After 48 hours of thrombolysis, angiography demonstrated normal patency of the superior sagittal, right transverse, and right sigmoid sinuses. The intracranial pressure decreased after thrombolysis and was manageable with conventional techniques. Within 48 hours of the completed thrombolysis, the barbiturates were withdrawn and the patient's neurological status rapidly improved until the time of discharge 2 weeks later. DISCUSSION AND CONCLUSION: This case documents a rare instance of traumatic dural sinus thrombosis resulting from a closed head injury. In addition, endovascular thrombolysis resulted in subsequent opening of the dural sinuses and effective intracranial pressure management, despite the presence of a hemorrhagic contusion. Heparin was effective in maintaining sinus patency and was used safely in conjunction with urokinase in this setting of head injury.	Oregon Hlth Sci Univ, Div Neurosurg L472, Dept Neurosurg, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dotter Intervent Inst, Portland, OR 97201 USA; Emanuel Hosp, Portland, OR USA; Oregon Hlth Sci Univ, Dept Neuroradiol, Portland, OR 97201 USA	Kuether, TA (corresponding author), Oregon Hlth Sci Univ, Div Neurosurg L472, Dept Neurosurg, 3181 SW Sam Jackson Rd, Portland, OR 97201 USA.						BARNWELL SL, 1991, NEUROSURGERY, V28, P135, DOI 10.1227/00006123-199101000-00019; CRIMMINS TJ, 1984, J NEUROSURG, V60, P179, DOI 10.3171/jns.1984.60.1.0179; HULCELLE PJ, 1989, NEURORADIOLOGY, V31, P217, DOI 10.1007/BF00344346; KINAL ME, 1967, J NEUROSURG, V27, P142, DOI 10.3171/jns.1967.27.2.0142; Ochagavia AR, 1996, LANCET, V347, P1564, DOI 10.1016/S0140-6736(96)90721-7; RIPPE DJ, 1990, AM J NEURORADIOL, V11, P199; SCOTT JA, 1988, J NEUROSURG, V68, P284, DOI 10.3171/jns.1988.68.2.0284; SMITH TP, 1994, AM J NEURORADIOL, V15, P801; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; TSURUDA JS, 1991, AM J NEURORADIOL, V12, P481; VIRAPONGSE C, 1987, RADIOLOGY, V162, P779, DOI 10.1148/radiology.162.3.3809494	11	47	50	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1998	42	5					1163	1166		10.1097/00006123-199805000-00129			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	ZK454	WOS:000073322500113	9588564				2021-06-18	
J	Ewing-Cobbs, L; Prasad, M; Fletcher, JM; Levin, HS; Miner, ME; Eisenberg, HM				Ewing-Cobbs, L; Prasad, M; Fletcher, JM; Levin, HS; Miner, ME; Eisenberg, HM			Attention after pediatric traumatic brain injury: A multidimensional assessment	CHILD NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; RECOGNITION MEMORY; CHILDREN; ADOLESCENTS; PERFORMANCE; COGNITION; SEQUELAE; SEVERITY; DEFICIT; COHORT	Attentional disturbance is a common complaint after TBI in children and adolescents, however, few studies have assessed post-traumatic attentional functions. The attentional constructs proposed by Mirsky, Anthony, Duncan, Ahearn, and Kellam (1991) provided a multidimensional framework for prospective assessment of late attentional disturbance after mild-moderate(n = 34) and severe (n = 57) traumatic brain injury (TBI). Attention was evaluated from 5 to 8 years after TBI in children ages 0 to 15 years at the time of injury. Children with severe TBI performed more poorly than children with mild-moderate TBI on tests comprising the focus/execute and shift constructs. Younger children scored below older children irrespective of injury severity on the Digit Span subtest and interstimulus interval scores from an adaptive rate continuous performance test reflecting the encode and sustain constructs of Mirsky et al. (1991). Age x Severity interaction effects were found for speeded perceptual-motor tests; scores were reduced following mild-moderate and severe TBI in younger children and following severe TBI in older patients. Results are discussed in terms of the vulnerability of skills in a rapid stage of development to disruption by acquired brain injury.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Baylor, TX USA; Ohio State Univ, Sch Med, Columbus, OH 43210 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 6431 Fannin,MSB 3-252, Houston, TX 77030 USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019				Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Beery K. E., 1982, DEV TEST VISUAL MOTO; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman S.B, 1995, TRAUMATIC HEAD INJUR, P95; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; DONDERS J, 1993, CLIN NEUROPSYCHOL, V7, P430, DOI 10.1080/13854049308401533; DRAKE AI, 1993, J CLIN EXP NEUROPSYC, V15, P62; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1994, NEUROSURGERY, V35, P225, DOI 10.1227/00006123-199408000-00007; EWINGCOBBS L, IN PRESS J INT NEURO; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; HALPERIN JM, 1996, ATTENTION MEMORY EXE, P119; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HAYES RL, SEMINARS NEUROLOGY, V14, P25; Heaton R., 1993, WISCONSIN CARD SORTI; HOLLINGSHEAD AB, 1958, 2 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KREMEN WS, 1992, J NERVOOUS MENT DIS, V180, P88; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Mirsky A.F., 1996, ATTENTION MEMORY EXE, P71; MIRSKY AF, 1995, J PSYCHIATR RES, V29, P23, DOI 10.1016/0022-3956(94)00041-O; MURPHYBERMAN V, 1987, PERCEPT MOTOR SKILL, V64, P1139, DOI 10.2466/pms.1987.64.3c.1139; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Pennington B.F., 1996, ATTENTION MEMORY EXE, P327; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Plum F., 1980, DIAGNOSIS STUPOR COM, V3; POGGE DL, 1994, J CLIN EXP NEUROPSYC, V16, P344, DOI 10.1080/01688639408402645; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROURKE BP, 1980, UNDERLINING TEST PRE; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Warschausky S, 1996, ARCH CLIN NEUROPSYCH, V11, P147, DOI 10.1016/0887-6177(95)00004-6; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375	50	47	47	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	APR	1998	4	1					35	48		10.1076/chin.4.1.35.3194			14	Clinical Neurology	Neurosciences & Neurology	ZN053	WOS:000073604000004					2021-06-18	
J	Youngjohn, JR; Davis, D; Wolf, I				Youngjohn, JR; Davis, D; Wolf, I			Head injury and the MMPI-2: Paradoxical severity effects and the influence of litigation	PSYCHOLOGICAL ASSESSMENT			English	Article							TRAUMATIC BRAIN INJURY; MEMORY TEST; COMPLAINTS; CONCUSSION; SCALE	Minnesota Multiphasic Personality Inventory-2 (MMPI-2) profiles of 30 consecutive patients with moderate/severe head injury were compared with those of 30 consecutive symptomatic minor/mild head injury patients. Of the severely injured, 18 had ongoing litigation and 12 did not. All 30 minor/mild patients were in litigation. The severe litigating group had significant elevations on Hypochondriasis (Hs), Hysteria (Hy), Schizophrenia (Sc), and Health Concerns relative to the severe nonlitigating group. The minor/mild group had significant elevations on Hs, Depression (D), Hy, and Psychasthenia (Pt) over both the litigating and nonlitigating severe groups and additional elevations on Sc and Health Concerns over the severe nonlitigating group. Results are discussed in terms of the influence of litigation and injury severity on symptom endorsement on the MMPI-2. A model explaining persisting claims of disability after minor/mild head injury is proposed.	ARIZONA STATE UNIV, DEPT PSYCHOL, TEMPE, AZ 85287 USA; ARIZONA STATE UNIV, DEPT EDUC PSYCHOL, TEMPE, AZ 85287 USA	Youngjohn, JR (corresponding author), NEUROPSYCHOL CLIN PC, 7434 E STETSON DR, SUITE 250, SCOTTSDALE, AZ 85251 USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barth JT., 1989, MILD HEAD INJURY, P257; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; BURKE J M, 1990, Brain Injury, V4, P223, DOI 10.3109/02699059009026171; BUTCHER JN, 1989, MANUAL ADM SCORING M, V2; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; FEE CRA, 1988, ARCH EMERG MED, V5, P12; FOX DD, 1994, ARCH CLIN NEUROPSYCH, V9, P211, DOI 10.1016/0887-6177(94)90026-4; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Hathaway SR, 1951, MINNESOTA MULTIPHASI; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; POPE KS, 1993, MMPI MMPI 2 MMPI A C; Putnam S. H., 1994, ADV MED PSYCHOTHERAP, V7, P1; Reitan RM., 1985, HALSTEAD REITAN NEUR; ROGERS R, 1994, LAW HUMAN BEHAV, V18, P543, DOI 10.1007/BF01499173; SELLERS AH, 1992, ANN M INT NEUR SOC S; Spreen O., 1991, COMPENDIUM NEUROPSYC; TEASDALE G, 1974, LANCET, V2, P81; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; YOUNGJOHN JR, 1989, REHABIL PSYCHOL, V34, P217, DOI 10.1037//0090-5550.34.3.217	32	47	47	0	7	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	SEP	1997	9	3					177	184		10.1037/1040-3590.9.3.177			8	Psychology, Clinical	Psychology	XV782	WOS:A1997XV78200002					2021-06-18	
J	Sakamoto, KI; Fujisawa, H; Koizumi, H; Tsuchida, E; Ito, H; Sadamitsu, D; Maekawa, T				Sakamoto, KI; Fujisawa, H; Koizumi, H; Tsuchida, E; Ito, H; Sadamitsu, D; Maekawa, T			Effects of mild hypothermia on nitric oxide synthesis following contusion trauma in the rat	JOURNAL OF NEUROTRAUMA			English	Article						nitric oxide; cerebral contusion; microdialysis; capillary electrophoresis; rodent	FOCAL CEREBRAL-ISCHEMIA; CONCUSSIVE BRAIN INJURY; INFARCT VOLUME; GLUTAMATE; RELEASE; ELEVATION; INHIBITOR; SYNTHASE; PLASMA; MODEL	The exact mechanism of hypothermic cerebroprotection after traumatic brain injury (TBI) is not fully understood. The present study was conducted to investigate the effects of mild hypothermia on trauma-induced synthesis of nitric oxide (NO), which has been implicated in the pathogenesis of ischemic brain damage associated with glutamate neurotoxicity. Cerebral contusion was created in the rat parietal cortex by a weight-drop method, and extracellular concentrations of the NO end products nitrite and nitrate were measured using in vivo brain microdialysis and capillary electrophoresis under normothermic (37 degrees C) and mild hypothermic (32 degrees C) conditions. In normothermic animals, the level of NO end products increased markedly 10 min after contusion, reaching a maximum level at 20 min. In the hypothermic rats, such increases were absent. Although it is unknown whether endothelial NO synthase, neuronal NO synthase, or both caused the elevation of the NO end products seen in the normothermic animals, the present results indicate that inhibition of NO synthesis may play a part in hypothermic cerebroprotection following TBI.	YAMAGUCHI UNIV,SCH MED,DEPT NEUROSURG,UBE,YAMAGUCHI 755,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT CRIT CARE MED,UBE,YAMAGUCHI 755,JAPAN							ARCHER S, 1993, FASEB J, V7, P349; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUISSON A, 1992, BRIT J PHARMACOL, V106, P766, DOI 10.1111/j.1476-5381.1992.tb14410.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHOI DW, 1987, J NEUROSCI, V7, P369; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; DAWSON DA, 1992, NEUROSCI LETT, V142, P151, DOI 10.1016/0304-3940(92)90361-A; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; KADER A, 1994, NEUROSURGERY, V35, P272, DOI 10.1227/00006123-199408000-00013; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KOZNIEWSKA E, 1992, J CEREBR BLOOD F MET, V12, P311; KUMURA E, 1994, J CEREBR BLOOD F MET, V14, P487, DOI 10.1038/jcbfm.1994.60; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; NAGAFUJI T, 1992, NEUROSCI LETT, V147, P159, DOI 10.1016/0304-3940(92)90584-T; PALMER RM, 1994, J NEUROTRUAMA, V10, P363; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; UEDA T, 1995, ELECTROPHORESIS, V16, P1002, DOI 10.1002/elps.11501601167; WANG Q, 1995, J CEREBR BLOOD F MET, V15, P774, DOI 10.1038/jcbfm.1995.97; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; YOSHIDA T, 1995, NEUROSCI LETT, V194, P214, DOI 10.1016/0304-3940(95)11752-I; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x; ZHANG ZG, 1995, J CEREB BLOOD FLOW S, V15, pS90	33	47	50	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	1997	14	5					349	353		10.1089/neu.1997.14.349			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XE298	WOS:A1997XE29800006	9199400				2021-06-18	
J	Linscott, RJ; Knight, RG; Godfrey, HPD				Linscott, RJ; Knight, RG; Godfrey, HPD			The Profile of Functional Impairment in Communication (PFIC): A measure of communication impairment for clinical use	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; VERBAL IMPAIRMENT; SOCIAL-INTERACTION; FOLLOW-UP; ADULTS; CONVERSATIONS; NARRATIVES; DISCOURSE; LANGUAGE; SKILLS	This article describes the construction of the Profile of Functional Impairment in Communication (PFIC), a scale designed for the assessment of communication impairments following traumatic brain injury. The measure comprises 10 feature summary scales, assessing severity of impairment, and 84 specific behaviour items, assessing the frequency of specific communication impairments. To assess the psychometric properties of the scale, videotaped dyadic social interactions of 20 patients with traumatic brain injury were rated by eight trained raters. The feature summary scales were found to have acceptable inter-rater reliabilities, and high concurrent validity and internal consistency. Four case descriptions are presented to illustrate the clinical application of the PFIC. It is concluded that the PFIC is a useful measure for the identification of specific communication impairments in clinical practice.	UNIV OTAGO,DEPT PSYCHOL,CLIN PSYCHOL RES & TRAINING CTR,DUNEDIN,NEW ZEALAND			Linscott, Richard J/C-1431-2008	Linscott, Richard J/0000-0001-5456-917X			ARTRIDGE FM, 1991, THESIS U OTAGO DUNED; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; DUNCAN S, 1972, J PERS SOC PSYCHOL, V23, P283, DOI 10.1037/h0033031; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; ENDLER NS, 1966, PERCEPT MOTOR SKILL, V22, P559, DOI 10.2466/pms.1966.22.2.559; FARRELL AD, 1985, BEHAV ASSESS, V7, P155; Forssmann-Falck R, 1989, Psychiatr Med, V7, P43; Giles G M, 1988, Brain Inj, V2, P75, DOI 10.3109/02699058809150933; Glosser G., 1990, BRAIN LANG, V40, P67; GODFREY H P D, 1991, Brain Injury, V5, P207, DOI 10.3109/02699059109008091; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; GODFREY HPD, 1988, ARCH PHYS MED REHAB, V69, P458; Gottman J. M., 1979, MARITAL INTERACTION; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Grice H. P., 1978, SYNTAX SEMANTICS, V9, P113; GROHER ME, 1990, REHABILITATION ADULT, P294; HAGEN C, 1982, COGNITIVE REHABILITA, P131; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; HOLM S, 1979, SCAND J STAT, V6, P65; KERNAN KT, 1982, SEMIOTICA, V42, P169, DOI 10.1515/semi.1982.42.2-4.169; KOLKO DJ, 1985, BEHAV MODIF, V9, P165, DOI 10.1177/01454455850092003; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LINSCOTT RJ, 1993, MANUAL PROFILE FUNCT; LINSCOTT RJ, 1993, UNPUB PROFILE FUNCTI; MARQUARDT TP, 1988, J LEARN DISABIL, V21, P240; Marsh NV, 1990, NEUROPSYCHOLOGY, V4, P13, DOI 10.1037/0894-4105.4.1.13; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Morgan J. L., 1978, SYNTAX SEMANTICS, P261; Nelson H., 1982, NATIONAL ADULT READI; Norman Donald A., 1975, EXPLORATIONS COGNITI; PALMER MT, 1989, COMMUN MONOGR, V56, P1, DOI 10.1080/03637758909390246; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P18; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Raven J.C.C.J., 1977, MANUAL RAVENS PROGR; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; SMITH L, 1995, REHABILITAITON TRAUM; SMITH RM, 1979, CLIN NEUROPSYCHOLOGY, P48; SOHLBERG MM, 1990, COMMUNITY INTEGRATIO, P67; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; Street Jr R.L., 1990, HDB LANGUAGE SOCIAL, P121; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trower P., 1978, SOCIAL SKILLS MENTAL; WOLFOLK WB, 1992, B PSYCHONOMIC SOC, V30, P226	61	47	50	0	9	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUN	1996	10	6					397	412		10.1080/026990596124269			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UR327	WOS:A1996UR32700001	8816094				2021-06-18	
J	KRUPP, WF; JANS, PJ				KRUPP, WF; JANS, PJ			TREATMENT OF CHRONIC SUBDURAL-HEMATOMA WITH BURR-HOLE CRANIOSTOMY AND CLOSED DRAINAGE	BRITISH JOURNAL OF NEUROSURGERY			English	Article						BURR-HOLE CRANIOSTOMY; CHRONIC SUBDURAL HEMATOMA; HEMATOMA-SUBDURAL SURGERY; HEAD INJURY	TWIST-DRILL CRANIOSTOMY; SYSTEM DRAINAGE; MAGNETIC-RESONANCE; HEMATOMA; ADULTS	Despite the high incidence of chronic subdural haematoma (SDH), to date relatively few authors have undertaken a systematic analysis of the results attained following burr-hole craniostomy and closed-system drainage on the basis of a study involving a large patient population defined according to clear-cut criteria. Between 1980 and 1993, surgery was performed on 212 patients with a chronic SDH. In a retrospective study, the condition of each patient was assessed at the time of admission on the basis of the Bender Scale and the results 4 weeks after discharge were classified according to the Glasgow Outcome Scale (GOS). At admission, 165 patients (78%) were in a satisfactory condition (Stage 1 or 2); 47 (22%) were at Stage 3 or 4, i.e. stuporous or comatose. Nine (4%) of the patients died; none of these deaths was attributable to the operation. In addition to significant extracerebral disease (2.4%), CT revealed ischaemic cerebral infarctions in three patients (1.4%) after removal of the SDH. The operative morbidity was 4.2%. In 22% of the patients, surgical intervention was required to remove a recurring SDH. In 90% of the patients, the results achieved could be graded as 'very good' or 'good' (GOS 1 or 2). The results were related to the condition at admission (p < 0.001) and the patient's age (p < 0.05). Factors that did not have a significant effect on the outcome included whether the SDH formation was bilateral or unilateral, the extent of neomembranous organization of the haematoma, and the amount of primary cerebral expansion following decompression. We were able to confirm the results of previous studies that the method used is a highly effective treatment, with a low incidence of complications.		KRUPP, WF (corresponding author), ALFRIED KRUPP HOSP, DEPT NEUROSURG, ALFRIED KRUPP STR 21, D-45117 ESSEN, GERMANY.						BENDER MB, 1976, CURRENT CONTROVERSIE, P556; BUSCH G, 1980, NEUROCHIRURGIA, V23, P224; CAMEL M, 1986, J NEUROSURG, V65, P183, DOI 10.3171/jns.1986.65.2.0183; DAVELLA D, 1986, J NEUROSURG, V65, P710, DOI 10.3171/jns.1986.65.5.0710; DIAMOND T, 1988, BRIT J NEUROSURG, V3, P351; EGGERT HR, 1984, NEUROCHIRURGIA, V27, P141; FOGELHOLM R, 1975, J NEUROSURG, V42, P43, DOI 10.3171/jns.1975.42.1.0043; Gilsbach J, 1980, Unfallchirurgie, V6, P183, DOI 10.1007/BF02588978; HARDERS A, 1982, NEUROCHIRURGIA, V25, P147; HEISS E, 1984, ADV NEUROSURG, V12, P192; HOSODA K, 1987, J NEUROSURG, V67, P677, DOI 10.3171/jns.1987.67.5.0677; ITO H, 1984, ACTA NEUROCHIR, V72, P211, DOI 10.1007/BF01406871; KALFF R, 1984, Zentralblatt fuer Neurochirurgie, V45, P210; KRETSCHMER H, 1981, Aktuelle Traumatologie, V11, P43; LALONDE AA, 1948, NEW ENGL J MED, V239, P493, DOI 10.1056/NEJM194809302391401; Lanksch W, 1979, COMPUTED TOMOGRAPHY; LOEW F, 1982, ADV TECHNICAL STANDA, V9, P113; MAGGIO WW, 1993, BRAIN SURGERY, V2, P1299; MARKWALDER TM, 1986, ACTA NEUROCHIR, V79, P100, DOI 10.1007/BF01407452; MARKWALDER TM, 1981, J NEUROSURG, V55, P390, DOI 10.3171/jns.1981.55.3.0390; MCKISSOCK W, 1960, LANCET, V1, P1365; MORINGLANE JR, 1981, NEUROCHIRURGIA, V24, P158; Munro D, 1942, NEW ENGL J MED, V227, P87, DOI 10.1056/NEJM194207162270301; OKU Y, 1984, J NEUROSURG, V61, P269, DOI 10.3171/jns.1984.61.2.0269; PROBST C, 1988, J NEUROSURG, V68, P908, DOI 10.3171/jns.1988.68.6.0908; RAM Z, 1993, ACTA NEUROCHIR, V120, P40, DOI 10.1007/BF02001467; RICHTER HP, 1984, ACTA NEUROCHIR, V71, P179, DOI 10.1007/BF01401313; ROBINSON RG, 1984, J NEUROSURG, V61, P263, DOI 10.3171/jns.1984.61.2.0263; ROBINSON RG, 1955, BMJ-BRIT MED J, V1, P21, DOI 10.1136/bmj.1.4904.21; Schulz W, 1988, Zentralbl Neurochir, V49, P280; SIPPONEN JT, 1984, RADIOLOGY, V150, P79, DOI 10.1148/radiology.150.1.6689791; SPRUNG C, 1984, ADV NEUROSURG, V12, P204; SVIEN HJ, 1964, J NEUROSURG, V21, P172, DOI 10.3171/jns.1964.21.3.0172; TABADDOR K, 1977, J NEUROSURG, V46, P220, DOI 10.3171/jns.1977.46.2.0220; TYSON G, 1980, J NEUROSURG, V52, P776, DOI 10.3171/jns.1980.52.6.0776; WEIR B, 1983, J NEUROSURG, V58, P242, DOI 10.3171/jns.1983.58.2.0242; WEIR BKA, 1983, CAN J NEUROL SCI, V10, P22, DOI 10.1017/S0317167100044516; YAMASHIMA T, 1985, Zentralblatt fuer Neurochirurgie, V46, P304	38	47	50	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		1995	9	5					619	627		10.1080/02688699550040909			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TC071	WOS:A1995TC07100006	8561934				2021-06-18	
J	BOHNEN, N; VANZUTPHEN, W; TWIJNSTRA, A; WIJNEN, G; BONGERS, J; JOLLES, J				BOHNEN, N; VANZUTPHEN, W; TWIJNSTRA, A; WIJNEN, G; BONGERS, J; JOLLES, J			LATE OUTCOME OF MILD HEAD-INJURY - RESULTS FROM A CONTROLLED POSTAL SURVEY	BRAIN INJURY			English	Article							CONCUSSION; SYMPTOMS	There is insufficient information about the long-term sequelae of mild head injury (postconcussional symptoms, PCS). Therefore, a questionnaire-based investigation was carried out in patients 1-5 years after mild head injury (MHI) and in non-concussed subjects in order to study the nature of long-term complaints after MHI. A three-factor model of residual subjective and psychological complaints that contained a dysthymic factor, a vegetative/bodily complaints factor, and a cognitive performance factor were identified in the patient population. Three rating scales were constructed from the relevant items or factors, and were used to compare the MHI patients with non-concussed controls. It was found that the profile of distresses and discomforts mentioned by a population of MHI patients 1-5 years after the trauma was similar to that of a non-concussed control population. These symptoms were indistinguishable from those encountered in ordinary everyday life. These symptoms were significantly more severe in the MHI patients. Stepwise regression analysis in the patient population indicated that a number of parameters were statistically of predictive importance: comorbidity, sex, and neurological complication at the time of the trauma. The results support the hypothesis that MHI may not ever be completely reversible.	UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG,DEPT GEN PRACTICE MED,MAASTRICHT,NETHERLANDS; STATE UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS			Bohnen, Nicolaas/A-1312-2007				ADAMOVICH BB, 1984, COGNITIVE REHABILITA; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; [Anonymous], 1985, STATISTICS; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CAVENESS WF, 1966, HEAD INJURY C P, P209; Cook J B, 1972, Scand J Rehabil Med, V4, P27; Denker P., 1944, NY STATE J MED, V44, P379; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; GRONWALL D, 1974, LANCET, V2, P605; INGHAM JG, 1979, J EPIDEMIOL COMMUN H, V33, P191, DOI 10.1136/jech.33.3.191; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Norrelund N, 1979, Ugeskr Laeger, V141, P1425; NOVICK MR, 1966, J MATH PSYCHOL, V3, P1, DOI 10.1016/0022-2496(66)90002-2; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Verhage R, 1964, THESIS ASSEN	19	47	47	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV-DEC	1994	8	8					701	708		10.3109/02699059409151024			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PT049	WOS:A1994PT04900006	7849689				2021-06-18	
J	WOBER, C; ODER, W; KOLLEGGER, H; PRAYER, L; BAUMGARTNER, C; WOBERBINGOL, C; WIMBERGER, D; BINDER, H; DEECKE, L				WOBER, C; ODER, W; KOLLEGGER, H; PRAYER, L; BAUMGARTNER, C; WOBERBINGOL, C; WIMBERGER, D; BINDER, H; DEECKE, L			POSTUROGRAPHIC MEASUREMENT OF BODY SWAY IN SURVIVORS OF SEVERE CLOSED-HEAD INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							DIFFUSE AXONAL INJURY; COMA DATA-BANK; TRAUMA; MR; SEQUELAE; FEATURES; LESIONS; CT		UNIV VIENNA,DEPT MAGNET RESONANCE IMAGING,VIENNA,AUSTRIA; UNIV VIENNA,DEPT NEUROPSYCHIAT CHILDHOOD & ADOLESCENCE,VIENNA,AUSTRIA	WOBER, C (corresponding author), UNIV VIENNA,NEUROL KLIN,DEPT NEUROL,WAHRINGER GURTEL 18-20,A-1090 VIENNA,AUSTRIA.		Wober, Christian/I-3574-2019	Wober, Christian/0000-0003-1382-1978			ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BORNSTEIN RA, 1988, NEUROSURGERY, V23, P622, DOI 10.1227/00006123-198811000-00013; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; DIENER HC, 1984, ELECTROEN CLIN NEURO, V57, P134, DOI 10.1016/0013-4694(84)90172-X; DUNCAN PW, 1990, REHABILITATION ADULT, P264; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HANS P, 1989, J NEUROSURG, V71, P54, DOI 10.3171/jns.1989.71.1.0054; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; JENNETT B, 1990, REHABILITATION ADULT, P3; KOLLEGGER H, 1992, EUR NEUROL, V32, P253, DOI 10.1159/000116836; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; NADJMI M, 1981, KRANIELLE COMPUTERTO; Newton R, 1989, Brain Inj, V3, P335, DOI 10.3109/02699058909004558; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; SINCLAIR A J, 1990, Comprehensive Therapy, V16, P44; SNOEK J, 1990, TRAUMATIC BRAIN INJU, P9; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TEASDALE G, 1974, LANCET, V2, P81; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; 1985, SAS USERS GUIDE STAT	32	47	49	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1993	74	11					1151	1156					6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	MD088	WOS:A1993MD08800005	8239952				2021-06-18	
J	KIHTIR, T; IVATURY, RR; SIMON, RJ; NASSOURA, Z; LEBAN, S				KIHTIR, T; IVATURY, RR; SIMON, RJ; NASSOURA, Z; LEBAN, S			EARLY MANAGEMENT OF CIVILIAN GUNSHOT WOUNDS TO THE FACE	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	6TH SCIENTIFIC ASSEMBLY OF THE EASTERN-ASSOC-FOR-THE-SURGERY-OF-TRAUMA	JAN 13-16, 1993	LONGBOAT KEY, FL	E ASSOC SURG TRAUMA				We analyzed 54 civilian patients (1988-1992) with gunshot wounds (GSWs) of the face to review the management principles and results. Urgent airway control was needed in 18 cases (33%): by orotracheal intubation in 13, cricothyroidotomy in two, tracheostomy in two, and nasotracheal intubation in one. Central nervous system injury was seen in 12 (22%): 40% with orbital, 38% with mid-face, and 0% with lower face injuries. Two patients died of intracranial injuries (mortality, 4%). Vascular injury was present in five patients (9%), all detected by angiography. The local complication rate was 39% in the presence of intra-oral injury and 0% without intra-oral injury (p < 0.001). The maxilla was the most commonly fractured facial bone (41%) followed by the mandible in 28%. All maxillary, orbital, and zygomatic fractures were treated without reduction. One of the seven nasal fractures required open reduction for deformity. Six of the 15 mandible fractures were treated without reduction. Of eight patients treated with closed reduction, one developed nonunion. One patient treated with immediate open reduction developed osteomyelitis of the mandible and nonunion. Five patients (9%) had palate injuries. Two of them later developed intraoral fistulas following conservative treatment. The airway needs immediate attention in GSWs of the face. Computed tomographic scanning of the head or spine should be done when the bullet trajectory is above the lower face (the level of the mandible). Angiography is indicated when the trajectory of the bullet is suggestive. A conservative approach that effectively reduces the fractures is the procedure of choice. Open reductions should not be performed in the initial treatment. Palate injuries should be repaired early in an attempt to prevent intra-oral fistula formation.	NEW YORK MED COLL,DEPT SURG,BRONX,NY; NEW YORK MED COLL,DEPT ORAL & MAXILLOFACIAL SURG,BRONX,NY			Ivatury, Rao R./H-2922-2019				BROADBENT TR, 1972, J TRAUM, V12, P229, DOI 10.1097/00005373-197203000-00006; DOLIN J, 1992, J TRAUMA, V33, P508, DOI 10.1097/00005373-199210000-00004; IRBY WB, 1979, FACIAL TAUMA CONCOMI, P1; JOY ED, 1973, J ORAL SURG, V31, P425; KELLY JF, 1973, J ORAL SURG, V31, P438; KHALIL AF, 1980, BRIT J ORAL SURG, V18, P205, DOI 10.1016/0007-117X(80)90064-5; KIHTIR T, 1991, J TRAUMA, V31, P6; MANSON PN, 1990, PLASTIC SURG, V2, P1124; MAY M, 1973, LARYNGOSCOPE, V83, P969, DOI 10.1288/00005537-197306000-00016; Nahum A M, 1975, Clin Plast Surg, V2, P59; NEUPERT EA, 1991, ORAL SURG ORAL MED O, V72, P383, DOI 10.1016/0030-4220(91)90544-M; OSBORNE TE, 1991, ORAL MAXILLOFACIAL T, V2, P672; SHUCK LW, 1980, J TRAUMA, V20, P370, DOI 10.1097/00005373-198020050-00002; WHITLOCK RIH, 1978, INT J ORAL MAXILLOF, V7, P240, DOI 10.1016/S0300-9785(78)80087-8; YAO ST, 1972, J TRAUM, V12, P523, DOI 10.1097/00005373-197206000-00011	15	47	50	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	1993	35	4					569	577		10.1097/00005373-199310000-00012			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	MD998	WOS:A1993MD99800012	8411281				2021-06-18	
J	FADEN, AI				FADEN, AI			COMPARISON OF SINGLE AND COMBINATION-DRUG TREATMENT STRATEGIES IN EXPERIMENTAL BRAIN TRAUMA	JOURNAL OF NEUROTRAUMA			English	Article							THYROTROPIN-RELEASING-HORMONE; SPINAL-CORD INJURY; INTRACELLULAR FREE MG-2+; RATS; ANTAGONIST; RECEPTORS; HYPOTENSION; NALOXONE; RECOVERY; ISCHEMIA	Effects of single-drug and combination drug treatments were examined in a model of lateral fluid percussion-induced traumatic brain injury (TBI) in rats. Treatments included the opioid receptor antagonist nalmefene, the thyrotropin releasing hormone (TRH) analog YM14673, the noncompetitive N-methyl-D-aspartate (NMDA) antagonist dextrorphan, nalmefene + dextrorphan, YM14673 + nalmefene, YM14673 + dextrorphan, and equal volume saline. Single-dose treatment with nalmefene, YM14673, or dextrorphan at 30 min after trauma each significantly improved behavioral recovery at two weeks as compared with vehicle-treated controls, confirming earlier studies with these agents. No combination treatment was superior to treatment with the most effective individual drug alone. Combination treatment with the TRH analog and the NMDA antagonist resulted in significantly less effectiveness than treatment with either drug alone. These findings indicate the need for preclinical studies to examine potential drug-drug interactions in the treatment of central nervous system (CNS) trauma.		FADEN, AI (corresponding author), GEORGETOWN UNIV, MED CTR, MED DENT BLDG, NW 101, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR 306634-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER		ALZHEIMER C, 1990, J PHARMACOL EXP THER, V255, P900; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CHOI DW, 1987, J NEUROSCI, V7, P369; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; GEORGE CP, 1988, BRAIN RES, V440, P375, DOI 10.1016/0006-8993(88)91011-6; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; KOSKINEN LOD, 1989, ANN NY ACAD SCI, V553, P353; LUX WE, 1983, NATURE, V302, P822, DOI 10.1038/302822a0; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MICHEL ME, 1984, PHARMACOLOGIST, V26, P201; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; TAKEMORI AE, 1988, J PHARMACOL EXP THER, V246, P255; VINK R, 1991, AM J PHYSIOL, V261, pR1527; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; YAMAMOTO M, 1989, STROKE, V20, P1089, DOI 10.1161/01.STR.20.8.1089; YAMAMOTO M, 1989, STROKE, V20, P362, DOI 10.1161/01.STR.20.3.362; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061; 1984, KEY PHARM	36	47	47	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SUM	1993	10	2					91	100		10.1089/neu.1993.10.91			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LM056	WOS:A1993LM05600001	8411221				2021-06-18	
J	MIYAZAWA, T; BONNEKOH, P; HOSSMANN, KA				MIYAZAWA, T; BONNEKOH, P; HOSSMANN, KA			TEMPERATURE EFFECT ON IMMUNOSTAINING OF MICROTUBULE-ASSOCIATED PROTEIN-2 AND SYNAPTOPHYSIN AFTER 30 MINUTES OF FOREBRAIN ISCHEMIA IN RAT	ACTA NEUROPATHOLOGICA			English	Article						CEREBRAL ISCHEMIA; HYPOTHERMIA; SELECTIVE VULNERABILITY; MICROTUBULE-ASSOCIATED PROTEIN-2; SYNAPTOPHYSIN	TRANSIENT CEREBRAL-ISCHEMIA; SYNAPTIC VESICLE MEMBRANE; GERBIL HIPPOCAMPUS; BRAIN TEMPERATURE; PRESYNAPTIC TERMINALS; MILD HYPOTHERMIA; CA1 REGION; OCCLUSION; DAMAGE; ULTRASTRUCTURE	The regional distribution of the postsynaptic microtubule-associated protein 2 (MAP2) and the presynaptic marker protein synaptophysin was investigated by immunohistochemistry in brains of rats submitted to 30-min forebrain ischemia by four-vessel occlusion. The following brain temperature profiles during ischemia were compared: (1) constant brain temperature of 36-degrees-C (normothermia; n = 5); (2) spontaneous temperature decline from 36-degrees to 31-degrees-C (spontaneous hypothermia; n = 5) and (3) constant temperature of 30-degrees-C (induced hypothermia; n = 5). Normothermia was produced by exposing the ischemic head to an external heat source, and induced hypothermia by cooling the head with liquid nitrogen vapours. Sham-operated animals were either kept at ambient temperature or exposed to the same heat source, as required for maintaining normothermia during ischemia. Seven days after sham operation or ischemia, brains were fixed by perfusion and processed for immunohistochemistry using monoclonal antibodies against MAP2 and synaptic vesicle-specific protein (synaptophysin). Normothermic ischemia resulted in complete loss of MAP2 immunostaining in the whole hippocampus, spontaneous hypothermic ischemia in complete loss of MAP2 in CA1 sector, and induced hypothermic ischemia only in variable loss of MAP2 in Ca sector. Post-ischemic immunostaining of synaptophysin revealed a temperature-dependent increase in stratum lacunosum-moleculare of CA1 sector, the density of which correlated inversely with MAP2 staining. Comparison with morphological alterations showed a close relationship between loss of MAP2 staining and histological injury. The post-ischemic activation of synaptophysin may reflect regenerative processes associated with synaptic remodelling and, therefore, is an indirect marker of the severity of ischemic injury.	MAX PLANCK INST NEUROL RES,DEPT EXPTL NEUROL,GLEUELER STR 50,D-50866 COLOGNE 41,GERMANY							ARAI H, 1991, NEUROSCI RES COMMUN, V9, P143; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BONNEKOH P, 1990, ACTA NEUROPATHOL, V80, P18, DOI 10.1007/BF00294217; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, STROKE, V20, P113; CACERES A, 1984, J NEUROSCI, V4, P394; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; GARNER CC, 1988, J CELL BIOL, V106, P779, DOI 10.1083/jcb.106.3.779; GEISERT EE, 1990, P NATL ACAD SCI USA, V87, P3967, DOI 10.1073/pnas.87.10.3967; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; INUZUKA T, 1990, BRAIN RES, V526, P177, DOI 10.1016/0006-8993(90)90269-H; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; JOHANSEN FF, 1984, BRAIN RES, V291, P373, DOI 10.1016/0006-8993(84)91272-1; JORGENSEN MB, 1987, ACTA NEUROPATHOL, V73, P189, DOI 10.1007/BF00693788; KIRINO T, 1990, BRAIN RES, V510, P17, DOI 10.1016/0006-8993(90)90722-N; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KITAGAWA K, 1990, NEUROSCIENCE, V35, P551, DOI 10.1016/0306-4522(90)90328-2; KITAGAWA K, 1992, NEUROSCIENCE, V46, P287, DOI 10.1016/0306-4522(92)90051-3; KNAUS P, 1986, J NEUROCHEM, V47, P1302; KUDO T, 1990, STROKE, V21, P1205, DOI 10.1161/01.STR.21.8.1205; KUNKEL DD, 1988, SYNAPSE, V2, P382, DOI 10.1002/syn.890020405; KUROIWA T, 1990, J CEREBR BLOOD F MET, V10, P550, DOI 10.1038/jcbfm.1990.97; KUWAKI T, 1989, STROKE, V20, P78, DOI 10.1161/01.STR.20.1.78; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; MILESON BE, 1992, J NEUROCHEM, V58, P600, DOI 10.1111/j.1471-4159.1992.tb09761.x; MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P488; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PETRUSZ P, 1980, HISTOCHEM J, V12, P333, DOI 10.1007/BF01006954; Pickel VM., 1981, NEUROANATOMICAL TRAC, P483; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; RISCHKE R, 1990, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1990, P129; SCHMIDTKASTNER R, 1989, STROKE, V20, P938, DOI 10.1161/01.STR.20.7.938; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TOMIOKA C, 1992, BRAIN RES, V586, P352, DOI 10.1016/0006-8993(92)91648-X; WALAAS SI, 1988, SYNAPSE, V2, P516, DOI 10.1002/syn.890020507; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; WESTERBERG E, 1989, J NEUROSCI, V9, P798; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YAMAMOTO K, 1990, ACTA NEUROPATHOL, V80, P487, DOI 10.1007/BF00294608; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610; YOSHIMI K, 1991, BRAIN RES, V560, P149, DOI 10.1016/0006-8993(91)91225-P	49	47	50	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	APR	1993	85	5					526	532					7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	KX439	WOS:A1993KX43900013	8493860				2021-06-18	
J	BOYER, MG; EDWARDS, P				BOYER, MG; EDWARDS, P			OUTCOME 1 TO 3 YEARS AFTER SEVERE TRAUMATIC BRAIN INJURY IN CHILDREN AND ADOLESCENTS	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article								This study reports a consecutive series of 220 children and adolescents who sustained traumatic brain injury (BI) and were admitted to a comprehensive paediatric rehabilitation programme. Progress in areas of mobility, activities of daily living, education and cognitive function were documented for up to 3 years after the injury. Physical recovery was most rapid in the first years and cognitive and language gains generally occurred later, even up to 3 years after the injury. Cognitive assessment at the time of admission proved helpful in predicting outcome; of those patients admitted in a conscious state only one remained dependent for any aspect of self care. Even for those admitted unconscious at a median of 62 days after injury there was good potential for recovery with 27-43 per cent achieving independence in the activities of daily living. For those still unconscious at 6 months, 72 per cent remained vegetative and none achieved the highest cognitive level. Overall, 14 per cent returned to regular education while 25 per cent remained incapable of any educational programme. In a well planned and multidisciplinary rehabilitation programme, patients with severe BI have potential for continued recovery and measurable improvement for at least 3 years. The emphasis should be targeted on differing areas of the therapy programme at different phases of recovery. A realistic appraisal of the ultimate potential for recovery can usually be made by 6 months.		BOYER, MG (corresponding author), ACCID HOSP BIRMINGHAM,BATH ROW,BIRMINGHAM B15 1NA,ENGLAND.							0	47	47	0	2	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0020-1383			INJURY	Injury-Int. J. Care Inj.	JUL	1991	22	4					315	320		10.1016/0020-1383(91)90014-6			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	FX584	WOS:A1991FX58400014	1937730				2021-06-18	
J	DAVIDOFF, G; JAKUBOWSKI, M; THOMAS, D; ALPERT, M				DAVIDOFF, G; JAKUBOWSKI, M; THOMAS, D; ALPERT, M			THE SPECTRUM OF CLOSED-HEAD INJURIES IN FACIAL TRAUMA VICTIMS - INCIDENCE AND IMPACT	ANNALS OF EMERGENCY MEDICINE			English	Article										DAVIDOFF, G (corresponding author), UNIV MICHIGAN HOSP,DEPT PHYS MED & REHABIL,ROOM 1D204,1500 E MED CTR DR,BOX 0042,ANN ARBOR,MI 48109, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-01120-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001120] Funding Source: NIH RePORTER			0	47	48	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JAN	1988	17	1					6	9		10.1016/S0196-0644(88)80492-X			4	Emergency Medicine	Emergency Medicine	L4328	WOS:A1988L432800002	3337417				2021-06-18	
J	KINAL, ME				KINAL, ME			TRAUMATIC THROMBOSIS OF DURAL VENOUS SINUSES IN CLOSED HEAD INJURIES	JOURNAL OF NEUROSURGERY			English	Article																BATSON OV, 1944, FED PROC, V3, P139; BELLER AJ, 1964, J NEUROL NEUROSUR PS, V27, P149, DOI 10.1136/jnnp.27.2.149; CARRIE AW, 1954, J NEUROSURG, V11, P173, DOI 10.3171/jns.1954.11.2.0173; ECKER AD, 1946, NEW YORK STATE J MED, V46, P1120; FOLEY J, 1955, BRAIN, V78, P1, DOI 10.1093/brain/78.1.1; KINAL ME, 1959, 1 INT C NEUR SCIENC, P178; MARTIN JP, 1955, BRIT MED J, V2, P467, DOI 10.1136/bmj.2.4937.467	7	47	47	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1967	27	2					142	&		10.3171/jns.1967.27.2.0142			0	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	97846	WOS:A19679784600009					2021-06-18	
J	White, JC; Brooks, JR; Goldthwait, JC; Adams, RD				White, JC; Brooks, JR; Goldthwait, JC; Adams, RD			Changes in brain volume and blood content after experimental concussion	ANNALS OF SURGERY			English	Article									Harvard Univ, Med Sch, Massachusetts Gen Hosp, Surg Res Labs, Boston, MA USA; Harvard Univ, Med Sch, Boston City Hosp, Dept Neurol,Neuropathol Lab, Boston, MA USA							Alexander L, 1938, ARCH NEURO PSYCHIATR, V40, P877, DOI 10.1001/archneurpsyc.1938.02270110031002; Apfelbach CW, 1922, ARCH SURG-CHICAGO, V4, P434, DOI 10.1001/archsurg.1922.01110110180007; ARNAUD M, 1933, B MEM SOC NAT CHIR, V59, P843; Bing FC, 1931, J BIOL CHEM, V92, P589; COURVILLE CB, 1942, B LOS ANGELES NEUROL, V7, P55; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Gurdjian ES, 1943, SURGERY, V13, P333; MAHONEY W, 1941, WAR MED, V1, P816; McConnell AA, 1942, BRAIN, V65, P266, DOI 10.1093/brain/65.3.266; Pilcher C, 1937, ARCH SURG-CHICAGO, V35, P512, DOI 10.1001/archsurg.1937.01190150095009; PILCHER C, 1941, SURG GYNECOL OBSTET, V72, P755; REICHARDT M, 1927, HDB NORMALEN PATHOLO, V10, P103; Shapiro P, 1939, ARCH SURG-CHICAGO, V38, P443, DOI 10.1001/archsurg.1939.01200090048005; White JC, 1942, ARCH SURG-CHICAGO, V44, P1; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	15	47	47	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-4932			ANN SURG	Ann. Surg.	JUL-DEC	1943	119						619	634		10.1097/00000658-194310000-00010			16	Surgery	Surgery	V21QX	WOS:000201463500056	17858295	Green Published			2021-06-18	
J	Nelson, LD; Temkin, NR; Dikmen, S; Barber, J; Giacino, JT; Yuh, E; Levin, HS; McCrea, MA; Stein, MB; Mukherjee, P; Okonkwo, DO; Diaz-Arrastia, R; Manley, GT; Adeoye, O; Badjatia, N; Boase, K; Bodien, Y; Bullock, MR; Chesnut, R; Corrigan, JD; Crawford, K; Duhaime, AC; Ellenbogen, R; Feeser, VR; Ferguson, A; Foreman, B; Gardner, R; Gaudette, E; Gonzalez, L; Gopinath, S; Gullapalli, R; Hemphill, JC; Hotz, G; Jain, S; Korley, F; Kramer, J; Kreitzer, N; Lindsell, C; Machamer, J; Madden, C; Martin, A; McAllister, T; Merchant, R; Noel, F; Palacios, E; Perl, D; Puccio, A; Rabinowitz, M; Robertson, CS; Rosand, J; Sander, A; Satris, G; Schnyer, D; Seabury, S; Sherer, M; Taylor, S; Toga, A; Valadka, A; Vassar, MJ; Vespa, P; Wang, K; Yue, JK; Zafonte, R				Nelson, Lindsay D.; Temkin, Nancy R.; Dikmen, Sureyya; Barber, Jason; Giacino, Joseph T.; Yuh, Esther; Levin, Harvey S.; McCrea, Michael A.; Stein, Murray B.; Mukherjee, Pratik; Okonkwo, David O.; Diaz-Arrastia, Ramon; Manley, Geoffrey T.; Adeoye, Opeolu; Badjatia, Neeraj; Boase, Kim; Bodien, Yelena; Bullock, M. Ross; Chesnut, Randall; Corrigan, John D.; Crawford, Karen; Duhaime, Ann-Christine; Ellenbogen, Richard; Feeser, V. Raman; Ferguson, Adam; Foreman, Brandon; Gardner, Raquel; Gaudette, Etienne; Gonzalez, Luis; Gopinath, Shankar; Gullapalli, Rao; Hemphill, J. Claude; Hotz, Gillian; Jain, Sonia; Korley, Frederick; Kramer, Joel; Kreitzer, Natalie; Lindsell, Chris; Machamer, Joan; Madden, Christopher; Martin, Alastair; McAllister, Thomas; Merchant, Randall; Noel, Florence; Palacios, Eva; Perl, Daniel; Puccio, Ava; Rabinowitz, Miri; Robertson, Claudia S.; Rosand, Jonathan; Sander, Angelle; Satris, Gabriela; Schnyer, David; Seabury, Seth; Sherer, Mark; Taylor, Sabrina; Toga, Arthur; Valadka, Alex; Vassar, Mary J.; Vespa, Paul; Wang, Kevin; Yue, John K.; Zafonte, Ross		TRACK-TBI Investigators	Recovery After Mild Traumatic Brain Injury in Patients Presenting to US Level I Trauma Centers: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Study	JAMA NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; COMMON DATA ELEMENTS; LONG-TERM OUTCOMES; SEVERE HEAD-INJURY; EARLY INTERVENTION; UNITED-STATES; MODERATE; RECOMMENDATIONS; CONCUSSION; DISABILITY	Key PointsQuestionHow common are persistent, injury-related functional limitations following mild traumatic brain injury vs orthopedic trauma? FindingsIn this cohort study of 1154 patients with mild traumatic brain injury and 299 patients with orthopedic trauma serving as controls, 53% of participants with mild traumatic brain injury reported impairment 12 months postinjury vs 38% of those with orthopedic trauma. Patients with intracranial abnormalities had the poorest outcomes; however, patients without abnormalities also reported problems at 12 months. MeaningMany patients who present to level I trauma centers with mild traumatic brain injury experience difficulties at 12 months postinjury, suggesting that this injury is not always benign; better follow-up and treatment appear to be needed. ImportanceMost traumatic brain injuries (TBIs) are classified as mild (mTBI) based on admission Glasgow Coma Scale (GCS) scores of 13 to 15. The prevalence of persistent functional limitations for these patients is unclear. ObjectivesTo characterize the natural history of recovery of daily function following mTBI vs peripheral orthopedic traumatic injury in the first 12 months postinjury using data from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study, and, using clinical computed tomographic (CT) scans, examine whether the presence (CT+) or absence (CT-) of acute intracranial findings in the mTBI group was associated with outcomes. Design, Setting, and ParticipantsTRACK-TBI, a cohort study of patients with mTBI presenting to US level I trauma centers, enrolled patients from February 26, 2014, to August 8, 2018, and followed up for 12 months. A total of 1453 patients at 11 level I trauma center emergency departments or inpatient units met inclusion criteria (ie, mTBI [n=1154] or peripheral orthopedic traumatic injury [n=299]) and were enrolled within 24 hours of injury; mTBI participants had admission GCS scores of 13 to 15 and clinical head CT scans. Patients with peripheral orthopedic trauma injury served as the control (OTC) group. ExposuresParticipants with mTBI or OTC. Main Outcomes and MeasuresThe Glasgow Outcome Scale Extended (GOSE) scale score, reflecting injury-related functional limitations across broad life domains at 2 weeks and 3, 6, and 12 months postinjury was the primary outcome. The possible score range of the GOSE score is 1 (dead) to 8 (upper good recovery), with a score less than 8 indicating some degree of functional impairment. ResultsOf the 1453 participants, 953 (65.6%) were men; mean (SD) age was 40.9 (17.1) years in the mTBI group and 40.9 (15.4) years in the OTC group. Most participants (mTBI, 87%; OTC, 93%) reported functional limitations (GOSE <8) at 2 weeks postinjury. At 12 months, the percentage of mTBI participants reporting functional limitations was 53% (95% CI, 49%-56%) vs 38% (95% CI, 30%-45%) for OTCs. A higher percentage of CT+ patients reported impairment (61%) compared with the mTBI CT- group (49%; relative risk [RR], 1.24; 95% CI, 1.08-1.43) and a higher percentage in the mTBI CT-group compared with the OTC group (RR, 1.28; 95% CI, 1.02-1.60). Conclusions and RelevanceMost patients with mTBI presenting to US level I trauma centers report persistent, injury-related life difficulties at 1 year postinjury, suggesting the need for more systematic follow-up of patients with mTBI to provide treatments and reduce the risk of chronic problems after mTBI. This cohort study examines the physical and neuropsychological outcomes in patients with mild traumatic brain injury up to 12 months after presentation.	[Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA; [Temkin, Nancy R.; Dikmen, Sureyya; Barber, Jason] Univ Washington, Seattle, WA 98195 USA; [Giacino, Joseph T.] Harvard Med Sch, Spaulding Rehabil Hosp, Boston, MA 02115 USA; [Giacino, Joseph T.; Bodien, Yelena; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Yuh, Esther; Mukherjee, Pratik; Manley, Geoffrey T.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Levin, Harvey S.] Baylor Coll Med, Houston, TX 77030 USA; [Stein, Murray B.; Adeoye, Opeolu; Foreman, Brandon; Kreitzer, Natalie] Univ Calif San Diego, La Jolla, CA 92093 USA; [Stein, Murray B.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Okonkwo, David O.] Univ Pittsburgh, Pittsburgh, PA USA; [Diaz-Arrastia, Ramon] Univ Penn, Philadelphia, PA 19104 USA; [Badjatia, Neeraj; Gullapalli, Rao] Univ Maryland, College Pk, MD 20742 USA; [Boase, Kim; Machamer, Joan] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Bullock, M. Ross; Hotz, Gillian] Univ Miami, Coral Gables, FL 33124 USA; [Chesnut, Randall; Ellenbogen, Richard] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Gaudette, Etienne; Seabury, Seth; Toga, Arthur] Univ Southern Calif, Los Angeles, CA USA; [Duhaime, Ann-Christine] MassGen Hosp Children, Boston, MA USA; [Feeser, V. Raman] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA 23284 USA; [Ferguson, Adam; Taylor, Sabrina; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Gardner, Raquel; Hemphill, J. Claude; Kramer, Joel] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Gonzalez, Luis; Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Gopinath, Shankar] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Korley, Frederick] Univ Michigan, Sch Med, Dept Emergency Med, Ann Arbor, MI USA; [Lindsell, Chris] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA; [Madden, Christopher] UT Southwestern Med Ctr, Dept Neurol Surg, Dallas, TX USA; [Martin, Alastair; Palacios, Eva] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [McAllister, Thomas] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN 46202 USA; [Merchant, Randall] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23284 USA; [Noel, Florence] Baylor Coll Med, Duncan L Inst Clin & Translat Res, Houston, TX 77030 USA; [Perl, Daniel] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD USA; [Puccio, Ava] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Rabinowitz, Miri] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Robertson, Claudia S.; Sander, Angelle] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Satris, Gabriela; Vassar, Mary J.; Yue, John K.] Zuckerberg San Francisco Gen Hosp & Trauma Ctr, Brain & Spinal Cord Injury Ctr, San Francisco, CA USA; [Schnyer, David] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Valadka, Alex] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23284 USA; [Vespa, Paul] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; [Wang, Kevin] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA 02115 USA	Nelson, LD (corresponding author), Med Coll Wisconsin, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	linelson@mcw.edu	Giacino, Joseph/AAF-1952-2021; Yue, John/P-1348-2015	Giacino, Joseph/0000-0002-7916-9698; Yue, John/0000-0001-9694-7722; Hemphill, Claude/0000-0003-4019-7525; Wang, Kevin/0000-0002-9343-6473; Ferguson, Adam/0000-0001-7102-1608; Bodien, Yelena/0000-0003-4858-2903	US NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS1365885]; US DoD TBI Endpoints Development Initiative grant [W81XWH-14-2-0176]; OneMind; NeuroTrauma Sciences LLC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS047996] Funding Source: NIH RePORTER	The study was funded by US NIH-NINDS grant U01 NS1365885, OneMind, NeuroTrauma Sciences LLC, and US DoD TBI Endpoints Development Initiative grant W81XWH-14-2-0176.	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Altman D, 1991, PRACTICAL STAT MED R; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bay E, 2011, J HEAD TRAUMA REHAB, V26, P355, DOI 10.1097/HTR.0b013e3181f20146; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Derogatis LR, 2001, BRIEF SYMPTOM INVENT; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Levin HS, 2012, J NEUROSURG, V116, P706; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McCaffrey DF, 2004, PSYCHOL METHODS, V9, P403, DOI 10.1037/1082-989X.9.4.403; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Nelson LD, 2018, J NEUROTRAUM, V35, P249, DOI 10.1089/neu.2017.4988; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Palermo TM, 2010, PAIN, V148, P387, DOI 10.1016/j.pain.2009.10.004; Pampallona S, 2004, ARCH GEN PSYCHIAT, V61, P714, DOI 10.1001/archpsyc.61.7.714; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Roden-Foreman K, 2017, J ORTHOP TRAUMA, V31, pE275, DOI 10.1097/BOT.0000000000000884; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schadel S, 2019, MEAS SCI TECHNOL, V30, DOI 10.1088/1361-6501/ab1501; Schmidt M., 1996, REY AUDITORY VERBAL; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seabury SA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0210; Sosin DM, 1996, BRAIN INJURY, V10, P47; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Wang KK, 2018, EXPERT REV MOL DIAGN, V18, P165, DOI 10.1080/14737159.2018.1428089; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	66	46	46	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	SEP	2019	76	9					1049	1059		10.1001/jamaneurol.2019.1313			11	Clinical Neurology	Neurosciences & Neurology	IZ2CY	WOS:000486895500009	31157856	Green Published, Bronze			2021-06-18	
J	Manek, R; Moghieb, A; Yang, ZH; Kumar, D; Kobessiy, F; Sarkis, GA; Raghavan, V; Wang, KKW				Manek, Rachna; Moghieb, Ahmed; Yang, Zhihui; Kumar, Dhwani; Kobessiy, Firas; Sarkis, George Anis; Raghavan, Vijaya; Wang, Kevin K. W.			Protein Biomarkers and Neuroproteomics Characterization of Microvesicles/Exosomes from Human Cerebrospinal Fluid Following Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Biomarkers; Neuronal injury; Glial injury; Systems biology; Exosome; Microvesicles	GLUTAMATE TRANSPORTERS; STROMAL CELLS; SERUM-LEVELS; EXOSOMES; MILD; MECHANISMS; BREAKDOWN; RECOVERY; TAU	Recently, there have been emerging interests in the area of microvesicles and exosome (MV/E) released from brain cells in relation to neurodegenerative diseases. However, only limited studies focused on MV/E released post-traumatic brain injury (TBI) as they highlight on the mechanistic roles of released proteins. This study sought to examine if CSF samples from severe TBI patients contain MV/E with unique protein contents. First, nanoparticle tracking analysis determined MV/E from TBI have a mode of 74-98 nm in diameter, while control CSF MV/E have a mode of 99-104 nm. Also, there are more MV/E were isolated from TBI CSF (27.8-33.6 x 10(8)/mL) than from control CSF (13.1-18.5 x 10(8)/mL). Transmission electron microscopy (TEM) visualization also confirmed characteristic MV/E morphology. Using targeted immunoblotting approach, we observed the presence of several known TBI biomarkers such as alpha II-spectrin breakdown products (BDPs), GFAP, and its BDPs and UCH-L1 in higher concentrations in MV/E from TBI CSF than their counterparts from control CSF. Furthermore, we found presynaptic terminal protein synaptophysin and known exosome marker Alix enriched in MV/E from human TBI CSF. In parallel, we conducted nRPLC-tandem mass spectrometry-based proteomic analysis of two control and two TBI CSF samples. Ninety-one proteins were identified with high confidence in MV/E from control CSF, whereas 466 proteins were identified in the counterpart from TBI CSF. MV/E isolated from human CSF contain cytoskeletal proteins, neurite-outgrowth related proteins, and synaptic proteins, extracellular matrix proteins, and complement protein C1q subcomponent subunit B. Taken together, following severe TBI, the injured human brain released increased number of extracellular microvesicles/exosomes (MV/E) into CSF. These TBI MV/E contain several known TBI biomarkers and previously undescribed brain protein markers. It is also possible that such TBI-specific MV/E might contain cell to cell communication factors related to both cell death signaling a well as neurodegeneration pathways.	[Manek, Rachna; Moghieb, Ahmed; Yang, Zhihui; Kumar, Dhwani; Kobessiy, Firas; Sarkis, George Anis; Raghavan, Vijaya; Wang, Kevin K. W.] Univ Florida, Dept Emergency Med, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Manek, Rachna; Moghieb, Ahmed; Yang, Zhihui; Kumar, Dhwani; Kobessiy, Firas; Sarkis, George Anis; Raghavan, Vijaya; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Moghieb, Ahmed] Pacific Northwest Natl Lab, 902 Battelle Blvd, Richland, WA 99352 USA; [Kobessiy, Firas] Amer Univ Beirut, Bliss St,POB 11-0236, Beirut, Lebanon; [Sarkis, George Anis] Alexandria Univ, Dept Chem, POB 426, Alexandria 21321, Egypt; [Raghavan, Vijaya] Schizophrenia Res Fdn, R-7A,North Main Rd, Madras 600101, Tamil Nadu, India; [Wang, Kevin K. W.] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA; [Wang, Kevin K. W.] Univ Florida, Dept Chem, Gainesville, FL 32603 USA	Wang, KKW (corresponding author), Univ Florida, Dept Emergency Med, Program Neurotrauma Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA.; Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA.; Wang, KKW (corresponding author), Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA.; Wang, KKW (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32603 USA.	kwang@ufl.edu		Wang, Kevin/0000-0002-9343-6473	UF Psychiatry Department development fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS085455-01, 1U01 NS086090-01]; DOD grant [W81XWH-14-2-0176]; Fogarty International Training Program in Chronic Non-Communicable Diseases and Disorders at the University of Florida [1D43TW009120]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER	This study is in part funded by UF Psychiatry Department development fund. This study is supported in part by NIH grant R21 NS085455-01 (KKW), NIH 1U01 NS086090-01), and DOD grant (W81XWH-14-2-0176) (KKW; G. Manley of UCSF). Post-Doctoral support is by the Fogarty International Training Program in Chronic Non-Communicable Diseases and Disorders at the University of Florida, Grant # 1D43TW009120 (L. Cottler, PI) (VR). We want to thank Dr. Linda Cottler for her support.	Bernath E, 2006, NEUROBIOL AGING, V27, P624, DOI 10.1016/j.neurobiolaging.2005.02.013; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Foran E, 2009, ANTIOXID REDOX SIGN, V11, P1587, DOI 10.1089/ars.2009.2444; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Haneklaus M, 2013, CURR OPIN IMMUNOL, V25, P40, DOI 10.1016/j.coi.2012.12.004; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Kobeissy FH, 2009, METHODS MOL BIOL, V566, P217, DOI 10.1007/978-1-59745-562-6_15; Kobeissy FH, 2015, MOL NEUROBIOL, V52, P696, DOI 10.1007/s12035-014-8898-z; Kumar D, 2017, MOL NEUROBIOL, P1; Laskowitz D., 2016, TRANSLATIONAL RES TR; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; Moghieb A, 2016, MOL CELL PROTEOMICS, V15, P2379, DOI 10.1074/mcp.M116.058115; Mondello S, 2010, J NEUROTRAUM, V27, P1203, DOI 10.1089/neu.2010.1278; Nekludov M, 2014, J NEUROTRAUM, V31, P1927, DOI 10.1089/neu.2013.3168; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Reilly P, 2017, NEUROBIOL DIS; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Russo Isabella, 2012, Am J Neurodegener Dis, V1, P217; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Taylor DD, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0503; TBI: Get the Facts, TBI GET FACTS CONC T; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Vaccari JPD, 2016, J NEUROCHEM, V136, P39, DOI 10.1111/jnc.13036; Vella LJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020173; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang Y, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-016-0143-y; Xin HQ, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00377; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yousefzadeh-Chabok S, 2015, ARCH TRAUMA RES, V4, DOI 10.5812/atr.18357; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	45	46	47	0	22	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUL	2018	55	7					6112	6128		10.1007/s12035-017-0821-y			17	Neurosciences	Neurosciences & Neurology	GI8VY	WOS:000434805100051	29188495	Green Accepted			2021-06-18	
J	Li, HL; Wang, P; Huang, F; Jin, JM; Wu, H; Zhang, BB; Wang, ZF; Shi, HL; Wu, XJ				Li, Hongli; Wang, Ping; Huang, Fei; Jin, Jinmei; Wu, Hui; Zhang, Beibei; Wang, Zhifei; Shi, Hailian; Wu, Xiaojun			Astragaloside IV protects blood-brain barrier integrity from LPS-induced disruption via activating Nrf2 antioxidant signaling pathway in mice	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Astragaloside IV; Blood-brain barrier; ROS; Nrf2; Tight junction	CEREBRAL ISCHEMIA-REPERFUSION; TRANSCRIPTION FACTOR NRF2; OXIDATIVE STRESS; ENDOTHELIAL-CELLS; COGNITIVE IMPAIRMENTS; PRIMARY CULTURES; DYSFUNCTION; DISEASE; STROKE; INJURY	Endothelial cells of cerebral microvessels are one of the components of blood-brain-barrier (BBB), which are connected by tight junctions (TJs). BBB disruption in cerebral diseases such as ischemic stroke, Alzhemer's disease, multiple sclerosis and traumatic brain injury is implicated to exacerbate the disease progression. Astragaloside IV (ASIV) isolated from Astragalus membranaceus prevents BBB breakdown in rodents induced with cerebral edema and experimental autoimmune encephalomyelitis. However, its underlying molecular mechanism has not been elucidated yet. In present study, ASIV was found to prevent the leakage of BBB in LPS-induced mice, which was accompanied with increased zo-1 and occludin but reduced VCAM-1 in brain micro vessels. Similarly, in brain endothelial cell line bEnd.3 cells, ASIV mitigated the increased permeability induced by LPS, as evidenced by increased TEER and reduced sodium fluorescein extravasation. ASIV also enhanced the expression of TJ proteins such as zo-1, occludin and claudin-5 in LPS stimulated bEnd.3 cells. Meanwhile, it inhibited the inflammatory responses and prevented the monocyte adhesion onto bEnd.3 cells upon LPS stimulation. Further study disclosed that ASIV could alleviate ROS level and activate Nrf2 antioxidant pathway in bEnd.3 cells. When Nrf2 was silenced, the protective effect of ASIV was abolished. In brain microvessels of LPS-induced mice, ASIV also enhanced the expression of Nrf2 antioxidant pathway related proteins. Collectively, our results demonstrated that ASIV protected the integrity of BBB in LPS-induced mice, the mechanism of which might be mediated via activating Nrf2 signaling pathway. The findings suggested that ASIV might be a potential neuroprotective drug acting on BBB.	[Li, Hongli; Wang, Ping; Huang, Fei; Jin, Jinmei; Wu, Hui; Zhang, Beibei; Wang, Zhifei; Shi, Hailian; Wu, Xiaojun] Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, Shanghai Key Lab Compound Chinese Med, Minist Educ MOE,Key Lab Standardizat Chinese Med, Shanghai 201203, Peoples R China	Shi, HL; Wu, XJ (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Chinese Mat Med, 1200 Cailun Rd,Zhangjiang Hitech Pk, Shanghai 201203, Peoples R China.	shihailian2003@163.com; xiaojunwu320@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81673626, 81603354]; Shanghai Eastern Scholar Program [2013-59]; Shanghai E-research Institute of Bioactive Constituent in TCM plan;  [QD2015037]	This work was supported by the National Natural Science Foundation of China (81673626, 81603354), Shanghai Eastern Scholar Program (2013-59), Shanghai Youth Eastern Scholar (QD2015037) and Shanghai E-research Institute of Bioactive Constituent in TCM plan.	Alfieri A, 2013, FREE RADICAL BIO MED, V65, P1012, DOI 10.1016/j.freeradbiomed.2013.08.190; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cai Y, 2017, ADV EXP MED BIOL, V964, P163, DOI 10.1007/978-3-319-50174-1_12; Carrano A, 2011, ANTIOXID REDOX SIGN, V15, P1167, DOI 10.1089/ars.2011.3895; Chang R, 2017, MOL PHARMACEUT, V14, P2340, DOI 10.1021/acs.molpharmaceut.7b00200; Chen ZW, 2015, NEUROCHEM RES, V40, P186, DOI 10.1007/s11064-014-1483-z; Choi BY, 2016, NEUROBIOL DIS, V94, P205, DOI 10.1016/j.nbd.2016.06.018; De Oliveira PA, 2017, BRAIN RES, V1663, P78, DOI 10.1016/j.brainres.2017.03.002; Fukuda S, 2016, J MOL NEUROSCI, V59, P211, DOI 10.1007/s12031-015-0696-1; Gu DM, 2015, BIOCHEM BIOPH RES CO, V457, P391, DOI 10.1016/j.bbrc.2015.01.002; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; He YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076495; Huang XP, 2014, PHARMACOGN MAG, V10, P402, DOI 10.4103/0973-1296.141765; Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005; Imai T, 2016, NEUROBIOL DIS, V89, P136, DOI 10.1016/j.nbd.2016.02.001; Jung Y. S., 2016, J BIOMED SCI, V2016, P23; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Khan M, 2012, J NEUROCHEM, V123, P86, DOI 10.1111/j.1471-4159.2012.07947.x; Li M, 2017, NEUROSCI LETT, V639, P114, DOI 10.1016/j.neulet.2016.12.046; Li M, 2013, EUR J PHARMACOL, V715, P189, DOI 10.1016/j.ejphar.2013.05.022; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Liu CL, 2016, INVEST OPHTH VIS SCI, V57, P2319, DOI 10.1167/iovs.16-19097; Liu GY, 2013, BEHAV BRAIN FUNCT, V9, DOI 10.1186/1744-9081-9-36; Liu HC, 2016, SCI REP, V6; McSweeney SR, 2016, HYPERTENSION, V67, P20, DOI 10.1161/HYPERTENSIONAHA.115.06146; Nakagawa S, 2007, CELL MOL NEUROBIOL, V27, P687, DOI 10.1007/s10571-007-9195-4; Patabendige A, 2013, BRAIN RES, V1521, P1, DOI 10.1016/j.brainres.2012.06.057; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Qu YZ, 2009, EUR J PHARMACOL, V606, P137, DOI 10.1016/j.ejphar.2009.01.022; Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2; Shang Y, 2017, TOXICOL IN VITRO, V44, P66, DOI 10.1016/j.tiv.2017.06.017; Tan S, 2017, CLIN SCI, V131, P1499, DOI 10.1042/CS20170984; Tebay LE, 2015, FREE RADICAL BIO MED, V88, P108, DOI 10.1016/j.freeradbiomed.2015.06.021; Wan WB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113126; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang H. L., 2017, OXID MED CELL LONGEV, V2017, P13, DOI 10.1155/2017/8424326; WANG Qiang, 2016, J INTERATION TECHNOL, V2, P1, DOI DOI 10.1016/j.sandf.2016.02.001; Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37098; Wei YH, 2015, P NATL ACAD SCI USA, V112, pE6927, DOI 10.1073/pnas.1512683112; Wolburg H, 2009, CELL TISSUE RES, V335, P75, DOI 10.1007/s00441-008-0658-9; Xu CH, 2016, INT IMMUNOPHARMACOL, V33, P119, DOI 10.1016/j.intimp.2016.02.009; Yang ST, 2014, AM J CHINESE MED, V42, P1357, DOI 10.1142/S0192415X14500852; Yu CH, 2007, EXP NEUROL, V203, P116, DOI 10.1016/j.expneurol.2006.07.023; Zehendner CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082823; Zhang M, 2017, CELL PHYSIOL BIOCHEM, V41, P2255, DOI 10.1159/000475640; Zhang WJ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/274314; Zhao Y, 2015, J ETHNOPHARMACOL, V169, P210, DOI 10.1016/j.jep.2015.04.030	47	46	49	3	64	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	FEB 1	2018	340						58	66		10.1016/j.taap.2017.12.019			9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	FV1JO	WOS:000424317600007	29294303				2021-06-18	
J	Page, D; Ablordeppey, E; Wessman, BT; Mohr, NM; Trzeciak, S; Kollef, MH; Roberts, BW; Fuller, BM				Page, David; Ablordeppey, Enyo; Wessman, Brian T.; Mohr, Nicholas M.; Trzeciak, Stephen; Kollef, Marin H.; Roberts, Brian W.; Fuller, Brian M.			Emergency department hyperoxia is associated with increased mortality in mechanically ventilated patients: a cohort study	CRITICAL CARE			English	Article						Hyperoxia; Mechanical ventilation; Emergency department	TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; ARTERIAL HYPEROXIA; OXYGEN-THERAPY; CARDIAC-ARREST; OBSERVATIONAL COHORT; MULTICENTER COHORT; LUNG INJURY; TRIAL; RESUSCITATION	Background: Providing supplemental oxygen is fundamental in the management of mechanically ventilated patients. Increasing amounts of data show worse clinical outcomes associated with hyperoxia. However, these previous data in the critically ill have not focused on outcomes associated with brief hyperoxia exposure immediately after endotracheal intubation. Therefore, the objectives of this study were to evaluate the impact of isolated early hyperoxia exposure in the emergency department (ED) on clinical outcomes among mechanically ventilated patients with subsequent normoxia in the intensive care unit (ICU). Methods: This was an observational cohort study conducted in the ED and ICUs of an academic center in the USA. Mechanically ventilated normoxic (partial pressure of arterial oxygen (PaO2) 60-120 mm Hg) ICU patients with mechanical ventilation initiated in the ED were studied. The cohort was categorized into three oxygen exposure groups based on PaO2 values obtained after ED intubation: hypoxia, normoxia, and hyperoxia (defined as PaO2 < 60 mmHg, PaO2 60-120 mm Hg, and PaO2 > 120 mm Hg, respectively, based on previous literature). Results: A total of 688 patients were included. ED normoxia occurred in 350 (50.9%) patients, and 300 (43.6%) had exposure to ED hyperoxia. The ED hyperoxia group had a median (IQR) ED PaO2 of 189 mm Hg (146-249), compared toan ED PaO2 of 88 mm Hg (76-101) in the normoxia group, P < 0.001. Patients with ED hyperoxia had greater hospitalmortality (29.7%), when compared to those with normoxia (19.4%) and hypoxia (13.2%). After multivariable logistic regression analysis, ED hyperoxia was an independent predictor of hospital mortality (adjusted OR 1.95 (1.34-2.85)). Conclusions: ED exposure to hyperoxia is common and associated with increased mortality in mechanically ventilated patients achieving normoxia after admission. This suggests that hyperoxia in the immediate post-intubation period could be particularly injurious, and targeting normoxia from initiation of mechanical ventilation may improve outcome.	[Ablordeppey, Enyo; Wessman, Brian T.; Fuller, Brian M.] Washington Univ, Sch Med St Louis, Dept Emergency Med, St Louis, MO 63110 USA; [Ablordeppey, Enyo; Wessman, Brian T.; Fuller, Brian M.] Washington Univ, Sch Med St Louis, Div Crit Care Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Page, David; Kollef, Marin H.] Washington Univ, Dept Med, Sch Med St Louis, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Mohr, Nicholas M.] Univ Iowa, Dept Emergency Med, Roy J & Lucille A Carver Coll Med, 200 Hawkins Dr,1008 RCP, Iowa City, IA 52242 USA; [Mohr, Nicholas M.] Univ Iowa, Dept Anesthesiol, Roy J & Lucille A Carver Coll Med, Div Crit Care Med, 200 Hawkins Dr,1008 RCP, Iowa City, IA 52242 USA; [Trzeciak, Stephen] Cooper Univ Hosp, Div Crit Care Med, Dept Med, One Cooper Plaza,K152, Camden, NJ 08103 USA; [Trzeciak, Stephen; Roberts, Brian W.] Cooper Univ Hosp, Dept Emergency Med, One Cooper Plaza,K152, Camden, NJ 08103 USA	Fuller, BM (corresponding author), Washington Univ, Sch Med St Louis, Dept Emergency Med, St Louis, MO 63110 USA.; Fuller, BM (corresponding author), Washington Univ, Sch Med St Louis, Div Crit Care Med, Dept Anesthesiol, St Louis, MO 63110 USA.	fullerb@wustl.edu	Wessman, Brian/ABF-3081-2020; Mohr, Nicholas/N-1112-2017	Wessman, Brian/0000-0002-8020-2678; Mohr, Nicholas/0000-0003-0497-5828; Ablordeppey, Enyo/0000-0003-4351-6720	KL2 Career Development Award; Washington University Institute of Clinical and Translational Sciences from National Center for Advancing Translational Sciences (NCATS) [UL1 TR000448, KL2 TR000450]; Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Washington University School of Medicine Faculty Scholars grant; Foundation for Barnes-Jewish Hospital; Barnes-Jewish Hospital Foundation; National Institutes of Health/National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL126979]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000450, UL1TR002345, UL1TR000448, KL2TR002346] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL126979] Funding Source: NIH RePORTER	BMF was funded by the KL2 Career Development Award, and this research was supported by the Washington University Institute of Clinical and Translational Sciences (Grants UL1 TR000448 and KL2 TR000450) from the National Center for Advancing Translational Sciences (NCATS). NMM was supported by grant funds from the Health Resources and Services Administration. EA was supported by the Washington University School of Medicine Faculty Scholars grant and the Foundation for Barnes-Jewish Hospital. MHK was supported by the Barnes-Jewish Hospital Foundation. BWR was supported by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL126979). Funders played no role in the design and conduct of the study, nor in the collection, management, analysis, and interpretation of the data, nor in the preparation, review, or approval of the manuscript.	Andrade PV, 2014, INFLAMMATION, V37, P486, DOI 10.1007/s10753-013-9762-4; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Cavassani SS, 2011, ACTA CIR BRAS, V26, P107, DOI 10.1590/S0102-86502011000200006; Cornet AD, 2013, CRIT CARE, V17, DOI 10.1186/cc12554; Damiani E, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0711-x; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; de Graaff AE, 2011, INTENS CARE MED, V37, P46, DOI 10.1007/s00134-010-2025-z; de Jonge E, 2008, CRIT CARE, V12, DOI 10.1186/cc7150; Eastwood G, 2012, INTENS CARE MED, V38, P91, DOI 10.1007/s00134-011-2419-6; Fuller BM, 2017, ANN EMERG MED, V70, P406, DOI 10.1016/j.annemergmed.2017.01.013; Fuller BM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010991; Fuller BM, 2015, CHEST, V148, P365, DOI 10.1378/chest.14-2476; Fuller BM, 2013, ACAD EMERG MED, V20, P659, DOI 10.1111/acem.12167; Girardis M, 2016, JAMA-J AM MED ASSOC, V316, P1583, DOI 10.1001/jama.2016.11993; Helmerhorst HJF, 2017, INTENS CARE MED EXP, V5, DOI 10.1186/s40635-017-0142-5; Helmerhorst HJF, 2017, CRIT CARE MED, V45, P187, DOI 10.1097/CCM.0000000000002084; Helmerhorst HJF, 2015, CRIT CARE MED, V43, P1508, DOI 10.1097/CCM.0000000000000998; Helmerhorst HJF, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0023-y; Iscoe S, 2005, CHEST, V128, P430, DOI 10.1378/chest.128.1.430; Janz DR, 2012, CRIT CARE MED, V40, P3135, DOI 10.1097/CCM.0b013e3182656976; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; Kilgannon JH, 2010, JAMA-J AM MED ASSOC, V303, P2165, DOI 10.1001/jama.2010.707; Li LF, 2007, CRIT CARE, V11, DOI 10.1186/cc5704; O'Driscoll BR, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2016-209729; Panwar R, 2013, ANAESTH INTENS CARE, V41, P505, DOI 10.1177/0310057X1304100412; Panwar R, 2016, AM J RESP CRIT CARE, V193, P43, DOI 10.1164/rccm.201505-1019OC; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Rincon F, 2014, CRIT CARE MED, V42, P387, DOI 10.1097/CCM.0b013e3182a27732; Rose L, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-30; Stolmeijer R, 2014, EUR J EMERG MED, V21, P233, DOI 10.1097/MEJ.0b013e328361c6c7; Stub D, 2015, CIRCULATION, V131, P2143, DOI 10.1161/CIRCULATIONAHA.114.014494; Suzuki S, 2013, J CRIT CARE, V28, P647, DOI 10.1016/j.jcrc.2013.03.010	33	46	49	1	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	JAN 18	2018	22								9	10.1186/s13054-017-1926-4			10	Critical Care Medicine	General & Internal Medicine	FS9JL	WOS:000422734100002	29347982	DOAJ Gold, Green Published			2021-06-18	
J	Giacoppo, S; Thangavelu, SR; Diomede, F; Bramanti, P; Conti, P; Trubiani, O; Mazzon, E				Giacoppo, Sabrina; Thangavelu, Soundara Rajan; Diomede, Francesca; Bramanti, Placido; Conti, Pio; Trubiani, Oriana; Mazzon, Emanuela			Anti-inflammatory effects of hypoxia-preconditioned human periodontal ligament cell secretome in an experimental model of multiple sclerosis: a key role of IL-37	FASEB JOURNAL			English	Article						inflammation; EAE; hPDLSC secretome; eperimental autoimmune ensephalomyelitis	MESENCHYMAL STEM-CELL; TRAUMATIC BRAIN-INJURY; IN-VITRO; CORTICAL-NEURONS; OXIDATIVE STRESS; MOUSE MODEL; AUTOPHAGY; APOPTOSIS; FAMILY; INTERLEUKIN-37	Recent research has widely investigated the anti-inflammatory effects of mesenchymal stem cells and their secretory products, termed the secretome, in the treatment of multiple sclerosis (MS). The present study examined the capacity of the conditioned medium (CM) from human periodontal ligament stem cells (hPLSCs) under hypoxia (H-hPDLSCs-CM) to suppress experimental autoimmune encephalomyelitis (EAE), a murine model of MS. To induce EAE, female C57BL/6 mice were immunized with myelin oligodendroglial glycoprotein peptide35-55. At the onset of symptoms, H-hPDLSCs-CM was infused via the tail vein of mice. Our results demonstrate the efficacy of H-hPDLSCs-CM treatment in diminishing clinical and histologic disease score. A key finding from this study is the marked expression of anti-inflammatory cytokine IL-37, paralleledby the suppression of proinflammatory cytokines in mice with EAE that were treated with H-hPDLSCs-CM. In addition, a consequent modulation of oxidative stress, autophagic, and apoptotic markers was observed in mice with EAE after hPDLSCsCM administration. In addition, to provide additional evidence of the molecular mechanisms that underlie H-hPDLSCs-CM, we investigated its therapeutic action in scratch injury-exposed NSC-34 neurons, an in vitro model of injury. This model reproduces severe inflammation and oxidative stress conditions as observed after EAE damage. In vitro results corroborate the ability of hPDLSCs-CM to modulate inflammatory, oxidative stress, and apoptotic pathways. Taken together, our findings suggest H-hPDLSCs-CM as a new pharmacologic opportunity for the management of MS.	[Giacoppo, Sabrina; Thangavelu, Soundara Rajan; Bramanti, Placido; Mazzon, Emanuela] IRCCS, Ctr Neurolesi Bonino Pulejo, Via Prov Palermo, I-98124 Messina, Italy; [Diomede, Francesca; Trubiani, Oriana] Univ G dAnnunzio, Dept Med Oral & Biotechnol Sci, Stem Cells & Regenerat Med Lab, Chieti, Italy; [Conti, Pio] Univ G dAnnunzio, Immunol Div, Postgrad Med Sch, Chieti, Italy	Mazzon, E (corresponding author), IRCCS, Ctr Neurolesi Bonino Pulejo, Via Prov Palermo, I-98124 Messina, Italy.	emazzon.irccs@gmail.com	Gao, Jing/M-8264-2018; Rajan, Thangavelu Soundara/J-9840-2016; Diomede, Francesca/AAL-6840-2020; Bramanti, Placido/K-5117-2016; Mazzon, Emanuela/AAL-4334-2020	Rajan, Thangavelu Soundara/0000-0001-8728-6176; Diomede, Francesca/0000-0002-0384-6509; mazzon, emanuela/0000-0002-5073-717X			Ahmed NEB, 2016, SCI REP-UK, V6, DOI 10.1038/srep35476; Biancone L, 2012, NEPHROL DIAL TRANSPL, V27, P3037, DOI 10.1093/ndt/gfs168; Bruck W, 2005, J NEUROL, V252, pV3, DOI 10.1007/s00415-005-5002-7; Bulau AM, 2014, P NATL ACAD SCI USA, V111, P2650, DOI 10.1073/pnas.1324140111; Cai Zhiyou, 2013, J Biochem Pharmacol Res, V1, P84; Carinci F, 2016, J BIOL REG HOMEOS AG, V30, P945; Chang CP, 2013, CLIN SCI, V124, P165, DOI 10.1042/CS20120226; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; DINARELLO CA, 1986, YALE J BIOL MED, V59, P97; Dulamea A, 2015, J Med Life, V8, P24; Farrokhi M, 2015, ACTA NEUROL BELG, V115, P609, DOI 10.1007/s13760-015-0491-3; Feng XD, 2017, BOSNIAN J BASIC MED, V17, P95, DOI 10.17305/bjbms.2017.1696; Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Giacoppo S, 2017, ARCH IMMUNOL THER EX, V65, P363, DOI 10.1007/s00005-017-0460-z; Giacoppo S, 2017, FITOTERAPIA, V116, P77, DOI 10.1016/j.fitote.2016.11.010; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Haque N, 2013, SCI WORLD J, DOI 10.1155/2013/632972; Imaeda H, 2013, CLIN EXP IMMUNOL, V172, P410, DOI 10.1111/cei.12061; Jarmalaviciute A, 2016, NEURAL REGEN RES, V11, P904, DOI 10.4103/1673-5374.184480; Khwanraj K, 2016, PARKINSONS DIS-US, V2016, DOI 10.1155/2016/8716016; Kumar S, 2013, NEUROBIOL DIS, V56, P131, DOI 10.1016/j.nbd.2013.04.005; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li JH, 2008, J ENDOCRINOL INVEST, V31, P103, DOI 10.1007/BF03345575; Li SZ, 2015, P NATL ACAD SCI USA, V112, P2497, DOI 10.1073/pnas.1424626112; Li TT, 2017, MOL IMMUNOL, V87, P132, DOI 10.1016/j.molimm.2017.04.010; Liu JJ, 2015, STEM CELLS, V33, P627, DOI 10.1002/stem.1909; Lovett-Racke AE, 2011, BBA-MOL BASIS DIS, V1812, P246, DOI 10.1016/j.bbadis.2010.05.012; Ma YH, 2012, NEUROSCI LETT, V510, P14, DOI 10.1016/j.neulet.2011.12.061; Madrigal M, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0260-8; McNamee EN, 2011, P NATL ACAD SCI USA, V108, P16711, DOI 10.1073/pnas.1111982108; Meamar Rokhsareh, 2016, Adv Biomed Res, V5, P46, DOI 10.4103/2277-9175.178791; Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022; Merino-Gonzalez C, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00024; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Paschalidis N, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-33; Payette DJ, 2008, INT J CLIN EXP PATHO, V1, P44; Rajan TS, 2017, J CELL BIOCHEM, V118, P1531, DOI 10.1002/jcb.25815; Rajan TS, 2017, J CELL BIOCHEM, V118, P819, DOI 10.1002/jcb.25757; Rajan TS, 2016, SCI REP-UK, V6, DOI 10.1038/srep38743; Rajan TS, 2016, EXP CELL RES, V349, P152, DOI 10.1016/j.yexcr.2016.10.008; Rodrigues DH, 2010, J NEUROIMMUNOL, V222, P90, DOI 10.1016/j.jneuroim.2010.02.016; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sarvar DP, 2016, ADV PHARM BULL, V6, P293, DOI 10.15171/apb.2016.041; Sharma S, 2008, J IMMUNOL, V180, P5477, DOI 10.4049/jimmunol.180.8.5477; Sharpe PT, 2016, DEVELOPMENT, V143, P2273, DOI 10.1242/dev.134189; Song LJ, 2013, J CLIN IMMUNOL, V33, P111, DOI 10.1007/s10875-012-9791-z; Sweeney P, 2017, TRANSL NEURODEGENER, V6, DOI 10.1186/s40035-017-0077-5; Teng X, 2014, J IMMUNOL, V192, P1815, DOI 10.4049/jimmunol.1300047; Tete S, 2012, INT J IMMUNOPATH PH, V25, P31, DOI 10.1177/039463201202500105; Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9; Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025; Vertelov G, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt153; Wahl SE, 2014, J NEUROSCI, V34, P4453, DOI 10.1523/JNEUROSCI.4311-13.2014; Weber MS, 2012, CURR PHARM DESIGN, V18, P209; Wu TT, 2016, INT J BIOL SCI, V12, P884, DOI 10.7150/ijbs.15194; Wyrsch P, 2012, MOL CELL BIOL, V32, P3541, DOI 10.1128/MCB.00437-12; Yang LB, 2015, APMIS, V123, P1025, DOI 10.1111/apm.12467; Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001; Yu J, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt234; Zhao YB, 2012, EXP NEUROL, V237, P489, DOI 10.1016/j.expneurol.2012.07.004; Zhuang XY, 2017, IMMUN INFLAMM DIS, V5, P373, DOI 10.1002/iid3.159	64	46	47	1	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2017	31	12					5592	5608		10.1096/fj.201700524R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FO2EX	WOS:000416588300039	28842429	Green Published			2021-06-18	
J	Yao, XL; Liu, SW; Ding, W; Yue, PJ; Jiang, Q; Zhao, M; Hu, F; Zhang, HQ				Yao, Xiaolong; Liu, Shengwen; Ding, Wei; Yue, Pengjie; Jiang, Qian; Zhao, Min; Hu, Feng; Zhang, Huaqiu			TLR4 signal ablation attenuated neurological deficits by regulating microglial M1/M2 phenotype after traumatic brain injury in mice	JOURNAL OF NEUROIMMUNOLOGY			English	Article							TOLL-LIKE RECEPTOR-4; INNATE IMMUNE-SYSTEM; SPINAL-CORD-INJURY; NERVOUS-SYSTEM; MACROPHAGE ACTIVATION; CELLS; POLARIZATION; DAMAGE; NEUROPROTECTION; RECOGNITION	Traumatic brain injury (TBI) initiates inflammatory responses that result in an enduring cascade of secondary neuronal loss and behavioural impairment. Toll-like receptor 4 (TLR4), predominantly expressed by microglia, recognizes damage-associated molecular patterns (DAMPs) and regulates inflammatory processes. Interestingly, the switch of microglial M1/M2 phenotypes after TBI is highly important regarding damage and restoration of neurological function. Therefore, we investigated the role and mechanisms of the TLR4 signalling pathway in regulating microglial M1/M2 phenotypes. Using a controlled cortical impact (CCI) model, we found that TLR4 knockout (KO) mice exhibited decreased infarct volumes and improved outcomes in behavioural tests. In addition, mice lacking TLR4 had higher expression of M2 phenotype biomarkers but lower expression of M1 phenotype biomarkers. Compared with microglia derived from wild-type (WT) mice, increased expression of M2 phenotype biomarkers and decreased expression of M1 phenotype biomarkers were also noted in primary cultures of microglia from TLR4 KO mice. In TLR4 KO mice, the expression levels of downstream signalling molecules of TLR4, such as active Rac-1 and phospho-AKT, were higher, while MyD88 and phospho-NF-kappa B p65 expression levels were lower than in WT mice. Our results demonstrate that the absence of TLR4 induces microglial polarization toward the M2 phenotype and promotes microglial migration and, in turn, alleviates the development of neuroinflammation, which indicates potential neuroprotective effects in the TBI mouse model. Furthermore, up-regulation of IL-4 expression in TLR4 KO mice could contribute to anti-inflammatory functions and promote microglial polarization toward the M2 phenotype, which might be mediated by active Rac-1 expression. Taken together, TLR4 deficiency contributes to regulating microglia to switch to the M2 phenotype, which ameliorates neurological impairment after TBI.	[Yao, Xiaolong; Liu, Shengwen; Ding, Wei; Yue, Pengjie; Jiang, Qian; Zhao, Min; Hu, Feng; Zhang, Huaqiu] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurosurg, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China	Zhang, HQ (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Dept Neurosurg, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.	zhanghq_04@yahoo.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371381]	This article was funded by the Natural Science Foundation of China (81371381).	Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Barcia C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002977; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Chakravarty S, 2005, J NEUROSCI, V25, P1788, DOI 10.1523/jneurosci.4268-04.2005; Lima IVDA, 2015, EXP NEUROL, V267, P123, DOI 10.1016/j.expneurol.2015.02.021; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Glezer I, 2007, NEUROSCIENCE, V147, P867, DOI 10.1016/j.neuroscience.2007.02.055; Johnson GB, 2002, J IMMUNOL, V168, P5233, DOI 10.4049/jimmunol.168.10.5233; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim D, 2007, J BIOL CHEM, V282, P14975, DOI 10.1074/jbc.M607277200; Kim YM, 2004, AM J OBSTET GYNECOL, V191, pS6, DOI 10.1016/j.ajog.2004.09.044; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee H, 2013, CURR PROTEIN PEPT SC, V14, P33, DOI 10.2174/1389203711314010006; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; O'Neill LAJ, 2003, BIOCHEM SOC T, V31, P643, DOI 10.1042/BST0310643; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Qi ZF, 2012, CNS NEUROSCI THER, V18, P965, DOI 10.1111/cns.12016; Saponaro C, 2012, IMMUNOPHARM IMMUNOT, V34, P858, DOI 10.3109/08923973.2012.665461; Tanaka T, 2015, GLIA, V63, P595, DOI 10.1002/glia.22770; Yang H, 2012, NEUROCHEM INT, V61, P175, DOI 10.1016/j.neuint.2012.04.020; Zhang YK, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-112; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhao XR, 2015, J NEUROSCI, V35, P11281, DOI 10.1523/JNEUROSCI.1685-15.2015; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	33	46	52	1	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	SEP 15	2017	310						38	45		10.1016/j.jneuroim.2017.06.006			8	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FE4KT	WOS:000408183500007	28778443				2021-06-18	
J	Yanguas-Casas, N; Barreda-Manso, MA; Nieto-Sampedro, M; Romero-Ramirez, L				Yanguas-Casas, Natalia; Asuncion Barreda-Manso, M.; Nieto-Sampedro, Manuel; Romero-Ramirez, Lorenzo			TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti-Inflammatory Effects in Microglial Cells	JOURNAL OF CELLULAR PHYSIOLOGY			English	Article							BETA SIGNALING PLAYS; TAUROURSODEOXYCHOLIC ACID; SPINAL-CORD; LEUKOCYTE RECRUITMENT; URSODEOXYCHOLIC ACID; ACTIVATED MICROGLIA; IMMUNE-RESPONSES; GENE-EXPRESSION; NITRIC-OXIDE; IN-VITRO	Bile acids are steroid acids found in the bile of mammals. The bile acid conjugate tauroursodeoxycholic acid (TUDCA) is neuroprotective in different animal models of stroke and neurological diseases. We have previously shown that TUDCA has anti-inflammatory effects on glial cell cultures and in a mouse model of acute neuroinflammation. We show now that microglial cells (central nervous system resident macrophages) express the G protein-coupled bile acid receptor 1/Takeda G protein-coupled receptor 5 (GPBAR1/TGR5) in vivo and in vitro. TUDCA binding to GPBAR1/TGR5 caused an increase in intracellular cAMP levels in microglia that induced anti-inflammatory markers, while reducing pro-inflammatory ones. This anti-inflammatory effect of TUDCA was inhibited by small interference RNA for GPBAR1/TGR5 receptor, as well as by treatment with a protein kinase A (PKA) inhibitor. In the mouse model of acute neuroinflammation, treating the animals with TUDCA was clearly anti-inflammatory. TUDCA biased the microglial phenotype in vivo and in vitro toward the anti-inflammatory. The bile acid receptor GPBAR1/TGR5 could be a new therapeutic target for pathologies coursing with neuroinflammation and microglia activation, such as traumatic brain injuries, stroke, or neurodegenerative diseases. TUDCA and other GPBAR1/TGR5 agonists need to be further investigated, to determine their potential in attenuating the neuropathologies associated with microglia activation. J. Cell. Physiol. 232: 2231-2245, 2017. (c) 2016 Wiley Periodicals, Inc.	[Yanguas-Casas, Natalia; Asuncion Barreda-Manso, M.; Nieto-Sampedro, Manuel] Inst Cajal CSIC, Dept Neurobiol Func & Sistemas, Madrid, Spain; [Asuncion Barreda-Manso, M.; Nieto-Sampedro, Manuel; Romero-Ramirez, Lorenzo] Hosp Nacl Paraplej SESCAM, Unidad Neurol Expt, Toledo, Spain	Romero-Ramirez, L (corresponding author), Hosp Nacl Paraplej SESCAM, Unidad Neurol Expt, Lab Plasticidad Neural, Finca Peraleda S-N, Toledo 45071, Spain.	lromeroramirez@sescam.jccm.es	Casas, Natalia Yanguas/AAB-6704-2019; Barreda-Manso, M.Asuncion/ABF-8918-2020	Casas, Natalia Yanguas/0000-0003-4368-0176; Barreda-Manso, M.Asuncion/0000-0003-4127-2101	Spanish Ministry of Science and InnovationSpanish Government [SAF2009-11257]; Spanish Ministry of Economics and Competitiveness [SAF2012-40126]; FISCAM-Comunidad de Castilla-La Mancha [PI2008/19, PI2009/51]	Contract grant sponsor: Spanish Ministry of Science and Innovation;; Contract grant number: SAF2009-11257.; Contract grant sponsor: Spanish Ministry of Economics and Competitiveness;; Contract grant number: SAF2012-40126.; Contract grant sponsor: FISCAM-Comunidad de Castilla-La Mancha;; Contract grant numbers: PI2008/19, PI2009/51.	Ackerman HD, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00263; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Aloisi F, 2001, ANN MED, V33, P510, DOI 10.3109/07853890108995960; Bala V, 2011, GASTROENTEROLOGY, V140, pS147; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; Bryan L, 2008, BBA-MOL CELL BIOL L, V1781, P459, DOI 10.1016/j.bbalip.2008.04.008; Castro-Caldas M, 2012, MOL NEUROBIOL, V46, P475, DOI 10.1007/s12035-012-8295-4; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Dello Russo C, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-9; Dent P, 2005, HEPATOLOGY, V42, P1291, DOI 10.1002/hep.20942; DEWIT H, 1994, BLOOD, V84, P608; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elia AE, 2015, EUR J NEUROL, V22, pE78, DOI 10.1111/ene.12756; FABRY Z, 1995, J IMMUNOL, V155, P325; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Gong DP, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-31; Grin'kina NM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036475; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Jensen DD, 2013, J BIOL CHEM, V288, P22942, DOI 10.1074/jbc.M113.455774; Joo SS, 2004, ARCH PHARM RES, V27, P954, DOI 10.1007/BF02975850; Kawamata Y, 2003, J BIOL CHEM, V278, P9435, DOI 10.1074/jbc.M209706200; Keene CD, 2002, P NATL ACAD SCI USA, V99, P10671, DOI 10.1073/pnas.162362299; Keitel V, 2008, BIOCHEM BIOPH RES CO, V372, P78, DOI 10.1016/j.bbrc.2008.04.171; Keitel V, 2010, GLIA, V58, P1794, DOI 10.1002/glia.21049; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim WK, 2000, J NEUROSCI, V20, P3622; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Lavoie B, 2010, J PHYSIOL-LONDON, V588, P3295, DOI 10.1113/jphysiol.2010.192146; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Lewis ND, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100883; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LINDOR KD, 1994, GASTROENTEROLOGY, V106, P1284, DOI 10.1016/0016-5085(94)90021-3; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Machwate M, 1998, MOL PHARMACOL, V54, P70; Magnus T, 2005, J NEUROSCI, V25, P2537, DOI 10.1523/JNEUROSCI.4794-04.2005; Mano N, 2004, J LIPID RES, V45, P295, DOI 10.1194/jlr.M300369-JLR200; Maruyama T, 2002, BIOCHEM BIOPH RES CO, V298, P714, DOI 10.1016/S0006-291X(02)02550-0; McMillin M, 2015, J NEUROCHEM, V135, P565, DOI 10.1111/jnc.13243; Moon EY, 2005, J NEUROSCI RES, V81, P38, DOI 10.1002/jnr.20535; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nunes AF, 2012, MOL NEUROBIOL, V45, P440, DOI 10.1007/s12035-012-8256-y; Paglinawan R, 2003, GLIA, V44, P219, DOI 10.1002/glia.10286; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Quinn M, 2012, J CELL SCI THE, V3, P7, DOI DOI 10.4172/2157-7013.1000e113; Rodrigues CMP, 2003, P NATL ACAD SCI USA, V100, P6087, DOI 10.1073/pnas.1031632100; Rodrigues TMP, 2002, J CEREBR BLOOD F MET, V22, P463, DOI 10.1097/00004647-200204000-00010; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Sato H, 2008, J MED CHEM, V51, P1831, DOI 10.1021/jm7015864; Standiford TJ, 2011, ONCOGENE, V30, P2475, DOI 10.1038/onc.2010.619; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; van Rossum D, 2004, METAB BRAIN DIS, V19, P393, DOI 10.1023/B:MEBR.0000043984.73063.d8; Wu FJ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0316-6; Yanguas-Casas N, 2017, MOL NEUROBIOL, V54, P6737, DOI 10.1007/s12035-016-0142-6; Yanguas-Casas N, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-50; Yoneno K, 2013, IMMUNOLOGY, V139, P19, DOI 10.1111/imm.12045; Zhou H, 2006, J IMMUNOL, V177, P8103, DOI 10.4049/jimmunol.177.11.8103; Zhou XL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-210	67	46	46	2	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9541	1097-4652		J CELL PHYSIOL	J. Cell. Physiol.	AUG	2017	232	8					2231	2245		10.1002/jcp.25742			15	Cell Biology; Physiology	Cell Biology; Physiology	ET0SF	WOS:000399973200030	27987324				2021-06-18	
J	Azouvi, P; Arnould, A; Dromer, E; Vallat-Azouvi, C				Azouvi, P.; Arnould, A.; Dromer, E.; Vallat-Azouvi, C.			Neuropsychology of traumatic brain injury: An expert overview	REVUE NEUROLOGIQUE			English	Article						Traumatic brain injury: Cognition; Executive function; Memory	CLOSED-HEAD INJURY; WORKING-MEMORY IMPAIRMENTS; IMPAIRED SELF-AWARENESS; DUAL-TASK PERFORMANCE; SUSTAINED ATTENTION; DIVIDED ATTENTION; EXECUTIVE DYSFUNCTION; WHITE-MATTER; SELECTIVE ATTENTION; MISERABLE MINORITY	Traumatic brain injury (TBI) is a serious healthcare problem, and this report is a selective review of recent findings on the epidemiology, pathophysiology and neuropsychological impairments following TBI. Patients who survive moderate-to-severe TBI frequently suffer from a wide range of cognitive deficits and behavioral changes due to diffuse axonal injury. These deficits include slowed information-processing and impaired long-term memory, attention, working memory, executive function, social cognition and self-awareness. Mental fatigue is frequently also associated and can exacerbate the consequences of neuropsychological deficits. Personality and behavioral changes can include combinations of impulsivity and apathy. Even mild TBI raises specific problems: while most patients recover within a few weeks or months, a minority of patients may suffer from long-lasting symptoms (post-concussion syndrome). The pathophysiology of such persistent problems remains a subject of debate, but seems to be due to both injury-related and non-injury-related factors. (C) 2017 Elsevier Masson SAS. All rights reserved.	[Azouvi, P.; Arnould, A.; Dromer, E.] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France; [Azouvi, P.; Arnould, A.; Dromer, E.; Vallat-Azouvi, C.] Univ Versailles St Quentin, HANDIReSP EA 4047, F-78423 Montigny Le Bretonneux, France; [Vallat-Azouvi, C.] Univ Paris 8 St Denis, EA 2027, Lab Psychopathol & Neuropsychol, 2 Rue Liberte, F-93526 St Denis, France; [Vallat-Azouvi, C.] Hop Raymond Poincare, Antenne UEROS UGECAMIDF, 104 Blvd Raymond Poincare, F-92380 Garches, France	Azouvi, P (corresponding author), Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France.; Azouvi, P (corresponding author), Univ Versailles St Quentin, HANDIReSP EA 4047, F-78423 Montigny Le Bretonneux, France.	Philippe.azouvi@aphp.fr			French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM04084]; Institut de Recherche en Sante Publique (IRESP); Assistance publique-Hopitaux de Paris (AP-HP)	Research presented in this paper has been supported by the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004) grant number AOM04084, and the Institut de Recherche en Sante Publique (IRESP). It was also supported by Assistance publique-Hopitaux de Paris (AP-HP).	Arnould A, 2016, ANN PHYS REHABIL MED, V59, P18, DOI 10.1016/j.rehab.2015.09.002; Arnould A, 2015, BRAIN INJURY, V29, P1597, DOI 10.3109/02699052.2015.1075156; Arnould A, 2013, NEUROPSYCHOL REV, V23, P210, DOI 10.1007/s11065-013-9236-3; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Azouvi P, 2016, J HEAD TRAUMA REHAB, V31, pE10, DOI 10.1097/HTR.0000000000000169; Bayen E, 2014, J HEAD TRAUMA REHABI; Bayen E, 2013, J HEAD TRAUMA REHAB, V28, P408, DOI 10.1097/HTR.0b013e31825413cf; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; Belmont A, 2009, NEUROREHAB NEURAL RE, V23, P939, DOI 10.1177/1545968309340327; Ben-David BM, 2011, J INT NEUROPSYCH SOC, V17, P354, DOI 10.1017/S135561771000175X; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1988, Acta Neurochir Suppl (Wien), V44, P59; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Cantin JF, 2007, BRAIN INJURY, V21, P327, DOI 10.1080/02699050701209972; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Cazalis F, 2001, J INT NEUROPSYCH SOC, V7, P795, DOI 10.1017/S1355617701777028; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chiou KS, 2015, J CLIN EXP NEUROPSYC, V37, P1074, DOI 10.1080/13803395.2015.1078293; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Ciurli P, 2010, J INT NEUROPSYCH SOC, V16, P360, DOI 10.1017/S135561770999141X; Coste C, 2015, NEUROPSYCHOLOGIA, V71, P133, DOI 10.1016/j.neuropsychologia.2015.03.014; Coste C, 2011, CORTEX, V47, P771, DOI 10.1016/j.cortex.2010.07.004; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; de Koning ME, 2016, INJURY, V47, P2041, DOI 10.1016/j.injury.2016.04.036; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Dikmen S, 2016, J NEUROTRAUMA; Dobryakova E, 2015, BRAIN CONNECT, V5, P433, DOI 10.1089/brain.2014.0283; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Dunning DL, 2016, NEUROPSYCHOLOGY, V30, P811, DOI 10.1037/neu0000285; Dymowski AR, 2015, J CLIN EXP NEUROPSYC, V37, P1024, DOI 10.1080/13803395.2015.1074663; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Hartvigsen Jan, 2014, Arch Phys Med Rehabil, V95, pS286, DOI 10.1016/j.apmr.2013.07.029; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hillary FG, 2011, INT J PSYCHOPHYSIOL, V82, P115, DOI 10.1016/j.ijpsycho.2011.03.011; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Jennett B, 1981, MANAGEMENT HEAD INJU; Jourdan C, 2016, ANN PHYS REHABIL MED, V59, P100, DOI 10.1016/j.rehab.2015.10.009; Jourdan C, 2013, BRAIN INJURY, V27, P1000, DOI 10.3109/02699052.2013.794971; Jourdan C, 2017, J HEAD TRAUMA REHABI; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Lange RT, 2005, J CLIN EXP NEUROPSYC, P27; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Mioni G, 2012, J INT NEUROPSYCH SOC, V18, P697, DOI 10.1017/S1355617712000306; Morton N, 2010, J INT NEUROPSYCH SOC, V16, P1089, DOI 10.1017/S1355617710000925; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Nordstrom A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f723; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Pandit AS, 2013, NEUROLOGY, V80, P1826, DOI 10.1212/WNL.0b013e3182929f38; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Piolino P, 2007, CORTEX, V43, P176, DOI 10.1016/S0010-9452(08)70474-X; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford JL, 2016, J NEUROTRAUM, V33, P997, DOI 10.1089/neu.2015.4025; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rasmussen KW, 2014, J NEUROPSYCHOL, V8, P34, DOI 10.1111/jnp.12003; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Robertson K, 2015, BRAIN INJURY, V29, P848, DOI 10.3109/02699052.2015.1005135; Rochat L, 2013, J INT NEUROPSYCH SOC, V19, P890, DOI 10.1017/S1355617713000672; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Shum DHK, 2000, J CLIN EXP NEUROPSYC, V22, P25, DOI 10.1076/1380-3395(200002)22:1;1-8;FT025; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Sinclair KL, 2013, J CLIN EXP NEUROPSYC, V35, P210, DOI 10.1080/13803395.2012.762340; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Spikman JM, 2012, J NEUROTRAUM, V29, P101, DOI 10.1089/neu.2011.2084; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vanderploeg RD, 2014, J CLIN EXP NEUROPSYC, V36, P58, DOI 10.1080/13803395.2013.864600; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zec RF, 2001, J CLIN EXP NEUROPSYC, V23, P671, DOI 10.1076/jcen.23.5.671.1247; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	167	46	48	5	44	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0035-3787	2213-0004		REV NEUROL-FRANCE	Rev. Neurol.	JUL-AUG	2017	173	7-8			SI		461	472		10.1016/j.neurol.2017.07.006			12	Clinical Neurology	Neurosciences & Neurology	FG7WU	WOS:000410636700005	28847474				2021-06-18	
J	Wallace, J; Covassin, T; Beidler, E				Wallace, Jessica; Covassin, Tracey; Beidler, Erica			Sex Differences in High School Athletes' Knowledge of Sport-Related Concussion Symptoms and Reporting Behaviors	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injuries; secondary school; sport culture	FOOTBALL PLAYERS; ICE HOCKEY; STATEMENT; PERFORMANCE; ATTITUDES; EDUCATION; RECOVERY; IDENTITY; INJURY	Context: Recent researchers have reported that athletes' knowledge of sport-related concussion (SRC) has increased but that athletes still lack knowledge of all the signs and symptoms of SRC. Understanding the signs and symptoms of SRC and the dangers of playing while symptomatic are critical to reporting behaviors in high school athletes. Objective: To examine sex differences in knowledge of SRC symptoms and reasons for not reporting a suspected SRC to an authoritative figure in high school athletes. Design: Cross-sectional study. Setting: Survey. Patients or Other Participants: A total of 288 athletes across 7 sports (198 males [68.8%] and 90 females [31.2%]). Main Outcome Measure(s): A validated knowledge-of-SRC survey consisted of demographic questions, a list of 21 signs and symptoms of SRC, and reasons why athletes would not report their SRC. The independent variable was sex. Athlete knowledge of SRC symptoms was assessed by having participants identify the signs and symptoms of SRC from a list of 21 symptoms. Knowledge scores were calculated by summing the number of correct answers; scores ranged from 0 to 21, with a score closer to 21 representing greater knowledge. Reporting-behavior questions asked athletes to choose reasons why they decided not to report any possible SRC signs and symptoms to an authoritative figure. Results: A sex difference in total SRC symptom knowledge was found (F-286 = 4.97, P = .03, d = 0.26). Female high school athletes had more total SRC symptom knowledge (mean 6 standard deviation = 15.06 +/- 2.63; 95% confidence interval = 14.54, 15.57) than males (14.36 +/- 2.76; 95% confidence interval = 13.97, 14.74). Chi-square tests identified significant relationships between sex and 8 different reasons for not reporting an SRC. Conclusions: High school males and females had similar SRC symptom knowledge; however, female athletes were more likely to report their concussive symptoms to an authoritative figure.	[Wallace, Jessica] Youngstown State Univ, Youngstown, OH 44555 USA; [Wallace, Jessica; Covassin, Tracey] Michigan State Univ, E Lansing, MI 48824 USA; [Beidler, Erica] Duquesne Univ, Pittsburgh, PA 15219 USA	Wallace, J (corresponding author), Youngstown State Univ, Beeghly Ctr 307L, 1 Univ Plaza, Youngstown, OH 44555 USA.	jwallace02@ysu.edu					Anderson B, 2013, PED AC SOC ANN M WAS; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; BREWER BW, 1993, INT J SPORT PSYCHOL, V24, P237; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Centers for Disease Control and Prevention, CONC MILD TBI; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cohen J, 1988, STAT POWER BEHAV SCI; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Cournoyer J, 2014, J ATHL TRAINING, V49, P654, DOI 10.4085/1062-6050-49.3.34; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Korngold C, 2013, J AM ACAD PSYCHIATRY, V41, P430; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Martin SB, 2005, J APPL SPORT PSYCHOL, V17, P127, DOI 10.1080/10413200590932434; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckinlay A, 2011, BRAIN INJURY, V25, P761, DOI 10.3109/02699052.2011.579935; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Messner MichaelA., 1992, POWER PLAY SPORTS PR; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Steinfeldt JA, 2009, PSYCHOL MEN MASCULIN, V10, P261, DOI 10.1037/a0017223; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	36	46	46	0	11	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL	2017	52	7					682	688		10.4085/1062-6050-52.3.06			7	Sport Sciences	Sport Sciences	FB4RH	WOS:000406128700008	28561626	Green Published, Bronze			2021-06-18	
J	Raoof, R; Jimenez-Mateos, EM; Bauer, S; Tackenberg, B; Rosenow, F; Lang, J; Onugoren, MD; Hamer, H; Huchtemann, T; Kortvelyessy, P; Connolly, NMC; Pfeiffer, S; Prehn, JHM; Farrell, MA; O'Brien, DF; Henshall, DC; Mooney, C				Raoof, Rana; Jimenez-Mateos, Eva M.; Bauer, Sebastian; Tackenberg, Bjoern; Rosenow, Felix; Lang, Johannes; Onugoren, Muejgan Dogan; Hamer, Hajo; Huchtemann, Tessa; Koertvelyessy, Peter; Connolly, Niamh M. C.; Pfeiffer, Shona; Prehn, Jochen H. M.; Farrell, Michael A.; O'Brien, Donncha F.; Henshall, David C.; Mooney, Catherine			Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus	SCIENTIFIC REPORTS			English	Article							NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; DIFFERENTIAL EXPRESSION; CIRCULATING MICRORNAS; HIPPOCAMPAL SCLEROSIS; ALZHEIMERS-DISEASE; MIRNA; PROFILES; PROTEIN; BLOOD	There is a need for diagnostic biomarkers of epilepsy and status epilepticus to support clinical examination, electroencephalography and neuroimaging. Extracellular microRNAs may be potentially ideal biomarkers since some are expressed uniquely within specific brain regions and cell types. Cerebrospinal fluid offers a source of microRNA biomarkers with the advantage of being in close contact with the target tissue and sites of pathology. Here we profiled microRNA levels in cerebrospinal fluid from patients with temporal lobe epilepsy or status epilepticus, and compared findings to matched controls. Differential expression of 20 microRNAs was detected between patient groups and controls. A validation phase included an expanded cohort and samples from patients with other neurological diseases. This identified lower levels of miR-19b in temporal lobe epilepsy compared to controls, status epilepticus and other neurological diseases. Levels of miR-451a were higher in status epilepticus compared to other groups whereas miR-21-5p differed in status epilepticus compared to temporal lobe epilepsy but not to other neurological diseases. Targets of these microRNAs include proteins regulating neuronal death, tissue remodelling, gliosis and inflammation. The present study indicates cerebrospinal fluid contains microRNAs that can support differential diagnosis of temporal lobe epilepsy and status epilepticus from other neurological and non-neurological diseases.	[Raoof, Rana; Jimenez-Mateos, Eva M.; Connolly, Niamh M. C.; Pfeiffer, Shona; Prehn, Jochen H. M.; Henshall, David C.; Mooney, Catherine] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland; [Raoof, Rana] Univ Mosul, Dept Anat, Mosul Med Coll, Mosul, Iraq; [Bauer, Sebastian; Tackenberg, Bjoern; Rosenow, Felix] Epilepsy Ctr Hessen, Dept Neurol, Baldingerstr, D-35043 Marburg, Germany; [Bauer, Sebastian; Rosenow, Felix] Goethe Univ, Epilepsy Ctr Frankfurt Rhine Main, Neuroctr, Schleusenweg 2-16,Haus 95, D-60528 Frankfurt, Germany; [Lang, Johannes; Onugoren, Muejgan Dogan; Hamer, Hajo] Univ Hosp Erlangen, Schwabachanlage 6, D-91054 Erlangen, Germany; [Huchtemann, Tessa; Koertvelyessy, Peter] Univ Hosp Magdeburg, Dept Neurol, Leipziger Str 44, D-39120 Magdeburg, Germany; [Farrell, Michael A.; O'Brien, Donncha F.] Beaumont Hosp, Beaumont Rd, Dublin 9, Ireland	Henshall, DC (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	dhenshall@rcsi.ie	Jimenez-Mateos, Eva/AAG-8072-2019; Raoof, Rana Mumtaz/J-9316-2019; Raoof, Rana/F-8562-2019; Prehn, Jochen HM/A-3928-2010; Connolly, Niamh M. C./U-6083-2019	Raoof, Rana Mumtaz/0000-0001-5418-1407; Raoof, Rana/0000-0001-5418-1407; Prehn, Jochen HM/0000-0003-3479-7794; Connolly, Niamh M. C./0000-0002-6005-1307; Jimenez-Mateos, Eva/0000-0001-6417-6580; Hamer, Hajo/0000-0003-1709-8617; Pfeiffer, Shona/0000-0002-8728-1620; Mooney, Catherine/0000-0002-7696-1364	European Union's 'Seventh Framework' Programme (FP7) [602130]; Science Foundation Ireland (SFI)Science Foundation Ireland [SFI/13/IA/1891, SFI/14/ADV/RC2721, 13/SIRG/2114, SFI/12/COEN/18, SFI/12/RC/2272]; Detlev-Wrobel-Fonds for Epilepsy Research Frankfurt; Iraqi Ministry of Higher Education and Scientific Research	We thank all the members of the EpimiRNA consortium. We also thank Petra M~ller, Dr. Susanne Knake, Dr. Ilka Immisch and the teams from the epilepsy monitoring unit and neurological intensive care unit for their support in sample acquisition. Also, we thank Kerstin Kaiser and Jeanette Witzke for technical assistance with neurochemistry aspects. This publication has emanated from research conducted with the financial support of the European Union's 'Seventh Framework' Programme (FP7) under Grant Agreement no. 602130. Additional funding was from Science Foundation Ireland (SFI) under grants SFI/13/IA/1891, SFI/14/ADV/RC2721, 13/SIRG/2114, SFI/12/COEN/18 and SFI/12/RC/2272, the Detlev-Wrobel-Fonds for Epilepsy Research Frankfurt and a fellowship from the Iraqi Ministry of Higher Education and Scientific Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlbrecht J, 2016, MULT SCLER J, V22, P1202, DOI 10.1177/1352458515613641; Aronica E, 2003, NEUROSCIENCE, V118, P417, DOI 10.1016/S0306-4522(02)00992-2; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Azzouzi I, 2015, EXP HEMATOL, V43, P382, DOI 10.1016/j.exphem.2015.01.007; Baraniskin A, 2011, BLOOD, V117, P3140, DOI 10.1182/blood-2010-09-308684; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bauer G, 2010, EPILEPSIA, V51, P177, DOI 10.1111/j.1528-1167.2009.02297.x; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bleazard T, 2015, BIOINFORMATICS, V31, P1592, DOI 10.1093/bioinformatics/btv023; Bot AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076051; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; Burgos KL, 2013, RNA, V19, P712, DOI 10.1261/rna.036863.112; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Chang BS, 2003, NEW ENGL J MED, V349, P1257, DOI 10.1056/NEJMra022308; Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282; Cheng HH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064795; Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258; Czech B, 2011, NAT REV GENET, V12, P19, DOI 10.1038/nrg2916; Dvinge H, 2009, BIOINFORMATICS, V25, P3325, DOI 10.1093/bioinformatics/btp578; Engel T, 2007, EPILEPSY RES, V77, P151, DOI 10.1016/j.eplepsyres.2007.09.001; Freischmidt A, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-42; Fromm B, 2015, ANNU REV GENET, V49, P213, DOI 10.1146/annurev-genet-120213-092023; Gallego JA, 2012, J MOL NEUROSCI, V47, P243, DOI 10.1007/s12031-012-9731-7; Gallo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030679; Godard P, 2015, NUCLEIC ACIDS RES, V43, P3490, DOI 10.1093/nar/gkv249; Gorter JA, 2014, NEUROBIOL DIS, V62, P508, DOI 10.1016/j.nbd.2013.10.026; Gross C, 2016, CELL REP, V17, P37, DOI 10.1016/j.celrep.2016.08.074; Haghikia A, 2012, NEUROLOGY, V79, P2166, DOI 10.1212/WNL.0b013e3182759621; Hegde M, 2014, BIOMARK MED, V8, P413, DOI [10.2217/BMM.13.142, 10.2217/bmm.13.142]; Henshall DC, 2016, LANCET NEUROL, V15, P1368, DOI 10.1016/S1474-4422(16)30246-0; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Henshall DC, 2001, CELL DEATH DIFFER, V8, P1169, DOI 10.1038/sj.cdd.4400921; Holm A, 2014, J NEUROL SCI, V347, P199, DOI 10.1016/j.jns.2014.09.047; Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]; Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Jeffries CD, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.148; Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834; Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Jovicic A, 2013, J NEUROSCI, V33, P5127, DOI 10.1523/JNEUROSCI.0600-12.2013; Kaalund SS, 2014, EPILEPSIA, V55, P2017, DOI 10.1111/epi.12839; Kan AA, 2012, CELL MOL LIFE SCI, V69, P3127, DOI 10.1007/s00018-012-0992-7; Kirschner MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024145; Knake S, 2001, EPILEPSIA, V42, P714, DOI 10.1046/j.1528-1157.2001.01101.x; Kretschmann A, 2015, J MOL NEUROSCI, V55, P466, DOI 10.1007/s12031-014-0368-6; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lee ST, 2016, MOL NEUROBIOL; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu CG, 2014, INT J MOL MED, V34, P160, DOI 10.3892/ijmm.2014.1780; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lobb RJ, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27031; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; McCall MN, 2014, BIOINFORMATICS, V30, P2310, DOI 10.1093/bioinformatics/btu239; McClelland S, 2014, ELIFE, V3, DOI 10.7554/eLife.01267; Meierkord H, 2007, LANCET NEUROL, V6, P329, DOI 10.1016/S1474-4422(07)70074-1; Mestdagh P, 2014, NAT METHODS, V11, P809, DOI [10.1038/nmeth.3014, 10.1038/NMETH.3014]; Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194; Miller-Delaney SFC, 2015, BRAIN, V138, P616, DOI 10.1093/brain/awu373; Mishra MK, 2016, NAT REV NEUROL, V12, P539, DOI 10.1038/nrneurol.2016.110; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mooney C, 2016, BIOINFORMATICS, V32, P1436, DOI 10.1093/bioinformatics/btw008; Mooney C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145316; Muller M, 2014, NEUROBIOL AGING, V35, P152, DOI 10.1016/j.neurobiolaging.2013.07.005; Peng J, 2013, J MOL NEUROSCI, V50, P291, DOI 10.1007/s12031-013-9953-3; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Petkar S, 2012, EUROPACE, V14, P1653, DOI 10.1093/europace/eus185; Pitkanen A, 2016, LANCET NEUROL, V15, P843, DOI 10.1016/S1474-4422(16)00112-5; Pitkanen A, 2016, LANCET NEUROL, V15, P185, DOI 10.1016/S1474-4422(15)00248-3; Pitkanen A, 2011, BIOMARK MED, V5, P629, DOI [10.2217/bmm.11.67, 10.2217/BMM.11.67]; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Prehn J. H., 2016, BIOINFORMATICS; Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198; Qureshi IA, 2012, NAT REV NEUROSCI, V13, P528, DOI 10.1038/nrn3234; Risbud RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053464; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77; Roncon P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14143; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shavit L, 2012, EUR J INTERN MED, V23, P701, DOI 10.1016/j.ejim.2012.06.015; Shinoda S, 2004, J CLIN INVEST, V113, P1059, DOI 10.1172/JCI200419971; Sorensen SS, 2016, TRANSL NEURODEGENER, V5, DOI 10.1186/s40035-016-0053-5; Spain E, 2015, RSC ADV, V5, P90071, DOI 10.1039/c5ra16352h; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Tan NCK, 2010, EPILEPSIA, V51, P686, DOI 10.1111/j.1528-1167.2009.02423.x; Team RCR, 2016, LANG ENV STAT COMP; Teplyuk NM, 2012, NEURO-ONCOLOGY, V14, P689, DOI 10.1093/neuonc/nos074; Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Donselaar CA, 2006, EPILEPSIA, V47, P9, DOI 10.1111/j.1528-1167.2006.00653.x; Wang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10201; Wang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep09522; Zaidi A, 2000, J AM COLL CARDIOL, V36, P181, DOI 10.1016/S0735-1097(00)00700-2	97	46	47	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 12	2017	7								3328	10.1038/s41598-017-02969-6			17	Multidisciplinary Sciences	Science & Technology - Other Topics	EX2UJ	WOS:000403082700013	28607431	DOAJ Gold, Green Published			2021-06-18	
J	Cox, CS; Hetz, RA; Liao, GP; Aertker, BM; Ewing-Cobbs, L; Juranek, J; Savitz, SI; Jackson, ML; Romanowska-Pawliczek, AM; Triolo, F; Dash, PK; Pedroza, C; Lee, DA; Worth, L; Aisiku, IP; Choi, HA; Holcomb, JB; Kitagawa, RS				Cox, Charles S., Jr.; Hetz, Robert A.; Liao, George P.; Aertker, Benjamin M.; Ewing-Cobbs, Linda; Juranek, Jenifer; Savitz, Sean I.; Jackson, Margaret L.; Romanowska-Pawliczek, Anna M.; Triolo, Fabio; Dash, Pramod K.; Pedroza, Claudia; Lee, Dean A.; Worth, Laura; Aisiku, Imoigele P.; Choi, Huimahn A.; Holcomb, John B.; Kitagawa, Ryan S.			Treatment of Severe Adult Traumatic Brain Injury Using Bone Marrow Mononuclear Cells	STEM CELLS			English	Article						traumatic brain injury; bone marrow stromal cells; cellular therapy; clinical trials; diffusion tensor imaging; adult stem cells; adult human bone marrow	MESENCHYMAL STEM-CELLS; STROMAL CELLS; TRANSPLANTATION; RATS; MICE; DEFINITION; ISCHEMIA; DELIVERY; MODERATE; THERAPY	Preclinical studies using bone marrow derived cells to treat traumatic brain injury have demonstrated efficacy in terms of blood-brain barrier preservation, neurogenesis, and functional outcomes. Phase 1 clinical trials using bone marrow mononuclear cells infused intravenously in children with severe traumatic brain injury demonstrated safety and potentially a central nervous system structural preservation treatment effect. This study sought to confirm the safety, logistic feasibility, and potential treatment effect size of structural preservation/inflammatory biomarker mitigation in adults to guide Phase 2 clinical trial design. Adults with severe traumatic brain injury (Glasgow Coma Scale 5-8) and without signs of irreversible brain injury were evaluated for entry into the trial. A dose escalation format was performed in 25 patients: 5 controls, followed 5 patients in each dosing cohort ( 6, 9, 12 310 6 cells/kgbody weight), then 5 more controls. Bone marrow harvest, cell processing to isolate the mononuclear fraction, and re-infusion occurred within 48 hours after injury. Patients were monitored for harvest-related hemodynamic changes, infusional toxicity, and adverse events. Outcome measures included magnetic resonance imaging-based measurements of supratentorial and corpus callosal volumes as well as diffusion tensor imaging-based measurements of fractional anisotropy and mean diffusivity of the corpus callosum and the corticospinal tract at the level of the brainstem at 1 month and 6 months postinjury. Functional and neurocognitive outcomes were measured and correlated with imaging data. Inflammatory cytokine arrays were measured in the plasma pretreatment, posttreatment, and at 1 and 6 month follow-up. There were no serious adverse events. There was a mild pulmonary toxicity of the highest dose that was not clinically significant. Despite the treatment group having greater injury severity, there was structural preservation of critical regions of interest that correlated with functional outcomes. Key inflammatory cytokines were downregulated. Treatment of severe, adult traumatic brain injury using an intravenously delivered autologous bone marrow mononuclear cell infusion is safe and logistically feasible. There appears to be a treatment signal as evidenced by central nervous system structural preservation, consistent with previous pediatric trial data. Inflammatory biomarkers are downregulated after cell infusion.	[Cox, Charles S., Jr.; Jackson, Margaret L.; Triolo, Fabio] Univ Texas Houston, McGovern Med Sch, Dept Pediat Surg, Houston, TX USA; [Hetz, Robert A.; Liao, George P.; Holcomb, John B.] Univ Texas Houston, McGovern Med Sch, Dept Surg, Houston, TX USA; [Aertker, Benjamin M.; Choi, Huimahn A.] Univ Texas Houston, McGovern Med Sch, Dept Neurol, Houston, TX USA; [Ewing-Cobbs, Linda; Juranek, Jenifer; Romanowska-Pawliczek, Anna M.] Univ Texas Houston, McGovern Med Sch, Dept Pediat, Houston, TX USA; [Ewing-Cobbs, Linda] Univ Texas Houston, McGovern Med Sch, Dept Psychiat & Behav Sci, Houston, TX USA; [Dash, Pramod K.] Univ Texas Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA; [Pedroza, Claudia] Univ Texas Houston, McGovern Med Sch, Ctr Clin Res & Evidence Based Med, Houston, TX USA; [Choi, Huimahn A.; Kitagawa, Ryan S.] Univ Texas Houston, McGovern Med Sch, Dept Neurosurg, Houston, TX USA; [Lee, Dean A.] Nationwide Childrens, Dept Hematol & Oncol, Columbus, OH USA; [Worth, Laura] MD Anderson Canc Ctr, Dept Pediat, Houston, TX USA; [Aisiku, Imoigele P.] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA	Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat Surg, 6431 Fannin St,MSB 5-234, Houston, TX 77030 USA.	Charles.S.Cox@uth.tmc.edu		holcomb, john/0000-0001-8312-9157; Pedroza, Claudia/0000-0003-4235-1282	DODUnited States Department of Defense [W81XWH-11-10460]; NIH 2T32United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM 0879201-11]; Glassell fundation Stem Cell Research Program; Brown Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	Research Coordinators: Steven Kosmach, RN, MSN., MaryClare Day, RN, BSN; Fernando Jimenez, RN, MS. Cell Processing Team: Andrew Havens, Sufira Kiran, James Roye, Philippa Smith, Suchit Sahai, Ph. D., Marysuna Wilkerson. Technical Support: Anthony Moore10. All Cellular Processing was performed at UTHealth-Medical School, The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory, FDA Establishment Identifier 3009561521. Funding Sources: DOD Grant: W81XWH-11-10460 (Cox, PI); NIH 2T32 GM 0879201-11 (Holcomb,PI); Glassell fundation Stem Cell Research Program (Cox, PI). Brown Foundation (Cox, PI).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Anbari F, 2014, NEURAL REGEN RES, V9, P919, DOI 10.4103/1673-5374.133133; Antonelli M, 1999, INTENS CARE MED, V25, P389, DOI 10.1007/s001340050863; Arien-Zakay H, 2014, J NEUROTRAUM, V31, P1405, DOI 10.1089/neu.2013.3270; Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bedi SS, 2013, J TRAUMA ACUTE CARE, V75, P410, DOI 10.1097/TA.0b013e31829617c6; Brenneman M, 2010, J CEREBR BLOOD F MET, V30, P140, DOI 10.1038/jcbfm.2009.198; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Cotton BA, 2012, J TRAUMA ACUTE CARE, V72, P1470, DOI 10.1097/TA.0b013e31824d56ad; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Francois M, 2012, CYTOTHERAPY, V14, P147, DOI 10.3109/14653249.2011.623691; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Jiang JD, 2012, NEURAL REGEN RES, V7, P46, DOI 10.3969/j.issn.1673-5374.2012.01.008; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Li LA, 2011, J NEUROTRAUM, V28, P535, DOI 10.1089/neu.2010.1619; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P3; Moll G, 2012, STEM CELLS, V30, P1565, DOI 10.1002/stem.1111; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Osanai T, 2012, NEUROSURGERY, V70, P435, DOI 10.1227/NEU.0b013e318230a795; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Salamon N, 2005, NEURORADIOLOGY, V47, P895, DOI 10.1007/s00234-005-1439-8; Sanberg PR, 2010, J CELL MOL MED, V14, P553, DOI 10.1111/j.1582-4934.2009.00903.x; Savitz SI, 2016, STEM CELLS, V34, P537, DOI 10.1002/stem.2253; Savitz SI, 2011, ANN NEUROL, V70, P59, DOI 10.1002/ana.22458; Sharma S, 2010, J NEUROSCI RES, V88, P2869, DOI 10.1002/jnr.22452; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Suda S, 2015, STEM CELLS DEV, V24, P2756, DOI 10.1089/scd.2015.0107; TEASDALE G, 1974, LANCET, V2, P81; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Turtzo LC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126551; Vahidy FS, 2016, STROKE, V47, P1632, DOI 10.1161/STROKEAHA.116.012701; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yang B, 2011, J NEUROSCI RES, V89, P833, DOI 10.1002/jnr.22614; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	49	46	46	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	APR	2017	35	4					1065	1079		10.1002/stem.2538			15	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	EQ5DM	WOS:000398102000020	27800660	Green Accepted, Bronze			2021-06-18	
J	Kerr, ZY; Roos, KG; Djoko, A; Dalton, SL; Broglio, SP; Marshall, SW; Dompier, TP				Kerr, Zachary Y.; Roos, Karen G.; Djoko, Aristarque; Dalton, Sara L.; Broglio, Steven P.; Marshall, Stephen W.; Dompier, Thomas P.			Epidemiologic Measures for Quantifying the Incidence of Concussion in National Collegiate Athletic Association Sports	JOURNAL OF ATHLETIC TRAINING			English	Article						traumatic brain injury; collegiate sports; risk	INJURY SURVEILLANCE SYSTEM; STATES HIGH-SCHOOL; LEAGUE; RATES	Context: Injury rates compare the relative frequency of sport-related concussions across groups. However, they may not be intuitive to policy makers, parents, or coaches in understanding the likelihood of concussion. Objective: To describe 4 measures of incidence (athlete-based rate, athlete-based risk, team-based rate, and team-based risk) during the 2011-2012 through 2014-2015 academic years. Design: Descriptive epidemiology study. Setting: Aggregate injury and exposure data collected from the National Collegiate Athletic Association Injury Surveillance Program in 13 sports (men's baseball, basketball, football, ice hockey, lacrosse, soccer, and wrestling and women's basketball, ice hockey, lacrosse, soccer, softball, and volleyball). Patients or Other Participants: Collegiate student-athletes. Main Outcome Measure(s): Sport-related concussion data from the National Collegiate Athletic Association Injury Surveillance Program during the 2011-2012 through 2014-2015 academic years were analyzed. We calculated concussion rates per 1000 athlete-exposures (AEs), concussion risk, average number of concussions per team, and percentage of teams with at least 1 concussion. Results: During the 2011-2012 through 2014-2015 academic years, 1485 concussions were sustained by 1410 student-athletes across 13 sports. Concussion rates ranged from 0.09/1000 AEs in men's baseball to 0.89/1000 AEs in men's wrestling. Concussion risk ranged from 0.74% in men's baseball to 7.92% in men's wrestling. The average +/- SD number of concussions per team ranged from 0.25 +/- 6 0.43 in men's baseball to 5.63 +/- 6 5.36 in men's football. The percentage of teams with a concussion ranged from 24.5% in men's baseball to 80.6% in men's football. Conclusions: Although men's wrestling had a higher concussion rate and risk, men's football had the largest average number of concussions per team and the largest percentage of teams with at least 1 concussion. The risk of concussion, average number of concussions per team, and percentage of teams with concussions may be more intuitive measures of incidence for decision makers. Calculating these additional measures is feasible within existing injury surveillance programs, and this method can be applied to other injury types.	[Kerr, Zachary Y.; Roos, Karen G.; Djoko, Aristarque; Dalton, Sara L.; Dompier, Thomas P.] Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Marshall, Stephen W.] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org		Kerr, Zachary/0000-0003-1423-1259	NCAA	The National Collegiate Athletic Association (NCAA) Injury Surveillance Program (ISP) data were provided by the Datalys Center for Sports Injury Research and Prevention, Inc. The ISP was funded by the NCAA. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NCAA. We thank the many athletic trainers who have volunteered their time and efforts to submit data to the NCAA-ISP. Their efforts are greatly appreciated and have had a tremendously positive effect on the safety of collegiate athletes.	Agel J, 2007, J ATHL TRAINING, V42, P249; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Beachy G, 2014, J ATHL TRAINING, V49, P493, DOI 10.4085/1062-6050-49.2.19; Berry JW, 2013, RES SPORTS MED, V21, P159, DOI 10.1080/15438627.2012.757229; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2003, J ATHL TRAINING, V38, P238; Dompier TP, 2015, J ATHL TRAINING, V50, P862, DOI 10.4085/1062-6050-50.5.04; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Epstein DM, 2013, AM J SPORT MED, V41, P343, DOI 10.1177/0363546512467612; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall Stephen W, 2015, Inj Epidemiol, V2, P13; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; National Collegiate Athletic Association, FOOTB PRACT GUID; National Collegiate Athletic Association, STUD ATHL PART 1981; Stephensen S, 1996, BRIT J SPORT MED, V30, P331, DOI 10.1136/bjsm.30.4.331; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	25	46	46	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2017	52	3					167	174		10.4085/1062-6050-51.6.05			8	Sport Sciences	Sport Sciences	ES0NE	WOS:000399222500003	27331336	Green Published, Bronze			2021-06-18	
J	Mason, S				Mason, Shayne			Lactate Shuttles in Neuroenergetics - Homeostasis, Allostasis and Beyond	FRONTIERS IN NEUROSCIENCE			English	Article						neuroenergetics; lactate; astrocyte-neuron lactate shuttle (ANLS); astrocyte-microglia lactate shuttle (AMLS); neuropathology; traumatic brain injury (TBI); neurodegenerative disease; infectious neuroinflammatory disease	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; HUMAN VISUAL-CORTEX; CEREBROSPINAL-FLUID; ENERGY-METABOLISM; IN-VIVO; AXONAL DEGENERATION; SYNAPTIC ACTIVITY; OXIDATIVE STRESS; LACTIC-ACID	Understanding brain energy metabolism neuroenergetics is becoming increasingly important as it can be identified repeatedly as the source of neurological perturbations. Within the scientific community we are seeing a shift in paradigms from the traditional neurocentric view to that of a more dynamic, integrated one where astrocytes are no longer considered as being just supportive, and activated microglia have a profound influence. Lactate is emerging as the "good guy," contrasting its classical "bad guy" position in the now superseded medical literature. This review begins with the evolution of the concept of "lactate shuttles"; goes on to the recent shift in ideas regarding normal neuroenergetics (homeostasis) specifically, the astrocytc-neuron lactate shuttle; and progresses to covering the metabolic implications whereby homeostasis is lost a state of allostasis, and the function of microglia. The role of lactate, as a substrate and shuttle, is reviewed in light of allostatic stress, and beyond in an acute state of allostatic stress in terms of physical brain trauma, and reflected upon with respect to persistent stress as allostatic overload-neurodegenerative diseases. Finally, the recently proposed astrocyte-microglia lactate shuttle is discussed in terms of chronic neuroinflammatory infectious diseases, using tuberculous meningitis as an example. The novelty extended by this review is that the directionality of lactate, as shuttles in the brain, in neuropathophysiological states is emerging as crucial in neuroenergetics.	[Mason, Shayne] North West Univ, Ctr Human Metab, Potchefstroom, South Africa	Mason, S (corresponding author), North West Univ, Ctr Human Metab, Potchefstroom, South Africa.	nmr.nwu@gmail.com		Mason, Shayne/0000-0002-2945-5768	Technological Innovation Agency (TIA) of the Department of Science and Technology of South Africa	Research funding was provided by the Technological Innovation Agency (TIA) of the Department of Science and Technology of South Africa. Opinions expressed and conclusions arrived at, are those of the author and are not necessarily to be attributed to the funding body TIA.	Albanese M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0502-1; Angamo EA, 2016, J NEUROPHYSIOL, V116, P2420, DOI 10.1152/jn.00327.2016; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Aubert A, 2005, P NATL ACAD SCI USA, V102, P16448, DOI 10.1073/pnas.0505427102; Aubert A, 2005, J CEREBR BLOOD F MET, V25, P1476, DOI 10.1038/sj.jcbfm.9600144; Aubert A, 2007, P NATL ACAD SCI USA, V104, P4188, DOI 10.1073/pnas.0605864104; Bak LK, 2006, J CEREBR BLOOD F MET, V26, P1285, DOI 10.1038/sj.jcbfm.9600281; Baltan S, 2015, METAB BRAIN DIS, V30, P25, DOI 10.1007/s11011-014-9595-3; Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bender AS, 1997, BRAIN RES, V750, P59, DOI 10.1016/S0006-8993(96)01331-5; Bergersen LH, 2007, NEUROSCIENCE, V145, P11, DOI 10.1016/j.neuroscience.2006.11.062; Berthet C, 2012, CEREBROVASC DIS, V34, P329, DOI 10.1159/000343657; Berthet C, 2009, J CEREBR BLOOD F MET, V29, P1780, DOI 10.1038/jcbfm.2009.97; Bittar PG, 1996, J CEREBR BLOOD F MET, V16, P1079, DOI 10.1097/00004647-199611000-00001; Blair C, 2011, DEV PSYCHOPATHOL, V23, P845, DOI 10.1017/S0954579411000344; Bliss TM, 2004, J NEUROSCI, V24, P6202, DOI 10.1523/JNEUROSCI.0805-04.2004; Boumezbeur F, 2010, J NEUROSCI, V30, P13983, DOI 10.1523/JNEUROSCI.2040-10.2010; Bourgeois NMA, 2016, ENDOCRINOLOGY, V157, P2560, DOI 10.1210/en.2015-2025; Bouzat P, 2014, CURR OPIN CRIT CARE, V20, P133, DOI 10.1097/MCC.0000000000000072; Bouzier-Sore AK, 2003, BIOCHIMIE, V85, P841, DOI 10.1016/j.biochi.2003.08.003; Bouzier-Sore AK, 2002, J PHYSIOL-PARIS, V96, P273, DOI 10.1016/S0928-4257(02)00016-5; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; Brooks G. A., 1985, CIRCULATION RESPIRAT, P208, DOI DOI 10.1007/978-3-642-70610-3_15; BROOKS GA, 1986, MED SCI SPORT EXER, V18, P360, DOI 10.1249/00005768-198606000-00019; BROOKS GA, 1986, FASEB J, V45, P2924; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/bst0300258; Brooks GA, 2000, MED SCI SPORT EXER, V32, P790, DOI 10.1097/00005768-200004000-00011; Brooks GA, 2015, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00408; Brooks GA, 2009, J PHYSIOL-LONDON, V587, P5591, DOI 10.1113/jphysiol.2009.178350; Cambron M, 2012, J CEREBR BLOOD F MET, V32, P413, DOI 10.1038/jcbfm.2011.193; Campbell GR, 2014, MULT SCLER J, V20, P1806, DOI 10.1177/1352458514544537; Capuani F, 2015, SCI REP-UK, V5, DOI 10.1038/srep11880; Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112; Carpenter KLH, 2014, EUR J PHARM SCI, V57, P87, DOI 10.1016/j.ejps.2013.12.012; Cater HL, 2003, J NEUROCHEM, V87, P1381, DOI 10.1046/j.1471-4159.2003.02100.x; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Chaumeil MM, 2016, NEUROIMAGE-CLIN, V12, P180, DOI 10.1016/j.nicl.2016.06.018; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; Chiry O, 2008, BRAIN RES, V1226, P61, DOI 10.1016/j.brainres.2008.06.025; Covarrubias-Pinto A, 2015, FREE RADICAL BIO MED, V89, P1085, DOI 10.1016/j.freeradbiomed.2015.09.024; Danese A, 2012, PHYSIOL BEHAV, V106, P29, DOI 10.1016/j.physbeh.2011.08.019; Cruz RSD, 2012, SCI WORLD J, DOI 10.1100/2012/420984; Debernardi R, 1999, BRAIN RES, V850, P39, DOI 10.1016/S0006-8993(99)02022-3; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; Dienel GA, 2004, NEUROCHEM INT, V45, P321, DOI 10.1016/j.neuint.2003.10.011; Dienel GA, 2003, NEUROCHEM INT, V43, P339, DOI 10.1016/S0197-0186(03)00021-4; Dienel GA, 2001, J NEUROSCI RES, V66, P824, DOI 10.1002/jnr.10079; Dienel GA, 2015, METAB BRAIN DIS, V30, P281, DOI 10.1007/s11011-014-9493-8; Dienel GA, 2014, J CEREBR BLOOD F MET, V34, P1736, DOI 10.1038/jcbfm.2014.153; DiNuzzo M, 2010, J CEREBR BLOOD F MET, V30, P1895, DOI 10.1038/jcbfm.2010.151; DiNuzzo M, 2010, J CEREBR BLOOD F MET, V30, P586, DOI 10.1038/jcbfm.2009.232; Draoui N, 2011, DIS MODEL MECH, V4, P727, DOI 10.1242/dmm.007724; Dutta R, 2006, ANN NEUROL, V59, P478, DOI 10.1002/ana.20736; Eder C, 1998, AM J PHYSIOL-CELL PH, V275, pC327; Erlichman JS, 2008, J NEUROSCI, V28, P4888, DOI 10.1523/JNEUROSCI.5430-07.2008; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Finsterwald C, 2015, CURR PHARM DESIGN, V21, P3570, DOI 10.2174/1381612821666150710144502; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Garseth M, 2000, J NEUROSCI RES, V60, P779, DOI 10.1002/1097-4547(20000615)60:6<779::AID-JNR10>3.0.CO;2-M; Genc S, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-162; Giaume C, 2007, CELL DEATH DIFFER, V14, P1324, DOI 10.1038/sj.cdd.4402144; Giaume C, 2010, NAT REV NEUROSCI, V11, P87, DOI 10.1038/nrn2757; Gjedde A, 2002, J CEREBR BLOOD F MET, V22, P1, DOI 10.1097/00004647-200201000-00001; Gjedde A, 2001, J CEREBR BLOOD F MET, V21, P1384, DOI 10.1097/00004647-200112000-00002; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; Glenn TC, 2015, J NEUROTRAUM, V32, P820, DOI 10.1089/neu.2014.3483; Glenn TC, 2015, J NEUROTRAUM, V32, P811, DOI 10.1089/neu.2014.3482; Gordon GRJ, 2008, NATURE, V456, P745, DOI 10.1038/nature07525; Gouarne C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081528; Guzman M, 2001, TRENDS ENDOCRIN MET, V12, P169, DOI 10.1016/S1043-2760(00)00370-2; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Hashimoto T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002915; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.3.CO;2-E; Itoh Y, 2003, P NATL ACAD SCI USA, V100, P4879, DOI 10.1073/pnas.0831078100; Jolivet R, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004036; Jolivet R, 2010, J CEREBR BLOOD F MET, V30, P1982, DOI 10.1038/jcbfm.2010.132; JUEPTNER M, 1995, NEUROIMAGE, V2, P148, DOI 10.1006/nimg.1995.1017; Karagiannis A, 2016, J CEREBR BLOOD F MET, V36, P1202, DOI 10.1177/0271678X15611912; KIMELBERG HK, 1989, SCI AM, V260, P66, DOI 10.1038/scientificamerican0489-66; Kolko M, 2016, NEUROCHEM RES, V41, P1229, DOI 10.1007/s11064-015-1792-x; Korogod N, 2015, ELIFE, V4, DOI 10.7554/eLife.05793; Kuchiiwa T, 2011, HISTOCHEM CELL BIOL, V135, P351, DOI 10.1007/s00418-011-0794-2; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P130, DOI 10.1038/jcbfm.1988.17; Laskas J. M., 2009, GAME BRAIN GENTLEMEN; Laskas J. M., 2015, CONCUSSION; Laughton JD, 2000, NEUROSCIENCE, V96, P619, DOI 10.1016/S0306-4522(99)00580-1; Laureys G, 2014, NEUROSCIENCE, V277, P367, DOI 10.1016/j.neuroscience.2014.07.022; Lee NY, 2016, PHARM RES-DORDR, V33, P1711, DOI 10.1007/s11095-016-1912-6; Leen WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042745; Li CY, 2011, CURR ALZHEIMER RES, V8, P67; Logan JG, 2008, J CLIN NURS, V17, P201, DOI 10.1111/j.1365-2702.2008.02347.x; Lutz NW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000595; Magistretti PJ, 2009, AM J CLIN NUTR, V90, p875S, DOI 10.3945/ajcn.2009.27462CC; Magistretti PJ, 2006, J EXP BIOL, V209, P2304, DOI 10.1242/jeb.02208; Magistretti PJ, 1996, CEREB CORTEX, V6, P50, DOI 10.1093/cercor/6.1.50; Magistretti PJ, 2000, BRAIN RES, V886, P108, DOI 10.1016/S0006-8993(00)02945-0; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; Mangia S, 2003, NEUROSCIENCE, V118, P7, DOI 10.1016/S0306-4522(02)00792-3; Mangia S, 2003, J NEUROSCI RES, V71, P463, DOI 10.1002/jnr.10531; Mangia S, 2009, J NEUROCHEM, V109, P55, DOI 10.1111/j.1471-4159.2009.06003.x; Mason S, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1053-2; Mason S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1597-9; Mason S, 2015, METABOLOMICS, V11, P822, DOI 10.1007/s11306-014-0741-z; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; McEwen BS, 2006, METABOLISM, V55, pS20, DOI 10.1016/j.metabol.2006.07.008; McEwen BS, 2011, ANNU REV MED, V62, P431, DOI 10.1146/annurev-med-052209-100430; McKenna MC, 2006, BIOCHEM PHARMACOL, V71, P399, DOI 10.1016/j.bcp.2005.10.011; Moffett John R, 2013, Front Neuroenergetics, V5, P11, DOI 10.3389/fnene.2013.00011; Moro N, 2013, BRAIN RES, V1535, P124, DOI 10.1016/j.brainres.2013.08.044; Newington Jordan T, 2013, J Neurodegener Dis, V2013, P234572, DOI 10.1155/2013/234572; Nijland PG, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0261-8; NORENBERG MD, 1987, J NEUROPATH EXP NEUR, V46, P154, DOI 10.1097/00005072-198703000-00004; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Olson JK, 2001, J VIROL, V75, P9780, DOI 10.1128/JVI.75.20.9780-9789.2001; Oresic M, 2008, TRENDS BIOTECHNOL, V26, P647, DOI 10.1016/j.tibtech.2008.09.001; Ovanesov MV, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-50; Patet C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0638-5; Pavlides S, 2010, AGING-US, V2, P185, DOI 10.18632/aging.100134; Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238; Pellerin L, 2004, NEUROSCIENTIST, V10, P53, DOI 10.1177/1073858403260159; Pellerin L, 2010, DIABETES METAB, V36, pS59, DOI 10.1016/S1262-3636(10)70469-9; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; Pellerin L, 2002, INT CONGR SER, V1235, P189, DOI 10.1016/S0531-5131(02)00186-3; Pellerin L, 2007, GLIA, V55, P1251, DOI 10.1002/glia.20528; Pellerin L, 2012, J CEREBR BLOOD F MET, V32, P1152, DOI 10.1038/jcbfm.2011.149; Perez-Escuredo J, 2016, BBA-MOL CELL RES, V1863, P2481, DOI 10.1016/j.bbamcr.2016.03.013; Pertega-Gomes N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-352; Peters A, 2015, NEUROSCI BIOBEHAV R, V56, P139, DOI 10.1016/j.neubiorev.2015.07.001; Pierre K, 2000, NEUROSCIENCE, V100, P617, DOI 10.1016/S0306-4522(00)00294-3; Pizzuto R, 2012, BBA-BIOENERGETICS, V1817, P1679, DOI 10.1016/j.bbabio.2012.05.010; Porras OH, 2004, J NEUROSCI, V24, P9669, DOI 10.1523/JNEUROSCI.1882-04.2004; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; Psychogios N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016957; Raghavendra V, 2003, J PHARMACOL EXP THER, V306, P624, DOI 10.1124/jpet.103.052407; Rake AJ, 2010, PEDIATR CRIT CARE ME, V11, P707, DOI 10.1097/PCC.0b013e3181e88b1f; Rakus D, 2016, J PROTEOME RES, V15, P2479, DOI 10.1021/acs.jproteome.5b01149; Ramautar R, 2013, CURR OPIN CHEM BIOL, V17, P841, DOI 10.1016/j.cbpa.2013.06.015; Ranjbar M, 2017, NEURAL COMPUT APPL, V28, P1109, DOI 10.1007/s00521-015-2112-8; Regenold WT, 2008, J NEUROL SCI, V275, P106, DOI 10.1016/j.jns.2008.07.032; Robinet C, 2011, NEUROSCIENCE, V192, P155, DOI 10.1016/j.neuroscience.2011.06.059; Rock RB, 2004, CLIN MICROBIOL REV, V17, P942, DOI 10.1128/CMR.17.4.942-964.2004; Rosafio K, 2016, NEUROSCIENCE, V317, P108, DOI 10.1016/j.neuroscience.2015.12.052; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Rothman DL, 2003, ANNU REV PHYSIOL, V65, P401, DOI 10.1146/annurev.physiol.65.092101.142131; Rouach N, 2008, SCIENCE, V322, P1551, DOI 10.1126/science.1164022; Sack GH, 2010, J BIOENERG BIOMEMBR, V42, P189, DOI 10.1007/s10863-010-9291-x; Sahlin K, 2002, J PHYSIOL-LONDON, V541, P569, DOI 10.1113/jphysiol.2002.016683; Sampol Denys, 2013, Front Neuroenergetics, V5, P5, DOI 10.3389/fnene.2013.00005; Sanita P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-154; SAPPEYMARINIER D, 1992, J CEREBR BLOOD F MET, V12, P584, DOI 10.1038/jcbfm.1992.82; Sawada Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep27758; Schurr A, 1997, BRAIN RES, V774, P221, DOI 10.1016/S0006-8993(97)81708-8; Schurr A, 1999, ANN NY ACAD SCI, V893, P386, DOI 10.1111/j.1749-6632.1999.tb07862.x; Schurr A, 2006, J CEREBR BLOOD F MET, V26, P142, DOI 10.1038/sj.jcbfm.9600174; Schurr A, 1999, J NEUROSCI, V19, P34; Schurr A, 1997, BRAIN RES, V744, P105, DOI 10.1016/S0006-8993(96)01106-7; Schurr A, 1997, J NEUROCHEM, V69, P423; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; Shannon M, 2007, JOGNN-J OBST GYN NEO, V36, P125, DOI 10.1111/J.1552-6909.2007.00126.x; Shulman RG, 2004, TRENDS NEUROSCI, V27, P489, DOI 10.1016/j.tins.2004.06.005; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Smith D, 2003, J CEREBR BLOOD F MET, V23, P658, DOI 10.1097/01.WCB.0000063991.19746.11; Sokoloff L, 1989, BASIC NEUROCHEMISTRY, V2, P338; Somashekar BS, 2011, J PROTEOME RES, V10, P4186, DOI 10.1021/pr2003352; Sone JY, 2017, J NEUROSURG, V126, P768, DOI 10.3171/2016.2.JNS151972; Steele ML, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.09.018; Sterling P, 1988, HDB LIFE STRESS COGN, P629; Stewart James A, 2006, J Physiol Anthropol, V25, P133, DOI 10.2114/jpa2.25.133; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Stumvoll M, 2004, REV ENDOCR METAB DIS, V5, P99, DOI 10.1023/B:REMD.0000021430.56457.2c; Stumvoll M, 2003, DIABETES, V52, P903, DOI 10.2337/diabetes.52.4.903; Sussman ES, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15610; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Tabernero A, 1996, NEUROSCI RES, V26, P369, DOI 10.1016/S0168-0102(96)01121-2; Taher M, 2016, EUR J PAEDIATR NEURO, V20, P3, DOI 10.1016/j.ejpn.2015.09.008; Tannenbaum B, 2002, BRAIN RES, V953, P82, DOI 10.1016/S0006-8993(02)03273-0; Tomiyama AJ, 2012, PHYSIOL BEHAV, V106, P40, DOI 10.1016/j.physbeh.2011.11.016; van Hall G, 2009, J CEREBR BLOOD F MET, V29, P1121, DOI 10.1038/jcbfm.2009.35; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; Verwaest KA, 2011, BBA-MOL BASIS DIS, V1812, P1371, DOI 10.1016/j.bbadis.2011.08.001; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; Wender R, 2000, J NEUROSCI, V20, P6804, DOI 10.1523/JNEUROSCI.20-18-06804.2000; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Wishart DS, 2008, J CHROMATOGR B, V871, P164, DOI 10.1016/j.jchromb.2008.05.001; Wyss MT, 2011, J NEUROSCI, V31, P7477, DOI 10.1523/JNEUROSCI.0415-11.2011; Yamanishi S, 2006, AM J PHYSIOL-HEART C, V290, pH925, DOI 10.1152/ajpheart.01012.2005; Zeis T, 2015, BRAIN BEHAV IMMUN, V48, P313, DOI 10.1016/j.bbi.2015.04.013; Zhou AP, 2015, TUBERCULOSIS, V95, P294, DOI 10.1016/j.tube.2015.02.038; Zuo RJ, 2015, J BIOL CHEM, V290, P21280, DOI 10.1074/jbc.M115.656629; Zwingmann C, 2000, GLIA, V32, P286, DOI 10.1002/1098-1136(200012)32:3<286::AID-GLIA80>3.0.CO;2-P	199	46	48	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	FEB 2	2017	11								43	10.3389/fnins.2017.00043			15	Neurosciences	Neurosciences & Neurology	EJ5CH	WOS:000393233600001	28210209	DOAJ Gold, Green Published			2021-06-18	
J	Dickstein, DL; Pullman, MY; Fernandez, C; Short, JA; Kostakoglu, L; Knesaurek, K; Soleimani, L; Jordan, BD; Gordon, WA; Dams-O'Connor, K; Delman, BN; Wong, E; Tang, CY; DeKosky, ST; Stone, JR; Cantu, RC; Sano, M; Hof, PR; Gandy, S				Dickstein, D. L.; Pullman, M. Y.; Fernandez, C.; Short, J. A.; Kostakoglu, L.; Knesaurek, K.; Soleimani, L.; Jordan, B. D.; Gordon, W. A.; Dams-O'Connor, K.; Delman, B. N.; Wong, E.; Tang, C. Y.; DeKosky, S. T.; Stone, J. R.; Cantu, R. C.; Sano, M.; Hof, P. R.; Gandy, S.			Cerebral [F-18]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy	TRANSLATIONAL PSYCHIATRY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; POSITRON-EMISSION-TOMOGRAPHY; BRAIN-INJURY; ALZHEIMERS-DISEASE; BASAL GANGLIA; BINDING CHARACTERISTICS; BROCAS AREA; PET; FLORBETAPIR; ROBUST	Chronic traumatic encephalopathy (CTE) is a neurodegenerative disorder most commonly associated with repetitive traumatic brain injury (TBI) and characterized by the presence of neurofibrillary tangles of tau protein, known as a tauopathy. Currently, the diagnosis of CTE can only be definitively established postmortem. However, a new positron emission tomography (PET) ligand, [F-18] T807/AV1451, may provide the antemortem detection of tau aggregates, and thus various tauopathies, including CTE. Our goal was to examine [F-18] T807/AV1451 retention in athletes with neuropsychiatric symptoms associated with a history of multiple concussions. Here we report a 39-year-old retired National Football League player who suffered 22 concussions and manifested progressive neuropsychiatric symptoms. Emotional lability and irritability were the chief complaints. Serial neuropsychological exams revealed a decline in executive functioning, processing speed and fine motor skills. Naming was below average but other cognitive functions were preserved. Structural analysis of longitudinally acquired magenetic resonance imaging scans revealed cortical thinning in the left frontal and lateral temporal areas, as well as volume loss in the basal ganglia. PET with [F-18] florbetapir was negative for amyloidosis. The [F-18] T807/AV1451 PET showed multifocal areas of retention at the cortical gray matter-white matter junction, a distribution considered pathognomonic for CTE. [F-18] T807/AV1451 standard uptake value (SUV) analysis showed increased uptake (SUVr >= 1.1) in bilateral cingulate, occipital, and orbitofrontal cortices, and several temporal areas. Although definitive identification of the neuropathological underpinnings basis for [F-18] T807/AV1451 retention requires postmortem correlation, our data suggest that [F-18] T807/AV1451 tauopathy imaging may be a promising tool to detect and diagnose CTE-related tauopathy in living subjects.	[Dickstein, D. L.; Pullman, M. Y.; Hof, P. R.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, One Gustave L Levy Pl, New York, NY 10029 USA; [Dickstein, D. L.; Pullman, M. Y.; Hof, P. R.; Gandy, S.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Fernandez, C.; Short, J. A.; Soleimani, L.; Wong, E.; Tang, C. Y.; Sano, M.; Gandy, S.] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA; [Kostakoglu, L.; Knesaurek, K.] Icahn Sch Med Mt Sinai, Dept Nucl Med, New York, NY 10029 USA; [Jordan, B. D.] Burke Rehabilitaiton Hosp, White Plains, NY USA; [Gordon, W. A.; Dams-O'Connor, K.] Icahn Sch Med Mt Sinai, NFL Neurol Program, New York, NY 10029 USA; [Gordon, W. A.; Dams-O'Connor, K.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Delman, B. N.; Wong, E.; Tang, C. Y.] Icahn Sch Med Mt Sinai, Dept Radiol, New York, NY 10029 USA; [DeKosky, S. T.] Univ Florida, Dept Neurol, Gainesville, FL USA; [Stone, J. R.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA; [Stone, J. R.] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA; [Cantu, R. C.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Cantu, R. C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Gandy, S.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA	Dickstein, DL (corresponding author), Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, One Gustave L Levy Pl, New York, NY 10029 USA.; Gandy, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA.	dickstein@mssm.edu; samuel.gandy@mssm.edu	Dickstein, Dara/AAH-6603-2020	Delman, Bradley/0000-0002-9792-8942; Fernandez, Corey/0000-0003-3901-5552; DeKosky, Steven/0000-0003-3743-2758	Alzheimer's Disease Drug Foundation; NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS 5U01NS086625, NICHD K01HD074651-01A]; Werber Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086625] Funding Source: NIH RePORTER	We extend our gratitude to the patient who consented for this investigation. The ligands for both amyloid and tau were a generous gift from Avid Radiopharmaceutical (Philadelphia, PA, USA). This research was supported by a grant from the Alzheimer's Disease Drug Foundation (SG and DLD) and by the NIH grants NINDS 5U01NS086625 (WG and KDO) and NICHD K01HD074651-01A (KDO). The Werber Family Foundation provided additional support.	Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Camus V, 2012, EUR J NUCL MED MOL I, V39, P621, DOI 10.1007/s00259-011-2021-8; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Clark CM, 2012, LANCET NEUROL, V11, P669, DOI 10.1016/S1474-4422(12)70142-4; Clark CM, 2011, JAMA-J AM MED ASSOC, V305, P275, DOI 10.1001/jama.2010.2008; Crosson B, 2003, J INT NEUROPSYCH SOC, V9, P1061, DOI 10.1017/S135561770397010X; Dams-O'Connor K, 2014, J HEAD TRAUMA REHAB, V29, P479, DOI 10.1097/HTR.0000000000000099; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dickerson B, 2014, NEUROLOGY SS8, V10; Fleisher AS, 2011, ARCH NEUROL-CHICAGO, V68, P1404, DOI 10.1001/archneurol.2011.150; Gandy Sam, 2014, F1000Res, V3, P229, DOI 10.12688/f1000research.5372.1; Gandy S, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-37; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Harada R, 2013, EUR J NUCL MED MOL I, V40, P125, DOI 10.1007/s00259-012-2261-2; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Johnson KA, 2016, ANN NEUROL, V79, P110, DOI 10.1002/ana.24546; Keightley M., 2014, ARCH PHYS MED REHAB, V95, pe68; Kelly JP, 1997, NEUROLOGY, V48, P581; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Lenihan MW, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-015-0541-5; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Marquie M, 2015, ANN NEUROL, V78, P787, DOI 10.1002/ana.24517; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2016, JAMA NEUROL, V73, P353, DOI 10.1001/jamaneurol.2015.3998; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nordberg A, 2013, EUR J NUCL MED MOL I, V40, P104, DOI 10.1007/s00259-012-2237-2; Okamura N, 2016, AGEING RES REV; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Papa L, 2015, BRAIN NEUROTRAUMA MO, DOI [DOI 10.1201/B18126-27, 10.1201/b18126-27]; Rabinovici G, 2015, NEUROLOGY S, V84; Reuter M, 2012, NEUROIMAGE, V61, P1402, DOI 10.1016/j.neuroimage.2012.02.084; Reuter M, 2010, NEUROIMAGE, V53, P1181, DOI 10.1016/j.neuroimage.2010.07.020; Schuhmann T, 2009, CORTEX, V45, P1111, DOI 10.1016/j.cortex.2008.10.013; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tateno A, 2015, INT J GERIATR PSYCH, V30, P505, DOI 10.1002/gps.4173; Thompson PW, 2009, J NEUROCHEM, V109, P623, DOI 10.1111/j.1471-4159.2009.05996.x; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Ullman MT, 2006, CORTEX, V42, P480, DOI 10.1016/S0010-9452(08)70382-4; Villemagne VL, 2016, CURR OPIN NEUROBIOL, V36, P43, DOI 10.1016/j.conb.2015.09.002; Wilde EA, 2015, BRAIN IMAGING BEHAV, V9, P367, DOI 10.1007/s11682-015-9444-y; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Zimmer ER, 2014, CAN J NEUROL SCI, V41, P547, DOI 10.1017/cjn.2014.15	59	46	47	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	SEP 27	2016	6								e900	10.1038/tp.2016.175			8	Psychiatry	Psychiatry	EH9YA	WOS:000392126800001	27676441	DOAJ Gold, Green Published			2021-06-18	
J	Russo, R; Varano, GP; Adornetto, A; Nucci, C; Corasaniti, MT; Bagetta, G; Morrone, LA				Russo, Rossella; Varano, Giuseppe Pasquale; Adornetto, Annagrazia; Nucci, Carlo; Corasaniti, Maria Tiziana; Bagetta, Giacinto; Morrone, Luigi Antonio			Retinal ganglion cell death in glaucoma: Exploring the role of neuroinflammation	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Glaucoma; Retinal ganglion cells; Neuroinflammation; Glial cells; Neurodegeneration; Neuroprotection; Antiinflammatory	OPTIC-NERVE HEAD; NECROSIS-FACTOR-ALPHA; OPEN-ANGLE GLAUCOMA; NITRIC-OXIDE SYNTHASE; MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; TRABECULAR MESHWORK CELLS; HIGH INTRAOCULAR-PRESSURE; TRAUMATIC BRAIN-INJURY; DBA/2J MOUSE MODEL; GROWTH-FACTOR-BETA	In clinical glaucoma, as well as in experimental models, the loss of retinal ganglion cells occurs by apoptosis. This final event is preceded by inflammatory responses involving the activation of innate and adaptive immunity, with retinal and optic nerve resident glial cells acting as major players. Here we review the current literature on the role of neuroinflammation in neurodegeneration, focusing on the inflammatory molecular mechanisms involved in the pathogenesis and progression of the optic neuropathy. (C) 2016 Elsevier B.V. All rights reserved.	[Russo, Rossella; Varano, Giuseppe Pasquale; Adornetto, Annagrazia; Bagetta, Giacinto; Morrone, Luigi Antonio] Univ Calabria, Dept Pharm Nutr & Hlth Sci, Arcavacata Di Rende, Italy; [Bagetta, Giacinto; Morrone, Luigi Antonio] Univ Calabria, Sect Neuiopharmacol Normal & Pathol Neuronal Plas, Univ Ctr Adapt Disorders & Head Pain, Arcavacata Di Rende, Italy; [Nucci, Carlo] Univ Roma Tor Vergata, Dept Expt Med & Surg, Ophthalmol Unit, Rome, Italy; [Corasaniti, Maria Tiziana] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy	Russo, R (corresponding author), Univ Calabria, Dept Pharm Nutr & Hlth Sci, Arcavacata Di Rende, Italy.	rossella.russo@unical.it	Bagetta, Giacinto/N-9716-2018; Adornetto, Annagrazia/AAG-5467-2020; Corasaniti, Maria Tiziana/N-1332-2015	Bagetta, Giacinto/0000-0001-8540-6218; Adornetto, Annagrazia/0000-0003-1869-2642; Corasaniti, Maria Tiziana/0000-0001-6472-0697; Russo, Rossella/0000-0001-8758-6523	PRINMinistry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN) [20109MXHMR_008]; University of Calabria	Partial financial support from PRIN (Project protocol 20109MXHMR_008) and from University of Calabria (ex quota 60%) are gratefully acknowledged.	Abcouwer SF, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-149; Agrawal A, 2008, CHEMMEDCHEM, V3, P812, DOI 10.1002/cmdc.200700290; Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Amin AR, 1996, P NATL ACAD SCI USA, V93, P14014, DOI 10.1073/pnas.93.24.14014; Amin AR, 1997, FEBS LETT, V410, P259, DOI 10.1016/S0014-5793(97)00605-4; Amor S, 2014, IMMUNOLOGY, V142, P151, DOI 10.1111/imm.12233; Bakalash S, 2002, INVEST OPHTH VIS SCI, V43, P2648; Balaiya S, 2011, CLIN OPHTHALMOL, V5, P553, DOI 10.2147/OPTH.S19453; Baptiste DC, 2005, NEUROSCIENCE, V134, P575, DOI 10.1016/j.neuroscience.2005.04.011; Barnett NL, 2001, NEUROCHEM INT, V39, P291, DOI 10.1016/S0197-0186(01)00033-X; Benhar I, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00296; Beynon SB, 2012, NEUROSCIENCE, V225, P162, DOI 10.1016/j.neuroscience.2012.07.029; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bolz S, 2008, GRAEF ARCH CLIN EXP, V246, P1249, DOI 10.1007/s00417-008-0872-x; Bonelli RM, 2004, INT CLIN PSYCHOPHARM, V19, P337, DOI 10.1097/00004850-200411000-00004; Borkenstein A, 2013, MOL VIS, V19, P2306; Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337; Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602; Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516; Bozkurt B, 2012, CLIN EXP OPHTHALMOL, V40, pE156, DOI 10.1111/j.1442-9071.2011.02595.x; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001; Bucolo C, 2013, CURR OPIN PHARMACOL, V13, P50, DOI 10.1016/j.coph.2012.09.012; Butt AM, 2004, EYE, V18, P1110, DOI 10.1038/sj.eye.6701595; Cagnin A, 2006, ACTA NEUROL SCAND, V114, P107, DOI 10.1111/j.1600-0404.2006.00694.x; Carter SF, 2012, J NUCL MED, V53, P37, DOI 10.2967/jnumed.110.087031; Chang ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055291; Chen C, 2013, J MOL NEUROSCI, V51, P47, DOI 10.1007/s12031-012-9943-x; Cheng JW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046632; Chiu K, 2010, CELL MOL IMMUNOL, V7, P61, DOI 10.1038/cmi.2009.110; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; de Hoz R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083733; Denoyer A., 2012, PLOS ONE, V7; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dvoriantchikova G, 2014, EUR J NEUROSCI, V40, P3171, DOI 10.1111/ejn.12710; Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10-5284; Ergorul C, 2010, J MOL NEUROSCI, V42, P183, DOI 10.1007/s12031-010-9343-z; Fingert JH, 1999, HUM MOL GENET, V8, P899, DOI 10.1093/hmg/8.5.899; Fisher J, 2001, J NEUROSCI, V21, P136, DOI 10.1523/JNEUROSCI.21-01-00136.2001; Fleenor DL, 2006, INVEST OPHTH VIS SCI, V47, P226, DOI 10.1167/iovs.05-1060; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Formichella C. R., 2014, J CLIN CELL IMMUNOL, V5; Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Frank MG, 2006, NEUROBIOL AGING, V27, P717, DOI 10.1016/j.neurobiolaging.2005.03.013; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Fu QL, 2008, CELL MOL NEUROBIOL, V28, P317, DOI 10.1007/s10571-007-9155-z; Fuchshofer R, 2011, EXP EYE RES, V93, P165, DOI 10.1016/j.exer.2010.07.014; Galindo-Romero C, 2013, INVEST OPHTH VIS SCI, V54, P974, DOI 10.1167/iovs.12-11207; Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92; Geissmann F, 2008, IMMUNOL CELL BIOL, V86, P398, DOI 10.1038/icb.2008.19; GOLUB LM, 1987, J DENT RES, V66, P1310, DOI 10.1177/00220345870660080401; Gordon PH, 2007, LANCET NEUROL, V6, P1045, DOI 10.1016/S1474-4422(07)70270-3; Gramlich OW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057557; Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074-7742(07)82002-2; Gronert K, 2010, EXP EYE RES, V91, P478, DOI 10.1016/j.exer.2010.07.004; HANGAI M, 1995, INVEST OPHTH VIS SCI, V36, P571; Harada T, 1998, P NATL ACAD SCI USA, V95, P4663, DOI 10.1073/pnas.95.8.4663; Hernandez MR, 2008, PROG BRAIN RES, V173, P353, DOI 10.1016/S0079-6123(08)01125-4; Hernandez MR, 2000, GLIA, V32, P122, DOI 10.1002/1098-1136(200011)32:2<122::AID-GLIA20>3.0.CO;2-J; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; Hirrlinger PG, 2010, NEUROSCI LETT, V472, P73, DOI 10.1016/j.neulet.2010.01.062; Howell GR, 2012, J CLIN INVEST, V122, P1246, DOI 10.1172/JCI61135; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Inatani M, 2001, GRAEF ARCH CLIN EXP, V239, P109, DOI 10.1007/s004170000241; Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516; Itakura T, 2015, MOL VIS, V21, P1071; Joachim SC, 2008, GRAEF ARCH CLIN EXP, V246, P573, DOI 10.1007/s00417-007-0737-8; Joachim SC, 2009, INVEST OPHTH VIS SCI, V50, P4734, DOI 10.1167/iovs.08-3144; Joe MK, 2003, BIOCHEM BIOPH RES CO, V312, P592, DOI 10.1016/j.bbrc.2003.10.162; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Johnson EC, 2011, INVEST OPHTH VIS SCI, V52, P504, DOI 10.1167/iovs.10-5317; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Kanamori A, 2005, EXP EYE RES, V81, P48, DOI 10.1016/j.exer.2005.01.012; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Kieburtz K, 2008, CLIN NEUROPHARMACOL, V31, P141, DOI 10.1097/WNF.0b013e3181342f32; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kim JH, 2006, J BIOCHEM MOL BIOL, V39, P339; King CE, 2007, EXP NEUROL, V205, P48, DOI 10.1016/j.expneurol.2007.01.017; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Kreutz MR, 2004, EUR J NEUROSCI, V19, P247, DOI 10.1111/j.1460-9568.2004.03087.x; Kuchtey J, 2014, INVEST OPHTH VIS SCI, V55, P5291, DOI 10.1167/iovs.14-14578; Lam D, 2009, MOL VIS, V15, P2217; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Leske MC, 2007, OPHTHALMOLOGY, V114, P1965, DOI 10.1016/j.ophtha.2007.03.016; Levkovitch-Verbin H, 2006, ARCH OPHTHALMOL-CHIC, V124, P520, DOI 10.1001/archopht.124.4.520; Liu YH, 2004, HUM MOL GENET, V13, P1193, DOI 10.1093/hmg/ddh128; London A, 2011, J EXP MED, V208, P23, DOI 10.1084/jem.20101202; Lopez-Herrera MPL, 2002, EXP NEUROL, V178, P243, DOI 10.1006/exnr.2002.8043; Lorber B, 2005, EUR J NEUROSCI, V21, P2029, DOI 10.1111/j.1460-9568.2005.04034.x; Lorber B, 2009, J NEUROSCI RES, V87, P2645, DOI 10.1002/jnr.22095; Lye-Barthel M, 2013, INVEST OPHTH VIS SCI, V54, P909, DOI 10.1167/iovs.12-10109; Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022; Mac Nair CE, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0194-3; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Maruyama I, 2000, INVEST OPHTH VIS SCI, V41, P1657; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Nadal-Nicolas FM, 2015, INVEST OPHTH VIS SCI, V56, P6095, DOI 10.1167/iovs.15-17195; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Nakazawa T, 2006, J NEUROSCI, V26, P12633, DOI 10.1523/JNEUROSCI.2801-06.2006; Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962; Neufeld AH, 1999, P NATL ACAD SCI USA, V96, P9944, DOI 10.1073/pnas.96.17.9944; Nguyen JV, 2011, P NATL ACAD SCI USA, V108, P1176, DOI 10.1073/pnas.1013965108; Niederkorn JY, 2010, OCUL IMMUNOL INFLAMM, V18, P19, DOI 10.3109/09273940903564766; Nikodemova M, 2006, J NEUROCHEM, V96, P314, DOI 10.1111/j.1471-4159.2005.03520.x; Nucci C, 2005, NEUROTOXICOLOGY, V26, P935, DOI 10.1016/j.neuro.2005.06.002; O'Reilly AM, 2010, MOL NEUROBIOL, V42, P124, DOI 10.1007/s12035-010-8143-3; Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6; Park SH, 2007, VISION RES, V47, P2732, DOI 10.1016/j.visres.2007.07.011; Pepe G, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0211-6; Picht G, 2001, GRAEF ARCH CLIN EXP, V239, P199, DOI 10.1007/s004170000252; Pisanu A, 2014, NEUROBIOL DIS, V71, P280, DOI 10.1016/j.nbd.2014.08.011; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Prendes MA, 2013, BRIT J OPHTHALMOL, V97, P680, DOI 10.1136/bjophthalmol-2011-301132; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Prokop Stefan, 2013, Acta Neuropathol, V126, P461; Qu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067094; Qu J, 2010, EXP EYE RES, V91, P48, DOI 10.1016/j.exer.2010.04.002; Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7; Ramirez AI, 2015, PROG BRAIN RES, V220, P155, DOI 10.1016/bs.pbr.2015.05.003; Ramirez AI, 2010, INVEST OPHTH VIS SCI, V51, P5690, DOI 10.1167/iovs.10-5248; Reichelt J, 2008, CURR EYE RES, V33, P253, DOI 10.1080/02713680701871157; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roh M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040065; Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133; Russo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069250; Russo R, 2009, INT REV NEUROBIOL, V85, P407, DOI 10.1016/S0074-7742(09)85028-9; Sappington RM, 2008, INVEST OPHTH VIS SCI, V49, P3004, DOI 10.1167/iovs.07-1355; Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P2932, DOI 10.1167/iovs.05-1407; Sawada H, 2010, INVEST OPHTH VIS SCI, V51, P903, DOI 10.1167/iovs.09-4247; Schneider M., 2015, EXP EYE RES; Schori H, 2001, P NATL ACAD SCI USA, V98, P3398, DOI 10.1073/pnas.041609498; Schuetz E, 2004, BRAIN RES BULL, V62, P391, DOI 10.1016/j.brainresbull.2003.10.008; Schwartz Michal, 2009, J Ocul Biol Dis Infor, V2, P104; Seitz R, 2013, CELL TISSUE RES, V353, P339, DOI 10.1007/s00441-013-1666-y; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Shepard AR, 2010, INVEST OPHTH VIS SCI, V51, P2067, DOI 10.1167/iovs.09-4567; Shimazawa M, 2005, BRAIN RES, V1053, P185, DOI 10.1016/j.brainres.2005.06.053; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Sobrado-Calvo P, 2007, J COMP NEUROL, V501, P866, DOI 10.1002/cne.21279; Soto I., 2014, COLD SPRING HARB PER, V4; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Stein-Streilein J, 2008, TRENDS IMMUNOL, V29, P548, DOI 10.1016/j.it.2008.08.002; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; Sullivan TA, 2012, EXP EYE RES, V96, P36, DOI 10.1016/j.exer.2012.01.006; Sun D, 2013, GLIA, V61, P1218, DOI 10.1002/glia.22507; Takai Y, 2012, INVEST OPHTH VIS SCI, V53, P241, DOI 10.1167/iovs.11-8434; Tang Y, 2014, CELL DEATH DIFFER, V21, P369, DOI 10.1038/cdd.2013.159; Tansey MG, 2007, EXP NEUROL, V208, P1, DOI 10.1016/j.expneurol.2007.07.004; Taupin J L, 1998, Int Rev Immunol, V16, P397, DOI 10.3109/08830189809043003; Taylor S, 2003, MOL BRAIN RES, V111, P189, DOI 10.1016/S0169-328X(03)00030-5; Taylor S, 2011, EXP EYE RES, V92, P338, DOI 10.1016/j.exer.2011.01.012; Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348; Tezel G, 1998, INVEST OPHTH VIS SCI, V39, P2277; Tezel G, 2000, ARCH OPHTHALMOL-CHIC, V118, P511, DOI 10.1001/archopht.118.4.511; Tezel G, 2003, INVEST OPHTH VIS SCI, V44, P3025, DOI 10.1167/iovs.02-1136; Tezel G, 2001, GLIA, V34, P178, DOI 10.1002/glia.1052; Tezel G, 2001, INVEST OPHTH VIS SCI, V42, P1787; Tezel G, 2000, J NEUROSCI, V20, P3552; Tezel G, 2013, CURR OPIN PHARMACOL, V13, P23, DOI 10.1016/j.coph.2012.09.013; Tezel G, 2008, PROG BRAIN RES, V173, P409, DOI 10.1016/S0079-6123(08)01128-X; Tezel Gulgun, 2004, Curr Opin Ophthalmol, V15, P80, DOI 10.1097/00055735-200404000-00003; Trost A, 2015, EXP EYE RES, V136, P59, DOI 10.1016/j.exer.2015.05.010; van Noort JM, 2009, PROG BRAIN RES, V175, P139, DOI 10.1016/S0079-6123(09)17509-X; Vargas JLC, 2015, J NEUROSCI, V35, P12088, DOI 10.1523/JNEUROSCI.1273-15.2015; Vecino E., 2015, PROG RETIN EYE RES; Vidal L, 2006, BRAIN RES BULL, V70, P406, DOI 10.1016/j.brainresbull.2006.07.009; Vivekanantham S, 2015, INT J NEUROSCI, V125, P717, DOI 10.3109/00207454.2014.982795; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang L, 2002, INVEST OPHTH VIS SCI, V43, P1088; Wang N, 2001, NAT MED, V7, P304, DOI 10.1038/85446; Wang X, 2000, EXP BRAIN RES, V132, P476, DOI 10.1007/s002210000360; Wang Zhe, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P113, DOI 10.3969/j.issn.1672-7347.2013.02.001; Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008; Wax MB, 2001, J GLAUCOMA, V10, pS22, DOI 10.1097/00061198-200110001-00009; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wilson GN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0399-0; Xin XY, 2013, MOL VIS, V19, P526; Yam GHF, 2007, AM J PATHOL, V170, P100, DOI 10.2353/ajpath.2007.060806; Yang BB, 2010, J OCUL PHARMACOL TH, V26, P11, DOI 10.1089/jop.2009.0037; Ye SM, 2001, NEUROIMMUNOMODULAT, V9, P183, DOI 10.1159/000049025; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; Yoneda S, 2001, EXP EYE RES, V73, P661, DOI 10.1006/exer.2001.1072; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104; Zhang C, 2003, J NEUROSCI RES, V73, P840, DOI 10.1002/jnr.10713; Zhang SSM, 2005, EXP EYE RES, V81, P103, DOI 10.1016/j.exer.2005.01.016; Zhang X, 2004, INVEST OPHTH VIS SCI, V45, P2374, DOI 10.1167/iovs.03-1239; Zhang X, 2004, EXP EYE RES, V78, P849, DOI 10.1016/j.exer.2003.10.018; Zhang X, 2004, NEUROSCI LETT, V356, P140, DOI 10.1016/j.neulet.2003.10.084; Zhong LC, 2007, INVEST OPHTH VIS SCI, V48, P1212, DOI 10.1167/iovs.06-0757; Zhou X, 2013, MOL CELL NEUROSCI, V54, P1, DOI 10.1016/j.mcn.2012.12.001	197	46	46	2	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	SEP 15	2016	787				SI		134	142		10.1016/j.ejphar.2016.03.064			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DW0EX	WOS:000383314800016	27044433				2021-06-18	
J	Heyer, GL; Schaffer, CE; Rose, SC; Young, JA; McNally, KA; Fischer, AN				Heyer, Geoffrey L.; Schaffer, Caroline E.; Rose, Sean C.; Young, Julie A.; McNally, Kelly A.; Fischer, Anastasia N.			Specific Factors Influence Postconcussion Symptom Duration among Youth Referred to a Sports Concussion Clinic	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; HEAD-INJURY; RECOVERY; PREDICTORS; CHILDREN; EPIDEMIOLOGY; MANAGEMENT	Objective To identify the clinical factors that influence the duration of postconcussion symptoms among youth referred to a sports concussion clinic. Study design A retrospective cohort study was conducted to evaluate several potential predictors of symptom duration via a Cox proportional hazards analyses. The individual postconcussion symptom scores were highly correlated, so these symptoms were analyzed in the statistical model as coefficients derived from principal component analyses. Results Among 1953 youth with concussion, 1755 (89.9%) had dates of reported symptom resolution. The remainder (10.1%) were lost to follow-up and censored. The median time to recovery was 18 days (range 1-353 days). By 30 days, 72.6% had recovered; by 60 days, 91.4% had recovered; and by 90 days, 96.8% had recovered. Several variables in a multivariate Cox model predicted postconcussion symptom duration: female sex (P < .001, hazard ratio [HR] = 1.28), continued activity participation (P = .02, HR = 1.13), loss of consciousness (P = .03, HR = 1.18), anterograde amnesia (P = .04, HR = 1.15), premorbid headaches (P = .03, HR = 1.15), symptom components from the day of concussion (emotion, P = .03, HR = 1.08), and the day of clinic evaluation (cognitive-fatigue, P < .001, HR = 1.22; cephalalgic, P < .001, HR = 1.27; emotional, P = .05, HR = 1.08; arousal-stimulation, P = .003, HR = 1.1). In univariate analyses, greater symptom scores generally predicted longer symptom durations. Worsening of symptoms from the day of concussion to the day of clinic evaluation also predicted longer recovery (P < .001, HR = 1.59). Conclusions Several factors help to predict protracted postconcussion symptom durations among youth referred to a sports concussion clinic.	[Heyer, Geoffrey L.; Rose, Sean C.] Ohio State Univ, Div Pediat Neurol, Nationwide Childrens Hosp, Columbus, OH 43205 USA; [Heyer, Geoffrey L.; Rose, Sean C.] Ohio State Univ, Dept Neurol, Columbus, OH 43205 USA; [Schaffer, Caroline E.] Clemson Univ, Dept Hlth Sci, Clemson, SC USA; [Young, Julie A.; Fischer, Anastasia N.] Ohio State Univ, Div Sports Med, Columbus, OH 43205 USA; [McNally, Kelly A.] Ohio State Univ, Div Pediat Psychol & Neuropsychol, Nationwide Childrens Hosp, Columbus, OH 43205 USA; [McNally, Kelly A.] Ohio State Univ, Dept Pediat, Columbus, OH 43205 USA	Heyer, GL (corresponding author), Nationwide Childrens Hosp, Dept Pediat, 700 Childrens Dr,ED-5, Columbus, OH 43205 USA.; Heyer, GL (corresponding author), Nationwide Childrens Hosp, Dept Neurol, 700 Childrens Dr,ED-5, Columbus, OH 43205 USA.; Heyer, GL (corresponding author), Ohio State Univ, 700 Childrens Dr,ED-5, Columbus, OH 43205 USA.	geoffrey.heyer@nationwidechildrens.org		Rose, Sean/0000-0001-5177-7715; McNally, Kelly/0000-0001-9278-9413; Heyer, Geoffrey/0000-0001-9334-3739			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Falk AC, 2006, ACTA PAEDIATR, V95, P1533, DOI 10.1080/08035250600731957; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Heyer GL, 2016, CEPHALALGIA, V36, P309, DOI 10.1177/0333102415590240; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kontos AP, 2013, AM J SPORT MED, V41, P1497, DOI 10.1177/0363546513488751; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	39	46	46	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JUL	2016	174						33	+		10.1016/j.jpeds.2016.03.014			8	Pediatrics	Pediatrics	DP6PX	WOS:000378620800009	27056449				2021-06-18	
J	Wright, DK; Trezise, J; Kamnaksh, A; Bekdash, R; Johnston, LA; Ordidge, R; Semple, BD; Gardner, AJ; Stanwell, P; O'Brien, TJ; Agoston, DV; Shultz, SR				Wright, David K.; Trezise, Jack; Kamnaksh, Alaa; Bekdash, Ramsey; Johnston, Leigh A.; Ordidge, Roger; Semple, Bridgette D.; Gardner, Andrew J.; Stanwell, Peter; O'Brien, Terence J.; Agoston, Denes V.; Shultz, Sandy R.			Behavioral, blood, and magnetic resonance imaging biomarkers of experimental mild traumatic brain injury	SCIENTIFIC REPORTS			English	Article							ENDOTHELIAL GROWTH-FACTOR; FLUID PERCUSSION INJURY; SPORTS-RELATED CONCUSSION; TIME-DEPENDENT CHANGES; DIFFUSE AXONAL INJURY; ICE HOCKEY PLAYERS; CEREBROSPINAL-FLUID; ANIMAL-MODEL; HEAD-INJURY; CELL-DEATH	Repeated mild traumatic brain injuries (mTBI) may lead to serious neurological consequences, especially if re-injury occurs within the period of increased cerebral vulnerability (ICV) triggered by the initial insult. MRI and blood proteomics might provide objective measures of pathophysiological changes in mTBI, and indicate when the brain is no longer in a state of ICV. This study assessed behavioral, MRI, and blood-based markers in a rat model of mTBI. Rats were given a sham or mild fluid percussion injury (mFPI), and behavioral testing, MRI, and blood collections were conducted up to 30 days post-injury. There were cognitive impairments for three days post-mFPI, before normalizing by day 5 post-injury. In contrast, advanced MRI (i.e., tractography) and blood proteomics (i.e., vascular endothelial growth factor) detected a number of abnormalities, some of which were still present 30 days post-mFPI. These findings suggest that MRI and blood proteomics are sensitive measures of the molecular and subtle structural changes following mTBI. Of particular significance, this study identified novel tractography measures that are able to detect mTBI and may be more sensitive than traditional diffusion-tensor measures. Furthermore, the blood and MRI findings may have important implications in understanding ICV and are translatable to the clinical setting.	[Wright, David K.; Ordidge, Roger] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Wright, David K.; Johnston, Leigh A.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Trezise, Jack; Semple, Bridgette D.; O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; [Kamnaksh, Alaa; Bekdash, Ramsey; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Johnston, Leigh A.] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic 3010, Australia; [Gardner, Andrew J.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Stroke & Brain Injury, Callaghan, NSW 2308, Australia; [Stanwell, Peter] Univ Newcastle, Sch Hlth Sci, Callaghan, NSW 2308, Australia	Shultz, SR (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au	Stanwell, Peter/F-9136-2012; Johnston, Leigh A/D-7102-2014	Stanwell, Peter/0000-0002-4780-0393; Johnston, Leigh A/0000-0002-5032-4674; O'Brien, Terence/0000-0002-7198-8621; Wright, David/0000-0002-7535-8651; Ordidge, Roger/0000-0002-1005-3654	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [1062653, 1087172]; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G170AZ]	The authors thank Mr. John Olson for his assistance with the blood biomarker assays and acknowledge the facilities, and the scientific and technical assistance of the National Imaging Facility at the Florey Institute of Neuroscience and Mental Health, Parkville. Research reported in this publication was supported by the Australian National Health and Medical Research Council (grant numbers 1062653, 1087172) and the Center for Neuroscience and Regenerative Medicine (grant number G170AZ).	Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Ahmed F, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00114; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Ayton S, 2014, FREE RADICAL BIO MED, V69, P331, DOI 10.1016/j.freeradbiomed.2014.01.041; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Harris JL, 2015, FRONT AGING NEUROSCI, V7, DOI [10.5589/fnagi.2015.00202, 10.3389/fnagi.2015.00202]; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Johnstone VPA, 2014, J NEUROTRAUM, V31, P1881, DOI 10.1089/neu.2014.3343; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Keihaninejad S, 2013, NEUROIMAGE, V72, P153, DOI 10.1016/j.neuroimage.2013.01.044; Khurana VG, 2012, J CLIN NEUROSCI, V19, P1, DOI 10.1016/j.jocn.2011.08.002; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Mannix R, 2014, J NEUROTRAUM, V31, P1072, DOI 10.1089/neu.2013.3265; McCrory P, 2013, J SCI MED SPORT, V16, P178, DOI 10.1016/j.jsams.2013.02.009; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Pannek K, 2011, NEUROIMAGE, V55, P133, DOI 10.1016/j.neuroimage.2010.12.010; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Randolph C, 2005, J ATHL TRAINING, V40, P139; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; ROSTAMI E, 2015, INT J NEUROREHABIL, V2, P2; Shahim P, 2016, J NEUROTRAUM, V33, P1995, DOI 10.1089/neu.2014.3741; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2014, NEUROTHERAPEUTICS, V11, P347, DOI 10.1007/s13311-014-0258-1; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Storkebaum E, 2004, J CLIN INVEST, V113, P14, DOI 10.1172/JCI200420682; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Thau-Zuchman O, 2012, NEUROSCIENCE, V202, P334, DOI 10.1016/j.neuroscience.2011.11.071; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Willats L, 2014, NEUROIMAGE, V87, P18, DOI 10.1016/j.neuroimage.2013.11.016; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zurek J, 2011, BRAIN INJURY, V25, P221, DOI 10.3109/02699052.2010.541895	74	46	46	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 28	2016	6								28713	10.1038/srep28713			16	Multidisciplinary Sciences	Science & Technology - Other Topics	DQ0DB	WOS:000378867500002	27349514	DOAJ Gold, Green Published			2021-06-18	
J	Terwilliger, VK; Pratson, L; Vaughan, CG; Gioia, GA				Terwilliger, Virginia K.; Pratson, Lincoln; Vaughan, Christopher G.; Gioia, Gerard A.			Additional Post-Concussion Impact Exposure May Affect Recovery in Adolescent Athletes	JOURNAL OF NEUROTRAUMA			English	Article						concussion; athletes; mTBI; brain injury	HEAD-INJURY; VULNERABILITY; WINDOW	Repeat concussion has been associated with risk for prolonged and pronounced clinical recovery in athletes. In this study of adolescent athletes, we examined whether an additional head impact within 24 h of a sports-related concussion (SRC) is associated with higher symptom burden and prolonged clinical recovery compared with a single-injury group. Forty-two student-athletes (52% male, mean age = 14.9 years) diagnosed with an SRC in a concussion clinic were selected for this study: (1) 21 athletes who sustained an additional significant head impact within 24 h of the initial injury (additional-impact group); (2) 21 single-injury athletes, age and gender matched, who sustained only one discrete concussive blow to the head (single-injury group). Groups did not differ on initial injury characteristics or pre-injury risk factors. The effect of injury status (single- vs. additional-impact) was examined on athlete- and parent-reported symptom burden (at first clinic visit) and length of recovery (LOR). Higher symptom burden was reported by the athletes and parents in the additional-impact group at the time of first visit. The additional-impact group also had a significantly longer LOR compared with the single-injury group. These findings provide preliminary, hypothesis-generating evidence for the importance of immediate removal from play following an SRC to protect athletes from re-injury, which may worsen symptoms and prolong recovery. The retrospective study design from a specialized clinical sample points to the need for future prospective studies of the relationship between single- and additional-impact injuries on symptom burden and LOR.	[Terwilliger, Virginia K.; Vaughan, Christopher G.; Gioia, Gerard A.] Childrens Natl Hlth Syst, Div Pediat Neuropsychol, Washington, DC USA; [Pratson, Lincoln] E Carolina Univ, Brody Sch Med, Greenville, NC USA; [Vaughan, Christopher G.; Gioia, Gerard A.] George Washington Univ, Dept Psychiat & Behav Sci, Washington, DC USA; [Terwilliger, Virginia K.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, 446 East Ontario,7-200, Chicago, IL 60611 USA	Terwilliger, VK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, 446 East Ontario,7-200, Chicago, IL 60611 USA.	virginia.k.terwilliger@gmail.com			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P30/HDO40677-07, U17/CCU323352] Funding Source: Medline; NCIPC CDC HHS [U49CE001385] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE001385] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER		Bompadre V, 2014, J ATHL TRAINING, V49, P486, DOI 10.4085/1062-6050-49.3.30; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Gioia G, 2012, POSTCONCUSSION SYMPT; Gioia G.A., 2006, ACUTE CONCUSSION EVA; Gioia GA, 2015, BRAIN INJURY, V29, P195, DOI 10.3109/02699052.2014.965210; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham R., 2014, SPORTS RELATED CONCU; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	14	46	46	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2016	33	8					761	765		10.1089/neu.2015.4082			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DJ0ZM	WOS:000373932900006	26421452	Green Published			2021-06-18	
J	Ren, CH; Kobeissy, F; Alawieh, A; Li, N; Li, N; Zibara, K; Zoltewicz, S; Guingab-Cagmat, J; Larner, SF; Ding, YC; Hayes, RL; Ji, XM; Mondello, S				Ren, Changhong; Kobeissy, Firas; Alawieh, Ali; Li, Na; Li, Ning; Zibara, Kazem; Zoltewicz, Susie; Guingab-Cagmat, Joy; Larner, Stephen F.; Ding, Yuchuan; Hayes, Ronald L.; Ji, Xunming; Mondello, Stefania			Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients	SCIENTIFIC REPORTS			English	Article							TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; C-TERMINAL HYDROLASE-L1; HEALTH-CARE PROFESSIONALS; ACUTE ISCHEMIC-STROKE; INTRACEREBRAL HEMORRHAGE; NEUROSURGICAL INTERVENTION; INTRACRANIAL LESIONS; COMPUTED-TOMOGRAPHY; BIOMARKERS	A rapid and reliable diagnostic test to distinguish ischemic from hemorrhagic stroke in patients presenting with stroke-like symptoms is essential to optimize management and triage for thrombolytic therapy. The present study measured serum concentrations of ubiquitin C-terminal hydrolase (UCH-L1) and glial fibrillary astrocytic protein (GFAP) in acute stroke patients and healthy controls and investigated their relation to stroke severity and patient characteristics. We also assessed the diagnostic performance of these markers for the differentiation of intracerebral hemorrhage (ICH) from ischemic stroke (IS). Both UCH-L1 and GFAP concentrations were significantly greater in ICH patients than in controls (p < 0.0001). However, exclusively GFAP differed in ICH compared with IS (p < 0.0001). GFAP yielded an AUC of 0.86 for differentiating between ICH and IS within 4.5hrs of symptom onset with a sensitivity of 61% and a specificity of 96% using a cut-off of 0.34ng/ml. Higher GFAP levels were associated with stroke severity and history of prior stroke. Our results demonstrate that blood UCH-L1 and GFAP are increased early after stroke and distinct biomarker-specific release profiles are associated with stroke characteristics and type. We also confirmed the potential of GFAP as a tool for early rule-in of ICH, while UCH-L1 was not clinically useful.	[Ren, Changhong; Li, Na; Li, Ning; Ji, Xunming] Capital Med Univ, Inst Hypoxia Med, Xuanwu Hosp, Beijing 100053, Peoples R China; [Ren, Changhong; Ji, Xunming] Beijing Key Lab Hypoxia Conditioning Translat Med, Beijing 100053, Peoples R China; [Ren, Changhong; Ji, Xunming] Beijing Inst Brain Disorder, Ctr Stroke, Beijing 100069, Peoples R China; [Kobeissy, Firas] Univ Florida, Dept Psychiat, Ctr Neuroprote & Biomarkers Res, Gainesville, FL 32611 USA; [Kobeissy, Firas] Amer Univ Beirut, Med Ctr, Fac Med, Dept Biochem & Mol Genet, Beirut, Lebanon; [Alawieh, Ali] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA; [Zibara, Kazem] Amer Univ Beirut, Med Ctr, Fac Med, Beirut, Lebanon; [Zibara, Kazem] Lebanese Univ, Dept Biol, Fac Sci, Beirut, Lebanon; [Zoltewicz, Susie; Guingab-Cagmat, Joy; Larner, Stephen F.; Hayes, Ronald L.] Banyan Biomarkers Inc, Banyan Labs, Alachua, FL USA; [Ding, Yuchuan] Wayne State Univ, Sch Med, Dept Neurosurg, Detroit, MI 48201 USA; [Mondello, Stefania] Univ Messina, Dept Biomed Dent & Morphol & Funct Imaging Sci, Messina, Italy	Ji, XM (corresponding author), Capital Med Univ, Inst Hypoxia Med, Xuanwu Hosp, Beijing 100053, Peoples R China.; Ji, XM (corresponding author), Beijing Key Lab Hypoxia Conditioning Translat Med, Beijing 100053, Peoples R China.; Ji, XM (corresponding author), Beijing Inst Brain Disorder, Ctr Stroke, Beijing 100069, Peoples R China.; Mondello, S (corresponding author), Univ Messina, Dept Biomed Dent & Morphol & Funct Imaging Sci, Messina, Italy.	jixm@ccmu.edu.cn; stm_mondello@hotmail.com	Alawieh, Ali/AAM-1420-2020; Alawieh, Ali/AAM-1898-2020; Kobeissy, Firas/E-7042-2017; Ji, Xunming/AAN-3370-2021; Mondello, Stefania/A-1813-2012	Alawieh, Ali/0000-0003-2601-8850; Kobeissy, Firas/0000-0002-5008-6944; Mondello, Stefania/0000-0002-8587-3614; Zibara, Kazem/0000-0002-9887-072X	Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81573867]; Scientific Special Funding of Capital Health Development [2011-1001-03]; China National Funds for Distinguished Youth Scientist [81325007]; Distinguished Professor of cheung kong scholars programme [T2014251]; 12th Five Year Plan of National Science and Technology [2013BAI07B00]	This work was partially supported by the program of Natural Science Foundation of China (No. 81573867), Scientific Special Funding of Capital Health Development (No. 2011-1001-03), China National Funds for Distinguished Youth Scientist (No. 81325007, Distinguished Professor of cheung kong scholars programme (No, T2014251) and The 12th Five Year Plan of National Science and Technology (No, 2013BAI07B00).	Barber M, 2004, STROKE, V35, P1421, DOI 10.1161/01.STR.0000126890.63512.41; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Brouns R, 2010, CLIN CHEM, V56, P451, DOI 10.1373/clinchem.2009.134122; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Cano Climaco P, 2003, Am J Ther, V10, P473, DOI 10.1097/00045391-200311000-00018; Chalela JA, 2007, LANCET, V369, P293, DOI 10.1016/S0140-6736(07)60151-2; Dambinova SA, 2002, STROKE, V33, P1181, DOI 10.1161/01.STR.0000014922.83673.86; Danton GH, 2002, STROKE, V33, P1113, DOI 10.1161/hs0402.105554; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dvorak F, 2009, CEREBROVASC DIS, V27, P37, DOI 10.1159/000172632; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Foerch C, 2009, NEUROLOGY, V73, P393, DOI 10.1212/WNL.0b013e3181b05ef9; Foerch C, 2012, CLIN CHEM, V58, P237, DOI 10.1373/clinchem.2011.172676; Furie KL, 2011, STROKE, V42, P227, DOI 10.1161/STR.0b013e3181f7d043; George PM, 2015, INT J STROKE, V10, P1204, DOI 10.1111/ijs.12603; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Mondello S, 2014, PARKINSONISM RELAT D, V20, P382, DOI 10.1016/j.parkreldis.2014.01.011; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mouhieddine TH, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0505-1; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Olivot JM, 2004, STROKE, V35, P1946, DOI 10.1161/01.STR.0000133340.37712.9b; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Ren CH, 2013, BRAIN RES, V1540, P84, DOI 10.1016/j.brainres.2013.09.051; Rodriguez-Yanez M, 2008, CURR OPIN NEUROL, V21, P353, DOI 10.1097/WCO.0b013e3282ffafbf; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Sato Mika, 2006, J Stroke Cerebrovasc Dis, V15, P1, DOI 10.1016/j.jstrokecerebrovasdis.2005.09.005; Schiff L, 2012, MOL DIAGN THER, V16, P79, DOI 10.2165/11631580-000000000-00000; Tombul T, 2005, J CLIN NEUROSCI, V12, P429, DOI 10.1016/j.jocn.2004.06.013; Tso AWK, 2011, NEUROLOGY, V76, P1968, DOI 10.1212/WNL.0b013e31821e54b3; Unden J, 2009, J NEUROL, V256, P72, DOI 10.1007/s00415-009-0054-8; Vos PE, 2006, EUR J NEUROL, V13, P632, DOI 10.1111/j.1468-1331.2006.01332.x; Whiteley W, 2011, J ROY COLL PHYS EDIN, V41, P152, DOI 10.4997/JRCPE.2011.207; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	44	46	48	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	APR 14	2016	6								24588	10.1038/srep24588			9	Multidisciplinary Sciences	Science & Technology - Other Topics	DJ2OK	WOS:000374044100001	27074724	DOAJ Gold, Green Published			2021-06-18	
J	McAllister, TW; Zafonte, R; Jain, S; Flashman, LA; George, MS; Grant, GA; He, F; Lohr, JB; Andaluz, N; Summerall, L; Paulus, MP; Raman, R; Stein, MB				McAllister, Thomas W.; Zafonte, Ross; Jain, Sonia; Flashman, Laura A.; George, Mark S.; Grant, Gerald A.; He, Feng; Lohr, James B.; Andaluz, Norberto; Summerall, Lanier; Paulus, Martin P.; Raman, Rema; Stein, Murray B.			Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury	NEUROPSYCHOPHARMACOLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; DEPLOYED MILITARY PERSONNEL; POSTCONCUSSIVE SYMPTOMS; PSYCHIATRIC-DISORDERS; SUICIDE RISK; DEPRESSION; IRAQ; SYMPTOMATOLOGY; AFGHANISTAN; VETERANS	We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful and statistically significant improvement compared with placebo on the primary outcome, a measure of cognitive complaints (Ruff Neurobehavioral Inventory-Postmorbid Cognitive Scale), as well as on the secondary outcomes reflecting post-concussive (Rivermead Post Concussive Symptom Questionnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist). Treatment was well tolerated. These results suggest the need for a larger RCT to replicate and confirm these findings. Design considerations for such a trial should include the need for multiple sites to facilitate adequate recruitment and extension of the treatment and follow-up periods.	[McAllister, Thomas W.] Indiana Univ Sch Med, Dept Psychiat, 355W,16th St,Suite 4800, Indianapolis, IN 46202 USA; [Zafonte, Ross] Brigham & Womens Hosp, Massachusetts Gen Hosp, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, 75 Francis St, Boston, MA 02115 USA; [Zafonte, Ross] Harvard Univ, Sch Med, Boston, MA USA; [Jain, Sonia; He, Feng; Raman, Rema] Univ Calif San Diego, Biostat Res Ctr, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA; [Flashman, Laura A.] Dartmouth Hitchcock Med Ctr, Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Program, Lebanon, NH 03766 USA; [George, Mark S.] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA; [Grant, Gerald A.] Stanford Univ, Lucile Packard Childrens Hosp, Dept Neurosurg, Stanford, CA 94305 USA; [Lohr, James B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Andaluz, Norberto] Univ Cincinnati, Mayfield Clin, Neurosci Inst, Dept Neurosurg,Coll Med, Cincinnati, OH USA; [Summerall, Lanier] Ralph H Johnson VA Med Ctr, Dept Psychiat, Charleston, SC USA; [Paulus, Martin P.] Laureate Inst Brain Res, Tulsa, OK USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA	McAllister, TW (corresponding author), Indiana Univ Sch Med, Dept Psychiat, 355W,16th St,Suite 4800, Indianapolis, IN 46202 USA.	twmcalli@iupui.edu		George, Mark/0000-0003-1767-1815	United States Department of Defense grant [W81XWH08-2-0159]; Janssen PharmaceuticaJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc; PfizerPfizer; Tonix Pharmaceuticals; Biological Psychiatry; UpToDate	This study was funded by the United States Department of Defense grant W81XWH08-2-0159. MBS reports consulting income in the past 3 years from Janssen Pharmaceutica, Pfizer, and Tonix Pharmaceuticals; and income for editorial work for Biological Psychiatry and UpToDate. RZ has received compensation from Demos Medical Publishing, as well as Oakstone Institute for educational products. The remaining authors declare no conflict of interest.	Abraham AD, 2012, LEARN MEMORY, V19, P67, DOI 10.1101/lm.024752.111; Advokat C, 2010, NEUROSCI BIOBEHAV R, V34, P1256, DOI 10.1016/j.neubiorev.2010.03.006; Aga-Mizrachi S, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.82; Arciniegas D, 2007, GUIDE NEUROPSYCHIATR, P24; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Brady KT, 2000, J CLIN PSYCHIAT, V61, P22; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Dawson DA, 2005, COMPR PSYCHIAT, V46, P405, DOI 10.1016/j.comppsych.2005.01.006; Falconer E, 2008, J PSYCHIATR NEUROSCI, V33, P413; Hankin CS, 1999, AM J PSYCHIAT, V156, P1924; Hart T, 2014, J NEUROTRAUM, V31, P610, DOI 10.1089/neu.2013.3041; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howlett JR, 2015, NEUROBIOLOGY OF PTSD; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Koontz Jennifer, 2005, Am J Alzheimers Dis Other Demen, V20, P295, DOI 10.1177/153331750502000502; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Loy C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001747.pub3; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Parker G, 2013, J AFFECT DISORDERS, V151, P360, DOI 10.1016/j.jad.2013.05.093; Ruff R. M., 2003, RNBI RUFF NEUROBEHAV; Schilstrom B, 2007, NEUROPSYCHOPHARMACOL, V32, P43, DOI 10.1038/sj.npp.1301087; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seeman P, 1998, MOL PSYCHIATR, V3, P386, DOI 10.1038/sj.mp.4000421; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanev KS, 2014, BRAIN INJURY, V28, P261, DOI 10.3109/02699052.2013.873821; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Thompson Sarah, 2004, Expert Opin Drug Saf, V3, P425, DOI 10.1517/14740338.3.5.425; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Willmott C, 2009, J NEUROL NEUROSUR PS, V80, P552, DOI 10.1136/jnnp.2008.159632; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	43	46	46	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	APR	2016	41	5					1191	1198		10.1038/npp.2015.282			8	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	DG1BW	WOS:000371801200002	26361060	Bronze, Green Published			2021-06-18	
J	Ono, KE; Burns, TG; Bearden, DJ; McManus, SM; King, H; Reisner, A				Ono, Kim E.; Burns, Thomas G.; Bearden, Donald J.; McManus, Susan M.; King, Harold; Reisner, Andrew			Sex-Based Differences as a Predictor of Recovery Trajectories in Young Athletes After a Sports-Related Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sex-based difference; concussion; trajectories of recovery; adolescents	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL FUNCTION; CLINICAL ARTICLE; HIGH-SCHOOL; SYMPTOMS; GENDER; AGE; PLAYERS; SCALE; LINE	Background: To date, few studies have delineated clear sex-based differences in symptom resolution after a sports-related concussion (SRC), and equivocal results have been identified in sex-based differences on baseline assessments. Purpose: To assess whether female athletes displayed prolonged recovery and more symptoms at baseline and after an SRC compared with male athletes. Study Design: Cohort study; Level of evidence, 3. Methods: The current study assessed 135 male and 41 female athletes (10-18 years old) who participated in high-impact sports in metropolitan Atlanta middle and high schools. All athletes completed a baseline assessment and at least 1 postconcussion assessment from the Immediate Post-Concussion Assessment and Cognitive Testing battery. Longitudinal hierarchical linear modeling was employed to examine individual-level variables and their associations with adolescents' rates of recovery in concussive symptoms after controlling for age and number of prior concussions. Results: Aggregate symptoms were rated as higher in female athletes compared with male athletes at baseline (mean SD: females, 13.49 +/- 11.20; males, 4.88 +/- 8.74; F(1,175) = 10.59, P < .001) and immediately after a concussion (females: 16.75 +/- 18.08; males: 10.58 +/- 14.21; F(1,175) = 3.99, P = .05). There were no group differences in the slope of recovery between male and female athletes, indicating generally similar trajectories of change for both groups. Post hoc analyses revealed higher baseline levels of migraine and neuropsychological symptoms in female athletes. Conclusion: Although female athletes in the current study reported increased symptoms, identical recovery patterns were observed in both sexes, suggesting that sex-based differences in concussion recovery are better explained by increased symptom frequency among female athletes when compared with their male counterparts.	[Ono, Kim E.; Burns, Thomas G.; Bearden, Donald J.; McManus, Susan M.; King, Harold; Reisner, Andrew] Childrens Healthcare Atlanta, 1547 Clifton Rd Northeast,Suite 200, Atlanta, GA 30322 USA; [Bearden, Donald J.] Boston Childrens Hosp, Boston, MA USA	Ono, KE (corresponding author), Childrens Healthcare Atlanta, 1547 Clifton Rd Northeast,Suite 200, Atlanta, GA 30322 USA.	kim.ono@choa.org	Meijer, Anna/K-5118-2016		Children's Healthcare of Atlanta	One or more of the authors has declared the following potential conflict of interest or source of funding: Children's Healthcare of Atlanta supplied the stipend for the authors as employees as well as data used for analyses.	Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; BRYK AS, 1987, PSYCHOL BULL, V101, P147, DOI 10.1037/0033-2909.101.1.147; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2001, CLIN SPORTS MED, V30, P125; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Farace E, 2000, NEUROSURG FOCUS, V8, pe8; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Hancock GR, 2006, QUANT METH EDUC BEHA, P1; King NS, 2014, BRAIN INJURY, V28, P1639, DOI 10.3109/02699052.2014.954271; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lindvall HF, 1974, ACTA NEUROL SCAND  S, V56, P3; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCartney Kathleen, 2006, Monogr Soc Res Child Dev, V71, P1, DOI 10.1111/j.1540-5834.2006.07103001.x; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Raudenbush SW., 2004, HIERARCHICAL LINEAR; RUTHERFORD WH, 1977, LANCET, V1, P1; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Weiss E, 2003, NEUROSCI LETT, V344, P169, DOI 10.1016/S0304-3940(03)00406-3; Zuckerman SL, 2014, J NEUROSURG-PEDIATR, V13, P72, DOI 10.3171/2013.9.PEDS13257; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	32	46	46	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2016	44	3					748	752		10.1177/0363546515617746			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DF9CQ	WOS:000371658300030	26672026				2021-06-18	
J	Gaw, CE; Zonfrillo, MR				Gaw, Christopher E.; Zonfrillo, Mark R.			Emergency department visits for head trauma in the United States	BMC EMERGENCY MEDICINE			English	Article						Concussion; Emergency department; Head trauma; National Electronic Injury Surveillance System; Traumatic brain injury	BRAIN-INJURY; CASE ASCERTAINMENT; CONCUSSION; EPIDEMIOLOGY; TRENDS; YOUTH; HOSPITALIZATION; SURVEILLANCE; ACCURACY; OUTCOMES	Background: Head trauma affects millions of Americans each year and has significant morbidity and economic costs to society. The objective of this study is to describe the epidemiology of head traumas presenting to emergency departments in the United States. Methods: The National Electronic Injury Surveillance System-All Injury Program was queried to conduct a retrospective analysis of head traumas treated in U.S. emergency departments. 207,159 cases of nonfatal head trauma from January 1, 2007 to December 31, 2011 were included in this study. Results: An estimated 10,746,629 (95 % confidence interval: 8,368,720-13,124,537) head traumas were treated in U.S. emergency departments (EDs) during the study period, averaging 2,149,326 cases annually. The annual injury rate per 10,000 population increased from 55.2 in 2007 to 85.4 in 2011, with the largest increases seen in children <= 11 years of age and in adults >65 years of age. Traffic-related head trauma accounted for an estimated 1,819,824 visits to U.S. EDs over the study period and was associated with a 1.74 times greater risk of a hospital admission compared to injuries due to non-traffic-related causes. Assaults (95.9 %) were the most common reason for head trauma in cases where injury intent was documented, and 16.9 % of assault-related head trauma occurred in children 0-17 years of age. When analyzed separately from other head traumas, concussions increased by 37.5 % over the study period, and nearly a third (29.9 %) of all concussions were sports-related. Conclusions: The increase in the number and rate of head traumas treated in U.S. EDs warrants continued injury prevention efforts and improvements in injury nomenclature and surveillance.	[Gaw, Christopher E.] Univ Penn, Perelman Sch Med, 3400 Civ Ctr Blvd,Bldg 421, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.] Brown Univ, Dept Emergency Med, Alpert Med Sch, 55 Claverick St,2nd Floor, Providence, RI 02903 USA	Zonfrillo, MR (corresponding author), Brown Univ, Dept Emergency Med, Alpert Med Sch, 55 Claverick St,2nd Floor, Providence, RI 02903 USA.	Zonfrillo@brown.edu	Gaw, Christopher/ABI-2314-2020; Zonfrillo, Mark R./H-9403-2017	Gaw, Christopher/0000-0002-2847-6372; Zonfrillo, Mark R./0000-0002-0610-9563	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08 HD073241, K08HD073241] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER		Asemota AO, 2013, J NEUROTRAUM, V30, P67, DOI 10.1089/neu.2012.2605; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Eisele JA, 2006, J HEAD TRAUMA REHAB, V21, P537, DOI 10.1097/00001199-200611000-00008; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Finkelhor D, 2005, CHILD MALTREATMENT, V10, P5, DOI 10.1177/1077559504271287; Finklestein E, 2006, INCIDENCE EC BURDENS; Garrick JG, 2005, CLIN J SPORT MED, V15, P385, DOI 10.1097/01.jsm.0000181438.48892.1b; HAHN YS, 1983, CHILD BRAIN, V10, P229; Hunt JP, 2000, J TRAUMA, V49, P679, DOI 10.1097/00005373-200010000-00016; Inter-university Consortium for Political and Social Research, 2014, NAT EL INJ SURV SYST; Irie F, 2011, J TRAUMA, V71, P847, DOI 10.1097/TA.0b013e3182032c9a; King NS, 2011, BRAIN INJURY, V25, P462, DOI 10.3109/02699052.2011.558042; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; NEISS, 2000, NAT EL INJ SURV SYST; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Schroeder T., 2001, NEISS SAMPLE DESIGN; Stevens Penelope K, 2010, J Trauma Nurs, V17, P178, DOI 10.1097/JTN.0b013e3181ff2789; Stevens PK, 2010, J TRAUMA NURS, V17, P183; Straus B., 2014, NY TIMES; Strauss B, 2014, NEW YORK TIMES; Thompson MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092052; Thompson MC, 2014, BRAIN INJURY, V28, P431, DOI 10.3109/02699052.2014.887146; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; U.S. Census Bureau, 2004, US EST90INT 07 INT E; U.S. Census Bureau, 2012, NC EST2011 ALLDATA M; U.S. Census Bureau, 2011, US EST00INT ALLDATA; U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Injury Prevention and Control U.S. Consumer Product Safety Commission, 2011, NAT EL INJ SURV SYST; Underwood E, 2013, SCIENCE, V339, P1367, DOI 10.1126/science.339.6126.1367; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Xiang HY, 2007, BRAIN INJURY, V21, P293, DOI 10.1080/02699050701311034; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	44	46	46	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-227X			BMC EMERG MED	BMC Emerg. Med.	JAN 19	2016	16								5	10.1186/s12873-016-0071-8			10	Emergency Medicine	Emergency Medicine	DO9QG	WOS:000378121000001	26781953	DOAJ Gold, Green Published			2021-06-18	
J	Gyoneva, S; Kim, D; Katsumoto, A; Kokiko-Cochran, ON; Lamb, BT; Ransohoff, RM				Gyoneva, Stefka; Kim, Daniel; Katsumoto, Atsuko; Kokiko-Cochran, O. Nicole; Lamb, Bruce T.; Ransohoff, Richard M.			Ccr2 deletion dissociates cavity size and tau pathology after mild traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; CCR2; Tau; MAPT; Monocyte	ALZHEIMERS-DISEASE; HEAD-INJURY; HYPERPHOSPHORYLATION; ENCEPHALOPATHY; INFLAMMATION; ACTIVATION; CONTRIBUTE; RESPONSES; PATHWAY; MODEL	Background: Millions of people experience traumatic brain injury (TBI) as a result of falls, car accidents, sports injury, and blast. TBI has been associated with the development of neurodegenerative conditions such as Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE). In the initial hours and days, the pathology of TBI comprises neuronal injury, breakdown of the blood-brain barrier, and inflammation. At the cellular level, the inflammatory reaction consists of responses by brain-resident microglia, astrocytes, and vascular elements as well as infiltration of peripheral cells. After TBI, signaling by chemokine (C-C motif) ligand 2 (CCL2) to the chemokine (C-C motif) receptor 2 (CCR2) is a key regulator of brain infiltration by monocytes. Methods: We utilized mice with one or both copies of Ccr2 disrupted by red fluorescent protein (RFP, Ccr2(RFP/+) and Ccr2(RFP/RFP)). We subjected these mice to the mild lateral fluid percussion model of TBI and examined several pathological outcomes 3 days later in order to determine the effects of altered monocyte entry into the brain. Results: Ccr2 deletion reduced monocyte infiltration, diminished lesion cavity volume, and lessened axonal damage after mild TBI, but the microglial reaction to the lesion was not affected. We further examined phosphorylation of the microtubule-associated protein tau, which aggregates in brains of people with TBI, AD, and CTE. Surprisingly, Ccr2 deletion was associated with increased tau mislocalization to the cell body in the cortex and hippocampus by tissue staining and increased levels of phosphorylated tau in the hippocampus by Western blot. Conclusions: Disruption of CCR2 enhanced tau pathology and reduced cavity volume in the context of TBI. The data reveal a complex role for CCR2(+) monocytes in TBI, as monitored by cavity volume, axonal damage, and tau phosphorylation.	[Gyoneva, Stefka; Katsumoto, Atsuko; Kokiko-Cochran, O. Nicole; Lamb, Bruce T.; Ransohoff, Richard M.] Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; [Kim, Daniel] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; [Gyoneva, Stefka; Kim, Daniel; Katsumoto, Atsuko; Kokiko-Cochran, O. Nicole; Lamb, Bruce T.; Ransohoff, Richard M.] Cleveland Clin Fdn, Neuroinflammat Res Ctr, Cleveland, OH 44195 USA; [Gyoneva, Stefka; Ransohoff, Richard M.] Biogen Inc, Neuroimmunol, Cambridge, MA 02142 USA	Gyoneva, S (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.	stefka.gyoneva@biogen.com; richard.ransohoff@biogen.com		Katsumoto, Atsuko/0000-0002-5582-3050; Kim, Daniel/0000-0001-8907-6420	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS082798]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS082798] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health (R21 NS082798) to BTL and RMR. We thank Anna Rietsch for technical assistance.	Ajami B, 2011, NAT NEUROSCI, V14, P1142, DOI 10.1038/nn.2887; Bhaskar K, 2010, NEURON, V68, P19, DOI 10.1016/j.neuron.2010.08.023; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Chu HX, 2014, J CEREBR BLOOD F MET, V34, P1425, DOI 10.1038/jcbfm.2014.120; Clavaguera F, 2013, P NATL ACAD SCI USA, V110, P9535, DOI 10.1073/pnas.1301175110; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Evans TA, 2014, EXP NEUROL, V254, P109, DOI 10.1016/j.expneurol.2014.01.013; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Ghosh S, 2013, J NEUROSCI, V33, P5053, DOI 10.1523/JNEUROSCI.4361-12.2013; Giunta B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-185; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Holscher C, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-100; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Lee S, 2014, J NEUROSCI, V34, P12538, DOI 10.1523/JNEUROSCI.0853-14.2014; Liu S, 2013, J MOL NEUROSCI, V51, P1021, DOI 10.1007/s12031-013-0091-8; Maphis N, 2015, BRAIN, V138, P1738, DOI 10.1093/brain/awv081; Mazanetz MP, 2007, NAT REV DRUG DISCOV, V6, P464, DOI 10.1038/nrd2111; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Run XQ, 2009, J ALZHEIMERS DIS, V16, P619, DOI 10.3233/JAD-2009-1003; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yi JY, 2013, CURR SPORT MED REP, V12, P28, DOI 10.1249/JSR.0b013e31827ec9e3	47	46	49	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	DEC 3	2015	12								228	10.1186/s12974-015-0443-0			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CX5ZZ	WOS:000365782300001	26634348	DOAJ Gold, Green Published			2021-06-18	
J	Greene, NH; Kernic, MA; Vavilala, MS; Rivara, FP				Greene, Nathaniel H.; Kernic, Mary A.; Vavilala, Monica S.; Rivara, Frederick P.			Validation of ICDPIC software injury severity scores using a large regional trauma registry	INJURY PREVENTION			English	Article							BRAIN-INJURY; UNITED-STATES; OUTCOMES; CARE	Background Administrative or quality improvement registries may or may not contain the elements needed for investigations by trauma researchers. International Classification of Diseases Program for Injury Categorisation (ICDPIC), a statistical program available through Stata, is a powerful tool that can extract injury severity scores from ICD-9-CM codes. We conducted a validation study for use of the ICDPIC in trauma research. Methods We conducted a retrospective cohort validation study of 40 418 patients with injury using a large regional trauma registry. ICDPIC-generated AIS scores for each body region were compared with trauma registry AIS scores (gold standard) in adult and paediatric populations. A separate analysis was conducted among patients with traumatic brain injury (TBI) comparing the ICDPIC tool with ICD-9-CM embedded severity codes. Performance in characterising overall injury severity, by the ISS, was also assessed. Results The ICDPIC tool generated substantial correlations in thoracic and abdominal trauma (weighted kappa 0.87-0.92), and in head and neck trauma (weighted kappa 0.76-0.83). The ICDPIC tool captured TBI severity better than ICD-9-CM code embedded severity and offered the advantage of generating a severity value for every patient (rather than having missing data). Its ability to produce an accurate severity score was consistent within each body region as well as overall. Conclusions The ICDPIC tool performs well in classifying injury severity and is superior to ICD-9-CM embedded severity for TBI. Use of ICDPIC demonstrates substantial efficiency and may be a preferred tool in determining injury severity for large trauma datasets, provided researchers understand its limitations and take caution when examining smaller trauma datasets.	[Greene, Nathaniel H.] Duke Univ, Dept Anesthesiol & Pediat, Sch Med, Durham, NC 27710 USA; [Kernic, Mary A.; Rivara, Frederick P.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Sch Med, Seattle, WA 98195 USA; [Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Vavilala, Monica S.; Rivara, Frederick P.] Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA	Greene, NH (corresponding author), Duke Univ, Dept Anesthesiol & Pediat, Sch Med, DUMC Box 3094, Durham, NC 27710 USA.	nathaniel.greene@dm.duke.edu	Greene, Nathaniel/J-3450-2014	Greene, Nathaniel/0000-0003-0230-0499	Department of Anesthesiology and Pain Medicine at the University of Washington School of Medicine	This project was funded internally by the Department of Anesthesiology and Pain Medicine at the University of Washington School of Medicine.	Agency for Healthcare Research and Quality, 2014, OV STAT INP DAT SID; Arroyo AC, 2012, ACAD EMERG MED, V19, P541, DOI 10.1111/j.1553-2712.2012.01356.x; Association for the Advancement of Automotive Medicine (AAAM), 2008, ABBR INJ SCAL AIS 20; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Centers for Medicare and Medicaid Services, 2014, EHR INC PROGR SEC EH; Chen CM, 2012, J STUD ALCOHOL DRUGS, V73, P531, DOI 10.15288/jsad.2012.73.531; Clark DE OT, 2010, ICDPIC STATA MODULE; Cook Alan, 2012, Proc (Bayl Univ Med Cent), V25, P6; Di Bartolomeo S, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-17; Greene NH, 2014, ARCH PHYS MED REHAB, V95, P1148, DOI 10.1016/j.apmr.2014.02.020; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Nakamura Y, 2012, ANN EMERG MED, V60, P335, DOI 10.1016/j.annemergmed.2012.04.006; Newgard C, 2012, ACAD EMERG MED, V19, P469, DOI 10.1111/j.1553-2712.2012.01324.x; Sanchez AI, 2012, J HEAD TRAUMA REHAB, V27, P159, DOI 10.1097/HTR.0b013e3182074c41; Scher AI, 2011, J NEUROTRAUM, V28, P1739, DOI 10.1089/neu.2011.1982; Sears JM, 2013, J OCCUP REHABIL, V23, P19, DOI 10.1007/s10926-012-9377-x; Weiss H, 2010, PEDIATRICS, V126, P1149, DOI 10.1542/peds.2010-0902	18	46	48	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	OCT	2015	21	5					325	330		10.1136/injuryprev-2014-041524			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CT4MC	WOS:000362779600007	25985974				2021-06-18	
J	De Leener, B; Cohen-Adad, J; Kadoury, S				De Leener, Benjamin; Cohen-Adad, Julien; Kadoury, Samuel			Automatic Segmentation of the Spinal Cord and Spinal Canal Coupled With Vertebral Labeling	IEEE TRANSACTIONS ON MEDICAL IMAGING			English	Article						Automatic segmentation; CSF; deformable model; MRI; spinal canal; spinal cord; vertebral labeling	MAGNETIC-RESONANCE IMAGES; SEMIAUTOMATIC SEGMENTATION; MULTIPLE-SCLEROSIS; ATROPHY; MRI; VOLUME; BRAIN; QUANTIFICATION; NORMALIZATION; MORPHOMETRY	Quantifying spinal cord (SC) atrophy in neurodegenerative and traumatic diseases brings important diagnosis and prognosis information for the clinician. We recently developed the PropSeg method, which allows for fast, accurate and automatic segmentation of the SC on different types of MRI contrast (e.g., T-1-, T-2- and T-3-weighted sequences) and any field of view. However, comparing measurements from the SC between subjects is hindered by the lack of a generic coordinate system for the SC. In this paper, we present a new framework combining PropSeg and a vertebral level identification method, thereby enabling direct inter-and intra-subject comparison of SC measurements for large cohort studies as well as for longitudinal studies. Our segmentation method is based on the multi-resolution propagation of tubular deformable models. Coupled with an automatic intervertebral disk identification method, our segmentation pipeline provides quantitative metrics of the SC and spinal canal such as cross-sectional areas and volumes in a generic coordinate system based on vertebral levels. This framework was validated on 17 healthy subjects and on one patient with SC injury against manual segmentation. Results have been compared with an existing active surface method and show high local and global accuracy for both SC and spinal canal (Dice coefficients =0.91 +/- 0.02) segmentation. Having a robust and automatic framework for SC segmentation and vertebral-based normalization opens the door to bias-free measurement of SC atrophy in large cohorts.	[De Leener, Benjamin; Cohen-Adad, Julien; Kadoury, Samuel] Polytech Montreal, Inst Biomed Engn, Montreal, PQ H3T 1J4, Canada; [Cohen-Adad, Julien] Univ Montreal, CRIUGM, Funct Neuroimaging Unit, Montreal, PQ H3W 1W5, Canada; [Kadoury, Samuel] CHU St Justine Res Ctr Montreal, Montreal, PQ H3T 1C4, Canada	De Leener, B (corresponding author), Polytech Montreal, Inst Biomed Engn, Montreal, PQ H3T 1J4, Canada.	benjamin.de-leener@polymtl.ca; jcohen@polymtl.ca; samuel.kadoury@polymtl.ca	De Leener, Benjamin/H-3765-2019	De Leener, Benjamin/0000-0002-1378-2756	SensoriMotor Rehabilitation Research Team (SMRRT) of the Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR) [229269]; National MS SocietyNational Multiple Sclerosis Society [FG1892A1/1]; Fonds de Recherche du Quebec-Sante (FRQS) [27130, 28826]; Quebec BioImaging Network (QBIN) [5886]; Canadian Research ChairsCanada Research Chairs [950-228359]; Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC) [435897-2013]	Manuscript received April 09, 2015; revised May 15, 2015; accepted May 18, 2015. Date of publication May 22, 2015; date of current version July 29, 2015. This work was funded by the SensoriMotor Rehabilitation Research Team (SMRRT) of the Canadian Institute of Health Research [229269], the National MS Society [FG1892A1/1], the Fonds de Recherche du Quebec-Sante (FRQS) [27130, 28826], the Quebec BioImaging Network (QBIN) [5886], the Canadian Research Chairs [950-228359] and the Natural Sciences and Engineering Research Council of Canada (NSERC) [435897-2013]. Asterisk indicates corresponding author.	Antiga L., 2007, INSIGHT J, V3; Archip N, 2002, IEEE T MED IMAGING, V21, P1504, DOI 10.1109/TMI.2002.806578; Asman AJ, 2014, MED IMAGE ANAL, V18, P460, DOI 10.1016/j.media.2014.01.003; Aspert N, 2002, IEEE INTERNATIONAL CONFERENCE ON MULTIMEDIA AND EXPO, VOL I AND II, PROCEEDINGS, P705, DOI 10.1109/ICME.2002.1035879; Bakshi R, 2005, J NEUROIMAGING, V15, p30S, DOI 10.1177/1051228405283901; BALLARD DH, 1981, PATTERN RECOGN, V13, P111, DOI 10.1016/0031-3203(81)90009-1; Burnett SSC, 2004, MED PHYS, V31, P251, DOI 10.1118/1.1634483; Cadotte D., 2014, AM J NEURORADIOL; Chen M, 2013, NEUROIMAGE, V83, P1051, DOI 10.1016/j.neuroimage.2013.07.060; Coulon O, 2002, MAGN RESON MED, V47, P1176, DOI 10.1002/mrm.10162; De Leener B, 2014, NEUROIMAGE, V98, P528, DOI 10.1016/j.neuroimage.2014.04.051; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; El Mendili M. M., 2014, J MAGN RESON IMAG; El Mendili MM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122224; Engl C, 2013, NEURORADIOLOGY, V55, P963, DOI 10.1007/s00234-013-1204-3; Fonov VS, 2014, NEUROIMAGE, V102, P817, DOI 10.1016/j.neuroimage.2014.08.057; Fradet L, 2014, SPINE, V39, pE262, DOI 10.1097/BRS.0000000000000125; Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/bfb0056195; Fujimoto K, 2014, NEUROIMAGE, V90, P60, DOI 10.1016/j.neuroimage.2013.12.012; Gill P.E., 1981, PRACTICAL OPTIMIZATI; Healy BC, 2012, J NEUROIMAGING, V22, pE12, DOI 10.1111/j.1552-6569.2011.00629.x; Horsfield MA, 2010, NEUROIMAGE, V50, P446, DOI 10.1016/j.neuroimage.2009.12.121; Jellus V., 2005, P 13 ANN M ISMRM MIA, P2247; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Kameyama T, 1996, SPINE, V21, P1285, DOI 10.1097/00007632-199606010-00001; KAMEYAMA T, 1994, SPINE, V19, P2077, DOI 10.1097/00007632-199409150-00013; Kato F, 2012, EUR SPINE J, V21, P1499, DOI 10.1007/s00586-012-2176-4; Kearney H, 2014, J MAGN RESON IMAGING, V39, P617, DOI 10.1002/jmri.24194; Ko HY, 2004, SPINAL CORD, V42, P35, DOI 10.1038/sj.sc.3101538; Koh J, 2010, IEEE ENG MED BIO, P3117, DOI 10.1109/IEMBS.2010.5626097; Leary SM, 1999, MAGN RESON IMAGING, V17, P773, DOI 10.1016/S0730-725X(99)00005-3; Lin X, 2003, ACTA NEUROL SCAND, V108, P401, DOI 10.1034/j.1600-0404.2003.00160.x; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; McIntosh C., 2011, 2011 IEEE International Conference on Healthcare Informatics, Imaging and Systems Biology, P25, DOI 10.1109/HISB.2011.42; McIntosh C, 2006, LECT NOTES COMPUT SC, V4190, P808; Nyul LG, 2005, LECT NOTES COMPUT SC, V3691, P456; Okada Y., 1994, SPINE PHILA PA 1976, V19; OLSSON DM, 1975, TECHNOMETRICS, V17, P45, DOI 10.2307/1267998; Peng ZG, 2005, P ANN INT IEEE EMBS, P2527; Pezold S., 2015, RECENT ADV COMPUTATI, P107, DOI [DOI 10.1007/978-3-319-14148-0_10, 10.1007/978-3-319-14148-0_10]; Rangayyan RM, 2006, J ELECTRON IMAGING, V15, DOI 10.1117/1.2234770; Seifert S, 2009, IEEE T MED IMAGING, V28, P494, DOI 10.1109/TMI.2008.2004659; SHERMAN JL, 1990, AM J NEURORADIOL, V11, P369; Tench CR, 2005, J MAGN RESON IMAGING, V21, P197, DOI 10.1002/jmri.20253; Terzopoulos D., 1988, Visual Computer, V4, P306, DOI 10.1007/BF01908877; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Ullmann E, 2014, INT J BIOMED IMAGING, V2014, DOI 10.1155/2014/719520; Valsasina P, 2012, AM J NEURORADIOL, V33, P2195, DOI 10.3174/ajnr.A3139; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; Weiler F., 2015, SPIE MED IMAG; Xu CY, 1998, SIGNAL PROCESS, V71, P131, DOI 10.1016/S0165-1684(98)00140-6; Yanase M, 2006, J SPINAL DISORD TECH, V19, P125, DOI 10.1097/01.bsd.0000181294.67212.79; Yoo TS, 2002, STUD HEALTH TECHNOL, V85, P586	54	46	46	2	26	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0278-0062	1558-254X		IEEE T MED IMAGING	IEEE Trans. Med. Imaging	AUG	2015	34	8			SI		1705	1718		10.1109/TMI.2015.2437192			14	Computer Science, Interdisciplinary Applications; Engineering, Biomedical; Engineering, Electrical & Electronic; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging	Computer Science; Engineering; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging	CO1DO	WOS:000358893300008	26011879				2021-06-18	
J	Maerlender, A; Rieman, W; Lichtenstein, J; Condiracci, C				Maerlender, Arthur; Rieman, Wanda; Lichtenstein, Jonathan; Condiracci, C.			Programmed Physical Exertion in Recovery From Sports-Related Concussion: A Randomized Pilot Study	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							EXERCISE	Although no data exist, general practice recommends only rest following concussion. This randomized clinical trial found that programmed physical exertion during recovery produced no significant differences in recovery time between groups of participants. However, high levels of exertion were deleterious. This study provides initial evidence that moderate physical activity is a safe replacement behavior during recovery.	[Maerlender, Arthur] Univ Nebraska, Ctr Brain Biol & Behav, Lincoln, NE 68558 USA; [Lichtenstein, Jonathan] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA; [Condiracci, C.] Antioch New England Grad Sch, Keene, NH USA	Maerlender, A (corresponding author), Univ Nebraska, Ctr Brain Biol & Behav, Lincoln, NE 68558 USA.	amaerlender2@unl.edu			Hitchcock Foundation	Funding for this study was provided by the Hitchcock Foundation.	Borg G., 1998, BORGS PERCEIVED EXER; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Hinton-Bayre AD, 2012, CLIN J SPORT MED, V22, P105, DOI 10.1097/JSM.0b013e318248a526; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9	13	46	47	0	18	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JUL 4	2015	40	5					273	278		10.1080/87565641.2015.1067706			6	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CP2MH	WOS:000359710700001	26230745	Green Published			2021-06-18	
J	DeMatteo, C; Stazyk, K; Giglia, L; Mahoney, W; Singh, SK; Hollenberg, R; Harper, JA; Missiuna, C; Law, M; McCauley, D; Randall, S				DeMatteo, Carol; Stazyk, Kathy; Giglia, Lucy; Mahoney, William; Singh, Sheila K.; Hollenberg, Robert; Harper, Jessica A.; Missiuna, Cheryl; Law, Mary; McCauley, Dayle; Randall, Sarah			A Balanced Protocol for Return to School for Children and Youth Following Concussive Injury	CLINICAL PEDIATRICS			English	Article						child; concussion; mild traumatic brain injury; return to school; return to learn; postconcussion syndrome; depression; anxiety	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; PROLONGED RECOVERY; COGNITIVE REST; TO-PLAY; RECOMMENDATIONS; SYMPTOMS; ADOLESCENTS; DEPRESSION; RISK	Background. Few protocols exist for returning children/youth to school after concussion. Childhood concussion can significantly affect school performance, which is vital to social development, academic learning, and preparation for future roles. The goal of this knowledge translation research was to develop evidence based materials to inform physicians about pediatric concussion. Methods. The Return to School (RTS) concussion protocol was developed following the National Institute for Health and Care Excellence procedures. Results. Based on a scoping review, and stakeholder opinions, an RTS protocol was developed for children/youth. This unique protocol focuses on school adaptation in 4 main areas: (a) timetable/attendance, (b) curriculum, (c) environmental modifications, and (d) activity modifications. Conclusion. A balance of cognitive rest and timely return to school need to be considered for returning any student to school after a concussion. Implementation of these new recommendations may be an important tool in prevention of prolonged absence from school and academic failure while supporting brain recovery.	[DeMatteo, Carol; Stazyk, Kathy; Giglia, Lucy; Mahoney, William; Singh, Sheila K.; Hollenberg, Robert; Harper, Jessica A.; Missiuna, Cheryl; Law, Mary; McCauley, Dayle; Randall, Sarah] McMaster Univ, Hamilton, ON L8S 1C7, Canada; [Giglia, Lucy; Mahoney, William; Singh, Sheila K.; Hollenberg, Robert] McMaster Childrens Hosp, Hamilton, ON, Canada	DeMatteo, C (corresponding author), McMaster Univ, Sch Rehabil Sci, 1400 Main St West,IAHS 403, Hamilton, ON L8S 1C7, Canada.	dematteo@mcmaster.ca	Singh, Sheila K/W-2799-2018; Meijer, Anna/K-5118-2016	Singh, Sheila K/0000-0003-1272-5300; 	Canadian Institute of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [115228]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Canadian Institute of Health Research (CIHR; grant number 115228).	Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Berlin AA, 2006, PSYCHOSOM MED, V68, P224, DOI 10.1097/01.psy.0000204628.73273.23; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Canadian Pediatric Society, 2006, PAEDIAT CHILD HLTH, V11, P420; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Casoli-Reardon M, 2012, EDUC LEADERSHIP, V70, P50; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; DeMatteo C, 2015, DISABIL REHABIL, V37, P1107, DOI 10.3109/09638288.2014.952452; DeMatteo C, 2015, CLIN PEDIATR, V54, P152, DOI 10.1177/0009922814558256; DeMatteo CA, 2014, BRAIN INJURY, V28, P114, DOI 10.3109/02699052.2013.848380; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Fedor A, 2015, APPL NEUROPSYCH-ADUL, V22, P108, DOI 10.1080/23279095.2013.860604; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Giza CC, 2001, J ATHL TRAINING, V36, P228; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Huebner ES, 2004, PSYCHOL SCHOOLS, V41, P81, DOI 10.1002/pits.10140; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Kearney CA, 2008, CLIN PSYCHOL REV, V28, P451, DOI 10.1016/j.cpr.2007.07.012; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Laker SR, 2011, PHYS MED REH CLIN N, V22, P619, DOI 10.1016/j.pmr.2011.08.004; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Morin D, HEADSMART HLTH BALAN; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Parsons JT, 2013, BRIT J SPORT MED, V47, pe1; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P42, DOI 10.1097/00001199-199512000-00007	56	46	46	0	47	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	JUL	2015	54	8					783	792		10.1177/0009922814567305			10	Pediatrics	Pediatrics	CK7NM	WOS:000356419200010	25601958				2021-06-18	
J	Rosenfeld, JV; Bell, RS; Armonda, R				Rosenfeld, Jeffrey V.; Bell, Randy S.; Armonda, Rocco			Current Concepts in Penetrating and Blast Injury to the Central Nervous System	WORLD JOURNAL OF SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; CIVILIAN GUNSHOT WOUNDS; SPINAL-INJURIES; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; WARTIME; MILITARY; COAGULOPATHY; PREDICTORS; FRACTURES	To review the current management, prognostic factors and outcomes of penetrating and blast injuries to the central nervous system and highlight the differences between gunshot wound, blast injury and stabbing. A review of the current literature was performed. Of patients with craniocerebral GSW, 66-90 % die before reaching hospital. Of those who are admitted to hospital, up to 51 % survive. The patient age, GCS, pupil size and reaction, ballistics and CT features are important factors in the decision to operate and in prognostication. Blast injury to the brain is a component of multisystem polytrauma and has become a common injury encountered in war zones and following urban terrorist events. GSW to the spine account for 13-17 % of all gunshot injuries. Urgent resuscitation, correction of coagulopathy and early surgery with wide cranial decompression may improve the outcome in selected patients with severe craniocerebral GSW. More limited surgery is undertaken for focal brain injury due to GSW. A non-operative approach may be taken if the clinical status is very poor (GCS 3, fixed dilated pupils) or GCS 4-5 with adverse CT findings or where there is a high likelihood of death or poor outcome. Civilian spinal GSWs are usually stable neurologically and biomechanically and do not require exploration. The indications for exploration are as follows: (1) compressive lesions with partial spinal cord or cauda equina injury, (2) mechanical instability and (3) complications. The principles of management of blast injury to the head and spine are the same as for GSW. Multidisciplinary specialist management is required for these complex injuries.	[Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Alfred Ctr, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.; Bell, Randy S.; Armonda, Rocco] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Surg, Bethesda, MD 20814 USA; [Bell, Randy S.; Armonda, Rocco] MedStar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC USA; [Bell, Randy S.; Armonda, Rocco] Washington Hosp Ctr, Washington, DC 20010 USA	Rosenfeld, JV (corresponding author), Monash Univ, Dept Surg, Alfred Ctr, 6th Floor,99 Commercial Rd, Melbourne, Vic 3004, Australia.	j.rosenfeld@alfred.org.au					Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; Aarabi B, 2014, J NEUROSURG, V120, P1138, DOI 10.3171/2014.1.JNS131869; [Anonymous], 2001, J TRAUMA, V51, pS34; [Anonymous], 2001, J TRAUMA, V51, pS29; [Anonymous], 2001, J Trauma, V51, pS3; [Anonymous], 2012, JOINT THEAT TRAUM SY; [Anonymous], 2012, JOINT THEAT TRAUM SY; Armonda R, 2011, J NEUROTRAUM, V28, pA5; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Aryan HE, 2005, NEUROSURGERY, V57, P748, DOI 10.1227/01.NEU.0000175728.93653.b1; Baraniuk S, 2014, INJURY, V45, P1287, DOI 10.1016/j.injury.2014.06.001; Bayston R, 2000, LANCET, V355, P1813, DOI 10.1016/S0140-6736(00)02275-3; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; Bell RS, 2010, NEUROSURGERY, V66, P66, DOI 10.1227/01.NEU.0000361285.50218.A8; Blair JA, 2012, SPINE J, V12, P762, DOI 10.1016/j.spinee.2011.10.009; Bono Christopher M, 2004, Spine J, V4, P230, DOI 10.1016/S1529-9430(03)00178-5; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Ecker RD, 2011, J NEUROSURG, V115, P124, DOI 10.3171/2011.2.JNS101490; Elserry Tarek, 2013, Surg Neurol Int, V4, pS448, DOI 10.4103/2152-7806.121642; Enicker B, 2014, INJURY, V45, P1355, DOI 10.1016/j.injury.2014.04.036; Epstein DS, 2015, BRIT J NEUROSURG, V29, P118, DOI 10.3109/02688697.2014.950632; Glapa M, 2009, AM SURGEON, V75, P223; Gressot LV, 2014, J NEUROSURG, V121, P645, DOI 10.3171/2014.5.JNS131872; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Heary RFMA, 2010, SEMIN SPINE SURG, V22, P73; Jaiswal M, 2013, ASIAN SPINE J, V7, P359, DOI 10.4184/asj.2013.7.4.359; Jandial R, 2008, NEUROSURGERY, V62, P472, DOI 10.1227/01.neu.0000316015.05550.7a; Joseph B, 2014, J AM COLL SURGEONS, V218, P58, DOI 10.1016/j.jamcollsurg.2013.08.018; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; Kazim Syed Faraz, 2011, J Emerg Trauma Shock, V4, P395, DOI 10.4103/0974-2700.83871; Klimo P, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1036; Levy M L, 2000, Neurosurg Focus, V8, pe2, DOI 10.3171/foc.2000.8.1.153; Lin David J, 2012, Surg Neurol Int, V3, P98, DOI 10.4103/2152-7806.100187; McCully SP, 2013, SEMIN THROMB HEMOST, V39, P896, DOI 10.1055/s-0033-1357484; McNatt SA, 2005, NEUROSURGERY, V57, pE191, DOI [10.1227/01.NEU.0000175727.76530.94, 10.1227/01.NEU.0000164174.07281.F9]; Medzon R, 2005, SPINE, V30, P2274, DOI 10.1097/01. brs.0000182083.43553.fa; Mitra B, 2013, ANZ J SURG, V83, P918, DOI 10.1111/ans.12417; Parks SE, 2014, MMWR SURVEILL SUMM, V63, P1; Patzkowski JC, 2012, SPINE J, V12, P791, DOI 10.1016/j.spinee.2011.10.001; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; Powers David B, 2013, Atlas Oral Maxillofac Surg Clin North Am, V21, P15, DOI 10.1016/j.cxom.2012.12.001; Ragel BT, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1028; Ramasamy A, 2009, INJURY, V40, P1342, DOI 10.1016/j.injury.2009.06.168; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Rosenfeld JV, 2002, J CLIN NEUROSCI, V9, P9, DOI 10.1054/jocn.2001.0949; Schoenfeld AJ, 2013, INJURY, V44, P1866, DOI 10.1016/j.injury.2013.08.001; Schoenfeld AJ, 2013, SPINE, V38, P1770, DOI 10.1097/BRS.0b013e31829ef226; Schoenfeld AJ, 2012, SPINE J, V12, P817, DOI 10.1016/j.spinee.2011.04.028; Schoenfeld AJ, 2012, SPINE J, V12, P771, DOI 10.1016/j.spinee.2010.05.004; Shahlaie K, 2006, J NEUROSURG-SPINE, V4, P400, DOI 10.3171/spi.2006.4.5.400; Shen FHT, 2013, ASIAN SPINE J, V7, P44, DOI 10.4184/asj.2013.7.1.44; Sidhu GS, 2013, CLIN ORTHOP RELAT R, V471, P3945, DOI 10.1007/s11999-013-2901-2; Smith CE BA, 2014, MASSIVE TRANSFUSION; Syre P, 2013, J NEUROSURG-SPINE, V19, P759, DOI 10.3171/2013.8.SPINE12907; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Trahan J, 2013, INJURY, V44, P1601, DOI 10.1016/j.injury.2013.06.021; Weisbrod AB, 2012, J TRAUMA ACUTE CARE, V73, P1525, DOI 10.1097/TA.0b013e318270e179	57	46	50	1	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JUN	2015	39	6					1352	1362		10.1007/s00268-014-2874-7			11	Surgery	Surgery	CH6FI	WOS:000354131400004	25446474	Green Published, Other Gold			2021-06-18	
J	Kroshus, E; Baugh, CM; Daneshvar, DH; Nowinski, CJ; Cantu, RC				Kroshus, Emily; Baugh, Christine M.; Daneshvar, Daniel H.; Nowinski, Christopher J.; Cantu, Robert C.			Concussion Reporting Intention: A Valuable Metric for Predicting Reporting Behavior and Evaluating Concussion Education	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; intention; knowledge; hockey; education	SOCIAL-SCIENCES THEORIES; ICE HOCKEY; INJURY; KNOWLEDGE; BRAIN; INTERVENTION; MODELS	Objective: This study aimed to evaluate whether preseason concussion knowledge and reporting intention predicted in-season concussion reporting behavior. Design: Prospective cohort study. Setting: Collegiate athletic facility of each participating team. Participants: National Collegiate Athletic Association Division I men's ice hockey players in 1 conference of competition (n = 116). Independent Variables: Intention to report symptoms of a "minor" concussion and concussion knowledge were assessed at preseason. Main Outcome Measures: Postseason recall of non-report of postimpact symptoms. Results: Preseason concussion knowledge was not significantly associated with in-season reporting behavior. Intention to report concussion symptoms was significantly related to in-season reporting behavior. There was a significant interaction between the number of different symptoms experienced and both preseason reporting intention and in-season reporting behavior. Conclusions: Evaluations of concussion education programs tend to measure concussion knowledge. The present findings suggest that reporting intention may be more strongly predictive of reporting behavior than concussion knowledge and should be included in evaluations of concussion effectiveness. New concussion education initiatives should consider targeting psychosocial constructs that increase reporting intention.	[Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Baugh, Christine M.; Daneshvar, Daniel H.; Nowinski, Christopher J.; Cantu, Robert C.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Baugh, Christine M.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Daneshvar, Daniel H.; Nowinski, Christopher J.; Cantu, Robert C.] Boston Univ, Sch Med, Sports Legacy Inst, Boston, MA 02118 USA; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA	Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave,Kresge Bldg, Boston, MA 02115 USA.	emk329@mail.harvard.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513	National Collegiate Athletic Association Graduate Student Research Grant	Supported in part by the National Collegiate Athletic Association Graduate Student Research Grant (E.K.).	Abraham C, 1998, PSYCHOL HEALTH, V13, P569, DOI 10.1080/08870449808407420; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I, 2011, BASIC APPL SOC PSYCH, V33, P101, DOI 10.1080/01973533.2011.568834; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; BANDURA A, 1980, SOCIAL FDN THOUGHT A; Borden BP, 2007, AM J SPORTS MED, V35, P1075; Chan DKC, 2012, SPORTS MED, V42, P725, DOI 10.2165/11633040-000000000-00000; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Elder JP, 1999, AM J PREV MED, V17, P275, DOI 10.1016/S0749-3797(99)00094-X; Fishbein M, 2003, COMMUN THEOR, V13, P164, DOI 10.1111/j.1468-2885.2003.tb00287.x; Fishbein M, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P3; Fishbein M., 1975, BELIEF ATTITUDE INTE; Gielen AC, 2003, EPIDEMIOL REV, V25, P65, DOI 10.1093/epirev/mxg004; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Keats MR, 2012, SPORTS MED, V42, P175, DOI 10.2165/11597050-000000000-00000; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McEachan RRC, 2011, HEALTH PSYCHOL REV, V5, P97, DOI 10.1080/17437199.2010.521684; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Montano D. E., 2008, HLTH BEHAV HLTH ED T, P67, DOI DOI 10.1016/S0033-3506(49)81524-1; NCAA, 2013 14 NCAA SPORTS; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Sheeran P., 2002, EUR REV SOC PSYCHOL, V12, P1, DOI DOI 10.1080/14792772143000003; Tator CH, 2012, J CLIN SPORT PSYCHOL, V6, P293, DOI 10.1123/jcsp.6.3.293; Trifiletti LB, 2005, HEALTH EDUC RES, V20, P298, DOI 10.1093/her/cyg126; Verhagen EALM, 2010, SPORTS MED, V40, P899, DOI 10.2165/11536890-000000000-00000; Webb TL, 2006, PSYCHOL BULL, V132, P249, DOI 10.1037/0033-2909.132.2.249	39	46	47	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2015	25	3					243	247		10.1097/JSM.0000000000000137			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	CH3EX	WOS:000353911700008	25051193				2021-06-18	
J	Guo, SX; Zhou, HL; Huang, CL; You, CG; Fang, Q; Wu, P; Wang, XG; Han, CM				Guo, Song-Xue; Zhou, Han-Lei; Huang, Chun-Lan; You, Chuan-Gang; Fang, Quan; Wu, Pan; Wang, Xin-Gang; Han, Chun-Mao			Astaxanthin Attenuates Early Acute Kidney Injury Following Severe Burns in Rats by Ameliorating Oxidative Stress and Mitochondrial-Related Apoptosis	MARINE DRUGS			English	Article							ACUTE-RENAL-FAILURE; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; GELATINASE-ASSOCIATED LIPOCALIN; HYDROGEN-RICH SALINE; EARLY BRAIN-INJURY; CEREBRAL-ISCHEMIA; PROTECTS; MODEL; SURVIVAL; CELLS	Early acute kidney injury (AKI) is a devastating complication in critical burn patients, and it is associated with severe morbidity and mortality. The mechanism of AKI is multifactorial. Astaxanthin (ATX) is a natural compound that is widely distributed in marine organisms; it is a strong antioxidant and exhibits other biological effects that have been well studied in various traumatic injuries and diseases. Hence, we attempted to explore the potential protection of ATX against early post burn AKI and its possible mechanisms of action. The classic severe burn rat model was utilized for the histological and biochemical assessments of the therapeutic value and mechanisms of action of ATX. Upon ATX treatment, renal tubular injury and the levels of serum creatinine and neutrophil gelatinase-associated lipocalin were improved. Furthermore, relief of oxidative stress and tubular apoptosis in rat kidneys post burn was also observed. Additionally, ATX administration increased Akt and Bad phosphorylation and further down-regulated the expression of other downstream pro-apoptotic proteins (cytochrome c and caspase-3/9); these effects were reversed by the PI3K inhibitor LY294002. Moreover, the protective effect of ATX presents a dose-dependent enhancement. The data above suggested that ATX protects against early AKI following severe burns in rats, which was attributed to its ability to ameliorate oxidative stress and inhibit apoptosis by modulating the mitochondrial-apoptotic pathway, regarded as the Akt/Bad/Caspases signalling cascade.	[Guo, Song-Xue; Zhou, Han-Lei; You, Chuan-Gang; Wu, Pan; Wang, Xin-Gang; Han, Chun-Mao] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Burns, Hangzhou 310009, Zhejiang, Peoples R China; [Huang, Chun-Lan] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Plast Surg, Hangzhou 310000, Zhejiang, Peoples R China; [Fang, Quan] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Plast Surg,Binjiang Branch, Hangzhou 310000, Zhejiang, Peoples R China	Han, CM (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Burns, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	11318225@zju.edu.cn; zhlei288@zju.edu.cn; 21418262@zju.edu.cn; 2314053@zju.edu.cn; 21218125@zju.edu.cn; wuzhiqiujin@zju.edu.cn; wangxingang8157@zju.edu.cn; zrssk@zju.edu.cn			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81401591]; Zhejiang Provincial National Natural Science Foundation of China [LQ13H150001]	This work was supported by grants from National Natural Science Foundation of China (NSFC) grant 81401591 and Zhejiang Provincial National Natural Science Foundation of China Grant: LQ13H150001.	Abali A. E., 2014, BURNS IN PRESS; Arora S, 2014, MOL CELL BIOCHEM, V393, P123, DOI 10.1007/s11010-014-2052-0; Arunkumar E, 2012, FOOD FUNCT, V3, P120, DOI 10.1039/c1fo10161g; Billings FT, 2014, CARDIORENAL MED, V4, P12, DOI 10.1159/000357871; Chalah A, 2008, ADV EXP MED BIOL, V615, P25, DOI 10.1007/978-1-4020-6554-5_3; Choi HD, 2011, BRIT J NUTR, V105, P220, DOI 10.1017/S0007114510003454; Coca SG, 2007, AM J KIDNEY DIS, V49, P517, DOI 10.1053/j.ajkd.2006.12.018; Colpaert K, 2008, CRIT CARE, V12, DOI 10.1186/cc7106; Dagher PC, 2012, AM J PHYSIOL-RENAL, V302, pF284, DOI 10.1152/ajprenal.00317.2011; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Elks CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024028; Fang Y, 2011, J BURN CARE RES, V32, pE82, DOI 10.1097/BCR.0b013e318217f84f; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Feng YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054593; Gal AF, 2012, ACTA VET SCAND, V54, DOI 10.1186/1751-0147-54-50; Gao CJ, 2009, BURNS, V35, P547, DOI 10.1016/j.burns.2008.10.006; Gravante G, 2007, APOPTOSIS, V12, P259, DOI 10.1007/s10495-006-0621-8; Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7; Hoetzenecker W, 2012, NAT MED, V18, P128, DOI 10.1038/nm.2557; Hong DY, 2013, J BURN CARE RES, V34, pE326, DOI 10.1097/BCR.0b013e31827d1f36; Hong Y, 2012, J NEUROSCI RES, V90, P1670, DOI 10.1002/jnr.22739; Horton JW, 2003, TOXICOLOGY, V189, P75, DOI 10.1016/S0300-483X(03)00154-9; Jiang L, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-53; Kim YJ, 2009, J AGR FOOD CHEM, V57, P8793, DOI 10.1021/jf9019745; Lauver DA, 2005, J PHARMACOL EXP THER, V314, P686, DOI 10.1124/jpet.105.087114; Leblanc M, 1997, BURNS, V23, P160, DOI 10.1016/S0305-4179(96)00085-X; Lee DH, 2010, J CLIN BIOCHEM NUTR, V47, P121, DOI 10.3164/jcbn.10-29; Li PKT, 2013, NAT REV NEPHROL, V9, P133, DOI 10.1038/nrneph.2013.20; Li YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093639; Liu CM, 2012, TOXICOL APPL PHARM, V258, P330, DOI 10.1016/j.taap.2011.11.015; Mariano F, 2008, CRIT CARE, V12, DOI 10.1186/cc6848; Mosier MJ, 2010, J BURN CARE RES, V31, P83, DOI 10.1097/BCR.0b013e3181cb8c87; Mustonen KM, 2008, J BURN CARE RES, V29, P227, DOI 10.1097/BCR.0b013e31815f3196; Nagendraprabhu P, 2011, INVEST NEW DRUG, V29, P207, DOI 10.1007/s10637-009-9342-5; Naguib YMA, 2000, J AGR FOOD CHEM, V48, P1150, DOI 10.1021/jf991106k; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Palipoch S, 2013, AFR J TRADIT COMPLEM, V10, P88, DOI 10.4314/ajtcam.v10i4.15; Palmieri T, 2010, BURNS, V36, P205, DOI 10.1016/j.burns.2009.08.012; Parihar A, 2008, BURNS, V34, P6, DOI 10.1016/j.burns.2007.04.009; Qiu XF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0388-1; Quoilin C, 2014, BBA-BIOENERGETICS, V1837, P1790, DOI 10.1016/j.bbabio.2014.07.005; Rael LT, 2009, J NEUROTRAUM, V26, P1203, DOI [10.1089/neu.2008.0816, 10.1089/neu.2008-0816]; Rael LT, 2009, J TRAUMA, V66, P76, DOI 10.1097/TA.0b013e318191bfe0; Rana A, 2001, APOPTOSIS, V6, P83, DOI 10.1023/A:1009680229931; Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852; Sahu BD, 2011, FOOD CHEM TOXICOL, V49, P3090, DOI 10.1016/j.fct.2011.08.018; Sedeek M, 2010, AM J PHYSIOL-RENAL, V299, pF1348, DOI 10.1152/ajprenal.00028.2010; Sener G, 2007, BURNS, V33, P587, DOI 10.1016/j.burns.2006.10.381; Shah SV, 2001, AM J KIDNEY DIS, V37, pS30, DOI 10.1053/ajkd.2001.20736; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Si YN, 2014, EUR REV MED PHARMACO, V18, P1843; Sila A, 2015, EUR J NUTR, V54, P301, DOI 10.1007/s00394-014-0711-2; Small DM, 2012, EXPERT OPIN DRUG MET, V8, P655, DOI 10.1517/17425255.2012.679657; Steinvall I, 2008, CRIT CARE, V12, DOI 10.1186/cc7032; Stoyanoff TR, 2014, TOXICOLOGY, V318, P13, DOI 10.1016/j.tox.2014.01.011; Tasanarong A, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-138; Wagener FADTG, 2009, APOPTOSIS, V14, P1451, DOI 10.1007/s10495-009-0359-1; Yavuz S, 2014, BURNS, V40, P648, DOI 10.1016/j.burns.2013.09.004; Yuan JP, 2011, MOL NUTR FOOD RES, V55, P150, DOI 10.1002/mnfr.201000414; Yuan L, 2011, AM J PHYSIOL-RENAL, V300, pF207, DOI 10.1152/ajprenal.00073.2010; Yuan X, 2014, EXP THER MED, V8, P973, DOI 10.3892/etm.2014.1820; Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730	63	46	49	0	14	MDPI AG	BASEL	POSTFACH, CH-4005 BASEL, SWITZERLAND	1660-3397			MAR DRUGS	Mar. Drugs	APR	2015	13	4					2105	2123		10.3390/md13042105			19	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	CH0NA	WOS:000353715900026	25871290	DOAJ Gold, Green Published			2021-06-18	
J	Katzenberger, RJ; Chtarbanova, S; Rimkus, SA; Fischer, JA; Kaur, G; Seppala, JM; Swanson, LC; Zajac, JE; Ganetzky, B; Wassarman, DA				Katzenberger, Rebeccah J.; Chtarbanova, Stanislava; Rimkus, Stacey A.; Fischer, Julie A.; Kaur, Gulpreet; Seppala, Jocelyn M.; Swanson, Laura C.; Zajac, Jocelyn E.; Ganetzky, Barry; Wassarman, David A.			Death following traumatic brain injury in Drosophila is associated with intestinal barrier dysfunction	ELIFE			English	Article							SENSITIVE PARALYTIC MUTANTS; TRANSCRIPTION FACTOR RELISH; GENETIC REFERENCE PANEL; INNATE IMMUNE-RESPONSE; EPITHELIAL MORPHOGENESIS; INCREASED MORTALITY; PREDICTIVE FACTORS; TIGHT JUNCTIONS; BLOOD-BRAIN; HEAD-INJURY	Traumatic brain injury (TBI) is a major cause of death and disability worldwide. Unfavorable TBI outcomes result from primary mechanical injuries to the brain and ensuing secondary non-mechanical injuries that are not limited to the brain. Our genome-wide association study of Drosophila melanogaster revealed that the probability of death following TBI is associated with single nucleotide polymorphisms in genes involved in tissue barrier function and glucose homeostasis. We found that TBI causes intestinal and blood-brain barrier dysfunction and that intestinal barrier dysfunction is highly correlated with the probability of death. Furthermore, we found that ingestion of glucose after a primary injury increases the probability of death through a secondary injury mechanism that exacerbates intestinal barrier dysfunction. Our results indicate that natural variation in the probability of death following TBI is due in part to genetic differences that affect intestinal barrier dysfunction.	[Katzenberger, Rebeccah J.; Rimkus, Stacey A.; Fischer, Julie A.; Kaur, Gulpreet; Seppala, Jocelyn M.; Swanson, Laura C.; Zajac, Jocelyn E.; Wassarman, David A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Cell & Regenerat Biol, Madison, WI 53706 USA; [Chtarbanova, Stanislava; Ganetzky, Barry] Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; [Kaur, Gulpreet] Univ Wisconsin, Grad Program Cellular & Mol Biol, Madison, WI 53706 USA; [Swanson, Laura C.] Univ Wisconsin, Sch Med & Publ Hlth, Med Scientist Training Program, Madison, WI 53706 USA	Ganetzky, B (corresponding author), Univ Wisconsin, Genet Lab, Madison, WI 53706 USA.	ganetzky@wisc.edu; dawassarman@wisc.edu		Chtarbanova, Stanislava/0000-0001-7865-028X; Swanson, Laura/0000-0002-9438-7546	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AG033620]; University of Wisconsin-Madison; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033620] Funding Source: NIH RePORTER	National Institutes of Health (NIH) R01 AG033620 Barry Ganetzky; University of Wisconsin-Madison Robert Draper Technology Innovation Funding David A Wassarman	Alexiou GA, 2014, BRAIN INJURY, V28, P438, DOI 10.3109/02699052.2014.888769; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Arroyo DS, 2011, INT IMMUNOPHARMACOL, V11, P1415, DOI 10.1016/j.intimp.2011.05.006; Babcock DT, 2015, GENETICS, V199, P511, DOI 10.1534/genetics.114.172403; Balsiger Z, 2014, HIT DEVICE HIGH SPEE; Banerjee S, 2008, DEV BIOL, V317, P585, DOI 10.1016/j.ydbio.2008.03.007; Bansal V, 2010, J TRAUMA, V68, P1059, DOI 10.1097/TA.0b013e3181d87373; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Bastide H, 2014, BMC EVOL BIOL, V14, DOI 10.1186/s12862-014-0179-y; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bonnay F, 2013, P NATL ACAD SCI USA, V110, P2957, DOI 10.1073/pnas.1221910110; Buchon N, 2013, NAT REV MICROBIOL, V11, P615, DOI 10.1038/nrmicro3074; Burg MG, 2012, J NEUROGENET, V26, P189, DOI 10.3109/01677063.2012.690011; Cao Y, 2013, P NATL ACAD SCI USA, V110, pE1752, DOI 10.1073/pnas.1306220110; Chinchore Y, 2012, P NATL ACAD SCI USA, V109, pE605, DOI 10.1073/pnas.1110666109; Copeland RJ, 2008, AM J PHYSIOL-ENDOC M, V295, pE17, DOI 10.1152/ajpendo.90281.2008; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Davceva N, 2012, J FORENSIC LEG MED, V19, P480, DOI 10.1016/j.jflm.2012.04.022; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Desalvo MK, 2011, GLIA, V59, P1322, DOI 10.1002/glia.21147; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Dionex, 2003, DET SUG MOL HIGH PER; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Elkon B, 2014, PEDIATR CRIT CARE ME, V15, P623, DOI 10.1097/PCC.0000000000000170; Failla MD, 2015, NEUROREHAB NEURAL RE, V29, P234, DOI 10.1177/1545968314542617; Falconer D., 1996, INTRO QUANTITATIVE G, V4; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; Feighery L, 2008, J TRAUMA, V64, P131, DOI 10.1097/TA.0b013e3181568d9f; Fergestad T, 2006, GENETICS, V172, P1031, DOI 10.1534/genetics.105.050625; Fergestad T, 2008, GENETICS, V178, P947, DOI 10.1534/genetics.107.082115; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Gnerer JP, 2006, P NATL ACAD SCI USA, V103, P14987, DOI 10.1073/pnas.0606887103; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Gratz SJ, 2013, FLY, V7, P249, DOI 10.4161/fly.26566; Greco T, 2013, J CHILD NEUROL, V28, P983, DOI 10.1177/0883073813487594; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Handke B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067208; Haron RH, 2011, MALAYS J MED SCI, V18, P69; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Haselton AT, 2010, AGING-US, V2, P523, DOI 10.18632/aging.100185; Huang W, 2014, GENOME RES, V24, P1193, DOI 10.1101/gr.171546.113; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jin W, 2008, CYTOKINE, V44, P135, DOI 10.1016/j.cyto.2008.07.005; Katzenberger RJ, 2013, P NATL ACAD SCI USA, V110, pE4152, DOI 10.1073/pnas.1316895110; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Ley EJ, 2011, J TRAUMA, V70, P1141, DOI 10.1097/TA.0b013e3182146d66; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Liu X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042725; Lustenberger T, 2013, BRAIN INJURY, V27, P281, DOI 10.3109/02699052.2012.743178; Mackay TFC, 2012, NATURE, V482, P173, DOI 10.1038/nature10811; Marshall Stephen, 2006, Sci STKE, V2006, pre7; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Narasimha M, 2008, J CELL SCI, V121, P747, DOI 10.1242/jcs.019422; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Palladino MJ, 2003, J NEUROSCI, V23, P1276; Palladino MJ, 2002, GENETICS, V161, P1197; Pare A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036254; Parker L, 2011, INT REV NEUROBIOL, V99, P1, DOI 10.1016/B978-0-12-387003-2.00001-X; Petersen AJ, 2013, GENETICS, V194, P133, DOI 10.1534/genetics.113.150854; Petersen AJ, 2012, P NATL ACAD SCI USA, V109, pE656, DOI 10.1073/pnas.1110470109; Pinsonneault RL, 2011, METHODS MOL BIOL, V686, P357, DOI 10.1007/978-1-60761-938-3_17; Piton G, 2011, INTENS CARE MED, V37, P911, DOI 10.1007/s00134-011-2172-x; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Prisco L, 2012, J NEUROSURG SCI, V56, P131; Reintam A, 2009, ACTA ANAESTH SCAND, V53, P318, DOI 10.1111/j.1399-6576.2008.01860.x; Rera M, 2012, P NATL ACAD SCI USA, V109, P21528, DOI 10.1073/pnas.1215849110; Rera M, 2011, CELL METAB, V14, P623, DOI 10.1016/j.cmet.2011.09.013; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Salim A, 2009, AM SURGEON, V75, P25; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Scrimgeour AG, 2014, J NEUROTRAUM, V31, P989, DOI 10.1089/neu.2013.3234; Senga K, 2012, MOL BIOL CELL, V23, P2845, DOI 10.1091/mbc.E12-02-0097; SIDDIQI O, 1976, P NATL ACAD SCI USA, V73, P3253, DOI 10.1073/pnas.73.9.3253; Sinclair DAR, 2009, P NATL ACAD SCI USA, V106, P13427, DOI 10.1073/pnas.0904638106; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; St Pierre SE, 2014, NUCLEIC ACIDS RES, V42, pD780, DOI 10.1093/nar/gkt1092; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Suzuki T, 2013, CELL MOL LIFE SCI, V70, P631, DOI 10.1007/s00018-012-1070-x; Tan LH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003966; Teleman AA, 2010, BIOCHEM J, V425, P13, DOI 10.1042/BJ20091181; Tennessen JM, 2014, METHODS, V68, P105, DOI 10.1016/j.ymeth.2014.02.034; Thorens B, 2010, AM J PHYSIOL-ENDOC M, V298, pE141, DOI 10.1152/ajpendo.00712.2009; Melo JRT, 2010, NEUROSURGERY, V67, P1542, DOI 10.1227/NEU.0b013e3181fa7049; Varghese J, 2010, GENE DEV, V24, P2748, DOI 10.1101/gad.1995910; Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030; Wei J, 2012, J TRAUMA ACUTE CARE, V73, P654, DOI 10.1097/TA.0b013e31825133c0; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; Werth M, 2010, DEVELOPMENT, V137, P3835, DOI 10.1242/dev.055483; Wong ACN, 2013, ISME J, V7, P1922, DOI 10.1038/ismej.2013.86; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang M, 2009, INT J NURS STUD, V46, P753, DOI 10.1016/j.ijnurstu.2009.01.004; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; Yu ZQ, 2008, DEV BIOL, V319, P56, DOI 10.1016/j.ydbio.2008.04.001; Yuan Q, 2014, NEUROCRIT CARE, V20, P69, DOI 10.1007/s12028-012-9730-0; Zhang LP, 2010, J BIOL CHEM, V285, P34477, DOI 10.1074/jbc.M110.133561	104	46	46	1	11	ELIFE SCIENCES PUBLICATIONS LTD	CAMBRIDGE	SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND	2050-084X			ELIFE	eLife	MAR 5	2015	4								e04790	10.7554/eLife.04790			24	Biology	Life Sciences & Biomedicine - Other Topics	CE5ID	WOS:000351863900002	25742603	DOAJ Gold, Green Published			2021-06-18	
J	Failla, MD; Kumar, RG; Peitzman, AB; Conley, YP; Ferrell, RE; Wagner, AK				Failla, Michelle D.; Kumar, Raj G.; Peitzman, Andrew B.; Conley, Yvette P.; Ferrell, Robert E.; Wagner, Amy K.			Variation in the BDNF Gene Interacts With Age to Predict Mortality in a Prospective, Longitudinal Cohort with Severe TBI	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						brain injury; BDNF; TrkB; mortality; age; genetic association study	TRAUMATIC BRAIN-INJURY; RESPIRATORY-DISTRESS-SYNDROME; ACTIVITY-DEPENDENT SECRETION; HPA-AXIS REACTIVITY; TRKB MESSENGER-RNA; NEUROTROPHIC FACTOR; VAL66MET POLYMORPHISM; TRUNCATED TRKB; HEAD-INJURY; LIFE-SPAN	Background. Mortality predictions following traumatic brain injury (TBI), and our understanding of TBI pathology, may be improved by including genetic risk in addition to traditional prognostic variables. One promising target is the gene coding for brain-derived neurotrophic factor (BDNF), a ubiquitous neurotrophin important for neuronal survival and neurogenesis. Objective. We hypothesized the addition of BDNF genetic variation would improve mortality prediction models and that BDNF Met-carriers (rs6265) and C-carriers (rs7124442) would have the highest mortality rates post-TBI. Methods. This study examined BDNF functional single nucleotide polymorphisms rs6265 (val66met) and rs7124442 (T>C) in relation to mortality in a prospective, longitudinal cohort with severe TBI. We examined 315 individuals receiving care for a closed head injury within the University of Pittsburgh Medical Center, aged 16 to 74 years. Mortality was examined acutely (0-7 days postinjury) and postacutely (8-365 days postinjury). A gene risk score (GRS) was developed to examine both BDNF loci. Cox proportional hazards models were used to calculate hazard ratios for survivability post-TBI while controlling for covariates. Results. BDNF GRS was significantly associated with acute mortality, regardless of age. Interestingly, subjects in the hypothesized no-risk allele group had the lowest survival probability. Postacutely, BDNF-GRS interacted with age such that younger participants in the no-risk group had the highest survival probability, while older participants in the hypothesized no-risk group had the lowest probability of survival. Conclusions. These data suggest complex relationships between BDNF and TBI mortality that interact with age to influence survival predictions beyond clinical variables alone. Evidence supporting dynamic, temporal balances of pro-survival/pro-apoptotic target receptors may explain injury and age-related gene associations.	[Failla, Michelle D.; Kumar, Raj G.; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Failla, Michelle D.; Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Peitzman, Andrew B.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA; [Ferrell, Robert E.] Univ Pittsburgh, Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Wagner, AK (corresponding author), Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Conley, Yvette/0000-0002-1784-6067	Department of DefenseUnited States Department of Defense [W81XWH-07-1-0701]; National Institute on Disability and Rehabilitation Research [NIDRR H133A120087]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD048162, R01NR008424, R01NR013342]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048162] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013342, R01NR008424] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Department of Defense (W81XWH-07-1-0701, Wagner), National Institute on Disability and Rehabilitation Research (NIDRR H133A120087, Wagner), and National Institute of Health (R01HD048162, Wagner; R01NR008424 and R01NR013342, Conley).	Alexander N, 2010, PSYCHONEUROENDOCRINO, V35, P949, DOI 10.1016/j.psyneuen.2009.12.008; Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; An JJ, 2008, CELL, V134, P175, DOI 10.1016/j.cell.2008.05.045; Barker PA, 2009, NAT NEUROSCI, V12, P105, DOI 10.1038/nn0209-105; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Brady R, 1999, J NEUROSCI, V19, P2131; Caporali A, 2009, PHYSIOL REV, V89, P279, DOI 10.1152/physrev.00007.2008; Centers for Disease Control and Prevention, 2010, TRAUMATIC BRAIN INJU; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; COX DR, 1972, J R STAT SOC B, V34, P187; Croll SD, 1998, BRAIN RES, V812, P200, DOI 10.1016/S0006-8993(98)00993-7; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Erickson KI, 2012, NEUROSCIENTIST, V18, P82, DOI 10.1177/1073858410397054; Failla MD, 2013, BRAIN INJURY, V27, P696, DOI 10.3109/02699052.2013.775481; Freedman ML, 2004, NAT GENET, V36, P388, DOI 10.1038/ng1333; GenealogyBank. com, 2013, SOC SEC DEATH IND; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Gomes JR, 2012, J NEUROSCI, V32, P4610, DOI 10.1523/JNEUROSCI.0374-12.2012; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; Hallden S, 2013, HEART, V99, P949, DOI 10.1136/heartjnl-2013-303634; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Kalish H, 2010, J CHROMATOGR B, V878, P194, DOI 10.1016/j.jchromb.2009.10.022; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Kasselman LJ, 2006, J NEUROIMMUNOL, V175, P118, DOI 10.1016/j.jneuroim.2006.03.008; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; Krabbe KS, 2009, J AM GERIATR SOC, V57, P1447, DOI 10.1111/j.1532-5415.2009.02345.x; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Matsumoto T, 2008, NAT NEUROSCI, V11, P131, DOI 10.1038/nn2038; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Orefice LL, 2013, J NEUROSCI, V33, P11618, DOI 10.1523/JNEUROSCI.0012-13.2013; Pruunsild P, 2007, GENOMICS, V90, P397, DOI 10.1016/j.ygeno.2007.05.004; Qin LY, 2014, J NEUROSCI, V34, P2493, DOI 10.1523/JNEUROSCI.4140-13.2014; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Ritter C, 2012, CRIT CARE, V16, DOI 10.1186/cc11902; Romanczyk TB, 2002, EUR J NEUROSCI, V15, P269, DOI 10.1046/j.0953-816x.2001.01858.x; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Rostami E, 2014, BRAIN RES, V1542, P195, DOI 10.1016/j.brainres.2013.10.047; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Rothman SM, 2012, ANN NY ACAD SCI, V1264, P49, DOI 10.1111/j.1749-6632.2012.06525.x; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Shalev I, 2009, PSYCHONEUROENDOCRINO, V34, P382, DOI 10.1016/j.psyneuen.2008.09.017; Siironen J, 2007, STROKE, V38, P2858, DOI 10.1161/STROKEAHA.107.485441; Silhol M, 2005, NEUROSCIENCE, V132, P613, DOI 10.1016/j.neuroscience.2005.01.008; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Vidaurre OG, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.143; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2012, BRAIN INJURY, V26, P1658, DOI 10.3109/02699052.2012.700089; Wan RQ, 2014, J NEUROCHEM, V129, P573, DOI 10.1111/jnc.12656; Wang H, 2002, NEUROSCIENCE, V112, P967, DOI 10.1016/S0306-4522(02)00085-4; Webster MJ, 2006, GENE EXPR PATTERNS, V6, P941, DOI 10.1016/j.modgep.2006.03.009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yang AC, 2010, AM J MED GENET B, V153B, P1024, DOI 10.1002/ajmg.b.31069; Yang B, 2002, NAT NEUROSCI, V5, P539, DOI 10.1038/nn853; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	65	46	47	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	MAR-APR	2015	29	3					234	246		10.1177/1545968314542617			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CB2PD	WOS:000349469000004	25063686	Green Accepted			2021-06-18	
J	Yang, JZ; Peek-Asa, C; Covassin, T; Torner, JC				Yang, Jingzhen; Peek-Asa, Corinne; Covassin, Tracey; Torner, James C.			Post-Concussion Symptoms of Depression and Anxiety in Division I Collegiate Athletes	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							PSYCHOLOGY; STATEMENT; SPORTS	This study examined the effect of baseline psychological symptoms on post-concussion symptoms among 67 concussed collegiate athletes. Depression at baseline was the strongest predictor of post-concussion depression and anxiety. Post-concussion depression and anxiety were significantly associated. These results support the importance of baseline screenings for risk of post-concussion psychological symptoms.	[Yang, Jingzhen; Peek-Asa, Corinne; Torner, James C.] Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA USA; [Yang, Jingzhen] Ohio State Univ, Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Peek-Asa, Corinne] Univ Iowa, Dept Occupat & Environm Hlth, Iowa City, IA USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Torner, James C.] Univ Iowa, Dept Epidemiol, Iowa City, IA USA	Yang, JZ (corresponding author), Ohio State Univ, Coll Med, Ctr Injury Res & Policy, Res Inst,Nationwide Childrens Hosp,Dept Pediat, 700 Childrens Dr, Columbus, OH 43205 USA.	ginger.yang@nationwidechildrens.org			University of Iowa Injury Prevention Research Center; Centers for Disease Control and Prevention (CDC)/National Center for Injury Prevention and Control [R49 CD001167-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001167] Funding Source: NIH RePORTER	This research work was supported by the University of Iowa Injury Prevention Research Center, and funded by grant # R49 CD001167-01 of the Centers for Disease Control and Prevention (CDC)/National Center for Injury Prevention and Control.	Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; Hootman JM, 2007, J ATHL TRAINING, V42, P311; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; RADLOFF LS, 1991, J YOUTH ADOLESCENCE, V20, P149, DOI 10.1007/BF01537606; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Wiese-Bjornstal DM, 2010, SCAND J MED SCI SPOR, V20, P103, DOI 10.1111/j.1600-0838.2010.01195.x	10	46	46	0	35	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	JAN 2	2015	40	1			SI		18	23		10.1080/87565641.2014.973499			6	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	CA6IR	WOS:000349015800004	25649775				2021-06-18	
J	Dutca, LM; Stasheff, SF; Hedberg-Buenz, A; Rudd, DS; Batra, N; Blodi, FR; Yorek, MS; Yin, T; Shankar, M; Herlein, JA; Naidoo, J; Morlock, L; Williams, N; Kardon, RH; Anderson, MG; Pieper, AA; Harper, MM				Dutca, Laura M.; Stasheff, Steven F.; Hedberg-Buenz, Adam; Rudd, Danielle S.; Batra, Nikhil; Blodi, Frederick R.; Yorek, Matthew S.; Yin, Terry; Shankar, Malini; Herlein, Judith A.; Naidoo, Jacinth; Morlock, Lorraine; Williams, Noelle; Kardon, Randy H.; Anderson, Michael G.; Pieper, Andrew A.; Harper, Matthew M.			Early Detection of Subclinical Visual Damage After Blast-Mediated TBI Enables Prevention of Chronic Visual Deficit by Treatment With P7C3-S243	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article						multielectrode array; retinal ganglion cell; pattern ERG; blast injury; neuroprotection	NEUROPROTECTIVE EFFICACY; MOUSE MODEL; AMINOPROPYL CARBAZOLES; DYSFUNCTION; DEGENERATION; DISCOVERY; CELLS; FIELD; EYE	PURPOSE. Traumatic brain injury (TBI) frequently leads to chronic visual dysfunction. The purpose of this study was to investigate the effect of TBI on retinal ganglion cells (RGCs), and to test whether treatment with the novel neuroprotective compound P7C3-S243 could prevent in vivo functional deficits in the visual system. METHODS. Blast-mediated TBI was modeled using an enclosed over-pressure blast chamber. The RGC physiology was evaluated using a multielectrode array and pattern electroretinogram (PERG). Histological analysis of RGC dendritic field and cell number were evaluated at the end of the study. Visual outcome measures also were evaluated based on treatment of mice with P7C3-S243 or vehicle control. RESULTS. We show that deficits in neutral position PERG after blast-mediated TBI occur in a temporally bimodal fashion, with temporary recovery 4 weeks after injury followed by chronically persistent dysfunction 12 weeks later. This later time point is associated with development of dendritic abnormalities and irreversible death of RGCs. We also demonstrate that ongoing pathologic processes during the temporary recovery latent period (including abnormalities of RGC physiology) lead to future dysfunction of the visual system. We report that modification of PERG to provocative postural tilt testing elicits changes in PERG measurements that correlate with a key in vitro measures of damage: the spontaneous and light-evoked activity of RGCs. Treatment with P7C3-S243 immediately after injury and throughout the temporary recovery latent period protects mice from developing chronic visual system dysfunction. CONCLUSIONS. Provocative PERG testing serves as a noninvasive test in the living organism to identify early damage to the visual system, which may reflect corresponding damage in the brain that is not otherwise detectable by noninvasive means. This provides the basis for developing an earlier diagnostic test to identify patients at risk for developing chronic CNS and visual system damage after TBI at an earlier stage when treatments may be more effective in preventing these sequelae. In addition, treatment with the neuroprotective agent P7C3-S243 after TBI protects from visual system dysfunction after TBI.	[Dutca, Laura M.; Hedberg-Buenz, Adam; Rudd, Danielle S.; Batra, Nikhil; Yorek, Matthew S.; Herlein, Judith A.; Kardon, Randy H.; Anderson, Michael G.; Pieper, Andrew A.; Harper, Matthew M.] Iowa City Dept Vet Affairs, Ctr Prevent & Treatment Visual Loss, Iowa City, IA USA; [Dutca, Laura M.; Stasheff, Steven F.; Kardon, Randy H.; Anderson, Michael G.; Harper, Matthew M.] Univ Iowa, Dept Ophthalmol, Iowa City, IA 52242 USA; [Dutca, Laura M.; Stasheff, Steven F.; Kardon, Randy H.; Anderson, Michael G.; Harper, Matthew M.] Univ Iowa, Dept Visual Sci, Iowa City, IA 52242 USA; [Stasheff, Steven F.; Blodi, Frederick R.; Shankar, Malini] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Stasheff, Steven F.; Pieper, Andrew A.] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA; [Hedberg-Buenz, Adam; Anderson, Michael G.] Univ Iowa, Dept Physiol & Mol Biophys, Iowa City, IA 52242 USA; [Yin, Terry; Pieper, Andrew A.] Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; [Naidoo, Jacinth; Morlock, Lorraine; Williams, Noelle] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	Harper, MM (corresponding author), Univ Iowa, Ctr Prevent & Treatment Visual Loss, Dept Vet Affairs, 601 Highway 6 W, Iowa City, IA 52242 USA.	andrew-pieper@uiowa.edu; matthew-harper@uiowa.edu	Anderson, Michael/B-4580-2009; Pieper, Andrew A/R-5552-2016	Anderson, Michael/0000-0001-5730-6105; Kardon, Randy/0000-0002-3173-7123; Pieper, Andrew/0000-0001-6299-6577; Harper, Matthew/0000-0003-3395-2406	Department of Veterans Affairs, Veterans Health Administration, Office of Research and [1I01RX000427-01]; University of Iowa Carver College of Medicine; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY017673, ZIAEY000545] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000427] Funding Source: NIH RePORTER	Supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Center for Prevention and Treatment of Visual Loss, a Rehabilitation Research and Development Career Development Award (MMH), an RR&D Merit Study Award (1I01RX000427-01), and funds from the University of Iowa Carver College of Medicine (AAP). The authors alone are responsible for the content and writing of thse paper.	Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Chichilnisky EJ, 2001, NETWORK-COMP NEURAL, V12, P199, DOI 10.1088/0954-898X/12/2/306; Cockerham GC, 2011, NEW ENGL J MED, V364, P2172, DOI 10.1056/NEJMc1010683; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; Della Santina L, 2013, J NEUROSCI, V33, P17444, DOI 10.1523/JNEUROSCI.5461-12.2013; Dougherty AL, 2011, BRAIN INJURY, V25, P8, DOI 10.3109/02699052.2010.536195; Feng L, 2013, INVEST OPHTH VIS SCI, V54, P1106, DOI 10.1167/iovs.12-10791; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Kemp SWP, 2015, NEUROSCIENCE, V284, P202, DOI 10.1016/j.neuroscience.2014.10.005; Lemke S, 2013, JAMA OPHTHALMOL, V131, P1602, DOI 10.1001/jamaophthalmol.2013.5028; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Luo XD, 2011, INVEST OPHTH VIS SCI, V52, P8571, DOI 10.1167/iovs.11-8376; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; Magone MT, 2014, J REHABIL RES DEV, V51, P71, DOI 10.1682/JRRD.2013.01.0008; MAUNSELL JHR, 1992, J NEUROPHYSIOL, V68, P1332; Miura G, 2009, EXP EYE RES, V89, P49, DOI 10.1016/j.exer.2009.02.009; Mohan K, 2013, INVEST OPHTH VIS SCI, V54, P3440, DOI 10.1167/iovs.12-11522; Mohan K, 2012, VET OPHTHALMOL, V15, P94, DOI 10.1111/j.1463-5224.2012.01034.x; Nagaraju M, 2007, INVEST OPHTH VIS SCI, V48, P4573, DOI 10.1167/iovs.07-0582; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Pieper AA, 2014, CHEM SOC REV, V43, P6716, DOI 10.1039/c3cs60448a; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Reid RC, 1997, VISUAL NEUROSCI, V14, P1015, DOI 10.1017/S0952523800011743; SOTA, 2008, STAT ART 9 TRAUM BRA; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Thompson S, 2014, INVEST OPHTH VIS SCI, V55, P1859, DOI 10.1167/iovs.13-13661; Ventura LM, 2013, J GLAUCOMA, V22, P255, DOI 10.1097/IJG.0b013e318232973b; Viswanathan S, 2000, INVEST OPHTH VIS SCI, V41, P2797; Walker A.K., 2014, MOL PSYCHIAT; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Williams PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072282; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030	34	46	46	0	10	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404	1552-5783		INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	DEC	2014	55	12					8330	8341		10.1167/iovs.14-15468			12	Ophthalmology	Ophthalmology	AX9KR	WOS:000347222300071	25468886	Green Published			2021-06-18	
J	Le Roux, P; Menon, DK; Citerio, G; Vespa, P; Bader, MK; Brophy, G; Diringer, MN; Stocchetti, N; Videtta, W; Armonda, R; Badjatia, N; Bosel, J; Chesnut, R; Chou, S; Claassen, J; Czosnyka, M; De Georgia, M; Figaji, A; Fugate, J; Helbok, R; Horowitz, D; Hutchinson, P; Kumar, M; McNett, M; Miller, C; Naidech, A; Oddo, M; Olson, D; O'Phelan, K; Provencio, JJ; Puppo, C; Riker, R; Roberson, C; Schmidt, M; Taccone, F				Le Roux, Peter; Menon, David K.; Citerio, Giuseppe; Vespa, Paul; Bader, Mary Kay; Brophy, Gretchen; Diringer, Michael N.; Stocchetti, Nino; Videtta, Walter; Armonda, Rocco; Badjatia, Neeraj; Boesel, Julian; Chesnut, Randall; Chou, Sherry; Claassen, Jan; Czosnyka, Marek; De Georgia, Michael; Figaji, Anthony; Fugate, Jennifer; Helbok, Raimund; Horowitz, David; Hutchinson, Peter; Kumar, Monisha; McNett, Molly; Miller, Chad; Naidech, Andrew; Oddo, Mauro; Olson, DaiWai; O'Phelan, Kristine; Provencio, J. Javier; Puppo, Corinna; Riker, Richard; Roberson, Claudia; Schmidt, Michael; Taccone, Fabio			The International Multidisciplinary Consensus Conference on Multimodality Monitoring in Neurocritical Care: A List of Recommendations and Additional Conclusions A Statement for Healthcare Professionals From the Neurocritical Care Society and the European Society of Intensive Care Medicine	NEUROCRITICAL CARE			English	Article						Consensus development conference; Grading of recommendations assessment development and evaluation (GRADE); Brain metabolism; Brain oxygen; Clinical trials; Intracranial pressure; Microdialysis; Multimodal monitoring; Neuromonitoring; Traumatic brain injury; Brain physiology; Bio-informatics; Biomarkers; Neurocritical care; Clinical guidelines		Careful patient monitoring using a variety of techniques including clinical and laboratory evaluation, bedside physiological monitoring with continuous or non-continuous techniques and imaging is fundamental to the care of patients who require neurocritical care. How best to perform and use bedside monitoring is still being elucidated. To create a basic platform for care and a foundation for further research the Neurocritical Care Society in collaboration with the European Society of Intensive Care Medicine, the Society for Critical Care Medicine and the Latin America Brain Injury Consortium organized an international, multidisciplinary consensus conference to develop recommendations about physiologic bedside monitoring. This supplement contains a Consensus Summary Statement with recommendations and individual topic reviews as a background to the recommendations. In this article, we highlight the recommendations and provide additional conclusions as an aid to the reader and to facilitate bedside care.	[Le Roux, Peter] Lankenau Med Ctr, Brain & Spine Ctr, Wynnewood, PA 19096 USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England; [Citerio, Giuseppe] Osped San Gerardo, Dept Anesthesia & Crit Care, I-20900 Monza, Italy; [Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Bader, Mary Kay] Neuro Crit Care CNS Mission Hosp, Mission Viejo, CA 92691 USA; [Brophy, Gretchen] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcomes Sci, Richmond, VA 23298 USA; [Brophy, Gretchen] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Diringer, Michael N.] Washington Univ, Neurocrit Care Sect, Dept Neurol, St Louis, MO 63110 USA; [Stocchetti, Nino] Univ Milan, Dept Physiopathol & Transplant, Maggiore Policlin, Fdn IRCCS Ca Granda Osped, I-20122 Milan, Italy; [Videtta, Walter] Hosp Nacl Prof A Posadas, ICU Neurocrit Care, El Palomar, Buenos Aires, Argentina; [Armonda, Rocco] MedStar Georgetown Univ Hosp, Dept Neurosurg, Medstar Hlth, Washington, DC 20007 USA; [Badjatia, Neeraj] Univ Maryland, Dept Neurol, Med Ctr, Baltimore, MD 21201 USA; [Boesel, Julian] Univ Heidelberg Hosp, Dept Neurol Ruprect Karls, D-69120 Heidelberg, Germany; [Chesnut, Randall] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Chou, Sherry] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA; [Claassen, Jan] Columbia Univ Coll Phys & Surg, Dept Neurol & Neurosurg, New York, NY 10017 USA; [Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 0QQ, England; [De Georgia, Michael] Case Western Reserve Univ, Sch Med, Dept Neurol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA; [Figaji, Anthony] Univ Cape Town, Inst Child Hlth Red Cross Childrens Hosp Rondebos, Dept Pediat Neurosurg, ZA-7700 Cape Town, South Africa; [Fugate, Jennifer] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA; [Helbok, Raimund] Med Univ Innsbruck, Dept Neurol, Neurocrit Care Unit, A-6020 Innsbruck, Austria; [Horowitz, David] Univ Penn Hlth Syst, Philadelphia, PA 19104 USA; [Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Kumar, Monisha] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [McNett, Molly] MetroHlth Syst, Cleveland, OH 44109 USA; [Miller, Chad] Ohio State Univ, Div Cerebrovasc Dis & Neurocrit Care, Columbus, OH 43210 USA; [Naidech, Andrew] Univ Feinberg SOM, Dept Neurol Northwestern, Chicago, IL 60611 USA; [Oddo, Mauro] Med Univ Lausanne, CHUV Univ Hosp, Dept Intens Care Med, Fac Biol, CH-1011 Lausanne, Switzerland; [Olson, DaiWai] Univ Texas Southwestern, Dept Neurol Neurotherapeut & Neurosurg, Dallas, TX 75390 USA; [O'Phelan, Kristine] Univ Miami, Miller Sch Med JMH, Dept Neurol, Miami, FL 33136 USA; [Provencio, J. Javier] Cleveland Clin, Lerner Coll Med, Cerebrovasc Ctr, Cleveland, OH 44195 USA; [Provencio, J. Javier] Cleveland Clin, Lerner Coll Med, Neuroinflammat Res Ctr, Cleveland, OH 44195 USA; [Puppo, Corinna] Univ Republica, Hosp Clin, Intens Care Unit, Montevideo, Uruguay; [Riker, Richard] Maine Med Ctr, Crit Care Med, Portland, ME 04102 USA; [Roberson, Claudia] Baylor Coll Med, Ben Taub Hosp, Dept Neurosurg, Houston, TX 77030 USA; [Schmidt, Michael] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Taccone, Fabio] Free Univ Brussels, Erasme Hosp, Dept Intens Care, Lab Rech Expt, B-1050 Brussels, Belgium	Le Roux, P (corresponding author), Lankenau Med Ctr, Brain & Spine Ctr, Suite 370,Med Sci Bldg,100 East Lancaster Ave, Wynnewood, PA 19096 USA.	lerouxp@mlhs.org; dkm13@wbic.cam.ac.uk; g.citerio@hsgerardo.org; PVespa@mednet.ucla.edu; Marykay.Bader@stjoe.org; gbrophy@vcu.edu; diringerm@neuro.wustl.edu; stocchet@policlinico.mi.it; wvidetta@ar.inter.net; Rocco.Armonda@gmail.com; nbadjatia@umm.edu; Julian.Boesel@med.uni-heidelberg.de; chesnutr@u.washington.edu; schou1@partners.org; jc1439@cumc.columbia.edu; mc141@medschl.cam.ac.uk; michael.degeorgia@uhhospitals.org; anthony.figaji@uct.ac.za; Jennifer@mayo.edu; raimund.helbok@uki.at; david.horowitz@uphs.upenn.edu; pjah2@cam.ac.uk; monisha.kumar@uphs.upenn.edu; mmcnett@metrohealth.org; ChadM.Miller@osumc.edu; ANaidech@nmff.org; Mauro.Oddo@chuv.ch; daiwai.olson@utsouthwestern.edu; kophelan@med.miami.edu; provenj@ccf.org; coripuppo@gmail.com; RRiker@cmamaine.com; claudiar@bcm.tmc.edu; mjs2134@columbia.edu; ftaccone@ulb.ac.be	Provencio, Jose Javier/AAG-5114-2021; Oddo, Mauro/R-3370-2016; Claassen, Jan/AAA-5451-2020; Helbok, Raimund/AAA-8361-2021; Chou, Sherry/G-5779-2015; Citerio, Giuseppe/B-1839-2015; Olson, DaiWai/I-5932-2019; Stocchetti, Nino/O-7444-2017; Diringer, Michael N/C-1165-2008	Provencio, Jose Javier/0000-0003-1298-1806; Oddo, Mauro/0000-0002-6155-2525; Citerio, Giuseppe/0000-0002-5374-3161; Olson, DaiWai/0000-0002-9280-078X; Stocchetti, Nino/0000-0003-3250-6834; Diringer, Michael N/0000-0003-2337-5537; Brophy, Gretchen/0000-0002-4749-2693; czosnyka, marek/0000-0003-2446-8006; Chesnut, Randall/0000-0001-6377-3666; Hutchinson, Peter/0000-0002-2796-1835; Figaji, Anthony/0000-0002-3357-6490	Department of HealthEuropean Commission [NIHR-RP-R3-12-013, 12/35/57] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0601025, G0001237, G0600986, G9439390] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS073806] Funding Source: Medline; National Institute for Health ResearchNational Institute for Health Research (NIHR) [12/35/57, NIHR-RP-R3-12-013, NF-SI-0512-10090] Funding Source: researchfish		Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Jaeschke R, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a744; Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Rochwerg B, 2014, INTENS CARE MED, V40, P877, DOI 10.1007/s00134-014-3273-0	5	46	46	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2014	21			2			282	296		10.1007/s12028-014-0077-6			15	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CD7AM	WOS:000351242600019	25501689	Green Accepted			2021-06-18	
J	Macpherson, A; Fridman, L; Scolnik, M; Corallo, A; Guttmann, A				Macpherson, Alison; Fridman, Liraz; Scolnik, Michal; Corallo, Ashley; Guttmann, Astrid			A population-based study of paediatric emergency department and office visits for concussions from 2003 to 2010	PAEDIATRICS & CHILD HEALTH			English	Article						Concussion; Concussion-related injury; Epidemiology; Paediatric	TRAUMATIC BRAIN-INJURY; HEAD-INJURIES; CHILDREN; SPORT; ADOLESCENTS; SEVERITY	BACKGROUND: There is a paucity of information regarding descriptive epidemiology of paediatric concussions over time, and few studies include both emergency department (ED) and physician office visits. OBJECTIVE: To describe trends in visits for paediatric concussions in both EDs and physician offices according to age and sex. A secondary objective was to describe the cause of concussion for children treated in EDs. METHODS: A retrospective, population-based study using linked health administrative data from all concussion-related visits to the ED or a physician office by school-age children and youth (three to 18 years of age) in Ontario between April 1, 2003 and March 3, 2011 was conducted. RESULTS: The number of children evaluated in both EDs and a physician offices increased between 2003 and 2010, and this linear trend was statistically significant (P=0.002 for ED visits and P=0.001 for office visits). The rate per 100,000 increased from 466.7 to 754.3 for boys and from 208.6 to 440.7 for girls during the study period. Falls accounted for approximately one-third of the paediatric concussions. Hockey/skating was the most common specific cause of paediatric sports-related concussions. CONCLUSIONS: The increasing use of health care services for concussions is likely related to changes in incidence over time and increased awareness of concussion as a health issue. Evidence-based prevention initiatives to help reduce the incidence of concussion are warranted, particularly in sports and recreation programs.	[Macpherson, Alison; Fridman, Liraz; Scolnik, Michal] York Univ, Toronto, ON M3J 1P3, Canada; [Macpherson, Alison; Corallo, Ashley; Guttmann, Astrid] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; [Guttmann, Astrid] Univ Toronto, Hosp Sick Children, Div Paediat Med, Toronto, ON M5G 1X8, Canada; [Guttmann, Astrid] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada	Macpherson, A (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	alison3@yorku.ca			Institute for Clinical Evaluative Sciences	The Institute for Clinical Evaluative Sciences.	Andersson EE, 2012, DEV NEUROREHABIL, V15, P26, DOI 10.3109/17518423.2011.633570; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Billette JM, 2011, STAT CANADA INJURIES; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Giannotti M, 2010, INJURY, V41, P907, DOI 10.1016/j.injury.2009.09.040; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harris AW, 2012, J SCI MED SPORT, V15, P298, DOI 10.1016/j.jsams.2011.12.005; Johnson LSM, 2011, CAN MED ASSOC J, V183, P921, DOI 10.1503/cmaj.110282; Kimbler DE, 2011, J NEUROSCI NURS, V43, P286, DOI 10.1097/JNN.0b013e31823858a6; Knox CL, 2006, PEDIATRICS, V118, P549, DOI 10.1542/peds.2005-2913; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Smith CA, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004046.pub3; Tabish A, 2006, INJURY, V37, P410, DOI 10.1016/j.injury.2006.01.039; Warsh JM, 2009, CLIN J SPORT MED, V19, P134, DOI 10.1097/JSM.0b013e3181987783; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017; Yang J, 2008, BRIT J SPORT MED, V42, P664, DOI 10.1136/bjsm.2007.040923	20	46	46	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1205-7088	1918-1485		PAED CHILD HEALT-CAN	Paediatr. Child Health	DEC	2014	19	10					543	546		10.1093/pch/19.10.543			4	Pediatrics	Pediatrics	AW4JZ	WOS:000346248700013	25587234	Green Published, Bronze			2021-06-18	
J	Kore, RA; Abraham, EC				Kore, Rajshekhar A.; Abraham, Edathara C.			Inflammatory cytokines, interleukin-1 beta and tumor necrosis factor-alpha, upregulated in glioblastoma multiforme, raise the levels of CRYAB in exosomes secreted by U373 glioma cells	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						IL-1 beta; TNF-alpha; GBM; Neuroinflammation; Cancer progression; CRYAB	CANCER-RELATED INFLAMMATION; HUMAN BRAIN-TUMORS; B-CRYSTALLIN; EXPRESSION; ROLES; MICROENVIRONMENT; COMMUNICATION; PROGRESSION; BIOGENESIS; INDUCTION	In the brain, levels of inflammatory cytokines, interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha), are elevated under traumatic brain injury, neuroinflammatory conditions and glioblastoma multiforme (GBM). In GBM, the levels of small heat shock protein, CRYAB (HspB5) are also reported to be elevated, where it has been shown to exert anti-apoptotic activity. Interestingly, CRYAB is secreted via exosomes by various cells. In order to understand the relation between inflammatory cytokines and CRYAB, U373 glioma cells, were stimulated with proinflammatory cytokines, IL-1 beta and TNF-alpha, and their effect on CRYAB levels in cells and secreted exosomes was studied. Our results show that U373 cells produce and secrete CRYAB via exosomes and that stimulation with IL-1 beta and TNF-alpha, significantly increase the levels of CRYAB in not only the cells but also in the secreted exosomes. In addition, cytokine stimulation of U373 cells brings about changes in the secreted exosomal proteome, many of which are involved in cancer progression. (C) 2014 Elsevier Inc. All rights reserved.	[Kore, Rajshekhar A.; Abraham, Edathara C.] Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	Kore, RA (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham St,Slot 516, Little Rock, AR 72205 USA.	RAKore@uams.edu			NIH/NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY011352-17]; Arkansas IDeA Network for Biomedical Research Excellence [P20GM103429]; UA Center for Protein Structure and Function [P30GM103450]; UAMS Center for Microbial Pathogenesis and Host Inflammatory Responses [P20GM103625]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY011352] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103429, P30GM103450, P20GM103625] Funding Source: NIH RePORTER	This study was supported by NIH/NEI Grant R01EY011352-17. The authors would like to acknowledge Jeffrey A. Kamykowski and UAMS Digital Microscopy Core for the electron microscopy images, and the UAMS Proteomics Core supported by the Arkansas IDeA Network for Biomedical Research Excellence (P20GM103429), the UA Center for Protein Structure and Function (P30GM103450), and the UAMS Center for Microbial Pathogenesis and Host Inflammatory Responses (P20GM103625) for proteomics studies. The authors would also like to thank Dr. Samuel G. Mackintosh, Ms. Linley Moreland and Dr. Alan J. Tackett for their help.	Allavena P, 2008, CURR OPIN GENET DEV, V18, P3, DOI 10.1016/j.gde.2008.01.003; AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; Byrum S, 2011, J CUTAN PATHOL, V38, P933, DOI 10.1111/j.1600-0560.2011.01761.x; Byrum Stephanie D, 2013, J Proteomics Bioinform, V6, P43; Cai ZJ, 2012, J IMMUNOL, V188, P5954, DOI 10.4049/jimmunol.1103466; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; Formolo CA, 2011, J PROTEOME RES, V10, P3149, DOI 10.1021/pr200210w; Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604; Fruhbeis C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00119; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Germano G, 2008, CYTOKINE, V43, P374, DOI 10.1016/j.cyto.2008.07.014; Goplen D, 2010, AM J PATHOL, V177, P1618, DOI 10.2353/ajpath.2010.090063; Gridley DS, 1998, CANCER DETECT PREV, V22, P20, DOI 10.1046/j.1525-1500.1998.00010.x; Guescini M, 2010, J NEURAL TRANSM, V117, P1, DOI 10.1007/s00702-009-0288-8; Gusachenko ON, 2013, BIOCHEMISTRY-MOSCOW+, V78, P1, DOI 10.1134/S000629791301001X; Henderson MC, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00038; Hitotsumatsu T, 1996, CANCER, V77, P352, DOI 10.1002/(SICI)1097-0142(19960115)77:2<352::AID-CNCR19>3.3.CO;2-Q; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Hosseini Hamideh Mahmoodzadeh, 2013, Inflammation & Allergy Drug Targets, V12, P29; Ilyin SE, 2000, BRAIN RES BULL, V51, P29, DOI 10.1016/S0361-9230(99)00190-2; IWAKI T, 1991, CANCER, V68, P2230, DOI 10.1002/1097-0142(19911115)68:10<2230::AID-CNCR2820681023>3.0.CO;2-7; Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kucharzewska P., 2013, P NATL ACAD SCI US; Liu CR, 2006, J IMMUNOL, V176, P1375, DOI 10.4049/jimmunol.176.3.1375; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118; Ohno S, 2013, ADV DRUG DELIVER REV, V65, P398, DOI 10.1016/j.addr.2012.07.019; Polisetty RV, 2011, J PROTEOMICS, V74, P1918, DOI 10.1016/j.jprot.2011.05.002; Putz U, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003084; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Stegh AH, 2008, P NATL ACAD SCI USA, V105, P10703, DOI 10.1073/pnas.0712034105; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Tarassishin L, 2014, J PROTEOMICS, V99, P152, DOI 10.1016/j.jprot.2014.01.024; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Tian TA, 2010, J CELL BIOCHEM, V111, P488, DOI 10.1002/jcb.22733; Venugopal C, 2012, J NEURO-ONCOL, V109, P457, DOI 10.1007/s11060-012-0917-1; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Zhou W., 2014, J CANC RES CLIN ONCO	40	46	48	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	OCT 24	2014	453	3					326	331		10.1016/j.bbrc.2014.09.068			6	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	CC3RR	WOS:000350267500007	25261722	Green Accepted			2021-06-18	
J	Juengst, SB; Kumar, RG; Arenth, PM; Wagner, AK				Juengst, S. B.; Kumar, R. G.; Arenth, P. M.; Wagner, A. K.			Exploratory associations with Tumor Necrosis Factor-alpha, disinhibition and suicidal endorsement after traumatic brain injury	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Brain injury; Depression; Inflammation; Suicide; Tumor Necrosis Factor-Alpha; Disinhibition; Impulsivity	POSTTRAUMATIC-STRESS-DISORDER; MAJOR DEPRESSIVE DISORDER; BEHAVIOR SCALE FRSBE; TNF-ALPHA; INFLAMMATORY CYTOKINES; EXECUTIVE DYSFUNCTION; COGNITIVE INHIBITION; PREFRONTAL CORTEX; DOWNS-SYNDROME; SEVERE TBI	Purpose: To examine the relationship of Tumor Necrosis Factor (TNF)-alpha to disinhibition and suicidal endorsement after traumatic brain injury (TBI). Participants: Adults with moderate to severe TBI (acute serum levels: n = 48, n = 543 samples; acute CSF levels: n = 37, n = 389 samples; chronic serum levels: n = 48, n = 326 samples). Main measures: TNF alpha levels (CSF, Serum) from time of injury to 12 months post-injury; Frontal Systems Behavior Scale - Disinhibition Subscale at 6 and 12 months post-injury; Patient Health Questionnaire at 6 and 12 months post-injury. Results: Participants with TBI had significantly higher CSF and serum TNF alpha levels than healthy controls (p < 0.05). Acute and chronic serum TNF alpha was significantly associated with disinhibition at 6 months post-injury (p = 0.009, p = 0.029 respectively), and 6 month disinhibition was associated with suicidal endorsement at both 6 and 12 months (p = 0.045, p = 0.033 respectively) and disinhibition at 12 months post-injury (p < 0.001). Conclusion: These preliminary data suggest a biological to behavioral pathway of suicidality after TBI, from TNF alpha to disinhibition to suicidal endorsement. Future investigation is warranted to validate these findings and clarify what biological mechanisms might underlie these relationships. (C) 2014 Elsevier Inc. All rights reserved.	[Juengst, S. B.; Kumar, R. G.; Arenth, P. M.; Wagner, A. K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, A. K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Wagner, A. K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Juengst, Shannon B/AAC-5891-2019	Juengst, Shannon/0000-0003-4709-545X	CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR 323155]; DODUnited States Department of Defense [W81XWH-071-0701]; University of Pittsburgh's Women's Studies Faculty Research Fund; NIDRR [H133A120087]; UPMC Rehabilitation Institute	This work was supported in part by: CDC: R49 CCR 323155, DOD: W81XWH-071-0701, the University of Pittsburgh's Women's Studies Faculty Research Fund (Amy Wagner); NIDRR H133A120087 and the UPMC Rehabilitation Institute (Amy Wagner & Shannon Juengst). The authors would like to acknowledge and thank the University of Pittsburgh Cancer Institute and their Luminex Facility for assay performance. Special thanks to Dr. Anna Lokshin and John Snyder for input on data scaling for inflammatory markers.	An C., 2013, PROG NEUROBIOL; Ball SL, 2010, J INTELL DISABIL RES, V54, P320, DOI 10.1111/j.1365-2788.2010.01261.x; Bennett MR, 2009, J THEOR BIOL, V261, P1, DOI 10.1016/j.jtbi.2009.07.024; Bertolote JM, 2003, BRIT J PSYCHIAT, V183, P382, DOI 10.1192/bjp.183.5.382; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Burton CZ, 2011, J NEUROPSYCH CLIN N, V23, P173, DOI 10.1176/appi.neuropsych.23.2.173; Carvalho JO, 2013, ASSESSMENT, V20, P632, DOI 10.1177/1073191113492845; Casada JH, 2005, J NERV MENT DIS, V193, P102, DOI 10.1097/01.nmd.0000152809.20938.37; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Colin A, 2003, ENCEPHALE, V29, P49; Currier D, 2008, PSYCHIAT CLIN N AM, V31, P247, DOI 10.1016/j.psc.2008.01.005; Desseilles M, 2012, J AFFECT DISORDERS, V136, P398, DOI 10.1016/j.jad.2011.11.013; Dilger RN, 2008, J LEUKOCYTE BIOL, V84, P932, DOI 10.1189/jlb.0208108; Dombrovski AY, 2013, JAMA PSYCHIAT, V70, P1020, DOI 10.1001/jamapsychiatry.2013.75; Failla MD, 2013, BRAIN INJURY, V27, P696, DOI 10.3109/02699052.2013.775481; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Felger JC, 2013, NEUROSCIENCE, V246, P199, DOI 10.1016/j.neuroscience.2013.04.060; Fountoulakis KN, 2004, NEUROPSYCHOBIOLOGY, V49, P42, DOI 10.1159/000075338; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Giakoumatos CI, 2013, J PSYCHIATR RES, V47, P1389, DOI 10.1016/j.jpsychires.2013.06.011; Giegling I, 2009, J PSYCHIATR RES, V43, P1262, DOI 10.1016/j.jpsychires.2009.04.013; Gill J, 2008, J TRAUMA STRESS, V21, P530, DOI 10.1002/jts.20372; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; Hammad Samar M, 2012, Neurobiol Lipids, V10, P2; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Himmerich H, 2008, EUR PSYCHIAT, V23, P421, DOI 10.1016/j.eurpsy.2008.03.013; Homaifar BY, 2012, REHABIL PSYCHOL, V57, P337, DOI 10.1037/a0030480; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; James LM, 2014, MIL MED, V179, P357, DOI 10.7205/MILMED-D-13-00241; Janelidze S, 2011, BRAIN BEHAV IMMUN, V25, P335, DOI 10.1016/j.bbi.2010.10.010; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Juengst S.B., 2014, J HEAD TRAUMA REHABI; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim YK, 2013, J AFFECT DISORDERS, V150, P668, DOI 10.1016/j.jad.2013.03.019; Krugel U, 2013, J PSYCHIATR RES, V47, P611, DOI 10.1016/j.jpsychires.2013.01.007; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Lee R, 2009, J PSYCHIATR RES, V43, P353, DOI 10.1016/j.jpsychires.2008.04.004; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lopez-Larson Melissa, 2013, Front Psychiatry, V4, P83, DOI 10.3389/fpsyt.2013.00083; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Lynch TR, 2004, AGING MENT HEALTH, V8, P486, DOI 10.1080/13607860412331303775; Mandelli L, 2013, NEUROSCI BIOBEHAV R, V37, P2375, DOI 10.1016/j.neubiorev.2013.07.011; Martinez JM, 2012, DEPRESS ANXIETY, V29, P32, DOI 10.1002/da.20876; Matthews S, 2012, PSYCHOSOM MED, V74, P471, DOI 10.1097/PSY.0b013e31824f888f; McGirr A, 2010, J PSYCHIATR NEUROSCI, V35, P399, DOI 10.1503/jpn.090121; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Myers CE, 2012, PSYCHIAT RES, V196, P271, DOI 10.1016/j.psychres.2011.11.015; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Niemeier JP, 2013, REHABIL PSYCHOL, V58, P51, DOI 10.1037/a0031612; O'Donovan A, 2013, DEPRESS ANXIETY, V30, P307, DOI 10.1002/da.22087; OKUSAGA O., 2012, NEUROBIOLOGICAL BASI; Omrani MD, 2009, ARCH SUICIDE RES, V13, P330, DOI 10.1080/13811110903266418; Pan LA, 2011, J AM ACAD CHILD PSY, V50, P602, DOI 10.1016/j.jaac.2011.03.018; Pan W, 2002, EXP NEUROL, V174, P193, DOI 10.1006/exnr.2002.7871; Pandey GN, 2012, J PSYCHIATR RES, V46, P57, DOI 10.1016/j.jpsychires.2011.08.006; Raison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4; Reeves RR, 2012, J PSYCHOSOC NURS MEN, V50, P32, DOI 10.3928/02793695-20120207-02; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Richard-Devantoy S, 2012, J AFFECT DISORDERS, V140, P193, DOI 10.1016/j.jad.2012.03.006; Richard-Devantoy S, 2012, CAN J PSYCHIAT, V57, P254, DOI 10.1177/070674371205700409; Saiz PA, 2011, PROG NEURO-PSYCHOPH, V35, P1518, DOI 10.1016/j.pnpbp.2011.04.011; Schroeter M.L., 2013, CURR DRUG TARGETS; Serafini G., 2013, EUR NEUROPSYCHOPHARM; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Steiner J, 2013, CNS NEUROL DISORD-DR, V12, P971, DOI 10.2174/18715273113129990099; Strong CAH, 2011, J INT NEUROPSYCH SOC, V17, P230, DOI 10.1017/S1355617710001451; Tarkowski E, 2003, DEMENT GERIATR COGN, V15, P207, DOI 10.1159/000068780; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tonelli LH, 2008, ACTA PSYCHIAT SCAND, V117, P198, DOI 10.1111/j.1600-0447.2007.01128.x; von Kanel R, 2007, J PSYCHIATR RES, V41, P744, DOI 10.1016/j.jpsychires.2006.06.009; Wagner AK, 2012, BRAIN INJURY, V26, P1226, DOI 10.3109/02699052.2012.667594; Wagner AK, 2011, PM&R, V3, pS28, DOI 10.1016/j.pmrj.2011.04.013; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Wilcock DM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-84; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	86	46	46	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	OCT	2014	41						134	143		10.1016/j.bbi.2014.05.020			10	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	AP2MD	WOS:000341905400016	24928066				2021-06-18	
J	Young, TJ; Daniel, RW; Rowson, S; Duma, SM				Young, Tyler J.; Daniel, Ray W.; Rowson, Steven; Duma, Stefan M.			Head Impact Exposure in Youth Football: Elementary School Ages 7-8 Years and the Effect of Returning Players	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; brain injury; biomechanics; pediatric; acceleration; helmet	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; COLLEGIATE; ACCELERATION; CONCUSSIONS; PERFORMANCE; KINEMATICS; MAGNITUDE	Objective: To provide data describing the head impact exposure of 7- to 8-year-old football players. Design: Head impact data were collected from 19 players over the course of 2 seasons using helmet-mounted accelerometer arrays. Setting: Data were collected from 2 youth football teams in Blacksburg, VA, spanning 2 seasons. Participants: A total of 19 youth football players aged 7-8 years. Independent Variables: Type of session (practice or game) and the player's experience. Main Outcome Measures: Head impact frequency, acceleration magnitude, and impact location for games, practices, and the season as a whole were measured. Results: The average instrumented player sustained 9 +/- 6 impacts per practice, 11 +/- 11 impacts per game, and 161 +/- 111 impacts per season. The average instrumented player had a median impact of 16 +/- 2 g and 686 +/- 169 rad/s(2) and a 95th percentile impact of 38 +/- 13 g and 2052 +/- 664 rad/s(2) throughout a season. Impacts of 40 g or greater tended to occur more frequently in practices than in games, and practices had a significantly higher 95th percentile impact magnitude than games (P = 0.023). Returning players had significantly more impacts than first time players (P = 0.007). Conclusions: These data are a further step toward developing effective strategies to reduce the incidence of concussion in youth football and have applications toward youth-specific football helmet designs.	[Young, Tyler J.; Daniel, Ray W.; Rowson, Steven; Duma, Stefan M.] Wake Forest Univ, Virginia Tech, Sch Biomed Engn & Sci, Blacksburg, VA USA	Rowson, S (corresponding author), 440 Kelly Hall,325 Stanger St,MC 0194, Blacksburg, VA 24061 USA.	srowson@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Highway Traffic Safety Administration	The authors gratefully acknowledge the National Highway Traffic Safety Administration for supporting this work.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, p54q9; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hamilton NA, 2010, SEMIN PEDIATR SURG, V19, P271, DOI 10.1053/j.sempedsurg.2010.06.005; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2010, CLIN J SPORT MED, V20, P344, DOI 10.1097/JSM.0b013e3181ed7e50; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Viano DC, 2012, ANN BIOMED ENG, V40, P97, DOI 10.1007/s10439-011-0377-3; Viano DC, 2012, ANN BIOMED ENG, V40, P160, DOI 10.1007/s10439-011-0384-4; Viano DC, 2012, ANN BIOMED ENG, V40, P47, DOI 10.1007/s10439-011-0399-x; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1	37	46	46	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2014	24	5					416	421					6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	AP3OO	WOS:000341986300014	24326933				2021-06-18	
J	Castro, CA; Kintzle, S				Castro, Carl Andrew; Kintzle, Sara			Suicides in the Military: The Post-Modern Combat Veteran and the Hemingway Effect	CURRENT PSYCHIATRY REPORTS			English	Article						Military; Suicide; Veteran; Combat; Interpersonal-psychological theory of suicide; Military transition theory; Modern veteran; Hemingway effect	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; US MILITARY; PERSONNEL; ARMY; PTSD; COMORBIDITY; BEHAVIOR; IRAQ; CARE	Suicides in the military have increased over the last ten years. Much effort has been focused on suicide prevention and treatment, as well as understanding the reasons for the sharp increase in military suicides. Despite this effort, the definitive causes of military suicides remain elusive. Further, highly effective suicide prevention and treatment approaches have not yet been developed. The purpose of this article is to present a short review of the current state of suicide prevention interventions within the context of the military. The root causes of suicidal behavior and the role of combat in the military are each discussed. Interpersonal-psychological theory of suicide and the military transition theory are introduced as guiding frameworks for understanding suicides and suicidal behavior amongst active military personnel and military veterans. The article concludes with a set of recommendations for moving forward in understanding and addressing suicides in the military.	[Castro, Carl Andrew; Kintzle, Sara] Univ So Calif, Sch Social Work, Ctr Innovat & Res Vet & Mil Families, Los Angeles, CA 90015 USA	Castro, CA (corresponding author), Univ So Calif, Sch Social Work, Ctr Innovat & Res Vet & Mil Families, 1150 South Olive,Suite 1400, Los Angeles, CA 90015 USA.	carl.castro@usc.edu; kintzle@usc.edu					Adler AB, 2013, MILITARY BEHAV HLTH, V1, P41, DOI DOI 10.1080/21635781.2012.721063; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; [Anonymous], 2014, GUIDE US MILITARY CA; [Anonymous], 2012, EXCEPT PARENT, V42, P55; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Baker C., 1969, ERNST HEMINGWAY LIFE; Baldessarini RJ, 2004, HARVARD REV PSYCHIAT, V12, P1, DOI 10.1080/10673220490425915; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bartone Paul T, 2013, Int J Emerg Ment Health, V15, P299; Brenner L.A., 2008, J MENT HLTH COUNS, V30, P211; Bryan CJ, 2014, J AFFECT DISORDERS, V159, P15, DOI 10.1016/j.jad.2014.02.021; Bryan CJ, 2013, J CLIN PSYCHOL, V69, P64, DOI 10.1002/jclp.21932; Castro CA, 2007, TRAUMATOLOGY, V13, P6, DOI [DOI 10.1177/1534765607309950, 10.1177/1534765607309950]; Castro CA, 2014, S ANN M SOC SO UNPUB; Conner KR, 2013, J ABNORM PSYCHOL, V122, P256, DOI 10.1037/a0030163; Crum-Cianflone N., 2013, MILITARY HLTH CARE P; Department of Veterans Affairs. Epidemiology Program Post Deployment Health Group Office of Public Health Veterans Health Administration, REP VA FAC SPEC OP E; DoDSER 2011 Department of Defense National Center for Telehealth & Technology (T2) Defense Centers of Excellence for Psychological Health & TBI (DCoE) & T2health.org, 2011, DODSER CAL YEAR 2011; DoDSER Department of Defense National Center for Telehealth & Technology (T2) Defense Centers of Excellence for Psychological Health & TBI (DCoE) & T2health.org, 2012, DODSER CAL YEAR 2012; Eaton KM, 2006, SUICIDE LIFE-THREAT, V36, P182, DOI 10.1521/suli.2006.36.2.182; Joiner T., 2005, WHY PEOPLE DIE SUICI, DOI [10.1037/13748-018, DOI 10.1037/13748-018]; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; Kaplan MS, 2012, AM J PUBLIC HEALTH, V102, pS131, DOI 10.2105/AJPH.2011.300445; Kemp J, 2012, SUICIDE DATA REPORT; Lambert MT, 1997, J MENT HEALTH ADMIN, V24, P350, DOI 10.1007/BF02832668; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Mann JJ, 1999, J CLIN PSYCHIAT, V60, P7; McGuffin P, 2001, Crisis, V22, P61, DOI 10.1027//0227-5910.22.2.61; Mental Health Advisory Team (MHAT), 2003, OP IR FREED OIF MENT; Mental Health Advisory Team (MHAT-III), 2006, 0406 MHAT 3 SURG MUL; Mental Health Advisory Team (MHAT-IV), 2006, 0507 MHAT 4 SURG MUL; MSMR Armed Forces Health Surveillance Center, 2014, MED SURVEILL MONTHLY, V21, P1; Murphy Sherry L, 2013, Natl Vital Stat Rep, V61, P1; Nicholson NR, 2009, J ADV NURS, V65, P1342, DOI 10.1111/j.1365-2648.2008.04959.x; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; Ramsawh HJ, 2014, J AFFECT DISORDERS, V161, P116, DOI 10.1016/j.jad.2014.03.016; Rosel P, 2000, PSYCHIAT RES-NEUROIM, V99, P173, DOI 10.1016/S0925-4927(00)00076-7; Rudd MD, 2011, PROF PSYCHOL-RES PR, V42, P354, DOI 10.1037/a0025164; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schoenbaum M, 2014, JAMA PSYCHIAT, V71, P493, DOI 10.1001/jamapsychiatry.2013.4417; Thomsen CJ, 2011, J PSYCHIATR RES, V45, P1321, DOI 10.1016/j.jpsychires.2011.04.003; Wilson KG, 2013, REHABIL PSYCHOL, V58, P111, DOI 10.1037/a0031390; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900	46	46	47	0	37	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1523-3812	1535-1645		CURR PSYCHIAT REP	Curr. Psychiatry Rep.	AUG	2014	16	8							460	10.1007/s11920-014-0460-1			9	Psychiatry	Psychiatry	AM4CX	WOS:000339801200002	24930521				2021-06-18	
J	Antonini, TN; Raj, SP; Oberjohn, KS; Cassedy, A; Makoroff, KL; Fouladi, M; Wade, SL				Antonini, Tanya N.; Raj, Stacey P.; Oberjohn, Karen S.; Cassedy, Amy; Makoroff, Kathi L.; Fouladi, Maryam; Wade, Shari L.			A Pilot Randomized Trial of an Online Parenting Skills Program for Pediatric Traumatic Brain Injury: Improvements in Parenting and Child Behavior	BEHAVIOR THERAPY			English	Article						TBI; online intervention; positive parenting; brain injury; randomized clinical trial	INTERACTION THERAPY; DISRUPTIVE BEHAVIOR; WARM RESPONSIVENESS; OUTCOMES; INTERVENTION; FEASIBILITY; NEGATIVITY; EFFICACY	This pilot study examined changes in parenting skills and child behavior following participation in an online positive parenting skills program designed for young children with traumatic brain injury (TBI). Thirty-seven families with a child between 3 and 9 years of age who sustained a moderate to severe TBI were randomly assigned to one of two interventions: online parenting skills training (n = 20) or access to Internet resources on managing brain injury (n = 17). Parent child interaction observations and parent ratings of child behavior were collected pre- and post-treatment. Generalized estimating equations and mixed models were used to examine changes in parenting skills and child behavior problems as well as the moderating role of family income on treatment response. Participants in the parenting skills group displayed significant improvements in observed positive parenting skills relative to participants in the Internet resource group. Income moderated improvements in parent ratings of child behavior, with participants in the low-income parenting skills group and high-income Internet resource group reporting the greatest improvements in behavior. This is the first randomized controlled trial examining online parenting skills training for families of young children with TBI. Improvements in positive parenting skills and child behavior support the utility of this intervention, particularly for families from lower socioeconomic backgrounds.	[Antonini, Tanya N.; Raj, Stacey P.; Oberjohn, Karen S.; Cassedy, Amy; Makoroff, Kathi L.; Fouladi, Maryam; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,ML 4009, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					Achenbach T. M., 2000, MANUAL ASEBA PRESCHO; Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Antonini TN, 2012, J TELEMED TELECARE, V18, P333, DOI 10.1258/jtt.2012.120404; Bagner DM, 2007, J CLIN CHILD ADOLESC, V36, P418, DOI 10.1080/15374410701448448; Bell S. K., 2002, INNOVATIONS CLIN PRA, V20, P57; BOGGS SR, 1990, J CLIN CHILD PSYCHOL, V19, P75, DOI 10.1207/s15374424jccp1901_9; Bor W, 2002, J ABNORM CHILD PSYCH, V30, P571, DOI 10.1023/A:1020807613155; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Cohen ML, 2012, J PEDIATR PSYCHOL, V37, P251, DOI 10.1093/jpepsy/jsr086; Department of Health and Human Services, 2013, 2013 POV GUID; Eyberg S., 1988, CHILD FAM BEHAV THER, V10, P33, DOI [DOI 10.1300/J019V10N01_04, 10.1300/J019v10n01_04]; Eyberg S., 1999, EYBERG CHILD BEHAV I; Eyberg S.M., 2005, MANUAL DYADIC PARENT, V3rd ed; Fairbanks JM, 2013, REHABIL PSYCHOL, V58, P223, DOI 10.1037/a0033119; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; JENNETT B, 1975, LANCET, V1, P480; Kaminski JW, 2008, J ABNORM CHILD PSYCH, V36, P567, DOI 10.1007/s10802-007-9201-9; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; MCNEIL CB, 1991, J CLIN CHILD PSYCHOL, V20, P140, DOI 10.1207/s15374424jccp2002_5; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; Newman MG, 2004, J CLIN PSYCHOL, V60, P141, DOI 10.1002/jclp.10240; Owens PL, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200206000-00013; Rainie L., 2010, INTERNET BROADBAND C; Raj S. P., 2013, J PEDIAT PSYCHOL; Rosner B., 2006, FUNDAMENTALS BIOSTAT; Ruskin PE, 2004, AM J PSYCHIAT, V161, P1471, DOI 10.1176/appi.ajp.161.8.1471; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Tate DF, 2004, J CLIN PSYCHOL, V60, P209, DOI 10.1002/jclp.10247; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Thomas R, 2007, J ABNORM CHILD PSYCH, V35, P475, DOI 10.1007/s10802-007-9104-9; Wade S. L., J HEAD TRAUMA REHABI; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2012, HEALTH PSYCHOL, V31, P767, DOI 10.1037/a0028440; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Webster-Stratton C, 2008, J CHILD PSYCHOL PSYC, V49, P471, DOI 10.1111/j.1469-7610.2007.01861.x; Wiggins TL, 2009, FAM PROCESS, V48, P517, DOI 10.1111/j.1545-5300.2009.01299.x; Woodcock R. W., 2001, EXAMINERS MANUAL WOO; Woods DT, 2012, NEUROREHABILITATION, V30, P189, DOI 10.3233/NRE-2012-0744	41	46	46	2	19	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	0005-7894	1878-1888		BEHAV THER	Behav. Therapy	JUL	2014	45	4					455	468					14	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	AJ7EQ	WOS:000337860400001	24912459				2021-06-18	
J	Grubenhoff, JA; Deakyne, SJ; Brou, L; Bajaj, L; Comstock, RD; Kirkwood, MW				Grubenhoff, Joseph A.; Deakyne, Sara J.; Brou, Lina; Bajaj, Lalit; Comstock, R. Dawn; Kirkwood, Michael W.			Acute Concussion Symptom Severity and Delayed Symptom Resolution	PEDIATRICS			English	Article						brain concussion; brain injury; acute; brain injury; traumatic; post-concussion symptoms; post-concussion syndrome; emergency medicine	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; SPORTS-RELATED CONCUSSION; POSTCONCUSSION SYNDROME; EMERGENCY-DEPARTMENT; CHILDREN; PREDICTION; ADOLESCENTS; RECOVERY; CRITERIA	BACKGROUND AND OBJECTIVES: Up to 30% of children who have concussion initially evaluated in the emergency department (ED) display delayed symptom resolution (DSR). Greater initial symptom severity may be an easily quantifiable predictor of DSR. We hypothesized that greater symptom severity immediately after injury increases the risk for DSR. METHODS: We conducted a prospective longitudinal cohort study of children 8 to 18 years old presenting to the ED with concussion. Acute symptom severity was assessed using a graded symptom inventory. Presence of DSR was assessed 1 month later. Graded symptom inventory scores were tested for association with DSR by sensitivity analysis. We conducted a similar analysis for post-concussion syndrome (PCS) as defined by the International Statistical Classification of Diseases and Related Health Problems, 10th revision. Potential symptoms characteristic of DSR were explored by using hierarchical cluster analysis. RESULTS: We enrolled 234 subjects; 179 (76%) completed follow-up. Thirty-eight subjects (21%) experienced DSR. Initial symptom severity was not significantly associated with DSR 1 month after concussion. A total of 22 subjects (12%) had PCS. Scores >10 (possible range, 0-28) were associated with an increased risk for PCS (RR, 3.1; 95% confidence interval 1.2-8.0). Three of 6 of the most characteristic symptoms of DSR were also most characteristic of early symptom resolution. However, cognitive symptoms were more characteristic of subjects reporting DSR. CONCLUSIONS: Greater symptom severity measured at ED presentation does not predict DSR but is associated with PCS. Risk stratification therefore depends on how the persistent symptoms are defined. Cognitive symptoms may warrant particular attention in future study. Follow-up is recommended for all patients after ED evaluation of concussion to monitor for DSR.	[Grubenhoff, Joseph A.; Brou, Lina; Bajaj, Lalit; Comstock, R. Dawn] Univ Colorado, Dept Pediat, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Grubenhoff, Joseph A.; Brou, Lina; Bajaj, Lalit] Childrens Hosp Colorado, Emergency Dept, Aurora, CO USA; [Deakyne, Sara J.] Childrens Hosp Colorado, Dept Res Informat, Aurora, CO USA; [Comstock, R. Dawn] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA	Grubenhoff, JA (corresponding author), 13123 East 16th Ave,B-251, Aurora, CO 80045 USA.	joe.grubenhoff@childrenscolorado.org	Meijer, Anna/K-5118-2016	Grubenhoff, Joseph/0000-0001-5072-4064	Thrasher Research Fund Early Career Award; NIH/NCATS Colorado CTSIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000154]	Funding for the conduct of this study was provided by a Thrasher Research Fund Early Career Award to Dr Grubenhoff. Use of REDCap Database was supported by NIH/NCATS Colorado CTSI grant UL1 TR000154. Contents are the authors' sole responsibility and do not necessarily represent official NIH or Thrasher Research Fund views.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Beckstead JW, 2002, WESTERN J NURS RES, V24, P307, DOI 10.1177/01939450222045923; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frances A, 2013, ANN INTERN MED, V159, P221, DOI 10.7326/0003-4819-159-3-201308060-00655; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kendell R, 2003, AM J PSYCHIAT, V160, P4, DOI 10.1176/appi.ajp.160.1.4; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Silverberg ND, 2011, NEUROREHABILITATION, V29, P317, DOI 10.3233/NRE-2011-0708; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; *WHO, 1992, ICD 10 CLASS MEN BEH; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	51	46	46	0	17	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2014	134	1					54	62		10.1542/peds.2013-2988			9	Pediatrics	Pediatrics	AK9UZ	WOS:000338774800050	24958583	Bronze			2021-06-18	
J	Ponsford, J; Janzen, S; McIntyre, A; Bayley, M; Velikonja, D; Tate, R				Ponsford, Jennie; Janzen, Shannon; McIntyre, Amanda; Bayley, Mark; Velikonja, Diana; Tate, Robyn		INCOG Expert Panel	INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part I: Posttraumatic Amnesia/Delirium	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; guidelines; knowledge translation; posttraumatic amnesia; traumatic brain injury	CLOSED-HEAD-INJURY; AGITATED BEHAVIOR SCALE; WESTMEAD PTA SCALE; REHABILITATION THERAPIES; COMMUNITY INTEGRATION; REALITY ORIENTATION; CONFUSIONAL STATE; AMNESIA DURATION; CLINICAL UTILITY; CORTEX INJURY	Introduction: After traumatic brain injury (TBI) and emergence from coma, the majority of people experience posttraumatic amnesia (PTA), characterized by confusion, disorientation, retrograde and anterograde amnesia, poor attention, and sometimes agitation and delusions. An international team of researchers and clinicians developed recommendations for assessment and management of PTA. Methods: The experts met to select recommendations, then reviewed literature to ensure they were current. The team then prioritized recommendations for implementation and developed audit criteria to evaluate the adherence to the best practice recommendations. Results: Evidence in support of assessment and management strategies during PTA is weak. It is recommended that duration of PTA be assessed prospectively using a validated tool. Consideration should also be given to use of a delirium assessment tool. No cognitive or pharmacological treatments are known to reduce PTA duration. Recommendations for environmental manipulations to reduce agitation during PTA are made. Minimizing use of neuroleptic medication is supported by animal research and 1 retrospective study. Conclusions: The duration of PTA is an important predictor of late outcome after TBI and should be monitored prospectively with a standardized tool. Neuroleptic medication should be avoided. There is a significant need for controlled studies evaluating the impact of therapy during PTA.	[Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Clayton, Vic 3800, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [Janzen, Shannon; McIntyre, Amanda] St Josephs Parkwood Hosp, Lawson Hlth Res Inst, London, ON, Canada; [Bayley, Mark] Univ Toronto, Toronto Rehabil Inst, Neuro Rehabil Program, Toronto, ON, Canada; [Velikonja, Diana] Hamilton Hlth Sci, Acquired Brain Injury Program, Neuropsychol, Hamilton, ON, Canada; [Velikonja, Diana] McMaster Univ, DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Tate, Robyn] Univ Sydney, Sydney Med Sch Northern, Kolling Inst, Rehabil Res Ctr, Sydney, NSW 2006, Australia; [Velikonja, Diana] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu		Bayley, Mark/0000-0001-7860-9463	Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University; Ontario Neurotrauma Foundation (ONF)	We gratefully acknowledge the support of the Victorian Transport Accident Commission (TAC) through its Victorian Neurotrauma Initiative (VNI), Monash University, and the Ontario Neurotrauma Foundation (ONF) for their support of this project.	Ahmed S, 2000, BRAIN INJURY, V14, P765; Amato S, 2012, REHABIL NURS, V37, P19, DOI 10.1002/RNJ.00001; Andriessen TMJC, 2009, BRAIN INJURY, V23, P345, DOI 10.1080/02699050902791414; Appraisal of Guidelines Research and Evaluation, AGREE ADV SCI PRACT; Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN, P59; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Bayley M., 2007, ABIKUS EVIDENCE BASE; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Bogner JA, 2001, AM J PHYS MED REHAB, V80, P636, DOI 10.1097/00002060-200109000-00002; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; COPE DN, 1987, J HEAD TRAUMA REHAB, V2, P1; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; De Guise E, 2005, BRAIN INJURY, V19, P263, DOI 10.1080/02699050400004971; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fleming J, 1999, BRAIN INJURY, V13, P417; Frey KL, 2007, BRAIN INJURY, V21, P513, DOI 10.1080/02699050701311026; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harmsen M, 2004, BRAIN INJURY, V18, P787, DOI 10.1080/02699050410001671757; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Jennett B, 1981, MANAGEMENT HEAD INJU; Kadyan V, 2004, AM J PHYS MED REHAB, V83, P747, DOI 10.1097/01.PHM.0000140790.30468.F4; Kean J, 2010, BRAIN INJURY, V24, P1222, DOI 10.3109/02699052.2010.498008; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Leach K, 2006, BRAIN INJURY, V20, P1241, DOI 10.1080/02699050601049874; Lequerica AH, 2007, J HEAD TRAUMA REHAB, V22, P177, DOI 10.1097/01.HTR.0000271118.96780.bc; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; McCarter RJ, 2007, BRAIN INJURY, V21, P1393, DOI 10.1080/02699050701793793; McFarland K, 2001, CLIN NEUROPSYCHOL, V15, P59, DOI 10.1076/clin.15.1.59.1916; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Moffat N., 1984, CLIN MANAGEMENT MEMO, P63; Mysiw WJ, 2006, BRAIN INJURY, V20, P905, DOI 10.1080/02699050600743972; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Nakase-Richardson R, 2013, ARCH PHYS MED REHAB, V94, P875, DOI 10.1016/j.apmr.2013.01.001; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Nott MT, 2008, BRAIN INJURY, V22, P669, DOI 10.1080/02699050802227170; Patton G, 1992, NEUROPSYCHOL REHABIL, V2, P169; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, TRAUMATIC BRAIN INJU; Ponsford J, J HEAD TRAU IN PRESS; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ponsford JL, 2013, J NEUROTRAUM, V30, P1498, DOI 10.1089/neu.2012.2843; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SANEDA D L, 1992, Brain Injury, V6, P167, DOI 10.3109/02699059209029655; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 2007, BRAIN INJURY, V18, P131; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Sherer M, 2009, ARCH PHYS MED REHAB, V90, P1749, DOI 10.1016/j.apmr.2009.05.011; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snow P, 2012, TRAUMATIC BRAIN INJU, P34; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds C.P., 1940, INJURIES SKULL BRAIN, P69; Symonds CP, 1943, LANCET, V1, P7; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; Tate RL, 2001, J HEAD TRAUMA REHAB, V16, P525, DOI 10.1097/00001199-200112000-00002; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; The ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; van der Naalt J, 2000, BRAIN INJURY, V14, P781; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Watanabe TK, 1998, BRAIN INJURY, V12, P81; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553	107	46	46	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					307	320		10.1097/HTR.0000000000000074			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300008	24984094				2021-06-18	
J	Alkhoury, F; Kyriakides, TC				Alkhoury, Fuad; Kyriakides, Tassos C.			Intracranial Pressure Monitoring in Children With Severe Traumatic Brain Injury National Trauma Data Bank-Based Review of Outcomes	JAMA SURGERY			English	Article							SEVERE HEAD-INJURY; UNITED-STATES; MANAGEMENT; CARE; GUIDELINES; HYPOXIA	IMPORTANCE The present study is the largest on the use and effect of intracranial pressure (ICP) monitoring in pediatric trauma patients. OBJECTIVE To determine the effect of ICP monitoring on survival in pediatric patients with severe head injuries using the National Trauma Data Bank. DESIGN, SETTING, AND PARTICIPANTS The National Trauma Data Bank was queried (version 6.2, 2001-2006) for information on patients younger than 17 years admitted to an intensive care unit with blunt traumatic brain injury (TBI), Injury Severity Score (ISS) greater than 9, and Glasgow Coma Scale (GCS) score less than 9. Patients with incomplete medical records and those with intensive care unit length of stay of less than 24 hours were excluded from the study. MAIN OUTCOMES AND MEASURES Parametric comparisons (t tests and.2 as appropriate) were performed to compare patients who received ICP monitoring with those who did not. Stepwise logistic regression methods were used to assess whether ICP monitoring in the presence of other variables (age, sex, ISS, Revised Trauma Score, and GCS score) was associated with survival. RESULTS Monitoring of ICP was performed in only 7.7% of patients who met the monitoring criteria recommended by the Brain Trauma Foundation. There were no significant differences in age, sex, or GCS score. After adjustment for admission GCS score, age group, sex, Revised Trauma Score, and injury ISS, ICP monitoring was associated with a reduction in mortality only for patients with a GCS score of 3 (odds ratio, 0.64; 95% CI, 0.43-1.00). Comparison between the 2 groups showed that the ICP monitoring group had a longer hospital length of stay (21.0 days vs 10.4 days; P <.001), longer intensive care unit stay (12.6 vs 6.3 days; P <.001), and more ventilator days (9.2 vs 4.7; P <.001). CONCLUSIONS AND RELEVANCE Despite current Brain Trauma Foundation guidelines, ICP monitoring is used infrequently in the pediatric population. The data suggest that there is a small, yet statistically significant, survival advantage in patients who have ICP monitors and a GCS score of 3. However, all patients with ICP monitors experienced longer hospital length of stay, longer intensive care unit stay, and more ventilator days compared with those without ICP monitors. A prospective observational study would be helpful to accurately define the population for whom ICP monitoring is advantageous.	[Alkhoury, Fuad; Kyriakides, Tassos C.] Joe DiMaggio Childrens Hosp, Dept Pediat Surg, Hollywood, FL 33021 USA	Alkhoury, F (corresponding author), Joe DiMaggio Childrens Hosp, Dept Pediat Surg, 1150 N 35th Ave,Ste 555, Hollywood, FL 33021 USA.	falkhoury@gmail.com	Kyriakides, Tassos/E-4980-2013	Kyriakides, Tassos/0000-0001-8913-108X			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BarrientosVega R, 1997, CRIT CARE MED, V25, P33, DOI 10.1097/00003246-199701000-00009; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; BUXTON RL, 1970, LANCET, V2, P498; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Dings J, 1996, ZBL NEUROCHIR, V57, P177; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vukic M, 1999, ACTA NEUROCHIR, V141, P1203, DOI 10.1007/s007010050419	24	46	46	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	JUN	2014	149	6					544	548		10.1001/jamasurg.2013.4329			5	Surgery	Surgery	AJ7WB	WOS:000337909900014	24789426	Bronze			2021-06-18	
J	Watts, LT; Long, JA; Chemello, J; Van Koughnet, S; Fernandez, A; Huang, SL; Shen, Q; Duong, TQ				Watts, Lora Talley; Long, Justin Alexander; Chemello, Jonathan; Van Koughnet, Samantha; Fernandez, Angelica; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.			Methylene Blue Is Neuroprotective against Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						antioxidant; mitochondria; MRI; oxidative stress; vasogenic edema	SPINAL-CORD-INJURY; CYCLOSPORINE-A; NEURONAL DEGENERATION; OXYGEN-CONSUMPTION; CEREBRAL-ISCHEMIA; REACTIVE GLIOSIS; FLUORO-JADE; MECHANISMS; GENERATION; PERFUSION	Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Methylene blue (MB) has known energy-enhancing and antioxidant properties. This study tested the hypothesis that MB treatment reduces lesion volume and behavioral deficits in a rat model of mild TBI. In a randomized double-blinded design, animals received either MB (n = 5) or vehicle (n = 6) after TBI. Studies were performed on 0, 1, 2, 7, and 14 days following an impact to the primary forelimb somatosensory cortex. MRI lesion was not apparent 1 h after TBI, became apparent 3 h after TBI, and peaked at 2 days for both groups. The MB-treated animals showed significantly smaller MRI lesion volume than the vehicle-treated animals at all time points studied. The MB-treated animals exhibited significantly improved scores on forelimb placement asymmetry and foot fault tests than did the vehicle-treated animals at all time points studied. Smaller numbers of dark-stained Nissl cells and Fluoro-Jade (R) positive cells were observed in the MB-treated group than in vehicle-treated animals 14 days post-TBI. In conclusion, MB treatment minimized lesion volume, behavioral deficits, and neuronal degeneration following mild TBI. MB is already approved by the United States Food and Drug Administration (FDA) to treat a number of indications, likely expediting future clinical trials in TBI.	[Watts, Lora Talley; Long, Justin Alexander; Chemello, Jonathan; Van Koughnet, Samantha; Fernandez, Angelica; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA; [Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA; [Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA; [Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA	Duong, TQ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.	wattsl@uthscsa.edu; duongt@uthscsa.edu	Watts, Lora Talley/A-2724-2012; Duong, Tim/AAL-8357-2021; Shen, Qiang/B-8784-2008	Watts, Lora Talley/0000-0002-2337-1504; Duong, Tim/0000-0001-6403-2827; Shen, Qiang/0000-0002-4287-3403	NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001118, TL1 TR001119, UL1 TR001120] Funding Source: Medline; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA 54174, P30 CA054174] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG19316] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA054174] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR001119, UL1TR001120, KL2TR001118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG019316] Funding Source: NIH RePORTER		Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bardakci H, 2006, EUR SURG RES, V38, P482, DOI 10.1159/000096007; Bruchey Aleksandra K, 2008, Am J Pharmacol Toxicol, V3, P72; Chaturvedi RK, 2008, ANN NY ACAD SCI, V1147, P395, DOI 10.1196/annals.1427.027; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; Clifton Jack 2nd, 2003, Am J Ther, V10, P289; DEITCH AD, 1957, J BIOPHYS BIOCHEM CY, V3, P449, DOI 10.1083/jcb.3.3.449; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Galluzzi L, 2009, BBA-BIOENERGETICS, V1787, P402, DOI 10.1016/j.bbabio.2008.09.006; HALKSMILLER M, 1986, J NEUROPATH EXP NEUR, V45, P471, DOI 10.1097/00005072-198607000-00008; Hensley K, 1997, INT REV NEUROBIOL, V40, P299; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Huang SL, 2013, NEUROIMAGE, V72, P237, DOI 10.1016/j.neuroimage.2013.01.027; Lin AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046585; LINDAHL PE, 1961, EXP CELL RES, V23, P228, DOI 10.1016/0014-4827(61)90033-7; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Medina DX, 2011, BRAIN PATHOL, V21, P140, DOI 10.1111/j.1750-3639.2010.00430.x; Meng XJ, 2004, ANN NEUROL, V55, P207, DOI 10.1002/ana.10803; Merenda A, 2006, CURR OPIN CRIT CARE, V12, P90, DOI 10.1097/01.ccx.0000216573.26686.27; Miclescu A, 2010, CRIT CARE MED, V38, P2199, DOI 10.1097/CCM.0b013e3181f26b0c; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; O'Leary JC, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-45; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OLEARY JL, 1968, STAIN TECHNOL, V43, P197, DOI 10.3109/10520296809115068; Oz M, 2009, BIOCHEM PHARMACOL, V78, P927, DOI 10.1016/j.bcp.2009.04.034; Palzur E, 2008, BRAIN RES, V1221, P126, DOI 10.1016/j.brainres.2008.04.078; Poteet E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048279; Riha PD, 2005, EUR J PHARMACOL, V511, P151, DOI 10.1016/j.ejphar.2005.02.001; Rojas JC, 2012, PROG NEUROBIOL, V96, P32, DOI 10.1016/j.pneurobio.2011.10.007; SALARIS SC, 1991, BIOCHEM PHARMACOL, V42, P499, DOI 10.1016/0006-2952(91)90311-R; Scheindlin S, 2008, MOL INTERV, V8, P268, DOI 10.1124/mi.8.6.1; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SCOTT A, 1966, J BIOL CHEM, V241, P1060; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Shen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079833; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Watts LT, 2013, J NEUROTRAUM, V30, P55, DOI 10.1089/neu.2012.2488; Wen Y, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.208447; Yoo AJ, 2013, J STROKE CEREBROVASC, V22, P742, DOI 10.1016/j.jstrokecerebrovasdis.2012.01.002; Zhang XA, 2006, NEUROTOX RES, V9, P47, DOI 10.1007/BF03033307	45	46	47	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2014	31	11					1063	1071		10.1089/neu.2013.3193			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AJ7RS	WOS:000337895300009	24479842	Green Published			2021-06-18	
J	Giuliani, D; Bitto, A; Galantucci, M; Zaffe, D; Ottani, A; Irrera, N; Neri, L; Cavallini, GM; Altavilla, D; Botticelli, AR; Squadrito, F; Guarini, S				Giuliani, Daniela; Bitto, Alessandra; Galantucci, Maria; Zaffe, Davide; Ottani, Alessandra; Irrera, Natasha; Neri, Laura; Cavallini, Gian Maria; Altavilla, Domenica; Botticelli, Annibale R.; Squadrito, Francesco; Guarini, Salvatore			Melanocortins protect against progression of Alzheimer's disease in triple-transgenic mice by targeting multiple pathophysiological pathways	NEUROBIOLOGY OF AGING			English	Article						Alzheimer's disease; Triple-transgenic mice; Pathophysiological pathways; Learning and memory; Melanocortins; Neuroprotection	MELANOCYTE-STIMULATING HORMONE; TRAUMATIC BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; SPINAL-CORD-INJURY; CEREBRAL-ISCHEMIA; NEURODEGENERATIVE DISEASES; MOUSE MODEL; SYNAPTIC DYSFUNCTION; COGNITIVE DEFICITS; DELAYED TREATMENT	Besides specific triggering causes, Alzheimer's disease (AD) involves pathophysiological pathways that are common to acute and chronic neurodegenerative disorders. Melanocortins induce neuroprotection in experimental acute neurodegenerative conditions, and low melanocortin levels have been found in occasional studies performed in AD-type dementia patients. Here we investigated the possible neuroprotective role of melanocortins in a chronic neurodegenerative disorder, AD, by using 12-week-old (at the start of the study) triple-transgenic (3xTg-AD) mice harboring human transgenes APP(Swe), PS1(M146V), and tau(P301L). Treatment of 3xTg-AD mice, once daily until the end of the study (30 weeks of age), with the melanocortin analog [Nle(4),D-Phe(7)]-alpha-melanocyte-stimulating hormone (NDP-alpha-MSH) reduced cerebral cortex/hippocampus phosphorylation/level of all AD-related biomarkers investigated (mediators of amyloid/tau cascade, oxidative/nitrosative stress, inflammation, apoptosis), decreased neuronal loss, induced over-expression of the synaptic activity-dependent gene Zif268, and improved cognitive functions, relative to saline-treated 3xTg-AD mice. Pharmacological blockade of melanocortin MC4 receptors prevented all neuroprotective effects of NDP-alpha-MSH. Our study identifies, for the first time, a class of drugs, MC4 receptor-stimulating melanocortins, that are able to counteract the progression of experimental AD by targeting pathophysiological mechanisms up- and down-stream of beta-amyloid and tau. These data could have important clinical implications. (C) 2014 Elsevier Inc. All rights reserved.	[Giuliani, Daniela; Galantucci, Maria; Ottani, Alessandra; Neri, Laura; Guarini, Salvatore] Univ Modena & Reggio Emilia, Sect Pharmacol & Mol Med, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy; [Bitto, Alessandra; Irrera, Natasha; Altavilla, Domenica; Squadrito, Francesco] Univ Messina, Pharmacol Sect, Dept Clin & Expt Med, Messina, Italy; [Zaffe, Davide] Univ Modena & Reggio Emilia, Sect Human Morphol, Dept Biomed Metab & Neural Sci, I-41125 Modena, Italy; [Cavallini, Gian Maria] Univ Modena & Reggio Emilia, Div Ophthalmol, I-41125 Modena, Italy; [Botticelli, Annibale R.] Univ Pavia, Dept Mol Med, I-27100 Pavia, Italy	Guarini, S (corresponding author), Univ Modena & Reggio Emilia, Sect Pharmacol & Mol Med, Dept Biomed Metab & Neural Sci, Via G Campi 287, I-41125 Modena, Italy.	salvatore.guarini@unimore.it	GUARINI, SALVATORE/O-3139-2013; Cavallini, Gian Maria/P-9705-2016; Giuliani, Daniela/B-2968-2016; Irrera, Natasha/K-5411-2018; Ottani, Alessandra/G-7316-2016; Zaffe, Davide/G-1181-2016	GUARINI, SALVATORE/0000-0002-1164-1706; Cavallini, Gian Maria/0000-0003-0914-2884; Giuliani, Daniela/0000-0001-6061-5662; Ottani, Alessandra/0000-0002-1676-051X; Zaffe, Davide/0000-0003-1241-385X	Ministero dell'IstruzioneMinistry of Education, Universities and Research (MIUR); dell'Universita e della Ricerca (MIUR), RomaMinistry of Education, Universities and Research (MIUR); University of Modena and Reggio Emilia, Italy	This work was supported in part by grants from Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR), Roma, and University of Modena and Reggio Emilia, Italy.	ANDERSON B, 1986, MED HYPOTHESES, V19, P379, DOI 10.1016/0306-9877(86)90113-1; ARAI H, 1986, BRAIN RES, V377, P305, DOI 10.1016/0006-8993(86)90873-5; Bagheri M, 2011, NEUROBIOL LEARN MEM, V95, P270, DOI 10.1016/j.nlm.2010.12.001; Banerjee R, 2010, TRENDS NEUROSCI, V33, P541, DOI 10.1016/j.tins.2010.09.001; BANKS WA, 1995, PEPTIDES, V16, P1157, DOI 10.1016/0196-9781(95)00043-J; Beug ST, 2012, TRENDS IMMUNOL, V33, P535, DOI 10.1016/j.it.2012.06.004; Bharne AP, 2011, NEUROPEPTIDES, V45, P25, DOI 10.1016/j.npep.2010.10.001; Bitto A, 2012, CRIT CARE MED, V40, P945, DOI 10.1097/CCM.0b013e318236efde; Blennow K, 2010, NAT MED, V16, P1218, DOI 10.1038/nm.2221; Brzoska T, 2008, ENDOCR REV, V29, P581, DOI 10.1210/er.2007-0027; Caruso C, 2012, MOL CELL ENDOCRINOL, V348, P47, DOI 10.1016/j.mce.2011.07.036; Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1; Chang KA, 2006, MOL CELL BIOL, V26, P4327, DOI 10.1128/MCB.02393-05; Chen G, 2008, NEUROPEPTIDES, V42, P331, DOI 10.1016/j.npep.2008.01.004; Corander MP, 2009, CIRCULATION, V120, P2260, DOI 10.1161/CIRCULATIONAHA.109.854612; Craig-Schapiro R, 2009, NEUROBIOL DIS, V35, P128, DOI 10.1016/j.nbd.2008.10.003; D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709; FACCHINETTI F, 1984, LIFE SCI, V35, P1691, DOI 10.1016/0024-3205(84)90181-4; Friedlander RM, 2003, NEW ENGL J MED, V348, P1365, DOI 10.1056/NEJMra022366; Galimberti D, 1999, BIOCHEM BIOPH RES CO, V263, P251, DOI 10.1006/bbrc.1999.1276; Galimberti D, 2013, J NEUROL SCI, V333, P50, DOI 10.1016/j.jns.2012.12.013; Gao HM, 2012, TRENDS PHARMACOL SCI, V33, P295, DOI 10.1016/j.tips.2012.03.008; Gatti S, 2012, EXP NEUROL, V234, P230, DOI 10.1016/j.expneurol.2011.12.039; Ghosh S, 2013, J NEUROSCI, V33, P5053, DOI 10.1523/JNEUROSCI.4361-12.2013; Giuliani D, 2007, BRIT J PHARMACOL, V150, P595, DOI 10.1038/sj.bjp.0707115; Giuliani D, 2006, ENDOCRINOLOGY, V147, P1126, DOI 10.1210/en.2005-0692; Giuliani D, 2007, EUR J PHARMACOL, V570, P57, DOI 10.1016/j.ejphar.2007.05.025; Giuliani D, 2013, NEUROBIOL LEARN MEM, V104, P82, DOI 10.1016/j.nlm.2013.05.006; Giuliani D, 2012, FRONT NEUROENDOCRIN, V33, P179, DOI 10.1016/j.yfrne.2012.04.001; Giuliani D, 2011, ACTA NEUROPATHOL, V122, P443, DOI 10.1007/s00401-011-0873-4; Giuliani D, 2009, BRAIN BEHAV IMMUN, V23, P844, DOI 10.1016/j.bbi.2009.03.009; Glat MJ, 2013, STEM CELLS DEV, V22, P1490, DOI 10.1089/scd.2012.0633; Grieco P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061614; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Hanisch K, 2010, J PROTEOME RES, V9, P1476, DOI 10.1021/pr901002t; Huang QH, 2002, NEUROSCI LETT, V334, P186, DOI 10.1016/S0304-3940(02)01088-1; Iqbal K, 2011, ACTA NEUROPATHOL, V122, P543, DOI 10.1007/s00401-011-0878-z; Iqbal K, 2010, ALZHEIMERS DEMENT, V6, P420, DOI 10.1016/j.jalz.2010.04.006; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Jakovcevski M, 2012, NAT MED, V18, P1194, DOI 10.1038/nm.2828; Karbowski M, 2012, ACTA NEUROPATHOL, V123, P157, DOI 10.1007/s00401-011-0921-0; Kumar S, 2013, ACTA NEUROPATHOL, V125, P699, DOI 10.1007/s00401-013-1107-8; Lo EH, 2010, NAT MED, V16, P1205, DOI 10.1038/nm.2226; Minutoli L, 2011, ENDOCRINOLOGY, V152, P3852, DOI 10.1210/en.2011-1016; Mountjoy KG, 2010, ADV EXP MED BIOL, V681, P29, DOI 10.1007/978-1-4419-6354-3_3; Munoz L, 2010, NEUROPHARMACOLOGY, V58, P561, DOI 10.1016/j.neuropharm.2009.11.010; Nagahara AH, 2011, NAT REV DRUG DISCOV, V10, P209, DOI 10.1038/nrd3366; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Ottani A, 2009, J CEREBR BLOOD F MET, V29, P512, DOI 10.1038/jcbfm.2008.140; RAINERO I, 1988, NEUROLOGY, V38, P1281, DOI 10.1212/WNL.38.8.1281; Salkovic-Petrisic M, 2011, J NEURAL TRANSM, V118, P765, DOI 10.1007/s00702-011-0651-4; Sanchez PE, 2012, P NATL ACAD SCI USA, V109, pE2895, DOI 10.1073/pnas.1121081109; Savos AV, 2011, J CEREBR BLOOD F MET, V31, P606, DOI 10.1038/jcbfm.2010.130; Schellenberg GD, 2012, ACTA NEUROPATHOL, V124, P305, DOI 10.1007/s00401-012-0996-2; Schioth HB, 2012, MOL NEUROBIOL, V46, P4, DOI 10.1007/s12035-011-8229-6; Sharma HS, 2006, J NEURAL TRANSM, V113, P463, DOI 10.1007/s00702-005-0404-3; Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Spaccapelo L, 2013, EUR J PHARMACOL, V707, P78, DOI 10.1016/j.ejphar.2013.03.030; Spaccapelo L, 2011, EUR J PHARMACOL, V670, P479, DOI 10.1016/j.ejphar.2011.09.015; Sperling RA, 2013, NAT REV NEUROL, V9, P54, DOI 10.1038/nrneurol.2012.241; Sy M, 2011, AM J PATHOL, V178, P2811, DOI 10.1016/j.ajpath.2011.02.012; Tashiro A, 2007, J NEUROSCI, V27, P3252, DOI 10.1523/JNEUROSCI.4941-06.2007; Tayeb HO, 2012, PHARMACOL THERAPEUT, V134, P8, DOI 10.1016/j.pharmthera.2011.12.002; Vergoni AV, 2000, EUR J PHARMACOL, V405, P25, DOI 10.1016/S0014-2999(00)00538-0; Wang JM, 2010, P NATL ACAD SCI USA, V107, P6498, DOI 10.1073/pnas.1001422107; Wikberg JES, 2008, NAT REV DRUG DISCOV, V7, P307, DOI 10.1038/nrd2331; Wolfe MS, 2009, J BIOL CHEM, V284, P6021, DOI 10.1074/jbc.R800013200; Yu Y, 2009, J NEUROCHEM, V108, P1480, DOI 10.1111/j.1471-4159.2009.05882.x; Zipp F, 2006, TRENDS NEUROSCI, V29, P518, DOI 10.1016/j.tins.2006.07.006	70	46	47	0	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	MAR	2014	35	3					537	547		10.1016/j.neurobiolaging.2013.08.030			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	275DE	WOS:000328655700011	24094579				2021-06-18	
J	Fayaz, SM; Kumar, VSS; Rajanikant, GK				Fayaz, S. M.; Kumar, V. S. Suvanish; Rajanikant, G. K.			Necroptosis: Who Knew There were so Many Interesting Ways to Die?	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Alzheimers disease; brain disorders; ischemia/reperfusion (I/R); necroptosis; neurodegeneration; Parkinson's disease; programmed cell death (PCD)	MITOCHONDRIAL PERMEABILITY TRANSITION; RECEPTOR-INTERACTING PROTEIN; NECROSIS-FACTOR-ALPHA; NONAPOPTOTIC CELL-DEATH; BLOOD-BRAIN-BARRIER; CYCLOPHILIN-D; PROGRAMMED NECROSIS; NEURONAL DEATH; ALZHEIMERS-DISEASE; MEDIATED APOPTOSIS	Conventional knowledge considered apoptosis as the sole form of programmed cell death during development, homeostasis and diseases, whereas necrosis was regarded as an unregulated and uncontrollable process. Recent revelations suggest that necrosis can also occur in a regulated, caspase-independent manner and shares characteristics with both necrosis and apoptosis. The major cell death processes namely apoptosis, autophagy and necrosis are interlinked and contain many common regulatory mechanisms. Mounting evidence indicates that necroptosis contributes to the pathogenesis of various diseases, including ischemic stroke, traumatic brain injury, neurodegenerative disorders and brain tumor. We present here an overview of the molecular mechanisms governing necroptosis and its connection with apoptosis and autophagy processes. Further, the necroptosis mechanisms underlying the neurodegeneration during ischemia reperfusion (I/R) injury are described, with an emphasis on the key proteins involved in this type of cell death. Knowledge regarding programmed cell death (PCD) with relevance to necroptosis may play a significant role in debilitating brain disorders.	[Fayaz, S. M.; Kumar, V. S. Suvanish; Rajanikant, G. K.] Natl Inst Technol Calicut, Sch Biotechnol, Calicut 673601, Kerala, India	Rajanikant, GK (corresponding author), Natl Inst Technol Calicut, Sch Biotechnol, Bioinformat Infrastruct Facil, Calicut 673601, Kerala, India.	rajanikant@nitc.ac.in	S.M., Fayaz/P-6103-2015; G.K, Rajanikant/H-3275-2019	S.M., Fayaz/0000-0002-1212-7952; KUMAR, SUVANISH/0000-0001-9033-0422; , Rajanikant/0000-0001-9754-997X			Asahi M, 2001, J NEUROSCI, V21, P7724; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bell BD, 2008, P NATL ACAD SCI USA, V105, P16677, DOI 10.1073/pnas.0808597105; Bianchi ME, 2004, BBA-GENE STRUCT EXPR, V1677, P181, DOI 10.1016/j.bbaexp.2003.10.017; Borsello T, 2003, J COMP NEUROL, V465, P286, DOI 10.1002/cne.10834; Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004; Byun HS, 2006, MOL PHARMACOL, V70, P1099, DOI 10.1124/mol.106.025452; Ch'en IL, 2008, P NATL ACAD SCI USA, V105, P17463, DOI 10.1073/pnas.0808043105; Ch'en IL, 2011, J EXP MED, V208, P633, DOI 10.1084/jem.20110251; Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLARKE PGH, 1984, HISTOCHEM J, V16, P955, DOI 10.1007/BF01003851; CLARKE PGH, 1982, NEUROSCI LETT, V30, P223, DOI 10.1016/0304-3940(82)90403-7; Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faraco G, 2007, J NEUROCHEM, V103, P590, DOI 10.1111/j.1471-4159.2007.04788.x; Germani A, 2007, J LEUKOCYTE BIOL, V81, P41, DOI 10.1189/jlb.0306165; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Guillot-Sestier MV, 2009, J BIOL CHEM, V284, P35973, DOI 10.1074/jbc.M109.051086; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Haraldsen G, 2009, TRENDS IMMUNOL, V30, P227, DOI 10.1016/j.it.2009.03.003; Hayashi T, 2007, FREE RADICAL BIO MED, V43, P1552, DOI 10.1016/j.freeradbiomed.2007.08.013; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Izumi Y, 2005, J NEUROSCI RES, V79, P849, DOI 10.1002/jnr.20382; Jagtap PG, 2007, J MED CHEM, V50, P1886, DOI 10.1021/jm061016o; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kang TB, 2008, J IMMUNOL, V181, P2522, DOI 10.4049/jimmunol.181.4.2522; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Li YL, 2008, NEUROSCI LETT, V447, P120, DOI 10.1016/j.neulet.2008.08.037; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Liu K, 2007, FASEB J, V21, P3904, DOI 10.1096/fj.07-8770com; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lo SC, 2008, EXP CELL RES, V314, P1789, DOI 10.1016/j.yexcr.2008.02.014; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lou M, 2006, BRAIN RES BULL, V69, P109, DOI 10.1016/j.brainresbull.2005.11.009; Vazquez CL, 2010, AUTOPHAGY, V6, P177, DOI 10.4161/auto.6.1.10743; Ma SL, 2004, NEUROLOGY, V62, P307, DOI 10.1212/01.WNL.0000103288.49441.E4; Mareninova OA, 2006, J BIOL CHEM, V281, P3370, DOI 10.1074/jbc.M511276200; Martin LJ, 2011, TOXICOL PATHOL, V39, P220, DOI 10.1177/0192623310389475; Mccoy MK, 2006, J NEUROSCI, V26, P9365, DOI 10.1523/JNEUROSCI.1504-06.2006; McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakajima A, 2008, ONCOGENE, V27, P76, DOI 10.1038/sj.onc.1210624; Nakamura M, 2007, BIOCHEMISTRY-US, V46, P12737, DOI 10.1021/bi701079z; Northington FJ, 2011, J CEREBR BLOOD F MET, V31, P178, DOI 10.1038/jcbfm.2010.72; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Piot C, 2008, NEW ENGL J MED, V359, P473, DOI 10.1056/NEJMoa071142; Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Ramos EM, 2006, ARCH NEUROL-CHICAGO, V63, P1165, DOI 10.1001/archneur.63.8.1165; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; Rosenbaum DM, 2010, J NEUROSCI RES, V88, P1569, DOI 10.1002/jnr.22314; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 2007, BRAIN RES, V1133, P186, DOI 10.1016/j.brainres.2006.11.041; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; Sayre LM, 2008, CHEM RES TOXICOL, V21, P172, DOI 10.1021/tx700210j; Schattenberg JM, 2011, J HEPATOL, V55, P1272, DOI 10.1016/j.jhep.2011.03.008; Schinder AF, 1996, J NEUROSCI, V16, P6125; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Simonson SJS, 2007, DEV CELL, V13, P601, DOI 10.1016/j.devcel.2007.10.009; Smith CCT, 2007, CARDIOVASC DRUG THER, V21, P227, DOI 10.1007/s10557-007-6035-1; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Storz P, 2005, BIOCHEM J, V387, P47, DOI 10.1042/BJ20041443; Tafani M, 2000, AM J PATHOL, V156, P2111, DOI 10.1016/S0002-9440(10)65082-1; Tauriello DVF, 2010, MOL CELL, V37, P607, DOI 10.1016/j.molcel.2010.01.035; Teng X, 2008, BIOORG MED CHEM LETT, V18, P3219, DOI 10.1016/j.bmcl.2008.04.048; Teng X, 2007, BIOORG MED CHEM LETT, V17, P6836, DOI 10.1016/j.bmcl.2007.10.024; Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906; Tsujimoto Y, 2007, APOPTOSIS, V12, P835, DOI 10.1007/s10495-006-0525-7; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234; Upton JW, 2010, CELL HOST MICROBE, V7, P302, DOI 10.1016/j.chom.2010.03.006; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vandenabeele P, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3115re4; Vanlangenakker N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.111; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang Y, 2009, EUR J NEUROSCI, V30, P2258, DOI 10.1111/j.1460-9568.2009.07025.x; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; WATSON AJM, 1995, GASTROENTEROLOGY, V109, P472, DOI 10.1016/0016-5085(95)90335-6; Welz PS, 2011, NATURE, V477, P330, DOI 10.1038/nature10273; West T, 2006, NEUROBIOL DIS, V22, P523, DOI 10.1016/j.nbd.2005.12.017; Whelan RS, 2010, ANNU REV PHYSIOL, V72, P19, DOI 10.1146/annurev.physiol.010908.163111; White RJ, 1996, J NEUROSCI, V16, P5688; Willingham SB, 2009, J IMMUNOL, V183, P2008, DOI 10.4049/jimmunol.0900138; Wright A, 2007, DEV CELL, V13, P705, DOI 10.1016/j.devcel.2007.09.007; Xiao JF, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-011-0239-z; Xu XS, 2007, J NEUROCHEM, V103, P2004, DOI 10.1111/j.1471-4159.2007.04884.x; Xu XS, 2010, BRAIN RES, V1355, P189, DOI 10.1016/j.brainres.2010.07.080; Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022; Yamanaka K, 2011, J BIOL CHEM, V286, P24666, DOI 10.1074/jbc.M111.236273; Yang QW, 2010, J CEREBR BLOOD F MET, V30, P243, DOI 10.1038/jcbfm.2009.202; Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu LY, 2006, NEUROCHEM RES, V31, P21, DOI 10.1007/s11064-005-9004-8; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yuan J, 2003, NEURON, V40, P401, DOI 10.1016/S0896-6273(03)00601-9; Yuan JY, 2010, GENE DEV, V24, P2592, DOI 10.1101/gad.1984410; Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109; Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006	130	46	50	0	19	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	FEB	2014	13	1					42	51		10.2174/18715273113126660189			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AB6DW	WOS:000331878800010	24152329				2021-06-18	
J	Hartings, JA; Vidgeon, S; Strong, AJ; Zacko, C; Vagal, A; Andaluz, N; Ridder, T; Stanger, R; Fabricius, M; Mathern, B; Pahl, C; Tolias, CM; Bullock, MR				Hartings, Jed A.; Vidgeon, Steven; Strong, Anthony J.; Zacko, Chris; Vagal, Achala; Andaluz, Norberto; Ridder, Thomas; Stanger, Richard; Fabricius, Martin; Mathern, Bruce; Pahl, Clemens; Tolias, Christos M.; Bullock, M. Ross		Co-Operative Studies Brain Injury	Surgical management of traumatic brain injury: a comparative-effectiveness study of 2 centers Clinical article	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; intracranial hypertension; cortical spreading depression; traumatic brain injury; acute subdural hematoma; brain contusion	CORTICAL SPREADING DEPRESSION; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; DENDRITIC INJURY; DEPOLARIZATIONS; CRANIOTOMY; MULTICENTER; STROKE; HEMICRANIECTOMY; INTERVENTION	Object. Mass lesions from traumatic brain injury (TBI) often require surgical evacuation as a life-saving measure and to improve outcomes, but optimal timing and surgical technique, including decompressive craniectomy, have not been fully defined. The authors compared neurosurgical approaches in the treatment of TBI at 2 academic medical centers to document variations in real-world practice and evaluate the efficacies of different approaches on postsurgical course and long-term outcome. Methods. Patients 18 years of age or older who required neurosurgical lesion evacuation or decompression for TBI were enrolled in the Co-Operative Studies on Brain Injury Depolarizations (COSBID) at King's College Hospital (KCH, n = 27) and Virginia Commonwealth University (VCU, n = 24) from July 2004 to March 2010. Subdural electrode strips were placed at the time of surgery for subsequent electrocorticographic monitoring of spreading depolarizations; injury characteristics, physiological monitoring data, and 6-month outcomes were collected prospectively. CT scans and medical records were reviewed retrospectively to determine lesion characteristics, surgical indications, and procedures performed. Results. Patients enrolled at KCH were significantly older than those enrolled at VCU (48 vs 34 years, p < 0.01) and falls were more commonly the cause of TBI in the KCH group than in the VCU group. Otherwise, KCH and VCU patients had similar prognoses, lesion types (subdural hematomas: 30%-35%; parenchymal contusions: 48%-52%), signs of mass effect (midline shift >= 5 mm: 43%-52%), and preoperative intracranial pressure (ICP). At VCU, however, surgeries were performed earlier (median 0.51 vs 0.83 days posttrauma, p < 0.05), bone flaps were larger (mean 82 vs 53 cm(2), p < 0.001), and craniectomies were more common (performed in 75% vs 44% of cases, p < 0.05). Postoperatively, maximum ICP values were lower at VCU (mean 22.5 vs 31.4 mm Hg, p < 0.01). Differences in incidence of spreading depolarizations (KCH: 63%, VCU: 42%, p = 0.13) and poor outcomes (KCH: 54%, VCU: 33%, p = 0.14) were not significant. In a subgroup analysis of only those patients who underwent early (< 24 hours) lesion evacuation (KCH: n = 14; VCU: n = 16), however, VCU patients fared significantly better. In the VCU patients, bone flaps were larger (mean 85 vs 48 cm(2) at KCH, p < 0.001), spreading depolarizations were less common (31% vs 86% at KCH, p < 0.01), postoperative ICP values were lower (mean: 20.8 vs 30.2 mm Hg at KCH, p < 0.05), and good outcomes were more common (69% vs 29% at KCH, p < 0.05). Spreading depolarizations were the only significant predictor of outcome in multivariate analysis. Conclusions. This comparative-effectiveness study provides evidence for major practice variation in surgical management of severe TBI. Although ages differed between the 2 cohorts, the results suggest that a more aggressive approach, including earlier surgery, larger craniotomy, and removal of bone flap, may reduce ICP, prevent cortical spreading depolarizations, and improve outcomes. In particular, patients requiring evacuation of subdural hematomas and contusions may benefit from decompressive craniectomy in conjunction with lesion evacuation, even when elevated ICP is not a factor in the decision to perform surgery.	[Hartings, Jed A.; Andaluz, Norberto] Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Coll Med, Cincinnati, OH 45267 USA; [Vagal, Achala] Univ Cincinnati, Dept Radiol, Inst Neurosci, Coll Med, Cincinnati, OH 45267 USA; [Vidgeon, Steven; Strong, Anthony J.; Tolias, Christos M.] Kings Coll London, Dept Clin Neurosci, London WC2R 2LS, England; [Pahl, Clemens] Kings Coll London, Dept Crit Care Med, London WC2R 2LS, England; [Zacko, Chris; Bullock, M. Ross] Univ Miami, Dept Neurol Surg, Coral Gables, FL 33124 USA; [Ridder, Thomas; Stanger, Richard; Mathern, Bruce] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; [Fabricius, Martin] Glostrup Cty Hosp, Dept Clin Neurophysiol, Copenhagen, Denmark	Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	jed.hartings@uc.edu		Hartings, Jed/0000-0001-8583-3471	US Army CDMRP PH/TBI Research Program [W81XWH-08-2-0016]; HeadFirst; King's College Hospital Foundation Trust's Research and Development Fund; Novo Nordisk FoundationNovo Nordisk Foundation	This work was funded in part by the US Army CDMRP PH/TBI Research Program, Contract No. W81XWH-08-2-0016. Dr. Strong acknowledges support from HeadFirst; Dr. Pahl from King's College Hospital Foundation Trust's Research and Development Fund; and Dr. Fabricius from the Novo Nordisk Foundation. Funding sources had no role in study design or in the collection, analysis, interpretation, or reporting of data.	Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bell RS, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1022; Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400; Bratton SL, 2008, J NEUROTRAUM, V25, P276; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper P R, 1976, Surg Neurol, V5, P25; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; De Bonis P, 2011, J NEUROTRAUM, V28, P2043, DOI 10.1089/neu.2011.1889; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2013, NEUROSCIENTIST, V19, P25, DOI 10.1177/1073858412453340; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; Ghajar J, 2009, MT SINAI J MED, V76, P190, DOI 10.1002/msj.20095; Guedes RCA, 1996, BRAZ J MED BIOL RES, V29, P1407; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hartings JA, 2009, J NEUROPHYSIOL, V102, P2563, DOI 10.1152/jn.00345.2009; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Marion DW, 2006, NEUROSURGERY, V58, P655; Maslarova A, 2011, STROKE, V42, P2917, DOI 10.1161/STROKEAHA.111.621581; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	56	46	47	0	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2014	120	2					434	446		10.3171/2013.9.JNS13581			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	301UA	WOS:000330556400027	24180566				2021-06-18	
J	Koriat, A; Ackerman, R; Adiv, S; Lockl, K; Schneider, W				Koriat, Asher; Ackerman, Rakefet; Adiv, Shiri; Lockl, Kathrin; Schneider, Wolfgang			The Effects of Goal-Driven and Data-Driven Regulation on Metacognitive Monitoring During Learning: A Developmental Perspective	JOURNAL OF EXPERIMENTAL PSYCHOLOGY-GENERAL			English	Article						metacognitive development; monitoring and control; judgments of learning; self-regulation; incentives	TRAUMATIC BRAIN-INJURY; CHILDRENS KNOWLEDGE; JUDGMENTS; TIME; ALLOCATION; RETRIEVAL; MEMORY; INCENTIVES; CONFIDENCE; FLUENCY	Research in metacognition (Koriat, Ma'ayan, & Nussinson, 2006) suggests bidirectional links between monitoring and control during learning: When self-regulation is goal-driven, monitoring affects control so that increased study time (ST) enhances judgments of learning (JOLs). However, when self-regulation is data-driven, JOLs are based on the feedback from control, and therefore JOLs decrease with ST under the heuristic that ease of encoding is diagnostic of successful recall. Evidence for both types of relationships occurring within the same situation was found for adults. We examined the development of the ability to respond differentially to data-driven and goal-driven variation in ST within the same task. Children in Grades 5 and 6 exhibited a positive ST-JOL relationship for goal-driven regulation and a negative relationship for data-driven regulation but never in the same task. In contrast, the JOLs and recall of 9th graders and college students yielded differential cosensitivity to data-driven and goal-driven variation. The 5th and 6th graders also evidenced an adult-like pattern of JOLs and recall under a partitioning procedure that helped them in factoring the variation in ST due to data-driven and goal-driven variation in ST. The results are discussed in terms of the metacognitive sophistication needed for considering both types of variation simultaneously in making metacognitive judgments.	[Koriat, Asher; Adiv, Shiri] Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel; [Ackerman, Rakefet] Technion Israel Inst Technol, Fac Ind Engn & Management, IL-32000 Haifa, Israel; [Lockl, Kathrin] Otto Friedrich Univ Bamberg, Dept Psychol, D-96047 Bamberg, Germany; [Schneider, Wolfgang] Univ Wurzburg, Dept Psychol, D-97070 Wurzburg, Germany	Koriat, A (corresponding author), Univ Haifa, Dept Psychol, IL-31905 Haifa, Israel.	akoriat@research.haifa.ac.il	Ackerman, Rakefet/J-4468-2019	Ackerman, Rakefet/0000-0001-9583-8014			Ackerman R, 2012, PSYCHON B REV, V19, P1187, DOI 10.3758/s13423-012-0305-z; Ackerman R, 2011, J EXP PSYCHOL-APPL, V17, P18, DOI 10.1037/a0022086; Annevirta T, 2001, EUR J PSYCHOL EDUC, V16, P257, DOI 10.1007/BF03173029; Ariel R, 2009, J EXP PSYCHOL GEN, V138, P432, DOI 10.1037/a0015928; Baumeister R.F., 2004, HDB SELF REGULATION; BUTTERFIELD EC, 1988, DEV PSYCHOL, V24, P654, DOI 10.1037/0012-1649.24.5.654; Castel AD, 2011, DEV PSYCHOL, V47, P1553, DOI 10.1037/a0025623; Castel AD, 2011, NEUROPSYCHOLOGY, V25, P15, DOI 10.1037/a0020298; Demmrich A., 2005, THESIS U POTSDAM POT; Derryberry D, 1997, DEV PSYCHOPATHOL, V9, P633, DOI 10.1017/S0954579497001375; Dunlosky J, 1998, EDUC PSYCHO, P249; Dunlosky J, 1998, ACTA PSYCHOL, V98, P37, DOI 10.1016/S0001-6918(97)00051-6; Eisenberg N, 2002, ADV CHILD DEV BEHAV, V30, P189, DOI 10.1016/S0065-2407(02)80042-8; Flavell J., 1977, PERSPECTIVES DEV MEM, P3; Flavell JH, 1999, ANNU REV PSYCHOL, V50, P21, DOI 10.1146/annurev.psych.50.1.21; FLAVELL JH, 1979, AM PSYCHOL, V34, P906, DOI 10.1037/0003-066X.34.10.906; Fritz CO, 2007, Q J EXP PSYCHOL, V60, P991, DOI 10.1080/17470210600823595; Ghetti S, 2008, CURR DIR PSYCHOL SCI, V17, P16, DOI 10.1111/j.1467-8721.2008.00540.x; Hanten G, 2004, ANN NEUROL, V56, P847, DOI 10.1002/ana.20298; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hanten G, 2007, DEV NEUROPSYCHOL, V32, P585, DOI 10.1080/87565640701361112; Hoffmann-Biencourt A, 2010, BRIT J DEV PSYCHOL, V28, P767, DOI 10.1348/026151009X479042; James W., 1884, MIND OS 9, V9, P34, DOI [10.1093/mind/os-IX.34.188, DOI 10.1093/MIND/OS-IX.34.188]; Kahneman D., 1973, ATTENTION EFFORT; KELLEY CM, 1993, J MEM LANG, V32, P1, DOI 10.1006/jmla.1993.1001; Kelley CM, 1998, ACTA PSYCHOL, V98, P127, DOI 10.1016/S0001-6918(97)00039-5; Koriat A, 2006, J EXP PSYCHOL GEN, V135, P36, DOI 10.1037/0096-3445.135.1.36; Koriat A, 1997, J EXP PSYCHOL GEN, V126, P349, DOI 10.1037/0096-3445.126.4.349; KORIAT A, 1993, PSYCHOL REV, V100, P609, DOI 10.1037/0033-295X.100.4.609; Koriat A, 1996, PSYCHOL REV, V103, P490, DOI 10.1037/0033-295X.103.3.490; Koriat A, 2005, J MEM LANG, V52, P478, DOI 10.1016/j.jml.2005.01.001; Koriat A., 2006, MEMORY EMOTION INTER; Koriat A., 2002, METACOGNITION PROCES, P1, DOI DOI 10.1007/978-1-4615-1099-4_1; Koriat A, 2008, MEM COGNITION, V36, P416, DOI 10.3758/MC.36.2.416; Koriat A, 2006, MEM COGNITION, V34, P959, DOI 10.3758/BF03193244; Koriat A, 2006, J EXP PSYCHOL LEARN, V32, P1133, DOI 10.1037/0278-7393.32.5.1133; Koriat A, 2010, DEVELOPMENTAL SCI, V13, P441, DOI 10.1111/j.1467-7687.2009.00907.x; Koriat A, 2009, COGNITIVE DEV, V24, P169, DOI 10.1016/j.cogdev.2009.01.001; Koriat A, 2009, J EXP PSYCHOL LEARN, V35, P1338, DOI 10.1037/a0016374; Koriat A, 2009, J EXP CHILD PSYCHOL, V102, P265, DOI 10.1016/j.jecp.2008.10.005; Kornell N, 2006, J EXP PSYCHOL LEARN, V32, P609, DOI 10.1037/0278-7393.32.3.609; Krebs SS, 2012, METACOGN LEARN, V7, P75, DOI 10.1007/s11409-011-9079-3; KREUTZER MA, 1975, MONOGR SOC RES CHILD, V40, P1, DOI 10.2307/1165955; KUNZINGER EL, 1984, J GENET PSYCHOL, V144, P19; Lockl K, 2002, INT J BEHAV DEV, V26, P327, DOI 10.1080/01650250143000210; Lockl K, 2004, EUR J DEV PSYCHOL, V1, P153, DOI 10.1080/17405620444000085; Lyons KE, 2010, TRENDS AND PROSPECTS IN METACOGNITION RESEARCH, P259, DOI 10.1007/978-1-4419-6546-2_12; Metcalfe J, 2008, PSYCHON B REV, V15, P174, DOI 10.3758/PBR.15.1.174; Mueller M. L., PSYCHONOMIC IN PRESS; Nelson T. O., 1990, PSYCHOL LEARN MOTIV, V26, P125, DOI DOI 10.1016/S0079-7421(08)60053-5; NELSON TO, 1988, J EXP PSYCHOL LEARN, V14, P676, DOI 10.1037/0278-7393.14.4.676; NELSON TO, 1994, PSYCHOL SCI, V5, P207, DOI 10.1111/j.1467-9280.1994.tb00502.x; NELSON TO, 1984, PSYCHOL BULL, V95, P109, DOI 10.1037/0033-2909.95.1.109; Niedenthal PM, 2007, SCIENCE, V316, P1002, DOI 10.1126/science.1136930; Ojose B., 2008, MATH ED, V18, P26, DOI DOI 10.1016/J.JCMS.2014.01.036; Osman M, 2006, PSYCHON B REV, V13, P935, DOI 10.3758/BF03213907; OSULLIVAN JT, 1993, J EXP CHILD PSYCHOL, V55, P396, DOI 10.1006/jecp.1993.1022; OSullivan JT, 1997, J EXP CHILD PSYCHOL, V65, P43, DOI 10.1006/jecp.1996.2355; Piaget J., 1977, KNOWLEDGE DEV, P17, DOI DOI 10.1007/978-1-4684-2547-5; Pressley M., 1997, MEMORY DEV 2 20; Roderer T., 2008, APPL MEMORY, P253; Roebers CM, 2007, J EXP CHILD PSYCHOL, V97, P117, DOI 10.1016/j.jecp.2006.12.006; Schneider W., 2008, HDB METAMEMORY MEMOR, P391, DOI DOI 10.4324/9780203805503; Schneider W, 2010, ON THINKING, P203, DOI 10.1007/978-3-642-03129-8_14; Schneider W, 2008, MIND BRAIN EDUC, V2, P114, DOI 10.1111/j.1751-228X.2008.00041.x; Son L.K, 2002, APPL METACOGNITION, P15, DOI [DOI 10.1017/CBO9780511489976.003, 10.1017/CBO9780511489976.003]; Son LK, 2000, J EXP PSYCHOL LEARN, V26, P204, DOI 10.1037/0278-7393.26.1.204; STIPEK DJ, 1984, CHILD DEV, V55, P1983, DOI 10.2307/1129773; Strack F, 2004, PERS SOC PSYCHOL REV, V8, P220, DOI 10.1207/s15327957pspr0803_1; Strack F, 2000, PERS SOC PSYCHOL B, V26, P762, DOI 10.1177/0146167200269002; Thiede KW, 2003, J EDUC PSYCHOL, V95, P66, DOI 10.1037/0022-0663.95.1.66; Thiede KW, 1999, J EXP PSYCHOL LEARN, V25, P1024, DOI 10.1037/0278-7393.25.4.1024; Tullis JG, 2011, J MEM LANG, V64, P109, DOI 10.1016/j.jml.2010.11.002; WELLMAN HM, 1981, CHILD DEV, V52, P1313, DOI 10.1111/j.1467-8624.1981.tb03182.x; ZACKS RT, 1969, J EXP PSYCHOL, V82, P441, DOI 10.1037/h0028369	75	46	47	1	35	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0096-3445	1939-2222		J EXP PSYCHOL GEN	J. Exp. Psychol.-Gen.	FEB	2014	143	1					386	403		10.1037/a0031768			18	Psychology, Experimental	Psychology	AA7TA	WOS:000331298600034	23421442				2021-06-18	
J	Klose, M; Stochholm, K; Janukonyte, J; Christensen, LL; Frystyk, J; Andersen, M; Laurberg, P; Christiansen, JS; Feldt-Rasmussen, U				Klose, Marianne; Stochholm, Kirstine; Janukonyte, Jourgita; Christensen, Louise Lehman; Frystyk, Jan; Andersen, Marianne; Laurberg, Peter; Christiansen, Jens Sandahl; Feldt-Rasmussen, Ulla			Prevalence of Posttraumatic Growth Hormone Deficiency Is Highly Dependent on the Diagnostic Set-up: Results From The Danish National Study on Posttraumatic Hypopituitarism	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							TRAUMATIC BRAIN-INJURY; GH-RELEASING HORMONE; ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY INSUFFICIENCY; ENDOCRINE-SOCIETY; ARGININE; TESTS; PYRIDOSTIGMINE; DYSFUNCTION; SECRETION	Context: Recent international guidelines suggest pituitary screening in patients with moderate and severe traumatic brain injury (TBI). Predominantly isolated GH deficiency (GHD) was reported in the literature, raising the question of potential methodological bias. Objective: Our objective was to assess the prevalence of GHD in patients admitted in 2008 with TBI, with concurrent assessment of methodological bias. Design and Setting: We conducted a nationwide population-based cohort study at tertiary referral university hospitals. Participants: Participants were Danish patients with a head trauma diagnosis from the Danish Board of Health diagnostic code registry; 439 patients and 124 healthy controls underwent dynamic assessment of GH secretion 2.5 years (median) after TBI. Main Outcome: We evaluated the prevalence of GHD given use of 1) local versus guideline cutoffs, 2) insulin tolerance test (ITT), pyridostigmine (PD)-GHRH or GHRH-arginine (arg) test, 3) single versus repeated testing, and 4) GH assessment by assays with different isoform specificities. Results: The prevalence of GHD was lower by local than by guideline cutoffs (12% vs 19% [PD-GHRH/GHRH-arg, P < .001]; 4.5% vs 5% [ITT, P = .9]), and by ITT than by PD-GHRH/GHRH-arg (P = .006 [local cutoffs]; P < .001 [guideline cutoffs]). Only 1% of patients had GHD according to 2 tests. GH assessment by the Immulite or iSYS assay caused no significant diagnostic differences. Conclusions: The study confirmed a high risk of bias in the management of pituitary testing of patients with TBI and stresses the importance of a proper control group and stringent GH testing including confirmatory testing in cohorts with low a priori likelihood of GHD such as in TBI. Our results question the evidence for newly introduced recommendations for routine pituitary assessment in TBI.	[Klose, Marianne; Feldt-Rasmussen, Ulla] Rigshosp, Copenhagen Univ Hosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark; [Stochholm, Kirstine; Janukonyte, Jourgita; Frystyk, Jan; Christiansen, Jens Sandahl] Aarhus Univ Hosp, Dept Internal Med & Endocrinol, DK-8000 Aarhus, Denmark; [Christensen, Louise Lehman; Andersen, Marianne] Odense Univ Hosp, Dept Med Endocrinol, DK-5000 Odense, Denmark; [Laurberg, Peter] Aalborg Univ Hosp, Dept Med Endocrinol, DK-9100 Aalborg, Denmark	Klose, M (corresponding author), Rigshosp, Copenhagen Univ Hosp, Dept Med Endocrinol, PE2131,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	klose@rh.dk	Feldt-Rasmussen, Ulla/AAB-9218-2021; Andersen, Marianne/AAE-1751-2019	Feldt-Rasmussen, Ulla/0000-0002-5903-3355; Andersen, Marianne/0000-0002-4603-9504; Stochholm, Kirstine/0000-0002-4408-3413	Danish Agency for Science, Technology, and Innovation; Reseach Council of the Capital Region of Denmark; Lundbeck FoundationLundbeckfonden; Novo NordiskNovo Nordisk; A.P. Moller Foundation for the Advancement of Medical Science; Arvid Nilsson's Foundation; Christenson-Ceson's Foundation; Axel-Muusfeldt's Foundation; Else and Mogens Wedell-Wedellsborg's Foundation	The study was funded by unrestricted grants from The Danish Agency for Science, Technology, and Innovation; The Reseach Council of the Capital Region of Denmark; The Lundbeck Foundation; Novo Nordisk; The A.P. Moller Foundation for the Advancement of Medical Science; Arvid Nilsson's Foundation; Christenson-Ceson's Foundation; Axel-Muusfeldt's Foundation; and Else and Mogens Wedell-Wedellsborg's Foundation. Immunodiagnostic Systems provided iSYS GH kits free of charge but had no influence on results or their interpretation.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; ANDERSEN M, 1996, ENDOCRINOL METAB, V3, P197; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Clemmons DR, 2011, CLIN CHEM, V57, P555, DOI 10.1373/clinchem.2010.150631; Colao A, 2009, J CLIN ENDOCR METAB, V94, P4414, DOI 10.1210/jc.2009-1134; CORDIDO F, 1990, J CLIN ENDOCR METAB, V70, P1361, DOI 10.1210/jcem-70-5-1361; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Fisker S, 1998, CLIN ENDOCRINOL, V48, P109; Gardner CJ, 2013, EUR J ENDOCRINOL, V168, P473, DOI 10.1530/EJE-12-0849; GHIGO E, 1989, METABOLISM, V38, P631, DOI 10.1016/0026-0495(89)90099-1; GHIGO E, 1990, J CLIN ENDOCR METAB, V71, P1481, DOI 10.1210/jcem-71-6-1481; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Hoeck HC, 1999, GROWTH HORM IGF RES, V9, P18, DOI 10.1054/ghir.1998.0085; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2010, CLIN ENDOCRINOL, V73, P95, DOI 10.1111/j.1365-2265.2010.03791.x; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V165, P225, DOI 10.1530/EJE-11-0365; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Lissett CA, 1999, CLIN ENDOCRINOL, V51, P551, DOI 10.1046/j.1365-2265.1999.00836.x; Makimura H, 2008, J CLIN ENDOCR METAB, V93, P4254, DOI 10.1210/jc.2008-1333; Manolopoulou J, 2012, CLIN CHEM, V58, P1446, DOI 10.1373/clinchem.2012.188128; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Procopio M, 1998, PANMINERVA MED, V40, P13; RASMUSSEN MH, 1995, J CLIN ENDOCR METAB, V80, P1407, DOI 10.1210/jc.80.4.1407; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Tanriverdi F, 2010, PITUITARY, V13, P146, DOI 10.1007/s11102-009-0215-x; van der Eerden AW, 2010, EUR J ENDOCRINOL, V162, P19, DOI 10.1530/EJE-09-0436; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011	36	46	47	0	4	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	JAN	2014	99	1					101	110		10.1210/jc.2013-2397			10	Endocrinology & Metabolism	Endocrinology & Metabolism	AD6WP	WOS:000333402200044	24243629	Bronze			2021-06-18	
J	Seel, RT; Douglas, J; Dennison, AC; Heaner, S; Farris, K; Rogers, C				Seel, Ronald T.; Douglas, Jennifer; Dennison, Andrew C.; Heaner, Sarah; Farris, Kathryn; Rogers, Catherine			Specialized Early Treatment for Persons With Disorders of Consciousness: Program Components and Outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Diagnosis; Prognosis; Rehabilitation; Vegetative state	COMA RECOVERY SCALE; TRAUMATIC BRAIN-INJURY; UPPER-LIMB SPASTICITY; TOXIN TYPE-A; VEGETATIVE STATE; BOTULINUM TOXIN; CONTROLLED-TRIAL; REHABILITATION; MANAGEMENT; CAREGIVERS	Objectives: To describe a specialized early treatment program for persons with disorders of consciousness (DOC) that includes family education; to identify rates of secondary conditions, imaging used, and selected interventions; and to evaluate outcomes. Design: A single-center, retrospective, pre-post design using electronic medical record data. Setting: A Commission on Accreditation of Rehabilitation Facilities accredited, long-term acute care hospital that provides acute medical and inpatient rehabilitation levels of care for people with catastrophic injuries. Participants: Persons (N=210) aged 14 to 69 years with DOC of primarily traumatic etiology admitted at a mean +/- SD of 41.0 +/- 27.2 days postinjury; 2% were in coma, 41% were in the vegetative state, and 57% were in the minimally conscious state. Interventions: An acute medical level of care with >= 90 minutes of daily interdisciplinary rehabilitation and didactic and hands-on caretaking education for families. Main Outcome Measures: Coma Recovery Scale Revised, Modified Ashworth Scale, and discharge disposition. Results: Program admission medical acuity included dysautonomia (15%), airway modifications (79%), infections (eg, pneumonia, 16%; urinary tract infection, 14%; blood, 11%), deep vein thrombosis (17%), pressure ulcers (14%), and marked hypertonia (30% in each limb). There were 168 program interruptions (ie, 139 surgeries, 29 nonsurgical intensive care unit transfers). Mean length of stay +/- SD was 39.1 +/- 29.4 days (range, 6-204d). Patients showed improved consciousness and respiratory function and reduced presence or severity of pressure ulcers and upper extremity hypertonia. At discharge, 54% showed sufficient emergence from a minimally conscious state to transition to mainstream inpatient rehabilitation, and 29% did not emerge but were discharged home to family with ongoing programmatic support; only 13% did not emerge and were institutionalized. Conclusions: Persons with DOC resulting primarily from a traumatic etiology who receive specialized early treatment that includes acute medical care and >= 90 minutes of daily rehabilitation are likely to show improved consciousness and body function; more than half may transition to mainstream inpatient rehabilitation. Families who receive comprehensive education and hands-on training with ongoing follow-up support may be twice as likely to provide care for medically stable persons with DOC in their homes versus nursing facility placement. (c) 2013 by the American Congress of Rehabilitation Medicine	[Seel, Ronald T.; Douglas, Jennifer; Dennison, Andrew C.; Heaner, Sarah; Farris, Kathryn; Rogers, Catherine] Shepherd Ctr, Crawford Res Inst, Brain Injury Program, Atlanta, GA 30309 USA	Seel, RT (corresponding author), Shepherd Ctr, Crawford Res Inst, 2020 Peachtree Rd, Atlanta, GA 30309 USA.	ron_seel@shepherd.org					Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Andrews K, 2005, NEUROPSYCHOL REHABIL, V15, P461, DOI 10.1080/09602010443000326; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bernat JL, 2009, ANNU REV MED, V60, P381, DOI 10.1146/annurev.med.60.060107.091250; Berube J, MOHONK REPORT DISORD; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Choi JH, 2008, J TRAUMA, V65, P1028, DOI 10.1097/TA.0b013e31815eba9b; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; Dumas HM, 2004, PHYS THER, V84, P232, DOI 10.1093/ptj/84.3.232; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Elliott L, 2005, NEUROPSYCHOL REHABIL, V15, P480, DOI 10.1080/09602010443000506; Elovic EP, 2008, ARCH PHYS MED REHAB, V89, P799, DOI 10.1016/j.apmr.2008.01.007; Elovic EP, 2004, J HEAD TRAUMA REHAB, V19, P155, DOI 10.1097/00001199-200403000-00007; Esquenazi A, 2012, AM J PHYS MED REHAB, V91, P729, DOI 10.1097/PHM.0b013e31824fa9ca; European Pressure Ulcer Advisory Panel, 2009, PREV TREATM PRESS UL; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2005, NEUROPSYCHOL REHABIL, V15, P166, DOI 10.1080/09602010443000498; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Puggina ACG, 2012, J NEUROSCI NURS, V44, P260, DOI 10.1097/JNN.0b013e3182666407; Giovannetti AM, 2013, ACTA NEUROL SCAND, V127, P10, DOI 10.1111/j.1600-0404.2012.01666.x; Gormley ME, 1997, MUSCLE NERVE, pS14; Hinderer SR, 1996, ARCH PHYS MED REHAB, V77, P1083, DOI 10.1016/S0003-9993(96)90073-8; Kalmar K, 2005, NEUROPSYCHOL REHABIL, V15, P454, DOI 10.1080/09602010443000425; Laureys S, 2005, CURR OPIN NEUROL, V18, P726, DOI 10.1097/01.wco.0000189874.92362.12; Legner VJ, 2009, ANN SURG, V249, P250, DOI 10.1097/SLA.0b013e318195e12f; Leonardi M, 2012, BRAIN INJURY, V26, P1201, DOI 10.3109/02699052.2012.667589; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; McNamee S, 2012, J HEAD TRAUMA REHAB, V27, P244, DOI 10.1097/HTR.0b013e31825e12c8; Mortenson PA, 2003, PHYS THER, V83, P648, DOI 10.1093/ptj/83.7.648; Moseley AM, 1997, PHYS THER, V77, P240, DOI 10.1093/ptj/77.3.240; Nakase-Richardson R, 2012, J NEUROTRAUM, V29, P59, DOI 10.1089/neu.2011.1829; Ng YS, 2005, NEUROREHABILITATION, V20, P97; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, pS10, DOI 10.1016/S0003-9993(98)90114-9; Plum F, 1982, DIAGNOSIS STUPOR COM; Reimer M, 2005, NEUROPSYCHOL REHABIL, V15, P473, DOI 10.1080/09602010443000362; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2010, EXPERT REV NEUROTHER, V10, P1725, DOI 10.1586/ERN.10.148; Schnakers C, 2010, PAIN, V148, P215, DOI 10.1016/j.pain.2009.09.028; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Simpson DM, 2009, J NEUROL NEUROSUR PS, V80, P380, DOI 10.1136/jnnp.2008.159657; Singer BJ, 2003, BRAIN INJURY, V17, P309, DOI 10.1080/0269905021000013237; Singer BJ, 2003, ARCH PHYS MED REHAB, V84, P483, DOI 10.1053/apmr.2003.50041; Sorbo A, 2005, BRAIN INJURY, V19, P493, DOI 10.1080/02699050400013709; Verplancke D, 2005, CLIN REHABIL, V19, P117, DOI 10.1191/0269215505cr827oa; Whyte J, 2005, ARCH PHYS MED REHAB, V86, P453, DOI 10.1016/j.apmr.2004.05.016; Winzelberg GS, 2003, ARCH INTERN MED, V163, P2552, DOI 10.1001/archinte.163.21.2552; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216; Zafonte R, 2004, J HEAD TRAUMA REHAB, V19, P89, DOI 10.1097/00001199-200403000-00002	63	46	47	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1908	1923		10.1016/j.apmr.2012.11.052			16	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100009	23732166				2021-06-18	
J	Arun, P; Abu-Taleb, R; Oguntayo, S; Tanaka, M; Wang, Y; Valiyaveettil, M; Long, JB; Zhang, YM; Nambiar, MP				Arun, Peethambaran; Abu-Taleb, Rania; Oguntayo, Samuel; Tanaka, Mikiei; Wang, Ying; Valiyaveettil, Manojkumar; Long, Joseph B.; Zhang, Yumin; Nambiar, Madhusoodana P.			Distinct patterns of expression of traumatic brain injury biomarkers after blast exposure: Role of compromised cell membrane integrity	NEUROSCIENCE LETTERS			English	Article						Blast exposure; Cell membrane integrity; GFAP; Tau; Polytrauma	FIBRILLARY ACIDIC PROTEIN; TOTAL TAU; SERUM; OVERPRESSURE; GFAP	Glial fibrillary acidic protein (GFAP), a protein enriched in astrocytes, and Tau, a protein abundant in neuronal microtubules, are being widely studied as biomarkers of brain injury, and persistent severity-dependent increases in brain and blood have been reported. Studies on the acute changes of these proteins after blast exposure are limited. Using a mouse model of closely-coupled repeated blast exposures, we have evaluated acute changes in the levels of GFAP and total Tau by Western blotting. Brain levels of GFAP and Tau proteins decreased significantly at 6 h and increased considerably at 24 h after repeated blast exposures. Plasma samples showed a similar initial decrease and later increase over this timeframe. This biphasic pattern points to possible absorption or sequestration of these proteins from plasma immediately after repeated blast exposures. Liver and spleen tissue showed significant increases in the levels of GFAP and Tau protein at 6 and 24 h post-blast exposures whereas semi-quantitative RT-PCR analysis of liver showed no significant changes in the levels of GFAP or Tau mRNAs. These results suggest that blast exposure causes transient changes in cell membrane integrity in multiple organs leading to abnormal migration of proteins from the tissues to the plasma and vice versa. This transient changes in cell membrane permeability and subsequent bidirectional movement of molecules may contribute to the pathophysiology of TBI and polytrauma after blast exposure. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Arun, Peethambaran; Abu-Taleb, Rania; Oguntayo, Samuel; Wang, Ying; Valiyaveettil, Manojkumar; Long, Joseph B.; Nambiar, Madhusoodana P.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD 20910 USA; [Tanaka, Mikiei; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Arun, P (corresponding author), Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	peethambaran.arun.ctr@mail.mil					Arun P, 2012, INTERV MED APPL SCI, V4, P125, DOI 10.1556/IMAS.4.2012.3.2; Arun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033798; Arun P, 2012, NEUROREPORT, V23, P342, DOI 10.1097/WNR.0b013e328351b58d; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; DEARMOND SJ, 1986, J NEUROCHEM, V47, P1749, DOI 10.1111/j.1471-4159.1986.tb13084.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Morales-Corraliza J., 2009, PLOS ONE, V4, pe7134; Morini Sergio, 2005, Italian Journal of Anatomy and Embryology, V110, P193; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Zurek J, 2012, ACTA NEUROCHIR, V154, P93, DOI 10.1007/s00701-011-1175-2	28	46	46	0	18	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	SEP 27	2013	552						87	91		10.1016/j.neulet.2013.07.047			5	Neurosciences	Neurosciences & Neurology	237YG	WOS:000325907000018	23933206	Green Published			2021-06-18	
J	Ahman, S; Saveman, BI; Styrke, J; Bjornstig, U; Stalnacke, BM				Ahman, Sara; Saveman, Britt-Inger; Styrke, Johan; Bjornstig, Ulf; Stalnacke, Britt-Marie			LONG-TERM FOLLOW-UP OF PATIENTS WITH MILD TRAUMATIC BRAIN INJURY: A MIXED-METHODS STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; brain concussion; post-concussion symptoms; post-traumatic stress disorder	POST-CONCUSSION SYMPTOMS; POSTTRAUMATIC-STRESS-DISORDER; NEURON-SPECIFIC ENOLASE; SF-36 HEALTH SURVEY; QUALITY-OF-LIFE; HEAD-INJURY; POSTCONCUSSIONAL-SYNDROME; SERUM-LEVELS; ACUTE-PHASE; POPULATION	Objective: To characterize the long-term consequences of mild traumatic brain injury regarding post-concussion symptoms, post-traumatic stress, and quality of life; and to investigate differences between men and women. Design: Retrospective mixed-methods study. Subjects/patients and methods: Of 214 patients with mild traumatic brain injury seeking acute care, 163 answered questionnaires concerning post-concussion symptoms (Rivermead Post-concussion Symptoms Questionnaire; RPQ), post-traumatic stress (Impact of Event Scale; IES), and quality of life (Short Form Health Survey; SF-36) 3 years post-injury. A total of 21 patients underwent a medical examination in connection with the survey. The patients were contacted 11 years later, and 10 were interviewed. Interview data were analysed with content analysis. Results: The mean total RPQ score was 12.7 (standard deviation; SD 12.9); 10.5 (SD 11.9) for men and 15.9 (SD 13.8) for women (p=0.006). The 5 most common symptoms were fatigue (53.4%), poor memory (52.5%), headache (50.9%), frustration (47.9%) and depression (47.2%). The mean total IES score was 9.6 (SD 12.9) 7.1 (SD 10.3) for men and 13.0 (SD 15.2) for women (p=0.004). In general, the studied population had low scores on the Short Form Health Survey (SF-36). The interviews revealed that some patients still had disabling post-concussion symptoms and consequences in many areas of life 11 years after the injury event. Conclusion: Long-term consequences were present for approximately 50% of the patients 3 years after mild traumatic brain injury and were also reported 11 years after mild traumatic brain injury. This needs to be taken into account by healthcare professionals and society in general when dealing with people who have undergone mild traumatic brain injury.	[Ahman, Sara; Stalnacke, Britt-Marie] Umea Univ, Dept Community Med & Rehabil, SE-90185 Umea, Sweden; [Saveman, Britt-Inger] Umea Univ, Dept Nursing, SE-90185 Umea, Sweden; [Styrke, Johan; Bjornstig, Ulf] Umea Univ, Dept Surg & Perioperat Sci, Div Surg, SE-90185 Umea, Sweden	Stalnacke, BM (corresponding author), Umea Univ, Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	brittmarie.stalnacke@rehabmed.umu.se	Styrke, Johan/AAE-1193-2021				Andersson EE, 2011, J REHABIL MED, V43, P323, DOI 10.2340/16501977-0666; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Fourtassi M, 2011, CLIN NEUROL NEUROSUR, V113, P716, DOI 10.1016/j.clineuro.2011.07.010; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Strandberg T, 2009, SOC WORK HEALTH CARE, V48, P276, DOI 10.1080/00981380802599240; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Sullivan M, 1998, J CLIN EPIDEMIOL, V51, P1105, DOI 10.1016/S0895-4356(98)00102-4; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; TEASDALE G, 1974, LANCET, V2, P81; Yeates GN, 2008, NEUROPSYCHOL REHABIL, V18, P566, DOI 10.1080/09602010802151532; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	40	46	47	0	23	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	SEP	2013	45	8					758	764		10.2340/16501977-1182			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	243ZS	WOS:000326357500010	24002311	DOAJ Gold, Green Published			2021-06-18	
J	Gil-Perotin, S; Duran-Moreno, M; Cebrian-Silla, A; Ramirez, M; Garcia-Belda, P; Garcia-Verdugo, JM				Gil-Perotin, Sara; Duran-Moreno, Maria; Cebrian-Silla, Arantxa; Ramirez, Monica; Garcia-Belda, Paula; Manuel Garcia-Verdugo, Jose			Adult Neural Stem Cells From the Subventricular Zone: A Review of the Neurosphere Assay	ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY BIOLOGY			English	Article						olfaction; neurosphere; adult neurogenesis; SVZ	CENTRAL-NERVOUS-SYSTEM; INTERMEDIATE-FILAMENT NESTIN; TRAUMATIC BRAIN-INJURY; FIBROBLAST GROWTH FACTOR-2; OLFACTORY-BULB; PROGENITOR CELLS; MAMMALIAN BRAIN; IN-VIVO; ANNULATE LAMELLAE; RAT BRAIN	The possibility of obtaining large numbers of cells with potential to become functional neurons implies a great advance in regenerative medicine. A source of cells for therapy is the subventricular zone (SVZ) where adult neural stem cells (NSCs) retain the ability to proliferate, self-renew, and differentiate into several mature cell types. The neurosphere assay, a method to isolate, maintain, and expand these cells has been extensively utilized by research groups to analyze the biological properties of aNSCs and to graft into injured brains from animal models. In this review we briefly describe the neurosphere assay and its limitations, the methods to optimize culture conditions, the identity and the morphology of aNSC-derived neurospheres (including new ultrastructural data). The controversy regarding the identity and stemness of cells within the neurosphere is revised. The fine morphology of neurospheres, described thoroughly, allows for phenotypical characterization of cells in the neurospheres and may reveal slight changes that indirectly inform about cell integrity, cell damage, or oncogenic transformation. Along this review we largely highlight the critical points that researchers have to keep in mind before extrapolating results or translating experimental transplantation of neurosphere-derived cells to the clinical setting. Anat Rec, 296:1435-1452, 2013. (c) 2013 Wiley Periodicals, Inc.	[Gil-Perotin, Sara; Duran-Moreno, Maria; Cebrian-Silla, Arantxa; Ramirez, Monica; Garcia-Belda, Paula; Manuel Garcia-Verdugo, Jose] Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Lab Comparat Neurobiol, Valencia, Spain; [Gil-Perotin, Sara] Fundac Invest La Fe, Grp Hematol & Hemoterapia, Grp Invest Esclerosis Multiple, Valencia 46020, Spain	Garcia-Verdugo, JM (corresponding author), Univ Valencia, Inst Cavanilles Biodiversidad & Biol Evolut, Catedratico Jose Beltran 2, Valencia, Spain.	sara.garcia@uv.es; j.manuel.garcia@uv.es	Gil-Perotin, Sara/AAK-9942-2021; Gil-Perotin, Sara/I-2467-2015; Garcia-Verdugo, Jose Manuel/L-8421-2017	Gil-Perotin, Sara/0000-0003-3793-0116; Gil-Perotin, Sara/0000-0003-3793-0116; Cebrian Silla, Arantxa/0000-0003-4623-7655; Ramirez, Monica/0000-0001-5386-8530; Garcia-Verdugo, Jose Manuel/0000-0001-9872-6499	Spanish Government MINECO [AP2010-4264, AP2009-4759]; Instituto de Salud Carlos III, Red de Terapia Celular (RETICS) [RD06/0010/0022]; PROMETEO grant from Generalitat ValencianaGeneralitat Valenciana [GVPROME-TEO 2009-11]; CONACYT-MexicoConsejo Nacional de Ciencia y Tecnologia (CONACyT) [165690]; Fundacion para la Investigacion La Fe	Grant sponsor: Spanish Government MINECO; Grant numbers: AP2010-4264; AP2009-4759; Grant sponsor: Instituto de Salud Carlos III, Red de Terapia Celular (RETICS); Grant number: RD06/0010/0022; Grant sponsor: PROMETEO grant from Generalitat Valenciana; Grant number: GVPROME-TEO 2009-11; Grant sponsor: CONACYT-Mexico; Grant number: 165690; Grant sponsor: Fundacion para la Investigacion La Fe.	Aberg MAI, 2000, J NEUROSCI, V20, P2896; Alvarez-Buylla A, 1998, J NEUROSCI, V18, P1020; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barraud P, 2007, J NEUROSCI RES, V85, P250, DOI 10.1002/jnr.21116; Beckervordersandforth R, 2010, CELL STEM CELL, V7, P744, DOI 10.1016/j.stem.2010.11.017; Bergmann O, 2012, NEURON, V74, P634, DOI 10.1016/j.neuron.2012.03.030; Bez A, 2003, BRAIN RES, V993, P18, DOI 10.1016/j.brainres.2003.08.061; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; Bonaguidi MA, 2012, CURR OPIN NEUROBIOL, V22, P754, DOI 10.1016/j.conb.2012.03.013; Bonfanti L, 2008, VET J, V175, P310, DOI 10.1016/j.tvjl.2007.01.023; Bowers WJ, 2011, HUM MOL GENET, V20, pR28, DOI 10.1093/hmg/ddr110; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; Chaichana K, 2006, STEM CELLS, V24, P2851, DOI 10.1634/stemcells.2006-0399; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; CHEN TY, 1988, J CELL BIOL, V107, P1299, DOI 10.1083/jcb.107.4.1299; Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200; Clarke L, 2011, STEM CELLS, V29, P1448, DOI 10.1002/stem.692; Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101; Coles-Takabe BLK, 2008, STEM CELLS, V26, P2938, DOI 10.1634/stemcells.2008-0558; Corti S, 2007, EXP NEUROL, V205, P547, DOI 10.1016/j.expneurol.2007.03.021; Curtis MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science.1136281; DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S; DAHLSTRAND J, 1992, J CELL SCI, V103, P589; Das AV, 2006, BIOCHEM BIOPH RES CO, V339, P708, DOI 10.1016/j.bbrc.2005.11.064; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Felling RJ, 2006, J NEUROSCI, V26, P4359, DOI 10.1523/JNEUROSCI.1898-05.2006; Giachino C, 2004, J NEUROBIOL, V58, P493, DOI 10.1002/neu.10290; Gil-Perotin S, 2006, J NEUROSCI, V26, P1107, DOI 10.1523/JNEUROSCI.3970-05.2006; Gil-Perotin S, 2009, J COMP NEUROL, V514, P533, DOI 10.1002/cne.22026; GOLDSTEIN MN, 1971, CANCER RES, V31, P209; GRITTI A, 2001, PROTOCOLS NEURAL CEL, P173, DOI DOI 10.1385/1-59259-207-4:173; Gurok U, 2004, J NEUROSCI, V24, P5982, DOI 10.1523/JNEUROSCI.0809-04.2004; Hack MA, 2005, NAT NEUROSCI, V8, P865, DOI 10.1038/nn1479; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Homman-Ludiye J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034383; Hunziker E, 2000, BIOCHEM BIOPH RES CO, V271, P116, DOI 10.1006/bbrc.2000.2611; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jensen JB, 2006, MOL NEUROBIOL, V34, P153, DOI 10.1385/MN:34:3:153; Jin KL, 2002, J NEUROSCI, V22, P5365; KACHINSKY AM, 1995, J HISTOCHEM CYTOCHEM, V43, P843, DOI 10.1177/43.8.7542682; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kempermann G, 2002, J NEUROSCI, V22, P635, DOI 10.1523/JNEUROSCI.22-03-00635.2002; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; KESSEL RG, 1983, INT REV CYTOL, V82, P181, DOI 10.1016/S0074-7696(08)60826-8; KESSEL RG, 1992, INT REV CYTOL, V133, P43, DOI 10.1016/S0074-7696(08)61858-6; Klassen H, 2004, J NEUROSCI RES, V77, P334, DOI 10.1002/jnr.20183; Kobayashi M, 1998, PEDIATR RES, V43, P386, DOI 10.1203/00006450-199803000-00013; Kohwi M, 2005, J NEUROSCI, V25, P6997, DOI 10.1523/JNEUROSCI.1435-05.2005; Korf HW, 2009, ADV ANAT EMBRYOL CEL, V203, P1, DOI 10.1007/978-3-540-88719-5; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lachapelle F, 2002, MOL CELL NEUROSCI, V20, P390, DOI 10.1006/mcne.2002.1124; Ladiwala U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038613; Lee JS, 2008, BIOCHEM BIOPH RES CO, V365, P496, DOI 10.1016/j.bbrc.2007.11.005; Lee WC, 2005, NEUROCHEM RES, V30, P263, DOI 10.1007/s11064-005-2449-y; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794; LILLIEN L, 1992, DEVELOPMENT, V115, P253; Liu ZP, 2003, J COMP NEUROL, V459, P368, DOI 10.1002/cne.10664; Lobo MK, 2003, DEV NEUROSCI-BASEL, V25, P384, DOI 10.1159/000075664; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Lu QR, 2001, P NATL ACAD SCI USA, V98, P10851, DOI 10.1073/pnas.181340798; Malik SZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036016; Mannello F, 2011, INT J DEV BIOL, V55, P569, DOI 10.1387/ijdb.103186fm; Markakis EA, 2004, J NEUROSCI, V24, P2886, DOI 10.1523/JNEUROSCI.4161-03.2004; Maurer MH, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-7; Migaud M, 2010, EUR J NEUROSCI, V32, P2042, DOI 10.1111/j.1460-9568.2010.07521.x; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Mori H, 2006, J NEUROSCI RES, V84, P1682, DOI 10.1002/jnr.21082; MORSHEAD CM, 1992, J NEUROSCI, V12, P249; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nishimura S, 2003, DIGEST DIS SCI, V48, P1523, DOI 10.1023/A:1024763723240; Pagano SF, 2000, STEM CELLS, V18, P295, DOI 10.1634/stemcells.18-4-295; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Parker MA, 2005, EXP NEUROL, V194, P320, DOI 10.1016/j.expneurol.2005.04.018; Parmar M, 2003, MOL CELL NEUROSCI, V24, P741, DOI 10.1016/S1044-7431(03)00239-2; Pastrana E, 2009, P NATL ACAD SCI USA, V106, P6387, DOI 10.1073/pnas.0810407106; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Peretto P, 1999, BRAIN RES BULL, V49, P221, DOI 10.1016/S0361-9230(99)00037-4; Platel JC, 2009, GLIA, V57, P66, DOI 10.1002/glia.20735; Pruszak J, 2007, STEM CELLS, V25, P2257, DOI 10.1634/stemcells.2006-0744; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; RICHARDS LJ, 1992, P NATL ACAD SCI USA, V89, P8591, DOI 10.1073/pnas.89.18.8591; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rietze RL, 2006, METHOD ENZYMOL, V419, P3, DOI 10.1016/S0076-6879(06)19001-1; Rodriguez EM, 2005, INT REV CYTOL, V247, P89, DOI 10.1016/S0074-7696(05)47003-5; Rodriguez-Perez LM, 2003, CELL TISSUE RES, V314, P325, DOI 10.1007/s00441-003-0794-1; Roisen FJ, 2001, BRAIN RES, V890, P11, DOI 10.1016/S0006-8993(00)03016-X; Ross HH, 2012, EXP NEUROL, V235, P238, DOI 10.1016/j.expneurol.2012.01.027; Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130; Sakakibara S, 1997, J NEUROSCI, V17, P8300; Sakata H, 2012, STROKE, V43, P2423, DOI 10.1161/STROKEAHA.112.656900; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sanai N, 2007, SCIENCE, V318, DOI 10.1126/science.1145011; SEJERSEN T, 1993, J CELL SCI, V106, P1291; Seri B, 2006, CEREB CORTEX, V16, pI103, DOI 10.1093/cercor/bhk027; Shimazaki T, 2001, J NEUROSCI, V21, P7642; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Singec I, 2006, NAT METHODS, V3, P801, DOI 10.1038/nmeth926; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Steindler DA, 1996, PROG BRAIN RES, V108, P349, DOI 10.1016/S0079-6123(08)62551-0; Studer L, 2000, J NEUROSCI, V20, P7377; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Sun YR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005498; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Sutovsky P, 1998, J CELL SCI, V111, P2841; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Tsujimura T, 2001, AM J PATHOL, V158, P817, DOI 10.1016/S0002-9440(10)64029-1; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Vik-Mo EO, 2011, EXP CELL RES, V317, P1049, DOI 10.1016/j.yexcr.2010.12.022; Vukicevic V, 2010, MECH AGEING DEV, V131, P124, DOI 10.1016/j.mad.2010.01.001; Wachs FP, 2003, LAB INVEST, V83, P949, DOI 10.1097/01.LAB.0000075556.74231.A5; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Wegner M, 2011, GENE DEV, V25, P2423, DOI 10.1101/gad.181487.111; Weiss S, 1996, J NEUROSCI, V16, P7599; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Young KM, 2007, J NEUROSCI, V27, P8286, DOI 10.1523/JNEUROSCI.0476-07.2007; Young KM, 2006, J NEUROSCI RES, V83, P39, DOI 10.1002/jnr.20702; Zhang K, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00005; Zhu LL, 2005, BRAIN RES, V1055, P1, DOI 10.1016/j.brainres.2005.04.075	130	46	48	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1932-8486	1932-8494		ANAT REC	Anat. Rec.	SEP	2013	296	9			SI		1435	1452		10.1002/ar.22746			18	Anatomy & Morphology	Anatomy & Morphology	237GR	WOS:000325857400014	23904071	Bronze			2021-06-18	
J	Hansen, CN; Fisher, LC; Deibert, RJ; Jakeman, LB; Zhang, HQ; Noble-Haeusslein, L; White, S; Basso, DM				Hansen, Christopher N.; Fisher, Lesley C.; Deibert, Rochelle J.; Jakeman, Lyn B.; Zhang, Haoqian; Noble-Haeusslein, Linda; White, Susan; Basso, D. Michele			Elevated MMP-9 in the Lumbar Cord Early after Thoracic Spinal Cord Injury Impedes Motor Relearning in Mice	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; CONTUSION INJURY; MATRIX METALLOPROTEINASES; FUNCTIONAL RECOVERY; INFLAMMATORY RESPONSE; SENSORIMOTOR CORTEX; VOLUNTARY EXERCISE; NEUROPATHIC PAIN; AXONAL GROWTH; MATRIX-METALLOPROTEINASE-9	Spinal cord injury results in distant pathology around putative locomotor networks that may jeopardize the recovery of locomotion. We previously showed that activated microglia and increased cytokine expression extend at least 10 segments below the injury to influence sensory function. Matrix metalloproteinase-9 (MMP-9) is a potent regulator of acute neuroinflammation. Whether MMP-9 is produced remote to the injury or influences locomotor plasticity remains unexamined. Therefore, we characterized the lumbar enlargement after a T9 spinal cord injury in C57BL/6 (wild-type [WT]) and MMP-9-null (knock-out [KO]) mice. Within 24 h, resident microglia displayed an activated phenotype alongside increased expression of progelatinase MMP-3 in WT mice. By 7 d, increases in active MMP-9 around lumbar vasculature and production of proinflammatory TNF-alpha were evident. Deletion of MMP-9 attenuated remote microglial activation and restored TNF-alpha expression to homeostatic levels. To determine whether MMP-9 impedes locomotor plasticity, we delivered lumbar-focused treadmill training in WT and KO mice during early (2-9 d) or late (35-42 d) phases of recovery. Robust behavioral improvements were observed by 7 d, when only trained KO mice stepped in the open field. Locomotor improvements were retained for 4 weeks as identified using state of the art mouse kinematics. Neither training nor MMP-9 depletion alone promoted recovery. The same intervention delivered late was ineffective, suggesting that lesion site sparing is insufficient to facilitate activity-based training and recovery. Our work suggests that by attenuating remote mechanisms of inflammation, acute treadmill training can harness endogenous spinal plasticity to promote robust recovery.	[Hansen, Christopher N.; Jakeman, Lyn B.; Basso, D. Michele] Ohio State Univ, Neurosci Grad Studies Program, Columbus, OH 43210 USA; [Hansen, Christopher N.; Fisher, Lesley C.; Deibert, Rochelle J.; Jakeman, Lyn B.; Basso, D. Michele] Ohio State Univ, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Fisher, Lesley C.; Deibert, Rochelle J.; White, Susan; Basso, D. Michele] Ohio State Univ, Sch Hlth & Rehabil Sci, Columbus, OH 43210 USA; [Jakeman, Lyn B.] Ohio State Univ, Dept Physiol & Cell Biol, Columbus, OH 43210 USA; [Noble-Haeusslein, Linda] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Zhang, Haoqian; Noble-Haeusslein, Linda] Univ Calif San Francisco, Dept Phys Therapy, San Francisco, CA 94143 USA; [Zhang, Haoqian; Noble-Haeusslein, Linda] Univ Calif San Francisco, Dept Rehabil Sci, San Francisco, CA 94143 USA	Basso, DM (corresponding author), Ohio State Univ, Sch Hlth & Rehabil Sci, 106 Atwell Hall,453 W 10th Ave, Columbus, OH 43210 USA.	Michele.Basso@osumc.edu	Zhang, Haoqian/N-6062-2014; Basso, Michele/B-3817-2011	Jakeman, Lyn/0000-0002-1760-8819	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS074882-01A1, 1F31NS080512-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS080512, R01NS074882] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (Grants #1R01NS074882-01A1 to D. M. B. and #1F31NS080512-01 to C.N.H.). We thank Dr. Kristina Kigerl for critical review of the manuscript.	Andrews EM, 2012, EXP NEUROL, V235, P174, DOI 10.1016/j.expneurol.2011.09.008; Basso DM, 2011, PM&R, V3, pS73, DOI 10.1016/j.pmrj.2011.02.019; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BASSO DM, 1994, RESTOR NEUROL NEUROS, V7, P95, DOI 10.3233/RNN-1994-7205; Buehner JJ, 2012, ARCH PHYS MED REHAB, V93, P1530, DOI 10.1016/j.apmr.2012.02.035; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Chen Y, 2006, J NEUROSCI, V26, P12537, DOI 10.1523/JNEUROSCI.2198-06.2006; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Ethell IM, 2007, J NEUROSCI RES, V85, P2813, DOI 10.1002/jnr.21273; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fawcett J, 2009, PROG BRAIN RES, V175, P501, DOI 10.1016/S0079-6123(09)17534-9; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Ghasemlou N, 2005, EXP NEUROL, V196, P9, DOI 10.1016/j.expneurol.2005.05.017; GOSLOW GE, 1973, J MORPHOL, V141, P1, DOI 10.1002/jmor.1051410102; Goussev S, 2003, J NEUROSURG, V99, P188, DOI 10.3171/spi.2003.99.2.0188; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Grill R, 1997, J NEUROSCI, V17, P5560; Hains BC, 2006, J NEUROSCI, V26, P4308, DOI 10.1523/JNEUROSCI.0003-06.2006; Hansen CN, 2012, BRAIN BEHAV, V2, P541, DOI 10.1002/brb3.71; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Harkema SJ, 2012, ARCH PHYS MED REHAB, V93, P1508, DOI 10.1016/j.apmr.2011.01.024; HODGSON JA, 1994, MED SCI SPORT EXER, V26, P1491; Hoschouer EL, 2010, PAIN, V148, P328, DOI 10.1016/j.pain.2009.11.023; Hougland MT, 2013, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00478; Hsu JYC, 2008, J NEUROSCI, V28, P13467, DOI 10.1523/JNEUROSCI.2287-08.2008; Huie JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039751; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Larsen PH, 2003, J NEUROSCI, V23, P11127, DOI 10.1523/jneurosci.23-35-11127.2003; Leblond H, 2003, J NEUROSCI, V23, P11411; Liu HQ, 2011, EXP NEUROL, V231, P236, DOI 10.1016/j.expneurol.2011.06.015; Ma MH, 2004, J COMP NEUROL, V474, P469, DOI 10.1002/cne.20149; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Magnuson DSK, 2009, NEUROREHAB NEURAL RE, V23, P535, DOI 10.1177/1545968308331147; Maldonado MA, 2008, NEUROREHAB NEURAL RE, V22, P250, DOI 10.1177/1545968307308551; McHugh MP, 2003, SCAND J MED SCI SPOR, V13, P88, DOI 10.1034/j.1600-0838.2003.02477.x; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Noble LJ, 2002, J NEUROSCI, V22, P7526; Oh LYS, 1999, J NEUROSCI, V19, P8464; Popovich PG, 1996, EXP NEUROL, V142, P258, DOI 10.1006/exnr.1996.0196; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Rajashekhar G, 2011, J CELL PHYSIOL, V226, P800, DOI 10.1002/jcp.22404; Rauch U, 2004, CELL MOL LIFE SCI, V61, P2031, DOI 10.1007/s00018-004-4043-x; Smith RR, 2009, J NEUROTRAUM, V26, P1017, DOI [10.1089/neu.2008.0829, 10.1089/neu.2008-0829]; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Thompson AK, 2013, J NEUROSCI, V33, P2365, DOI 10.1523/JNEUROSCI.3968-12.2013; Vempati P, 2007, J BIOL CHEM, V282, P37585, DOI 10.1074/jbc.M611500200; Vichaya EG, 2009, BRAIN BEHAV IMMUN, V23, P969, DOI 10.1016/j.bbi.2009.05.001; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; WHISHAW IQ, 1992, BEHAV BRAIN RES, V52, P29, DOI 10.1016/S0166-4328(05)80322-5; Wolpaw JR, 2010, NEUROSCIENTIST, V16, P532, DOI 10.1177/1073858410368314; Yirmiya R, 2011, BRAIN BEHAV IMMUN, V25, P181, DOI 10.1016/j.bbi.2010.10.015; Young EE, 2007, BRAIN BEHAV IMMUN, V21, P748, DOI 10.1016/j.bbi.2007.02.001; Zhang HQ, 2011, NEUROTHERAPEUTICS, V8, P206, DOI 10.1007/s13311-011-0038-0	64	46	48	1	15	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 7	2013	33	32					13101	13111		10.1523/JNEUROSCI.1576-13.2013			11	Neurosciences	Neurosciences & Neurology	197BQ	WOS:000322823300020	23926264	Bronze, Green Published			2021-06-18	
J	Brydges, CR; Anderson, M; Reid, CL; Fox, AM				Brydges, Christopher R.; Anderson, Mike; Reid, Corinne L.; Fox, Allison M.			Maturation of Cognitive Control: Delineating Response Inhibition and Interference Suppression	PLOS ONE			English	Article							ANTERIOR CINGULATE CORTEX; LATENT-VARIABLE ANALYSIS; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTIONS; FRONTAL-LOBE; PREFRONTAL CORTEX; FUNCTIONAL MRI; CHILDREN; PERFORMANCE; CONFLICT	Cognitive control is integral to the ability to attend to a relevant task whilst suppressing distracting information or inhibiting prepotent responses. The current study examined the development of these two subprocesses by examining electrophysiological indices elicited during each process. Thirteen 18 year-old adults and thirteen children aged 8-11 years (mean = 9.77 years) completed a hybrid Go/Nogo flanker task while continuous EEG data were recorded. The N2 topography for both response inhibition and interference suppression changed with increasing age. The neural activation associated with response inhibition became increasingly frontally distributed with age, and showed decreases of both amplitude and peak latency from childhood to adulthood, possibly due to reduced cognitive demands and myelination respectively occurring during this period. Interestingly, a significant N2 effect was apparent in adults, but not observed in children during trials requiring interference suppression. This could be due to more diffuse activation in children, which would require smaller levels of activation over a larger region of the brain than is reported in adults. Overall, these results provide evidence of distinct maturational processes occurring throughout late childhood and adolescence, highlighting the separability of response inhibition and interference suppression.	[Brydges, Christopher R.; Anderson, Mike; Reid, Corinne L.; Fox, Allison M.] Univ Western Australia, Sch Psychol, Neurocognit Dev Unit, Perth, WA 6009, Australia; [Anderson, Mike; Reid, Corinne L.] Murdoch Univ, Sch Psychol, Perth, WA, Australia	Brydges, CR (corresponding author), Univ Western Australia, Sch Psychol, Neurocognit Dev Unit, Perth, WA 6009, Australia.	brydgc01@student.uwa.edu.au	Fox, Allison M/H-9218-2014	Fox, Allison M/0000-0001-5189-6271; Brydges, Christopher/0000-0001-5901-638X	Australian Postgraduate AwardAustralian Government; Princess Margaret HospitalUniversity of Toronto [EP1910]; Channel 7-Telethon Trust	Funding support was provided for by an Australian Postgraduate Award scholarship for Christopher Brydges. The child research was supported by grants from Princess Margaret Hospital grant EP1910 and the Channel 7-Telethon Trust. The adult research was funded by the School of Psychology at the University of Western Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bayless S, 2007, EARLY HUM DEV, V83, P247, DOI 10.1016/j.earlhumdev.2006.05.021; Botvinick M, 1999, NATURE, V402, P179, DOI 10.1038/46035; Braver TS, 2001, CEREB CORTEX, V11, P825, DOI 10.1093/cercor/11.9.825; Brouwer RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032316; Brydges CR, 2012, INTELLIGENCE, V40, P458, DOI 10.1016/j.intell.2012.05.006; Brydges CR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034482; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Cardenas VA, 2005, HUM BRAIN MAPP, V25, P317, DOI 10.1002/hbm.20103; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Cooke RWI, 1999, ARCH DIS CHILD-FETAL, V81, pF116, DOI 10.1136/fn.81.2.F116; Cragg L, 2009, DEV PSYCHOBIOL, V51, P533, DOI 10.1002/dev.20391; DEMPSTER FN, 1991, INTELLIGENCE, V15, P157, DOI 10.1016/0160-2896(91)90028-C; Dempster FN, 1993, EMERGING THEMES COGN, V1, P3; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; DIAMOND A, 1988, CHILD DEV, V59, P523, DOI 10.2307/1130330; Duan X., 2010, PSYCHOL TEST ASSESSM, V52, P419, DOI DOI 10.1044/2F2016_JSLHR-L-15-0310; Falkenstein M, 1999, ACTA PSYCHOL, V101, P267, DOI 10.1016/S0001-6918(99)00008-6; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; Fuster JM, 2002, J NEUROCYTOL, V31, P373, DOI 10.1023/A:1024190429920; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; GUTHRIE D, 1991, PSYCHOPHYSIOLOGY, V28, P240, DOI 10.1111/j.1469-8986.1991.tb00417.x; Harnishfeger Katherine Kipp, 1995, P175, DOI 10.1016/B978-012208930-5/50007-6; Hershey T, 2010, BRAIN, V133, P3625, DOI 10.1093/brain/awq256; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; JODO E, 1992, ELECTROEN CLIN NEURO, V82, P477, DOI 10.1016/0013-4694(92)90054-L; Johnstone SJ, 2005, J PSYCHOPHYSIOL, V19, P11, DOI 10.1027/0269-8803.19.1.11; Jonkman LM, 2007, CLIN NEUROPHYSIOL, V118, P1069, DOI 10.1016/j.clinph.2007.01.017; Kelly AMC, 2009, CEREB CORTEX, V19, P640, DOI 10.1093/cercor/bhn117; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Konishi S, 1999, BRAIN, V122, P981, DOI 10.1093/brain/122.5.981; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lehto JE, 2003, BRIT J DEV PSYCHOL, V21, P59, DOI 10.1348/026151003321164627; Leon-Carrion J, 2004, INT J NEUROSCI, V114, P1291, DOI 10.1080/00207450490476066; LOGAN GD, 1986, J EXP PSYCHOL HUMAN, V12, P549, DOI 10.1037/0096-1523.12.4.549; Michel F, 2009, DEVELOPMENTAL SCI, V12, P272, DOI 10.1111/j.1467-7687.2008.00759.x; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nigg JT, 2000, PSYCHOL BULL, V126, P220, DOI 10.1037/0033-2909.126.2.220; Nosarti C, 2002, BRAIN, V125, P1616, DOI 10.1093/brain/awf157; Obonsawin MC, 2002, NEUROPSYCHOLOGIA, V40, P970, DOI 10.1016/S0028-3932(01)00171-3; Picton TW, 2007, DEV NEUROPSYCHOL, V31, P249, DOI 10.1080/87565640701228732; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; Ridderinkhof KR, 2004, BRAIN COGNITION, V56, P129, DOI 10.1016/j.bandc.2004.09.016; Rueda MR, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-39; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; St Clair-Thompson HL, 2006, Q J EXP PSYCHOL, V59, P745, DOI 10.1080/17470210500162854; Swick D, 2002, NEUROPSYCHOLOGIA, V40, P1240, DOI 10.1016/S0028-3932(01)00226-3; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Tamnes CK, 2010, CEREB CORTEX, V20, P534, DOI 10.1093/cercor/bhp118; Tanji J, 2008, PHYSIOL REV, V88, P37, DOI 10.1152/physrev.00014.2007; Tillman CM, 2011, PSYCHOPHYSIOLOGY, V48, P1405, DOI 10.1111/j.1469-8986.2011.01203.x; van Boxtel GJM, 2001, BIOL PSYCHOL, V58, P229, DOI 10.1016/S0301-0511(01)00117-X	56	46	48	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2013	8	7							e69826	10.1371/journal.pone.0069826			8	Multidisciplinary Sciences	Science & Technology - Other Topics	228SX	WOS:000325211000161	23894548	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Zickefoose, S; Hux, K; Brown, J; Wulf, K				Zickefoose, Samantha; Hux, Karen; Brown, Jessica; Wulf, Katrina			Let the games begin: A preliminary study using Attention Process Training-3 and Lumosity (TM) brain games to remediate attention deficits following traumatic brain injury	BRAIN INJURY			English	Article						Acquired brain injury remediation; APT; APT-3; attention deficits; attention deficits following traumatic brain injury; Attention Process Training; attention treatment; brain games; computer-based brain injury treatment; Lumosity	MEMORY	Primary objective: Computer-based treatments for attention problems have become increasingly popular and available. The researchers sought to determine whether improved performance by survivors of severe traumatic brain injury (TBI) on two computer-based treatments generalized to improvements on comparable, untrained tasks and ecologically-plausible attention tasks comprising a standardized assessment. Research design: The researchers used an -A-B-A-C-A treatment design repeated across four adult survivors of severe TBI. Methods and procedures: Participants engaged in 8 weeks of intervention using both Attention Process Training-3 (APT-3) and Lumosity (TM) (2010) Brain Games. Two participants received APT-3 treatment first, while the other two received Lumosity (TM) treatment first. All participants received both treatments throughout the course of two, 1-month intervention phases. Main outcomes and results: Individual growth curve analyses showed participants made significant improvements in progressing through both interventions. However, limited generalization occurred: one participant demonstrated significantly improved performance on one of five probe measures and one other participant showed improved performance on some sub-tests of the Test of Everyday Attention; no other significant generalization results emerged. These findings call into question the assumption that intervention using either APT-3 or Lumosity (TM) will prompt generalization beyond the actual tasks performed during treatment.	[Zickefoose, Samantha; Hux, Karen; Brown, Jessica] Univ Nebraska, Barkley Mem Ctr, Lincoln, NE 68583 USA; [Wulf, Katrina] Qual Living, Omaha, NE USA	Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr 351, Lincoln, NE 68583 USA.	khux1@unl.edu	Hux, Karen/AAQ-2078-2020				ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Dakim Inc., 2010, DAK BRAIN FITN CLIN; Fuyuno I, 2007, NATURE, V447, P18, DOI 10.1038/447018a; George DR, 2011, GERONTOLOGIST, V51, P590, DOI 10.1093/geront/gnr042; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; Hardy J, 2009, SCI LUMOSITY; Kawashima R, 2005, J GERONTOL A-BIOL, V60, P380, DOI 10.1093/gerona/60.3.380; Kertesz A., 2006, W APHASIA BATTERY RE; Kesler SR, 2011, BRAIN INJURY, V25, P101, DOI 10.3109/02699052.2010.536194; Klingberg T, 2005, J AM ACAD CHILD PSY, V44, P177, DOI 10.1097/00004583-200502000-00010; Labs Lumos, 2010, LUM RECL YOUR BRAIN; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Palmese CA, 2000, BRAIN INJURY, V14, P535; Papp KV, 2009, ALZHEIMERS DEMENT, V5, P50, DOI 10.1016/j.jalz.2008.10.008; Park N, 1999, NEUROPSYCHOL REHABIL, V9, P117; Pierce SM, 2001, J HEAD TRAUMA REHAB, V16, P406, DOI 10.1097/00001199-200108000-00009; Robertson I. H., 1994, TEST EVERYDAY ATTENT; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Smith GE, 2009, J AM GERIATR SOC, V57, P594, DOI 10.1111/j.1532-5415.2008.02167.x; Sohlberg M. M., 2011, ATTENTION PROCESS TR; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg M M, 1994, ATTENTION PROCESS TR; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; SOHLBERG MM, 1986, ATTENTION PROCESS TR; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Sullivan K, 2011, ANN CONV AM SPEECH L; World Health Organization, 2001, INT CLASS FUNCT DIS	29	46	47	1	92	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2013	27	6					707	716		10.3109/02699052.2013.775484			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	143QO	WOS:000318882500010	23672446				2021-06-18	
J	Fitzgerald, M; Hodgetts, S; Van den Heuvel, C; Natoli, R; Hart, NS; Valter, K; Harvey, AR; Vink, R; Provis, J; Dunlop, SA				Fitzgerald, Melinda; Hodgetts, Stuart; Van den Heuvel, Corinna; Natoli, Riccardo; Hart, Nathan S.; Valter, Krisztina; Harvey, Alan R.; Vink, Robert; Provis, Jan; Dunlop, Sarah A.			Red/near-infrared irradiation therapy for treatment of central nervous system injuries and disorders	REVIEWS IN THE NEUROSCIENCES			English	Article						irradiation therapy; Parkinson's disease; retinal degeneration; trauma - nervous system	LOW-LEVEL LASER; TRAUMATIC BRAIN-INJURY; EMITTING DIODE IRRADIATION; ACUTE ISCHEMIC-STROKE; CYTOCHROME-C-OXIDASE; LIGHT-INDUCED DAMAGE; SPINAL-CORD-INJURY; OPTICAL-PROPERTIES; OXIDATIVE STRESS; ABSORPTION-MEASUREMENTS	Irradiation in the red/near-infrared spectrum (R/NIR, 630-1000 nm) has been used to treat a wide range of clinical conditions, including disorders of the central nervous system (CNS), with several clinical trials currently underway for stroke and macular degeneration. However, R/NIR irradiation therapy (R/NIR-IT) has not been widely adopted in clinical practice for CNS injury or disease for a number of reasons, which include the following. The mechanism/s of action and implications of penetration have not been thoroughly addressed. The large range of treatment intensities, wavelengths and devices that have been assessed make comparisons difficult, and a consensus paradigm for treatment has not yet emerged. Furthermore, the lack of consistent positive outcomes in randomised controlled trials, perhaps due to sub-optimal treatment regimens, has contributed to scepticism. This review provides a balanced precis of outcomes described in the literature regarding treatment modalities and efficacy of R/NIR-IT for injury and disease in the CNS. We have addressed the important issues of specification of treatment parameters, penetration of R/NIR irradiation to CNS tissues and mechanism/s, and provided the necessary detail to demonstrate the potential of R/NIR-IT for the treatment of retinal degeneration, damage to white matter tracts of the CNS, stroke and Parkinson's disease.	[Fitzgerald, Melinda; Hodgetts, Stuart; Harvey, Alan R.] Univ Western Australia, Crawley 6009, Australia; [Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley 6009, Australia; [Hodgetts, Stuart; Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley 6009, Australia; [Van den Heuvel, Corinna; Vink, Robert] Univ Adelaide, Sch Med Sci, Adelaide, SA 5005, Australia; [Natoli, Riccardo; Valter, Krisztina; Provis, Jan] Australian Natl Univ, ANU Med Sch, Acton 0200, Australia; [Natoli, Riccardo; Valter, Krisztina; Provis, Jan] Australian Natl Univ, John Curtin Sch Med Res, Acton 0200, Australia; [Hart, Nathan S.] Univ Western Australia, Sch Anim Biol, Crawley 6009, Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Crawley 6009, Australia.	lindy.fitzgerald@uwa.edu.au	Dunlop, Sarah A/G-9357-2013; Valter, Krisztina/L-3015-2016; Fitzgerald, Melinda/C-4235-2011; Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019; Hart, Nathan S/B-8564-2011; Provis, Jan/C-9529-2009	Fitzgerald, Melinda/0000-0002-4823-8179; Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Hart, Nathan S/0000-0002-7289-9399; Valter, Krisztina/0000-0002-2033-0408; Natoli, Riccardo/0000-0002-9350-0439; Dunlop, Sarah/0000-0002-1306-3962; , Corinna/0000-0003-0664-8935; Provis, Jan/0000-0002-6405-2868; Hodgetts, Stuart/0000-0002-3318-0410; , Alan/0000-0002-2590-831X	Neurotrauma Research Program (Western Australia); NHMRC, AustraliaNational Health and Medical Research Council of Australia [APP1002347]	This work was supported by the Neurotrauma Research Program (Western Australia). Prof. Dunlop is a Principal Research Fellow of the NH&MRC, Australia (Grant ID: APP1002347). Prof. Nathan Hart would like to acknowledge the support of Prof. Shaun Collin.	Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4; Albarracin R, 2012, PHOTOCHEM PHOTOBIOL, V88, P1418, DOI 10.1111/j.1751-1097.2012.01130.x; Albarracin R, 2011, INVEST OPHTH VIS SCI, V52, P3582, DOI 10.1167/iovs.10-6664; Albarracin RS, 2012, ADV EXP MED BIOL, V723, P121, DOI 10.1007/978-1-4614-0631-0_17; Alves G, 2008, J NEUROL, V255, P18, DOI 10.1007/s00415-008-5004-3; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Ankri R, 2010, LASER SURG MED, V42, P760, DOI 10.1002/lsm.20955; ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006-8993(89)91240-7; Balaratnasingam C, 2009, INVEST OPHTH VIS SCI, V50, P2824, DOI 10.1167/iovs.08-3206; Ball KA, 2011, J PHOTOCH PHOTOBIO B, V102, P182, DOI 10.1016/j.jphotobiol.2010.12.002; Banerjee R, 2009, BBA-MOL BASIS DIS, V1792, P651, DOI 10.1016/j.bbadis.2008.11.007; Baptiste DC, 2006, J NEUROTRAUM, V23, P318, DOI 10.1089/neu.2006.23.318; Biron KE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023789; Bjordal JM, 2003, AUST J PHYSIOTHER, V49, P107, DOI 10.1016/S0004-9514(14)60127-6; Bradaric BD, 2012, J NEURAL TRANSM, V119, P59, DOI 10.1007/s00702-011-0684-8; BRAMBILLA R, 2006, CYTOKINES CNS, P299; BROSSEAU L, 2003, COCHRANE DB SYST REV; Brosseau L, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004377; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Camello-Almaraz MC, 2006, J CELL PHYSIOL, V206, P487, DOI 10.1002/jcp.20498; CARTER K, 1982, J BIOL CHEM, V257, P13507; Cauwels RGEC, 2011, EUR ARCH PAEDIATR DE, V12, P118, DOI 10.1007/BF03262791; CHEONG WF, 1990, IEEE J QUANTUM ELECT, V26, P2166, DOI 10.1109/3.64354; Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140-6736(09)61522-1; Christie A, 2007, PHYS THER, V87, P1697, DOI 10.2522/ptj.20070039; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402; de Lima AG, 2012, INT J RADIAT ONCOL, V82, P270, DOI 10.1016/j.ijrobp.2010.10.012; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Demontis GC, 2002, INVEST OPHTH VIS SCI, V43, P2421; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Dimauro TM, 2007, U.S. Patent, Patent No. [7, 288, 108, 7288108]; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; EICHLER J, 1977, RADIAT ENVIRON BIOPH, V14, P239, DOI 10.1007/BF01323942; FIRBANK M, 1993, PHYS MED BIOL, V38, P503, DOI 10.1088/0031-9155/38/4/002; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Hartz AMS, 2012, STROKE, V43, P514, DOI 10.1161/STROKEAHA.111.627562; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; HEBEDA KM, 1994, NEUROSURGERY, V35, P720, DOI 10.1227/00006123-199410000-00019; Hegedus B, 2009, PHOTOMED LASER SURG, V27, P577, DOI 10.1089/pho.2008.2297; Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709; Hom J, 2011, AM J NEURORADIOL, V32, P41, DOI 10.3174/ajnr.A2244; Howard RS, 2012, QJM-INT J MED, V105, P551, DOI 10.1093/qjmed/hcs016; Huang YY, 2012, J BIOPHOTONICS, V5, P827, DOI 10.1002/jbio.201200077; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Ishiguro M, 2010, J ORTHOP SCI, V15, P233, DOI 10.1007/s00776-009-1438-4; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Jenkins PA, 2011, PHOTOMED LASER SURG, V29, P785, DOI 10.1089/pho.2011.9895; JOHNSON VE, 2012, EXP NEUROL IN PRESS; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; Karu TI, 2008, PHOTOMED LASER SURG, V26, P593, DOI 10.1089/pho.2008.2246; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439; Kaviani A, 2011, PHOTOMED LASER SURG, V29, P109, DOI 10.1089/pho.2009.2680; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kokkinopoulos I, 2013, NEUROBIOL AGING, V34, P602, DOI 10.1016/j.neurobiolaging.2012.04.014; Kokol R, 2005, HAUTARZT, V56, P570, DOI 10.1007/s00105-004-0864-7; KOMELKOVA LV, 2004, PATOL FIZIOL EKSP TE, V1, P15; Kowaltowski AJ, 2009, FREE RADICAL BIO MED, V47, P333, DOI 10.1016/j.freeradbiomed.2009.05.004; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lansberg MG, 2009, STROKE, V40, P2438, DOI 10.1161/STROKEAHA.109.552547; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2002, STROKE, V33, P1411, DOI 10.1161/01.STR.0000015346.00054.8B; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2012, EXPERT REV MED DEVIC, V9, P71, DOI 10.1586/ERD.11.64; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Silva GBL, 2011, PHOTOMED LASER SURG, V29, P27, DOI 10.1089/pho.2009.2699; Lenz P, 1999, APPL OPTICS, V38, P3662, DOI 10.1364/AO.38.003662; Leonarduzzi G, 2011, CURR PHARM DESIGN, V17, P3994, DOI 10.2174/138161211798764906; Leung MCP, 2002, LASER SURG MED, V31, P283, DOI 10.1002/lsm.10096; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Lim J, 2010, J PHOTOCH PHOTOBIO B, V99, P105, DOI 10.1016/j.jphotobiol.2010.03.002; Lim J, 2009, J BIOCHEM MOL TOXIC, V23, P1, DOI 10.1002/jbt.20257; Liu XZ, 1997, J NEUROSCI, V17, P5395; Mason MG, 2006, P NATL ACAD SCI USA, V103, P708, DOI 10.1073/pnas.0506562103; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; Medalha CC, 2010, PHOTOMED LASER SURG, V28, P669, DOI 10.1089/pho.2009.2691; MESTER E, 1985, LASER SURG MED, V5, P31, DOI 10.1002/lsm.1900050105; Mitchell Ulrike H., 2011, Physiotherapy Theory and Practice, V27, P345, DOI 10.3109/09593985.2010.511440; Mitra S, 2004, PHYS MED BIOL, V49, P1891, DOI 10.1088/0031-9155/49/10/005; Moftakhar P, 2010, J NEUROPATH EXP NEUR, V69, P1201, DOI 10.1097/NEN.0b013e3181fd252c; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; MULLER PJ, 1986, PHYS MED BIOL, V31, P1295, DOI 10.1088/0031-9155/31/11/012; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nashmi R, 2001, BRAIN RES REV, V38, P165, DOI 10.1016/S0165-0173(01)00134-5; Natoli R, 2010, MOL VIS, V16, P1801; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Neupane J, 2010, PHOTODIAGN PHOTODYN, V7, P44, DOI 10.1016/j.pdpdt.2009.12.006; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Oron U, 2001, LASER SURG MED, V28, P204, DOI 10.1002/lsm.1039; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; PARRISH JA, 1981, J INVEST DERMATOL, V77, P45, DOI 10.1111/1523-1747.ep12479235; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Peoples Cassandra, 2012, ISRN Neurol, V2012, P850150, DOI 10.5402/2012/850150; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; PETRATOS S, 2004, NEUROBIOL DIS, V15, P415; Posten W, 2005, DERMATOL SURG, V31, P334, DOI 10.1097/00042728-200503000-00016; PROFIO AE, 1989, APPL OPTICS, V28, P2216, DOI 10.1364/AO.28.002216; Qu C, 2010, ADV EXP MED BIOL, V664, P365, DOI 10.1007/978-1-4419-1399-9_42; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Quirk BJ, 2011, PHOTOMED LASER SURG, V29, P143, DOI 10.1089/pho.2011.3014; Rochkind S, 2009, INT REV NEUROBIOL, V87, P445, DOI 10.1016/S0074-7742(09)87025-6; RODIECK RW, 1998, 1 STEPS SEEING; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010; Rutar M, 2010, CURR EYE RES, V35, P631, DOI 10.3109/02713681003682925; SANDEMAN DR, 1986, LASER MED SCI, V3, P47; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Segura T, 2008, EXPERT OPIN PHARMACO, V9, P1071, DOI 10.1517/14656560802049322; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Seme MT, 1999, J PHARMACOL EXP THER, V289, P361; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Shen JF, 2008, J CEREBR BLOOD F MET, V28, P1460, DOI 10.1038/jcbfm.2008.37; Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346; Shi QL, 2007, ALZ DIS ASSOC DIS, V21, P276, DOI 10.1097/WAD.0b013e31815721c3; Stemer Andrew B, 2010, Curr Cardiol Rep, V12, P29, DOI 10.1007/s11886-009-0071-3; STERENBORG H J C M, 1989, Lasers in Medical Science, V4, P221, DOI 10.1007/BF02032451; Stolik S, 2000, J PHOTOCH PHOTOBIO B, V57, P90, DOI 10.1016/S1011-1344(00)00082-8; Stone J, 1999, PROG RETIN EYE RES, V18, P689, DOI 10.1016/S1350-9462(98)00032-9; Streeter J, 2004, MITOCHONDRION, V4, P569, DOI 10.1016/j.mito.2004.07.037; STREETER J, 2012, Patent No. 11844205; Sutherland JC, 2002, PHOTOCHEM PHOTOBIOL, V76, P164, DOI 10.1562/0031-8655(2002)076<0164:BEOPL>2.0.CO;2; SVAASAND LO, 1983, PHOTOCHEM PHOTOBIOL, V38, P293, DOI 10.1111/j.1751-1097.1983.tb02674.x; Sykova E, 2008, NEUROCHEM INT, V52, P5, DOI 10.1016/j.neuint.2007.04.007; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tascioglu F, 2010, J INT MED RES, V38, P1233, DOI 10.1177/147323001003800404; Teggi R, 2009, AUDIOL NEURO-OTOL, V14, P115, DOI 10.1159/000161235; Topakian R, 2010, J NEUROL NEUROSUR PS, V81, P192, DOI 10.1136/jnnp.2009.172072; TOSELLI R, 2008, Patent No. 12041405; Tretter L, 2007, J NEUROSCI RES, V85, P3471, DOI 10.1002/jnr.21405; Tsukahara H, 2004, LIFE SCI, V75, P933, DOI 10.1016/j.lfs.2004.01.025; VONBUSSMANN KA, 1993, NEUROREPORT, V4, P247, DOI 10.1097/00001756-199303000-00005; WAN S, 1981, PHOTOCHEM PHOTOBIOL, V34, P679, DOI 10.1111/j.1751-1097.1981.tb09424.x; Whelan HT, 2003, J CLIN LASER MED SUR, V21, P67, DOI 10.1089/104454703765035484; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; WINKLER BS, 1981, J GEN PHYSIOL, V77, P667, DOI 10.1085/jgp.77.6.667; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Ying R, 2008, BRAIN RES, V1243, P167, DOI 10.1016/j.brainres.2008.09.057; YOUSEFINOORAIE R, 2008, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD005107.PUB4; Yu DY, 1999, INVEST OPHTH VIS SCI, V40, P2082; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	158	46	46	0	28	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	APR	2013	24	2					205	226		10.1515/revneuro-2012-0086			22	Neurosciences	Neurosciences & Neurology	199CD	WOS:000322971000007	23492552				2021-06-18	
J	Len, TK; Neary, JP; Asmundson, GJG; Candow, DG; Goodman, DG; Bjornson, B; Bhambhani, YN				Len, Trevor K.; Neary, J. Patrick; Asmundson, Gordon J. G.; Candow, Darren G.; Goodman, David G.; Bjornson, Bruce; Bhambhani, Yagesh N.			Serial monitoring of CO2 reactivity following sport concussion using hypocapnia and hypercapnia	BRAIN INJURY			English	Article						Transcranial Doppler; mild traumatic brain injury; cerebral blood flow; breath holding; hyperventilation; cerebrovascular reactivity	MIDDLE CEREBRAL-ARTERY; TRANSCRANIAL DOPPLER; BLOOD-FLOW; CEREBROVASCULAR REACTIVITY; INTERNATIONAL-CONFERENCE; AUTOREGULATION; PATHOPHYSIOLOGY; STATEMENT; VELOCITY; REST	Primary objective: This study examined the effects of mild traumatic brain injury (mTBI) on cerebrovascular reactivity (CVR). Research design: A repeated measures design was used to examine serial changes in CVR. Methods and procedures: Twenty subjects who recently suffered a mTBI were subjected to a respiratory challenge consisting of repeated 20 s breath-holds (BH) and hyperventilations (HV). Testing occurred on days 2 (D2), 4 (D4) and 8 (D8) post-injury as well as a baseline (BASE) assessment (after return-to-play). Transcranial Doppler was used to assess mean cerebral blood velocity (vMCA) and expired gas analysis provided end-tidal carbon dioxide (PETCO2) levels. Results: There was no significant difference in resting vMCA across all testing days for mTBI. No significant differences in PETCO2 were found throughout the testing protocol. A significant effect (p < 0.001) of testing day on vMCA was found during BH and HV challenges for mTBI. Post-hoc analysis revealed significant differences (p < 0.05) in vMCA between D2 and the other testing days. Conclusions: These data suggest that, following mTBI: (1) CVR is not impaired at rest; (2) CVR is impaired in response to respiratory stress; and (3) the impairment may be resolved as early as 4 days post-injury.	[Len, Trevor K.; Neary, J. Patrick; Candow, Darren G.] Univ Regina, Fac Kinesiol & Hlth Studies, Regina, SK S4S 0A2, Canada; [Asmundson, Gordon J. G.] Univ Regina, Traumat Stress Grp, Regina, SK S4S 0A2, Canada; [Goodman, David G.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada; [Bjornson, Bruce] Univ British Columbia, Fac Med Neurol, Vancouver, BC V5Z 1M9, Canada; [Bhambhani, Yagesh N.] Univ Alberta, Dept Occupat Therapy, Edmonton, AB, Canada	Neary, JP (corresponding author), Univ Regina, Fac Kinesiol & Hlth Studies, CK 164-23,3737 Wascana Pkwy, Regina, SK S4S 0A2, Canada.	patrick.neary@uregina.ca	Bjornson, Bruce Hal/A-8616-2010	Bjornson, Bruce Hal/0000-0002-1465-6196	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Heart & Stroke Foundation of Saskatchewan; Saskatchewan Health Research Foundation	This study was supported in part by grants received from the Canadian Institutes of Health Research (JPN), Heart & Stroke Foundation of Saskatchewan (TKL), and the Saskatchewan Health Research Foundation (JPN). The authors report no conflicts of interest.	Ainslie PN, 2009, AM J PHYSIOL-REG I, V296, pR1473, DOI 10.1152/ajpregu.91008.2008; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Foreman Megan, 2010, State Legis, V36, P28; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giza CC, 2001, J ATHL TRAINING, V36, P228; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Grindel Scott H, 2003, Curr Sports Med Rep, V2, P18, DOI 10.1249/00149619-200302000-00005; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Karadeniz U, 2005, ANN THORAC SURG, V79, P139, DOI 10.1016/j.athoracsur.2004.06.046; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KLINGELHOFER J, 1992, STROKE, V23, P1427, DOI 10.1161/01.STR.23.10.1427; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Little J. A. R., 1987, STAT ANAL MISSING DA; MARKUS HS, 1992, STROKE, V23, P668, DOI 10.1161/01.STR.23.5.668; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Netzer N, 1998, STROKE, V29, P87, DOI 10.1161/01.STR.29.1.87; Ogoh S, 2008, J PHYSIOL-LONDON, V586, P4327, DOI 10.1113/jphysiol.2008.157073; RINGELSTEIN EB, 1990, ULTRASOUND MED BIOL, V16, P745, DOI 10.1016/0301-5629(90)90039-F; Rubin DB., 1987, MULTIPLE IMPUTATION; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tegeler C, 2004, CEREBROVASC DIS, V17, P1; Tegeler C, 2003, 26 ANN M AM SOC NEUR, V13, P174; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willie CK, 2011, J NEUROSCI METH, V196, P221, DOI 10.1016/j.jneumeth.2011.01.011	37	46	46	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2013	27	3					346	353		10.3109/02699052.2012.743185			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	096OG	WOS:000315413400012	23438354				2021-06-18	
J	D'Ambrosio, R; Eastman, CL; Darvas, F; Fender, JS; Verley, DR; Farin, FM; Wilkerson, HW; Temkin, NR; Miller, JW; Ojemann, J; Rothman, SM; Smyth, MD				D'Ambrosio, Raimondo; Eastman, Clifford L.; Darvas, Felix; Fender, Jason S.; Verley, Derek R.; Farin, Federico M.; Wilkerson, Hui-Wen; Temkin, Nancy R.; Miller, John W.; Ojemann, Jeffrey; Rothman, Steven M.; Smyth, Matthew D.			Mild passive focal cooling prevents epileptic seizures after head injury in rats	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; FLUID PERCUSSION INJURY; POSTTRAUMATIC EPILEPSY; INTRACRANIAL-PRESSURE; LONG-TERM; HYPOTHERMIA; PROVIDES	Objective Post-traumatic epilepsy is prevalent, often difficult to manage, and currently cannot be prevented. Although cooling is broadly neuroprotective, cooling-induced prevention of chronic spontaneous recurrent seizures has never been demonstrated. We examined the effect of mild passive focal cooling of the perilesional neocortex on the development of neocortical epileptic seizures after head injury in the rat. Methods Rostral parasagittal fluid percussion injury in rats reliably induces a perilesional, neocortical epileptic focus within weeks after injury. Epileptic seizures were assessed by 5-electrode video-electrocorticography (ECoG) 2 to 16 weeks postinjury. Focal cooling was induced with ECoG headsets engineered for calibrated passive heat dissipation. Pathophysiology was assessed by glial fibrillary acidic protein immunostaining, cortical sclerosis, gene expression of inflammatory cytokines interleukin (IL)-1 and IL-1, and ECoG spectral analysis. All animals were formally randomized to treatment groups, and data were analyzed blind. Results Cooling by 0.5 to 2 degrees C inhibited the onset of epileptic seizures in a dose-dependent fashion. The treatment induced no additional pathology or inflammation, and normalized the power spectrum of stage N2 sleep. Cooling by 2 degrees C for 5.5 weeks beginning 3 days after injury virtually abolished ictal activity. This effect persisted through the end of the study, >10 weeks after cessation of cooling. Rare remaining seizures were shorter than in controls. Interpretation These findings demonstrate potent and persistent prevention and modification of epileptic seizures after head injury with a cooling protocol that is neuroprotective, compatible with the care of head injury patients, and conveniently implemented. The required cooling can be delivered passively without Peltier cells or electrical power. ANN NEUROL 2013;73:199209	[D'Ambrosio, Raimondo; Eastman, Clifford L.; Darvas, Felix; Fender, Jason S.; Verley, Derek R.; Temkin, Nancy R.; Miller, John W.; Ojemann, Jeffrey] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [D'Ambrosio, Raimondo; Miller, John W.; Ojemann, Jeffrey] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [D'Ambrosio, Raimondo; Miller, John W.; Ojemann, Jeffrey] Univ Washington, Reg Epilepsy Ctr, Seattle, WA 98195 USA; [D'Ambrosio, Raimondo; Farin, Federico M.; Wilkerson, Hui-Wen; Ojemann, Jeffrey] Univ Washington, Ctr Human Dev & Disabil, Seattle, WA 98195 USA; [Farin, Federico M.; Wilkerson, Hui-Wen] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Rothman, Steven M.] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; [Smyth, Matthew D.] Washington Univ, Dept Neurol Surg, St Louis, MO USA	D'Ambrosio, R (corresponding author), Harborview Med Ctr, Dept Neurosurg, Box 359915,325 9th Ave, Seattle, WA 98104 USA.	raid@u.washington.edu	Verley, Derek/J-4550-2015	Verley, Derek/0000-0002-2670-6568; Ojemann, Jeffrey/0000-0001-7580-8934	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NIBIBUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [NS053928, NS042936, EB007362]; CURE [5154001.01, 5154001.05]; University of WashingtonUniversity of Washington; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD002274] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [K01EB007362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042936, R21NS076570, R01NS053928] Funding Source: NIH RePORTER	This work was supported by the NIH, NINDS and NIBIB (NS053928, R.D.; NS042936, S.M.R.; EB007362, F.D.), CURE (5154001.01, R.D.; 5154001.05, M.D.S.; both were made possible by a cooperative agreement with the US Army Medical Research and Materiel Command), and the University of Washington. We acknowledge the assistance of the University of Washington Center for Ecogenetics and Environmental Health (P30ES07033) and of the Center on Human Development and Disability (P30HD02274).	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Bancaud J, 1992, Adv Neurol, V57, P3; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Burton JM, 2005, EPILEPSIA, V46, P1881, DOI 10.1111/j.1528-1167.2005.00299.x; Choi J, 2008, YONSEI MED J, V49, P1, DOI 10.3349/ymj.2008.49.1.1; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Curia G, 2011, CEREB CORTEX, V21, P1574, DOI 10.1093/cercor/bhq218; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; D'Ambrosio R, 2010, EPILEPSY CURR, V10, P61, DOI 10.1111/j.1535-7511.2010.01358.x; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; Doll H, 2009, J NEUROTRAUM, V26, P235, DOI 10.1089/neu.2008.0741; Eastman CL, 2011, J PHARMACOL EXP THER, V336, P779, DOI 10.1124/jpet.110.175133; Eastman CL, 2010, EXP NEUROL, V224, P369, DOI 10.1016/j.expneurol.2010.04.013; Eftekhar B, 2009, J NEUROSURG, V110, P319, DOI 10.3171/2008.4.17519; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fox JL, 2010, CAN J EMERG MED, V12, P355; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fujii M, 2012, EPILEPSIA, V53, P485, DOI 10.1111/j.1528-1167.2011.03388.x; Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004; Leppik IE, 2006, HDB HLTH CARE, P9; Linares G, 2009, CRIT CARE MED, V37, pS243, DOI 10.1097/CCM.0b013e3181aa5de1; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Lu Y, 2009, CNS DRUGS, V23, P351, DOI 10.2165/00023210-200923040-00006; Norwood BA, 2010, J COMP NEUROL, V518, P3381, DOI 10.1002/cne.22406; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Rothman SM, 2009, NEUROTHERAPEUTICS, V6, P251, DOI 10.1016/j.nurt.2008.12.002; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Stover JF, 2006, EUR J TRAUMA, V32, P10; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Tokutomi T, 2009, J TRAUMA, V66, P166, DOI 10.1097/TA.0b013e318157dbec; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vezzani A, 2013, NEUROPHARMACOLOGY, V69, P16, DOI 10.1016/j.neuropharm.2012.04.004; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; WILLIAMSON PD, 1985, ANN NEUROL, V18, P497, DOI 10.1002/ana.410180413	48	46	46	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	FEB	2013	73	2					199	209		10.1002/ana.23764			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	113UA	WOS:000316693200009	23225633	Green Accepted			2021-06-18	
J	Guiza, F; Depreitere, B; Piper, I; Van den Berghe, G; Meyfroidt, G				Guiza, Fabian; Depreitere, Bart; Piper, Ian; Van den Berghe, Greet; Meyfroidt, Geert			Novel Methods to Predict Increased Intracranial Pressure During Intensive Care and Long-Term Neurologic Outcome After Traumatic Brain Injury: Development and Validation in a Multicenter Dataset	CRITICAL CARE MEDICINE			English	Article						automated; data mining; decision support techniques; forecasting; Glasgow Outcome Scale; intensive care; intracranial hypertension; models; pattern recognition; statistical; traumatic brain injury	SECONDARY INSULTS; HYPERTENSION	Objective: Intracranial pressure monitoring is standard of care after severe traumatic brain injury. Episodes of increased intracranial pressure are secondary injuries associated with poor outcome. We developed a model to predict increased intracranial pressure episodes 30 mins in advance, by using the dynamic characteristics of continuous intracranial pressure and mean arterial pressure monitoring. In addition, we hypothesized that performance of current models to predict long-term neurologic outcome could be substantially improved by adding dynamic characteristics of continuous intracranial pressure and mean arterial pressure monitoring during the first 24 hrs in the ICU. Design: Prognostic modeling. Noninterventional, observational, retrospective study. Setting and Patients: The Brain Monitoring with Information Technology dataset consisted of 264 traumatic brain injury patients admitted to 22 neuro-ICUs from 11 European countries. Interventions: None. Measurements: Predictive models were built with multivariate logistic regression and Gaussian processes, a machine learning technique. Predictive attributes were Corticosteroid Randomisation After Significant Head Injury-basic and International Mission for Prognosis and Clinical Trial design in TBI-core predictors, together with time-series summary statistics of minute-by-minute mean arterial pressure and intracranial pressure. Main Results: Increased intracranial pressure episodes could be predicted 30 mins ahead with good calibration (Hosmer-Lemeshow p value 0.12, calibration slope 1.02, calibration-in-the-large -0.02) and discrimination (area under the receiver operating curve = 0.87) on an external validation dataset. Models for prediction of poor neurologic outcome at six months (Glasgow Outcome Score 1-2) based only on static admission data had 0.72 area under the receiver operating curve; adding dynamic information of intracranial pressure and mean arterial pressure during the first 24 hrs increased performance to 0.90. Similarly, prediction of Glasgow Outcome Score 1-3 was improved from 0.68 to 0.87 when including dynamic information. Conclusion: The dynamic information in continuous mean arterial pressure and intracranial pressure monitoring allows to accurately predict increased intracranial pressure in the neuro-ICU. Adding information of the first 24 hrs of intracranial pressure and mean arterial pressure monitoring to known baseline risk factors allows very accurate prediction of long-term neurologic outcome at 6 months. (Crit Care Med 2013; 41: 554-564)	[Guiza, Fabian; Van den Berghe, Greet; Meyfroidt, Geert] Katholieke Univ Leuven, Dept Intens Care Med, Louvain, Belgium; [Depreitere, Bart] Katholieke Univ Leuven, Dept Neurosurg, Louvain, Belgium; [Piper, Ian] So Gen Hosp, Dept Clin Phys, Glasgow G51 4TF, Lanark, Scotland	Guiza, F (corresponding author), Katholieke Univ Leuven, Dept Intens Care Med, Louvain, Belgium.	fabian.guiza@med.kuleuven.be	Van den Berghe, Greet/J-6788-2018; Viani, Rafael/V-1196-2018; Depreitere, Bart/AAA-9846-2020	Van den Berghe, Greet/0000-0002-5320-1362; Depreitere, Bart/0000-0002-7458-0648; Guiza, Fabian/0000-0001-7026-0957	European-Framework-Programme [FP5-QLRI-2000-00454, QLGT-2002-00160, FP7-IST-2007-217049]; Foundation-for-Scientific-Research (in part) Flanders (FWO), Belgium [G. 0904.11]; Flemish government Methusalem-program	Supported by The European-Framework-Programme (FP5-QLRI-2000-00454, QLGT-2002-00160 and FP7-IST-2007-217049); by the Foundation-for-Scientific-Research (in part) Flanders (FWO), Belgium (research project G. 0904.11); and a senior clinical investigator postdoctoral fellowship to Professor Meyfroidt); and the Flemish government Methusalem-program (to G.V.d.B.).	[Anonymous], 2008, BMJ-BRIT MED J, V336, P425, DOI DOI 10.1136/bmj.39461.643438.25; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Box G, 1976, TIME SERIES ANAL FOR, P141; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, P37; Budohoski KP, 2012, BRIT J ANAESTH, V108, P89, DOI 10.1093/bja/aer324; Efron B, 1997, J AM STAT ASSOC, V92, P548, DOI 10.2307/2965703; Hall M. A, 1998, CORRELATION BASED FE; JENNETT B, 1976, LANCET, V1, P1031; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kahraman S, 2011, J TRAUMA, V70, P547, DOI 10.1097/TA.0b013e31820c768a; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kirkness CJ, 2008, ACTA NEUROCHIR SUPPL, V102, P105, DOI 10.1007/978-3-211-85578-2_21; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Lu J, 2005, ACT NEUR S, V95, P281; Meyfroidt G, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-64; Meyfroidt G, 2009, BEST PRACT RES-CLIN, V23, P127, DOI 10.1016/j.bpa.2008.09.003; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Piper I, 2003, ACTA NEUROCHIR, V145, P615, DOI 10.1007/s00701-003-0066-6; Rasmussen C.E., DOCUMENTATION GPML M; Rasmussen CE, 2005, ADAPT COMPUT MACH LE, P1; Sahiner B, 2008, MED PHYS, V35, P1559, DOI 10.1118/1.2868757; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Witten IH, 2005, DATA MINING PRACTICA	26	46	46	1	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2013	41	2					554	564		10.1097/CCM.0b013e3182742d0a			11	Critical Care Medicine	General & Internal Medicine	078NO	WOS:000314106000040	23263587				2021-06-18	
S	Ferroni, L; Gardin, C; Tocco, I; Epis, R; Casadei, A; Vindigni, V; Mucci, G; Zavan, B		Weyand, B; Dominici, M; Hass, R; Jacobs, R; Kasper, C		Ferroni, Letizia; Gardin, Chiara; Tocco, Ilaria; Epis, Roberta; Casadei, Alessandro; Vindigni, Vincenzo; Mucci, Giuseppe; Zavan, Barbara			Potential for Neural Differentiation of Mesenchymal Stem Cells	MESENCHYMAL STEM CELLS: BASICS AND CLINICAL APPLICATION I	Advances in Biochemical Engineering-Biotechnology		English	Article; Book Chapter						MSC; Adipose derived stem cells; Neuronal commitment; Clinical application	HUMAN ADIPOSE-TISSUE; SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; SKIN-DERIVED PRECURSORS; PLATELET-RICH PLASMA; MARROW STROMAL CELLS; HUMAN BONE-MARROW; CEREBRAL-ISCHEMIA; IN-VITRO; ADIPOGENIC DIFFERENTIATION	Adult human stem cells have gained progressive interest as a promising source of autologous cells to be used as therapeutic vehicles. Particularly, mesenchymal stem cells (MSCs) represent a great tool in regenerative medicine because of their ability to differentiate into a variety of specialized cells. Among adult tissues in which MSCs are resident, adipose tissue has shown clear advantages over other sources of MSCs (ease of surgical access, availability, and isolation), making adipose tissue the ideal large-scale source for research on clinical applications. Stem cells derived from the adipose tissue (adipose-derived stem cells = ADSCs) possess a great and unique regenerative potential: they are self-renewing and can differentiate along several mesenchymal tissue lineages (adipocytes, osteoblasts, myocytes, chondrocytes, endothelial cells, and cardiomyocytes), among which neuronal-like cells gained particular interest. In view of the promising clinical applications in tissue regeneration, research has been conducted towards the creation of a successful protocol for achieving cells with a well-defined neural phenotype from adipose tissue. The promising results obtained open new scenarios for innovative approaches for a cell-based treatment of neurological degenerative disorders.	[Ferroni, Letizia; Gardin, Chiara; Zavan, Barbara] Univ Padua, Dept Biomed Sci, I-35100 Padua, Italy; [Tocco, Ilaria; Vindigni, Vincenzo] Univ Padua, Dept Neurosci, I-35128 Padua, Italy; [Epis, Roberta; Mucci, Giuseppe] Biosci Inst, Falciano 47891, San Marino	Zavan, B (corresponding author), Univ Padua, Dept Biomed Sci, Via G Colombo 3, I-35100 Padua, Italy.	barbara.zavan@unipd.it	Vindigni, Vincenzo/K-5059-2016	Vindigni, Vincenzo/0000-0001-6638-9010; Gardin, Chiara/0000-0003-3817-0032; Ferroni, Letizia/0000-0002-5457-0338			Aguiari P, 2008, P NATL ACAD SCI USA, V105, P1226, DOI 10.1073/pnas.0711402105; Ahrens N, 2004, TRANSPLANTATION, V78, P925, DOI 10.1097/01.tp.0000133305.81823.2a; Al Battah F, 2011, THESCIENTIFICWORLDJO, V11, P1568, DOI [10.1100/tsw.2011.146, 10.1100/tsw.2011.146.]; Amos PJ, 2010, TISSUE ENG PT A, V16, P1595, DOI [10.1089/ten.tea.2009.0616, 10.1089/ten.TEA.2009.0616]; Arboleda D, 2011, CELL MOL NEUROBIOL, V31, P1113, DOI 10.1007/s10571-011-9712-3; Arrigoni E, 2009, CELL TISSUE RES, V338, P401, DOI 10.1007/s00441-009-0883-x; Aust L, 2004, CYTOTHERAPY, V6, P7, DOI 10.1080/14653240310004539; Aziz A, 2009, DEV BIOL, V332, P116, DOI 10.1016/j.ydbio.2009.05.555; Bailey AM, 2010, CURR STEM CELL RES T, V5, P95; Banerjee M, 2006, CYTOTECHNOLOGY, V51, P1, DOI 10.1007/s10616-006-9001-z; Belicchi M, 2004, J NEUROSCI RES, V77, P475, DOI 10.1002/jnr.20151; Bieback K., 2011, STEM CELLS INT, V2010; Bieback K, 2009, STEM CELLS, V27, P2331, DOI 10.1002/stem.139; Blande IS, 2009, TRANSFUSION, V49, P2680, DOI 10.1111/j.1537-2995.2009.02346.x; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Carpenter MK, 2001, EXP NEUROL, V172, P383, DOI 10.1006/exnr.2001.7832; Casteilla L, 2005, ARCH MAL COEUR VAISS, V98, P922; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chi GF, 2010, EXP NEUROL, V222, P304, DOI 10.1016/j.expneurol.2010.01.008; Choi YS, 2008, BIOTECHNOL LETT, V30, P593, DOI 10.1007/s10529-007-9584-2; Cizkova D, 2006, CELL MOL NEUROBIOL, V26, P1167, DOI 10.1007/s10571-006-9093-1; Pinheiro CHD, 2012, STEM CELL REV REP, V8, P363, DOI 10.1007/s12015-011-9304-0; De Bari C, 2001, ARTHRITIS RHEUM-US, V44, P1928, DOI 10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P; Dodson MV, 2010, INT J BIOL SCI, V6, P465; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Elabd C, 2009, STEM CELLS, V27, P2753, DOI 10.1002/stem.200; Faulkner J, 2005, TRANSPL IMMUNOL, V15, P131, DOI 10.1016/j.trim.2005.09.007; Feng JF, 2010, EXPERT OPIN BIOL TH, V10, P1441, DOI 10.1517/14712598.2010.517191; Fernandes KJL, 2006, EXP NEUROL, V201, P32, DOI 10.1016/j.expneurol.2006.03.018; FERREIRA A, 1992, J NEUROSCI RES, V32, P516, DOI 10.1002/jnr.490320407; Fink Trine, 2011, Front Biosci (Elite Ed), V3, P256, DOI 10.2741/e241; Lambert APF, 2009, DIFFERENTIATION, V77, P221, DOI 10.1016/j.diff.2008.10.016; Freyberg S, 2009, J VASC RES, V46, P98, DOI 10.1159/000142727; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Gimble JM, 2008, TRANSFUS MED HEMOTH, V35, P228, DOI 10.1159/000124281; Gimble JM, 2007, CIRC RES, V100, P1249, DOI 10.1161/01.RES.0000265074.83288.09; Gimble JM, 2011, STEM CELLS, V29, P749, DOI 10.1002/stem.629; Gruber HE, 2012, BIOTECH HISTOCHEM, V87, P303, DOI 10.3109/10520295.2011.649785; Guilak F, 2006, J CELL PHYSIOL, V206, P229, DOI 10.1002/jcp.20463; Hicok KC, 2004, TISSUE ENG, V10, P371, DOI 10.1089/107632704323061735; Izadpanah R, 2006, J CELL BIOCHEM, V99, P1285, DOI 10.1002/jcb.20904; Jeon BG, 2011, CELL TISSUE RES, V345, P149, DOI 10.1007/s00441-011-1191-9; Kakudo N, 2008, PLAST RECONSTR SURG, V122, P1352, DOI 10.1097/PRS.0b013e3181882046; Kang SK, 2003, EXP NEUROL, V183, P355, DOI 10.1016/S0014-4886(03)00089-X; Kang YJ, 2005, J CELL BIOCHEM, V95, P1135, DOI 10.1002/jcb.20499; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kim HJ, 2009, TISSUE ENG PT A, V15, P1543, DOI 10.1089/ten.tea.2008.0368; Kim JM, 2007, BRAIN RES, V1183, P43, DOI 10.1016/j.brainres.2007.09.005; Knippenberg M, 2005, TISSUE ENG, V11, P1780, DOI 10.1089/ten.2005.11.1780; Kocaoemer A, 2007, STEM CELLS, V25, P1270, DOI 10.1634/stemcells.2006-0627; Kozlov G, 2003, J BIOL CHEM, V278, P46021, DOI 10.1074/jbc.M305176200; Kubal WS, 2012, RADIOL CLIN N AM, V50, P15, DOI 10.1016/j.rcl.2011.08.010; Kulikov AV, 2008, B EXP BIOL MED+, V145, P514, DOI 10.1007/s10517-008-0131-5; Lee J, 2005, J CELL BIOL, V170, P661, DOI 10.1083/jcb.200411047; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lindroos B, 2011, STEM CELL REV REP, V7, P269, DOI 10.1007/s12015-010-9193-7; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Locke M, 2011, STEM CELLS, V29, P404, DOI 10.1002/stem.593; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Madonna R, 2011, EUR J CLIN INVEST, V41, P126, DOI 10.1111/j.1365-2362.2010.02384.x; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Michalczyk K, 2005, HISTOL HISTOPATHOL, V20, P665, DOI 10.14670/HH-20.665; Mitchell JB, 2006, STEM CELLS, V24, P376, DOI 10.1634/stemcells.2005-0234; Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100; Mojallal A, 2011, AESTHET PLAST SURG, V35, P1097, DOI 10.1007/s00266-011-9743-7; Oedayrajsingh-Varma MJ, 2006, CYTOTHERAPY, V8, P166, DOI 10.1080/14653240600621125; Ogawa R, 2004, BIOCHEM BIOPH RES CO, V313, P871, DOI 10.1016/j.bbrc.2003.12.017; Onda T, 2008, J CEREBR BLOOD F MET, V28, P329, DOI 10.1038/sj.jcbfm.9600527; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Planat-Benard V, 2004, CIRC RES, V94, P223, DOI 10.1161/01.RES.0000109792.43271.47; Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x; Rodriguez AM, 2005, BIOCHIMIE, V87, P125, DOI 10.1016/j.biochi.2004.11.007; Romanov YA, 2005, B EXP BIOL MED+, V140, P138, DOI 10.1007/s10517-005-0430-z; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Safford KM, 2004, EXP NEUROL, V187, P319, DOI 10.1016/j.expneurol.2004.01.027; Safwani WKZW, 2012, APPL BIOCHEM BIOTECH, V166, P2101, DOI 10.1007/s12010-012-9637-4; Sakaguchi Y, 2005, ARTHRITIS RHEUM-US, V52, P2521, DOI 10.1002/art.21212; Savitz Sean I, 2004, NeuroRx, V1, P406; Schipper BM, 2008, ANN PLAS SURG, V60, P538, DOI 10.1097/SAP.0b013e3181723bbe; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Shi M, 2009, STEM CELLS, V27, P949, DOI 10.1002/stem.4; Slaper-Cortenbach ICM, 2008, TRANSFUS MED HEMOTH, V35, P295, DOI 10.1159/000144043; Smith P, 2006, PLAST RECONSTR SURG, V117, P1836, DOI 10.1097/01.prs.0000218825.77014.78; Soncini M, 2007, J TISSUE ENG REGEN M, V1, P296, DOI 10.1002/term.40; Song L, 2005, STEM CELLS DEV, V14, P712, DOI 10.1089/scd.2005.14.712; Sterodimas A, 2010, J PLAST RECONSTR AES, V63, P1886, DOI 10.1016/j.bjps.2009.10.028; Takamori Y, 2009, BRAIN RES, V1270, P10, DOI 10.1016/j.brainres.2009.03.014; Talens-Visconti R, 2006, WORLD J GASTROENTERO, V12, P5834, DOI 10.3748/wjg.v12.i36.5834; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Tholpady SS, 2006, CLIN PLAST SURG, V33, P55, DOI 10.1016/j.cps.2005.08.004; Timper K, 2006, BIOCHEM BIOPH RES CO, V341, P1135, DOI 10.1016/j.bbrc.2006.01.072; Todorov P, 2010, CELL BIOL INT, V34, P455, DOI 10.1042/CBI20090127; Tohda C, 2011, PHARMACOL THERAPEUT, V132, P57, DOI 10.1016/j.pharmthera.2011.05.006; Toma JG, 2005, STEM CELLS, V23, P727, DOI 10.1634/stemcells.2004-0134; Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475; van Harmelen V, 2003, INT J OBESITY, V27, P889, DOI 10.1038/sj.ijo.0802314; Vindigni V, 2009, NEUROL RES; WILLIAMS SK, 1995, CELL TRANSPLANT, V4, P281, DOI 10.1016/0963-6897(95)00006-J; Yen AHH, 2008, CELL TISSUE RES, V331, P359, DOI 10.1007/s00441-007-0467-6; Yuan AD, 2006, J NEUROSCI, V26, P10006, DOI 10.1523/JNEUROSCI.2580-06.2006; Zachar V, 2011, METHODS MOL BIOL, V698, P37, DOI 10.1007/978-1-60761-999-4_4; Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210; Zavan B, 2010, DISCOV MED, V10, P37; Zavan B, 2010, NEUROL RES, V32, P47, DOI 10.1179/174313209X385743; Zeidan-Chulia Fares, 2009, Eur J Dent, V3, P240; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	112	46	47	0	15	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0724-6145		978-3-642-35671-1; 978-3-642-35670-4	ADV BIOCHEM ENG BIOT	Adv. Biochem. Eng. Biotechnol.		2013	129						89	115		10.1007/10_2012_152	10.1007/978-3-642-35671-1		27	Cell & Tissue Engineering; Biotechnology & Applied Microbiology	Cell Biology; Biotechnology & Applied Microbiology	BFR89	WOS:000321104500007	22899379				2021-06-18	
J	Szaflarski, JP; Altaye, M; Rajagopal, A; Eaton, K; Meng, XX; Plante, E; Holland, SK				Szaflarski, Jerzy P.; Altaye, Mekibib; Rajagopal, Akila; Eaton, Kenneth; Meng, XiangXiang; Plante, Elena; Holland, Scott K.			A 10-year longitudinal fMRI study of narrative comprehension in children and adolescents	NEUROIMAGE			English	Article						Longitudinal language development; Narrative comprehension; Language; fMRI; Child; Brain; Development	TRAUMATIC BRAIN-INJURY; SCHOOL-AGE-CHILDREN; LANGUAGE LATERALIZATION; SENTENCE COMPREHENSION; LEARNING-DISABILITIES; STORY COMPREHENSION; NEURAL-NETWORKS; FUNCTIONAL MRI; YOUNG-CHILDREN; RESTING STATE	Comprehension of spoken narratives requires coordination of multiple language skills. As such, for normal children narrative skills develop well into the school years and, during this period, are particularly vulnerable in the face of brain injury or developmental disorder. For these reasons, we sought to determine the developmental trajectory of narrative processing using longitudinal fMRI scanning. 30 healthy children between the ages of 5 and 18 enrolled at ages 5, 6, or 7, were examined annually for up to 10 years. At each fMRI session, children were presented with a set of five, 30 s-long, stories containing 9, 10, or 11 sentences designed to be understood by a 5 year old child. fMRI data analysis was conducted based on a hierarchical linear model (HLM) that was modified to investigate developmental changes while accounting for missing data and controlling for factors such as age, linguistic performance and IQ. Performance testing conducted after each scan indicated well above the chance (p<0.002) comprehension performance. There was a linear increase with increasing age in bilateral superior temporal cortical activation (BAs 21 and 22) linked to narrative processing. Conversely, age-related decreases in cortical activation were observed in bilateral occipital regions, cingulate and cuneus, possibly reflecting changes in the default mode networks. The dynamic changes observed in this longitudinal fMRI study support the increasing role of bilateral BAs 21 and 22 in narrative comprehension, involving non-domain-specific integration in order to achieve final story interpretation. The presence of a continued linear development of this area throughout childhood and teenage years with no apparent plateau, indicates that full maturation of narrative processing skills has not yet occurred and that it may be delayed to early adulthood. (C) 2012 Elsevier Inc. All rights reserved.	[Szaflarski, Jerzy P.] Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, Cincinnati, OH 45267 USA; [Szaflarski, Jerzy P.; Rajagopal, Akila] Cincinnati Childrens Hosp, Med Ctr, Pediat Neuroimaging Res Consortium, Cincinnati, OH USA; [Eaton, Kenneth; Holland, Scott K.] Cincinnati Childrens Hosp, Med Ctr, Imaging Res Ctr, Cincinnati, OH USA; [Rajagopal, Akila; Eaton, Kenneth; Holland, Scott K.] Cincinnati Childrens Hosp, Med Ctr, Dept Radiol, Cincinnati, OH USA; [Altaye, Mekibib] Cincinnati Childrens Hosp, Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA; [Holland, Scott K.] Cincinnati Childrens Hosp, Med Ctr, Dept Neurol, Cincinnati, OH USA; [Meng, XiangXiang] SAS Inst Inc, Adv Analyt Div, Cary, NC USA; [Plante, Elena] Univ Arizona, Dept Speech Language & Hearing Sci, Tucson, AZ USA	Szaflarski, JP (corresponding author), Univ Cincinnati, Acad Hlth Ctr, Dept Neurol, 260 Stetson St,Rm 2350, Cincinnati, OH 45267 USA.	jerzy.Szaflarski@uc.edu; Mekibib.Altaye@cchmc.org; Akila.Rajagopal@cchmc.org; Kenneth.Eaton@cchmc.org; Xiangxiang.Meng@sas.com; eplante@u.arizona.edu; Scott.Holland@cchmc.org	Altaye, Mekibib/N-5274-2015	Holland, Scott/0000-0003-3719-0875	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2RO1 HD38578]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038578] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER	This study was presented in part at the Human Brain Mapping Conference, Florence, Italy 6/2006. Support was provided by NIH 2RO1 HD38578 (to SKH).	Ahmad Z, 2003, NEUROLOGY, V60, P1598, DOI 10.1212/01.WNL.0000059865.32155.86; Alexander KJ, 2001, SOC DEV, V10, P374, DOI 10.1111/1467-9507.00171; Beckmann CF, 2003, NEUROIMAGE, V20, P1052, DOI 10.1016/S1053-8119(03)00435-X; Binder JR, 2011, NEUROIMAGE, V54, P1465, DOI 10.1016/j.neuroimage.2010.09.048; Bird EKR, 2008, J SPEECH LANG HEAR R, V51, P436, DOI 10.1044/1092-4388(2008/032); Bohn-Gettler CM, 2011, MEM COGNITION, V39, P992, DOI 10.3758/s13421-011-0085-0; Brown DD, 2011, READ PSYCHOL, V32, P372, DOI 10.1080/02702711.2010.495573; Bullmore ET, 2000, NEUROIMAGE, V11, P289, DOI 10.1006/nimg.2000.0544; Byars AW, 2002, J CHILD NEUROL, V17, P885, DOI 10.1177/08830738020170122201; Carrow-Woolfolk E., 1996, ORAL WRITTEN LANGUAG; Ceponiene R, 2002, CLIN NEUROPHYSIOL, V113, P870, DOI 10.1016/S1388-2457(02)00078-0; Chang CJ, 2006, NARRAT INQ, V16, P275, DOI 10.1075/ni.16.2.04cha; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; COPMANN KSP, 1994, J PSYCHOLINGUIST RES, V23, P231, DOI 10.1007/BF02139086; Curenton SM, 2011, EARLY CHILD DEV CARE, V181, P791, DOI 10.1080/03004430.2010.490946; DiFrancesco MW, 2008, J CLIN NEUROPHYSIOL, V25, P255, DOI 10.1097/WNP.0b013e3181879d56; Donnelly KM, 2011, BRAIN RES, V1419, P105, DOI 10.1016/j.brainres.2011.08.065; Duewell S, 1996, RADIOLOGY, V199, P780, DOI 10.1148/radiology.199.3.8638005; FLYNN JR, 1987, PSYCHOL BULL, V101, P171, DOI 10.1037/0033-2909.101.2.171; FLYNN JR, 1984, PSYCHOL BULL, V95, P29, DOI 10.1037/0033-2909.95.1.29; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Friederici AD, 2003, CEREB CORTEX, V13, P170, DOI 10.1093/cercor/13.2.170; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Friston KJ, 2005, NEUROIMAGE, V24, P244, DOI 10.1016/j.neuroimage.2004.08.055; Gaillard WD, 2003, NEUROLOGY, V60, P94, DOI 10.1212/WNL.60.1.94; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Gaillard WD, 2001, NEUROLOGY, V57, P47, DOI 10.1212/WNL.57.1.47; Goldman RI, 2002, NEUROREPORT, V13, P2487, DOI 10.1097/00001756-200212200-00022; Holland SK, 2007, INT J AUDIOL, V46, P533, DOI 10.1080/14992020701448994; Karasinski C, 2010, J SPEECH LANG HEAR R, V53, P1268, DOI 10.1044/1092-4388(2009/09-0006); Karunanayaka P, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00029; Karunanayaka P, 2011, EPILEPSY BEHAV, V20, P623, DOI 10.1016/j.yebeh.2010.12.029; Karunanayaka P, 2010, NEUROIMAGE, V51, P472, DOI 10.1016/j.neuroimage.2009.12.108; Karunanayaka PR, 2007, NEUROIMAGE, V34, P349, DOI 10.1016/j.neuroimage.2006.08.028; Kay BP, 2012, BRAIN RES, V1447, P53, DOI 10.1016/j.brainres.2012.01.064; Kennedy MRT, 2003, J SPEECH LANG HEAR R, V46, P98, DOI 10.1044/1092-4388(2003/008); Kim KK, 2011, EPILEPSY BEHAV, V20, P613, DOI 10.1016/j.yebeh.2010.11.010; Kobayashi C, 2007, NEUROPSYCHOLOGIA, V45, P1522, DOI 10.1016/j.neuropsychologia.2006.11.017; Kuperberg GR, 2006, NEUROIMAGE, V33, P343, DOI 10.1016/j.neuroimage.2006.06.001; Laufs H, 2003, NEUROIMAGE, V19, P1463, DOI 10.1016/S1053-8119(03)00286-6; Lin XD, 2011, BRAIN CONNECT, V1, P389, DOI 10.1089/brain.2011.0045; Long DL, 2002, J COGNITIVE NEUROSCI, V14, P228, DOI 10.1162/089892902317236867; Lorch E P, 1998, Clin Child Fam Psychol Rev, V1, P163, DOI 10.1023/A:1022602814828; Mar RA, 2004, NEUROPSYCHOLOGIA, V42, P1414, DOI 10.1016/j.neuropsychologia.2003.12.016; Marini A, 2010, J NEUROLINGUIST, V23, P97, DOI 10.1016/j.jneuroling.2009.10.002; Meyer M, 2000, COGNITIVE BRAIN RES, V9, P19, DOI 10.1016/S0926-6410(99)00039-7; Morgan VL, 2008, MED SCI MONITOR, V14, pCR345; Morosan P, 2001, NEUROIMAGE, V13, P684, DOI 10.1006/nimg.2000.0715; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; Poluenko A., 2009, APPL PSYCHOLINGUIST, V30, P3485; Price CJ, 2010, ANN NY ACAD SCI, V1191, P62, DOI 10.1111/j.1749-6632.2010.05444.x; SamsonDollfus D, 1997, INT J PSYCHOPHYSIOL, V26, P395, DOI 10.1016/S0167-8760(97)00778-2; Schlaggar BL, 2002, SCIENCE, V296, P1476, DOI 10.1126/science.1069464; Schmithorst VJ, 2006, NEUROIMAGE, V29, P254, DOI 10.1016/j.neuroimage.2005.07.020; Schmithorst VJ, 2001, IEEE T MED IMAGING, V20, P535, DOI 10.1109/42.929619; Schneider P., 1997, J SPEECH LANGUAGE PA, V21, P8; SILLIMAN ER, 1989, ANN DYSLEXIA, V39, P125, DOI 10.1007/BF02656905; Szaflarski JP, 2008, EPILEPSY BEHAV, V12, P74, DOI 10.1016/j.yebeh.2007.07.015; Szaflarski JP, 2012, BRAIN RES, V1433, P85, DOI 10.1016/j.brainres.2011.11.026; Szaflarski JP, 2006, ANN NEUROL, V59, P796, DOI 10.1002/ana.20817; Szaflarski JP, 2006, HUM BRAIN MAPP, V27, P202, DOI 10.1002/hbm.20177; Szaflarski JP, 2002, NEUROLOGY, V59, P238, DOI 10.1212/WNL.59.2.238; Talairach J., 1988, COPLANAR STEREOTAXIC; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; TONNQUISTUHLEN I, 1995, ELECTROEN CLIN NEURO, V95, P34, DOI 10.1016/0013-4694(95)00044-Y; Troiani V, 2008, NEUROIMAGE, V40, P932, DOI 10.1016/j.neuroimage.2007.12.002; vandenBroek P, 1996, CHILD DEV, V67, P3010, DOI 10.2307/1131764; Vieiro P, 1997, READ WRIT, V9, P41, DOI 10.1023/A:1007932429184; Wansapura JP, 1999, JMRI-J MAGN RESON IM, V9, P531, DOI 10.1002/(SICI)1522-2586(199904)9:4<531::AID-JMRI4>3.0.CO;2-L; Westerveld MF, 2010, INT J SPEECH-LANG PA, V12, P178, DOI 10.3109/17549500903194125; Westerveld MF, 2008, INT J SPEECH-LANG PA, V10, P132, DOI 10.1080/14417040701422390; Wilke M, 2002, HUM BRAIN MAPP, V17, P48, DOI 10.1002/hbm.10053; Wolf D, 2004, FIRST LANG, V24, P123, DOI [10.1177/0142723704042369, DOI 10.1177/0142723704042369]; Wright HH, 2001, AM J SPEECH-LANG PAT, V10, P308, DOI 10.1044/1058-0360(2001/027); Xu J, 2005, NEUROIMAGE, V25, P1002, DOI 10.1016/j.neuroimage.2004.12.013; Yakovlev P.I., 1967, RETIONAL DEV BRAIN E, P3	79	46	46	1	44	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	NOV 15	2012	63	3					1188	1195		10.1016/j.neuroimage.2012.08.049			8	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	027UK	WOS:000310379100021	22951258	Green Accepted			2021-06-18	
J	Wang, KY; Yu, GF; Zhang, ZY; Huang, Q; Dong, XQ				Wang, Ke-Yi; Yu, Guo-Feng; Zhang, Zu-Yong; Huang, Qiang; Dong, Xiao-Qiao			Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury	CLINICA CHIMICA ACTA			English	Article						High-mobility group box 1; Traumatic brain injury; Functional outcome; Mortality	DNA-BINDING PROTEINS; SUBARACHNOID HEMORRHAGE; CHROMATIN PROTEIN; HEAD-INJURY; HMGB1; ISCHEMIA; RELEASE; HMG-1; INFLAMMATION; ARTHRITIS	Background: High-mobility group box 1 (HMGB1), a marker of inflammation, has been associated with poor outcome of critical illness. The present study was undertaken to investigate the plasma HMGB1 concentrations in patients with traumatic brain injury (TBI) and to analyze the correlation of HMGB1 with TBI outcome. Methods: We performed an observational, clinical study. Plasma HMGB1 concentration of 106 healthy subjects and 106 patients with severe TBI was measured by ELISA. The correlation with 1-y mortality and unfavorable outcome (Glasgow Outcome Scale score of 1-3) was analyzed. Results: Thirty-one patients (29.2%) died and 48 patients (45.3%) had an unfavorable outcome at 1 y after TBI. Plasma HMGB1 level was substantially higher in patients than in healthy controls. A multivariate analysis selected plasma HMGB1 level as an independent predictor for 1-y mortality and unfavorable outcome of patients. A receiver operating characteristic curve analysis showed plasma HMGB1 level statistically significantly predicted 1-y mortality and unfavorable outcome. The prognostic value of HMGB1 was similar to that of Glasgow Coma Scale score for 1-y clinical outcomes. Conclusions: Plasma HMGB1 concentration emerges as a novel biomarker for predicting 1-y clinical outcomes of TBI. (c) 2012 Elsevier B.V. All rights reserved.	[Zhang, Zu-Yong; Dong, Xiao-Qiao] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, Hangzhou 310006, Zhejiang, Peoples R China; [Yu, Guo-Feng; Huang, Qiang] Quzhou Peoples Hosp, Dept Neurosurg, Quzhou 324100, Peoples R China; [Wang, Ke-Yi] Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Cent Lab, Hangzhou 310006, Zhejiang, Peoples R China	Dong, XQ (corresponding author), Nanjing Med Univ, Hangzhou Municipal Peoples Hosp 1, Dept Neurosurg, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China.	dxqhyy@163.com			Zhejiang Provincial Program [2012KYB148]	This work was financially supported by the Zhejiang Provincial Program (No. 2012KYB148).	Abraham E, 2000, J IMMUNOL, V165, P2950, DOI 10.4049/jimmunol.165.6.2950; Agnello D, 2002, CYTOKINE, V18, P231, DOI 10.1006/cyto.2002.0890; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Goldstein RS, 2006, SHOCK, V25, P571, DOI 10.1097/01.shk.0000209540.99176.72; Guazzi S, 2003, GENE EXPR PATTERNS, V3, P29, DOI 10.1016/S1567-133X(02)00093-5; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; King MD, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09223; Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune; Kokkola R, 2003, ARTHRITIS RHEUM, V48, P2052, DOI 10.1002/art.11161; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Muhammad S, 2008, J NEUROSCI, V28, P12023, DOI 10.1523/JNEUROSCI.2435-08.2008; Murakami K, 2011, TRANSL STROKE RES, V2, P72, DOI 10.1007/s12975-010-0052-2; Nakahara T, 2009, NEUROCRIT CARE, V11, P362, DOI 10.1007/s12028-009-9276-y; Ombrellino M, 1999, LANCET, V354, P1446, DOI 10.1016/S0140-6736(99)02658-6; Qiu J, 2008, J CEREBR BLOOD F MET, V28, P927, DOI 10.1038/sj.jcbfm.9600582; Qiu JH, 2010, STROKE, V41, P2077, DOI 10.1161/STROKEAHA.110.590463; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Tang DL, 2008, CRIT CARE MED, V36, P291, DOI 10.1097/01.CCM.0000295316.86942.CE; Taniguchi N, 2003, ARTHRITIS RHEUM, V48, P971, DOI 10.1002/art.10859; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-188OC; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Vogelgesang A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008718; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang HC, 1999, SURGERY, V126, P389, DOI 10.1067/msy.1999.99167; Watanabe M, 2012, ACTA NEUROCHIR SUPPL, V113, P91, DOI 10.1007/978-3-7091-0923-6_19; Yang H, 2004, P NATL ACAD SCI USA, V101, P296, DOI 10.1073/pnas.2434651100; Zhou Y, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/142458	36	46	49	0	94	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0009-8981			CLIN CHIM ACTA	Clin. Chim. Acta	NOV 12	2012	413	21-22					1737	1741		10.1016/j.cca.2012.07.002			5	Medical Laboratory Technology	Medical Laboratory Technology	003PB	WOS:000308622700004	22789964				2021-06-18	
J	Barbosa, RR; Jawa, R; Watters, JM; Knight, JC; Kerwin, AJ; Winston, ES; Barraco, RD; Tucker, B; Bardes, JM; Rowell, SE				Barbosa, Ronald R.; Jawa, Randeep; Watters, Jennifer M.; Knight, Jennifer C.; Kerwin, Andrew J.; Winston, Eleanor S.; Barraco, Robert D.; Tucker, Brian; Bardes, James M.; Rowell, Susan E.			Evaluation and management of mild traumatic brain injury: An Eastern Association for the Surgery of Trauma practice management guideline	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Mild traumatic brain injury; concussion; guidelines	MINOR HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; POST-CONCUSSION SYMPTOMS; COMPUTED-TOMOGRAPHY SCAN; DIFFUSE AXONAL INJURY; NEW-ORLEANS CRITERIA; OF-THE-LITERATURE; COGNITIVE REHABILITATION; INTRACRANIAL INJURY; RANDOMIZED-TRIAL	BACKGROUND: An estimated 1.1 million people sustain a mild traumatic brain injury (MTBI) annually in the United States. The natural history of MTBI remains poorly characterized, and its optimal clinical management is unclear. The Eastern Association for the Surgery of Trauma had previously published a set of practice management guidelines for MTBI in 2001. The purpose of this review was to update these guidelines to reflect the literature published since that time. METHODS: The PubMed and Cochrane Library databases were searched for articles related to MTBI published between 1998 and 2011. Selected older references were also examined. RESULTS: A total of 112 articles were reviewed and used to construct a series of recommendations. CONCLUSION: The previous recommendation that brain computed tomographic (CT) should be performed on patients that present acutely with suspected brain trauma remains unchanged. A number of additional recommendations were added. Standardized criteria that may be used to determine which patients receive a brain CT in resource-limited environments are described. Patients with an MTBI and negative brain CT result may be discharged from the emergency department if they have no other injuries or issues requiring admission. Patients taking warfarin who present with an MTBI should have their international normalized ratio (INR) level determined, and those with supratherapeutic INR values should be admitted for observation. Deficits in cognition and memory usually resolve within 1 month but may persist for longer periods in 20% to 40% of cases. Routine use of magnetic resonance imaging, positron emission tomography, nuclear magnetic resonance, or biochemical markers for the clinical management of MTBI is not supported at the present time. (J Trauma Acute Care Surg. 2012;73: S307-S314. Copyright (c) 2012 by Lippincott Williams & Wilkins)	[Barbosa, Ronald R.] Legacy Emanuel Hosp & Hlth Ctr, Portland, OR USA; [Watters, Jennifer M.; Rowell, Susan E.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Jawa, Randeep] Nebraska Med Ctr, Dept Surg, Omaha, NE USA; [Knight, Jennifer C.; Bardes, James M.] W Virginia Univ, Div Acute Care Surg, Dept Surg, Sch Med, Morgantown, WV 26506 USA; [Kerwin, Andrew J.] Univ Florida, Coll Med, Dept Surg, Jacksonville, FL USA; [Winston, Eleanor S.] Baystate Med Ctr, Dept Surg, Div Trauma Crit Care & Emergency Surg Serv, Springfield, MA 01107 USA; [Barraco, Robert D.] Lehigh Valley Hlth Network, Dept Surg, Allentown, PA USA; [Tucker, Brian] Univ Kentucky, Dept Surg, Lexington, KY USA	Barbosa, RR (corresponding author), Legacy Emanuel Hosp, 2801 N Gantenbein,MOB 130, Portland, OR 97227 USA.	Rbarbosa91@yahoo.com	Rowell, Susan/S-7480-2019	Bardes, James/0000-0002-9361-6263			af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KA, 2009, ARCH PHYS MED REHAB, V90, pS52, DOI 10.1016/j.apmr.2009.05.019; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Committee on Trauma-American College of Surgeons, 2008, ATLS ADV TRAUM LIF S; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Crowe L, 2010, ARCH DIS CHILD, V95, P1017, DOI 10.1136/adc.2009.174854; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Dutton RP, 2011, J TRAUMA, V70, P554, DOI 10.1097/TA.0b013e31820d1062; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Fiedler ER, 2001, ASSESSMENT HEAD INJU; Fisk GD, 1998, BRAIN INJURY, V12, P683; Gamache PL, 2011, BRAIN INJURY, V25, P416, DOI 10.3109/02699052.2011.558039; Gerberding JL, 2003, C MILD TRAUM BRAIN I; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guzel A, 2010, AM J EMERG MED, V28, P399, DOI 10.1016/j.ajem.2008.12.025; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holmes JF, 2011, ANN EMERG MED, V58, P315, DOI 10.1016/j.annemergmed.2011.03.060; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lange RT, 2010, J TRAUMA, V68, P1065, DOI 10.1097/TA.0b013e3181bb9890; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Lundqvist A, 2007, BRAIN INJURY, V21, P1109, DOI 10.1080/02699050701651660; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Management of Concussion/mTBI Working Group, 2016, VA DOD CLIN PRACT GU; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Podell K, 2010, PSYCHIAT CLIN N AM, V33, P855, DOI 10.1016/j.psc.2010.08.003; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Preece MHW, 2011, J NEUROL NEUROSUR PS, V82, P447, DOI 10.1136/jnnp.2010.215228; Preece MHW, 2010, NEUROPSYCHOLOGY, V24, P493, DOI 10.1037/a0018903; Riggio S, 2009, MT SINAI J MED, V76, P163, DOI 10.1002/msj.20097; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; Sherer M, 2010, J HEAD TRAUMA REHAB, V25, P92, DOI 10.1097/HTR.0b013e3181c9d887; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; World Health Organization (WHO), 2008, ICD 10 INT STAT CLAS; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578	80	46	47	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2012	73			4			S307	S314		10.1097/TA.0b013e3182701885			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	043VO	WOS:000311578300006	23114486	Bronze			2021-06-18	
J	Geiling, J; Rosen, JM; Edwards, RD				Geiling, James; Rosen, Joseph M.; Edwards, Ryan D.			Medical Costs of War in 2035: Long-Term Care Challenges for Veterans of Iraq and Afghanistan	MILITARY MEDICINE			English	Article								War-related medical costs for U.S. veterans of Iraq and Afghanistan may be enormous because of differences between these wars and previous conflicts: (1) Many veterans survive injuries that would have killed them in past wars, and (2) improvised explosive device attacks have caused "polytraumatic" injuries (multiple amputations; brain injury; severe facial trauma or blindness) that require decades of costly rehabilitation. In 2035, today's veterans will be middle-aged, with health issues like those seen in aging Vietnam veterans, complicated by comorbidities of posttraumatic stress disorder, traumatic brain injury, and polytrauma. This article cites emerging knowledge about best practices that have demonstrated cost-effectiveness in mitigating the medical costs of war. We propose that clinicians employ early interventions (trauma care, physical therapy, early post-traumatic stress disorder diagnosis) and preventive health programs (smoking cessation, alcohol-abuse counseling, weight control, stress reduction) to treat primary medical conditions now so that we can avoid treating costly secondary and tertiary complications in 2035. (We should help an amputee reduce his cholesterol and maintain his weight at age 30, rather than treating his heart disease or diabetes at age 50.) Appropriate early interventions for primary illness should preserve veterans' functional status, ensure quality clinical care, and reduce the potentially enormous cost burden of their future health care.	[Geiling, James; Rosen, Joseph M.] Geisel Sch Med Dartmouth, Hanover, NH 03755 USA; [Geiling, James; Rosen, Joseph M.] VA Med Ctr, White River Jct, VT 05009 USA; [Rosen, Joseph M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Edwards, Ryan D.] CUNY, Queens Coll, Dept Econ, New York, NY 10016 USA; [Edwards, Ryan D.] Natl Bur Econ Res, Fac Res Fellow Hlth Econ, Cambridge, MA 02138 USA	Geiling, J (corresponding author), Geisel Sch Med Dartmouth, One Rope Ferry Rd, Hanover, NH 03755 USA.						[Anonymous], GULF WAR HLTH, V7; [Anonymous], 2008, MILITARY HEADLINES D; Barrett DH, 2002, PSYCHOSOMATICS, V43, P195, DOI 10.1176/appi.psy.43.3.195; Basu S, 2010, US MED MAGAZINE; Beckham JC, 2004, ADDICT BEHAV, V29, P1579, DOI 10.1016/j.addbeh.2004.02.036; BECKHAM JC, 1995, J TRAUMA STRESS, V8, P461, DOI 10.1007/BF02102970; Bilmes L, 2010, VIDEO INFORMATION; Bilmes L, 2007, KENNEDY SCH GOVT FAC; Boyko EJ, 2010, DIABETES CARE, V33, P1771, DOI 10.2337/dc10-0296; Brown D., 2011, WASHINGTON POST; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Campbell P, 2012, J HOPK APPL PHYS LAB; Carter-Visscher R, 2010, J TRAUMA STRESS, V23, P78, DOI 10.1002/jts.20481; Chan D, 2009, PSYCHIAT SERV, V60, P1612, DOI 10.1176/ps.2009.60.12.1612; Congressional Budget Office (CBO), 2010, POT COSTS VET HLTH C; Congressional Research Service (CRS), 2010, AM WAR MIL OP CAS LI; Connelly E, 2011, ARMY TIMES; David D, 2004, PSYCHIAT SERV, V55, P82, DOI 10.1176/appi.ps.55.1.82; Department of Defense Task Force on Mental Health, 2007, ACH VIS DEF MENT HLT; Donnelly J, MORE TROOPS LOST SUI; Epstein RA, 2010, J REHABIL RES DEV, V47, P373, DOI 10.1682/JRRD.2009.03.0023; Fineout G, 2012, MARINE CORPS TIMES; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Frayne SM, 2004, ARCH INTERN MED, V164, P1306, DOI 10.1001/archinte.164.12.1306; Gasidn TA, 2009, BUILDING MAINTAINING; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Gawande A, 2007, BETTER SURGEON NOTES, P51; Gray GC, 2002, MIL MED, V167, P483; Grotto J, 2010, CHICAGO TRIBUNE; Hananel S, 2012, AIR FORCE TIMES; Hefling K, 2011, ARMY TIMES; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Hoffman M, 2011, ARM TIM; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Institute of Medicine (TOM), 2010, I MED IOM REP RET HO; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jakupcak M, 2008, J NERV MENT DIS, V196, P425, DOI 10.1097/NMD.0b013e31817108ed; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Jervis S, 2012, ARMED FORCES ALLOWAN; Jowers K, 2012, AIR FORCE TIMES; Jowers K, 2011, ARMY TIMES; Kahende JW, 2009, INT J ENV RES PUB HE, V6, P51, DOI 10.3390/ijerph6010051; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Kilmer B, 2011, PSYCHOL TRAUMA-US, V3, P201, DOI 10.1037/a0020592; Kime P, 2012, AIR FORCE TIMES; Kime P, 2012, NAVY TIMES; Kix P, 2010, BOSTON MAGAZINE, P63; Koop CE, 2008, IEEE ENG MED BIOL, V27, P29, DOI 10.1109/MEMB.2008.929888; Laraway LA, 2009, NAVY RESILIENCE INIT; Lehnert T, 2012, OBES REV, V13, P537, DOI 10.1111/j.1467-789X.2011.00980.x; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; Mary Free Bed Rehabilitation Hospital, WOUNDED WARR TRAUM B; Matarrese A, 2012, NAVY TIMES; McFall M, 2005, AM J PSYCHIAT, V162, P1311, DOI 10.1176/appi.ajp.162.7.1311; Melcer T, 2010, MIL MED, V175, P147, DOI 10.7205/MILMED-D-09-00120; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Nagorski T, 2010, ABC NEWS POLITI 0607; Nelson KM, 2006, J GEN INTERN MED, V21, P915, DOI 10.1007/BF02743137; Paul F, 2008, J ADV NURS, V62, P276, DOI 10.1111/j.1365-2648.2007.04568.x; Popova S, 2011, INT J ENV RES PUB HE, V8, P3351, DOI 10.3390/ijerph8083351; Qureshi SU, 2010, J AM GERIATR SOC, V58, P1627, DOI 10.1111/j.1532-5415.2010.02977.x; Reynolds M, 2005, DRUG ALCOHOL DEPEN, V77, P251, DOI 10.1016/j.drugalcdep.2004.08.017; Robbins CB, 2009, MIL MED, V174, P588, DOI 10.7205/MILMED-D-00-0608; Saha S, 2010, INT J ENV RES PUB HE, V7, P3150, DOI 10.3390/ijerph7083150; Satava RM, PEACEKEEPING OPERATI; Schnurr PP, 2000, HEALTH PSYCHOL, V19, P91, DOI 10.1037/0278-6133.19.1.91; Schnurr PP, 2004, TRAUMA HLTH PHYS HLT; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Shane III L, 2010, VA HOPES TO ELIMINAT; Smith B, 2008, AM J PREV MED, V35, P539, DOI 10.1016/j.amepre.2008.07.009; Statistical Information Analysis Division (SIAD) Department of Defense (DoD), PERS PROC STAT PERS; Steele D, 2010, ARMY MAGAZINE, P39; Stiglitz J.E., 2008, 3 TRILLION DOLLAR WA; Stinner DJ, 2010, J TRAUMA, V68, P1476, DOI 10.1097/TA.0b013e3181bb9a6c; Szabo L, 2010, ARMY TIMES; Tanielian T, 2008, RAND REPORT; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Trief PM, 2006, J BEHAV MED, V29, P411, DOI 10.1007/s10865-006-9067-2; U.S. Department of Defense, MILL COH STUD; US Department of Veterans Affairs (VA), 2012, 2012 MONDAY MORNING; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vieweg W Victor R, 2006, Prim Care Companion J Clin Psychiatry, V8, P25; Weaver FM, 2007, AM J PHYS MED REHAB, V86, P22, DOI 10.1097/PHM.0b013e31802b8937; Xydakis MS, 2008, NEW ENGL J MED, V358, P2177, DOI 10.1056/NEJMc086083; Zoroya G, 2011, ARMY TIMES; Zoroya G, 2007, US TODAY, p8a; Zoroya G, US TODAY	88	46	47	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	NOV	2012	177	11					1235	1244		10.7205/MILMED-D-12-00031			10	Medicine, General & Internal	General & Internal Medicine	V33OF	WOS:000209027400002	23198496	Bronze			2021-06-18	
J	Huang, YY; Gupta, A; Vecchio, D; de Arce, VJB; Huang, SF; Xuan, WJ; Hamblin, MR				Huang, Ying-Ying; Gupta, Asheesh; Vecchio, Daniela; de Arce, Vida J. Bil; Huang, Shih-Fong; Xuan, Weijun; Hamblin, Michael R.			Transcranial low level laser (light) therapy for traumatic brain injury	JOURNAL OF BIOPHOTONICS			English	Article						Low level laser therapy; photobiomodulation; NIR laser; traumatic brain injury; stroke; mouse models; neurogenesis; clinical trials	TERM NEUROLOGICAL DEFICITS; ACUTE ISCHEMIC-STROKE; CYTOCHROME-C-OXIDASE; NEAR-INFRARED LIGHT; NITRIC-OXIDE; EMBOLIC STROKES; UNITED-STATES; IR RADIATION; IRRADIATION; RATS	We review the use of transcranial low-level laser (light) therapy (LLLT) as a possible treatment for traumatic-brain injury (TBI). The basic mechanisms of LLLT at the cellular and molecular level and its effects on the brain are outlined. Many interacting processes may contribute to the beneficial effects in TBI including neuroprotection, reduction of inflammation and stimulation of neurogenesis. Animal studies and clinical trials of transcranial-LLLT for ischemic stroke are summarized. Several laboratories have shown that LLLT is effective in increasing neurological performance and memory and learning in mouse models of TBI. There have been case report papers that show beneficial effects of transcranial-LLLT in a total of three patients with chronic TBI. Our laboratory has conducted three studies on LLLT and TBI in mice. One looked at pulsed-vs-continuous wave laser-irradiation and found 10 Hz to be superior. The second [GRAPHICS] looked at four different laser-wavelengths (660, 730, 810, and 980 nm); only 660 and 810 nm were effective. The last looked at different treatment repetition regimens (1, 3 and 14-daily laser-treatments).	[Huang, Ying-Ying; Gupta, Asheesh; Vecchio, Daniela; de Arce, Vida J. Bil; Huang, Shih-Fong; Xuan, Weijun; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Huang, Ying-Ying; Gupta, Asheesh; Vecchio, Daniela; Huang, Shih-Fong; Xuan, Weijun; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Gupta, Asheesh] Def Inst Physiol & Allied Sci, Delhi 110054, India; [Huang, Shih-Fong] Taipei Vet Gen Hosp, Taipei 112, Taiwan; [Xuan, Weijun] Chinese Med Univ Guangxi, Dept Otolaryngol, Nanning, Peoples R China; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR414,40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019; Huang, Ying-ying/G-3153-2011; Gupta, Asheesh/M-1076-2019; Huang, yingying/J-7329-2012	Hamblin, Michael R/0000-0001-6431-4605; Huang, Ying-ying/0000-0003-3066-6981; Huang, yingying/0000-0002-4038-0277	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific Research Military Photomedicine Program [FA9550-11-1-0331]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	Supported by NIH grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research Military Photomedicine Program (FA9550-11-1-0331).	Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Antunes F, 2004, P NATL ACAD SCI USA, V101, P16774, DOI 10.1073/pnas.0405368101; Bossini PS, 2009, LASER MED SCI, V24, P209, DOI 10.1007/s10103-008-0551-5; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CAPALDI RA, 1983, BIOCHIM BIOPHYS ACTA, V726, P135, DOI 10.1016/0304-4173(83)90003-4; Chen ACH, 2011, PHOTOMED LASER SURG, V29, P383, DOI 10.1089/pho.2010.2837; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; Coombe A R, 2001, Clin Orthod Res, V4, P3, DOI 10.1034/j.1600-0544.2001.040102.x; Corazza AV, 2007, PHOTOMED LASER SURG, V25, P102, DOI 10.1089/pho.2006.2011; Dai T, 2009, PHOTODIAGN PHOTODYN, V6, P170, DOI 10.1016/j.pdpdt.2009.10.008; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Garavello I, 2004, HISTOL HISTOPATHOL, V19, P43, DOI 10.14670/HH-19.43; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hemvani N, 2005, PHOTOMED LASER SURG, V23, P571, DOI 10.1089/pho.2005.23.571; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2005, LASER SURG MED, V36, P307, DOI 10.1002/lsm.20148; KARU TI, 1995, DOKL AKAD NAUK+, V342, P693; KARU TI, 1987, IEEE J QUANTUM ELECT, V23, P1703, DOI 10.1109/JQE.1987.1073236; Khuman J., 2011, J NEUROTRAUMA; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Leung MCP, 2002, LASER SURG MED, V31, P283, DOI 10.1002/lsm.10096; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Lohr NL, 2009, J MOL CELL CARDIOL, V47, P256, DOI 10.1016/j.yjmcc.2009.03.009; Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3; Malinovskaya SL, 2008, B EXP BIOL MED+, V145, P573, DOI 10.1007/s10517-008-0142-2; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mirsky N, 2002, ANTIOXID REDOX SIGN, V4, P785, DOI 10.1089/152308602760598936; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; Mungrue IN, 2003, CIRC RES, V93, pE74, DOI 10.1161/01.RES.0000095452.77140.7A; Naeser M. A., 2010, PHOTOMED LASER SURG; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Oron U, 2001, CIRCULATION, V103, P296; Pearson-Fuhrhop KM, 2009, TOP STROKE REHABIL, V16, P282, DOI 10.1310/tsr1604-282; Rocha AM, 2009, PHOTOMED LASER SURG, V27, P303, DOI 10.1089/pho.2008.2277; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sushko B S, 2007, Fiziol Zh, V53, P51; Sutherland JC, 2002, PHOTOCHEM PHOTOBIOL, V76, P164, DOI 10.1562/0031-8655(2002)076<0164:BEOPL>2.0.CO;2; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Yaakobi T, 2001, J APPL PHYSIOL, V90, P2411; Zhang L, 2000, J NEUROL SCI, V174, P141, DOI 10.1016/S0022-510X(00)00268-9; Zhang R, 2009, J MOL CELL CARDIOL, V46, P4, DOI 10.1016/j.yjmcc.2008.09.707; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	64	46	47	2	28	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1864-063X	1864-0648		J BIOPHOTONICS	J. Biophotonics	NOV	2012	5	11-12			SI		827	837		10.1002/jbio.201200077			11	Biochemical Research Methods; Biophysics; Optics	Biochemistry & Molecular Biology; Biophysics; Optics	033MS	WOS:000310801800006	22807422	Green Accepted			2021-06-18	
J	Jones, JM; Williams, WH; Jetten, J; Haslam, SA; Harris, A; Gleibs, IH				Jones, Janelle M.; Williams, W. Huw; Jetten, Jolanda; Haslam, S. Alexander; Harris, Adrian; Gleibs, Ilka H.			The role of psychological symptoms and social group memberships in the development of post-traumatic stress after traumatic injury	BRITISH JOURNAL OF HEALTH PSYCHOLOGY			English	Article							FORM HEALTH SURVEY; BRAIN-INJURY; DISORDER; IDENTITY; PREDICTORS; SUPPORT; RELIABILITY; INSTRUMENT; CONTINUITY; RESOURCES	Objectives. The costs associated with traumatic injury are often exacerbated by the development of post-traumatic stress symptoms. However, it is unclear what decreases the development of post-traumatic symptoms over time. The aim of the present research was to examine the role of psychological symptoms and social group memberships in reducing the development of post-traumatic stress symptoms after orthopaedic injuries (OIs) and acquired brain injuries (ABIs). Design and Methods. A longitudinal prospective study assessed self-reported general health symptoms, social group memberships, and post-traumatic stress symptoms among participants with mild or moderate ABI (n= 62) or upper limb OI (n= 31) at 2 weeks (T1) and 3 months (T2) after injury. Results. Hierarchical regressions revealed that having fewer T1 general health symptoms predicted lower levels of T2 post-traumatic stress symptoms after OI but forming more new group memberships at T1 predicted lower levels of T2 post-traumatic stress symptoms after ABI. Conclusion. A focus on acquiring group memberships may be particularly important in reducing the development of post-traumatic stress symptoms after injuries, such as ABI, which result in long-term life changes.	[Jones, Janelle M.] Simon Fraser Univ, Dept Psychol, Burnaby, BC V5A 1S6, Canada; [Williams, W. Huw; Haslam, S. Alexander] Univ Exeter, Sch Psychol, Exeter EX4 4QJ, Devon, England; [Jetten, Jolanda] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia; [Harris, Adrian] Royal Devon & Exeter NHS Fdn Trust, Dept Emergency Med, Exeter, Devon, England; [Gleibs, Ilka H.] Univ Surrey, Sch Psychol, Guildford GU2 5XH, Surrey, England	Jones, JM (corresponding author), Simon Fraser Univ, Dept Psychol, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	janellej@sfu.ca	Gleibs, Ilka/T-4655-2019; Haslam, Alex/AAA-2512-2019; Jetten, Jolanda/H-3285-2014	Haslam, Alex/0000-0001-9523-7921; Jetten, Jolanda/0000-0002-7588-5355; Gleibs, Ilka/0000-0002-9913-250X; Jones, Janelle/0000-0002-0910-2404; williams, huw/0000-0003-0670-2620			Bluck S., 2008, SELF CONTINUITY INDI, P55, DOI DOI 10.4324/9780203888513; Boden-Albala B, 2005, NEUROLOGY, V64, P1888, DOI 10.1212/01.WNL.0000163510.79351.AF; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brewin CR, 2002, BRIT J PSYCHIAT, V181, P158, DOI 10.1192/bjp.181.2.158; Clapp JD, 2009, BEHAV RES THER, V47, P237, DOI 10.1016/j.brat.2008.12.006; Cohen S, 2004, AM PSYCHOL, V59, P676, DOI 10.1037/0003-066X.59.8.676; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Davison KP, 2000, AM PSYCHOL, V55, P205, DOI 10.1037/0003-066X.55.2.205; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Ertel KA, 2008, AM J PUBLIC HEALTH, V98, P1215, DOI 10.2105/AJPH.2007.113654; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; Gleibs IH, 2011, PSYCHOL HEALTH, V26, P1361, DOI 10.1080/08870446.2010.529140; Gleibs IH, 2011, AGING MENT HEALTH, V15, P456, DOI 10.1080/13607863.2010.536137; Goldberg D., 1992, GEN HLTH QUESTIONNAI; Haslam C., 2011, SOCIAL CURE IDENTITY, P319; Haslam C, 2008, NEUROPSYCHOL REHABIL, V18, P671, DOI 10.1080/09602010701643449; Haslam SA, 2009, APPL PSYCHOL-INT REV, V58, P1, DOI 10.1111/j.1464-0597.2008.00379.x; Haslam SA, 2005, BRIT J SOC PSYCHOL, V44, P355, DOI 10.1348/014466605X37468; Hobfoll S. E., 1991, ANXIETY RES, V4, P187, DOI [10.1080/08917779108248773, DOI 10.1080/08917779108248773]; HOBFOLL SE, 1989, AM PSYCHOL, V44, P513, DOI 10.1037/0003-066X.44.3.513; Hobfoll SE, 2002, REV GEN PSYCHOL, V6, P307, DOI 10.1037//1089-2680.6.4.307; Iyer A, 2011, J PERS SOC PSYCHOL, V101, P94, DOI 10.1037/a0022496; Iyer A, 2009, BRIT J SOC PSYCHOL, V48, P707, DOI 10.1348/014466608X397628; Jetten J., 2011, SOCIAL CURE IDENTITY; Jetten J., 2009, SCI AM MIND, V20, P26, DOI DOI 10.1038/SCIENTIFICAMERICANMIND0909-26; Jetten J, 2010, J CLIN EXP NEUROPSYC, V32, P408, DOI 10.1080/13803390903140603; Johnson R, 2009, STATE INJURY INDICAT; Jones JM, 2011, SOC PSYCHOL PERS SCI, V2, P239, DOI 10.1177/1948550610386806; Jones JM, 2011, PSYCHOL HEALTH, V26, P353, DOI 10.1080/08870440903440699; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; Mellman TA, 2001, DEPRESS ANXIETY, V14, P226, DOI 10.1002/da.1071; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; Nielsen MS, 2003, REHABIL PSYCHOL, V48, P289, DOI 10.1037/0090-5550.48.4.289; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Peden M, 2002, INJURY CHART BOOK GR; Polinder S, 2004, SURVEILLANCE BASED A; Putnam R.D., 2000, BOWLING ALONE COLLAP; Sani F, 2008, EUR J SOC PSYCHOL, V38, P365, DOI 10.1002/ejsp.461; Starr AJ, 2004, J BONE JOINT SURG AM, V86A, P1115, DOI 10.2106/00004623-200406000-00001; Stinson DA, 2008, J PERS SOC PSYCHOL, V94, P412, DOI 10.1037/0022-3514.94.3.412; Swaab, 2005, EUROPEAN REV SOCIAL, V16, P1, DOI [10.1080/10463280440000062, DOI 10.1080/10463280440000062]; Tajfel Henri, 1986, PSYCHOL INTERGROUP R, P7, DOI DOI 10.4324/9780203505984-16; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; World Health Organization (WHO), 2008, GLOB BURD DIS 2004 U; Yehuda R, 2002, NEW ENGL J MED, V346, P108, DOI 10.1056/NEJMra012941	50	46	46	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1359-107X	2044-8287		BRIT J HEALTH PSYCH	Br. J. Health Psychol.	NOV	2012	17		4				798	811		10.1111/j.2044-8287.2012.02074.x			14	Psychology, Clinical	Psychology	000GG	WOS:000308373900010	22524293	Green Accepted			2021-06-18	
J	Kleber, C; Giesecke, MT; Tsokos, M; Haas, NP; Schaser, KD; Stefan, P; Buschmann, CT				Kleber, Christian; Giesecke, Moritz T.; Tsokos, Michael; Haas, Norbert P.; Schaser, Klaus D.; Stefan, Poloczek; Buschmann, Claas T.			Overall Distribution of Trauma-related Deaths in Berlin 2010: Advancement or Stagnation of German Trauma Management?	WORLD JOURNAL OF SURGERY			English	Article							EPIDEMIOLOGY; CARE; MORTALITY	Trauma is the leading cause of death among children, adolescents, and young adults. The latest data from the German Trauma Registry reveals a constant decrease in trauma mortality, indicating that 11.6 % of all trauma patients in 2010 died in hospital. Notably, trauma casualties dying before admission to hospital have not been systematically surveyed and analyzed in Germany. We conducted a prospective observational study of all traumatic deaths in Berlin, recording demographic data, trauma mechanisms, and causes/localization and time of death after trauma. Inclusion criteria were all deaths following trauma from 1 January 2010 to 31 December 2010. A total of 440 trauma fatalities were included in this study, with a mortality rate of 13/100,000 inhabitants; 78.6 % were blunt injuries, and fall from a height > 3 m (32.7 %) was the leading trauma mechanism. 32.5 % died immediately, 23.9 % died within 60 min, 7.7 % died within 1-4 h, 16.8 % died within 4-48 h, 11.1 % died < 1 week later, and 8 % died > 1 week after trauma. The predominant causes of death were polytrauma (45.7 %), sTBI (38 %), exsanguination (9.5 %), and thoracic trauma (3.2 %). Death occurred on-scene in 58.7 % of these cases, in the intensive care unit in 33.2 %, and in 2.7 % of the cases, in the emergency department, the operating room, and the ward, respectively. Polytrauma is the leading cause of death, followed by severe traumatic brain injury (sTBI). The temporal analysis of traumatic death indicates a shift from the classic "trimodal" distribution to a new "bimodal" distribution. Besides advances in road safety, prevention programs and improvement in trauma management-especially the pre-hospital phase-have the potential to significantly improve the survival rate after trauma.	[Kleber, Christian; Giesecke, Moritz T.; Haas, Norbert P.; Schaser, Klaus D.] Charite, Campus Virchow Klinikum, Ctr Musculoskeletal Surg, AG Polytrauma, D-13353 Berlin, Germany; [Tsokos, Michael; Buschmann, Claas T.] Charite, Inst Legal Med & Forens Sci, D-10559 Berlin, Germany; [Stefan, Poloczek] Berlin Fire Dept, D-10179 Berlin, Germany	Kleber, C (corresponding author), Charite, Campus Virchow Klinikum, Ctr Musculoskeletal Surg, AG Polytrauma, Augustenburger Pl 1, D-13353 Berlin, Germany.	christian.kleber@charite.de			DFG through the Berlin-Brandenburg School for Regenerative Therapies [GSC 203]	Contributions were made possible by DFG funding through the Berlin-Brandenburg School for Regenerative Therapies GSC 203.	BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; Buschmann CT, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-55; Chiara O, 2002, INJURY, V33, P553, DOI 10.1016/S0020-1383(02)00123-7; DALY KE, 1992, INJURY, V23, P393, DOI 10.1016/0020-1383(92)90015-K; Demetriades D, 1998, J AM COLL SURGEONS, V187, P373, DOI 10.1016/S1072-7515(98)00209-9; Evans JA, 2010, WORLD J SURG, V34, P158, DOI 10.1007/s00268-009-0266-1; HAAS NP, 1995, CLIN ORTHOP RELAT R, P25; Kleber C, 2012, UNFALLCHIRURG; Kleber C, 2011, LANGENBECK ARCH SURG, V396, P429, DOI 10.1007/s00423-011-0765-z; MacLeod JBA, 2007, AM J SURG, V193, P195, DOI 10.1016/j.amjsurg.2006.09.010; Maio RF, 1996, J TRAUMA, V41, P83, DOI 10.1097/00005373-199607000-00013; Masella CA, 2008, J TRAUMA, V65, P653, DOI 10.1097/TA.0b013e3181802077; Mock CN, 1998, J TRAUMA, V44, P804, DOI 10.1097/00005373-199805000-00011; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Potenza BM, 2004, J TRAUMA, V56, P68, DOI 10.1097/01.TA.0000101490.32972.9F; Probst C, 2009, INJURY, V40, P77, DOI 10.1016/j.injury.2008.10.004; Probst C, 2009, J TRAUMA, V66, P1212, DOI 10.1097/TA.0b013e318197b97c; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SPAIN DM, 1984, AM J PUBLIC HEALTH, V74, P1122, DOI 10.2105/AJPH.74.10.1122; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28	20	46	48	0	6	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	SEP	2012	36	9					2125	2130		10.1007/s00268-012-1650-9			6	Surgery	Surgery	987DP	WOS:000307397000021	22610265				2021-06-18	
J	Magdesian, MH; Sanchez, FS; Lopez, M; Thostrup, P; Durisic, N; Belkaid, W; Liazoghli, D; Grutter, P; Colman, DR				Magdesian, Margaret H.; Sanchez, Fernando S.; Lopez, Monserratt; Thostrup, Peter; Durisic, Nela; Belkaid, Wiam; Liazoghli, Dalinda; Gruetter, Peter; Colman, David R.			Atomic Force Microscopy Reveals Important Differences in Axonal Resistance to Injury	BIOPHYSICAL JOURNAL			English	Article							EXPERIMENTAL NERVE COMPRESSION; TRAUMATIC BRAIN-INJURY; STRETCH-INJURY; CELL MECHANICS; DEGENERATION; NEUROFILAMENTS; MICROTUBULES; MECHANOTRANSDUCTION; PRESSURE; CULTURE	Axonal degeneration after traumatic brain injury and nerve compression is considered a common underlying cause of temporary as well as permanent disability. Because a proper functioning of neural network requires phase coherence of all components, even subtle changes in circuitry may lead to network failure. However, it is still not possible to determine which axons will recover or degenerate after injury. Several groups have studied the pressure threshold for axonal injury within a nerve, but difficulty accessing the injured region; insufficient imaging methods and the extremely small dimensions involved have prevented the evaluation of the response of individual axons to injury. We combined microfluidics with atomic force microscopy and in vivo imaging to estimate the threshold force required to 1), uncouple axonal transport without impairing axonal survival, and 2), compromise axonal survival in both individual and bundled axons. We found that rat hippocampal axons completely recover axonal transport with no detectable axonal loss when compressed with pressures up to 65 +/- 30 Pa for 10 min, while dorsal root ganglia axons can resist to pressures up to 540 +/- 220 Pa. We investigated the reasons for the differential susceptibility of hippocampal and DRG axons to mechanical injury and estimated the elasticity of live axons. We found that dorsal root ganglia axons have a 20% lower elastic modulus than hippocampal axons. Our results emphasize the importance of the integrity of the axonal cytoskeleton in deciding the axonal fate after damage and open up new avenues to improve injury diagnosis and to identify ways to protect axons.	[Magdesian, Margaret H.; Belkaid, Wiam; Liazoghli, Dalinda; Colman, David R.] McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada; [Magdesian, Margaret H.; Sanchez, Fernando S.; Thostrup, Peter; Belkaid, Wiam; Liazoghli, Dalinda; Gruetter, Peter; Colman, David R.] McGill Univ, Program NeuroEngn, Montreal, PQ, Canada; [Magdesian, Margaret H.] Univ Fed Rio de Janeiro, Inst Med Biochem, Rio De Janeiro, Brazil; [Sanchez, Fernando S.; Lopez, Monserratt; Thostrup, Peter; Durisic, Nela; Gruetter, Peter] McGill Univ, Dept Phys, Montreal, PQ, Canada	Magdesian, MH (corresponding author), McGill Univ, Montreal Neurol Inst & Hosp, Montreal, PQ, Canada.	margaret.magdesian@mcgill.ca	Grutter, Peter/AAQ-2501-2020	Grutter, Peter/0000-0003-1719-8239; Durisic, Nela/0000-0002-7668-1039	MNI-NeuroEngineering Fund; Natural Sciences and Engineering Research Council of Canada, Canadian Institutes of Health ResearchNatural Sciences and Engineering Research Council of Canada (NSERC)Canadian Institutes of Health Research (CIHR); Canadian Institute for Advanced ResearchCanadian Institute for Advanced Research (CIFAR)	This work was supported by grants from the MNI-NeuroEngineering Fund (to D.R.C.) and from the Natural Sciences and Engineering Research Council of Canada, Canadian Institutes of Health Research, and Canadian Institute for Advanced Research (to P.G.). M.H.M. was an International Brain Research Organization Research Fellow. We thank Dr. Patricia Yam. Dr. Timothy Kennedy. Dr. Ben Barres, Jennifer Goldman, Dr. Ajit Dhaunchak. and Dr. Liliana Pedraza for helpful comments and discussion.	Abr`amoff M.D., 2005, BIOPHOTONICS INT, V11, P36, DOI [10.1117/1.3589100, DOI 10.1117/1.3589100]; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Andersen SSL, 2009, PROG NEUROBIOL, V88, P104, DOI 10.1016/j.pneurobio.2009.03.002; BANKER G, 1988, NATURE, V336, P185, DOI 10.1038/336185a0; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Bausch AR, 2006, NAT PHYS, V2, P231, DOI 10.1038/nphys260; Beirowski B, 2010, J NEUROPATH EXP NEUR, V69, P455, DOI 10.1097/NEN.0b013e3181da84db; Bocquet A, 2009, J NEUROSCI, V29, P11043, DOI 10.1523/JNEUROSCI.1924-09.2009; Chien S, 2007, AM J PHYSIOL-HEART C, V292, pH1209, DOI 10.1152/ajpheart.01047.2006; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Costa KD, 2006, J BIOMECH ENG-T ASME, V128, P176, DOI 10.1115/1.2165690; DAHLIN LB, 1984, EXP NEUROL, V84, P29, DOI 10.1016/0014-4886(84)90003-7; Geiger B, 2002, CELL, V110, P139, DOI 10.1016/S0092-8674(02)00831-0; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Griesbauer J, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.198103; Heimburg T, 2005, P NATL ACAD SCI USA, V102, P9790, DOI 10.1073/pnas.0503823102; Hoffman BD, 2009, ANNU REV BIOMED ENG, V11, P259, DOI 10.1146/annurev.bioeng.10.061807.160511; Janmey PA, 2004, TRENDS BIOCHEM SCI, V29, P364, DOI 10.1016/j.tibs.2004.05.003; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kasza KE, 2007, CURR OPIN CELL BIOL, V19, P101, DOI 10.1016/j.ceb.2006.12.002; Keir PJ, 2007, HUM FACTORS, V49, P88, DOI 10.1518/001872007779598127; Kilinc D, 2008, EXP NEUROL, V212, P422, DOI 10.1016/j.expneurol.2008.04.025; Kushkuley J, 2009, J CELL SCI, V122, P3579, DOI 10.1242/jcs.051318; Lucido AL, 2009, J NEUROSCI, V29, P12449, DOI 10.1523/JNEUROSCI.1381-09.2009; LUNDBORG G, 1983, J NEUROL NEUROSUR PS, V46, P1119, DOI 10.1136/jnnp.46.12.1119; Mahaffy RE, 2004, BIOPHYS J, V86, P1777, DOI 10.1016/S0006-3495(04)74245-9; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MORI H, 1979, CELL STRUCT FUNCT, V4, P163, DOI 10.1247/csf.4.163; OBLINGER MM, 1987, J NEUROSCI, V7, P453; Orr AW, 2006, DEV CELL, V10, P11, DOI 10.1016/j.devcel.2005.12.006; Park JW, 2006, NAT PROTOC, V1, P2128, DOI 10.1038/nprot.2006.316; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POWELL HC, 1986, LAB INVEST, V55, P91; Puttock M.J., 1969, 25 COMM SCI IND RES, P64; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Wagner OI, 2007, EXP CELL RES, V313, P2228, DOI 10.1016/j.yexcr.2007.04.025; Wang JT, 2012, J CELL BIOL, V196, P7, DOI 10.1083/jcb.201108111; WEISS P, 1948, J EXP ZOOL, V107, P315, DOI 10.1002/jez.1401070302; Witt A, 2000, GLIA, V29, P112, DOI 10.1002/(SICI)1098-1136(20000115)29:2<112::AID-GLIA3>3.0.CO;2-Z	44	46	46	0	25	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0006-3495			BIOPHYS J	Biophys. J.	AUG 8	2012	103	3					405	414		10.1016/j.bpj.2012.07.003			10	Biophysics	Biophysics	987OT	WOS:000307427700005	22947856	Green Published, Bronze			2021-06-18	
J	Walker, KR; Kang, EL; Whalen, MJ; Shen, Y; Tesco, G				Walker, Kendall R.; Kang, Eugene L.; Whalen, Michael J.; Shen, Yong; Tesco, Giuseppina			Depletion of GGA1 and GGA3 Mediates Postinjury Elevation of BACE1	JOURNAL OF NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE PATHOGENESIS; APP TRANSGENIC MICE; TRANSLATIONAL REGULATION; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; CLEAVING ENZYME-1	Traumatic brain injury (TBI) is one of the most robust environmental risk factors for Alzheimer's disease (AD). Compelling evidence is accumulating that a single event of TBI is associated with increased levels of A beta. However, the underlying molecular mechanisms remain unknown. We report here that the BACE1 interacting protein, GGA3, is depleted while BACE1 levels increase in the acute phase after injury (48 h) in a mouse model of TBI. We further demonstrated the role of GGA3 in the regulation of BACE1 in vivo by showing that BACE1 levels are increased in the brain of GGA3-null mice. We next found that head trauma potentiates BACE1 elevation in GGA3-null mice in the acute phase after TBI, and discovered that GGA1, a GGA3 homolog, is a novel caspase-3 substrate depleted at 48 h after TBI. Moreover, GGA1 silencing potentiates BACE1 elevation induced by GGA3 deletion in neurons in vitro, indicating that GGA1 and GGA3 synergistically regulate BACE1. Accordingly, we found that levels of both GGA1 and GGA3 are depleted while BACE1 levels are increased in a series of postmortem AD brains. Finally, we show that GGA3 haploinsufficiency results in sustained elevation of BACE1 and A beta levels while GGA1 levels are restored in the subacute phase (7 d) after injury. In conclusion, our data indicate that depletion of GGA1 and GGA3 engender a rapid and robust elevation of BACE1 in the acute phase after injury. However, the efficient disposal of the acutely accumulated BACE1 solely depends on GGA3 levels in the subacute phase of injury.	[Walker, Kendall R.; Kang, Eugene L.; Tesco, Giuseppina] Tufts Univ, Sch Med, Dept Neurosci, Alzheimers Dis Res Lab, Boston, MA 02111 USA; [Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Boston, MA 02129 USA; [Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02129 USA; [Shen, Yong] Roskamp Inst, CATSBD, Sarasota, FL 34243 USA	Tesco, G (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, Alzheimers Dis Res Lab, 136 Harrison Ave,St 328A, Boston, MA 02111 USA.	Giuseppina.Tesco@Tufts.edu			National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033016, 1R01AG025952]; Cure Alzheimer's Fund; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG025888, R01AG025952, R01AG033016, R01AG034155] Funding Source: NIH RePORTER	This work was supported by Award Number R01AG033016 (to G.T.) and 1R01AG025952 (to G.T.) from the National Institute on Aging, and a grant from Cure Alzheimer's Fund (to G.T.). We thank Dr. Rudy Tanzi for his useful comments in the preparation and editing of this manuscript.	Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI [10.1089/neu.2008.0765, 10.1089/neu.2008-0765]; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Boissonneault V, 2009, J BIOL CHEM, V284, P1971, DOI 10.1074/jbc.M807530200; Bourne KZ, 2007, J NEUROSCI RES, V85, P1194, DOI 10.1002/jnr.21252; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cho HJ, 2009, BIOCHEM BIOPH RES CO, V386, P175, DOI 10.1016/j.bbrc.2009.06.006; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Cole SL, 2008, J BIOL CHEM, V283, P29621, DOI 10.1074/jbc.R800015200; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; D'Amelio M, 2011, NAT NEUROSCI, V14, P69, DOI 10.1038/nn.2709; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; Faghihi MA, 2008, NAT MED, V14, P723, DOI 10.1038/nm1784; Frohlich S, 2011, IRISH J MED SCI, V180, P423, DOI 10.1007/s11845-011-0674-8; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; He XY, 2005, J BIOL CHEM, V280, P11696, DOI 10.1074/jbc.M411296200; Hebert SS, 2008, P NATL ACAD SCI USA, V105, P6415, DOI 10.1073/pnas.0710263105; Hirata-Fukae C, 2008, NEUROSCI LETT, V435, P186, DOI 10.1016/j.neulet.2008.02.032; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kang EL, 2010, J BIOL CHEM, V285, P24108, DOI 10.1074/jbc.M109.092742; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Koh YH, 2005, J BIOL CHEM, V280, P32499, DOI 10.1074/jbc.M506199200; Lammich S, 2004, EMBO REP, V5, P620, DOI 10.1038/sj.embor.7400166; LeBlanc Andrea C., 2005, Current Alzheimer Research, V2, P389, DOI 10.2174/156720505774330573; Lee EB, 2005, J CELL BIOL, V168, P291, DOI 10.1083/jcb.200407070; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200; Mihailovich M, 2007, NUCLEIC ACIDS RES, V35, P2975, DOI 10.1093/nar/gkm191; Ninan I, 2004, NEURON, V42, P129, DOI 10.1016/S0896-6273(04)00143-6; Nowak K, 2006, J NEUROCHEM, V96, P1696, DOI 10.1111/j.1471-4159.2006.03692.x; O'Connor T, 2008, NEURON, V60, P988, DOI 10.1016/j.neuron.2008.10.047; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Reitz C, 2011, NAT REV NEUROL, V7, P137, DOI 10.1038/nrneurol.2011.2; Rockenstein E, 2005, J BIOL CHEM, V280, P32957, DOI 10.1074/jbc.M507016200; Rogaeva E, 2007, NAT GENET, V39, P168, DOI 10.1038/ng1943; Rogers GW, 2004, P NATL ACAD SCI USA, V101, P2794, DOI 10.1073/pnas.0308576101; Rossner S, 2006, PROG NEUROBIOL, V79, P95, DOI 10.1016/j.pneurobio.2006.06.001; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; Sena-Esteves M, 2004, J VIROL METHODS, V122, P131, DOI 10.1016/j.jviromet.2004.08.017; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; Stryke D, 2003, NUCLEIC ACIDS RES, V31, P278, DOI 10.1093/nar/gkg064; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Tamagno E, 2005, J NEUROCHEM, V92, P628, DOI 10.1111/j.1471-4159.2004.02895.x; Tamagno E, 2003, NEUROBIOL DIS, V14, P291, DOI 10.1016/S0969-9961(03)00131-1; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Tesco G, 2003, J BIOL CHEM, V278, P46074, DOI 10.1074/jbc.M307809200; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Tonelli DD, 2004, NUCLEIC ACIDS RES, V32, P1808, DOI 10.1093/nar/gkh348; Tong Y, 2005, J NEURAL TRANSM, V112, P455, DOI 10.1007/s00702-004-0255-3; Tyler SJ, 2002, BIOCHEM BIOPH RES CO, V299, P373, DOI 10.1016/S0006-291X(02)02635-9; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vassar R, 2009, J NEUROSCI, V29, P12787, DOI 10.1523/JNEUROSCI.3657-09.2009; Velliquette RA, 2005, J NEUROSCI, V25, P10874, DOI 10.1523/JNEUROSCI.2350-05.2005; von Arnim CAF, 2006, J NEUROSCI, V26, P9913, DOI 10.1523/JNEUROSCI.2290-06.2006; Wahle T, 2005, MOL CELL NEUROSCI, V29, P453, DOI 10.1016/j.mcn.2005.03.014; Wahle T, 2006, J NEUROSCI, V26, P12838, DOI 10.1523/JNEUROSCI.1982-06.2006; Wang WX, 2008, J NEUROSCI, V28, P1213, DOI 10.1523/JNEUROSCI.5065-07.2008; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Wen Y, 2008, NEURON, V57, P680, DOI 10.1016/j.neuron.2008.02.024; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhou WH, 2006, MOL CELL BIOL, V26, P3353, DOI 10.1128/MCB.26.9.3353-3364.2006	77	46	48	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 25	2012	32	30					10423	10437		10.1523/JNEUROSCI.5491-11.2012			15	Neurosciences	Neurosciences & Neurology	983NF	WOS:000307125300030	22836275	Bronze, Green Published, Green Accepted			2021-06-18	
J	Jee, MK; Jung, JS; Im, YB; Jung, SJ; Kang, SK				Jee, Min Ki; Jung, Jin Sun; Im, Young Bin; Jung, Sung Jun; Kang, Soo Kyung			Silencing of miR20a Is Crucial for Ngn1-Mediated Neuroprotection in Injured Spinal Cord	HUMAN GENE THERAPY			English	Article							MICRORNA EXPRESSION; PRONEURAL GENES; MOUSE; DIFFERENTIATION; LINEAGES; BRAIN	MicroRNAs (miRNAs) compose a relatively new discipline in biomedical research, and many physiological processes in disease have been associated with changes in miRNA expression. Several studies report that miRNAs participate in biological processes such as the control of secondary injury in several disease models. Recently, we identified novel miRNAs that were abnormally up-regulated in a traumatic spinal cord injury (SCI). In the current study, we focused on miR20a, which causes continuing motor neuron degeneration when overexpressed in SCI lesions. Blocking miR20a in SCI animals led to neural cell survival and eventual neurogenesis with rescued expression of the key target gene, neurogenin 1 (Ngn1). Infusion of siNgn1 resulted in functional deficit in the hindlimbs caused by aggressive secondary injury and actively enhanced the inflammation involved in secondary injury progression. The events involving miR20a underlie motor neuron and myelin destruction and pathophysiology and ultimately block regeneration in injured spinal cords. Inhibition of miR20a expression effectively induced definitive motor neuron survival and neurogenesis, and SCI animals showed improved functional deficit. In this study, we showed that abnormal expression of miR20a induces secondary injury, which suggests that miR20a could be a potential target for therapeutic intervention following SCI.	[Jee, Min Ki; Jung, Jin Sun; Im, Young Bin; Kang, Soo Kyung] Seoul Natl Univ, Coll Vet Med, Dept Biotechnol, Lab Stem Cell Biol, Seoul 151742, South Korea; [Jung, Sung Jun] Han Yang Univ, Coll Med, Dept Physiol, Seoul 110710, South Korea	Kang, SK (corresponding author), Seoul Natl Univ, Coll Vet Med, Lab Stem Cell Biol, Dept Vet Biotechnol, Seoul, South Korea.	sookang@snu.ac.kr			21st Century Frontier/Stem Cell Research Committee [SC5110]; National Research Foundation of Korea (NRF)National Research Foundation of Korea; Korea Government (MEST)Ministry of Education, Science and Technology, Republic of KoreaKorean Government [2010-0020265]	This work was supported by the 21stCentury Frontier/Stem Cell Research Committee (SC5110) and was also supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MEST, 2010-0020265).	Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Bala S, 2009, WORLD J GASTROENTERO, V15, P5633, DOI 10.3748/wjg.15.5633; Beek CW, 2006, MECH DEVELOP, V123, P674, DOI 10.1016/j.mod.2006.07.001; Berninger B, 2007, J NEUROSCI, V27, P8654, DOI 10.1523/JNEUROSCI.1615-07.2007; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Bilen J, 2006, MOL CELL, V24, P157, DOI 10.1016/j.molcel.2006.07.030; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Chekulaeva M, 2009, CURR OPIN CELL BIOL, V21, P452, DOI 10.1016/j.ceb.2009.04.009; Chen J, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn387; Ivey KN, 2008, CELL STEM CELL, V2, P219, DOI 10.1016/j.stem.2008.01.016; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jang JH, 2012, ANTIOXID REDOX SIGN, V16, P95, DOI 10.1089/ars.2011.3975; Jee MK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009026; Jesus ABD, 2009, CELL CYCLE, V8, P394; Kang SK, 2006, PROTEOMICS, V6, P2797, DOI 10.1002/pmic.200500621; Kim BS, 2011, AGING CELL, V10, P277, DOI 10.1111/j.1474-9726.2011.00670.x; Kim EJ, 2011, J COMP NEUROL, V519, P1355, DOI 10.1002/cne.22574; Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481; Kim JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007166; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Krichevsky Anna M, 2007, ScientificWorldJournal, V7, P155; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marcucci G, 2008, NEW ENGL J MED, V358, P1919, DOI 10.1056/NEJMoa074256; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Morrison SJ, 2001, CURR BIOL, V11, pR349, DOI 10.1016/S0960-9822(01)00191-9; Quinones HI, 2010, DEV BIOL, V340, P283, DOI 10.1016/j.ydbio.2010.02.012; Schaefer A, 2007, J EXP MED, V204, P1553, DOI 10.1084/jem.20070823; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Shepherd RK, 2006, J INHERIT METAB DIS, V29, P86, DOI 10.1007/s10545-006-0148-8; Smirnova L, 2005, EUR J NEUROSCI, V21, P1469, DOI 10.1111/j.1460-9568.2005.03978.x; Takaya T, 2009, CIRC J, V73, P1492, DOI 10.1253/circj.CJ-08-1032; Thatcher EJ, 2008, P NATL ACAD SCI USA, V105, P18384, DOI 10.1073/pnas.0803713105; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; wIm Y.B., 2012, ANTIOXID RE IN PRESS; Wu HH, 2003, NEURON, V37, P197, DOI 10.1016/S0896-6273(02)01172-8; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Zhao Y, 2007, CELL, V129, P303, DOI 10.1016/j.cell.2007.03.030	42	46	52	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1043-0342	1557-7422		HUM GENE THER	Hum. Gene Ther.	MAY	2012	23	5					508	520		10.1089/hum.2011.121			13	Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine	952FW	WOS:000304777700064	22182208				2021-06-18	
J	Renison, B; Ponsford, J; Testa, R; Richardson, B; Brownfield, K				Renison, Belinda; Ponsford, Jennie; Testa, Renee; Richardson, Barry; Brownfield, Kylie			The Ecological and Construct Validity of a Newly Developed Measure of Executive Function: The Virtual Library Task	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Executive function; Brain injuries; Neuropsychological tests; Validation studies; Cognitive function; Virtual systems	TRAUMATIC BRAIN-INJURY; MULTIPLE ERRANDS TEST; CARD SORTING TEST; DYSEXECUTIVE SYNDROME; SIMPLIFIED VERSION; REHABILITATION; DYSFUNCTION; DEFICITS; RELIABILITY; PERFORMANCE	Virtual reality (VR) assessment paradigms have the potential to address the limited ecological validity of pen and paper measures of executive function (EF) and the pragmatic and reliability issues associated with functional measures. To investigate the ecological validity and construct validity of a newly developed VR measure of EF, the Virtual Library Task (VLT); a real life analogous task-the Real Library Task (RLT); and five neuropsychological measures of EF were administered to 30 patients with traumatic brain injury (TBI) and 30 healthy Controls. Significant others for each participant also completed the Dysexecutive Questionnaire (DEX), which is a behavioral rating scale of everyday EF. Performances on the VLT and the RLT were significantly positively correlated indicating that VR performance is similar to real world performance. The TBI group performed significantly worse than the Control group on the VLT and the Modified Six Elements Test (MSET) but the other four neuropsychological measures of EF failed to differentiate the groups. Both the MSET and the VLT significantly predicted everyday EF suggesting that they are both ecologically valid tools for the assessment of EF. The VLT has the advantage over the MSET of providing objective measurement of individual components of EF. (JINS, 2012, 18, 440-450)	[Renison, Belinda; Ponsford, Jennie; Testa, Renee; Brownfield, Kylie] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Ponsford, Jennie] MERRC, Melbourne, Vic, Australia; [Testa, Renee] Univ Melbourne, Melbourne Neuropsychiat Ctr, Melbourne, Vic, Australia; [Richardson, Barry] Monash Univ, Sch Human Commun & Social Sci, Melbourne, Vic 3004, Australia	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu			Jack Brockhoff Foundation; Monash University's Faculty of Medicine, Nursing and Health Sciences	We thank the participants in this study, who generously donated their time. We also thank Johnathan Wells for programming the virtual library environment. The development of the virtual library environment was supported by a grant from the Jack Brockhoff Foundation and completion of the study was supported by a grant from Monash University's Faculty of Medicine, Nursing and Health Sciences. There are no conflicts of interest relating to this manuscript.	Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Axelrod BN, 1996, J CLIN EXP NEUROPSYC, V18, P338, DOI 10.1080/01688639608408991; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Brownfield K., 2008, VIRTUAL LIB TASK; Burgess PW, 2009, RESTOR NEUROL NEUROS, V27, P493, DOI 10.3233/RNN-2009-0511; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 1996, HAYLING BRIXTON TEST; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chan RCK, 2002, J INT NEUROPSYCH SOC, V8, P771, DOI 10.1017/S1355617702860052; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Coakes SJ, 2003, SPSS ANAL ANGUISH; Crawford J.R., 2005, ASSESSMENT EXECUTIVE; Cushman LA, 2008, NEUROLOGY, V71, P888, DOI 10.1212/01.wnl.0000326262.67613.fe; DAMASIO AR, 2003, CLIN NEUROPSYCHOLOGY; Dawson DR, 2009, ARCH PHYS MED REHAB, V90, pS41, DOI 10.1016/j.apmr.2009.07.012; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; Duncan J, 2005, CORTEX, V41, P215, DOI 10.1016/S0010-9452(08)70896-7; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Greve KW, 1997, BRIT J CLIN PSYCHOL, V36, P283, DOI 10.1111/j.2044-8260.1997.tb01414.x; HEATON RK, 2005, WISCONSIN CARD SORTI; Jansari A., 2004, S NEUR REH SAT S JOI; Jovanovski D., 2004, COGNITIVE SET SHIFTI; Joyner KB, 2009, J PSYCHOEDUC ASSESS, V27, P452, DOI 10.1177/0734282909333945; Katz N, 2007, OTJR-OCCUP PART HEAL, V27, P44, DOI 10.1177/153944920702700202; Klinger E, 2006, CYBERPSYCHOL BEHAV, V9, P342, DOI 10.1089/cpb.2006.9.342; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Knight RG, 2009, BRAIN IMPAIR, V10, P3, DOI 10.1375/brim.10.1.3; Lamberts KF, 2010, J CLIN EXP NEUROPSYC, V32, P56, DOI 10.1080/13803390902806550; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; LONG CJ, 1997, CRIT ISS NE, P153; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Matheis R.J., 2004, THESIS FAIRLEIGH DIC; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Monis R.G., 2002, INT C DIS VIRT REAL; Morganti F., 2004, CYBERTHERAPY INTERNE; Moriyama Y, 2002, ALCOHOL CLIN EXP RES, V26, P1239, DOI 10.1097/01.ALC.0000026103.08053.86; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Stuss D. T., 2007, HUMAN FRONTAL LOBES, P292; Testa R., 2011, ARCH CLIN N IN PRESS; Titov N, 2005, BRAIN INJURY, V19, P315, DOI 10.1080/02699050400013725; Tyson PJ, 2008, INT J PSYCHIAT CLIN, V12, P112, DOI 10.1080/13651500701687133; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zhang L, 2003, ARCH PHYS MED REHAB, V84, P1118, DOI 10.1016/S0003-9993(03)00203-X	60	46	48	3	42	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2012	18	3					440	450		10.1017/S1355617711001883			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	937VG	WOS:000303690500006	22339816				2021-06-18	
J	Whitmore, RG; Thawani, JP; Grady, MS; Levine, JM; Sanborn, MR; Stein, SC				Whitmore, Robert G.; Thawani, Jayesh P.; Grady, M. Sean; Levine, Joshua M.; Sanborn, Matthew R.; Stein, Sherman C.			Is aggressive treatment of traumatic brain injury cost-effective?	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; decompressive hemicraniectomy; intracranial pressure monitoring; cost analysis; quality-adjusted life year	SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; CLINICAL-TRIALS; UNITED-STATES; OUTCOMES; MANAGEMENT; GUIDELINES; SURVIVAL; BENEFIT; DEATH	Object. The object of this study was to determine whether aggressive treatment of severe traumatic brain injury (TBI), including invasive intracranial monitoring and decompressive craniectomy, is cost-effective. Methods. A decision-analytical model was created to compare costs, outcomes, and cost-effectiveness of 3 strategies for treating a patient with severe TBI. The aggressive-care approach is compared with "routine care," in which Brain Trauma Foundation guidelines are not followed. A "comfort care" category, in which a single day in the ICU is followed by routine floor care, is included for comparison only. Probabilities of each treatment resulting in various Glasgow Outcome Scale (GOS) scores were obtained from the literature The GOS scores were converted to quality-adjusted life years (QALYs), based on expected longevity and calculated quality of life associated with each GOS category. Estimated direct (acute and long-term medical care) and indirect (loss of productivity) costs were calculated from the perspective of society. Sensitivity analyses employed a 2D Monte Carlo simulation of 1000 trials, each with 1000 patients. The model was also used to estimate these values for patients 40, 60, and 80 years of age. Results. For the average 20-year-old, aggressive care yields 11.7 ( +/- 1.6 [SD]) QALYs, compared with routine care (10.0 +/- 1.5 QALYs). This difference is highly significant (p < 0.0001). Although the differences in effectiveness between the 2 strategies diminish with advancing age, aggressive care remains significantly better at all ages. When all costs are considered, aggressive care is also significantly less costly than routine care ($1,264,000 +/- $118,000 vs $1,361,000 +/- $107,000) for the average 20-year-old. Aggressive care remains significantly less costly until age 80, at which age it costs more than routine care. However, even in the 80-year-old, aggressive care is likely the more cost-effective approach. Comfort care is associated with poorer outcomes at all ages and with higher costs for all groups except 80-year-olds. Conclusions. When all the costs of severe TBI are considered, aggressive treatment is a cost-effective option, even for older patients. Comfort care for severe TBI is associated with poor outcomes and high costs, and should be reserved for situations in which aggressive approaches have failed or testing suggests such treatment is futile. (http://thejns.org/doi/abs/10.317/2012.1.JNS11962)	[Whitmore, Robert G.; Thawani, Jayesh P.; Grady, M. Sean; Levine, Joshua M.; Sanborn, Matthew R.; Stein, Sherman C.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Hosp Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Levine, Joshua M.] Hosp Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Whitmore, RG (corresponding author), Hosp Univ Penn, Dept Neurosurg, 3rd Floor Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.	robert.whitmore@uphs.upenn.edu			National Institutes of Health's National Institute of Neurological Disorders and Stroke [5T32NS43126-08]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126] Funding Source: NIH RePORTER	This study was funded by the National Institutes of Health's National Institute of Neurological Disorders and Stroke (5T32NS43126-08). The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	Akopian G, 2007, AM SURGEON, V73, P447; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; Arias Elizabeth, 2004, Natl Vital Stat Rep, V53, P1; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Braithwaite RS, 2008, MED CARE, V46, P349, DOI 10.1097/MLR.0b013e31815c31a7; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Centers for Medicare and Medicaid Services, 2010, AC INP PROSP PAYM SY; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gold M., 1996, Cost-Effectiveness in Health and Medicine.; Harris OA, 2008, J NEUROSURG, V109, P433, DOI 10.3171/JNS/2008/109/9/0433; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Ibrahim MI, 2007, ASIAN J SURG, V30, P261, DOI 10.1016/S1015-9584(08)60036-6; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KUMAR R, 1991, CHILD NERV SYST, V7, P299, DOI 10.1007/BF00304824; LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673; Le QA, 2009, CANCER-AM CANCER SOC, V115, P489, DOI 10.1002/cncr.24033; Lipscomb J, 2009, MED CARE, V47, pS1, DOI 10.1097/MLR.0b013e3181a7e401; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Malmivaara K, 2011, EUR J NEUROL, V18, P656, DOI 10.1111/j.1468-1331.2010.03294.x; Marion D. W., 1998, TRAUMATIC BRAIN INJU; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Shiroiwa T, 2010, MOL DIAGN THER, V14, P375, DOI 10.2165/11587610-000000000-00000; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; Tilford JM, 2007, J TRAUMA, V63, pS113, DOI 10.1097/TA.0b013e31815acc8b; Tosteson ANA, 2008, ANN INTERN MED, V149, P845, DOI 10.7326/0003-4819-149-12-200812160-00003; US Bureau of Labor Statistics, CPI INFL CALC; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E	49	46	46	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1106	1113		10.3171/2012.1.JNS11962			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800027	22394292				2021-06-18	
J	Smith, DW; Bailes, JE; Fisher, JA; Robles, J; Turner, RC; Mills, JD				Smith, David W.; Bailes, Julian E.; Fisher, Joseph A.; Robles, Javier; Turner, Ryan C.; Mills, James D.			Internal Jugular Vein Compression Mitigates Traumatic Axonal Injury in a Rat Model by Reducing the Intracranial Slosh Effect	NEUROSURGERY			English	Article						Amyloid precursor protein (APP); Concussion; Intracranial compliance; Slosh; Traumatic brain injury	INTRAOCULAR-PRESSURE; BRAIN-INJURY; DOCOSAHEXAENOIC ACID; REBOUND TONOMETER; SUPPLEMENTATION	BACKGROUND: Traumatic brain injury (TBI) remains a devastating condition for which extracranial protection traditionally has been in the form of helmets, which largely fail to protect against intracranial injury. OBJECTIVE: To determine whether the pathological outcome after traumatic brain injury can be improved via slosh mitigation by internal jugular vein (IJV) compression. METHODS: Two groups of 10 adult male Sprague-Dawley rats were subjected to impact-acceleration traumatic brain injury. One group underwent IJV compression via application of a collar before injury; the second group did not. Intracranial pressure and intraocular pressure were measured before and after IJV compression to assess collar performance. All rats were killed after a 7-day recovery period, and brainstem white matter tracts underwent fluorescent immunohistochemical processing and labeling of beta-amyloid precursor protein, a marker of axonal injury. Digital imaging and statistical analyses were used to determine whether IJV compression resulted in a diminished number of injured axons. RESULTS: Compression of the IJV resulted in an immediate 30% increase in intraocular and intracranial pressures. Most notably, IJV compression resulted in. 80% reduction in the number of amyloid precursor protein-positive axons as indicated by immunohistochemical analysis. CONCLUSION: Using a standard acceleration-deceleration laboratory model of mild traumatic brain injury, we have shown successful prevention of axonal injury after IJV compression as indicated by immunohistochemical staining of amyloid precursor protein. We argue that IJV compression reduces slosh-mediated brain injury by increasing intracranial blood volume, which can be indirectly measured by intracranial and intraocular pressures.	[Bailes, Julian E.] NorthShore Univ Hlth Syst, Dept Neurosurg, Evanston, IL 60201 USA; [Smith, David W.; Robles, Javier; Turner, Ryan C.; Mills, James D.] W Virginia Univ, Dept Neurosurg, Morgantown, WV 26506 USA; [Fisher, Joseph A.] Univ Toronto, Dept Anesthesiol, Toronto, ON, Canada; [Fisher, Joseph A.] Univ Hlth Network, Toronto, ON, Canada	Bailes, JE (corresponding author), NorthShore Univ Hlth Syst, Dept Neurosurg, 2650 Ridge Ave, Evanston, IL 60201 USA.	jbailes@northshore.org		Turner, Ryan/0000-0001-5523-0645			Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Lee EJ, 2008, JPN J OPHTHALMOL, V52, P500, DOI 10.1007/s10384-008-0591-1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAY PRA, 1979, ARCH NEUROL-CHICAGO, V36, P370, DOI 10.1001/archneur.1979.00500420080011; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Mills JD, 2003, J BIOMED OPT, V8, P347, DOI 10.1117/1.1584443; Ohashi M, 2008, JPN J OPHTHALMOL, V52, P399, DOI 10.1007/s10384-008-0532-z; Rai R, 2008, CLINICS, V63, P521, DOI 10.1590/S1807-59322008000400018; RAPHAEL JH, 1994, ANAESTHESIA, V49, P437; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Teng C, 2003, BRIT J OPHTHALMOL, V87, P946, DOI 10.1136/bjo.87.8.946; Wang WH, 2005, INVEST OPHTH VIS SCI, V46, P4617, DOI 10.1167/iovs.05-0781	18	46	46	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2012	70	3					740	746		10.1227/NEU.0b013e318235b991			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	898ZU	WOS:000300781700032	21904255				2021-06-18	
J	Post, A; Hoshizaki, B; Gilchrist, MD				Post, Andrew; Hoshizaki, Blaine; Gilchrist, Michael D.			Finite element analysis of the effect of loading curve shape on brain injury predictors	JOURNAL OF BIOMECHANICS			English	Article						Brain injury; Concussion; Finite element modelling	HUMAN HEAD; IMPACT; BIOMECHANICS	Prediction of traumatic and mild traumatic brain injury is an important factor in managing their prevention. Currently, the prediction of these injuries is limited to peak linear and angular acceleration loading curves derived from laboratory reconstructions. However it remains unclear as to what aspect of these loading curves contributes to brain tissue damage. This research uses the University College Dublin Brain Trauma Model (UCDBTM) to analyse three distinct loading curve shapes meant to represent different helmet loading scenarios. The loading curves were applied independently in each axis of linear and angular acceleration and their effect on currently used predictors of TBI and mTBI was examined. Loading curve shape A had a late time to peak. B an early time to peak and C had a consistent plateau. The areas under the curve for all three loading curve shapes were identical. The results indicate that loading curve A produced consistently higher maximum principal strains and Von Mises stress than the other two loading curve types. Loading curve C consistently produced the lowest values of maximum principal strain and Von Mises stress, with loading curve B being lowest in only 2 cases. The areas of peak Von Mises stress and Principal strain also varied depending on loading curve shape and acceleration input. (C) 2011 Elsevier Ltd. All rights reserved.	[Post, Andrew; Hoshizaki, Blaine; Gilchrist, Michael D.] Univ Ottawa, Ottawa, ON K1N 6N5, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, UCD Mech & Mat Engn, Dublin 4, Ireland	Post, A (corresponding author), Univ Ottawa, 200 Lees Ave, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X; Post, Andrew/0000-0002-5960-5552			Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; Bradshaw DRS, 2001, P 17 INT TECHN C ENH; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Gennarelli TA, 1979, P 23 STAPP CAR CRASH; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Hardy W.N., 2001, STAPP CAR CRASH J ST; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; King A., 2003, P IRCOBI C LISB PORT; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Post A., 2010, P 8 C INT SPORTS ENG; Rousseau P., 2009, J ASTM INT, V6; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Schreiber DI, 1997, P 41 STAPP CAR CRASH; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	23	46	49	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	FEB 23	2012	45	4					679	683		10.1016/j.jbiomech.2011.12.005			5	Biophysics; Engineering, Biomedical	Biophysics; Engineering	911VR	WOS:000301748800009	22239921				2021-06-18	
J	Siegel, JA; Haley, GE; Raber, J				Siegel, Jessica A.; Haley, Gwendolen E.; Raber, Jacob			Apolipoprotein E isoform-dependent effects on anxiety and cognition in female TR mice	NEUROBIOLOGY OF AGING			English	Article						Aging; Anxiety; Apolipoprotein E; Cognition	TRAUMATIC BRAIN-INJURY; TARGETED-REPLACEMENT MICE; KNOCKOUT HDC(-/-) MICE; E GENE POLYMORPHISMS; RAT ADRENAL-GLAND; EPSILON 4 ALLELE; E MESSENGER-RNA; ALZHEIMERS-DISEASE; E GENOTYPE; APOE GENOTYPE	Compared with apoE3, apoE4 is associated with increased risk to develop age-related cognitive decline, particularly in women. In this study, young, middle-aged, and old female mice expressing human apoE under control of the mouse apoE promoter were behaviorally analyzed. Cognitive performance in the water maze decreased with age in all mice. Compared with apoE2 and apoE3 mice, apoE4 mice showed better cognitive performance and higher measures of anxiety than apoE2 and apoE3 mice. Measures of anxiety correlated with cognitive performance in the water maze and passive avoidance tests and might have contributed to the enhanced cognitive performance of the apoE4 mice. ApoE4 mice showed better water maze learning and higher cortical apoE levels than mice expressing apoE4 in astrocytes under control of the GFAP promoter. This was not seen in apoE3 mice. There were no line differences in either genotype in spatial memory retention in the probe trial following the last day of hidden platform training. Thus, the promoter used to express apoE4 critically modulates its effects on brain function. (C) 2012 Elsevier Inc. All rights reserved.	[Siegel, Jessica A.; Haley, Gwendolen E.; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA; [Raber, Jacob] Oregon Hlth & Sci Univ, Div Neurosci ONPRC, Portland, OR 97239 USA	Raber, J (corresponding author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 8131 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	raberj@ohsu.edu			Alzheimer's AssociationAlzheimer's Association [IIRG-05-14021]; NASANational Aeronautics & Space Administration (NASA) [NNJ05HE63G]; NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32DA07262]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007262] Funding Source: NIH RePORTER	The authors thank Summer Acevedo, Wendy McGinnis, and Anthony Bader for their help with the data analysis. This work was supported by IIRG-05-14021 (Alzheimer's Association), NNJ05HE63G (NASA) grants, and T32DA07262 (NIDA).	Abrari K, 2009, NEUROBIOL LEARN MEM, V91, P260, DOI 10.1016/j.nlm.2008.10.008; Acevedo SF, 2006, BRAIN RES, V1071, P113, DOI 10.1016/j.brainres.2005.11.067; Acevedo SF, 2008, RADIAT RES, V170, P422, DOI 10.1667/RR1494.1; Acevedo SF, 2010, PEDIATR RES, V67, P293, DOI 10.1203/PDR.0b013e3181cb8e68; Acevedoa SF, 2006, BEHAV BRAIN RES, V168, P92, DOI 10.1016/j.bbr.2005.10.016; Alexander DM, 2007, BIOL PSYCHOL, V75, P229, DOI 10.1016/j.biopsycho.2007.03.001; Amaral DG, 2002, BIOL PSYCHIAT, V51, P11, DOI 10.1016/S0006-3223(01)01307-5; Andreano JM, 2006, PSYCHOL SCI, V17, P466, DOI 10.1111/j.1467-9280.2006.01729.x; Arendt T, 1997, J NEUROSCI, V17, P516; BARCLAY LL, 1985, BIOL PSYCHIAT, V20, P86, DOI 10.1016/0006-3223(85)90139-8; Benice TS, 2006, NEUROSCIENCE, V137, P413, DOI 10.1016/j.neuroscience.2005.08.029; Berteau-Pavy F, 2007, NEUROSCIENCE, V147, P6, DOI 10.1016/j.neuroscience.2007.03.005; Bongers G, 2004, NEUROPSYCHOPHARMACOL, V29, P441, DOI 10.1038/sj.npp.1300352; Bour A, 2008, BEHAV BRAIN RES, V193, P174, DOI 10.1016/j.bbr.2008.05.008; Brichtova E, 2008, CHILD NERV SYST, V24, P349, DOI 10.1007/s00381-007-0459-6; BURVILL PW, 1991, BRIT J PSYCHIAT, V158, P64, DOI 10.1192/bjp.158.1.64; Cahill L, 2003, NEUROBIOL LEARN MEM, V79, P194, DOI 10.1016/S1074-7427(02)00036-9; Caselli RJ, 2004, J NEUROPSYCH CLIN N, V16, P320, DOI 10.1176/appi.neuropsych.16.3.320; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Davidson RJ, 2002, BIOL PSYCHIAT, V51, P68, DOI 10.1016/S0006-3223(01)01328-2; DAVIS M, 1992, ANNU REV NEUROSCI, V15, P353, DOI 10.1146/annurev.ne.15.030192.002033; de Toledo M, 2004, REV NEUROLOGIA, V38, P901, DOI 10.33588/rn.3810.2003520; Deary IJ, 2002, NATURE, V418, P932, DOI 10.1038/418932a; den Heijer T, 2002, NEUROLOGY, V59, P746, DOI 10.1212/WNL.59.5.746; Domes G, 2005, BEHAV NEUROSCI, V119, P512, DOI 10.1037/0735-7044.119.2.512; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GILLEY DW, 1991, J GERONTOL, V46, pP362, DOI 10.1093/geronj/46.6.P362; Gochee PA, 2004, PSYCHOSOMATICS, V45, P49, DOI 10.1176/appi.psy.45.1.49; Greenwood PM, 2005, NEUROPSYCHOLOGY, V19, P830, DOI 10.1037/0894-4105.19.6.830; Greenwood PM, 2005, NEUROPSYCHOLOGY, V19, P199, DOI 10.1037/0894-4105.19.2.199; Grootendorst J, 2005, BEHAV BRAIN RES, V159, P1, DOI 10.1016/j.bbr.2004.09.019; Guangda Xiang, 1999, Atherosclerosis, V147, P293, DOI 10.1016/S0021-9150(99)00198-7; Gustavson A., 2004, CURRENT CLIN NEUROLO; Jorm AF, 2000, PSYCHOL MED, V30, P11, DOI 10.1017/S0033291799001452; Kang JE, 2005, NEUROBIOL AGING, V26, P475, DOI 10.1016/j.neurobiolaging.2004.05.003; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Lehtovirta M, 1996, J NEUROL NEUROSUR PS, V60, P644, DOI 10.1136/jnnp.60.6.644; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARTIN RJ, 1994, ALZ DIS ASSOC DIS, V8, pS360; Morris CM, 1996, J NEURAL TRANSM-SUPP, P205; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOSIA M, 1992, MOL ENDOCRINOL, V6, P288, DOI 10.1210/me.6.2.288; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PLOMIN R, 1995, INTELLIGENCE, V21, P31, DOI 10.1016/0160-2896(95)90037-3; Porter VR, 2003, J NEUROPSYCH CLIN N, V15, P180, DOI 10.1176/appi.neuropsych.15.2.180; PRACK MM, 1991, J LIPID RES, V32, P1611; Pritchard AL, 2007, J NEUROL NEUROSUR PS, V78, P123, DOI 10.1136/jnnp.2006.092122; Putman P, 2004, PSYCHONEUROENDOCRINO, V29, P953, DOI 10.1016/j.psyneuen.2003.09.001; Raber J, 2000, J NEUROSCI, V20, P2064; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Raber J, 2000, NATURE, V404, P352, DOI 10.1038/35006165; Raber J, 1997, J BIOL CHEM, V272, P15057, DOI 10.1074/jbc.272.24.15057; Raber J, 2002, J NEUROSCI, V22, P5204, DOI 10.1523/JNEUROSCI.22-12-05204.2002; Raber Jacob, 2004, Sci Aging Knowledge Environ, V2004, pre2, DOI 10.1126/sageke.2004.11.re2; Raber Jacob, 2007, Neural Plasticity, V2007, P1, DOI 10.1155/2007/91236; RABINS PV, 1982, JAMA-J AM MED ASSOC, V248, P333, DOI 10.1001/jama.248.3.333; Ramaswamy G, 2005, J NEUROSCI, V25, P10658, DOI 10.1523/JNEUROSCI.1922-05.2005; Rizk A, 2004, EUR J NEUROSCI, V19, P1992, DOI 10.1111/j.1460-9568.2004.03251.x; Robertson J, 2005, NEUROBIOL AGING, V26, P637, DOI 10.1016/j.neurobiolaging.2004.06.003; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; ROSES AD, 1995, ANN NEUROL, V38, P6, DOI 10.1002/ana.410380105; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shaw P, 2007, LANCET NEUROL, V6, P494, DOI 10.1016/S1474-4422(07)70106-0; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Sullivan PM, 2004, NEUROSCIENCE, V124, P725, DOI 10.1016/j.neuroscience.2003.10.011; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Turic D, 2001, NEUROSCI LETT, V299, P97, DOI 10.1016/S0304-3940(00)01789-4; van Meer P, 2007, BEHAV BRAIN RES, V176, P372, DOI 10.1016/j.bbr.2006.10.024; Villasana L., 2008, RAD BIOL RADIOECOL, V48, P191; Villasana L, 2006, RADIAT RES, V166, P883, DOI 10.1667/RR0642.1; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE; Yu VWY, 2000, NEUROSCI LETT, V294, P179, DOI 10.1016/S0304-3940(00)01569-X	73	46	46	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	FEB	2012	33	2					345	358		10.1016/j.neurobiolaging.2010.03.002			14	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	863NR	WOS:000298171800013	20400205	Green Accepted			2021-06-18	
J	Scorza, KA; Raleigh, MF; O'Connor, FG				Scorza, Keith A.; Raleigh, Meghan F.; O'Connor, Francis G.			Current Concepts in Concussion: Evaluation and Management	AMERICAN FAMILY PHYSICIAN			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; SYMPTOMS; FOOTBALL; PLAYERS; MARKERS	Concussion is a disturbance in brain function caused by direct or indirect force to the head. It is a functional rather than structural injury that results from shear stress to brain tissue caused by rotational or angular forces direct impact to the head is not required. Initial evaluation involves eliminating cervical spine injury and serious traumatic brain injury. Headache is the most common symptom of concussion, although a variety of clinical domains (e.g., somatic, cognitive, affective) can be affected. Signs and symptoms are nonspecific; therefore, a temporal relationship between an appropriate mechanism of injury and symptoms must be determined. There are numerous assessment tools to aid diagnosis, including symptom checklists, neuropsychological tests, postural stability tests, and sideline assessment tools. These tools are also used to monitor recovery. Cognitive and physical rest are the cornerstones of initial management. There are no specific treatments for concussion; therefore, focus is on managing symptoms and return to play. Because concussion recovery is variable, rigid classification systems have mostly been abandoned in favor of an individualized approach. A graded return-to-play protocol can be implemented once a patient has recovered in all affected domains. Children, adolescents, and those with a history of concussions may require a longer recovery period. There is limited research on the management of concussions in children and adolescents, but concern for potential consequences of injury to the developing brain suggests that a more conservative approach to management is appropriate in these patients. (Am Fam Physician. 2012;85(2):123-132. Copyright (C) 2012 American Academy of Family Physicians.)	[Scorza, Keith A.] Ft Belvoir Community Hosp, Ft Belvoir, VA 22060 USA; [Raleigh, Meghan F.] Evans Army Community Hosp, Ft Carson, CO USA; [O'Connor, Francis G.] Uniformed Serv Univ Hlth Sci, Consortium Hlth & Mil Performance, Bethesda, MD 20814 USA	Scorza, KA (corresponding author), Ft Belvoir Community Hosp, 9300 DeWitt Loop, Ft Belvoir, VA 22060 USA.	kascorza@hotmail.com					Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; [Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; [Anonymous], YOUTH SPORTS CONC HE; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Bergman DA, 1999, PEDIATRICS, V104, P1407; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hunt T, 2010, CLIN SPORT MED, V29, P5, DOI 10.1016/j.csm.2009.09.002; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Patel DR, 2010, PEDIATR CLIN N AM, V57, P649, DOI 10.1016/j.pcl.2010.03.006; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Whiteside JW, 2006, AM FAM PHYSICIAN, V74, P1357	33	46	47	1	36	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X	1532-0650		AM FAM PHYSICIAN	Am. Fam. Physician	JAN 15	2012	85	2					123	132					10	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	980AX	WOS:000306867100005	22335212				2021-06-18	
J	Ruff, RL; Riechers, RG; Wang, XF; Piero, T; Ruff, SS				Ruff, Robert Louis; Riechers, Ronald George, II; Wang, Xiao-Feng; Piero, Traci; Ruff, Suzanne Smith			A case-control study examining whether neurological deficits and PTSD in combat veterans are related to episodes of mild TBI	BMJ OPEN			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MONTREAL COGNITIVE ASSESSMENT; RECURRENT CONCUSSION; SCREENING TOOL; IRAQ; RECOVERY; MOCA; DYSFUNCTION; AFGHANISTAN	Background: Mild traumatic brain injury (mTBI) is a common injury among military personnel serving in Iraq or Afghanistan. The impact of repeated episodes of combat mTBI is unknown. Objective: To evaluate relationships among mTBI, post-traumatic stress disorder (PTSD) and neurological deficits (NDs) in US veterans who served in Iraq or Afghanistan. Methods: This was a case control study. From 2091 veterans screened for traumatic brain injury, the authors studied 126 who sustained mTBI with one or more episodes of loss of consciousness (LOC) in combat. Comparison groups: 21 combat veterans who had definite or possible episodes of mTBI without LOC and 21 veterans who sustained mTBI with LOC as civilians. Results: Among combat veterans with mTBI, 52% had NDs, 66% had PTSD and 50% had PTSD and an ND. Impaired olfaction was the most common ND, found in 65 veterans. The prevalence of an ND or PTSD correlated with the number of mTBI exposures with LOC. The prevalence of an ND or PTSD was >90% for more than five episodes of LOC. Severity of PTSD and impairment of olfaction increased with number of LOC episodes. The prevalence of an ND for the 34 combat veterans with one episode of LOC (4/34=11.8%) was similar to that of the 21 veterans of similar age and educational background who sustained civilian mTBI with one episode of LOC (2/21=9.5%, p-NS). Conclusions: Impaired olfaction was the most frequently recognised ND. Repeated episodes of combat mTBI were associated with increased likelihood of PTSD and an ND. Combat setting may not increase the likelihood of an ND. Two possible connections between mTBI and PTSD are (1) that circumstances leading to combat mTBI likely involve severe psychological trauma and (2) that altered cerebral functioning following mTBI may increase the likelihood that a traumatic event results in PTSD.	[Ruff, Robert Louis; Riechers, Ronald George, II] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Neurol Serv, Cleveland, OH USA; [Ruff, Robert Louis; Riechers, Ronald George, II] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Robert Louis; Riechers, Ronald George, II; Piero, Traci; Ruff, Suzanne Smith] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Polytrauma Syst Care, Cleveland, OH USA; [Wang, Xiao-Feng] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA; [Ruff, Suzanne Smith] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Psychol Serv, Cleveland, OH USA	Ruff, RL (corresponding author), Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Neurol Serv, Cleveland, OH USA.	robert.ruff1@va.gov			Center of Excellence Award from the Rehabilitation Research and Development Service of the Office of Research and Development of the Department of Veterans AffairsUS Department of Veterans Affairs; Department of Veterans Affairs through the Center of Excellence AwardUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs	RLR is the Medical Director of the Functional Electrical Stimulation Center of Cleveland, which is supported by a Center of Excellence Award from the Rehabilitation Research and Development Service of the Office of Research and Development of the Department of Veterans Affairs. X-FW was retained as a biostatistician for the Functional Electrical Stimulation Center of Cleveland. His involvement on this project was supported by funding from the Department of Veterans Affairs through the Center of Excellence Award to the Functional Electrical Stimulation Center of Cleveland. The work in this manuscript was supported through funding for the care of veterans from the Veterans Health Administration. RLR and SSR and RGR and TP are salaried clinicians of the Veterans Health Administration.	Altman KW, 2011, INT ARCH OCC ENV HEA, V84, P131, DOI 10.1007/s00420-010-0556-9; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Burgess Paula, 2010, J Emerg Trauma Shock, V3, P164, DOI 10.4103/0974-2700.62120; Carlson K, 2009, ASSESSMENT TREATMENT; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Kruijk JR, 2003, BRAIN INJURY, V17, P73, DOI 10.1080/0269905021000010221; DEEMS DA, 1991, ARCH OTOLARYNGOL, V117, P519; Department of Veterans Affairs, 2010, NAT CTR PTSD US PTSD; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 2001, ANNU REV PSYCHOL, V52, P423, DOI 10.1146/annurev.psych.52.1.423; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; FRYE RE, 1990, JAMA-J AM MED ASSOC, V263, P1233, DOI 10.1001/jama.263.9.1233; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Gurvits TV, 2006, ARCH GEN PSYCHIAT, V63, P571, DOI 10.1001/archpsyc.63.5.571; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harrell Frank E., 2001, REGRESSION MODELING; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hollander M., 1973, NONPARAMETRIC STAT M, P185; Hoops S, 2009, NEUROLOGY, V73, P1738, DOI 10.1212/WNL.0b013e3181c34b47; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kern RC, 2000, LARYNGOSCOPE, V110, P2106, DOI 10.1097/00005537-200012000-00025; Khasnis A, 2003, J Postgrad Med, V49, P169; King DW, 1999, J ABNORM PSYCHOL, V108, P164, DOI 10.1037/0021-843X.108.1.164; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Leigh R. J., 2006, NEUROLOGY EYE MOVEME; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; London B, 2008, ANN NEUROL, V63, P159, DOI 10.1002/ana.21293; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Pendlebury ST, 2010, STROKE, V41, P1290, DOI 10.1161/STROKEAHA.110.579888; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Peterson AL, 2011, J CLIN PSYCHOL MED S, V18, P164, DOI 10.1007/s10880-011-9238-3; Pickett TC, 2007, J REHABIL RES DEV, V44, P983, DOI 10.1682/JRRD.2007.01.0001; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Rossetti HC, 2011, NEUROLOGY, V77, P1272, DOI 10.1212/WNL.0b013e318230208a; Ruff Robert L, 2010, F1000 Med Rep, V2, P64, DOI 10.3410/M2-64; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sailer U, 2008, NEUROPSYCHOLOGIA, V46, P2836, DOI 10.1016/j.neuropsychologia.2008.05.022; SAWYER RN, 1993, NEUROLOGY, V43, P1596, DOI 10.1212/WNL.43.8.1596; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Vermetten E, 2007, PSYCHOPHARMACOL BULL, V40, P8; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Whalley MG, 2009, BRAIN COGNITION, V69, P98, DOI 10.1016/j.bandc.2008.05.008	62	46	46	2	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2012	2	2							e000312	10.1136/bmjopen-2011-000312			12	Medicine, General & Internal	General & Internal Medicine	091IF	WOS:000315042100004	22431700	DOAJ Gold, Green Published			2021-06-18	
J	Lew, HL; Pogoda, TK; Baker, E; Stolzmann, KL; Meterko, M; Cifu, DX; Amara, J; Hendricks, AM				Lew, Henry L.; Pogoda, Terri K.; Baker, Errol; Stolzmann, Kelly L.; Meterko, Mark; Cifu, David X.; Amara, Jomana; Hendricks, Ann M.			Prevalence of Dual Sensory Impairment and Its Association With Traumatic Brain Injury and Blast Exposure in OEF/OIF Veterans	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast injuries; hearing impairment; traumatic brain injury; vision impairment	VISUAL FUNCTION; POLYTRAUMA; MILITARY; HEARING; IRAQI; WAR; DYSFUNCTION; POPULATION; SOLDIERS; OUTCOMES	Objective: To describe the prevalence of self-reported rates of auditory, visual, and dual sensory impairment (DSI) in Afghanistan and Iraq war Veterans receiving traumatic brain injury (TBI) evaluations. Design: Retrospective medical chart review. Participants: Thirty-six thousand nine hundred nineteen Veterans who received a TBI evaluation between October 2007 and June 2009. Final sample included 12,521 subjects judged to have deployment-related TBI and a comparison group of 9106 participants with no evidence of TBI. Main Outcome Measure: Self-reported auditory and visual impairment. Results: Self-reported sensory impairment rates were: 34.6% for DSI, 31.3% for auditory impairment only, 9.9% for visual impairment only, and 24.2% for none/mild sensory impairment. Those with TBI and blast exposure had highest rate of DSI. Regression analyses showed that auditory impairment was the strongest predictor of visual impairment, and vice versa, suggesting these impairments may derive from a common source. Conclusions: Veterans who self-report clinically significant hearing or vision difficulty during routine TBI evaluation should be evaluated systematically and comprehensively to determine the extent of sensory impairment. Identifying DSI could allow clinicians to collaborate and maximize rehabilitation.	[Pogoda, Terri K.; Stolzmann, Kelly L.; Meterko, Mark] Ctr Org Leadership & Management Res, VA Boston Healthcare Syst, Boston, MA 02130 USA; [Lew, Henry L.] Virginia Commonwealth Univ, Def & Vet Brain Injury Ctr DVBIC, Richmond, VA USA; [Lew, Henry L.; Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA USA; [Pogoda, Terri K.; Meterko, Mark; Hendricks, Ann M.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Richmond, VA USA; [Amara, Jomana] Naval Postgrad Sch, Def Resources Management Inst, Monterey, CA USA; [Hendricks, Ann M.] VA Boston Healthcare Syst, Boston, MA USA	Pogoda, TK (corresponding author), Ctr Org Leadership & Management Res, VA Boston Healthcare Syst, 150 S Huntington Ave 152M, Boston, MA 02130 USA.	terri.pogoda@va.gov	; Pogoda, Terri/F-6243-2012	Cifu, David/0000-0003-1600-9387; Pogoda, Terri/0000-0003-1397-8780	Office of Research and Development, Health Services R&D Service, Department of Veterans AffairsUS Department of Veterans Affairs [SDR 08-405]	This article is based on work supported by the Office of Research and Development, Health Services R&D Service, Department of Veterans Affairs, through SDR 08-405. The study was reviewed and approved by the Institutional Review Board of the VA Boston Healthcare System.	[Anonymous], ARMY TIMES; Burnam A, 2009, HEALTH AFFAIR, V28, P771, DOI 10.1377/hlthaff.28.3.771; *CDCP, BLAST INJ ESS FACTS; Centers for Disease Control and Prevention, BLAST INJ EYE BLAST; Centers for Disease Control and Prevention, BLAST INJ EAR INJ; Cicerone K. D., 1995, J HEAD TRAUMA REHABI; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Doucet ME, 2005, EXP BRAIN RES, V160, P194, DOI 10.1007/s00221-004-2000-4; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Injury Prevention and Control, INJ PREV CONTR TRAUM; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2010, NEUROREHABILITATION, V26, P213, DOI 10.3233/NRE-2010-0557; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; Mader TH, 2006, OPHTHALMOLOGY, V113, P97, DOI 10.1016/j.ophtha.2005.07.018; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Myers Paula J., 2009, Seminars in Hearing, V30, P5, DOI 10.1055/s-0028-1111103; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Smith SL, 2008, J REHABIL RES DEV, V45, P597, DOI 10.1682/JRRD.2007.02.0023; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tharpe AM, 2008, J AM ACAD AUDIOL, V19, P741, DOI 10.3766/jaaa.19.10.2; Tun C, 2009, HEAR J, V62, P24; Veterans Health Administration, 2009, VET INT SERV NETW SU; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033	33	46	46	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2011	26	6					489	496		10.1097/HTR.0b013e318204e54b			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	859AC	WOS:000297845000005	21386715				2021-06-18	
J	Arciniegas, DB				Arciniegas, David B.			Clinical electrophysiologic assessments and mild traumatic brain injury: State-of-the-science and implications for clinical practice	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Electroencephalography; Quantitative electroencephalography; Mild traumatic brain injury; Concussion; Postconcussive syndrome; Differential diagnosis; Neuropsychiatric assessment	MINOR HEAD-INJURY; POST-CONCUSSION SYNDROME; PERSISTENT POSTCONCUSSION SYNDROME; QUANTITATIVE EEG; SPECTRAL-ANALYSIS; AMERICAN ACADEMY; NEUROPHYSIOLOGY SOCIETY; POSTTRAUMATIC EPILEPSY; BIOPHYSICAL LINKAGE; COMPUTED-TOMOGRAPHY	Conventional and quantitative electroencephalography (EEG and qEEG, respectively) may enhance clinical diagnosis and treatment planning provided to persons with mild traumatic brain injury (mTBI) and postconcussive symptoms. Effective and appropriate use of EEG and qEEG in this context requires expert-level knowledge of these technologies, mTBI, and the differential diagnosis for postconcussive symptoms. A practical and brief review from the perspective of a clinician-scientist engaged principally in the care and study of persons with mTBI therefore may be of use and value to other clinicians and scientists interested in these matters. Toward that end, this article offers an overview of the current applications of conventional EEG and qEEG to the study and clinical evaluation of persons with mTBI. The clinical case definition of TBI, the differential diagnosis of post-injury neuropsychiatric disturbances, and the typical course of recovery following mTBI are reviewed. With this background and context, the strengths and limitations of the literature describing EEG and qEEG studies in this population are considered. The implications of this review on the applications of these electrophysiologic assessments to the clinical evaluation of persons with mTBI and postconcussive symptoms are then considered. Finally, suggestions are offered regarding the design of future studies using these technologies in this population. Although this review may be of interest and value to professionals engaged in clinical or research electrophysiology in their daily work, it is intended to serve more immediately the needs of clinicians less familiar with these types of clinical electrophysiologic assessments. (C) 2011 Elsevier B.V. All rights reserved.	[Arciniegas, David B.] Univ Colorado, Sch Med, Dept Psychiat, Neurobehav Disorders Program, Aurora, CO 80045 USA; [Arciniegas, David B.] Univ Colorado, Sch Med, Dept Neurol, Behav Neurol Sect, Aurora, CO 80045 USA	Arciniegas, DB (corresponding author), Univ Colorado, Sch Med, Dept Psychiat, Neurobehav Disorders Program, 13007 E 17th Pl,Campus Box F546, Aurora, CO 80045 USA.	David.Arciniegas@UCDenver.edu					Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 1989, Neurology, V39, P1100; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Arciniegas D.B., 2003, J NEUROPSYCHIATRY CL, V15, P276; Arciniegas DB, 2008, CRIT CARE CLIN, V24, P737, DOI 10.1016/j.ccc.2008.06.001; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Arciniegas David B, 2004, Phys Med Rehabil Clin N Am, V15, P177, DOI 10.1016/S1047-9651(03)00104-9; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BAKER NJ, 1990, BIOL PSYCHIAT, V27, P519, DOI 10.1016/0006-3223(90)90443-6; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Busek P, 2000, Sb Lek, V101, P233; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chen Xi-Ping, 2006, Neurosci Bull, V22, P165; Coburn KL, 2006, J NEUROPSYCH CLIN N, V18, P460, DOI 10.1176/appi.neuropsych.18.4.460; Coutin-Churchman P, 2003, CLIN NEUROPHYSIOL, V114, P2294, DOI 10.1016/S1388-2457(03)00228-1; Coutin-Churchman P., 2010, J NEUROPSYCHIATRY CL, V22; Coutin-Churchman P., 2010, J NEUROPSYCHIATRY CL, V22; Demaree HA, 1996, INT J NEUROSCI, V87, P97, DOI 10.3109/00207459608990757; DENKER PG, 1954, NEUROLOGY, V4, P912, DOI 10.1212/WNL.4.12.912; Derogatis LR, 1994, SCL 90 R SYMPTOM CHE; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Duff J, 2004, CLIN EEG NEUROSCI, V35, P198, DOI 10.1177/155005940403500410; Ebersole J. S., 2003, CURRENT PRACTICE CLI; Everhart DE, 2008, CLIN NEUROPHYSIOL, V119, P134, DOI 10.1016/j.clinph.2007.09.122; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fein G, 1996, BIOL PSYCHIAT, V39, P955, DOI 10.1016/0006-3223(95)00299-5; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Fenton GW, 1996, CLIN ELECTROENCEPHAL, V27, P174; FREEDMAN R, 1983, BIOL PSYCHIAT, V18, P537; Freedman R, 1985, Alcohol Drug Res, V6, P289; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Geets W, 1983, Rev Electroencephalogr Neurophysiol Clin, V13, P253, DOI 10.1016/S0370-4475(83)80036-7; Geets W, 1985, Rev Electroencephalogr Neurophysiol Clin, V14, P333; GEETS W, 1985, ACTA NEUROL BELG, V85, P277; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glaser M. A., 1940, W J SURG, V48, P689; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Henry G K, 2000, Appl Neuropsychol, V7, P65, DOI 10.1207/S15324826AN0702_1; Hessen E, 2009, BRAIN INJURY, V23, P234, DOI 10.1080/02699050902748349; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoffer Michael E, 2007, Int Tinnitus J, V13, P69; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holstein DH, 2010, J AFFECT DISORDERS, V126, P188, DOI 10.1016/j.jad.2010.02.122; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Hunter AM, 2010, J PSYCHIATR RES, V44, P90, DOI 10.1016/j.jpsychires.2009.06.006; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; JACOME DE, 1987, CLIN ELECTROENCEPHAL, V18, P41; JACOME DE, 1984, CLIN ELECTROENCEPHAL, V15, P214, DOI 10.1177/155005948401500406; Jasper HH, 1940, ARCH NEURO PSYCHIATR, V44, P328, DOI 10.1001/archneurpsyc.1940.02280080088005; Johnson DL, 2010, COMPENDIUM PSYCHOSOC; Johnstone J, 1991, J Insur Med, V23, P228; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kane NM, 1998, ELECTROEN CLIN NEURO, V106, P244, DOI 10.1016/S0013-4694(97)00141-7; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; KOUFEN H, 1978, FORTSCHR NEUROL PSYC, V46, P165; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Leon-Carrion J, 2008, BRAIN INJURY, V22, P61, DOI 10.1080/02699050701824143; Leuchter AF, 2009, PSYCHIAT RES, V169, P132, DOI 10.1016/j.psychres.2009.04.004; Leuchter AF, 2009, CLIN EEG NEUROSCI, V40, P78, DOI 10.1177/155005940904000207; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Luccas FJC, 1999, ARQ NEURO-PSIQUIAT, V57, P132, DOI 10.1590/S0004-282X1999000100026; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mallinson AI, 1998, AM J OTOL, V19, P814; Marr A, 2002, CENTRAL NERVOUS SYST; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MAS F, 1993, CLIN ELECTROENCEPHAL, V24, P118, DOI 10.1177/155005949302400309; McAllister TW, 2009, J HEAD TRAUMA REHAB, V24, P65, DOI 10.1097/HTR.0b013e3181996e6b; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Montgomery K., 2006, DOCTORS THINK CLIN J; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Neufeld MY, 2000, EPILEPSY RES, V42, P197, DOI 10.1016/S0920-1211(00)00183-2; Neylan TC, 1999, BIOL PSYCHIAT, V46, P1656, DOI 10.1016/S0006-3223(99)00047-5; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; PARSONS LC, 1982, NURS RES, V31, P260; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; Paus T, 2010, BRAIN COGNITION, V72, P26, DOI 10.1016/j.bandc.2009.06.002; Ponomarev V A, 2010, Fiziol Cheloveka, V36, P5; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Schmithorst VJ, 2010, BRAIN COGNITION, V72, P16, DOI 10.1016/j.bandc.2009.06.005; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; TEASDALE G, 1974, LANCET, V2, P81; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Thatcher RW, 2001, CLIN NEUROPHYSIOL, V112, P1729, DOI 10.1016/S1388-2457(01)00609-5; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; THOMAIDES TN, 1992, EUR NEUROL, V32, P79, DOI 10.1159/000116796; Thornton KE, 2009, APPL PSYCHOPHYS BIOF, V34, P59, DOI 10.1007/s10484-009-9075-4; TORRES F, 1961, ARCH NEUROL-CHICAGO, V5, P28, DOI 10.1001/archneur.1961.00450130030005; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; VONBIERBRAUER A, 1992, EEG-EMG-Z ELEK ELEKT, V23, P151; WALDO MC, 1986, PSYCHIAT RES, V19, P233, DOI 10.1016/0165-1781(86)90102-2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; White T, 2010, BRAIN COGNITION, V72, P36, DOI 10.1016/j.bandc.2009.10.009; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wortzel HS, 2008, J AM ACAD PSYCHIATRY, V36, P310; Yee CM, 1998, J ABNORM PSYCHOL, V107, P691, DOI 10.1037/0021-843X.107.4.691	156	46	48	1	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2011	82	1			SI		41	52		10.1016/j.ijpsycho.2011.03.004			12	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	859PZ	WOS:000297889600005	21419178				2021-06-18	
J	Longhi, L; Gesuete, R; Perego, C; Ortolano, F; Sacchi, N; Villa, P; Stocchetti, N; De Simoni, MG				Longhi, Luca; Gesuete, Raffaella; Perego, Carlo; Ortolano, Fabrizio; Sacchi, Noemi; Villa, Pia; Stocchetti, Nino; De Simoni, Maria-Grazia			Long-lasting protection in brain trauma by endotoxin preconditioning	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						inflammation; neuroprotection; pathophysiology; preconditioning; traumatic brain injury	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; CLOSED-HEAD INJURY; INFLAMMATORY RESPONSE; BLOOD-FLOW; TNF-ALPHA; TOLERANCE; MICE; LIPOPOLYSACCHARIDE; RATS	We investigated the occurrence of endotoxin (lipopolysaccharide, LPS) preconditioning in traumatic brain injury (TBI), evaluating the time window of LPS-induced protection, its persistence, and the associated molecular mechanisms. Mice received 0.1 mg/kg LPS or saline intraperitoneally and subsequently TBI (by controlled cortical impact brain injury) at various time intervals. Mice receiving LPS 3, 5, or 7 days before TBI showed attenuated motor deficits at 1 week after injury compared with mice receiving saline. Those receiving LPS 5 days before injury had also a reduced contusion volume (7.9 +/- 1.3 versus 12 +/- 2.3 mm(3)) and decreased cell death. One month after injury, the protective effect of LPS on contusion volume (14.5 +/- 1.2 versus 18.2 +/- 1.2 mm(3)) and neurologic function was still present. Traumatic brain injury increased glial fibrillary acidic protein, CD11b, CD68, tumor necrosis factor-cc, interleukin (IL)-10, and IL-6 mRNA expression 24 hours after injury. Lipopolysaccharide administered 5 (but not 9) days before injury increased the expression of CD11b (233%) and of interferon beta (500%) in uninjured mice, while it reduced the expression of CD68 (by 46%) and increased that of IL-6 (by 52%) in injured mice. Lipopolysaccharide preconditioning conferred a long-lasting neuroprotection after TBI, which was associated with a modulation of microglia/macrophages activity and cytokine production. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 1919-1929; doi:10.1038/jcbfm.2011.42; published online 6 April 2011	[Longhi, Luca; Gesuete, Raffaella; Perego, Carlo; Villa, Pia; De Simoni, Maria-Grazia] Mario Negri Inst Pharmacol Res, Dept Neurosci, Lab Inflammat & Nervous Syst Dis, I-20156 Milan, Italy; [Longhi, Luca; Ortolano, Fabrizio; Sacchi, Noemi; Stocchetti, Nino] Univ Milan, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; [Villa, Pia] CNR, Inst Neurosci, I-20133 Milan, Italy	De Simoni, MG (corresponding author), Mario Negri Inst Pharmacol Res, Dept Neurosci, Lab Inflammat & Nervous Syst Dis, I-20156 Milan, Italy.	desimoni@marionegri.it	Perego, Carlo/AAA-6513-2020; De Simoni, Maria Grazia/I-6021-2012; Stocchetti, Nino/O-7444-2017; Longhi, Luca/AAF-9903-2021	Perego, Carlo/0000-0002-0259-0003; De Simoni, Maria Grazia/0000-0001-6695-5297; Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788; Ortolano, Fabrizio/0000-0003-1996-948X	Fondazione CariploFondazione Cariplo [2006.0864]	This study was supported by the Fondazione Cariplo, Grant # 2006.0864.	Ahmed SH, 2000, STROKE, V31, P193, DOI 10.1161/01.STR.31.1.193; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Bastide M, 2003, J CEREBR BLOOD F MET, V23, P399, DOI 10.1097/01.WCB.0000050064.57184.F2; Botker HE, 2010, LANCET, V375, P727, DOI 10.1016/S0140-6736(09)62001-8; Capone C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000373; Dawson DA, 1999, J CEREBR BLOOD F MET, V19, P616, DOI 10.1097/00004647-199906000-00004; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Faden AI, 2007, ARCH NEUROL-CHICAGO, V64, P794, DOI 10.1001/archneur.64.6.794; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Furuya K, 2005, J NEUROSURG, V103, P715, DOI 10.3171/jns.2005.103.4.0715; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Kunz A, 2007, J NEUROSCI, V27, P7083, DOI 10.1523/JNEUROSCI.1645-07.2007; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marsh B, 2009, J NEUROSCI, V29, P9839, DOI 10.1523/JNEUROSCI.2496-09.2009; Marsh BJ, 2008, CURR OPIN PHARMACOL, V8, P8, DOI 10.1016/j.coph.2007.09.009; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Penkowa M, 1999, GLIA, V25, P343; Perez-Pinzon MA, 1999, NEUROREPORT, V10, P2951, DOI 10.1097/00001756-199909290-00014; Pignataro G, 2009, FEBS J, V276, P46, DOI 10.1111/j.1742-4658.2008.06769.x; Rosenzweig HL, 2004, STROKE, V35, P2576, DOI 10.1161/01.STR.0000143450.04438.ae; Rosenzweig HL, 2007, J CEREBR BLOOD F MET, V27, P1663, DOI 10.1038/sj.jcbfm.9600464; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Storini C, 2005, NEUROBIOL DIS, V19, P10, DOI 10.1016/j.nbd.2004.11.001; Suzuki S, 2009, J CEREBR BLOOD F MET, V29, P464, DOI 10.1038/jcbfm.2008.141; Troglio F, 2004, P NATL ACAD SCI USA, V101, P15476, DOI 10.1073/pnas.0403283101; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	41	46	49	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2011	31	9					1919	1929		10.1038/jcbfm.2011.42			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	815KK	WOS:000294524300010	21468087	Bronze, Green Published			2021-06-18	
J	Plurad, DS; Talving, P; Lam, L; Inaba, K; Green, D; Demetriades, D				Plurad, David S.; Talving, Peep; Lam, Lydia; Inaba, Kenji; Green, Donald; Demetriades, Demetrios			Early Vasopressor Use in Critical Injury Is Associated With Mortality Independent From Volume Status	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Critical Care; Vasopressor; Hypovolemia; Resuscitation; Mortality; Hemorrhagic shock; Vasopressin	FLUID RESUSCITATION; HEMORRHAGIC-SHOCK	Background: Complications of excessive crystalloid after critical injury have increased interest in vasopressor support. However, it is hypothesized that vasopressor use in patients who are under-resuscitated is associated with death. We performed this study to determine whether volume status is associated with increased mortality in the critically injured exposed to early vasopressors. Methods: The intensive care unit database at a Level I center was queried for all adult admissions surviving for >24 hours from January 1, 2001, to December 31, 2008. Patients with spinal cord injury and severe traumatic brain injury were excluded. The vasopressor group [Vaso (+)] was exposed to dopamine, epinephrine, phenylephrine, norepinephrine, or arginine vasopressin within 24 hours of admission. Demographic and injury data were studied including intensive care unit admission central venous pressure. Hypovolemia [Hypov (+)] was considered an admission central venous pressure <= 8 mm Hg. The Vaso (+) group was analyzed to determine whether Hypov (+) was independently associated with death. Results: Of 1,349 eligible patients, 26% (351) were Vaso (+). Mortality was 43.6% (153) in the Vaso (+) versus 4.2% (42) in the Vaso (-) group (17.60 [12.10-25.60], <0.01). Vasopressor exposure was associated with death independent of injury severity. In Vaso (+) patients, Hypov (+) was not associated with mortality, whereas Emergency Department admission Glasgow Coma Scale <= 8 and multiple vasopressor use were. Conclusions: Vasopressor exposure early after critical injury is independently associated with death and mortality is increased regardless of fluid status. Although it is not advisable to withhold support with impending cardiovascular collapse, use of any vasopressor during ongoing resuscitation should be approached with extreme caution regardless of volume status.	[Plurad, David S.; Talving, Peep; Lam, Lydia; Inaba, Kenji; Green, Donald; Demetriades, Demetrios] LAC USC Dept Surg, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA	Plurad, DS (corresponding author), Navy Trauma Training Ctr, 1200 N State St,Room 1050, Los Angeles, CA 90033 USA.	plurad@usc.edu	Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013; INABA, KENJI/AAC-8532-2020	Talving, Peep/0000-0002-9741-2073; 			Alam HB, 2007, SURG CLIN N AM, V87, P55, DOI 10.1016/j.suc.2006.09.015; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Cavus E, 2008, J TRAUMA, V64, P641, DOI 10.1097/TA.0b013e3181637a6c; Cohn SM, 2007, J TRAUMA, V62, pS56, DOI 10.1097/TA.0b013e318065ab06; Collier B, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2009.05.003; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Devlin JJ, 2008, J TRAUMA, V65, P498, DOI 10.1097/TA.0b013e31817de454; Fangio P, 2005, J TRAUMA, V58, P978, DOI 10.1097/01.TA.0000163435.39881.26; Haas T, 2004, J TRAUMA, V57, P177, DOI 10.1097/01.TA.0000044357.25191.1B; Joshi GP, 2005, ANESTH ANALG, V101, P601, DOI 10.1213/01.ANE.0000159171.26521.31; LANSING A M, 1962, J Trauma, V2, P386, DOI 10.1097/00005373-196207000-00007; Lee JH, 2009, J EMERG MED, V37, P376, DOI 10.1016/j.jemermed.2008.07.004; Meybohm P, 2007, J TRAUMA, V62, P640, DOI 10.1097/01.ta.0000240962.62319.c8; Plurad D, 2007, J TRAUMA, V63, P1, DOI 10.1097/TA.0b013e318068b1ed; Plurad D, 2006, J TRAUMA, V61, P1120, DOI 10.1097/01.ta.0000244737.54032.98; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Sharma RM, 2005, ANESTH ANALG, V101, P833, DOI 10.1213/01.ANE.0000175209.61051.7F; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Voelckel WG, 2003, CRIT CARE MED, V31, P2552, DOI 10.1097/01.CCM.0000089944.54391.D6; Wenzel V, 2008, BEST PRACT RES-CLIN, V22, P299, DOI 10.1016/j.bpa.2008.02.003	20	46	47	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2011	71	3					565	572		10.1097/TA.0b013e3182213d52			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	818MX	WOS:000294756900014	21908995				2021-06-18	
J	Folkersma, H; Boellaard, R; Yaqub, M; Kloet, RW; Windhorst, AD; Lammertsma, AA; Vandertop, WP; van Berckel, BNM				Folkersma, Hedy; Boellaard, Ronald; Yaqub, Maqsood; Kloet, Reina W.; Windhorst, Albert D.; Lammertsma, Adriaan A.; Vandertop, W. Peter; van Berckel, Bart N. M.			Widespread and Prolonged Increase in (R)-C-11-PK11195 Binding After Traumatic Brain Injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						craniocerebral trauma; humans; microglia; positron emission tomography; (R)-C-11-PK11195	IN-VIVO; MICROGLIAL ACTIVATION; PERIPHERAL BENZODIAZEPINE; COMPUTERIZED-TOMOGRAPHY; DEMENTIA; RECEPTOR; SYSTEM; SITES; MODEL	Our objective was to measure (R)-C-11-PK11195 binding as an indirect marker of neuronal damage after traumatic brain injury (TBI). Methods: Dynamic (R)-C-11-PK11195 PET scans were acquired for 8 patients 6 mo after TBI and for 7 age-matched healthy controls. (R)-C-11-PK11195 binding was assessed using the simplified reference tissue model. Because of widespread traumatic changes in TBI, an anatomic reference region could not be defined. Therefore, supervised cluster analysis was used to generate an appropriate reference tissue input. Results: Increased whole-brain binding of (R)-C-11-PK11195 was observed in TBI patients. Regional analysis indicated that increased (R)-C-11-PK11195 binding was widespread over the brain. Conclusion: Six months after TBI, there was a prolonged and widespread increase in (R)-C-11-PK11195 binding, which is indicative of diffuse neuronal damage.	[Folkersma, Hedy; Vandertop, W. Peter] Vrije Univ Amsterdam Med Ctr, Neurosurg Ctr Amsterdam, NL-1007 MB Amsterdam, Netherlands; [Boellaard, Ronald; Yaqub, Maqsood; Kloet, Reina W.; Windhorst, Albert D.; Lammertsma, Adriaan A.; van Berckel, Bart N. M.] Vrije Univ Amsterdam Med Ctr, Dept Nucl Med, NL-1007 MB Amsterdam, Netherlands; [Boellaard, Ronald; Yaqub, Maqsood; Kloet, Reina W.; Windhorst, Albert D.; Lammertsma, Adriaan A.; van Berckel, Bart N. M.] Vrije Univ Amsterdam Med Ctr, PET Res, NL-1007 MB Amsterdam, Netherlands	Folkersma, H (corresponding author), Vrije Univ Amsterdam Med Ctr, Neurosurg Ctr Amsterdam, POB 7057, NL-1007 MB Amsterdam, Netherlands.	hedy.folkersma@vumc.nl	Vandertop, William P./K-9288-2018	Boellaard, Ronald/0000-0002-0313-5686; Lammertsma, Adriaan/0000-0003-1237-2891; Windhorst, Albert/0000-0002-1250-7656	Dutch Brain Foundation [9F01.21]; Netherlands Organisation for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO) [016.066.309]	We acknowledge Wiesje van der Flier for statistical support. This study was supported by the Dutch Brain Foundation (9F01.21) and by the Netherlands Organisation for Scientific Research (NWO, VIDI grant 016.066.309). No other potential conflict of interest relevant to this article was reported.	Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Boellaard R, 2008, IEEE NUCL SCI S C, P5400, DOI DOI 10.1109/NSSMIC.2008.4774453; Cagnin A, 2004, ANN NEUROL, V56, P894, DOI 10.1002/ana.20332; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Defrise M, 1997, IEEE T MED IMAGING, V16, P145, DOI 10.1109/42.563660; Folkersma H, 2009, J NUCL MED, V50, P1975, DOI 10.2967/jnumed.109.067512; Gerhard A, 2003, NEUROLOGY, V61, P686, DOI 10.1212/01.WNL.0000078192.95645.E6; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; Peden Margie, 2005, Int J Inj Contr Saf Promot, V12, P85, DOI 10.1080/15660970500086130; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Provenzano FA, 2010, NUCL MED COMMUN, V31, P952, DOI 10.1097/MNM.0b013e32833e37c4; Ransohoff RM, 2002, J INFECT DIS, V186, pS152, DOI 10.1086/344266; RAO N, 1984, ARCH PHYS MED REHAB, V65, P18; SHAH F, 1994, NUCL MED BIOL, V21, P573, DOI 10.1016/0969-8051(94)90022-1; Turkheimer FE, 2007, J NUCL MED, V48, P158	22	46	46	0	14	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505			J NUCL MED	J. Nucl. Med.	AUG 1	2011	52	8					1235	1239		10.2967/jnumed.110.084061			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	800CJ	WOS:000293336000038	21764792	Bronze			2021-06-18	
J	Tiesman, HM; Konda, S; Bell, JL				Tiesman, Hope M.; Konda, Srinivas; Bell, Jennifer L.			The Epidemiology of Fatal Occupational Traumatic Brain Injury in the US	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							UNITED-STATES; SAFETY; FALLS; HEALTH; SLIPS; TRIPS	Background: Although traumatic brain injury (TBI) is one of the leading causes of death and disability in the U. S., work-related TBI has not been well documented. Purpose: The aim of this study was to describe the epidemiologic characteristics and temporal trends of fatal occupational TBI in the U. S between 2003 and 2008. Methods: A cross-sectional analysis of the Census of Fatal Occupational Injury database was performed. Both the Occupational Injury and Illness Classification System nature of injury codes and body part codes were used to define TBIs. Fatality rates were calculated using denominators derived from the Current Population Survey. Fatality rates were compared among industries, cause of death, and demographics with rate ratios (RRs) and 95% CIs. Poisson regression was used to assess trends in fatality rates. Data were analyzed in 2009-2010. Results: Nearly 7300 occupational TBI deaths occurred between 2003 and 2008, for an average fatality rate of 0.8 per 100,000 workers per year. The leading causes of occupational TBI death were as follows: motor vehicle (31%); falls (29%); assaults and violent acts (20%); and contact with objects/equipment (18%). Fatality rates were 15 times higher in men compared with women (RR = 15, 95% CI = 13.7, 16.3). Workers aged >= 65 years experienced the highest TBI fatality rate of all age groups (2.5 per 100,000 per year). Construction, transportation, and agriculture/forestry/fishing industries recorded nearly half of all TBI fatalities (n = 1828, n = 825, n = 761, respectively). Occupational TBI death rates declined 23% over the 6-year period (p < 0.0001). Conclusions: This study provides the first national profile of fatal TBIs occurring in the U. S. workplace. Prevention efforts should be directed at those industries with the highest frequency and/or highest risk. The construction industry had the highest number of TBIs, and the agriculture, forestry, and fishing industry had the highest rates. Additionally, workers aged >65 years in all industries would be a good target for future prevention efforts. (Am J Prev Med 2011; 41(1): 61-67) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine	[Tiesman, Hope M.; Konda, Srinivas; Bell, Jennifer L.] NIOSH, Div Safety Res, Anal & Field Evaluat Branch, Morgantown, WV 26506 USA	Tiesman, HM (corresponding author), NIOSH, Div Safety Res, Anal & Field Evaluat Branch, 1095 Willowdale Rd,M-S 1811, Morgantown, WV 26506 USA.	htiesman@cdc.gov	Konda, Srinivas/G-2747-2015	Konda, Srinivas/0000-0002-8934-4111			AGNEW J, 1993, HUM FACTORS, V35, P731; Alexander BH, 1999, AM J IND MED, V36, P317, DOI 10.1002/(SICI)1097-0274(199908)36:2<317::AID-AJIM11>3.3.CO;2-I; Aschkenasy MT, 2006, EMERG MED CLIN N AM, V24, P413, DOI 10.1016/j.emc.2006.01.005; BELL CA, 1990, JAMA-J AM MED ASSOC, V263, P3047, DOI 10.1001/jama.263.22.3047; Bell JL, 2006, J SAFETY RES, V37, P53, DOI 10.1016/j.jsr.2005.10.019; Bell JL, 2002, J SAFETY RES, V33, P463, DOI 10.1016/S0022-4375(02)00048-8; Bentley TA, 2005, APPL ERGON, V36, P165, DOI 10.1016/j.apergo.2004.10.009; Bobick TG, 2010, J SAFETY RES, V41, P203, DOI 10.1016/j.jsr.2010.02.008; Bohle P, 2010, INT J HEALTH SERV, V40, P23, DOI 10.2190/HS.40.1.b; *BUR LAB STAT, 1992, OCC INJ ILLN CLASS M; *BUR LAB STAT, 1998, COMP WORK COND LOGG; *BUR LAB STAT, 2009, 1015 US DEP LAB BUR; *BUR LAB STAT, 2009, 1014 US DEP LAB BUR; *BUR LAB STAT, BLS SPOTL STAT OLD W; Bureau of Labor Statistics, BLS HDB METH; Choi SD, 2009, WORK, V33, P307, DOI 10.3233/WOR-2009-0878; Colantonio A, 2010, CAN J PUBLIC HEALTH, V101, pS58, DOI 10.1007/BF03403848; Colantonio A, 2009, BRAIN INJURY, V23, P873, DOI 10.1080/02699050903036033; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Finkelstein EA., 2006, INCIDENCE EC BURDEN; HEYER NJ, 1994, AM J PUBLIC HEALTH, V84, P1106, DOI 10.2105/AJPH.84.7.1106; Ho SC, 2010, OCCUP ENVIRON MED, V67, P251, DOI 10.1136/oem.2009.047407; Kemmlert K, 1998, SAFETY SCI, V28, P59, DOI 10.1016/S0925-7535(97)00071-4; Kim H, 2006, NEUROREHABILITATION, V21, P269; Kisner SM, 1999, AM J IND MED, P24; KRAUS JF, 1985, J OCCUP ENVIRON MED, V27, P757; Layne LA, 2004, AM J IND MED, V46, P32, DOI 10.1002/ajim.20038; MESSING K, 1994, J OCCUP ENVIRON MED, V36, P913; MYERS JR, 1994, J SAFETY RES, V25, P97, DOI 10.1016/0022-4375(94)90021-3; *NAT CTR INJ PREV, 1999, TRAUM BRAIN INJ US R; National Center for Injury Prevention and Control, TRAUM BRAIN INJ US E; Office of Management and Budget, 2002, N AM IND CLASS SYST; Rodriguez-Acosta R., 1997, INT J OCCUP ENV HEAL, V3, P259, DOI 10.1179/oeh.1997.3.4.259; Scott DF, 2004, INJURY PREV, V10, P239, DOI 10.1136/ip.2003.004663; Silverstein M, 2008, AM J IND MED, V51, P269, DOI 10.1002/ajim.20569; Smith GS, 2005, J OCCUP ENVIRON MED, V47, P640, DOI 10.1097/01.jom.0000165746.26873.d1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tiesman HM, 2007, AM J PREV MED, V33, P464, DOI 10.1016/j.amepre.2007.07.034; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; Tricco AC, 2006, BRAIN INJURY, V20, P719, DOI 10.1080/02699050600664640; West R, 1996, AM J FOREN MED PATH, V17, P299, DOI 10.1097/00000433-199612000-00004; Wrona RM, 2006, J SAFETY RES, V37, P75, DOI 10.1016/j.jsr.2005.08.008	42	46	46	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	JUL	2011	41	1					61	67		10.1016/j.amepre.2011.03.007			7	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	775OC	WOS:000291468700010	21665064				2021-06-18	
J	Caeyenberghs, K; Leemans, A; Coxon, J; Leunissen, I; Drijkoningen, D; Geurts, M; Gooijers, J; Michiels, K; Sunaert, S; Swinnen, SP				Caeyenberghs, Karen; Leemans, Alexander; Coxon, James; Leunissen, Inge; Drijkoningen, David; Geurts, Monique; Gooijers, Jolien; Michiels, Karla; Sunaert, Stefan; Swinnen, Stephan P.			Bimanual Coordination and Corpus Callosum Microstructure in Young Adults with Traumatic Brain Injury: A Diffusion Tensor Imaging Study	JOURNAL OF NEUROTRAUMA			English	Article						bimanual coordination; corpus callosum; diffusion tensor MRI; traumatic brain injury	UPPER-LIMB FUNCTION; WHITE-MATTER; AXONAL INJURY; MULTIPLE-SCLEROSIS; FINGER MOVEMENTS; BEHAVIOR RELATIONSHIPS; MOTOR COORDINATION; MUTUAL INFORMATION; EXECUTIVE FUNCTION; CONTROLLED-TRIAL	Bimanual actions are ubiquitous in daily life. Many coordinated movements of the upper extremities rely on precise timing, which requires efficient interhemispheric communication via the corpus callosum (CC). As the CC in particular is known to be vulnerable to traumatic brain injury (TBI), furthering our understanding of its structure-function association is highly valuable for TBI diagnostics and prognosis. In this study, 21 young adults with TBI and 17 controls performed object manipulation tasks (insertion of pegs with both hands and bilateral daily life activities) and cognitive control tasks (i.e., switching maneuvers during spatially and temporally coupled bimanual circular motions). The structural organization of 7 specific subregions of the CC (prefrontal, premotor/supplementary motor, primary motor, primary sensory, parietal, temporal, and occipital) was subsequently investigated in these subjects with diffusion tensor imaging (DTI). Findings revealed that bimanual coordination was impaired in TBI patients as shown by elevated movement time values during daily life activities, a decreased number of peg insertions, and slower response times during the switching task. Furthermore, the DTI analysis demonstrated a significantly decreased fractional anisotropy and increased radial diffusivity in prefrontal, primary sensory, and parietal regions in TBI patients versus controls. Finally, multiple regression analyses showed evidence of the high specificity of callosal subregions accounting for the variance associated with performance of the different bimanual coordination tasks. Whereas disruption in commissural pathways between occipital areas played a role in performance on the clinical tests of bimanual coordination, deficits in the switching task were related to disrupted interhemispheric communication in prefrontal, sensory, and parietal regions. This study provides evidence that structural alterations of several subregional callosal fibers in adults with TBI are associated with differential behavioral manifestations of bimanual motor functioning.	[Caeyenberghs, Karen; Coxon, James; Leunissen, Inge; Drijkoningen, David; Geurts, Monique; Gooijers, Jolien; Swinnen, Stephan P.] Katholieke Univ Leuven, Res Ctr Movement Control & Neuroplast, Motor Control Lab, Louvain, Belgium; [Leemans, Alexander] Univ Med Ctr Utrecht, Image Sci Inst, Utrecht, Netherlands; [Michiels, Karla] Univ Hosp Leuven, Dept Phys Med & Rehabil, Louvain, Belgium; [Sunaert, Stefan] Katholieke Univ Leuven, Univ Hosp, Dept Radiol, Louvain, Belgium	Caeyenberghs, K (corresponding author), Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Tervuursevest 101, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@faber.kuleuven.be	Coxon, James/S-1286-2019; Gooijers, Jolien/AAH-9202-2020; Leemans, Alexander/A-1784-2011; Sunaert, Stefan/E-8031-2011	Coxon, James/0000-0003-2351-8489; Leemans, Alexander/0000-0002-9306-6126; Sunaert, Stefan/0000-0002-1177-4680; Caeyenberghs, Karen/0000-0001-7009-6843; Leunissen, Inge/0000-0002-3977-3620; Gooijers, Jolien/0000-0002-7569-7223	Research Foundation - Flanders (FWO)FWO [G.0482.010]; Belgian federal government [P6/29]; FWOFWO	Support for this study was provided through a grant from the Research Programme of the Research Foundation - Flanders (FWO) (Levenslijn # G.0482.010), and grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. K. Caeyenberghs is funded by a post-doctoral fellowship of the FWO.	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Asikainen I, 1999, EUR J NEUROL, V6, P179, DOI 10.1111/j.1468-1331.1999.tb00011.x; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bonzano L, 2008, J NEUROSCI, V28, P3227, DOI 10.1523/JNEUROSCI.4076-07.2008; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; Byblow WD, 1999, MOTOR CONTROL, V3, P372, DOI 10.1123/mcj.3.4.372; Byblow WD, 2000, EXP BRAIN RES, V131, P366, DOI 10.1007/s002219900271; Byblow WD, 2002, MOVEMENT DISORD, V17, P20, DOI 10.1002/mds.1281; Caeyenberghs K, 2010, NEUROPSYCHOLOGIA, V48, P1472, DOI 10.1016/j.neuropsychologia.2010.01.017; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Carson RG, 1997, Q J EXP PSYCHOL-A, V50, P664, DOI 10.1080/027249897392062; Catani M, 2008, CORTEX, V44, P1105, DOI 10.1016/j.cortex.2008.05.004; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coxon JP, 2010, CEREB CORTEX, V20, P2368, DOI 10.1093/cercor/bhp306; Debaere F, 2004, NEUROIMAGE, V21, P1416, DOI 10.1016/j.neuroimage.2003.12.011; Deiber MP, 2001, CLIN NEUROPHYSIOL, V112, P1419, DOI 10.1016/S1388-2457(01)00536-3; DESROSIERS J, 1995, DISABIL REHABIL, V17, P217, DOI 10.3109/09638289509166638; DESROSIERS J, 1995, ARCH PHYS MED REHAB, V76, P1125, DOI 10.1016/S0003-9993(95)80120-0; Dougherty RF, 2007, P NATL ACAD SCI USA, V104, P8556, DOI 10.1073/pnas.0608961104; Eliassen JC, 1999, EXP BRAIN RES, V128, P573, DOI 10.1007/s002210050884; Eliassen JC, 2000, BRAIN, V123, P2501, DOI 10.1093/brain/123.12.2501; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Feys P, 2002, CLIN REHABIL, V16, P166, DOI 10.1191/0269215502cr471oa; Gilbert SJ, 2008, CURR BIOL, V18, pR110, DOI 10.1016/j.cub.2007.12.014; Higgins J, 2006, CLIN REHABIL, V20, P296, DOI 10.1191/0269215505cr943oa; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Hsu JL, 2010, NEUROIMAGE, V49, P32, DOI 10.1016/j.neuroimage.2009.08.031; Huang L, 2006, CHINESE MED J-PEKING, V119, P1304, DOI 10.1097/00029330-200608010-00012; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Immisch I, 2001, NEUROIMAGE, V14, P674, DOI 10.1006/nimg.2001.0856; Ito S, 2008, NEURORADIOLOGY, V50, P981, DOI 10.1007/s00234-008-0447-x; Jancke L, 2000, NEUROPSYCHOLOGIA, V38, P164, DOI 10.1016/S0028-3932(99)00062-7; Jancke L, 2000, NEUROIMAGE, V12, P528, DOI 10.1006/nimg.2000.0626; Johansen-Berg H, 2007, NEUROIMAGE, V36, pT16, DOI 10.1016/j.neuroimage.2007.03.041; Jones DK, 2011, METHODS MOL BIOL, V711, P127, DOI 10.1007/978-1-61737-992-5_6; Kermadi I, 2000, SOMATOSENS MOT RES, V17, P255; Klein S, 2010, IEEE T MED IMAGING, V29, P196, DOI 10.1109/TMI.2009.2035616; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Larson EB, 2002, CORTEX, V38, P201, DOI 10.1016/S0010-9452(08)70650-6; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Leemans A, 2005, LECT NOTES COMPUT SC, V3708, P523; Leemans A., 2009, P INT SOC MAG RESON, V17, P3537, DOI DOI 10.1093/occmed/kqr069; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Madden DJ, 2004, NEUROIMAGE, V21, P1174, DOI 10.1016/j.neuroimage.2003.11.004; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Moseley AM, 2003, J HEAD TRAUMA REHAB, V18, P526, DOI 10.1097/00001199-200311000-00006; Muetzel RL, 2008, NEUROIMAGE, V39, P1918, DOI 10.1016/j.neuroimage.2007.10.018; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park BS, 2009, APPL NEUROPSYCHOL, V16, P1, DOI 10.1080/09084280802636371; Pfefferbaum A, 2007, BRAIN, V130, P48, DOI 10.1093/brain/awl242; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; Powell KB, 2004, J CHILD NEUROL, V19, P785, DOI 10.1177/08830738040190100801; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Rossi C, 1996, ARCH PHYS MED REHAB, V77, P1062, DOI 10.1016/S0003-9993(96)90069-6; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Sadato N, 1997, J NEUROSCI, V17, P9667; Sadato N, 1997, J CEREBR BLOOD F MET, V17, P670; Sage CA, 2009, HUM BRAIN MAPP, V30, P3657, DOI 10.1002/hbm.20794; Schroeter ML, 2007, NEUROPSYCHOLOGIA, V45, P3149, DOI 10.1016/j.neuropsychologia.2007.07.004; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Serrien DJ, 2001, EUR J NEUROSCI, V14, P1897, DOI 10.1046/j.0953-816x.2001.01798.x; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stephan KM, 1999, BRAIN, V122, P351, DOI 10.1093/brain/122.2.351; Stephen KM, 1999, EXP BRAIN RES, V128, P243, DOI 10.1007/s002210050844; Sternad D, 2007, EXP BRAIN RES, V176, P559, DOI 10.1007/s00221-006-0640-2; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Swinnen SP, 2002, NAT REV NEUROSCI, V3, P350, DOI 10.1038/nrn807; Swinnen SP, 2004, TRENDS COGN SCI, V8, P18, DOI 10.1016/j.tics.2003.10.017; Tiffin J, 1948, J APPL PSYCHOL, V32, P234, DOI 10.1037/h0061266; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Van Hecke W, 2008, NEUROIMAGE, V43, P69, DOI 10.1016/j.neuroimage.2008.07.006; Van Hecke W, 2007, IEEE T MED IMAGING, V26, P1598, DOI 10.1109/TMI.2007.906786; Van Hecke W, 2010, J MAGN RESON IMAGING, V31, P1492, DOI 10.1002/jmri.22198; Van Hecke W, 2009, NEUROIMAGE, V46, P692, DOI 10.1016/j.neuroimage.2009.02.032; Verhoeven JS, 2010, HUM BRAIN MAPP, V31, P470, DOI 10.1002/hbm.20880; Vos SB, 2011, NEUROIMAGE, V55, P1566, DOI 10.1016/j.neuroimage.2011.01.048; Wahl M, 2007, J NEUROSCI, V27, P12132, DOI 10.1523/JNEUROSCI.2320-07.2007; Wallen MA, 2001, ARCH PHYS MED REHAB, V82, P642, DOI 10.1053/apmr.2001.22620; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wenderoth N, 2005, HUM BRAIN MAPP, V26, P286, DOI 10.1002/hbm.20151; Wenderoth N, 2009, J NEUROPHYSIOL, V102, P302, DOI 10.1152/jn.91090.2008; Wenderoth N, 2005, EUR J NEUROSCI, V22, P235, DOI 10.1111/j.1460-9568.2005.04176.x; Wenderoth N, 2004, CEREB CORTEX, V14, P1153, DOI 10.1093/cercor/bhh075; Wenderoth N, 2009, PROG BRAIN RES, V174, P179, DOI 10.1016/S0079-6123(09)01315-6; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wu T, 2010, BRAIN, V133, P2394, DOI 10.1093/brain/awq151	108	46	46	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					897	913		10.1089/neu.2010.1721			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600005	21501046	Green Published			2021-06-18	
J	Pannek, K; Mathias, JL; Bigler, ED; Brown, G; Taylor, JD; Rose, SE				Pannek, Kerstin; Mathias, Jane L.; Bigler, Erin D.; Brown, Greg; Taylor, Jamie D.; Rose, Stephen E.			The average pathlength map: A diffusion MRI tractography-derived index for studying brain pathology	NEUROIMAGE			English	Article						Magnetic resonance; Diffusion weighted imaging; HARDI; Quantitative tractography; Constrained spherical deconvolution	METRICS	Magnetic resonance diffusion tractography provides a powerful tool for the assessment of white matter architecture in vivo. Quantitative tractography metrics, such as streamline length, have successfully been used in the study of brain pathology. To date, these studies have relied on a priori knowledge of which tracts are affected by injury or pathology and manual delineation of regions of interest (ROIs) for use as waypoints in tractography. This limits the analyses to specific tracts under investigation and relies on the accurate and consistent placement of ROIs. We present a fully automated technique for the voxel-wise analysis of streamline length within the entire brain, the Average Pathlength Map (APM). We highlight the precision and reproducibility of voxel-wise average streamline length over time, and assess normal variability of pathlength values in a cohort of 43 healthy participants. Additionally, we demonstrate the utility of this approach by performing voxel-wise comparison between pathlength values obtained from a patient with a severe traumatic brain injury (TBI, Glasgow Coma Scale Score = 7) and those from contROI participants. Our analysis shows that voxel-wise average pathlength values are comparable to fractional anisotropy (FA) in terms of reproducibility and variability. For the TBI patient, we observed a significant reduction in streamline pathlength in the genu of the corpus callosum and its projections into the frontal lobe. This study demonstrates that the average pathlength map can be used for voxel-based analysis of a quantitative tractography metric within the whole brain, removing both the dependence on a priori knowledge of affected pathways and time-consuming manual delineation of ROIs. (c) 2010 Elsevier Inc. All rights reserved.	[Pannek, Kerstin; Rose, Stephen E.] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia; [Pannek, Kerstin; Rose, Stephen E.] Univ Queensland, Ctr Adv Imaging, Brisbane, Qld, Australia; [Mathias, Jane L.] Univ Adelaide, Sch Psychol, Adelaide, SA, Australia; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA; [Brown, Greg; Taylor, Jamie D.] Royal Adelaide Hosp, Magnet Resonance Imaging Unit, Adelaide, SA 5000, Australia; [Rose, Stephen E.] Univ Queensland, Ctr Med Diagnost Technol Queensland, Brisbane, Qld, Australia	Rose, SE (corresponding author), Royal Brisbane Hosp, UQ Ctr Clin Res, Brisbane, Qld 4029, Australia.	stephen.rose@cai.uq.edu.au	Brown, Gregory/D-3983-2013; Pannek, Kerstin/C-8059-2011; Mathias, J L/L-6295-2013; Rose, Stephen/C-8044-2009	Brown, Gregory/0000-0001-7994-2743; Pannek, Kerstin/0000-0002-6512-7630; Mathias, Jane/0000-0001-8957-8594	National Health and Medical Research [519220]	This research was funded by a National Health and Medical Research Project Grant (ID 519220).	Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Behrens TEJ, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P333, DOI 10.1016/B978-0-12-374709-9.00015-8; Bodini B, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P175, DOI 10.1016/B978-0-12-374709-9.00009-2; Calamante F, 2010, NEUROIMAGE, V53, P1233, DOI 10.1016/j.neuroimage.2010.07.024; Correia S, 2008, NEUROIMAGE, V42, P568, DOI 10.1016/j.neuroimage.2008.05.022; Jenkinson M, 2003, MAGNET RESON MED, V49, P193, DOI 10.1002/mrm.10354; JENKINSON M, 2004, 10 ANN M ORG HUM BRA; Jeurissen B, 2011, HUM BRAIN MAPP, V32, P461, DOI 10.1002/hbm.21032; Johansen-Berg H, 2006, CURR OPIN NEUROL, V19, P379, DOI 10.1097/01.wco.0000236618.82086.01; Jones D. K., 2010, IMAGING MED, V2, P341; Jones DK, 2008, CORTEX, V44, P936, DOI 10.1016/j.cortex.2008.05.002; Jones DK, 2010, NMR BIOMED, V23, P803, DOI 10.1002/nbm.1543; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kumar A., 2009, ALTERATIONS FRONTAL; Lewis JD, 2009, CEREB CORTEX, V19, P554, DOI 10.1093/cercor/bhn105; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Nakata Y, 2009, AM J NEURORADIOL, V30, P1142, DOI 10.3174/ajnr.A1527; Pannek K, 2010, NEUROIMAGE, V50, P1044, DOI 10.1016/j.neuroimage.2010.01.020; Raffelt D.A., 2010, P ISMRM 2010 STOCKH; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P147, DOI 10.1016/B978-0-12-374709-9.00008-0; Tate DF, 2010, BRAIN IMAGING BEHAV, V4, P68, DOI 10.1007/s11682-009-9086-z; Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016; Tuch DS, 2003, NEURON, V40, P885, DOI 10.1016/S0896-6273(03)00758-X; Wedeen V.J., 1999, P 7 ANN M ISMR PHIL; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	29	46	46	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAR 1	2011	55	1					133	141		10.1016/j.neuroimage.2010.12.010			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	716YH	WOS:000287008900011	21147236				2021-06-18	
J	Wu, DY; Cai, G; Yuan, Y; Liu, L; Li, GQ; Song, WQ; Wang, MB				Wu, Dong-yu; Cai, Gui; Yuan, Ying; Liu, Lin; Li, Guang-qing; Song, Wei-qun; Wang, Mao-bin			Application of nonlinear dynamics analysis in assessing unconsciousness: A preliminary study	CLINICAL NEUROPHYSIOLOGY			English	Article						Electroencephalography; Nonlinear dynamics; Unconsciousness; Traumatic brain injury; Stroke	CROSS-APPROXIMATE ENTROPY; VEGETATIVE STATE; EVOKED-POTENTIALS; BISPECTRAL INDEX; SPECTRAL ENTROPY; EEG COMPLEXITY; BRAIN-INJURY; PROPOFOL; ELECTROENCEPHALOGRAM; SEVOFLURANE	Objectives: To quantify the degree of unconsciousness with EEG nonlinear analysis and investigate the change of EEG nonlinear properties under different conditions. Methods: Twenty-one subjects in persistent vegetative state (PVS), 16 in minimally conscious state (MCS) and 30 normal conscious subjects (control group) with brain trauma or stroke were involved in the study. EEG was recorded under three conditions: eyes closed, auditory stimuli and painful stimuli. EEG nonlinear indices such as Lempel-Ziv complexity (LZC), approximate entropy (ApEn) and cross-approximate entropy (cross-ApEn) were calculated for all the subjects. Results: The PVS subjects had the lowest nonlinear indices followed by the MCS subjects and the control group had the highest. The PVS and MCS group had poorer response to auditory and painful stimuli than the control group. Under painful stimuli, nonlinear indices of subjects who recovered (REC) increased more significantly than non-REC subjects. Conclusions: With EEG nonlinear analysis, the degree of suppression for PVS and MCS could be quantified. The changes of brain function for unconscious subjects could be captured by EEG nonlinear analysis. Significance: EEG nonlinear analysis could characterise the changes of brain function for unconscious state and might have some value in predicting prognosis of unconscious subjects. (c) 2010 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Wu, Dong-yu; Yuan, Ying; Liu, Lin; Li, Guang-qing; Song, Wei-qun; Wang, Mao-bin] Capital Med Univ, Xuanwu Hosp, Dept Rehabil, Beijing, Peoples R China; [Cai, Gui] China Astronaut Res & Training Ctr, Beijing, Peoples R China	Wu, DY (corresponding author), Capital Med Univ, Xuanwu Hosp, Dept Rehabil, 45 Changchun St,POB 100053, Beijing, Peoples R China.	wudongyu73@yahoo.com.cn	Wu, Dongyu/AAW-6037-2020		National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30600186, 30770714]	This study was supported by two grants from National Natural Science Foundation of China (Grant Nos. 30600186 and 30770714). Thanks to Richard D. Zorowitz, MD, Associate Professor and Chairman of Physical Medicine and Rehabilitation, Johns Hopkins Bay-view Medical Center, Baltimore, MD, USA, for his help in editing this manuscript.	Amantini A, 2005, CLIN NEUROPHYSIOL, V116, P229, DOI 10.1016/j.clinph.2004.07.008; Anderson RE, 2004, ANAESTHESIA, V59, P52, DOI 10.1111/j.1365-2044.2004.03523.x; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Bruhn J, 2003, ANESTHESIOLOGY, V98, P621, DOI 10.1097/00000542-200303000-00008; Burioka N, 2005, CLIN EEG NEUROSCI, V36, P21, DOI 10.1177/155005940503600106; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Carter BG, 2005, INTENS CARE MED, V31, P840, DOI 10.1007/s00134-005-2634-0; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Ferenets R, 2007, ANESTHESIOLOGY, V106, P696, DOI 10.1097/01.anes.0000264790.07231.2d; Ferenets R, 2006, IEEE T BIO-MED ENG, V53, P1067, DOI 10.1109/TBME.2006.873543; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; Giacino J, 2005, J HEAD TRAUMA REHAB, V20, P30, DOI 10.1097/00001199-200501000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hans P, 2005, BRIT J ANAESTH, V94, P336, DOI 10.1093/bja/aei047; Hudetz AG, 2003, ANESTHESIOLOGY, V99, P1125, DOI 10.1097/00000542-200311000-00019; Hudetz AG, 2002, BRAIN RES, V954, P123, DOI 10.1016/S0006-8993(02)03358-9; Husain AM, 2006, J CLIN NEUROPHYSIOL, V23, P208, DOI 10.1097/01.wnp.0000220094.60482.b5; JANSEN BH, 1991, INT J BIOMED COMPUT, V27, P95, DOI 10.1016/0020-7101(91)90090-2; Jelles B, 1999, ACTA NEUROL SCAND, V100, P360; Jeong JS, 2004, CLIN NEUROPHYSIOL, V115, P1490, DOI 10.1016/j.clinph.2004.01.001; KASPAR F, 1987, PHYS REV A, V36, P842, DOI 10.1103/PhysRevA.36.842; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; Kumar A., 2007, Journal of Medical Engineering & Technology, V31, P46, DOI 10.1080/03091900500431874; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; LEMPEL A, 1976, IEEE T INFORM THEORY, V22, P75, DOI 10.1109/TIT.1976.1055501; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Li YJ, 2008, CLIN NEUROPHYSIOL, V119, P1232, DOI 10.1016/j.clinph.2008.01.104; Melloni L, 2007, J NEUROSCI, V27, P2858, DOI 10.1523/JNEUROSCI.4623-06.2007; Noh GJ, 2006, ANESTHESIOLOGY, V104, P921, DOI 10.1097/00000542-200605000-00006; Owen AM, 2005, NEUROPSYCHOL REHABIL, V15, P290, DOI 10.1080/09602010443000579; Papadelis C, 2007, CLIN NEUROPHYSIOL, V118, P1906, DOI 10.1016/j.clinph.2007.04.031; Pincus S, 1996, P NATL ACAD SCI USA, V93, P2083, DOI 10.1073/pnas.93.5.2083; Pincus SM, 2001, ANN NY ACAD SCI, V954, P245; Pincus SM, 2006, BIPOLAR DISORD, V8, P430, DOI 10.1111/j.1399-5618.2006.00375.x; PRITCHARD WS, 1995, BRAIN COGNITION, V27, P353, DOI 10.1006/brcg.1995.1027; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Robinson Lawrence R, 2004, Phys Med Rehabil Clin N Am, V15, P43, DOI 10.1016/S1047-9651(03)00102-5; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Stevens RD, 2006, CRIT CARE MED, V34, P31, DOI 10.1097/01.CCM.0000194534.42661.9F; Vakkuri A, 2004, ACTA ANAESTH SCAND, V48, P145, DOI 10.1111/j.0001-5172.2004.00323.x; Voss LJ, 2006, ACTA ANAESTH SCAND, V50, P313, DOI 10.1111/j.1399-6576.2006.00914.x; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; Yan B, 2005, NEUROSCI LETT, V383, P236, DOI 10.1016/j.neulet.2005.04.021; Young GB, 2004, J CLIN NEUROPHYSIOL, V21, P379; Young GB, 1997, CAN J NEUROL SCI, V24, P320, DOI 10.1017/S0317167100032996; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263; Zhang WT, 2004, NEUROSCI LETT, V354, P50, DOI 10.1016/j.neulet.2003.09.080; Zhang XS, 2001, IEEE T BIO-MED ENG, V48, P1424, DOI 10.1109/10.966601; Zheng Lu, 2005, Zhongguo Zhen Jiu, V25, P82	55	46	58	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAR	2011	122	3					490	498		10.1016/j.clinph.2010.05.036			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	709QL	WOS:000286456300012	20719560				2021-06-18	
J	Brown, AW; Moessner, AM; Mandrekar, J; Diehl, NN; Leibson, CL; Malec, JF				Brown, Allen W.; Moessner, Anne M.; Mandrekar, Jay; Diehl, Nancy N.; Leibson, Cynthia L.; Malec, James F.			A Survey of Very-Long-Term Outcomes after Traumatic Brain Injury among Members of a Population-Based Incident Cohort	JOURNAL OF NEUROTRAUMA			English	Article						data collection; rehabilitation; time factors	QUALITY-OF-LIFE; FOLLOW-UP; HEAD TRAUMA; OLMSTED-COUNTY; PSYCHOSOCIAL ADJUSTMENT; ALZHEIMERS-DISEASE; RECOVERY; MINNESOTA; SEVERITY; SURVIVAL	To assess quality of life and barriers to participation in vocational and community life for persons with traumatic brain injury (TBI) over the very-long term, a population-based cohort was identified in Olmsted County, Minnesota; 1623 individuals were identified as having experienced a confirmed TBI while a resident of Olmsted County, Minnesota, during the period from 1935-2000. A survey was sent to eligible individuals that included elements of standardized instruments addressing health status and disability, and questions that assessed issues important to successful social reintegration after TBI. Of 1623 eligible participants sent surveys, 605 responded (37% response rate). Thirty-nine percent of respondents were female and 79% had mild injuries. Mean age at injury was 30.8 years, and mean years since injury was 28.8. Overall, respondents reported living in the community; the majority were married and had achieved education beyond high school. Problems with memory, thinking, and physical and emotional health were most often reported. Respondents reported low levels of depression and anxiety, and high levels of satisfaction with life. Seventy-three percent of respondents reported no problems that they attributed to their TBI. Increasing injury severity was associated with a significant risk of reporting injury-related problems at survey completion. Respondents with a longer time since injury were less likely to report any TBI-related problems. These results indicate that self-reported outcomes and adaptation to impairment-related limitations improve as the time since injury increases. These findings highlight the importance of providing coordinated medical rehabilitation and community-based support services to promote positive outcomes over the life span after TBI.	[Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Moessner, Anne M.] Mayo Clin, Dept Nursing, Rochester, MN 55905 USA; [Mandrekar, Jay] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN 55905 USA; [Diehl, Nancy N.] Mayo Clin, Dept Biostat, Rochester, MN 55905 USA; [Leibson, Cynthia L.] Mayo Clin, Dept Epidemiol, Rochester, MN 55905 USA; [Malec, James F.] Indiana Univ, Sch Med, Rehabil Hosp Indiana, Indianapolis, IN USA	Brown, AW (corresponding author), Mayo Clin, Dept Phys Med & Rehabil, 200 1st St SW, Rochester, MN 55905 USA.	brown.allen@mayo.edu		Brown, Allen W./0000-0001-7228-3351	National Institute on Disability and Rehabilitation Research; U.S. Department of EducationUS Department of Education; Mayo Foundation for Medical Education and Research; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [RO1 AG034676]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034676] Funding Source: NIH RePORTER	This work is a product of the Mayo Clinic TBI Model System Center, funded by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education, and supported by the Mayo Foundation for Medical Education and Research. This study was also made possible by the Rochester Epidemiology Project (grant no. RO1 AG034676 from the National Institute on Aging). The authors thank Ms. Patricia Perkins for her consultation and tireless record abstraction.	ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Baguley I, 2000, BRAIN INJURY, V14, P505; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Centers for Disease Control and Prevention, 2001, BEH RISK FACT SURV S; CHAMBERLAIN A, 1995, HEAD INJURY CHALLENG; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hellawell DJ, 2000, DISABIL REHABIL, V22, P446, DOI 10.1080/09638280050045910; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Melton LJ, 1997, NEW ENGL J MED, V337, P1466, DOI 10.1056/NEJM199711133372012; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; NELSON EL, 1984, NEUROSURGERY, V15, P318, DOI 10.1227/00006123-198409000-00005; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Sendroy-Terrill M, 2010, ARCH PHYS MED REHAB, V91, P489, DOI 10.1016/j.apmr.2009.11.011; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WIEDERHOLT WC, 1989, NEUROLOGY, V39, P96, DOI 10.1212/WNL.39.1.96; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540	53	46	47	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					167	176		10.1089/neu.2010.1400			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700001	21121813	Green Published			2021-06-18	
J	Itoh, T; Imano, M; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, A; Satou, T				Itoh, Tatsuki; Imano, Motohiro; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Akihiko; Satou, Takao			Exercise increases neural stem cell proliferation surrounding the area of damage following rat traumatic brain injury	JOURNAL OF NEURAL TRANSMISSION			English	Article						Exercise; Neural stem cell; Traumatic brain injury; Nestin; Neurosphere	CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; DENTATE GYRUS; CEREBRAL-CORTEX; NEUROGENESIS; EXPRESSION; HIPPOCAMPUS; ASTROCYTES; NEURONS; NESTIN	Exercise enhances neuronal stem cell (NSC) proliferation and neurogenesis. However, the effect of exercise on NSC proliferation surrounding the area of damage after traumatic brain injury (TBI) is unknown. Here, we investigate the effect of running on NSC proliferation following TBI in the rat. Wistar rats received TBI and were randomly divided into two groups: (1) non-exercise group and (2) exercise group. The exercise group ran on a treadmill for 30 min/day at 22 m/min for 7 consecutive days. Immunohistochemistry was used to monitor NSC proliferation around the damaged area, and ex vivo techniques were used to isolate NSCs from the damaged region in both groups. The number of nestin- and Ki67-positive cells observed at 3 and 7 days after TBI was significantly greater in the exercise group than in the non-exercise group (P < 0.01). Furthermore, most nestin-positive cells in the exercise group co-localized with Ki67-positive cells. In ex vivo studies, spheres could be isolated from injured brain tissue from the exercise group at 3 and 7 days following TBI, but at only 3 days in the non-exercise group. The number of spheres isolated from injured brain tissue was greater in the exercise group than in the non-exercise group. Spheres were immunopositive for nestin and comprised NSCs that could differentiate into neurons and glia. Exercise increases the proliferation of NSCs around the damaged area following TBI. Therefore, exercise therapy (rehabilitation) in the early phase following TBI is important for recuperation from cerebral dysfunction induced by TBI.	[Itoh, Tatsuki; Ito, Akihiko; Satou, Takao] Kinki Univ, Sch Med, Dept Pathol, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Sch Med, Dept Surg, Osaka 5898511, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Sch Pharmaceut Sci, Osaka 5898511, Japan; [Hashimoto, Shigeo] PL Hosp, Div Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ Hosp, Div Hosp Pathol, Sch Med, Osaka, Japan; [Satou, Takao] Kinki Univ, Div Sports Med, Inst Life Sci, Osaka 5898511, Japan	Itoh, T (corresponding author), Kinki Univ, Sch Med, Dept Pathol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp			ZENRYOKEN;  [20500472];  [21500803]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21500803, 20500472] Funding Source: KAKEN	This work was supported by a Grant-in-Aid for Scientific Research (20500472 and 21500803) and ZENRYOKEN. The authors thank Mari Yachi for technical assistance.	AZBILL R, 1997, STEM CELLS, V765, P2044; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2006, NEUROCHEM RES, V31, P1381, DOI 10.1007/s11064-006-9186-8; Itoh T, 2010, J MOL NEUROSCI, V41, P55, DOI 10.1007/s12031-009-9279-3; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Itoh T, 2009, NEUROTOX RES, V16, P378, DOI 10.1007/s12640-009-9081-6; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Komitova M, 2005, EUR J NEUROSCI, V21, P2397, DOI 10.1111/j.1460-9568.2005.04072.x; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leasure JL, 2010, EXP NEUROL, V226, P58, DOI 10.1016/j.expneurol.2010.08.003; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Luo CX, 2007, J NEUROSCI RES, V85, P1637, DOI 10.1002/jnr.21317; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; Parent JM, 1997, J NEUROSCI, V17, P3727; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Radak Z, 2001, NEUROCHEM INT, V38, P17, DOI 10.1016/S0197-0186(00)00063-2; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Tani M, 2010, J NEUROCHEM, V115, P854, DOI 10.1111/j.1471-4159.2010.06727.x; Uda M, 2006, BRAIN RES, V1104, P64, DOI 10.1016/j.brainres.2006.05.066; Wu CW, 2008, J APPL PHYSIOL, V105, P1585, DOI 10.1152/japplphysiol.90775.2008; Wu CW, 2007, J NEUROCHEM, V103, P2471, DOI 10.1111/j.1471-4159.2007.04987.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yagita Y, 2006, NEUROSCI LETT, V409, P24, DOI 10.1016/j.neulet.2006.09.040; Yamamoto S, 2001, J NEUROSCI, V21, P9814, DOI 10.1523/JNEUROSCI.21-24-09814.2001; Yi SS, 2009, NEUROCHEM RES, V34, P1039, DOI 10.1007/s11064-008-9870-y	34	46	50	0	11	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564			J NEURAL TRANSM	J. Neural Transm.	FEB	2011	118	2					193	202		10.1007/s00702-010-0495-3			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	732JE	WOS:000288180000006	20924619				2021-06-18	
J	Kulkarni, J; de Castella, A; Headey, B; Marston, N; Sinclair, K; Lee, S; Gurvich, C; Fitzgerald, PB; Burger, H				Kulkarni, Jayashri; de Castella, Anthony; Headey, Barbara; Marston, Natasha; Sinclair, Kelly; Lee, Stuart; Gurvich, Caroline; Fitzgerald, Paul B.; Burger, Henry			Estrogens and men with schizophrenia: Is there a case for adjunctive therapy?	SCHIZOPHRENIA RESEARCH			English	Article						Oestrogen/estrogen; Schizophrenia; Men; Sex hormones	QUALITY-OF-LIFE; AGGRESSIVE-BEHAVIOR; NEGATIVE SYMPTOMS; ELDERLY-PATIENTS; CONTROLLED-TRIAL; DOUBLE-BLIND; SHORT-TERM; BRAIN; WOMEN; ESTRADIOL	Adjunctive use of estrogen therapy has been shown to be effective in enhancing the treatment of schizophrenia in women. In men, consideration of estrogen therapy has been impacted by concerns of feminising side effects, however, clinical trials of the use of estrogen in treating prostate cancer, bone density loss and even aggression and psychosis in dementia or traumatic brain injury, show this to be a safe and effective therapy. The current 14-day randomised placebo-controlled trial in 53 men with schizophrenia was conducted to evaluate the efficacy of 2 mg oral estradiol valerate as an adjunct to atypical antipsychotic treatment. Results demonstrated for estradiol participants a more rapid reduction in general psychopathology that occurred in the context of greater increases in serum estrogen levels and reductions in FSH and testosterone levels. Approximately 28% of estradiol participants did not achieve an increase (at least a 50% from baseline) in serum estrogen suggesting that further research is needed to refine the type, dose and administration route for estrogen therapy in men. Findings do, however, suggest further exploration of a therapeutic role for adjunctive estradiol treatment in men with schizophrenia is warranted. (C) 2010 Elsevier B.V. All rights reserved.	[Kulkarni, Jayashri; de Castella, Anthony; Headey, Barbara; Marston, Natasha; Sinclair, Kelly; Lee, Stuart; Gurvich, Caroline; Fitzgerald, Paul B.] Alfred Hosp, Monash Alfred Psychiat Res Ctr, Melbourne, Vic 3004, Australia; [Kulkarni, Jayashri; de Castella, Anthony; Headey, Barbara; Marston, Natasha; Sinclair, Kelly; Lee, Stuart; Gurvich, Caroline; Fitzgerald, Paul B.] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Burger, Henry] Monash Med Ctr, Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia	Kulkarni, J (corresponding author), Alfred Hosp, Monash Alfred Psychiat Res Ctr, Level 1,Old Baker Bldg,Commercial Rd, Melbourne, Vic 3004, Australia.	jayashri.Kulkarni@med.monash.edu.au	Fitzgerald, Paul B/A-1225-2008; Kulkarni, Jayashri/B-8917-2012; Gurvich, Caroline/AAB-9115-2019	Fitzgerald, Paul B/0000-0003-4217-8096; Kulkarni, Jayashri/0000-0002-3875-5623; Gurvich, Caroline/0000-0002-5663-3419; Burger, Henry/0000-0002-5333-6144; Lee, Stuart James/0000-0002-5071-7443	National Health and Medical Research Council (NHMRC), Canberra, AustraliaNational Health and Medical Research Council of Australia [1997/8]	Funding for the study was provided by the National Health and Medical Research Council (NHMRC), Canberra, Australia (Grant ID: 1997/8), The NHMRC had no further role in study design; collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.	Akhondzadeh S, 2003, PROG NEURO-PSYCHOPH, V27, P1007, DOI 10.1016/S0278-5846(03)00161-1; Akhondzadeh S, 2006, SCHIZOPHR RES, V84, P405, DOI 10.1016/j.schres.2006.02.008; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARNOLD SE, 1993, AM J PSYCHIAT, V150, P1564; Bergemann N, 2007, PSYCHOL MED, V37, P1427, DOI 10.1017/S0033291707000578; Cornil CA, 2006, BRAIN RES, V1126, P2, DOI 10.1016/j.brainres.2006.07.098; Cyr M, 2002, J PSYCHIATR NEUROSCI, V27, P12; DELIGNIERES B, 1986, J CLIN ENDOCR METAB, V62, P536, DOI 10.1210/jcem-62-3-536; DELRIO G, 1994, J CLIN ENDOCR METAB, V79, P836, DOI 10.1210/jc.79.3.836; Drake RJ, 2007, J CLIN PSYCHIAT, V68, P81, DOI 10.4088/JCP.v68n0111; *EXP CONS PAN, 2003, J CLIN PSYCHIAT S12, V64, P26; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gillies GE, 2010, PHARMACOL REV, V62, P155, DOI 10.1124/pr.109.002071; Hafner H, 2003, PSYCHONEUROENDOCRINO, V28, P17, DOI 10.1016/S0306-4530(02)00125-7; HAFNER H, 1991, PSYCHIAT RES, V38, P125, DOI 10.1016/0165-1781(91)90038-Q; Hall KA, 2005, INT PSYCHOGERIATR, V17, P165, DOI 10.1017/S1041610205001535; Hedlund PO, 2000, UROLOGY, V55, P328, DOI 10.1016/S0090-4295(99)00580-4; Hofer A, 2004, J CLIN PSYCHIAT, V65, P932; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kirschbaum C, 1996, J CLIN ENDOCR METAB, V81, P3639, DOI 10.1210/jc.81.10.3639; Ko YH, 2007, PSYCHONEUROENDOCRINO, V32, P385, DOI 10.1016/j.psyneuen.2007.02.002; Kulkarni J, 1996, SCHIZOPHR RES, V20, P247, DOI 10.1016/0920-9964(96)82949-5; Kulkarni J, 1999, SCHIZOPHR RES, V36, P286; Kulkarni J, 2001, SCHIZOPHR RES, V48, P137, DOI 10.1016/S0920-9964(00)00088-8; Kulkarni J, 2008, ARCH GEN PSYCHIAT, V65, P955, DOI 10.1001/archpsyc.65.8.955; Kyomen HH, 2002, AM J PSYCHIAT, V159, P1225, DOI 10.1176/appi.ajp.159.7.1225; Kyomen HH, 1999, AM J GERIAT PSYCHIAT, V7, P339; LOBO RA, 1995, AM J OBSTET GYNECOL, V173, P981, DOI 10.1016/0002-9378(95)90246-5; MAURER K, 1995, SCHIZOPHR RES, V15, P265, DOI 10.1016/0920-9964(94)00051-9; Pallanti S, 1997, AM J PSYCHIAT, V154, P792; Perez-Neri I, 2006, NEUROCHEM RES, V31, P1279, DOI 10.1007/s11064-006-9162-3; Rossler W, 2005, EUR NEUROPSYCHOPHARM, V15, P399, DOI 10.1016/j.euroneuro.2005.04.009; Sayed Y, 2003, CURR OPIN PHARMACOL, V3, P650, DOI 10.1016/j.coph.2003.07.004; Seeman MV, 1996, J PSYCHIATR NEUROSCI, V21, P123; Sumner BEH, 1998, MOL BRAIN RES, V59, P205, DOI 10.1016/S0169-328X(98)00148-X; Taherianfard M, 2004, Indian J Med Sci, V58, P3; Tollefson GD, 1999, J CLIN PSYCHIAT, V60, P23	37	46	47	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	FEB	2011	125	2-3					278	283		10.1016/j.schres.2010.10.009			6	Psychiatry	Psychiatry	733ZW	WOS:000288304000021	21062669				2021-06-18	
J	Amen, DG; Wu, JC; Taylor, D; Willeumier, K				Amen, Daniel G.; Wu, Joseph C.; Taylor, Derek; Willeumier, Kristen			Reversing Brain Damage in Former NFL Players: Implications for Traumatic Brain Injury and Substance Abuse Rehabilitation	JOURNAL OF PSYCHOACTIVE DRUGS			English	Article						brain trauma; football; MicroCog; rehabilitation; SPECT	PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; PERFORMANCE; ATLAS; SPECT	Brain injuries are common in professional American football players. Finding effective rehabilitation strategies can have widespread implications not only for retired players but also for patients with traumatic brain injury and substance abuse problems. An open label pragmatic clinical intervention was conducted in an outpatient neuropsychiatric clinic with 30 retired NFL players who demonstrated brain damage and cognitive impairment. The study included weight loss (if appropriate); fish oil (5.6 grams a day); a high-potency multiple vitamin; and a formulated brain enhancement supplement that included nutrients to enhance blood flow (ginkgo and vinpocetine), acetylcholine (acetyl-l-carnitine and huperzine A), and antioxidant activity (alpha-lipoic acid and n-acetyl-cysteine). The trial average was six months. Outcome measures were Microcog Assessment of Cognitive Functioning and brain SPECT imaging. In the retest situation, corrected for practice effect, there were statistically significant increases in scores of attention, memory, reasoning, information processing speed and accuracy on the Microcog. The brain SPECT scans, as a group, showed increased brain perfusion, especially in the prefrontal cortex, parietal lobes, occipital lobes, anterior cingulate gyros and cerebellum. This study demonstrates that cognitive and cerebral blood flow improvements are possible in this group with multiple interventions.	[Amen, Daniel G.] UC Irvine Sch Med, Irvine, CA USA; [Wu, Joseph C.] Irvine Sch Med, Brain Imaging Ctr, UC, Irvine, CA USA; [Taylor, Derek; Willeumier, Kristen] Amen Clin Inc, Newport Beach, CA 92660 USA	Amen, DG (corresponding author), Amen Clin Inc, 4019 Westerly Pl,Suite 100, Newport Beach, CA 92660 USA.	docamen@amenclinic.com					Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Amen DG, 2010, J PSYCHOACTIVE DRUGS, V42, P153, DOI 10.1080/02791072.2010.10400688; ARGUELLES S, 2010, BIOSCIENCE BIOT 0707; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ; Conklin SM, 2007, NEUROSCI LETT, V421, P209, DOI 10.1016/j.neulet.2007.04.086; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI 10.1517/14728220802517901 ; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gold MS, 2009, BIOL PSYCHIAT, V66, P118, DOI 10.1016/j.biopsych.2009.02.021; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Gulyas B, 2002, ACTA NEUROL SCAND, V106, P325, DOI 10.1034/j.1600-0404.2002.01302.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Kennedy DO, 2010, PSYCHOPHARMACOLOGY, V211, P55, DOI 10.1007/s00213-010-1870-3; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Maldjian JA, 2004, NEUROIMAGE, V21, P450, DOI 10.1016/j.neuroimage.2003.09.032; Michael-Titus AT, 2009, CLIN LIPIDOL, V4, P343, DOI 10.2217/CLP.09.19; MONTELEONE P, 1990, NEUROENDOCRINOLOGY, V52, P243, DOI 10.1159/000125593; OLSONMADDEN JH, 2010, J HEAD TRAUMA R 0420; Powell D, 2004, MICROCOG ASSESSMENT; POWELL DH, 1993, MANUAL MICROCOG ASSE; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Santos RF, 2003, PHARMACOPSYCHIATRY, V36, P127; Weir D. R., 2009, STUDY RETIRED NFL PL; Zhang HY, 2008, CELL MOL NEUROBIOL, V28, P173, DOI 10.1007/s10571-007-9163-z	26	46	47	0	28	HAIGHT-ASHBURY PUBL	SAN FRANCISCO	409 CLAYTON ST, SAN FRANCISCO, CA 94117 USA	0279-1072			J PSYCHOACTIVE DRUGS	J. Psychoact. Drugs	JAN-MAR	2011	43	1					1	5		10.1080/02791072.2011.566489			5	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	749ES	WOS:000289447000001	21615001	Bronze			2021-06-18	
J	Formisano, R; D'Ippolito, M; Risetti, M; Riccio, A; Caravasso, CF; Catani, S; Rizza, F; Forcina, A; Buzzi, MG				Formisano, Rita; D'Ippolito, Mariagrazia; Risetti, Monica; Riccio, Angela; Caravasso, Chiara Falletta; Catani, Sheila; Rizza, Federica; Forcina, Antonio; Buzzi, Maria Gabriella			Vegetative state, minimally conscious state, akinetic mutism and Parkinsonism as a continuum of recovery from disorders of consciousness: an exploratory and preliminary study	FUNCTIONAL NEUROLOGY			English	Article						disorders of consciousness; evaluation scales; minimally conscious state; vegetative state	TRAUMATIC BRAIN-INJURY; REHABILITATION; STIMULATION; AMANTADINE; DIAGNOSIS; CONSENSUS; LESIONS; PAIN; TIME	The aim of this study was to review the usefulness of clinical and instrumental evaluation in individuals with disorders of consciousness (DOC). Thirteen subjects with severe acquired brain injury (ABI) and a diagnosis of DOC were evaluated using the Coma Recovery Scale in its revised version (CRS-R) and a new global disability index, the Post-Coma Scale (PCS). These instruments were administered both by a neutral examiner (professional) and by a professional in the presence of a caregiver. All patients were also scored using the International Classification of Functioning, Disability and Health (ICF). A statistically significant correlation between CRS-R and PCS was demonstrated. However, there also emerged significant differences in responsiveness between professional versus caregiver+professional assessment using the two scales. The emotional stimulation provided by significant others (caregivers) during administration of DOC evaluation scales may improve the assessment of responsiveness.	[Formisano, Rita; D'Ippolito, Mariagrazia; Caravasso, Chiara Falletta; Catani, Sheila; Rizza, Federica; Buzzi, Maria Gabriella] IRCCS Santa Lucia Fdn, Postcoma Unit, I-00179 Rome, Italy; [Risetti, Monica; Riccio, Angela] IRCCS Santa Lucia Fdn, Lab Neuroelect Imaging & Brain Comp Interface, I-00179 Rome, Italy; [Caravasso, Chiara Falletta] IRCCS Santa Lucia Fdn, Dept Radiol, I-00179 Rome, Italy; [Forcina, Antonio] Univ Cassino, Dept Ind Engn, Cassino, Italy	Formisano, R (corresponding author), IRCCS Santa Lucia Fdn, Postcoma Unit, Via Ardeatina 306, I-00179 Rome, Italy.	r.formisano@hsantalucia.it	D'Ippolito, Mariagrazia/K-4010-2016; Riccio, Angela/K-2745-2016; Buzzi, Maria Gabriella/K-5468-2016	D'Ippolito, Mariagrazia/0000-0001-7818-7352; Riccio, Angela/0000-0002-4098-9461; Buzzi, Maria Gabriella/0000-0003-1307-8707; Falletta Caravasso, Chiara/0000-0003-3389-2853	European ICT Programme [FP7-247919 (DECODER)]	This work is supported by the European ICT Programme Project FP7-247919 (DECODER). This paper only reflects the authors' views and funding agencies are not liable for any use that may be made of the information contained herein.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Blandini F, 2010, FUNCT NEUROL, V25, P65; Danze F, 1993, Soins, P4; DE MORSIER G., 1960, PSYCHIAT ET NEUROL, V139, P60; Di Russo F, 2005, J NEUROTRAUM, V22, P297; Formisano R, 2005, ACT NEUR S, V93, P201; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Formisano R, 2004, BRAIN INJURY, V18, P103, DOI 10.1080/0269905031000149470; FORMISANO R, 2009, CRITICAL CARE, P2254; FORMISANO R, 2008, VEGETATIVE STATE MIN; Formisano R, 1996, P 5 C INT ASS STUD T, P110; Formisano R, 2009, MED SCI MONITOR, V15, pCR101; Fujimoto K, 2006, J NEUROL, V253, P16, DOI 10.1007/s00415-006-3003-9; Gerstenbrand F., 1967, TRAUMATISCHE APALLIS; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Hughes S, 2005, BRAIN INJURY, V19, P1197, DOI 10.1080/02699050500309296; Incoccia C, 2004, CORTEX, V40, P111, DOI 10.1016/S0010-9452(08)70924-9; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P1082; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1976, LANCET, V1, P1031; Kassubek J, 2003, J NEUROL SCI, V212, P85, DOI 10.1016/S0022-510X(03)00106-0; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Krimchansky BZ, 2004, BRAIN INJURY, V18, P1099, DOI 10.1080/02699050310001646206; Laureys S, 2004, NEUROREHABILITATION, V19, P335; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; LINDENBERG R, 1964, Dtsch Z Nervenheilkd, V185, P637; Lombardi F, 2007, FUNCT NEUROL, V22, P47; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Orient-Lopez F, 2002, REV NEUROLOGIA, V35, P362, DOI 10.33588/rn.3504.2001457; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Peppe A, 1998, ELECTROEN CLIN NEURO, V106, P374, DOI 10.1016/S0013-4694(97)00075-8; Plum F., 1966, DIAGNOSIS STUPOR COM; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2009, ANN NY ACAD SCI, V1157, P101, DOI 10.1111/j.1749-6632.2008.04123.x; Schnakers C, 2008, NEUROLOGY, V71, P1614, DOI 10.1212/01.wnl.0000334754.15330.69; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Schnakers C, 2009, NEUROCASE, V15, P271, DOI 10.1080/13554790902724904; Sinforiani E, 2010, FUNCT NEUROL, V25, P205; Smith E, 2005, BMJ-BRIT MED J, V330, P406, DOI 10.1136/bmj.330.7488.406; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trojano L, 2009, J REHABIL MED, V41, P393, DOI 10.2340/16501977-0344; World Health Organization, 2001, INT CLASS FUNCT DIS	53	46	47	0	8	C I C-EDIZIONI INT SRL	ROME	CORSO TRIESTE, 42, 00198 ROME, ITALY	0393-5264	1971-3274		FUNCT NEUROL	Funct. Neurol.	JAN-MAR	2011	26	1					15	24					10	Clinical Neurology	Neurosciences & Neurology	789OJ	WOS:000292524900003	21693084				2021-06-18	
J	Matheson, GO; Shultz, R; Bido, J; Mitten, MJ; Meeuwisse, WH; Shrier, I				Matheson, Gordon O.; Shultz, Rebecca; Bido, Jennifer; Mitten, Matthew J.; Meeuwisse, Willem H.; Shrier, Ian			Return-to-Play Decisions: Are They the Team Physician's Responsibility?	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						return to play; medical decision making; sport participation; injury	CRUCIATE LIGAMENT RECONSTRUCTION; SPORT; INJURIES; ISSUES; COSTS; CARE	Objective: Return-to-play (RTP) decisions are a central component of the Team Physician's clinical work, yet there is little more than anecdotal reference to these in the literature. We recently published a 3-step model for return-to-play medical decision making and, in the current paper, undertook a systematic review of the literature to determine the level of evidence in support of this model. Data Sources: PubMed, Web of Science, and CINAHL electronic databases. Any article specifically related to concussion, head injuries, neck injuries, illness, medical conditions (including cardiovascular and renal), and preparticipation in sport or that reported RTP as a clinical outcome was excluded. Any article that contained a discussion on one of the components of the 3-step decision-based RTP model was included. Results: We reviewed 148 articles that met the criteria for inclusion and found 98 review articles, 39 original articles, 6 case reports, and 5 editorials. Of these, 141 articles mentioned Step 1 of the medical decision-making process for RTP (Medical Factors), 26 mentioned Step 2 (Sport Risk Modifiers), and 20 mentioned Step 3 (Decision Modifiers). Of the 148 articles in total, only 13 focused on RTP as the main subject and the remaining 135 mentioned RTP anecdotally. Of these 13 articles, 5 were reviews, 4 were editorials, and 4 were original research. Conclusions: Although 148 articles we retrieved mention RTP in relation to a specific injury, medical condition, or specific topic, only 13 articles focused specifically on the RTP decision-making process, and 6 of 13 were restricted to Step 1 of the 3-step model (Medical Factors). Return-to-play is a fertile field for research and thought leadership beginning with a focus on the Team Physician's appropriate role in RTP decision making, particularly considering the factors identified in Step 3 (Decision Modification).	[Matheson, Gordon O.] Stanford Univ, Sch Med, Dept Orthopaed Surg, Ctr Sports Med,Div Sports Med, Stanford, CA 94305 USA; [Matheson, Gordon O.; Shultz, Rebecca; Meeuwisse, Willem H.; Shrier, Ian] Res Alliance Sport & Exercise Med, Stanford, CA USA; [Shultz, Rebecca; Bido, Jennifer] Stanford Univ, Sch Med, Dept Orthopaed Surg, Human Performance Lab, Stanford, CA 94305 USA; [Mitten, Matthew J.] Marquette Univ, Sch Law, Milwaukee, WI 53233 USA; [Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Shrier, Ian] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Ctr Clin Epidemiol & Community Studies, Montreal, PQ H3T 1E2, Canada	Matheson, GO (corresponding author), Stanford Univ, Sch Med, Dept Orthopaed Surg, Ctr Sports Med,Div Sports Med, 341 Galvez St, Stanford, CA 94305 USA.	gord@stanford.edu	Shrier, Ian/AAI-6502-2020	Shrier, Ian/0000-0001-9914-3498			Anderson RB, 2010, J AM ACAD ORTHOP SUR, V18, P546, DOI 10.5435/00124635-201009000-00006; Bauman J, 2005, CLIN J SPORT MED, V15, P432, DOI 10.1097/01.jsm.0000186682.21040.82; Best TM, 2005, CLIN J SPORT MED, V15, P403, DOI 10.1097/01.jsm.0000187076.74606.75; Bolin D, 2005, CLIN J SPORT MED, V15, P405, DOI 10.1097/01.jsm.0000187078.20348.2c; Bowen TR, 2004, CLIN SPORT MED, V23, P381, DOI 10.1016/j.csm.2004.03.001; Brukner P, 2005, CLIN J SPORT MED, V15, P459, DOI 10.1097/01.jsm.0000192511.38996.99; Button K, 2005, BRIT J SPORT MED, V39, P866, DOI 10.1136/bjsm.2005.019984; Button K, 2005, BRIT J SPORT MED, V39, P866; Cantu RC, 1998, CLIN SPORT MED, V17, pXI, DOI 10.1016/S0278-5919(05)70055-7; Cascio BM, 2004, CLIN SPORT MED, V23, P395, DOI 10.1016/j.csm.2004.03.004; Clover J, 2010, CLIN SPORT MED, V29, P169, DOI 10.1016/j.csm.2009.09.008; Creighton DW, 2010, CLIN J SPORT MED, V20, P379, DOI 10.1097/JSM.0b013e3181f3c0fe; Diehl JJ, 2006, CLIN SPORT MED, V25, P17, DOI 10.1016/j.csm.2005.08.012; Fagan K, 2004, CLIN SPORT MED, V23, P409, DOI 10.1016/j.csm.2004.03.003; Friedman SM, 2009, ARCH INTERN MED, V169, P1712, DOI 10.1001/archinternmed.2009.321; Fuller CW, 2007, CLIN J SPORT MED, V17, P197, DOI 10.1097/JSM.0b013e3180471b89; Fuller CW, 2006, BRIT J SPORT MED, V40, P151, DOI 10.1136/bjsm.2005.021048; Glazer DD, 2009, J ATHL TRAINING, V44, P185, DOI 10.4085/1062-6050-44.2.185; Gobbi A, 2006, KNEE SURG SPORT TR A, V14, P1021, DOI 10.1007/s00167-006-0050-9; Herring SA, 2002, MED SCI SPORT EXER, V34, P1212; Ho DM, 2007, J AM COLL SURGEONS, V205, P97, DOI 10.1016/j.jamcollsurg.2007.03.009; Kim K, 2008, ACAD EMERG MED, V15, P319, DOI 10.1111/j.1553-2712.2008.00070.x; Kovacic J, 2005, CLIN J SPORT MED, V15, P448, DOI 10.1097/01.jsm.0000188208.00727.0b; Langford JL, 2009, BRIT J SPORT MED, V43, P377, DOI 10.1136/bjsm.2007.044818; LEVINE BD, 1994, MED SCI SPORT EXER, V26, P1190; Liebert PL, 2006, MERCK MANUAL, P2631; McFarland EG, 2004, CLIN SPORT MED, V23, pXV, DOI 10.1016/S0278-5919(04)00039-0; Miller Mark D, 2009, Instr Course Lect, V58, P437; MITTEN MJ, 1995, J ORTHOP SPORT PHYS, V21, P38, DOI 10.2519/jospt.1995.21.1.38; MITTEN MJ, 1993, U PITT LAW REV, V55, P129; Mitten MJ, 1998, MARQUETTE SPORTS LAW, V8, P189; MITTEN MJ, 2002, ST JOHNS L REV, V76, P5; Moeller JL, 1996, PHYSICIAN SPORTSMED, V24, P47, DOI 10.3810/psm.1996.08.1376; Moeller JL, 1998, MANUAL SPORTS MED, P21; Myklebust G, 2005, BRIT J SPORT MED, V39, P127, DOI 10.1136/bjsm.2004.010900; Orchard JW, 2004, SPORTS MED, V34, P209, DOI 10.2165/00007256-200434040-00001; Podlog L, 2006, J APPL SPORT PSYCHOL, V18, P44, DOI 10.1080/10413200500471319; Podlog L, 2007, PSYCHOL SPORT EXERC, V8, P535, DOI 10.1016/j.psychsport.2006.07.008; Putukian M, 1998, PHYSICIAN SPORTSMED, V26, P25, DOI 10.3810/psm.1998.09.1125; Stovitz Steven D, 2006, Curr Sports Med Rep, V5, P120; Tripp DA, 2007, REHABIL PSYCHOL, V52, P74, DOI 10.1037/0090-5550.52.1.74; Tucker AM, 2004, CLIN SPORT MED, V23, P227, DOI 10.1016/j.csm.2004.01.001; Verrall GM, 2006, MED J AUSTRALIA, V184, P244, DOI 10.5694/j.1326-5377.2006.tb00215.x	43	46	48	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2011	21	1					25	30		10.1097/JSM.0b013e3182095f92			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	702AM	WOS:000285866300005	21200167				2021-06-18	
J	Novikova, LN; Brohlin, M; Kingham, PJ; Novikov, LN; Wiberg, M				Novikova, Liudmila N.; Brohlin, Maria; Kingham, Paul J.; Novikov, Lev N.; Wiberg, Mikael			Neuroprotective and growth-promoting effects of bone marrow stromal cells after cervical spinal cord injury in adult rats	CYTOTHERAPY			English	Article						bone marrow; mesenchymal stromal cells; red nucleus; retrograde degeneration; spinal cord trauma; transplantation	AXOTOMIZED RUBROSPINAL NEURONS; OLFACTORY ENSHEATHING GLIA; ISCHEMIC BOUNDARY ZONE; TRAUMATIC BRAIN-INJURY; STEM-CELLS; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTOR; AXONAL REGENERATION; CONTUSION INJURY; NERVOUS-SYSTEM	Background aims. Bone marrow stromal cells (BMSC) have been shown to provide neuroprotection after transplantation into the injured central nervous system. The present study investigated whether adult rat BMSC differentiated along a Schwann cell lineage could increase production of trophic factors and support neuronal survival and axonal regeneration after transplantation into the injured spinal cord. Methods. After cervical C4 hemi-section, 5-bromo-2-deoxyuridine (BrdU)/ green fluorescent protein (GFP)-labeled BMSC were injected into the lateral funiculus at 1 mm rostral and caudal to the lesion site. Spinal cords were analyzed 2-13 weeks after transplantation. Results and Conclusions. Treatment of native BMSC with Schwann cell-differentiating factors significantly increased production of brain-derived neurotrophic factor in vitro. Transplanted undifferentiated and differentiated BMSC remained at the injection sites, and in the trauma zone were often associated with neurofilament-positive fibers and increased levels of vascular endothelial growth factor. BMSC promoted extensive in-growth of serotonin-positive raphaespinal axons and calcitonin gene-related peptide (CGRP)-positive dorsal root sensory axons into the trauma zone, and significantly attenuated astroglial and microglial cell reactions, but induced aberrant sprouting of CGRP-immunoreactive axons in Rexed's lamina III. Differentiated BMSC provided neuroprotection for axotomized rubrospinal neurons and increased the density of rubrospinal axons in the dorsolateral funiculus rostral to the injury site. The present results suggest that BMSC induced along the Schwann cell lineage increase expression of trophic factors and have neuroprotective and growth-promoting effects after spinal cord injury.	[Novikova, Liudmila N.; Brohlin, Maria; Kingham, Paul J.; Novikov, Lev N.; Wiberg, Mikael] Umea Univ, Sect Anat, Dept Integrat Med Biol, SE-90187 Umea, Sweden; [Wiberg, Mikael] Umea Univ, Sect Hand & Plast Surg, Dept Surg & Perioperat Sci, SE-90187 Umea, Sweden	Novikova, LN (corresponding author), Umea Univ, Sect Anat, Dept Integrat Med Biol, SE-90187 Umea, Sweden.	liudmila.novikova@anatomy.umu.se	Novikov, Lev/I-1983-2012	Novikov, Lev/0000-0001-5520-3890; Kingham, Paul/0000-0003-2596-5936	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Umea University; County of Vasterbotten; Ake Wibergs Stiftelse; Magn. Bergvalls Stiftelse; Clas Groschinskys Minnesfond; Anna-Stina och John Mattsons Minnesstiftelse for sonen Johan; Gunvor and Josef Aner Foundation	This study was supported by the Swedish Medical Research Council, Umea University, County of Vasterbotten, Ake Wibergs Stiftelse, Magn. Bergvalls Stiftelse, Clas Groschinskys Minnesfond, Anna-Stina och John Mattsons Minnesstiftelse for sonen Johan and the Gunvor and Josef Aner Foundation. We thank Mrs G. Folkesson and Mrs G. Hallstrom for technical assistance.	Abrams MB, 2009, RESTOR NEUROL NEUROS, V27, P307, DOI 10.3233/RNN-2009-0480; Adams M, 2007, SPINAL CORD, V45, P2, DOI 10.1038/sj.sc.3101963; Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Brass LM, 2006, EXP NEUROL, V199, P16, DOI 10.1016/j.expneurol.2006.03.009; Brohlin M, 2009, NEUROSCI RES, V64, P41, DOI 10.1016/j.neures.2009.01.010; Caddick J, 2006, GLIA, V54, P840, DOI 10.1002/glia.20421; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen CJ, 2007, EXP NEUROL, V204, P443, DOI 10.1016/j.expneurol.2006.12.004; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chopp M, 2009, J NEUROSURG, V110, P1186, DOI 10.3171/2008.10.JNS081254; Coutts M, 2008, EXP NEUROL, V209, P368, DOI 10.1016/j.expneurol.2007.09.002; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Deumens R, 2005, PROG NEUROBIOL, V77, P57, DOI 10.1016/j.pneurobio.2005.10.004; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dezawa M, 2008, MED MOL MORPHOL, V41, P14, DOI 10.1007/s00795-007-0389-0; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Enzmann GU, 2006, J NEUROTRAUM, V23, P479, DOI 10.1089/neu.2006.23.479; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Franssen EHP, 2007, BRAIN RES REV, V56, P236, DOI 10.1016/j.brainresrev.2007.07.013; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; Hejcl A, 2010, STEM CELLS DEV, V19, P1535, DOI 10.1089/scd.2009.0378; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Houle JD, 1999, NEUROSCIENCE, V94, P929, DOI 10.1016/S0306-4522(99)00359-0; Ide C, 2010, BRAIN RES, V1332, P32, DOI 10.1016/j.brainres.2010.03.043; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kamada T, 2011, NEUROPATHOLOGY, V31, P48, DOI 10.1111/j.1440-1789.2010.01130.x; Karussis D, 2008, J NEUROL SCI, V265, P131, DOI 10.1016/j.jns.2007.05.005; Kobayashi NR, 1997, J NEUROSCI, V17, P9583; Kocsis JD, 2004, J NEUROTRAUM, V21, P441, DOI 10.1089/089771504323004584; Kuroda Y, 2010, P NATL ACAD SCI USA, V107, P8639, DOI 10.1073/pnas.0911647107; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Lowry N, 2008, EXP NEUROL, V209, P510, DOI 10.1016/j.expneurol.2007.09.031; Lu P, 2004, J NEUROSCI RES, V77, P174, DOI 10.1002/jnr.20148; Lu P, 2008, EXP NEUROL, V209, P313, DOI 10.1016/j.expneurol.2007.08.004; Ma JJ, 2001, EXP BRAIN RES, V139, P216, DOI 10.1007/s002210100769; Munoz-Quiles C, 2009, J NEUROPATH EXP NEUR, V68, P1294, DOI 10.1097/NEN.0b013e3181c34bbe; Namiki J, 2000, J NEUROTRAUM, V17, P1219, DOI 10.1089/neu.2000.17.1219; Nandoe RDS, 2006, CELL TRANSPLANT, V15, P563, DOI 10.3727/000000006783981602; Neuhuber B, 2005, BRAIN RES, V1035, P73, DOI 10.1016/j.brainres.2004.11.055; Neuhuber B, 2004, J NEUROSCI RES, V77, P192, DOI 10.1002/jnr.20147; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; Novikov LN, 2002, BIOMATERIALS, V23, P3369, DOI 10.1016/S0142-9612(02)00037-6; Novikov LN, 2001, J NEUROSCI METH, V112, P145, DOI 10.1016/S0165-0270(01)00461-7; Novikova L, 1996, NEUROSCI LETT, V220, P203, DOI 10.1016/S0304-3940(96)13267-5; Novikova LN, 2000, EUR J NEUROSCI, V12, P776, DOI 10.1046/j.1460-9568.2000.00978.x; Novikova LN, 2002, J COMP NEUROL, V452, P255, DOI 10.1002/cne.10381; Osaka M, 2010, BRAIN RES, V1343, P226, DOI 10.1016/j.brainres.2010.05.011; Oudega M, 2006, J NEUROTRAUM, V23, P453, DOI 10.1089/neu.2006.23.453; Park HW, 2010, GLIA, V58, P1118, DOI 10.1002/glia.20992; Parr AM, 2008, SURG NEUROL, V70, P600, DOI 10.1016/j.surneu.2007.09.043; PAXINOS G, 1985, RAT NERVOUS SYSTEM, P362; Pearse DD, 2006, J NEUROTRAUM, V23, P438, DOI 10.1089/neu.2006.23.437; Raisman G, 2004, NAT REV NEUROSCI, V5, P157, DOI 10.1038/nrn1328; Raisman G, 2011, EXP NEUROL, V229, P168, DOI 10.1016/j.expneurol.2010.05.007; Ratajczak MZ, 2009, AM J PATHOL, V174, P1985, DOI 10.2353/ajpath.2009.081143; Richter MW, 2008, EXP NEUROL, V209, P353, DOI 10.1016/j.expneurol.2007.06.011; Rossignol S, 2007, J NEUROSCI, V27, P11782, DOI 10.1523/JNEUROSCI.3444-07.2007; Ruitenberg MJ, 2003, J NEUROSCI, V23, P7045, DOI 10.1523/JNEUROSCI.23-18-07045.2003; Sasaki M, 2009, J NEUROSCI, V29, P14932, DOI 10.1523/JNEUROSCI.2769-09.2009; Schuhmann B, 2005, J NEUROIMMUNOL, V163, P15, DOI 10.1016/j.jneuroim.2005.01.023; Sharp J, 2009, NEUROSCI LETT, V456, P107, DOI 10.1016/j.neulet.2008.04.106; Shen LH, 2010, GLIA, V58, P1074, DOI 10.1002/glia.20988; Singec I, 2007, ANNU REV MED, V58, P313, DOI 10.1146/annurev.med.58.070605.115252; Someya Y, 2008, J NEUROSURG-SPINE, V9, P600, DOI 10.3171/SPI.2008.9.08135; Swanger SA, 2005, CELL TRANSPLANT, V14, P775, DOI 10.3727/000000005783982594; Tator CH, 2006, NEUROSURGERY, V59, P957, DOI 10.1227/01.NEU.0000245591.16087.89; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Widenfalk J, 2003, NEUROSCIENCE, V120, P951, DOI 10.1016/S0306-4522(03)00399-3; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wright KT, 2007, BIOCHEM BIOPH RES CO, V354, P559, DOI 10.1016/j.bbrc.2007.01.013; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Yaghoobi MM, 2006, NEUROSCI LETT, V397, P149, DOI 10.1016/j.neulet.2005.12.009; Yoshihara H, 2006, BRAIN RES, V1119, P65, DOI 10.1016/j.brainres.2006.08.080; Zhukareva V, 2010, CYTOKINE, V50, P317, DOI 10.1016/j.cyto.2010.01.004; Zurita M, 2008, TRANSPLANTATION, V86, P845, DOI 10.1097/TP.0b013e318186198f	82	46	56	0	12	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1465-3249			CYTOTHERAPY	Cytotherapy		2011	13	7					873	887		10.3109/14653249.2011.574116			15	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	807BM	WOS:000293868300011	21521004				2021-06-18	
J	Schiehser, DM; Delis, DC; Filoteo, JV; Delano-Wood, L; Han, SD; Jak, AJ; Drake, AI; Bondi, MW				Schiehser, Dawn M.; Delis, Dean C.; Filoteo, J. Vincent; Delano-Wood, Lisa; Han, S. Duke; Jak, Amy J.; Drake, Angela I.; Bondi, Mark W.			Are self-reported symptoms of executive dysfunction associated with objective executive function performance following mild to moderate traumatic brain injury?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Neuropsychology; Cognition; Behavior; Depression	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; MAJOR DEPRESSIVE DISORDER; GULF-WAR VETERANS; HEAD-INJURY; COGNITIVE COMPLAINTS; MILITARY POPULATION; DEFICITS; IMPAIRMENT; PREDICTORS; SOLDIERS	Background and objective: We examined the relationship between self-reported pre- and post-injury changes in executive dysfunction, apathy, disinhibition, and depression, and performance on neuropsychological tests of executive function, attention/processing speed, and memory in relation to mood levels and effort test performance in individuals in the early stages of recovery from mild to moderate traumatic brain injury (TBI). Method: Participants were 71 noncombat military personnel who were in a semiacute stage of recovery (<3 months post injury) from mild to moderate TBI. Pre- and post-TBI behaviors were assessed with the Frontal Systems Behavior Scale (FrSBe; Grace & Malloy, 2001) and correlated with levels of depressive symptoms, effort test performance, and performance on objective measures of attention, executive function, and memory. Results: Self-reported symptoms of executive dysfunction generally failed to predict performance on objective measures of executive function and memory, although they predicted poorer performance on measures of attention/processing speed. Instead, higher levels of depressive symptomatology best predicted poorer performance on measures of executive function and memory. However, the relationship between memory performance and TBI symptoms was no longer significant when effort performance was controlled. Conclusions: Our findings suggest that, among individuals in early recovery from mild to moderate TBI, self-reported depressive symptoms, rather than patients' cognitive complaints, are associated with objective executive function. However, self-reported cognitive complaints may be associated with objectively measured inattention and slow processing speed.	[Schiehser, Dawn M.; Delis, Dean C.; Filoteo, J. Vincent; Delano-Wood, Lisa; Jak, Amy J.; Bondi, Mark W.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92161 USA; [Schiehser, Dawn M.; Delis, Dean C.; Filoteo, J. Vincent; Delano-Wood, Lisa; Jak, Amy J.; Bondi, Mark W.] VA San Diego Healthcare Syst, Psychol Serv, San Diego, CA 92161 USA; [Schiehser, Dawn M.; Delis, Dean C.; Filoteo, J. Vincent; Delano-Wood, Lisa; Jak, Amy J.; Bondi, Mark W.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Delis, Dean C.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA; [Han, S. Duke] Rush Univ, Med Ctr, Dept Behav Sci, Chicago, IL 60612 USA; [Drake, Angela I.] USN, Med Ctr, Def & Vet Brain Injury Ctr, Neurosci Dept, San Diego, CA 92152 USA	Bondi, MW (corresponding author), VA San Diego Healthcare Syst, Psychol Serv 116B, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	mbondi@ucsd.edu	Han/N-1246-2019		Medical Research Service; Center of Excellence for Stress and Mental Health (CESAMH) of the Department of Veterans Affairs; Defense and Veterans Brain Injury Center, San Diego, California, USA; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24AG026431] Funding Source: NIH RePORTER	This study was supported by Merit Review Research Programs from the Medical Research Service and the Center of Excellence for Stress and Mental Health (CESAMH) of the Department of Veterans Affairs (M. W. B. and D. C. D.) and by the Defense and Veterans Brain Injury Center, San Diego, California, USA. The authors gratefully acknowledge the staff, patients, and volunteers at the Naval Medical Center San Diego and the U. S. Marine Corps Base Camp Pendleton for their assistance with this study. Dean C. Delis is a coauthor of the D-KEFS (Delis-Kaplan Executive Function System) and the California Verbal Learning Test-Second Edition (CVLT-II). There were no other actual or potential conflicts of interest for the authors that could have inappropriately influenced the present work. Subjects were recruited in accordance with Internal Review Board (IRB) approved policies and procedures. Standard ethical and professional guidelines were upheld during the research study and manuscript preparation. The views expressed in this article do not necessarily reflect those of the funding agency, the United States Navy, the United States Marine Corps, the Department of Defense, or the United States Government.	ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Beer JS, 2006, J COGNITIVE NEUROSCI, V18, P871, DOI 10.1162/jocn.2006.18.6.871; Binder LM, 1999, ARCH CLIN NEUROPSYCH, V14, P531, DOI 10.1016/S0887-6177(98)00047-X; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Defense and Veterans Brain Injury Center, 2010, DEP DEF NUMB TRAUM B; Defense and Veterans Brain Injury Center, 2007, DEF VET BRAIN INJ CT; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; Han SD, 2009, J HEAD TRAUMA REHAB, V24, P57, DOI 10.1097/HTR.0b013e3181957055; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Levin H. S., 1987, NEUROBEHAVIORAL SEQU; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; MASSMAN PJ, 1992, J CLIN EXP NEUROPSYC, V14, P687, DOI 10.1080/01688639208402856; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Ottowitz WE, 2002, HARVARD REV PSYCHIAT, V10, P86, DOI 10.1080/10673220216210; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sillanpaa MC, 1997, J CLIN EXP NEUROPSYC, V19, P211, DOI 10.1080/01688639708403852; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M	52	46	46	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	6					704	714		10.1080/13803395.2011.553587			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	882GA	WOS:000299550100010	21958432	Green Accepted			2021-06-18	
J	Schroeder, RW; Marshall, PS				Schroeder, Ryan W.; Marshall, Paul S.			Evaluation of the Appropriateness of Multiple Symptom Validity Indices in Psychotic and Non-Psychotic Psychiatric Populations	CLINICAL NEUROPSYCHOLOGIST			English	Article						Psychotic; Psychiatric; Suspect effort; Symptom validity; Malingering	MALINGERED NEUROCOGNITIVE DYSFUNCTION; DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; WORD MEMORY TEST; SUSPECT EFFORT; DIGIT SPAN; CLASSIFICATION ACCURACY; NEGATIVE SYMPTOMS; MAJOR DEPRESSION; CHRONIC PAIN	Although it is recognized that significant cognitive deficits are inherent in many psychiatric disorders, there is minimal research on whether the deficits can cause a failing score on symptom validity tests (SVTs). The performances of 104 and 178 patients with psychotic disorders and non-psychotic psychiatric disorders, respectively, on seven SVTs were examined. Analyses indicate that most of these SVTs have specificity rates of 90% or better for both clinical groups. Further, only 7% of patients in the psychotic group and 5% of patients in the non-psychotic psychiatric group produced false-positive classifications based on malingering criteria similar to those suggested by Slick etal. (i.e., failure of two or more SVTs or failure of one SVT at statistically significantly worse than chance rates). Consequently this research indicates that psychiatric disorders typically do not adversely affect SVT performance.	[Schroeder, Ryan W.; Marshall, Paul S.] Hennepin Cty Med Ctr, Dept Psychiat, Minneapolis, MN 55404 USA; [Schroeder, Ryan W.] Univ Kansas, Sch Med, Wichita, KS 67214 USA	Schroeder, RW (corresponding author), Hennepin Cty Med Ctr, Dept Psychiat, Room S110,914 S 8th St, Minneapolis, MN 55404 USA.	Ryan.W.Schroeder.PsyD@hotmail.com					Allen MD, 2007, BRAIN INJURY, V21, P1425, DOI 10.1080/02699050701769819; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andreasen N.C., 1983, SCALE ASSESSMENT NEG; Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Batt K, 2008, J INT NEUROPSYCH SOC, V14, P1074, DOI 10.1017/S135561770808137X; Boone K., 2002, B TEST MANUAL; Boone K., 2002, DOT COUNTING TEST; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2001, DELISKAPLAN EXECUTIV; EATON WW, 1995, ARCH GEN PSYCHIAT, V52, P127; Elvevag B, 2000, CRIT REV NEUROBIOL, V14, P1; GOLDBERG HB, 2007, ASSESSMENT FEIGNED C; Gorissen M, 2005, SCHIZOPHR RES, V78, P199, DOI 10.1016/j.schres.2005.02.016; Gorlyn M, 2006, J CLIN EXP NEUROPSYC, V28, P1145, DOI 10.1080/13803390500246944; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; Green P, 2003, WORD MEMORY TEST WIN; Green P., 1995, MANUAL ORAL WORD MEM; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2010, CLIN NEUROPSYCHOL, V24, P137, DOI 10.1080/13854040902927546; HAMMER MA, 1995, BIOL PSYCHIAT, V37, P828, DOI 10.1016/0006-3223(95)00040-N; Heaton RK, 2001, ARCH GEN PSYCHIAT, V58, P24, DOI 10.1001/archpsyc.58.1.24; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Keefe RSE, 2007, ARCH GEN PSYCHIAT, V64, P633, DOI 10.1001/archpsyc.64.6.633; Killgore WDS, 2000, J CLIN EXP NEUROPSYC, V22, P761; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lewis R, 1977, ANN M SE PSYCH ASS H; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LIDDLE PF, 1991, BRIT J PSYCHIAT, V158, P340, DOI 10.1192/bjp.158.3.340; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Meyers J., 1995, REY COMPLEX FIGURE T; Porter RJ, 2007, AUST NZ J PSYCHIAT, V41, P115, DOI 10.1080/00048670601109881; Reichenberg A, 2007, PSYCHOL BULL, V133, P833, DOI 10.1037/0033-2909.133.5.833; Reitan R.M., 1993, HALSTEADREITAN NEURO; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Rund BR, 2006, ACTA PSYCHIAT SCAND, V113, P350, DOI 10.1111/j.1600-0447.2005.00626.x; Schroeder RW, 2010, CLIN NEUROPSYCHOL, V24, P326, DOI 10.1080/13854040903369441; Seidman L. J., 1992, CLIN SYNDROMES ADULT, P381; SHORES EA, 2008, EXPT ANAL IMME UNPUB; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sullivan BK, 2007, APPL NEUROPSYCHOL, V14, P189, DOI 10.1080/09084280701509083; Tombaugh TN, 1996, TEST MEMORY MALINGER; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weiser M, 2004, ACTA PSYCHIAT SCAND, V110, P471, DOI 10.1111/j.1600-0447.2004.00385.x	58	46	46	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					437	453	PII 934343359	10.1080/13854046.2011.556668			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100007	21391153				2021-06-18	
J	Melo, JRT; Di Rocco, F; Blanot, S; Oliveira, J; Roujeau, T; Sainte-Rose, C; Duracher, C; Vecchione, A; Meyer, P; Zerah, M				Tude Melo, Jose Roberto; Di Rocco, Federico; Blanot, Stephane; Oliveira-Filho, Jamary; Roujeau, Thomas; Sainte-Rose, Christian; Duracher, Caroline; Vecchione, Antonio; Meyer, Philippe; Zerah, Michel			Mortality in Children With Severe Head Trauma: Predictive Factors and Proposal for a New Predictive Scale	NEUROSURGERY			English	Article						Craniocerebral trauma; Mortality; Pediatric; Prognosis	SEVERE BRAIN-INJURY; PREHOSPITAL EMERGENCY CARE; PROGNOSTIC FACTORS; HYPERGLYCEMIA; EPIDEMIOLOGY; EXPERIENCE; MANAGEMENT; IMPACT; HYPOTHERMIA; OUTCOMES	BACKGROUND: Traumatic brain injury is a public health problem around the world, and recognition of systemic sources of secondary brain lesions is crucial to improve outcome. OBJECTIVE: To identify the main predictors of mortality and to propose a grading scale to measure the risk of death. METHODS: This retrospective study was based on medical records of children with severe traumatic brain injury who were hospitalized at a level I pediatric trauma center between January 2000 and December 2005. Multiple logistic regression analysis was done to identify independent factors related to mortality. A receiver-operating characteristics curve was performed to verify the accuracy of the multiple logistic regression, and associations that increased mortality were verified. RESULTS: We identified 315 children with severe head injury. Median Glasgow Coma Scale score was 6, and median Pediatric Trauma Score was 4. Global mortality rate was 30%, and deaths occurred despite adequate medical management within the first 48 hours in 79% of the patients. Age < 2 years (P = .02), Glasgow Coma Scale <= 5 (P < 10(-5)), accidental hypothermia (P = .0002), hyperglycemia (P = .0003), and coagulation disorders (P = .02) were all independent factors predicting mortality. A prognostic scale ranging from 0 to 6 that included these independent factors was then calculated for each patient and resulted in mortality rates ranging from 1% with a score of 6 to 100% with a score of 0. CONCLUSION: Independent and modifiable mortality predictors could be identified and used for a new grading scale correlated with the risk of mortality in pediatric traumatic brain injury.	[Tude Melo, Jose Roberto; Di Rocco, Federico; Roujeau, Thomas; Sainte-Rose, Christian; Zerah, Michel] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Dept Pediat Neurosurg, Paris, France; [Tude Melo, Jose Roberto; Oliveira-Filho, Jamary] Univ Fed Bahia, Sch Med, Postgrad Program Med & Hlth, BR-41170290 Salvador, BA, Brazil; [Blanot, Stephane; Duracher, Caroline; Vecchione, Antonio; Meyer, Philippe] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Pediat Surg Crit Care Unit & Anesthesiol, Paris, France	Melo, JRT (corresponding author), Alameda Jasmins 200,702 B Cidade Jardim, BR-40296200 Salvador, BA, Brazil.	robertotude@gmail.com	Meyer, Philippe/ABE-4242-2020; DI ROCCO, Federico/C-6343-2015; ZERAH, Michel/E-6473-2012; Oliveira-Filho, Jamary/B-6441-2016	Meyer, Philippe/0000-0002-3829-6631; Oliveira-Filho, Jamary/0000-0003-1915-0423; Di Rocco, Federico/0000-0003-2145-5533	Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	This work was supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Exchange Program for PhD studies. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Balzan S, 2005, ANN SURG, V242, P824, DOI 10.1097/01.sla.0000189131.90876.9e; Bardella IJ, 1999, AM FAM PHYSICIAN, V60, P1743; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; Bochicchio GV, 2007, J TRAUMA, V63, P1353, DOI 10.1097/TA.0b013e31815b83c4; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Danzl D, 2002, SEMIN RESP CRIT CARE, V23, P57, DOI 10.1055/s-2002-20589; Davis P R, 2005, J R Army Med Corps, V151, P223; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; GAILLARD M, 1989, ANN PEDIATR-PARIS, V36, P194; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; Grinkeviciute DE, 2007, MEDICINA-LITHUANIA, V43, P861, DOI 10.3390/medicina43110111; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Jagannathan J, 2007, J NEUROSURG, V106, pA761; Javouhey E, 2006, EUR J PEDIATR, V165, P519, DOI 10.1007/s00431-006-0118-z; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Meyer P, 1999, CHILD NERV SYST, V15, P732, DOI 10.1007/s003810050462; Meyer P, 2006, ARCH PEDIATRIE, V13, P737, DOI 10.1016/j.arcped.2006.03.023; Meyer P G, 2001, Curr Opin Crit Care, V7, P81, DOI 10.1097/00075198-200104000-00005; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Orliaguet C, 2000, ANN FR ANESTH, V19, P164; Orliaguet GA, 2008, PEDIATR ANESTH, V18, P455, DOI 10.1111/j.1460-9592.2008.02507.x; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; Melo JRT, 2006, ARQ NEURO-PSIQUIAT, V64, P994, DOI 10.1590/S0004-282X2006000600020; Tentillier E, 2000, ANN FR ANESTH, V19, P275; Tentillier E, 2004, ANN FR ANESTH, V23, P109, DOI 10.1016/j.annfar.2003.11.019; Thelot B, 2006, Sante Publique, V18, P523; Trabold F, 2002, ANN FR ANESTH, V21, P141, DOI 10.1016/S0750-7658(01)00513-5; Tursz A, 1990, Paediatr Perinat Epidemiol, V4, P408, DOI 10.1111/j.1365-3016.1990.tb00668.x; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Weigand K, 2009, MED KLIN, V104, P331, DOI 10.1007/s00063-009-1070-2	38	46	48	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2010	67	6					1542	1547		10.1227/NEU.0b013e3181fa7049			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	685DF	WOS:000284606500026	21107185				2021-06-18	
J	Echlin, PS; Johnson, AM; Riverin, S; Tator, CH; Cantu, RC; Cusimano, MD; Taunton, JE; Upshur, REG; Hall, CR; Forwell, LA; Skopelja, EN				Echlin, Paul Sean; Johnson, Andrew M.; Riverin, Suzanne; Tator, Charles H.; Cantu, Robert C.; Cusimano, Michael D.; Taunton, Jack E.; Upshur, Ross E. G.; Hall, Craig R.; Forwell, Lorie A.; Skopelja, Elaine N.			A prospective study of concussion education in 2 junior ice hockey teams: implications for sports concussion education	NEUROSURGICAL FOCUS			English	Article						concussion; ice hockey; education; Hockey Concussion Education Project; Canada	PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; INJURY PREVENTION; HEAD-INJURY; KNOWLEDGE; COACHES; RETURN; GUIDELINES; BRAIN; VIDEO	Object. The aim of this study was to evaluate the effectiveness of an educational intervention on concussion knowledge within a sample of junior fourth-tier ice hockey players. Methods. A prospective cohort study, called the Hockey Concussion Education Project, was conducted during 1 junior ice hockey regular season (2009-2010) with 67 male fourth-tier ice hockey players (mean age 18.2 +/- 1.2 years, range 16-21 years) from 2 teams. All participating players were randomized into 3 concussion education intervention groups (DVD group, interactive computer module [ICM] group, or control group) before the beginning of the season. Each individual received a preintervention knowledge test prior to the intervention. The DVD and ICM groups received a posttest after the completion of their intervention. All participants were offered the same knowledge test at 15 games (50 days) and 30 games (91 days) later. Results. In the concussion education intervention component no significant group differences were observed at baseline between individuals in the control group and between individuals within the interventional group. At the 15-game follow-up, however, the difference between groups approached significance (F [1,30] = 3.91, p = 0.057). This group difference remained consistent at the 30-game follow-up. Conclusions. This study demonstrates a positive trend concerning concussion education intervention and knowledge acquisition with either the ICMs or the educational DVD. Both forms of intervention produced a positive and sustainable improvement that approached statistical significance when compared with the control group. The control group demonstrated a negative longitudinal trend concerning concussion knowledge. (DOI: 10.3171/2010.9.FOCUS10187)	[Echlin, Paul Sean] AIM Hlth Grp Family Med, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Fac Hlth Sci, London, ON, Canada; [Riverin, Suzanne] Nipissing Univ, Fac Educ, N Bay, ON, Canada; [Tator, Charles H.; Cusimano, Michael D.] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Taunton, Jack E.] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC V5Z 1M9, Canada; [Taunton, Jack E.] Univ British Columbia, Sch Human Kinet, Vancouver, BC V5Z 1M9, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Family, Toronto, ON M5S 1A1, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Community Med, Toronto, ON M5S 1A1, Canada; [Hall, Craig R.] Univ Western Ontario, Sch Kinesiol, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Dept Physiotherapy, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Sch Med Lib, Indianapolis, IN 46204 USA	Echlin, PS (corresponding author), 320 Adelaide St, S London, ON N5Z 3L2, Canada.	p_echlinfp@hotmail.com	Cusimano, Michael/X-4059-2019; Johnson, Andrew M/B-2048-2012	Cusimano, Michael/0000-0002-9989-0650; Johnson, Andrew M./0000-0002-7269-3016; Upshur, Ross/0000-0003-1128-0557	Ontario Trillium Foundation; Dr. Tom Pashby Safety Fund; Dave Irwin Foundation for Brain Injury; Canadian Institutes of Health Strategic Teams in Applied Injury Research	This work was funded by the Ontario Trillium Foundation, the Dr. Tom Pashby Safety Fund, and the Dave Irwin Foundation for Brain Injury. The Ontario Neurotrauma Foundation made administrative and facilitative contributions. Dr. Cusimano is funded by the Canadian Institutes of Health Strategic Teams in Applied Injury Research.	Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; Bonk C. J., 2006, DISTANCE EDUC, V27, P249, DOI DOI 10.1080/01587910600789670; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; Ciavarro C, 2008, COMPUT HUM BEHAV, V24, P2862, DOI 10.1016/j.chb.2008.04.011; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; SCHWARZ A, 2010, NY TIMES        0628; SCHWARZ A, 2010, NY TIMES        1217; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	27	46	46	0	20	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E6	10.3171/2010.9.FOCUS10187			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900007	21039140				2021-06-18	
J	Provenzano, FA; Jordan, B; Tikofsky, RS; Saxena, C; Van Heertum, RL; Ichise, M				Provenzano, Frank Anthony; Jordan, Barry; Tikofsky, Ronald S.; Saxena, Chitra; Van Heertum, Ronald L.; Ichise, Masanori			F-18 FDG PET imaging of chronic traumatic brain injury in boxers: a statistical parametric analysis	NUCLEAR MEDICINE COMMUNICATIONS			English	Article						boxers; chronic traumatic brain injury; positron emission tomography; statistical parametric mapping	CEREBRAL GLUCOSE-METABOLISM; PROFESSIONAL BOXERS; DIFFUSION; DEFICITS; RISK; SIGN; MRI	Purpose The participation in concussive susceptible sports such as boxing may cause chronic traumatic brain injury. The objective of this study was to determine whether there are unique patterns of reduced brain glucose metabolism in professional and amateur boxers. Method We compared the fluorine-18 fluorodeoxyglucose (F-18 FDG) PET brain scans of boxers (group) (N=19) with those of controls (group) (N=7) using both statistical parametric mapping and region of interest analysis. Results Boxers showed decreased F-18 FDG uptake by 8-15% in the following brain areas: posterior cingulate cortex, parieto-occipito, frontal lobes (Broca's area) bilaterally, and the cerebellum (P < 0.005) as compared with controls. Conclusion Our results suggest that F-18 FDG PET scans of boxers suspected of chronic traumatic brain injury show unique patterns of hypometabolism, and that these patterns may reflect the mechanisms of repeated traumatic brain injury unique to boxers. Nucl Med Commun 31: 952-957 (C) 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins.	[Provenzano, Frank Anthony] Columbia Univ, Med Ctr, Taub Inst, White Plains, NY USA; [Tikofsky, Ronald S.; Saxena, Chitra; Van Heertum, Ronald L.; Ichise, Masanori] Columbia Univ, Med Ctr, Kreitchman PET Ctr, Dept Radiol, White Plains, NY USA; [Jordan, Barry] Burke Rehabil Hosp, White Plains, NY USA	Provenzano, FA (corresponding author), Columbia Univ, Med Ctr, Taub Inst, 630 W 168th St,PS Box 16, New York, NY 10032 USA.	fap2005@columbia.edu					Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bonte FJ, 2004, J NUCL MED, V45, P771; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; GUR RC, 1995, SCIENCE, V267, P528, DOI 10.1126/science.7824953; Handratta V, 2010, NEUROCASE, V16, P125, DOI 10.1080/13554790903329166; Houston AS, 1998, J NUCL MED, V39, P425; ICHISE M, 1994, J NUCL MED, V35, P217; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; KUNG S, 2005, J NUCL MED S, V46, P187; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Tikofsky R. S., 2009, FUNCTIONAL CEREBRAL; TIKOFSKY RS, 2010, FUNCTIONAL CEREBRAL, P161; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	23	46	47	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0143-3636			NUCL MED COMMUN	Nucl. Med. Commun.	NOV	2010	31	11					952	957		10.1097/MNM.0b013e32833e37c4			6	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	664VX	WOS:000282992400005	20717065				2021-06-18	
J	Donders, J; DenBraber, D; Vos, L				Donders, Jacobus; DenBraber, Deborah; Vos, Leia			Construct and criterion validity of the Behaviour Rating Inventory of Executive Function (BRIEF) in children referred for neuropsychological assessment after paediatric traumatic brain injury	JOURNAL OF NEUROPSYCHOLOGY			English	Article							WORKING-MEMORY; PERFORMANCE; ADOLESCENTS; TBI; DEFICITS; TERM	The construct and criterion validities of the parent version of the Behaviour Rating Inventory of Executive Function (BRIEF) were evaluated in a sample of 100 6- to 16-year-old children with traumatic brain injury (TBI). Maximum-likelihood factor analysis identified two latent constructs that largely replicated the factor structure reported for the standardization sample, with the notable exception that the Inhibit scale covaried primarily with the metacognition factor and not with behavioural regulation factor. Only the former factor demonstrated evidence for sensitivity to the severity of TBI. Results on both factors were affected by a premorbid history of attention-deficit/hyperactivity disorder or other out-patient psychiatric treatment. It is concluded that the BRIEF has construct and criterion validity in the evaluation of children with TBI but that findings on this instrument can only be interpreted within the context of review of the child's premorbid history.	[Donders, Jacobus] Mary Free Bed Rehabil Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; [DenBraber, Deborah; Vos, Leia] Calvin Coll, Grand Rapids, MI 49506 USA	Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com	Vos, Leia/AAJ-8364-2020				American Educational Research Association American Psychological Association National Council of Measurement in Education Joint Committee on Standards for Educational Psychological Testing (US), 1999, STAND ED PSYCH TEST; Bigler ED, 2007, PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE, P415; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; Brown TM, 2008, CHILD NEUROPSYCHOL, V14, P118, DOI 10.1080/09297040601147605; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Hatcher L., 1994, STEP BY STEP APPROAC; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Morgan JE, 2008, TXB CLIN NEUROPSYCHO, P158; Murphy KR, 2004, STAT POWER ANAL; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Shum D, 2000, BRAIN COGNITION, V44, P59; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Tarazi RA, 2008, CLIN NEUROPSYCHOL, V22, P585, DOI 10.1080/13854040701425940; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; Woodward H, 1998, APPL NEUROPSYCHOL, V5, P113, DOI 10.1207/s15324826an0503_1; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	30	46	46	0	14	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	1748-6645			J NEUROPSYCHOL	J. Neuropsychol.	SEP	2010	4		2				197	209		10.1348/174866409X478970			13	Psychology; Psychology, Experimental	Psychology	670DO	WOS:000283401600005	19930791				2021-06-18	
J	Fang, BY; Wang, DJ; Huang, MF; Yu, GH; Li, H				Fang, Boyan; Wang, Dajiang; Huang, Meifeng; Yu, Guohua; Li, Hua			Hypothesis on the Relationship Between the Change in Intracellular pH and Incidence of Sporadic Alzheimer's Disease or Vascular Dementia	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; intracellular pH; vascular dementia	AMYLOID PRECURSOR PROTEIN; INSULIN-DEGRADING ENZYME; SENSING ION-CHANNEL; NA+/H+ EXCHANGER; BETA-SECRETASE; NEURODEGENERATIVE DISEASES; CELLS; CANCER; ACTIVATION; LYMPHOBLASTS	In order to perform their normal physiological functions, it is important that cells maintain the intracellular pH within the physiological range. Intracellular enzyme activity, cytoskeleton component integration, and cellular growth and differentiation rates are all closely associated with the intracellular pH. It has been demonstrated that in nervous system diseases, such as ischemic stroke, traumatic brain injury, epilepsy, Parkinson's disease, and Alzheimer's disease (AD), the common characteristics are decreased pH or acidosis at both tissular and cellular levels. Particularly, some AD-associated enzymes will have altered activities under acidic conditions. We inferred that aging or ischemia may cause intracellular acidification. This acidification not only induces apoptosis but also substantially alters enzyme activities and promotes the development of AD or vascular dementia. The hypothesis of an intracellular pH role in sporadic AD or vascular dementia will be discussed in this paper. If confirmed, this hypothesis may lead to the formulation of new pathogenesis and new therapeutic approaches to AD or vascular dementia.	[Fang, Boyan; Huang, Meifeng; Yu, Guohua; Li, Hua] Liaoning Med Coll, Dept Neurol, First Affiliated Hosp, Jinzhou 121001, Peoples R China; [Wang, Dajiang] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China	Fang, BY (corresponding author), Liaoning Med Coll, Dept Neurol, First Affiliated Hosp, Renmin St 2, Jinzhou 121001, Peoples R China.	fangboyanv@yahoo.com.cn		Fang, Boyan/0000-0002-9935-433X	Liaoning Province, China [20060524]	This work was supported by the scientific technologic fund (no. 20060524) of Liaoning Province, China.	Bian L, 2004, NEUROLOGY, V63, P241, DOI 10.1212/01.WNL.0000129987.70037.DB; Cho JH, 2008, J NEUROPHYSIOL, V99, P426, DOI 10.1152/jn.00940.2007; DEITMER JW, 2007, ACID BASE TRANSPORT; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; Guenette SY, 2003, NEUROMOL MED, V4, P147, DOI 10.1385/NMM:4:3:147; Harguindey S, 2005, BBA-REV CANCER, V1756, P1, DOI 10.1016/j.bbcan.2005.06.004; Harguindey S, 2007, CURR ALZHEIMER RES, V4, P53, DOI 10.2174/156720507779939841; Harguindey Salvador, 2008, Neuropsychiatr Dis Treat, V4, P1073; Hegde M, 2004, J PHARMACOL EXP THER, V310, P67, DOI 10.1124/jpet.103.065029; Herreman A, 2000, NAT CELL BIOL, V2, P461; Herrera Y, 2008, J PHARMACOL EXP THER, V327, P491, DOI 10.1124/jpet.108.143974; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ibarreta D, 1998, ANN NEUROL, V44, P216, DOI 10.1002/ana.410440212; Jovov B, 2003, HISTOCHEM CELL BIOL, V119, P437, DOI 10.1007/s00418-003-0525-4; Lagana A, 2000, J CELL SCI, V113, P3649; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; Li YM, 2000, NATURE, V405, P689; Malo ME, 2006, CAN J PHYSIOL PHARM, V84, P1081, DOI 10.1139/Y06-065; Marinho CFM, 1997, EUR ARCH PSY CLIN N, V247, P275, DOI 10.1007/BF02900306; Mohajeri MH, 2002, J BIOL CHEM, V277, P35460, DOI 10.1074/jbc.M202899200; OSTOVSKAYA OI, 2003, NEUROPHYSIOLOGY, V35, P90; Prince M, 2004, INT J GERIATR PSYCH, V19, P178, DOI 10.1002/gps.1059; Reshkin SJ, 2000, J BIOL CHEM, V275, P5361, DOI 10.1074/jbc.275.8.5361; Rich IN, 2000, BLOOD, V95, P1427, DOI 10.1182/blood.V95.4.1427.004k48_1427_1434; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Song ES, 2003, J BIOL CHEM, V278, P49789, DOI 10.1074/jbc.M308983200; Urcelay E, 2001, NEUROBIOL DIS, V8, P289, DOI 10.1006/nbdi.2000.0381; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406; Xiong ZG, 2008, CURR OPIN PHARMACOL, V8, P25, DOI 10.1016/j.coph.2007.09.001; Xue SF, 2006, NEUROSCI LETT, V405, P231, DOI 10.1016/j.neulet.2006.07.013; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zohar O, 2003, MOL BRAIN RES, V115, P63, DOI 10.1016/S0169-328X(03)00182-7	37	46	47	5	29	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.	SEP	2010	120	9					591	595		10.3109/00207454.2010.505353			5	Neurosciences	Neurosciences & Neurology	639XX	WOS:000281011500002	20707633				2021-06-18	
J	Szmydynger-Chodobska, J; Fox, LM; Lynch, KM; Zink, BJ; Chodobski, A				Szmydynger-Chodobska, Joanna; Fox, Leora M.; Lynch, Kirsten M.; Zink, Brian J.; Chodobski, Adam			Vasopressin Amplifies the Production of Proinflammatory Mediators in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						arginine vasopressin; c-Jun N-terminal kinase; CXC and CC chemokines; monocytes; neutrophils; traumatic brain injury	MONOCYTE CHEMOATTRACTANT PROTEIN-1; PLASMA ARGININE-VASOPRESSIN; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; RAT-BRAIN; INCREASED EXPRESSION; REPERFUSION INJURY; CEREBRAL-ISCHEMIA; BRATTLEBORO RATS; RECEPTOR-BINDING	Arginine vasopressin (AVP) has previously been shown to promote disruption of the blood-brain barrier, exacerbate edema, and augment the loss of neural tissue in various forms and models of brain injury. However, the mechanisms underlying these AVP actions are not well understood. These mechanisms were studied in AVP-deficient Brattleboro rats (Avp(di/di)), and their parental Long-Evans strain, using a controlled cortical impact model of traumatic brain injury (TBI). The increased influx of inflammatory cells into the injured cortex in wildtype versus Avp(di/di) rats was associated with higher levels of cortical synthesis of the CXC and CC chemokines found in wild-type versus Avp(di/di) rats. These chemokines were predominantly produced by the cerebrovascular endothelium and astrocytes. In astrocyte and brain endothelial cell cultures, AVP acted synergistically with tumor necrosis factor-alpha (TNF-alpha) to increase the TNF-alpha-dependent production of CXC and CC chemokines. These AVP actions were mediated by c-Jun N-terminal kinase (JNK), as shown by Western blotting and pharmacological inhibition of JNK activity. The activity of JNK was increased in response to injury, and the differences in the magnitude of its post-traumatic activation between Avp(di/di) and wild-type rats were observed. These data demonstrate that AVP plays an important role in exacerbating the brain inflammatory response to injury.	[Szmydynger-Chodobska, Joanna; Fox, Leora M.; Lynch, Kirsten M.; Zink, Brian J.; Chodobski, Adam] Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02903 USA	Szmydynger-Chodobska, J (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Coro Ctr W,Room 112,1 Hoppin St, Providence, RI 02903 USA.	Joanna_Szmydynger-Chodobska@brown.edu		Lynch, Kirsten/0000-0003-3976-5783	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS49479]; Department of Emergency Medicine at Alpert Medical School of Brown University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049479] Funding Source: NIH RePORTER	We thank Dr. Danica Stanimirovic (Institute for Biological Sciences, National Research Council, Ottawa, Canada) for providing the SV-RBEC and SV-NRA cell lines. We also thank Ms. Julie Sarri for her technical assistance and Ms. Virginia Hovanesian for her help in acquiring and processing confocal microscopy images. This work was supported by grant NS49479 from the National Institutes of Health (to A. C.), and by funds from the Department of Emergency Medicine at Alpert Medical School of Brown University.	Barreca T, 2001, CEREBROVASC DIS, V11, P113, DOI 10.1159/000047622; Beech JS, 2001, J CEREBR BLOOD F MET, V21, P683, DOI 10.1097/00004647-200106000-00006; Bell MD, 1996, EUR J NEUROSCI, V8, P1803, DOI 10.1111/j.1460-9568.1996.tb01324.x; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; Chang Y, 2006, J APPL PHYSIOL, V100, P1445, DOI 10.1152/japplphysiol.00763.2005; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Cunningham LA, 2005, GLIA, V50, P329, DOI 10.1002/glia.20169; DEPASQUALE M, 1989, AM J PHYSIOL, V256, pF1059; DICKINSON LD, 1992, J CEREBR BLOOD F MET, V12, P681, DOI 10.1038/jcbfm.1992.93; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Garberg P, 2005, TOXICOL IN VITRO, V19, P299, DOI 10.1016/j.tiv.2004.06.011; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HIRASAWA A, 1994, EUR J PHARM-MOLEC PH, V267, P71, DOI 10.1016/0922-4106(94)90226-7; Kim DS, 2003, MOL IMMUNOL, V40, P633, DOI 10.1016/j.molimm.2003.07.001; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Liu XZ, 2000, HEALTH POLICY PLANN, V15, P157, DOI 10.1093/heapol/15.2.157; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; OSTROWSKI NL, 1994, ENDOCRINOLOGY, V135, P1511, DOI 10.1210/en.135.4.1511; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; SATO H, 1993, ONCOGENE, V8, P395; SCHMALE H, 1984, NATURE, V308, P705, DOI 10.1038/308705a0; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; SORENSEN PS, 1985, J NEUROL NEUROSUR PS, V48, P50, DOI 10.1136/jnnp.48.1.50; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Waetzig V, 2005, TRENDS PHARMACOL SCI, V26, P455, DOI 10.1016/j.tips.2005.07.006; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wang YF, 2006, J NEUROCHEM, V98, P1046, DOI 10.1111/j.1471-4159.2006.03950.x; Xu Miao, 2007, Chin J Traumatol, V10, P90; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yoshida M, 2006, ENDOCRINOLOGY, V147, P2850, DOI 10.1210/en.2005-1222; Young LJ, 1999, J NEUROENDOCRINOL, V11, P291	44	46	46	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1449	1461		10.1089/neu.2010.1331			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900009	20504162	Green Published			2021-06-18	
J	Soustiel, JF; Sviri, GE; Mahamid, E; Shik, V; Abeshaus, S; Zaaroor, M				Soustiel, Jean F.; Sviri, Gill E.; Mahamid, Eugenia; Shik, Veniamin; Abeshaus, Sergey; Zaaroor, Menashe			Cerebral Blood Flow and Metabolism Following Decompressive Craniectomy for Control of Increased Intracranial Pressure	NEUROSURGERY			English	Article						Cerebral blood flow; Cerebral metabolism; Decompressive craniectomy; Intracranial pressure; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; SURGICAL DECOMPRESSION; PRACTICAL SCALE; HYPERTENSION; OXYGENATION; MODERATE; HYPERVENTILATION; HEMICRANIECTOMY	OBJECTIVE: Decompressive craniectomy (DC) is a common practice for control of intracranial pressure (ICP) following traumatic brain injury (TBI), although the impact of this procedure on the fate of operated patients is still controversial. METHODS: Cerebral blood flow (CBF) and metabolic rates were monitored prospectively and daily as a surrogate of neuronal viability in 36 TBI patients treated by DC and compared with those of 86 nonoperated patients. DC was performed either on admission (n = 29) or within 48 hours of admission (n = 7). RESULTS: DC successfully controlled ICP levels and maintained CBF within a normal range although the cerebral metabolic rate of oxygen (CMRO2) was significantly lower in this group. In 7 patients, pre-and postoperative recordings showed a significant ICP decrease that correlated with CBF augmentation but not with concurrent improvement of CMRO2 that remained particularly low. Logistic regression analysis of all investigated variables showed that DC was not associated with higher mortality despite more severe injuries in this group. However, operated patients were 7-fold more likely to have poor functional outcomes than nonoperated patients. Good functional outcome was strongly associated with higher CMRO2 but not with higher CBF values. CMRO2 levels were significantly lower in the DC group, even after adjustment for injury severity, and showed a progressive and sustained trend of deterioration significantly different from that of the non-DC group. CONCLUSION: These results suggest that DC may enhance survival in the presence of severe brain swelling, although it is unlikely to represent an adequate answer to mitochondrial damage responsible for cellular energy crisis and edema.	[Soustiel, Jean F.; Zaaroor, Menashe] Technion Israel Inst Technol, Dept Neurosurg, Rambam Med Ctr, Acute Brain Injury Res Lab,Fac Med, IL-31096 Haifa, Israel	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Dept Neurosurg, Rambam Med Ctr, Acute Brain Injury Res Lab,Fac Med, POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Guilburd JN, 2001, J NEUROSURG, V95, P263, DOI 10.3171/jns.2001.95.2.0263; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Jaeger M, 2005, ACT NEUR S, V95, P117; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; Marmarou A, 2005, ACT NEUR S, V95, P149; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Oertel M, 2002, ACT NEUR S, V81, P69; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Pompucci A, 2007, J NEUROTRAUM, V24, P1182, DOI 10.1089/neu.2006.0244; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Schaller B, 2003, BRAIN RES, V982, P31, DOI 10.1016/S0006-8993(03)02900-7; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Soustiel JF, 2003, STROKE, V34, P1876, DOI 10.1161/01.STR.0000080942.32331.39; Soustiel JF, 2002, J ULTRAS MED, V21, P1405, DOI 10.7863/jum.2002.21.12.1405; Spiller WG, 1906, J AMER MED ASSOC, V47, P679; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616	31	46	51	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUL	2010	67	1					65	72		10.1227/01.NEU.0000370604.30037.F5			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	612CW	WOS:000278875400018	20559092				2021-06-18	
J	Brandi, G; Bechir, M; Sailer, S; Haberthur, C; Stocker, R; Stover, JF				Brandi, Giovanna; Bechir, Markus; Sailer, Susanne; Haberthuer, Christoph; Stocker, Reto; Stover, John F.			Transcranial color-coded duplex sonography allows to assess cerebral perfusion pressure noninvasively following severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Pulsatility index; Secondary brain damage; Transcranial Doppler	DOPPLER SONOGRAPHY; HEAD-INJURY; INTRACRANIAL-PRESSURE; SUBARACHNOID HEMORRHAGE; ULTRASONOGRAPHY; AUTOREGULATION; PULSATILITY; VELOCITY; THERAPY	Objective Assess optimal equation to noninvasively estimate intracranial pressure (eICP) and cerebral perfusion pressure (eCPP) following severe traumatic brain injury (TBI) using transcranial color-coded duplex sonography (TCCDS). Design and setting This is an observational clinical study in a university hospital. Patients A total of 45 continuously sedated (BIS<50), normoventilated (paCO(2)>35 mmHg), and non-febrile TBI patients. Methods eICP and eCPP based on TCCDS-derived flow velocities and arterial blood pressure values using three different equations were compared to actually measured ICP and CPP in severe TBI patients subjected to standard treatment. Optimal equation was assessed by Bland-Altman analysis. Results The equations: ICP = 10.927 x PI(pulsatility index) = 1.284 and CPP = 89.646 - 8: 258 x PI resulted in eICP and eCPP similar to actually measured ICP and CPP with eICP 10.6 +/- 4.8 vs. ICP 10.3 +/- 2.8 and eCPP 81.1 +/- 7.9 vs. CPP 80.9 +/- 2.1 mmHg, respectively. The other two equations, eCPP - (MABP x EDV)/mFV + 14 and eCPP - [mFV/(mFV - EDV)] x (MABP RRdiast), resulted in significantly decreased eCPP values: 72.9 +/- 10.1 and 67 +/- 19.5 mmHg, respectively. Superiority of the first equation was confirmed by Bland-Altman revealing a smallest standard deviations for eCPP and eICP. Conclusions TCCDS-based equation (ICP 10: 927 x PI - 1.284) allows to screen patients at risk of increased ICP and decreased CPP. However, adequate therapeutic interventions need to be based on continuously determined ICP and CPP values.	[Brandi, Giovanna; Bechir, Markus; Sailer, Susanne; Stocker, Reto; Stover, John F.] Univ Hosp Zuerich, Surg Intens Care, CH-8091 Zurich, Switzerland; [Brandi, Giovanna] Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Neurosurg Intens Care Unit, Dept Anesthesia & Crit Care Med, Milan, Italy; [Haberthuer, Christoph] Kantonsspital, Dept Anesthesiol, Luzern, Switzerland; [Stover, John F.] Univ Spital Zurich, CH-8091 Zurich, Switzerland	Stover, JF (corresponding author), Univ Spital Zurich, Ramistrasse 100, CH-8091 Zurich, Switzerland.	john.stover@access.unizh.ch			Swiss National Research FoundationSwiss National Science Foundation (SNSF); SUVA Fonds	This study was supported in parts by grants from the Swiss National Research Foundation and the SUVA Fonds to JFS and RS.	Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; *BRAINIT, BRAINIT STAND HYDR P; Edouard AR, 2005, BRIT J ANAESTH, V94, P216, DOI 10.1093/bja/aei034; Kochanowicz J, 2006, NEURORADIOLOGY, V48, P31, DOI 10.1007/s00234-005-0009-4; Krejza J, 2007, AM J NEURORADIOL, V28, P1613, DOI 10.3174/ajnr.A0591; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; McMahon CJ, 2007, BRIT J NEUROSURG, V21, P21, DOI 10.1080/02688690701210539; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Rainov NG, 2000, NEUROSURG REV, V23, P34, DOI 10.1007/s101430050029; Schmidt EA, 2001, J NEUROL NEUROSUR PS, V70, P198, DOI 10.1136/jnnp.70.2.198; Soehle M, 2007, ACTA NEUROCHIR, V149, P575, DOI 10.1007/s00701-007-1149-6; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Swiat M, 2009, CRIT CARE MED, V37, P963, DOI 10.1097/CCM.0b013e31819b8165; White H, 2006, INTENS CARE MED, V32, P981, DOI 10.1007/s00134-006-0173-y	17	46	49	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUN	2010	152	6					965	972		10.1007/s00701-010-0643-4			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	597TA	WOS:000277783300006	20379747	Green Accepted			2021-06-18	
J	Sendroy-Terrill, M; Whiteneck, GG; Brooks, CA				Sendroy-Terrill, Melissa; Whiteneck, Gale G.; Brooks, Cynthia A.			Aging With Traumatic Brain Injury: Cross-Sectional Follow-Up of People Receiving Inpatient Rehabilitation Over More Than 3 Decades	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Brain injury; chronic; Follow-up studies; Outcomes assessment (health care); Rehabilitation	SPINAL-CORD-INJURY; QUALITY-OF-LIFE; FUNCTIONAL INDEPENDENCE MEASURE; SICKNESS IMPACT PROFILE; SEVERE HEAD-INJURY; ENVIRONMENTAL-FACTORS; UPPER EXTREMITY; SHOULDER PAIN; OLDER-ADULTS; HEALTH	Sendroy-Terrill M, Whiteneck GG, Brooks CA. Aging with traumatic brain injury: cross-sectional follow-up of people receiving inpatient rehabilitation over more than 3 decades. Arch Phys Med Rehabil 2010;91:489-97. Objective: To investigate aging with traumatic brain injury (TBI) by determining if long-term outcomes after TBI are predicted by years postinjury and age at injury after controlling for the severity of the injury and sex. Design: Cross-sectional follow-up telephone survey. Setting: Community residents who had received initial treatment in a comprehensive inpatient rehabilitation hospital. Participants: Survivors of TBI (N=243) stratified by years postinjury (in seven 5-year cohorts ranging from I to over 30 years postinjury) and by age at injury (in 2 cohorts of people injured before or after age 30). Interventions: None. Main Outcome Measures: Measures of postconcussive symptoms, major secondary conditions including fatigue (Modified Fatigue Impact Scale), physical and cognitive activity limitations (FIM, Alertness Behavior Subscale of the Sickness Impact Profile, Medical Outcomes Study 12-Item Health Status Survey Short Form), societal participation restrictions (Craig Handicap Assessment and Reporting Technique), environmental barriers (Craig Hospital Inventory of Environmental Factors), and perceived quality of life (Satisfaction with Life Scale). Results: Most problems identified by the outcome measures were reported by one fourth to one half of the study participants. Increasing decades postinjury predicted declines in physical and cognitive functioning, declines in societal participation, and increases in contractures. Increasing age at injury predicted declines in functional independence, increases in fatigue, declines in societal participation, and declines in perceived environmental barriers. Conclusions: This investigation has increased our understanding of the aging process after TBI by demonstrating that both components of aging (years postinjury and age at injury) are predictive of several outcomes after TBI.	[Sendroy-Terrill, Melissa; Whiteneck, Gale G.; Brooks, Cynthia A.] Craig Hosp, Res Dept, Englewood, CO 80113 USA	Sendroy-Terrill, M (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson, Englewood, CO 80113 USA.	msendroy@craighospital.org			National Institute of Disability Rehabilitation and Research [H133A020510]	Supported by an award to Rocky Mountain Regional Brain Injury Model Systems from the National Institute of Disability Rehabilitation and Research (grant no. H133A020510). The opinions expressed are those of the authors and do not necessarily reflect the views of the National Institute of Disability Rehabilitation and Research.	AGRE J, 2000, PHYS MED REHABILITAT, P1591; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ballinger DA, 2000, ARCH PHYS MED REHAB, V81, P1575, DOI 10.1053/apmr.2000.18216; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Brooks D N, 1979, Int Rehabil Med, V1, P160; Chamberlain M. A., 1995, TRAUMATIC BRAIN INJU, P3; Charlifue S, 2004, ARCH PHYS MED REHAB, V85, P1848, DOI 10.1016/j.apmr.2004.03.017; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Colantonio A, 2004, INT J REHABIL RES, V27, P209, DOI 10.1097/00004356-200409000-00006; Craig Hospital Research Department, 2001, CRAIG HOSP INV ENV F; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FISK JD, 1994, CLIN INFECT DIS, V18, pS79, DOI 10.1093/clinids/18.Supplement_1.S79; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; GROSWASSER Z, 1977, SCAND J REHABIL MED, V9, P147; Gutierrez DD, 2007, J SPINAL CORD MED, V30, P251, DOI 10.1080/10790268.2007.11753933; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; He W., 2005, 65 US 2005; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hulley SB, 2001, DESIGNING CLIN RES E; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; KARPMAN T, 1985, J APPL REHABILITATIO, V17, P28; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; *KESSL MED REH RES, 2001, TRAUM BRAIN INJ MOD; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lesser I M, 1991, J Neuropsychiatry Clin Neurosci, V3, P33; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; MILLER LL, 1989, COMPUT CHEM, V13, P1, DOI 10.1016/0097-8485(89)80021-X; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Pennings JL, 1993, ARCH SURG-CHICAGO, V128, P93; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; PENTLAND WE, 1991, PARAPLEGIA, V29, P521, DOI 10.1038/sc.1991.75; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Prigatano G. P., 1987, COMMUNITY REENTRY HE, P1; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Ravesloot C, 1998, CLIN PSYCHOL PSYCHOT, V5, P76, DOI 10.1002/(SICI)1099-0879(199806)5:2<76::AID-CPP156>3.0.CO;2-5; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; ROSENTHAL M, 1990, REHABILITATION ADULT, P190; Ross A M, 1992, J Neurosci Nurs, V24, P88; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SIE IH, 1992, ARCH PHYS MED REHAB, V73, P44; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; *STAT U NY, 1997, GUID UN DAT SYST MED; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TRIESCHMANN RB, 1990, J HEAD TRAUMA REHAB, V5, P57; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Ware J.E., 1994, SF 36 PHYS MENTAL SU; WATERS RL, 1993, AGING SPINAL CORD IN, P53; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, P1793, DOI 10.1016/j.apmr.2004.04.024; Whiteneck G, 2001, COLORADO TRAUMATIC B; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519	88	46	47	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2010	91	3					489	497		10.1016/j.apmr.2009.11.011			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	592YM	WOS:000277417900025	20298844				2021-06-18	
J	Zahedi, K; Huttinger, F; Morrison, R; Murray-Stewart, T; Casero, RA; Strauss, KI				Zahedi, Kamyar; Huttinger, Francis; Morrison, Ryan; Murray-Stewart, Tracy; Casero, Robert A., Jr.; Strauss, Kenneth I.			Polyamine Catabolism Is Enhanced after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; colocalization immunofluorescence; gene expression; polyamine back-conversion; polyamine quantification; polyamine therapeutic potential; spermine oxidase (SMO); spermidine/spermine-N-1-acetyltransferase (SSAT); time course	ORNITHINE-DECARBOXYLASE ACTIVITY; ISCHEMIA-REPERFUSION INJURY; CEREBRAL-ARTERY OCCLUSION; RAT-LIVER MITOCHONDRIA; BARRIER BREAKDOWN; ALDEHYDE LOAD; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; REACTIVE ALDEHYDES; DANSYL DERIVATIVES; HYDROGEN-PEROXIDE	Polyamines spermine and spermidine are highly regulated, ubiquitous aliphatic cations that maintain DNA structure and function as immunomodulators and as antioxidants. Polyamine homeostasis is disrupted after brain injuries, with concomitant generation of toxic metabolites that may contribute to secondary injuries. To test the hypothesis of increased brain polyamine catabolism after traumatic brain injury (TBI), we determined changes in catabolic enzymes and polyamine levels in the rat brain after lateral controlled cortical impact TBI. Spermine oxidase (SMO) catalyzes the degradation of spermine to spermidine, generating H2O2 and aminoaldehydes. Spermidine/spermine-N-1-acetyltransferase (SSAT) catalyzes acetylation of these polyamines, and both are further oxidized in a reaction that generates putrescine, H2O2, and aminoaldehydes. In a rat cortical impact model of TBI, SSAT mRNA increased subacutely (6-24 h) after TBI in ipsilateral cortex and hippocampus. SMO mRNA levels were elevated late, from 3 to 7 days post-injury. Polyamine catabolism increased as well. Spermine levels were normal at 6 h and decreased slightly at 24 h, but were normal again by 72 h post-injury. Spermidine levels also decreased slightly (6-24 h), then increased by similar to 50% at 72 h post-injury. By contrast, normally low putrescine levels increased up to sixfold (6-72 h) after TBI. Moreover, N-acetylspermidine (but not N-acetylspermine) was detectable (24-72 h) near the site of injury, consistent with increased SSAT activity. None of these changes were seen in the contralateral hemisphere. Immunohistochemical confirmation indicated that SSAT and SMO were expressed throughout the brain. SSAT-immunoreactivity (SSAT-ir) increased in both neuronal and nonneuronal (likely glial) populations ipsilateral to injury. Interestingly, bilateral increases in cortical SSAT-ir neurons occurred at 72 h post-injury, whereas hippocampal changes occurred only ipsilaterally. Prolonged increases in brain polyamine catabolism are the likely cause of loss of homeostasis in this pathway. The potential for simple therapeutic interventions ( e. g., polyamine supplementation or inhibition of polyamine oxidation) is an exciting implication of these studies.	[Zahedi, Kamyar] Univ Cincinnati, Coll Med, Div Nephrol, Dept Internal Med, Cincinnati, OH 45267 USA; [Huttinger, Francis; Morrison, Ryan; Strauss, Kenneth I.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; [Murray-Stewart, Tracy; Casero, Robert A., Jr.] Johns Hopkins Univ, Coll Med, Dept Oncol, Baltimore, MD USA	Strauss, KI (corresponding author), Univ Cincinnati, Mayfield Neurotrauma Res Lab, Dept Neurosurg, Coll Med ML517, 231 Albert Sabin Way,MSB 4458, Cincinnati, OH 45267 USA.	kstrauss@uc.edu	Stewart, Tracy Murray/B-6137-2017; Zahedi, Kamyar/AAQ-3428-2021	Stewart, Tracy Murray/0000-0001-8679-6414; Casero, Robert/0000-0001-5653-3306	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA051085, R01CA098454] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054890] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA098454, R01 CA051085] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS054890] Funding Source: Medline		Abelson-Mitchell N, 2008, J CLIN NURS, V17, P46, DOI 10.1111/j.1365-2702.2007.01941.x; Adibhatla RM, 2002, BRAIN RES, V938, P81, DOI 10.1016/S0006-8993(02)02447-2; AIZENMAN E, 1995, NEUROSCI LETT, V189, P57, DOI 10.1016/0304-3940(95)11442-Y; Babu GN, 2003, NEUROCHEM RES, V28, P1851, DOI 10.1023/A:1026123809033; Babu GN, 2001, NEUROSCI LETT, V300, P17, DOI 10.1016/S0304-3940(01)01538-5; Barone S, 2005, AM J PHYSIOL-CELL PH, V289, pC826, DOI 10.1152/ajpcell.00629.2004; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; Clarkson AN, 2004, FASEB J, V18, P1114, DOI 10.1096/fj.03-1203fje; Conti AC, 1998, J NEUROSCI, V18, P5663; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; GILAD GM, 1991, EUR J PHARMACOL, V193, P41, DOI 10.1016/0014-2999(91)90198-Y; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1993, MOL CHEM NEUROPATHOL, V18, P197, DOI 10.1007/BF03160034; Gilad VH, 2001, BIOCHEM PHARMACOL, V61, P207, DOI 10.1016/S0006-2952(00)00517-7; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; HASAN R, 1995, FEBS LETT, V368, P27, DOI 10.1016/0014-5793(95)00591-V; Heby O, 1988, Adv Exp Med Biol, V250, P291; IENTILE R, 1988, J NEUROCHEM, V51, P677, DOI 10.1111/j.1471-4159.1988.tb01797.x; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; Igarashi K, 2006, YAKUGAKU ZASSHI, V126, P455, DOI 10.1248/yakushi.126.455; Ingi T, 2001, EUR J NEUROSCI, V13, P1459, DOI 10.1046/j.0953-816x.2001.01529.x; JENSEN JR, 1989, J NEUROCHEM, V53, P1173, DOI 10.1111/j.1471-4159.1989.tb07411.x; Kaasinen K, 2000, EUR J NEUROSCI, V12, P540, DOI 10.1046/j.1460-9568.2000.00940.x; Kaasinen SK, 2003, EXP NEUROL, V183, P645, DOI 10.1016/S0014-4886(03)00186-9; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; KINDY MS, 1994, J CEREBR BLOOD F MET, V14, P1040, DOI 10.1038/jcbfm.1994.136; KOENIG H, 1989, J NEUROCHEM, V52, P101, DOI 10.1111/j.1471-4159.1989.tb10903.x; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; Kramer DL, 2008, J BIOL CHEM, V283, P4241, DOI 10.1074/jbc.M706806200; Layton ME, 1997, NEUROSCI LETT, V236, P63, DOI 10.1016/S0304-3940(97)00765-9; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Li J, 2007, CURR MED CHEM, V14, P1807; Li W, 2003, BIOCHEM J, V371, P429, DOI 10.1042/BJ20021520; Liu W, 2001, J NEUROCHEM, V79, P976, DOI 10.1046/j.1471-4159.2001.00650.x; LOVAAS E, 1991, FREE RADICAL BIO MED, V11, P455, DOI 10.1016/0891-5849(91)90061-7; Lovaas E, 1997, Adv Pharmacol, V38, P119; MARCE M, 1995, J CHROMATOGR B, V666, P329, DOI 10.1016/0378-4347(94)00586-T; Mello CF, 2007, ALCOHOL CLIN EXP RES, V31, P887, DOI 10.1111/j.1530-0277.2007.00369.x; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; PASCHEN W, 1992, MOL CHEM NEUROPATHOL, V16, P241, DOI 10.1007/BF03159973; Rao AM, 2000, J NEUROCHEM, V74, P1106; Rao VLR, 1998, BRAIN RES, V783, P163, DOI 10.1016/S0006-8993(97)01301-2; Samanta S, 1998, J NEUROCHEM, V70, P2082; Sava IG, 2006, FREE RADICAL BIO MED, V41, P1272, DOI 10.1016/j.freeradbiomed.2006.07.008; Schimchowitsch S, 2006, J PHYSIOL-PARIS, V99, P221, DOI 10.1016/j.jphysparis.2005.12.015; SCHMITZ MP, 1993, NEUROSURGERY, V33, P882; SEILER N, 1975, J NEUROCHEM, V24, P5, DOI 10.1111/j.1471-4159.1975.tb07621.x; SEILER N, 1985, NEUROCHEM RES, V10, P529, DOI 10.1007/BF00964656; Seiler N, 2000, NEUROCHEM RES, V25, P471, DOI 10.1023/A:1007508008731; SHAPPELL NW, 1993, FEBS LETT, V321, P179, DOI 10.1016/0014-5793(93)80103-2; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Sparapani M, 1996, EXP BRAIN RES, V108, P433; Takano K, 2005, NEUROSCIENCE, V134, P1123, DOI 10.1016/j.neuroscience.2005.05.014; Tassani V, 1996, BIOCHEM BIOPH RES CO, V226, P850, DOI 10.1006/bbrc.1996.1439; Temiz C, 2005, J CLIN NEUROSCI, V12, P449, DOI 10.1016/j.jocn.2004.05.019; TROUT JJ, 1995, J NEUROCYTOL, V24, P341, DOI 10.1007/BF01189061; Wang ZH, 2004, J AM SOC NEPHROL, V15, P1844, DOI 10.1097/01.ASN.0000131525.77636.D5; Weinberg JM, 2000, AM J PHYSIOL-RENAL, V279, pF927; Weinberg JM, 2000, P NATL ACAD SCI USA, V97, P2826, DOI 10.1073/pnas.97.6.2826; Wood PL, 2007, BRAIN RES, V1145, P150, DOI 10.1016/j.brainres.2006.10.004; Wood PL, 2006, BRAIN RES, V1095, P190, DOI 10.1016/j.brainres.2006.04.038; Wood PL, 2006, BRAIN RES, V1122, P184, DOI 10.1016/j.brainres.2006.09.003; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Zahedi K, 2003, AM J PHYSIOL-RENAL, V284, pF1046, DOI 10.1152/ajprenal.00318.2002; Zhang MH, 1999, MOL MED, V5, P595, DOI 10.1007/BF03402072; Zhang MH, 1997, J EXP MED, V185, P1759, DOI 10.1084/jem.185.10.1759; Zhao YJ, 2007, EUR J PHARMACOL, V562, P236, DOI 10.1016/j.ejphar.2007.01.096; ZINI I, 1990, NEUROSCI LETT, V120, P13, DOI 10.1016/0304-3940(90)90156-4	71	46	48	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					515	525		10.1089/neu.2009.1097			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100006	19968558	Green Published			2021-06-18	
J	Taya, K; Marmarou, CR; Okuno, K; Prieto, R; Marmarou, A				Taya, Keisuke; Marmarou, Christina R.; Okuno, Kenji; Prieto, Ruth; Marmarou, Anthony			Effect of Secondary Insults upon Aquaporin-4 Water Channels following Experimental Cortical Contusion in Rats	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin-4; blood-brain barrier; brain edema; controlled cortical impact; secondary insult; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MIDDLE CEREBRAL-ARTERY; CELLULAR EDEMA; HYPOXIA; EXPRESSION; BARRIER; SODIUM; FLUID; PERMEABILITY; HYPOTHERMIA	Although secondary insults of hypoxia and hypotension (HH) are generally considered to cause fulminant brain edema in traumatic brain injury (TBI), the combined effect of TBI with HH on brain edema and specifically the expression of aquaporin-4 (AQP4) have not been fully elucidated. The goal of this study was to document the effect of secondary insults on brain water, AQP4 expression, electrolytes, and blood-brain barrier (BBB) permeability during the acute stage of edema development. We measured brain water content and electrolytes (series 1); BBB permeability based on Evans blue (EB) dye extravasation (series 2); and AQP4 expression using immunoblotting (series 3) at 1 h and 5 h following cortical contusion injury (CCI). Secondary insults significantly worsened BBB function at 5 h post injury. Moreover, a significant reduction of upregulation on AQP4 expression was observed in trauma, coupled with a mild secondary insult of hypoxia hypotension. These findings indicate that a secondary insult following CCI at 5 h post injury worsens brain edema, disrupts ionic homeostasis, and blunts the normal upregulation of AQP4 that occurs after trauma, suggesting that the blunting of AQP4 may contribute to the detrimental effects of secondary insults.	[Taya, Keisuke; Marmarou, Christina R.; Okuno, Kenji; Prieto, Ruth; Marmarou, Anthony] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, 1101 E Marshall St,Box 980508,Sanger 9-036,Med Co, Richmond, VA 23298 USA.	marmarou@vcu.edu			National Institutes of Health, Bethesda, MDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS12587, RO1 NS19235]; Commonwealth Neurotrauma Initiative Trust Fund, Richmond, VA [RFP 07-302]; Beverly and Wallace Hudson Research Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235] Funding Source: NIH RePORTER	We would like to thank Caroline Dermer for her technical assistance in the preparation of this manuscript. This research was supported by grants RO1 NS12587, RO1 NS19235 from the National Institutes of Health, Bethesda, MD; RFP 07-302 from the Commonwealth Neurotrauma Initiative Trust Fund, Richmond, VA; and the Beverly and Wallace Hudson Research Fund. The contents are the sole responsibility of the authors and do not necessarily represent the official views of the Fund or the Advisory Board.	Agre P, 2003, FEBS LETT, V555, P72, DOI 10.1016/S0014-5793(03)01083-4; Ates O, 2007, NEUROL RES, V29, P317, DOI 10.1179/016164107X159225; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bauman RA, 2005, BEHAV BRAIN RES, V160, P25, DOI 10.1016/j.bbr.2004.11.031; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fujita Y, 2003, NEUROSCI RES, V47, P437, DOI 10.1016/j.neures.2003.08.006; Fukui S, 2003, J CEREBR BLOOD F MET, V23, P1212, DOI 10.1097/01.WCB.0000088762.02615.30; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; Gulsen S, 2006, J NEUROTRAUM, V23, P1040; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATAYAMA Y, 1989, NEUROTRAUMA SOC, V6, P200; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P393; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Pearigen P, 1996, BRAIN RES, V725, P184; Rolfe DFS, 1997, PHYSIOL REV, V77, P731; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Verkman AS, 2002, ANN MED, V34, P192, DOI 10.1080/713782138; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Zeuthen T, 1997, BIOL CELL, V89, P307, DOI 10.1016/S0248-4900(97)83383-7	41	46	53	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2010	27	1					229	239		10.1089/neu.2009.0933			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	548RF	WOS:000273983200020	19705963	Green Published			2021-06-18	
J	Togher, L; Power, E; Tate, R; McDonald, S; Rietdijk, R				Togher, Leanne; Power, Emma; Tate, Robyn; McDonald, Skye; Rietdijk, Rachel			Measuring the social interactions of people with traumatic brain injury and their communication partners: The adapted Kagan scales	APHASIOLOGY			English	Article; Proceedings Paper	39th Annual Clinical Aphasiology Conference	MAY 26-30, 2009	Keystone, CO			Traumatic brain injury; Rating scales; Conversation; Assessment; Cognitive-communication	CONVERSATION; IMPAIRMENT; DISCOURSE; ADULTS	Background: Considerable attention has been given to the nature of communication impairments of individuals with TBI (Coelho, 2007; Ylvisaker, Turkstra, Coelho, 2005). However, there have been few data focusing on the way communication partners deal with the often distressing sequelae of TBI. Aims: This study reports inter- and intra-rater reliability of the Adapted Measure of Support in Conversation (MSC) and Measure of Participation in Conversation (MPC) for TBI interactions. Method Procedures: The MSC and MPC were adapted to reflect theoretical models of cognitive-communication support for people with TBI. A total of 10 casual and 10 purposeful TBI interactions were independently rated by two raters to establish inter-rater reliability and by one rater on two separate occasions to determine intra-rater reliability. Outcomes Results: Excellent inter-rater agreement was established on the MSC (ICC = 0.85-0.97) and the MPC (ICC = 0.84-0.89). Intra-rater agreement was also strong (MSC: ICC = 0.80-0.90; MPC: ICC = 0.81-0.92). Over 90% of all ratings scored within 0.5 on a 9-point scale. Conclusions: This is the first scale to measure the communication partner during TBI interactions. It shows promise in evaluating communication partner training programmes.	[Togher, Leanne] Univ Sydney, Natl Hlth & Med Res Council, Fac Hlth Sci, Lidcombe, NSW 1825, Australia; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia; [McDonald, Skye] Univ New S Wales, Sydney, NSW, Australia	Togher, L (corresponding author), Univ Sydney, Natl Hlth & Med Res Council, Fac Hlth Sci, POB 170, Lidcombe, NSW 1825, Australia.	leanne.togher@usyd.edu.au	Power, Emma/A-9263-2015; Togher, Leanne/AAC-7083-2019; McDonald, Skye/G-4118-2014; Rietdijk, Rachael/J-6573-2012	Power, Emma/0000-0002-2638-0406; McDonald, Skye/0000-0003-0723-6094; Rietdijk, Rachael/0000-0003-4343-4039; Togher, Leanne/0000-0002-4518-6748			Adamovich B. B., 1992, SCALES COGNITIVE ABI; Bellon ML, 2006, BRAIN INJURY, V20, P1069, DOI 10.1080/02699050600909813; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cicchetti D.V., 1994, PSYCHOL ASSESS, V6, P284, DOI [10.1037/1040-3590.6.4.284, DOI 10.1037/1040-3590.6.4.284]; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Shelton C, 2007, BRAIN INJURY, V21, P1259, DOI 10.1080/02699050701716935; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Togher L, 2009, BRAIN IMPAIR, V10, P188, DOI 10.1375/brim.10.2.188; Turkstra L.S., 2006, BRAIN IMPAIR, V7, P234, DOI [DOI 10.1375/BRIM.7.3.234, 10.1375/brim.7.3.234]; Walter SD, 1998, STAT MED, V17, P101, DOI 10.1002/(SICI)1097-0258(19980115)17:1<101::AID-SIM727>3.0.CO;2-E; World Health Organization, 2001, INT CLASS FUNCT DIS; Ylvisaker M., 1993, STAFF DEV CLIN INTER, P57; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P303; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	26	46	46	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2010	24	6-8					914	927	PII 919045510	10.1080/02687030903422478			14	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	628WL	WOS:000280154900020					2021-06-18	
J	Bay, E; Sikorskii, A; Saint-Arnault, D				Bay, Esther; Sikorskii, Alla; Saint-Arnault, Denise			Sex Differences in Depressive Symptoms and Their Correlates After Mild-to-Moderate Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE NURSING			English	Article							HIPPOCAMPAL VOLUME; MAJOR DEPRESSION; GENDER DIFFERENCES; RISK-FACTORS; STRESS; WOMEN; MOOD; RESPONSES; NEUROBIOLOGY; PREVALENCE	The purpose of this secondary data analysis, guided by allostatic load theory, was to compare depressive symptoms and their correlates in men and women following mild or moderate traumatic brain injury (n = 159). Using general linear modeling procedures in the Statistical Analysis Software, women reported significantly higher Center for Epidemiological Studies-Depression scores compared with men. According to the Neurobehavioral Functioning Inventory subscales, women also reported higher somatic and motor symptoms and difficulties with memory and cognition. Further, women within the first 6 months of their injury reported higher levels of depressive and depressive-somatic symptoms, perceived chronic stress, pain, memory difficulties, and somatic symptoms. These findings were no longer present at the 6- to 12-month or >12-month cutoffs. Women's depressive symptoms during the early recovery period are explained by higher symptom loads and perceived stress, yet mechanisms responsible for these differences remain to be elucidated. Future research is needed to describe hormonal, perceptual, or brain structure differences that may account for these findings. Findings from such research will most likely to contribute to our understanding of postconcussion syndrome.	[Bay, Esther; Sikorskii, Alla; Saint-Arnault, Denise] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA	Bay, E (corresponding author), Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA.	baye@msu.edu		Saint Arnault, Denise/0000-0002-4436-8347			Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bay E, 2007, ARCH PSYCHIAT NURS, V21, P2, DOI 10.1016/j.apnu.2006.07.005; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/088971804780957108; Bay E, 2009, BIOL RES NURS, V10, P213, DOI 10.1177/1099800408326453; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bierut LJ, 1999, ARCH GEN PSYCHIAT, V56, P557, DOI 10.1001/archpsyc.56.6.557; Blehar MC, 2006, ANNU REV CLIN PSYCHO, V2, P135, DOI 10.1146/annurev.clinpsy.2.022305.095344; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1995, HEALTH PSYCHOL, V14, P374, DOI 10.1037/0278-6133.14.5.374; Cohen S. C. R., 1995, MEASURING STRESS GUI, P1; Darnall BD, 2009, BRAIN BEHAV IMMUN, V23, P595, DOI 10.1016/j.bbi.2009.02.019; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355; Fillingim R B, 2000, Curr Rev Pain, V4, P24; Gerhart KA, 1999, SPINAL CORD, V37, P183, DOI 10.1038/sj.sc.3100804; Gordon EJ, 2008, ACS CHEM BIOL, V3, P6; Hammen C, 2003, J AFFECT DISORDERS, V74, P49, DOI 10.1016/S0165-0327(02)00430-5; Heim C, 2000, JAMA-J AM MED ASSOC, V284, P592, DOI 10.1001/jama.284.5.592; Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X; Heim Christine, 2002, Semin Clin Neuropsychiatry, V7, P147, DOI 10.1053/scnp.2002.33127; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hughes RB, 2005, WOMEN HEALTH ISS, V15, P14, DOI 10.1016/j.whi.2004.09.001; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kajantie E, 2006, PSYCHONEUROENDOCRINO, V31, P151, DOI 10.1016/j.psyneuen.2005.07.002; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; KELLY M, J BEHAV THE IN PRESS; Kendler KS, 2000, AM J PSYCHIAT, V157, P1243, DOI 10.1176/appi.ajp.157.8.1243; KESSLER RC, 1993, J AFFECT DISORDERS, V29, P85, DOI 10.1016/0165-0327(93)90026-G; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Lasiuk GC, 2007, BIOL RES NURS, V9, P147, DOI 10.1177/1099800407305600; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MCEWEN B, 2002, END STRESS WE KNOW I; MEARES S, 2007, J NEUROL NEUROSUR PS, V8, P1; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Nemeroff CB, 2005, J CLIN PSYCHIAT, V66, P5; NOLENHOEKSEMA S, 1987, PSYCHOL BULL, V101, P259, DOI 10.1037/0033-2909.101.2.259; Piccinelli M, 2000, BRIT J PSYCHIAT, V177, P486, DOI 10.1192/bjp.177.6.486; PICCINELLI M, 1997, EPIDEMIOLOGY AFFECTI; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; *SAS I, 2002, SAS SYST WIND VERS; SEARLE SR, 1980, AM STAT, V34, P216, DOI 10.2307/2684063; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shors TJ, 2003, J AFFECT DISORDERS, V74, P85, DOI 10.1016/S0165-0327(02)00428-7; Silverstein B, 1999, AM J PSYCHIAT, V156, P480; Silverstein B, 2002, AM J PSYCHIAT, V159, P1051, DOI 10.1176/appi.ajp.159.6.1051; SMITH B, 2001, EUROPEAN J PAIN, P257; Taylor SE, 2000, PSYCHOL REV, V107, P411, DOI 10.1037/0033-295X.107.3.411; TEASDALE G, 1974, LANCET, V2, P81; *US DEP HHS, 2007, TRAUM BRAIN INJ FACT; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WALKER EA, 1992, PSYCHOSOM MED, V54, P658, DOI 10.1097/00006842-199211000-00005; Weekes NY, 2005, STRESS HEALTH, V21, P147, DOI 10.1002/smi.1046; Weiss EL, 1999, AM J PSYCHIAT, V156, P816, DOI 10.1176/ajp.156.6.816; WHO. Geneva: World Health Organisation, 2004, WORLD REP ROAD TRAFF; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	75	46	46	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	DEC	2009	41	6					298	309		10.1097/JNN.0b013e3181b6be81			12	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	526CL	WOS:000272265200003	19998681				2021-06-18	
J	Braet, W; Johnson, KA; Tobin, CT; Acheson, R; Bellgrove, MA; Robertson, IH; Garavan, H				Braet, Wouter; Johnson, Katherine A.; Tobin, Claire T.; Acheson, Ruth; Bellgrove, Mark A.; Robertson, Ian H.; Garavan, Hugh			Functional developmental changes underlying response inhibition and error-detection processes	NEUROPSYCHOLOGIA			English	Article						Response inhibition; fMRI; Developmental; Error awareness	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; ANTERIOR CINGULATE; EXECUTIVE FUNCTIONS; WORKING-MEMORY; LATE CHILDHOOD; PERFORMANCE; TASK; SENSITIVITY; ACTIVATION	This study examined the developmental trajectories associated with response inhibition and error processing as exemplar executive processes. We present fMRI data showing developmental changes to the functional networks underlying response inhibition and error-monitoring, comparing activation between adults and young adolescents performing the sustained attention to response task (SART). During successful inhibitions, we observed greater activation for the young adolescents than for the adults, in a widely distributed network including frontal, parietal and medial regions. When inhibition failed, however, adults showed increased activation compared to young adolescents in a number of regions, including bilateral parahippocampal gyrus, left and right lingual gyri, the right insula, and cerebellar regions. These differences largely remained even when the two groups were matched for performance, suggesting that performance differences are unlikely to be the driving factor behind these developmental differences. Instead, the neurodevelopmental trajectory of these important executive functions may reveal the basis for the immature executive functioning of the young adolescent. (C) 2009 Elsevier Ltd. All rights reserved.	[Braet, Wouter] Univ Louvain, Expt Psychol Lab, B-3000 Louvain, Belgium; [Braet, Wouter; Johnson, Katherine A.; Tobin, Claire T.; Acheson, Ruth; Robertson, Ian H.; Garavan, Hugh] Univ Dublin Trinity Coll, Inst Neurosci, Dublin 2, Ireland; [Braet, Wouter; Johnson, Katherine A.; Tobin, Claire T.; Acheson, Ruth; Robertson, Ian H.; Garavan, Hugh] Univ Dublin Trinity Coll, Sch Psychol, Dublin 2, Ireland; [Bellgrove, Mark A.] Queensland Brain Inst, Brisbane, Qld, Australia; [Bellgrove, Mark A.] Univ Queensland, Sch Psychol, Brisbane, Qld, Australia	Braet, W (corresponding author), Univ Louvain, Expt Psychol Lab, Tiensestr 102, B-3000 Louvain, Belgium.	Wouter.braet@gmail.com	Johnson, Katherine A/K-8469-2015; Bellgrove, Mark/AAB-3114-2019; Braet, Wouter/A-5061-2009	Johnson, Katherine A/0000-0002-2029-163X; Bellgrove, Mark/0000-0003-0186-8349; Robertson, Ian H/0000-0001-8637-561X	Science Foundation IrelandScience Foundation IrelandEuropean Commission; Irish Health Research Board; Irish Higher Education Authority's Programme for Research in Third-Level Institutions; Australian National Health and Medical Research Council Howard Florey Centenary FellowshipNational Health and Medical Research Council of Australia; FWO Research Foundation FlandersFWO	This study was supported by grants from the Science Foundation Ireland, the Irish Health Research Board, the Irish Higher Education Authority's Programme for Research in Third-Level Institutions, the Australian National Health and Medical Research Council Howard Florey Centenary Fellowship, and the FWO Research Foundation Flanders. The authors would like to thank all participants, as well as the parents of the adolescents who took part in the study.	Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Bellgrove MA, 2004, NEUROPSYCHOLOGIA, V42, P1910, DOI 10.1016/j.neuropsychologia.2004.05.007; Booth JR, 2003, NEUROIMAGE, V20, P737, DOI 10.1016/S1053-8119(03)00404-X; Brown JW, 2005, SCIENCE, V307, P1118, DOI 10.1126/science.1105783; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Casey BJ, 1997, J COGNITIVE NEUROSCI, V9, P835, DOI 10.1162/jocn.1997.9.6.835; Castellanos FX, 2005, BIOL PSYCHIAT, V57, P1416, DOI 10.1016/j.biopsych.2004.12.005; Chan RCK, 2004, CLIN NEUROPSYCHOL, V18, P114, DOI 10.1080/13854040490507208; Clark CR, 2006, ARCH CLIN NEUROPSYCH, V21, P449, DOI 10.1016/j.acn.2006.06.005; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cragg L, 2008, DEVELOPMENTAL SCI, V11, P819, DOI 10.1111/j.1467-7687.2008.00730.x; Daniel DB, 2000, PERCEPT MOTOR SKILL, V90, P483, DOI 10.2466/PMS.90.2.483-484; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Denckla M., 1996, ATTENTION MEMORY EXE; Durston S, 2006, DEVELOPMENTAL SCI, V9, P1, DOI 10.1111/j.1467-7687.2005.00454.x; Durston S, 2002, DEVELOPMENTAL SCI, V5, pF9, DOI 10.1111/1467-7687.00235; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fernandez G, 1998, J NEUROSCI, V18, P1841; Fronczek R, 2006, SLEEP, V29, P187; Garavan H, 2003, NEUROIMAGE, V20, P1132, DOI 10.1016/S1053-8119(03)00334-3; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Garavan H, 1999, P NATL ACAD SCI USA, V96, P8301, DOI 10.1073/pnas.96.14.8301; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gray JA, 2000, NEUROPSYCHOLOGY ANXI; GREEN JD, 1954, J NEUROPHYSIOL, V17, P533; Hester R, 2008, CEREB CORTEX, V18, P1933, DOI 10.1093/cercor/bhm219; Jansma JM, 2004, SCHIZOPHR RES, V68, P159, DOI 10.1016/S0920-9964(03)00127-0; Johnson KA, 2008, AM J MED GENET B, V147B, P927, DOI 10.1002/ajmg.b.30718; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P2234, DOI 10.1016/j.neuropsychologia.2007.02.019; Jones LB, 2003, DEVELOPMENTAL SCI, V6, P498, DOI 10.1111/1467-7687.00307; Jonkman LM, 2007, CLIN NEUROPHYSIOL, V118, P1069, DOI 10.1016/j.clinph.2007.01.017; Jonkman LM, 2006, BRAIN RES, V1097, P181, DOI 10.1016/j.brainres.2006.04.064; Karatekin C, 2007, PSYCHOPHYSIOLOGY, V44, P128, DOI 10.1111/j.1469-8986.2006.00477.x; Kelly AMC, 2005, CEREB CORTEX, V15, P1089, DOI 10.1093/cercor/bhi005; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; Lin CCH, 1999, J ABNORM CHILD PSYCH, V27, P403, DOI 10.1023/A:1021932119311; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Magno E, 2006, J NEUROSCI, V26, P4769, DOI 10.1523/JNEUROSCI.0369-06.2006; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Murphy K, 2004, NEUROIMAGE, V22, P879, DOI 10.1016/j.neuroimage.2004.02.005; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Ramautar JR, 2006, BRAIN RES, V1105, P143, DOI 10.1016/j.brainres.2006.02.091; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rubia K, 2007, HUM BRAIN MAPP, V28, P1163, DOI 10.1002/hbm.20347; Rubia K, 2006, HUM BRAIN MAPP, V27, P973, DOI 10.1002/hbm.20237; Steven MC, 2007, BEHAV BRAIN RES, V181, P12, DOI 10.1016/j.bbr.2007.03.023; Stevens MC, 2009, HUM BRAIN MAPP, V30, P24, DOI 10.1002/hbm.20478; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Tamm L, 2002, J AM ACAD CHILD PSY, V41, P1231, DOI 10.1097/00004583-200210000-00013; Ungerleider LG, 2002, NEUROBIOL LEARN MEM, V78, P553, DOI 10.1006/nlme.2002.4091; Velanova K, 2008, CEREB CORTEX, V18, P2505, DOI 10.1093/cercor/bhn012; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507; Whyte J, 2006, NEUROPSYCHOLOGIA, V44, P2007, DOI 10.1016/j.neuropsychologia.2006.02.012	56	46	47	0	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	DEC	2009	47	14					3143	3151		10.1016/j.neuropsychologia.2009.07.018			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	529SQ	WOS:000272537900014	19651151	Green Accepted			2021-06-18	
J	Mollica, RF; Lyoo, IK; Chernoff, MC; Bui, HX; Lavelle, J; Yoon, SJ; Kim, JE; Renshaw, PF				Mollica, Richard F.; Lyoo, In Kyoon; Chernoff, Miriam C.; Bui, Hoan X.; Lavelle, James; Yoon, Sujung J.; Kim, Jieun E.; Renshaw, Perry F.			Brain Structural Abnormalities and Mental Health Sequelae in South Vietnamese Ex-Political Detainees Who Survived Traumatic Head Injury and Torture	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; HOPKINS SYMPTOM CHECKLIST-25; CONCENTRATION CAMP SURVIVORS; COLLEGIATE FOOTBALL PLAYERS; MAGNETIC-RESONANCE IMAGES; MAJOR DEPRESSIVE DISORDER; SURFACE-BASED ANALYSIS; POW SURVIVORS; PREFRONTAL CORTEX; PSYCHOLOGICAL SEQUELAE	Context: A pilot study of South Vietnamese ex political detainees who had been incarcerated in Vietnamese reeducation camps and resettled in the United States disclosed significant mental health problems associated with torture and traumatic head injury (THI). Objectives: To identify structural brain alterations associated with THI and to investigate whether these deficits are associated with posttraumatic stress disorder and depression. Design: Cross-sectional neuroimaging study. Setting: Massachusetts General Hospital and McLean Hospital. Participants: A subsample of Vietnamese ex-political detainees (n=42) and comparison subjects (n=16) selected from a community study of 337 ex-political detainees and 82 comparison subjects. Main Outcome Measures: Scores on the Vietnamese versions of the Hopkins Symptom Checklist-25 (HSCL) and Harvard Trauma Questionnaire for depression and posttraumatic stress disorder, respectively; cerebral regional cortical thickness; and manual volumetric morphometry of the amygdala, hippocampus, and thalamus. Results: Ex-political detainees exposed to THI (n=16) showed a higher rate of depression (odds ratio, 10.2; 95% confidence interval, 1.2-90.0) than those without THI exposure (n=26). Ex-political detainees with THI had thinner prefrontotemporal cortices than those without THI exposure (P<.001 by the statistical difference brain map) in the left dorsolateral prefrontal and bilateral superior temporal cortices, controlling for age, handedness, and number of trauma/torture events (left superior frontal cortex [SFC], P=.006; left middle frontal cortex, P=.01; left superior temporal cortex [STC], P=.007; right STC, P=.01). Trauma/ torture events were associated with bilateral amygdala volume loss ( left, P=.045; right, P=.003). Cortical thinning associated with THI in the left SFC and bilateral STC was related to HSCL depression scores in THI-exposed (vs non THI-exposed) ex-political detainees (left SFC, P for interaction=.007; left STC, P for interaction=.03; right STC, P for interaction=.02). Conclusions: Structural deficits in prefrontotemporal brain regions are linked to THI exposures. These brain lesions are associated with the symptom severity of depression in Vietnamese ex-political detainees.	[Mollica, Richard F.; Lavelle, James] Massachusetts Gen Hosp, Harvard Program Refugee Trauma, Dept Psychiat, Cambridge, MA 02139 USA; [Lyoo, In Kyoon; Kim, Jieun E.] Seoul Natl Univ, Dept Psychiat, Seoul, South Korea; [Lyoo, In Kyoon] Seoul Natl Univ, Dept Neurosci, Seoul, South Korea; [Lyoo, In Kyoon] Harvard Univ, McLean Hosp, Sch Med, Brain Imaging Ctr, Belmont, MA 02178 USA; [Lyoo, In Kyoon] Harvard Univ, Sch Med, Dept Psychiat, Belmont, MA 02178 USA; [Chernoff, Miriam C.] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA 02115 USA; [Bui, Hoan X.] Vietnamese Amer Civic Assoc, Dorchester, MA USA; [Yoon, Sujung J.] Catholic Univ, Coll Med, Dept Psychiat, Seoul, South Korea; [Renshaw, Perry F.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Renshaw, Perry F.] Univ Utah, Inst Brain, Salt Lake City, UT USA; [Renshaw, Perry F.] VISN 19 Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Salt Lake City, UT USA	Mollica, RF (corresponding author), Massachusetts Gen Hosp, Harvard Program Refugee Trauma, Dept Psychiat, 22 Putnam Ave, Cambridge, MA 02139 USA.	rmollica@partners.org	Renshaw, Perry/O-1384-2018		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH R01-059559-04]; Brain Research Center of the 21st Century Frontier Research ProgramMinistry of Education, Science and Technology, Republic of Korea [2009K001272]; Ministry of Education, Science, and Technology of South Korea; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH059559] Funding Source: NIH RePORTER	Research for this report was supported by grants MH R01-059559-04 from the National Institutes of Health and 2009K001272 from the Brain Research Center of the 21st Century Frontier Research Program, Ministry of Education, Science, and Technology of South Korea.	Affifi A, 2004, COMPUTER AIDED MULTI; Aharon I, 2001, NEURON, V32, P537, DOI 10.1016/S0896-6273(01)00491-3; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Ashburner J, 2003, LANCET NEUROL, V2, P79, DOI 10.1016/S1474-4422(03)00304-1; Ashman TA, 2006, MT SINAI J MED, V73, P999; Basoglu M, 1997, PSYCHOL MED, V27, P1421, DOI 10.1017/S0033291797005679; Basoglu M, 2005, JAMA-J AM MED ASSOC, V294, P580, DOI 10.1001/jama.294.5.580; Basoglu M, 2007, ARCH GEN PSYCHIAT, V64, P277, DOI 10.1001/archpsyc.64.3.277; Bechara A, 2003, ANN NY ACAD SCI, V985, P356, DOI 10.1111/j.1749-6632.2003.tb07094.x; Bechara A, 1999, J NEUROSCI, V19, P5473; Beck JG, 2007, PROF PSYCHOL-RES PR, V38, P629, DOI 10.1037/0735-7028.38.6.629; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Breiter HC, 1997, NEURON, V19, P591, DOI 10.1016/S0896-6273(00)80374-8; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Carlsson JM, 2006, NORD J PSYCHIAT, V60, P51, DOI 10.1080/08039480500504982; CASPIYAVIN Y, 1995, THESIS HARVARD SCH P; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Clark CR, 2003, BIOL PSYCHIAT, V53, P474, DOI 10.1016/S0006-3223(02)01505-6; Convit A, 1999, PSYCHIAT RES-NEUROIM, V90, P113, DOI 10.1016/S0925-4927(99)00007-4; COURVILLE CB, 1937, PATHOLOGY CENTRAL NE; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Drevets WC, 2008, BRAIN STRUCT FUNCT, V213, P93, DOI 10.1007/s00429-008-0189-x; EITINGER L, 1965, ISRAEL J MED SCI, V1, P883; ELTINGER L, 1973, MORTALITY MORBIDITY; Eritaia J, 2000, MAGN RESON MED, V44, P973, DOI 10.1002/1522-2594(200012)44:6<973::AID-MRM21>3.0.CO;2-H; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Fawzi MCS, 1997, J TRAUMA STRESS, V10, P101, DOI 10.1023/A:1024812514796; Fawzi MCS, 1997, ACTA PSYCHIAT SCAND, V95, P87, DOI 10.1111/j.1600-0447.1997.tb00379.x; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Flannelly KJ, 2007, J NERV MENT DIS, V195, P996, DOI 10.1097/NMD.0b013e31815c19b1; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; Gordon WA, 2006, J HEAD TRAUMA REHAB, V21, P156, DOI 10.1097/00001199-200603000-00008; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Gorst-Unsworth C, 1998, BRIT J PSYCHIAT, V172, P90, DOI 10.1192/bjp.172.1.90; GULLEN WH, 1980, JAMA-J AM MED ASSOC, V244, P2279, DOI 10.1001/jama.244.20.2279; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamilton JP, 2008, MOL PSYCHIATR, V13, P993, DOI 10.1038/mp.2008.57; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hollander AC, 2007, J NERV MENT DIS, V195, P955, DOI 10.1097/NMD.0b013e318159604b; Jacobs U, 2001, PROF PSYCHOL-RES PR, V32, P458, DOI 10.1037/0735-7028.32.5.458; JENSEN TS, 1982, NEW ENGL J MED, V307, P1341; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Joseph S, 1999, J TRAUMA STRESS, V12, P437, DOI 10.1023/A:1024762919372; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kemether EM, 2003, ARCH GEN PSYCHIAT, V60, P983, DOI 10.1001/archpsyc.60.9.983; Kleijn WC, 2001, PSYCHOL REP, V88, P527, DOI 10.2466/PR0.88.2.527-532; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; LIPSEY JR, 1983, BRIT J PSYCHIAT, V143, P266, DOI 10.1192/bjp.143.3.266; Lyoo IK, 2006, BIPOLAR DISORD, V8, P65, DOI 10.1111/j.1399-5618.2006.00284.x; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Makris N, 2008, NEURON, V60, P174, DOI 10.1016/j.neuron.2008.08.011; McAllister TW, 1997, COMMUNITY MENT HLT J, V33, P341, DOI 10.1023/A:1025055426260; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MOLLICA R, 1991, PSYCHOL ASSESSMENT, V3, P1; Mollica R. F., 2004, MEASURING TRAUMA MEA; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P497; Mollica RF, 1998, J NERV MENT DIS, V186, P543, DOI 10.1097/00005053-199809000-00005; Mollica RF, 2002, BRIT J PSYCHIAT, V181, P339, DOI 10.1192/bjp.181.4.339; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Mollica RF, 2007, J NERV MENT DIS, V195, P572, DOI 10.1097/NMD.0b013e318093ed2c; Moreno A, 2002, SPINAL CORD, V40, P213, DOI 10.1038/sj.sc.3101284; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Olver John, 2005, Aust Fam Physician, V34, P269; Oruc L, 2008, INTJCULTURE MENTHEAL, V1, P117; Patterson C M, 1998, J Ark Med Soc, V95, P109; PETERSEN HD, 1985, FORENSIC SCI INT, V29, P179, DOI 10.1016/0379-0738(85)90111-2; Pruessner JC, 2001, J NEUROSCI, V21, P194, DOI 10.1523/JNEUROSCI.21-01-00194.2001; QUIROGA J, 2006, TORTURE, V15, P1; Rasekh Z, 1998, JAMA-J AM MED ASSOC, V280, P449, DOI 10.1001/jama.280.5.449; RASMUSSEN OV, 1990, DAN MED BULL, V37, P1; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Roberts B, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-38; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; Roemer L, 1998, J TRAUMA STRESS, V11, P597, DOI 10.1023/A:1024469116047; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Shrestha NM, 1998, JAMA-J AM MED ASSOC, V280, P443, DOI 10.1001/jama.280.5.443; Sinnerbrink I, 1997, J PSYCHOL, V131, P463, DOI 10.1080/00223989709603533; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; Steel Z, 2002, LANCET, V360, P1056, DOI 10.1016/S0140-6736(02)11142-1; Steele JD, 2007, J AFFECT DISORDERS, V101, P1, DOI 10.1016/j.jad.2006.11.009; STROM A, 1962, J NEUROPSYCHIATRY, V4, P43; STROM A, 1964, NORWEGIAN CONCENTRAT; Sulway MR, 1996, NEUROLOGY, V46, P650, DOI 10.1212/WNL.46.3.650; SUTKER PB, 1995, NEUROPSYCHOLOGY, V9, P118, DOI 10.1037/0894-4105.9.1.118; SUTKER PB, 1990, J PERS ASSESS, V54, P170, DOI 10.1207/s15327752jpa5401&2_17; Sutker PB, 1996, PSYCHOL ASSESSMENT, V8, P18, DOI 10.1037/1040-3590.8.1.18; SUTKER PB, 1990, J CONSULT CLIN PSYCH, V58, P323, DOI 10.1037/0022-006X.58.3.323; SUTKER PB, 1992, ARCH CLIN NEUROPSYCH, V7, P431, DOI 10.1016/0887-6177(92)90156-H; THYGESEN P, 1970, DAN MED BULL, V17, P65; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Vasterling JJ, 1997, ASSESSMENT, V4, P51, DOI 10.1177/107319119700400107; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Weinstein CS, 2001, NEUROPSYCHOL REV, V11, P131, DOI 10.1023/A:1016650623996; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	110	46	47	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	NOV	2009	66	11					1221	1232		10.1001/archgenpsychiatry.2009.127			12	Psychiatry	Psychiatry	514WS	WOS:000271427500008	19884610	Bronze			2021-06-18	
J	Erez, ABH; Rothschild, E; Katz, N; Tuchner, M; Hartman-Maeir, A				Erez, Asnat Bar-Haim; Rothschild, Ettie; Katz, Noomi; Tuchner, Maya; Hartman-Maeir, Adina			Executive Functioning, Awareness, and Participation in Daily Life After Mild Traumatic Brain Injury: A Preliminary Study	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						awareness; brain injuries; cognition; self-concept	PORTLAND ADAPTABILITY INVENTORY; SELF-AWARENESS; DYSEXECUTIVE SYNDROME; MAJOR DEPRESSION; HEAD TRAUMA; REHABILITATION; VALIDITY; DEFICITS; MODERATE; RELIABILITY	OBJECTIVE. We investigated the relationship of executive functioning and self-awareness to participation in daily life of people after mild traumatic brain injury (mTBI) referred to occupational therapy in the postacute phase. METHOD. Thirteen participants who sustained mTBI (average time since injury = 4.7 months, mean age 43.4 years) were evaluated with the Behavioral Assessment of the Dysexecutive Syndrome, the Dysexecutive Questionnaire, the Self-Awareness of Deficits Interview, and the Participation Index (PI) of the Mayo-Portland Adaptability Inventory. RESULTS. Analysis revealed high frequencies of deficits in executive functions such as planning and shifting. However, self-awareness of the executive deficits was intact. A significant percentage (62%-85%) of participants experienced restrictions in everyday life activities, and PI scores were significantly correlated with measures of executive functioning. CONCLUSIONS. After mTBI, people may be at significant risk for persistent executive deficits and restrictions in participation that warrant occupational therapy intervention.	[Rothschild, Ettie] Soroka Med Ctr, Rehabil Dept, IL-84101 Beer Sheva, Israel; [Katz, Noomi] Hebrew Univ Jerusalem, Sch Occupat Therapy, Jerusalem, Israel; [Tuchner, Maya; Hartman-Maeir, Adina] Hadassah & Hebrew Univ, Occupat Therapy Dept, Fac Med, Jerusalem, Israel		aaerez@zahav.net.il					American Occupational Therapy Association, 2008, AM J OCCUPATIONAL TH, V62, P625, DOI DOI 10.5014/AJOT.62.6.625; Baum CM, 2008, AM J OCCUP THER, V62, P446, DOI 10.5014/ajot.62.4.446; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Dvir O., 2003, ISRAEL J OCCUPATION, V12, P207; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Fleming JM, 1996, BRAIN INJURY, V10, P1; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; KATZ N, 2005, COGNITION OCCUPATION, P3; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kiernan R.J., 1995, COGNISTAT NEUROBEHAV; KRAUS JF, 1996, NEUROTRAUMA, P13; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Malec J. F., 2003, MANUAL MAYO PORTLAND; Malec JF, 2004, ARCH PHYS MED REHAB, V85, P1989, DOI 10.1016/j.apmr.2004.01.032; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; TEASDALE G, 1974, LANCET, V2, P81; Wilson B.A., 1996, BADS BEHAV ASSESSMEN; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; World Health Organization, 2001, INT CLASS FUNCT DIS	37	46	48	0	18	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2009	63	5			SI		634	640					7	Rehabilitation	Rehabilitation	493SG	WOS:000269757700014	19785263				2021-06-18	
J	Sheedy, J; Harvey, E; Faux, S; Geffen, G; Shores, EA				Sheedy, Joanne; Harvey, Evelyn; Faux, Steven; Geffen, Gina; Shores, E. Arthur			Emergency Department Assessment of Mild Traumatic Brain Injury and the Prediction of Postconcussive Symptoms: A 3-Month Prospective Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain; concussion; injury; mild; prediction; traumatic	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; NATURAL-HISTORY; RAPID SCREEN; RISK-FACTORS; MODERATE; RECOVERY; DIAGNOSIS; TIME	Objective: To investigate the utility of a brief emergency department (ED) bedside screen for the prediction of postconcussive symptoms at 3 months following mild traumatic brain injury (MTBI). Participants: One hundred patients with MTBI (78% men; mean age = 33.6 years); 2 control groups (each n = 100), a "minor nonhead injury" group (77% men; mean age = 32.2 years) and an "uninjured ED visitor" group (78% men; mean age = 33.6 years). Main Measures: Brief measures of neuropsychological functioning, acute pain, and postural stability were collected in the ED; telephone follow-up at 3 months using the Rivermead Post-Concussion Symptoms Questionnaire was undertaken. Results: Neuropsychological deficits, acute pain, and postural instability in the ED were significantly associated with postconcussive symptoms at 3-month follow-up. A regression formula using 3 easily obtainable measures obtained during acute stage of injury-immediate and delayed memory for 5 words and a visual analog scale score of acute headache-provided 80% sensitivity and 76% specificity for the prediction of clinically significant symptoms at 3 months postinjury. Conclusion: A small combination of variables assessable in the ED may predict MTBI patients likely to experience persistent postconcussive symptoms.	[Sheedy, Joanne] St Vincents Hosp, Darlinghurst, NSW 2010, Australia; [Shores, E. Arthur] Macquarie Univ, Dept Psychol, Sydney, NSW 2109, Australia; [Harvey, Evelyn] Westmead Hosp, Sydney, NSW, Australia; [Geffen, Gina] Univ Queensland, Sch Psychol, Cognit Psychophysiol Lab, Brisbane, Qld, Australia	Sheedy, J (corresponding author), St Vincents Hosp, Victoria St, Sydney, NSW 2010, Australia.	jmshe9@student.monash.edu	Faux, Steven/Y-3409-2019	Faux, Steven/0000-0001-8846-216X; Shores, Edwin A/0000-0003-1553-5131			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM ASS AUT MED, 1990, ABBR INJ SCAL 1990; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P624, DOI 10.1080/13803390490918589; De Monte VE., 2005, BRAIN IMPAIR, V6, P109, DOI [10.1375/brim.2005.6.2.109, DOI 10.1375/BRIM.2005.6.2.109]; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; Greiffenstein MF, 2003, CLIN NEUROPSYCHOL, V17, P561, DOI 10.1076/clin.17.4.561.27937; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; HINTONBAYRE AD, 1997, SPORT HLTH, V15, P4; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Marzo SJ, 2004, LARYNGOSCOPE, V114, P1720, DOI 10.1097/00005537-200410000-00008; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; REITAN RM, 1999, BRAIN, V55, P549; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; RUBIN AM, 1995, AM J OTOL, V16, P216; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wrisley DM, 2000, J ORTHOP SPORT PHYS, V30, P755, DOI 10.2519/jospt.2000.30.12.755	55	46	46	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2009	24	5					333	343		10.1097/HTR.0b013e3181aea51f			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	509WG	WOS:000271049300004	19858967				2021-06-18	
J	Shoakazemi, A; Flannery, T; McConnell, RS				Shoakazemi, Alireza; Flannery, Thomas; McConnell, Robert Scoff			LONG-TERM OUTCOME OF SUBCUTANEOUSLY PRESERVED AUTOLOGOUS CRANIOPLASTY	NEUROSURGERY			English	Article						Abdominal wall; Autologous bone flap; Cranial defect; Cranioplasty; Decompressive craniectomy	TRAUMATIC BRAIN-INJURY; CRANIOTOMY BONE FLAPS; DECOMPRESSIVE CRANIECTOMY; POSTTRAUMATIC HYDROCEPHALUS; DEFECTS; FROZEN; FRESH; FATE; HEAD	OBJECTIVE: Decompressive craniectomy for intracranial hypertension mandates later cranioplasty. Autologous cranioplasties can be preserved either by freezing or placement in a subcutaneous pocket. There are few data on the long-term follow-up of patients treated in such a fashion. METHODS: A retrospective study was conducted on 100 consecutive patients who underwent decompressive craniectomy and placement of the bone flap in a subcutaneous pocket in the abdominal wall between 2000 and 2005. Initial diagnosis, Glasgow Coma Scale score on admission, complications, and Glasgow Outcome Score were recorded. RESULTS: Of the 100 patients who underwent autocranioplasty, the primary diagnosis was traumatic brain injury (76%), subarachnoid hemorrhage (17%), primary intracerebral hemorrhage (3%), and tumor (4%). The mean age of the sample was 39 years (age range, 10-72 years). The mean follow-up duration was 25 months. The average Glasgow Coma Scale score on admission was 7. Eight patients died before replacement of the bone flap. The average time between craniectomy and replacement of bone flap was 42 days. The mean Glasgow Outcome Score was 4 at the time of the 1-year follow-up evaluation. Seven of the 79 patients (9%) for whom 1-year review data were available had a cosmetic result that was unacceptable and required removal of the flap (bone flap infections in 5 patients, unacceptable bone flap resorption in 2 patients) CONCLUSION: Our study indicates that storage of a cranioplasty flap in a subcutaneous pouch in the abdominal wall has a favorable long-term outcome.	[Shoakazemi, Alireza; Flannery, Thomas; McConnell, Robert Scoff] Royal Victoria Hosp, Dept Neurosurg, Reg Neurosci Unit, Belfast BT12 6BA, Antrim, North Ireland	McConnell, RS (corresponding author), Royal Victoria Hosp, Dept Neurosurg, Reg Neurosci Unit, Level 6A OPC, Belfast BT12 6BA, Antrim, North Ireland.	roy.mcconnell@belfasttrust.hscni.net					ABBOTT KH, 1953, J NEUROSURG, V10, P380, DOI 10.3171/jns.1953.10.4.0380; ACIKGOZ B, 1986, SURG NEUROL, V26, P557, DOI 10.1016/0090-3019(86)90339-3; CABANELA ME, 1972, J BONE JOINT SURG AM, VA 54, P278, DOI 10.2106/00004623-197254020-00005; CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; COULDWELL WT, 1994, J NEUROSURG, V81, P483, DOI 10.3171/jns.1994.81.3.0483; Curry WT, 2005, NEUROSURGERY, V56, P681, DOI 10.1227/01.NEU.0000156604.41886.62; Czosnyka M, 2000, J NEUROL NEUROSUR PS, V68, P246; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; ELLIOTT H, 1951, BRIT J SURG, V39, P31, DOI 10.1002/bjs.18003915305; Flannery T, 2001, BRIT J NEUROSURG, V15, P518, DOI 10.1080/02688690120097732; Goel A, 1995, SURG NEUROL, V44, P181, DOI 10.1016/0090-3019(95)00161-1; GORDON DS, 1974, BRIT MED J, V2, P478, DOI 10.1136/bmj.2.5917.478; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; HANCOCK DO, 1963, J NEUROSURG, V20, P983, DOI 10.3171/jns.1963.20.11.0983; HAUPTLI J, 1980, HELV CHIR ACTA, V47, P121; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; KAWAKAMI K, 1989, Neurological Surgery, V17, P1023; KORFALI E, 1988, SURG NEUROL, V30, P269, DOI 10.1016/0090-3019(88)90297-2; KORLOF B, 1973, PLAST RECONSTR SURG, V52, P378, DOI 10.1097/00006534-197352040-00009; KREIDER GN, 1920, JAMA-J AM MED ASSOC, V64, P1024; KREUZ FP, 1951, J BONE JOINT SURG AM, V33-A, P863, DOI 10.2106/00004623-195133040-00005; Krishnan P, 2006, NEUROL INDIA, V54, P291; KRISS F C, 1969, Journal of Neurosurgery, V30, P698, DOI 10.3171/jns.1969.30.6.0698; LEIVY DM, 1970, NEUROCHIRURGIA, V13, P82; LONGACRE J J, 1957, Plast Reconstr Surg (1946), V20, P281, DOI 10.1097/00006534-195710000-00003; LONGACRE J J, 1958, Plast Reconstr Surg Transplant Bull, V21, P372, DOI 10.1097/00006534-195805000-00005; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; MCCLINTOCK HG, 1951, SURGERY, V30, P955; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Nakajima T, 1975, No Shinkei Geka, V3, P925; Nakajima T, 1977, No Shinkei Geka, V5, P1329; ODOM GL, 1952, J NEUROSURG, V9, P606, DOI 10.3171/jns.1952.9.6.0606; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; PRABHU SS, 2004, YOUMANS NEUROLOGICAL, V6, P5174; PROLO DJ, 1984, NEUROSURGERY, V15, P846, DOI 10.1227/00006123-198412000-00013; PROLO DJ, 1979, NEUROSURGERY, V4, P18, DOI 10.1227/00006123-197901000-00005; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Tsukagoshi T, 1998, PLAST RECONSTR SURG, V102, P2114, DOI 10.1097/00006534-199811000-00047; Tybor Krzysztof, 2005, Neurol Neurochir Pol, V39, P220; Valentini LG, 2008, NEUROSURGERY, V62, P88, DOI 10.1227/01.NEU.0000311065.95496.C5; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Wegeforth P, 1919, ANN SURG, V69, P384, DOI 10.1097/00000658-191904000-00005; Yano H, 2006, J CRANIOFAC SURG, V17, P1076, DOI 10.1097/01.scs.0000244916.84511.b6	47	46	46	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2009	65	3					505	510		10.1227/01.NEU.0000350870.69891.86			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	488CB	WOS:000269325600011	19687696				2021-06-18	
J	Crawford, DK; Mangiardi, M; Tiwari-Woodruff, SK				Crawford, Daniel K.; Mangiardi, Mario; Tiwari-Woodruff, Seema K.			Assaying the functional effects of demyelination and remyelination: Revisiting field potential recordings	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Functional remyelination; Brain slice electrophysiology; Extracellular field potential recording; Compound action potential; Corpus callosum; Demyelination; Pathophysiology	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; RAT CORPUS-CALLOSUM; UNMYELINATED AXONS; CUPRIZONE; CONDUCTION; MYELINATION; MODEL; EAE	The occurrence and histopathological characteristics of demyelination and neurodegeneration have been well described in different demyelinating mouse models. However, histopathological analysis is limiting in that it is unable to describe the functional consequences of demyelination and recovery after remyelination. Establishing the functional correlates of axon demyelination and remyelination is an important goal and can be used to measure axon function and develop neuroprotective therapies. This report describes a previously established, simple, easily applied method of electrophysiological measurement that can characterize white matter axonal dysfunction following demyelination and potential recovery after remyelination. It is designed to study in vitro stimulated compound action potentials in the corpus callosum of superfused brain slices at various time points and can be similarly used on white matter tracts in the optic nerve, spinal cord and cerebellum. Since behavioral testing can be performed prior to the brain slice electrophysiology, and the recorded slices can be post-fixed and subjected to histological analysis, correlates between behavior, axon function, and pathology can be determined. A temporal pattern of white matter functional deterioration and recovery can also be established to study mechanisms of demyelination-induced white matter injury and repair. Published by Elsevier B.V.	[Crawford, Daniel K.; Mangiardi, Mario; Tiwari-Woodruff, Seema K.] Univ Calif Los Angeles, Multiple Sclerosis Program, Dept Neurol, Sch Med, Los Angeles, CA 90095 USA; [Tiwari-Woodruff, Seema K.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	Tiwari-Woodruff, SK (corresponding author), Univ Calif Los Angeles, Multiple Sclerosis Program, Dept Neurol, Sch Med, Neurosci Res Bldg 1,475C,635 Charles E Young Dr, Los Angeles, CA 90095 USA.	seemaw@ucla.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Crawford, Daniel/0000-0002-0169-8645			Aguirre A, 2007, NAT NEUROSCI, V10, P990, DOI 10.1038/nn1938; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bando Y, 2008, EUR J NEUROSCI, V28, P1731, DOI 10.1111/j.1460-9568.2008.06474.x; Blakemore W F, 1981, Prog Clin Biol Res, V59A, P105; BLAKEMORE WF, 1973, J NEUROL SCI, V20, P63, DOI 10.1016/0022-510X(73)90118-4; Craner MJ, 2005, GLIA, V49, P220, DOI 10.1002/glia.20112; Craner MJ, 2004, BRAIN, V127, P294, DOI 10.1093/brain/awh032; CRAWFORD D, FUNCTIONAL REC UNPUB; Erlanger J, 1924, AM J PHYSIOL, V70, P624; FOSTER RE, 1980, J NEUROL SCI, V48, P221, DOI 10.1016/0022-510X(80)90202-6; Fuss B, 2001, MOL CELL NEUROSCI, V18, P221, DOI 10.1006/mcne.2001.1011; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Koutsoudaki PN, 2009, NEUROSCI LETT, V451, P83, DOI 10.1016/j.neulet.2008.11.058; Lindner M, 2008, NEUROPATH APPL NEURO, V34, P105, DOI 10.1111/j.1365-2990.2007.00879.x; Mallon BS, 2002, J NEUROSCI, V22, P876, DOI 10.1523/JNEUROSCI.22-03-00876.2002; Matsushima GK, 2001, BRAIN PATHOL, V11, P107; Moyer JR, 1998, J NEUROSCI METH, V86, P35, DOI 10.1016/S0165-0270(98)00143-5; PRESTON RJ, 1983, EXP NEUROL, V79, P808, DOI 10.1016/0014-4886(83)90044-4; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Skripuletz T, 2008, AM J PATHOL, V172, P1053, DOI 10.2353/ajpath.2008.070850; Smith SL, 2005, P NATL ACAD SCI USA, V102, P14901, DOI 10.1073/pnas.0505028102; Stidworthy MF, 2003, BRAIN PATHOL, V13, P329; SWADLOW HA, 1978, EXP BRAIN RES, V33, P455; Swanson TH, 1998, BRAIN RES, V784, P188, DOI 10.1016/S0006-8993(97)01323-1; Tiwari-Woodruff S, 2007, P NATL ACAD SCI USA, V104, P14813, DOI 10.1073/pnas.0703783104; Tiwari-Woodruff S, 2006, AM J PHYSIOL-CELL PH, V291, pC687, DOI 10.1152/ajpcell.00510.2005; Torkildsen O, 2008, ACTA NEUROL SCAND, V117, P72, DOI 10.1111/j.1600-0404.2008.01036.x; Watson T W, 1987, Proc West Pharmacol Soc, V30, P361; Waxman S G, 1988, Adv Neurol, V47, P185; WAXMAN SG, 1980, MUSCLE NERVE, V3, P141, DOI 10.1002/mus.880030207; ZHOU QH, 1995, J NEUROSCI METH, V59, P85, DOI 10.1016/0165-0270(94)00197-O	32	46	46	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	AUG 30	2009	182	1					25	33		10.1016/j.jneumeth.2009.05.013			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	482QW	WOS:000268904800004	19481113				2021-06-18	
J	Gibson, CL; Coomber, B; Rathbone, J				Gibson, Claire L.; Coomber, Ben; Rathbone, James			Is Progesterone a Candidate Neuroprotective Factor for Treatment following Ischemic Stroke?	NEUROSCIENTIST			English	Article						progesterone; focal ischemia; neuroprotection; steroids; stroke	CEREBRAL-ARTERY OCCLUSION; ESTROGEN PLUS PROGESTIN; TRAUMATIC BRAIN-INJURY; BINDING PROTEIN 25-DX; INFARCT VOLUME; UP-REGULATION; COGNITIVE DEFICITS; HORMONE-THERAPY; CLINICAL-TRIAL; CELL-DEATH	Gender differences in stroke outcome have implicated steroid hormones as potential neuroprotective candidates. However, no clinical trials examining hormone replacement therapy on outcome following ischemic stroke have investigated the effect of progesterone-only treatment. In this review the authors examine the experimental evidence for the neuroprotective potential of progesterone and give an insight into potential mechanisms of action following ischemic stroke. To date, 17 experimental studies have investigated the neuroprotective potential of progesterone for ischemic stroke in terms of ability to both reduce cell loss and increase functional Outcome. Of these 17 published studies the majority reported a beneficial effect with three studies reporting a nil effect and only one study reporting a negative effect. However, there are important issues that the authors address in this review in terms of the methodological quality of studies in relation to the STAIR recommendations. In terms of the proposed mechanisms of progesterone neuroprotection we show that progesterone is versatile and acts at Multiple targets to facilitate neuronal survival and minimize cell damage and loss. A large amount of experimental evidence indicates that progesterone is a neuroprotective candidate for ischemic stroke: however, to progress to clinical trial a number of key experimental studies remain outstanding.	[Gibson, Claire L.; Coomber, Ben; Rathbone, James] Univ Leicester, Sch Psychol, Leicester LE1 9HN, Leics, England	Gibson, CL (corresponding author), Univ Leicester, Sch Psychol, Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	cg95@le.ac.uk		Gibson, Claire/0000-0002-3358-7341			Aggarwal R, 2008, J PHARM PHARMACOL, V60, P731, DOI 10.1211/jpp.60.6.0008; Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Bingham D, 2005, J CEREBR BLOOD F MET, V25, P414, DOI 10.1038/sj.jcbfm.9600031; Brann DW, 2005, NEUROENDOCRINOLOGY, V81, P120, DOI 10.1159/000086405; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Carswell HV, 2004, J CEREBR BLOOD F MET, V24, P298, DOI 10.1097/01.WCB.0000112322.75217.FD; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Coughlan T, 2005, J NEUROCHEM, V93, P932, DOI 10.1111/j.1471-4159.2005.03068.x; Cutler SM, 2006, PHARMACOL BIOCHEM BE, V84, P420, DOI 10.1016/j.pbb.2006.05.029; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Gebel JM, 2002, STROKE, V33, P2636, DOI 10.1161/01.STR.0000035283.34109.EA; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2006, J CEREBR BLOOD F MET, V26, P1103, DOI 10.1038/sj.jcbfm.9600270; Ginsberg MD, 2009, STROKE, V40, pS111, DOI 10.1161/STROKEAHA.108.528877; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; Green AR, 2003, TRENDS PHARMACOL SCI, V24, P402, DOI 10.1016/S0165-6147(03)00192-5; Guennoun R, 2008, BRAIN RES REV, V57, P493, DOI 10.1016/j.brainresrev.2007.05.009; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hattori K, 2000, STROKE, V31, P1939, DOI 10.1161/01.STR.31.8.1939; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; HURN PD, 2002, PHARM CEREBRAL ISCHE, P17; Irwin RW, 2008, ENDOCRINOLOGY, V149, P3167, DOI 10.1210/en.2007-1227; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; LENA C, 1993, TRENDS NEUROSCI, V16, P181, DOI 10.1016/0166-2236(93)90150-K; Liu XQ, 2008, J CEREBR BLOOD F MET, V28, P1898, DOI 10.1038/jcbfm.2008.83; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Macleod MR, 2005, J CEREBR BLOOD F MET, V25, P713, DOI 10.1038/sj.jcbfm.9600064; Macrae IM, 2006, BIOCHEM SOC T, V34, P1362, DOI 10.1042/BST0341362; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Maurice T, 2006, PHARMACOL BIOCHEM BE, V84, P581, DOI 10.1016/j.pbb.2006.07.009; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Murphy SJ, 2000, STROKE, V31, P1173, DOI 10.1161/01.STR.31.5.1173; Murphy SJ, 2004, ILAR J, V45, P147, DOI 10.1093/ilar.45.2.147; MURPHY SJ, 2002, J CEREB BLOOD FLOW M, V22, P367; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Prencipe M, 1997, STROKE, V28, P531, DOI 10.1161/01.STR.28.3.531; Quick AM, 2005, FASEB J, V19, P170, DOI 10.1096/fj.04-1901hyp; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Reglodi D, 2003, BRAIN RES BULL, V59, P459, DOI 10.1016/S0361-9230(02)00962-0; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Sacco RL, 1997, STROKE, V28, P1507, DOI 10.1161/01.STR.28.7.1507; Savitz SI, 2008, STROKE, V39, P1389, DOI 10.1161/STROKEAHA.107.504415; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schneider A, 1999, NAT MED, V5, P554; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Singh M, 2006, ENDOCRINE, V29, P271, DOI 10.1385/ENDO:29:2:271; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; Toung TJ, 2004, J CEREBR BLOOD F MET, V24, P1160, DOI 10.1097/01.WCB.0000135594.13576.D2; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Turgeon JL, 2004, SCIENCE, V304, P1269, DOI 10.1126/science.1096725; Turtzo LC, 2008, CEREBROVASC DIS, V26, P462, DOI 10.1159/000155983; VALERA S, 1992, P NATL ACAD SCI USA, V89, P9949, DOI 10.1073/pnas.89.20.9949; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; Wise PM, 2001, BRAIN RES REV, V37, P313, DOI 10.1016/S0165-0173(01)00136-9; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	86	46	48	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	AUG	2009	15	4					324	332		10.1177/1073858409333069			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	479KP	WOS:000268658500008	19359672				2021-06-18	
J	Hong, X; Miller, C; Savant-Bhonsale, S; Kalkanis, SN				Hong, Xin; Miller, Cathie; Savant-Bhonsale, Smita; Kalkanis, Steven N.			ANTITUMOR TREATMENT USING INTERLEUKIN-12-SECRETING MARROW STROMAL CELLS IN AN INVASIVE GLIOMA MODEL	NEUROSURGERY			English	Article						Animal model; Glioma; Interleukin-12; Invasion; Marrow stromal cells	NEURAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; RATS; MIGRATION; STROKE	OBJECTIVE: Marrow stromal cells (MSCs) have the potential to migrate toward sites of injury or disease in the central nervous system. Encouraging results have been obtained by using MSCs to deliver therapeutic molecules. However, most brain tumor animal models-unlike in actual human disease states-use cells with limited invasion properties. In the present study, C57/B16 mice were implanted with the highly invasive Ast11.9-2 glioma cell line to investigate the potential therapeutic effects of interleukin-12 (IL-12)-secreting MSCs. METHODS: MSCs were infected with adenovirus encoding murine IL-12 (AdIL 12). The infection conditions were optimized by determination of cytotoxicity and IL-12 secretion after AdIL 12 infection in vitro. After implanting Ast11.9-2 tumor into mouse brain, we conducted a survival experiment to compare 4 distinct treatment groups by injecting culture medium control (sham), MSCs alone, MSCs infected with control virus (MSC-adenovirus encoding green fluorescent protein), and MSCs infected with IL-12-expressing virus (MSC-AdIL 12) in the peritumoral region of the brain. Tumor tissues were analyzed by hematoxylin and eosin staining. IL-12 expression was analyzed by immunohistochemistry staining. Y chromosome fluorescent in situ hybridization was used to detect injected MSCs. Cell populations of CD57(+) (natural killer cells), CD3(+) (total T cells), and 7-AAD (dead cells) in whole brain tissue were analyzed by fluorescence-activated cell sorting at days 4 and 7 after therapeutic treatment. RESULTS: Serum IL-12 increased significantly at days 4 and 7 after MSC-AdIL 12 implantation. IL-12-expressing cells were detected by immunohistochemistry staining and Y chromosome-positive staining cells were found in the tumor area, confirming successful IL-12 delivery. MSC-AdIL 12 treatment yielded increased natural killer cell infiltration in brain tissue at day 4, leading to an expected increase in nonspecific cell death, while total T-cell counts remained unchanged. MSC-IL-12 treatment extended animal survival but did not result in a statistically significant difference in comparison to other groups. Because all animals ultimately died of the brain tumors, MSC-AdIL 12 treatment did not completely arrest the invasive growth pattern of these lesions. CONCLUSION: The results indicate that MSCs may serve as useful delivery vehicles for IL-12 and other antineoplastic agents in brain tumor therapy.	[Hong, Xin; Kalkanis, Steven N.] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Miller, Cathie] Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Savant-Bhonsale, Smita] Theradigm Inc, Baltimore, MD USA	Kalkanis, SN (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	kalkanis@neuro.hfh.edu					Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Benedetti S, 2000, NAT MED, V6, P447; BOGLER O, 1995, CANCER RES, V55, P2746; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; COHEN J, 1995, SCIENCE, V270, P908; Ehtesham M, 2002, CANCER RES, V62, P5657; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Leonard JP, 1997, BLOOD, V90, P2541; Li Y, 2006, EXP NEUROL, V198, P313, DOI 10.1016/j.expneurol.2005.11.029; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008-5472.CAN-04-1874; Nakamura K, 2004, GENE THER, V11, P1155, DOI 10.1038/sj.gt.3302276; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 2000, PROG BRAIN RES, V128, P293; Trinchieri G, 1996, J LEUKOCYTE BIOL, V59, P505; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P237, DOI 10.1016/0167-5699(93)90173-I; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009	20	46	51	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUN	2009	64	6					1139	1146		10.1227/01.NEU.0000345646.85472.EA			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	452YE	WOS:000266576300029	19487894				2021-06-18	
J	Bhat, MA; Charoo, BA; Bhat, JI; Ahmad, SM; Ali, SW; Mufti, MUH				Bhat, Mushtaq Ahmad; Charoo, Bashir Ahmad; Bhat, Javeed Iqbal; Ahmad, Sheikh Mushtaq; Ali, Syed Wajid; Mufti, Masood-ul-Hassan			Magnesium Sulfate in Severe Perinatal Asphyxia: A Randomized, Placebo-Controlled Trial	PEDIATRICS			English	Article						asphyxia; perinatal; magnesium sulfate	TRANSIENT HYPOXIA-ISCHEMIA; CEREBRAL ENERGY FAILURE; TRAUMATIC BRAIN-INJURY; NEWBORN PIGLET; BIRTH ASPHYXIA; ENCEPHALOPATHY; INFUSION; PALSY; RISK; TERM	OBJECTIVE. The goal was to study whether postnatal magnesium sulfate infusion could improve neurologic outcomes at discharge for term neonates with severe perinatal asphyxia. METHODS. Forty term (>= 37 weeks of gestation) neonates with severe perinatal asphyxia were studied in a prospective, longitudinal, placebo-controlled trial. Patients were assigned randomly to receive either 3 doses of magnesium sulfate infusion at 250 mg/kg per dose (1 mL/kg per dose) 24 hours apart (treatment group) or 3 doses of normal saline infusion (1 mL/kg per dose) 24 hours apart (placebo group). Both groups also received supportive care according to the unit protocol for perinatal asphyxia. RESULTS. In the treatment group, moderate encephalopathy was present in 35% (7 of 20) of the patients and severe encephalopathy in 65% (13 of 20) of patients at admission. In the placebo group, 40% (8 of 20) of patients had moderate encephalopathy and 60% (12 of 20) of patients had severe encephalopathy. The mean serum magnesium concentration in the treatment group remained at >= 1.2 mmol/L for 72 hours after the first infusion. At discharge, 22% (4 of 18) of infants in the treatment group had neurologic abnormalities, compared with 56% (10 of 18) of infants in the placebo group. Also, neuroimaging (head computed tomography) performed on day 14 yielded abnormal findings for fewer infants in the treatment group than in the placebo group (16% vs 44%). Infants in the treatment group were more likely to be receiving oral feedings (sucking) at discharge than were those in the placebo group (77% vs 37%). Good short-term outcomes at discharge occurred for 77% of the patients in the treatment group, compared with 37% of the patients in the placebo group. CONCLUSION. Postnatal magnesium sulfate treatment improves neurologic outcomes at discharge for term neonates with severe perinatal asphyxia. Pediatrics 2009; 123: e764-e769	[Bhat, Mushtaq Ahmad; Charoo, Bashir Ahmad; Bhat, Javeed Iqbal; Ahmad, Sheikh Mushtaq; Ali, Syed Wajid; Mufti, Masood-ul-Hassan] SKIMS, Dept Pediat, Srinagar 190011, Jammu & Kashmir, India	Bhat, MA (corresponding author), SKIMS, Dept Pediat, Srinagar 190011, Jammu & Kashmir, India.	mbhat47@rediffmail.com	charoo, bashir ahmad/ABB-9310-2020				ADCOCK LM, 2008, MANUAL NEONATAL CARE, P518; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bhat MA, 2006, J PEDIATR-US, V149, P180, DOI 10.1016/j.jpeds.2006.03.053; CHOI DW, 1993, RES P ARNMD, V71, P23; Dixon G, 2002, PEDIATRICS, V109, P26, DOI 10.1542/peds.109.1.26; DUBOWITZ LMS, 1998, CLINICS DEV MED, V148; Greenwood K, 2000, PEDIATR RES, V48, P346, DOI 10.1203/00006450-200009000-00014; Grether JK, 1998, AM J OBSTET GYNECOL, V178, P1, DOI 10.1016/S0002-9378(98)70617-9; Harrison V, 2007, BJOG-INT J OBSTET GY, V114, P994, DOI 10.1111/j.1471-0528.2007.01409.x; HENNEBERRY RC, 1989, ANN NY ACAD SCI, V568, P225; HOFFMAN DJ, 1994, BRAIN RES, V644, P144, DOI 10.1016/0006-8993(94)90357-3; HORI N, 1994, NEUROSCI LETT, V173, P75, DOI 10.1016/0304-3940(94)90153-8; Ichiba H, 2002, PEDIATR INT, V44, P505, DOI 10.1046/j.1442-200X.2002.01610.x; LEVENE M, 1995, ARCH DIS CHILD-FETAL, V73, pF174, DOI 10.1136/fn.73.3.F174; LOREK A, 1994, PEDIATR RES, V36, P699, DOI 10.1203/00006450-199412000-00003; MARRET S, 1995, DEV MED CHILD NEUROL, V37, P473; MCDONALD JW, 1990, NEUROSCI LETT, V109, P234, DOI 10.1016/0304-3940(90)90569-U; Natale JE, 2007, PEDIATR CRIT CARE ME, V8, P1, DOI 10.1097/01.pcc.0000256620.55512.5f; NELSON KB, 1995, PEDIATRICS, V95, P263; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PANETH N, 1993, CLIN INVEST MED, V16, P95; Paul V K, 1999, Indian Pediatr, V36, P167; Penrice J, 1997, PEDIATR RES, V41, P443, DOI 10.1203/00006450-199703000-00024; PORTMAN RJ, 1990, AM J OBSTET GYNECOL, V162, P174, DOI 10.1016/0002-9378(90)90844-W; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; Schendel DE, 1996, JAMA-J AM MED ASSOC, V276, P1805, DOI 10.1001/jama.276.22.1805; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Spandou E, 2007, REPROD SCI, V14, P667, DOI 10.1177/1933719107305864; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Volpe JJ, 2001, NEUROLOGY NEWBORN, P331	30	46	49	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAY	2009	123	5					E764	E769		10.1542/peds.2007-3642			6	Pediatrics	Pediatrics	438AS	WOS:000265528900029	19349375				2021-06-18	
J	Makdissi, M; Ugoni, A; Darby, D; Brukner, P				Makdissi, Michael; Ugoni, Antony; Darby, David; Brukner, Peter			A Prospective Study of Postconcussive Outcomes After Return to Play in Australian Football	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain trauma; concussion; Australian football	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; AGREEMENT STATEMENT; 2ND-IMPACT SYNDROME; HEAD-INJURY; CONCUSSION; SPORT; SEQUELAE; RISK	Background: Decisions regarding safe return to play after concussion in sport remain difficult. Objective: To determine whether a concussed player returned to play using an individual clinical management strategy is at risk of impaired performance or increased risk of injury or concussion. Study Design: Cohort study; Level of evidence, 3. Methods: All elite Australian football players were followed for 4 seasons. Players were recruited into the study after sustaining a concussive injury. Outcome measures included performance statistics (disposals per hour match-time), injury rates, and recurrence of concussion on return to play. A subset of players had brief screening cognitive tests performed at baseline and after their concussion. Noninjured players matched for team, position, age, and size were chosen as controls. Results: A total of 199 concussive injuries were observed in 158 players. Sixty-one concussive injuries were excluded from analysis because of incomplete data (45 players) or presence of concurrent injury (16 players). Of the 138 concussive injuries assessed, 127 players returned to play without missing a game (92%). The remainder of concussed players returned to play after missing a single game (8%). Overall, there was no significant decline in disposal rates in concussed players on return to competition. Furthermore, there were no significant differences in injury rates between concussed and team, position, and game-matched controls. In the subset of players who had completed screening cognitive tests, all had returned to their individual baseline performance before being returned to play. Conclusion: Return to play decisions based on individual clinical assessment of recovery allows safe and appropriate return to sport following a concussive injury.	[Makdissi, Michael; Ugoni, Antony; Brukner, Peter] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia; [Darby, David] CogState Ltd, Melbourne, Vic, Australia	Makdissi, M (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3010, Australia.	makdissi@unimelb.edu.au		McCrory, Paul/0000-0003-4850-0568			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Congress of Neurological Surgeon, 1966, CLIN NEUROSURG, V12, P386; Efron B, 1993, INTRO BOOTSTRAP MONO, Vxvi; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Norton K I, 1999, J Sci Med Sport, V2, P389, DOI 10.1016/S1440-2440(99)80011-5; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; RUTHERFORD WH, 1977, LANCET, V1, P1; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; WESCHLER D, 1981, WESCHLER ADULT INTEL	27	46	46	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAY	2009	37	5					877	883		10.1177/0363546508328118			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	440GU	WOS:000265689600002	19204366				2021-06-18	
J	Paintlia, AS; Paintlia, MK; Singh, I; Skoff, RB; Singh, AK				Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit; Skoff, Robert B.; Singh, Avtar K.			Combination Therapy of Lovastatin and Rolipram Provides Neuroprotection and Promotes Neurorepair in Inflammatory Demyelination Model of Multiple Sclerosis	GLIA			English	Article						combination therapy; EAE/MS; demyelination; inflammation	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; COA REDUCTASE INHIBITOR; TRAUMATIC BRAIN-INJURY; GLATIRAMER ACETATE; SPINAL-CORD; PHOSPHODIESTERASE INHIBITOR; AXONAL REGENERATION; NEUROTROPHIC FACTOR; NEURITE OUTGROWTH	Drug combination therapies for central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS) are gaining momentum over monotherapy. Over the past decade, both in vitro and in vivo studies established that statins (HMG-CoA reductase inhibitors) and rolipram (phosphodiesterase-4 inhibitor; blocks the degradation of intracellular cyclic AMP) can prevent the progression of MS in affected individuals via different mechanisms of action. In this study, we evaluated the effectiveness of lovastatin (LOV) and rolipram (RLP) in combination therapy to promote neurorepair in an inflammatory CNS demyelination model of MS, experimental autoimmune encephalomyelitis (EAE). Combination treatment with suboptimal doses of these drugs in an established case of EAE (clinical disease score >= 2.0) significantly attenuated the infiltration of inflammatory cells and protected myelin sheath and axonal integrity in the CNS. It was accompanied with elevated level of cyclic AMP and activation of its associated protein kinase A. Interestingly, combination treatment with these drugs impeded neurodegeneration and promoted neurorepair in established EAE animals (clinical disease score >= 3.5) as verified by quantitative real-time polymerase chain reaction, immunohistochemistry and electron microscopic analyses. These effects of combination therapy were minimal and/or absent with either drug alone in these settings. Together, these data suggest that combination therapy with LOV and RLP has the potential to provide neuroprotection and promote neurorepair in MS, and may have uses in other related CNS demyelinating diseases. (C) 2008 Wiley-Liss, Inc.	[Paintlia, Ajaib S.; Paintlia, Manjeet K.; Singh, Inderjit; Singh, Avtar K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; [Skoff, Robert B.] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA	Singh, AK (corresponding author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA.	paintlia@musc.edu; singhi@musc.edu		Skoff, Robert/0000-0001-5049-9020; Paintlia, Ajaib/0000-0003-4525-5333	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455, C06-RR018823]; Merck CompanyMerck & Company; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455, C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS022576, R01NS040144, R01NS037766, R01NS022576, R01NS038236, R01NS034741] Funding Source: NIH RePORTER	NIH; Grant number: NS-22576, NS-34741, NS-37766, NS-40144, NS-038236, C06-RR015455, C06-RR018823; Grant sponsor; Merck & Company.	Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Arbizu T, 2000, ACTA NEUROL SCAND, V102, P209, DOI 10.1034/j.1600-0404.2000.102004209.x; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Barnett FH, 2004, NEUROSURGERY, V55, P468, DOI 10.1227/00006123-200408000-00083; Besser M, 1999, J IMMUNOL, V162, P6303; Bielekova B, 2000, J IMMUNOL, V164, P1117, DOI 10.4049/jimmunol.164.2.1117; Bjartmar C, 2003, J NEUROL SCI, V206, P165, DOI 10.1016/S0022-510X(02)00069-2; Bolton S, 2006, EXP NEUROL, V202, P36, DOI 10.1016/j.expneurol.2006.05.009; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Cui Qi, 2004, Anatomical Science International, V79, P209, DOI 10.1111/j.1447-073x.2004.00089.x; Dhib-Jalbut S, 2003, PHARMACOL THERAPEUT, V98, P245, DOI 10.1016/S0163-7258(03)00036-6; Dhib-Jalbut S, 2002, MULT SCLER, V8, P485, DOI 10.1191/1352458502ms862oa; Domeniconi M, 2005, J NEUROL SCI, V233, P43, DOI 10.1016/j.jns.2005.03.023; Echeverria V, 2005, EUR J NEUROSCI, V22, P2199, DOI 10.1111/j.1460-9568.2005.04427.x; ENG LF, 1989, GLIA, V2, P308, DOI 10.1002/glia.440020504; Eralinna JP, 1996, J NEUROIMMUNOL, V66, P103, DOI 10.1016/0165-5728(96)00031-8; GENAIN CP, 1995, P NATL ACAD SCI USA, V92, P3601, DOI 10.1073/pnas.92.8.3601; Giuliani F, 2005, J NEUROIMMUNOL, V165, P83, DOI 10.1016/j.jneuroim.2005.04.020; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; Hanson MG, 1998, J NEUROSCI, V18, P7361; Holmberg E, 2006, J NEUROTRAUM, V23, P1366, DOI 10.1089/neu.2006.23.1366; Jeffery DR, 2005, MULT SCLER, V11, P296, DOI 10.1191/1352458505ms1154oa; Johnson-Anuna LN, 2007, J NEUROCHEM, V101, P77, DOI 10.1111/j.1471-4159.2006.04375.x; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Kirstein M, 2002, CELL MOL LIFE SCI, V59, P1787, DOI 10.1007/PL00012506; KRAUSE W, 1988, XENOBIOTICA, V18, P561, DOI 10.3109/00498258809041693; Kwak B, 2001, SWISS MED WKLY, V131, P41; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; LUBLIN FD, 1985, SPRINGER SEMIN IMMUN, V8, P197; Luccanini I, 2008, EXP NEUROL, V211, P214, DOI 10.1016/j.expneurol.2008.01.022; Markovic-Plese S, 2001, Curr Neurol Neurosci Rep, V1, P257, DOI 10.1007/s11910-001-0028-4; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; Miron VE, 2007, GLIA, V55, P130, DOI 10.1002/glia.20441; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; O'Garra A, 1997, CURR OPIN IMMUNOL, V9, P872, DOI 10.1016/S0952-7915(97)80192-6; Paintlia AS, 2006, AM J PATHOL, V169, P1012, DOI 10.2353/ajpath.2006.051309; Paintlia AS, 2008, MOL PHARMACOL, V73, P1381, DOI 10.1124/mol.107.044230; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Paintlia AS, 2004, J NEUROSCI RES, V77, P63, DOI 10.1002/jnr.20130; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; Paul F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001928; PENDER MP, 1989, J NEUROIMMUNOL, V25, P125, DOI 10.1016/0165-5728(89)90130-6; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Pooler AM, 2006, J NEUROCHEM, V97, P716, DOI 10.1111/j.1471-4159.2006.03763.x; Ransohoff RM, 2002, TRENDS IMMUNOL, V23, P512, DOI 10.1016/S1471-4906(02)02321-9; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Sanchez AJ, 2005, J NEUROIMMUNOL, V168, P13, DOI 10.1016/j.jneuroim.2005.03.024; Schulz JG, 2004, J NEUROCHEM, V89, P24, DOI 10.1046/j.1471-4159.2003.02305.x; SOMMER N, 1995, NAT MED, V1, P244, DOI 10.1038/nm0395-244; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Sorensen PS, 2003, J NEUROL SCI, V206, P123, DOI 10.1016/S0022-510X(02)00343-X; Stankoff B, 2002, J NEUROSCI, V22, P9221; Stuve O, 2006, J CLIN INVEST, V116, P1037, DOI 10.1172/JCI25805; TORPHY TJ, 1991, THORAX, V46, P512, DOI 10.1136/thx.46.7.512; Tullman Mark J, 2005, Curr Neurol Neurosci Rep, V5, P245, DOI 10.1007/s11910-005-0053-9; Vanderlocht J, 2006, J NEUROIMMUNOL, V177, P189, DOI 10.1016/j.jneuroim.2006.04.012; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Wong BM, 2001, J LEUKOCYTE BIOL, V69, P959; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wujek JR, 2002, J NEUROPATH EXP NEUR, V61, P23, DOI 10.1093/jnen/61.1.23; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Ytterberg C, 2007, ACTA NEUROL SCAND, V116, P96, DOI 10.1111/j.1600-0404.2007.00801.x; Zhang B, 2002, NEUROPHARMACOLOGY, V42, P262, DOI 10.1016/S0028-3908(01)00174-5	65	46	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN 15	2009	57	2					182	193		10.1002/glia.20745			12	Neurosciences	Neurosciences & Neurology	383OA	WOS:000261681700005	18720408	Bronze, Green Accepted			2021-06-18	
J	Tokutomi, T; Miyagi, T; Takeuchi, Y; Karukaya, T; Katsuki, H; Shigemori, M				Tokutomi, Takashi; Miyagi, Tomoya; Takeuchi, Yasuharu; Karukaya, Takashi; Katsuki, Hiroshi; Shigemori, Minoru			Effect of 35 degrees C Hypothermia on Intracranial Pressure and Clinical Outcome in Patients With Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Hypothermia; Intracranial hypertension; Intracranial pressure; Traumatic brain injury	SEVERE HEAD-INJURY; SERUM POTASSIUM CONCENTRATION; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; PLATELET-FUNCTION; PROTEIN-LEVELS; DEEP HYPOTHERMIA; FOLLOW-UP	Background. From 1994, we have used therapeutic hypothermia in patients with severe traumatic brain injury (Glasgow Coma Scale scores of 5 or less). In 2000, we altered the target temperature to 35 degrees C from the former 33 degrees C, as our findings suggested that cooling to 35 degrees C is sufficient to control intracranial hypertension, and that hypothermia below 35 degrees C may predispose patients to persistent cumulative oxygen debt. We attempted to clarify whether 35 degrees C hypothermia has the same effect as 33 degrees C hypothermia in reducing intracranial hypertension and whether it is associated with fewer complications and improved outcomes. Methods. we compared intracranial pressure (ICP) and biochemical parameters in the 30 patients treated with 35 degrees C hypothermia (January 2000 to June 2005) with those in the 31 patients treated with 33 degrees C hypothermia (July 1994 to December 1999). Results: Patient characteristics were similar in the two groups. The mean temperature during hypothermia was 35.1 +/- 0.7 degrees C in the 35 degrees C hypothermia group and 33.4 +/- 0.8 degrees C in the 33 degrees C hypothermia group. Mean ICP was controlled tinder 20 mm Hg during hypothermia in both the 35 degrees C hypothermia and 33 degrees C hypothermia groups. The incidence of intracranial hypertension and low cerebral perfusion pressure did not differ between the two groups. The 35 degrees C hypothermic patients exhibited a significant improvement in the decline of serum potassium concentrations during hypothermia and in the increment of C-reactive protein after rewarming. The mortality rate and the incidence of systemic complications tended to be lower in the 35 degrees C group. Conclusions. Cooling patients to 35 degrees C is safe and the ICP reduction effects of 35 degrees C hypothermia are similar to those of 33 degrees C hypothermia.	[Tokutomi, Takashi; Miyagi, Tomoya; Takeuchi, Yasuharu; Karukaya, Takashi; Katsuki, Hiroshi; Shigemori, Minoru] Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan	Tokutomi, T (corresponding author), Kurume Univ, Sch Med, Dept Neurosurg, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	toku@med.kurume-u.ac.jp					Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Birdi I, 1997, J THORAC CARDIOV SUR, V114, P475, DOI 10.1016/S0022-5223(97)70196-X; BOELHOUWER RU, 1987, CRIT CARE MED, V15, P310, DOI 10.1097/00003246-198704000-00006; BOLDT J, 1993, ANN THORAC SURG, V55, P652, DOI 10.1016/0003-4975(93)90269-N; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BULLOCK R, 1995, GUIDELINE MANAGEMENT; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cortiana M, 1986, J Neurosurg Sci, V30, P133; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HESSEL EA, 1980, J SURG RES, V28, P23, DOI 10.1016/0022-4804(80)90078-5; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JOHNSTON TD, 1994, J TRAUMA, V37, P413, DOI 10.1097/00005373-199409000-00014; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kettner SC, 2003, ANESTH ANALG, V96, P1772, DOI 10.1213/01.ANE.0000062520.65192.C9; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lobo SMA, 2003, CHEST, V123, P2043, DOI 10.1378/chest.123.6.2043; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Matsui T, 2006, J NEUROSURG ANESTH, V18, P189, DOI 10.1097/01.ana.0000188639.39844.f6; MAZER CD, 1995, ANN THORAC SURG, V59, P1481, DOI 10.1016/0003-4975(95)00153-C; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Miller PR, 1999, J TRAUMA, V47, P1004, DOI 10.1097/00005373-199912000-00003; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NAYLOR CD, 1994, LANCET, V343, P559; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Polderman KH, 2002, INTENS CARE MED, V28, P1, DOI 10.1007/s00134-001-1154-9; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Reny JL, 2002, CRIT CARE MED, V30, P529, DOI 10.1097/00003246-200203000-00006; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Russwurm S, 2002, J INTERF CYTOK RES, V22, P215, DOI 10.1089/107999002753536185; SHEFFIELD CW, 1994, ACTA ANAESTH SCAND, V38, P201, DOI 10.1111/j.1399-6576.1994.tb03873.x; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SPRUNG J, 1992, ACTA ANAESTH SCAND, V36, P825, DOI 10.1111/j.1399-6576.1992.tb03572.x; SPRUNG J, 1991, CRIT CARE MED, V19, P1545, DOI 10.1097/00003246-199112000-00018; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tveita T, 1998, J APPL PHYSIOL, V85, P2135; VALERI CR, 1992, J THORAC CARDIOV SUR, V104, P108; VECHT CHJ, 1973, J NEUROL NEUROSUR PS, V38, P567; VILLALOBOS TJ, 1958, J CLIN INVEST, V37, P1, DOI 10.1172/JCI103576; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wolberg AS, 2004, J TRAUMA, V56, P1221, DOI 10.1097/01.TA.0000064328.97941.FC; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	62	46	49	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					166	173		10.1097/TA.0b013e318157dbec			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	395SJ	WOS:000262543500022	19131820				2021-06-18	
J	Liepert, J				Liepert, Joachim			Pharmacotherapy in restorative neurology	CURRENT OPINION IN NEUROLOGY			English	Article						aphasia; drug; motor recovery; rehabilitation; stroke; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; STROKE PATIENTS; MOTOR-PERFORMANCE; COGNITIVE FUNCTION; RECOVERY; AMPHETAMINE; AMANTADINE; PHYSIOTHERAPY	Purpose of review To evaluate current evidence that recovery after stroke or traumatic brain injury (TBI) can be enhanced by drugs that modulate neurotransmission in the brain. Recent findings Small studies performed in chronic stroke patients have indicated that single doses of reboxetine or citalopram improved different aspects of motor functions and that long-lasting application of donepezil reduced aphasic symptoms. Methylphenidate shortened intensive care treatment periods in TBI patients and amantadine improved arousal and cognition. Recent studies in stroke patients did not find beneficial effects of levodopa or dextroamphetamine. Summary Evidence of drug-related improvement of functions after stroke or TBI is still limited, either because of small and highly selected patient groups or due to conflicting results. Currently, most convincing evidence exists for piracetam for improvement of poststroke aphasia and amantadine for enhancing arousal and cognition after TBI. Some evidence can be found for improvement of stroke-related motor deficits by levodopa, enhanced speed of mental processing in TBI by methylphenidate and improvement of poststroke aphasia by dextroamphetamine. Large randomized controlled trials are needed to evaluate the effectiveness of serotonin reuptake inhibitors or noradrenaline reuptake inhibitors on motor functions.	Kliniken Schmieder, Dept Neurorehabil, D-78476 Allensbach, Germany	Liepert, J (corresponding author), Kliniken Schmieder, Dept Neurorehabil, Zum Tafelholz 8, D-78476 Allensbach, Germany.	j.liepert@kliniken-schmieder.de					Berthier ML, 2006, NEUROLOGY, V67, P1687, DOI 10.1212/01.wnl.0000242626.69666.e2; Broeks JG, 1999, DISABIL REHABIL, V21, P357; Chandler M C, 1988, Brain Inj, V2, P309; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Dam M, 1996, STROKE, V27, P1211, DOI 10.1161/01.STR.27.7.1211; ENDERBY P, 1994, CLIN NEUROPHARMACOL, V17, P320, DOI 10.1097/00002826-199408000-00003; Floel A, 2005, NEUROLOGY, V65, P472, DOI 10.1212/01.wnl.0000172340.56307.5e; Gladstone DJ, 2006, STROKE, V37, P179, DOI 10.1161/01.STR.0000195169.42447.78; Grade C, 1998, ARCH PHYS MED REHAB, V79, P1047, DOI 10.1016/S0003-9993(98)90169-1; Greener J, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858, DOI 10.1002/14651858.CD000424]; Hankey GJ, 2007, NEUROLOGY, V68, P1583, DOI 10.1212/01.wnl.0000260967.77422.97; Huber W, 1997, ARCH PHYS MED REHAB, V78, P245, DOI 10.1016/S0003-9993(97)90028-9; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; Kessler J, 2000, STROKE, V31, P2112, DOI 10.1161/01.STR.31.9.2112; Kraus MF, 2005, BRAIN INJURY, V19, P471, DOI 10.1080/02699050400025059; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Laska AC, 2005, CEREBROVASC DIS, V19, P125, DOI 10.1159/000083256; Leone H, 2005, J CLIN PHARM THER, V30, P101, DOI 10.1111/j.1365-2710.2005.00628.x; Martinsson L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002090.pub2; Martinsson L, 2003, CEREBROVASC DIS, V16, P338, DOI 10.1159/000072555; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Moein H, 2006, CLIN NEUROL NEUROSUR, V108, P539, DOI 10.1016/j.clineuro.2005.09.003; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; Pariente J, 2001, ANN NEUROL, V50, P718, DOI 10.1002/ana.1257; Platz T, 2005, RESTOR NEUROL NEUROS, V23, P271; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Plewnia C, 2004, NEUROLOGY, V62, P2124, DOI 10.1212/01.WNL.0000128041.92710.17; Resterneyer C, 2007, RESTOR NEUROL NEUROS, V25, P143; Sawyer E, 2008, ANN PHARMACOTHER, V42, P247, DOI 10.1345/aph.1K284; Scheidtmann K, 2001, LANCET, V358, P787, DOI 10.1016/S0140-6736(01)05966-9; Schneider WN, 1999, BRAIN INJURY, V13, P863; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Sonde L, 2007, ACTA NEUROL SCAND, V115, P55, DOI 10.1111/j.1600-0404.2006.00728.x; Sonde L, 2001, CEREBROVASC DIS, V12, P253, DOI 10.1159/000047712; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Treig T, 2003, CLIN REHABIL, V17, P590, DOI 10.1191/0269215503cr653oa; Walker-Batson D, 2001, STROKE, V32, P2093, DOI 10.1161/hs0901.095720; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254; Whiting E, 2007, J INT NEUROPSYCH SOC, V13, P972, DOI 10.1017/S1355617707071317; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; Zittel S, 2008, NEUROREHAB NEURAL RE, V22, P311, DOI 10.1177/1545968307312173; Zittel S, 2007, J NEUROL, V254, P197, DOI 10.1007/s00415-006-0326-5	44	46	56	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2008	21	6					639	643		10.1097/WCO.0b013e32831897a3			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	379HK	WOS:000261387100004	18989105				2021-06-18	
J	Hadjizacharia, P; Beale, EO; Inaba, K; Chan, LS; Demetriades, D				Hadjizacharia, Pantelis; Beale, Elizabeth O.; Inaba, Kenji; Chan, Linda S.; Demetriades, Demetrios			Acute Diabetes Insipidus in Severe Head Injury: A Prospective Study	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; CRANIOPHARYNGIOMA; HYPOPITUITARISM; ABNORMALITIES; LESIONS; DEATH; GLAND; TIME	BACKGROUND: The incidence and risk factors for acute diabetes insipidus after severe head injury and the effect of this complication on outcomes have not been evaluated in any large prospective studies. STUDY DESIGN: We conducted a prospective study of all patients admitted to the surgical ICU of a Level I trauma center with severe head injury (head Abbreviated Injury Score [AIS] 3). The following potential risk factors with p < 0.2 on bivariate analysis were included in a stepwise logistic regression to identify independent risk factors for diabetes insipidus and its association with mortality: age, mechanism of injury (blunt or penetrating), blood pressure, Glasgow Coma Scale, Injury Severity Score, head and other body area AIS, skull fracture, cerebral edema and shift, intracranial hemorrhage, and pneumocephaly. RESULTS: There were 436 patients (blunt injuries, 392; penetrating injuries, 44); 387 patients had isolated head injury. Diabetes insipidus occurred in 15.4% of all patients (blunt, 12.5%; penetrating, 40.9%; p < 0.0001) and in 14.7% of patients with isolated head Injury (blunt, 11.8%; penetrating, 39.5%; p < 0.0001). The presence of major extracranial injuries did not influence the incidence of diabetes insipidus. Independent risk factors for diabetes insipidus in isolated head injury were Glasgow Coma Scale : 8, cerebral edema, and head AIS > 3. Diabetes insipidus was an independent risk factor for death (adjusted odds ratio, 3.96; 95% Cl [1.65, 9.72]; adjusted p value = 0.002). CONCLUSIONS: The incidence of acute diabetes insipidus in severe head injury is high, especially in penetrating injuries. Independent risk factors for diabetes insipidus include a Glasgow Coma Scale :5 8, cerebral edema, and head AIS > 3. Acute diabetes insipidus was associated with significantly increased mortality. (J Am Coll Surg 2008;207:477-484. (C) 2008 by the American College of Surgeons)	[Hadjizacharia, Pantelis; Inaba, Kenji; Demetriades, Demetrios] Univ So Calif, Div Trauma & Surg Crit Care, Keck Sch Med, Los Angeles, CA 90033 USA; [Beale, Elizabeth O.] Univ So Calif, Div Endocrinol, Keck Sch Med, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Dept Pediat, Keck Sch Med, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Dept Surg, Keck Sch Med, Los Angeles, CA 90033 USA; [Chan, Linda S.] Univ So Calif, Dept Emergency Med, Keck Sch Med, Los Angeles, CA 90033 USA	Beale, EO (corresponding author), Univ So Calif, Div Trauma, Dept Surg, LAC USC Med Ctr,Keck Sch Med, Rm 1105,1200 N State St, Los Angeles, CA 90033 USA.						Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Bohn D, 2005, QJM-INT J MED, V98, P691, DOI 10.1093/qjmed/hci101; Ceballos R, 1966, Ala J Med Sci, V3, P185; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; EDWARDS OM, 1986, MEDICINE, V65, P281; Ghirardello S, 2006, J PEDIATR ENDOCR MET, V19, P413; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KERN KB, 1984, J TRAUMA, V24, P69, DOI 10.1097/00005373-198401000-00012; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; Salehi F, 2007, BRAIN INJURY, V21, P651, DOI 10.1080/02699050701426956; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	22	46	48	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	OCT	2008	207	4					477	484		10.1016/j.jamcollsurg.2008.04.017			8	Surgery	Surgery	363NM	WOS:000260274000003	18926448				2021-06-18	
J	Otterspoor, LC; Kalkman, CJ; Cremer, OL				Otterspoor, Luuk C.; Kalkman, Cornelis J.; Cremer, Olaf L.			Update on the propofol infusion syndrome in ICU management of patients with head injury	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cardiovascular failure; lactacidosis; propofol infusion syndrome; rhabdomyolysis; traumatic brain injury	FATAL MYOCARDIAL FAILURE; INTENSIVE-CARE UNIT; METABOLIC-ACIDOSIS; LACTIC-ACIDOSIS; SUDDEN-DEATH; CHILDREN; ADULT; RHABDOMYOLYSIS; DEFICIENCY; CARDIOMYOPATHY	Purpose of review The propofol infusion syndrome is a rare condition characterized by the occurrence of lactic acidosis, rhabdomyolysis and cardiovascular collapse following high-dose propofol infusion over prolonged periods of time. Patients with traumatic brain injury are particularly at risk of developing this complication because large doses of propofol are commonly used to control intracranial pressure, whereas vasopressors are administered to augment cerebral perfusion pressure. In this review, we provide an update on the literature with particular emphasis on patients with traumatic brain injury. Recent findings Several new case reports and reviews, as well as a number of experiments, have contributed significantly to our increased understanding of the cause of the syndrome. At the basis of the syndrome lies an imbalance between energy utilization and demand resulting in cell dysfunction, and ultimately necrosis of cardiac and peripheral muscle cells. Uncertainty remains whether a genetic susceptibility exists. Nonetheless, the growing number of case reports has made it possible to identify several risk factors. Summary Propofol infusion syndrome is a rare but frequently lethal complication of propofol use. In patients with risk factors, such as traumatic brain injury, it is suggested that an infusion rate of 4 mg/kg per hour should not be exceeded. Early warning signs include unexplained lactic acidosis, lipemia and Brugada-like ECG changes. When these occur, propofol infusion should be discontinued immediately.	[Kalkman, Cornelis J.] Univ Med Ctr Utrecht, Dept Anesthesiol, NL-3584 CX Utrecht, Netherlands; [Otterspoor, Luuk C.; Cremer, Olaf L.] Univ Med Ctr Utrecht, Dept Intens Care, NL-3584 CX Utrecht, Netherlands	Otterspoor, LC (corresponding author), Univ Med Ctr Utrecht, Dept Intens Care, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	l.c.otterspoor@umcutrecht.nl	Kalkman, Cor/O-3215-2019; Cremer, Olaf L/G-3855-2016	Kalkman, Cor/0000-0002-8372-6960; Cremer, Olaf L/0000-0003-4264-1108			Abrahams J, 2002, J NEUROSURG, V96, P1160; Ahlen K, 2006, EUR J ANAESTH, V23, P990, DOI 10.1017/S0265021506001281; BARCLAY K, 1992, BRIT MED J, V305, P953, DOI 10.1136/bmj.305.6859.953; Baumeister FAM, 2004, NEUROPEDIATRICS, V35, P250, DOI 10.1055/s-2004-820992; BRANCA D, 1991, ARCH BIOCHEM BIOPHYS, V290, P517, DOI 10.1016/0003-9861(91)90575-4; BRAY RJ, 1995, ANAESTHESIA, V50, P94, DOI 10.1111/j.1365-2044.1995.tb04544.x; Cannon ML, 2001, J NEUROSURG, V95, P1053, DOI 10.3171/jns.2001.95.6.1053; Casserly B, 2004, AM J KIDNEY DIS, V44, DOI 10.1053/j.ajkd.2004.08.036; CEBELIN MS, 1980, HUM PATHOL, V11, P123, DOI 10.1016/S0046-8177(80)80129-8; Chukwuemeka A, 2006, ANAESTH INTENS CARE, V34, P651, DOI 10.1177/0310057X0603400503; Corbett SM, 2006, CRIT CARE MED, V34, P2479, DOI 10.1097/01.CCM.0000230238.72846.B3; Cornfield DN, 2002, PEDIATRICS, V110, P1177, DOI 10.1542/peds.110.6.1177; Cravens GT, 2007, ANESTHESIOLOGY, V106, P1134, DOI 10.1097/01.anes.0000265421.40477.a3; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Culp KE, 2004, ANESTH ANALG, V99, P221, DOI 10.1213/01.ane.0000117285.12600.c1; De Waele JJ, 2006, ANAESTH INTENS CARE, V34, P676, DOI 10.1177/0310057X0603400516; Enting D, 2005, ANESTH ANALG, V100, P1864, DOI 10.1213/01.ANE.0000156682.59859.F3; Eriksen J, 2006, ACTA ANAESTH SCAND, V50, P117, DOI 10.1111/j.1399-6576.2006.00904.x; Ernest D, 2003, ANAESTH INTENS CARE, V31, P316; Farag E, 2002, CAN J ANAESTH, V49, P958, DOI 10.1007/BF03016883; Feillet F, 2003, INTENS CARE MED, V29, P1594, DOI 10.1007/s00134-003-1871-3; Friedman JA, 2002, J NEUROSURG, V96, P1161; FUDICKAR A, 2008, EUR J ANAESTH, V9, P1; Fudickar A, 2006, CURR OPIN ANESTHESIO, V19, P404, DOI 10.1097/01.aco.0000236140.08228.f1; Gottschling S, 2005, ANAESTHESIA, V60, P660, DOI 10.1111/j.1365-2044.2005.04231.x; Haase R, 2005, J NEUROSURG ANESTH, V17, P122, DOI 10.1097/01.ana.0000161267.63160.13; Hanna JP, 1998, NEUROLOGY, V50, P301, DOI 10.1212/WNL.50.1.301; HARRIS CE, 1990, ANAESTHESIA, V45, P366, DOI 10.1111/j.1365-2044.1990.tb14777.x; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Holzki J, 2004, PEDIATR ANESTH, V14, P265, DOI 10.1046/j.1460-9592.2003.01179.x; Jouven X, 2001, CIRCULATION, V104, P756, DOI 10.1161/hc3201.094151; Kam PCA, 2007, ANAESTHESIA, V62, P690, DOI 10.1111/j.1365-2044.2007.05055.x; Karakitsos D, 2007, ACTA ANAESTH SCAND, V51, DOI 10.1111/j.1399-6576.2007.01266.x; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kelly DF, 2001, J NEUROSURG, V95, P925, DOI 10.3171/jns.2001.95.6.0925; Kill C, 2003, PAEDIATR ANAESTH, V13, P823, DOI 10.1046/j.1460-9592.2003.01114.x; Koch M, 2004, INTENS CARE MED, V30, P522, DOI 10.1007/s00134-003-2130-3; Kurisu S, 2002, AM HEART J, V143, P448, DOI 10.1067/mhj.2002.120403; Machata AM, 2005, J TRAUMA, V58, P643, DOI 10.1097/01.TA.0000159697.03562.D6; MASSA R, 1992, MUSCLE NERVE, V15, P1290, DOI 10.1002/mus.880151112; McKeage K, 2003, CNS DRUGS, V17, P235, DOI 10.2165/00023210-200317040-00003; Mehta N, 1999, LANCET, V354, P866, DOI 10.1016/S0140-6736(05)75936-5; Merz TM, 2006, ANESTH ANALG, V103, P1050, DOI 10.1213/01.ane.0000239080.82501.c7; Motsch J, 2004, ANAESTHESIST, V53, P1009, DOI 10.1007/s00101-004-0756-3; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; Nanda S, 2008, CHEST, V133, P583, DOI 10.1378/chest.07-1745; Okamoto MP, 2003, AM J HEALTH-SYST PH, V60, P2007, DOI 10.1093/ajhp/60.19.2007; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Plotz FB, 1996, ANAESTH INTENS CARE, V24, P724; Pulsford AH, 2003, ANN PHARMACOTHER, V37, P594, DOI 10.1345/aph.1A321a; Rosen DJ, 2007, J TRAUMA, V63, P443, DOI 10.1097/TA.0b013e31809fe910; Roth MS, 1997, AM J HEALTH-SYST PH, V54, P694, DOI 10.1093/ajhp/54.6.694; Sabsovich I, 2007, AM J CRIT CARE, V16, P82, DOI 10.4037/ajcc2007.16.1.82; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; Schenkman KA, 2000, CRIT CARE MED, V28, P172, DOI 10.1097/00003246-200001000-00028; Short Timothy G, 2003, Best Pract Res Clin Anaesthesiol, V17, P77, DOI 10.1053/bean.2002.0266; Steiner LA, 2002, PAEDIATR ANAESTH, V12, P187, DOI 10.1046/j.1460-9592.2002.00809.x; Stelow EB, 2000, CLIN CHEM, V46, P577; STRICKLAND RA, 1995, CRIT CARE MED, V23, P405, DOI 10.1097/00003246-199502000-00029; Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681; Trampitsch E, 2006, ANAESTHESIST, V55, P1166, DOI 10.1007/s00101-006-1085-5; Uezono S, 2005, ANESTHESIOLOGY, V103, P909, DOI 10.1097/00000542-200510000-00046; vanStraaten EA, 1996, INTENS CARE MED, V22, P997, DOI 10.1007/BF02044132; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Vernooy K, 2006, HEART RHYTHM, V3, P131, DOI 10.1016/j.hrthm.2005.11.005; Westhout FD, 2007, J NEUROSURG, V106, P139, DOI 10.3171/ped.2007.106.2.139; Withington DE, 2004, PEDIATR ANESTH, V14, P505, DOI 10.1111/j.1460-9592.2004.01299.x; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2; Wolf AR, 2004, PEDIATR ANESTH, V14, P435, DOI 10.1111/j.1460-9592.2004.01332.x; Ypsilantis P, 2007, ANESTH ANALG, V105, P155, DOI 10.1213/01.ane.0000265544.44948.0b; Zaccheo MA, 2008, CRIT CARE NURSE, V28, P18; Zarovnaya EL, 2007, EPILEPSIA, V48, P1002, DOI 10.1111/j.1528-1167.2007.01042.x; Zhou WG, 1999, ANESTH ANALG, V89, P604, DOI 10.1097/00000539-199909000-00011	75	46	50	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2008	21	5					544	551		10.1097/ACO.0b013e32830f44fb			8	Anesthesiology	Anesthesiology	398ER	WOS:000262715900004	18784477				2021-06-18	
J	Paulose, CS; Chathu, F; Khan, SR; Krishnakumar, A				Paulose, C. S.; Chathu, Finla; Khan, S. Reas; Krishnakumar, Amee			Neuroprotective role of Bacopa monnieri extract in epilepsy and effect of glucose supplementation during hypoxia: Glutamate receptor gene expression	NEUROCHEMICAL RESEARCH			English	Article						glutamate gene expression; metabotropic glutamate receptor 8 (mGluR8); NMDAR1; neurodegeneration; epilepsy; hypoxia; seizures; Bacopa monnieri; glucose; oxygen; epinephrine; cerebellum; cerebral cortex; CT value; Morris water maze test and open field test	TRAUMATIC BRAIN-INJURY; RAT-BRAIN; STATUS EPILEPTICUS; PILOCARPINE MODEL; TRANSPORTER GENE; DOWN-REGULATION; FREE-RADICALS; SEIZURES; AGONIST; POTENT	The experiments were designed to study the glutamate gene expression during epilepsy in adult and hypoxic insult to brain during the neonatal period and the therapeutic role of neuroprotective supplements. We investigated the role of metabotropic glutamate-8 receptor (mGluR8) gene expression in cerebellum during epilepsy and neuroprotective role of Bacopa monnieri extract in epilepsy. We also studied the effect of NMDA receptor 1 (NMDAR1) gene expression during neonatal hypoxia and therapeutic role of glucose, oxygen and epinephrine supplementation. During epilepsy a significant down-regulation (P < 0.01) of mGluR8 gene expression was observed which was up-regulated (P < 0.05) near control level after B. monnieri treatment which is supported by Morris water maze experiment. In hypoxic neonates we observed up-regulation (P < 0.001) of the NMDAR1 gene expression whereas glucose and glucose + oxygen was able to significantly reverse (P < 0.001) the gene expression to near control level when compared to hypoxia and epinephrine treatment which was supported by open field test. Our results showed that B. monnieri treatment to epileptic rats significantly brought the reversal of the down-regulated mgluR8 gene expression toward control level. In neonatal rats, hypoxia induced expressional and functional changes in the NMDAR1 receptors of neuronal cells which is corrected by supplementation of glucose alone or glucose followed by oxygen during the resuscitation to prevent the glutamate related neuronal damage. Thus, the results suggest the clinical significance of corrective measures for epileptic and hypoxic management.	[Paulose, C. S.; Chathu, Finla; Khan, S. Reas; Krishnakumar, Amee] Cochin Univ Sci & Technol, Mol Neurobiol & Cell Biol Unit, Ctr Neurosci, Dept Biotechnol, Cochin 682022, Kerala, India	Paulose, CS (corresponding author), Cochin Univ Sci & Technol, Mol Neurobiol & Cell Biol Unit, Ctr Neurosci, Dept Biotechnol, Cochin 682022, Kerala, India.	cspaulose@cusat.ac.in					Attwell PJE, 1998, BRAIN RES, V805, P138, DOI 10.1016/S0006-8993(98)00698-2; Bhattacharya SK, 2000, PHYTOTHER RES, V14, P174, DOI 10.1002/(SICI)1099-1573(200005)14:3&lt;174::AID-PTR624&gt;3.0.CO;2-O; BHATTACHARYA SK, 1999, PHARMACOL TOXICOL, V4, P111; Caccamo D, 2004, AMINO ACIDS, V27, P373, DOI 10.1007/s00726-004-0117-1; Cannizzaro C, 2001, BRAIN RES, V904, P225, DOI 10.1016/S0006-8993(01)02462-3; Casolini P, 2005, J NEUROCHEM, V95, P137, DOI 10.1111/j.1471-4159.2005.03349.x; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; CHOI DW, 1988, NEURON, P1623; Covolan L, 2000, EPILEPSY RES, V41, P9, DOI 10.1016/S0920-1211(00)00122-4; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dash R, 1996, EXP NEUROL, V137, P43, DOI 10.1006/exnr.1996.0005; DELIVORIAPAPADO.M, 1998, J PEDIATR, V132, P30; Dhawan, 1998, PHYTOTHER RES, V2, P70, DOI [10.1002/ptr.2650020205, DOI 10.1002/PTR.2650020205]; Dhawan B. N., 1996, EUR NEUROPSYCHOPHARM, V6, P144, DOI DOI 10.1016/0924-977X(96)87969.7; Fedosiewicz-Wasiluk M, 2005, AMINO ACIDS, V28, P111, DOI 10.1007/s00726-004-0122-4; Gasparini F, 1999, J PHARMACOL EXP THER, V289, P1678; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; HO DY, 1995, J NEUROCHEM, V65, P842; HOFFMAN DJ, 1994, NEUROSCI LETT, V167, P156, DOI 10.1016/0304-3940(94)91051-0; Hort J, 1999, EPILEPSIA, V40, P1177, DOI 10.1111/j.1528-1157.1999.tb00845.x; Hudspith MJ, 1997, BRIT J ANAESTH, V78, P731, DOI 10.1093/bja/78.6.731; Jiang FL, 2007, EPILEPSIA, V48, P783, DOI 10.1111/j.1528-1167.2007.01000.x; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KANDEL A, 1993, EPILEPSY RES, V16, P1, DOI 10.1016/0920-1211(93)90033-4; KITAY JI, 1961, ENDOCRINOLOGY, V68, P818, DOI 10.1210/endo-68-5-818; Kral T, 2003, SYNAPSE, V47, P278, DOI 10.1002/syn.10178; Launes J, 1998, NEUROREPORT, V9, P577, DOI 10.1097/00001756-199803090-00003; Lawrence MS, 1996, J CEREBR BLOOD F MET, V16, P181, DOI 10.1097/00004647-199603000-00001; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; Machaalani R, 2002, BRAIN RES, V951, P293, DOI 10.1016/S0006-8993(02)03175-X; MALHOTRA C. L., 1959, INDIAN JOUR MED RES, V47, P294; Mar A, 2002, PHARMACOL BIOCHEM BE, V73, P703, DOI 10.1016/S0091-3057(02)00881-X; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Mishra OP, 2000, NEUROCHEM RES, V25, P1559, DOI 10.1023/A:1026610301978; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; OLNEY JW, 1982, RETINA-J RET VIT DIS, V2, P341, DOI 10.1097/00006982-198202040-00020; Omata N, 2000, J CEREBR BLOOD F MET, V20, P350, DOI 10.1097/00004647-200002000-00017; Otoya RE, 1997, EXP NEUROL, V148, P92, DOI 10.1006/exnr.1997.6612; PAYLOR R, 1990, BEHAV BRAIN RES, V36, P79, DOI 10.1016/0166-4328(90)90162-8; PERSINGER MA, 1988, PHYSIOL BEHAV, V44, P27, DOI 10.1016/0031-9384(88)90342-3; PRINCE HK, 1995, J NEUROCHEM, V64, P462; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P269, DOI 10.1016/0013-4694(72)90176-9; RASTOGI S, 1994, PHYTOCHEMISTRY, V36, P133, DOI 10.1016/S0031-9422(00)97026-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Ruiz A, 2004, J NEUROPHYSIOL, V91, P1091, DOI 10.1152/jn.00755.2003; Sairam K, 2002, PHYTOMEDICINE, V9, P207, DOI 10.1078/0944-7113-00116; SINGH HK, 1982, J ETHNOPHARMACOL, V5, P205, DOI 10.1016/0378-8741(82)90044-7; Singh HK, 1997, INDIAN J PHARM, V29, P359; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; WHISHAW IQ, 1986, J COMP PSYCHOL, V100, P422, DOI 10.1037/0735-7036.100.4.422; Zhang YL, 1999, J NEUROSCI, V19, P3307	53	46	50	0	8	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	SEP	2008	33	9					1663	1671		10.1007/s11064-007-9513-8			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	332EJ	WOS:000258064900002	17940877				2021-06-18	
J	Bedell, G; Coster, W				Bedell, Gary; Coster, Wendy			Measuring participation of school-aged children with traumatic brain injuries: Considerations and approaches	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; International Classification of Functioning; Disability and Health; outcomes; pediatric rehabilitation; social integration	INPATIENT REHABILITATION; SOCIAL-PARTICIPATION; SHORT-TERM; DISABILITIES; ADOLESCENTS; OUTCOMES; YOUTH; LIFE	This article discusses key issues to consider and selected approaches for assessing participation of school-aged children with traumatic brain injury. Approaches discussed include measures that explicitly assess participation, subsections from other measures that implicitly assess participation, and tailored methods that assess outcomes linked to person-centered goals or programs and interventions that address participation. Key considerations discussed include what should be measured, how should it be measured, what is the level of focus (individual, program, or population), and how does or could the selected approach address stakeholders' "information goals," that is, what stakeholders want and need to know?.	[Bedell, Gary] Tufts Univ, Dept Occupat Therapy, Medford, MA 02155 USA; [Coster, Wendy] Boston Univ, Dept Occupat Therapy, Boston, MA 02215 USA; [Coster, Wendy] Boston Univ, Rehabil Counseling Sargent Coll, Boston, MA 02215 USA	Bedell, G (corresponding author), Tufts Univ, Dept Occupat Therapy, 26 Winthrop St,Room 211, Medford, MA 02155 USA.	gary.bedell@tufts.edu					Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Bedell GM, 2005, AM J OCCUP THER, V59, P273, DOI 10.5014/ajot.59.3.273; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Bedell GM, 2002, BRAIN INJURY, V16, P659, DOI 10.1080/02699050210128924; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; BROWN M, 1987, ARCH PHYS MED REHAB, V68, P828; Coster W., 1998, SCH FUNCTION ASSESSM; Coster W, 2008, DISABIL REHABIL, V30, P639, DOI 10.1080/09638280701400375; Cusick A, 2006, Pediatr Rehabil, V9, P149, DOI 10.1080/13638490500235581; Dunst CJ, 2002, PSYCHOL REP, V91, P875, DOI 10.2466/PR0.91.7.875-897; Glang A, 1997, J HEAD TRAUMA REHAB, V12, P32, DOI 10.1097/00001199-199704000-00005; Hwang JL, 2002, OTJR-OCCUP PART HEAL, V22, P48, DOI 10.1177/153944920202200202; King G., 2004, CHILDRENS ASSESSMENT; King GA, 2007, CHILD CARE HLTH DEV, V33, P28, DOI 10.1111/j.1365-2214.2006.00613.x; King Gillian, 2003, Physical & Occupational Therapy in Pediatrics, V23, P63, DOI 10.1300/J006v23n01_05; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Law M, 2002, AM J OCCUP THER, V56, P640, DOI 10.5014/ajot.56.6.640; Mahoney JL, 2003, J EDUC PSYCHOL, V95, P409, DOI 10.1037/0022-0663.95.2.409; Mancini MC, 2000, ARCH PHYS MED REHAB, V81, P339, DOI 10.1053/apmr.2000.0810339; McConachie H, 2006, DISABIL REHABIL, V28, P1157, DOI 10.1080/09638280500534507; NOREAU L, 2005, MEASURE LIFIE HABITS; Noreau L, 2007, DEV MED CHILD NEUROL, V49, P666, DOI 10.1111/j.1469-8749.2007.00666.x; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Sakzewski L, 2007, DEV MED CHILD NEUROL, V49, P232, DOI 10.1111/j.1469-8749.2007.00232.x; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Schmidt LJ, 2002, CHILD CARE HLTH DEV, V28, P227, DOI 10.1046/j.1365-2214.2002.00266.x; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Simeonsson RJ, 2001, DISABIL REHABIL, V23, P49; Simeonsson RJ, 2003, DISABIL REHABIL, V25, P602, DOI 10.1080/0963828031000137117; Sparrow S, 2005, VINELAND ADAPTIVE BE; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Thomas-Stonell N, 2006, Pediatr Rehabil, V9, P14, DOI 10.1080/13638490500050097; Ueda S, 2003, DISABIL REHABIL, V25, P596, DOI 10.1080/0963828031000137108; World Health Organization, INT CLASS FUNCT DIS; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; YEATES KO, 2007, BRAIN INJ PROF, V3, P20; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	42	46	46	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2008	23	4					220	229		10.1097/01.HTR.0000327254.61751.e7			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	331KU	WOS:000258011900004	18650766				2021-06-18	
J	Cameron, CM; Purdie, DM; Kliewer, EV; McClure, RJ				Cameron, C. M.; Purdie, D. M.; Kliewer, E. V.; McClure, R. J.			Ten-year outcomes following traumatic brain injury: A population-based cohort	BRAIN INJURY			English	Article						epidemiology; traumatic brain injury; data linkage; outcomes; mortality; morbidity; health service utilization	LONG-TERM SURVIVAL; SPINAL-CORD-INJURY; QUALITY-OF-LIFE; DATA LINKAGE; HEAD-INJURY; HEALTH; MORTALITY; DISEASE; HOSPITALIZATION; SEVERITY	Primary objective: To quantify the 10 year health service use (HSU) and mortality outcomes for people with a traumatic brain injury (TBI). Research design: A population-based matched cohort study using linked administrative data from Manitoba, Canada (Manitoba Injury Outcome Study). Methods and procedures: An inception cohort (1988-1991) of hospitalized cases with TBI aged 18-64 years (n = 1290) was identified and matched to a non-injured comparison group (n = 1290). Survival analysis, Negative binomial and Poisson regression were used to quantify associations between injury and HSU/mortality outcomes for 10 years following the TBI event. Main outcome and results: The majority of deaths (47.2%) occurred in the first 60 days following injury. Excluding the first 60 days, the adjusted 10 year mortality remained elevated (mortality rate ratio = 1.48, 95% CI = 1.02-2.15). After adjusting for demographic characteristics and pre-existing health status, the TBI cohort had more post-injury hospitalizations (rate ratio (RR) = 1.54, 95% CI = 1.39-1.71), greater cumulative lengths of stay (RR= 5.14, 95% CI = 3.29-8.02) and a greater post-injury physician claims rate (RR = 1.44, 95% CI = 1.35-1.53) than the non-injured cohort. Conclusions: People who sustain a TBI and survive the initial acute phase of care experience substantially increased long-term morbidity compared to the general population, regardless of the level of injury severity.	[McClure, R. J.] Monash Univ, Accident Res Ctr, Clayton, Vic 3800, Australia; [Cameron, C. M.; McClure, R. J.] Griffith Univ, Sch Med, Logan, Australia; [Purdie, D. M.] Genentech Inc, San Francisco, CA 94080 USA; [Kliewer, E. V.] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada	McClure, RJ (corresponding author), Monash Univ, Accident Res Ctr, Clayton, Vic 3800, Australia.	rod.mcclure@muarc.monash.edu.au		Cameron, Cate/0000-0003-1476-5744; McClure, Roderick/0000-0002-9067-8282			*AIHW, 2000, AUSTR HLTH 2000 7 BI; Baguley I, 2000, BRAIN INJURY, V14, P505; Bernstein CN, 2000, ANN INTERN MED, V133, P795, DOI 10.7326/0003-4819-133-10-200011210-00012; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Burchill C, 2000, J MED INTERNET RES, V2, DOI 10.2196/jmir.2.2.e10; Cameron C M, 2007, Int J Inj Contr Saf Promot, V14, P11, DOI 10.1080/17457300600890103; Cameron CM, 2006, B WORLD HEALTH ORGAN, V84, P802, DOI 10.2471/BLT.06.030833; Cameron CM, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-114; Cameron CM, 2007, AUST NZ J PUBL HEAL, V31, P459, DOI 10.1111/j.1753-6405.2007.00118.x; Cameron CM, 2006, J EPIDEMIOL COMMUN H, V60, P341, DOI 10.1136/jech.2005.041046; Cameron CM, 2005, J TRAUMA, V59, P639, DOI 10.1097/01.ta.0000183222.79685.23; Cameron CM, 2005, B WORLD HEALTH ORGAN, V83, P345; Cohen MM, 1995, MED CARE, V33, pDS21, DOI 10.1097/00005650-199512001-00006; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Conner KR, 2003, AM J PUBLIC HEALTH, V93, P1128, DOI 10.2105/AJPH.93.7.1128; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DRISCOLL T, 2004, SCI BASIS INJURY PRE, P13; Dryden DM, 2004, SPINAL CORD, V42, P513, DOI 10.1038/sj.sc.3101629; Dunn LT, 2000, BRIT J NEUROSURG, V14, P219; Gabbe BJ, 2007, J ORTHOP TRAUMA, V21, P223, DOI 10.1097/BOT.0b013e31803eb13c; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Greenspan AI, 2002, J TRAUMA, V53, P709, DOI 10.1097/00005373-200210000-00015; *HLTH CAN, 1999, CAN HLTH CAR SYST; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; HOSMER DW, 1999, WILEY PS TX, P1; Johnson RL, 1998, SPINAL CORD, V36, P45, DOI 10.1038/sj.sc.3100494; Kristman V, 2004, EUR J EPIDEMIOL, V19, P751, DOI 10.1023/B:EJEP.0000036568.02655.f8; Leibson CL, 2002, J AM GERIATR SOC, V50, P1644, DOI 10.1046/j.1532-5415.2002.50455.x; MacKenzie EJ, 2001, INJURY CONTROL, P250; Marwitz JH, 2001, J HEAD TRAUMA REHAB, V16, P307, DOI 10.1097/00001199-200108000-00002; Mathers CD, 2005, B WORLD HEALTH ORGAN, V83, P171; Mathers CD, 2001, B WORLD HEALTH ORGAN, V79, P1076; McCullagh P., 1989, GEN LINEAR MODELS, P511, DOI DOI 10.1007/978-1-4899-3242-6; MCEVOY S, 2004, SCI BASIS INJURY PRE, P62; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; Nordin M, 2002, J OCCUP ENVIRON MED, V44, P677, DOI 10.1097/00043764-200207000-00015; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Connor PJ, 2005, ARCH PHYS MED REHAB, V86, P37, DOI 10.1016/j.apmr.2004.03.018; Peden M, 2002, INJURY CHART BOOK GR; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Rice DP, 1989, COST INJURY US REPOR; Richmond TS, 1997, NURS RES, V46, P262, DOI 10.1097/00006199-199709000-00004; Rochon PA, 1996, MED CARE, V34, P1093, DOI 10.1097/00005650-199611000-00004; Roos LL, 1999, J CLIN EPIDEMIOL, V52, P39, DOI 10.1016/S0895-4356(98)00126-7; Roos LL, 1997, HEALTH SERV RES, V32, P229; ROOS LL, 1997, HEALTH SERV RES, V32, P239; Roos NP, 1995, MED CARE, V33, pDS13, DOI 10.1097/00005650-199512001-00005; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P737; SACCO WJ, 1993, J TRAUMA, V35, P538, DOI 10.1097/00005373-199310000-00007; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; Savic G, 2000, SPINAL CORD, V38, P371, DOI 10.1038/sj.sc.3101019; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wardle TD, 1999, BRIT MED BULL, V55, P744, DOI 10.1258/0007142991902754; Watson WL, 2007, INJURY PREV, V13, P45, DOI 10.1136/ip.2005.010157; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Young TK, 2000, AM J PUBLIC HEALTH, V90, P1466, DOI 10.2105/AJPH.90.9.1466; Zunzunegui MV, 2001, J CLIN EPIDEMIOL, V54, P501, DOI 10.1016/S0895-4356(00)00325-5	71	46	46	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2008	22	6					437	449		10.1080/02699050802060621			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	316TW	WOS:000256973600001	18465385				2021-06-18	
J	George, ME; Skarda, DE; Watts, CR; Pham, HD; Beilman, GJ				George, Mark E.; Skarda, David E.; Watts, Charles R.; Pham, Hoai D.; Beilman, Greg J.			Aggressive red blood cell transfusion: No association with improved outcomes for victims of isolated traumatic brain injury	NEUROCRITICAL CARE			English	Article						anemia; resuscitation; trauma; head injury; transfusion	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; CRITICALLY-ILL PATIENTS; SUBARACHNOID HEMORRHAGE; SEVERITY SCORE; ANEMIA; CARE; OXYGENATION; MANAGEMENT; RISK	Background Clinical studies have caused blood transfusion practices in critically ill patients to become more conservative in the last decade. However, few studies have focused on trauma patients, particularly those with severe isolated traumatic brain injury. Methods We conducted a retrospective study to test the hypothesis that patients with severe brain injury would not benefit from aggressive red blood cell transfusion (RBCT). End points of the study were in-hospital mortality and morbidity (pneumonia, urinary tract infection, deep venous thrombosis, pulmonary embolus, decubitus ulcer, bacteremia, septic shock, myocardial infarction, and seizure). Included in our retrospective study were patients at two urban, level I trauma centers who were admitted with a diagnosis of isolated head injury and with a Glasgow Coma Scale (GCS) score of 8 or less. We recorded demographic, interventional, and outcome variables. Results In 289 patients, 24 of 25 (96%) were transfused if their lowest recorded intensive care unit (ICU) hemoglobin level was 8.0 g/dl or less. In contrast, only 9/182 (5%) of these 289 patients were transfused if the hemoglobin levels were 10.0 g/dl or greater. In the remaining 82 patients with lowest ICU hemoglobin levels of 8.0-10.0 g/dl, 52% were transfused. These 82 patients (43 underwent RBCT and 39 did not) were included in our analysis. Discussion The overall in-hospital mortality rate was 32%; rates were similar between the two groups (29%, non-RBCT; 35%, RBCT) (P = 0.64). Likewise, in-hospital morbidity was similar between groups. Logistic and proportional hazard regression analyses identified RBCT as one predictor of mortality. Conclusions Our results suggest that a restrictive transfusion practice is safe for severely head-injured patients.	[George, Mark E.; Skarda, David E.; Pham, Hoai D.; Beilman, Greg J.] Univ Minnesota, Dept Surg, Div Crit Care, Med Ctr, Minneapolis, MN 55455 USA; [Watts, Charles R.] Hennepin Cty Med Ctr, Dept Surg, Minneapolis, MN 55415 USA; [Beilman, Greg J.] N Mem Med Ctr, Robbinsdale, MN USA	George, ME (corresponding author), Univ Minnesota, Dept Surg, Div Crit Care, Med Ctr, Fairview,MMC 11,420 Delaware St SE, Minneapolis, MN 55455 USA.	geor0040@umn.edu	Watts, Charles R./AAK-9849-2020	Watts, Charles R./0000-0002-5011-487X; Beilman, Gregory/0000-0001-5036-3027			AUDET AM, 1992, ANN INTERN MED, V116, P403, DOI 10.7326/0003-4819-116-5-403; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BORDIN JO, 1994, BLOOD, V84, P1703; *BRAIN TRAUM FDN, GUID PREH MAN TRAUM; *BRAIN TRAUM FDN I, 2000, GUID MAN SEV TRAUM B, P165; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; DIETRICH KA, 1990, CRIT CARE MED, V18, P940, DOI 10.1097/00003246-199009000-00007; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Fischer J, 2001, Crit Care Nurs Q, V23, P52; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hebert PC, 1997, AM J RESP CRIT CARE, V155, P1618, DOI 10.1164/ajrccm.155.5.9154866; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; LORENTE JA, 1993, CRIT CARE MED, V21, P1312, DOI 10.1097/00003246-199309000-00013; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McIntyre L, 2004, J TRAUMA, V57, P563, DOI 10.1097/01.TA.0000136158.93864.54; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Naidech AM, 2006, NEUROSURGERY, V59, P775, DOI 10.1227/01.NEU.0000232662.86771.A9; Nilsson KR, 2007, ARCH SURG-CHICAGO, V142, P126, DOI 10.1001/archsurg.142.2.126; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shapiro MJ, 2003, J TRAUMA, V55, P269, DOI 10.1097/01.TA.0000080530.77566.04; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Smith MJ, 2004, J NEUROSURG, V101, P1, DOI 10.3171/jns.2004.101.1.0001; TEASDALE G, 1974, LANCET, V2, P81; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Winn HR, 2004, YOUMANS NEUROLOGICAL	33	46	48	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	JUN	2008	8	3					337	343		10.1007/s12028-008-9066-y			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	301DT	WOS:000255877300005	18273711				2021-06-18	
J	Ityas, C; Beyer, GM; Dutton, RP; Scatea, TM; Hess, JR				Ityas, Can; Beyer, Ginine M.; Dutton, Richard P.; Scatea, Thomas M.; Hess, John R.			Recombinant factor VIIa for warfarin-associated intracranial bleeding	JOURNAL OF CLINICAL ANESTHESIA			English	Article						factor VIIa; traumatic brain injury; elderly; international normalization ratio; prothrombin time; trauma	CENTRAL-NERVOUS-SYSTEM; ACTIVATED FACTOR-VII; FRESH-FROZEN PLASMA; INTRACEREBRAL HEMORRHAGE; VITAMIN-K; PREINJURY WARFARIN; COMPLICATIONS; TRAUMA; ANTICOAGULATION; PROGRESSION	Study objective: To examine the efficacy of recombinant factor VIIa (rVIIa) in reversing warfarin-induced coagulopathy in trauma patients presenting with intracranial hemorrhage (ICH). Design: Retrospective, cohort-controlled database review. Setting: Level 1, university-affiliated trauma center. Patients: 54 patients presenting with ICH associated with chronic warfarin therapy, 30 of whom were treated with rVIIa, and the other 24 patients treated conventionally. Measurements: We examined initial and subsequent coagulation studies (prothrombin time, international normalized ratio [INR]), blood product requirement, and clinical outcome, including time to reverse anticoagulation, duration of reversal, and subsequent mortality. Main results: Patients treated with rVIIa required significantly less plasma (4 vs 7 units) to correct their INR, and corrected in a much shorter period of time (2.4 vs 10 hrs). The duration of corrected INR after rVIIa was dose-dependent. Conclusions: Factor rVIIa provides prompt correction of the INR of dose-dependent duration in patients with ICH intracranial hemorrhage associated with warfarin use. (C) 2008 Elsevier Inc. All rights reserved.	[Ityas, Can; Hess, John R.] Univ Maryland, Med Ctr, Blood Bank, Sch Med,Dept Med, Baltimore, MD 21201 USA; [Beyer, Ginine M.; Hess, John R.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Dutton, Richard P.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Scatea, Thomas M.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA	Hess, JR (corresponding author), Univ Maryland, Med Ctr, Blood Bank, Sch Med,Dept Med, NW50A, Baltimore, MD 21201 USA.	jhess@umm.edu	Hess, John R./K-4001-2013	Hess, John R./0000-0001-8596-4420			Ansell J, 2004, CHEST, V126, p204S, DOI 10.1378/chest.126.3_suppl.204S; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; CAIRD E, 2006, IRAN MED J, V99, P206; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Flaherty ML, 2007, NEUROLOGY, V68, P116, DOI 10.1212/01.wnl.0000250340.05202.8b; Flibotte JJ, 2004, NEUROLOGY, V63, P1059, DOI 10.1212/01.WNL.0000138428.40673.83; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Goldstein JN, 2006, STROKE, V37, P151, DOI 10.1161/01.STR.0000195047.21562.23; Huttner HB, 2006, STROKE, V37, P1465, DOI 10.1161/01.STR.0000221786.81354.d6; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Kucher N, 2004, AM J CARDIOL, V94, P403, DOI 10.1016/j.amjcard.2004.04.050; Lee SB, 2006, NEUROLOGY, V67, P1272, DOI 10.1212/01.wnl.0000238104.75563.2f; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Nicolini A, 2002, HAEMATOLOGICA, V87, P948; Punthakee X, 2002, THROMB RES, V108, P31, DOI 10.1016/S0049-3848(02)00398-5; Sam C, 2004, AM J CARDIOL, V94, P947, DOI 10.1016/j.amjcard.2004.06.038; Sorensen B, 2003, BLOOD COAGUL FIBRIN, V14, P469, DOI 10.1097/00001721-200307000-00007; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Veshchev Igor, 2002, Med Sci Monit, V8, pCS98; Yasaka M, 2002, THROMB RES, V108, P25, DOI 10.1016/S0049-3848(02)00402-4	22	46	47	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2008	20	4					276	279		10.1016/j.jclinane.2007.12.012			4	Anesthesiology	Anesthesiology	331LM	WOS:000258013700007	18617125				2021-06-18	
J	Minambres, E; Ballesteros, MA; Mayorga, M; Marin, MJ; Munoz, P; Figols, J; Lopez-Hoyos, M				Minambres, Eduardo; Ballesteros, Maria Angeles; Mayorga, Marta; Marin, Maria Jose; Munoz, Pedro; Figols, Javier; Lopez-Hoyos, Marcos			Cerebral apoptosis in severe traumatic brain injury patients: An in vitro, in vivo, and postmortem study	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; apoptosis-related proteins; outcome; PC12 cells; traumatic brain injury	GLASGOW COMA SCALE; FATAL HEAD-INJURY; CELL-DEATH; CEREBROSPINAL-FLUID; PRACTICAL SCALE; JUGULAR BULB; CYTOCHROME-C; BCL-2; EXPRESSION; CASPASE-3	One of the most important recent observations in traumatic brain injury (TBI) relates to the potential role of apoptosis in secondary brain injury. We aimed to analyze the presence of apoptosis and the expression of apoptosis-related proteins in brain samples from patients with TBI. We also tried to find any association between the in situ results and the in vitro observations in a neuronal model of induced-apoptosis. Brain tissue from the pericontusional zone (PCZ) of patients with traumatic contusions and from post-mortem samples was analyzed. Immunohistochemical analyses of apoptosis-related proteins and the terminal deoxynucleotide transferase-mediated nick end labeling (TUNEL) method to determine the presence of apoptotic cells were performed. Apoptotic rates on neuronal cells induced by jugular bulb vein sera was determined by flow cytometry. TUNEL-positive cells were detected in all PCZ of traumatic contusions and in most of PCZ in post-mortem specimens (none in control; p = 0.026). In vivo samples showed higher expression of antiapoptotic proteins Bcl-2 (p = 0.027) and Bcl-XL (p = 0.014) than post-mortem samples. In autopsies, the expression of Fas and Bim (p < 0.05) were higher in PCZ than in the zone distal from the contusion. In vitro studies showed that apoptotic rate was an independent factor associated with mortality at 6 months (p = 0.014). In the receiving operator curve (ROC) curve, a cut-off point of 66.5% showed a sensitivity of 89.5% and specificity of 66.7% in the prediction of patients' death. Cerebral apoptosis is a prominent form of cell death in the PCZ of human traumatic cerebral contusions, and high rates of in vitro apoptosis are associated with a poorer prognosis after TBI.	[Marin, Maria Jose; Lopez-Hoyos, Marcos] Hosp Univ Marques Valdecilla, Serv Inmunol, Santander 39008, Spain; [Minambres, Eduardo; Ballesteros, Maria Angeles] Hosp Univ Marques Valdecilla, Serv Intens Care, Santander 39008, Spain; [Mayorga, Marta; Figols, Javier] Hosp Univ Marques Valdecilla, Dept Pathol, Santander 39008, Spain; [Munoz, Pedro] Atenc Primaria, Santander, Spain	Lopez-Hoyos, M (corresponding author), Hosp Univ Marques Valdecilla, Serv Inmunol, Avda Marques Valdecilla S-N, Santander 39008, Spain.	inmlhm@humv.es	Lopez-Hoyos, Marcos/ABC-1024-2020; Minambres, Eduardo/H-7761-2019; Munoz, Pedro/C-8361-2015	Lopez-Hoyos, Marcos/0000-0003-0562-427X; Ballesteros, Maria A/0000-0002-4032-9973; Munoz, Pedro/0000-0002-1387-2655			AANS, 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2007.9999; ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; Ballesteros MA, 2007, INTENS CARE MED, V33, P58, DOI 10.1007/s00134-006-0361-9; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Conti AC, 1998, J NEUROSCI, V18, P5663; Diaz-Reganon G, 2002, INTENS CARE MED, V28, P1724, DOI 10.1007/s00134-002-1543-8; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Hosmer D, 1989, APPL LOGISTIC REGRES; JENNETT B, 1975, LANCET, V1, P480; Katz MH, 2003, ANN INTERN MED, V138, P644, DOI 10.7326/0003-4819-138-8-200304150-00012; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Lopez-Escribano H, 2002, ARTHRITIS RHEUM, V46, P3290, DOI 10.1002/art.10684; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Mikrogianakis A, 2007, J NEUROTRAUM, V24, P338, DOI 10.1089/neu.2006.003615; Minambres E, 2005, INTENS CARE MED, V31, P791, DOI 10.1007/s00134-005-2635-z; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; MINAMBRES E, 2004, MED INTENSIVA, V28, P319; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RINK A, 1995, AM J PATHOL, V147, P1575; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; SCHMID I, 1992, CYTOMETRY, V13, P204, DOI 10.1002/cyto.990130216; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; TEASDALE G, 1974, LANCET, V2, P81; Zhang XP, 2006, J NEUROTRAUM, V23, P1583, DOI 10.1089/neu.2006.23.1583; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje	47	46	51	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					581	591		10.1089/neu.2007.0398			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900002	18363508				2021-06-18	
J	Fan, YJ; Wu, LLY; Li, HY; Wang, YJ; Zhou, XF				Fan, Yong-jun; Wu, Linda Lin-yan; Li, Hong-yun; Wang, Yan-Jiang; Zhou, Xin-Fu			Differential effects of pro-BDNF on sensory neurons after sciatic nerve transection in neonatal rats	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						p75NTR; proneurotrophins; sciatic nerve injury; sensory neurons; sortilin	DORSAL-ROOT GANGLIA; ACTIVITY-DEPENDENT SECRETION; P75 NEUROTROPHIN RECEPTOR; GROWTH-FACTOR; HIPPOCAMPAL-NEURONS; AXONAL-TRANSPORT; PERIPHERAL-NERVE; MESSENGER-RNA; CELL-DEATH; ADULT-RAT	Brain-derived neurotrophic factor (BDNF) plays a critical role in the development of the central and peripheral nervous systems, and also in neuronal survival after injury. The actions of BDNF are mediated by its high-affinity receptors TrkB and p75NTR. Recent studies have shown that proneurotrophins bind p75NTR and sortilin with high affinity, and trigger apoptosis of neurons in vitro. As proneurotrophins are a dominant form of gene products in developing and adult animals, it is imperative to understand their physiological functions in animals. Here, we showed differential roles of proBDNF in injured and uninjured sensory neurons. proBDNF, p75NTR and sortilin are highly expressed in dorsal root ganglia (DRG) neurons. Recombinant proBDNF induced a dose-dependent death of PC12 cells and the death activity was completely abolished in the presence of antibodies against the prodomain of BDNF. The exogenous proBDNF enhanced the death of axotomized sensory neurons and the neutralizing antibodies to the prodomain or exogenous sortilin-extracellular domain-Fc fusion molecule reduced the death of axotomized sensory neurons. Interestingly, the treatment of neutralizing antibody in vivo increased the number of sensory neurons in the contralateral DRG. We conclude that proBDNF may induce the death of axotomized sensory neurons and suppress neuronal addition in the intact DRG in neonatal rats, and the suppression of endogenous proBDNF may protect neurons after neurotrauma.	[Zhou, Xin-Fu] Flinders Univ S Australia, Dept Human Physiol, Adelaide, SA 5001, Australia; Flinders Univ S Australia, Ctr Neurosci, Adelaide, SA 5001, Australia	Zhou, XF (corresponding author), Flinders Univ S Australia, Dept Human Physiol, GPO Box 2100, Adelaide, SA 5001, Australia.	Xin-fu.zhou@flinders.edu.au	Zhou, Xiaofang/C-6169-2013; zhou, xin-fu/G-6643-2011; Wang, Yanjiang/F-3703-2012; zhou, xin-fu/F-4119-2013; Li, Hongyun/G-2301-2011	Zhou, Xiaofang/0000-0001-6343-1455; Wang, Yanjiang/0000-0002-6227-6112; zhou, xin-fu/0000-0002-8687-0175; Li, Hongyun/0000-0003-3332-3132			ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; Agthong S, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-45; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Arnett MG, 2007, BRAIN RES, V1183, P32, DOI 10.1016/j.brainres.2007.09.051; Balkowiec A, 2002, J NEUROSCI, V22, P10399; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Bruno MA, 2006, P NATL ACAD SCI USA, V103, P6735, DOI 10.1073/pnas.0510645103; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; Chen ZY, 2004, J NEUROSCI, V24, P4401, DOI 10.1523/JNEUROSCI.0348-04.2004; Conner JM, 1997, J NEUROSCI, V17, P2295; Deinhardt K, 2007, TRAFFIC, V8, P1736, DOI 10.1111/j.1600-0854.2007.00645.x; Domeniconi M, 2007, MOL CELL NEUROSCI, V34, P271, DOI 10.1016/j.mcn.2006.11.005; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; ElShamy WM, 1997, J NEUROSCI, V17, P8667; Erickson JT, 1996, J NEUROSCI, V16, P5361; Fahnestock M, 2004, J NEUROCHEM, V89, P581, DOI 10.1111/j.1471-4159.2004.02360.x; Fayard B, 2005, J NEUROSCI RES, V80, P18, DOI 10.1002/jnr.20432; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Gu CH, 1999, J NEUROSCI, V19, P3043; Gueorguiev VD, 1999, AM J PHYSIOL-CELL PH, V276, pC54; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Hashimoto K, 2007, BIOESSAYS, V29, P116, DOI 10.1002/bies.20534; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; Hu P, 2002, NEUROSCIENCE, V112, P23, DOI 10.1016/S0306-4522(02)00065-9; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; JONES KR, 1994, CELL, V76, P989, DOI 10.1016/0092-8674(94)90377-8; Kelly KJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1309, DOI 10.1152/ajpcell.00353.2002; Kenchappa RS, 2006, NEURON, V50, P219, DOI 10.1016/j.neuron.2006.03.011; KOLBECK R, 1994, EUR J BIOCHEM, V225, P995, DOI 10.1111/j.1432-1033.1994.0995b.x; Lagares A, 2007, J NEUROSCI, V27, P7939, DOI 10.1523/JNEUROSCI.1203-07.2007; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Li HY, 2007, STEM CELLS, V25, P2053, DOI 10.1634/stemcells.2007-0080; Li WP, 1999, NEUROSCI LETT, V260, P49, DOI 10.1016/S0304-3940(98)00958-6; Ma QF, 1999, GENE DEV, V13, P1717, DOI 10.1101/gad.13.13.1717; Matsumoto T, 2008, NAT NEUROSCI, V11, P131, DOI 10.1038/nn2038; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; Mowla SJ, 1999, J NEUROSCI, V19, P2069; Mowla SJ, 2001, J BIOL CHEM, V276, P12660, DOI 10.1074/jbc.M008104200; Numata S, 2006, NEUROSCI LETT, V401, P1, DOI 10.1016/j.neulet.2006.02.054; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; Tonra JR, 1998, J NEUROSCI, V18, P4374; Traficante A, 2007, NEUROREPORT, V18, P1997, DOI 10.1097/WNR.0b013e3282f262ca; Volosin M, 2006, J NEUROSCI, V26, P7756, DOI 10.1523/JNEUROSCI.1560-06.2006; Wang H, 2006, EUR J NEUROSCI, V24, P2444, DOI 10.1111/j.1460-9568.2006.05138.x; Woo NH, 2005, NAT NEUROSCI, V8, P1069, DOI 10.1038/nn1510; Yoon SO, 1998, J NEUROSCI, V18, P3273; Zhou XF, 2005, NEUROSCIENCE, V132, P591, DOI 10.1016/j.neuroscience.2004.12.034; Zhou XF, 1999, NEUROSCIENCE, V92, P841, DOI 10.1016/S0306-4522(99)00027-5; Zhou XF, 1996, NEUROSCIENCE, V74, P945, DOI 10.1016/S0306-4522(96)00237-0; Zhou XF, 2004, J NEUROCHEM, V91, P704, DOI 10.1111/j.1471-4159.2004.02775.x	61	46	56	1	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2008	27	9					2380	2390		10.1111/j.1460-9568.2008.06215.x			11	Neurosciences	Neurosciences & Neurology	292SG	WOS:000255285800018	18430030				2021-06-18	
J	Hsu, AA; Fenton, K; Weinstein, S; Carpenter, J; Dalton, H; Bell, MJ				Hsu, Angela A.; Fenton, Kimberly; Weinstein, Steven; Carpenter, Jessica; Dalton, Heidi; Bell, Michael J.			Neurological injury markers in children with septic shock	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						septic shock; neurological injury; pediatrics; serum markers; sepsis; S100 beta; neuron-specific enolase; glial fibrillary acidic protein	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID CSF; SERUM S100B; PROTEIN CONCENTRATIONS; ENCEPHALOPATHY; S-100B; DAMAGE; INFANTS; SEPSIS	Objective: To determine whether known serum markers of neurologic injury are increased in children with septic shock. Design: Prospective, observational study. Setting: Tertiary-care, pediatric intensive care unit. Patients: Two cohorts of children (n = 24) with septic shock were prospectively enrolled within 24 hrs of their diagnosis. In cohort 1, serum markers (S100 beta, neuron-specific enolase [NSE], and glial fibrillary acidic protein [GFAP]) were determined (n = 18). In cohort 2, in addition to serum markers, urine S100 beta and GFAP were determined, and continuous electroencephalography (cEEG) was performed. Children who presented to the emergency room with a fever served as controls (n = 32). Children with known neurologic conditions were excluded. Interventions. None. Measurements and Main Results. Serum and urine were collected daily for up to 7 days or until pediatric intensive care unit discharge. Biomarker concentrations were determined by commercially available enzyme-linked immunosorbent assays. cEEG was performed on days 1, 2, 4, and 7 in a 16-channel montage for at least 6 hrs. Physical examinations did not reveal focal neurologic deficits. Children with septic shock demonstrated increased serum S100 beta and NSE compared with controls (mean +/- SEM: 10.5 mu g/L +/- 2.4 vs. .9 mu g/L +/- .1, p < .001; 96.6 mu g/L +/- 8.9 vs. 4.0 mu g/L +/- 1.3, p < .001, respectively). Serum GFAP was detectable in five septic children and none of the controls. In cohort 2, urine of four patients demonstrated measurable S100 beta levels, and GFAP was detected in one child (nonsurvivor). cEEG demonstrated moderate to severe encephalopathy in all children studied. Conclusions. Markers of neurologic injuries are increased in children with septic shock. This may indicate subclinical injuries that are either transient or permanent. Studies that correlate the long-term neurologic outcome of children with these markers are needed to identify children at risk for neurologic injuries from septic shock.	[Hsu, Angela A.; Fenton, Kimberly; Dalton, Heidi; Bell, Michael J.] Childrens Natl Med Ctr, Childrens Res Inst, Div Crit Care Med, Washington, DC 20010 USA; [Weinstein, Steven; Carpenter, Jessica] Childrens Natl Med Ctr, Childrens Res Inst, Dept Neurol, Washington, DC 20010 USA; [Bell, Michael J.] Childrens Natl Med Ctr, Childrens Res Inst, Ctr Neurosci, Washington, DC 20010 USA; [Fenton, Kimberly] SUNY HSC, Div Crit Care Med, Stony Brook, NY USA	Hsu, AA (corresponding author), Childrens Natl Med Ctr, Childrens Res Inst, Div Crit Care Med, Washington, DC 20010 USA.	ahsu@cnmc.org					Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Anand N, 2005, CEREBROVASC DIS, V20, P213, DOI 10.1159/000087701; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Di Legge S, 2003, NEUROL SCI, V24, P351, DOI 10.1007/s10072-003-0188-x; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Dworschak M, 2003, CRIT CARE MED, V31, P2085, DOI 10.1097/01.CCM.0000079610.88771.62; Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470; Foerch C, 2005, ARCH NEUROL-CHICAGO, V62, P1130, DOI 10.1001/archneur.62.7.1130; Gazzolo D, 2003, ARCH PEDIAT ADOL MED, V157, P1163, DOI 10.1001/archpedi.157.12.1163; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Hellstrom-Westas L, 2006, CLIN PERINATOL, V33, P633, DOI 10.1016/j.clp.2006.06.003; Herrmann M, 2003, RESTOR NEUROL NEUROS, V21, P177; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kay AD, 2003, J NEUROTRAUM, V20, P243, DOI 10.1089/089771503321532824; KO F-J, 1990, Kaohsiung Journal of Medical Sciences, V6, P137; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Larsson A, 2005, ANESTH ANALG, V101, P1465, DOI 10.1213/01.ANE.0000180193.29655.6A; Lima JE, 2004, BRAZ J MED BIOL RES, V37, P19, DOI 10.1590/S0100-879X2004000100003; Mandel R, 2002, J PEDIATR-US, V141, P45, DOI 10.1067/mpd.2002.125005; Mewasingh LD, 2003, PEDIATR NEUROL, V28, P178, DOI 10.1016/S0887-8994(02)00509-X; Murdoch-Eaton D, 2001, DEV MED CHILD NEUROL, V43, P91, DOI 10.1017/S0012162201000159; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Nomura F, 1998, ONCOL REP, V5, P389; Oertel M, 2006, J CLIN NEUROSCI, V13, P834, DOI 10.1016/j.jocn.2005.11.030; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; RamachandranNair R, 2005, CAN J NEUROL SCI, V32, P518, DOI 10.1017/S0317167100004546; RamachandranNair R, 2005, PEDIATR NEUROL, V33, P345, DOI 10.1016/j.pediatrneurol.2005.05.007; Selakovic V, 2005, J CLIN NEUROSCI, V12, P542, DOI 10.1016/j.jocn.2004.07.019; SHAABAN AM, 2004, ANAESTHESIA, V59, P20; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; Tanaka Y, 2007, BRAIN RES, V1137, P140, DOI 10.1016/j.brainres.2006.12.025; Thorngren-Jerneck K, 2004, PEDIATR RES, V55, P406, DOI 10.1203/01.PDR.0000106806.75086.D3; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016; Zauner C, 2002, CRIT CARE MED, V30, P1136, DOI 10.1097/00003246-200205000-00030	50	46	57	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2008	9	3					245	251		10.1097/PCC.0b013e3181727b22			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	303NG	WOS:000256046600001	18446104				2021-06-18	
J	Arango-Lasprilla, JC; Ketchum, JM; Dezfulian, T; Kreutzer, JS; O'Neil-Pirozzi, TM; Hammond, F; Jha, A				Arango-Lasprilla, Juan Carlos; Ketchum, Jessica M.; Dezfulian, Taryn; Kreutzer, Jeffrey S.; O'Neil-Pirozzi, Therese M.; Hammond, Flora; Jha, Amitabh			Predictors of marital stability 2 years following traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; marital stability; ethnicity	HEAD TRAUMA; PATTERNS; COMA	Objective: The purpose of the present study was to determine the predictors of continuous marital stability over 2 years post-injury and examine the moderating effects of ethnicity. Design: Retrospective study. Setting: Longitudinal dataset of the TBI Model Systems National Database. Participants: Nine hundred and seventy-seven individuals with primarily moderate-to-severe TBI (751 Caucasians and 226 minorities) hospitalized between 1989-2005. Main outcomes: Marital stability was defined as 'stably married' (married at admission and married at follow-up years 1 and 2) and 'unstably married' (being single, divorced or separated at any of the two follow-up years). Results: Across the 2 years post-injury, 85% of study participants who reported being married upon admission for TBI had stable marital status, while 15% indicated being separated or divorced. Younger age, being a male with a TBI, suffering a TBI as a result of a violent injury and having moderate injury severity predicted marital instability. Furthermore, within minorities, increases in disability resulted in a higher likelihood of being stably married. Conclusions: These research findings are clinically relevant and assist marital/couples/family intervention therapists and/or rehabilitation professionals to design programmes early after injury to target these at risk couples. Further research on the modifiable factors contributing to marital instability after TBI and potential moderators is needed.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Harvard Med Sch Speech Language Pathol & Audiol, Boston, MA 02115 USA; [Hammond, Flora] Carolinas Rehabil, Charlotte, NC USA; [Jha, Amitabh] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Craig Hosp, Englewood, CO USA	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, MCV Campus,W Hosp,3rd Floor Room 3-102,1200 E Bro, Richmond, VA 23298 USA.	jcarangolasp@vcu.edu	Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691			Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; BROOKS DN, 1984, CLOSED HEAD INJURY P, P148; *CDCP NAT CTR HLTH, 1999, MAR STAT HLTH US; Christensen T. M., 1997, FAMILY J COUNSELING, V5, P317, DOI DOI 10.1177/1066480797054007; Cunningham JM, 1999, HLTH CARE DISABILITY, P475; Easterlin RA, 2003, P NATL ACAD SCI USA, V100, P11176, DOI 10.1073/pnas.1633144100; FRISBIE WP, 1986, J MARRIAGE FAM, V48, P99, DOI 10.2307/352232; GLENN ND, 1984, J MARRIAGE FAM, V46, P563, DOI 10.2307/352598; Gosling J, 1999, BRAIN INJURY, V13, P785; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lynch R. T., 1986, APPL REHABILITATION, P262; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Molloy M., 1983, AUSTR REHABILITATION, V7, P34; MOORE AD, 1992, CANADIAN J REHABILIT, V2, P89; Panting A., 1972, REHABILITATION, V38, P33; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Smith L.M., 1995, FAMILY SUPPORT PROGR; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Webster G, 1999, BRAIN INJURY, V13, P593; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	29	46	46	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	7-8					565	574		10.1080/02699050802172004			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	318MG	WOS:000257095300007	18568709				2021-06-18	
J	Chytrova, G; Ying, Z; Gomez-Pinilla, F				Chytrova, Gabriela; Ying, Zhe; Gomez-Pinilla, Fernando			Exercise normalizes levels of MAG and Nogo-A growth inhibitors after brain trauma	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						BDNF; myelin-associated glycoprotein; rat; traumatic brain injury; voluntary exercise	MYELIN-ASSOCIATED GLYCOPROTEIN; NEUROTROPHIC FACTOR; AXONAL REGENERATION; SPINAL-CORD; COGNITIVE FUNCTION; ADULT-RAT; FUNCTIONAL RECOVERY; PROTEIN EXPRESSION; CEREBRAL-CORTEX; MESSENGER-RNA	Myelin is a major obstacle for axonal growth after CNS injury, to the extent that it is crucial to develop interventions to counteract postinjury growth inhibition and foster neural repair. We have studied the effects of the fluid percussion injury (FPI) model of traumatic brain injury (TBI) on protein levels of two myelin-associated molecules, myelin-associated glycoprotein (MAG) and Nogo-A, in the adult rat. We found that FPI elevated hippocampal levels of MAG and Nogo-A. Given the beneficial effects of exercise on CNS function, we evaluated the capacity of exercise to reduce these myelin-derived proteins after FPI. One week of voluntary running wheel exercise overcame the injury-related increase in MAG and Nogo-A. The action of brain-derived neurotrophic factor (BDNF) has been associated with exercise as well as with the modulation of growth inhibition in vitro. We found that the selective blockade of BDNF using the immunoadhesive chimera TrkB-IgG abolished the effects of exercise on MAG and Nogo-A. FPI reduced levels of growth-associated protein 43 (GAP-43), a marker of axonal growth, and synaptophysin (SYP), an indicator of synaptic growth. Exercise counteracted the effects of FPI on GAP-43 and SYP, while BDNF blockade abolished these effects of exercise. Protein kinase A (PKA) has been related to the ability of BDNF to overcome growth inhibition. In agreement, we found that exercise increased PKA levels and this effect was prevented by BDNF blockade. These results indicate that exercise promotes a permissive cellular environment for repair after TBI, in a process in which BDNF plays a central role.	[Chytrova, Gabriela; Ying, Zhe; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Brain Injury Res Ctr, Div Neurosurg, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	Fgomezpi@ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045804] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45804, NS50465] Funding Source: Medline		Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Brabeck C, 2004, J NEUROTRAUM, V21, P697, DOI 10.1089/0897715041269597; Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chaudhry N, 2007, J CEREBR BLOOD F MET, V27, P1096, DOI 10.1038/sj.jcbfm.9600407; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Croll SD, 1998, EXP NEUROL, V152, P20, DOI 10.1006/exnr.1998.6836; Dai XD, 2001, GLIA, V34, P234, DOI 10.1002/glia.1057; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Domeniconi M, 2005, J NEUROL SCI, V233, P43, DOI 10.1016/j.jns.2005.03.023; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Emery DL, 2000, J COMP NEUROL, V424, P521; Erb M, 2006, MOL CELL NEUROSCI, V31, P613, DOI 10.1016/j.mcn.2005.12.001; Eslamboli A, 2006, NEUROSCI LETT, V408, P89, DOI 10.1016/j.neulet.2006.08.056; Filbin MT, 2006, PHILOS T R SOC B, V361, P1565, DOI 10.1098/rstb.2006.1885; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Gao Y, 2003, J NEUROSCI, V23, P11770; Ghiani CA, 2007, GLIA, V55, P966, DOI 10.1002/glia.20521; Gomez-Pinilla F, 2002, J NEUROPHYSIOL, V88, P2187, DOI 10.1152/jn.00152.2002; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; Govek EE, 2005, GENE DEV, V19, P1, DOI 10.1101/gad.1256405; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Henley JR, 2004, NEURON, V44, P909, DOI 10.1016/j.neuron.2004.11.030; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Huber AB, 2002, J NEUROSCI, V22, P3553; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Hunt D, 2003, MOL CELL NEUROSCI, V24, P1083, DOI 10.1016/j.mcn.2003.09.002; Irving EA, 2005, J CEREBR BLOOD F MET, V25, P98, DOI 10.1038/sj.jcbfm.9600011; Kubova H, 2001, J NEUROSCI, V21, P3593, DOI 10.1523/JNEUROSCI.21-10-03593.2001; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Lessmann V, 2003, PROG NEUROBIOL, V69, P341, DOI 10.1016/S0301-0082(03)00019-4; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Lom B, 1999, J NEUROSCI, V19, P9928; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Mimura F, 2006, J BIOL CHEM, V281, P15970, DOI 10.1074/jbc.M510934200; Ming GL, 2001, NEURON, V29, P441, DOI 10.1016/S0896-6273(01)00217-3; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; Molteni R, 2004, P NATL ACAD SCI USA, V101, P8473, DOI 10.1073/pnas.0401443101; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Quarles RH, 2002, CELL MOL LIFE SCI, V59, P1851, DOI 10.1007/PL00012510; Riddle DR, 1997, BIOTECHNIQUES, V23, P928, DOI 10.2144/97235rr02; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Schweigreiter R, 2006, J NEUROTRAUM, V23, P384, DOI 10.1089/neu.2006.23.384; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Skup M, 2002, EXP NEUROL, V176, P289, DOI 10.1006/exnr.2002.7943; Song XY, 2004, J NEUROSCI, V24, P542, DOI 10.1523/JNEUROSCI.4281-03.2004; Spencer T, 2004, J ANAT, V204, P49, DOI 10.1111/j.1469-7580.2004.00259.x; Spencer T, 2003, CURR OPIN NEUROBIOL, V13, P133, DOI 10.1016/S0959-4388(03)00012-6; Teng FYH, 2005, J NEUROCHEM, V94, P865, DOI 10.1111/j.1471-4159.2005.03238.x; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; Vaynman S, 2004, J NEUROSCI RES, V76, P356, DOI 10.1002/jnr.20077; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Vaynman SS, 2006, BRAIN RES, V1070, P124, DOI 10.1016/j.brainres.2005.11.062; Wang XX, 2002, J NEUROSCI, V22, P5505; Weinmann O, 2006, MOL CELL NEUROSCI, V32, P161, DOI 10.1016/j.mcn.2006.03.007; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Yamashita T, 2003, NAT NEUROSCI, V6, P461, DOI 10.1038/nn1045; Yiu G, 2003, CURR OPIN NEUROBIOL, V13, P545, DOI 10.1016/j.conb.2003.09.006; Zhao XH, 2007, MOL CELL NEUROSCI, V36, P260, DOI 10.1016/j.mcn.2007.07.008; Zheng BH, 2005, P NATL ACAD SCI USA, V102, P1205, DOI 10.1073/pnas.0409026102; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3; Zhou CM, 2003, BIOCHEM BIOPH RES CO, V309, P368, DOI 10.1016/j.bbrc.2003.08.006	84	46	50	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JAN	2008	27	1					1	11		10.1111/j.1460-9568.2007.05982.x			11	Neurosciences	Neurosciences & Neurology	247ZG	WOS:000252120500001	18093178				2021-06-18	
J	Luo, J; Shi, RY				Luo, Jian; Shi, Riyi			Polyethylene glycol inhibits apoptotic cell death following traumatic spinal cord injury	BRAIN RESEARCH			English	Article						calcium; mitochondria; oxidative stress; cytochrome c; membrane repair; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; OXIDATIVE STRESS; NEURONAL APOPTOSIS; BRAIN-INJURY; MOLECULAR REPAIR; NERVE MEMBRANES; FREE-RADICALS; CYTOCHROME-C; CNS INJURY; GLUTATHIONE	We have previously shown that local administration of polyethylene glycol (PEG, MW: 2000 Da, 50% by weight), a known membrane repair agent, immediately after trauma in guinea pig spinal cord repairs neuronal membrane disruptions and reduces oxidative injury. Here we report that a similar application of PEG resulted in marked decreases in apoptotic cell death and caspase-3 activity. We suggest that PEG may suppress apoptosis through interactions with mitochondria. This is based on our current findings that in isolated mitochondria, PEG improves mitochondrial function and reduces the release of cytochrome c, a pro-apoptotic cell death factor. This hypothesis is further supported by our previous observation that PEG enters injured cells after spinal cord injury, placing PEG in a position to directly interact with mitochondria. In summary, we conclude that PEG reduces both necrosis and apoptosis through two distinct yet synergistic pathways: repair of disrupted plasma membranes and protection of mitochondria through direct interaction. (C) 2007 Published by Elsevier B.V.	Purdue Univ, Sch Vet Med, Dept Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA	Shi, RY (corresponding author), Purdue Univ, Sch Vet Med, Dept Med Sci, Ctr Paralysis Res, W Lafayette, IN 47907 USA.	riyi@purdue.edu	Luo, Jian/B-8449-2014	Luo, Jian/0000-0002-2064-8467			Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Carmody RJ, 2001, REDOX REP, V6, P77, DOI 10.1179/135100001101536085; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gorman AM, 2000, DEV NEUROSCI-BASEL, V22, P348, DOI 10.1159/000017460; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gurtu V, 1997, ANAL BIOCHEM, V251, P98, DOI 10.1006/abio.1997.2220; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; Kaufmann SH, 2000, METHOD ENZYMOL, V322, P3; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Koob AO, 2006, J NEUROSCI RES, V83, P1558, DOI 10.1002/jnr.20837; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lai J C, 1979, Methods Enzymol, V55, P51; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; Namura S, 1998, J NEUROSCI, V18, P3659; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raha S, 2001, AM J MED GENET, V106, P62, DOI 10.1002/ajmg.1398; REED DJ, 1990, ANNU REV PHARMACOL, V30, P603, DOI 10.1146/annurev.pa.30.040190.003131; SAVAGE MK, 1994, ARCH BIOCHEM BIOPHYS, V315, P142, DOI 10.1006/abbi.1994.1483; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; WOOD KA, 1995, J NEUROSCI, V15, P5851; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	45	46	54	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 25	2007	1155						10	16		10.1016/j.brainres.2007.03.091			7	Neurosciences	Neurosciences & Neurology	187OM	WOS:000247857600002	17512912				2021-06-18	
J	Reeves, TM; Phillips, LL; Lee, NN; Povlishock, JT				Reeves, Thomas M.; Phillips, Linda L.; Lee, Nancy N.; Povlishock, John T.			Preferential neuroprotective effect of tacrolimus (FK506) on unmyelinated axons following traumatic brain injury	BRAIN RESEARCH			English	Article						traumatic axonal injury; traumatic brain injury; FKS06; compound action potential; corpus callosum; neuroprotection	SPINAL-CORD-INJURY; RAT CORPUS-CALLOSUM; FUNCTIONAL RECOVERY; WHITE-MATTER; DAMAGE; CALCINEURIN; EXPRESSION; PROTEIN; DEPHOSPHORYLATION; CYCLOSPORINE	Prior investigations of traumatic axonal injury (TAI), and pharmacological treatments of TAI pathology, have focused exclusively on the role of myelinated axons, with no systematic observations directed towards unmyelinated axon pathophysiology. Recent electrophysiological evidence, however, indicates that unmyelinated axons are more vulnerable than myelinated axons in a rodent model of experimental TAL Given their susceptibility to TAI, the present study examines whether unmyelinated axons also respond differentially to FK506, an immunophilin ligand with well-established neuroprotective efficacy in the myelinated fiber population. Adult rats received 3.0 mg/kg FK506 intravenously at 30 min prior to midline fluid percussion injury. in brain slice electrophysiological recordings, conducted at 24 h postinjury, compound action potentials (CAPs) were evoked in the corpus callosum, and injury effects quantified separately for CAP waveform components generated by myelinated axons (Ni wave) and unmyelinated axons (N-2 wave). The amplitudes of both CAP components were suppressed postinjury, although this deficit was 16% greater for the N2 CAP. While FK506 treatment provided significant neuroprotection for both N-1 and N-2 CAPS, the drug benefit for the N-2 CAP amplitude was 122% greater than that for the N-1 CAPs, and improved postinjury strength - duration and refractoriness properties only in N-2 CAPS. Immunocytochemical observations, of TAI reflected in intra-axonal pooling of amyloid precursor protein, indicated that FK506 reduced the extent of postinjury impairments to axonal transport and subsequent axonal damage. Collectively, these studies further substantiate a distinctive role of unmyelinated axons in TAI, and suggest a highly efficacious neuroprotective strategy to target this axonal population. (C) 2007 Elsevier B.V. All rights reserved.	Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA	Reeves, TM (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, 1217 E Marshall St,Room 740,Med Campus Box 980709, Richmond, VA 23298 USA.	tmreeves@vcu.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD055813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044372, R56NS044372, P30NS047463, R01NS056247] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD055813, R01 HD055813-24, HD055813] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56 NS044372, R01 NS044372, R01 NS044372-04, NS44372, P30 NS047463, R01 NS056247] Funding Source: Medline		ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; BOSTOCK H, 1983, J PHYSIOL-LONDON, V341, P41, DOI 10.1113/jphysiol.1983.sp014791; Bostock H, 1997, J PHYSIOL-LONDON, V498, P277, DOI 10.1113/jphysiol.1997.sp021857; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Burke D, 2000, BRAIN, V123, P992, DOI 10.1093/brain/123.5.992; Butcher SP, 1997, J NEUROSCI, V17, P6939; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; GRAVEL C, 1990, J COMP NEUROL, V291, P147, DOI 10.1002/cne.902910110; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; LAMANTIA AS, 1990, J COMP NEUROL, V291, P520, DOI 10.1002/cne.902910404; Levin H.S., 1996, TRAUMATIC BRAIN INJU, P105; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mobley Lloyd W 3rd, 2003, Spine J, V3, P11, DOI 10.1016/S1529-9430(02)00442-4; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; Noto T, 2004, MOL BRAIN RES, V128, P30, DOI 10.1016/j.molbrainres.2004.06.003; Nottingham S, 2002, EXP NEUROL, V177, P242, DOI 10.1006/exnr.2002.7975; OCHIAI T, 1989, TRANSPLANT P, V21, P829; Partadiredja G, 2003, J NEUROCYTOL, V32, P1165, DOI 10.1023/B:NEUR.0000021910.65920.41; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PRESTON RJ, 1983, EXP NEUROL, V79, P808, DOI 10.1016/0014-4886(83)90044-4; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Springer JE, 2000, J NEUROSCI, V20, P7246; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; SWADLOW HA, 1980, ARCH NEUROL-CHICAGO, V37, P114, DOI 10.1001/archneur.1980.00500510072016; Swanson TH, 1998, BRAIN RES, V784, P188, DOI 10.1016/S0006-8993(97)01323-1	49	46	48	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 18	2007	1154						225	236		10.1016/j.brainres.2007.04.002			12	Neurosciences	Neurosciences & Neurology	187OK	WOS:000247857400025	17481596	Green Accepted			2021-06-18	
J	Pascual, JM; Solivera, J; Prieto, R; Barrios, L; Lopez-Larrubia, P; Cerdan, S; Roda, JM				Pascual, Jose M.; Solivera, Juan; Prieto, Ruth; Barrios, Laura; Lopez-Larrubia, Pilar; Cerdan, Sebastian; Roda, Jose M.			Time course of early metabolic changes following diffuse traumatic brain injury in rats as detected by H-1 NMR spectroscopy	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; H-1-NMR spectroscopy; myo-inositol; organic osmolyte; taurine; traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; ORGANIC OSMOLYTES; CELLULAR EDEMA; TAURINE; GLUTAMATE; VOLUME; MODEL; PATHOPHYSIOLOGY	Experimental models of traumatic brain injury (TBI) provide a useful tool for understanding the cerebral metabolic changes induced by this pathological condition. Here, we report on the time course of changes in cerebral metabolites after TBI and its correlation with early brain morphological changes using a combination of high-resolution proton magnetic resonance spectroscopy (H-1 MRS) and magnetic resonance imaging (MRI). Adult male Sprague-Dawley rats were subjected to closed head impact and examined by MRI at 1, 9, 24, 48, and and 72 h after the injury. Extracts from funnel frozen rat brains were then obtained and analyzed quantitatively by high-resolution 1H MRS. Finally, statistical multivariate analysis was carried out to identify the combination of cerebral metabolites that best described the time evolution of diffuse TBI. The temporal changes observed in the concentration of cerebral metabolites followed three different patterns. The first pattern included taurine, threonine, and glycine, with concentrations peaking 24 h after the injury. The second pattern included glutamate, GABA, and alanine, with concentrations remaining elevated between 24 and 48 h post-injury. The third one involved creatine-phosphocreatine, N-acetylaspartate, and myo-inositol, with concentrations peaking 48 h after the injury. A multivariate stepwise discriminant analysis revealed that the combination of the organic osmolytes taurine and myo-inositol allowed optimal discrimination among the different time groups. Our findings suggest that the profile of some specific brain molecules that play a role as organic osmolytes can be used to follow-up the progression of the early diffuse brain edema response induced by TBI.	Hosp Univ La Princesa, Dept Neurosurg, C Diego de Leon 62, E-28006 Madrid, Spain; Sant Creu & Sant Pau Univ Hosp, Dept Neurosurg, Barcelona, Spain; La Paz Univ Hosp, Dept Neurosurg, Madrid, Spain; CSIC, Comp Tech Ctr, Dept Stat, Madrid, Spain; CSIC, Biomed Res Inst Alberto Sols, Madrid, Spain	Pascual, JM (corresponding author), Hosp Univ La Princesa, Dept Neurosurg, C Diego de Leon 62, E-28006 Madrid, Spain.	jmpascual@iib.uam.es	Lopez-Larrubia, Pilar/B-3902-2013; Lopez-Larrubia, Pilar/AAC-7964-2020; Solivera, Juan/AAG-8863-2019	Lopez-Larrubia, Pilar/0000-0002-5141-8736; Lopez-Larrubia, Pilar/0000-0002-5141-8736; Cerdan, Sebastian/0000-0001-9965-0270; Solivera Vela, Juan/0000-0003-2860-6656			Afifi A., 2004, COMPUTER AIDED MULTI; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alexander JJ, 2005, NEUROCHEM INT, V47, P143, DOI 10.1016/j.neuint.2005.04.016; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Barzo P, 1997, ACT NEUR S, V70, P243; BAUMGARTEN CM, 2001, CELL PHYSL SOURCE BO, P253; BEHAR KL, 1991, MAGNET RESON MED, V17, P285, DOI 10.1002/mrm.1910170202; Bothwell JH, 2001, J NEUROCHEM, V77, P1632, DOI 10.1046/j.1471-4159.2001.00403.x; Bouma GJ, 1998, ACT NEUR S, V71, P272; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; CERDAN S, 1990, ANNU REV BIOPHYS BIO, V19, P43; CERDAN S, 1985, FEBS LETT, V187, P167, DOI 10.1016/0014-5793(85)81235-7; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; DUTTON GR, 1991, ANN NY ACAD SCI, V633, P489; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gruetter R, 1998, J MAGN RESON, V135, P260, DOI 10.1006/jmre.1998.1542; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; KEMPSKI OS, 1994, ACT NEUR S, V60, P7; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Lang F, 1998, PHYSIOL REV, V78, P247; LEE JH, 1994, NEW ENGL J MED, V331, P439, DOI 10.1056/NEJM199408183310704; Lin Alexander, 2005, NeuroRx, V2, P197, DOI 10.1602/neurorx.2.2.197; Lobato R D, 1993, Adv Tech Stand Neurosurg, V20, P3; LUST WD, 1989, NEUROMETHODS, V11, P1; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, ACT NEUR S, V60, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; Mongin A. A., 2005, NEUROGLIA, P550; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; NAGELHUS EA, 1993, NEUROSCIENCE, V54, P615, DOI 10.1016/0306-4522(93)90233-6; Nonaka M, 1998, J NEUROL SCI, V157, P25, DOI 10.1016/S0022-510X(98)00062-8; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pasantes-Morales H, 2000, CELL PHYSIOL BIOCHEM, V10, P361, DOI 10.1159/000016369; PASANTESMORALES H, 1994, AM J PHYSIOL, V266, pC172; PasantesMorales H, 1997, AMINO ACIDS, V12, P281, DOI 10.1007/BF01373008; Pascual JM, 1998, STROKE, V29, P1048, DOI 10.1161/01.STR.29.5.1048; PAXINOS G, 1998, PHARM RES, V48, P101; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Rumpel H, 2003, J MAGN RESON IMAGING, V17, P11, DOI 10.1002/jmri.10233; SCHNEIDER GH, 1993, J PHYSIOL PHARMACOL, V70, pS334; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2000, ACTA NEUROCHIR SUPPL, V76, P3; Seki Y, 2005, NEUROCHEM RES, V30, P123, DOI 10.1007/s11064-004-9693-4; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; SON BC, 2000, ACTA NEUROCHIR S, V76, P6; Stover JF, 2000, BRAIN RES, V875, P51, DOI 10.1016/S0006-8993(00)02597-X; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; STRANGE K, 1992, AM J PHYSIOL, V263, pC412; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; Tkac I, 2001, MAGNET RESON MED, V46, P451, DOI 10.1002/mrm.1213; TORP R, 1991, NEUROSCIENCE, V41, P433, DOI 10.1016/0306-4522(91)90339-P; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Weber D., 2000, 1 COURSE DESIGN EXPT	68	46	49	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2007	24	6					944	959		10.1089/neu.2006.0190			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	184EA	WOS:000247622700004	17600512				2021-06-18	
J	Douglas, JM; Bracy, CA; Snow, PC				Douglas, Jacinta M.; Bracy, Christine A.; Snow, Pamela C.			Exploring the factor structure of the La Trobe communication questionnaire: Insights into the nature of communication deficits following traumatic brain injury	APHASIOLOGY			English	Article							CLOSED HEAD-INJURY; DISCOURSE ASSESSMENT; COMPETENCE; ABILITIES; AWARENESS; CORTEX	Background: Self and close other reports of communication ability can provide a time-efficient means of evaluating conversational discourse after traumatic brain injury ( TBI). The La Trobe Communication Questionnaire (LCQ) measures perceived communication ability from various sources including self-perceptions and perceptions of others. Content and test-retest reliability and discriminant validity of the LCQ have been demonstrated previously with adults following TBI. Aims: This study was undertaken to explore the factor structure of the LCQ as revealed within the data collected from 88 adults with severe TBI and their close others. Methods & Procedures: Construct validity was examined using a Principal Component Factor Analytic procedure with Varimax rotation. Outcomes & Results: A seven-factor structure that accounted for 60.88% of the variance was revealed. Of the LCQ items, 27 clearly loaded on to one of the seven communication factors that were identified. Conclusions: The factor structure that emerged depicts the multidimensional nature of conversation and the complex interplay between cognitive and communication processes that social discourse demands. These results support the construct validity of the LCQ and indicate that it can be used as a reliable and valid measure of communication ability after severe TBI.	La Trobe Univ, Bundoora, Vic, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	J.Douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Snow, Pamela/0000-0002-2426-8349			[Anonymous], 1988, ASHA, V30, P79; Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; BRYANT FB, 1995, READING MULTIVARIATE; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1999, BRAIN DAM B, P55; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Damico JS, 1985, COMMUNICATION SKILLS, P165; DOUGLAS J, IN PRESS J HEAD TRAU; DOUGLAS J, 2004, EVIDENCE BASED PRACT; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Fleming JM, 1996, BRAIN INJURY, V10, P1; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GARSON GD, 2005, STATNOTES ONLINE TXB; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [DOI 10.1007/BF02214959, 10.1007/BF02214959]; Grafman J, 1999, LANCET, V354, P1921, DOI 10.1016/S0140-6736(99)90438-5; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Hutcheson G., 1999, MULTIVARIATE SOCIAL; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Lawley D. N., 1971, FACTOR ANAL STAT MET; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, 2002, AWARNESS SOCIAL INFE; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; NOWICKI S, 1993, J SOC PSYCHOL, V133, P749, DOI 10.1080/00224545.1993.9713934; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Prigatano G., 1986, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; REILLY S, 2004, EVIDENCE BASED PRACT; Rolls ET, 1999, NEUROCASE, V5, P301, DOI 10.1080/13554799908411984; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Snow PC, 2000, BRAIN INJURY, V14, P397; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Tabachnik B. G., 2001, USING MULTIVARIATE S; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Ylvisaker M., 2001, LANGUAGE INTERVENTIO	57	46	47	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2007	21	12					1181	1194		10.1080/02687030600980950			14	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	237FW	WOS:000251360600004					2021-06-18	
J	Sara, M; Sacco, S; Cipolla, F; Onorati, P; Scoppetta, C; Albertini, G; Carolei, A				Sara, Marco; Sacco, Simona; Cipolla, Francesco; Onorati, Paolo; Scoppetta, Ciriaco; Albertini, Giorgio; Carolei, Antonio			An unexpected recovery from permanent vegetative state	BRAIN INJURY			English	Article						vegetative state; consciousness; spasticity; baclofen	MANAGEMENT	Primary objective: To challenge the Multi-Society Task Force's ruling that a persistent vegetative state (PVS) can be judged to be permanent for non traumatic brain injury after three months. Method: We report the case of a 44-year-old man who had recovery of consciousness with persistent severe disability 19 months after a non-traumatic brain injury at least in part triggered and maintained by intrathecal baclofen administration. Result: This unexpected and late recovery of consciousness raises an interesting hypothesis of possible effects of partially regained spinal cord outputs on reactivation of cognition. Conclusion: Considering that several ethical, legal, and socio-economic issues have been raised about the opportunity of withdrawing treatment and life support in patients with PVS the report of this case might add further documentation to the ongoing debate.	Ist San Raffaele Tosinvest Sanita, Post Coma Intens & Rehabil Care Unit, Cassino, Italy; Univ Laquila, Dept Neurol, Laquila, Italy; San Raffaele Pisana Tosinvest Sanita, Pediat Adult & Dev Ctr, Rome, Italy; Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, Rome, Italy; Osped San Camillo, Neurol Unit 2, Rome, Italy	Sara, M (corresponding author), Casa Cura San Raffaele Via Gaetano Di Biasio 1, I-03043 Cassino, FR, Italy.	marco.sara@sanraffaele.it	Sara, Marco/AAB-3651-2019; Sacco, Simona/I-5253-2012	Sacco, Simona/0000-0003-0651-1939			ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; McLean SAM, 1999, J CLIN PATHOL, V52, P490, DOI 10.1136/jcp.52.7.490; MOTOKIZAWA F, 1964, JPN J PHYSIOL, V14, P344; Penn RD, 1989, NEUROSURGERY, V4, P325; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Taira T, 2003, ACT NEUR S, V87, P37; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	12	46	49	0	5	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2007	21	1					101	103		10.1080/02699050601151761			3	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600012	17364525				2021-06-18	
J	Lu, KT; Wu, CY; Cheng, NC; Wo, YYP; Yang, JT; Yen, HH; Yang, YL				Lu, Kwok-Tung; Wu, Chang-Yen; Cheng, Nai-Chi; Wo, Yu-Yuan Peter; Yang, Jen-Tsung; Yen, Hao-Han; Yang, Yi-Ling			Inhibition of the Na+-K+-2Cl(-)-cotransporter in choroid plexus attenuates traumatic brain injury-induced brain edema and neuronal damage	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						traumatic brain injury; Na-K-2Cl cotransporter; brain edema; bumetanide	K+-CL-COTRANSPORTER; FOCAL CEREBRAL-ISCHEMIA; NA+-K+-2CL(-) COTRANSPORTER; CEREBROSPINAL-FLUID; NA-K-2CL COTRANSPORTER; POTASSIUM COTRANSPORT; GLOBAL-ISCHEMIA; EAA RELEASE; RAT-BRAIN; CHLORIDE	The present study was aimed to elucidate the possible role of Na+-K+-2Cl(-)-cotransporter (NKCC1) on traumatic brain injury-induced brain edema, cerebral contusion and neuronal death by using traumatic brain injury animal model. Contusion volume was verified by 2,3,5,triphenyltetrazolium chloride momohydrate staining. NKCC1 mRNA expression was detected by RT-PCR and the protein expression of NKCC1 was measured by Western blot. We found that the expression of NKCC1 RNA and protein were up-regulated in choroid plexus apical membrane from 2 h after traumatic brain injury, peaked at 8 h, and lasted for 24 h. Rats in the experimental group displayed severe brain edema (water content: 81.45 +/- 0.32% compared with 78.38 +/- 0.62% of sham group) and contusion volume significantly increased 8 h after traumatic brain injury (864.14 +/- 28.07 mm(3)). Administration of the NKCC1 inhibitor bumetanide (15 mg/kg, I.V.) significantly attenuated the contusion volume (464.03 +/- 23.62 mm(3)) and brain edema (water content: 79.12 +/- 0.28%) after traumatic brain injury. Our study demonstrates that NKCC1 contributes to traumatic brain injury-induced brain edema and neuronal damage. (c) 2006 Elsevier B.V. All rights reserved.	Natl Chiayi Univ, Dept Biochem & Mol Biol, Inst Biotechnol, Chiayi, Taiwan; Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Neurosurg, Chiayi, Taiwan	Yang, YL (corresponding author), Natl Chiayi Univ, Dept Biochem & Mol Biol, Inst Biotechnol, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw	Yang, Jen-Tsung/C-3187-2011				Anderson CM, 2000, GLIA, V32, P1; BAIRAMIAN D, 1991, J NEUROCHEM, V56, P1623, DOI 10.1111/j.1471-4159.1991.tb02060.x; Betz AL, 1996, ADV NEUROL, V71, P301; Busse S, 2005, BRAIN RES, V1046, P116, DOI 10.1016/j.brainres.2005.03.055; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Chodobski A, 2001, MICROSC RES TECHNIQ, V52, P65; Emerich DF, 2005, BIOESSAYS, V27, P262, DOI 10.1002/bies.20193; Ferrand-Drake M, 1999, NEUROSCIENCE, V93, P537, DOI 10.1016/S0306-4522(99)00181-5; Ferrand-Drake M, 2001, MICROSC RES TECHNIQ, V52, P130, DOI 10.1002/1097-0029(20010101)52:1<130::AID-JEMT14>3.0.CO;2-6; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HOLOPAINEN I, 1990, NEUROSCIENCE, V36, P115, DOI 10.1016/0306-4522(90)90355-8; HOSSMANN KA, 1989, NEUROSURG REV, V12, P263, DOI 10.1007/BF01780838; Iadecola C, 1999, CONT NEUROS, P3; Ikebe M, 2001, J AM SOC NEPHROL, V12, P423, DOI 10.1681/ASN.V123423; JAVAHERI S, 1991, J APPL PHYSIOL, V71, P795; JOHNSON DC, 1987, J APPL PHYSIOL, V63, P1591; KEEP RF, 1994, AM J PHYSIOL-CELL PH, V267, pC1616; Kimelberg HK, 1999, CONT NEUROS, P45; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; Kraus JF, 1996, OCCUP MED, V11, P201; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MAX W, 1990, INQUIRY-J HEALTH CAR, V27, P332; O'Donnell ME, 2005, AM J PHYSIOL-CELL PH, V289, pC283, DOI 10.1152/ajpcell.00001.2005; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; Obermuller N, 1996, J CLIN INVEST, V98, P635, DOI 10.1172/JCI118834; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173; Ringel F, 2000, J NEUROCHEM, V75, P125, DOI 10.1046/j.1471-4159.2000.0750125.x; Russell JM, 2000, PHYSIOL REV, V80, P211; Schomberg SL, 2001, J NEUROPHYSIOL, V85, P2563; Segal MB, 2000, CELL MOL NEUROBIOL, V20, P183, DOI 10.1023/A:1007045605751; SEGAL MB, 1993, J INHERIT METAB DIS, V16, P617, DOI 10.1007/BF00711896; Speake T, 2001, MICROSC RES TECHNIQ, V52, P49, DOI 10.1002/1097-0029(20010101)52:1<49::AID-JEMT7>3.0.CO;2-C; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Sun DD, 1998, AM J PHYSIOL-CELL PH, V275, pC772; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; VOGH BP, 1981, BRAIN RES, V221, P171, DOI 10.1016/0006-8993(81)91071-4; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Wu Q, 1998, AM J PHYSIOL-CELL PH, V275, pC1565; Yan YP, 2003, BRAIN RES, V961, P22, DOI 10.1016/S0006-8993(02)03832-5; Yan YP, 2001, BRAIN RES, V911, P43, DOI 10.1016/S0006-8993(01)02649-X	50	46	48	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	OCT 24	2006	548	1-3					99	105		10.1016/j.ejphar.2006.07.048			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	093MO	WOS:000241172600013	16962576				2021-06-18	
J	Yeo, RA; Phillips, JP; Jung, RE; Brown, AJ; Campbell, RC; Brooks, WM				Yeo, Ronald A.; Phillips, John P.; Jung, Rex E.; Brown, April J.; Campbell, Richard C.; Brooks, William M.			Magnetic resonance spectroscopy detects brain injury and predicts cognitive functioning in children with brain injuries	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	14th Annual Conference on Traumatic Brain Injury - From Molecule to Family Systems	2004	Rotman Res Inst, Toronto, CANADA		Rotman Res Inst	cognitive; outcome; pediatric; spectroscopy; traumatic brain injury	PROTON MR SPECTROSCOPY; N-ACETYLASPARTATE; IN-VIVO; VERTEBRATE BRAIN; AXONAL INJURY; METABOLISM; GLUTAMATE/GLUTAMINE; REPRODUCIBILITY; ADOLESCENTS; DYSFUNCTION	Proton magnetic resonance spectroscopy (H-1-MRS) and neuropsychological assessment were utilized in a longitudinal investigation of traumatic brain injury (TBI) in children. A spectroscopic imaging protocol was implemented, and neurometabolite ratios of NAA/Cre and Cho/Cre were calculated for anterior and posterior halves of a supraventricular slab of brain tissue. NAA/Cre was reduced and Cho/Cre increased in TBI patients as compared to controls, for both brain regions. Each ratio predicted aspects of neuropsychological performance; though the specific relationships varied somewhat by region and function. Anterior NAA/Cre increased and anterior Cho/Cre decreased from 3 to 21 weeks post-injury, suggesting neurometabolic recovery.	Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; MIND Inst, Albuquerque, NM USA; Univ New Mexico, Sch Med, Dept Psychiat, Albuquerque, NM USA; Univ Kansas, Med Ctr, Sch Med, Hogland Brain Imaging Ctr, Kansas City, KS USA	Yeo, RA (corresponding author), Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA.	ryeo@unm.edu		brooks, william/0000-0001-6227-7636	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039123, R21NS041390] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR00997] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41390, NS39123] Funding Source: Medline		Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Baslow MH, 2003, NEUROCHEM RES, V28, P941, DOI 10.1023/A:1023250721185; Baslow MH, 2000, J NEUROCHEM, V75, P453, DOI 10.1046/j.1471-4159.2000.0750453.x; Bergman ML, 2001, J AUTOIMMUN, V16, P105, DOI 10.1006/jaut.2000.0474; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Boulanger Y, 2000, BRAIN RES REV, V33, P380, DOI 10.1016/S0165-0173(00)00037-0; BRDICZKA D, 1994, MOL CELL BIOCHEM, V133, P69, DOI 10.1007/BF01267948; Brooks WM, 1999, MAGNET RESON MED, V41, P193, DOI 10.1002/(SICI)1522-2594(199901)41:1<193::AID-MRM27>3.0.CO;2-P; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2003, NEUROPSYCHOL REHABIL, V13, P517, DOI 10.1080/09602010343000084; *CDCP, 2006, TRAUM BRIAN INJ US A; Dautry W, 2000, J CEREBR BLOOD F MET, V20, P789, DOI 10.1097/00004647-200005000-00005; DAVIE CA, 1994, BRAIN, V34, P721; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; GENTLEMAN SM, 1999, J NEUROTRAUM, V16, P994; GONIDARAJU V, 1999, NMR BIOMED, V13, P129; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hugg JW, 1996, ANN NEUROL, V40, P236, DOI 10.1002/ana.410400215; Hunter JV, 2005, AM J NEURORADIOL, V26, P482; KREIS R, 1993, MAGNET RESON MED, V30, P424, DOI 10.1002/mrm.1910300405; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; LEZAK M, 1995, NEUROPSYCHOLOGICAL E; Mason GF, 2005, ALCOHOL CLIN EXP RES, V29, P150, DOI 10.1097/01.ALC.0000150010.72739.58; Moses P, 2002, DEV PSYCHOBIOL, V40, P266, DOI 10.1002/dev.10031; Mullins PG, 2003, MAGNET RESON MED, V50, P704, DOI 10.1002/mrm.10598; Parry L, 2004, CHILD NEUROPSYCHOL, V10, P248, DOI 10.1080/09297040490909279; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Sager TN, 2000, J CEREBR BLOOD F MET, V20, P780, DOI 10.1097/00004647-200005000-00004; Saks VA, 1996, BBA-BIOENERGETICS, V1274, P81, DOI 10.1016/0005-2728(96)00011-4; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Shetty HU, 2000, CURR ORG CHEM, V4, P1, DOI 10.2174/1385272003376382; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; STEFANO GD, 2000, J NEUROL NEUROSUR PS, V69, P210; URENJAK J, 1993, J NEUROSCI, V13, P981, DOI 10.1523/jneurosci.13-03-00981.1993; Verger K, 2000, BRAIN INJURY, V14, P495; WEERS DC, 2004, ANN M INT NEUR SOC B; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010	51	46	48	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1427	1435		10.1089/neu.2006.23.1427			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500005	17020480				2021-06-18	
J	Hernandez, AV; Steyerberg, EW; Butcher, I; Mushkudiani, N; Taylor, GS; Murray, GD; Marmarou, A; Choi, SC; Lu, J; Habbema, JDF; Maas, AIR				Hernandez, Adrian V.; Steyerberg, Ewout W.; Butcher, Isabella; Mushkudiani, Nino; Taylor, Gillian S.; Murray, Gordon D.; Marmarou, Anthony; Choi, Sung C.; Lu, Juan; Habbema, J. Dik F.; Maas, Andrew I. R.			Adjustment for strong predictors of outcome in traumatic brain injury trials: 25% reduction in sample size requirements in the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						covariate adjustment; model performance; randomized clinical trials; reduction in sample size; traumatic brain injury	RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS; HEAD-INJURY; COVARIATE ADJUSTMENT; NEUROPROTECTIVE AGENTS; EPIDEMIOLOGY; VALIDATION; REGRESSION	The aim of this study was to quantify the potential reduction in sample size that can be achieved by adjustment for predictors of outcome in traumatic brain injury (TBI) trials. We used individual patient data from seven therapeutic phase III randomized clinical trials (RCTs; n = 6166) in moderate or severe TBI, and three TBI surveys (n = 2238.). The primary outcome was the dichotomized Glasgow Outcome Scale at 6 months (favorable/unfavorable). Baseline predictors of outcome considered were age, motor score, pupillary reactivity, computed tomography (CT) classification, traumatic subarachnoid hemorrhage, hypoxia, hypotension, glycemia, and hemoglobin. We calculated the potential sample size reduction obtained by adjustment of a hypothetical treatment effect for one to seven predictors with logistic regression models. The distribution of predictors was more heterogeneous in surveys than in trials. Adjustment of the treatment effect for the strongest predictors (age, motor score, and pupillary reactivity) yielded a reduction in sample size of 16-23% in RCTs and 28-35% in surveys. Adjustment for seven predictors yielded a reduction of about 25% in most studies: 20-28% in RCTs and 32-39% in surveys. A major reduction in sample size can be obtained with covariate adjustment in TBI trials. Covariate adjustment for strong predictors should be incorporated in the analysis of future TBI trials.	Erasmus Univ, Erasmus MC, Med Ctr, Dept Publ Hlth,Ctr Med Decis Making, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Erasmus MC, Med Ctr, Dept Neurol Surg, NL-3000 DR Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh, Midlothian, Scotland; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Steyerberg, EW (corresponding author), Erasmus Univ, Erasmus MC, Med Ctr, Dept Publ Hlth,Ctr Med Decis Making, POB 2040, NL-3000 DR Rotterdam, Netherlands.	e.steyerberg@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122; Lu, Juan/0000-0002-5389-7603; Hernandez, Adrian V./0000-0002-9999-4003	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 RO1 NS-042691-001A] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Choi S C, 1998, J Biopharm Stat, V8, P367, DOI 10.1080/10543409808835246; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Edwards P, 2005, LANCET, V365, P1957; GAIL MH, 1984, BIOMETRIKA, V71, P431; Hauck WW, 1998, CONTROL CLIN TRIALS, V19, P249, DOI 10.1016/S0197-2456(97)00147-5; Hernandez AV, 2006, ANN EPIDEMIOL, V16, P41, DOI 10.1016/j.annepidem.2005.09.007; Hernandez AV, 2005, NEUROSURGERY, V57, P1244, DOI 10.1227/01.NEU.0000186039.57548.96; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Little R, 2004, STAT SINICA, V14, P949; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MARMAROU A, 2006, UNPUB J NEUROTRAUMA; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Masson F, 2000, ANN FR ANESTH, V19, P261; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; MUSHKUDANI N, 2004, MED DECIS MAKING, V24, P437; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Steyerberg EW, 2000, AM HEART J, V139, P745, DOI 10.1016/S0002-8703(00)90001-2; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; TAYLOR GS, 2006, UNPUB J NEUROTRAUMA; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276	31	46	47	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1295	1303		10.1089/neu.2006.23.1295			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900002	16958582				2021-06-18	
J	Chronister, J; Chan, F				Chronister, Julie; Chan, Fong			A stress process model of caregiving for individuals with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article						caregiving; TBI; social support; coping; stress process	COMPETENCE RATING-SCALE; BLUNT HEAD-INJURY; SOCIAL SUPPORT; FAMILY NEEDS; PSYCHOSOCIAL ADAPTATION; PSYCHOLOGICAL DISTRESS; COPING STRATEGIES; LIFE; PREDICTORS; RELATIVES	Objective: To test a stress process model of caregiving for persons with traumatic brain injury. Design: A correlational study using path analysis. Participants: One hundred eight caregivers affiliated with community- or Web-based support groups. Main Outcome Measures: The Modified Caregiver Appraisal Scale, the World Health Organization Quality of Life-Brief Version, the Interpersonal Support Evaluation List, and the COPE. Results: The normed fit index, comparative fit index, and parsimony ratio indicated a good fit for the model, suggesting that coping, social support, and caregiving appraisal contribute to quality of life. A more parsimonious model was respecified and achieved a better fit with fewer paths and variables. Conclusions: Empirical support was found for the proposed caregiving stress process model, which appears to provide useful information for future research and clinical interventions.	CUNY Hunter Coll, Dept Educ Fdn & Counseling, New York, NY 10021 USA; Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA	Chronister, J (corresponding author), CUNY Hunter Coll, Dept Educ Fdn & Counseling, 695 Pk Ave,Room W 1127, New York, NY 10021 USA.	julie.chronister@hunter.cuny.edu					ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Aneshensel C.S., 1995, PROFILES CAREGIVING; ARBUCKLE JL, 1999, AMOS J 0 SOFTWARE US; BARUSCH AS, 1989, GERONTOLOGIST, V29, P667, DOI 10.1093/geront/29.5.667; BENTLER PM, 1987, SOCIOL METHOD RES, V16, P78, DOI 10.1177/0049124187016001004; BILLINGS AG, 1984, J PERS SOC PSYCHOL, V46, P877, DOI 10.1037/0022-3514.46.4.877; Bollen K.A., 1989, STRUCTURAL EQUATIONS, P514, DOI 10.1002/9781118619179; Bradburn NM, 1969, STRUCTURE PSYCHOL WE; Brissette I, 2002, J PERS SOC PSYCHOL, V82, P102, DOI 10.1037//0022-3514.82.1.102; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Byrne B. M, 2001, STRUCTURAL EQUATION; CANTOR MH, 1983, GERONTOLOGIST, V23, P597, DOI 10.1093/geront/23.6.597; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; COHEN S, 1983, SOCIAL SUPPORT THEOR, P73; CREWE NM, 1980, MINN MED, V63, P586; DOUGLAS JM, 2000, DISABILITY REHABILIT, V22, P683; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fitting M, 1985, GENERATIONS, V10, P23; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Goode KT, 1998, HEALTH PSYCHOL, V17, P190, DOI 10.1037/0278-6133.17.2.190; GRAD J, 1963, LANCET, V1, P544; HALEY WE, 1987, PSYCHOL AGING, V2, P323, DOI 10.1037/0882-7974.2.4.323; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris JKJ, 2001, BRAIN INJURY, V15, P223; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; HOLAHAN CJ, 1990, J PERS SOC PSYCHOL, V58, P909, DOI 10.1037/0022-3514.58.5.909; Holmbeck GN, 1997, J CONSULT CLIN PSYCH, V65, P599, DOI 10.1037/0022-006X.65.4.599; HOYLE RH, 1994, J CONSULT CLIN PSYCH, V62, P429, DOI 10.1037/0022-006X.62.3.429; Hu L.-T., 1995, EVALUATING MODEL FIT, P76; James L. R., 1982, CAUSAL ANAL ASSUMPTI; KINNEY JM, 1995, J APPL GERONTOL, V14, P3, DOI 10.1177/073346489501400101; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/0090-5550.39.4.215; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lazarus R.S., 1984, STRESS APPRAISAL COP; Leathem J, 1996, BRAIN INJURY, V10, P27; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Livneh H, 2005, J COUNS DEV, V83, P12, DOI 10.1002/j.1556-6678.2005.tb00575.x; Livneh H, 2003, REHABIL COUNS BULL, V46, P194, DOI 10.1177/003435520304600401; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Moore A. D., 1991, J HEAD TRAUMA REHAB, V6, P83; Moos R., 1993, HDB STRESS THEORETIC, P234; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; *NIH CONS DEV PAN, 1999, JAMA-J AM MED ASSOC, V232, P974; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Pakenham K. I., 2001, PSYCHOL HEALTH MED, V6, P13, DOI [DOI 10.1080/13548500125141, 10.1080/13548500125141]; PANTING A, 1972, J REHABIL, V82, P33; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; Pot AM, 1998, PATIENT EDUC COUNS, V34, P43, DOI 10.1016/S0738-3991(98)00048-2; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; PRIGATANO GP, 1989, NEUROPSYCHOLOGICAL R; PRUCHNO RA, 1989, GERONTOLOGIST, V29, P159, DOI 10.1093/geront/29.2.159; ROESSLER RT, 1990, REHABIL COUNS BULL, V34, P82; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Tabachnik B. G., 2001, USING MULTIVARIATE S; Tarter S B, 1990, Arch Clin Neuropsychol, V5, P15; THOITS PA, 1987, J HEALTH SOC BEHAV, V28, P7, DOI 10.2307/2137137; THOMSEN I, 1972, SCANDINAVIAN J REHAB, V6, P180; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wrubel, 1989, PRIMACY CARING STRES; Zanetti O, 1998, INT J GERIATR PSYCH, V13, P358, DOI 10.1002/(SICI)1099-1166(199806)13:6<358::AID-GPS772>3.0.CO;2-J; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	87	46	48	0	18	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2006	51	3					190	201		10.1037/0090-5550.51.3.190			12	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	072OK	WOS:000239682500002					2021-06-18	
J	Trahan, E; Pepin, M; Hopps, S				Trahan, Evelyne; Pepin, Michel; Hopps, Sandra			Impaired awareness of deficits and treatment adherence among people with traumatic brain injury or spinal cord injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						impaired awareness; traumatic brain injury; treatment adherence	BEHAVIORAL LIMITATIONS; SELF-AWARENESS; HEAD-INJURY; ANOSOGNOSIA; PERFORMANCE; DISABILITY; ADULTS; TBI	To examine the relation between impaired awareness of deficits (LAD) and treatment adherence and to verify previous findings regarding the types of disabilities that people with traumatic brain injury (TBI) tend to underestimate. Design: Cross-sectional study. Participants: Twenty-four persons with moderate to severe TBI and 16 persons with traumatic spinal cord injury (SCI) admitted to an inpatient neurorehabilitation program. Main outcome measures: LAD assessed using the short version of the Problem Checklist of the Head Injury Family Interview and treatment adherence using the Medical Regimen Adherence Scale. Results: Presence of IAD is linked with poor adherence. Patients with TBI significantly underestimate their emotional/behavioural and cognitive disabilities, but accurately assess their physical disabilities, whereas patients with SCI accurately assess all spheres. Patients with TBI are significantly less aware of their disabilities compared with the patients with SCI as expected. Conclusions: These results confirm IAD's link to treatment adherence, and support the observation that IAD is a common clinical feature of brain injury that should be carefully considered when making prognoses and developing and applying interventions with this population.	Univ Laval, Sch Psychol, Laval, PQ G1K 7P4, Canada	Pepin, M (corresponding author), Univ Laval, Sch Psychol, Laval, PQ G1K 7P4, Canada.	michel.pepin@psy.ulaval.ca					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Barco P.P., 1991, COGNITIVE REHABILITA, P129; Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Croteau D, 1997, REV NEUROPSYCHOL, V7, P3; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gauggel S, 2000, J HEAD TRAUMA REHAB, V15, P710, DOI 10.1097/00001199-200002000-00009; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hess DW, 2003, REHABIL PSYCHOL, V48, P151, DOI 10.1037/0090-5550.48.3.151; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kennedy P, 2001, COMPREHENSIVE CLINICAL PSYCHOLOGY, VOL 8, P445; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LAM CS, 1988, BRAIN INJURY, V2, P233; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; NIELSEN ML, 1997, INT J REHABILITATION, V3, P143; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RHEINER NW, 1995, REHABILITATION NURSI, V4, P90; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; Schacter D. L., 1991, AWARENESS DEFICIT BR, P258; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sohlberg McKay Moore, 2000, Seminars in Speech and Language, V21, P135; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Stutts M, 1991, NEUROREHABILITATION, V1; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; VALLERAND RJ, 1989, CAN PSYCHOL, V30, P662, DOI 10.1037/h0079856; WAGNER MT, 1994, ARCH CLIN NEUROPSYCH, V9, P57, DOI 10.1016/0887-6177(94)90014-0; YOUNGJOHN JR, 1989, REHABIL PSYCHOL, V34, P217, DOI 10.1037//0090-5550.34.3.217	34	46	47	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2006	21	3					226	235		10.1097/00001199-200605000-00003			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	044YL	WOS:000237709600003	16717500				2021-06-18	
J	Conti, L; Reitano, E; Cattaneo, E				Conti, Luciano; Reitano, Erika; Cattaneo, Elena			Neural stem cell systems: Diversities and properties after transplantation in animal models of diseases	BRAIN PATHOLOGY			English	Article							FIBROBLAST GROWTH FACTOR-2; MARROW STROMAL CELLS; PROGENITOR CELLS; IN-VITRO; PRECURSOR CELLS; BONE-MARROW; DOPAMINERGIC-NEURONS; SELF-RENEWAL; OLIGODENDROCYTE PROGENITORS; LINEAGE RESTRICTION	Currently available effective treatments of the diseased or damaged central nervous system (CNS) are restricted to a limited pharmacological relief of symptoms or those given to avoid further damage. Therefore the search is on for treatments that can restore function in the CNS. During recent years replacement of damaged neurons by cell transplantation is being enthusiastically explored as a potential treatment for many neurodegenerative diseases, stroke and traumatic brain injury. Several references in both scientific journals and popular newspapers concerning different types of cultured stem cells, potentially exploitable to treat pathological conditions of the brain, raise important questions pertinent to the fundamental and realistic differences between grafts of primary neural cells and the transplantation of in vitro expanded neural stem cells (NSCs). Our aim is to review the available information on the grafting of different NSC types into the adult rodent brain, focusing on critical aspects for the development of clinical therapies to replace damaged neurons.	Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy	Cattaneo, E (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	Elena.Cattaneo@unimi.it	Conti, Luciano/H-4184-2012	Conti, Luciano/0000-0002-2050-9846; CATTANEO, ELENA/0000-0002-0755-4917	TelethonFondazione Telethon [GGP02457] Funding Source: Medline		Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Armstrong RJE, 2002, EXP NEUROL, V175, P98, DOI 10.1006/exnr.2002.7889; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bachoud-Levi AC, 2000, EXP NEUROL, V161, P194, DOI 10.1006/exnr.1999.7239; Bain G, 1998, PERSPECT DEV NEUROBI, V5, P175; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Bartlett PF, 1998, IMMUNOL CELL BIOL, V76, P414, DOI 10.1046/j.1440-1711.1998.00762.x; Benoit BO, 2001, J NEUROBIOL, V46, P265, DOI 10.1002/1097-4695(200103)46:4<265::AID-NEU1007>3.3.CO;2-2; Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; BJORKLUND A, 2005, NOVART FDN SYMP, V265, P204; Bjorklund Anders, 2005, V265, P174; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Brustle O, 1999, BRAIN PATHOL, V9, P527; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Campos LS, 2004, J NEUROSCI RES, V78, P761, DOI 10.1002/jnr.20333; Carpenter MK, 1999, EXP NEUROL, V158, P265, DOI 10.1006/exnr.1999.7098; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Chambers I, 2004, ONCOGENE, V23, P7150, DOI 10.1038/sj.onc.1207930; Chu K, 2004, NEUROSCI RES, V50, P459, DOI 10.1016/j.neures.2004.08.015; Chu K, 2004, BRAIN RES, V1016, P145, DOI 10.1016/j.brainres.2004.04.038; Chung S, 2002, EUR J NEUROSCI, V16, P1829, DOI 10.1046/j.1460-9568.2002.02255.x; Conti L, 2005, PLOS BIOL, V3, P1594, DOI 10.1371/journal.pbio.0030283; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Dunnett SB, 1997, BRAIN RES PROTOC, V1, P91, DOI 10.1016/S1385-299X(96)00015-3; Dziewczapolski G, 2003, EXP NEUROL, V183, P653, DOI 10.1016/S0014-4886(03)00212-7; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; Gomes WA, 2003, DEV BIOL, V255, P164, DOI 10.1016/S0012-1606(02)00037-4; Gorba T, 2003, PHARMACOL RES, V47, P269, DOI 10.1016/S1043-6618(03)00036-7; Gotz M, 2002, BRAIN RES BULL, V57, P777, DOI 10.1016/S0361-9230(01)00777-8; Gritti A, 2002, J NEUROSCI, V22, P437, DOI 10.1523/JNEUROSCI.22-02-00437.2002; Gritti A, 1999, J NEUROSCI, V19, P3287; Halfpenny CA, 2003, J NEUROIMMUNOL, V139, P9, DOI 10.1016/S0165-5728(03)00125-5; Harper JM, 2004, P NATL ACAD SCI USA, V101, P7123, DOI 10.1073/pnas.0401103101; Hartfuss E, 2001, DEV BIOL, V229, P15, DOI 10.1006/dbio.2000.9962; Hauser RA, 2002, NEUROLOGY, V58, P687, DOI 10.1212/WNL.58.5.687; Hsieh J, 2004, J CELL BIOL, V164, P111, DOI 10.1083/jcb.200308101; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kelly CM, 2003, CELL TRANSPLANT, V12, P215, DOI 10.3727/000000003108746777; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kim SU, 2004, NEUROPATHOLOGY, V24, P159, DOI 10.1111/j.1440-1789.2004.00552.x; Kitajima H, 2005, J NEUROSCI RES, V80, P467, DOI 10.1002/jnr.20469; Kriegstein AR, 2003, GLIA, V43, P37, DOI 10.1002/glia.10250; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee JB, 2003, NEUROPATHOLOGY, V23, P169, DOI 10.1046/j.1440-1789.2003.00496.x; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lee ST, 2006, J NEUROSCI METH, V152, P250, DOI 10.1016/j.jneumeth.2005.09.013; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Lie DC, 2002, J NEUROSCI, V22, P6639; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lindvall Olle, 2004, NeuroRx, V1, P382; Liour SS, 2003, GLIA, V42, P109, DOI 10.1002/glia.10202; Louis Sharon A, 2005, Methods Mol Biol, V290, P265; Lowit Alison, 2005, BMC Fam Pract, V6, P38, DOI 10.1186/1471-2296-6-38; Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8; McBride JL, 2004, J COMP NEUROL, V475, P211, DOI 10.1002/cne.20176; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Mezey E, 2000, EUR J PHARMACOL, V405, P297, DOI 10.1016/S0014-2999(00)00561-6; Mezey E, 2003, SCIENCE, V299; Morshead CM, 2004, DEV NEUROSCI-BASEL, V26, P93, DOI 10.1159/000082130; Morshead CM, 2002, NAT MED, V8, P268, DOI 10.1038/nm0302-268; Muller FJ, 2006, NAT REV NEUROSCI, V7, P75, DOI 10.1038/nrn1829; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Ostenfeld T, 2002, J NEUROSCI RES, V69, P955, DOI 10.1002/jnr.10396; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pera MF, 2004, DEVELOPMENT, V131, P5515, DOI 10.1242/dev.01451; Peschanski M., 2001, Journal de la Societe de Biologie, V195, P51; Pluchino S, 2005, BRAIN RES REV, V48, P211, DOI 10.1016/j.brainresrev.2004.12.011; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Richardson RM, 2004, J NEUROSURG, V100, P659, DOI 10.3171/jns.2004.100.4.0659; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; Sanchez-Pernaute R, 2001, J NEUROSCI RES, V65, P284, DOI 10.1002/jnr.1152; Schmandt T, 2005, STEM CELLS DEV, V14, P55, DOI 10.1089/scd.2005.14.55; Schuurmans C, 2002, CURR OPIN NEUROBIOL, V12, P26, DOI 10.1016/S0959-4388(02)00286-6; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; SCOLDING NJ, 1995, NEUROREPORT, V6, P441, DOI 10.1097/00001756-199502000-00009; Shetty AK, 1998, J NEUROBIOL, V35, P395, DOI 10.1002/(SICI)1097-4695(19980615)35:4<395::AID-NEU7>3.0.CO;2-U; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Sun PZ, 2003, J MAGN RESON, V161, P168, DOI 10.1016/S1090-7807(02)00199-4; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Wernig M, 2002, J NEUROSCI RES, V69, P918, DOI 10.1002/jnr.10395; Whittemore SR, 1999, EXP CELL RES, V252, P75, DOI 10.1006/excr.1999.4621; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Xu Y, 2003, J NEUROSCI RES, V74, P533, DOI 10.1002/jnr.10769; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Ying QL, 2003, METHOD ENZYMOL, V365, P327; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zeng XM, 2004, STEM CELLS, V22, P925, DOI 10.1634/stemcells.22-6-925; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zhou FC, 2000, EXP NEUROL, V164, P200, DOI 10.1006/exnr.2000.7425	119	46	58	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	APR	2006	16	2					143	154		10.1111/j.1750-3639.2006.00009.x			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	051ET	WOS:000238144600007	16768755				2021-06-18	
J	Dou, ZL; Man, DWK; Ou, HN; Zheng, JL; Tam, SF				Dou, ZL; Man, DWK; Ou, HN; Zheng, JL; Tam, SF			Computerized errorless learning-based memory rehabilitation for Chinese patients with brain injury: A preliminary quasi-experimental clinical design study	BRAIN INJURY			English	Article						brain injury; rahabilitation; memory; errorless learning; computer training	SEVERE HEAD-INJURY	Aim: To evaluate the effectiveness of a computerized, errorless learning-based memory rehabilitation program for Chinese patients with traumatic brain injury (TBI). Methods: This study adopted a pre- and post-test quasi-experimental design. A total of 37 patients with TBI were randomly assigned to a Computer-Assisted Memory Training Group (CAMG), a Therapist-administered Memory Training Group (TAMG) and a Control Group (CG). Except for the CG, the patients in both the CAMG and TAMG groups received, respectively, 1-month memory training programmes that were similar in content but differed in delivery mode. All patients were followed up 1 month after treatment. The outcome measures that were taken were the Neurobehavioural Cognitive Status Examination (NCSE or Cognistat), the Rivermead Behavioural Memory Test (RBMT) and The Hong Kong List Learning Test (HKLLT). Repeated measure analyses were performed to investigate differences among the three groups. Results: The patients in the Computer-assisted Memory Rehabilitation ( CAMG) and Therapist-administered Memory Rehabilitation group ( TAMG) were found to perform better than the CG in the NCSE and RBMT, but no significant differences were found between the CAMG and TAMG. The CAMG showed significant improvement in their HKLLT assessment as compared with the TAMG and CG. No statistically significant differences were found between the CAMG and TAMG when comparing the post-training outcome measures with the follow-up results. Conclusion: There is no difference between CAMG and TAMG, but the efficacy has been demonstrated when comparing with CG. It is suggested that the combined use of an errorless learning and a computerized approach may be an effective way of enhancing the memories of patients with TBI. This new method may smooth the progress of the whole human memory process and produce a better carryover treatment effect.	Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China; Sun Yat Sen Univ, Dept Rehabil Med, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China	Man, DWK (corresponding author), Hong Kong Polytech Univ, Dept Rehabil Sci, Kowloon, Hong Kong, Peoples R China.	rsdavid@polyu.edu.hk					BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Chan AS, 2003, PSYCHOL ASSESSMENT, V15, P257, DOI 10.1037/1040-3590.15.3.257; CHAN AS, 1999, MANUAL PRELIMINARY N; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; CONNOR BB, 2002, DISS ABSTR INT B, V62, P4767; Delis DC, 1987, CALIFORNIA VERBAL LE; DEVANY SC, 1994, NEUROREHABILITATION, V4, P53; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dou ZL, 2004, INT J REHABIL RES, V27, P81, DOI 10.1097/00004356-200403000-00013; DOU ZL, 2003, BRAIN INJURY S1, V17, P169; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; GLISKY EL, 1990, HDB MEMORY DISORDERS, P557; Hunkin NM, 1998, NEUROPSYCHOLOGIA, V36, P25, DOI 10.1016/S0028-3932(97)00106-1; Hunkin NM, 1998, NEUROPSYCHOL REHABIL, V8, P433, DOI 10.1080/713755581; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; KOSSLYN SM, 1995, NEUROPSYCHOLOGIA, V33, P1335, DOI 10.1016/0028-3932(95)00067-D; MILLER L, 1992, J COGNITIVE REHABILI, V10, P14; *NEUROREHABILITATI, 1996, HONG KONG J OCCUP TH, V9, P18; *NO CAL NEUR GROUP, 1995, COGN NEUR COGN STAT; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rodriguez-Fornells A, 2004, COGNITIVE BRAIN RES, V19, P160, DOI 10.1016/j.cogbrainres.2003.11.009; SARGEANT R, 2000, J COGNIT REHABIL, V18, P20; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; SUNDERLAND A, 1986, J GERONTOL, V41, P376, DOI 10.1093/geronj/41.3.376; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; TAM SF, 2003, CHINESE J PHYS MED R, V25, P572; Tsukiura T, 2000, BRAIN COGNITION, V44, P98; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; WANG ZC, 2001, CHINESE J NEUROSURGE, V17, P122; WILSON B, 1989, MODELS BRAIN INJURY, P117; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006; ZHU G, 1994, ACTA 3 MILITARY U, V16, P137; 窦祖林, 2003, [中华物理医学与康复杂志, Chinese Journal of Physical Medicine and Rehabilitation], V25, P568	37	46	50	1	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2006	20	3					219	225		10.1080/02699050500488215			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400001	16537263				2021-06-18	
J	Ruitenberg, MJ; Vukovic, J; Sarich, J; Busfield, SJ; Plant, GW				Ruitenberg, MJ; Vukovic, J; Sarich, J; Busfield, SJ; Plant, GW			Olfactory ensheathing cells: Characteristics, genetic engineering, and therapeutic potential	JOURNAL OF NEUROTRAUMA			English	Article						gene therapy; neurotrophic factors; olfactory ensheathing glia; regeneration; spinal cord	PROMOTE AXONAL REGENERATION; SPINAL-CORD; SCHWANN-CELLS; IN-VIVO; DELAYED TRANSPLANTATION; FUNCTIONAL RECOVERY; CORTICOSPINAL TRACT; LOCOMOTOR RECOVERY; NGF-RECEPTOR; RAT	Injured neurons in the mammalian central nervous system (CNS) do not normally regenerate their axons after injury. Neurotrauma to the CNS usually results in axonal damage and subsequent loss of communication between neuronal networks, causing long-term functional deficits. For CNS regeneration, repair strategies need to be developed that promote regrowth of lesioned axon projections and restoration of neuronal connectivity. After spinal cord injury (SCI), cystic cavitations are often found, particularly in the later stages, due to the loss of neural tissue at the original impact site. Ultimately, for the promotion of axonal regrowth in these situations, some form of transplantation will be required to provide lesioned axons with a supportive substrate along which they can extend. Here, we review the use of olfactory ensheathing cells: their location and role in the olfactory system, their use as cellular transplants in SCI paradigms, alone or in combination with gene therapy, and the unique properties of these cells that may give them a potential advantage over other cellular transplants.	Univ Western Australia, Sch Anat & Human Biol, Reds Spinal Cord Res Lab, Perth, WA 6009, Australia; Univ Western Australia, Western Australian Med Res, Perth, WA 6009, Australia; Univ Western Australia, UWA Ctr Med Res, Perth, WA 6009, Australia	Plant, GW (corresponding author), Univ Western Australia, Sch Anat & Human Biol, Reds Spinal Cord Res Lab, Mail Bag Delivery Point M309,35 Stirling Highway, Perth, WA 6009, Australia.	gplant@anhb.uwa.edu.au	Vukovic, Jana/B-4845-2013	Vukovic, Jana/0000-0002-3739-1688; Ruitenberg, Marc/0000-0002-6917-0708			Andrews MR, 2004, EXP NEUROL, V190, P311, DOI 10.1016/j.expneurol.2004.08.011; Au E, 2003, GLIA, V41, P224, DOI 10.1002/glia.10160; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; Barnett SC, 2004, J NEUROTRAUM, V21, P375, DOI 10.1089/089771504323004520; Barnett Susan C, 2002, Methods Mol Biol, V198, P41; Bianco JI, 2004, GLIA, V45, P111, DOI 10.1002/glia.10298; Blesch A, 2001, GENE THER, V8, P954, DOI 10.1038/sj.gt.3301480; Blits B, 2004, EXP NEUROL, V189, P303, DOI 10.1016/j.expneurol.2004.05.014; Blits P, 2000, EXP NEUROL, V164, P25, DOI 10.1006/exnr.2000.7413; Boruch AV, 2001, GLIA, V33, P225, DOI 10.1002/1098-1136(200103)33:3<225::AID-GLIA1021>3.3.CO;2-P; Boyd JG, 2004, P NATL ACAD SCI USA, V101, P2162, DOI 10.1073/pnas.0303842101; Bunge MB, 2003, J REHABIL RES DEV, V40, P55, DOI 10.1682/JRRD.2003.08.0055; BUNGE RP, 1993, ADV NEUROL, V59, P75; Cao L, 2004, BRAIN, V127, P535, DOI 10.1093/brain/awh072; CARR VM, 1993, EXP NEUROL, V124, P308, DOI 10.1006/exnr.1993.1201; CHUAH MI, 1991, J NEUROSCI RES, V29, P172, DOI 10.1002/jnr.490290206; Chuah MI, 2004, EXP NEUROL, V185, P15, DOI 10.1016/j.expneurol.2003.09.008; Chuah MI, 2002, MICROSC RES TECHNIQ, V58, P216, DOI 10.1002/jemt.10151; DEVON R, 1992, BRAIN RES, V589, P175; DOUCETTE R, 1989, J COMP NEUROL, V285, P514, DOI 10.1002/cne.902850407; DOUCETTE R, 1991, J COMP NEUROL, V312, P451, DOI 10.1002/cne.903120311; DOUCETTE R, 1990, GLIA, V3, P433, DOI 10.1002/glia.440030602; Dunning MD, 2004, J NEUROSCI, V24, P9799, DOI 10.1523/JNEUROSCI.3126-04.2004; Field PM, 2003, J NEUROCYTOL, V32, P317, DOI 10.1023/B:NEUR.0000010089.37032.48; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; Franceschini IA, 1996, DEV BIOL, V173, P327, DOI 10.1006/dbio.1996.0027; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; Garcia-Alias G, 2004, J NEUROSCI RES, V75, P632, DOI 10.1002/jnr.20029; Gomez VM, 2003, J NEUROCYTOL, V32, P53, DOI 10.1023/A:1027328331832; GONG QZ, 1994, J COMP NEUROL, V344, P336, DOI 10.1002/cne.903440303; GOODMAN MN, 1993, BRAIN RES, V619, P199; Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451; Iwashita Y, 2000, NEUROREPORT, V11, P1013, DOI 10.1097/00001756-200004070-00023; Kafitz KW, 1998, ANN NY ACAD SCI, V855, P266, DOI 10.1111/j.1749-6632.1998.tb10580.x; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Keyvan-Fouladi N, 2003, J NEUROSCI, V23, P9428; Lakatos A, 2000, GLIA, V32, P214, DOI 10.1002/1098-1136(200012)32:3<214::AID-GLIA20>3.0.CO;2-7; Lakatos A, 2003, EXP NEUROL, V184, P237, DOI 10.1016/S0014-4886(03)00270-X; Lee IH, 2004, EXP NEUROL, V187, P509, DOI 10.1016/j.expneurol.2004.02.007; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Li Y, 2004, EXP NEUROL, V188, P300, DOI 10.1016/j.expneurol.2004.04.021; Li Y, 2003, J NEUROSCI, V23, P727; Li Y, 1998, J NEUROSCI, V18, P10514; Liebl DJ, 2001, EXP NEUROL, V167, P15, DOI 10.1006/exnr.2000.7548; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Menei P, 1998, EUR J NEUROSCI, V10, P607, DOI 10.1046/j.1460-9568.1998.00071.x; Myckatyn TM, 2004, TRANSPL IMMUNOL, V12, P343, DOI 10.1016/j.trim.2003.12.017; Nash HH, 2002, J NEUROSCI, V22, P7111; Navarro X, 1999, ANN NEUROL, V45, P207, DOI 10.1002/1531-8249(199902)45:2<207::AID-ANA11>3.0.CO;2-K; Plant GW, 2003, J NEUROTRAUM, V20, P1, DOI 10.1089/08977150360517146; Plant GW, 2002, J NEUROSCI, V22, P6083; Plant GW, 2001, MOL CELL NEUROSCI, V17, P471, DOI 10.1006/mcne.2000.0948; PLANT GW, 2001, NEUROL DIS, V52, P529; Polentes J, 2004, NEUROBIOL DIS, V16, P638, DOI 10.1016/j.nbd.2004.04.009; Ramer LM, 2004, GLIA, V47, P189, DOI 10.1002/glia.20054; Ramer LM, 2004, J COMP NEUROL, V473, P1, DOI 10.1002/cne.20049; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Ramon-Cueto A, 1998, BRAIN RES BULL, V46, P175, DOI 10.1016/S0361-9230(97)00463-2; RAMONCUETO A, 1993, EUR J NEUROSCI, V5, P1172, DOI 10.1111/j.1460-9568.1993.tb00971.x; RAMONCUETO A, 1994, EXP NEUROL, V127, P232, DOI 10.1006/exnr.1994.1099; Reier Paul J, 2004, NeuroRx, V1, P424, DOI 10.1007/BF03206629; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; Riddell JS, 2004, GLIA, V47, P150, DOI 10.1002/glia.20041; Ruitenberg MJ, 2005, BRAIN, V128, P839, DOI 10.1093/brain/awh424; Ruitenberg MJ, 2003, J NEUROSCI, V23, P7045, DOI 10.1523/JNEUROSCI.23-18-07045.2003; Ruitenberg MJ, 2002, GENE THER, V9, P135, DOI 10.1038/sj.gt.3301626; Sasaki M, 2004, J NEUROSCI, V24, P8485, DOI 10.1523/JNEUROSCI.1998-04.2004; Schwob James E., 2002, Anatomical Record, V269, P33, DOI 10.1002/ar.10047; Takami T, 2002, J NEUROSCI, V22, P6670; Treloar HB, 1996, J NEUROBIOL, V31, P41, DOI 10.1002/(SICI)1097-4695(199609)31:1<41::AID-NEU4>3.0.CO;2-F; TURNQUIST PK, 1994, AGR ENG, V75, P12; VALVERDE F, 1993, DEV BRAIN RES, V71, P209, DOI 10.1016/0165-3806(93)90173-8; Verdu E, 2003, GLIA, V42, P275, DOI 10.1002/glia.10217; Verdu E, 2001, NEUROREPORT, V12, P2303, DOI 10.1097/00001756-200108080-00005; Weiler E, 1997, J NEUROSCI, V17, P3610; Williams SK, 2004, J COMP NEUROL, V470, P50, DOI 10.1002/cne.11045; Woodhall E, 2003, CELL MOL LIFE SCI, V60, P2241, DOI 10.1007/s00018-003-3265-7; Woodhall E, 2001, MOL BRAIN RES, V88, P203, DOI 10.1016/S0169-328X(01)00044-4; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309	81	46	57	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR-APR	2006	23	3-4					468	478		10.1089/neu.2006.23.468			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	039WF	WOS:000237337700018	16629630				2021-06-18	
J	Williams, GP; Greenwood, KM; Robertson, VJ; Goldie, PA; Morris, ME				Williams, GP; Greenwood, KM; Robertson, VJ; Goldie, PA; Morris, ME			High-level mobility assessment tool (HiMAT): Interrater reliability, retest reliability, and internal consistency	PHYSICAL THERAPY			English	Article						brain injuries; neurologic gait disorders; outcome assessment; reliability	TRAUMATIC BRAIN-INJURY; REHABILITATION; VALIDITY	Background and Purpose. The High-Level Mobility Assessment Tool (HiMAT) assesses high-level mobility in people who have sustained a traumatic brain injury (TBI). The purpose of this study was to investigate the interrater reliability, retest reliability, and internal consistency of data obtained with the HiMAT. Subjects. Three physical therapists and 103 people with TBI were recruited from a rehabilitation hospital. Methods. Three physical therapists concurrently assessed a subset of 17 subjects with TBI to investigate interrater reliability. One physical therapist assessed a different subset of 20 subjects with TBI on 2 occasions, 2 days apart, to investigate retest reliability. Data from the entire sample of 103 subjects were used to investigate the internal consistency of this new scale. Results. Both the interrater reliability (intraclass correlation coefficient [ICC]=.99) and the retest reliability (ICC=.99) of the HiMAT data were very high. For retest reliability, a small systematic change was detected (t=3.82, df=19), indicating a marginal improvement of 1 point at retest. Internal consistency also was very high (Cronbach alpha=.97). Discussion and Conclusion. The HiMAT is a new tool specifically designed to measure high-level mobility, which currently is not a component of existing scales used in TBI. This study demonstrated that the HiMAT is a reliable tool for measuring high-level mobility.	Epworth Med Fdn, Physiotherapy Dept, Melbourne, Vic 3121, Australia; Univ Canberra, Sch Hlth Sci, Belconnen, ACT 2616, Australia; Univ Newcastle, Newcastle, NSW 2308, Australia; La Trobe Univ, Sch Physiotherapy, Bundoora, Vic, Australia; Univ Melbourne, Sch Physiotherapy, Parkville, Vic 3052, Australia	Williams, GP (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Melbourne, Vic 3121, Australia.	gavinw@epworth.org.au	Greenwood, Kenneth M/J-8993-2015	Greenwood, Kenneth M/0000-0002-8420-6588; Williams, Gavin/0000-0003-2758-7473; Morris, Meg/0000-0002-0114-4175			Beaton DE, 2001, J CLIN EPIDEMIOL, V54, P1204, DOI 10.1016/S0895-4356(01)00407-3; BLOOM M, 1995, EVALUATING PRACTICE; Fitzpatrick R, 1998, Health Technol Assess, V2, P1; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Jackson A., 1991, MEASUREMENT EVALUATI; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, pS3; MENDENHALL W, 1977, STAT PSYCHOL; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; ROTHSTEIN JM, 1985, MEASUREMENT PHYSICAL, P1; Stratford P., 1999, PHYSIOTHER CAN, V2, P107; Streiner D., 1995, HLTH MEASUREMENT SCA, V2; Williams G, 2005, BRAIN INJURY, V19, P925, DOI 10.1080/02699050500058687; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; Williams G, 2001, BRAIN INJURY, V15, P831; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711	15	46	46	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	MAR	2006	86	3					395	400		10.1093/ptj/86.3.395			6	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	022DV	WOS:000236035800008	16506875	Bronze			2021-06-18	
J	Teasdale, TW; Engberg, AW				Teasdale, TW; Engberg, AW			Subjective well-being and quality of life following traumatic brain injury in adults: A long-term population-based follow-up	BRAIN INJURY			English	Article						quality of life; follow-up; traumatic brain injury	CLOSE RELATIVES; INDIVIDUALS; EXPERIENCE; SCALE; REHABILITATION; QUESTIONNAIRE; DISABILITY; SYMPTOMS; SEQUELAE; DENMARK	Primary objective: To assess subjective well-being and quality-of-life in nationally representative samples of patients at long intervals following traumatic brain injuries. Methods and procedures: Patients with either cranial fractures or cerebral lesions were identified in a national computer-based register of hospital admissions and random samples were selected among those who had suffered the injury at 5, 10 or 15 years prior to the follow-up. Postal questionnaires were sent to them covering quality of life, e. g. return to employment, family relations and current subjective well-being in terms of symptomatology, e. g. somatic complaints, cognitive dysfunction. A response rate of 76% was obtained, comprising 114 patients with cranial fracture and 126 with cerebral lesions. Main outcomes and results: The group with cerebral lesions had markedly poorer quality of life and subjective well-being than the group with cranial fractures and this did not vary across time. In both groups, the most common symptoms concerned cognition. Among the cerebral lesion group, quality of life outcome was fairly well predicted by severity of injury, but subjective well-being was less well predicted. Conclusions: The negative consequences of traumatic cerebral lesions are marked and do not vary at long periods following injury.	Univ Copenhagen, Dept Psychol, DK-2300 Copenhagen, Denmark; Copenhagen Univ Hosp, Div Neurol Rehabil, Hvidovre, Denmark	Teasdale, TW (corresponding author), Univ Copenhagen, Dept Psychol, Njalsgade 88, DK-2300 Copenhagen, Denmark.	tom.teasdale@psy.ku.dk					Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersen TF, 1999, DAN MED BULL, V46, P263; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Caetano R, 2003, ADDICTION, V98, P791, DOI 10.1046/j.1360-0443.2003.00407.x; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hoofien D, 2001, BRAIN INJURY, V15, P189; Howell D. C., 2002, STAT METHODS PSYCHOL; JENNETT B, 1975, LANCET, V1, P480; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kotaniemi JT, 2001, EUR J EPIDEMIOL, V17, P809, DOI 10.1023/A:1015615130459; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Svendsen HA, 2004, NEUROPSYCHOL REHABIL, V14, P495, DOI 10.1080/09602010343000318; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089	33	46	47	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2005	19	12					1041	1048		10.1080/02699050500110397			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZA	WOS:000233269700011	16263647				2021-06-18	
J	Wade, SL; Wolfe, CR; Brown, TM; Pestian, JP				Wade, SL; Wolfe, CR; Brown, TM; Pestian, JP			Can a web-based family problem-solving intervention work for children with traumatic brain injury?	REHABILITATION PSYCHOLOGY			English	Article						brain injury; telehealth; adaptation; problem solving	SHORT-TERM; ADOLESCENTS; PREDICTORS; BEHAVIOR; RELIABILITY; DISORDERS; OUTCOMES; EPILEPSY; BURDEN; HOME	Objective: To examine the feasibility and efficacy of a Web-based intervention for children with traumatic brain injury (TBI). Participants: 6 families comprising 8 parents, 5 siblings, and 6 children with TBI (mean age = 10.5 years). Intervention: Families received computers, Web cameras, and Internet access. Participants completed 7-11 online sessions and accompanying weekly videoconferences with the therapist. Main Outcome Measures: Outcomes included child behavior problems, social competence, executive function skills, and parent-child conflict. Results: Children with TBI rated Web site content as very to extremely helpful and reported high overall satisfaction. There was a trend for children with TBI to rate the videoconferences as less helpful than did other family members and relative to a face-to-face visit. Parents reported improvements in antisocial behaviors, and children with TBI reported reductions in conflict with parents regarding school. Conclusions: Web-based interventions hold promise for improving child outcomes following pediatric TBI.	Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA; Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA; Med Coll Wisconsin, Dept Psychol, Milwaukee, WI 53226 USA; Childrens Hosp, Med Ctr, Dept Biomed Informat, Cincinnati, OH 45229 USA	Wade, SL (corresponding author), Childrens Hosp, Med Ctr, Dept Phys Med & Rehabil, MLC 4009,3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org					Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROWN T, 2000, P AUSTR US INT C AUI, V1, P11; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Foster SL., 1989, NEGOTIATING PARENT A; Gega L, 2004, J CLIN PSYCHOL, V60, P147, DOI 10.1002/jclp.10241; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; Greist JH, 1998, PSYCHIAT SERV, V49, P887, DOI 10.1176/ps.49.7.887; Hewson CM, 1996, BEHAV RES METH INSTR, V28, P186, DOI 10.3758/BF03204763; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Joinson AN, 1998, PSYCHOL INTERNET INT, P43; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Marks I, 1998, CLIN PSYCHOL-SCI PR, V5, P151, DOI 10.1111/j.1468-2850.1998.tb00141.x; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Ritterband LM, 2003, J CONSULT CLIN PSYCH, V71, P910, DOI 10.1037/0022-006X.71.5.910; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Robin A.L., 1990, PSYCHOL ASSESSMENT J, V2, P451, DOI [10.1037/1040-3590.2.4.451, DOI 10.1037/1040-3590.2.4.451]; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SINGER GHS, 1994, J HEAD TRAUMA REHAB, V9, P38, DOI DOI 10.1097/00001199-199412000-00006; Sitarenios G., 1999, USE PSYCHOL TESTING, P267; Sturges JW, 1998, PROF PSYCHOL-RES PR, V29, P183, DOI 10.1037/0735-7028.29.2.183; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WADE SL, IN PRESS NEURODEVELO; WADE SL, IN PRESS J HEAD TRAU; WOLFE CR, 2001, LEARNING TEACHING WO; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Ylvisaker M., 1998, COLLABORATIVE BRAIN	42	46	46	0	10	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2005	50	4					337	345		10.1037/0090-5550.50.4.337			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	990KL	WOS:000233741700003					2021-06-18	
J	Qu, CS; Lu, DY; Goussev, A; Schallert, T; Mahmood, A; Chopp, M				Qu, CS; Lu, DY; Goussev, A; Schallert, T; Mahmood, A; Chopp, M			Effects of atorvastatin on spatial memory, neuronal survival, and vascular density in female rats after traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						neuroplasticity; spatial memory; traumatic brain injury; atorvastatin; rat	CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; MARROW STROMAL CELLS; INTRACEREBRAL HEMORRHAGE; TRANSPLANTATION; SYNAPTOGENESIS; NEUROGENESIS; ANGIOGENESIS; ACQUISITION; IMPROVEMENT	Object. Atorvastatin administered after traumatic brain injury (TBI) induced by controlled cortical impact promotes functional improvement in male rats. Note, however, that parallel studies have not been performed in female rats. Therefore, the authors tested the effect of atorvastatin on TBI in female rats. Methods. Atorvastatin (I mg/kg/day) was orally administered for 7 consecutive days in female Wistar rats starting I day after TBI; control animals received saline. Modified neurological severity scores, the corner turn test, and the Morris water maze test were used to evaluate functional response to treatment. Rats were killed on Day 15 post-TBI, and brain tissue samples were processed for immunohistochemical staining. Atorvastatin administration after brain injury significantly promoted the restoration of spatial memory but did not reduce sensorimotor functional deficits. Treatment of TBI with atorvastatin increased neuronal survival in the CA3 region and the lesion boundary zone and prevented the loss of neuronal processes of damaged neurons in the hippocampal CA3 region but not in the lesion boundary zone on Day 15 after TBI. The protective effect of atorvastatin on the injured neurons perhaps is mediated by increasing the density of vessels in the lesion boundary zone and the hippocampus after TBI. Conclusions. These data indicate that atorvastatin is beneficial in the treatment of TBI in female rats, although the effect may differ between sexes.	Henry Ford Hosp, Dept Neurol, Hlth Sci Ctr, Detroit, MI 48202 USA; Henry Ford Hosp, Dept Neurosurg, Hlth Sci Ctr, Detroit, MI 48202 USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA; Univ Texas, Dept Psychol, Austin, TX 78712 USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, Hlth Sci Ctr, K-11,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 40225] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline		Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Hua Y, 2002, STROKE, V33, P2478, DOI 10.1161/01.STR.0000032302.91894.0F; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mercuro G, 2002, AM J CARDIOL, V90, P747, DOI 10.1016/S0002-9149(02)02602-4; REH T, 1982, J COMP NEUROL, V211, P276, DOI 10.1002/cne.902110306; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; Yamada K, 1999, BRIT J PHARMACOL, V126, P235, DOI 10.1038/sj.bjp.0702309; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	28	46	47	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2005	103	4					695	701		10.3171/jns.2005.103.4.0695			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	971LG	WOS:000232385000017	16266052				2021-06-18	
J	Gupta, RK; Saksena, S; Agarwal, A; Hasan, KM; Husain, M; Gupta, V; Narayana, PA				Gupta, RK; Saksena, S; Agarwal, A; Hasan, KM; Husain, M; Gupta, V; Narayana, PA			Diffusion tensor imaging in late posttraumatic epilepsy	EPILEPSIA			English	Article						diffusion tensor imaging; traumatic brain injury; posttraumatic epilepsy; fractional anisotropy; magnetic resonance imaging	TRAUMATIC BRAIN-INJURY; VOXEL-BASED MORPHOMETRY; WATER DIFFUSION; AXONAL INJURY; WHITE-MATTER; HEAD-INJURY; SPIN-ECHO; FRACTIONAL ANISOTROPY; MULTIPLE-SCLEROSIS; CEREBRAL-ISCHEMIA	Purpose: The main objective of this study was to use diffusion tensor imaging (DTI) to search and quantify the extent of abnormality beyond the obvious lesions seen on the T-2 and fluid-attenuation inversion recovery (FLAIR) magnetic resonance images in patients with chronic traumatic brain injury (TBI) with and without epilepsy. Methods: DTI was performed on 23 chronic TBI patients (with late posttraumatic epilepsy, n = 14; without epilepsy, n = 9) and 11 age-matched controls. The ratios of fractional anisotropy (FA) and mean diffusivity (MD) between the regions of interest beyond the T-2/FLAIR-visualized abnormality and the corresponding contralateral normal-appearing region were calculated. FA and MD ratios were compared for relative changes in these parameters among the TBI subjects with and without epilepsy and controls. Tissue volumes exhibiting abnormalities on DTI also were measured in these patients. Results: The mean regional FA ratio was significantly lower, whereas the mean regional MD value was higher in patients with TBI compared with controls. The mean regional FA ratio was significantly lower in TBI patients with epilepsy (0.57 +/- 0.059) than in those without epilepsy (0.68 +/- 0.039). Although the regional MD ratio was higher in TBI patients with epilepsy (1.15 +/- 0.140) relative to those without epilepsy (1.09 +/- 0.141), the difference did not reach statistical significance. The tissue volume with low FA value also was found to be higher in TBI patients with epilepsy than without. Conclusions: Severity of injury as predicted by the DTI-derived increased volume of microstructure damage is associated with delayed posttraumatic epilepsy in TBI patients. These findings could be valuable in predicting epileptogenesis in patients with chronic TBI.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, MR Sect, Lucknow 226014, Uttar Pradesh, India; King George Med Hosp, Dept Neurol, Lucknow, Uttar Pradesh, India; King George Med Hosp, Dept Neurosurg, Lucknow, Uttar Pradesh, India; Univ Texas, Sch Med, Dept Diagnost & Intervent Imaging, Houston, TX USA	Gupta, RK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, MR Sect, Lucknow 226014, Uttar Pradesh, India.	rakeshree@hotmail.com	Hasan, Khader M./ABB-5767-2020				Alsop DC, 2002, EPILEPSIA, V43, P69, DOI 10.1046/j.1528-1157.2002.043s1069.x; Arfanakis K, 2002, MAGN RESON IMAGING, V20, P511, DOI 10.1016/S0730-725X(02)00509-X; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Batchelor PG, 2003, MAGN RESON MED, V49, P1143, DOI 10.1002/mrm.10491; Bookstein FL, 2001, NEUROIMAGE, V14, P1454, DOI 10.1006/nimg.2001.0770; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; Davatzikos C, 2004, NEUROIMAGE, V23, P17, DOI 10.1016/j.neuroimage.2004.05.010; Droogan AG, 1999, MAGN RESON IMAGING, V17, P653, DOI 10.1016/S0730-725X(99)00011-9; DUNN LT, 1994, ANN ROY COLL SURG, V76, P147; Eriksson SH, 2001, BRAIN, V124, P617, DOI 10.1093/brain/124.3.617; HARDIMAN O, 1988, NEUROLOGY, V38, P1041, DOI 10.1212/WNL.38.7.1041; Hasan KM, 2003, MAGNET RESON MED, V50, P589, DOI 10.1002/mrm.10552; Hasan KM, 2004, MAGN RESON MED, V51, P413, DOI 10.1002/mrm.10682; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; JENNET WB, 2005, EPILEPSY AFTER NON M; Kazemi NJ, 1997, EPILEPSIA, V38, P670, DOI 10.1111/j.1528-1157.1997.tb01236.x; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kumar R, 2003, AM J NEURORADIOL, V24, P218; KURTZKE JF, 1987, CLIN NEUROLOGY, P1; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; Lim KO, 1999, ARCH GEN PSYCHIAT, V56, P367, DOI 10.1001/archpsyc.56.4.367; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lythgoe MF, 1997, MAGN RESON MED, V38, P662, DOI 10.1002/mrm.1910380421; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rugg-Gunn FJ, 2002, LANCET, V359, P1748, DOI 10.1016/S0140-6736(02)08615-4; Rugg-Gunn FJ, 2001, BRAIN, V124, P627, DOI 10.1093/brain/124.3.627; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; TIEN RD, 1994, AM J ROENTGENOL, V162, P671, DOI 10.2214/ajr.162.3.8109520; VANGELDEREN P, 1994, MAGNET RESON MED, V31, P154, DOI 10.1002/mrm.1910310209; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; Werring DJ, 1999, NEUROLOGY, V52, P1626, DOI 10.1212/WNL.52.8.1626; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Wieshmann UC, 1999, MAGN RESON IMAGING, V17, P29, DOI 10.1016/S0730-725X(98)00153-2; Wieshmann UC, 1999, MAGN RESON IMAGING, V17, P1269, DOI 10.1016/S0730-725X(99)00082-X; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Yoo SY, 2002, AM J NEURORADIOL, V23, P809	51	46	47	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	SEP	2005	46	9					1465	1471		10.1111/j.1528-1167.2005.01205.x			7	Clinical Neurology	Neurosciences & Neurology	959GV	WOS:000231507100014	16146442	Bronze			2021-06-18	
J	Schwartz, MF; Brecher, AR; Whyte, J; Klein, MG				Schwartz, MF; Brecher, AR; Whyte, J; Klein, MG			A patient registry for cognitive rehabilitation research: A strategy for balancing patients' privacy rights with researchers' need for access	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; cerebrovascular accident; cognition; registries; rehabilitation; research	INFORMED-CONSENT; PROTECTION; DATABASES; NETWORK; STATE	Objective: To describe a consent-based Patient Research Registry designed to improve the quality and efficiency of cognitive rehabilitation research by balancing patients' privacy rights with researchers' need for access to research participants. Design: Description of a protocol for a Patient Research Registry. Setting: Three rehabilitation hospitals. Participants: Inpatients with stroke or traumatic brain injury (TBI) at the 3 participating hospitals. Interventions: Not applicable. Main Outcome Measures: Percentages of eligible patients with stroke or TBI who consented to be enrolled in the Registry, were subsequently contacted about a study, and ultimately participated in a study. A survey examined satisfaction with the Registry among researchers who used it for recruitment. Results: After 36 months of operation, 58% of patients approached have consented to be in the Registry (N= 1256). Eighty-seven percent of those later identified as potential subjects for research studies expressed interest, and 63% eventually participated. Researchers reported satisfaction with the recruitment opportunities afforded by the Registry. Conclusions: The Registry succeeded in identifying eligible patients interested in participating in research studies, while safeguarding their privacy rights. We identify its strengths and limitations and characterize the type of facility that would most profit from adopting this recruitment model.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Schwartz, MF (corresponding author), Moss Rehabil Res Inst, Korman Bldg,Ste 213,1200 W Tabor Rd, Philadelphia, PA 19141 USA.	mschwart@einstein.edu		Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1-R24HD039621] Funding Source: Medline		ABRAMOVITZ R, 2003, EFFECTS HIPAA PRIV P; BLACKMER J, 2004, BMC MED ETHICS, V4, pE2; Clark AM, 2004, NEW ENGL J MED, V351, P612; Feeney DM, 2001, STROKE, V32, P2097; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gilkes CE, 2003, BRIT J NEUROSURG, V17, P426, DOI 10.1080/02688690310001611215; Goodglass H., 1983, ASSESSMENT APHASIA R; Heaton R., 1993, WISCONSIN CARD SORTI; Howard D., 1992, PYRAMIDS PALM TREES; Izquierdo JN, 2000, AM J PUBLIC HEALTH, V90, P695, DOI 10.2105/AJPH.90.5.695; Phipps E, 2004, AM J PHYS MED REHAB, V83, P875, DOI 10.1097/01.PHM.0000143436.57173.E1; Rabeneck L, 2001, J CLIN EPIDEMIOL, V54, P1195, DOI 10.1016/S0895-4356(01)00397-3; *SECR ADV COMM HUM, 2004, SUMM MIN; Stineman MG, 2001, ARCH PHYS MED REHAB, V82, pS9, DOI 10.1053/apmr.2001.31002; Tu JV, 2004, NEW ENGL J MED, V350, P1414, DOI 10.1056/NEJMsa031697; Walker-Batson D, 2001, STROKE, V32, P2093, DOI 10.1161/hs0901.095720; Wattigney WA, 2003, STROKE, V34, P151, DOI 10.1161/01.STR.0000048160.41821.B5; Wilson B., 1987, BEHAV INATTENTION TE; Wylie JE, 2003, TRENDS BIOTECHNOL, V21, P113, DOI 10.1016/S0167-7799(02)00039-2	19	46	46	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2005	86	9					1807	1814		10.1016/j.apmr.2005.03.009			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	962QM	WOS:000231747300016	16181947				2021-06-18	
J	Tilford, JM; Aitken, ME; Anand, KJS; Green, JW; Goodman, AC; Parker, JG; Killingsworth, JB; Fiser, DH; Adelson, PD				Tilford, John M.; Aitken, Mary E.; Anand, K. J. S.; Green, Jerril W.; Goodman, Allen C.; Parker, James G.; Killingsworth, Jeffrey B.; Fiser, Debra H.; Adelson, P. David			Hospitalizations for critically ill children with traumatic brain injuries: A longitudinal analysis	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; children; mortality; insurance; economic evaluation	UNITED-STATES; HEAD-INJURY; INTRACRANIAL-PRESSURE; CEREBRAL PERFUSION; MANAGEMENT; CARE; HEALTH; TRENDS; MORTALITY; OUTCOMES	Objective: This study examines the incidence, utilization of procedures, and outcomes for critically ill children hospitalized with traumatic brain injury over the period 1988-1999 to describe the benefits of improved treatment. Design: Retrospective analysis of hospital discharges was conducted using data from the Health Care Cost and Utilization Project Nationwide Inpatient Sample that approximates a 20% sample of U.S. acute care hospitals. Setting., Hospital inpatient stays from all types of U.S. community hospitals. Participants., The study sample included all children aged 0-21 with a primary or secondary ICD-9-CM diagnosis code for traumatic brain injury and a procedure code for either endotracheal intubation or mechanical ventilation. Interventions., None. Measurements and Main Results. Deaths occurring during hospitalization were used to calculate mortality rates. Use of intracranial pressure monitoring and surgical openings of the skull were investigated as markers for the aggressiveness of treatment. Patients were further classified by insurance status, household income, and hospital characteristics. Over the 12-yr study period, mortality rates decreased 8 percentage points whereas utilization of intracranial pressure monitoring increased by 11 percentage points. The trend toward more aggressive management of traumatic brain injury corresponded with improved hospital outcomes over time. Lack of insurance was associated with vastly worse outcomes. An estimated 6,437 children survived their traumatic brain injury hospitalization because of improved treatment, and 1,418 children died because of increased mortality risk associated with being uninsured. Improved treatment was valued at approximately $17 billion, whereas acute care hospitalization costs increased by $1.5 billion (in constant 2000 dollars). Increased mortality in uninsured children was associated with a $3.76 billion loss in economic benefits. Conclusions. More aggressive management of pediatric traumatic brain injury appears to have contributed to reduced mortality rates over time and saved thousands of lives. Additional lives could be saved it mortality rates could be equalized between insured and uninsured children.	Univ Arkansas Med Sci Hosp, Arkansas Childrens Hosp, Ctr Appl Res & Evaluat, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Coll Med, Dept Pediat, Little Rock, AR 72205 USA; Wayne State Univ, Dept Econ, Detroit, MI USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Tilford, JM (corresponding author), Univ Arkansas Med Sci Hosp, Arkansas Childrens Hosp, Ctr Appl Res & Evaluat, 800 Marshall St, Little Rock, AR 72202 USA.	tilfordmickj@uams.edu	Adelson, David/W-2083-2019; Anand, Kanwaljeet/B-3287-2014	Anand, Kanwaljeet/0000-0001-6498-1483			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; *AG HEALTHC RES QU, 2003, HEALTHC COST UT PROJ; *AG HEALTHC RES QU, 2004, CALC NAT INP SAMPL V; Agency for Healthcare Research and Quality, 2002, DES HCUP NAT INP SAM; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; BULLOCK R, 1995, GUIDELINES MANAGEMEN; Chang RKR, 2003, PEDIATRICS, V111, P1124, DOI 10.1542/peds.111.5.1124; Chang RKR, 2002, PEDIATRICS, V110, P292, DOI 10.1542/peds.110.2.292; *CTR INJ RES POL J, 1997, ICDMAP90 J HOPK U TR; Cutler DM, 2000, NBER FR HLTH POL RES, V3, P33, DOI 10.1162/109623100300091069; Cutler DM., 2004, YOUR MONEY YOUR LIFE; CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; David MCutler, 1999, MEASURING PRICES MED, P34; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Diesner F, 1997, NEUROSURG REV, V20, P274, DOI 10.1007/BF01105899; Durbin D R, 2001, Inj Prev, V7, P96, DOI 10.1136/ip.7.2.96; Durbin DR, 2000, AM J PUBLIC HEALTH, V90, P1782, DOI 10.2105/AJPH.90.11.1782; FESSLER RD, 1993, ANN EMERG MED, V22, P998, DOI 10.1016/S0196-0644(05)82741-6; Frank RG, 1999, HEALTH AFFAIR, V18, P71, DOI 10.1377/hlthaff.18.5.71; Friedman Bernard, 2002, J Health Care Finance, V29, P1; GADKARY CS, 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001048; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JB, 1996, NEUROTRAUMA; Greenspan A I, 1996, Curr Probl Pediatr, V26, P170, DOI 10.1016/S0045-9380(96)80004-1; Greenwald B M, 1995, Adv Pediatr, V42, P47; Hadley J, 2003, MED CARE RES REV, V60, p3S, DOI 10.1177/1077558703254101; Harper Rita G, 2002, J Perinatol, V22, P555, DOI 10.1038/sj.jp.7210789; Heidenreich PA, 2001, AM J MED, V110, P165, DOI 10.1016/S0002-9343(00)00712-9; Holman RC, 2003, PEDIATRICS, V111, P448, DOI 10.1542/peds.111.2.448; Institute of Medicine, 2003, HIDD COSTS VAL LOST; Kaiser Jeffrey R, 2004, J Perinatol, V24, P343, DOI 10.1038/sj.jp.7211113; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; KRAUS JF, 1996, NEUROTRAUMA, P13; LOPEZ AM, IN PRESS PEDIAT CRIT; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1990, J TRAUMA, V30, P681, DOI 10.1097/00005373-199006000-00005; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; TORNER J, 1998, TRAUMATIC BRAIN INJU, P9; Volpp KGM, 2003, HEALTH SERV RES, V38, P515, DOI 10.1111/1475-6773.00131; Westfall JM, 2001, MED CARE, V39, P459, DOI 10.1097/00005650-200105000-00006	51	46	48	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2005	33	9					2074	2081		10.1097/01.CCM.0000171839.65687.F5			8	Critical Care Medicine	General & Internal Medicine	042CG	WOS:000237504200026	16148483				2021-06-18	
J	van den Broek, MD				van den Broek, MD			Why does neurorehabilitation fail?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						goal setting; motivation; neurorehabilitation; outcome	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION	Following neurorehabilitation, many patients show limited benefit, generalization, or maintenance of gains over time. Some of the reasons that account for modest outcomes are discussed with particular reference to the differences between patients' needs and aspirations, the nature of patient-clinician interactions, and patients' rehabilitation readiness. The role of a more client-centered approach is reviewed, as well as the importance of facilitating patients' capacity to identify problems, develop goals, consider options, and make choices. It is proposed that effective outcomes depend on the clinicians' success in harnessing patients' intrinsic motivation to change.	Wolfson Neurorehabil Ctr, London SW20 0NE, England; Gen Hosp St Georg, Reg Neurosci Ctr, London SW20 0NE, England	van den Broek, MD (corresponding author), Wolfson Neurorehabil Ctr, Copse Hill, London SW20 0NE, England.	martin.vandenbroek@stgeorges.nhs.uk					Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; D'Zurilla T. J., 1999, PROBLEM SOLVING THER; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Ingersoll KS, 2000, MOTIVATIONAL GROUPS; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; Miller W.R., 1999, MOTIVATIONAL ENHANCE; Miller W. R., 2002, MOTIVATIONAL INTERVI; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Rollnick S, 2000, HLTH BEHAV CHANGE GU; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199604000-00007; SOHLBERG MM, 1994, MANUAL TEACHING PATI; VANDENBROEK MD, 2002, HEAD INJURY ED GROUP	15	46	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					464	473		10.1097/00001199-200509000-00007			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600008	16170254				2021-06-18	
J	Soeda, A; Nakashima, T; Okumura, A; Kuwata, K; Shinoda, J; Iwama, T				Soeda, A; Nakashima, T; Okumura, A; Kuwata, K; Shinoda, J; Iwama, T			Cognitive impairment after traumatic brain injury: a functional magnetic resonance imaging study using the Stroop task	NEURORADIOLOGY			English	Article						cognitive function; functional MRI; brain injury; Stroop task	POSITRON-EMISSION-TOMOGRAPHY; ANTERIOR CINGULATE CORTEX; CLOSED HEAD-INJURY; WORKING-MEMORY; COUNTING STROOP; INTERFERENCE TASK; PREFRONTAL CORTEX; MRI; ATTENTION; FMRI	The anterior cingulate cortex (ACC) plays a key role in cognition, motor function, and emotion processing. However, little is known about how traumatic brain injury (TBI) affects the ACC system. Our purpose was to compare, by functional magnetic resonance imaging (fMRI) studies, the patterns of cortical activation in patients with cognitive impairment after TBI and those of normal subjects. Cortical activation maps of 11 right-handed healthy control subjects and five TBI patients with cognitive impairment were recorded in response to a Stroop task during a block-designed fMRI experiment. Statistical parametric mapping (SPM99) was used for individual subjects and group analysis. In TBI patients and controls, cortical activation, found in similar regions of the frontal, occipital, and parietal lobes, resembled patterns of activation documented in previous neuroimaging studies of the Stroop task in healthy controls. However, the TBI patients showed a relative decrease in ACC activity compared with the controls. Cognitive impairment in TBI patients seems to be associated with alterations in functional cerebral activity, especially less activation of the ACC. These changes are probably the result of destruction of neural networks after diffuse axonal injury and may reflect cortical disinhibition attributable to disconnection or compensation for an inefficient cognitive process.	Gifu Univ, Sch Med, Dept Neurosurg, Gifu 5011194, Japan; Kizawa Mem Hosp, Dept Neurosurg, Chubu Med Ctr Prolonged Traumat Brain Dysfunct, Minokamo, Japan; Gifu Univ, Sch Med, Dept Biochem & Biophys, Gifu 500, Japan	Soeda, A (corresponding author), Gifu Univ, Sch Med, Dept Neurosurg, 1-1 Yanagido, Gifu 5011194, Japan.	ccd29400@nyc.odn.ne.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17028019] Funding Source: KAKEN		Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bullmore E, 1999, HUM BRAIN MAPP, V8, P86, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<86::AID-HBM3>3.0.CO;2-S; Bush G, 1998, HUM BRAIN MAPP, V6, P270, DOI 10.1002/(SICI)1097-0193(1998)6:4<270::AID-HBM6>3.3.CO;2-H; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cabeza R, 1997, NEUROREPORT, V8, P3479, DOI 10.1097/00001756-199711100-00013; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; COHEN JD, 1990, PSYCHOL REV, V97, P332, DOI 10.1037/0033-295X.97.3.332; D 'Esposito M, 2000, SEMIN NEUROL, V20, P487, DOI 10.1055/s-2000-13182; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDMANRAKIC PS, 1988, ANNU REV NEUROSCI, V11, P137, DOI 10.1146/annurev.neuro.11.1.137; Gruber SA, 2002, NEUROIMAGE, V16, P349, DOI 10.1006/nimg.2002.1089; GUR RC, 1982, SCIENCE, V217, P659, DOI 10.1126/science.7089587; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; Leung HC, 2000, CEREB CORTEX, V10, P552, DOI 10.1093/cercor/10.6.552; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Menon RS, 1999, TRENDS COGN SCI, V3, P207, DOI 10.1016/S1364-6613(99)01329-7; Raz N, 1997, CEREB CORTEX, V7, P268, DOI 10.1093/cercor/7.3.268; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Stamatakis EA, 2002, J NUCL MED, V43, P476; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Talairach J., 1988, COPLANAR STEREOTACTI; TEASDALE G, 1974, LANCET, V2, P81; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; Wechsler D, 1985, WECHSLER ADULT INTEL; Wechsler D., 1987, WECHSLER MEMORY SCAL; Weiss EM, 2003, PSYCHIAT RES-NEUROIM, V123, P1, DOI 10.1016/S0925-4927(03)00019-2; Whalen PJ, 1998, BIOL PSYCHIAT, V44, P1219, DOI 10.1016/S0006-3223(98)00251-0	35	46	52	0	18	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940	1432-1920		NEURORADIOLOGY	Neuroradiology	JUL	2005	47	7					501	506		10.1007/s00234-005-1372-x			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	947NR	WOS:000230653400002	15973537				2021-06-18	
J	Haskins, WE; Kobeissy, FH; Wolper, RA; Ottens, AK; Kitlen, JW; McClung, SH; O'Steen, BE; Chow, MM; Pineda, JA; Denslow, ND; Hayes, RL; Wang, KKW				Haskins, WE; Kobeissy, FH; Wolper, RA; Ottens, AK; Kitlen, JW; McClung, SH; O'Steen, BE; Chow, MM; Pineda, JA; Denslow, ND; Hayes, RL; Wang, KKW			Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact (CCI); differential in-gel electrophoresis (DIGE); sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE); tandem mass spectometry (MS2); traumatic brain injury (TBI)	CONTROLLED CORTICAL IMPACT; DIFFERENTIAL GEL-ELECTROPHORESIS; NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; BREAKDOWN PRODUCTS; PROTEOMICS TECHNOLOGY; SHOTGUN PROTEOMICS; RAT; IMMUNOREACTIVITY; ACCUMULATION	We report the rapid discovery of putative protein biomarkers of traumatic brain injury (TBI) by SDS-PAGE-capillary liquid chromatography-tandem mass spectrometry (SDS-PAGE-Capillary LC-MS2). Ipsilateral hippocampus (111) samples were collected from naive rats and rats subjected to controlled cortical impact (a rodent model of TBI). Protein database searching with 15,558 uninterpreted MS2 spectra, collected in 3 days via data-dependent capillary LC-MS2 of pooled cyanine dye-labeled samples separated by SDS-PAGE, identified more than 306 unique proteins. Differential proteomic analysis revealed differences in protein sequence coverage for 170 mammalian proteins (57 in naive only, 74 in injured only, and 39 of 64 in both), suggesting these are putative biomarkers of TBI. Confidence in our results was obtained by the presence of several known biomarkers of TBI (including all-spectrin, brain creatine kinase, and neuron-specific enolase) in our data set. These results show that SDS-PAGE prior to in vitro proteolysis and capillary LC-MS2 is a promising strategy for the rapid discovery of putative protein biomarkers associated with a specific physiological state (i.e., TBI) without a priori knowledge of the molecules involved.	Univ Florida, Ctr Neuroproteom & Biomarkers Res, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Psychiat, Gainesville, FL 32610 USA; Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, Gainesville, FL 32610 USA; Univ Florida, Interdisciplinary Ctr Biotechnol Res, Gainesville, FL 32610 USA	Wang, KKW (corresponding author), Univ Florida, McKnight Brain Inst, L4-100F,POB 100256,100 S Newell Dr, Gainesville, FL 32610 USA.	kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017; Pineda, Jose/W-2806-2019; Ottens, Andrew/K-3352-2012	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473; Ottens, Andrew/0000-0002-2118-3796	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, R01NS040182] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39091, R01 NS40182] Funding Source: Medline		BANIK NL, 1985, J NEUROCHEM, V45, P581, DOI 10.1111/j.1471-4159.1985.tb04026.x; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bodovitz S, 2004, TRENDS BIOTECHNOL, V22, P4, DOI 10.1016/j.tibtech.2003.10.013; Bramlett HM, 2003, EXP NEUROL, V184, P27, DOI 10.1016/S0014-4886(03)00401-1; Buki A, 2000, J NEUROSCI, V20, P2825; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOMANSKAJANIK K, 1992, MOL CHEM NEUROPATHOL, V16, P273, DOI 10.1007/BF03159974; Fountoulakis M, 1999, ELECTROPHORESIS, V20, P3572; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; GERBER SA, 2003, MS P NATL ACAD SCI U, V100, P6940; Gharbi S, 2002, MOL CELL PROTEOMICS, V1, P91, DOI 10.1074/mcp.T100007-MCP200; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Haskins WE, 2001, ANAL CHEM, V73, P5005, DOI 10.1021/ac010774d; Huh JW, 2003, J NEUROTRAUM, V20, P975, DOI 10.1089/089771503770195821; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Kernec F, 2001, PHYSIOL GENOMICS, V6, P117; Kornblum HI, 2001, NAT REV NEUROSCI, V2, P843, DOI 10.1038/35097597; Leimgruber RM, 2002, PROTEOMICS, V2, P135, DOI 10.1002/1615-9861(200202)2:2<135::AID-PROT135>3.3.CO;2-T; Macdonald N, 2001, ARCH TOXICOL, V75, P415, DOI 10.1007/s002040100259; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McDonald WH, 2002, DIS MARKERS, V18, P99, DOI 10.1155/2002/505397; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pike BR, 2002, J NEUROCHEM, V81, P73; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Shaw J, 2003, PROTEOMICS, V3, P1181, DOI 10.1002/pmic.200300439; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tonge R, 2001, PROTEOMICS, V1, P377; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Yan JX, 2002, PROTEOMICS, V2, P1682, DOI 10.1002/1615-9861(200212)2:12<1682::AID-PROT1682>3.0.CO;2-Y; Yates JR, 1998, ANAL CHEM, V70, P3557, DOI 10.1021/ac980122y; ZELMAN FP, 2002, BRAIN RES, V947, P131	40	46	47	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					629	644		10.1089/neu.2005.22.629			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400003	15941373				2021-06-18	
J	Jaffres, P; Brun, J; Declety, P; Bosson, JL; Fauvage, B; Schleiermacher, A; Kaddour, A; Anglade, D; Jacquot, C; Payen, JF				Jaffres, P; Brun, J; Declety, P; Bosson, JL; Fauvage, B; Schleiermacher, A; Kaddour, A; Anglade, D; Jacquot, C; Payen, JF			Transcranial Doppler to detect on admission patients at risk for neurological deterioration following mild and moderate brain trauma	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; mild head injury; moderate head injury; transcranial Doppler	SEVERE HEAD-INJURY; BLOOD-FLOW-VELOCITY; COMPUTERIZED-TOMOGRAPHY; CEREBRAL AUTOREGULATION; INTRACRANIAL-PRESSURE; EMERGENCY-DEPARTMENT; PULSATILITY INDEX; MANAGEMENT; REACTIVITY; DIAGNOSIS	Objective: To investigate the contribution of transcranial Doppler measurements obtained in the emergency room for detecting patients with secondary neurological deterioration after mild or moderate brain trauma. Design and setting: Prospective cohort study in the emergency room in a university teaching hospital. Patients: Seventy-eight adult patients admitted to the emergency room after a traumatic brain injury (TBI), including 42 patients with Glasgow Coma Score 14 15 and 36 with 9 - 13. Measurements and results: All patients had transcranial Doppler measurements on both middle cerebral arteries and computed tomography on admission. Neurological outcome was assessed 7 days after trauma. Of the patients included 7 and 10 had secondary neurological deterioration after mild and moderate TBI, respectively. On admission these groups of patients had significantly more injuries on computed tomography using the Trauma Coma Data Bank classification and higher pulsatility index using transcranial Doppler than the patients having no subsequent neurological worsening. Conclusions: Increased pulsatility index after mild or moderate TBI is a reason for concern about the possibility of further neurological deterioration. Computed tomography and Doppler measurements could be combined to detect on admission patients at risk for secondary neurological deterioration in order to improve their initial disposition.	Albert Michallon Hosp, Dept Anaesthesiol & Crit Care Med, F-38043 Grenoble, France; Albert Michallon Hosp, Div Biostat, Grenoble, France; Albert Michallon Hosp, Dept Emergency Med, Grenoble, France	Payen, JF (corresponding author), Albert Michallon Hosp, Dept Anaesthesiol & Crit Care Med, F-38043 Grenoble, France.	jfpayen@ujf-grenoble.fr	bosson, jean-luc/AAP-5163-2020; Payen, Jean-Francois/L-6667-2014	bosson, jean-luc/0000-0003-0967-6026; 			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; af Geijerstam JL, 2004, EMERG MED J, V21, P54, DOI 10.1136/emj.2003.003178; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kidwell CS, 2001, J NEUROIMAGING, V11, P229, DOI 10.1111/j.1552-6569.2001.tb00039.x; KLINGELHOFER J, 1988, J NEUROL, V235, P159, DOI 10.1007/BF00314307; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Moppett IK, 2004, BRIT J ANAESTH, V93, P710, DOI 10.1093/bja/aeh205; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Richards HK, 1998, ACT NEUR S, V71, P229; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shafe M, 2004, ACAD EMERG MED, V11, P774, DOI 10.1197/j.aem.2004.02.518; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; 1990, ABBREVIATED INUJURY	35	46	47	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUN	2005	31	6					785	790		10.1007/s00134-005-2630-4			6	Critical Care Medicine	General & Internal Medicine	932UC	WOS:000229578000006	15834704				2021-06-18	
J	Lea, PM; Movsesyan, VA; Faden, AI				Lea, PM; Movsesyan, VA; Faden, AI			Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						mGluR5; NMDA receptors; MTEP; MPEP; neuroprotection	METABOTROPIC GLUTAMATE RECEPTORS; STRETCH-INDUCED ENHANCEMENT; TRAUMATIC BRAIN INJURY; IN-VITRO; NEURONAL INJURY; KNOCKOUT MICE; CELL-DEATH; ACTIVATION; APOPTOSIS; NMDA	1 Neuroprotection has been reported after either activation or blockade of the group I metabotropic glutamate receptor subtype 5 (mGluR5). However, some recent evidence suggests that protection provided by mGluR5 antagonists may reflect their ability to inhibit N-methyl-D-aspartate (NMDA) receptor activity. 2 Here, in both rat and mouse cortical neurons, we compare the neuroprotective actions of two mGluR5 antagonists: 2-methyl-6-(phenylethynyl)-pyridine ( MPEP), which has been commonly used and 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine (MTEP), a more recently developed compound believed to have greater mGluR5 selectivity. We have previously shown that MPEP directly reduces single-channel NMDA receptor open time at the same concentrations (20 mu M or greater) that show neuroprotection, whereas MPEP antagonizes mGluR5 agonist ((RS)-2-chloro-5-hydroxyphenylglycine (CHPG))-induced changes in inositol phosphates (IP) at concentrations as low as 0.2 mu M. 3 In the present studies, MTEP significantly inhibited CHPG-mediated IP hydrolysis at concentrations as low as 0.02 mu M. In contrast to MPEP, which significantly reduced glutamate- or NMDA-mediated cell death in primary rat neuronal cultures at a concentration of 20 mu M, small neuroprotective effects were observed with MTEP only at a concentration of 200 mu M. Neither MPEP- nor MTEP-mediated mGluR5 inhibition had any effect on etoposide-induced apoptotic cell death. In rat cortical neurons, the neuroprotective effects of MTEP at very high concentrations, like those of MPEP, reflect ability to directly reduce NMDA receptor peak and steady-state currents. 4 We also compared the effects of MPEP and MTEP in primary cortical neuronal cultures from parental and mGluR5 knockout mice. Both agents were neuroprotective, at high concentrations in normal as well as in the knockout cultures. In contrast to rat cortical neurons, neither MPEP nor MTEP appears to directly alter NMDA receptor activity. 5 Combined, these studies support the conclusion that MTEP has greater mGluR5 selectivity than MPEP, and that neuroprotection provided by either antagonist in neuronal cultures does not reflect inhibition of mGluR5 receptors.	Georgetown Univ, Ctr Med, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Ctr Med, Dept Pharmacol, Washington, DC 20057 USA	Faden, AI (corresponding author), Georgetown Univ, Ctr Med, Dept Neurosci, Room EP-12,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	fadena@georgetown.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037313, R01NS37313] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER		Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Allen JW, 1999, NEUROPHARMACOLOGY, V38, P1243, DOI 10.1016/S0028-3908(99)00044-1; Allen JW, 2001, EXP NEUROL, V169, P449, DOI 10.1006/exnr.2001.7672; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Anderson JJ, 2003, EUR J PHARMACOL, V473, P35, DOI 10.1016/S0014-2999(03)01935-6; Anderson JJ, 2002, J PHARMACOL EXP THER, V303, P1044, DOI 10.1124/jpet.102.040618; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; Brodkin J, 2002, EUR J NEUROSCI, V16, P2241, DOI 10.1046/j.1460-9568.2002.02294.x; Bruno V, 1998, PROG BRAIN RES, V116, P209, DOI 10.1016/S0079-6123(08)60439-2; Bruno V, 1999, NEUROPHARMACOLOGY, V38, P199, DOI 10.1016/S0028-3908(98)00159-2; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; COPANI A, 1995, MOL PHARMACOL, V47, P890; Cosford NDP, 2003, J MED CHEM, V46, P204, DOI 10.1021/jm025570j; Cosford NDP, 2003, BIOORG MED CHEM LETT, V13, P351, DOI 10.1016/S0960-894X(02)00997-6; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Lea PM, 2003, J NEUROTRAUM, V20, P1233, DOI 10.1089/089771503770802907; Lea PM, 2003, DRUG NEWS PERSPECT, V16, P513, DOI 10.1358/dnp.2003.16.8.829350; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; Meli E, 2002, PHARMACOL BIOCHEM BE, V73, P439, DOI 10.1016/S0091-3057(02)00834-1; Mills CD, 2002, J NEUROTRAUM, V19, P23, DOI 10.1089/089771502753460213; Moldrich RX, 2001, NEUROPHARMACOLOGY, V41, P19, DOI 10.1016/S0028-3908(01)00045-4; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Mukhin A, 1996, J NEUROSCI, V16, P6012; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; SINENSKY MC, 1995, TOXICOL LETT, V75, P101; Strasser U, 1998, EUR J NEUROSCI, V10, P2848, DOI 10.1111/j.1460-9568.1998.00291.x; Varney MA, 1999, J PHARMACOL EXP THER, V290, P170; Yakovlev AG, 2001, MOL MED, V7, P205, DOI 10.1007/BF03401955; Yakovlev AG, 2001, J NEUROSCI, V21, P7439	36	46	48	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	JUN	2005	145	4					527	534		10.1038/sj.bjp.0706219			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	940IR	WOS:000230137900014	15821750	Green Published			2021-06-18	
J	Fahrig, T; Gerlach, I; Horvath, E				Fahrig, T; Gerlach, I; Horvath, E			A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury	MOLECULAR PHARMACOLOGY			English	Article							NF-KAPPA-B; DOPAMINERGIC-NEURONS; KINASE COMPLEX; C-JUN; ACTIVATION; STRESS; TRANSCRIPTION; EXPRESSION; INDUCTION; RECEPTOR	Many acute and chronic neurodegenerative diseases are characterized by a localized inflammatory response and constitutive activation of the transcription factors nuclear factor-kappa B (NF-kappa B) and activator protein-1 (AP-1) as well as their upstream activating signaling cascades. Ample evidence indicates the implication of these processes in the pathogenesis of several diseases of the central nervous system. In this study, we show that a synthetic derivative of the natural product rocaglaol (compound A) displays potent anti-inflammatory properties in human endothelial and murine glial cells in vitro. Compound A inhibited cytokine- and lipopolysaccharide-induced release of various cytokines/chemokines and of nitric oxide as well as expression of the adhesion molecule endothelial leukocyte adhesion molecule-1 and the inducible enzymes nitric-oxide synthase and cyclooxygenase-2. As shown by immunocytochemistry and immunoblotting, compound A inhibited NF-kappa B and AP-1 activity in mixed glial cultures. Compound A exhibited neuroprotective activity in vitro and in vivo. 1-Methyl-4-phenylpyridiniuminduced damage of mesencephalic dopaminergic neurons was significantly decreased, and long-term treatment of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine-injected mice with compound A significantly and dose-dependently reduced dopaminergic neuronal cell death. In addition, shortterm application of compound A to rats suffering from traumatic brain injury induced by subdural hematoma resulted in a significant reduction of the cerebral infarct volume. These results suggest that by inhibiting NF-kappa B and AP-1 signaling, compound A is able to reduce tissue inflammation and neuronal cell death, resulting in significant neuroprotection in animal models of neurodegeneration.	Bayer HealthCare, Pharma Res CNS, D-51368 Leverkusen, Germany	Fahrig, T (corresponding author), Bayer HealthCare, Pharma Res CNS, D-51368 Leverkusen, Germany.	thomas.fahrig@bayorhealthcare.com	Mat Zain, Mazatulikhma/B-2025-2010				Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Basu A, 2002, J NEUROSCI, V22, P6071; Baumann B, 2002, J BIOL CHEM, V277, P44791, DOI 10.1074/jbc.M208003200; Bezard E, 1997, NEUROSCI LETT, V234, P47, DOI 10.1016/S0304-3940(97)00663-0; Cassarino DS, 2000, J NEUROCHEM, V74, P1384, DOI 10.1046/j.1471-4159.2000.0741384.x; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Eijkenboom M, 2000, NEUROPHARMACOLOGY, V39, P817, DOI 10.1016/S0028-3908(00)00002-2; Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gearan T, 2001, PARKINSONISM RELAT D, V8, P19, DOI 10.1016/S1353-8020(00)00078-X; Hirsch EC, 2000, J NEUROL, V247, P58, DOI 10.1007/PL00007762; Hoozemans JJM, 2002, DRUGS TODAY, V38, P429, DOI 10.1358/dot.2002.38.6.678350; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Kyriakis JM, 2001, PHYSIOL REV, V81, P807; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Nagatsu T, 2000, J NEURAL TRANSM-SUPP, P143; Nelson EL, 1996, J COMP NEUROL, V369, P361, DOI 10.1002/(SICI)1096-9861(19960603)369:3<361::AID-CNE3>3.0.CO;2-3; Ping DS, 1999, J IMMUNOL, V162, P727; Pizzi M, 2002, J BIOL CHEM, V277, P20717, DOI 10.1074/jbc.M201014200; Proksch P, 2001, CURR ORG CHEM, V5, P923, DOI 10.2174/1385272013375049; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Roebuck KA, 1999, INT J MOL MED, V4, P223; Schneider A, 1999, NAT MED, V5, P554; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Teismann P, 2001, SYNAPSE, V39, P167, DOI 10.1002/1098-2396(200102)39:2<167::AID-SYN8>3.0.CO;2-U; Tong LQ, 2003, NEUROCHEM RES, V28, P111, DOI 10.1023/A:1021656430576; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Zhu XW, 2003, J NEUROCHEM, V85, P87, DOI 10.1046/j.1471-4159.2003.01645.x	40	46	50	1	7	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0026-895X	1521-0111		MOL PHARMACOL	Mol. Pharmacol.	MAY	2005	67	5					1544	1555		10.1124/mol.104.008177			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	916MA	WOS:000228387900021	15716464				2021-06-18	
J	Luaute, J; Fischer, C; Adeleine, P; Morlet, D; Tell, L; Boisson, D				Luaute, J; Fischer, C; Adeleine, P; Morlet, D; Tell, L; Boisson, D			Late auditory and event-related potentials can be useful to predict good functional outcome after coma	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						coma; evoked potentials; logistic regression; rehabilitation	SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; MULTIMODALITY EVOKED-POTENTIALS; INTRA-CRANICAL PRESSURE; HOSPITAL CARDIAC-ARREST; MISMATCH NEGATIVITY; PROGNOSTIC VALUE; CARDIOPULMONARY-RESUSCITATION; COMPUTERIZED-TOMOGRAPHY; CLINICAL-ASSESSMENT	Objective: To investigate whether late auditory and event-related potentials, and in particular N100 and mismatch negativity, together with clinical parameters, can help to predict good functional outcome in comatose patients. Design: Prospective cohort study. Setting: Hospital. Participants: Consecutively sampled comatose patients (N = 346) whose etiologies of coma were stroke (125 patients), brain injury (96 patients), anoxia (64 patients), complication of neurosurgery (54 patients), and encephalitis (7 patients). Interventions: Not applicable. Main Outcome Measures: Glasgow Outcome Scale score at 1 year postonset. Patients in a minimally conscious state and those who awoke and died during the follow-up period were classified separately. Results: Univariate analysis showed that all variables studied, except brainstem auditory evoked potentials, correlated significantly with functional outcome. Mismatch negativity showed the highest positive predictive value for good outcome. A validated model was obtained with multivariate logistic analysis, including pupillary light reflex, N100, mismatch negativity, etiology, and age. Conclusions: Late auditory and event-related potentials, and particularly N100 and mismatch negativity, provide strong prognostic factors for good functional outcome. Furthermore, these components may enhance the accuracy of prognosis when associated with other clinical parameters available at the early stage of coma.	Hospices Civils Lyon, Hop H Gabrielle, Lyon, France; Hospices Civils Lyon, Hop Neurol, Lyon, France; Hospices Civils Lyon, Serv Biostat, Lyon, France; INSERM, U280, F-69008 Lyon, France	Luaute, J (corresponding author), Hop Henry Gabrielle, Serv Pr D Boisson, Route Vourles, F-69230 St Genis Laval, France.	jacques.luaute@chu-lyon.fr	Luaute, jacques/H-4618-2017	Luaute, jacques/0000-0002-6387-9572			ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Berek K, 1997, J NEUROL, V244, P556, DOI 10.1007/s004150050143; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; FISCHER C, 1994, NEUROSURGERY, V35, P45, DOI 10.1227/00006123-199407000-00007; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; GROSWASSER Z, 1989, ARCH PHYS MED REHAB, V70, P186; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; HOLLIDAY PO, 1982, NEUROSURGERY, V10, P25, DOI 10.1227/00006123-198201000-00005; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; Kane NM, 2000, AUDIOL NEURO-OTOL, V5, P186, DOI 10.1159/000013879; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KARKELA J, 1992, CRIT CARE MED, V20, P378; Kass G., 1980, J R STAT SOC C-APPL, V29, P119, DOI DOI 10.2307/2986296; Krieger DW, 1998, LANCET, V352, P1796, DOI 10.1016/S0140-6736(98)00081-6; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Lew HL, 2002, AM J PHYS MED REHAB, V81, P524, DOI 10.1097/00002060-200207000-00011; Litscher G, 1995, INT J NEUROSCI, V83, P253, DOI 10.3109/00207459508986342; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Madl C, 2000, CRIT CARE MED, V28, P721, DOI 10.1097/00003246-200003000-00020; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NAATANEN R, 1978, ACTA PSYCHOL, V42, P313, DOI 10.1016/0001-6918(78)90006-9; Naatanen R, 2000, AUDIOL NEURO-OTOL, V5, P105, DOI 10.1159/000013874; NAATANEN R, 1995, EAR HEARING, V16, P6; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; RIVAS JJ, 1988, NEUROSURGERY, V23, P44, DOI 10.1227/00006123-198807000-00010; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Tervaniemi M, 1999, CLIN NEUROPHYSIOL, V110, P1388, DOI 10.1016/S1388-2457(99)00108-X; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; Zhang H, 1999, RECURSIVE PARTITIONI	49	46	52	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2005	86	5					917	923		10.1016/j.apmr.2004.08.011			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	928NM	WOS:000229278500011	15895337				2021-06-18	
J	Rennaker, RL; Street, S; Ruyle, AM; Sloan, AM				Rennaker, RL; Street, S; Ruyle, AM; Sloan, AM			A comparison of chronic multi-channel cortical implantation techniques: manual versus mechanical insertion	JOURNAL OF NEUROSCIENCE METHODS			English	Article						chronic implant; micioelectrode array; cortex; insertion	TRAUMATIC BRAIN-INJURY; MICROELECTRODE ARRAYS; RECORDINGS; RAT; REPRESENTATION; CONTUSION; MULTISITE; CORTEX	High-density multi-channel intra-cortical electrode arrays allow researchers to record simultaneously from populations of neurons for the purpose of understanding neural coding and plasticity. These devices have tens to hundreds of electrodes spaced within a few square millimeters. During insertion, the high-density probes can compress the cortex several millimeters prior to breaking through the pia. Compression of cortical tissue has been demonstrated to result in traumatic brain injury (TBI) which may be a major contributor to low electrode yield and decreased recording longevity. Two insertion techniques for chronically implanting multi-wire electrode arrays in layer IV of primary auditory cortex were compared. A mechanical insertion device, capable of rapidly inserting the electrode array without visible compression of the brain, was constructed. The neural responses to broadband clicks and pure tones recorded from the arrays inserted with the mechanical device were compared to the results from a manual insertion method using a micromanipulator. Both techniques result in a similar number of active channels directly following surgery with a mean signal-to-noise ratio of approximately 4.5. Over 60% of the animals implanted with the mechanical insertion device had driven activity at week 6 whereas none of the animals with manually inserted arrays exhibited functional responses after 3 weeks. This report provides initial evidence that mechanical insertion devices, which prevent cortical compression, increase electrode recording longevity. (C) 2004 Published by Elsevier B.V.	Univ Oklahoma, Ctr Bioengn, Norman, OK 73019 USA	Rennaker, RL (corresponding author), Univ Oklahoma, Ctr Bioengn, 865 Asp Ave Felgar Hall 210, Norman, OK 73019 USA.	rennaker@ou.edu	Rennaker, Robert/K-9049-2013	Rennaker, Robert/0000-0003-1260-1973			Bai Q, 2000, IEEE T BIO-MED ENG, V47, P281, DOI 10.1109/10.827288; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; deCharms RC, 2000, ANNU REV NEUROSCI, V23, P613, DOI 10.1146/annurev.neuro.23.1.613; deCharms RC, 1999, J NEUROSCI METH, V93, P27, DOI 10.1016/S0165-0270(99)00087-4; deCharms RC, 1996, NATURE, V381, P610, DOI 10.1038/381610a0; Donoghue JP, 2002, NAT NEUROSCI, V5, P1085, DOI 10.1038/nn947; Kipke DR, 2003, IEEE T NEUR SYS REH, V11, P151, DOI 10.1109/TNSRE.2003.814443; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kralik JD, 2001, METHODS, V25, P121, DOI 10.1006/meth.2001.1231; Loeb GE, 1995, J NEUROSCI METH, V63, P175, DOI 10.1016/0165-0270(95)00107-7; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; Nicolelis MAL, 2003, P NATL ACAD SCI USA, V100, P11041, DOI 10.1073/pnas.1934665100; Normann RA, 1999, VISION RES, V39, P2577, DOI 10.1016/S0042-6989(99)00040-1; Porada I, 2000, J NEUROSCI METH, V95, P13, DOI 10.1016/S0165-0270(99)00139-9; Rao VLR, 1998, J NEUROCHEM, V70, P2020; RENNAKER RL, 2004, IN PRESS J NEUROSCI; ROUSCHE PJ, 1992, ANN BIOMED ENG, V20, P413, DOI 10.1007/BF02368133; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SCHMIDT EM, 1976, EXP NEUROL, V52, P496, DOI 10.1016/0014-4886(76)90220-X; SCHMIDT EM, 1988, MED BIOL ENG COMPUT, V26, P96, DOI 10.1007/BF02441836; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Taylor DM, 2003, IEEE T NEUR SYS REH, V11, P195, DOI 10.1109/TNSRE.2003.814451; Venkatachalam S, 1999, J NEUROSCI METH, V90, P37, DOI 10.1016/S0165-0270(99)00065-5; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; VILLA AE, 1999, P NATL AC SCI US AM, P1106; Westby GWM, 1997, J NEUROSCI METH, V76, P123, DOI 10.1016/S0165-0270(97)00088-5; Williams JC, 1999, NEUROCOMPUTING, V26-7, P1069, DOI 10.1016/S0925-2312(99)00106-X; Williams JC, 1999, BRAIN RES PROTOC, V4, P303, DOI 10.1016/S1385-299X(99)00034-3	28	46	48	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 30	2005	142	2					169	176		10.1016/j.jneumeth.2004.08.009			8	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	901FT	WOS:000227269100001	15698656				2021-06-18	
J	Chambers, IR; Stobbart, L; Jones, PA; Kirkham, FJ; Marsh, M; Mendelow, AD; Minns, RA; Struthers, S; Tasker, RC				Chambers, IR; Stobbart, L; Jones, PA; Kirkham, FJ; Marsh, M; Mendelow, AD; Minns, RA; Struthers, S; Tasker, RC			Age-related differences in intracranial pressure and cerebral perfusion pressure in the first 6 hours of monitoring after children's head injury: association with outcome	CHILDS NERVOUS SYSTEM			English	Article						intracranial monitoring; intracranial hypertension; children; traumatic coma; age; thresholds; sensitivity; specificity	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; MANAGEMENT; ADULTS; COMA	Objectives: Severe head injury in childhood is associated with considerable mortality and morbidity. In this study we determined age-related differences in the relationship between outcome and intracranial pressure (ICP) and cerebral perfusion pressure (CPP) in the first 6 h of monitoring in a large cohort of head-injured children. Methods: Two hundred and thirty-five head-injured children (admitted to five UK hospitals over a 15-year period) in whom intracranial pressure monitoring was clinically indicated were studied. Results: Patients were divided into three age groups (2-6, 7-10 and 11-16 years). The sensitivity of ICP and CPP were similar. Differences were found in the specificity of ICP and CPP for each group and these were more marked for CPP. For a specificity of 50% the pressures were 53, 63 and 66 mmHg for the three age groups. Conclusions: There are age-related differences in the specificity of intracranial pressure and cerebral perfusion pressure in relation to outcome. These differences may be important in the clinical management of head-injured children. Thus cerebral perfusion pressures of 53, 63 and 66 mmHg should be the minimum to strive for in these three age groups respectively.	Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Univ, Sch Med, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Edinburgh, Edinburgh EH9 1UW, Midlothian, Scotland; Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland; Southampton Gen Hosp, Dept Child Hlth, Southampton SO16 6YD, Hants, England; Newcastle Univ, Newcastle Gen Hosp, Dept Neurosurg, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Great Ormond St Hosp Sick Children, Paediat Intens Care & Neurosci Unit, London WC1N 3JH, England; Addenbrookes Hosp, Paediat Intens Care Unit, Cambridge CB2 2QQ, England; Guys Hosp, Newcomen Ctr, London SE1 9RT, England	Chambers, IR (corresponding author), Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	i.r.chambers@ncl.ac.uk	Tasker, Robert C/R-5837-2019; Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958; Tasker, Robert/0000-0003-3647-8113			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BROOKES M, 1990, J EPIDEMIOL COMMUN H, V44, P147, DOI 10.1136/jech.44.2.147; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; HULL D, 1981, ESSENTIL PAEDIAT, P134; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Lam WH, 1999, PAEDIATR ANAESTH, V9, P377; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MILLER JD, 1994, LANCET, V344, P421; National Collaborating Centre for Acute Care, 2003, HEAD INJ TRIAG ASS I; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; TEASDALE GM, 2000, EARLY MANAGEMENT PAT; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	21	46	46	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAR	2005	21	3					195	199		10.1007/s00381-004-1060-x			5	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	902OY	WOS:000227367600005	15580513				2021-06-18	
J	Turnbull, OH; Evans, CEY; Owen, V				Turnbull, OH; Evans, CEY; Owen, V			Negative emotions and anosognosia	CORTEX			English	Article						Anosognosia; positive emotion; negative emotions; affect	TRAUMATIC BRAIN-INJURY; VESTIBULAR STIMULATION; FUNCTIONAL NEUROANATOMY; RIGHT-HEMISPHERE; MOOD DISORDERS; PHANTOM LIMBS; NEGLECT; CONFABULATION; PERSONALITY; DEPRESSION	Patients with anosognosia fail to acknowledge, or feel distressed by, their disability. Given the recent suggestion that right (frontal) systems are selectively involved in negative emotions, it might be claimed that anosognosia results from a disruption in negative emotions. This is not consistent with the finding that some anosognosic patients exhibit substantial fluctuations in emotion, including the experience of negative emotions such as sadness. The present study investigates a patient (IW) with a right convexity lesion and anosognosia. He reported being frequently overcome by powerful emotions, especially sadness. IW was assessed on a self-report emotion questionnaire, where his reports were typically of higher levels of emotion than the control group. He was also assessed on the more indirect measure of Affective Story Recall. Here his pattern of emotional experience was similar to that of two control groups, one of which consisted of nonanosognosic patients with hemiparesis. His performance on Story Recall was notable in that he directed his emotions to a different 'object' to that of controls (other vs. self, respectively). These findings are not consistent with any claim that anosognosia results from an absence of negative emotions.	Univ Wales, Sch Psychol, Ctr Cognit Neurosci, Bangor LL57 2AS, Gwynedd, Wales	Turnbull, OH (corresponding author), Univ Wales, Sch Psychol, Ctr Cognit Neurosci, Bangor LL57 2AS, Gwynedd, Wales.	o.turnbull@bangor.ac.uk					ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Anderson MC, 2001, NATURE, V410, P366, DOI 10.1038/35066572; BANDLER R, 1994, TRENDS NEUROSCI, V17, P379, DOI 10.1016/0166-2236(94)90047-7; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; Blakemore SJ, 2002, TRENDS COGN SCI, V6, P237, DOI 10.1016/S1364-6613(02)01907-1; Borod J. C, 2000, NEUROPSYCHOLOGY EMOT; BREIER JI, 1995, NEUROLOGY, V45, P65, DOI 10.1212/WNL.45.1.65; Calder AJ, 2001, NAT REV NEUROSCI, V2, P352, DOI 10.1038/35072584; CAPPA S, 1987, NEUROPSYCHOLOGIA, V25, P775, DOI 10.1016/0028-3932(87)90115-1; CLONINGER CR, 1994, CURR OPIN NEUROBIOL, V4, P266, DOI 10.1016/0959-4388(94)90083-3; CRITCHLE.M, 1974, MT SINAI J MED, V41, P82; Dam~asio A., 1999, FEELING WHAT HAPPENS; Damasio A., 1994, DESCARTESERROR EMOTI; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; Daprati E, 2000, NEUROCASE, V6, P477, DOI 10.1080/13554790008402718; Davidson RJ, 2001, ANN NY ACAD SCI, V935, P191, DOI 10.1111/j.1749-6632.2001.tb03481.x; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; DAVIS KL, 1999, AFFECTIVE NEUROSCIEN; Depaulis A., 1991, MIDBRAIN PERIAQUEDUC; Everitt B.J., 1992, SEMIN NEUROSCI, V4, P119, DOI 10.1016/1044-5765(92)90010-Y.; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Feinberg T.E., 1997, BEHAV NEUROLOGY NEUR, P369; Fink GR, 1999, BRAIN, V122, P497, DOI 10.1093/brain/122.3.497; FIRTH C, 2000, PHILOS T R SOC B, V355, P1771; Gainotti G, 1972, Cortex, V8, P41; GAINOTTI G, 1975, PSYCHIAT CLIN, V8, P99, DOI 10.1159/000283622; GAINOTTI G, 1997, BEHAV NEUROLOGY NEUR, P369; Goldstein K., 1939, ORGANISM HOLISTIC AP; HALLIGAN PW, 1995, CORTEX, V31, P173, DOI 10.1016/S0010-9452(13)80115-3; Heilman K.M., 2003, INT J CLIN NEUROPSYC, V4th ed., P296, DOI DOI 10.1016/J.NEUR0PSYCHOLOGIA.2011.09.030; Heilman KM, 1998, PHILOS T R SOC B, V353, P1903, DOI 10.1098/rstb.1998.0342; Hoebel BG, 1997, APPETITE, V29, P119, DOI 10.1006/appe.1997.0126; HOUSE A, 1990, BRAIN, V113, P1113, DOI 10.1093/brain/113.4.1113; HOUSE A, 1988, J NEUROL NEUROSUR PS, V51, P112, DOI 10.1136/jnnp.51.1.112; Ikemoto S, 1999, BRAIN RES REV, V31, P6, DOI 10.1016/S0165-0173(99)00023-5; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Kaplan-Solms K., 2000, CLIN STUDIES NEUROPS; LeDoux J., 1996, EMOTIONAL BRAIN; Lu LH, 1997, NEUROLOGY, V49, P1316, DOI 10.1212/WNL.49.5.1316; Marcel AJ, 2004, CORTEX, V40, P19, DOI 10.1016/S0010-9452(08)70919-5; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Meador KJ, 2000, NEUROLOGY, V55, P816, DOI 10.1212/WNL.55.6.816; Mose AD, 1996, J NEUROL NEUROSUR PS, V61, P210, DOI 10.1136/jnnp.61.2.210; Normansell L., 2003, NEUROPSYCHOANALYSIS, V5, P57, DOI DOI 10.1080/15294145.2003.10773410; Panksepp J., 1998, AFFECTIVE NEUROSCIEN; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; RAMACHANDRAN VS, 1994, INT REV NEUROBIOL, V37, P291; Ramachandran VS, 1996, COLD SPRING HARB SYM, V61, P115; Ramachandran VS, 1998, PHANTOMS BRAIN HUMAN; REITAN RM, 1972, PERCEPT MOTOR SKILL, V34, P515, DOI 10.2466/pms.1972.34.2.515; Rode G, 1998, CORTEX, V34, P253; Rolls ET, 1999, BRAIN EMOTION; ROSS ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; Schacter DL., 1991, AWARENESS DEFICIT BR, P17; Schilder P., 1935, IMAGE APPEARANCE HUM; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; Sirigu A, 1999, BRAIN, V122, P1867, DOI 10.1093/brain/122.10.1867; Solms M, 1998, BRAIN COGNITION, V38, P358, DOI 10.1006/brcg.1998.1032; STARKSTEIN SE, 1988, J NERV MENT DIS, V176, P87, DOI 10.1097/00005053-198802000-00004; STARKSTEIN SE, 1990, NEUROLOGY, V40, P1380, DOI 10.1212/WNL.40.9.1380; Turnbull O H, 1997, J Int Neuropsychol Soc, V3, P288; Turnbull O. H., 2002, NEUROPSYCHOANALYSIS, V4, P69; Turnbull OH, 1997, NEUROPSYCHOLOGIA, V35, P153, DOI 10.1016/S0028-3932(96)00063-2; VALLAR G, 1990, CORTEX, V26, P123, DOI 10.1016/S0010-9452(13)80078-0; Walsh K. W., 1985, UNDERSTANDING BRAIN; Weinstein E., 1991, AWARENESS DEFICIT BR; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; WEINSTEIN EA, 1953, AMA ARCH NEUROL PSY, V69, P355, DOI 10.1001/archneurpsyc.1953.02320270076008; Weinstein EA, 1996, B MENNINGER CLIN, V60, P331	72	46	46	1	13	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2005	41	1					67	75		10.1016/S0010-9452(08)70179-5			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	881UM	WOS:000225894900008	15633708				2021-06-18	
J	Lenzlinger, PM; Shimizu, S; Marklund, N; Thompson, HJ; Schwab, ME; Saatman, KE; Hoover, RC; Bareyre, FM; Motta, M; Luginbuhl, A; Pape, R; Clouse, AK; Morganti-Kossmann, C; Mcintosh, TK				Lenzlinger, PM; Shimizu, S; Marklund, N; Thompson, HJ; Schwab, ME; Saatman, KE; Hoover, RC; Bareyre, FM; Motta, M; Luginbuhl, A; Pape, R; Clouse, AK; Morganti-Kossmann, C; Mcintosh, TK			Delayed inhibition of Nogo-A does not alter injury-induced axonal sprouting but enhances recovery of cognitive function following experimental traumatic brain injury in rats	NEUROSCIENCE			English	Article						head injury; myelin inhibitors; tract-tracing; cognition; hippocampus	NEURITE GROWTH-INHIBITORS; CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; CORTICOSPINAL TRACT FIBERS; CEREBRAL-ARTERY OCCLUSION; MONOCLONAL-ANTIBODY IN-1; ADULT-RAT; HEAD-INJURY; CELL-DEATH	Traumatic brain injury causes long-term neurological motor and cognitive deficits, often with limited recovery. The inability of CNS axons to regenerate following traumatic brain injury may be due, in part, to inhibitory molecules associated with myelin. One of these myelin-associated proteins, Nogo-A, inhibits neurite outgrowth in vitro, and inhibition of Nogo-A in vivo enhances axonal outgrowth and sprouting and improves outcome following experimental CNS insults. However, the involvement of Nogo-A in the neurobehavioral deficits observed in experimental traumatic brain injury remains unknown and was evaluated in the present study using the 11C7 monoclonal antibody against Nogo-A. Anesthetized, male Sprague-Dawley rats were subjected to either lateral fluid percussion brain injury of moderate severity (2.5-2.6 atm) or sham injury. Beginning 24 h post-injury, monoclonal antibody 11C7 (n=17 injured, n=6 shams included) or control Ab (IgG) (n=16 injured, n=5 shams included) was infused at a rate of 5 mu l/h over 14 days into the ipsilateral ventricle using osmotic minipumps connected to an implanted cannula. Rats were assessed up to 4 weeks post-injury using tests for neurological motor function (composite neuroscore, and sensorimotor test of adhesive paper removal) and, at 4 weeks, cognition was assessed using the Morris water maze. Hippocampal CA3 pyramidal neuron damage and corticospinal tract sprouting, using an anterograde tracer (biotinylated dextran amine), were also evaluated. Brain injury significantly increased sprouting from the uninjured corticospinal tract but treatment with monoclonal antibody 11C7 did not further increase the extent of sprouting nor did it alter the extent of CA3 cell damage. Animals treated with 11C7 showed no improvement in neurologic motor deficits but did show significantly improved cognitive function at 4 weeks post-injury when compared with brain-injured, IgG-treated animals. To our knowledge, the present findings are the first to suggest that (1) traumatic brain injury induces axonal sprouting in the corticospinal tract and this sprouting may be independent of myelin-associated inhibitory factors and (2) that post-traumatic inhibition of Nogo-A may promote cognitive recovery unrelated to sprouting in the corticospinal tract or neuroprotective effects on hippocampal cell loss following experimental traumatic brain injury. (c) 2005 Published by Elsevier Ltd on behalf of IBRO.	Univ Penn, Dept Neurosurg, Traumat Bain Injury Lab, Philadelphia, PA 19104 USA; Univ Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Brain Res, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland; Monash Univ, Dept Trauma Surg, Clayton, Vic, Australia; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, SE-75648 Uppsala, Sweden.	niklas.marklund@neurokir.uu.se	Lenzlinger, Philipp/A-3822-2008; Schwab, Martin E/B-6818-2016	Marklund, Niklas/0000-0002-9797-5626; Morganti-Kossmann, Cristina/0000-0002-0807-2063	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM-34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS-08803, R01-NS 40978, T32 NS07413-04] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978, T32NS007413] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BANDTLOW C, 1990, J NEUROSCI, V10, P3837; Bareyre FM, 2002, J NEUROSCI, V22, P7097; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bomze HM, 2001, NAT NEUROSCI, V4, P38; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brosamle C, 2000, J NEUROSCI, V20, P8061; Buki A, 2000, J NEUROSCI, V20, P2825; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Conte V., 2003, EUR J TRAUMA, V29, P335; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Dergham P, 2002, J NEUROSCI, V22, P6570; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fiedler M, 2002, PROTEIN ENG, V15, P931, DOI 10.1093/protein/15.11.931; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Fournier AE, 2002, J NEUROSCI, V22, P8876; Fournier AE, 2003, J NEUROSCI, V23, P1416; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Grados-Munro EM, 2003, J NEUROSCI RES, V74, P479, DOI 10.1002/jnr.10803; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Herzog A, 1997, J NEUROSCI METH, V72, P57, DOI 10.1016/S0165-0270(96)00156-2; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; Laurer HL, 2001, CURR PHARM DESIGN, V7, P1505, DOI 10.2174/1381612013397285; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Li SX, 2003, J NEUROSCI, V23, P4219; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; *NAT AC SCI, 1996, GUID CAR US LAB AN; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Oertle T, 2003, J NEUROSCI, V23, P5393; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Raineteau O, 2001, P NATL ACAD SCI USA, V98, P6929, DOI 10.1073/pnas.111165498; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SIMPSON FA, 1997, HEAD INJURY PATHOPHY; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Thurman DJ, 2001, HEAD TRAUMA, P327; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wang XX, 2002, J NEUROSCI, V22, P5505; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Z'Graggen WJ, 2000, J NEUROSCI, V20, P6561, DOI 10.1523/JNEUROSCI.20-17-06561.2000	87	46	48	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2005	134	3					1047	1056		10.1016/j.neuroscience.2005.04.048			10	Neurosciences	Neurosciences & Neurology	959BF	WOS:000231491200030	15979242				2021-06-18	
J	Xiang, HY; Kelleher, K; Shields, BJ; Brown, KJ; Smith, GA				Xiang, HY; Kelleher, K; Shields, BJ; Brown, KJ; Smith, GA			Skiing- and snowboarding-related injuries treated in US emergency departments, 2002	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						skiing; snowboarding; injuries; United States	HEAD-INJURIES; CHILDREN; SKIERS; PATTERNS; SPORTS	Background: This study aims to describe the characteristics of skiing- and snowboarding-related injuries treated in U.S. emergency departments (EDs). Methods: Skiing- and snowboarding-related injuries collected by the National Electronic Injury Surveillance System in 2002 were analyzed. Data regarding skiing and snowboarding participation were used to calculate injury rates by age group and activity (skiing versus snowboarding). Results: An estimated 77,300 (95% CI = 11,600-143,000) skiing- and 62,000 (95% CI = 32,800-91,200) snowboarding-related injuries were treated in U.S. hospital EDs in 2002. Wrist injuries (17.9%) and arm injuries (16.6%) among snowboarders and knee injuries (22.7%) among skiers were the most common injuries. The age groups that have the highest skiing-related injury rates were the 55-64 years (29.0 per 1,000 participants), the 65+ years (21.7 per 1,000 participants), and the 45-54 years (15.5 per 1,000 participants). The age groups that have the highest snowboarding-related injuries were the 10-13 years (15.9 per 1,000 participants), the 14-17 years (15.0 per 1,000 participants), and the 18-24 years (13.5 per 1,000 participants). Traumatic brain injury (TBI) rates were higher among older skiers, 55-64 years (2.15 per 1,000 participants), and younger skiers, 10-13 years (1.69 per 1,000 participants). Conclusions: Our study is the first to demonstrate that older skiers are at highest risk for injury. Adolescents are at highest risk for snowboarding-related injury. Prevention of TBI should be a top injury control priority among skiers and snowboarders.	Ohio State Univ, Ctr Injury Res & Policy, Childrens Res Inst, Columbus Childrens Hosp,Coll Med & Publ Hlth, Columbus, OH 43205 USA	Xiang, HY (corresponding author), Ohio State Univ, Ctr Injury Res & Policy, Childrens Res Inst, Columbus Childrens Hosp,Coll Med & Publ Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	xiangh@pediatrics.ohio-state.edu	Kelleher, Kelly/E-3361-2011; Xiang, Huiyun/E-4335-2011				*AM MED ASS, 1997, HELM RECR SKIING OTH; BLITZER CM, 1984, AM J SPORT MED, V12, P142, DOI 10.1177/036354658401200210; BOUTER LM, 1989, PHYSICIAN SPORTSMED, V17, P81; BROWN JM, 1997, CONT PEDIAT, V14, P115; CADMAN R, 1996, ASTM STP, V1266; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Deibert MC, 1998, J BONE JOINT SURG AM, V80A, P25, DOI 10.2106/00004623-199801000-00006; EKELAND A, 1993, SKIING TRAUM SAF 9 I; Ferrera PC, 1999, AM J EMERG MED, V17, P575, DOI 10.1016/S0735-6757(99)90199-7; FURRER M, 1995, J TRAUMA, V39, P737, DOI 10.1097/00005373-199510000-00024; Goulet C, 1999, AM J SPORT MED, V27, P644, DOI 10.1177/03635465990270051701; Hagel BE, 2004, EPIDEMIOLOGY, V15, P279, DOI 10.1097/01.ede.0000120044.62029.b4; Hagel BE, 2003, CAN J PUBLIC HEALTH, V94, P458, DOI 10.1007/BF03405085; Levy AS, 2002, J TRAUMA, V53, P695, DOI 10.1097/00005373-200210000-00013; LYNCH J, 2003, SNOW SPORTS IND INTE; Macnab A J, 1996, Inj Prev, V2, P286, DOI 10.1136/ip.2.4.286; Macnab AJ, 2002, INJURY PREV, V8, P324, DOI 10.1136/ip.8.4.324; Marshall SW, 2003, INJURY PREV, V9, P100, DOI 10.1136/ip.9.2.100; MORROW PL, 1988, J TRAUMA, V28, P95, DOI 10.1097/00005373-198801000-00014; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; SANDEGAARD J, 1991, SKIING TRAUM SAF 9 I; SAS Institute Inc, 1999, SAS STAT US GUID VER; SHAH BV, 1996, SUDAAN USERS MANUAL; Shephard RJ, 2003, INJURY PREV, V9, P99, DOI 10.1136/ip.9.2.99; SHERRY E, 1988, MED J AUSTRALIA, V149, P615, DOI 10.5694/j.1326-5377.1988.tb120803.x; Shorter NA, 1996, J TRAUMA, V40, P997, DOI 10.1097/00005373-199606000-00024; Smith GA, 1998, PEDIATRICS, V101, P406, DOI 10.1542/peds.101.3.406; SUGAWARA M, 1985, SKIING TRAUM SAF 6 I; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TOUGH SC, 1993, AM J FOREN MED PATH, V14, P12, DOI 10.1097/00000433-199303000-00003; *US CONS PROD SAF, 1999, EV POT RED HEAD INJ; *US CONS PROD SAF, 2001, NAT EL INJ SURV NEIS; US Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; WARME WJ, 1995, AM J SPORT MED, V23, P597, DOI 10.1177/036354659502300514; Xiang HY, 2003, INJURY, V34, P892, DOI 10.1016/S0020-1383(03)00055-X	38	46	47	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2005	58	1					112	118		10.1097/01.TA.0000151270.26634.DD			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	894HS	WOS:000226782300020	15674160				2021-06-18	
J	Ouellet, MC; Morin, CM				Ouellet, MC; Morin, CM			Cognitive behavioral therapy for insomnia associated with traumatic brain injury: A single-case study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the Association-of-Professional-Sleep-Societies	JUN, 2002	Seattle, WA	Assoc Professional Sleep Soc		behavior therapy; cognitive; brain injuries; insomnia; rehabilitation	PSYCHOMETRIC PROPERTIES; SLEEP COMPLAINTS; INVENTORY; PROGRAM	Objective: To test the efficacy of a cognitive behavioral therapy (CBT) for insomnia with a patient with traumatic brain injury (TBI). Design: Single-case study. Setting: Outpatient rehabilitation center. Participant: A man in his late thirties who sustained a moderate TBI in a motor vehicle crash and who developed insomnia. He complained of difficulties falling asleep and staying asleep, despite pharmacotherapy with zopiclone. Interventions: Eight weekly individual CBT sessions. Treatment included stimulus control, sleep restriction, cognitive therapy, and sleep hygiene education. Main Outcome Measures: Sleep diary and polysomnography data. Results: Sleep onset decreased from 47 to 18 minutes, and nocturnal awakenings dropped from 85 to 28 minutes on average at posttreatment. Sleep efficiency also increased substantially (58% to 83%). Polysomnography evaluations corroborated the diary data by showing a decrease in total time awake (63.2 to 26.3 min) and in the number of awakenings (21 to 7.5). The majority of gains were well maintained at 1- and 3-month follow-up assessments. Conclusions: These preliminary results suggest that sleep disturbances after TBI can be alleviated with a nonpharmacologic intervention. CBT for post-TBI insomnia is a promising therapeutic avenue deserving more scientific and clinical attention. (C) 2004 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Laval, Ecole Psychol, Ctr Etudes Troubles Sommeil, St Foy, PQ G1K 7P4, Canada	Ouellet, MC (corresponding author), Univ Laval, Ecole Psychol, Ctr Etudes Troubles Sommeil, St Foy, PQ G1K 7P4, Canada.	mcouellet@psy.ulaval.ca	Morin, Charles M./A-4700-2008; Morin, Charles/G-1021-2011	Morin, Charles M./0000-0002-8649-8895; Ouellet, Marie-Christine/0000-0003-3477-1893			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Sleep Disorders Association, 1997, INT CLASS SLEEP DIS; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bootzin R. R., 1991, CASE STUDIES INSOMNI, P19, DOI DOI 10.1007/978-1-4757-9586-8_2; CHAMBERS MJ, 1992, J BEHAV THER EXP PSY, V23, P289, DOI 10.1016/0005-7916(92)90051-J; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Dashevsky BA, 1998, J CLIN PSYCHIAT, V59, P693, DOI 10.4088/JCP.v59n1210; Hauri PJ, 1991, CASE STUDIES INSOMNI; Jacobs GD, 1996, AM J MED, V100, P212, DOI 10.1016/S0002-9343(97)89461-2; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; MORIN CM, 1993, PSYCHOL AGING, V8, P463, DOI 10.1037/0882-7974.8.3.463; Morin CM, 1996, CLIN PSYCHOL REV, V16, P521, DOI 10.1016/0272-7358(96)00027-X; MORIN CM, 1994, BEHAV THER, V25, P291, DOI 10.1016/S0005-7894(05)80289-8; Morin CM., 1993, INSOMNIA PSYCHOL ASS; MURTAGH DR, 1994, J CONSULT CLIN PSYCH, V63, P79; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; SPIELMAN AJ, 1987, SLEEP, V10, P45	20	46	48	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2004	85	8					1298	1302		10.1016/j.apmr.2003.11.036			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	846CK	WOS:000223292200014	15295756				2021-06-18	
J	Szmydynger-Chodobska, J; Chung, I; Kozniewska, E; Tran, B; Harrington, JF; Duncan, JA; Chodobski, A				Szmydynger-Chodobska, J; Chung, I; Kozniewska, E; Tran, B; Harrington, JF; Duncan, JA; Chodobski, A			Increased expression of vasopressin V-1a receptors after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; cerebrovascular endothelium; neurons; rat; V-1a receptor; vasopressin	ENDOTHELIAL GROWTH-FACTOR; POTASSIUM-CHLORIDE COTRANSPORT; SMOOTH-MUSCLE-CELLS; PROTEIN-KINASE-C; ARGININE-VASOPRESSIN; MESSENGER-RNA; RAT-BRAIN; INTRACELLULAR-DISTRIBUTION; VOLUME REGULATION; STROKE PATIENTS	Experimental evidence obtained in various animal models of brain injury indicates that vasopressin promotes the formation of cerebral edema. However, the molecular and cellular mechanisms underlying this vasopressin action are not fully understood. In the present study, we analyzed the temporal changes in expression of vasopressin V-1a receptors after traumatic brain injury (TBI) in rats. In the intact brain, the V-1a receptor was expressed in neurons located in all layers of the frontoparietal cortex. The V-1a receptor-immunoreactive product was predominantly localized to neuronal nuclei and had both a diffused and punctate staining pattern. The V-1a receptors were also expressed in astrocytes, especially in layer 1 of the frontoparietal cortex. In these cells, two distinctive patterns of immunopositive staining for V-1a receptors were observed: a diffused cytosolic staining of cell bodies and processes and a clearly punctate staining pattern that was predominantly localized to the astrocytic cell bodies. The real-time reverse-transcriptase polymerase chain reaction analysis of changes in mRNA for the V-1a receptor demonstrated that after TBI, there is an early (4 h post-TBI) increase in the number of transcripts in the ipsilateral frontoparietal cortex, when compared to the contralateral hemisphere or the sham-injured rats. This increase in the message was followed by the up-regulation of expression of the V-1a receptors at the protein level. This was most evident in cortical astrocytes in the areas surrounding the lesion. The number of the V-1a receptor-immunopositive astrocytes in the traumatized parenchyma gradually increased, starting at 8 h and peaking at 4-6 days after TBI. Furthermore, a redistribution of V-1a receptors from the astrocytic cell bodies to the astrocytic processes was observed. In addition to astrocytes, an increased expression of V-1a receptors was found in the endothelium of both blood microvessels and the large-diameter blood vessels in the frontoparietal cortex ipsilateral to injury. This increase in the V-1a receptor expression was apparent between 2 and 4 days after TBI. As early as 1-2 h following the impact, there was also a striking increase in the number of the V-1a receptor-immunopositive beaded axonal processes, with greatly enlarged varicosities, that were localized to various areas of the injured parenchyma. It is suggested that the increased expression of V-1a receptors plays an important role in the vasopressin-mediated formation of edema in the injured brain.	Brown Univ, Sch Med, Dept Clin Neurosci, Providence, RI 02903 USA; Polish Acad Sci, Med Res Ctr, Dept Neurosurg, Warsaw, Poland	Chodobski, A (corresponding author), Brown Univ, Sch Med, Dept Clin Neurosci, Aldrich Bldg,Room 405,593 Eddy St, Providence, RI 02903 USA.	adam_chodobski@brown.edu		Kozniewska, Ewa/0000-0003-0675-1238; Tran, Bao/0000-0002-0980-7594	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039921] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-39921] Funding Source: Medline		Barreca T, 2001, CEREBROVASC DIS, V11, P113, DOI 10.1159/000047622; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bates DO, 1999, MICROCIRCULATION, V6, P83, DOI 10.1038/sj.mn.7300054; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; Bkaily G, 2000, J CARDIOVASC PHARM, V36, pS414, DOI 10.1097/00005344-200036051-00121; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Castejon OJ, 1998, BRAIN INJURY, V12, P409, DOI 10.1080/026990598122539; Chen Q, 2000, NEUROSCIENCE, V101, P19, DOI 10.1016/S0306-4522(00)00323-7; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chritin M, 1999, MOL BRAIN RES, V70, P210, DOI 10.1016/S0169-328X(99)00148-5; Chung I, 2003, NEUROSCIENCE, V116, P349, DOI 10.1016/S0306-4522(02)00720-0; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; DEPASQUALE M, 1989, AM J PHYSIOL, V256, pF1059; DICKINSON LD, 1992, J CEREBR BLOOD F MET, V12, P681, DOI 10.1038/jcbfm.1992.93; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hernando F, 2001, ENDOCRINOLOGY, V142, P1659, DOI 10.1210/en.142.4.1659; Hertz L, 2000, J NEUROSCI RES, V62, P480, DOI 10.1002/1097-4547(20001115)62:4<480::AID-JNR2>3.0.CO;2-K; HOCHER B, 1992, BIOCHEM BIOPH RES CO, V184, P498, DOI 10.1016/0006-291X(92)91222-C; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Huang Wei-dong, 2003, Chin J Traumatol, V6, P139; JOHNSON DM, 2003, SOC NEUR ABST; JOYNT RJ, 1981, ANN NEUROL, V9, P182, DOI 10.1002/ana.410090212; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KATO Y, 1995, DIFFERENTIATION, V59, P163, DOI 10.1046/j.1432-0436.1995.5930163.x; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; LATZKOVITS L, 1993, AM J PHYSIOL, V264, pC603; Liu KF, 2001, STROKE, V32, P1897, DOI 10.1161/01.STR.32.8.1897; Lu D, 1998, ENDOCRINOLOGY, V139, P365, DOI 10.1210/endo.139.1.5679; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; MURASAWA S, 1995, J BIOL CHEM, V270, P20042, DOI 10.1074/jbc.270.34.20042; NATHANSON MH, 1992, AM J PHYSIOL, V262, pG1079; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; O'Donnell ME, 2003, FASEB J, V17, pA76; ODONNELL ME, 1995, AM J PHYSIOL-CELL PH, V268, pC747; ODONNELL ME, 1991, J BIOL CHEM, V266, P11559; OSTROWSKI NL, 1994, ENDOCRINOLOGY, V135, P1511, DOI 10.1210/en.135.4.1511; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; RAICHLE ME, 1978, BRAIN RES, V143, P191, DOI 10.1016/0006-8993(78)90766-7; REITH J, 1987, J NEUROCHEM, V49, P1471, DOI 10.1111/j.1471-4159.1987.tb01016.x; Rosenberg G A, 1990, Adv Neurol, V52, P149; ROSENBERG GA, 1986, AM J PHYSIOL, V251, pF485; ROSENBERG GA, 1992, STROKE, V23, P1767, DOI 10.1161/01.STR.23.12.1767; Russell JM, 2000, PHYSIOL REV, V80, P211; Sarfaraz D, 1999, AM J PHYSIOL-ENDOC M, V276, pE596; Schoneberg T, 1998, ADV EXP MED BIOL, V449, P347; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; SORENSEN PS, 1985, J NEUROL NEUROSUR PS, V48, P50, DOI 10.1136/jnnp.48.1.50; Strakova Z, 1997, MOL PHARMACOL, V51, P217; SZOT P, 1994, MOL BRAIN RES, V24, P1, DOI 10.1016/0169-328X(94)90111-2; Tahara A, 1999, EUR J PHARMACOL, V368, P89, DOI 10.1016/S0014-2999(99)00004-7; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; TRIBOLLET E, 1994, P NATL ACAD SCI USA, V91, P9636, DOI 10.1073/pnas.91.20.9636; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; Yan YP, 2001, J CEREBR BLOOD F MET, V21, P711, DOI 10.1097/00004647-200106000-00009; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	61	46	50	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2004	21	8					1090	1102		10.1089/0897715041651033			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	846AK	WOS:000223286800011	15319008				2021-06-18	
J	Karlsson, J; Fong, KSK; Hansson, MJ; Elmer, E; Csiszar, K; Keep, MF				Karlsson, J; Fong, KSK; Hansson, MJ; Elmer, E; Csiszar, K; Keep, MF			Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis	JOURNAL OF NEUROSURGERY			English	Article						amyotrophic lateral sclerosis; mitochondria; neurodegenerative disease; Parkinson disease; G93A transgenic mouse; superoxide dismutase	MITOCHONDRIAL PERMEABILITY TRANSITION; TRAUMATIC BRAIN-INJURY; SUPEROXIDE-DISMUTASE; CELL-DEATH; CYTOCHROME-C; RAT-BRAIN; DIFFERENTIAL EXPRESSION; OXIDATIVE INACTIVATION; PROLONGS SURVIVAL; INNER MEMBRANE	Object. The authors investigated whether cyclosporin A (CsA), a cyclophilin ligand with mitochondrial permeability transition pore-blocking and calcineurin-inhibiting properties, affects motor function, neuronal death, and life span in the G93A transgenic mouse model of familial amyotrophic lateral sclerosis (FALS). Methods. The G93A mice received weekly intracerebroventricular injections of CsA (20 mug/mouse/week) starting at the age of 65 days, and physical performance on an exercise wheel was monitored beginning at 84 days of age. Mice were allowed to survive for clinical observation of body weight, hindlimb weakness, and life span or until a defined end stage or were killed at 110 days of age for histological analysis. Conclusions. Treatment with CsA significantly delayed the onset of hindlimb weakness and also extended the time from its onset to paralysis. The overall life span of CsA-treated G93A mice was significantly extended, by 12% compared with vehicle-treated transgenic littermates. The CsA also prolonged physical performance on the exercise wheel and delayed weight loss. Histologically, there was significant preservation of both cervical and lumbar spine motor neurons and also tyrosine hydroxylase-positive dopaminergic substantia nigra neurons in 110-day-old CsA-treated mice compared with their transgenic littermates. The local administration of CsA directly into the brain ventricles is an effective means of central nervous system drug delivery (because CsA does not readily cross the blood-brain barrier), which in this study ameliorated clinical and neuropathological features of FALS in G93A mice. The remarkably low intrathecal CsA dose required for neuroprotection reduces potential adverse effects of systemic immunosuppression or nephrotoxicity seen with chronic systemic delivery of the drug.	Univ Hawaii, John A Burns Sch Med, Lab Matrix Pathobiol, Honolulu, HI 96822 USA; Lund Univ, Wallenberg Neruosci Ctr, Expt Brain Res Lab, Lund, Sweden; LLC, Maas BiolAB, Albuquerque, NM USA	Keep, MF (corresponding author), Univ New Mexico, Hlth Sci Ctr, Dept Surg, Div Neurosurg, MSC 10 5610,1 Univ New Mexico, Albuquerque, NM 87131 USA.	mkeep@salud.unm.edu	Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [2G12RR03061-16] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [G12RR003061] Funding Source: NIH RePORTER		Almer G, 2001, ANN NEUROL, V49, P176, DOI 10.1002/1531-8249(20010201)49:2<176::AID-ANA37>3.3.CO;2-O; Anneser JMH, 2001, NEUROREPORT, V12, P2663, DOI 10.1097/00001756-200108280-00015; APPEL SH, 1988, ARCH NEUROL-CHICAGO, V45, P381, DOI 10.1001/archneur.1988.00520280027011; BALLARD PA, 1985, NEUROLOGY, V35, P949, DOI 10.1212/WNL.35.7.949; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; Borlongan CV, 1999, CELL TRANSPLANT, V8, P153, DOI 10.1177/096368979900800107; Borlongan CV, 2000, NEUROSCI LETT, V279, P73, DOI 10.1016/S0304-3940(99)00962-3; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; DALCANTO MC, 1995, BRAIN RES, V676, P25, DOI 10.1016/0006-8993(95)00063-V; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; Ferri A, 2001, J NEUROCHEM, V79, P531, DOI 10.1046/j.1471-4159.2001.00558.x; Ferri A, 2000, J NEUROCHEM, V75, P606, DOI 10.1046/j.1471-4159.2000.0750606.x; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Friberg H, 1998, J NEUROSCI, V18, P5151; Goldner FM, 1996, J COMP NEUROL, V372, P283; Guegn C, 2001, J NEUROSCI, V21, P6569; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gurney ME, 1996, ANN NEUROL, V39, P147, DOI 10.1002/ana.410390203; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Hensley K, 2002, J NEUROCHEM, V82, P365, DOI 10.1046/j.1471-4159.2002.00968.x; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; KEEP M, 2002, IMMUNOSUPPRESSANT AN, P3; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Knirsch U, 2001, BRAIN RES, V889, P234, DOI 10.1016/S0006-8993(00)03048-1; Kong JM, 1998, J NEUROSCI, V18, P3241; Kostic V, 1997, ANN NEUROL, V41, P497, DOI 10.1002/ana.410410413; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kriz J, 2002, NEUROBIOL DIS, V10, P268, DOI 10.1006/nbdi.2002.0487; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Lacomblez L, 1996, LANCET, V347, P1425, DOI 10.1016/S0140-6736(96)91680-3; LAD RP, 1991, MOL BRAIN RES, V9, P239, DOI 10.1016/0169-328X(91)90007-K; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Leventhal L, 2000, J COMP NEUROL, V425, P471, DOI 10.1002/1096-9861(20001002)425:4<471::AID-CNE1>3.0.CO;2-U; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Malaspina A, 2001, J NEUROCHEM, V77, P132, DOI 10.1046/j.1471-4159.2001.t01-1-00231.x; Matsuura K, 1997, EXP NEUROL, V146, P526, DOI 10.1006/exnr.1997.6575; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ochs G, 2000, AMYOTROPH LATERAL SC, V1, P201, DOI 10.1080/14660820050515197; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pasinelli P, 2000, P NATL ACAD SCI USA, V97, P13901, DOI 10.1073/pnas.240305897; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Penn RD, 1997, NEUROSURGERY, V40, P94, DOI 10.1097/00006123-199701000-00021; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; SCHARFE T, 1989, UROL INT, V44, P1, DOI 10.1159/000281439; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Seaton TA, 1998, BRAIN RES, V809, P12, DOI 10.1016/S0006-8993(98)00790-2; SNOW BJ, 1990, ARCH NEUROL-CHICAGO, V47, P870, DOI 10.1001/archneur.1990.00530080052010; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Volkel H, 2001, FEBS LETT, V503, P201, DOI 10.1016/S0014-5793(01)02730-2; Vukosavic S, 2000, J NEUROSCI, V20, P9119; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Wu AS, 2003, J NEUROCHEM, V85, P142, DOI 10.1046/j.1471-4159.2003.01639.x; Yoshihara T, 2002, J NEUROCHEM, V80, P158, DOI 10.1046/j.0022-3042.2001.00683.x; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZHANG ET, 1990, J ANAT, V170, P111; Zhang LC, 2003, BRAIN RES, V989, P1, DOI 10.1016/S0006-8993(03)03123-8; Zhang WH, 2003, ANN NEUROL, V53, P267, DOI 10.1002/ana.10476; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	76	46	47	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2004	101	1					128	137		10.3171/jns.2004.101.1.0128			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	834GD	WOS:000222398700020	15255263				2021-06-18	
J	Brabeck, C; Beschorner, R; Conrad, S; Mittelbronn, M; Bekure, K; Meyermann, R; Schluesener, HJ; Schwab, JM				Brabeck, C; Beschorner, R; Conrad, S; Mittelbronn, M; Bekure, K; Meyermann, R; Schluesener, HJ; Schwab, JM			Lesional expression of RhoA and RhoB following traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						pharmacological target; regeneration; Rho GTPases; tissue remodeling; traumatic brain injury	ADP-RIBOSYLATING EXOENZYME; CENTRAL-NERVOUS-SYSTEM; CLOSTRIDIUM-BOTULINUM; AXONAL REGENERATION; ACTIN CYTOSKELETON; NEURITE OUTGROWTH; TYROSINE KINASE; HEAD-INJURY; G-PROTEIN; GTPASES	Inhibition of the small GTPase Rho or of its downstream target Rho-associated kinase (ROCK) has been shown to promote axon regeneration and to improve functional recovery following traumatic CNS lesions in the adult rat. In order to determine the expression pattern of RhoA and RhoB following human traumatic brain injury (TBI) and to assess whether Rho is a possible target for pharmacological intervention in humans, we investigated expression patterns of RhoA and RhoB in brain specimens from 25 patients who died after closed TBI in comparison to brain tissue derived from four neuropathologically unaffected control patients by immunohistochemistry. A highly significant lesional upregulation of both RhoA and RhoB was observed beginning several hours after the traumatic event and continuing for months after TBI. The cellular sources of both molecules included polymorphonuclear granulocytes, monocytes/macrophages, and reactive astrocytes. Additionally, expression of RhoA was also detected in neuronal cells in some of the cases. From our data, we conclude that inhibition of Rho is a promising mechanism for the development of new pharmacological interventions in human TBI. As the observed upregulation of RhoA and RhoB was still detectable months after TBI, we speculate that even delayed treatment with Rho inhibitors might be a therapeutic option.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Paris 06, CNRS, UMR 7102, Equipe Dev Neuronal, Paris, France	Schwab, JM (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	jmschwab@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Beschorner, Rudi/0000-0003-1109-915X; Mittelbronn, Michel/0000-0002-2998-052X; Schwab, Jan/0000-0001-6784-4919			Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Angkachatchai V, 1999, J IMMUNOL, V163, P3819; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; Dergham P, 2002, J NEUROSCI, V22, P6570; Donovan FM, 1997, J NEUROSCI, V17, P5316; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Fournier AE, 2001, CURR OPIN NEUROBIOL, V11, P89, DOI 10.1016/S0959-4388(00)00178-1; Fournier AE, 2003, J NEUROSCI, V23, P1416; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Jin Z, 1997, J NEUROSCI, V17, P6256; JUST I, 1995, BIOCHEMISTRY-US, V34, P334, DOI 10.1021/bi00001a041; JUST I, 1992, J BIOL CHEM, V267, P10274; Kanumilli S, 2002, NEUROPHARMACOLOGY, V42, P1, DOI 10.1016/S0028-3908(01)00161-7; Kawaguchi A, 2000, EUR J PHARMACOL, V403, P203, DOI 10.1016/S0014-2999(00)00593-8; Knaus UG, 2000, IMMUNOL RES, V21, P103, DOI 10.1385/IR:21:2-3:103; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Negishi M, 2002, J BIOCHEM, V132, P157, DOI 10.1093/oxfordjournals.jbchem.a003205; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Redmond L, 2001, CURR OPIN NEUROBIOL, V11, P111, DOI 10.1016/S0959-4388(00)00181-1; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Safavi-Abbasi S, 2001, GLIA, V36, P102, DOI 10.1002/glia.1099; Saito H, 2002, J LEUKOCYTE BIOL, V72, P829; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schwab JM, 2004, J NEUROPATH EXP NEUR, V63, P180, DOI 10.1093/jnen/63.2.180; SCHWAB JM, 2002, SOC NEUR ABSTR; Stichel CC, 1998, CELL TISSUE RES, V294, P1, DOI 10.1007/s004410051151; Suidan HS, 1997, GLIA, V21, P244, DOI 10.1002/(SICI)1098-1136(199710)21:2<244::AID-GLIA7>3.0.CO;2-6; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Trapp T, 2001, MOL CELL NEUROSCI, V17, P883, DOI 10.1006/mcne.2001.0971; Wilde C, 2002, BIOCHEMISTRY-US, V41, P1539, DOI 10.1021/bi015809i; Winton MJ, 2002, J BIOL CHEM, V277, P32820, DOI 10.1074/jbc.M201195200; Woolf CJ, 2002, SCIENCE, V297, P1132, DOI 10.1126/science.1076247; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	46	46	46	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					697	706		10.1089/0897715041269597			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600006	15253798				2021-06-18	
J	Lew, HL; Lee, EH; Pan, SSL; Date, ES				Lew, HL; Lee, EH; Pan, SSL; Date, ES			Electrophysiologic abnormalities of auditory and visual information processing in patients with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article							EVENT-RELATED POTENTIALS; RESPONSE-MONITORING DYSFUNCTION; CLOSED-HEAD-INJURY; BIOLOGICAL DETERMINANTS; PREDICTING OUTCOMES; P300 ABNORMALITIES; ALZHEIMERS-DISEASE; EVOKED POTENTIALS; SCHIZOPHRENIA; LATENCY	Objective: Through both auditory and visual modalities, we sought to explore the efficacy of event-related potentials in detecting residual cognitive impairments in patients with traumatic brain injury (TBI). Design: Control subjects and TBI patients with favorable recovery were recruited. Pure tone and primary color discrimination tasks were utilized to elicit auditory and visual event-related potentials, respectively. All subjects were instructed to push a response button when they detected the target stimuli. Both behavioral and electrophysiologic responses were obtained simultaneously. We analyzed the event-related potential waveforms and examined the differences in amplitude, latency, behavioral reaction time, and response accuracy. Results: A total of 11 TBI patients and 11 control subjects were tested. Results showed that (1) TBI patients had significantly lower P300 amplitude in both auditory (11.2 vs. 22.7 muV) and visual (11.6 vs. 20.9 muV) domains, (2) TBI patients had significantly longer P300 latency in both auditory (355 vs. 294 msecs) and visual (376 vs. 341 msecs) modalities, and (3) although there was no significant difference in response accuracy (97.7% vs. 100%), reaction time for both auditory and visual tasks were significantly longer in TBI patients (auditory, 404 vs. 277 msecs; visual, 397 vs. 346 msecs). Conclusion: Although TBI patients with good recovery showed similar response accuracy when compared with control subjects, they demonstrated significantly poorer performance in both electrophysiologic and behavioral responses. Diminished amplitudes and prolonged latencies in P300 responses indicate impaired organization and categorization of incoming sensory information; prolonged behavioral reaction times suggest slowing in the response execution process. Clinical and theoretical implications and goals for continued research are discussed.	VAPAHCS, PM&R Serv, Comprehens Rehabil Ctr, Palo Alto, CA 94304 USA; Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA	Lew, HL (corresponding author), VAPAHCS, PM&R Serv, Comprehens Rehabil Ctr, MS-B117,3801, Palo Alto, CA 94304 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5K12HD01097] Funding Source: Medline		Bennington JY, 1999, INT J PSYCHOPHYSIOL, V34, P171, DOI 10.1016/S0167-8760(99)00070-7; BIRDSALL HH, 1994, OTOLARYNG HEAD NECK, V110, P53, DOI 10.1016/S0194-5998(94)70792-8; Cass M, 1997, BIOL PSYCHOL, V46, P51, DOI 10.1016/S0301-0511(96)05233-7; FORD JM, 1994, ELECTROEN CLIN NEURO, V90, P214, DOI 10.1016/0013-4694(94)90093-0; Ford JM, 1999, PSYCHOPHYSIOLOGY, V36, P667, DOI 10.1111/1469-8986.3660667; Ford JM, 2001, BIOL PSYCHIAT, V49, P848, DOI 10.1016/S0006-3223(00)01051-9; FORD JM, 1995, BIOL PSYCHOL, V39, P57, DOI 10.1016/0301-0511(94)00959-2; Fowler B, 1997, BIOL PSYCHOL, V46, P113, DOI 10.1016/S0301-0511(97)05253-8; Friedman D, 2003, J CLIN EXP NEUROPSYC, V25, P702, DOI 10.1076/jcen.25.5.702.14578; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Ilan AB, 1999, CLIN NEUROPHYSIOL, V110, P367; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; Knott V, 2003, CLIN ELECTROENCEPHAL, V34, P182, DOI 10.1177/155005940303400404; Lew H, 1997, J Am Acad Audiol, V8, P104; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Lew HL, 2002, AM J PHYS MED REHAB, V81, P524, DOI 10.1097/00002060-200207000-00011; LEW HL, 1997, J NEUROVASC DIS, V2, P265; Mathalon DH, 2003, NEUROBIOL AGING, V24, P675, DOI 10.1016/S0197-4580(02)00154-9; Mathalon DH, 2002, J ABNORM PSYCHOL, V111, P22, DOI 10.1037//0021-843X.111.1.22; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; NISHIMURA N, 1995, PSYCHIAT CLIN NEUROS, V49, P79, DOI 10.1111/j.1440-1819.1995.tb01863.x; Olichney JM, 2002, J NEUROL NEUROSUR PS, V73, P377, DOI 10.1136/jnnp.73.4.377; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P104, DOI 10.1016/0168-5597(84)90027-3; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Polich J, 1998, J CLIN NEUROPHYSIOL, V15, P14, DOI 10.1097/00004691-199801000-00004; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P334, DOI 10.1111/j.1469-8986.1996.tb01058.x; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; POLICH J, 2004, PM R CLIN N AM; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Viggiano MP, 1996, J CLIN EXP NEUROPSYC, V18, P631, DOI 10.1080/01688639608408288; WAYMAN JW, 1992, J ACOUST SOC AM, V91, P3527, DOI 10.1121/1.402841	36	46	52	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	2004	83	6					428	433		10.1097/00002060-200406000-00004			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	822QB	WOS:000221553600003	15166686				2021-06-18	
J	Moriarity, J; Collie, A; Olson, D; Buchanan, J; Leary, P; McStephen, M; McCrory, P				Moriarity, J; Collie, A; Olson, D; Buchanan, J; Leary, P; McStephen, M; McCrory, P			A prospective controlled study of cognitive function during an amateur boxing tournament	NEUROLOGY			English	Article							CHRONIC BRAIN-DAMAGE; REACTION-TIME; NEUROPSYCHOLOGICAL ASSESSMENT; IMPAIRMENT; INJURY; LEAD; AFTERMATH; BOXERS; LONG	Background: Few studies have reported acute postbout cognitive function in amateur boxers, and none have documented the effects of repeated boxing bouts within a short time frame. Objective: To determine whether participation in a 7-day amateur boxing tournament is associated with acute deterioration in cognitive test performance. Methods: A prospective study was done of 82 collegiate amateur boxers participating in a 7-day single elimination tournament and a group of 30 matched nonboxing control participants. No participants had a history of recent concussion or past history of brain injury. For boxers, cognitive assessment using a computerized test battery was performed before the tournament and within 2 hours of completing each bout. Tests of simple and choice reaction time, working memory, and learning were administered. Analysis of variance was conducted to compare the serial performance of control participants with that of boxers participating in one, two, and three bouts. Results: The 82 boxers fought 159 times. Cognitive testing was performed after 142 of these bouts. On simple reaction time, choice reaction time, and working memory tasks, the serial performance of boxers participating in three bouts (n = 22) was equivalent to that of boxers participating in two bouts (n = 22) and one bout (n = 32) and to nonboxing control participants (n = 30). An improvement in performance was observed on the learning task in boxers participating in three bouts. Boxers whose bout was stopped by the referee (n = 7) displayed significant slowing in simple and choice reaction time. Conclusions: With the exception of boxers whose contest is stopped by the referee, amateur boxers participating in multiple bouts during a 7-day tournament display no evidence of cognitive dysfunction in the immediate postbout period.	Univ Notre Dame, Ctr Hlth, Notre Dame, IN 46556 USA; CogState Ltd, Melbourne, Vic, Australia; Univ Melbourne, Ctr Sports Med Res & Educ, Parkville, Vic 3052, Australia; Univ Melbourne, Ctr Neurosci, Parkville, Vic 3052, Australia; Mercy Walworth Med Ctr, Lake Geneva, WI USA; Univ Melbourne, Brain Res Inst, Parkville, Vic 3052, Australia	Moriarity, J (corresponding author), Univ Notre Dame, Ctr Hlth, Notre Dame, IN 46556 USA.	Moriarity.1@nd.edu	McCrory, Paul/Q-8688-2019	Collie, Alex/0000-0003-2617-9339			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Basso MR, 1999, CLIN NEUROPSYCHOL, V13, P283, DOI 10.1076/clin.13.3.283.1743; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; Cohen J, 1988, STAT POWER BEHAV SCI; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLIE A, 2004, IN PRESS NEUROPSYCHO; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Darby D, 2002, NEUROLOGY, V59, P1042, DOI 10.1212/WNL.59.7.1042; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jako P, 2002, BRIT J SPORT MED, V36, P394, DOI 10.1136/bjsm.36.6.394; Jordan B. D., 1998, SPORTS NEUROLOGY, P351; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; JORDAN BD, 1991, HOSP MED, V27, P93; KEMP PM, 1995, J NEUROL NEUROSUR PS, V59, P368, DOI 10.1136/jnnp.59.4.368; KEMP PM, 1995, J R MED SERV, V81, P183; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Luce R.D., 1986, RESPONSE TIMES THEIR; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; Porter M, 1996, CLIN J SPORT MED, V6, P97, DOI 10.1097/00042752-199604000-00006; Porter MD, 1996, CLIN J SPORT MED, V6, P90, DOI 10.1097/00042752-199604000-00005; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; SILBERT B, 2004, IN PRESS ANESTH ANAL; STEWART WF, 1994, AM J EPIDEMIOL, V139, P573, DOI 10.1093/oxfordjournals.aje.a117047; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Unterharnscheidt F, 1995, Rev Neurol, V23, P1027; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	43	46	47	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 11	2004	62	9					1497	1502		10.1212/WNL.62.9.1497			6	Clinical Neurology	Neurosciences & Neurology	819XU	WOS:000221350400008	15136671				2021-06-18	
J	Cernak, I; Vink, R; Natale, J; Stoica, B; Lea, PM; Movsesyan, V; Ahmed, F; Knoblach, SM; Fricke, ST; Faden, AI				Cernak, I; Vink, R; Natale, J; Stoica, B; Lea, PM; Movsesyan, V; Ahmed, F; Knoblach, SM; Fricke, ST; Faden, AI			The "dark side" of endocannabinoids: A neurotoxic role for anandamide	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						endocannabinoids; anandamide; cell death; microarray; magnetic resonance imaging; cognitive deficit	TRAUMATIC BRAIN-INJURY; CULTURED CORTICAL-NEURONS; VANILLOID-INDUCED APOPTOSIS; CB1 CANNABINOID RECEPTOR; FOCAL CEREBRAL-ISCHEMIA; INDUCED AXONAL INJURY; CELL-DEATH; N-ACYLETHANOLAMINE; RAT-BRAIN; MATRIX METALLOPROTEINASES	Endocannabinoids, including 2-arachidonoylglycerol and anandamide (N-arachidonoylethanolamine; AEA), have neuroprotective effects in the brain through actions at CB1 receptors. However, AEA also binds to vanilloid (VR1) receptors and induces cell death in several cell lines. Here we show that anandamide causes neuronal cell death in vitro and exacerbates cell loss caused by stretch-induced axonal injury or trophic withdrawal in rat primary neuronal cultures. Administered intracerebroventricularly, AEA causes sustained cerebral edema, as reflected by diffusion-weighted magnetic resonance imaging, regional cell loss, and impairment in long-term cognitive function. These effects are mediated, in part, through VR1 as well as through calpain-dependent mechanisms, but not through CB1 receptors or caspases. Central administration of AEA also significantly upregulates genes involved in proinflammatory/microglial-related responses. Thus, anandamide produces neurotoxic effects both in vitro and in vivo through multiple mechanisms independent of the CB1 receptor.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Univ Adelaide, Dept Pathol, Adelaide, SA, Australia	Cernak, I (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd,Res Bldg,Room EP04, Washington, DC 20057 USA.	ifc@georgetown.edu	Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012; STOICA, BOGDAN/H-9782-2013; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; STOICA, BOGDAN/0000-0002-2501-6434; AM, Robert Vink/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Benham CD, 2002, NEUROPHARMACOLOGY, V42, P873, DOI 10.1016/S0028-3908(02)00047-3; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; Boisvert D P, 1990, Adv Neurol, V52, P407; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Campbell VA, 2001, NEUROPHARMACOLOGY, V40, P702, DOI 10.1016/S0028-3908(00)00210-0; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Chan D, 1998, NETW COMPUT, V9, P18; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; Chapman GA, 2000, J NEUROSCI, V20; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; del Pulgar TG, 2002, J BIOL CHEM, V277, P36527, DOI 10.1074/jbc.M205797200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Di Marzo V, 2000, J NEUROCHEM, V75, P2434, DOI 10.1046/j.1471-4159.2000.0752434.x; Di Marzo V, 2002, CURR OPIN NEUROBIOL, V12, P372, DOI 10.1016/S0959-4388(02)00340-9; Downer E, 2001, NEUROREPORT, V12, P3973, DOI 10.1097/00001756-200112210-00024; Downer EJ, 2003, BRIT J PHARMACOL, V140, P547, DOI 10.1038/sj.bjp.0705464; Eldadah BA, 1997, J NEUROSCI, V17, P6105; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; EPPS DE, 1980, BIOCHIM BIOPHYS ACTA, V618, P420, DOI 10.1016/0005-2760(80)90260-X; Faden AI, 2003, ANN NEUROL, V54, pS77; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Galve-Roperh I, 2002, MOL PHARMACOL, V62, P1385, DOI 10.1124/mol.62.6.1385; GRAY GM, 1976, BIOCHIM BIOPHYS ACTA, V431, P1, DOI 10.1016/0005-2760(76)90253-8; Guzman M, 2003, BRIT J PHARMACOL, V140, P439, DOI 10.1038/sj.bjp.0705465; Hail N, 2003, APOPTOSIS, V8, P251, DOI 10.1023/A:1023620821878; Hail N, 2002, JNCI-J NATL CANCER I, V94, P1281, DOI 10.1093/jnci/94.17.1281; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; Hampson AJ, 1998, J NEUROCHEM, V70, P671; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; Hansen HS, 1997, J NEUROCHEM, V69, P753; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Jambrina E, 2003, J BIOL CHEM, V278, P14134, DOI 10.1074/jbc.M211388200; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Jiang Q, 1998, J CEREBR BLOOD F MET, V18, P758, DOI 10.1097/00004647-199807000-00007; Kim SY, 2002, MOL CELLS, V13, P429; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; LaFleur M, 1996, J EXP MED, V184, P2311; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Li FH, 1996, DRUG TODAY, V32, P615; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; Maccarrone M, 2001, J NEUROCHEM, V76, P594, DOI 10.1046/j.1471-4159.2001.00092.x; Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mechoulam R, 2002, TRENDS MOL MED, V8, P58, DOI 10.1016/S1471-4914(02)02276-1; Mechoulam R, 2003, SCIENCE, V302, P65, DOI 10.1126/science.1091256; Mechoulam R, 2002, PROSTAG LEUKOTR ESS, V66, P93, DOI 10.1054/plef.2001.0340; MECHOULAM R, 2002, SCI STKE; Melendez A, 1998, CURR BIOL, V8, P210, DOI 10.1016/S0960-9822(98)70085-5; Mombouli JV, 1999, BRIT J PHARMACOL, V126, P1593, DOI 10.1038/sj.bjp.0702483; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Nagayama T, 1999, J NEUROSCI, V19, P2987; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; Olah Z, 2001, J BIOL CHEM, V276, P11021, DOI 10.1074/jbc.M008392200; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Povlishock JT, 1999, ACT NEUR S, V73, P15; Qiao M, 2001, STROKE, V32, P958, DOI 10.1161/01.STR.32.4.958; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Ross RA, 2003, BRIT J PHARMACOL, V140, P790, DOI 10.1038/sj.bjp.0705467; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; Sagan S, 1999, EUR J NEUROSCI, V11, P691, DOI 10.1046/j.1460-9568.1999.00480.x; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; Sarker KP, 2003, CELL MOL LIFE SCI, V60, P1200, DOI 10.1007/s00018-003-3055-2; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Szallasi A, 2000, TRENDS NEUROSCI, V23, P491, DOI 10.1016/S0166-2236(00)01630-1; Szallasi A, 2002, AM J CLIN PATHOL, V118, P110; SZALLASI A, 1990, LIFE SCI, V47, P1399, DOI 10.1016/0024-3205(90)90518-V; Szoke E, 2000, NEUROREPORT, V11, P1949; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Toman RE, 2002, J NEUROSCI RES, V68, P323, DOI 10.1002/jnr.10190; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; VEECH RL, 1979, J BIOL CHEM, V254, P6538; Veldhuis WB, 2003, J NEUROSCI, V23, P4127; VENANCE L, 1995, NATURE, V376, P590, DOI 10.1038/376590a0; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Vink R, 1990, Magnes Res, V3, P163; Walter L, 2002, J BIOL CHEM, V277, P20869, DOI 10.1074/jbc.M110813200; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zygmunt PM, 1999, NATURE, V400, P452	100	46	46	1	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2004	24	5					564	578		10.1097/00004647-200405000-00011			15	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	818SP	WOS:000221265100011	15129189	Bronze			2021-06-18	
J	Borgens, RB; Bohnert, D; Duerstock, B; Spomar, D; Lee, RC				Borgens, RB; Bohnert, D; Duerstock, B; Spomar, D; Lee, RC			Subcutaneous tri-block copolymer produces recovery from spinal cord injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						spinal cord; neurotrauma; copolymer; P188; polyethylene glycol	BEHAVIORAL RECOVERY; FUNCTIONAL RECOVERY; MOLECULAR REPAIR; NERVE MEMBRANES; POLOXAMER 188; GUINEA-PIGS; HEMISECTION; MACROPHAGE; ISCHEMIA; NEURONS	We have studied the ability of nonionic detergents and hydrophilic polymers to seal permeabilized membranes of damaged cells, rescuing them from progressive dissolution, degeneration, and death. We report that a single subcutaneous injection of the tri-block copolymer, Poloxamer 188 (P188) 6 hr after a severe compression of the adult guinea pig spinal cord is able to: (1) preserve the anatomic integrity of the cord; (2) produce a rapid recovery of nerve impulse conduction through the lesion; and (3) produce a behavioral recovery of a spinal cord dependent long tract spinal cord reflex. These observations stood out against a control group in blinded evaluation. Conduction through the lesion was monitored by stimulating the tibial nerve of the hind limb, and measuring the arrival of evoked potentials at the contralateral sensory cortex of the brain (somatosensory evoked potentials; SSEP). Behavioral recovery was determined by a return of sensitivity of formerly areflexic receptive fields of the cutaneous trunchi muscle (CTM) reflex. This contraction of back skin in response to tactile stimulation is totally dependent on the integrity of an identified bilateral column of ascending long tract axons. A statistically significant recovery of both SSEP conduction through the lesion and the CTM reflex occurred in P188-treated animals compared to vehicle-treated controls. Quantitative 3D computer reconstruction of the lesioned vertebral segment of spinal cord revealed a statistically significant sparing of spinal cord parenchyma and a significant reduction in cavitation of the spinal cord compared to control animals We determined that the proportion of P188-treated animals that recovered evoked potentials were nearly identical to that produced by a subcutaneous injection of polyethylene glycol (PEG). In contrast, P188 was not as effective as PEG in producing a recovery of CTM functioning. We discuss the likely differences in the mechanisms of action of these two polymers, and the possibilities inherent in a combined treatment. (C) 2004 Wiley-Liss, Inc.	Purdue Univ, Sch Vet Med, Ctr Paralysis Res, W Lafayette, IN 47907 USA; Univ Chicago, Dept Surg Mol Med & Organismal Biol & Anat, Chicago, IL 60637 USA; Indiana Univ, Wishard Mem Hosp, Med Ctr, Div Neurosurg, Indianapolis, IN 46202 USA	Borgens, RB (corresponding author), Purdue Univ, Sch Vet Med, Ctr Paralysis Res, 408 S Univ St, W Lafayette, IN 47907 USA.	cpr@purdue.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM64757, R01 GM61101] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS/HD39288-01A1, 1 R01 NS 39288-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM064757, R01GM061101] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER		Bajaj CL, 1997, VISUALIZATION '97 - PROCEEDINGS, P167, DOI 10.1109/VISUAL.1997.663875; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 1982, INT REV CYTOL, V76, P245, DOI 10.1016/S0074-7696(08)61793-3; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; BORGENS RB, 2003, RESTORING FUNCTION I; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Donaldson J, 2002, NEUROSURGERY, V50, P147, DOI 10.1097/00006123-200201000-00023; Duerstock BS, 2000, COMPUT MED IMAG GRAP, V24, P389, DOI 10.1016/S0895-6111(00)00034-3; Duerstock BS, 2002, J EXP BIOL, V205, P13; Follis F, 1996, J INVEST SURG, V9, P149, DOI 10.3109/08941939609012466; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Hannig J, 2000, RADIAT RES, V154, P171, DOI 10.1667/0033-7587(2000)154[0171:SSOMPB]2.0.CO;2; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; LEE RC, 1994, ANN NY ACAD SCI, V720, P239, DOI 10.1111/j.1749-6632.1994.tb30453.x; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; Leskovar A, 2000, J EXP BIOL, V203, P1783; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; MELLORS A, 1966, J BIOL CHEM, V241, P4353; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; Moriarty LJ, 1999, RESTOR NEUROL NEUROS, V14, P53; PADANLAM JT, 1994, ANN NY ACAD SCI, V92, P111; Palmer JS, 1998, J UROLOGY, V159, P2136, DOI 10.1016/S0022-5347(01)63295-6; Quick KL, 2000, J NEUROSCI METH, V97, P139, DOI 10.1016/S0165-0270(00)00179-5; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Terry MA, 1999, ANN NY ACAD SCI, V888, P274, DOI 10.1111/j.1749-6632.1999.tb07962.x; Tuszynski MH, 1999, J NEUROTRAUM, V16, P523, DOI 10.1089/neu.1999.16.523; Young Wise, 1993, Journal of Emergency Medicine, V11, P13	42	46	47	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	APR 1	2004	76	1					141	154		10.1002/jnr.20053			14	Neurosciences	Neurosciences & Neurology	809NV	WOS:000220644300014	15048938				2021-06-18	
J	Dunham, CM; Ransom, KJ; Flowers, LL; Siegal, JD; Kohli, CM				Dunham, CM; Ransom, KJ; Flowers, LL; Siegal, JD; Kohli, CM			Cerebral hypoxia in severely brain-injured patients is associated with admission Glasgow Coma Scale score, computed tomographic severity, cerebral perfusion pressure, and survival	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma		cerebral hypoxia; Glasgow Coma Scale score; cerebral perfusion pressure; computed tomographic scan score; traumatic brain injury	SEVERE HEAD-INJURY; NEAR-INFRARED SPECTROSCOPY; VENOUS OXYGEN-SATURATION; TISSUE PO(2); BLOOD-FLOW; INTRACRANIAL HYPERTENSION; OXIMETRY; PO2; EXPERIENCE; SJVO(2)	Background. The purpose of this study was to determine the relationship of cerebral hypoxia with admission Glasgow Coma Scale (GCS) score, brain computed tomographic (CT) severity, cerebral perfusion pressure (CPP), and survival in patients with severe brain injury. Methods. CPP and noninvasive transcranial oximetry (Stco(2)) were recorded hourly for 6 days in patients with a GCS score :5 8 (3,722 observations). CT score was derived from midline shift (0/1) plus abnormal cisterns (0/1) plus subarachnoid hemorrhage (SAH) (0/1) (range, 0-3). Results. Brain CT results were as follows: shift, 10 (56%); abnormal cisterns, 14 (78%); SAH, 9 (50%); epidural hematoma, 2 (11%); subdural hematoma, 11 (61%); and contusion, 17 (94%). The incidences of Stco(2) < 60 were: GCS score 3-4, 26.5%; GCS score 5-7, 12.4%; and kGCS score 8, 2.8% (p < 0.0001); CT score 2/3, 26.4%; and CT score 0/1, 10.0% (p < 0.0001); nonsurvivors 36.1%; and survivors 16.3% (p < 0.0001). For incidence of CPP < 70, the results were as follows: Stco(2) < 60%, 33% of observations; Stco(2) greater than or equal to 60%, 10% of observations (odds ratio, 4.3; p < .01). Despite CPP greater than or equal to 70, Stco(2) < 60 incidence was 16% of observations. Conclusion. Cerebral hypoxia is common, even with CPP greater than or equal to 70, and is associated with GCS score, CT scan severity, and mortality. Cerebral hypoxia is related to cerebral hypoperfusion. Additional studies may prove that Stco(2) monitoring will enhance the treatment of severe brain injury.	St Elizabeth Hlth Ctr, Trauma Crit Care Serv, Youngstown, OH 44501 USA	Dunham, CM (corresponding author), St Elizabeth Hlth Ctr, Trauma Crit Care Serv, 1044 Belmont Ave, Youngstown, OH 44501 USA.	michael_dunham@hmis.org					Abdul-Khaliq H, 2000, BIOMED TECH, V45, P328, DOI 10.1515/bmte.2000.45.11.328; Bardt TF, 1998, ACT NEUR S, V71, P153; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Bruzzone P, 1998, ACT NEUR S, V71, P111; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; De Deyne C, 1996, Eur J Emerg Med, V3, P69, DOI 10.1097/00063110-199606000-00002; Dings J, 1998, NEUROL RES, V20, pS71; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Dunham CM, 2002, J TRAUMA, V52, P40, DOI 10.1097/00005373-200201000-00009; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fandino J, 2000, J CLIN NEUROSCI, V7, P226, DOI 10.1054/jocn.1999.0202; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Filippi R, 2000, NEUROSURG REV, V23, P94; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Kampfl A, 1997, ACT NEUR S, V70, P112; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kim MB, 2000, J CLIN MONIT COMPUT, V16, P191, DOI 10.1023/A:1009940031063; KIRKPATRICK PJ, 1995, J NEUROSURG, V83, P963, DOI 10.3171/jns.1995.83.6.0963; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Levis S, 1998, ACT NEUR S, V71, P174; Lewis SB, 1996, CRIT CARE MED, V24, P1334, DOI 10.1097/00003246-199608000-00011; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P28; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Metz C, 1998, ACT NEUR S, V71, P324; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rothoerl RD, 2002, ACT NEUR S, V81, P311; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Schoon P, 2002, ACT NEUR S, V81, P285; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Vigue B, 1999, INTENS CARE MED, V25, P445, DOI 10.1007/s001340050878; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zauner A., 1996, J NEUROTRAUM, V13, P619; Zhi DS, 1999, SURG NEUROL, V52, P393, DOI 10.1016/S0090-3019(99)00101-9; 2000, J NEUROTRAUMA, V17, P479	56	46	54	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2004	56	3					482	489		10.1097/01.TA.0000114537.52540.95			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	808CM	WOS:000220547200005	15128117				2021-06-18	
J	Jokeit, H; Schacher, M				Jokeit, H; Schacher, M			Neuropsychological aspects of type of epilepsy and etiological factors in adults	EPILEPSY & BEHAVIOR			English	Article						epilepsy; cognition; neuropsychology; type of epilepsy; etiology	OCCIPITAL LOBE EPILEPSY; CLOSED HEAD-INJURY; JUVENILE MYOCLONIC EPILEPSY; TONIC-CLONIC SEIZURES; FRONTAL-LOBE; ALZHEIMERS-DISEASE; ARTERIOVENOUS-MALFORMATIONS; INTELLECTUAL FUNCTIONS; COGNITIVE IMPAIRMENT; BRAIN-TUMORS	Whether certain types of epilepsies and etiologies are related to profiles of cognitive impairment is of interest for diagnostics and treatment. The dichotomy between generalized and focal epilepsies (mesial temporal lobe, frontal lobe, parietal, and occipital lobe epilepsies) is considered. Then the most frequent etiologies are discussed. We conclude that specific associations between neuropsychological deficits and type of epilepsy and etiology are rather exceptions. However, knowledge of the type of epilepsy and pathology provides eminent information to evaluate the nature of deficits, to estimate chances of functional recovery, to provide rehabilitation recommendations, and to support decisions about treatment options. (C) 2003 Elsevier Inc. All rights reserved.	Swiss Epilepsy Ctr, CH-8008 Zurich, Switzerland	Jokeit, H (corresponding author), Swiss Epilepsy Ctr, Bleulerstr 60, CH-8008 Zurich, Switzerland.	h.jokeit@swissepi.ch					Annegers JF, 1996, MAYO CLIN PROC, V71, P570, DOI 10.4065/71.6.570; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Babb T.L., 1987, SURGICAL TREATMENT E, P511; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Damasio H., 1989, LESION ANAL NEUROPSY; Devinsky O, 1997, NEUROPSY NEUROPSY BE, V10, P243; DIKMEN S, 1977, EPILEPSIA, V18, P21, DOI 10.1111/j.1528-1157.1977.tb05583.x; DODRILL CB, 1986, EPILEPSIA, V27, P399, DOI 10.1111/j.1528-1157.1986.tb03559.x; Exner C, 2002, SEIZURE-EUR J EPILEP, V11, P20, DOI 10.1053/seiz.2001.0572; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; Fujii T, 1999, CORTEX, V35, P599, DOI 10.1016/S0010-9452(08)70822-0; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Gulgonen S, 2000, EPILEPSIA, V41, P405, DOI 10.1111/j.1528-1157.2000.tb00181.x; HAUSER WA, 1997, EPILEPSY COMPREHENSI, V1, P47; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; Helmstaedter C, 1996, NEUROPSYCHOLOGIA, V34, P399, DOI 10.1016/0028-3932(95)00121-2; Hermann BP, 1997, ARCH NEUROL-CHICAGO, V54, P369, DOI 10.1001/archneur.1997.00550160019010; Huff F J, 1990, Adv Neurol, V51, P61; Jokeit H, 1997, BRAIN, V120, P2283, DOI 10.1093/brain/120.12.2283; Jokeit H, 2002, PROG BRAIN RES, V135, P455; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LUDERS HO, 1991, EPILEPSY SURG, P51; MAHALICK DM, 1991, NEUROSURGERY, V29, P351, DOI 10.1227/00006123-199109000-00003; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; MENDEZ MF, 1990, NEUROLOGY, V40, P439, DOI 10.1212/WNL.40.3_Part_1.439; MOORE AJ, 1988, POSTGRAD MED, V84, P163; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; NIEDERMEYER E, 1990, EPILEPSIES DIAGNOIS; OGDEN JA, 1993, NEUROSURGERY, V33, P572, DOI 10.1227/00006123-199310000-00004; PARASURAMAN R, 1994, CURR OPIN NEUROBIOL, V4, P237, DOI 10.1016/0959-4388(94)90079-5; Pasquier F, 1999, J NEUROL, V246, P6, DOI 10.1007/s004150050299; Pavone A, 2000, CLIN ELECTROENCEPHAL, V31, P153, DOI 10.1177/155005940003100309; RAUSCH R, 1997, EPILEPSY COMPREHENSI, P977; Rausch R, 1991, EPILEPSY BEHAV, P213; ROMANELLI MF, 1990, ARCH NEUROL-CHICAGO, V47, P847, DOI 10.1001/archneur.1990.00530080029006; SALANOVA V, 1992, BRAIN, V115, P1655, DOI 10.1093/brain/115.6.1655; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; Sands S, 2000, PSYCHO-ONCOL, V9, P259, DOI 10.1002/1099-1611(200005/06)9:3<259::AID-PON448>3.0.CO;2-Y; Savic I, 1998, EPILEPSIA, V39, P364, DOI 10.1111/j.1528-1157.1998.tb01388.x; Savic I, 2000, EPILEPSIA, V41, P290, DOI 10.1111/j.1528-1157.2000.tb00158.x; SMITH DF, 1998, ATLAS EPILEPSY; Spanaki MV, 2000, ARCH NEUROL-CHICAGO, V57, P1447, DOI 10.1001/archneur.57.10.1447; Steinvorth S, 2002, INT J RADIAT ONCOL, V54, P1430, DOI 10.1016/S0360-3016(02)03800-2; SVEINBJORNSDOTTIR S, 1993, EPILEPSIA, V34, P493, DOI 10.1111/j.1528-1157.1993.tb02590.x; Swartz BE, 1996, NEUROLOGY, V47, P1203, DOI 10.1212/WNL.47.5.1203; Tucha O, 2000, NEUROSURGERY, V47, P324, DOI 10.1097/00006123-200008000-00011; Upton D, 1997, EPILEPSIA, V38, P1103, DOI 10.1111/j.1528-1157.1997.tb01200.x; VOLICER L, 1995, DEMENTIA, V6, P258, DOI 10.1159/000106956; WILLIAMSON PD, 1997, EPILEPSY COMPREHENSI, V3, P2405; WOLF P, 1997, EPILEPSY COMPREHENSI, V3, P2475	52	46	46	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	FEB	2004	5			1			S14	S20		10.1016/j.yebeh.2003.11.003			7	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	772ZY	WOS:000188874300003	14725842				2021-06-18	
J	Shibuya, S; Miyamoto, O; Janjua, NA; Itano, T; Mori, S; Norimatsu, H				Shibuya, S; Miyamoto, O; Janjua, NA; Itano, T; Mori, S; Norimatsu, H			Post-traumatic moderate systemic hypothermia reduces TUNEL positive cells following spinal cord injury in rat	SPINAL CORD			English	Article						moderate hypothermia; TUNEL; spinal cord injury; rats	DELAYED NEURONAL DEATH; COMPRESSION INJURY; BRAIN INJURY; WALLERIAN DEGENERATION; MILD HYPOTHERMIA; ADULT RATS; APOPTOSIS; ISCHEMIA; TRAUMA; GERBIL	Study design: A standardized animal model of contusive spinal cord injury (SCI) with incomplete paraplegia was used to test the hypothesis that moderate systemic hypothermia reduces neural cell death. Terminal deoxynucleotidyl transferase [TdT]-mediated deoxyuridine triphosphate [dUTP] nick-end labeling (TUNEL) staining was used as a marker of apoptosis or cell damage. Objective: To determine whether or not moderate hypothermia could have a neuroprotective effect in neural cell death following spinal cord injury in rats. Setting: Kagawa Medical University, Japan. Methods: Male Sprague-Dawley (SD) rats (n = 39) weighing on average 300 g (280-320 g) were used to prepare SCI models. After receiving contusive injury at T11/12, rats were killed at 24 h, 72 h, or 7 days after injury. The spinal cord was removed en bloc and of examined at five segments: 5 and 10 mm rostral to the center of injury, center of injury, and 5 and 10 mm caudal to the center of injury. Rats that received hypothermia (32degreesC/4 h) were killed at the same time points as those that received normothermia (37degreesC/3 h). The specimens were stained with hematoxylin and eosin, and subjected to in situ nick-end labeling (TUNEL), a specific method for visualizing cell death in the spinal cord. Results: At 24 h postinjury, TUNEL positive cells (TPC) decreased significantly 10 mm rostral to center of injury in hypothermic animals compared to the normothermia group. At 72 h post-SCI, TPC also decreased significantly at 5 mm rostral, and 5 and 10 mm caudal to the lesion center compared to normothermic animals. At 7 days postinjury, a significant decrease of TPC was observed at the 5 mm rostral and 5 mm caudal sites compared to normothermic animals. Conclusion: These results indicate that systemic hypothermia has a neuroprotective effect following SCI by attenuating post-traumatic TPC.	Kagawa Med Univ, Dept Orthopaed Surg, Miki, Kagawa 7610793, Japan; Kagawa Med Univ, Dept Neurobiol, Miki, Kagawa 7610793, Japan	Itano, T (corresponding author), Kagawa Med Univ, Dept Biol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.				Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [14571383] Funding Source: KAKEN		Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; BENSASSON SA, 1995, METHOD CELL BIOL, V46, P29; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; CHOI DW, 1987, J NEUROSCI, V7, P369; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRIFFITHS IR, 1978, ACTA NEUROPATHOL, V41, P33, DOI 10.1007/BF00689554; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hayashi R, 1998, J HISTOCHEM CYTOCHEM, V46, P1051, DOI 10.1177/002215549804600909; Jou IM, 2000, SPINE, V25, P1878, DOI 10.1097/00007632-200008010-00004; Katoh K, 1996, NEUROSCI LETT, V216, P9; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LIANG F, 1991, J COMP NEUROL, V311, P356; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; Miyamoto O, 2000, BRAIN RES, V873, P168, DOI 10.1016/S0006-8993(00)02521-X; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; NITATORI T, 1995, J NEUROSCI, V15, P1001; RIVLIN AS, 1978, J NEUROSURG, V49, P844, DOI 10.3171/jns.1978.49.6.0844; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; Shibuya S, 2002, NEUROSCIENCE, V114, P905, DOI 10.1016/S0306-4522(02)00323-8; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WALLACE MC, 1986, NEUROSURGERY, V18, P433; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; WIJSMAN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P7, DOI 10.1177/41.1.7678025; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1992, EUR J PHARMACOL, V218, P273, DOI 10.1016/0014-2999(92)90179-8; Xu RX, 1998, NEUROSURGERY, V43, P107, DOI 10.1097/00006123-199807000-00070; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206	46	46	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	JAN	2004	42	1					29	34		10.1038/sj.sc.3101516			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	761LA	WOS:000187909200005	14713941	Bronze			2021-06-18	
J	Miller, LJ; Donders, J				Miller, LJ; Donders, J			Prediction of educational outcome after pediatric traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							HEAD-INJURY; ACADEMIC PLACEMENT; WISC-III; CHILDREN; ADOLESCENTS; SEVERITY; MEMORY; SENSITIVITY; ATTENTION; RECOVERY	Objective: Evaluation of the predictive value of neuropsychological test scores with respect to special education placement following pediatric traumatic brain injury (TBI). Study Design: Longitudinal follow-up and hierarchical logistic regression analyses. Setting: Regional rehabilitation center. Participants: Consecutive series of referrals, including 58 children with TBI and no confounding premorbid histories or other complicating factors. Main Outcome Measures: Special education placement at, respectively, 12 and 24 months postinjury. Results: Children who obtained a composite T score of less than 45 on the California Verbal Learning Test-Children's Version during initial postinjury neuropsychological assessment were 8-13 times more likely to be placed in special education 12-24 months later compared with children who obtained higher scores. Conclusions: Neuropsychological test scores are not only sensitive to acute injury severity but also explain a substantial proportion of the variance in educational outcome after pediatric TBI, above and beyond that accounted for by demographic and medical variables.	Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						BOLL T, 1993, CHILDRENS CATEGORY T; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Clark E, 1999, SCHOOL PSYCHOL REV, V28, P242; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DELIS D, 1994, CALIFORNIA VERBAL LE; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; DONDERS J, 1998, HDB PEDIAT PSYCHOL P, V2, P166; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Fletcher JM, 1995, HDB PEDIAT PSYCHOL, P362; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Papero PH, 1997, J HEAD TRAUMA REHAB, V12, P51, DOI 10.1097/00001199-199706000-00006; Reitan R.M., 1992, NEUROPSYCHOLOGICAL E; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YLVISAKER M, 1994, ED DIMENSIONS ACQUIR, P185	29	46	46	0	4	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2003	48	4					237	241		10.1037/0090-5550.48.4.237			5	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	741ER	WOS:000186446200002					2021-06-18	
J	Steiner, LA; Coles, JP; Johnston, AJ; Czosnyka, M; Fryer, TD; Smielewski, P; Chatfield, DA; Salvador, R; Aigbirhio, FI; Clark, JC; Menon, DK; Pickard, JD				Steiner, LA; Coles, JP; Johnston, AJ; Czosnyka, M; Fryer, TD; Smielewski, P; Chatfield, DA; Salvador, R; Aigbirhio, FI; Clark, JC; Menon, DK; Pickard, JD			Responses of posttraumatic pericontusional cerebral blood flow and blood volume to an increase in cerebral perfusion pressure	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; cerebral contusion; cerebral blood flow; cerebral blood volume; cerebral perfusion pressure; positron emission tomography	TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; FOCAL ISCHEMIA; TOMOGRAPHY; CONTUSIONS; RAT	In and around traumatic contusions, cerebral blood flow (CBF) is often near or below the threshold for ischemia. Increasing cerebral perfusion pressure (CPP) in patients with head injuries may improve CBF in these regions. However, the pericontusional response to this intervention has not been studied. Using positron emission tomography (PET), we have quantified the response to an increase in CPP in and around contusions in 18 contusions in 18 patients. Regional CBF and cerebral blood volume (CBV) were measured with PET at CPPs of 70 and 90 mmHg using norepinephrine to control CPP. Based upon computed tomography, regions of interest (ROIs) were placed as two concentric ellipsoids, each of 1-cm width, around the core of the contusions. Measurements were compared with a control ROI in tissue with normal anatomic appearance. Baseline CBF and CBV increased significantly with increasing distance from the core of the lesion. The increase in CPP led to small increases in CBF in all ROIs except the core. The largest absolute CBF increase was found in the control ROI. Relative CBF increases did not differ between ROIs so that ischemic areas remained ischemic. Pericontusional oedema on computed tomography was associated with lower absolute values of CBF and CBV but did not differ from nonoedematous tissue in the relative response to CPP elevation.	Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge, England; Addenbrookes Hosp, Univ Dept Anesthesia, Cambridge, England; Addenbrookes Hosp, Acad Neurosurg, Cambridge, England	Steiner, LA (corresponding author), Univ Basel, Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland.	lsteiner@uhbs.ch	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011	Salvador, Raymond/0000-0001-5557-1562; Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390] Funding Source: Medline		BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; Golding EA, 2003, J CEREBR BLOOD F MET, V23, P210, DOI 10.1097/01.WCB.0000044739.64940.B5; Hartl R, 1997, J CEREBR BLOOD F MET, V17, P1210; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; KUROIWA T, 1994, ACTA NEUROCHIR, P158; MacGregor DG, 2000, EUR J NEUROSCI, V12, P58, DOI 10.1046/j.1460-9568.2000.00880.x; Marchal G, 1999, BRAIN, V122, P2387, DOI 10.1093/brain/122.12.2387; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MILLER JD, 1975, J NEUROL NEUROSUR PS, V38, P657, DOI 10.1136/jnnp.38.7.657; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schroder ML, 1998, ACT NEUR S, V71, P127; Schumann P, 1998, BRAIN, V121, P1369, DOI 10.1093/brain/121.7.1369; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; STEINER LA, 2002, J NEUROTRAUM, V19, P1301; Studholme C, 1996, Med Image Anal, V1, P163, DOI 10.1016/S1361-8415(96)80011-9; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; Talairach J., 1988, COPLANAR STEREOTAXIC; Videen TO, 1999, J COMPUT ASSIST TOMO, V23, P248, DOI 10.1097/00004728-199903000-00014; WHITTLE IR, 1990, ACT NEUR S, V51, P71	26	46	46	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2003	23	11					1371	1377		10.1097/01.WCB.0000090861.67713.10			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	741TY	WOS:000186477500014	14600445	Bronze			2021-06-18	
J	Makaroff, KL; Putnam, FW				Makaroff, KL; Putnam, FW			Outcomes of infants and children with inflicted traumatic brain injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							YOUNG-CHILDREN; HEAD-INJURY; SHAKEN; PROGNOSIS; ABUSE		Childrens Hosp, Med Ctr, Mayerson Ctr Safe & Healthy Children, Cincinnati, OH 45229 USA	Makaroff, KL (corresponding author), Childrens Hosp, Med Ctr, Mayerson Ctr Safe & Healthy Children, SEB 5,3333 Burnet Ave, Cincinnati, OH 45229 USA.	makok0@chmcc.org					Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Feldman KW, 1997, CHILD ABUSE NEGLECT, V21, P199, DOI 10.1016/S0145-2134(96)00145-7; FISCHER H, 1994, CLIN PEDIATR, V33, P696, DOI 10.1177/000992289403301113; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; Fung ELW, 2002, PEDIATR INT, V44, P37, DOI 10.1046/j.1442-200X.2002.01500.x; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Han D P, 1990, J Pediatr Ophthalmol Strabismus, V27, P299; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; JASPAN T, 1992, PEDIATR RADIOL, V22, P237, DOI 10.1007/BF02019848; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Levin AV, 2000, RECENT ADV PAEDIAT, P151; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; Matthews GP, 1996, J PEDIATR OPHTHALMOL, V33, P260, DOI 10.3928/0191-3913-19960701-13; McCabe CF, 2000, ARCH OPHTHALMOL-CHIC, V118, P373, DOI 10.1001/archopht.118.3.373; OLIVER JE, 1975, BRIT MED J, V2, P262, DOI 10.1136/bmj.2.5965.262; SINAL SH, 1987, SOUTHERN MED J, V80, P1505, DOI 10.1097/00007611-198712000-00006; Sugar NF, 1999, ARCH PEDIAT ADOL MED, V153, P399, DOI 10.1001/archpedi.153.4.399; Swenson J, 1997, Minn Med, V80, P41; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037	26	46	46	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUL	2003	45	7					497	502		10.1017/S0012162203000926			6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	698DD	WOS:000183981600012	12828406				2021-06-18	
J	Shiozaki, T; Nakajima, Y; Taneda, M; Tasaki, O; Inoue, Y; Ikegawa, H; Matsushima, A; Tanaka, H; Shimazu, T; Sugimoto, H				Shiozaki, T; Nakajima, Y; Taneda, M; Tasaki, O; Inoue, Y; Ikegawa, H; Matsushima, A; Tanaka, H; Shimazu, T; Sugimoto, H			Efficacy of moderate hypothermia in patients with severe head injury and intracranial hypertension refractory to mild hypothermia	JOURNAL OF NEUROSURGERY			English	Article						head injury; intracranial pressure; hypothermia	TRAUMATIC BRAIN INJURY; THERAPY; PRESSURE	Object. This study was performed to determine whether moderate hypothermia (31degreesC) improves clinical outcome in severely head injured patients whose intracranial hypertension cannot be controlled using mild hypothennia (34degreesC). Methods. Twenty-two consecutive severely head injured patients who fulfilled the following criteria were included in this study: an intracranial pressure (ICP) that remained higher than 40 mm Hg despite the use of mild hypothermia combined with conventional therapies; and a Glasgow Coma Scale score of 8 or less on admission. After the failure of mild hypothermia in combination with conventional therapies; patients were exposed to moderate hypothermia as quickly as possible. As brain temperature was reduced from 34 to 31degreesC, the volume of intravenous fluid infusion was increased significantly from 1.9 +/- 0.9 to 2.6 +/- 1.2 mg/kg/hr (p < 0.01), and the dose of dopamine infusion increased significantly from 4.3 +/- 3.1 to 8.2 +/- 4.4 mug/kg/min (p < 0.01). Nevertheless, mean arterial blood pressure and heart rate decreased significantly from 97.1 &PLUSMN; 13.1 to 85.1 &PLUSMN; 10.5 mm Hg (p &LT; 0.01) and from 92.2 &PLUSMN; 13.8 to 72.2 &PLUSMN; 14.3 beats/minute at (p &LT; 0.01) at 34 and 31&DEG;C, respectively. Arterial base excess was significantly aggravated from -3.3 &PLUSMN; 4 at 34&DEG;C to -5.6 &PLUSMN; 5.4 mEq/L (at 31&DEG;C; p &LT; 0.05). Likewise, serum potassium concentration, white blood cell counts, and platelet counts at 31&DEG;C decreased significantly compared with those at 34&DEG;C (p &LT; 0.01). In 19 (86%) of 22 patients, elevation of ICP could not be prevented using moderate hypothermia. In the remaining three patients, ICP was maintained below 40 mm Hg by inducing moderate hypothermia; however, these three patients died of multiple organ failure. These results clearly indicate that moderate hypothermia induces complications more severe than those induced by mild hypothennia without improving outcomes. Conclusions. The authors concluded that moderate hypothermia is not effective in improving clinical outcomes in severely head injured patients whose ICP remains higher than 40 mm Hg after treatment with mild hypothermia combined with conventional therapies.	Osaka Univ, Grad Sch Med, Dept Traumatol, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neurosurg, Osaka 5650871, Japan; Kinki Univ, Sch Med, Dept Neurosurg, Osaka, Japan	Shiozaki, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Traumatol, 2-2 Yamada Oka, Osaka 5650871, Japan.				Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [14571311, 15390545] Funding Source: KAKEN		BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; HASHIGUCHI N, IN PRESS J TRAUMA; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Klementavicius R, 1996, J NEUROSURG, V85, P482, DOI 10.3171/jns.1996.85.3.0482; Kuwagata Y, 1999, J TRAUMA, V47, P666, DOI 10.1097/00005373-199910000-00010; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; TEASDALE G, 1974, LANCET, V2, P81; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007	17	46	56	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	JUL	2003	99	1					47	51		10.3171/jns.2003.99.1.0047			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	696BN	WOS:000183865500009	12854743				2021-06-18	
J	Johnstone, B; Vessell, R; Bounds, T; Hoskins, S; Sherman, A				Johnstone, B; Vessell, R; Bounds, T; Hoskins, S; Sherman, A			Predictors of success for state vocational rehabilitation clients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; rehabilitation; rehabilitation, vocational; treatment outcomes	SUBSTANCE-ABUSE; HEAD-INJURIES; EMPLOYMENT; RETURN; WORK; INTEGRATION; OUTCOMES; SERVICES	Objectives: To determine the characteristics of individuals with traumatic brain injury (TBI) who request state vocational rehabilitation services and to determine the best predictors of their successful vocational outcomes. Design: Observational study. Setting: Vocational services data from the Missouri Division of Vocational Rehabilitation (DVR). Participants: Seventy-eight individuals with TBI who requested services from the Missouri DVR. Interventions: Not applicable. Main Outcome Measures: Demographic, injury severity, neuropsychologic variables, vocational services offered, and vocational status at time of case closure (successful, unsuccessful, services interrupted, no services provided). Results: Individuals requesting DVR services were primarily men (71%), white (82%), single (47%), of low average intelligence (Wechsler Adult Intelligence Scales-III full scale IQ score, 84.8), and of limited education (11.8y). The majority experienced a significant TBI (ie, 66% were hospitalized after their TBI; 56% reported loss of consciousness; 37% reported posttraumatic amnesia; 32% reported multiple TBIs; avg time since injury, 9.2y). At DVR case closure, 17% were rated as being successfully employed, with nearly all working in industrial, service, or clerical positions (2 in a sheltered workshop, 1 in a professional position). Stepwise logistic regressions indicated that delivery of DVR services (ie, vocational guidance and counseling, on-the-job training) predicted vocational outcome and demographic, injury severity, and neuropsychologic variables did not. Conclusions: DVR clients have multiple impairments that affect them several years postinjury; the provision of DVR services may be more important in determining vocational outcomes than traditional medical, psychologic, and demographic variables.	Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, Columbia, MO 65212 USA; Univ Missouri, Hlth Sci Ctr, Dept Biostat, Columbia, MO 65212 USA; Missouri Div Vocat Rehabil, Dept Elementary & Secondary Educ, Jefferson City, MO USA	Johnstone, B (corresponding author), Univ Missouri, Dept Hlth Psychol, Sch Hlth Profess, DC046-00, Columbia, MO 65212 USA.			Johnstone, Brick/0000-0001-8845-9649			[Anonymous], TRAUMATIC BRAIN INJU; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; BOUNDS TA, IN PRESS J NEURO REH; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Buffington ALH, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199710000-00002; DEFILIPPIS NA, 1991, MANUAL BOOKLET CATEG; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FROMMAUCH D, 1983, J CLIN NEUROPSYCHOL, V5, P221, DOI 10.1080/01688638308401171; GOODYEAR C, 1994, EARTH ISL J, V9, P2; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; KlOve H, 1963, MED CLIN N AM; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Reitan RM., 1985, HALSTEAD REITAN NEUR; REITAN RM, 1992, REITAN NEUROPSYCHOLO; ROESSLER RT, 1992, J REHABIL, V58, P17; *RUR POL RES I, METR NON METR COUNT; Sander AM, 1997, J HEAD TRAUMA REHAB, V12, P28, DOI 10.1097/00001199-199710000-00004; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schopp L, 2000, PROF PSYCHOL-RES PR, V31, P179, DOI 10.1037/0735-7028.31.2.179; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; SEELMAN KD, P TIDE 3 C ASS TECHN; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Spreen O., 1998, COMPENDIUM NEUROPSYC; Wechsler D, 1997, WMS 3 ADM SCORING MA; Wechsler D., 1997, WAIS 3 ADM SCORING M; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; 1998, NIH CONSENS STATEMEN, V16, P1	33	46	46	1	12	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					161	167		10.1053/apmr.2003.50098			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700003	12601645				2021-06-18	
J	Duff, MC; Proctor, A; Haley, K				Duff, MC; Proctor, A; Haley, K			Mild traumatic brain injury (MTBI): assessment and treatment procedures used by speech-language pathologists (SLPs)	BRAIN INJURY			English	Article							HEAD-INJURY; HOSPITALIZATION; CONCUSSION; KNOWLEDGE; SEQUELAE	The purposes of this study were to identify how individuals with MTBI are assessed, to determine the referral process to and from speech-language pathologists (SLPs), to describe the frequency, structure, and nature of treatment, to identify how individuals with MTBI and their families are educated about the injury and counselled, and to assess current follow-up procedures. One-hundred and forty-three hospital and rehabilitation centre based SLPs from North Carolina and Illinois responded to a survey developed to address these areas of interest. Findings indicated current diagnostic tools used by SLPs lack the sensitivity to detect the subtle cognitive communication deficits associated with MTBI, referral and follow-up procedures are not sufficiently implemented in facilities to meet the growing needs of individuals with MTBI, and SLPs would benefit from increased training regarding the management of individuals with MTBI including educating and counselling patients and their families.	Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL 61820 USA; Univ N Carolina, Chapel Hill, NC USA	Duff, MC (corresponding author), Univ Illinois, Dept Speech & Hearing Sci, Champaign, IL 61820 USA.			Haley, Katarina/0000-0002-1158-2160			ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; [Anonymous], 1988, ASHA, V30, P79; BIGLER E, 1999, MILD TRAUMATIC BRAIN, P11; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Feinstein A, 2000, BRAIN COGNITION, V44, P78; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; FRANK E, 1997, J CHILDRENS COMMUNIC, V2, P49; Goodglass H., 1983, ASSESSMENT APHASIA R; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAMMILL D, 1985, DETROIT TESTS LEARNI, V2; Hux K, 1996, LANG SPEECH HEAR SER, V27, P171, DOI 10.1044/0161-1461.2702.171; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; Levin H. S., 1991, FRONTAL LOBE FUNCTIO; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; McGrane SA, 2000, BRAIN INJURY, V14, P975; MITTNEBERT W, 1992, J NEUROL NEUROSUR PS, V65, P200; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; RAYMOND MJ, 1999, MILD TRAUMATIC BRAIN; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSENTHAL M, 1993, ANN EMERG MED, V22, P1048, DOI 10.1016/S0196-0644(05)82749-0; ROSSSWAIN D, 1996, ROSS INFORMATION PRO; RUTHERFORD WH, 1977, LANCET, V1, P1; SARTIN K, 1998, M AM SPEECH LANG HEA; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sohlberg MM., 2000, NEUROPSYCHOLOGICAL M, P137; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; *US DEP HHS, 1989, INT HEAD INJ TASK FO; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wilson BA, 1996, BEHAV ASSESSMENT DYS; WILSON G, 1985, RIVERMEAD BEHAV MEMO; ZASLER N, 2000, NEUROPSYCHOLOGICAL M, P137	40	46	47	0	11	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2002	16	9					773	787		10.1080/02699050210128870			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	585PD	WOS:000177532800003	12217203				2021-06-18	
J	Aitken, ME; Tilford, JM; Barrett, KW; Parker, JG; Simpson, P; Landgraf, J; Robbins, JM				Aitken, ME; Tilford, JM; Barrett, KW; Parker, JG; Simpson, P; Landgraf, J; Robbins, JM			Health status of children after admission for injury	PEDIATRICS			English	Article						pediatrics; injury; outcome; morbidity; Child Health Questionnaire	TRAUMATIC BRAIN INJURY; PEDIATRIC TRAUMA; COHORT; PERFORMANCE; MORBIDITY; RETURN; WORK	Objective. Injury is the major cause of death in children ages 1 to 19 in the United States and is a leading cause of morbidity. Few studies have described the impact of injuries on the health status of affected children over time or used newer, child-specific measures in this population. The objective of this study was to describe the health status of children in the 6 months after admission for injury using child-specific health status measures. Methods. Injured children who were ages 3 to 18 years and admitted to an academic children's hospital were evaluated at discharge and at 1 and 6 months after discharge with a battery of outcome measures. The Child Health Questionnaire (CHQ) measured health status. The scores on the Functional Independence Measure (FIM) or pediatric version of the FIM tracked physical function. Results. A total of 195 children were enrolled. Boys outnumbered girls (67% vs 33%). Injury mechanisms and severity scores were typical of pediatric injury populations reported in other studies. Most (90%) children had at least 1 area of functional limitation by FIM at discharge, and 57% had some impairment at 1 month. By 6 months, 28% reported some limitation. At discharge, CHQ summary scores for the injury group were markedly depressed compared with normative populations. Differences in both physical health and psychosocial health summary scores between the injured and normal children persisted through 6 months of follow-up. Scores on 11 of 12 subscales were significantly below the normal population at discharge. This was particularly evident for bodily pain (injury group mean 49.1 vs normative mean 81.7) and parental impact-emotional (43.9 vs 80.3), and physical functioning (50.9 vs 96.1). Significant differences persisted in all subscales at 1 month and in 6 subscales at 6 months. Conclusions. The CHQ provided useful information about the impact of injuries on children and their families over time. Significantly reduced scores in several domains of the CHQ highlight problem areas for injury patients, several of which persist through 6 months of follow-up. Low scores in areas of bodily pain and parental emotional burden suggest that improved management of these problems is required. Additional study of risk factors for persistent problems after injury may suggest ways to improve functional outcomes of injured children and reduce the impact on their families.	Arkansas Childrens Hosp, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Healthact Inc, Boston, MA USA	Aitken, ME (corresponding author), Arkansas Childrens Hosp, 800 Marshall St,Slot 512-26, Little Rock, AR 72202 USA.	aitkenmarye@uams.edu		Aitken, Mary/0000-0002-8318-9755; Robbins, James/0000-0003-2200-1947	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCH 054003-01-0] Funding Source: Medline		ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Aitken ME, 1999, ARCH PHYS MED REHAB, V80, P889, DOI 10.1016/S0003-9993(99)90079-5; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Davis T C, 1991, Fam Med, V23, P433; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Granger CV, 1986, GUIDE USE UNIFORM DA; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HALEY SM, 1993, PHYS MED REH CLIN N, V43, P529; HARRIS BH, 1989, J PEDIATR SURG, V24, P103, DOI 10.1016/S0022-3468(89)80311-2; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; LANDGRAF JM, 1996, CHQ USERS MANUAL; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; MCCARTHY ML, 1995, J TRAUMA, V39, P828, DOI 10.1097/00005373-199511000-00005; MERBITZ C, 1989, ARCH PHYS MED REHAB, V70, P308; *MICR CORP, 1997, ACCESS COMP PROGR; MORRIS JA, 1991, J TRAUMA, V31, P827, DOI 10.1097/00005373-199106000-00014; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Osberg JS, 1996, PEDIATRICS, V98, P890; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; *SAS I, 1998, SAS COMP PROGR; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008	28	46	46	0	0	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	2002	110	2					337	342		10.1542/peds.110.2.337			6	Pediatrics	Pediatrics	581DA	WOS:000177274800028	12165587				2021-06-18	
J	Schultheis, MT; Matheis, RJ; Nead, R; DeLuca, J				Schultheis, MT; Matheis, RJ; Nead, R; DeLuca, J			Driving behaviors following brain injury: Self-report and motor vehicle records	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						accidents; driving; motor vehicle; traumatic brain injury	DAMAGE	Background: This study examined both objective and subjective measures of driving behaviors occurring in the past 5 ears for 47 individuals with traumatic brain injury (TBI) and 22 health), controls (HQ, matched forage. gender, education, and years of driving experience, Results: Overall, subtle descriptive differences in driving characteristics were observed between the two groups. However, comparison of self-reported and documented reports of aberrant driving behaviors did not reveal a significantly greater number of accidents or violations among TBI participants compared with HC drivers. The results suggest that individuals with TBI, who successfully complete a driving evaluation program, are able to reintegrate into the driving community with minimal difficulty.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Kessler Inst Rehabil, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Newark, NJ 07103 USA	Schultheis, MT (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	mschultheis@kmrrec.org		Schultheis, Maria/0000-0002-6558-548X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD08589-01] Funding Source: Medline		BOAKE C, 1993, ARCH PHYS MED REHAB, V74, P1246; BOAKE M, 1998, J INT NEUROPSYCHOLL, V4, P75; BROOKE MM, 1992, AM J PHYS MED REHAB, V71, P177, DOI 10.1097/00002060-199206000-00009; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Fisk GD, 1998, BRAIN INJURY, V12, P683; Fox GK, 1998, ARCH PHYS MED REHAB, V79, P1288, DOI 10.1016/S0003-9993(98)90277-5; GALSKI T, 1993, AM J OCCUP THER, V47, P391, DOI 10.5014/ajot.47.5.391; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; HANDLER BS, 1995, J REHABIL, V61, P43; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PRIDDY D A, 1990, Brain Injury, V4, P267, DOI 10.3109/02699059009026176; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	16	46	49	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2002	17	1					38	47		10.1097/00001199-200202000-00006			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	519MM	WOS:000173730100007	11860328				2021-06-18	
J	Broholm, H; Madsen, FF; Wagner, AA; Laursen, H				Broholm, H; Madsen, FF; Wagner, AA; Laursen, H			Papillary glioneuronal tumor - a new tumor entity	CLINICAL NEUROPATHOLOGY			English	Article						papillary; glioneuronal tumor; low grade; frontal; immunohistochemistry	NEUROCYTOMA; LOBE	Glioneuronal neoplasms of the CNS comprises a heterogeneous group of generally low-grade tumors expressing glial and neuronal cells of varying differentiation. Recently, a new variant of the glioneuronal tumors has been identified. We present a case of a glioneuronal tumor located in the left frontal lobe of a 16-year-old boy who developed seizures 6 months after brain concussion. MR scan demonstrated an irregular, but well circumscribed, mixed cystic and solid tumor with contrast enhancement in the solid part. Histology showed a papillary glioneuronal tumor. The tumor is indolent with no sign of recurrence after gross total resection.	Univ Copenhagen Hosp, Rigshosp, Neuropathol Lab, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Dept Neurosurg, DK-2100 Copenhagen, Denmark; Univ Copenhagen Hosp, Rigshosp, Dept Neuroradiol, DK-2100 Copenhagen, Denmark	Broholm, H (corresponding author), Univ Copenhagen Hosp, Rigshosp 6301, Neuropathol Lab, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	hbroholm@rh.dk					Biernat W, 2000, BRAIN PATHOL, V10, P313; Blumcke I, 1999, MICROSC RES TECHNIQ, V46, P53; Bouvier-Labit C, 2000, ACTA NEUROPATHOL, V99, P321, DOI 10.1007/PL00007445; Giangaspero F, 1997, AM J SURG PATHOL, V21, P206, DOI 10.1097/00000478-199702000-00011; Hamilton R, 1997, BRAIN PATHOL, V7, P713, DOI 10.1111/j.1750-3639.1997.tb01086.x; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kim DH, 1997, ACTA NEUROPATHOL, V94, P187, DOI 10.1007/s004010050692; KLEIHUES P, 2000, WHO CLASSIFICATION T, P96; Komori T, 1998, AM J SURG PATHOL, V22, P1171, DOI 10.1097/00000478-199810000-00002; Komori T, 1996, J NEUROPATH EXP NEUR, V55, P654; MCLENDON RE, 2000, PATHOLOGY TUMORS CEN, P232; Prayson RA, 2000, ARCH PATHOL LAB MED, V124, P1820; Teo JGC, 1999, AM J SURG PATHOL, V23, P502, DOI 10.1097/00000478-199905000-00002	13	46	49	0	0	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	JAN-FEB	2002	21	1					1	4					4	Clinical Neurology; Pathology	Neurosciences & Neurology; Pathology	518FY	WOS:000173657000001	11846038				2021-06-18	
J	Greve, KW; Love, JM; Sherwin, E; Mathias, CW; Ramzinski, P; Levy, J				Greve, KW; Love, JM; Sherwin, E; Mathias, CW; Ramzinski, P; Levy, J			Wisconsin Card Sorting Test in chronic severe traumatic brain injury: factor structure and performance subgroups	BRAIN INJURY			English	Article; Proceedings Paper	19th Annual Meeting of the National-Academy-of-Neuropsychology	NOV, 1999	SAN ANTONIO, TEXAS	Natl Acad Neuropsychol			DAMAGE	Objective: The present study further investigated the factor structure of the WCST in traumatic brain injury and investigated the construct validity and relationships among scores through the use of cluster analysis. Design: Participants were 68 survivors of chronic severe TBI, living at a residential brain injury rehabilitation facility. Methods and procedures: Three sets of WCST scores were submitted to factor analysis; the regression factor scores based on the standard WCST were examined using cluster analysis. Results Factor analysis of the WCST raw scores replicated the three-factor solution which has been previously reported. When t-scores were analysed, two-to-four-factor solutions could be justified. The cluster analysis identified four groups representing; (1) impaired response maintenance, (2) problem-solving deficits; (3) intact WCST performance; and (4) deficits in set shifting. Conclusions: The results support previous research indicating that the WCST is sensitive to three distinct cognitive processes: cognitive flexibility, problem-solving, and response maintenance. However, unlike the cognitive processes underlying WCST performance, the WCST scores representing these processes are not independent. The potential clinical relevance of these results is discussed.	Univ New Orleans, Dept Psychol, UNO Lakefront, New Orleans, LA 70148 USA; Georgia So Univ, Statesboro, GA 30460 USA; Tangram Premier, San Marcos, TX USA	Greve, KW (corresponding author), Univ New Orleans, Dept Psychol, UNO Lakefront, New Orleans, LA 70148 USA.			Mathias, Charles/0000-0003-1902-673X			*AM PSYCH ASS, 1992, AM PSYCHOL, V47, P1597, DOI DOI 10.1037/0003-066X.47.12.1597; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Cattell R.B., 1988, HDB MULTIVARIATE EXP, P131; Greve KW, 1997, BRIT J CLIN PSYCHOL, V36, P283, DOI 10.1111/j.2044-8260.1997.tb01414.x; Greve KW, 1999, ARCH CLIN NEUROPSYCH, V14, P497; Greve KW, 1998, ARCH CLIN NEUROPSYCH, V13, P597; GREVE KW, IN PRESS HDB REYOSTE; Heaton R., 1993, WISCONSIN CARD SORTI; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; PEDHAZUR EJ, 1991, MEASUREMENT DESIGN A; *PSYCH ASS RES, 1993, WISC CARD SORT TEST; SCHNEIDER SG, 1987, J ABNORM CHILD PSYCH, V15, P29, DOI 10.1007/BF00916464; Stevens J., 1996, APPL MULTIVARIATE ST; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; STUSS DT, 1983, NEUROPSYCHOLOGIA, V21, P235, DOI 10.1016/0028-3932(83)90040-4; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Varney NR, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P115; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205	19	46	47	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2002	16	1					29	40		10.1080/0269905011008803			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	515BM	WOS:000173475600003	11796097				2021-06-18	
J	Faden, AI				Faden, AI			Neuroprotection and traumatic brain injury - The search continues	ARCHIVES OF NEUROLOGY			English	Article							APOPTOTIC CELL-DEATH; SEVERE HEAD-INJURY; PHARMACOLOGICAL TREATMENT; TRIALS; STRATEGIES; RAT	During the last decade, experimental studies of traumatic brain injury (TBI) have provided important new insights into the pathophysiological mechanisms leading to posttraumatic tissue damage and associated neurological dysfunction. The concept of delayed or secondary tissue injury has strong experimental support and a cascade of secondary injury factors has been delineated.(1,2) These observations have led to the application of targeted pharmaco therapies, whose aim is to block specific pathobiological pathways.(2,3) Such research has been aided by the development of rodent models of head injury that simulate critical components of clinical neurotrauma, as well as by the development of novel neuroprotective agents.(3,4) These experimental studies have identified mechanisms of delayed tissue damage and have demonstrated the effectiveness of a number of pharmacological treatment strategies.(1-4) However, despite this enormous experimental promise, the clinical studies to date have been disappointing.(5,6) Here we explore the conceptual and methodological issues that have contributed to this discrepancy between preclinical and clinical studies.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Dept Neurol, Washington, DC 20007 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Dept Neurosci, EP-12 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.						Allen JW, 1999, FASEB J, V13, P1875; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Povlishock JT., 1996, NEUROTRAUMA, P1325; RINK A, 1995, AM J PATHOL, V147, P1575; TEASDALE G, 1990, ACT NEUR S, V51, P315; Temple MD, 2001, HEAD TRAUMA, P87; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	21	46	48	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	OCT	2001	58	10					1553	1555		10.1001/archneur.58.10.1553			3	Clinical Neurology	Neurosciences & Neurology	480CL	WOS:000171444400004	11594912	Bronze			2021-06-18	
J	Diamond, PT; Gale, SD				Diamond, PT; Gale, SD			Head injuries in men's and women's lacrosse: a 10 year analysis of the NEISS database	BRAIN INJURY			English	Article							EYE INJURIES; EYEWEAR	Introduction: Although protective headgear is required in men's lacrosse, women's lacrosse is viewed as non-contact, and use of helmets and faceguards is prohibited. Yet, women remain at risk for injury to the head and face region from contact with the ball and stick. This study was designed to examine differences in lacrosse-related injuries between genders and amongst various age groups. Methods: Data on lacrosse-related injuries maintained through the Consumer Product Safety Commission's National Electronic Injury Surveillance System, In-depth Investigation File, and Injuries/Potential Injuries File were analysed over a 10-year period ( January 1990-April 2000). Results: A total of 1727 cases of lacrosse-related trauma, mean age 16.9 years, range 4-59 years, were recorded. Males accounted for 80.5% of cases. The head and face region was the most common area injured (20.4%). Injuries to the head and face were significantly more prevalent among females (30.1% of all injuries) than males (18.0% of all injuries), p < 0.001, and often resulted from contact with the ball (33.6% of incidents). Children aged 4-11 years experienced the highest percentage of injuries to the head and face. Closed head injuries represented 5.6% of all lacrosse-related injuries and were slightly more prevalent among females. Conclusions: Women and children lacrosse players are at risk of serious injury to the head and face region. The use of protective head/face gear should be encouraged.	Univ Virginia Hlth Syst, Dept Phys Med & Rehabil, Charlottesville, VA 22908 USA	Diamond, PT (corresponding author), Univ Virginia Hlth Syst, Dept Phys Med & Rehabil, 545 Ray C Hunt Dr,Suite 240,POB 801004, Charlottesville, VA 22908 USA.		Gale, Shawn/M-3144-2013	Gale, Shawn/0000-0002-8989-0964			BENSON M, 2000, NCAA LACROSSE 2000 M; BENSON M, 1996, NCAA NEWS       0422, P6; BENSON M, 1998, NCAA NEWS       0330, P6; Casazza B A, 1999, Phys Med Rehabil Clin N Am, V10, P141; Goldenberg Michael S., 1995, Journal of Athletic Training, V30, P37; Harmer PA, 1993, SPORT HLTH, V11, P14; LAPIDUS CS, 1992, J TRAUMA, V32, P555, DOI 10.1097/00005373-199205000-00003; Livingston LA, 1996, J TRAUMA, V40, P144, DOI 10.1097/00005373-199601000-00030; MAYER NE, 1986, J EMERG MED, V5, P177; *NCAA, 2000, INJ SURV SYST 1999 2; URICK D, 1988, SPORTS ILLUSTRATED L; *US CONS PROD SAF, 2000, NAT INJ INF CLEAR; *US LACR, 2000, WOM RUL 2000 OFF RUL; Webster DA, 1999, MED SCI SPORT EXER, V31, P938, DOI 10.1097/00005768-199907000-00004; 1999, NCAA NEWS       0927, P7	15	46	47	0	1	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2001	15	6					537	544		10.1080/02699050010007362			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439VE	WOS:000169137600007	11394973				2021-06-18	
J	Munch, EC; Bauhuf, C; Horn, P; Roth, HR; Schmiedek, P; Vajkoczy, P				Munch, EC; Bauhuf, C; Horn, P; Roth, HR; Schmiedek, P; Vajkoczy, P			Therapy of malignant intracranial hypertension by controlled lumbar cerebrospinal fluid drainage	CRITICAL CARE MEDICINE			English	Article						adults; brain injury; cerebral edema; herniation; intracranial hypertension; lumbar drainage; outcome; subarachnoid hemorrhage	SEVERE HEAD-INJURY; PRESSURE; MANAGEMENT	Objectives: To evaluate the effect of controlled lumbar cerebrospinal fluid drainage in adult patients with refractory intracranial hypertension. Design: Prospective, pre- vs, postintervention study. Setting: Surgical intensive care unit of a university hospital. Patients: Twenty-three patients with severe traumatic brain injury or delayed ischemia after subarachnoid hemorrhage with intracranial hypertension refractory to aggressive treatment, including repeated applications of tromethamine, hypertonic saline solution, barbiturate coma, and decompressive craniectomy, Patients were considered for controlled lumbar cerebrospinal fluid drainage if basal cisterns on computerized tomography scan were discernible. Interventions: After institution of a lumbar drain, cerebrospinal fluid was gradually aspirated, and then, continuous cerebrospinal fluid drainage was maintained under control of intracranial pressure (ICP) and pupillary status. Measurements and Main Results: ICP and cerebral perfusion pressure before and after initiation of lumbar cerebrospinal fluid drainage and related complications were documented. The neurologic outcome of the patients was assessed according to the Glasgow Outcome Scale 6 months after injury. As a result of lumbar cerebrospinal fluid drainage, all patients demonstrated an immediate and lasting decrease of ICP and a concomitant increase of cerebral perfusion pressure. Two patients temporarily showed a unilateral fixed and dilated pupil 6 and 8 hrs after onset of lumbar cerebrospinal fluid drainage, respectively. Ten patients showed a favorable outcome, four patients survived with a severe permanent neurologic deficit, one patient remained in a persistent vegetative state, and eight patients died. Conclusions: Controlled lumbar cerebrospinal fluid drainage significantly reduces refractory intracranial hypertension. The danger of transtentorial or tonsillar herniation is minimized by considering lumbar drainage in the presence of discernible basilar cisterns only.	Heidelberg Univ, Fac Clin Med Mannheim, Dept Anesthesiol & Crit Care Med, D-68167 Mannheim, Germany; Heidelberg Univ, Fac Clin Med Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany	Munch, EC (corresponding author), Heidelberg Univ, Fac Clin Med Mannheim, Dept Anesthesiol & Crit Care Med, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.						BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; Cushing H, 1909, BOSTON MED SURG J, V161, P71, DOI 10.1056/NEJM190907151610301; Fremont-Smith F, 1932, J NERV MENT DIS, V76, P261; Fritsch MJ, 1997, ZBL NEUROCHIR, V58, P192; Hepburn HH, 1938, CAN MED ASSOC J, V39, P449; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JENNETT B, 1975, LANCET, V1, P480; KOREIN J, 1959, NEUROLOGY, V9, P290, DOI 10.1212/WNL.9.4.290; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Munch E, 2000, NEUROSURGERY, V47, P315; NASH CS, 1937, ANN OTO RHINOL LARYN, V46, P673; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SENCER W, 1956, J Mt Sinai Hosp N Y, V23, P808; VERBRUGGHEN A, 1946, SURG CLIN N AM, V26, P78; Willemse RB, 1998, ACT NEUR S, V71, P37	19	46	57	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2001	29	5					976	981					6	Critical Care Medicine	General & Internal Medicine	431DB	WOS:000168615700011	11378607				2021-06-18	
J	Bazarian, JJ; Veenema, T; Brayer, AF; Lee, E				Bazarian, JJ; Veenema, T; Brayer, AF; Lee, E			Knowledge of concussion guidelines among practitioners caring for children	CLINICAL PEDIATRICS			English	Article							CLINICAL-PRACTICE GUIDELINES; HEAD-INJURIES; 2ND IMPACT; SPORTS; PREVENTION	The objective of this study in Rochester, NY was to determine clinicians' knowledge of the Colorado Medical Society Guidelines (CMSG) on return to contact sports after a concussion. A survey was mailed to 1,140 pediatric, family practice, and emergency physicians, as well as 302 pediatric and family practice nurse practitioners in the Rochester, NY, area. Participants were gir-en 3 hypothetical concussion scenarios and asked to pick 1 of 4 multiple-choice time intervals for when they would advise return to contact sports. Answers were compared with the latest version of the CMSG. The survey response rate was 57%. Only 7.6% responded correctly for Grade 1 concussion scenario, 56% for the Grade 2 scenario, and 28% for the Grade 3 scenario. Only 5.6% listed the CMSG as the source of the return-to-play advice they gave. Thus, respondents' knowledge of the CMSG was low, with few giving return-to-play advice consistent with the CMSG and even fewer acknowledging the CMSG as the source of such advice. Improving the availability of the CMSG may improve clinicians' knowledge and use of these guidelines.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; St Lukes Roosevelt Hosp Ctr, Dept Emergency Med, New York, NY USA	Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Med Box 4-9200,601 Elmwood Ave, Rochester, NY 14642 USA.			Veenema, Tener/0000-0001-8977-9900			Bergman DA, 1999, PEDIATRICS, V104, P1407; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1992, SPORTS MED, V14, P65; CANTU RC, 1988, SPORTS MED DIGEST, V10, P2; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Davis DA, 1997, CAN MED ASSOC J, V157, P408; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; FITZPATRICK MH, 1996, AM COLL EM PHYS SCI; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GRONWALL D, 1975, LANCET, V2, P995; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; *SPORTS MED COMM C, 1991, GUID MAN CONC SPORTS; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	25	46	46	1	15	WESTMINSTER PUBL INC	GLEN HEAD	708 GLEN COVE AVE, GLEN HEAD, NY 11545 USA	0009-9228			CLIN PEDIATR	Clin. Pediatr.	APR	2001	40	4					207	212		10.1177/000992280104000405			6	Pediatrics	Pediatrics	422UR	WOS:000168138100005	11336419				2021-06-18	
J	Bryant, RA; Guthrie, RM; Moulds, ML				Bryant, RA; Guthrie, RM; Moulds, ML			Hypnotizability in acute stress disorder	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN INJURY; MULTIPLE PERSONALITY; DISSOCIATION; HYPNOSIS; SCALE; EXPECTANCY; ABSORPTION	Objective: This study investigated the relationship between acute dissociative reactions to trauma and hypnotizability. Method: Acutely traumatized patients (N=61) with acute stress disorder, subclinical acute stress disorder (no dissociative symptoms), and no acute stress disorder were administered the Stanford Hypnotic Clinical Scale within 4 weeks of their trauma. Results: Although patients with acute stress disorder and patients with subclinical acute stress disorder displayed comparable levels of nondissociative psychopathology, acute stress disorder patients had higher levels of hypnotizability and were more likely to display reversible posthypnotic amnesia than both patients with subclinical acute stress disorder and patients with no acute stress disorder. Conclusions: The findings may be interpreted in light of a diathesis-stress process mediating trauma-related dissociation. People who develop acute stress disorder in response to traumatic experience may have a stronger ability to experience dissociative phenomena than people who develop subclinical acute stress disorder or no acute stress disorder.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	r.bryant@unsw.edu.au	Bryant, Richard/AAA-6479-2019; Moulds, Michelle/B-2928-2010	Bryant, Richard/0000-0002-9607-819X; Moulds, Michelle/0000-0001-7064-4248			Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck AT., 1990, BECK ANXIETY INVENTO; BERNSTEIN EM, 1986, J NERV MENT DIS, V174, P727, DOI 10.1097/00005053-198612000-00004; BLISS EL, 1984, J NERV MENT DIS, V172, P203, DOI 10.1097/00005053-198404000-00003; BOWERS KS, 1991, INT J CLIN EXP HYP, V39, P155, DOI 10.1080/00207149108409632; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 2000, HDB THEORY ASSESSMEN; Butler LD, 1996, AM J PSYCHIAT, V153, P42; Carlson E.B., 1989, DISSOCIATION, V2, P32; COUNCIL JR, 1986, J PERS SOC PSYCHOL, V50, P182, DOI 10.1037/0022-3514.50.1.182; COVINO NA, 1994, J ABNORM PSYCHOL, V103, P455, DOI 10.1037/0021-843X.103.3.455; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; FRANKEL FH, 1990, AM J PSYCHIAT, V147, P823; FRANKEL FH, 1976, ARCH GEN PSYCHIAT, V33, P1259; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Janet P., 1907, MAJOR SYMPTOMS HYSTE, V2nd; KIHLSTROM JF, 1985, ANNU REV PSYCHOL, V36, P385, DOI 10.1146/annurev.ps.36.020185.002125; KIHLSTROM JF, 1994, J ABNORM PSYCHOL, V103, P117, DOI 10.1037/0021-843X.103.1.117; KIHLSTROM JF, 1984, INT J CLIN EXP HYP, V32, P51, DOI 10.1080/00207148408416000; LAVOIE G, 1973, INT J CLIN EXP HYP, V21, P157, DOI 10.1080/00207147308409120; LIEBERMAN J, 1978, INT J CLIN EXP HYP, V26, P268, DOI 10.1080/00207147808411252; MORGAN AH, 1979, AM J CLIN HYPN, V21, P134; NASH MR, 1993, J CONSULT CLIN PSYCH, V61, P276, DOI 10.1037/0022-006X.61.2.276; PICCIONE C, 1989, J PERS SOC PSYCHOL, V56, P289, DOI 10.1037/0022-3514.56.2.289; ROCHE SM, 1990, J PERS SOC PSYCHOL, V59, P91, DOI 10.1037/0022-3514.59.1.91; SILVA CE, 1992, J PERS SOC PSYCHOL, V63, P847, DOI 10.1037/0022-3514.63.5.847; SPIEGEL D, 1988, AM J PSYCHIAT, V145, P301; SPIEGEL D, 1984, PSYCHIAT CLIN N AM, V7, P101; Spiegel David, 1996, P367; STUTMAN RK, 1985, AM J PSYCHIAT, V142, P741; Waller NG, 1996, PSYCHOL METHODS, V1, P300, DOI 10.1037/1082-989X.1.3.300; Weitzenhoffer A., 1963, STANFORD HYPNOTIC SU; WOODY EZ, 1992, CONT HYPNOSIS RES, P3	39	46	47	0	1	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	APR	2001	158	4					600	604		10.1176/appi.ajp.158.4.600			5	Psychiatry	Psychiatry	419CN	WOS:000167931900013	11282695				2021-06-18	
J	Coward, K; Aitken, A; Powell, A; Plumpton, C; Birch, R; Tate, S; Bountra, C; Anand, P				Coward, K; Aitken, A; Powell, A; Plumpton, C; Birch, R; Tate, S; Bountra, C; Anand, P			Plasticity of TTX-sensitive sodium channels PNI and brain III in injured human nerves	NEUROREPORT			English	Article						brain III; human; nerve injury; pain; PNI	SPINAL SENSORY NEURONS; SUBUNIT MESSENGER-RNAS; ALPHA-SUBUNIT; EXPRESSION; PAIN; RAT; EXCITABILITY; CNS	Sensory neurones co-express voltage-gated sodium channels that mediate TTX-sensitive (TTX-S) and TTX-resistant (TTX-R) currents, which may contribute to chronic pain after nerve injury. We previously demonstrated that TTX-R channels were decreased acutely in human sensory cell bodies after central axotomy, but accumulated in nerve terminals after peripheral axotomy. We have now studied the TTX-S channels PNI and Brain III, using specific antibodies for immunohistochemistry, in dorsal root ganglia (DRG) from 10 patients with traumatic central axotomy, nerves from 16 patients with peripheral axotomy, and controls. PNI showed temporal changes similar to the TTX-R channels in sensory cell bodies of injured DRG. In contrast, Brain III was found only in injured nerves (not control nerves, or control/central axotomy DRG). PNI and Brain III are distinct targets for novel analgesics. NeuroReport 12:495-500 (C) 2001 Lippincott Williams & Wilkins.	Hammersmith Hosp, Univ London Imperial Coll Sci Technol & Med, Dept Neurol, Peripheral Neuropathy Unit, London W12 0NN, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Dept Mol Pharmacol, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Mol Recognit Dept, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Neurosci & Rheumatol Syst Dept, Stevenage SG1 2NY, Herts, England; Royal Natl Orthopaed Hosp, Peripheral Nerve Injury Unit, Stanmore HA7 4LP, Middx, England	Anand, P (corresponding author), Hammersmith Hosp, Univ London Imperial Coll Sci Technol & Med, Dept Neurol, Peripheral Neuropathy Unit, Area A,Ground Floor,Du Cane Rd, London W12 0NN, England.			Powell, Andrew/0000-0003-1540-537X			AHMED CMI, 1992, P NATL ACAD SCI USA, V89, P8220, DOI 10.1073/pnas.89.17.8220; Akopian AN, 1999, NAT NEUROSCI, V2, P541; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BAINES D, 1992, MOL BRAIN RES, V16, P330, DOI 10.1016/0169-328X(92)90243-5; Black JA, 1999, J NEUROPHYSIOL, V82, P2776; Black JA, 1996, MOL BRAIN RES, V43, P117, DOI 10.1016/S0169-328X(96)00163-5; BLACK JA, 1994, MOL BRAIN RES, V22, P275, DOI 10.1016/0169-328X(94)90056-6; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15; Coward K, 2000, PAIN, V85, P41, DOI 10.1016/S0304-3959(99)00251-1; ENGLAND JD, 1998, NEUROLOGY, V50; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; LU CM, 1992, FEBS LETT, V303, P53, DOI 10.1016/0014-5793(92)80476-W; Lu CM, 1998, J MOL NEUROSCI, V10, P67, DOI 10.1007/BF02737087; Powell AJ, 1998, EUR J NEUROSCI, V10, P68; ROY ML, 1992, J NEUROSCI, V12, P2104; Sangameswaran L, 1997, J BIOL CHEM, V272, P14805, DOI 10.1074/jbc.272.23.14805; TOLEDOARAL JJ, 1995, NEURON, V14, P607, DOI 10.1016/0896-6273(95)90317-8; ToledoAral JJ, 1997, P NATL ACAD SCI USA, V94, P1527, DOI 10.1073/pnas.94.4.1527; Waxman SG, 1999, PAIN, pS133, DOI 10.1016/S0304-3959(99)00147-5; Waxman SG, 1999, P NATL ACAD SCI USA, V96, P7635, DOI 10.1073/pnas.96.14.7635; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466; Waxman SG, 1999, MUSCLE NERVE, V22, P1177, DOI 10.1002/(SICI)1097-4598(199909)22:9<1177::AID-MUS3>3.3.CO;2-G; Whitaker WRJ, 1999, ANN NY ACAD SCI, V868, P88, DOI 10.1111/j.1749-6632.1999.tb11278.x	24	46	47	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	MAR 5	2001	12	3					495	500		10.1097/00001756-200103050-00014			6	Neurosciences	Neurosciences & Neurology	403XT	WOS:000167069000014	11234752				2021-06-18	
J	Bentzer, P; Mattiasson, G; McIntosh, TK; Wieloch, T; Grande, PO				Bentzer, P; Mattiasson, G; McIntosh, TK; Wieloch, T; Grande, PO			Infusion of prostacyclin following experimental brain injury in the rat reduces cortical lesion volume	JOURNAL OF NEUROTRAUMA			English	Article						brain contusion; endothelium; lateral fluid percussion; microvessels; prostacyclin; rat; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; MISSILE HEAD-INJURY; CAT SKELETAL-MUSCLE; VASCULAR-PERMEABILITY; NEURONAL DEGENERATION; NITRIC-OXIDE; CELL LOSS; CONTUSION; ANALOG; ILOPROST	Endothelial-derived prostacyclin is an important regulator of microvascular function, and its main actions are inhibition of platelet/leukocyte aggregation and adhesion, and vasodilation. Disturbances in endothelial integrity following traumatic brain injury (TBI) may result in insufficient prostacyclin production and participate in the pathophysiological sequelae of brain injury. The objective of this study was to evaluate the potential therapeutic effects of a low-dose prostacyclin infusion on cortical lesion volume, CA3 neuron survival and functional outcome following TBI in the rat. Anesthetized animals (sodium pentobarbital, 60 mg/kg, i.p.) were subjected to a lateral fluid percussion brain injury (2.5 atm) or sham injury. Following TBI, animals were randomized to receive a constant infusion of either prostacyclin (1 ng/kg . min(-l) i.v.) or vehicle over 48 h. All sham animals received vehicle (n = 6). Evaluation of neuromotor function, lesion volume, and CA3 neuronal loss was performed blindly. By 7 days postinjury, cortical lesion volume was significantly reduced by 43% in the prostacyclin-treated group as compared to the vehicle treated group (p < 0.01; n = 12 prostacyclin, n = 12 vehicle). No differences were observed in neuromotor function (48 h and 7 days following TBI), or in hippocampal cell loss (7 days following TBI) between the prostacyclin- and vehicle-treated groups. We conclude that prostacyclin in a low dose reduces loss of neocortical neurons following TBI and may be a potential clinical therapeutic agent to reduce neuronal cell death associated with brain trauma.	Univ Lund, Dept Physiol Sci, SE-22362 Lund, Sweden; Univ Lund Hosp, Wallenberg Neurosci Ctr, Div Expt Brain Res, S-22185 Lund, Sweden; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Bentzer, P (corresponding author), Univ Lund, Dept Physiol Sci, Solvegatan 19, SE-22362 Lund, Sweden.			Wieloch, Tadeusz/0000-0002-7669-2520			ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Al-Turki A, 1998, CRIT CARE MED, V26, P917, DOI 10.1097/00003246-199805000-00029; Armstead WM, 1998, J NEUROTRAUM, V15, P721, DOI 10.1089/neu.1998.15.721; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; AUER RN, 1984, DIABETES, V33, P1090, DOI 10.2337/diabetes.33.11.1090; AWAD I, 1983, STROKE, V14, P203, DOI 10.1161/01.STR.14.2.203; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bentzer P, 1999, J VASC RES, V36, P516, DOI 10.1159/000025695; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1990, ACT NEUR S, V51, P286; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Dogan A, 1996, GEN PHARMACOL-VASC S, V27, P1163; ERLANSSON M, 1991, PROSTAGLANDINS, V41, P157, DOI 10.1016/0090-6980(91)90028-E; FENSTERMACHER JD, 1984, EDEMA, P383; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; GRANDE PO, 1997, J TRAUMA, V42, P23; GRYGLEWSKI RJ, 1988, HYPERTENSION, V12, P530, DOI 10.1161/01.HYP.12.6.530; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HICKS RR, 1993, NEUROTRAUMA, V10, P405; HIGGS EA, 1978, PROSTAGLANDINS, V16, P17, DOI 10.1016/0090-6980(78)90197-1; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; JOHNSON G, 1990, CIRC RES, V66, P1362, DOI 10.1161/01.RES.66.5.1362; Karasawa Y., 1999, Society for Neuroscience Abstracts, V25, P583; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Kraus JF, 1993, HEAD INJURY, P1; LEFER AM, 1994, METHOD FIND EXP CLIN, V16, P623; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Maeda T, 1997, ACT NEUR S, V70, P102; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Moller AD, 1999, J VASC RES, V36, P245, DOI 10.1159/000025648; Moller AD, 1997, AM J PHYSIOL-HEART C, V273, pH200; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; PAXINOS G, 1996, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RABOW L, 1989, ACTA NEUROCHIR, V100, P155, DOI 10.1007/BF01403604; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Scheeren T, 1997, INTENS CARE MED, V23, P146, DOI 10.1007/s001340050309; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHIMA K, 1995, ACTA NEUROCHIR, V137, P89, DOI 10.1007/BF02188788; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; TANAKA K, 1988, STROKE, V19, P1267, DOI 10.1161/01.STR.19.10.1267; Taoka Y, 1997, J NEUROSURG, V86, P1007, DOI 10.3171/jns.1997.86.6.1007; TERAWAKI T, 1988, EUR J PHARMACOL, V152, P63, DOI 10.1016/0014-2999(88)90836-9; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; ZUSMAN RM, 1981, NEW ENGL J MED, V304, P934, DOI 10.1056/NEJM198104163041603	61	46	47	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					275	285		10.1089/08977150151070919			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000005	11284548				2021-06-18	
J	Gasparovic, C; Arfai, N; Smid, N; Feeney, DM				Gasparovic, C; Arfai, N; Smid, N; Feeney, DM			Decrease and recovery of N-acetylaspartate/creatine in rat brain remote from focal injury	JOURNAL OF NEUROTRAUMA			English	Article						brain; diaschisis; injury; metabolism; MRS; N-acetylaspartate; spectroscopy	MAGNETIC-RESONANCE-SPECTROSCOPY; CEREBRAL GLUCOSE-UTILIZATION; MITOCHONDRIAL DYSFUNCTION; HEAD-INJURY; CORTICAL INJURY; AXONAL INJURY; BLOOD-FLOW; METABOLISM; TRAUMA; DEPRESSION	Magnetic resonance spectroscopy (MRS) studies on traumatic brain injury (TBI) have shown that the neuronal metabolite N-acetylaspartate (NAA) may be reduced in regions of brain remote from sites of focal injury. Such reductions have generally been attributed to diffuse axonal injury (DAI) or neuron death. The aim of the present study was to investigate the contribution of metabolic depression, in the absence of DAI or cell death, to remote NAA reduction after TBI, The right sensorimotor cortices of adult rats were injured by weight drop. Two and six days later, tissue slices from the ipsilateral occipital cortex, or from the same region in uninjured rats, were superfused and examined by H-1-MRS. The occipital cortex has been shown to have negligible DAI or cell death but marked transient metabolic depression in this model of TBI, Two days after injury, the ratio of the NAA peak height to the total creatine peak height (NAA/TCr) was 14% lower than in control samples. Six days after injury, NAA/TCr recovered to within 7% of the control value. The time course of NAA/TCr decrease and recovery was similar to the time courses of widespread depression and recovery of 2-deoxyglucose uptake and mitochondrial alpha -glycerophosphate dehydrogenase activity measured previously in this model of TBI. Together, these results suggest that at least one component of remote NAA depression after TBI may be associated with a widespread and reversible metabolic depression that is unrelated to either DAI or cell death.	Univ New Mexico, Sch Med, Clin & Magnet Resonance Res Ctr, Albuquerque, NM 87131 USA; Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Gasparovic, C (corresponding author), Univ New Mexico, Sch Med, Clin & Magnet Resonance Res Ctr, 1201 Yale NE, Albuquerque, NM 87131 USA.	chuck@unm.edu	Gasparovic, Charles/E-7289-2010				Alavi A, 1997, J NUCL MED, V38, P1717; BACHELARD HS, 1985, BIOCHEM SOC T, V13, P835, DOI 10.1042/bst0130835; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DellaCorte F, 1997, ACTA NEUROCHIR, V139, P636; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1995, IMAGING NEUROLOGIC R, P91; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; FEENEY DM, 1995, P 2 INT WORLD C BIOM; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Gasparovic C, 1999, BRAIN RES PROTOC, V4, P97, DOI 10.1016/S1385-299X(99)00010-0; Gasparovic C, 1998, J NEUROCHEM, V71, P1727; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1996, NEUROTRAUMA, P1459; Kalra S, 1998, NEUROREPORT, V9, P1757, DOI 10.1097/00001756-199806010-00016; Kalra S, 1999, J NEUROL SCI, V165, pS27, DOI 10.1016/S0022-510X(99)00023-4; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; Queen SA, 1996, BRAIN RES, V724, P246, DOI 10.1016/0006-8993(96)00308-3; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; Scremin OU, 1997, J NEUROTRAUM, V14, P573, DOI 10.1089/neu.1997.14.573; SIGNORETTI S, 1999, 17 ANN NAT NEUR SOC; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Wild JM, 1999, MAGN RESON MATER PHY, V8, P109; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	41	46	54	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					241	246		10.1089/08977150151070856			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000002	11284545				2021-06-18	
J	Potter, DD; Bassett, MRA; Jory, SH; Barrett, K				Potter, DD; Bassett, MRA; Jory, SH; Barrett, K			Changes in event-related potentials in a three-stimulus auditory oddball task after mild head injury	NEUROPSYCHOLOGIA			English	Article						attention; memory; ERP; oddball; P-3; novelty; mild; closed; traumatic; head; brain; injury	NEUROPSYCHOLOGICAL DEFICITS; BRAIN POTENTIALS; ATTENTION; SYMPTOMS; SEQUELAE; P300; DISTRACTIBILITY; MECHANISMS	Previous research has demonstrated changes in event-related potentials in a variety of cognitive tasks after severe closed head injury. We sought to establish if similar changes were present in patients who had sustained only apparently mild head injury (MHI) by recording event-related potentials in a group of 24 mild head injured and 24 control participants during a three-stimulus auditory target detection task. For this 'oddball' task participants were required to press a button every time they heard a rare target tone and to ignore rare novel sounds and frequent non-target tones. Neuropsychological test results indicated that the mild head injured group had mild memory and attention impairments. Analysis of behavioural performance on the three-stimulus 'oddball' task showed no difference in reaction times or error rates between the two groups. Target condition N2 deflections appeared to be larger in the mild head injured but peak amplitude measures revealed that this effect was not significant. There were no significant differences in the amplitude or latency of the P3b evoked by target stimuli or the P3a evoked by novel stimuli. However, a putative 'O-wave' or 'reorienting negativity' following the P3a was more negative in the mild head injured group suggesting increased activation of components of the attention network. These findings lend support to the hypothesis that MHI can cause subtle cognitive impairments that are associated with abnormal allocation of attention resources in the context of normal behavioural performance. (C) 2001 Elsevier Science Ltd. All rights reserved.	Keele Univ, Dept Psychol, Keele, Staffs, England; Haywood Hosp, Neurobehav Unit, Stoke On Trent, Staffs, England	Potter, DD (corresponding author), Keele Univ, Dept Psychol, Keele, Staffs, England.	d.d.potter@dundee.ac.uk					BARIBEAU J, 1990, PSYCHOPHYSIOLOGICAL, P161; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Escera C, 1998, J COGNITIVE NEUROSCI, V10, P590, DOI 10.1162/089892998562997; EVANS RW, 1992, NEUROL CLIN, V10, P815; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; Gronwall D, 1989, MILD HEAD INJURY, P153; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Jory SH, 2000, J PSYCHOPHYSIOL, V14, P187; JORY SH, IN PRESS J PSYCHOPHY; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Loveless NE, 1979, ORIENTING REFLEX HUM, P77; Nelson HE, 1982, NATL ADULT READING T; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Nobre AC, 2000, NEUROIMAGE, V11, P210, DOI 10.1006/nimg.2000.0539; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P74, DOI 10.1055/s-2008-1041062; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; POTTER DD, 1999, J PSYCHOPHYSIOLOGY, P13; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; ROHRBAUGH JW, 1984, VARIETIES ATTENTION; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Schroger E, 1998, NEUROREPORT, V9, P3355, DOI 10.1097/00001756-199810260-00003; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1991, COMPENDIUM NEUROPSYC; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VONZOMEREN AH, 1984, CLOSED HEAD INJURY; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058	53	46	49	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2001	39	13					1464	1472		10.1016/S0028-3932(01)00057-4			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	487WM	WOS:000171902100011	11585614				2021-06-18	
J	Vigue, B; Ract, C; Zlotine, N; Leblanc, PE; Samii, K; Bissonnette, B				Vigue, B; Ract, C; Zlotine, N; Leblanc, PE; Samii, K; Bissonnette, B			Relationship between intracranial pressure, mild hypothermia and temperature-corrected PaCO2 in patients with traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						carbon dioxide; hypothermia; intracranial pressure; jugular venous blood oxygen saturation; traumatic brain injury	CEREBRAL BLOOD-FLOW; MODERATE HYPOTHERMIA; CARDIOPULMONARY BYPASS; CARBON-DIOXIDE; VALIDATION; METABOLISM; VELOCITY; ARTERIAL; TENSION; PH	Objective: To study the effects of mild hypothermia and associated changes in temperature-corrected PaCO2 (cPaCO(2)) on intracranial pressure (ICP), mean velocity of the middle cerebral artery (Vm), and venous jugular saturation in O-2 (SjvO(2)) in patients with severe traumatic brain injury (TBI). Design: Prospective, observational study. Setting: Intensive care unit. Patients: Severe TBI patients mechanically ventilated, sedated and paralyzed. Interventions: Twenty patients were subjected to four consecutive periods: (a) normocapnia-normothermia; (b) hypocapnia-normothermia, where hypocapnia was induced by an increase in minute volume: (c) hypocapnia-hypothermia, where hypocapnia was induced by hypothermia maintaining the ventilatory settings constant; (d) normocapnia-hypothermia, where normocapnia was achieved by a decrease in minute volume. Measurements and results: cPaCO(2) was 41 +/- 8 mmHg in periods 1 and 4, and 31 +/- 7 mmHg in periods 2 and 3. Core temperature was 37.1 +/- 0.8 degrees C in periods 1 and 2, and 34.1 +/- 1.1 degrees C in periods 3 and 4. End-tidal CO2 and cPaCO(2) values showed no difference between periods 1 and 4 and periods 2 and 3. ICP and Vm were dependent on cPaCO(2) but independent of core temperature values. SjvO(2) was related to cPaCO(2) and was significantly higher during period 3 than during period 2 (P < 0.05). Conclusion: The decrease in ICP was similar when hypocapnia was induced by hyperventilation or as a result of hypothermia alone. The relationship between cPaCO(2) and ICP might predict variations in ICP during changes in core temperature. Further studies are needed to confirm the cerebral metabolic effects of moderate hypothermia in TBI patients.	Univ Bicetre, Hop Bicetre, Dept Anesthesiol, F-94275 Le Kremlin Bicetre, France; Univ Toronto, Dept Anesthesiol, Toronto, ON, Canada	Vigue, B (corresponding author), Univ Bicetre, Hop Bicetre, Dept Anesthesiol, 78 Rue Gen Leclerc, F-94275 Le Kremlin Bicetre, France.						ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BRIAN JE, 1998, ANESTHESIOLOGY, V69, P547; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; DEXTER F, 1995, ANESTHESIOLOGY, V83, P405, DOI 10.1097/00000542-199508000-00021; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; HAGERDAL M, 1975, ACTA ANAESTH SCAND, P25; Huber P, 1967, Invest Radiol, V2, P17, DOI 10.1097/00004424-196701000-00016; Kofstad J, 1996, SCAND J CLIN LAB INV, V56, P21, DOI 10.3109/00365519609088622; MADDEN JA, 1993, PHARMACOL THERAPEUT, V59, P229, DOI 10.1016/0163-7258(93)90045-F; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; MORRAY JP, 1990, ANESTHESIOLOGY, V72, P510, DOI 10.1097/00000542-199003000-00020; MURKIN JM, 1987, ANESTH ANALG, V66, P825; Nemoto EM, 1996, J NEUROSURG ANESTH, V8, P52, DOI 10.1097/00008506-199601000-00012; PROUGH DS, 1986, ANESTHESIOLOGY, V64, P576, DOI 10.1097/00000542-198605000-00006; REAM AK, 1982, ANESTHESIOLOGY, V56, P41, DOI 10.1097/00000542-198201000-00009; ROGERS AT, 1988, ANESTHESIOLOGY, V69, P547, DOI 10.1097/00000542-198810000-00015; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SIESJO BK, 1972, KIDNEY INT, V1, P360, DOI 10.1038/ki.1972.47; Sitzwohl C, 1998, ANESTH ANALG, V86, P1131, DOI 10.1097/00000539-199805000-00043; TIAN R, 1995, CIRC RES, V76, P269, DOI 10.1161/01.RES.76.2.269; VERHAEGEN MJJ, 1993, STROKE, V24, P407, DOI 10.1161/01.STR.24.3.407; VOLPE JJ, 1982, PEDIATRICS, V70, P147	25	46	47	0	3	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUN	2000	26	6					722	728		10.1007/s001340051238			7	Critical Care Medicine	General & Internal Medicine	334WH	WOS:000088208300012	10945389				2021-06-18	
J	Genis, L; Chen, Y; Shohami, E; Michaelson, DM				Genis, L; Chen, Y; Shohami, E; Michaelson, DM			Tau hyperphosphorylation in apolipoprotein E-deficient and control mice after closed head injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						Alzheimer disease; apolipoprotein E; closed head injury; microtubule associated protein tau; phosphorylation	PAIRED HELICAL FILAMENTS; ALZHEIMERS-DISEASE; MONOCLONAL-ANTIBODIES; MICROTUBULE-BINDING; PHOSPHORYLATION; PROTEIN; EPITOPES; BRAIN	Apolipoprotein E (apoE)-deficient mice have learning and memory impairments that are associated with specific neurochemical changes and hyperphosphorylation of distinct epitopes of the cytoskeletal protein tau. Furthermore, such mice are highly susceptible to the sequelae of brain trauma and their ability to recover from head injury is impaired. in the present study we investigated the extent that the neuronal maintenance and repair impairments of apoE-deficient mice are related to aberrations at the tau phosphorylation level. This was pursued by subjecting control and apoE-deficient mice to closed head injury (CHI) and examination, utilizing immunoblot assays, of the resulting effects on tau phosphorylation. The results thus obtained revealed that tau of apoE-deficient mice is hyperphosphorylated before CHI and that this insult results in transient tau hyperphosphorylation, whose extent and time course in the two mouse groups varied markedly. Tau hyperphosphorylation in the injured controls was maximal by about 4 hr after injury and reverted to basal levels by 24 hr, In contrast, almost no head injury-induced tau hyperphosphorylation was observed in the apoE-deficient mice at 4 hr after injury. Some tau hyper-phosphorylation was detected in the head-injured apoE-deficient mice after longer time intervals, but its extent was markedly lower than the maximal values obtained in the head injured controls. These findings show that the chronic neuronal impairments brought about by apoE deficiency and the acute response to head injury are both associated with hyperphosphorylation of the same tau domain and that the ability of apoE-deficient mice to mount the acute tau hyperphosphorylation response to head injury is impaired. (C) 2000 Wiley-Liss, Inc.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel	Michaelson, DM (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.						BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRION JP, 1993, J NEUROCHEM, V60, P1372, DOI 10.1111/j.1471-4159.1993.tb03298.x; Chapman S, 1998, J NEUROCHEM, V70, P708; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Genis I, 1999, J NEUROCHEM, V72, P206, DOI 10.1046/j.1471-4159.1999.0720206.x; GENIS I, 1995, NEUROSCI LETT, V199, P5, DOI 10.1016/0304-3940(95)12007-Q; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1993, TINS, V11, P460; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; Kosik Kenneth S., 1994, P335; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; MANDELKOW EM, 1993, TRENDS BIOCHEM SCI, V18, P480, DOI 10.1016/0968-0004(93)90011-B; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P262; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Reynolds CH, 1997, J NEUROCHEM, V69, P191; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P243; Zelman FP, 1996, J NEUROSCI RES, V46, P90, DOI 10.1002/(SICI)1097-4547(19961001)46:1<90::AID-JNR11>3.0.CO;2-G	24	46	49	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAY 15	2000	60	4					559	564		10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K			6	Neurosciences	Neurosciences & Neurology	310ME	WOS:000086831300015	10797559				2021-06-18	
J	Kane, NM; Butler, SR; Simpson, T				Kane, NM; Butler, SR; Simpson, T			Coma outcome prediction using event-related potentials: P-3 and mismatch negativity	AUDIOLOGY AND NEURO-OTOLOGY			English	Article						coma; outcome prediction; evoked and event-related potentials; mismatch negativity (MMN)	SOMATOSENSORY-EVOKED POTENTIALS; TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; NONTRAUMATIC COMA; P300; RECOVERY; EMERGENCE; STATES; NAME	The prediction of the outcome from coma is of considerable importance to the patients, their relatives and attendant medical staff, and yet current clinical methods lack sensitivity and specificity. Objective investigations can enhance the accuracy of such predictions and are an important adjuvant when reaching decisions to continue or terminate life support. Of the neurophysiological methods available, electroencephalography and short-latency somatosensory evoked potentials have proved the most useful in the clinical setting. These tests are good predictors of an adverse outcome; however, they tell us only about the ongoing cerebral activity and integrity of the primary somatosensory pathways, respectively. The presence of long-latency event-related potentials has been shown to be a useful predictor of a favourable neurological outcome, and thus their use complements other neurophysiological techniques. Their potential application in clinical practice is reviewed. Copyright (C) 2000 S. Karger AG, Basel.	Frenchay Hosp, Grey Walter Dept Cin Neurophysiol, Bristol BS16 1LE, Avon, England; Burden Neurol Inst, Bristol BS16 1QT, Avon, England	Kane, NM (corresponding author), Frenchay Hosp, Grey Walter Dept Cin Neurophysiol, Bristol BS16 1LE, Avon, England.						BERLAD I, 1995, EVOKED POTENTIAL, V96, P472, DOI 10.1016/0168-5597(95)00116-A; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DEGIORGIO CM, 1993, ACTA NEUROL SCAND, V87, P423; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Folmer RL, 1997, BRAIN LANG, V56, P306, DOI 10.1006/brln.1997.1828; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; JONES SJ, IN PRESS ELECTROENCE; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; KANE NM, 1995, J PSYCHOPHYSIOL, V9, P183; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; KANE NM, IN PRESS ELECTROENCE; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KEREN O, 1994, BRAIN INJURY, V8, P239, DOI 10.3109/02699059409150976; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; OMAHONY D, 1990, LANCET, V336, P1265, DOI 10.1016/0140-6736(90)92887-N; Ozbudak-Demir S, 1999, ARCH PHYS MED REHAB, V80, P252, DOI 10.1016/S0003-9993(99)90134-X; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V62, P88, DOI 10.1016/0168-5597(85)90020-6; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P138, DOI 10.1016/0013-4694(86)90007-6; Prevec T., 1993, ELECTROENCEPHALOGR C, V87, pS130; RAPPAPORT M, 1977, ARCH PHYS MED REHAB, V58, P333; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; RAPPAPORT M, 1986, J HEAD TRAUMA REHABI, P00015, DOI DOI 10.1097/00001199-198603000-00005; Reuter B., 1989, TOPOGRAPHIC BRAIN MA, P192; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; SIGNORINO M, 1995, LANCET, V345, P255, DOI 10.1016/S0140-6736(95)90252-X; *SOC CRIT CAR MED, 1988, CRIT CARE MED, V16, P807; YINGLING CD, 1990, LANCET, V336, P873, DOI 10.1016/0140-6736(90)92372-O; Young G. B., 1998, COMA IMPAIRED CONSCI	37	46	46	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-3030			AUDIOL NEURO-OTOL	Audiol. Neuro-Otol.	MAY-AUG	2000	5	3-4					186	191		10.1159/000013879			6	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	326MR	WOS:000087739800006	10859412				2021-06-18	
J	Turkstra, LS				Turkstra, LS			Should my shirt be tucked in or left out? The communication contest of adolescence	APHASIOLOGY			English	Article							TRAUMATIC BRAIN INJURY; DISCOURSE; CHILDREN; LANGUAGE; SKILLS; RULES	Adolescence is a time of significant psychosocial development. Sophisticated communication skills also emerge during this time, helping adolescents to meet increasingly complex social needs. These developments shape the functional communication goals for adolescents with traumatic brain (TBI). The purpose of this paper is to present the major characteristics of psychosocial development in adolescence, and to relate this information to adolescents with TBI. Data on daily social communication in adolescence are also presented, to complement the psychosocial data and facilitate the identification of functional communication goals.	Case Western Reserve Univ, Dept Commun Sci, Cleveland, OH 44106 USA	Turkstra, LS (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.						ARGYLE M, 1986, INT J PSYCHOL, V21, P287, DOI 10.1080/00207598608247591; ARGYLE M, 1985, BRIT J SOC PSYCHOL, V24, P125, DOI 10.1111/j.2044-8309.1985.tb00671.x; BEGALI V, 1992, HEAD INJURY CHILDREN; Belenky MF., 1986, WOMENS WAYS KNOWING; BLOSSER J, 1994, PEDIAT TRAMATIC BRAI; BLUMKULKA S, 1990, J PRAGMATICS, V14, P259, DOI 10.1016/0378-2166(90)90083-P; BOURGAULT R, 1985, COMMUNICATION SKILLS, P241; Brice A, 1996, LANG SPEECH HEAR SER, V27, P68, DOI 10.1044/0161-1461.2701.68; BROWN LM, 1992, M CROSSROADS; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COHEN B, 1989, AI EXPERT, V4, P22; Cooper D., 1988, LATER LANGUAGE DEV A, P225; CSIKSZENTMIHALY.M, 1986, BEING ADOLESCENT CON; Damon W., 1983, SOCIAL PERSONALITY D; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Duck, 1991, STUDYING INTERPERSON, P197; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; EHRLICH J, 1985, COGNITIVE REHABILITA, P32; ERIKSON EH, 1959, IDENTITY LIFE CYCLE, V1; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; FEENEY TJ, 1998, STUDENTS ACQUIRED BR, P229; Hansen DJ, 1996, BEHAV MODIF, V20, P281, DOI 10.1177/01454455960203003; Hartley L. L., 1995, COGNITIVE COMMUNICAT; Hecht M.L., 1993, AFRICAN AM COMMUNICA; HOLMES CB, 1988, HEAD INJURED COLLEGE; Kenny D.A., 1991, STUDYING INTERPERSON, P275; Kim Young Yun, 1986, INTERETHNIC COMMUNIC; Lehr E., 1990, COMMUNITY INTEGRATIO, P301; LURIA AR, 1973, MACLEANS MAGAZI 0119, P44; Muuss R.E., 1996, THEORIES ADOLESCENCE, V6th ed.; Nippold M. A., 1988, LATER LANGUAGE DEV; Paul R., 1995, LANGUAGE DISORDERS I; Piaget Jean, 1947, PSYCHOL INTELLIGENCE; RADER MC, 1993, WHAT WE KNOW ED STUD; RAFFAELLI M, 1989, J YOUTH ADOLESCENCE, V18, P567, DOI 10.1007/BF02139074; SMITH F, 1990, VOCATIONAL ED J  NOV, P28; STEINBERG L, 1991, YUO YOUR ADOLESCENT; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TOWNE RL, 1993, LANG SPEECH HEAR SER, V24, P100; *TUCS UN SCH DISTR, 1994, PROF 21 CENT GRAD; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Worthington J, 1989, Rehabil Nurs, V14, P118; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU	46	46	46	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	APR	2000	14	4					349	364		10.1080/026870300401405			16	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	315AV	WOS:000087091200002					2021-06-18	
J	Chapline, JF; Ferguson, SA; Lillis, RP; Lund, AK; Williams, AF				Chapline, JF; Ferguson, SA; Lillis, RP; Lund, AK; Williams, AF			Neck pain and head restraint position relative to the driver's head in rear-end collisions	ACCIDENT ANALYSIS AND PREVENTION			English	Article; Proceedings Paper	World Congress on Whiplash Associated Disorders	1999	VANCOUVER, CANADA			head restraints; neck pain; neck injury; whiplash; rear-end collisions; rear-end crashes		This two-year investigation was designed to estimate the incidence of driver neck pain in rear-struck vehicles involved in two-vehicle collisions and to determine the relationship between neck pain and specific vehicle, human, and environmental factors. Neck pain percentages were significantly higher for female (45%) than for male (28%) drivers. For female and male drivers, neck pain likelihood increased as head restraint height decreased below the head's center of gravity, although this effect was significant only for females. Head restraint backset, the horizontal distance measured from the back of the driver's head to the front of the head restraint, was not found to be related to neck pain for female drivers. Backset trends for male drivers could not be evaluated because few male drivers had head restraints that were high enough for backset to be relevant. Reported neck pain decreased for older drivers (females only), drivers in less severe crashes, and drivers in heavier cars (females only); all head restraint analyses were adjusted for these characteristics. Women, and most likely men, in the United States would benefit greatly from international harmonization to European head restraint standards. Until then, both women and men should be encouraged to adjust their adjustable head restraints, if possible, behind their heads' centers of gravity and to sit with the backs of their heads as close as possible to their head restraints. (C) 2000 Elsevier Science Ltd. All rights reserved.	Insurance Inst Highway Safety, Arlington, VA 22201 USA; Univ Rochester, Sch Med, Dept Community & Prevent Med, Res Accident Invest Team, Rochester, NY 14642 USA	Chapline, JF (corresponding author), Insurance Inst Highway Safety, 1005 N Glebe Rd, Arlington, VA 22201 USA.	iihs@highwaysafety.org					CARROLL S, 1995, COSTS EXCESS MED CLA; Farmer CM, 1999, ACCIDENT ANAL PREV, V31, P719, DOI 10.1016/S0001-4575(99)00035-4; *HIGHW LOSS DAT I, 1997, VINDICATOR US MAN VI; *INS RES COUNC, 1994, AUT INJ CLAIM BEH IT, P21; KAHANE C, 1982, HS806108 DOT US DEP; KIHLBERG JK, 1969, CALVJ2721R2, P1; MORRIS CR, 1998, MEASUREMENT EVALUATI; *NAT HIGHW TRAFF S, 1996, HEAD RESTR ID ISS RE; *NAT SAF COUNC, 1984, VEH DAM SCAL TRAFF A; O'Neill B, 2000, ACCIDENT ANAL PREV, V32, P143, DOI 10.1016/S0001-4575(99)00057-3; Olsson I, 1990, P INT IRCOBI C BIOM, P269; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; RUEDEMANN AD, 1957, JAMA-J AM MED ASSOC, V164, P1889, DOI 10.1001/jama.1957.62980170001006; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4th; SCHUTT CH, 1968, J AMER MED ASSOC, V206, P2689, DOI 10.1001/jama.206.12.2689; STATES JD, 1973, P 16 STAPP CAR CRASH, P228; TEMMING J, 1998, P 1998 INT IRCOBI C, P219; *U MICH TRANSP RES, 1983, ANTHR SPEC MID SIZ M; Vann, 1995, MEASUREMENT EVALUATI; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	20	46	47	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	MAR	2000	32	2					287	297		10.1016/S0001-4575(99)00126-8			11	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	282GG	WOS:000085209300017	10688485				2021-06-18	
J	Dietzmann, K; von Bossanyi, P; Krause, D; Wittig, H; Mawrin, C; Kirches, E				Dietzmann, K; von Bossanyi, P; Krause, D; Wittig, H; Mawrin, C; Kirches, E			Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: An immunohistochemical study	PATHOLOGY RESEARCH AND PRACTICE			English	Article						neurotrauma; necrosis; microglia; astrocytes; plasminogen activator system; plasminogen activator inhibitor; serine proteases; brain degradation; laminin; tetranectin	MATRIX METALLOPROTEINASE EXPRESSION; NECROSIS-FACTOR-ALPHA; EXTRACELLULAR-MATRIX; PROTEOLYTIC ACTIVITY; NEURONAL DEATH; MESSENGER-RNA; IN-VITRO; TISSUE; CELL; RAT	Plasminogen activators as inducible extracellular serine proteases are involved in a variety of processes, such as the degradation of brain structures. In regions of brain degradation, an increase in the expression of genes encoding cytokines and proteinases has recently been demonstrated. We tested the hypothesis, whether the plasminogen activator system as well as the plasminogen activator inhibitors are expressed and possibly involved in a proteolytic cascade that breaks down the extracellular matrix as a result of ischemic or posttraumatic brain destructions. To study this supposition, we investigated immunohistochemically the expression of tPA, uPA and its receptor, the plasminogen activator inhibitors PAI-1 and PAI-2, tetranectin as well as the laminin breakdown as an event of secondary brain injury. Brain tissue from 21 autopsy cases with severe brain injuries, material from 14 ischemic infarcts and 11 controls with acute hypoxia were used. All components of the plasminogen activator system studied were overexpressed immunohistochemically in reactive astrocytes, microglia and endothelial cells around the lesion zone. Tetranectin showed an analogous distribution to the plasminogen activator system. A reduced immunoreactivity of laminin within the identical region of destruction was detected concomitant with laminin remnants in perivascular macrophages, so that a remarkable role of the plasmin cascade in the degradation of extracellular matrix proteins in the brain is taken into consideration.	Univ Magdeburg, Inst Neuropathol, Sch Med, Dept Neuropathol, D-39120 Magdeburg, Germany; Univ Magdeburg, Sch Med, Dept Legal Med, D-39120 Magdeburg, Germany	Dietzmann, K (corresponding author), Univ Magdeburg, Inst Neuropathol, Sch Med, Dept Neuropathol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Knut.Dietzmann@Medizin.Uni-Magdeburg.DE	Wittig, Holger/AAA-5421-2021	Wittig, Holger/0000-0002-3454-0721			Anthony DC, 1997, NEUROPATH APPL NEURO, V23, P406, DOI 10.1111/j.1365-2990.1997.tb01315.x; Blomgren K, 1997, ANN NY ACAD SCI, V825, P104, DOI 10.1111/j.1749-6632.1997.tb48420.x; Boudaoud L, 1997, SPINAL CORD, V35, P151, DOI 10.1038/sj.sc.3100373; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; CHRISTENSEN L, 1989, HISTOCHEMISTRY, V92, P29, DOI 10.1007/BF00495012; CHURLIAEV IUA, 1996, ANESTEZIOL REANIMAT, V1, P37; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; CONSTANTINI V, 1996, CANCER, V77, P1079; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; EDGAR D, 1991, J CELL SCI, P9; FABERELMAN A, 1995, J NEUROCHEM, V65, P1524; GOLDBERG WJ, 1992, BRAIN RES, V581, P81, DOI 10.1016/0006-8993(92)90346-B; HIBINO T, 1988, FEBS LETT, V231, P202, DOI 10.1016/0014-5793(88)80731-2; Hogdall C K, 1998, APMIS Suppl, V86, P1; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KEETON M, 1993, AM J PATHOL, V142, P59; KINDER DH, 1993, ONCOL RES, V5, P409; KOBAYASHI H, 1994, CANCER RES, V54, P6539; KRISTENSEN P, 1985, J CELL BIOL, V101, P305, DOI 10.1083/jcb.101.1.305; MACDONALD RL, 1992, J NEUROSURG, V76, P81, DOI 10.3171/jns.1992.76.1.0081; Masos T, 1997, MOL BRAIN RES, V47, P157, DOI 10.1016/S0169-328X(97)00040-5; McCulloch J, 1993, Acta Neurochir Suppl (Wien), V57, P73; McIntosh TK, 1996, LAB INVEST, V74, P315; MOHANAM S, 1993, CANCER RES, V53, P4143; MORI S, 1992, HISTOCHEMISTRY, V97, P237, DOI 10.1007/BF00267633; MURPHY P, 1992, EXP CELL RES, V198, P93, DOI 10.1016/0014-4827(92)90153-Y; MURTOMAKI S, 1995, DEV BIOL, V168, P635, DOI 10.1006/dbio.1995.1108; NAKAJIMA K, 1992, BRAIN RES, V577, P285, DOI 10.1016/0006-8993(92)90285-H; PRESTA M, 1990, J NEUROCHEM, V55, P1647, DOI 10.1111/j.1471-4159.1990.tb04951.x; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; REITH A, 1992, BIOCHEM BIOPH RES CO, V186, P348, DOI 10.1016/S0006-291X(05)80814-9; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SAKATA Y, 1988, J BIOL CHEM, V263, P1960; SAKSELA O, 1985, J CELL PHYSIOL, V122, P125, DOI 10.1002/jcp.1041220119; Seeds NW, 1996, SEMIN NEUROSCI, V8, P405, DOI 10.1006/smns.1996.0049; SEUBERT P, 1988, BRAIN RES, V459, P226, DOI 10.1016/0006-8993(88)90638-5; Seyfried D, 1997, J NEUROSURG, V87, P716, DOI 10.3171/jns.1997.87.5.0716; STEPHENS R, 1992, FIBRINOLYSIS, V6, P35; TRANQUE P, 1994, ENDOCRINOLOGY, V134, P2606, DOI 10.1210/en.134.6.2606; Tsirka SE, 1997, J MOL MED, V75, P341, DOI 10.1007/s001090050119; vanderLaan LJW, 1997, J NEUROSCI RES, V50, P539, DOI 10.1002/(SICI)1097-4547(19971115)50:4<539::AID-JNR5>3.0.CO;2-F; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WARE JH, 1995, J NEUROBIOL, V28, P9, DOI 10.1002/neu.480280103; YAMAMOTO M, 1994, CANCER RES, V54, P5016	50	46	50	0	1	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.		2000	196	1					15	21		10.1016/S0344-0338(00)80017-5			7	Pathology	Pathology	278FX	WOS:000084979000003	10674268				2021-06-18	
J	Hanten, G; Bartha, M; Levin, HS				Hanten, G; Bartha, M; Levin, HS			Metacognition following pediatric traumatic brain injury: A preliminary study	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; DEVELOPMENTAL-CHANGES; MEMORY VARIABLES; KNOWLEDGE; ORGANIZATION; METAMEMORY; ATTENTION	Metacognition is one of the cognitive processes included under the general term executive functions. The executive functions are widely held to be under the control of the prefrontal cortex, an area often damaged after severe traumatic brain injury (TBI). We examined the metacognitive processing of a group of 9 children with TBI, and a group of 9 healthy, age-matched control children. Children with TBI showed significant impairments in their accuracy of prediction of the ease with which an item would be learned and their ability to predict recall of an item after a 2-hr delay. No significant differences in recall performance between the TBI and control groups were exhibited. The results are interpreted as suggesting an impairment in metacognitive processing resulting from frontal lobe damage after TBI in children. Additional research is necessary to confirm the relation of frontal lobe pathology and severity of injury to metacognitive impairments.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Hanten, G (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 6560 Fannin,Suite 1144, Houston, TX 77030 USA.	ghanten@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Brown AL, 1978, ADV INSTRUCTIONAL PS, P367; BROWN AL, 1978, CHILDRENS THINKING D; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FLAVELL JH, 1970, COGNITIVE PSYCHOL, V1, P324, DOI 10.1016/0010-0285(70)90019-8; Flavell JH., 1981, COGNITIVE MONITORING, P35; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; JANOWSKY JS, 1989, PSYCHOBIOLOGY, V17, P3; KEENEY TJ, 1967, CHILD DEV, V38, P953, DOI 10.1111/j.1467-8624.1967.tb04373.x; KENNEDY BA, 1976, CHILD DEV, V47, P566, DOI 10.2307/1128824; LEONESIO RJ, 1990, J EXP PSYCHOL LEARN, V16, P464, DOI 10.1037/0278-7393.16.3.464; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LYON TD, 1993, CHILD DEV, V64, P789, DOI 10.2307/1131218; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Metcalfe J., 1996, METACOGNITION KNOWIN; MOYNAHAN ED, 1973, CHILD DEV, V44, P238; ROGOFF B, 1974, CHILD DEV, V45, P972, DOI 10.2307/1128084; SHIMAMURA AP, 1986, J EXP PSYCHOL LEARN, V12, P452, DOI 10.1037/0278-7393.12.3.452; SHIMAMURA AP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P173; TEASDALE G, 1974, LANCET, V2, P81; WELLMAN HM, 1981, CHILD DEV, V52, P1313, DOI 10.1111/j.1467-8624.1981.tb03182.x; WELLMAN HM, 1978, DEV PSYCHOL, V14, P24, DOI 10.1037/0012-1649.14.1.24; YUSSEN SR, 1979, DEV PSYCHOL, V15, P447	29	46	46	0	4	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2000	18	3					383	398		10.1207/S1532694206Hanten			16	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	432UW	WOS:000168714900006	11385831				2021-06-18	
J	Solbakk, AK; Reinvang, I; Nielsen, C; Sundet, K				Solbakk, AK; Reinvang, I; Nielsen, C; Sundet, K			ERP indicators of disturbed attention in mild closed head injury: A frontal lobe syndrome?	PSYCHOPHYSIOLOGY			English	Article						attention; mild closed head injury; frontal injury; event-related potentials; processing negativity; P3; reaction time	EVENT-RELATED POTENTIALS; HUMAN PREFRONTAL CORTEX; AUDITORY ODDBALL TASK; SELECTIVE ATTENTION; BRAIN POTENTIALS; LESIONS; P300; DISTRACTIBILITY; SYMPTOMS; DEFICITS	The purpose of the study was to examine the hypothesis that distractibility is a fundamental characteristic of mild closed head injury (MHI). The claim that cognitive symptoms in MHI are due to a mild type of frontotemporal injury was also investigated. Cognitive event-related potentials (ERPs), accuracy and reaction time to target stimuli in a dichotic listening paradigm, and neuropsychological test results were studied in patients with MHI (N = 15), patients with verified frontal lobe damage (N = 10), and healthy controls (N = 13). Information processing reflecting target detection (N2, P3b) and sustained selective attention (processing negativity) was studied. The MHI and frontal patients did not differ on behavioral measures, except that the MHI group had significantly longer reaction times to target stimuli in the ERP task. Both patient groups had deviant ERPs compared with controls, but their ERP patterns differed in important respects. Contrary to expectations, the MHI patients had the most abnormal ERPs. They showed significantly smaller N2 and Nd amplitudes than frontal patients and controls, indicating that the mediating cognitive mechanisms were not equivalent in MHI and frontal injury. The data suggest that MHI patients allocated less processing resources to the task than either the control subjects or the patients with frontal lobe damage.	Univ Oslo, Inst Psychol, Blindern, Norway; Natl Hosp Norway, Dept Psychosomat & Behav Med, Oslo, Norway	Solbakk, AK (corresponding author), Univ Oslo, Inst Psychol, POB 1094, Blindern, Norway.	a.k.solbakk@psykologi.uio.no					ALHO K, 1992, PSYCHOPHYSIOLOGY, V29, P247, DOI 10.1111/j.1469-8986.1992.tb01695.x; ALHO K, 1987, ELECTROEN CLIN NEURO, V68, P458, DOI 10.1016/0168-5597(87)90057-8; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; Baribeau J., 1989, J NEUROL REHABIL, V3, P71; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; Boller F, 1995, ANN NY ACAD SCI, V769, P23, DOI 10.1111/j.1749-6632.1995.tb38129.x; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, P269; CHAO LL, 1995, NEUROREPORT, V6, P1605, DOI 10.1097/00001756-199508000-00005; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Jacobs A, 1996, J NUCL MED, V37, P1605; KNIGHT RT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P139; KNIGHT RT, 1981, ELECTROEN CLIN NEURO, V52, P571, DOI 10.1016/0013-4694(81)91431-0; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; KNIGHT RT, 1989, BRAIN RES, V504, P338, DOI 10.1016/0006-8993(89)91381-4; KNIGHT RT, 1995, ADV NEUROL, V66, P21; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LEVIN HS, 1987, NEUROBEHAVIORAL RECO, P221; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; NAATANEN R, 1982, PSYCHOL BULL, V92, P605; NAATANEN R, 1995, HDB NEUROPSYCHOLOGY, P75; Naatanen R., 1992, ATTENTION BRAIN FUNC; NIELSEN CS, 1997, READPEACK DATA PROGR; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REINVANG I, 1999, J CLIN EXPT NEUROPSY; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SEGALOWITZ SJ, 1995, SOC PSYCH RES TOR ON; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; SERVANSCHREIBER D, 1990, SCIENCE, V249, P892, DOI 10.1126/science.2392679; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spreen O., 1998, COMPENDIUM NEUROPSYC; STAM CJ, 1993, BRAIN, V116, P1139, DOI 10.1093/brain/116.5.1139; STECKLER T, 1995, BEHAV BRAIN RES, V67, P165, DOI 10.1016/0166-4328(94)00157-B; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WOODS DL, 1986, NEUROLOGY, V36, P212, DOI 10.1212/WNL.36.2.212; YAMAGUCHI S, 1990, BRAIN RES, V521, P281, DOI 10.1016/0006-8993(90)91553-S	55	46	46	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0048-5772	1469-8986		PSYCHOPHYSIOLOGY	Psychophysiology	NOV	1999	36	6					802	817					16	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	249BB	WOS:000083311300013	10554593				2021-06-18	
J	Trembovler, V; Beit-Yannai, E; Younis, F; Gallily, R; Horowitz, M; Shohami, E				Trembovler, V; Beit-Yannai, E; Younis, F; Gallily, R; Horowitz, M; Shohami, E			Antioxidants attenuate acute toxicity of tumor necrosis factor-alpha induced by brain injury in rat	JOURNAL OF INTERFERON AND CYTOKINE RESEARCH			English	Article							CLOSED-HEAD INJURY; NF-KAPPA-B; TNF-ALPHA; TRANSCRIPTION FACTOR; CYTOKINE EXPRESSION; NITROXIDE RADICALS; OXIDATIVE STRESS; NERVOUS-SYSTEM; BARRIER; MECHANISMS	Tumor necrosis factor-alpha alpha (TNF-alpha) and reactive oxygen species (ROS) are produced in the brain after traumatic injury and have deleterious effects. In a rat model of closed head injury (CHI), the synthetic antioxidant from the nitroxide family, Tempol, improved recovery and protected the blood-brain barrier. Similar protection was found after CHI in heat-acclimated rats, in which the endogenous antioxidants have been shown to be elevated after CHI, The present study examined the relationship between TNF-alpha and ROS after CHI, namely, whether after CHI, antioxidants that afforded cerebroprotection also attenuated brain levels of TNF-alpha, Three groups of rats were subjected to CHI: (1) control, nontreated, (2) Tempol-treated, and (3) heat-acclimated (30 days at 34 degrees C). Four hours after injury (time for peak production of TNF-alpha), the activity of TNF-alpha was measured. Although clinical recovery was facilitated in rats of the two treated groups, TNF-alpha activity was as high as in the traumatized, untreated rats. Moreover, direct injection of TNF-alpha into mouse brain induced disruption of the blood-brain barrier, indicating its acute harmful effect. This toxic effect was attenuated by before and after treatment with Tempol, Our results support the hypothesis that in vivo antioxidants neutralize TNF-alpha toxicity, probably by interfering with activation of the transcription factor NF-kappa-B.	Hebrew Univ Jerusalem, Sch Pharm & Med, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm & Med, Dept Immunol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm & Med, Dept Physiol, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, POB 12065, IL-91120 Jerusalem, Israel.		Beit-Yannai, Elie/F-2141-2012	Beit-Yannai, Elie/0000-0001-9347-822X			BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; CLAUDIO L, 1994, LAB INVEST, V70, P850; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dong WM, 1998, J INTERF CYTOK RES, V18, P629, DOI 10.1089/jir.1998.18.629; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GINSBURG I, 1992, INFLAMMATION, V16, P519, DOI 10.1007/BF00918977; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Lahdenpohja N, 1998, J IMMUNOL, V160, P1354; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; LEVI E, 1993, J APPL PHYSIOL, V75, P883; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; McIntosh TK, 1996, LAB INVEST, V74, P315; Meistrell ME, 1997, SHOCK, V8, P341; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; POGREBNIAK H, 1991, J SURG RES, V50, P469, DOI 10.1016/0022-4804(91)90026-I; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHOHAMI E, 1994, RESTOR NEUROL NEUROS, V6, P107, DOI 10.3233/RNN-1994-6204; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WRIGHT JL, 1994, J NEURO-ONCOL, V20, P17, DOI 10.1007/BF01057957; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	30	46	47	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	1079-9907			J INTERF CYTOK RES	J. Interferon Cytokine Res.	JUL	1999	19	7					791	795		10.1089/107999099313640			5	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	224LA	WOS:000081899500012	10454350				2021-06-18	
J	Feinberg, TE; Eaton, LA; Roane, DM; Giacino, JT				Feinberg, TE; Eaton, LA; Roane, DM; Giacino, JT			Multiple Fregoli delusions after traumatic brain injury	CORTEX			English	Article						Fregoli syndrome; misidentification	RIGHT-HEMISPHERE DAMAGE; REDUPLICATIVE PARAMNESIA; FALSE RECOGNITION; CAPGRAS-SYNDROME; MISIDENTIFICATION; DISEASE; ATROPHY	A 61 year old man after a traumatic brain injury resulting in right frontal and left temporoparietal contusions developed florid Fregoli-type misidentifications. Extensive neuropsychological testing demonstrated significant deficits in executive and memory functions. The patient's neuropsychological profile closely resembled that seen in previously reported patients with Capgras syndrome. Our findings are consistent with the hypothesis that a combination of executive and memory deficits may account for cases of delusional misidentification associated with brain lesions. However, the form which the delusion takes may be influenced by other factors including motivation.	Beth Israel Med Ctr, Yarmon Neurobehav & Alzheimers Dis Ctr, New York, NY 10003 USA; JFK Johnson Rehabil Inst, Dept Neuropsychol, Edison, NJ USA; Beth Israel Med Ctr, Dept Psychiat, New York, NY 10003 USA	Feinberg, TE (corresponding author), Beth Israel Med Ctr, Yarmon Neurobehav & Alzheimers Dis Ctr, 317 East 17th St,Fierman Hall,9th Floor, New York, NY 10003 USA.		Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698			ALEXANDER MP, 1979, NEUROLOGY, V29, P334, DOI 10.1212/WNL.29.3.334; Capgras Joseph, 1923, B SOC CLIN MED MENTA, P6; CHRISTODOULOU GN, 1978, AM J PSYCHIAT, V135, P249; CHRISTODOULOU GN, 1976, ACTA PSYCHIAT SCAND, V54, P305, DOI 10.1111/j.1600-0447.1976.tb00125.x; CHRISTODOULOU GN, 1986, DELUSIONAL MISIDENTI, V164; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Courbon P., 1927, ANN MED-PSYCHOL, V85, P289; Courbon P., 1932, ANN MED-PSYCHOL, V90, P401; Critchley M, 1953, PARIETAL LOBES; DELIS D, 1987, CALIFORNIA VERBAL LE; Denman S. B., 1984, MANUAL DENMAN NEUROP; DEPAUW KW, 1987, J NERV MENT DIS, V175, P433, DOI 10.1097/00005053-198707000-00008; DEPAUW KW, 1994, PSYCHOPATHOLOGY, V27, P123, DOI 10.1159/000284858; ELLIS HD, 1994, PSYCHOPATHOLOGY, V27; ELLIS W V, 1990, Pain Clinic, V3, P239; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1093/neucas/3.1.73; FEINBERG TE, 1997, BEHAV NEUROLOGY NEUR, P391; FEINBERG TE, 1989, NEUROPSY NEUROPSY BE, V2, P39; FLEMINGER S, 1994, PSYCHOPATHOLOGY, V27, P161, DOI 10.1159/000284865; FORSTL H, 1991, PSYCHOL MED, V21, P905, DOI 10.1017/S0033291700029895; Heaton R. K, 1981, WISCONSIN CARD SORTI; JOSEPH AB, 1987, J CLIN PSYCHIAT, V48, P409; JOSEPH AB, 1985, AM J PSYCHIAT, V142, P146; JOSEPH AB, 1986, DELUSIONAL MISIDENTI; Kaplan E., 1983, BOSTON NAMING TEST; Korsakoff S, 1955, NEUROLOGY, V5, P394; Korsakoff S S, 1891, ALLG Z PSYCHIAT, V47, P390; LEVIN M, 1945, J MENT SCI, V91, P447; MENDEZ MF, 1992, J NERV MENT DIS, V180, P94, DOI 10.1097/00005053-199202000-00005; OConnor M, 1996, NEUROPSY NEUROPSY BE, V9, P265; Paterson A, 1944, BRAIN, V67, P54, DOI 10.1093/brain/67.1.54; Pick A, 1903, BRAIN, V26, P242, DOI 10.1093/brain/26.2.242; Rapcsak SZ, 1996, CORTEX, V32, P593, DOI 10.1016/S0010-9452(96)80033-5; RAPCSAK SZ, 1994, CORTEX, V30, P565, DOI 10.1016/S0010-9452(13)80236-5; REITAN RM, 1985, HELSTEADREITAN NEURO; Roane DM, 1998, J NEUROPSYCH CLIN N, V10, P194, DOI 10.1176/jnp.10.2.194; RUFF RL, 1981, J NEUROL NEUROSUR PS, V44, P382, DOI 10.1136/jnnp.44.5.382; Spreen O., 1977, NEUROSENSORY CTR COM; STATON RD, 1982, CORTEX, V18, P23, DOI 10.1016/S0010-9452(82)80016-6; TALLAND GA, 1961, J NERV MENT DIS, V132, P361, DOI 10.1097/00005053-196105000-00001; TAYLOR J, 1958, SELECTED WRITINGS J; VI JJ, 1930, ANN MED-PSYCHOL, V88, P214; VICTOR M, 1955, NEUROLOGY, V5, P394, DOI 10.1212/WNL.5.6.394; VICTOR M, 1989, WERNICKEKORSAKOFF SY; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; Wetzel L., 1987, SHORT CATEGORY TEST; Williams HW, 1938, AM J PSYCHIAT, V95, P395, DOI 10.1176/ajp.95.2.395	49	46	47	0	5	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	JUN	1999	35	3					373	387		10.1016/S0010-9452(08)70806-2			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	219WG	WOS:000081630400005	10440075				2021-06-18	
J	Paniak, C; Phillips, K; Toller-Lobe, G; Durand, A; Nagy, J				Paniak, C; Phillips, K; Toller-Lobe, G; Durand, A; Nagy, J			Sensitivity of three recent questionnaires to mild traumatic brain injury-related effects	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	Meeting of the American-Neuro-Psychiatric-Association	FEB   01, 1998	HONOLULU, HAWAII	Amer Neuro Psychiat Assoc			HEALTH SURVEY SF-36; SCALING ASSUMPTIONS; DATA QUALITY; HEAD-INJURY; RELIABILITY; VALIDITY; TESTS	Objective: To evaluate the sensitivity of three recently developed questionnaires to mild traumatic brain injury (MTBI)-related effects. Design: Comparison of an MTBI group, within 3 weeks of injury, to a normal control group, setting: Outpatient rehabilitation clinic. Subjects: 120 MTBI patients and 120 age, education, sex, and preinjury socioeconomic status-matched normal control subjects. Main outcome measures: The Problem Checklist (PCL) from the New York Head Injury Family Interview to assess MTBI symptoms, the Short Form-36 Health Survey (SF-36) to assess functional burden associated with health problems, and the Community Integration Questionnaire (CIQ) to assess home, social, and productive activities. Results: Patients' self-ratings on the PCL and SF-36, but not the CIQ, were generally worse than those of the normal controls. The largest differences were obtained on SF-36 measures that appear to assess musculoskeletal injury effects. Conclusions: The PCL and SF-36 show promise as sensitive measures of MTBI-related effects. The SF-36 may be particularly useful in evaluating associated musculoskeletal injuries, which might otherwise be overlooked by MTBI health care providers.	Glenrose Rehabil Hosp, Dept Psychol, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB T6G 2M7, Canada; Glenrose Rehabil Hosp, Psychol Serv, Edmonton, AB T5G 0B7, Canada; Glenrose Rehabil Hosp, Phys Therapy Serv, Edmonton, AB T5G 0B7, Canada; Glenrose Rehabil Hosp, Med Serv, Edmonton, AB T5G 0B7, Canada	Paniak, C (corresponding author), Glenrose Rehabil Hosp, Dept Psychol, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Deane M, 1996, BRIT J NEUROSURG, V10, P187; GLASS GV, STAT METHODS ED PSYC, P84; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hannay HJ, 1996, J HEAD TRAUMA REHAB, V11, P41, DOI 10.1097/00001199-199612000-00007; JENKINSON C, 1994, QUAL LIFE RES, V3, P7, DOI 10.1007/BF00647843; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KRAUS JF, 1989, MILD HEAD INJURY, P8; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ruff R.M., 1989, MILD HEAD INJURY, P176; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SULLIVAN M, 1995, SOC SCI MED, V41, P1349, DOI 10.1016/0277-9536(95)00125-Q; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; WARE JE, 1994, INT J MENT HEALTH, V23, P49, DOI 10.1080/00207411.1994.11449283; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARE JE, 1992, SF 36 HLTH SURVEY MA; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Willer B., 1993, BRAIN INJURY REHABIL, P355	28	46	46	0	9	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1999	14	3					211	219		10.1097/00001199-199906000-00002			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	203XY	WOS:000080734500002	10381974				2021-06-18	
J	Silber, JH; Gleeson, SP; Zho, HQ				Silber, JH; Gleeson, SP; Zho, HQ			The influence of chronic disease on resource utilization in common acute pediatric conditions - Financial concerns for children's hospitals	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article; Proceedings Paper	15th Annual Meeting of the Association-for-Health-Services-Research	JUN 21-23, 1998	WASHINGTON, D.C.	Assoc Hlth Serv Res			PROSPECTIVE PAYMENT SYSTEM; DIAGNOSIS-RELATED-GROUPS; CASE-MIX; MEASURING SEVERITY; CHRONIC ILLNESSES; MANAGED CARE; IMPACT; REIMBURSEMENT; MORTALITY; COST	Objectives: To estimate the resource utilization in hospitalizations for common pediatric conditions dr procedures involving patients with chronic disease vs those with no chronic disease and to develop an economic model of hospital per-patient profit (or loss) when insurance contracts fail to account for the presence of chronic disease. Setting and Design: A retrospective analysis of selected acute pediatric conditions found in the 1991 and 1992 MedisGroups National Comparative Data Base. Patients: We studied 30379 pediatric admissions for common acute conditions, including concussion; croup, pneumonia, appendicitis, gastroenteritis, fractures, cellulitis, urinary tract infection, and viral illness. Main Outcome Measures: Hospital length of stay and total hospital charges. Results: For patients without chronic disease, mean (geometric) length of stay was 2.53 vs 3.05 days (P<.001) for patients with at least I chronic disease. For patients without chronic disease, mean (arithmetic) total hospital charge was $2614 vs $3663 (P<.001) for patients with at least 1 chronic disease. Assuming 75% of patients with chronic disease are admitted to a children's hospital vs 25% to a general hospital, overall loss per patient at the children's hospital ranged between 1.5% and 2.9%, depending on assumptions regarding cost-to-charge ratios and the treatment of charge outliers. Pneumonia cases were associated with a 4.0% to 5.85% loss. Conclusions: Length of stay and charges are higher for everyday pediatric conditions or procedures when patients also have a chronic disease. If insurance contracts fail to account for chronic disease, then children's hospitals will realize significant financial losses, and over time this will lead to a decline in their financial viability, a reduction in quality, or a change in their mission.	Childrens Hosp Philadelphia, Ctr Outcomes Res, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Outcomes Res, Dept Anesthesia, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Outcomes Res, Div Epidemiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Outcomes Res, Div Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	Silber, JH (corresponding author), Childrens Hosp Philadelphia, Ctr Outcomes Res, Dept Pediat, Abramson Bldg,Room 702,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Silberj@wharton.upenn.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS006560] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01-HS06560] Funding Source: Medline		*AM AC PED COMM IN, 1994, 1994 REDBR, P280; BREWSTER AC, 1985, INQUIRY-J HEALTH CAR, V22, P377; BUTLER JRG, 1995, DEV HLTH EC PUBLIC P, P1; Coile R C Jr, 1995, Healthc Financ Manage, V49, P60; Durbin DR, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.3.e8; FEDER J, 1987, NEW ENGL J MED, V317, P867, DOI 10.1056/NEJM198710013171405; Fishman P, 1997, HEALTH AFFAIR, V16, P239, DOI 10.1377/hlthaff.16.3.239; FREEMAN JL, 1995, MED CARE, V33, P806, DOI 10.1097/00005650-199508000-00006; FROEHLICH H, 1991, J PEDIATR-US, V118, P693, DOI 10.1016/S0022-3476(05)80028-9; Gabel J, 1997, HEALTH AFFAIR, V16, P134, DOI 10.1377/hlthaff.16.3.134; GAY EG, 1990, SOC SCI MED, V31, P1103; Gay JC, 1997, PEDIATR ANN, V26, P655, DOI 10.3928/0090-4481-19971101-07; Glied SA, 1996, HEALTH SERV RES, V31, P593; GOLDFARB MG, 1992, HEALTH SERV RES, V27, P385; GREEN J, 1991, JAMA-J AM MED ASSOC, V265, P1849; GREEN J, 1990, JAMA-J AM MED ASSOC, V263, P241, DOI 10.1001/jama.263.2.241; HINZ CA, 1991, HLTH CARE STRATEGIC, V9, P19; IEZZONI LI, 1993, MED CARE, V31, P277, DOI 10.1097/00005650-199303000-00009; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; Ireys HT, 1997, PEDIATRICS, V100, P197, DOI 10.1542/peds.100.2.197; Ireys HT, 1996, PEDIATRICS, V98, P178; JENCKS SF, 1987, NEW ENGL J MED, V317, P679, DOI 10.1056/NEJM198709103171106; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; JOY SA, 1990, J TRAUMA, V30, P866, DOI 10.1097/00005373-199007000-00017; Kaufman S L, 1982, Inquiry, V19, P167; LAVE JR, 1970, AM ECON REV, V60, P379; LICHTIG LK, 1989, MED CARE, V27, P491, DOI 10.1097/00005650-198905000-00005; Long M J, 1986, Health Care Financ Rev, V8, P55; MAXWELL JH, 1987, INQUIRY-J HEALTH CAR, V24, P57; NEFF JM, 1995, JAMA-J AM MED ASSOC, V274, P1866, DOI 10.1001/jama.274.23.1866; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; Ozatalay S, 1987, J Med Syst, V11, P331, DOI 10.1007/BF00996348; PAULY MV, 1997, FUTURE US HLTH CARE, P353; PHELAN PD, 1993, J PAEDIATR CHILD H, V29, P266, DOI 10.1111/j.1440-1754.1993.tb00509.x; Shwartz M, 1995, INQUIRY-J HEALTH CAR, V32, P476; SILBER JH, 1995, JAMA-J AM MED ASSOC, V274, P317, DOI 10.1001/jama.274.4.317; SKOLNICK AA, 1993, JAMA-J AM MED ASSOC, V270, P2151, DOI 10.1001/jama.270.18.2151; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; THOMAS JW, 1989, INQUIRY-J HEALTH CAR, V26, P483; THOMAS JW, 1991, INQUIRY-J HEALTH CAR, V28, P39; Ungerleider RM, 1997, ANN THORAC SURG, V64, P44, DOI 10.1016/S0003-4975(97)00503-1	42	46	46	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	FEB	1999	153	2					169	179					11	Pediatrics	Pediatrics	164PZ	WOS:000078473900009	9988247				2021-06-18	
J	Barnes, MP				Barnes, MP			Rehabilitation after traumatic brain injury	BRITISH MEDICAL BULLETIN			English	Article							UPPER EXTREMITY SPASTICITY; SEVERE HEAD-INJURY; EARLY INTERVENTION; CONTROLLED TRIAL; BOTULINUM TOXIN; FOLLOW-UP; RELATIVES; EFFICACY	Head injury is a common disabling condition but regrettably facilities for rehabilitation are sparse. There is now increasing evidence of the efficacy of a comprehensive multidisciplinary rehabilitation team compared to natural recovery following brain injury. This chapter outlines some basic concepts of rehabilitation and emphasises the importance of valid and reliable outcome measures. The evidence of the efficacy of a rehabilitation programme is discussed in some detail. A number of specific rehabilitation problems are outlined including the management of spasticity, nutrition, pressure sores and urinary continence. The increasingly important role of assistive technology is illustrated, particularly in terms of communication aids and environmental control equipment. However, the major long-term difficulties after head injury focus around the cognitive, intellectual, behavioural and emotional problems. The complex management of these disorders is briefly addressed and the evidence of the efficacy of some techniques discussed. The importance of recognition of the vegetative state and avoidance of misdiagnosis is emphasised. Finally, the important, but often neglected, area of employment rehabilitation is covered.	Univ Newcastle Upon Tyne, Hunters Moor Reg Neurorehabil Ctr, Acad Unit Neurol Rehabil, Newcastle Upon Tyne NE2 4NR, Tyne & Wear, England	Barnes, MP (corresponding author), Univ Newcastle Upon Tyne, Hunters Moor Reg Neurorehabil Ctr, Acad Unit Neurol Rehabil, Hunters Rd, Newcastle Upon Tyne NE2 4NR, Tyne & Wear, England.						Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Bader DL, 1990, PRESSURE SORES CLIN; BLACKERBY W F, 1990, Brain Injury, V4, P167, DOI 10.3109/02699059009026162; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; BROOKS DN, 1984, CLOSED HEAD INJURY P; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FOSTER HG, 1989, PROG NEURO-PSYCHOPH, V13, P865, DOI 10.1016/0278-5846(89)90038-9; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOODKIN DE, 1988, ARCH PHYS MED REHAB, V69, P850; Granger CV, 1986, GUIDE USE UNIFORM DA; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LARSON DE, 1987, GASTROENTEROLOGY, V93, P48, DOI 10.1016/0016-5085(87)90312-X; LIPIDES J, 1974, J UROLOGY, V111, P184; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MATTES JA, 1985, AM J PSYCHIAT, V142, P1108; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; Semlyen JK, 1997, J NEUROL REHABIL, V11, P213; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SIMPSON DM, 1986, J CLIN PSYCHIAT, V47, P191; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; TENNANT A, 1995, TRAUMATIC BRAIN INJU; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Turner-Stokes L, 1998, CLIN REHABIL, V12, P304, DOI 10.1191/026921598669173600; Wade D T, 1988, Int Disabil Stud, V10, P64; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wade DT, 1992, MEASUREMENT NEUROLOG; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson BA, 1984, CLIN MANAGEMENT MEMO; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	38	46	48	0	6	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND	0007-1420			BRIT MED BULL	Br. Med. Bull.		1999	55	4					927	943		10.1258/0007142991902727			17	Medicine, General & Internal	General & Internal Medicine	272YD	WOS:000084678300016	10746340				2021-06-18	
J	Vukic, M; Negovetic, L; Kovac, D; Ghajar, J; Glavic, Z; Gopcevic, A				Vukic, M; Negovetic, L; Kovac, D; Ghajar, J; Glavic, Z; Gopcevic, A			The effect of implementation of guidelines for the management of severe head injury on patient treatment and outcome	ACTA NEUROCHIRURGICA			English	Article						severe head injury; intracranial pressure monitoring; the implementation of Guidelines	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; CEREBRAL PERFUSION-PRESSURE; POST-TRAUMATIC SEIZURES; INTRACRANIAL-PRESSURE; CLINICAL-TRIAL; BRAIN INJURY; FAILURE; COMA; MANNITOL; SCALE	The authors retrospectively analysed two groups of consecutive patients who were similarly matched for brain injury severity. From a total of 39 severe head injury patients, 23 were treated according to the Guidelines for the Management of Severe Severe Head Injury with intracranial pressure (ICP) monitoring ("Guidelines group"). Such an approach allowed the maintenance of ICP within normal values, especially in patients with intraventricular ICP monitoring allowing the release of cerebrospinal fluid (CSF) From the ventricular system. In the Guidelines group only two patients were administered barbiturates, after all other means of ICP lowering had been exhausted. The second group consisted of 16 patients who were not monitored for ICP ("non-Guidelines group"). In this group, management consisted of the prophylactic administration of barbiturates, high dose osmotic diuretics and hyperventilation usually at levels below 25 mm Hg. In the Guidelines group the mortality rate was 30% compared to 44% in the non-Guidelines group. Almost twice as many patients achieved a "favourable" (good recovery and moderate disability) outcome (49%) compared to the non-Guidelines treated patients (25%). Furthermore, there was a 32% decrease in severe neurological disabilities in those patients in the Guidelines group. It seems that the implementation of "Guidelines" in the treatment of severe head injury, based on the result of our clinical study, reduces death and disability rates in patients with severe head injury. The administration of therapy based on the "Guidelines principles" and monitoring of ICP, can minimise the application of those therapeutic modalities (barbiturate coma and prolonged hyperventilation) which, in addition to favourable effects, may also have harmful effects on patients with severe head injury.	Sisters Mercy Univ Hosp, Dept Neurosurg, Zagreb 10000, Croatia; Cornell Univ, Weill Med Coll, Div Neurosurg, New York, NY USA; Aitken Neurosci Ctr, New York, NY USA; Pozega Gen Hosp, Dept Surg, Pozega, Croatia; Sisters Mercy Univ Hosp, Dept Anesthesiol, Zagreb 10000, Croatia	Vukic, M (corresponding author), Sisters Mercy Univ Hosp, Dept Neurosurg, Vinogradska 29, Zagreb 10000, Croatia.		Pozega, County Hospital/X-7568-2019				BECKER DP, 1987, TXB HEAD INJURY, P192; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BULLOCK R, 1995, GUIDELINES MANAGEMEN; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1992, P AM ASS NEUR SURG S; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; GULLIAUME J, 1951, REV NEUROL, V84, P131; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; JENETT B, 1975, LANCET, V1, P480; KOVAC D, 1987, ACTA CHIR JUGOSLAV S, V34, P73; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MCGRAW CP, 1983, NEUROSURGERY, V13, P269, DOI 10.1227/00006123-198309000-00009; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MURRAY LS, 1993, LANCET, V341, P1478; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; TEASDALE G, 1974, LANCET, V2, P81; WARD JD, 1985, J NEUROSURG, V69, P15; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x	33	46	48	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1999	141	11					1203	1208		10.1007/s007010050419			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	258BH	WOS:000083817800020	10592121				2021-06-18	
J	Levin, HS				Levin, HS			Cognitive function outcomes after traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article							CLOSED-HEAD-INJURY	Investigations of cognitive recovery from traumatic brain injury have utilized experimental cognitive tasks, including measures of executive function and discourse processing, to elucidate specific sequelae, The scope of research, which includes brain imaging and pharmacologic intervention, could potentially enhance rehabilitation of patients with brain injury. Curr Opin Neurol 11:643-646. (C) 1998 Lippincott Williams & Wilkins.	Baylor Coll Med, Phys Med & Rehab Res Off, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, Phys Med & Rehab Res Off, 1333 Moursund Ave,Room A205, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu					Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Eslinger P. J., 1996, ATTENTION MEMORY EXE, P367; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; GRONWALL D, 1974, LANCET, V2, P605; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9	15	46	46	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	1998	11	6					643	646		10.1097/00019052-199812000-00006			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	148EC	WOS:000077490900006	9870131				2021-06-18	
J	Umile, EM; Plotkin, RC; Sandel, ME				Umile, EM; Plotkin, RC; Sandel, ME			Functional assessment of mild traumatic brain injury using SPECT and neuropsychological testing	BRAIN INJURY			English	Article							MINOR HEAD-INJURY; CEREBRAL BLOOD-FLOW; HM-PAO-SPECT; TECHNETIUM-99M-HMPAO SPECT; COMPUTED-TOMOGRAPHY; MOOD DISORDERS; EMISSION TOMOGRAPHY; CT; CONCUSSION; PERFORMANCE	The aim of this study was to ascertain whether SPECT and neuropsychological testing provide converging evidence of normal and abnormal regional cerebral function in patients with mild traumatic brain injury (mTBI). Four patients with mTBI were evaluated with SPECT and selected neuropsychological tests with putative localizing capabilities to specific cortical regions. The performance of each patient on each test was graded as either normal or abnormal. Additionally, SPECT images were graded for normal and/or abnormal patterns of regional cerebral blood now (rCBF) in eight regions of the cortex. These data were then used to predict outcomes from one modality to the other, i.e. rCBF patterns on SPECT were used to predict either normal or abnormal performance on specific tests and performance on specific tests was used to predict the presence or absence of rCBF abnormalities on SPECT. Statistical analysis of composite data from all four patients showed that test performance predicted SPECT findings, but SPECT findings did not predict test performance.	Univ Penn, Med Ctr, Dept Rehabil Med, Philadelphia, PA 19104 USA; Kaiser Permanente Med Ctr, Kaiser Fdn Rehabil Ctr, Vallejo, CA 94589 USA	Umile, EM (corresponding author), Univ Penn, Med Ctr, Dept Rehabil Med, 6 Ravdin,3400 Spruce St, Philadelphia, PA 19104 USA.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ABDELDAYEM HM, 1994, EUROPEAN J NUCL MED, V21, P750; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ALVES WM, 1985, CENTRAL NERVOUS SYST, P255; AUSTIN MP, 1992, J AFFECT DISORDERS, V26, P31, DOI 10.1016/0165-0327(92)90032-2; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENTON AL, 1989, MULTILINGUAL ALPHASI, P14; BENTON AL, 1994, CONTIRUBIONS NEUROPS; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dixon CE, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI [10.1097/00001199-199309000-00003, DOI 10.1097/00001199-199309000-00003]; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FUMEYA H, 1990, ACT NEUR S, V51, P283; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GEORGE MS, 1993, J CLIN PSYCHIAT, V54, P6; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GONCALVES JM, 1992, ACTA NEUROCHIRURGI S, V51, P11; GRAY BG, 1992, J NUCL MED, V33, P52; GRAY KF, 1994, LOCALIZATION NEUROIM, P621; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; *HEAD INJ INT SPEC, 1993, J HEAD TRAUMA REHAB, V8, P86; Heaton R., 1981, MANUAL WISCONSIN CAR; Heaton R., 1993, WISCONSIN CARD SORTI; Holbourn AHS, 1943, LANCET, V2, P438; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KAY T, 1992, Neurology, V42, P411; KELLNER CH, 1991, BIOL PSYCHIAT, V29, pS564; KIERNAN RJ, 1976, J CONSULT CLIN PSYCH, V44, P951, DOI 10.1037/0022-006X.44.6.951; LEHMAN RS, 1991, STAT RES DESIGN BEHA, P476; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Masdeu J C, 1994, J Neuroimaging, V4, P177; MAYBERG H S, 1991, Journal of Nuclear Medicine, V32, P951; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; PRAYER L, 1993, ACTA RADIOL, V34, P593; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROPER SN, 1991, J NUCL MED, V32, P1684; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SACKEIM HA, 1990, ARCH GEN PSYCHIAT, V47, P60; TRAHAN DE, 1987, J CLIN EXP NEUROPSYC, V9, P52; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Trites R, 1977, NEUROPSYCHOLOGICAL T; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29	62	46	46	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1998	12	7					577	594					18	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200004	9653521				2021-06-18	
J	Millis, SR; Ross, SR; Ricker, JH				Millis, SR; Ross, SR; Ricker, JH			Detection of incomplete effort on the Wechsler Adult Intelligence Scale Revised: A cross-validation	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	19th Annual Mid-Year Meeting of the International-Neuropsychological-Society	JUN 19-22, 1996	VELDHOVEN, NETHERLANDS	Int Neuropsychol Soc			CLOSED-HEAD-INJURY; RECOVERY	This study determined whether the Vocabulary-Digit Span difference score and a discriminant function based on subtests of the Wechsler Adult Intelligence Scale-Revised (WAIS-R) developed by Mittenberg et al. (1995) could differentiate patients with moderate and severe traumatic brain injuries (n = 50) from persons with financially compensable mild head injuries who were giving incomplete effort (n = 50). Employing modified cutoff scores, the discriminant function and Vocabulary-Digit Span difference score accurately classified 90% and 79% of the cases, respectively Persons with traumatic brain injuries may produce WAIS-R subtest patterns that can be differentiated from individuals showing incomplete effort. These WAIS-R algorithms appear useful in making that distinction.	Rehabil Inst Michigan, Dept Psychol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Detroit, MI 48202 USA; Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA	Millis, SR (corresponding author), Rehabil Inst Michigan, Dept Psychol, 261 Mack Blvd, Detroit, MI 48201 USA.	smillis@med.wayne.edu		Ricker, Joseph/0000-0003-3415-991X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32HD07421] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007421] Funding Source: NIH RePORTER		Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CHARTER RA, 1994, J CLIN EXP NEUROPSYC, V16, P744, DOI 10.1080/01688639408402687; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DRUDGE OW, 1984, J CLIN PSYCHOL, V40, P259, DOI 10.1002/1097-4679(198401)40:1<259::AID-JCLP2270400149>3.0.CO;2-C; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Metz CE, 1984, INFORMATION PROCESSI, P432; METZ CE, 1993, CLABROC 1 2 1; Millis SR, 1996, NEUROREHABILITATION, V7, P55, DOI 10.3233/NRE-1996-7106; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Putnam S. H., 1996, NEUROPSYCHOLOGICAL A, P529; SOLTYSIK RC, 1993, ODA 1 0 OPTIMAL DISC; The Psychological Corporation, 1997, WAIS III WMS III TEC; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; YARNOLD PR, 1991, DECISION SCI, V22, P739, DOI 10.1111/j.1540-5915.1991.tb00362.x; YUEN KK, 1974, BIOMETRIKA, V61, P165, DOI 10.2307/2334299	22	46	46	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1998	20	2					167	173		10.1076/jcen.20.2.167.1171			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	122GG	WOS:000076063100004	9777470				2021-06-18	
J	Mukhin, AG; Ivanova, SA; Allen, JW; Faden, AI				Mukhin, AG; Ivanova, SA; Allen, JW; Faden, AI			Mechanical injury to neuronal/glial cultures in microplates: Role of NMDA receptors and pH in secondary neuronal cell death	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						neuronal death; NMDA receptor antagonists; in vitro model; antisense oligonucleotides	TRAUMATIC BRAIN INJURY; GLUTAMATE NEUROTOXICITY; ANTISENSE OLIGODEOXYNUCLEOTIDES; CORTICAL CULTURES; AMINO-ACIDS; IN-VITRO; INVITRO; ANTAGONISTS; CHANNEL; MODEL	In vitro models of traumatic injury are useful adjuncts to animal models for studying mechanisms of post-traumatic cell death, Here we describe a new in vitro model in which reproducible levels of injury are delivered by a punch device that produces 28 parallel cuts in individual wells of 96-well microplates, Cell loss is measured by LDH assay or quantitative fluorometric assay for ethidium homodimer staining, Glial cultures show cell death restricted to the initial injury site, whereas neuronal/glial cultures demonstrate substantial spread of cell loss over time, We used this model to examine the role of pH and NMDA receptors in delayed post-traumatic injury, NMDA receptor blockade by dizocilpine (MK-801) or treatment with antisense oligodeoxynucleotides directed against NMDAR1 was neuroprotective. Decreased cell death was observed under acidic conditions whereas increased extracellular pH was associated with increased, MK-801 sensitive cell loss, Advantages of our model include: reproducible trauma induction; rapid measurements of cell injury; and use of 96-well microplates which reduce time and cost, This model appears to be well-suited for the study of selected mechanisms of post-traumatic neuronal injury as well as for screening potential neuroprotective agents, (C) 1998 Wiley-Liss, Inc.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Room EP-04, Washington, DC 20007 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634-07] Funding Source: Medline		AMADOR E, 1963, CLIN CHEM, V9, P391; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; CHOI DW, 1987, J NEUROSCI, V7, P357; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; GIFFARD RG, 1990, BRAIN RES, V506, P339, DOI 10.1016/0006-8993(90)91276-M; Girard J, 1996, EUR J PHARMACOL, V300, P43, DOI 10.1016/0014-2999(95)00804-7; GROSS GW, 1983, J NEUROSCI, V3, P1979; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; KAKU DA, 1993, SCIENCE, V260, P1516, DOI 10.1126/science.8389056; KEILHOFF G, 1993, NEUROREPORT, V5, P129, DOI 10.1097/00001756-199311180-00008; KIRKPATRICK JB, 1985, J NEUROPATH EXP NEUR, V44, P268, DOI 10.1097/00005072-198505000-00005; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LEVESQUE A, 1995, J IMMUNOL METHODS, V178, P71, DOI 10.1016/0022-1759(94)00243-P; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MARK RJ, 1995, J NEUROSCI, V15, P6239; Mattson MP, 1996, ADV NEUROL, V71, P1; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723; Mena MA, 1997, J NEUROCHEM, V69, P21; MITCHELL HL, 1995, NEUROSURGERY, V36, P1003, DOI 10.1227/00006123-199505000-00017; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; REGAN RF, 1995, BRAIN RES, V682, P144, DOI 10.1016/0006-8993(95)00330-S; Rosa R, 1997, TOXICOL APPL PHARM, V142, P31, DOI 10.1006/taap.1996.7968; SanchezRamos JR, 1997, J NEUROCHEM, V68, P58; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; TAKADERA T, 1992, BRAIN RES, V572, P126, DOI 10.1016/0006-8993(92)90460-Q; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WAHLESTEDT C, 1993, NATURE, V363, P260, DOI 10.1038/363260a0; Yoon KW, 1996, STROKE, V27, P122, DOI 10.1161/01.STR.27.1.122	40	46	47	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAR 15	1998	51	6					748	758		10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B			11	Neurosciences	Neurosciences & Neurology	ZD129	WOS:000072654300008	9545088				2021-06-18	
J	Dings, J; Meixensberger, J; Roosen, K				Dings, J; Meixensberger, J; Roosen, K			Brain tissue pO(2)-monitoring: Catheter stability and complications	NEUROLOGICAL RESEARCH			English	Article						brain tissue pO(2); complications; brain oxygenation; head injury; subarachnoid hemorrhage; catheter stability	VENOUS OXYGEN-SATURATION; HEAD-INJURED PATIENTS; CEREBRAL BLOOD-FLOW; PRESSURE	The authors report on the stability and complications of 73 LICOX brain ti-pO(2)-microcatheters in 70 patients. Mean monitoring time was 7.5 +/- 4.0 days. Patients prone to cerebral hypoxia (after severe head injury (GCS < 9) or a subarachnoid hemorrhage) had a ti-pO(2)-microcatheter inserted next to the ICP-probe in the typical frontal position. After the first 15 insertions, instead of the 3-way-screw (needing a 6 mm burrhole), a I-way-screw (needing a 2.7 mm burrhole) was used for fixation in the bone; by doing so, the procedure can be performed in the ICU and takes only 15 min. Whenever possible a calibration at room air (to determine the sensitivity-drift) and in oxygen free solution (to determine the zero-drift) was performed after removal of the catheters. Ideally the expected pO(2) at room air was around 154 mmHg (temperature dependent) and at zero calibration 0 mmHg. Mean sensitivity-drift for 54 catheters was -8.5 +/- 15.4%. Dividing the catheters into groups, depending on the duration of monitoring (1-4, 5-8 and 9-16 days), revealed that the greatest part of the (negative) sensitivity-drift occurred during day 1-4 after insertion. After 1 week of monitoring sometimes a positive drift occurred (being far less than the negative drift during the first 4 days). Compared to the old catheters (-10.3 +/- 17.3%) ion the first half of the patients) the new ones showed a lower sensitivity-drift (-6.8 +/- 13.4%). The zero-drift of 56 catheters was low with mean drift after 7.5 +/- 4.0 days of 1.5 +/- 1.5 mmHg. Here also the highest drift occurred on day 1-4 after insertion. No infection was seen and 2 times (2.7%) a small hematoma, not needing evacuation occurred. As the ti-pO(2)-catheter (having a smaller diameter) and the ICP-catheter were inserted at the same time, one cannot distinguish which catheter caused the hematoma. A possible explanation for the occurrence of the two hematomas is the insertion of the catheters too close to the midline. The authors conclude that LICOX ti-pO(2)-monitoring is a safe and reliable method. Further decrease of the complication rate and increase of the catheter-stability may be expected.		Dings, J (corresponding author), UNIV WURZBURG, DEPT NEUROSURG, JOSEPH SCHNEIDER STR 11, D-97080 WURZBURG, GERMANY.						BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CARTER LP, 1991, SURG NEUROL, V35, P36, DOI 10.1016/0090-3019(91)90199-J; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; Luerssen T.G.S.P., 1989, INTRACRANIAL PRESSUR, P35; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; METZ C, 1993, ANASTH INTENSIVMED, V34, P345; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Piek J, 1994, Zentralbl Neurochir, V55, P48; PIEK J, 1993, INTRACRANIAL PRESSUR, V8, P11; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38	13	46	49	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	1997	19	3					241	245		10.1080/01616412.1997.11740806			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	XC468	WOS:A1997XC46800005	9192373				2021-06-18	
J	Gass, CS; Apple, C				Gass, CS; Apple, C			Cognitive complaints in closed-head injury: Relationship to memory test performance and emotional disturbance	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SELF-REPORT; OLDER ADULTS; DIFFICULTIES; PERSONALITY; IMPAIRMENT; DEPRESSION; SCALE	Self-appraisal of cognitive difficulties by a sample of 63 male patients with closed head injury (CHI) was examined in relation to their performance on the Wechsler Memory Scale - Revised (WMS-R; Wechsler, 1987), WAIS-R Digit Span (Wechsler, 1981), and to their scores on MMPI-2 (Butcher, Dahlstrom, Graham, Tellegen, & Kaemmer, 1989) measures of anxiety and depression. In an initial step, the Cognitive Difficulties Scale (CDS; McNair & Kahn, 1983), consisting of 39 self-report items, was factor analyzed using a sample of 255 consecutive neuropsychological referrals with documented brain impairment. Seven orthogonal dimensions emerged: Attention and Concentration, Orientation and Memory, Praxis, Domestic Activities, Facial Recognition, Task Efficiency and Errand and Name Recall. Within a sample subset consisting of 63 patients with CHI, subjective complaints on the CDS were predictive of WMS-R Logical Memory performance (r = -.51, p < .0005). In contrast, CDS scores were generally poor predictors of Digit Span and Visual Reproduction scores (rs < .31). Cognitive complaints were also associated with emotional distress on the MMPI-2. The CDS appears to be a useful measure of self-appraised cognitive difficulties in patients with CHI, and may assist in the assessment of their self-reflective insight.		Gass, CS (corresponding author), DEPT VET AFFAIRS MED CTR,PSYCHOL SERV 116B,1201 NW 16TH ST,MIAMI,FL 33125, USA.		Gass, Carlton/AAO-5906-2020				Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; BOLLA KI, 1991, ARCH NEUROL-CHICAGO, V48, P61, DOI 10.1001/archneur.1991.00530130069022; BROWN FH, 1991, J CLIN PSYCHOL, V47, P772, DOI 10.1002/1097-4679(199111)47:6<772::AID-JCLP2270470607>3.0.CO;2-P; Butcher JN, 1989, MANUAL ADM SCORING M; CAVANAUGH JC, 1987, INT J AGING HUM DEV, V24, P271, DOI 10.2190/8WTA-P1WP-EJYJ-Q33D; Darlington R. B., 1990, REGRESSION LINEAR MO; DEROUESNE C, 1993, INT J GERIATR PSYCH, V8, P599, DOI 10.1002/gps.930080712; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; FOX DD, 1995, ANN CONV AM PSYCH AS; GAGNON M, 1994, NEUROEPIDEMIOLOGY, V13, P145, DOI 10.1159/000110373; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; GASS CS, 1995, ARCH CLIN NEUROPSYCH, V10, P475, DOI 10.1016/0887-6177(95)98192-G; Gass CS, 1996, PSYCHOL ASSESSMENT, V8, P135, DOI 10.1037/1040-3590.8.2.135; GASS CS, 1995, ARCH CLINNEUROPSYCHO, V9, P461; GASS CS, 1990, PSYCHOL ASSESSMENT J, V2, P175, DOI DOI 10.1037//1040-3590.2.2.175; Gass CS., 1992, PSYCHOL ASSESSMENT, V4, P272, DOI [10.1037/1040-3590.4.3.272, DOI 10.1037/1040-3590.4.3.272]; HANNINEN T, 1994, J AM GERIATR SOC, V42, P1; HARRINGTON DE, 1993, ARCH PHYS MED REHAB, V74, P579, DOI 10.1016/0003-9993(93)90155-4; KAHN RL, 1975, ARCH GEN PSYCHIAT, V32, P1569; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; McNair M, 1983, ASSESSMENT GERIATRIC, P137; OCONNOR DW, 1990, ARCH GEN PSYCHIAT, V47, P224; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; OTTO MW, 1994, ARCH CLIN NEUROPSYCH, V9, P81, DOI 10.1016/0887-6177(94)90016-7; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; PRIGATANO GP, 1986, CLIN NEUROPSYCHOLOGY, P136; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; Schacter D. L., 1990, NEUROPSYCHOLOGY EVER, P231; SEIDENBERG M, 1994, ARCH CLIN NEUROPSYCH, V9, P353, DOI 10.1016/0887-6177(94)90023-X; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; VERMEULEN J, 1993, EPILEPSY RES, V15, P157, DOI 10.1016/0920-1211(93)90096-P; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLIAMS JM, 1987, J CONSULT CLIN PSYCH, V55, P595, DOI 10.1037/0022-006X.55.4.595; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; ZELINSKI EM, 1988, PSYCHOPHARMACOL BULL, V24, P523	44	46	46	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	1997	19	2					290	299		10.1080/01688639708403858			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	XC634	WOS:A1997XC63400012	9240487				2021-06-18	
J	Ommaya, AK; Salazar, AM; Dannenberg, AL; Ommaya, AK; Chervinsky, AB; Schwab, K				Ommaya, AK; Salazar, AM; Dannenberg, AL; Ommaya, AK; Chervinsky, AB; Schwab, K			Outcome after traumatic brain injury in the US military medical system	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injury; outcome; behavior	HEAD-INJURY; FOLLOW-UP; SEVERITY	Personality and behavioral change after traumatic brain injury (TBI) are often the most significant concerns for the families of TBI patients, This report examines discharge from military service after TBI for medical and behavioral criteria, When compared with the total discharge population (n = 1,879,724), the relative risk for behavioral discharge was 1.8 times greater for those with mild TBI (n = 1,778), and no difference for those with moderate (n = 174) or severe TBI (n = 274). Discharge for alcoholism or drug use was 2.6 times for mild TBI, 5.4 times for moderate TBI, and no difference for severe TBI compared with the total discharge population, Discharge for criminal conviction was 2.7 times for those with mild head injury, and no difference for those with moderate or severe TBI when compared with the total discharge population. Discharge for medical disability ranged from 7.5 times to 40.4 times, and mortality ranged from 11.6 to 142.4 times the total discharge population. Total sick days defined as the time from admission to return to duty or separation from service increased with head injury severity. Mean Injury Severity Score for mild TBI was 5.5, and 20.9 for severe TBI. Patients who sustain TBI should be monitored after injury for development of behavioral problems, The most effective way to reduce the cost of TBI is primary prevention of these injuries and examining military practices to reduce exposure to risk of TBI. Secondary and tertiary prevention measures such as evaluation and rehabilitation, where indicated, should be undertaken on a routine basis after TBI.	UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814; JOHNS HOPKINS UNIV,SCH PUBL HLTH,CTR INJURY RES & POLICY,BALTIMORE,MD; GEORGE WASHINGTON UNIV,DEPT NEUROSURG,WASHINGTON,DC	Ommaya, AK (corresponding author), WALTER REED ARMY MED CTR,DEF & VET HEAD INJURY PROGRAM,BLDG 1,RM B219A,WASHINGTON,DC 20307, USA.				AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R03 HS08414-01] Funding Source: Medline		BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; *DEF MANP DAT CTR, ACT DUT MIL MAST LOS; GALSKI T, 1994, ARCH PHYS MED REHAB, V75, P380, DOI 10.1016/0003-9993(94)90158-9; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HARMAN DE, 1995, NEUROPSYCHOLOGICAL T, P225; HONKANEN R, 1990, INJURY, V21, P353, DOI 10.1016/0020-1383(90)90117-D; KHAN HA, 1989, STAT METHODS EPIDEMI, P56; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LI GH, 1995, J TRAUMA, V38, P871, DOI 10.1097/00005373-199506000-00007; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260	17	46	46	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1996	41	6					972	975		10.1097/00005373-199612000-00005			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	VY407	WOS:A1996VY40700005	8970548				2021-06-18	
J	Imaizumi, S; Kondo, T; Deli, MA; Gobbel, G; Joo, F; Epstein, CJ; Yoshimoto, T; Chan, PH				Imaizumi, S; Kondo, T; Deli, MA; Gobbel, G; Joo, F; Epstein, CJ; Yoshimoto, T; Chan, PH			The influence of oxygen free radicals on the permeability of the monolayer of cultured brain endothelial cells	NEUROCHEMISTRY INTERNATIONAL			English	Article; Proceedings Paper	Workshop on Antioxidants	NOV 12, 1994	HOLLYWOOD, FL				CUZN-SUPEROXIDE-DISMUTASE; TRANSGENIC MICE; HYDROGEN-PEROXIDE; ISCHEMIC-INJURY; NITRIC-OXIDE; INFARCTION; HYPOXIA; MODEL	Free radicals have been implicated in the pathogenesis of vasogenic brain edema caused by ischemic or traumatic injury. It has been reported that in transgenic mice overexpressing the human CuZn-superoxide dismutase, brain edema is decreased in many cerebral disorders. To investigate the effects of free radicals on the permeability of the blood-brain barrier, we established an in vitro model system of the blood-brain barrier using brain endothelial cells cultivated from transgenic mice and non-transgenic mice. The blood-brain barrier model is originated by a monolayer of brain endothelial cells cultured on a membrane which has 0.45-mu m pores. Electrical resistance across the cell monolayer, which reflects the paracellular flux of ionic molecules, was measured. The blood-brain barrier models were incubated with menadione (vitamin K-3, an intracellular O-2(-) producing agent), and segmental changes in the electrical resistance across the monolayer were compared between the transgenic and the non-transgenic mice. Superoxide dismutase activity of the cultured brain endothelial cells was 1.7 times higher in the transgenic than in the non-transgenic mice (n = 3, P < 0.001). The electrical resistance was reduced by menadione in the transgenic but not in the non-transgenic mice (n = 7, P < 0.05) in the early stage. Moreover, desferroxamine mesylate (Fe2+ chelating agent) inhibited the menadione-induced early decrease in electrical resistance in the transgenic mice (n = 7, P < 0.05). These results suggest that the permeability of the blood-brain barrier may be affected by hydroxyl radicals and/or peroxynitrite rather than the O-2(-) itself. Copyright (C) 1996 Elsevier-Science Ltd.	TOHOKU UNIV, SCH MED, DEPT NEUROSURG, SENDAI, MIYAGI 980, JAPAN; BIOL RES CTR, DEPT NEUROPHYSIOL, H-6701 SZEGAD, HUNGARY; UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, SAN FRANCISCO, CA 94143 USA	Imaizumi, S (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT NEUROL & NEUROSURG, C-224, 521 PARNASSUS AVE, SAN FRANCISCO, CA 94143 USA.		Deli, Maria A./I-2885-2019	Deli, Maria A./0000-0001-6084-6524			ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; AFANASEV IB, 1990, ARCH BIOCHEM BIOPHYS, V281, P245, DOI 10.1016/0003-9861(90)90439-6; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1990, NATURE, V345, P27, DOI 10.1038/345027b0; CHAN PH, 1994, ANN NY ACAD SCI, V738, P93; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; GOBBEL GT, 1994, BRAIN RES, V653, P23, DOI 10.1016/0006-8993(94)90367-0; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; IMAIZUMI S, 1990, JPN J STROKE, V12, P592; JOO F, 1973, CYTOBIOS, V8, P41; JOO F, 1989, Neurological Research, V11, P67; JOO F, 1992, J NEUROCHEM, V58, P1, DOI 10.1111/j.1471-4159.1992.tb09272.x; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KONDO T, 1994, CELL TRANSPLANT, V3, pS35; MAO GD, 1993, J BIOL CHEM, V268, P416; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mikawa S., 1994, Society for Neuroscience Abstracts, V20, P195; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; RUBIN LL, 1991, J CELL BIOL, V115, P1725, DOI 10.1083/jcb.115.6.1725; SAUGSTAD OD, 1980, EUR SURG RES, V12, P123, DOI 10.1159/000128117; SUNDQVIST T, 1991, J CELL PHYSIOL, V148, P152, DOI 10.1002/jcp.1041480118	24	46	47	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	AUG	1996	29	2					205	211		10.1016/0197-0186(95)00120-4			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	UY764	WOS:A1996UY76400014	8837050				2021-06-18	
J	Bohbot, V; Otahal, P; Liu, Z; Nadel, L; Bures, J				Bohbot, V; Otahal, P; Liu, Z; Nadel, L; Bures, J			Electroconvulsive shock and lidocaine reveal rapid consolidation of spatial working memory in the water maze	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							TASK	Head trauma leading to concussion and electroconvulsive shock (ECS) in humans causes amnesia for events that occurred shortly before the injury (retrograde amnesia). The present experiment investigated the amnesic effect of lidocaine and ECS in 25 rats trained on a corking memory version of the Morris water task Each day, the escape platform was moved to a new location; learning was evidenced by a decrease in the latency to find the platform from the first to the second trial. ''Consolidation'' of this newly encoded spatial engram was disrupted by bilateral inactivation of the dorsal hippocampus with 1 mu l of 4% lidocaine applied as soon as possible after the first trial. When trial 2 was given after recovery from the lidocaine (30 min after the injection), a normal decrease in latency indicated that the new engram was not disrupted, When trial 2 was given under the influence of lidocaine (5 min after injection), absence of latency decrease demonstrated both the success of the inactivation and the importance of hippocampus for the task To examine the role of events immediately after learning, ECS (30 or 100 mA, 50 Hz, 1.2 sec) Was applied 0 sec to 45 sec after a single escape to the new platform location. A 2-h delay between ECS and trial 2 allowed the effects of ECS to dissipate. ECS applied 45 sec or 30 sec after trial 1 caused no retrograde amnesia: escape latencies on trial 2 were the same as in control rats. However, ECS applied 0 sec or 15 sec after trial 1 induced clear retrograde amnesia: escape latencies on trial 2 were no shorter than on trial 1. It is concluded that the consolidation of a newly formed memory for spatial location can only be disrupted by ECS within 30 sec after learning.	ACAD SCI CZECH REPUBL,INST PHYSIOL,CR-14220 PRAGUE 4,CZECH REPUBLIC; UNIV ARIZONA,DEPT PSYCHOL,TUCSON,AZ 85721; ARIZONA RES LABS,TUCSON,AZ 85721							BARNES CA, 1988, TRENDS NEUROSCI, V11, P163, DOI 10.1016/0166-2236(88)90143-9; FENTON AA, 1994, NEUROSCIENCE, V58, P481, DOI 10.1016/0306-4522(94)90074-4; FIFKOVA E, 1967, ELECTROPHYSIOLOGICAL, P653; HOLZHAUER MS, 1986, PHYSIOL BEHAV, V38, P551, DOI 10.1016/0031-9384(86)90424-5; LYNCH S, 1973, AM J PSYCHOL, V86, P643, DOI 10.2307/1421950; MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; PANAKHOVA E, 1984, INT J PSYCHOPHYSIOL, V2, P5, DOI 10.1016/0167-8760(84)90066-7; Ribot T., 1882, DISEASES MEMORY; RUSSELL WR, 1959, BRAIN MEMORY LEARNIN; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; Zubin J, 1941, P SOC EXP BIOL MED, V48, P596	13	46	46	0	7	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	APR 30	1996	93	9					4016	4019		10.1073/pnas.93.9.4016			4	Multidisciplinary Sciences	Science & Technology - Other Topics	UK557	WOS:A1996UK55700052	8633008	Green Published, Bronze			2021-06-18	
J	Oulis, CJ; Berdouses, ED				Oulis, CJ; Berdouses, ED			Dental injuries of permanent teeth treated in private practice in Athens	ENDODONTICS & DENTAL TRAUMATOLOGY			English	Article						dental trauma; permanent teeth; private practice	TRAUMATIC INJURIES; CHILDREN	Although there are several epidemiological studies on dental trauma internationally, there are not many studies that record, analyse and follow different kinds of dental trauma treated in a private office, and that evaluate how parameters such as type of dental trauma, as well as time lapse until treatment might influence the final outcome and the prognosis of the teeth. The sample consisted of 242 patients, 6-17 years of age, with 369 injured teeth treated within a period of 5 years. All the cases were treated by the first author and were followed for at least 3 years. The treatment modalities used were based upon the clinical examination and the history of the case and included direct and indirect pulp capping, partial pulpotomy, pulpotomy, pulpectomy and splinting. The type of trauma was classified based on WHO classification partially modified. Seventy six percent of the teeth suffered only hard tissue injuries and 22% had only periodontal ligament (PDL) trauma. Of the total number of teeth class I represented 3%, class II 59%, class III 20% and class IV 2%. Of the PDL injuries 14% of the teeth suffered concussion, 69% luxation and 17% exarticulation. The highest incidence of dental trauma was observed at the age of 10. Sixty eight percent of the patients sought treatment 3 days or more after the trauma had occurred (delayed treatment), while only 32% within the first 3 days (immediate treatment). The main reasons for delayed treatment were neglect (50%) and unawareness (37%). Of the teeth with delayed treatment 43% became necrotic, while only 28% of the teeth that were treated on time needed pulpectomy. Luxations caused more pulp necrosis (46%) than class I (0%) Class II (7%) or Class III (34%) type of trauma. The data from this study suggested that a) most of the dental injuries on permanent teeth were class II or III type, b) a high percentage (68%) of the patients sought treatment more than 3 days after the injury (delayed treatment), c) delayed treatment caused more necrotic teeth, d) the public should be informed of the importance of immediate treatment in an effort to improve the prognosis of the pulp, e) dentists should be informed of the appropriate treatment of dental injuries since 10.3% of the cases were mistreated.	UNIV ATHENS, DEPT PAEDIAT DENT, SCH DENT, ATHENS, GREECE			OULIS, CONSTANTINE/AAG-5931-2021; Berdouses, Elias/AAG-4349-2020	Berdouses, Elias Demetrios/0000-0002-6718-2967			Andreasen J O, 1970, Scand J Dent Res, V78, P273; Andreasen J O, 1970, Scand J Dent Res, V78, P329; Andreasen J O, 1972, Int J Oral Surg, V1, P235, DOI 10.1016/S0300-9785(72)80042-5; ANDREASEN JO, 1990, ENDOD DENT TRAUMATOL, V6, P78; Andreasen JO, 1981, TRAUMATIC INJURIES T, P19; BECK JJ, 1968, DEP HLTH SPECIAL REP, V29, P65; Clarkson B H, 1973, J Int Assoc Dent Child, V4, P21; CRONALARSSON G, 1989, ENDOD DENT TRAUMATOL, V5, P176; DELROSARIO MEL, 1992, ENDOD DENT TRAUMATOL, V8, P213; EICHENBAUM IW, 1963, J DENT CHILD, V30, P229; Ellis RG, 1970, CLASSIFICATION TREAT; Ferguson F S, 1979, J Pedod, V4, P3; FORSBERG CM, 1993, SWED DENT J, V17, P183; GALEA H, 1984, J AM DENT ASSOC, V109, P434, DOI 10.14219/jada.archive.1984.0419; GARCIA-GODOY F, 1987, Endodontics and Dental Traumatology, V3, P126; GARCIAGODOY F, 1989, ENDOD DENT TRAUMATOL, V5, P180; GARCIAGODOY F, 1986, COMMUNITY DENT ORAL, V14, P287, DOI 10.1111/j.1600-0528.1986.tb01074.x; GARCIAGODOY F, 1979, J CAN DENT ASSOC, V45, P181; Gelbier S, 1967, Br Dent J, V123, P331; GUTZ DP, 1971, J DENT CHILD, V38, P94; Haavikko K, 1976, Proc Finn Dent Soc, V72, P152; HARGRAVES JA, 1970, MANAGEMENT TRAUMATIS; HAYRINENIMMONEN R, 1990, ENDOD DENT TRAUMATOL, V6, P208; Hedegard B, 1973, Sven Tandlak Tidskr, V66, P431; HUNTER ML, 1990, ENDOD DENT TRAUMATOL, V6, P260; JARVINEN S, 1979, ACTA ODONTOL SCAND, V37, P47, DOI 10.3109/00016357909004684; JARVINEN S, 1980, ACTA ODONTOL SCAND, V38, P151, DOI 10.3109/00016358009004714; KABA AD, 1989, J DENT CHILD, V56, P417; KORNS RD, 1960, J DENT CHILD, V27, P244; KRAMER LR, 1973, J AM DENT, V28, P1351; Lewis TE, 1959, ANGLE ORTHOD, V29, P128; MACKO DJ, 1979, J DENT CHILD, V46, P130; MAGNUSON B, 1969, SWED DENT J, V62, P72; MCEWEN JD, 1967, J DENT RES, V46, P1290; MEADOW D, 1984, Pediatric Dentistry, V6, P248; NEEDLEMAN H L, 1986, Pediatric Dentistry, V8, P71; Nicholas N K, 1980, N Z Dent J, V76, P8; Oluwole T O, 1986, Pediatr Dent, V8, P221; OMULLANE DM, 1973, BRIT DENT J, V134, P328, DOI 10.1038/sj.bdj.4803000; RAVN JJ, 1974, COMMUNITY DENT ORAL, V2, P231, DOI 10.1111/j.1600-0528.1974.tb01658.x; ROCK WP, 1974, BRIT DENT J, V136, P236, DOI 10.1038/sj.bdj.4803162; Skieller V., 1960, ACTA ODONTOL SCAND, V18, P171; Stalhane I, 1975, Sven Tandlak Tidskr, V68, P157; STOCKWELL AJ, 1988, COMMUNITY DENT ORAL, V16, P294, DOI 10.1111/j.1600-0528.1988.tb01779.x; SUGANIDIS D, 1984, ODONT PROG, V38, P311; *WHO, 1978, APPL INT CLASS DIS S; ZADIK D, 1976, COMMUNITY DENT ORAL, V4, P149, DOI 10.1111/j.1600-0528.1976.tb00973.x; ZADIK D, 1972, J DENT CHILD, V39, P185; ZADIK D, 1979, ORAL SURG, P173	49	46	50	0	4	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0109-2502			ENDOD DENT TRAUMATOL	Endod. Dent. Traumatol.	APR	1996	12	2					60	65					6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	UR760	WOS:A1996UR76000004	9028198				2021-06-18	
J	Panizzon, KL; Dwyer, BE; Nishimura, RN; Wallis, RA				Panizzon, KL; Dwyer, BE; Nishimura, RN; Wallis, RA			Neuroprotection against CA1 injury with metalloporphyrins	NEUROREPORT			English	Article						cerebral ischemia; hypoxia; traumatic brain injury; heme oxygenase; metalloporphyrins; LTP; oxidative stress; slice	LONG-TERM POTENTIATION; HEME OXYGENASE; CARBON-MONOXIDE; NITRIC-OXIDE; HYPERBILIRUBINEMIA; SUPPRESSION; HIPPOCAMPUS; INHIBITORS	THE hippocampal slice was used to examine neuroprotection with metalloporphyrins, a class of drug which inhibits heme oxygenase and which has been found to be effective in the treatment of neonatal hyperbilirubinemia. Tin-protoporphyrin given during hypoxia significantly improved recovery of CA1 antidromic PS to a mean of 82 +/- 2% of initial amplitude, while unmedicated slices regained only 6 +/- 3% of initial amplitude. Tin-protoporphyrin also protected against fluid percussion injury with an EC(50) Of 10 mu M when given after trauma. This protection extended to induction of long-term potentiation. Tin-mesoporphyrin and zinc-protoporphyrin protected against trauma with EC(50)'s of 4 and 32 mu M. Treatment with Sn-PP also protected against exposure to hydrogen peroxide, but not NMDA, AMPA, glycine or nitric oxide. These findings indicate that metalloporphyrins protect against CA1 neuronal injury through direct neural effects.	VET AFFAIRS MED CTR 111 N1,NEURONAL INJURY LAB,SEPULVEDA,CA 91343; VET AFFAIRS MED CTR 111 N1,IN VITRO REMYELINAT LAB,SEPULVEDA,CA 91343; UNIV CALIF LOS ANGELES,SCH MED,BRAIN RES INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; VET AFFAIRS MED CTR,MOLEC NEUROBIOL LAB,WHITE RIVER JCT,VT 05009; DARTMOUTH COLL SCH MED,DIV NEUROL,DEPT MED,HANOVER,NH 03755							DRUMMOND GS, 1986, J CLIN INVEST, V77, P971, DOI 10.1172/JCI112398; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; DWYER BE, 1995, NEUROREPORT, V6, P973, DOI 10.1097/00001756-199505090-00006; FAIRCHILD MD, 1988, BRAIN RES, V453, P357, DOI 10.1016/0006-8993(88)90178-3; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; KAPPAS A, 1988, PEDIATRICS, V81, P485; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LUO DS, 1994, EUR J PHARM-MOLEC PH, V267, P263, DOI 10.1016/0922-4106(94)90149-X; MAINES MD, 1988, FASEB J, V2, P2557; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; PANIZZON KL, 1994, NEUROLOGY, V20; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; TRUKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732; VALAES T, 1994, PEDIATRICS, V93, P1; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VREMAN HJ, 1993, PEDIATR RES, V33, P195; WALLIS RA, 1993, NEUROREPORT, V5, P245; WALLIS RA, 1994, BRAIN RES, V664, P115, DOI 10.1016/0006-8993(94)91961-5; WALLIS RA, 1993, EUR J PHARMACOL, V238, P165, DOI 10.1016/0014-2999(93)90844-8; WALLIS RA, IN PRESS BRAIN RES; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368; ZORUMSKI CF, 1993, BIOCHEM PHARMACOL, V46, P777, DOI 10.1016/0006-2952(93)90484-E	25	46	49	0	0	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	JAN 31	1996	7	2					662	666		10.1097/00001756-199601310-00067			5	Neurosciences	Neurosciences & Neurology	UC299	WOS:A1996UC29900067	8730852				2021-06-18	
J	Levin, HS; Scheller, J; Richard, T; Grafman, J; Martinkowski, K; Winslow, M; Mirvis, S				Levin, HS; Scheller, J; Richard, T; Grafman, J; Martinkowski, K; Winslow, M; Mirvis, S			Dyscalculia and dyslexia after right hemisphere injury in infancy	ARCHIVES OF NEUROLOGY			English	Article							UNILATERAL BRAIN-LESIONS; AGE ONE	Objective: To use the findings from neuropsychological evaluation and functional magnetic resonance imaging (fMRI) to assess interhemispheric reorganization of function after early unilateral brain injury. Design and Methods: The study focused on one case of early brain injury that resulted in both dyscalculia and dyslexia. Brain injury was studied using both structural and fMRI. Intellectual function was evaluated using the Wechsler Intelligence Scale for Children, Third Edition, awhile visuospatial skins were assessed using the Block Design subtest of the Wechsler Intelligence Scale for Children, Third Edition, and Judgment of line Orientation subtest. The Selective Reminding Test and the Recurring Figures Test were used to evaluate memory and orientation; language and speech skills were evaluated using the Boston Naming Test, Controlled Oral Word Association, Gates-MacGinitie Reading Test, and color naming. Various methods were used to study arithmetic skills, including the Wide Range Achievement Test-Revised and the Peabody Individual Achievement Test. The control group for fMRI consisted of nine normal subjects. Setting: Neuropsychological laboratory in primary care hospital. Patient: A 17-year-old boy who had sustained a closed head injury associated with a partially depressed, right parietal skull fracture, and right temporal hemorrhage in a motor vehicle crash at age 7 months (November 9, 1977). Subsequent social behavior was normal, but the patient had difficulty throughout school in mathematics and spelling and was characterized as having a ''short attention span.'' Intervention: None. Main Outcome Measures: Standardized tests of arithmetic and reading supplemented by an assessment of calculation and quantitative skills. While performing calculations, fh?RI disclosed predominantly left hemisphere activation involving the frontal and posterior parietal regions, whereas this task produced bilateral activation of the supramarginal gyrus in seven of nine normal subjects. Results: Neuropsychological findings confirmed the presence of dyscalculia and dyslexia despite normal intellectual functioning. Visuospatial skills ranged from the low normal to average level. The fMRI findings were consistent with early interhemispheric transfer of visuospatial skills normally committed to the right parietal area to the left parietal region. The patient's dyscalculia and reading ability raise a question of acquired left parietal dysfunction as a consequence of the competition between verbal and visuospatial functions for left hemisphere representation. Conclusion: Interhemispheric reorganization of function may be bidirectional rather than a feature unique to the left hemisphere substrate for language.	NINCDS,MNB,COGNIT NEUROSCI SECT,BETHESDA,MD 20892; UNIV MARYLAND,MED SYST,DIV NEUROSURG,BALTIMORE,MD 21201; UNIV MARYLAND,MED SYST,DEPT PEDIAT,BALTIMORE,MD 21201				Grafman, Jordan H./0000-0001-8645-4457	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; Benton A. L., 1994, CONTRIBUTIONS NEUROP; BENTON AL, 1993, MANUAL MULTILINGUAL; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Damasio H., 1989, LESION ANAL NEUROPSY; DUNN LM, 1970, PEABODY INDIVIDUAL A; GATES AI, 1969, GATES MACGINITIE REA; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; JASTAK S, 1984, WIDE RANGE ACHLEVEME; Kaplan E., 1983, BOSTON NAMING TEST; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; MCCLOSKEY M, 1985, BRAIN COGNITION, V4, P171, DOI 10.1016/0278-2626(85)90069-7; RIVA D, 1986, NEUROPSYCHOLOGIA, V24, P423, DOI 10.1016/0028-3932(86)90029-1; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SHAYWITZ BA, 1995, HUMAN BRAIN MAP, V2, P197; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; STILESDAVIS J, 1988, NEUROPSYCHOLOGIA, V26, P359, DOI 10.1016/0028-3932(88)90091-7; STRAUSS E, 1990, NEUROPSYCHOLOGIA, V28, P1221, DOI 10.1016/0028-3932(90)90057-U; Talairach J, 1988, CO PLANAR STEREOTAXI; Teuber H., 1974, NEUROSCIENCES 3 STUD, P71; Wechsler D., 1991, WECHSLER INTELLIGENC; WEINSTEIN S, 1957, SCIENCE, V125, P1036, DOI 10.1126/science.125.3256.1036; Weintraub S., 1985, PRINCIPLES BEHAV NEU, P71; WOODS BT, 1980, NEUROPSYCHOLOGIA, V18, P65, DOI 10.1016/0028-3932(80)90084-6	24	46	48	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JAN	1996	53	1					88	96		10.1001/archneur.1996.00550010108024			9	Clinical Neurology	Neurosciences & Neurology	TP709	WOS:A1996TP70900015	8599565				2021-06-18	
J	MATHERN, GW; BABB, TL; VICKREY, BG; MELENDEZ, M; PRETORIUS, JK				MATHERN, GW; BABB, TL; VICKREY, BG; MELENDEZ, M; PRETORIUS, JK			TRAUMATIC COMPARED TO NONTRAUMATIC CLINICAL-PATHOLOGICAL ASSOCIATIONS IN TEMPORAL-LOBE EPILEPSY	EPILEPSY RESEARCH			English	Article						HIPPOCAMPAL SCLEROSIS; ETIOLOGY; COMPLEX PARTIAL SEIZURES; PATHOGENESIS	CONCUSSIVE BRAIN INJURY; HEAD-INJURY; VULNERABILITY; RAT	This study determined differences in clinical-pathologic characteristics of intractable temporal lobe epilepsy (TLE) patients whose mechanism of cerebral injury and chronic seizures involved a prior history of cerebral trauma compared to those with non-traumatic initial injuries. TLE patients (n = 120) from a single epilepsy center were retrospectively and blindly catalogued into pathogenic groups (independent variables) based on if there was a significant Birth injury (n = 11) or Cerebral trauma (n = 26). These two 'trauma' categories were compared to TLE patients with non-seizure non-trauma histories (Non-St/Non-Trauma; n = 17), or a first Prolonged seizure (n = 66). The four groups were compared for differences in the time course of their clinical injuries and seizures, quantified hippocampal neuron counts, other temporal neocortical pathologies, and seizure outcomes (dependent variables). Between group statistically significant (at least P < 0.05) results showed: (1) In Birth injury, 33% had Ammon's Horn (AH) neuron loss under 50%, 54% had other temporal neocortical pathologies, they showed the most CA4 neuron loss, and the worse seizure outcomes. (2) Cerebral trauma were older when injured, 29% had AH loss under 50%, 50% showed other pathologies, and they had the best seizure outcomes. (3) Non-St/Non-Trauma showed the least AH and CA4 neuron losses, only 12% had other temporal pathologies, and they had seizure outcomes that were intermediate. (4) Prolonged seizure showed the youngest age of habitual TLE onsets, the greatest AH, CA1, and prosubiculum neuron loss, only 11% had other temporal pathologies, and their seizure outcomes were excellent. These results indicate that in intractable surgically treated TLE, a history of cerebral trauma or birth injury as the pathogenic mechanism of their seizures show different clinical-pathologic features and seizure outcomes compared to non-trauma patients. This supports the notion that in TLE there are different pathogenic mechanisms associated with different types of initial injuries and that patients will have different responses to surgical therapy.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,REED NEUROL RES CTR,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,REED NEUROL RES CTR,BRAIN RES INST,LOS ANGELES,CA 90024	MATHERN, GW (corresponding author), UNIV CALIF LOS ANGELES,CTR HLTH SCI,REED NEUROL RES CTR,DIV NEUROSURG,LOS ANGELES,CA 90024, USA.		Mathern, Gary W./J-2483-2016		AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01 HS06856] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 02808, K08 NS 01603] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS006856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54NS081764, K08NS001603, P01NS002808] Funding Source: NIH RePORTER		ABOUKHALIL B, 1993, EPILEPSIA, V34, P878, DOI 10.1111/j.1528-1157.1993.tb02105.x; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; BABB TL, 1984, EPILEPSIA, V25, P729, DOI 10.1111/j.1528-1157.1984.tb03484.x; BABB TL, 1991, EPILEPSY SURGERY, P719; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; COHADON F, 1991, J NEUROL SCI, V103, pS27; COURVILLE CB, 1958, TEMPORAL LOBE EPILEP, P220; CRANDALL PH, 1963, J NEUROSURG, V20, P827, DOI 10.3171/jns.1963.20.10.0827; CRANDALL PH, 1987, SURGICAL TREATMENT E, P377; DENO RL, 1933, J PSYCHOL NEUROL, V45, P113; Dinner Dudley S., 1993, P654; EARLE KM, 1953, AMA ARCH NEUROL PSY, V69, P27, DOI 10.1001/archneurpsyc.1953.02320250033003; ENGEL J, 1991, PRINCIPLES NEUROSURG, P319; ENGEL J, 1989, SEIZURES EPILEPSY; Engel JJ, 1993, SURG TREATMENT EPILE, P743; Engel Jr J, 1987, SURG TREATMENT EPILE, P553; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GADA GF, 1990, NEUROLOGICAL SURGERY, P1965; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jennett B, 1975, EPILEPSY NONMISSILE; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MALAMUD N, 1958, TEMPORAL LOBE EPILEP, P149; MATHERN GW, 1994, DEV BRAIN RES, V78, P70, DOI 10.1016/0165-3806(94)90011-6; MATHERN GW, 1994, UNPUB BRAIN; MATHERN GW, 1991, IN PRESS J NEUROSURG; MATHERN GW, 1994, IN PRESS J NEUROSURG; McCormick W.F., 1985, NEUROSURGERY, P1544; MOURITZENDAM A, 1980, EPILEPSIA, V21, P617; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; TEMKIN O, 1945, FALLING SICKNESS; VICKREY BG, 1992, MED CARE, V30, P299, DOI 10.1097/00005650-199204000-00002; WEISER HG, 1993, SURGICAL TREATMENT E, P49; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG B, 1990, NEUROLOGICAL SURGERY, P2243	42	46	47	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	OCT	1994	19	2					129	139		10.1016/0920-1211(94)90023-X			11	Clinical Neurology	Neurosciences & Neurology	PN683	WOS:A1994PN68300005	7843168				2021-06-18	
J	RIVADEPATY, I; FARDEAU, C; MARIANI, J; BOUCHAUD, C; DELHAYEBOUCHAUD, N				RIVADEPATY, I; FARDEAU, C; MARIANI, J; BOUCHAUD, C; DELHAYEBOUCHAUD, N			CONTRIBUTION OF PERIPHERAL MACROPHAGES AND MICROGLIA TO THE CELLULAR REACTION AFTER MECHANICAL OR NEUROTOXIN-INDUCED LESIONS OF THE RAT-BRAIN	EXPERIMENTAL NEUROLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; WALLERIAN DEGENERATION; INFLAMMATORY RESPONSE; CORPUS-CALLOSUM; OPTIC-NERVE; CELLS; 3-ACETYLPYRIDINE; EXPRESSION; INJECTION; AXOTOMY	Lesions of the central nervous system result in invasion of peripheral phagocytes and/or in situ activation and proliferation of microglia, depending on the direct or indirect nature of the injury. Neurotoxins which are widely used to induce neurodegeneration have been reported to elicit a pure microglial reaction when administered intraventricularly. However, the mechanical lesion at the injection site, although remote from the lesioned area, could give access to blood-derived cells. Therefore, this study compares the phagocytic reaction occurring after a traumatic lesion of the brain causing a breakdown of the blood-brain barrier (BBB), or after degeneration of the inferior olivary neurons induced by intraperitoneal administration of 3-acetylpyridine, a process that respects the integrity of the BBB as suggested by the results of intravascular injection of Evans blue. The identification of the macrophages at the lesion site used specific binding of the B-4 isolectin from Griffonia simplicifolia, preloading of the peripheral monocytes/macrophages with trypan blue, and characteristic morphological features. In traumatically lesioned rats, the lectin-labeled macrophages were mainly large rounded peripheral cells recruited 1-3 days postlesion, whereas in chemically lesioned rats, the cellular reaction appeared 24-36 h postinjection and peaked between 3 and 12 days before undergoing a slow decline. Lectin binding and morphological characteristics indicated that these small cells were reactive microglia. These results confirm that a brain injury leaving the BBB intact involves essentially the recruitment and/or the proliferation of microglia. (C) 1994 Academic Press, Inc.	UNIV PARIS 06,F-75005 PARIS,FRANCE	RIVADEPATY, I (corresponding author), INST NEUROSCI,DEV NEUROBIOL LAB,CNRS,URA 1488,F-75005 PARIS,FRANCE.			Fardeau, Christine/0000-0003-1935-2711; Mariani, Jean/0000-0002-2701-1581			AKIYAMA H, 1989, BRAIN RES, V489, P247, DOI 10.1016/0006-8993(89)90857-3; ALLIOT F, 1991, P NATL ACAD SCI USA, V88, P1541, DOI 10.1073/pnas.88.4.1541; ANDERSON WA, 1980, J COMP NEUROL, V190, P157, DOI 10.1002/cne.901900111; BALABAN CD, 1985, BRAIN RES REV, V9, P21, DOI 10.1016/0165-0173(85)90017-7; BARRON KD, 1990, BRAIN RES, V523, P219, DOI 10.1016/0006-8993(90)91490-8; BIGNAMI A, 1981, J NEUROPATH EXP NEUR, V40, P537, DOI 10.1097/00005072-198109000-00005; BOOTH PL, 1991, BRAIN RES, V548, P163, DOI 10.1016/0006-8993(91)91118-K; CHEVREMONT M, 1960, NOTIONS CYTOLOGIE HI, P589; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; COFFEY PJ, 1988, NEUROSCI LETT, V84, P178, DOI 10.1016/0304-3940(88)90404-1; CUPEDO RN, 1989, ACTA MORPHOL NEERLAN, V26, P19; DELHAYEBOUCHAUD N, 1988, CR ACAD SCI III-VIE, V307, P69; DENK H, 1968, ACTA NEUROPATHOL BER, V10, P349; DESCLIN JC, 1974, BRAIN RES, V77, P349, DOI 10.1016/0006-8993(74)90627-1; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; FULCRAND J, 1977, J COMP NEUROL, V176, P189, DOI 10.1002/cne.901760204; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; HARDEBO JE, 1980, EXP NEUROL, V70, P155, DOI 10.1016/0014-4886(80)90013-8; HAYES CE, 1974, J BIOL CHEM, V249, P1904; HORTEGA PD, 1932, CYTOLOGY CELLULAR PA, P483; IMAMOTO K, 1978, J COMP NEUROL, V180, P139, DOI 10.1002/cne.901800109; JORDAN FL, 1988, BRAIN RES REV, V13, P165, DOI 10.1016/0165-0173(88)90019-7; KERNS JM, 1973, J COMP NEUROL, V151, P237, DOI 10.1002/cne.901510303; LING EA, 1980, J COMP NEUROL, V193, P631, DOI 10.1002/cne.901930304; LING EA, 1987, J NEUROCYTOL, V16, P373, DOI 10.1007/BF01611348; LING EA, 1992, HISTOL HISTOPATHOL, V7, P93; LING EA, 1981, ADV CELL NEUROBIOL, V2, P33; MADDOX DE, 1982, P NATL ACAD SCI-BIOL, V79, P166, DOI 10.1073/pnas.79.1.166; MARTY S, 1991, NEUROSCIENCE, V45, P529, DOI 10.1016/0306-4522(91)90268-S; MATSUYAMA H, 1975, ACTA PATHOL JAPON, V25, P691; MILLIGAN CE, 1991, J COMP NEUROL, V314, P136, DOI 10.1002/cne.903140113; MURABE Y, 1981, CELL TISSUE RES, V218, P75; OEHMICHEN M, 1975, MONONUCLEAR PHAGOCYT, P223; Ogawa Matsuo, 1992, Neurodegeneration, V1, P37; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; SCHELPER RL, 1986, J NEUROPATH EXP NEUR, V45, P1, DOI 10.1097/00005072-198601000-00001; STAGAARD M, 1987, J NEUROCYTOL, V16, P131, DOI 10.1007/BF02456704; STOLL G, 1989, J NEUROSCI, V9, P2327; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; THOMAS WE, 1992, BRAIN RES REV, V17, P61; TORVIK A, 1975, BRAIN RES, V95, P519, DOI 10.1016/0006-8993(75)90125-0; Volkman A, 1970, Ser Haematol, V3, P62; WHITELAW DM, 1972, CELL TISSUE KINET, V5, P215, DOI 10.1111/j.1365-2184.1972.tb00360.x; WISLOCKI GB, 1952, J COMP NEUROL, V96, P371, DOI 10.1002/cne.900960302	50	46	47	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	JUL	1994	128	1					77	87		10.1006/exnr.1994.1114			11	Neurosciences	Neurosciences & Neurology	PC985	WOS:A1994PC98500008	8070525				2021-06-18	
J	PACE, GM; IVANCIC, MT; JEFFERSON, G				PACE, GM; IVANCIC, MT; JEFFERSON, G			STIMULUS FADING AS TREATMENT FOR OBSCENITY IN A BRAIN-INJURED ADULT	JOURNAL OF APPLIED BEHAVIOR ANALYSIS			English	Article						ANTECEDENT TREATMENT PROCEDURES; STIMULUS FADING; NEGATIVE REINFORCEMENT; OBSCENITY; BRAIN INJURY	INJURIOUS ESCAPE BEHAVIOR; EXTINCTION	Obscene verbalizations of a person with traumatic brain injury were treated using stimulus fading as the singular form of intervention. Results of a functional assessment revealed that obscenity was maintained by negative reinforcement. Stimulus fading (initial elimination of instructional demands followed by their gradual reintroduction) produced immediate and substantial reductions in obscenity that were maintained as the frequency of demands increased to baseline levels. Potential applications of the use of antecedent treatment strategies are discussed.	KENNEDY KRIEGER INST,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,BALTIMORE,MD 21205; WESTERN CAROLINA CTR,MORGANTON,NC; UNIV OREGON,EUGENE,OR 97403							CARR EG, 1976, J ABNORM CHILD PSYCH, V4, P139, DOI 10.1007/BF00916518; IWATA BA, 1987, J APPL BEHAV ANAL, V20, P361, DOI 10.1901/jaba.1987.20-361; IWATA BA, 1982, ANAL INTERVEN DEVEL, V2, P3, DOI 10.1016/0270-4684(82)90003-9; IWATA BA, 1990, J APPL BEHAV ANAL, V23, P11, DOI 10.1901/jaba.1990.23-11; MASON SA, 1990, J APPL BEHAV ANAL, V23, P361, DOI 10.1901/jaba.1990.23-361; MICHAEL J, 1993, BEHAV ANALYST, V16, P191, DOI 10.1007/BF03392623; PACE GM, 1993, J APPL BEHAV ANAL, V26, P205, DOI 10.1901/jaba.1993.26-205; Sidman M., 1960, TACTICS SCI RES; STEEGE MW, 1989, J APPL BEHAV ANAL, V22, P23, DOI 10.1901/jaba.1989.22-23; ULMAN JD, 1975, BEHAVIOR ANAL AREAS, P359; ZARCONE JR, 1993, J APPL BEHAV ANAL, V26, P353, DOI 10.1901/jaba.1993.26-353; ZARCONE JR, 1994, J APPL BEHAV ANAL, V27, P307, DOI 10.1901/jaba.1994.27-307	12	46	46	0	2	JOURNAL APPL BEHAV ANAL	LAWRENCE	DEPT HUMAN DEVELOPMENT, UNIV KANSAS, LAWRENCE, KS 66045	0021-8855			J APPL BEHAV ANAL	J. Appl. Behav. Anal.	SUM	1994	27	2					301	305		10.1901/jaba.1994.27-301			5	Psychology, Clinical	Psychology	NV446	WOS:A1994NV44600010	8063628	Green Published			2021-06-18	
J	LYETH, BG; JIANG, JY; ROBINSON, SE; GUO, HZ; JENKINS, LW				LYETH, BG; JIANG, JY; ROBINSON, SE; GUO, HZ; JENKINS, LW			HYPOTHERMIA BLUNTS ACETYLCHOLINE INCREASE IN CSF OF TRAUMATICALLY BRAIN INJURED RATS	MOLECULAR AND CHEMICAL NEUROPATHOLOGY			English	Article						TRAUMATIC BRAIN INJURY; HYPOTHERMIA; ACETYLCHOLINE; CHOLINE; CSF; PLASMA	CHOLINE UPTAKE; SYNAPTOSOMES; ISCHEMIA; BEHAVIOR; ACIDS; MODEL	Activation of muscarinic acetylcholine (ACh) receptors contributes to the pathophysiological consequences of moderate experimental traumatic brain injury (TBI). Hypothermia (30-degrees-C) provides protection in experimental TBI. We measured ACh levels in CSF and plasma 5 min after moderate fluid percussion TBI under normothermic or hypothermic conditions, because ACh in the CSF has been correlated with the severity of behavioral deficits after TBI. Three groups were examined: TBI with hypothermic brain (30-degrees-C), TBI with normothermic brain (37-degrees-C), or sham TBI with normothermic brain (37-degrees-C). ACh concentrations in CSF were significantly higher in 37-degrees-C TBI rats, but not in 30-degrees-C TBI rats compared to shams. ACh concentratons in plasma did not differ between groups. These results suggest that a contributing factor to the neuroprotective effects of moderate hypothermia in TBI may be related to the reduction of excessive ACh levels in the central nervous system following injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298	LYETH, BG (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,BOX 693,MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587, R01NS019550, R01NS024413] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 24413, NS 19550] Funding Source: Medline		BOKSA P, 1988, J NEUROCHEM, V50, P1309, DOI 10.1111/j.1471-4159.1988.tb10609.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ENTERS EK, 1992, BRAIN RES, V576, P271; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAYES RL, 1988, J NEUROTRAUM, V5, P287; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JOPE RS, 1991, NEUROCHEM RES, V16, P1219, DOI 10.1007/BF00966699; KAKIHANA M, 1989, ARCH GERONTOL GERIAT, V8, P247, DOI 10.1016/0167-4943(89)90007-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P884; LOFFELHOLZ K, 1989, BIOCHEM PHARMACOL, V38, P1543, DOI 10.1016/0006-2952(89)90299-2; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MACEDO TM, 1983, NEUROPHARMACOLOGY, V22, P233, DOI 10.1016/0028-3908(83)90014-X; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; ROBINSON S E, 1991, Society for Neuroscience Abstracts, V17, P721; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1986, J NEUROCHEM, V46, P1632, DOI 10.1111/j.1471-4159.1986.tb01786.x; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SCREMIN OU, 1989, STROKE, V20, P1524, DOI 10.1161/01.STR.20.11.1524; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; YAMAMURA HI, 1973, J NEUROCHEM, V21, P1355, DOI 10.1111/j.1471-4159.1973.tb06022.x	34	46	49	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512	1044-7393			MOL CHEM NEUROPATHOL	Mol. Chem. Neuropathol.	APR	1993	18	3					247	256		10.1007/BF03160117			10	Neurosciences; Pathology	Neurosciences & Neurology; Pathology	KZ118	WOS:A1993KZ11800004	8507303				2021-06-18	
J	ANDERSON, PA; BOHLMAN, HH				ANDERSON, PA; BOHLMAN, HH			ANTERIOR DECOMPRESSION AND ARTHRODESIS OF THE CERVICAL-SPINE - LONG-TERM MOTOR IMPROVEMENT .2. IMPROVEMENT IN COMPLETE TRAUMATIC QUADRIPLEGIA	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							CORD INJURIES; COMPRESSION; FRACTURES; CLASSIFICATION; DISLOCATIONS	Fifty-one patients who had complete motor quadriplegia secondary to a fracture or dislocation of the cervical spine were managed by anterior cervical decompression and arthrodesis with iliac bone grafts between 1973 and 1983. In all patients, myelography demonstrated that displaced fragments of bone and disc were compressing the anterior aspect of the spinal cord. Decompression was performed in an attempt to gain further improvement of the motor-roots in the upper extremities and thereby to improve the ability of the patients to care for themselves. The average interval from the injury to the decompression was fifteen months (range, one month to eight years). Two patients died within two months after the operation, one had a respiratory arrest that resulted in brain damage one day after the operation, and two died from cardiovascular disease more than one year after the operation. The remaining forty-six patients were followed for an average of five years (range, two to thirteen years). Neurological improvement of at least two new functional motor-root levels was documented in seven patients and of one level, in eighteen. Increased motor strength by two or three grades was seen in six patients. Noteworthy motor improvement did not occur in the remaining twenty patients. The mean modified Barthel index (used to measure improvement in the ability to perform activities of daily living) increased from 17 to 33 (of a possible 100) points. Functionally important improvement of the caudad part of the cord occurred in only one patient. In one patient, neural injury, with loss of one motor-root level, occurred, with only partial improvement. At the latest follow-up examination, the result was poor in nine of eleven patients who had decompression eighteen months or more after the injury. Only two of these patients had any improvement in the Barthel index, and then of only 5 points each. The result also was poor in the five patients who were more than fifty-three years old; two had no improvement in the Barthel index, one improved by 5 points, and two died.	VET ADM MED CTR, ACUTE SPINAL CORD INJURY SERV, CLEVELAND, OH 44106 USA; HIGHLAND VIEW HOSP, CLEVELAND, OH USA; UNIV HOSP CLEVELAND, CTR RECONSTRUCT & TRAUMAT SPINE SURG, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT ORTHOPAED SURG, CLEVELAND, OH 44106 USA							ALLEN BL, 1982, SPINE, V7, P1, DOI 10.1097/00007632-198200710-00001; BAILEY RW, 1960, J BONE JOINT SURG AM, V42, P565, DOI 10.2106/00004623-196042040-00001; BOHLMAN HH, 1979, J BONE JOINT SURG AM, V61, P1119, DOI 10.2106/00004623-197961080-00001; BOHLMAN HH, 1982, EARLY MANAGEMENT ACU, P315; BOHLMAN HH, 1981, CLIN ORTHOP RELAT R, V154, P57; BOHLMAN HH, 1992, SPINE, V2, P973; BOSCH A, 1971, J AMER MED ASSOC, V216, P473; CHEN L, 1990, J NEUROSURG, V72, P600, DOI 10.3171/jns.1990.72.4.0600; CLOWARD RB, 1961, J NEUROSURG, V18, P201, DOI 10.3171/jns.1961.18.2.0201; COOPER PR, 1984, J NEUROSURG, V61, P281, DOI 10.3171/jns.1984.61.2.0281; DOLAN EJ, 1980, J NEUROSURG, V53, P749, DOI 10.3171/jns.1980.53.6.0749; Frankel H L, 1969, Paraplegia, V7, P179; Guttmann L., 1976, SPINAL CORD INJURIES, V2nd ed; HANSEBOUT RR, 1982, EARLY MANAGEMENT ACU, P181; HOPPENFELD S, 1976, PHYSICAL EXAMINATION; HORSEY WJ, 1982, EARLY MANAGEMENT ACU, P305; JACOBS B, 1975, CLIN ORTHOP RELAT R, P18; JELSMA RK, 1982, SURG NEUROL, V18, P156, DOI 10.1016/0090-3019(82)90383-4; JELSMA RK, 1982, SURG NEUROL, V18, P79, DOI 10.1016/0090-3019(82)90357-3; LOEWEN SC, 1988, PHYS THER, V68, P1077, DOI 10.1093/ptj/68.7.1077; LUCAS JT, 1979, AM SURGEON, V45, P151; LUCAS JT, 1979, NEUROVASCULAR SURGER, V7, P281; MAHONEY F I, 1965, Md State Med J, V14, P61; MICHAELIS LS, 1976, HDB CLIN NEUROLOGY, V26, P307; Morgan T H, 1971, Paraplegia, V9, P14; PIERCE DS, 1972, AAOS INSTR COURSE LE, V21, P102; RAYNOR R B, 1977, Spine, V2, P39, DOI 10.1097/00007632-197703000-00004; RAYNOR RB, 1968, J NEUROSURG, V28, P311, DOI 10.3171/jns.1968.28.4.0311; RIVLIN AS, 1978, SURG NEUROL, V10, P39; ROSSIER AB, 1977, SURG NEUROL, V7, P55; Schneider R C, 1973, Clin Neurosurg, V20, P424; SCHNEIDER RC, 1955, J NEUROSURG, V12, P95, DOI 10.3171/jns.1955.12.2.0095; SCHNEIDER RC, 1956, J BONE JOINT SURG AM, V38, P985, DOI 10.2106/00004623-195638050-00003; STAUFFER ES, 1975, CLIN ORTHOP RELAT R, V112, P9; VERBIEST H, 1962, J NEUROSURG, V19, P389, DOI 10.3171/jns.1962.19.5.0389; Verbiest H, 1973, Clin Neurosurg, V20, P334	36	46	48	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	JUN	1992	74A	5					683	692		10.2106/00004623-199274050-00007			10	Orthopedics; Surgery	Orthopedics; Surgery	JD677	WOS:A1992JD67700007	1624484				2021-06-18	
J	ABRUNZO, TJ				ABRUNZO, TJ			COMMOTIO CORDIS - THE SINGLE, MOST COMMON CAUSE OF TRAUMATIC DEATH IN YOUTH BASEBALL	AMERICAN JOURNAL OF DISEASES OF CHILDREN			English	Article							SUDDEN-DEATH; YOUNG-ADULTS; CHILDREN; INJURY	Two cases of blunt chest trauma caused by a baseball are reported, including one death. At least one of these was in consequence of cardiac concussion or commotio cordis, an entity not described in the pediatric literature. Concussion of the heart is a functional injury, in contrast to cardiac contusion or cardiac rupture, which pertains to structural injury. However, a cardiac concussion appears more likely to have immediate, dire consequences than the structural injury of cardiac contusion. Both of the cases presented occurred in the Little League baseball setting. Blunt chest trauma is reported to cause two to three deaths in youth baseball each year. There appears to be an increased pediatric susceptibility to this type of injury. Unfortunately, these cases are quite resistant to resuscitative therapy. Devices and techniques for primary and secondary prevention exist, but have yet to be systematically verified and implemented.	ST JOSEPHS HOSP,PEDIAT EMERGENCY SERV,TAMPA,FL							ALBARRANSOTELO R, 1987, TXB ADV CARDIAC LIFE; ANDERSON DM, 1985, DORLANDS ILLUSTRATED, P370; ANDERSON RH, 1987, PEDIATRIC CARDIOLOGY; BEHRMAN RE, 1987, NELSON TXB PEDIATRIC; CHAMEIDES L, 1988, TXB PEDIATRIC ADV LI; COHN PF, 1988, HEART DISEASE TXB CA, P1535; DENFIELD SW, 1990, PEDIATR CLIN N AM, V37, P215; Dickman Gerald L, 1978, Phys Sportsmed, V6, P85, DOI 10.1080/00913847.1978.11948393; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; EICHELBERGER MR, 1988, PEDIATRIC TRAUMA CAR; FERSTLE J, 1978, PHYSICIAN SPORTSMED, V6, P21; FLEISHER GR, 1988, TXB PEDIATRIC EMERGE; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FROEDE RC, 1979, J FORENSIC SCI, V24, P752; GOLDBERG B, 1989, Physician and Sportsmedicine, V17, P175; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; HALE C, 1979, PHYSICIAN SPORTSMED, V7, P59; HALLER JA, 1983, JAMA-J AM MED ASSOC, V245, P47; KAROFSKY PS, 1990, PHYSICIAN SPORTSMED, V18, P99, DOI 10.1080/00913847.1990.11709976; KING AI, 1986, BASEBALL RELATED CHE; LANGER JC, 1989, J PEDIATR SURG, V24, P1091, DOI 10.1016/S0022-3468(89)80225-8; LAU VK, 1982, J TRAUMA, V21, P39; LIEDTKE AJ, 1980, J TRAUMA, V20, P777, DOI 10.1097/00005373-198009000-00012; LINDSEY D, 1978, CHEST, V74, P15, DOI 10.1378/chest.74.1.15; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MAYER TA, 1985, EMERGENCY MANAGEMENT; MCINTYRE KM, 1981, TXB ADV CARDIAC LIFE; MOSS AJ, 1989, HEART DISEASE INFANT; Mueller F, 1982, Clin Sports Med, V1, P343; NEUSPIEL DR, 1985, JAMA-J AM MED ASSOC, V254, P1321, DOI 10.1001/jama.254.10.1321; ROGERS MC, 1987, TXB PEDIATRIC INTENS; Rudolph AM, 1987, PEDIATRICS; RUTHERFORD GW, 1984, HAZARD ANAL BASEBALL; SHOEMAKER WC, 1984, TXB CRITICAL CARE; TELLEZ DW, 1987, J PEDIATR SURG, V12, P1223; TENZER ML, 1985, J TRAUMA, V25, P620, DOI 10.1097/00005373-198507000-00008; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; WELCH KJ, 1986, PEDIATRIC SURGERY; ZUCKERMAN BS, 1985, PEDIATR CLIN N AM, V32, P17	40	46	46	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0002-922X			AM J DIS CHILD	Am. J. Dis. Child.	NOV	1991	145	11					1279	1282		10.1001/archpedi.1991.02160110071023			4	Pediatrics	Pediatrics	GN260	WOS:A1991GN26000021	1951221				2021-06-18	
J	VAKIL, E; BLACHSTEIN, H; HOOFIEN, D				VAKIL, E; BLACHSTEIN, H; HOOFIEN, D			AUTOMATIC TEMPORAL-ORDER JUDGMENT - THE EFFECT OF INTENTIONALITY OF RETRIEVAL ON CLOSED-HEAD-INJURED PATIENTS	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							INFORMATION; MEMORY	Closed-head-injured (CHI) and control groups were tested on a temporal order task under intentional and incidental retrieval conditions. Subjects were given five presentations of a list of nouns. In the incidental retrieval condition, subjects were told that they were to remember the words but that the order was not important. In the intentional retrieval condition, subjects were given the words in an order different from that in which they were originally presented and were asked to reorder the words to match the original order. For both conditions we compared the order in which words were recalled to the order in which they were originally presented. The results suggest that temporal order memory had more effortful characteristics in the intentional than in the incidental retrieval condition. The two groups did not differ significantly in the incidental retrieval condition. However, while the control group showed a significant improvement in the intentional retrieval condition, CHI groups performance did not significantly change. This study highlights two major points: (1) intentionality at the retrieval stage determines the effortfulness with which information is processed; (2) the more automatic the tasks, the better it is preserved following closed-head injury.	BAR ILAN UNIV,RAMAT GAN,ISRAEL	VAKIL, E (corresponding author), NATL INST REHAB BRAIN INJURED,RECANATI REHAB CTR,89 ITZHAK SADEH ST,IL-67228 TEL AVIV,ISRAEL.						HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; HUPPERT FA, 1976, CORTEX, V12, P3, DOI 10.1016/S0010-9452(76)80024-X; JANOWSKY JS, 1988, PSCYHOBIOLOGY, V17, P1; KOHL D, 1985, MEMORY DYSFUNCTION I, P460; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Meudell P, 1982, NORMALITY PATHOLOGY, P203; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; NAVEHBENJAMIN M, 1987, J EXP PSYCHOL LEARN, V13, P595, DOI 10.1037/0278-7393.13.4.595; PARKIN AJ, 1982, CORTEX, V18, P417, DOI 10.1016/S0010-9452(82)80040-3; TWEEDY JR, 1988, J CLIN EXP NEUROPSYC, V10, P664, DOI 10.1080/01688638808402803; TZENG OJL, 1979, J EXP PSYCHOL-HUM L, V5, P52, DOI 10.1037/0278-7393.5.1.52; VAKIL E, 1985, FEB INT NEUR SOC C S; VAKIL E, 1990, UNPUB TEMPORAL ORDER; WINOCUR G, 1978, NEUROPSYCHOLOGIA, V16, P671, DOI 10.1016/0028-3932(78)90002-7; ZACKS RT, 1984, MEM COGNITION, V12, P387, DOI 10.3758/BF03198299	16	46	46	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR	1991	13	2					291	298		10.1080/01688639108401044			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	FL580	WOS:A1991FL58000008	1864916				2021-06-18	
J	HIGH, WM; LEVIN, HS; GARY, HE				HIGH, WM; LEVIN, HS; GARY, HE			RECOVERY OF ORIENTATION FOLLOWING CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DIV NEUROSURG D73,GALVESTON,TX 77550; DEL ORO INST REHABIL,DEPT NEUROPSYCHOL,HOUSTON,TX; CTR DIS CONTROL,ATLANTA,GA 30333					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; BENSON DF, 1967, J NEUROL NEUROSUR PS, V30, P539, DOI 10.1136/jnnp.30.6.539; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; HETTMANSPERGER TP, 1984, STATISTICAL INFERENC; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1983, CORTEX, V19, P427, DOI 10.1016/S0010-9452(83)80025-2; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; NATELSON BH, 1979, ARCH NEUROL-CHICAGO, V36, P444, DOI 10.1001/archneur.1979.00500430074014; RIBOT T, 1885, DISEASES MEMORY; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1946, BRAIN, V69, P183; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SANDERS HI, 1971, BRAIN, V94, P661, DOI 10.1093/brain/94.4.661	17	46	46	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	1990	12	5					703	714		10.1080/01688639008401013			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EE600	WOS:A1990EE60000007	2258432				2021-06-18	
J	GOLDSTEIN, FC; LEVIN, HS; BOAKE, C; LOHREY, JH				GOLDSTEIN, FC; LEVIN, HS; BOAKE, C; LOHREY, JH			FACILITATION OF MEMORY PERFORMANCE THROUGH INDUCED SEMANTIC PROCESSING IN SURVIVORS OF SEVERE CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550; UNIV TEXAS,MED BRANCH,DEPT NEUROSURG,GALVESTON,TX 77550; DALLAS REHABIL INST,DEPT BEHAV MED,DALLAS,TX 75235; FT HAYS STATE UNIV,DEPT PSYCHOL,HAYS,KS 67601							BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bousfield WA, 1953, J GEN PSYCHOL, V49, P229, DOI 10.1080/00221309.1953.9710088; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Butters N, 1980, ALCOHOLIC KORSAKOFFS; CERMAK LS, 1974, BRAIN LANG, V1, P141, DOI 10.1016/0093-934X(74)90030-3; CERMAK LS, 1978, J EXP PSYCHOL-HUM L, V4, P165, DOI 10.1037/0278-7393.4.2.165; CERMAK LS, 1976, BRAIN LANG, V3, P375, DOI 10.1016/0093-934X(76)90033-X; CORKIN S, 1982, ALZHEIMERS DISEASE R, V19, P149; CRAIK FIM, 1975, J EXP PSYCHOL GEN, V104, P268, DOI 10.1037/0096-3445.104.3.268; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; CROVITZ HF, 1979, CORTEX, V15, P131, DOI 10.1016/S0010-9452(79)80013-1; CUSHMAN LA, 1988, J CLIN EXP NEUROPSYC, V10, P685, DOI 10.1080/01688638808402807; FREEDMAN M, 1986, BRAIN COGNITION, V5, P108, DOI 10.1016/0278-2626(86)90063-1; GIANUTSOS R, 1979, Journal of Clinical Neuropsychology, V1, P117, DOI 10.1080/01688637908414446; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; GOLDSTEIN FC, 1989, CORTEX, V25, P541, DOI 10.1016/S0010-9452(89)80016-4; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HARRIS JE, 1980, MEM COGNITION, V8, P31, DOI 10.3758/BF03197549; HASHER L, 1984, AM PSYCHOL, V39, P1372, DOI 10.1037/0003-066X.39.12.1372; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1988, BRAIN COGNITION, V7, P283, DOI 10.1016/0278-2626(88)90003-6; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; MCDOWALL J, 1981, NEUROPSYCHOLOGIA, V19, P43, DOI 10.1016/0028-3932(81)90042-7; MCDOWALL J, 1979, MEM COGNITION, V7, P232, DOI 10.3758/BF03197543; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; OCONNOR M, 1986, NEUROPSYCHOLOGICAL R, P260; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; RUBIN DC, 1981, NEUROPSYCHOLOGIA, V19, P137, DOI 10.1016/0028-3932(81)90053-1; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SALMON DP, 1986, NEUROPSYCHOLOGICAL R, P280; *SAS I INC, 1985, SAS STAT GUID PERS C; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; SQUIRE LR, 1982, J EXP PSYCHOL LEARN, V8, P560, DOI 10.1037/0278-7393.8.6.560; SQUIRE LR, 1986, BEHAV NEUROSCI, V100, P866, DOI 10.1037/0735-7044.100.6.866; TEASDALE G, 1974, LANCET, V2, P81; THORNDIKE EL, 1944, TEACHERS WORDBOOK 30; TULVING E, 1984, BEHAV BRAIN SCI, V7, P257, DOI 10.1017/S0140525X00044617; Tulving E, 1983, ELEMENTS EPISODIC ME; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; WILSON B, 1982, CORTEX, V18, P581, DOI 10.1016/S0010-9452(82)80055-5	50	46	46	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR	1990	12	2					286	300		10.1080/01688639008400975			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	DB328	WOS:A1990DB32800010	2341558				2021-06-18	
J	MEYER, JS; DENNYBROWN, D				MEYER, JS; DENNYBROWN, D			STUDIES OF CEREBRAL CIRCULATION IN BRAIN INJURY .2. CEREBRAL CONCUSSION	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article																BROWN GW, 1954, AMA ARCH NEUROL PSY, V71, P707, DOI 10.1001/archneurpsyc.1954.02320420035004; BROWN GW, 1951, 6737 AIR FORC TECH R; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Denny-Brown D., 1942, NEW ENGL J MED, V227, P771; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DENNYBROWN D, 1942, NEW ENGL J MED, V227, P813; DENNYBROWN D, 1950, YB PUBLICATIONS, V2, P127; DODGE PR, 1952, J NEUROSURG, V9, P472, DOI 10.3171/jns.1952.9.5.0472; GOLDRING S, 1951, J NEUROPHYSIOL, V14, P275; Groat RA, 1944, AM J PHYSIOL, V141, P0117; Jasper H, 1941, J NEUROPHYSIOL, V4, P333; KEMPINSKY WH, 1954, ELECTROENCEPHALOG CL, V6, P315; KNAUER A, 1922, J PSYCHOL NEUROL, V29, P1; KREMS A. D., 1942, PROC SOC EXP BIOL AND MED, V49, P73; LARSSON LE, 1954, ACTA PSYCHIAT SCAND, V95, P1; MERRITT HH, 1943, WAR MED, V4, P61; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; MEYER JS, 1954, AMA ARCH NEUROL PSY, V72, P296, DOI 10.1001/archneurpsyc.1954.02330030030003; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P511, DOI 10.1016/0013-4694(55)90077-8; MEYER JS, 1955, ARCH NEUROL PSYCHIAT; MEYER JS, 1955, UNPUB STUDIES CEREBR; POLIS A, 1894, REV CHIR, V14, P645; Polis A, 1894, REV CHIR, V14, P273; RUSSELL WR, 1945, BRAIN, V68, P79, DOI 10.1093/brain/68.2.79; SPIEGEL EA, 1946, AM J PHYSIOL, V146, P12; SPIEGEL EA, 1947, RES PUBL ASS RES NER, V26, P84; STONE WE, 1945, RES PUBL ASS NERV ME, V24, P226; Trotter W, 1924, LANCET, V1, P935; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WEIL A, 1945, RES PUBL ASS NERV ME, V24, P250; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	31	46	47	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.		1955	7	4					529	544		10.1016/0013-4694(55)90078-X			16	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	WR944	WOS:A1955WR94400002	13270685				2021-06-18	
J	Lu, YH; Zhou, Y; Zhang, RY; Wen, LL; Wu, KM; Li, YF; Yao, YB; Duan, RR; Jia, YJ				Lu, Yanhui; Zhou, Yan; Zhang, Ruiyi; Wen, Lulu; Wu, Kaimin; Li, Yanfei; Yao, Yaobing; Duan, Ranran; Jia, Yanjie			Bone Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Recovery Following Spinal Cord Injury via Improvement of the Integrity of the Blood-Spinal Cord Barrier	FRONTIERS IN NEUROSCIENCE			English	Article						extracellular vesicles; bone mesenchymal stromal cells; spinal cord injury; blood spinal cord barrier; pericytes; migration; NF-kappa B	STROMAL CELLS; FUNCTIONAL RECOVERY; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; CONTRIBUTES; PERICYTES; EXOSOMES; MSC	Mesenchymal stem cell (MSC) transplantation has been shown to represent a potential treatment for traumatic spinal cord injury (SCI). However, there are several obstacles that need to be overcome before MSCs can be considered for clinical application, such as failure of MSCs to reach the spinal cord lesion core and possible tumor formation. Recent studies have suggested that MSC treatment is beneficial owing to paracrine-secreted factors. Extracellular vesicles are considered to be some of the most valuable paracrine molecules. However, the therapeutic mechanism of extracellular vesicles on spinal cord injury has not been studied clearly. Therefore, our study investigated the effect of systemic administration of extracellular vesicles on the loss of motor function after SCI and examined the potential mechanisms underlying their effects. Disruption of the blood-spinal cord barrier (BSCB) is a crucial factor that can be detrimental to motor function recovery. Pericytes are an important component of the neurovascular unit, and play a pivotal role in maintaining the structural integrity of the BSCB. Our study demonstrated that administration of bone mesenchymal stem cell-derived extracellular vesicles (BMSC-EV) reduced brain cell death, enhanced neuronal survival and regeneration, and improved motor function compared with the administration of BMSC-EV free culture media (EV-free CM). Besides, the BSCB was attenuated and pericyte coverage was significantly decreased in vivo. Furthermore, we found that exosomes reduced pericyte migration via downregulation of NF-kappa B p65 signaling, with a consequent decrease in the permeability of the BSCB. In summary, we identified that extracellular vesicles treatment suppressed the migration of pericytes and further improved the integrity of the BSCB via NF-kappa B p65 signaling in pericytes. Our data suggest that extracellular vesicles may serve as a promising treatment strategy for SCI.	[Lu, Yanhui; Zhang, Ruiyi; Wen, Lulu; Wu, Kaimin; Li, Yanfei; Yao, Yaobing; Duan, Ranran; Jia, Yanjie] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Henan, Peoples R China; [Lu, Yanhui; Zhang, Ruiyi] Zhengzhou Univ, Acad Med Sci, Zhengzhou, Henan, Peoples R China; [Zhou, Yan] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiol, Zhengzhou, Henan, Peoples R China	Jia, YJ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Henan, Peoples R China.	jiayanjie1971@zzu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [U1604170]	This study was supported by National Natural Science Foundation of China (U1604170).	Bartanusz V, 2011, ANN NEUROL, V70, P194, DOI 10.1002/ana.22421; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008; Cheng JP, 2018, ACTA NEUROPATHOL, V136, P507, DOI 10.1007/s00401-018-1893-0; Cizkova D, 2011, J NEUROTRAUM, V28, P1951, DOI 10.1089/neu.2010.1413; Eckert MJ, 2017, SURG CLIN N AM, V97, P1031, DOI 10.1016/j.suc.2017.06.008; Figley SA, 2014, J NEUROTRAUM, V31, P541, DOI 10.1089/neu.2013.3034; Goodarzi P, 2018, ADV EXP MED BIOL, V1119, P119, DOI 10.1007/5584_2018_251; He QW, 2013, MOL NEUROBIOL, V47, P976, DOI 10.1007/s12035-013-8396-8; He ZL, 2017, AM J TRANSL RES, V9, P1012; Jo DH, 2013, MOL CELLS, V36, P465, DOI 10.1007/s10059-013-0228-1; Juan T, 2018, SEMIN CELL DEV BIOL, V74, P66, DOI 10.1016/j.semcdb.2017.08.022; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kjell J, 2016, DIS MODEL MECH, V9, P1125, DOI 10.1242/dmm.025833; Li D, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00845; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Marote A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00231; Pfister F, 2008, DIABETES, V57, pA234, DOI 10.2337/db08-0325; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Rahimifard M, 2017, AGEING RES REV, V36, P11, DOI 10.1016/j.arr.2017.02.004; Ratajczak MZ, 2014, POL ARCH MED WEWN, V124, P417, DOI 10.20452/pamw.2355; Ren K, 2019, ODONTOLOGY, V107, P271, DOI 10.1007/s10266-018-0395-9; Schwab ME, 2004, CURR OPIN NEUROBIOL, V14, P118, DOI 10.1016/j.conb.2004.01.004; Shende P, 2017, BIOMED PHARMACOTHER, V91, P693, DOI 10.1016/j.biopha.2017.04.126; Shostak K, 2015, TRENDS MOL MED, V21, P385, DOI 10.1016/j.molmed.2015.04.001; Sun F, 2011, NATURE, V480, P372, DOI 10.1038/nature10594; Sweeney MD, 2016, NAT NEUROSCI, V19, P771, DOI 10.1038/nn.4288; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Venkatesh K, 2017, CURR STEM CELL RES T, V12, P326, DOI 10.2174/1574888X12666161114122059; Wan Y, 2018, FASEB J, V32, P3133, DOI 10.1096/fj.201701121R; Wang Y, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4971261; Winkler EA, 2013, ACTA NEUROPATHOL, V125, P111, DOI 10.1007/s00401-012-1039-8; Xu PF, 2019, CELL TRANSPLANT, V28, P36, DOI 10.1177/0963689718808471; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Zagrean AM, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00811; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhou HJ, 2016, EXP CELL RES, V349, P60, DOI 10.1016/j.yexcr.2016.09.020	42	45	47	4	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-453X		FRONT NEUROSCI-SWITZ	Front. Neurosci.	MAR 12	2019	13								209	10.3389/fnins.2019.00209			12	Neurosciences	Neurosciences & Neurology	HO7FK	WOS:000461102300001	30914918	DOAJ Gold, Green Published	Y	N	2021-06-18	
J	Xian, PP; Hei, Y; Wang, R; Wang, T; Yang, JL; Li, JY; Di, ZL; Liu, ZQ; Baskys, A; Liu, WP; Wu, SX; Long, QF				Xian, Panpan; Hei, Yue; Wang, Rui; Wang, Tian; Yang, Junle; Li, Jianying; Di, Zhengli; Liu, Zhiqin; Baskys, Andrius; Liu, Weiping; Wu, Shengxi; Long, Qianfa			Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice	THERANOSTICS			English	Article						MSC-Exo; astrocyte alterations; calcium signaling; Nrf2-NF-kappa B signaling; Nanotherapy	BONE-MARROW; ACTIVATION; NEUROINFLAMMATION; PATHWAY; STIMULATION; INHIBITION; PLASTICITY; IL-1-BETA; SYSTEM; MSCS	Mesenchymal stem cell-derived exosomes (MSC-Exo) have robust anti-inflammatory effects in the treatment of neurological diseases such as epilepsy, stroke, or traumatic brain injury. While astrocytes are thought to be mediators of these effects, their precise role remains poorly understood. To address this issue, we investigated the putative therapeutic effects and mechanism of MSC-Exo on inflammation-induced alterations in astrocytes. Methods: Lipopolysaccharide (LPS)-stimulated hippocampal astrocytes in primary culture were treated with MSC-Exo, which were also administered in pilocarpine-induced status epilepticus (SE) mice. Exosomal integration, reactive astrogliosis, inflammatory responses, calcium signaling, and mitochondrial membrane potentials (MMP) were monitored. To experimentally probe the molecular mechanism of MSC-Exo actions on the inflammation-induced astrocytic activation, we inhibited the nuclear factor erythroid-derived 2, like 2 (Nrf2, a key mediator in neuroinflammation and oxidative stress) by sgRNA (in vitro) or ML385 (Nrf2 inhibitor) in vivo. Results: MSC-Exo were incorporated into hippocampal astrocytes as well as attenuated reactive astrogliosis and inflammatory responses in vitro and in vivo. Also, MSC-Exo ameliorated LPS-induced aberrant calcium signaling and mitochondrial dysfunction in culture, and SE-induced learning and memory impairments in mice. Furthermore, the putative therapeutic effects of MSC-Exo on inflammation-induced astrocytic activation (e.g., reduced reactive astrogliosis, NF-kappa B deactivation) were weakened by Nrf2 inhibition. Conclusions: Our results show that MSC-Exo ameliorate inflammation-induced astrocyte alterations and that the Nrf2-NF-kappa B signaling pathway is involved in regulating astrocyte activation in mice. These data suggest the promising potential of MSC-Exo as a nanotherapeutic agent for the treatment of neurological diseases with hippocampal astrocyte alterations.	[Xian, Panpan; Wang, Tian; Baskys, Andrius; Long, Qianfa] Xian Cent Hosp, Miniinvas Neurosurg & Translat Med Ctr, 161,West 5th Rd, Xian 710003, Shaanxi, Peoples R China; [Hei, Yue; Yang, Junle; Li, Jianying; Liu, Weiping] Fourth Mil Med Univ, Xijing Hosp, Dept Neurosurg, 17 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Wang, Rui; Wu, Shengxi] Fourth Mil Med Univ, Sch Basic Med, Dept Neurobiol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China; [Di, Zhengli; Liu, Zhiqin] Xian Cent Hosp, Dept Neurol, 161,West 5th Rd, Xian 710003, Shaanxi, Peoples R China; [Baskys, Andrius] Western Univ Hlth Sci, Grad Coll Biomed Sci, Pomona, CA 91766 USA	Long, QF (corresponding author), Xian Cent Hosp, Miniinvas Neurosurg & Translat Med Ctr, 161,West 5th Rd, Xian 710003, Shaanxi, Peoples R China.; Wu, SX (corresponding author), Fourth Mil Med Univ, Sch Basic Med, Dept Neurobiol, 169 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.	shengxi@fmmu.edu.cn; lonva@live.cn	; Long, Qianfa/F-6461-2017	Zhiqin, Liu/0000-0003-2328-4897; Long, Qianfa/0000-0001-8848-9688	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81871084]; key R&D Projects of Shaanxi Province [2018ZDXM-SF-046]; Major Projects of Xi'an Medical Research [201805104YX12SF38(1)]; Xi'an Science and Technology Project [2017115SF/YX009]	This work was supported by grants from National Natural Science Foundation of China (81871084), key R&D Projects of Shaanxi Province (2018ZDXM-SF-046), Major Projects of Xi'an Medical Research (201805104YX12SF38(1)) and Xi'an Science and Technology Project (2017115SF/YX009). We also thank Dr. Iqbal Ali for her English language editing services.	[Anonymous], 2011, GUIDE CARE USE LAB A, DOI [10.17226/12910, DOI 10.17226/12910]; Arena A, 2019, BRAIN PATHOL, V29, P351, DOI 10.1111/bpa.12661; Bebensee DF, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3064016; Cayce JM, 2014, CELL CALCIUM, V55, P183, DOI 10.1016/j.ceca.2014.01.004; Cheli VT, 2016, GLIA, V64, P1396, DOI 10.1002/glia.23013; Chen JK, 2017, EUR J PHARMACOL, V806, P1, DOI 10.1016/j.ejphar.2017.03.025; Choi JH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01444; Dendrou CA, 2016, NAT REV NEUROL, V12, P685, DOI 10.1038/nrneurol.2016.171; Devinsky O, 2013, TRENDS NEUROSCI, V36, P174, DOI 10.1016/j.tins.2012.11.008; Dominguez-Prieto MD, 2018, J ALZHEIMERS DIS, V65, P1109, DOI 10.3233/JAD-180332; Draheim T, 2016, GLIA, V64, P2219, DOI 10.1002/glia.23058; Drommelschmidt K, 2017, BRAIN BEHAV IMMUN, V60, P220, DOI 10.1016/j.bbi.2016.11.011; EL Andaloussi S, 2013, NAT REV DRUG DISCOV, V12, P348, DOI 10.1038/nrd3978; Friedman A, 2011, EPILEPSIA, V52, P33, DOI 10.1111/j.1528-1167.2011.03034.x; Garbers C, 2012, CYTOKINE GROWTH F R, V23, P85, DOI 10.1016/j.cytogfr.2012.04.001; Gerard F, 2012, BRAIN RES, V1473, P1, DOI 10.1016/j.brainres.2012.07.032; Haskew-Layton RE, 2010, P NATL ACAD SCI USA, V107, P17385, DOI 10.1073/pnas.1003996107; Hennessy E, 2015, J NEUROSCI, V35, P8411, DOI 10.1523/JNEUROSCI.2745-14.2015; Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6; Hung CC, 2016, J NEUROSCI, V36, P2027, DOI 10.1523/JNEUROSCI.3457-15.2016; Kelic S, 2001, MOL CELL NEUROSCI, V17, P551, DOI 10.1006/mcne.2000.0955; Kornilov R, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2017.1422674; Lai RC, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.29828; Levy S, 2014, IMMUNOL RES, V58, P179, DOI 10.1007/s12026-014-8490-7; Li YX, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1278-2; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Liu J, 2018, AUTOPHAGY, V14, P845, DOI 10.1080/15548627.2017.1390636; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Long Q, 2015, NEUROSCIENCE, V311, P464, DOI 10.1016/j.neuroscience.2015.10.055; Long QF, 2017, AGING DIS, V8, P301, DOI 10.14336/AD.2016.1018; Long Q, 2017, P NATL ACAD SCI USA, V114, pE3536, DOI 10.1073/pnas.1703920114; Lu XF, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-46; Muller MS, 2014, GLIA, V62, P526, DOI 10.1002/glia.22623; Mustaly-Kalimi S, 2018, ANTIOXID REDOX SIGN, V29, P1158, DOI 10.1089/ars.2017.7266; Narayanan SV, 2018, TRANSL STROKE RES, V9, P99, DOI 10.1007/s12975-017-0574-y; Nikolic L, 2018, GLIA, V66, P2673, DOI 10.1002/glia.23519; Niquet J, 2016, EPILEPSIA, V57, P1406, DOI 10.1111/epi.13480; Niranjan R, 2014, MOL NEUROBIOL, V49, P28, DOI 10.1007/s12035-013-8483-x; Ouali Alami N, 2018, EMBO J, V37, DOI 10.15252/embj.201798697; Pacheco SM, 2018, CELL MOL NEUROBIOL, V38, P1107, DOI 10.1007/s10571-018-0581-x; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Patel H, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0967-6; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Roberts-Dalton HD, 2017, NANOSCALE, V9, P13693, DOI 10.1039/c7nr04128d; Shang FQ, 2017, THERANOSTICS, V7, P4370, DOI 10.7150/thno.19888; Shanmugam G, 2017, REDOX BIOL, V12, P937, DOI 10.1016/j.redox.2017.04.038; Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581-018-0023-5; Si YL, 2011, AGEING RES REV, V10, P93, DOI 10.1016/j.arr.2010.08.005; Sivandzade F, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.017; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Tian GF, 2005, NAT MED, V11, P973, DOI 10.1038/nm1277; Tjalkens Ronald B, 2017, Adv Neurobiol, V18, P159, DOI 10.1007/978-3-319-60189-2_8; Vargas-Sanchez Karina, 2018, Oncotarget, V9, P26954, DOI 10.18632/oncotarget.25485; Verkhratsky A, 2016, PROG NEUROBIOL, V144, P188, DOI 10.1016/j.pneurobio.2015.09.003; Wang L, 2018, CELL PHYSIOL BIOCHEM, V50, P1535, DOI 10.1159/000494652; Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002; Wegierski T, 2018, CELL CALCIUM, V74, P102, DOI 10.1016/j.ceca.2018.07.001; Xie XT, 2012, BIOMATERIALS, V33, P7008, DOI 10.1016/j.biomaterials.2012.06.058; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Yang Y, 2019, REDOX BIOL, V20, P157, DOI 10.1016/j.redox.2018.09.019; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yun SP, 2018, NAT MED, V24, P931, DOI 10.1038/s41591-018-0051-5	66	45	46	5	16	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1838-7640			THERANOSTICS	Theranostics		2019	9	20					5956	5975		10.7150/thno.33872			20	Medicine, Research & Experimental	Research & Experimental Medicine	IR7DP	WOS:000481601200017	31534531	DOAJ Gold, Green Published	Y	N	2021-06-18	
J	Webber, TA; Soble, JR				Webber, Troy A.; Soble, Jason R.			Utility of various WAIS-IV Digit Span indices for identifying noncredible performance validity among cognitively impaired and unimpaired examinees	CLINICAL NEUROPSYCHOLOGIST			English	Article						Assessment; malingering/symptom validity testing; elderly/geriatrics/aging	MEMORY MALINGERING TOMM; ADULT INTELLIGENCE SCALE; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; INSUFFICIENT EFFORT; SCREENING MEASURE; AMERICAN-ACADEMY; EDITION; TESTS; SPECIFICITY	Objective: Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV) Reliable Digit Span (RDS), RDS-revised (RDS-R), and age-corrected scaled score (ACSS) are validated and commonly used embedded performance validity tests (PVTs), though existing validation studies have largely examined younger (approximate ages 19-35) patients with mild traumatic brain injury or those without cognitive impairment. This study compared the classification accuracy of RDS, RDS-R, and ACSS in a mixed clinical sample of relatively older (M age=54.61) veterans with and without neurocognitive impairment. Method: During a comprehensive neuropsychological evaluation, 113 clinically-referred veterans completed the WAIS-IV Digit Span subtest and the following criterion PVTs: Dot Counting Test, Word Choice Test, and Test of Memory Malingering. Those with <= 1 criterion PVT failure were classified as valid (n=87), whereas those with >= 2 failures were classified as noncredible (n=26). Among valid participants, 49% were cognitively impaired. Results: RDS, RDS-R, and ACSS all significantly predicted validity group membership with respective areas under the curve (AUCs) of .79, .81, and .85, and optimal cut scores of RDS <= 5, RDS-R <= 9, and ACSS <= 5. Lower accuracy and AUCs were observed for the valid-cognitively impaired subsample across indices, but to a greater degree for traditional RDS. ACSS evidenced maximal sensitivity/specificity for the total sample (<= 5; .62/.87), cognitively unimpaired subsample (<= 5; .62/.95), and cognitively impaired subsample (<= 4; .39/.86). Conclusions: ACSS yielded better classification accuracy and sensitivity/specificity than RDS and RDS-R. While all three indices have utility as embedded PVTs, ACSS <= 5 may be most robust to cognitive impairment while identifying noncredible performance.	[Webber, Troy A.; Soble, Jason R.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA; [Soble, Jason R.] Univ Illinois, Dept Psychiat, Coll Med, Chicago, IL 60612 USA; [Soble, Jason R.] Univ Illinois, Coll Med, Dept Neurol, Chicago, IL USA	Webber, TA (corresponding author), South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX 78229 USA.	Troy.Webber@va.gov					American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Bain KM, 2019, ASSESSMENT, V26, P1320, DOI 10.1177/1073191117725172; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Boone, 2007, ASSESSMENT FEIGNED C; Boone K., 2002, DOT COUNTING TEST; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Denning J., 2012, ARCH CLIN NEUROPSYCH, V27, P576; Dorociak KE, 2018, CLIN NEUROPSYCHOL, V32, P81, DOI 10.1080/13854046.2017.1339830; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hilsabeck RC, 2011, CLIN NEUROPSYCHOL, V25, P1228, DOI 10.1080/13854046.2011.589409; Jasinski LJ, 2011, J CLIN EXP NEUROPSYC, V33, P300, DOI 10.1080/13803395.2010.516743; Kiewel NA, 2012, CLIN NEUROPSYCHOL, V26, P965, DOI 10.1080/13854046.2012.694478; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Loring DW, 2016, ARCH CLIN NEUROPSYCH, V31, P313, DOI 10.1093/arclin/acw014; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Pearson, 2009, ADV CLIN SOL WAIS 4; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Roman GC, 2002, LANCET NEUROL, V1, P426, DOI 10.1016/S1474-4422(02)00190-4; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schutte C., 2013, MILD TRAUMATIC BRAIN; Spencer RJ, 2017, BRAIN INJURY, V31, P32, DOI 10.1080/02699052.2016.1218546; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Suhr J.A., 2007, ASSESSMENT MALINGERE; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D, 2008, WAIS 4 ADM SCORING M; Wechsler D., 1997, WAIS 3 ADM SCORING M; Whitney KA, 2013, APPL NEUROPSYCH-ADUL, V20, P83, DOI 10.1080/09084282.2012.670167; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Zenisek R, 2016, ARCH CLIN NEUROPSYCH, V31, P426, DOI 10.1093/arclin/acw025	44	45	45	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2018	32	4					657	670		10.1080/13854046.2017.1415374			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	GD3XQ	WOS:000430437500002	29256334				2021-06-18	
J	Shen, M; Wang, S; Wen, X; Han, XR; Wang, YJ; Zhou, XM; Zhang, MH; Wu, DM; Lu, J; Zheng, YL				Shen, Min; Wang, Shan; Wen, Xin; Han, Xin-Rui; Wang, Yong-Jian; Zhou, Xiu-Min; Zhang, Man-He; Wu, Dong-Mei; Lu, Jun; Zheng, Yuan-Lin			Dexmedetomidine exerts neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with traumatic brain injury	BIOMEDICINE & PHARMACOTHERAPY			English	Article						Dexmedetomidine; PI3K/Akt/mTOR signaling pathway; Traumatic brain injury; Neuroprotective effect; Autophagy	INDUCED CELL-DEATH; ISCHEMIA-REPERFUSION; TIGHT JUNCTION; AUTOPHAGY; INHIBITION; CONTRIBUTES; DEFICITS; PROTEIN	Objective: : This study aims to explore the neuroprotective effects of dexmedetomidine (Dex) in rats suffering from traumatic brain injury (TBI) via the PI3K/Akt/mTOR signaling pathway. Methods: A weight drop model was performed for TBI model establishment. A total of 150 Sprague Dawley rats were selected and assigned into control, sham, TBI, TBI + Dex, TBI + LY294002 (LY) and TBI + Dex + LY groups. Modified Neurological Severity Score (mNSS) was conducted in order to evaluate the neurological injury. The water content in brain tissues was measured. The expressions of PI3K/Akt/mTOR signaling pathway-related proteins, tight junction proteins (ZO-1 and Claudin-5) and autophagy proteins (LC3 I/II and Beclin-1) were detected using Western blot assay. A TUNEL assay was applied for cell apoptosis, immunofluorescence was employed for the detection of the positive expression of LC3, and ELISA was applied for detection of levels of inflammatory factors [tumor necrosis factor-alph (TNF-a), interleukin-1 beta (IL-1 beta), interferon-gamma (INF-gamma) as well as IL-6], respectively. Results: Compared with the control group, the other four groups exhibited increased mNSS, brain water content, expression of LC3, TNF-a, IL-1 beta, INF-gamma and IL-6, and positive expression of LC3, expression of LC3 I/II and Beclin-1, but decreased expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5. Compared with the TBI group, the TBI + Dex group exhibited reduced mNSS, brain water content, expression of LC3, TNF-a, IL-1 beta, INF-gamma and IL-6, positive expression of LC3, as well as expression of LC3 I/II and Beclin-1 but demonstrated an elevated expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5, while opposite trends were observed in the TBI + LY group. The TBI + Dex group exhibited reduced mNSS, brain water content, expression of LC3, TNF-a, IL-1 beta, INF-gamma and IL-6, positive expression of LC3, as well as expression of LC3 I/II and Beclin-1 but demonstrated an elevated expression of pp-PI3K/t-PI3K, p-Akt/t-Akt, p-mTOR/t-mTOR, ZO-1 and Claudin-5, while opposite trends were observed in the TBI + LY group, as compared with the TBI + Dex + LY group. Conclusion: The data shows that Dex exerts a neuroprotective effect via the activation of the PI3K/Akt/mTOR signaling pathway in rats with TBI.	[Shen, Min; Wang, Shan; Wen, Xin; Han, Xin-Rui; Wang, Yong-Jian; Wu, Dong-Mei; Lu, Jun; Zheng, Yuan-Lin] Jiangsu Normal Univ, Sch Life Sci, Key Lab Biotechnol Med Plants Jiangsu Prov, Xuzhou 221116, Peoples R China; [Zhou, Xiu-Min; Zhang, Man-He] Tangshan Gongren Hosp, Dept Anesthesiol, Tangshan 063000, Peoples R China	Wu, DM; Lu, J; Zheng, YL (corresponding author), Jiangsu Normal Univ, Sch Life Sci, Key Lab Biotechnol Med Plants Jiangsu Prov, Xuzhou 221116, Peoples R China.	wdm8610@jsnu.edu.cn; lu-jun75@163.com; ylzheng@jsnu.edu.cn	Lu, Jun/N-6109-2019	Lu, Jun/0000-0002-2801-5330	Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); "333 Project" Award of Jiangsu Province; "Qinglan Project" of the Young and Middle-aged Academic Leader of Jiangsu College and University; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571055, 81400902, 81271225, 31201039, 81171012, 30950031]; Major Fundamental Research Program of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China [13KJA180001]; Cultivate National Science Fund for Distinguished Young Scholars of Jiangsu Normal University; Graduate Student Innovation Program of Jiangsu Province [KYCX17_1625]	This work was supported by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); the 2016 "333 Project" Award of Jiangsu Province, the 2013 "Qinglan Project" of the Young and Middle-aged Academic Leader of Jiangsu College and University, the National Natural Science Foundation of China (81571055, 81400902, 81271225, 31201039, 81171012, and 30950031), the Major Fundamental Research Program of the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (13KJA180001), and grants from the Cultivate National Science Fund for Distinguished Young Scholars of Jiangsu Normal University and the Graduate Student Innovation Program of Jiangsu Province (KYCX17_1625). We would like to give our sincere appreciation to the reviewers for their helpful comments on this article.	Beziaud T, 2011, CRIT CARE MED, V39, P2300, DOI 10.1097/CCM.0b013e3182227e4a; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chen A, 2013, MOL MED REP, V8, P1011, DOI 10.3892/mmr.2013.1628; Chen HW, 2011, J NAT PROD, V74, P2408, DOI 10.1021/np200631v; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Farag E, 2012, CURR PHARM DESIGN, V18, P6257, DOI 10.2174/138161212803832272; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Hue CD, 2015, J CEREBR BLOOD F MET, V35, P1191, DOI 10.1038/jcbfm.2015.38; Kitagishi Y, 2013, ALZHEIMERS RES THER, V5, DOI [10.1186/1758-9193-5-42, 10.1186/alzrt208]; Li X, 2017, J OCCUP HEALTH, V59, P8, DOI 10.1539/joh.16-0089-OA; Li Y, 2016, POWER SYST, P1, DOI 10.1007/978-3-662-48627-6; Li YG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111707; Liu HQ, 2012, BRAIN RES BULL, V89, P65, DOI 10.1016/j.brainresbull.2012.06.010; Lou HY, 2011, BIOORGAN MED CHEM, V19, P4021, DOI 10.1016/j.bmc.2011.05.021; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Orlans FB, 1997, ETHICS BEHAV, V7, P163, DOI 10.1207/s15327019eb0702_7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; Schoeler M, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-20; Skovira JW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0769-2; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Sun LQ, 2014, MOL MED REP, V9, P77, DOI 10.3892/mmr.2013.1787; Wang JK, 2010, BRAIN RES, V1357, P142, DOI 10.1016/j.brainres.2010.08.009; Weigl W, 2016, J CEREBR BLOOD F MET, V36, P1825, DOI 10.1177/0271678X16667953; Wen JF, 2014, EXP THER MED, V8, P881, DOI 10.3892/etm.2014.1818; Wu YT, 2009, AUTOPHAGY, V5, P824, DOI 10.4161/auto.9099; Xie Chunyan, 2015, Zhonghua Jie He He Hu Xi Za Zhi, V38, P761; Xue JF, 2017, BIOMED PHARMACOTHER, V89, P1252, DOI 10.1016/j.biopha.2017.01.130; Yu CS, 2016, ASIAN AUSTRAL J ANIM, V29, P731, DOI 10.5713/ajas.15.0415; Zeng XZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151620; Zhang XY, 2012, ANESTHESIOLOGY, V116, P1035, DOI 10.1097/ALN.0b013e3182503964; Zhang YL, 2017, J NEUROSURG, V126, P782, DOI 10.3171/2016.3.JNS152699; Zhao SF, 2012, NEUROL RES, V34, P400, DOI 10.1179/1743132812Y.0000000025; Zhua YM, 2013, BRAIN RES, V1494, P1, DOI 10.1016/j.brainres.2012.11.047	37	45	48	2	11	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0753-3322	1950-6007		BIOMED PHARMACOTHER	Biomed. Pharmacother.	NOV	2017	95						885	893		10.1016/j.biopha.2017.08.125			9	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	FP6OC	WOS:000417744400102	28903184				2021-06-18	
J	Yoo, D; Magsam, AW; Kelly, AM; Stayton, PS; Kievit, FM; Convertine, AJ				Yoo, Dasom; Magsam, Alexander W.; Kelly, Abby M.; Stayton, Patrick S.; Kievit, Forrest M.; Convertine, Anthony J.			Core-Cross-Linked Nanoparticles Reduce Neuroinflammation and Improve Outcome in a Mouse Model of Traumatic Brain Injury	ACS NANO			English	Article						polysorbate 80; antioxidant; controlled cortical impact; gliosis; hippocampus; startle habituation	CONTROLLED CORTICAL IMPACT; SUPEROXIDE-DISMUTASE; PATTERN SEPARATION; DENTATE GYRUS; THIOL; DELIVERY; MEMORY; MICE; NEURODEGENERATION; INHIBITION	Traumatic brain injury (TBI) is the leading cause of death and disability in children and young adults, yet there are currently no treatments available that prevent the secondary spread of damage beyond the initial insult. The chronic progression of this secondary injury is in part caused by the release of reactive oxygen species (ROS) into surrounding normal brain. Thus, treatments that can enter the brain and reduce the spread of ROS should improve outcome from TBI. Here a highly versatile, reproducible, and scalable method to synthesize core-cross-linked nanoparticles (NPs) from polysorbate 80 (PS80) using a combination of thiol-ene and thiol-Michael chemistry is described. The resultant NPs consist of a ROS-reactive thioether cross-linked core stabilized in aqueous solution by hydroxy-functional oligoethylene oxide segments. These NPs show narrow molecular weight distributions and have a high proportion of thioether units that reduce local levels of ROS. In a controlled cortical impact mouse model of TBI, the NPs are able to rapidly accumulate and be retained in damaged brain as visualized through fluorescence imaging, reduce neuroinflammation and the secondary spread of injury as determined through magnetic resonance imaging and histopathology, and improve functional outcome as determined through behavioral analyses. Our findings provide strong evidence that these NPs may, upon further development and testing, provide a useful strategy to help improve the outcome of patients following a TBI.	[Yoo, Dasom; Kelly, Abby M.; Stayton, Patrick S.; Convertine, Anthony J.] Mol Engn & Sci Inst, Dept Bioengn, Box 355061, Seattle, WA 98195 USA; [Magsam, Alexander W.; Kievit, Forrest M.] Univ Nebraska, Dept Biol Syst Engn, Lincoln, NE 68583 USA	Convertine, AJ (corresponding author), Mol Engn & Sci Inst, Dept Bioengn, Box 355061, Seattle, WA 98195 USA.; Kievit, FM (corresponding author), Univ Nebraska, Dept Biol Syst Engn, Lincoln, NE 68583 USA.	fkievit2@unl.edu; aconv@uw.edu	Stayton, Patrick/C-1975-2018; Kelly, Abby/E-5986-2016	Stayton, Patrick/0000-0001-6939-6371; Kievit, Forrest/0000-0002-9847-783X; Kelly, Abby/0000-0001-7202-3701	National Institute of General Medical Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104320]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM103480]; Nebraska Settlement Biomedical Research Development Funds	We acknowledge the Biomedical and Obesity Research Core facility supported by a grant (P20GM104320) from the National Institute of General Medical Sciences, National Institutes of Health, for use of the iBox small-animal imaging system, startle response system, and Rotor-Rod. We also thank D. Yates for use of his microscope. We thank A. Manske, B. Murphy, and C. Gee for assistance with animal procedures. F.K. acknowledges support from an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (P20GM103480) and the Nebraska Settlement Biomedical Research Development Funds.	Astete CE, 2011, ACS NANO, V5, P9313, DOI 10.1021/nn102845t; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Bast T, 2003, PROG NEUROBIOL, V70, P319, DOI 10.1016/S0301-0082(03)00112-6; Bharadwaj VN, 2016, SCI REP-UK, V6, DOI 10.1038/srep29988; Bird CM, 2008, NAT REV NEUROSCI, V9, P182, DOI 10.1038/nrn2335; Bitner BR, 2012, ACS NANO, V6, P8007, DOI 10.1021/nn302615f; BORCHARD G, 1994, INT J PHARMACEUT, V110, P29, DOI 10.1016/0378-5173(94)90372-7; Boyd BJ, 2015, J DRUG TARGET, V23, P847, DOI 10.3109/1061186X.2015.1034280; Carlson S, 1998, J NEUROPHYSIOL, V79, P2603; Chan JW, 2010, MACROMOLECULES, V43, P6381, DOI 10.1021/ma101069c; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clond MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061819; Cruz LJ, 2016, J CONTROL RELEASE, V223, P31, DOI 10.1016/j.jconrel.2015.12.029; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Girgis F, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00008; Goff HD, 1997, INT DAIRY J, V7, P363, DOI 10.1016/S0958-6946(97)00040-X; Gulyaev AE, 1999, PHARM RES-DORDR, V16, P1564, DOI 10.1023/A:1018983904537; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hayashi K, 2010, CHEM MATER, V22, P3768, DOI 10.1021/cm100810g; Hiemstra C, 2007, BIOMACROMOLECULES, V8, P1548, DOI 10.1021/bm061191m; Hoyle CE, 2004, J POLYM SCI POL CHEM, V42, P5301, DOI 10.1002/pola.20366; Hoyle CE, 2010, CHEM SOC REV, V39, P1355, DOI 10.1039/b901979k; Hoyle CE, 2010, ANGEW CHEM INT EDIT, V49, P1540, DOI 10.1002/anie.200903924; Huynh VT, 2011, BIOMACROMOLECULES, V12, P1738, DOI 10.1021/bm200135e; Impellizzeri D, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00458; KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J; Kwon EJ, 2016, ACS NANO, V10, P7926, DOI 10.1021/acsnano.6b03858; Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801; Lowe AB, 2010, POLYM CHEM-UK, V1, P17, DOI 10.1039/b9py00216b; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263; Nair DP, 2014, CHEM MATER, V26, P724, DOI 10.1021/cm402180t; Napoli A, 2004, NAT MATER, V3, P183, DOI 10.1038/nmat1081; OSWALD AA, 1966, J ORG CHEM, V31, P830, DOI 10.1021/jo01341a044; Pang KCH, 2015, J NEUROTRAUM, V32, P801, DOI 10.1089/neu.2014.3451; Qiu B, 2003, BIOMATERIALS, V24, P11, DOI 10.1016/S0142-9612(02)00227-2; Rebola N, 2017, NAT REV NEUROSCI, V18, P209, DOI 10.1038/nrn.2017.10; Reddy MK, 2008, APPL BIOCHEM BIOTECH, V151, P565, DOI 10.1007/s12010-008-8232-1; Reddy MK, 2009, FASEB J, V23, P1384, DOI 10.1096/fj.08-116947; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Singer P, 2013, BEHAV BRAIN RES, V242, P166, DOI 10.1016/j.bbr.2012.12.011; Singhal A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.362; Spizzirri UG, 2009, BIOMACROMOLECULES, V10, P1923, DOI 10.1021/bm900325t; Syrett JA, 2011, CHEM COMMUN, V47, P1449, DOI 10.1039/c0cc04532b; Wan AJ, 2013, J AGR FOOD CHEM, V61, P6921, DOI 10.1021/jf402242e; Xu JL, 2016, ADV FUNCT MATER, V26, P4124, DOI 10.1002/adfm.201504416	50	45	45	1	32	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	SEP	2017	11	9					8600	8611		10.1021/acsnano.7b03426			12	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	FI4CV	WOS:000411918200007	28783305				2021-06-18	
J	Cortes, N; Lincoln, AE; Myer, GD; Hepburn, L; Higgins, M; Putukian, M; Caswell, SV				Cortes, Nelson; Lincoln, Andrew E.; Myer, Gregory D.; Hepburn, Lisa; Higgins, Michael; Putukian, Margot; Caswell, Shane V.			Video Analysis Verification of Head Impact Events Measured by Wearable Sensors	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						head injury/concussion; wearable sensor; accelerometer; methodology	HIGH-SCHOOL FOOTBALL; ACCELERATION MEASUREMENT; LABORATORY EVALUATION; EXPOSURE; SYSTEM; BIOMECHANICS; KINEMATICS; LOCATION; PLAYERS; VALIDATION	Background: Wearable sensors are increasingly used to quantify the frequency and magnitude of head impact events in multiple sports. There is a paucity of evidence that verifies head impact events recorded by wearable sensors. Purpose: To utilize video analysis to verify head impact events recorded by wearable sensors and describe the respective frequency and magnitude. Study Design: Cohort study (diagnosis); Level of evidence, 2. Methods: Thirty male (mean age, 16.6 +/- 1.2 years; mean height, 1.77 +/- 0.06 m; mean weight, 73.4 +/- 12.2 kg) and 35 female (mean age, 16.2 +/- 1.3 years; mean height, 1.66 +/- 0.05 m; mean weight, 61.2 +/- 6.4 kg) players volunteered to participate in this study during the 2014 and 2015 lacrosse seasons. Participants were instrumented with GForceTracker (GFT; boys) and X-Patch sensors (girls). Simultaneous game video was recorded by a trained videographer using a single camera located at the highest midfield location. One-third of the field was framed and panned to follow the ball during games. Videographic and accelerometer data were time synchronized. Head impact counts were compared with video recordings and were deemed valid if (1) the linear acceleration was >= 20g, (2) the player was identified on the field, (3) the player was in camera view, and (4) the head impact mechanism could be clearly identified. Descriptive statistics of peak linear acceleration (PLA) and peak rotational velocity (PRV) for all verified head impacts >= 20g were calculated. Results: For the boys, a total recorded 1063 impacts (2014: n = 545; 2015: n = 518) were logged by the GFT between game start and end times (mean PLA, 46 +/- 31g; mean PRV, 1093 +/- 661 deg/s) during 368 player-games. Of these impacts, 690 were verified via video analysis (65%; mean PLA, 48 +/- 34g; mean PRV, 1242 +/- 617 deg/s). The X-Patch sensors, worn by the girls, recorded a total 180 impacts during the course of the games, and 58 (2014: n = 33; 2015: n = 25) were verified via video analysis (32%; mean PLA, 39 +/- 21g; mean PRV, 1664 +/- 619 rad/s). Conclusion: The current data indicate that existing wearable sensor technologies may substantially overestimate head impact events. Further, while the wearable sensors always estimated a head impact location, only 48% of the impacts were a result of direct contact to the head as characterized on video. Using wearable sensors and video to verify head impacts may decrease the inclusion of false-positive impacts during game activity in the analysis.	[Cortes, Nelson; Lincoln, Andrew E.; Myer, Gregory D.; Hepburn, Lisa; Higgins, Michael; Putukian, Margot; Caswell, Shane V.] George Mason Univ, Sports Med Assessment Res & Testing SMART Lab, 10890 George Mason Circle,Bull Run Hall 220, Manassas, VA 20110 USA; [Lincoln, Andrew E.; Hepburn, Lisa] MedStar Hlth Res Inst, Baltimore, MD USA; [Myer, Gregory D.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Higgins, Michael] Univ Virginia, Charlottesville, VA USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA	Cortes, N (corresponding author), George Mason Univ, Sports Med Assessment Res & Testing SMART Lab, 10890 George Mason Circle,Bull Run Hall 220, Manassas, VA 20110 USA.	ncortes@gmu.edu	; Myer, Gregory/H-6572-2016	/0000-0001-8762-3144; Myer, Gregory/0000-0002-9983-8422	US Lacrosse Sports Science and Safety Committee grant	One or more of the authors has declared the following potential conflict of interest or source of funding: Financial support via US Lacrosse Sports Science and Safety Committee grant funding was received to conduct the study. Funding was primarily used to support equipment and personnel.	Allison MA, 2015, ANN BIOMED ENG, V43, P1896, DOI 10.1007/s10439-014-1197-z; Allison MA, 2014, MED SCI SPORT EXER, V46, P115, DOI 10.1249/MSS.0b013e3182a32d0d; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Belanger HG, 2016, J HEAD TRAUMA REHAB, V31, P159, DOI 10.1097/HTR.0000000000000138; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kuo C, 2016, J BIOMECH, V49, P1845, DOI 10.1016/j.jbiomech.2016.04.017; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Miyashita T., 2016, ATHL TRAIN SPORTS HL, V8, P202, DOI DOI 10.3928/19425864-20160503-01; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Myer GD, 2016, BRIT J SPORT MED, V50, P1276, DOI 10.1136/bjsports-2016-096134; Myer GD, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00074; Nevins D, 2015, PROCEDIA ENGINEER, V112, P175, DOI 10.1016/j.proeng.2015.07.195; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Reynolds BB, 2016, AM J SPORT MED, V44, P2947, DOI 10.1177/0363546516648442; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Schmidt JD, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4231; Schmidt JD, 2015, CLIN J SPORT MED, V25, P494, DOI 10.1097/JSM.0000000000000143; Schmidt JD, 2014, AM J SPORT MED, V42, P2056, DOI 10.1177/0363546514536685; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wilcox BJ, 2014, J ATHL TRAINING, V49, P514, DOI 10.4085/1062-6050-49.3.19; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	52	45	45	1	26	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2017	45	10					2379	2387		10.1177/0363546517706703			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	FC4VS	WOS:000406839600022	28541813				2021-06-18	
J	Kota, DJ; Prabhakara, KS; Toledano-Furman, N; Bhattarai, D; Chen, QZ; DiCarlo, B; Smith, P; Triolo, F; Wenzel, PL; Cox, CS; Olson, SD				Kota, Daniel J.; Prabhakara, Karthik S.; Toledano-Furman, Naama; Bhattarai, Deepa; Chen, Qingzheng; DiCarlo, Bryan; Smith, Philippa; Triolo, Fabio; Wenzel, Pamela L.; Cox, Charles S.; Olson, Scott D.			Prostaglandin E2 Indicates Therapeutic Efficacy of Mesenchymal Stem Cells in Experimental Traumatic Brain Injury	STEM CELLS			English	Article						Mesenchymal stem cells; Inflammation; Immunomodulation; Traumatic brain injury; Prostaglandin E2	VERSUS-HOST-DISEASE; REGULATORY T-CELLS; STROMAL CELLS; AMNIOTIC-FLUID; MICROGLIAL ACTIVATION; MYOCARDIAL-INFARCTION; BARRIER DISRUPTION; IMMUNE-RESPONSE; CLINICAL-TRIALS; IN-VITRO	Traumatic brain injury (TBI) is soon predicted to become the third leading cause of death and disability worldwide. After the primary injury, a complex set of secondary injuries develops hours and days later with prolonged neuroinflammation playing a key role. TBI and other inflammatory conditions are currently being treated in preclinical and clinical trials by a number of cellular therapies. Mesenchymal stem cells (MSC) are of great interest due to their widespread usage, safety, and relative ease to isolate and culture. However, there has been a wide range in efficacy reported using MSC clinically and in preclinical models, likely due to differences in cell preparations and a significant amount of donor variability. In this study, we seek to find a correlation between in vitro activity and in vivo efficacy. We designed assays to explore the responsiveness of MSC to immunological cues to address the immunomodulatory properties of MSC, one of their primary modes of therapeutic activity in TBI. Our results showed intrinsic differences in the immunomodulatory capacity of MSC preparations from different bone marrow and amniotic fluid donors. This difference mirrored the therapeutic capacity of the MSC in an experimental model of TBI, an effect confirmed using siRNA knockdown of COX2 followed by overexpressing COX2. Among the immunomodulatory factors assessed, the therapeutic benefit correlated with the secretion of prostaglandin E2 (PGE(2)) by MSC prior to treatment, suggesting that measurement of PGE(2) could be a very useful potency marker to create an index of predicted efficacy for preparations of MSC to treat TBI. Stem Cells2017;35:1416-1430	[Kota, Daniel J.] Sanford Res, Children Hlth Res Ctr S, Sioux Falls, SD USA; [Prabhakara, Karthik S.; Toledano-Furman, Naama; Bhattarai, Deepa; Chen, Qingzheng; DiCarlo, Bryan; Smith, Philippa; Triolo, Fabio; Wenzel, Pamela L.; Cox, Charles S.; Olson, Scott D.] Univ Texas Houston, Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St MSE R162, Houston, TX 77030 USA	Olson, SD (corresponding author), Univ Texas Houston, Hlth Sci Ctr Houston, Dept Pediat Surg, 6431 Fannin St MSE R162, Houston, TX 77030 USA.	Scott.D.Olson@uth.tmc.edu	Wenzel, Pamela/AAJ-1944-2021; Toledano Furman, Naama/N-1854-2016	Wenzel, Pamela/0000-0002-4530-015X; Toledano Furman, Naama/0000-0002-2687-7068; Olson, Scott/0000-0001-8032-3755	Clare A. Glassell Family Pediatric Stem Cell Research Fund; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K01DK092365] Funding Source: NIH RePORTER	This study was supported by the Clare A. Glassell Family Pediatric Stem Cell Research Fund. We thank our colleague, Dr. Richard Kulmacz, for kindly providing the SG5-COX2 expression vector.	Abdi R, 2008, DIABETES, V57, P1759, DOI 10.2337/db08-0180; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Ankrum JA, 2014, SCI REP-UK, V4, DOI 10.1038/srep04645; Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Chen PM, 2014, J LEUKOCYTE BIOL, V96, P295, DOI 10.1189/jlb.3A0513-242R; Chinnadurai R, 2014, J IMMUNOL, V192, P1491, DOI 10.4049/jimmunol.1301828; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Darlington PJ, 2011, EXPERT REV NEUROTHER, V11, P1295, DOI [10.1586/ERN.11.113, 10.1586/ern.11.113]; Davis NE, 2012, CURR DIABETES REP, V12, P612, DOI 10.1007/s11892-012-0305-4; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; English K, 2013, IMMUNOL CELL BIOL, V91, P19, DOI 10.1038/icb.2012.56; Fauza D, 2004, BEST PRACT RES CL OB, V18, P877, DOI 10.1016/j.bpobgyn.2004.07.001; Fiorina P, 2009, J IMMUNOL, V183, P993, DOI 10.4049/jimmunol.0900803; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Galipeau J, 2013, CYTOTHERAPY, V15, P2, DOI 10.1016/j.jcyt.2012.10.002; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Ge W, 2010, TRANSPLANTATION, V90, P1312, DOI 10.1097/TP.0b013e3181fed001; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Harting MT, 2008, BRAIN, V131, DOI 10.1093/brain/awn142; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Hsu WT, 2013, J IMMUNOL, V190, P2372, DOI 10.4049/jimmunol.1202996; Iso Y, 2007, BIOCHEM BIOPH RES CO, V354, P700, DOI 10.1016/j.bbrc.2007.01.045; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004; Kirchhoff C, 2006, J NEUROTRAUM, V23, P943, DOI 10.1089/neu.2006.23.943; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kota DJ, 2016, STEM CELL TRANSL MED, V5, P33, DOI 10.5966/sctm.2015-0065; Kota DJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep04565; Kota DJ, 2013, DIABETES, V62, P2048, DOI 10.2337/db12-0931; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Lee RH, 2012, CELL STEM CELL, V11, P825, DOI 10.1016/j.stem.2012.10.001; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Li D, 2015, INT J MOL MED, V35, P1309, DOI 10.3892/ijmm.2015.2137; Li P, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0361-9; Liao GP, 2014, J SURG RES, V190, P628, DOI 10.1016/j.jss.2014.05.011; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lopez F, 2010, RISK ANAL, V30, P1857, DOI 10.1111/j.1539-6924.2010.01465.x; Luo CF, 2014, CURR STEM CELL RES T, V9, P36; Luz-Crawford P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt216; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Moorefield EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026535; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Ohsawa K, 2010, GLIA, V58, P790, DOI 10.1002/glia.20963; Ooi YY, 2010, INT IMMUNOPHARMACOL, V10, P1532, DOI 10.1016/j.intimp.2010.09.001; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Prevosto C, 2007, HAEMATOLOGICA, V92, P881, DOI 10.3324/haematol.11240; Prockop DJ, 2010, J CELL MOL MED, V14, P2190, DOI 10.1111/j.1582-4934.2010.01151.x; Prockop DJ, 2009, MOL THER, V17, P939, DOI 10.1038/mt.2009.62; Puissant N, 2005, BRIT J HAEMATOL, V129, P118, DOI 10.1111/j.1365-2141.2005.05409.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rasmusson I, 2003, TRANSPLANTATION, V76, P1208, DOI 10.1097/01.TP.0000082540.43730.80; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Rozenberg A, 2016, STEM CELL TRANSL MED, V5, P1506, DOI 10.5966/sctm.2015-0243; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Tang YH, 2015, ADV FUNCT MATER, V25, P1024, DOI 10.1002/adfm.201402930; Teixeira FG, 2013, CELL MOL LIFE SCI, V70, P3871, DOI 10.1007/s00018-013-1290-8; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Uccelli A, 2010, CURR OPIN IMMUNOL, V22, P768, DOI 10.1016/j.coi.2010.10.012; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; Waterman RS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010088; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wostradowski T, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0715-3; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Yang B, 2012, STROKE, V43; Ylostalo JH, 2012, STEM CELLS, V30, P2283, DOI 10.1002/stem.1191; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zheng B, 2016, THERANOSTICS, V6, P291, DOI 10.7150/thno.13728; Zhou J, 2014, ARCH GYNECOL OBSTET, V290, P223, DOI 10.1007/s00404-014-3231-7	91	45	48	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells	MAY	2017	35	5					1416	1430		10.1002/stem.2603			15	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	ET1HC	WOS:000400017200025	28233425	Bronze			2021-06-18	
J	Palacios, EM; Martin, AJ; Boss, MA; Ezekiel, F; Chang, YS; Yuh, EL; Vassar, MJ; Schnyer, DM; MacDonald, CL; Crawford, KL; Irimia, A; Toga, AW; Mukherjee, P				Palacios, E. M.; Martin, A. J.; Boss, M. A.; Ezekiel, F.; Chang, Y. S.; Yuh, E. L.; Vassar, M. J.; Schnyer, D. M.; MacDonald, C. L.; Crawford, K. L.; Irimia, A.; Toga, A. W.; Mukherjee, P.		TRACK-TBI Investigators	Toward Precision and Reproducibility of Diffusion Tensor Imaging: A Multicenter Diffusion Phantom and Traveling Volunteer Study	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; FRACTIONAL ANISOTROPY; FIBER TRACTOGRAPHY; RELIABILITY; 3T; IMPLEMENTATION; MEDICINE; SCANNERS	BACKGROUND AND PURPOSE: Precision medicine is an approach to disease diagnosis, treatment, and prevention that relies on quantitative biomarkers that minimize the variability of individual patient measurements. The aim of this study was to assess the intersite variability after harmonization of a high-angular-resolution 3T diffusion tensor imaging protocol across 13 scanners at the 11 academic medical centers participating in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury multisite study. MATERIALS AND METHODS: Diffusion MR imaging was acquired from a novel isotropic diffusion phantom developed at the National Institute of Standards and Technology and from the brain of a traveling volunteer on thirteen 3T MR imaging scanners representing 3 major vendors (GE Healthcare, Philips Healthcare, and Siemens). Means of the DTI parameters and their coefficients of variation across scanners were calculated for each DTI metric and white matter tract. RESULTS: For the National Institute of Standards and Technology diffusion phantom, the coefficients of variation of the apparent diffusion coefficient across the 13 scanners was <3.8% for a range of diffusivities from 0.4 to 1.1 x 10(-6) mm(2)/s. For the volunteer, the coefficients of variations across scanners of the 4 primary DTI metrics, each averaged over the entire white matter skeleton, were all <5%. In individual white matter tracts, large central pathways showed good reproducibility with the coefficients of variation consistently below 5%. However, smaller tracts showed more variability, with the coefficients of variation of some DTI metrics reaching 10%. CONCLUSIONS: The results suggest the feasibility of standardizing DTI across 3T scanners from different MR imaging vendors in a large-scale neuroimaging research study.	[Palacios, E. M.; Martin, A. J.; Ezekiel, F.; Chang, Y. S.; Yuh, E. L.; Mukherjee, P.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Palacios, E. M.; Martin, A. J.; Ezekiel, F.; Chang, Y. S.; Yuh, E. L.; Mukherjee, P.] Univ Calif San Francisco, Dept Biomed Imaging, San Francisco, CA 94143 USA; [Vassar, M. J.] Univ Calif San Francisco, Neurol Surg & Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Mukherjee, P.] Univ Calif San Francisco, Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Boss, M. A.] NIST, Boulder, CO USA; [Yuh, E. L.; Vassar, M. J.; Mukherjee, P.] San Francisco Gen Hosp, Brain & Spinal Cord Injury Ctr, San Francisco, CA 94110 USA; Ctr Trauma, San Francisco, CA USA; [Schnyer, D. M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [MacDonald, C. L.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Crawford, K. L.; Irimia, A.; Toga, A. W.] Univ Southern Calif, Mark & Mary Stevens Neuroimaging & Informat Inst, Los Angeles, CA USA	Mukherjee, P (corresponding author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 185 Berry St, San Francisco, CA 94107 USA.	pratik.mukherjee@ucsf.edu	Yue, John K/P-1348-2015; Boss, Michael/I-2904-2019; Irimia, Andrei/B-8275-2008	Yue, John K/0000-0001-9694-7722; Boss, Michael/0000-0002-9492-767X; Irimia, Andrei/0000-0002-9254-9388; Sergot, Paulina/0000-0003-0796-8009; Schnyer, David/0000-0002-7472-2853; Ferguson, Adam/0000-0001-7102-1608; Martin, Alastair/0000-0002-7963-4000	Voyager Therapeutics; Quest Diagnostics Incorporated;  [NIH R01EB012031];  [NIH U01NS086090];  [NIH R21CA186140];  [NIH R01CA194533];  [NIH U01 NS086090];  [DoD W81XWH-14-2-0176];  [DoD-Navy W911QY-14-C-0070];  [NIH R01AG046460];  [NIH R01HD083126];  [DoD PT108802-SC104833-S1];  [NIH R44 NS 081792];  [NIH R01MH094343];  [NIH P41EB015922];  [NIH R24MH106096];  [NIH R01HD072074];  [DoD W81XWH-13-1-0494];  [GE 114-2014-GES-0001]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD072074] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD031526] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA186140, R01CA194533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB012031, P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R24MH106096, R01MH094343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090, R44NS081792, R01NS060776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG046460] Funding Source: NIH RePORTER	A.J.M., NIH R01EB012031, NIH U01NS086090, NIH R21CA186140, NIH R01CA194533, Voyager Therapeutics, Quest Diagnostics Incorporated; E.L.Y., NIH U01 NS086090, DoD W81XWH-14-2-0176, D.M.S., DoD-Navy W911QY-14-C-0070, NIH U01NS086090, NIH R01AG046460; C.L.M., NIH R01HD083126, DoD PT108802-SC104833-S1, NIH U01NS086090, DoD W81XWH-14-2-0176; A. I., NIH R44 NS 081792, NIH U01NS086090; A.W.T., NIH R01MH094343, NIH P41EB015922, NIH U01NS086090; and P.M., NIH R24MH106096, NIH R01HD072074, NIH U01 NS086090, DoD W81XWH-14-2-0176, DoD W81XWH-13-1-0494, GE 114-2014-GES-0001.	Andersson J., TR07JA2 FMRIB; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bisdas S, 2008, AM J NEURORADIOL, V29, P1128, DOI 10.3174/ajnr.A1044; Collins FS, 2015, NEW ENGL J MED, V372, P793, DOI 10.1056/NEJMp1500523; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Fox RJ, 2012, AM J NEURORADIOL, V33, P695, DOI 10.3174/ajnr.A2844; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Grech-Sollars M, 2015, NMR BIOMED, V28, P468, DOI 10.1002/nbm.3269; Hsu W, 2013, J AM MED INFORM ASSN, V20, P1010, DOI 10.1136/amiajnl-2013-002315; Huang LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047684; Jansen JFA, 2007, INVEST RADIOL, V42, P327, DOI 10.1097/01.rli.0000262757.10271.e5; Kamagata K, 2015, MAGN RESON MED SCI, V14, P227, DOI 10.2463/mrms.2014-0077; Magnotta VA, 2012, BRAIN CONNECT, V2, P345, DOI 10.1089/brain.2012.0112; Mirzaalian H, 2015, LECT NOTES COMPUT SC, V9349, P12, DOI 10.1007/978-3-319-24553-9_2; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Mukherjee P, 2008, AM J NEURORADIOL, V29, P632, DOI 10.3174/ajnr.A1051; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pagani E, 2010, J MAGN RESON IMAGING, V31, P1458, DOI 10.1002/jmri.22186; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Pierpaoli C., 2009, P 17 ANN M ISMRM HON, P1414; Polders DL, 2011, J MAGN RESON IMAGING, V33, P1456, DOI 10.1002/jmri.22554; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Takao H, 2012, HUM BRAIN MAPP, V33, P466, DOI 10.1002/hbm.21225; Veenith TV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065941; Venkatraman VK, 2015, NEUROIMAGE, V119, P406, DOI 10.1016/j.neuroimage.2015.06.078; Vollmar C, 2010, NEUROIMAGE, V51, P1384, DOI 10.1016/j.neuroimage.2010.03.046; Walker L, 2013, HUM BRAIN MAPP, V34, P2439, DOI 10.1002/hbm.22081; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhu T, 2011, NEUROIMAGE, V56, P1398, DOI 10.1016/j.neuroimage.2011.02.010	32	45	45	1	9	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2017	38	3					537	545		10.3174/ajnr.A5025			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EN6JB	WOS:000396109200024	28007768	Green Accepted, Green Published, Other Gold			2021-06-18	
J	Wallace, J; Covassin, T; Nogle, S; Gould, D; Kovan, J				Wallace, Jessica; Covassin, Tracey; Nogle, Sally; Gould, Daniel; Kovan, Jeffrey			Knowledge of Concussion and Reporting Behaviors in High School Athletes With or Without Access to an Athletic Trainer	JOURNAL OF ATHLETIC TRAINING			English	Article						traumatic brain injuries; secondary school; health care	SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; SECONDARY-SCHOOLS; ASSOCIATION; STATEMENT; BENCHMARK	Context: Increased sport participation and sport-related concussion incidence has led to an emphasis on having an appropriate medical professional available to high school athletes. The medical professional best suited to provide medical care to high school athletes is a certified athletic trainer (AT). Access to an AT may influence the reporting of sport-related concussion in the high school athletic population; however, little is known about how the presence of an AT affects concussion knowledge, prevention, and recognition. Objective: To evaluate knowledge of concussion and reporting behaviors in high school athletes who did or did not have access to an AT. Design: Cross-sectional study. Setting: Survey. Patients or Other Participants: A total of 438 athletes with access to an AT and 277 without access to an AT. Intervention(s): A validated knowledge-of-concussion survey consisting of 83 items addressing concussion history, concussion knowledge, scenario questions, signs and symptoms of a concussion, and reasons why an athlete would not report a concussion. The independent variable was access to an AT. Main Outcome Measure(s): We examined the proportion of athletes who correctly identified knowledge of concussion, signs and symptoms of concussion, and reasons why high school student-athletes would not disclose a potential concussive injury by access to an AT. Frequency statistics, chi(2) tests, independent t tests, and linear regression were conducted to analyze the data. Results: The underreporting of concussion among high school athletes was 55%. Athletes with access to an AT had more knowledge of concussion than did athletes without such access (P < .001). Chi-square tests did not demonstrate a significant relationship between AT access and a higher percentage reporting concussions. Conclusions: High school athletes with access to an AT had more concussion knowledge, but they did not report suspected concussions to an authority figure more frequently than athletes without access to an AT.	[Wallace, Jessica] Youngstown State Univ, 1 Univ Plaza,Beeghly Ctr 307L, Youngstown, OH 44555 USA; [Wallace, Jessica; Covassin, Tracey; Nogle, Sally; Gould, Daniel; Kovan, Jeffrey] Michigan State Univ, E Lansing, MI 48824 USA	Wallace, J (corresponding author), Youngstown State Univ, 1 Univ Plaza,Beeghly Ctr 307L, Youngstown, OH 44555 USA.	jwallace02@ysu.edu					Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Cournoyer J, 2014, J ATHL TRAINING, V49, P654, DOI 10.4085/1062-6050-49.3.34; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gourley MM., 2010, ATHL TRAIN SPORTS HL, V2, P208, DOI DOI 10.3928/19425864-20100524-03; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kurowski B, 2014, J TRAUMA ACUTE CARE, V77, pS12, DOI 10.1097/TA.0000000000000316; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lyznicki JM, 1999, J ATHL TRAINING, V34, P272; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2013, J ATHL TRAINING, V48, P483, DOI 10.4085/1062-6050-48.4.04; Pryor RR, 2015, J ATHL TRAINING, V50, P156, DOI 10.4085/1062-6050-50.2.03; Ransone J, 1999, J ATHL TRAINING, V34, P267; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511	23	45	45	0	3	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	MAR	2017	52	3					228	235		10.4085/1062-6050-52.1.07			8	Sport Sciences	Sport Sciences	ES0NE	WOS:000399222500008	28387561	Green Published, Bronze			2021-06-18	
J	Marussich, L; Lu, KH; Wen, HG; Liu, ZM				Marussich, Lauren; Lu, Kun-Han; Wen, Haiguang; Liu, Zhongming			Mapping white-matter functional organization at rest and during naturalistic visual perception	NEUROIMAGE			English	Article							TRAUMATIC BRAIN-INJURY; SENSORY STIMULATION; FIELD POTENTIALS; CORPUS-CALLOSUM; FMRI ACTIVATION; CONNECTIVITY; CORTEX; SIGNAL; BOLD; MRI	Despite the wide applications of functional magnetic resonance imaging (fMRI) to mapping brain activation and connectivity in cortical gray matter, it has rarely been utilized to study white-matter functions. In this study, we investigated the spatiotemporal characteristics of fMRI data within the white matter acquired from humans both in the resting state and while watching a naturalistic movie. By using independent component analysis and hierarchical clustering, resting-state fMRI data in the white matter were de-noised and decomposed into spatially independent components, which were further assembled into hierarchically organized axonal fiber bundles. Interestingly, such components were partly reorganized during natural vision. Relative to resting state, the visual task specifically induced a stronger degree of temporal coherence within the optic radiations, as well as significant correlations between the optic radiations and multiple cortical visual networks. Therefore, fMRI contains rich functional information about the activity and connectivity within white matter at rest and during tasks, challenging the conventional practice of taking white-matter signals as noise or artifacts.	[Marussich, Lauren; Liu, Zhongming] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Lu, Kun-Han; Wen, Haiguang; Liu, Zhongming] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Liu, Zhongming] Purdue Univ, Purdue Inst Integrat Neurosci, W Lafayette, IN 47907 USA	Liu, ZM (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.	zmliu@purdue.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01MH104402]; National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award [TL1 TR001107, UL1 TR001108]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR001107, UL1TR001108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH104402] Funding Source: NIH RePORTER	The research was supported in part by NIH R01MH104402 (Z Liu, PI), and a predoctoral fellowship to Lauren Marussich as supported by TL1 TR001107 and UL1 TR001108 (A. Shekhar, PI) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. The authors would also like to thank Yu Tang for her assistance with data analysis during the exploratory phase of this project.	Astafiev SV, 2016, NEUROIMAGE-CLIN, V11, P10, DOI 10.1016/j.nicl.2016.01.004; Astafiev SV, 2015, J NEUROTRAUM, V32, P1254, DOI 10.1089/neu.2014.3547; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Belitski A, 2008, J NEUROSCI, V28, P5696, DOI 10.1523/JNEUROSCI.0009-08.2008; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Bianciardi M, 2009, MAGN RESON IMAGING, V27, P1019, DOI 10.1016/j.mri.2009.02.004; BISWAL B, 1995, MAGNET RESON MED, V34, P537, DOI 10.1002/mrm.1910340409; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Catani M, 2003, BRAIN, V126, P2093, DOI 10.1093/brain/awg203; Cordes D, 2002, MAGN RESON IMAGING, V20, P305, DOI 10.1016/S0730-725X(02)00503-9; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dasgupta S, 2005, J COMPUT SYST SCI, V70, P555, DOI 10.1016/j.jcss.2004.10.006; Ding Z., 2013, PLOS ONE, V8; Ding ZH, 2016, MAGN RESON IMAGING, V34, P8, DOI 10.1016/j.mri.2015.10.003; Duyn J, 2013, J MAGN RESON, V229, P198, DOI 10.1016/j.jmr.2012.11.013; Fabri M, 2011, BRAIN RES, V1370, P99, DOI 10.1016/j.brainres.2010.11.039; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Ffytche DH, 2005, PHILOS T R SOC B, V360, P767, DOI 10.1098/rstb.2005.1621; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Gawryluk JR, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-56; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Harris JJ, 2012, J NEUROSCI, V32, P356, DOI 10.1523/JNEUROSCI.3430-11.2012; Hasson U, 2004, SCIENCE, V303, P1634, DOI 10.1126/science.1089506; Jaaskelainen Iiro P, 2008, Open Neuroimag J, V2, P14, DOI 10.2174/1874440000802010014; Jensen JH, 2006, MAGN RESON MED, V56, P1145, DOI 10.1002/mrm.21052; Jo HJ, 2010, NEUROIMAGE, V52, P571, DOI 10.1016/j.neuroimage.2010.04.246; Johnstone T, 2006, HUM BRAIN MAPP, V27, P779, DOI 10.1002/hbm.20219; Kenet T, 2003, NATURE, V425, P954, DOI 10.1038/nature02078; Kundu P, 2012, NEUROIMAGE, V60, P1759, DOI 10.1016/j.neuroimage.2011.12.028; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; Lee J, 2011, NEUROIMAGE, V57, P225, DOI 10.1016/j.neuroimage.2011.04.026; Leopold DA, 2012, NEUROIMAGE, V62, P2190, DOI 10.1016/j.neuroimage.2011.10.059; LIERSE W, 1965, ACTA NEUROL SCAND, VS 41, P15; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Makedonov I, 2016, NEUROBIOL AGING, V37, P12, DOI 10.1016/j.neurobiolaging.2015.09.010; Mandl RCW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003631; Mazerolle EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058130; Mazerolle EL, 2010, NEUROIMAGE, V50, P616, DOI 10.1016/j.neuroimage.2009.12.102; McMahon DBT, 2015, J NEUROSCI, V35, P5537, DOI 10.1523/JNEUROSCI.3825-14.2015; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Mosier KM, 1999, AM J NEURORADIOL, V20, P1520; Mukamel R, 2005, SCIENCE, V309, P951, DOI 10.1126/science.1110913; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Pelled G, 2009, P NATL ACAD SCI USA, V106, P14114, DOI 10.1073/pnas.0903153106; Petzold GC, 2011, NEURON, V71, P782, DOI 10.1016/j.neuron.2011.08.009; Rash JE, 2010, NEUROSCIENCE, V168, P982, DOI 10.1016/j.neuroscience.2009.10.028; Rauch A, 2008, P NATL ACAD SCI USA, V105, P6759, DOI 10.1073/pnas.0800312105; Rostrup E, 2000, NEUROIMAGE, V11, P87, DOI 10.1006/nimg.1999.0526; Shattuck DW, 2008, NEUROIMAGE, V39, P1064, DOI 10.1016/j.neuroimage.2007.09.031; Shirer WR, 2012, CEREB CORTEX, V22, P158, DOI 10.1093/cercor/bhr099; Smith AJ, 2002, P NATL ACAD SCI USA, V99, P10765, DOI 10.1073/pnas.132272199; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Spees WM, 2013, NEUROIMAGE, V65, P209, DOI 10.1016/j.neuroimage.2012.10.021; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Tavor I, 2016, SCIENCE, V352, P216, DOI 10.1126/science.aad8127; Tettamanti M, 2002, J NEUROPHYSIOL, V88, P1051, DOI 10.1152/jn.2002.88.2.1051; Thomas BP., 2014, J CEREB BLOOD FLOW M; van den Heuvel MP, 2013, J NEUROSCI, V33, P14489, DOI 10.1523/JNEUROSCI.2128-13.2013; Van Dijk KRA, 2012, NEUROIMAGE, V59, P431, DOI 10.1016/j.neuroimage.2011.07.044; Van Dijk KRA, 2010, J NEUROPHYSIOL, V103, P297, DOI 10.1152/jn.00783.2009; van Osch MJP, 2009, MAGN RESON MED, V62, P165, DOI 10.1002/mrm.22002; Viswanathan A, 2007, NAT NEUROSCI, V10, P1308, DOI 10.1038/nn1977; Wang YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076315; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; Weber B, 2002, NEUROIMAGE, V16, P993, DOI 10.1006/nimg.2002.1104; Wilf M., 2015, CEREB CORTEX	73	45	45	5	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	FEB 1	2017	146						1128	1141		10.1016/j.neuroimage.2016.10.005			14	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EL3ZX	WOS:000394560700098	27720819	Green Accepted			2021-06-18	
J	Roy, S; Butman, JA; Pham, DL				Roy, Snehashis; Butman, John A.; Pham, Dzung L.		Alzheimers Dis Neuroimaging Initia	Robust skull stripping using multiple MR image contrasts insensitive to pathology	NEUROIMAGE			English	Article						Skull stripping; Brain extraction; Patches; Atlas; Segmentation; Non-local; Sparsity	BRAIN EXTRACTION; AUTOMATIC SEGMENTATION; ALGORITHM; REGISTRATION; ACCURATE; VOLUME; REGULARIZATION; PERFORMANCE; MESHES	Automatic skull-stripping or brain extraction of magnetic resonance (MR) images is often a fundamental step in many neuroimage processing pipelines. The accuracy of subsequent image processing relies on the accuracy of the skull-stripping. Although many automated stripping methods have been proposed in the past, it is still an active area of research particularly in the context of brain pathology. Most stripping methods are validated on T-1-w MR images of normal brains, especially because high resolution T-1-w sequences are widely acquired and ground truth manual brain mask segmentations are publicly available for normal brains. However, different MR acquisition protocols can provide complementary information about the brain tissues, which can be exploited for better distinction between brain, cerebrospinal fluid, and unwanted tissues such as skull, dura, marrow, or fat. This is especially true in the presence of pathology, where hemorrhages or other types of lesions can have similar intensities as skull in a T-1-w image. In this paper, we propose a sparse patch based Multi-cONtrast brain STRipping method (MONSTR),(2) where non-local patch information from one or more atlases, which contain multiple MR sequences and reference delineations of brain masks, are combined to generate a target brain mask. We compared MONSTR with four state-of-the-art, publicly available methods: BEaST, SPECTRE, ROBEX, and OptiBET. We evaluated the performance of these methods on 6 datasets consisting of both healthy subjects and patients with various pathologies. Three datasets (ADNI, MRBrainS, NAMIC) are publicly available, consisting of 44 healthy volunteers and 10 patients with schizophrenia. Other three in-house datasets, comprising 87 subjects in total, consisted of patients with mild to severe traumatic brain injury, brain tumors, and various movement disorders. A combination of T-1-w, T-2-w were used to skull-strip these datasets. We show significant improvement in stripping over the competing methods on both healthy and pathological brains. We also show that our multi-contrast framework is robust and maintains accurate performance across different types of acquisitions and scanners, even when using normal brains as atlases to strip pathological brains, demonstrating that our algorithm is applicable even when reference segmentations of pathological brains are not available to be used as atlases.	[Roy, Snehashis; Butman, John A.; Pham, Dzung L.] Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, Bethesda, MD 20817 USA; [Butman, John A.] NIH, Dept Diagnost Radiol, Bethesda, MD USA	Roy, S (corresponding author), Henry M Jackson Fdn, Ctr Neurosci & Regenerat Med, Bethesda, MD 20817 USA.	snehashis.roy@nih.gov	Butman, John/J-2780-2013; Pham, Dzung/AAR-8263-2020; Butman, John A/A-2694-2008	Butman, John/0000-0002-1547-9195; Roy, Snehashis/0000-0002-7997-3993	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; intramural research program at NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS070906]; National MS SocietyNational Multiple Sclerosis Society [RG-1507-05243]; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging, the National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); AbbVieAbbVie; Alzheimer's AssociationAlzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; BiogenBiogen; Bristol-Myers Squibb CompanyBristol-Myers Squibb; CereSpir, Inc.; Eisai Inc.Eisai Co Ltd; Elan Pharmaceuticals, Inc.; Eli Lilly and CompanyEli Lilly; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE HealthcareGE Healthcare; IXICO Ltd.; Janssen Alzheimer Immuno therapy Research AMP; Development, LLC.; Johnson AMP; Johnson Pharmaceutical Research AMP; Development LLC.; Lumosity; LundbeckLundbeck Corporation; Merck Co., Inc.Merck & Company; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals CorporationNovartis; Pfizer Inc.Pfizer; Piramal Imaging; ServierServier; Takeda Pharmaceutical CompanyTakeda Pharmaceutical Company Ltd; Transition Therapeutics; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Northern California Institute for Research and Education; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS070906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG024904] Funding Source: NIH RePORTER	Support for this work included funding from the Department of Defense in the Center for Neuroscience and Regenerative Medicine and intramural research program at NIH. This work was also partially supported by grants NIH/NINDS R01NS070906 and National MS Society RG-1507-05243. This work utilized the computational resources of the NIH HPC Biowulf cluster. (http://hpc.nih.gov).r For the ADNI-29 dataset, data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immuno therapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.	Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Boesen K, 2004, NEUROIMAGE, V22, P1255, DOI 10.1016/j.neuroimage.2004.03.010; Buades A, 2005, PROC CVPR IEEE, P60, DOI 10.1109/cvpr.2005.38; Burgos N, 2014, IEEE T MED IMAGING, V33, P2332, DOI 10.1109/TMI.2014.2340135; Carass A, 2011, NEUROIMAGE, V56, P1982, DOI 10.1016/j.neuroimage.2011.03.045; Carass A, 2007, I S BIOMED IMAGING, P656, DOI 10.1109/ISBI.2007.356937; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Coupe P, 2012, NEUROIMAGE, V59, P3736, DOI 10.1016/j.neuroimage.2011.10.080; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Desbrun M, 1999, COMP GRAPH, P317; Donoho DL, 2006, COMMUN PUR APPL MATH, V59, P907, DOI 10.1002/cpa.20131; Doshi J, 2013, ACAD RADIOL, V20, P1566, DOI 10.1016/j.acra.2013.09.010; Eskildsen SF, 2012, NEUROIMAGE, V59, P2362, DOI 10.1016/j.neuroimage.2011.09.012; Galdames FJ, 2012, J NEUROSCI METH, V206, P103, DOI 10.1016/j.jneumeth.2012.02.017; Geremia E, 2011, NEUROIMAGE, V57, P378, DOI 10.1016/j.neuroimage.2011.03.080; Guizard N, 2015, NEUROIMAGE-CLIN, V8, P376, DOI 10.1016/j.nicl.2015.05.001; Hahn HK, 2000, LECT NOTES COMPUT SC, V1935, P134; Heckemann RA, 2006, NEUROIMAGE, V33, P115, DOI 10.1016/j.neuroimage.2006.05.061; Heckemann RA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129211; Hu SY, 2014, HUM BRAIN MAPP, V35, P377, DOI 10.1002/hbm.22183; Iglesias JE, 2013, LECT NOTES COMPUT SC, V8149, P631, DOI 10.1007/978-3-642-40811-3_79; Iglesias JE, 2011, IEEE T MED IMAGING, V30, P1617, DOI 10.1109/TMI.2011.2138152; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jog A, 2015, MED IMAGE ANAL, V24, P63, DOI 10.1016/j.media.2015.05.002; Jog A, 2013, PROC SPIE, V8669, DOI 10.1117/12.2007062; Kleesiek J, 2016, NEUROIMAGE, V129, P460, DOI 10.1016/j.neuroimage.2016.01.024; Ledig C, 2015, MED IMAGE ANAL, V21, P40, DOI 10.1016/j.media.2014.12.003; Lemieux L, 1999, MAGN RESON MED, V42, P127; Leung KK, 2011, NEUROIMAGE, V55, P1091, DOI 10.1016/j.neuroimage.2010.12.067; Lutkenhoff ES, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115551; Mairal J, 2012, FOUND TRENDS COMPUT, V8, DOI 10.1561/0600000058; Malone IB, 2015, NEUROIMAGE, V104, P366, DOI 10.1016/j.neuroimage.2014.09.034; Manjon JV, 2010, INT J BIOMED IMAGING, V2010, DOI 10.1155/2010/425891; Mendrik AM, 2015, COMPUT INTEL NEUROSC, V2015, DOI 10.1155/2015/813696; Mikheev A, 2008, J MAGN RESON IMAGING, V27, P1235, DOI 10.1002/jmri.21372; Mueller SG, 2005, NEUROIMAG CLIN N AM, V15, P869, DOI 10.1016/j.nic.2005.09.008; Park JG, 2009, NEUROIMAGE, V47, P1394, DOI 10.1016/j.neuroimage.2009.04.047; Pham DL, 1999, IEEE T MED IMAGING, V18, P737, DOI 10.1109/42.802752; Rehm K, 2004, NEUROIMAGE, V22, P1262, DOI 10.1016/j.neuroimage.2004.03.011; Rex DE, 2004, NEUROIMAGE, V23, P625, DOI 10.1016/j.neuroimage.2004.06.019; Roura E, 2014, COMPUT METH PROG BIO, V113, P655, DOI 10.1016/j.cmpb.2013.11.015; Rousseau F, 2011, IEEE T MED IMAGING, V30, P1852, DOI 10.1109/TMI.2011.2156806; Rousseau F, 2008, LECT NOTES COMPUT SC, V5302, P497, DOI 10.1007/978-3-540-88682-2_38; Roy Snehashis, 2015, Mach Learn Med Imaging, V9352, P194, DOI 10.1007/978-3-319-24888-2_24; Roy S, 2015, IEEE J BIOMED HEALTH, V19, P1598, DOI 10.1109/JBHI.2015.2439242; Roy S, 2014, J NUCL MED, V55, P2071, DOI 10.2967/jnumed.114.143958; Roy S, 2014, PROC SPIE, V9034, DOI 10.1117/12.2043917; Roy S, 2014, PROC SPIE, V9034, DOI 10.1117/12.2043954; Roy S, 2013, I S BIOMED IMAGING, P1384; Roy S, 2013, IEEE T MED IMAGING, V32, P2348, DOI 10.1109/TMI.2013.2282126; Roy S, 2010, I S BIOMED IMAGING, P932, DOI 10.1109/ISBI.2010.5490140; Roy S, 2010, PROC SPIE, V7623, DOI 10.1117/12.844575; Sadananthan SA, 2010, NEUROIMAGE, V49, P225, DOI 10.1016/j.neuroimage.2009.08.050; Serag A, 2016, SCI REP-UK, V6, DOI 10.1038/srep23470; Shan ZY, 2002, NEUROIMAGE, V17, P1587, DOI 10.1006/nimg.2002.1287; Shattuck DW, 2001, NEUROIMAGE, V13, P856, DOI 10.1006/nimg.2000.0730; Shi F, 2012, NEUROIMAGE, V62, P1975, DOI 10.1016/j.neuroimage.2012.05.042; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; van der Kouwe AJW, 2008, NEUROIMAGE, V40, P559, DOI 10.1016/j.neuroimage.2007.12.025; van Tulder G, 2015, LECT NOTES COMPUT SC, V9349, P531, DOI 10.1007/978-3-319-24553-9_65; Wang HZ, 2013, IEEE T PATTERN ANAL, V35, P611, DOI 10.1109/TPAMI.2012.143; Wang L, 2014, NEUROIMAGE, V89, P152, DOI 10.1016/j.neuroimage.2013.11.040; Wang YP, 2011, LECT NOTES COMPUT SC, V6893, P635, DOI 10.1007/978-3-642-23626-6_78; Warfield SK, 2004, IEEE T MED IMAGING, V23, P903, DOI 10.1109/TMI.2004.828354; Zhao C., 2016, P SPIE MED IM SPIE, P97840; Zhuang AH, 2006, NEUROIMAGE, V32, P79, DOI 10.1016/j.neuroimage.2006.03.019; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	69	45	45	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	FEB 1	2017	146						132	147		10.1016/j.neuroimage.2016.11.017			16	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EL3ZX	WOS:000394560700013	27864083	Green Accepted, Bronze			2021-06-18	
J	Bodart, O; Gosseries, O; Wannez, S; Thibaut, A; Annen, J; Boly, M; Rosanova, M; Casali, AG; Casarotto, S; Tononi, G; Massimini, M; Laureys, S				Bodart, Olivier; Gosseries, Olivia; Wannez, Sarah; Thibaut, Aurore; Annen, Jitka; Boly, Melanie; Rosanova, Mario; Casali, Adenauer G.; Casarotto, Silvia; Tononi, Giulio; Massimini, Marcello; Laureys, Steven			Measures of metabolism and complexity in the brain of patients with disorders of consciousness	NEUROIMAGE-CLINICAL			English	Article						Transcranial magnetic stimulation; Electroencephalography; Positron emission tomography; Disorders of consciousness; Unresponsive wakefulness syndrome minimally conscious state; Brain injury	CORTICAL EFFECTIVE CONNECTIVITY; PLACEBO-CONTROLLED TRIAL; VEGETATIVE STATE; INJURY; AWARENESS; RESPONSES; COMA; STIMULATION; REACTIVITY; BREAKDOWN	Background: Making an accurate diagnosis in patients with disorders of consciousness remains challenging. F-18-fluorodeoxyglucose (FDG)-PET has been validated as a diagnostic tool in this population, and allows identifying unresponsive patients with a capacity for consciousness. In parallel, the perturbational complexity index (PCI), a new measure based on the analysis of the electroencephalographic response to transcranial magnetic stimulation, has also been suggested as a tool to distinguish between unconscious and conscious states. The aim of the study was to cross-validate FDG-PET and PCI, and to identify signs of consciousness in otherwise unresponsive patients. Methods: We jointly applied the Coma Recovery Scale-Revised, FDG-PET and PCI to assess 24 patients with non-acute disorders of consciousness or locked-in syndrome(13 male; 19-54 years old; 12 traumatic; 9 unresponsive wakefulness syndrome, 11 minimally conscious state; 2 emergence from the minimally conscious state, and 2 locked-in syndrome). Results: FDG-PET and PCI provided congruent results in 22 patients, regardless of their behavioural diagnosis. Notably, FDG-PET and PCI revealed preserved metabolic rates and high complexity levels in four patients who were behaviourally unresponsive. Conclusion: We propose that jointly measuring the metabolic activity and the electrophysiological complexity of cortical circuits is a useful complement to the diagnosis and stratification of patients with disorders of consciousness. (C) 2017 The Authors. Published by Elsevier Inc.	[Bodart, Olivier; Gosseries, Olivia; Wannez, Sarah; Thibaut, Aurore; Annen, Jitka; Boly, Melanie; Laureys, Steven] Univ Liege, Gigo Consciousness, Coma Sci Grp, Liege, Belgium; [Bodart, Olivier; Gosseries, Olivia; Wannez, Sarah; Thibaut, Aurore; Annen, Jitka; Boly, Melanie; Laureys, Steven] Univ Liege, Neurol Dept, Liege, Belgium; [Bodart, Olivier; Gosseries, Olivia; Wannez, Sarah; Thibaut, Aurore; Annen, Jitka; Boly, Melanie; Laureys, Steven] Univ Hosp Liege, Liege, Belgium; [Gosseries, Olivia; Boly, Melanie; Tononi, Giulio] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA; [Rosanova, Mario; Casali, Adenauer G.; Casarotto, Silvia; Massimini, Marcello] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy; [Casali, Adenauer G.] Fed Univ Sao Paolo, Inst Sci & Technol, Sao Jose Dos Campos, Brazil; [Massimini, Marcello] Fdn Don Carlo Gnocchi, Ist Ricovero & Cura Carattere Sci, Milan, Italy; [Rosanova, Mario] FERB Onlus, Fdn Europea Ric Biomed, Milan, Italy	Bodart, O (corresponding author), Coma Sci Grp, Giga Consciousness, B34,1 Ave Hop, B-4000 Liege, Belgium.	coma@chu.ulg.ac.be	Laureys, Steven/AAN-2097-2021; Annen, Jitka/ABH-5297-2020; Rosanova, Mario/S-8440-2017; Thibaut, Aurore/U-8101-2019; Casarotto, Silvia/Q-9402-2019; Casali, Adenauer G/G-9911-2012; Laureys, Steven/A-3349-2011; Gosseries, Olivia/AAB-6469-2020; Massimini, Marcello/T-8115-2017	Laureys, Steven/0000-0002-3096-3807; Annen, Jitka/0000-0002-7459-4345; Rosanova, Mario/0000-0001-7486-7617; Casarotto, Silvia/0000-0002-7548-7664; Casali, Adenauer G/0000-0001-7024-9029; Gosseries, Olivia/0000-0001-9011-7496; Massimini, Marcello/0000-0003-2271-957X	Belgian National Fund for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Human Brain ProjectUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [EU-H2020-FETFLAGSHIP-HBP-SGA1-GA720270]; Luminous project [EU-H2020-FETOPEN-GA686764]; Belgian American Education Foundation; Wallonie-Bruxelles International; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; Fonds Leon Fredericq; James S. McDonnell Foundation; Mind Science Foundation; French Speaking Community Concerted Research Action [ARC-06/11-340]; University and University Hospital of Liege	This research was supported by the Belgian National Fund for Scientific Research (FNRS), Human Brain Project (EU-H2020-FETFLAGSHIP-HBP-SGA1-GA720270), Luminous project (EU-H2020-FETOPEN-GA686764), the Belgian American Education Foundation, the Wallonie-Bruxelles International, the European Commission, the Fonds Leon Fredericq, the James S. McDonnell Foundation, the Mind Science Foundation, the French Speaking Community Concerted Research Action (ARC-06/11-340), and the University and University Hospital of Liege.	Bardin JC, 2012, ARCH NEUROL-CHICAGO, V69, P176, DOI 10.1001/archneurol.2011.892; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Bodart O, 2013, SEMIN NEUROL, V33, P83, DOI 10.1055/s-0033-1348965; Casali AG, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006294; Casarotto S, 2016, ANN NEUROL, V80, P718, DOI 10.1002/ana.24779; Casarotto S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010281; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Gantner IS, 2013, FUTUR NEUROL, V8, P43, DOI 10.2217/FNL.12.77; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goldfine AM, 2011, CLIN NEUROPHYSIOL, V122, P2157, DOI 10.1016/j.clinph.2011.03.022; Gosseries O, 2015, BRAIN STIMUL, V8, P142, DOI 10.1016/j.brs.2014.10.008; Gosseries O, 2014, BRAIN INJURY, V28, P1141, DOI 10.3109/02699052.2014.920522; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Massimini M, 2012, ARCH ITAL BIOL, V150, P44, DOI 10.4449/aib.v150i2.1361; Massimini M, 2010, COGN NEUROSCI-UK, V1, P176, DOI 10.1080/17588921003731578; Massimini M, 2009, PROG BRAIN RES, V177, P201, DOI 10.1016/S0079-6123(09)17714-2; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Rosanova M, 2012, BRAIN, V135, P1308, DOI 10.1093/brain/awr340; Sarasso S, 2015, CURR BIOL, V25, P3099, DOI 10.1016/j.cub.2015.10.014; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2016, CURR BIOL, V26, pR572, DOI 10.1016/j.cub.2016.02.027; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Stender J., 2014, Lancet, V6736, P8, DOI DOI 10.1016/S0140-6736(14)60042-8; Stender J, 2016, CURR BIOL, V26, P1494, DOI 10.1016/j.cub.2016.04.024; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0	36	45	47	1	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2017	14						354	362		10.1016/j.nicl.2017.02.002			9	Neuroimaging	Neurosciences & Neurology	FB2OY	WOS:000405984300038	28239544	DOAJ Gold, Green Published			2021-06-18	
J	Korley, FK; Kelen, GD; Jones, CM; Diaz-Arrastia, R				Korley, Frederick K.; Kelen, Gabor D.; Jones, Courtney M.; Diaz-Arrastia, Ramon			Emergency Department Evaluation of Traumatic Brain Injury in the United States, 2009-2010	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						emergency department; epidemiology; head CT scan; imaging; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; INTRACRANIAL LESIONS; OUTCOME PREDICTION; MILD; BIOMARKERS; MANAGEMENT; DIAGNOSIS; ACCURACY	Objective: To determine the dimensions of traumatic brain injury (TBI) evaluation in US emergency department (EDs) to inform potential application of novel diagnostic tests. Setting: US EDs. Participants: National Hospital Ambulatory Medical Care Survey of ED visits in 2009 and 2010 where TBI was evaluated (1) and diagnosed either clinically or (2) with head computed tomographic (CT) scans. Design: Retrospective cross-sectional. Results: TBI was evaluated during 4.8 (95% confidence interval [CI], 4.2-5.4) million visits per year; and head CT scan was performed in 82% of TBI evaluations (3.9 [95% CI, 3.4-4.4] million visits per year). TBI was diagnosed in 52% of evaluations (2.5 [95% CI, 2.1-2.8] million visits per year). Among those who received head CT scans, 9% had CT evidence of traumatic abnormalities. Among patients evaluated for TBI who had a Glasgow Coma Scale score recorded, 94.5% were classified as having mild TBI, 2.1% as moderate TBI, and 3.5% as severe TBI. Among patients with International Classification of Diseases, Ninth Revision, Clinical Modification, codes permitting the calculation of head Abbreviated Injury Scale scores 9.0%, 85.0%, 2.5%, 3.2%, 0.3%, and 0% had head Abbreviated Injury Scale scores of 1, 2, 3, 4, 5, and 6, respectively. Of patients evaluated for TBI, 31% had other head/face/neck injuries, 10% had spine and back injuries, 7% had torso injuries, and 14% had extremity injuries. Conclusion: The ED is the main gateway to medical care for millions of patients evaluated for TBI each year. Novel diagnostic tests are needed to improve ED diagnosis and management of TBI.	[Korley, Frederick K.; Kelen, Gabor D.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Davis Bldg,Ste 3220,5801 Smith Ave, Baltimore, MD 21209 USA; [Jones, Courtney M.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Korley, FK (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, Davis Bldg,Ste 3220,5801 Smith Ave, Baltimore, MD 21209 USA.	fkorley1@jhmi.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594; Kelen, Gabor/0000-0002-3236-8286	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z99 NS999999] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS086090] Funding Source: Medline		[Anonymous], TRAUM BRAIN INJ US F; [Anonymous], AMB HLTH CAR SURV; Barell V, 2002, INJ PREV, V8, P91, DOI 10.1136/ip.8.2.91; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bender R, 1998, STAT MED, V17, P946, DOI 10.1002/(SICI)1097-0258(19980430)17:8<946::AID-SIM2823>3.0.CO;2-3; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Centers for Disease Control and Prevention, 2010 NHAMCS MICR FIL; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA, P1; Centers for Disease Control and Prevention National Center for Health Statistics., 2009, 2009 NHAMCS MICR FIL; Chong VE, 2015, J SURG RES, V199, P177, DOI 10.1016/j.jss.2015.03.086; Clark DE OT, 2010, ICDPIC STATA MODULE; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Institute of Medicine, 2013, BEST CARE LOWER COST; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Korley FK, 2010, JAMA-J AM MED ASSOC, V304, P1465, DOI 10.1001/jama.2010.1408; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marr AL., 2004, CENTRAL NERVOUS SYST; McCaig L F, 1994, Vital Health Stat 1, P1; McCaig LF, 2007, 2006 DAT US C; McCaig LF, 2012, ANN EMERG MED, V60, P716, DOI 10.1016/j.annemergmed.2012.07.010; McHugh M, 2012, ACAD EMERG MED, V19, P106, DOI 10.1111/j.1553-2712.2011.01240.x; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Owens PL, 2010, ANN EMERG MED, V56, P150, DOI 10.1016/j.annemergmed.2009.11.022; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Prichep LS, 2015, J NEUROTRAUM, V32, P17, DOI 10.1089/neu.2014.3365; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI [10.1089/neu.2009.0928, 10.1089/neu.2009-0928]; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zarzaur BL, 2010, J AM COLL SURGEONS, V211, P216, DOI 10.1016/j.jamcollsurg.2010.03.036; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	48	45	47	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2016	31	6					379	387		10.1097/HTR.0000000000000187			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EC0IW	WOS:000387784800009	26360006	Green Accepted			2021-06-18	
J	McKee, AC; Alosco, ML; Huber, BR				McKee, Ann C.; Alosco, Michael L.; Huber, Bertrand R.			Repetitive Head Impacts and Chronic Traumatic Encephalopathy	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Chronic traumatic encephalopathy; Repetitive head impacts; Traumatic brain injury; Neurodegenerative disease; Tau protein; Subconcussion; Concussion	FOOTBALL-LEAGUE PLAYER; PUNCH-DRUNK; INJURY; SPORT; NEUROPATHOLOGY; DEMENTIA	Chronic traumatic encephalopathy (CTE) is a distinctive neurodegenerative disease that occurs as a result of repetitive head impacts. CTE can only be diagnosed by postmortem neuropathologic examination of brain tissue. CTE is a unique disorder with a pathognomonic lesion that can be reliably distinguished from other neurodegenerative diseases. CTE is associated with violent behaviors, explosivity, loss of control, depression, suicide, memory loss and cognitive changes. There is increasing evidence that CTE affects amateur athletes as well as professional athletes and military veterans. CTE has become a major public health concern.	[McKee, Ann C.; Huber, Bertrand R.] VA Boston Healthcare Syst, Dept Pathol & Lab Med, 150 South Huntington Ave, Boston, MA 02130 USA; [McKee, Ann C.; Alosco, Michael L.; Huber, Bertrand R.] Boston Univ, Sch Med, Dept Neurol, 72 East Concord St, Boston, MA 02118 USA; [McKee, Ann C.; Alosco, Michael L.] Boston Univ, Sch Med, Alzheimers Dis Ctr, CTE Program, 72 East Concord St, Boston, MA 02118 USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, 72 East Concord St, Boston, MA 02118 USA	McKee, AC (corresponding author), 72 East Concord St,Robinson 7800, Boston, MA 02118 USA.	amckee@bu.edu			Department of Veterans Affairs, the Veterans Affairs Biorepository [CSP 501]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086659-01]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; Department of DefenseUnited States Department of Defense [W81XWH-13-2-0064]; Department of Defense (CENC award) [WXWH-13-2-0095]; National Operating Committee on Standards for Athletic Equipment; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment; National Football League; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32-AG06697, 1F32NS096803-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803, U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX002170, I01RX000991] Funding Source: NIH RePORTER	The authors gratefully acknowledge the use of the resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, Massachusetts), the Boston VA Healthcare System, and the Boston University School of Medicine. They also gratefully acknowledge the help of all members of the Chronic Traumatic Encephalopathy Program at Boston University School of Medicine, the Boston VA, as well as the individuals and families whose participation and contributions made this work possible. This work was supported by the Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), National Institute of Neurological Disorders and Stroke (1U01NS086659-01), the National Institute of Aging Boston University Alzheimer's Disease Center (P30AG13846; supplement 0572063345-5), Department of Defense (W81XWH-13-2-0064, CENC award WXWH-13-2-0095), the National Operating Committee on Standards for Athletic Equipment and the Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation, the World Wrestling Entertainment and the National Football League. Michael Alosco is also supported by the T32-AG06697 post-doctoral fellowship and National Institutes of Health under grant (1F32NS096803-01).	Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Critchley M., 1949, HOMMAGE CLOVIS VINCE; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Landau SM, 2013, J NUCL MED, V54, P70, DOI 10.2967/jnumed.112.109009; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2016, JAMA NEUROL, V73, P353, DOI 10.1001/jamaneurol.2015.3998; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2015, NEUROLOGY, V85, P1008; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653	28	45	46	1	60	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					529	+		10.1016/j.nec.2016.05.009			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800014	27637402	Bronze, Green Accepted			2021-06-18	
J	Ozdemir, US; Naziroglu, M; Senol, N; Ghazizadeh, V				Ozdemir, Umit Sinan; Naziroglu, Mustafa; Senol, Nilgun; Ghazizadeh, Vahid			Hypericum perforatum Attenuates Spinal Cord Injury-Induced Oxidative Stress and Apoptosis in the Dorsal Root Ganglion of Rats: Involvement of TRPM2 and TRPV1 Channels	MOLECULAR NEUROBIOLOGY			English	Article						Hypericum perforatum; Spinal cord injury; Apoptosis; Oxidative stress; TRPM2; TRPV1	ST-JOHNS-WORT; TRAUMATIC BRAIN-INJURY; NEUROPATHIC PAIN; CALCIUM-CHANNELS; N-ACETYLCYSTEINE; NITRIC-OXIDE; ADP-RIBOSE; CELLS; PATHWAY; INFLUX	Oxidative stress and cytosolic Ca2+ overload have important roles on apoptosis in dorsal root ganglion (DRG) neurons after spinal cord injury (SCI). Hypericum perforatum (HP) has an antioxidant property in the DRGs due to its ability to modulate NADPH oxidase and protein kinase C pathways. We aimed to investigate the protective property of HP on oxidative stress, apoptosis, and Ca2+ entry through transient receptor potential melastatin 2 (TRPM2) and transient receptor potential vanilloid 1 (TRPV1) channels in SCI-induced DRG neurons of rats. Rats were divided into four groups as control, HP, SCI, and SCI + HP. The HP groups received 30 mg/kg HP for three concessive days after SCI induction. The SCI-induced TRPM2 and TRPV1 currents and cytosolic free Ca2+ concentration were reduced by HP. The SCI-induced decrease in glutathione peroxidase and cell viability values were ameliorated by HP treatment, and the SCI-induced increase in apoptosis, caspase 3, caspase 9, cytosolic reactive oxygen species (ROS) production, and mitochondrial membrane depolarization values in DRG of SCI group were overcome by HP treatment. In conclusion, we observed a protective role of HP on SCI-induced oxidative stress, apoptosis, and Ca2+ entry through TRPM2 and TRPV1 in the DRG neurons. Our findings may be relevant to the etiology and treatment of SCI by HP.	[Ozdemir, Umit Sinan; Senol, Nilgun] Suleyman Demirel Univ, Dept Neurosurg, Fac Med, Isparta, Turkey; [Naziroglu, Mustafa; Ghazizadeh, Vahid] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey	Naziroglu, M (corresponding author), Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.	mustafanaziroglu@sdu.edu.tr			Unit of Scientific Research Project, Suleyman Demirel UniversitySuleyman Demirel University [BAP: 3266-TU2-12]	The study was partially supported by the Unit of Scientific Research Project, Suleyman Demirel University (NO: BAP: 3266-TU2-12). There is no financial disclosure for the current study.	Akpinar A, 2014, J MEMBRANE BIOL, V247, P451, DOI 10.1007/s00232-014-9652-1; Bejarano I, 2009, J PINEAL RES, V46, P392, DOI 10.1111/j.1600-079X.2009.00675.x; Chang Y, 2010, EUR J PHARMACOL, V634, P53, DOI 10.1016/j.ejphar.2010.02.035; Cook NL, 2010, J MOL NEUROSCI, V42, P192, DOI 10.1007/s12031-010-9347-8; Espino J, 2010, J MEMBRANE BIOL, V233, P105, DOI 10.1007/s00232-010-9230-0; Galeotti N, 2010, BIOCHEM PHARMACOL, V79, P1327, DOI 10.1016/j.bcp.2009.12.016; Genovese T, 2006, SHOCK, V25, P608, DOI 10.1097/01.shk.0000209560.54328.69; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Heemskerk JWM, 1997, EUR J BIOCHEM, V249, P547, DOI 10.1111/j.1432-1033.1997.00547.x; Heilmann J, 2003, PLANTA MED, V69, P202, DOI 10.1055/s-2003-38477; Ibi M, 2008, J NEUROSCI, V28, P9486, DOI 10.1523/JNEUROSCI.1857-08.2008; Ito N, 2013, NAT MED, V19, P101, DOI 10.1038/nm.3019; Krishtal O, 2001, PHARMACOPSYCHIATRY, V34, pS74, DOI 10.1055/s-2001-15510; Kumar VSS, 2014, CURR MED CHEM, V21, P2065, DOI 10.2174/0929867321666131228204246; Kumar V, 2006, J PHARMACOL SCI, V102, P47, DOI 10.1254/jphs.FP0060378; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Liu J, 2015, PROCEEDINGS OF 2015 INTERNATIONAL SYMPOSIUM - SAFETY AND HIGH EFFICIENCY MINING IN COAL, P230; Miyake T, 2014, BIOCHEM BIOPH RES CO, V444, P212, DOI 10.1016/j.bbrc.2014.01.022; Naziroglu M, 2015, NEUROSCIENCE, V293, P55, DOI 10.1016/j.neuroscience.2015.02.041; Naziroglu M, 2014, NEUROSCIENCE, V263, P27, DOI 10.1016/j.neuroscience.2014.01.006; Naziroglu M, 2008, NEUROCHEM RES, V33, P1256, DOI 10.1007/s11064-007-9577-5; Naziroglu M, 2008, J NEUROL SCI, V270, P152, DOI 10.1016/j.jns.2008.03.003; Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x; Naziroglu M, 2014, CELL MOL NEUROBIOL, V34, P895, DOI 10.1007/s10571-014-0069-2; Naziroglu M, 2014, NUTR NEUROSCI, V17, P214, DOI 10.1179/1476830513Y.0000000083; Naziroglu M, 2014, J MEMBRANE BIOL, V247, P253, DOI 10.1007/s00232-014-9630-7; Naziroglu M, 2013, MUSCLE NERVE, V48, P945, DOI 10.1002/mus.23844; Naziroglu M, 2013, J BIOENERG BIOMEMBR, V45, P541, DOI 10.1007/s10863-013-9524-x; Naziroglu M, 2012, NEUROCHEM RES, V37, P2065, DOI 10.1007/s11064-012-0850-x; Nishio N, 2013, NEUROSCIENCE, V247, P201, DOI 10.1016/j.neuroscience.2013.05.023; Ovey IS, 2015, NEUROSCIENCE, V284, P225, DOI 10.1016/j.neuroscience.2014.09.078; Ozgul C, 2012, PHYSIOL BEHAV, V106, P122, DOI 10.1016/j.physbeh.2012.01.014; Pei ZH, 2014, PHARMACOL RES, V82, P40, DOI 10.1016/j.phrs.2014.03.010; PLACER ZA, 1966, ANAL BIOCHEM, V16, P359, DOI 10.1016/0003-2697(66)90167-9; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Sakurai E, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-74; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Susankova K, 2006, MOL PHARMACOL, V70, P383, DOI 10.1124/mol.106.023069; Tok L, 2014, J RECEPT SIG TRANSD, V34, P410, DOI 10.3109/10799893.2014.910812; Tzellos TG, 2008, EUR J CLIN PHARMACOL, V64, P851, DOI 10.1007/s00228-008-0523-5; Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x; Vance KM, 2014, NUTRITION, V30, pS37, DOI 10.1016/j.nut.2014.02.008; Wang S, 2015, PAIN; Wu KLH, 2009, J NEUROTRAUM, V26, P965, DOI 10.1089/neu.2008.0692; Wu ZZ, 2013, PAIN, V154, P2130, DOI 10.1016/j.pain.2013.06.040; Zanoli P, 2002, BEHAV PHARMACOL, V13, P645, DOI 10.1097/00008877-200212000-00006	47	45	47	0	10	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2016	53	6					3540	3551		10.1007/s12035-015-9292-1			12	Neurosciences	Neurosciences & Neurology	DR2AO	WOS:000379707600003	26099309				2021-06-18	
J	Rogers, JM; Johnstone, SJ; Aminov, A; Donnelly, J; Wilson, PH				Rogers, Jeffrey M.; Johnstone, Stuart J.; Aminov, Anna; Donnelly, James; Wilson, Peter H.			Test-retest reliability of a single-channel, wireless EEG system	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						EEG; Test-retest reliability; Portable; NeuroSky ThinkGear; Adults; Youth	TRAUMATIC BRAIN-INJURY; SPECTRAL PARAMETERS; POWER SPECTRA; LONG-TERM; CHILDREN; PERFORMANCE; DEPRESSION; STABILITY; ANXIETY; ADULTS	Recording systems to acquire electroencephalogram (EEG) data are traditionally lab-based. However, there are shortcomings to this method, and the ease of use and portability of emerging wireless EEG technologies offer a promising alternative. A previous validity study demonstrated data derived from a single-channel, wireless system (NeuroSky ThinkGear, San Jose, California) is comparable to EEG recorded from conventional lab-based equipment. The current study evaluated the reliability of this portable system using test-retest and reliable change analyses. Relative power (RP) of delta, theta, alpha, and beta frequency bands was derived from EEG data obtained from a single electrode over FP1 in 19 healthy youth (10-17 years old), 21 healthy adults (1828 years old), and 19 healthy older adults (55-79 years old), during eyes-open, eyes-closed, auditory oddball, and visual n-back conditions. Intra-class correlations (ICCs) and Coefficients of Repeatability (CRs) were calculated from RP data re-collected one-day, one-week, and one-month later. Participants' levels of mood and attention were consistent across sessions. Eyes-closed resting EEG measurements using the portable device were reproducible (ICCs 0.76-0.85) at short and longer retest intervals in all three participant age groups. While still of at least fair reliability (ICCs 0.57-0.85), EEG obtained during eyes-open paradigms was less stable, and any change observed over time during these testing conditions can be interpreted utilizing the CR values provided. Combined with existing validity data, these findings encourage application of the portable EEG system for the study of brain function. (C) 2016 Elsevier B.V. All rights reserved.	[Rogers, Jeffrey M.; Aminov, Anna; Wilson, Peter H.] Australian Catholic Univ, Sch Psychol, Sydney, NSW 2059, Australia; [Johnstone, Stuart J.] Univ Wollongong, Sch Psychol, Wollongong, NSW 2522, Australia; [Donnelly, James] Southern Cross Univ, Sch Hlth & Human Sci, Lismore, NSW, Australia	Rogers, JM (corresponding author), Univ Sydney, Brain & Mind Ctr, 94 Mallet St, Camperdown, NSW 2050, Australia.	jeffrey.rogers@sydney.edu.au; stuart_johnstone@uow.edu.au; anna.aminov@acu.edu.au; jim.donnelly@scu.edu.au; peterH.wilson@acu.edu.au	Donnelly, James F/P-5932-2015; Wilson, Peter H./E-2881-2018	Donnelly, James F/0000-0002-2052-7948; Wilson, Peter H./0000-0003-3747-0287; Rogers, Jeffrey M/0000-0002-0320-969X			Andreassi J. L., 2007, PSYCHOPHYSIOLOGY HUM; Badcock NA, 2013, PEERJ, V1, DOI 10.7717/peerj.38; Barry RJ, 2007, CLIN NEUROPHYSIOL, V118, P2765, DOI 10.1016/j.clinph.2007.07.028; Barry RJ, 2014, INT J PSYCHOPHYSIOL, V94, P236, DOI 10.1016/j.ijpsycho.2014.08.915; Barton B., 2014, MED STAT GUIDE SPSS, V2nd; Bennett CM, 2010, ANN NY ACAD SCI, V1191, P133, DOI 10.1111/j.1749-6632.2010.05446.x; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BURGESS A, 1993, ELECTROEN CLIN NEURO, V86, P219, DOI 10.1016/0013-4694(93)90101-Z; Cacioppo J. T., 2007, HDB PSYCHOPHYSIOLOGY; Cannon RL, 2012, NEUROSCI LETT, V518, P27, DOI 10.1016/j.neulet.2012.04.035; Catafau AM, 2008, SYNAPSE, V62, P62, DOI 10.1002/syn.20465; Chi Y. M., 2010, IEEE REV BIOMED ENG, V3, P106, DOI DOI 10.1109/RBME.2010.2084078; Clarke AR, 2001, CLIN NEUROPHYSIOL, V112, P806, DOI 10.1016/S1388-2457(01)00488-6; Collado-Mateo D, 2015, SOMATOSENS MOT RES, V32, P219, DOI 10.3109/08990220.2015.1074566; Corsi-Cabrera M, 2007, CLIN NEUROPHYSIOL, V118, P9, DOI 10.1016/j.clinph.2006.08.013; Egerton A, 2010, NEUROIMAGE, V50, P524, DOI 10.1016/j.neuroimage.2009.12.058; Ekandem JI, 2012, ERGONOMICS, V55, P592, DOI 10.1080/00140139.2012.662527; Enoch MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003620; FEIN G, 1983, ELECTROEN CLIN NEURO, V55, P399, DOI 10.1016/0013-4694(83)90127-X; Fernandez T, 1993, Int J Neurosci, V68, P255; Forn C, 2007, HUM BRAIN MAPP, V28, P424, DOI 10.1002/hbm.20284; Gargiulo G, 2010, CLIN NEUROPHYSIOL, V121, P686, DOI 10.1016/j.clinph.2009.12.025; GASSER T, 1985, ELECTROEN CLIN NEURO, V60, P312, DOI 10.1016/0013-4694(85)90005-7; Gevins A, 2012, CLIN NEUROPHYSIOL, V123, P1291, DOI 10.1016/j.clinph.2011.11.004; Gevins A, 2011, CLIN NEUROPHYSIOL, V122, P114, DOI 10.1016/j.clinph.2010.06.010; Gudmundsson S, 2007, CLIN NEUROPHYSIOL, V118, P2162, DOI 10.1016/j.clinph.2007.06.018; Guevara MA, 1996, INT J PSYCHOPHYSIOL, V23, P145, DOI 10.1016/S0167-8760(96)00038-4; Handy T.C., 2005, EVENT RELATED POTENT; Hatz F, 2014, CLIN NEUROPHYSIOL; Jaeggi SM, 2010, INTELLIGENCE, V38, P625, DOI 10.1016/j.intell.2010.09.001; Jatoi MA, 2014, BIOMED SIGNAL PROCES, V11, P42, DOI 10.1016/j.bspc.2014.01.009; Johnstone SJ, 2012, CLIN EEG NEUROSCI, V43, P112, DOI 10.1177/1550059411435857; Kennett R, 2012, J NEUROL, V259, P783, DOI 10.1007/s00415-012-6425-6; Koenig T, 2002, NEUROIMAGE, V16, P41, DOI 10.1006/nimg.2002.1070; Lewis RS, 2007, BIOL PSYCHOL, V75, P239, DOI 10.1016/j.biopsycho.2007.03.004; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; LUND TR, 1995, PSYCHOPHYSIOLOGY, V32, P66, DOI 10.1111/j.1469-8986.1995.tb03407.x; Lyneham HJ, 2013, J ANXIETY DISORD, V27, P711, DOI 10.1016/j.janxdis.2013.09.008; Martin-Buro MC, 2016, HUM BRAIN MAPP, V37, P179, DOI 10.1002/hbm.23027; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; McEvoy LK, 2000, CLIN NEUROPHYSIOL, V111, P457, DOI 10.1016/S1388-2457(99)00258-8; Messer SC, 1995, INT J METH PSYCH RES, V5, P251; Mollica CM, 2005, CHILD NEUROPSYCHOL, V11, P303, DOI 10.1080/092970490911306; Mostow J, 2011, LECT NOTES ARTIF INT, V6738, P230, DOI 10.1007/978-3-642-21869-9_31; Napflin M, 2007, CLIN NEUROPHYSIOL, V118, P2519, DOI 10.1016/j.clinph.2007.07.022; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; Paasch Valerie, 2012, Neurodiagn J, V52, P333; POLLOCK VE, 1991, ELECTROEN CLIN NEURO, V79, P20, DOI 10.1016/0013-4694(91)90152-T; Portney LG, 2009, FDN CLIN RES APPL PR; Rijsdijk M, 2008, NETH J CRIT CARE, V12, P157; Rogers JM, 2015, BRAIN INJURY, V29, P343, DOI 10.3109/02699052.2014.976273; Rogers JM, 2012, ADV COGN PSYCHOL, V8, P281, DOI [10.5709/acp-0123-z, 10.2478/v10053-008-0123-z]; SALINSKY MC, 1991, ELECTROEN CLIN NEURO, V79, P382, DOI 10.1016/0013-4694(91)90203-G; Schlaggar BL, 2002, SCIENCE, V296, P1476, DOI 10.1126/science.1069464; Schomer DL., 2010, NIEDERMEYERS ELECTRO; Seshia SS, 2008, CAN J NEUROL SCI, V35, P133; Shao SY, 2009, IEEE T BIO-MED ENG, V56, P336, DOI 10.1109/TBME.2008.2005969; Sheorajpanday RVA, 2009, CLIN NEUROPHYSIOL, V120, P845, DOI 10.1016/j.clinph.2009.02.171; Shrout P E, 1998, Stat Methods Med Res, V7, P301, DOI 10.1191/096228098672090967; The Psychological Corporation, 1998, PAC AUD SER ADD TEST; Tong S., 2009, QUANTITATIVE EEG ANA; Vaz S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073990; Vuga M, 2006, INT J PSYCHOPHYSIOL, V59, P107, DOI 10.1016/j.ijpsycho.2005.02.008; Wilk CM, 2002, AM J PSYCHIAT, V159, P838, DOI 10.1176/appi.ajp.159.5.838; Woodman GF, 2010, ATTEN PERCEPT PSYCHO, V72, P2031, DOI 10.3758/APP.72.8.2031; Zuo XN, 2014, NEUROSCI BIOBEHAV R, V45, P100, DOI 10.1016/j.neubiorev.2014.05.009	66	45	49	3	44	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	AUG	2016	106						87	96		10.1016/j.ijpsycho.2016.06.006			10	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	DT7EG	WOS:000381649300009	27318008				2021-06-18	
J	Demarest, TG; Schuh, RA; Waddell, J; McKenna, MC; Fiskum, G				Demarest, Tyler G.; Schuh, Rosemary A.; Waddell, Jaylyn; McKenna, Mary C.; Fiskum, Gary			Sex-dependent mitochondrial respiratory impairment and oxidative stress in a rat model of neonatal hypoxic-ischemic encephalopathy	JOURNAL OF NEUROCHEMISTRY			English	Article						glutathione; glutathione peroxidase; oxidative phosphorylation; protein carbonyl	ACETYL-L-CARNITINE; TRAUMATIC BRAIN-INJURY; HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; DISMUTASE TRANSGENIC MICE; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; CELL-DEATH; THERAPEUTIC HYPOTHERMIA; FREE-RADICALS; NEUROPROTECTION	Increased male susceptibility to long-term cognitive deficits is well described in clinical and experimental studies of neonatal hypoxic-ischemic encephalopathy. While cell death signaling pathways are known to be sexually dimorphic, a sex dependent pathophysiological mechanism preceding the majority of secondary cell death has yet to be described. Mitochondria' dysfunction contributes to cell death following cerebral hypoxic-ischemia (HI). Several lines of evidence suggest that there are sex differences in the mitochondrial metabolism of adult mammals. Therefore, this study tested the hypothesis that brain mitochondrial respiratory impairment and associated oxidative stress is more severe in males than females following HI. Maximal brain mitochondrial respiration during oxidative phosphorylation was two-fold more impaired in males following HI. The endogenous antioxidant glutathione was 30% higher in the brain of sham females compared to males. Females also exhibited increased glutathione peroxidase (GPx) activity following HI injury. Conversely, males displayed a reduction in mitochondria! GPx4 protein levels and mitochondrial GPx activity. Moreover, a 3-4-fold increase in oxidative protein carbonylation was observed in the cortex, perirhinal cortex, and hippocampus of injured males, but not females. These data provide the first evidence for sex dependent mitochondrial respiratory dysfunction and oxidative damage, which may contribute to the relative male susceptibility to adverse long-term outcomes following HI.	[Demarest, Tyler G.; Fiskum, Gary] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Demarest, Tyler G.; Fiskum, Gary] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA; [Demarest, Tyler G.; McKenna, Mary C.; Fiskum, Gary] Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA; [Schuh, Rosemary A.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Waddell, Jaylyn; McKenna, Mary C.] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Sch Med, 685 West Baltimore St,Bldg MSTF 5-34, Baltimore, MD 21201 USA.	gfiskum@anes.umm.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01 HD016596]; M. Jane Matjasko Research Endowment; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD016596] Funding Source: NIH RePORTER	These studies were supported by NIH grant 5P01 HD016596 and the M. Jane Matjasko Research Endowment. The authors declare no conflict of interest.	Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Black SM, 1995, NEUROBIOL DIS, V2, P145, DOI 10.1006/nbdi.1995.0016; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Brown GC, 2000, ACTA PHYSIOL SCAND, V168, P667, DOI 10.1046/j.1365-201x.2000.00718.x; Davidson JO, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00198; Deierborg T, 2008, J CEREBR BLOOD F MET, V28, P1186, DOI 10.1038/jcbfm.2008.8; DellAnna E, 1997, NEUROSCI LETT, V223, P201, DOI 10.1016/S0304-3940(97)13411-5; Demarest TG, 2015, J BIOENERG BIOMEMBR, V47, P173, DOI 10.1007/s10863-014-9583-7; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Ferriero DM, 1996, NEUROBIOL DIS, V3, P64, DOI 10.1006/nbdi.1996.0006; Ferriero DM, 2001, DEV NEUROSCI-BASEL, V23, P198, DOI 10.1159/000046143; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Goo MJ, 2012, ARCH PHARM RES, V35, P145, DOI 10.1007/s12272-012-0116-9; Gulcan H, 2005, BIOL NEONATE, V88, P87, DOI 10.1159/000084905; Hagberg H, 2014, LANCET NEUROL, V13, P217, DOI 10.1016/S1474-4422(13)70261-8; Hagberg H, 2009, J CHILD NEUROL, V24, P1141, DOI 10.1177/0883073809338212; Haynes RL, 2005, BRAIN PATHOL, V15, P225; Hill CA, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/867531; Jones LL, 2010, PROG LIPID RES, V49, P61, DOI 10.1016/j.plipres.2009.08.004; Konkle ATM, 2011, ENDOCRINOLOGY, V152, P223, DOI 10.1210/en.2010-0607; Korde AS, 2005, J NEUROCHEM, V94, P1676, DOI 10.1111/j.1471-4159.2005.03328.x; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Lazarus RC, 2015, FREE RADICAL BIO MED, V78, P89, DOI 10.1016/j.freeradbiomed.2014.10.507; LIU YB, 1993, FREE RADICAL BIO MED, V15, P667, DOI 10.1016/0891-5849(93)90171-P; MBEMBA F, 1985, BIOCHIM BIOPHYS ACTA, V838, P211, DOI 10.1016/0304-4165(85)90081-9; McCullough LD, 2005, J CEREBR BLOOD F MET, V25, P502, DOI 10.1038/sj.jcbfm.9600059; Mendez M, 2015, BRAIN RES BULL, V117, P16, DOI 10.1016/j.brainresbull.2015.07.004; Morken TS, 2014, STROKE, V45, P2777, DOI 10.1161/STROKEAHA.114.005341; Mueller-Burke D, 2008, INT J DEV NEUROSCI, V26, P67, DOI 10.1016/j.ijdevneu.2007.08.015; Niatsetskaya ZV, 2012, J NEUROSCI, V32, P3235, DOI 10.1523/JNEUROSCI.6303-11.2012; Okado-Matsumoto A, 2001, J BIOL CHEM, V276, P38388, DOI 10.1074/jbc.M105395200; Olesen KM, 2005, J NEUROENDOCRINOL, V17, P255, DOI 10.1111/j.1365-2826.2005.01302.x; Patel SP, 2012, NEUROSCIENCE, V210, P296, DOI 10.1016/j.neuroscience.2012.03.006; Puka-Sundvall M, 2000, DEV BRAIN RES, V125, P43, DOI 10.1016/S0165-3806(00)00111-5; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Robertson CL, 2015, J BIOENERG BIOMEMBR, V47, P43, DOI 10.1007/s10863-014-9585-5; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scafidi S, 2010, J NEUROCHEM, V114, P820, DOI 10.1111/j.1471-4159.2010.06807.x; Sheldon RA, 2007, PEDIATR RES, V61, P666, DOI 10.1203/pdr.0b013e318053664c; Simpkins JW, 2008, ALZHEIMERS DEMENT, V4, pS131, DOI 10.1016/j.jalz.2007.10.009; Singh M, 2008, FRONT BIOSCI-LANDMRK, V13, P1083, DOI 10.2741/2746; Smith AL, 2014, EXP NEUROL, V254, P54, DOI 10.1016/j.expneurol.2014.01.003; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Ten VS, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/542976; Ten VS, 2010, J NEUROSCI, V30, P2077, DOI 10.1523/JNEUROSCI.5249-09.2010; Thornton C, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/506320; Tsuji M, 2010, EXP NEUROL, V226, P285, DOI 10.1016/j.expneurol.2010.09.002; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1986, INT J TISSUE REACT, V8, P99; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Waddell J, 2016, EXP NEUROL, V275, P285, DOI 10.1016/j.expneurol.2015.09.003; Weis SN, 2012, MITOCHONDRION, V12, P271, DOI 10.1016/j.mito.2011.10.002; Xu S, 2015, MAGN RESON MED, V74, P1530, DOI 10.1002/mrm.25537; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Yoo SE, 2012, FREE RADICAL BIO MED, V52, P1820, DOI 10.1016/j.freeradbiomed.2012.02.043; Zanelli SA, 2005, ANN NY ACAD SCI, V1053, P153, DOI 10.1196/annals.1344.013; Zheng JZ, 2010, J NEUROSCI RES, V88, P3376, DOI 10.1002/jnr.22488	67	45	46	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2016	137	5					714	729		10.1111/jnc.13590			16	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DS0BQ	WOS:000380260600005	27197831	Green Accepted			2021-06-18	
J	Zanier, ER; Marchesi, F; Ortolano, F; Perego, C; Arabian, M; Zoerle, T; Sammali, E; Pischiutta, F; De Simoni, MG				Zanier, Elisa R.; Marchesi, Federica; Ortolano, Fabrizio; Perego, Carlo; Arabian, Maedeh; Zoerle, Tommaso; Sammali, Eliana; Pischiutta, Francesca; De Simoni, Maria-Grazia			Fractalkine Receptor Deficiency Is Associated with Early Protection but Late Worsening of Outcome following Brain Trauma in Mice	JOURNAL OF NEUROTRAUMA			English	Article						fractalkine receptor; inflammation; macrophages; microglia; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; ANTIINFLAMMATORY CYTOKINES; MICROGLIAL ACTIVATION; WHITE-MATTER; MOUSE MODEL; CX(3)CR1; INFLAMMATION; DISEASE	An impaired ability to regulate microglia activation by fractalkine (CX3CL1) leads to microglia chronic sub-activation. How this condition affects outcome after acute brain injury is still debated, with studies showing contrasting results depending on the timing and the brain pathology. Here, we investigated the early and delayed consequences of fractalkine receptor (CX3CR1) deletion on neurological outcome and on the phenotypical features of the myeloid cells present in the lesions of mice with traumatic brain injury (TBI). Wild type (WT) and CX3CR1(-/-) C57Bl/6 mice were subjected to sham or controlled cortical impact brain injury. Outcome was assessed at 4 days and 5 weeks after TBI by neuroscore, neuronal count, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Compared with WT mice, CX3CR1(-/-) TBI mice showed a significant reduction of sensorimotor deficits and lower cellular damage in the injured cortex 4 days post-TBI. Conversely, at 5 weeks, they showed a worsening of sensorimotor deficits and pericontusional cell death. Microglia (M) and macrophage () activation and polarization were assessed by quantitative immunohistochemistry for CD11b, CD68, Ym1, and inducible nitric oxide synthase (iNOS)markers of M/ activation, phagocytosis, M2, and M1 phenotypes, respectively. Morphological analysis revealed a decreased area and perimeter of CD11b(+) cells in CX3CR1(-/-) mice at 4 days post-TBI, whereas, at 5 weeks, both parameters were significantly higher, compared with WT mice. At 4 days, CX3CR1(-/-) mice showed significantly decreased CD68 and iNOS immunoreactivity, while at 5 weeks post-injury, they showed a selective increase of iNOS. Gene expression on CD11b(+) sorted cells revealed an increase of interleukin 10 and insulin-like growth factor 1 (IGF1) at 1 day and a decrease of IGF1 4 days and 5 weeks post-TBI in CX3CR1(-/-), compared with WT mice. These data show an early protection followed by a chronic exacerbation of TBI outcome in the absence of CX3CR1. Thus, longitudinal effects of myeloid cell manipulation at different stages of pathology should be investigated to understand how and when their modulation may offer therapeutic chances.	[Zanier, Elisa R.; Marchesi, Federica; Perego, Carlo; Arabian, Maedeh; Sammali, Eliana; Pischiutta, Francesca; De Simoni, Maria-Grazia] IRCCS Ist Recerche Farmacol Mario Negri, Dept Neurosci, Milan, Italy; [Ortolano, Fabrizio; Zoerle, Tommaso] Osped Maggiore Policlin, Neurosci ICU, Fdn IRCCS Ca Granda, Milan, Italy; [Arabian, Maedeh] Univ Tehran Med Sci, Dept Physiol, Fac Med, Tehran, Iran; [Sammali, Eliana] Fdn IRCCS Ist Neurol Carlo Besta, Milan, Italy; [Marchesi, Federica] Univ Milan, Div Med 3, Osped San Paolo, Dipartimiento Szienze Salute, Milan, Italy	Zanier, ER (corresponding author), IRCCS Mario Negri Inst, Dept Neurosci, I-20154 Milan, Italy.	elisa.zanier@marionegri.it	De Simoni, Maria Grazia/I-6021-2012; arabian, maedeh/AAZ-2614-2020; Zanier, Elisa/AAA-8095-2020; Sammali, Eliana/AAA-2464-2019; Pischiutta, Francesca/AAA-7927-2020; Perego, Carlo/AAA-6513-2020	De Simoni, Maria Grazia/0000-0001-6695-5297; Pischiutta, Francesca/0000-0002-7151-0812; Perego, Carlo/0000-0002-0259-0003; Zanier, Elisa/0000-0002-3011-8718; Zoerle, Tommaso/0000-0001-8713-8085; Ortolano, Fabrizio/0000-0003-1996-948X			Amantea D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00147; Amantea D, 2010, BRAIN RES, V1313, P259, DOI 10.1016/j.brainres.2009.12.017; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Blomster LV, 2013, EXP NEUROL, V247, P226, DOI 10.1016/j.expneurol.2013.05.002; Briones TL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-13; Cardona AE, 2008, BLOOD, V112, P256, DOI 10.1182/blood-2007-10-118497; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268; Cipriani R, 2011, J NEUROSCI, V31, P16327, DOI 10.1523/JNEUROSCI.3611-11.2011; Cohen M, 2014, EMBO J, V33, P2906, DOI 10.15252/embj.201489293; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cunningham CL, 2013, J NEUROSCI, V33, P4216, DOI 10.1523/JNEUROSCI.3441-12.2013; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64; Denes A, 2007, J CEREBR BLOOD F MET, V27, P1941, DOI 10.1038/sj.jcbfm.9600495; Donnelly DJ, 2011, J NEUROSCI, V31, P9910, DOI 10.1523/JNEUROSCI.2114-11.2011; Fuhrmann M, 2010, NAT NEUROSCI, V13, P411, DOI 10.1038/nn.2511; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Fumagalli S, 2013, GLIA, V61, P827, DOI 10.1002/glia.22474; Garcia JA, 2013, J IMMUNOL, V191, P1063, DOI 10.4049/jimmunol.1300040; Gesuete R, 2009, ANN NEUROL, V66, P332, DOI 10.1002/ana.21740; Gosselin D, 2014, CELL, V159, P1327, DOI 10.1016/j.cell.2014.11.023; Grizenkova J, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-44; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Karlstrom S, 2013, J MED CHEM, V56, P3177, DOI 10.1021/jm3012273; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Lastres-Becker I, 2014, BRAIN, V137, P78, DOI 10.1093/brain/awt323; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longhi L, 2014, CRIT CARE MED, V42, P1910, DOI 10.1097/CCM.0000000000000399; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Longhi L, 2009, CRIT CARE MED, V37, P659, DOI 10.1097/CCM.0b013e318195998a; McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Ortolano F, 2009, J NEUROPATH EXP NEUR, V68, P964, DOI 10.1097/NEN.0b013e3181b20670; Perego C, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-174; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Prinz M, 2010, J NEUROIMMUNOL, V224, P80, DOI 10.1016/j.jneuroim.2010.05.015; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rogers JT, 2011, J NEUROSCI, V31, P16241, DOI 10.1523/JNEUROSCI.3667-11.2011; Rojo AI, 2014, ANTIOXID REDOX SIGN, V21, P1766, DOI 10.1089/ars.2013.5745; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4; Tang ZW, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-26; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Taylor SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097096; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Ueno M, 2013, NAT NEUROSCI, V16, P543, DOI 10.1038/nn.3358; Vitkovic L, 2001, NEUROIMMUNOMODULAT, V9, P295, DOI 10.1159/000059387; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wolf Y, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00026; Wollberg AR, 2014, P NATL ACAD SCI USA, V111, P5409, DOI 10.1073/pnas.1316510111; Zanier Elisa R, 2015, Intensive Care Med Exp, V3, P39, DOI 10.1186/s40635-015-0039-0; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zanier ER, 2011, CRIT CARE MED, V39, P2501, DOI 10.1097/CCM.0b013e31822629ba; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	64	45	47	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2016	33	11					1060	1072		10.1089/neu.2015.4041			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DN3SU	WOS:000376984600010	26180940	Green Published			2021-06-18	
J	Ramsey, MT; Fabian, TC; Shahan, CP; Sharpe, JP; Mabry, SE; Weinberg, JA; Croce, MA; Jennings, LK				Ramsey, Matthew T.; Fabian, Timothy C.; Shahan, Charles P.; Sharpe, John P.; Mabry, Scott E.; Weinberg, Jordan A.; Croce, Martin A.; Jennings, Lisa K.			A prospective study of platelet function in trauma patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Platelet function; acute traumatic coagulopathy; traumatic brain injury	ACTIVATED PROTEIN-C; ACUTE COAGULOPATHY; DYSFUNCTION; HYPOPERFUSION; MECHANISMS	BACKGROUND: Exsanguination associated with acute traumatic coagulopathy is a leading cause of death following injury. While platelets occupy a pivotal role in clot formation, clinical research has been scant because of complexities resulting from the need for rapid handling and complex testing of platelet functions. While the thrombin pathway has been proposed as a mediator of platelet dysfunction in trauma, it has not been systematically investigated. The purpose of this study was to evaluate the thrombin pathway in platelet dysfunction. METHODS: Forty trauma patients and 20 noninjured controls were enrolled in the study at a Level I trauma center. Platelet aggregation was tested by light transmission aggregometry with two agonists, adenosine diphosphate (ADP) and thrombin receptor agonist peptide (TRAP). Mean fluorescence intensity and percent positivity of CD62 on ADP-activated platelets were evaluated using flow cytometry. Enzyme-linked immunosorbent assays were performed to evaluate the concentrations of D-dimer, thrombin-antithrombin complex (TAT), and prothrombin fragment 1 + 2 (PF 1 + 2) in each sample. RESULTS: Compared with healthy controls, trauma patients had significantly decreased ADP-and TRAP-mediated platelet aggregation and ADP-mediated CD62 expression. In trauma patients, TRAP-mediated aggregation was inversely proportional to head Abbreviated Injury Scale (AIS) score. Glasgow Coma Scale (GCS) score was directly proportional to TRAP-and ADP-mediated aggregation. When compared with controls, significant differences of D-dimer, TAT, and PF 1 + 2 were found. Measures of shock, including admission blood pressure, pulse, base deficit, and lactate level, did not correlate with platelet dysfunction. CONCLUSION: Trauma patients have significantly lower levels of platelet activation and aggregation compared with healthy controls. Severity of head injury was significantly correlated with platelet dysfunction in a stepwise fashion. Trauma patients also have significantly increased levels of D-dimer, TAT, and PF 1 + 2 when compared with healthy controls. Our data suggest that the thrombin receptor pathway plays an important role in platelet dysfunction in trauma. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.	[Ramsey, Matthew T.; Fabian, Timothy C.; Shahan, Charles P.; Sharpe, John P.; Mabry, Scott E.; Weinberg, Jordan A.; Croce, Martin A.; Jennings, Lisa K.] Univ Tennessee, Dept Surg, Hlth Sci Ctr, Memphis, TN USA	Fabian, TC (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Surg, 910 Madison Ave,Second Floor, Memphis, TN 38163 USA.	tfabian@uthsc.edu					Andrews RK, 1997, INT J BIOCHEM CELL B, V29, P91, DOI 10.1016/S1357-2725(96)00122-7; Berndt MC, 1995, AUST NZ J MED, V25, P822, DOI 10.1111/j.1445-5994.1995.tb02887.x; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Bune LT, 2010, BLOOD COAGUL FIBRIN, V21, P436, DOI 10.1097/MBC.0b013e328338db27; Chandler AB, 2010, THROMB RES, V125, P44, DOI 10.1016/j.thromres.2009.04.017; Chesebro BB, 2009, SHOCK, V32, P659, DOI 10.1097/SHK.0b013e3181a5a632; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Esmon CT, 2001, CRIT CARE, V5, pS7, DOI 10.1186/cc1333; Giri S, 2015, THROMB RES, V135, P782, DOI 10.1016/j.thromres.2015.02.013; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Graff J, 2002, J PHARMACOL EXP THER, V300, P952, DOI 10.1124/jpet.300.3.952; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Hoyt DB, 2004, SEMIN HEMATOL, V41, P40, DOI 10.1053/j.seminhematol.2003.11.009; HULTIN MB, 1982, J CLIN INVEST, V69, P950, DOI 10.1172/JCI110534; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Jennings LK, 2009, THROMB HAEMOSTASIS, V102, P248, DOI 10.1160/TH09-03-0192; Jennings LK, 2006, PLATELETS, P495; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39; Solomon C, 2011, THROMB HAEMOSTASIS, V106, P322, DOI 10.1160/TH11-03-0175; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; WALSH PN, 1981, BLOOD, V57, P106; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050	27	45	45	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2016	80	5					726	732		10.1097/TA.0000000000001017			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DM9ZB	WOS:000376723100008	26895088				2021-06-18	
J	Wade, SL; Zhang, N; Yeates, KO; Stancin, T; Taylor, HG				Wade, Shari L.; Zhang, Nanhua; Yeates, Keith Owen; Stancin, Terry; Taylor, H. Gerry			Social Environmental Moderators of Long-term Functional Outcomes of Early Childhood Brain Injury	JAMA PEDIATRICS			English	Article							FAMILY ASSESSMENT DEVICE; EXECUTIVE DYSFUNCTION; PARENTING PRACTICES; BEHAVIOR PROBLEMS; ASSESSMENT SCALE; YOUNG-CHILDREN; RELIABILITY; PREDICTORS; RECOVERY; VALIDITY	IMPORTANCE Pediatric traumatic brain injury (TBI) contributes to impairments in behavior and academic performance. However, the long-term effects of early childhood TBI on functioning across settings remain poorly understood. OBJECTIVE To examine the long-term functional outcomes of early childhood TBI relative to early childhood orthopedic injuries (OIs). We also examine the moderating role of the social environment as defined by parent report and observational measures of family functioning, parenting practices, and home environment. DESIGN, SETTING, AND PARTICIPANTS A prospective, longitudinal, observational cohort study conducted at each child's home, school, and hospital, including 3 children's hospitals and 1 general hospital in the Midwest. Patients were enrolled in the initial study between January 2003 and October 2006. Follow-ups were completed between January 2010 and April 2015. Fifty-eight children who sustained a TBI (67% of original enrolled cohort) and 72 children who sustained an OI (61% of the original enrolled cohort) were prospectively followed up from shortly after injury (between the ages of 3 and 7 years at enrollment) to an average of 6.7 years after injury, with assessments occurring at multiple points. MAIN OUTCOMES AND MEASURES Long-term functional outcomes in everyday settings, as assessed through the Child and Adolescent Functional Assessment Scale (CAFAS). RESULTS Of the 130 children included, the median age for those with OIs was 11.72 years and 11.97, 12.21, and 11.72 years for those with complicated mild, moderate, and severe TBIs, respectively. Children with moderate and severe TBI were rated as having more functional impairments in multiple domains than those with OIs (P <.05). Children with complicated mild TBI had greater impairments in school (odds ratio = 2.93; 95% CI = 1.10-7.82) and with thinking (odds ratio = 15.72; 95% CI = 3.31-74.73) than those with OIs. Functional impairments in children with TBI were more pronounced among children from families with higher levels of permissive (mean CAFAS of 49.71, 35.74, 58.14, and 16.16 for severe TBI, moderate TBI, complicated mild TBI, and OI, respectively, with significant difference between severe TBI and OI [difference = 33.55; P <.001] and complicated mild TBI and OI [difference = 41.98; P <.001]) or authoritarian (mean CAFAS of 56.45, 41.80, 54.90, and 17.12 for severe TBI, moderate TBI, complicated mild TBI, and OI, respectively, with significant difference between severe TBI and OI [difference = 39.33; P <.001], moderate TBI and OI [difference = 24.68; P =.003], and complicated mild TBI and OI [difference = 37.78; P <.001]) parenting or with fewer home resources (mean CAFAS of 69.57, 47.45, 49.00, and 23.81 for severe TBI, moderate TBI, complicated mild TBI, and OI, respectively, with significant difference between severe TBI and OI [difference = 45.77; P <.001], moderate TBI and OI [difference = 23.64; P <.001], and complicated mild TBI and OI [difference = 25.20; P <.001]). CONCLUSIONS AND RELEVANCE Even children with relatively mild early TBI experience long-term functional impairments, particularly in the context of less favorable home environments. These findings suggest that improving parenting skills and the quality of the home environment may promote functional recovery following early TBI.	[Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA; [Wade, Shari L.; Zhang, Nanhua] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Yeates, Keith Owen] Univ Calgary, Dept Psychol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada; [Yeates, Keith Owen] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Yeates, Keith Owen] Univ Calgary, Alberta Childrens Hosp, Res Inst, Cumming Sch Med, Calgary, AB, Canada; [Stancin, Terry] Case Western Reserve Univ, Dept Psychiat, Div Child & Adolescent Psychiat & Psychol, Cleveland, OH 44106 USA; [Stancin, Terry] Metrohlth Med Ctr, Cleveland, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Dept Pediat, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Zhang, Nanhua/0000-0001-5796-3404; Yeates, Keith/0000-0001-7680-2892	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; Trauma Research grants from the State of Ohio Emergency Medical Services; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8 UL1 TR000077]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077, UL1TR001425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [F30AI109893] Funding Source: NIH RePORTER	This publication was supported by grant R01 HD42729 from the National Institute of Child Health and Human Development and by Trauma Research grants from the State of Ohio Emergency Medical Services. Additional support was provided through grant 8 UL1 TR000077 from the National Center for Advancing Translational Sciences of the National Institutes of Health.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Antonini TN, 2014, BEHAV THER, V45, P455, DOI 10.1016/j.beth.2014.02.003; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; BAUMRIND D, 1971, DEV PSYCHOL, V4, P1, DOI 10.1037/h0030372; Bender R, 1997, J ROY COLL PHYS LOND, V31, P546; BRADLEY RH, 1984, DEV PSYCHOL, V20, P315, DOI 10.1037/0012-1649.20.2.315; Bradley RH, 2000, J RES ADOLESCENCE, V10, P247, DOI 10.1207/SJRA1003_1; Brown FL, 2014, J CHILD PSYCHOL PSYC, V55, P1172, DOI 10.1111/jcpp.12227; Brown FL, 2013, J HEAD TRAUMA REHAB, V28, P349, DOI 10.1097/HTR.0b013e318245fed5; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Hodges K, 1998, J BEHAV HEALTH SER R, V25, P325, DOI 10.1007/BF02287471; Hodges K, 1997, J MENT HEALTH ADMIN, V24, P278, DOI 10.1007/BF02832662; Hodges K., 1994, CHILD ADOLESCENT FUN; Hodges K., 2003, CAFAS MANUAL TRAININ; Hodges K., 1996, J CHILD FAM STUD, V5, P445, DOI [10.1007/BF02233865, DOI 10.1007/BF02233865]; Hosmer Jr David W., 2013, APPL LOGISTIC REGRES, V398; Ilie G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094936; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Potter JL, 2011, REHABIL PSYCHOL, V56, P351, DOI 10.1037/a0025445; Robinson C, 2001, HDB FAMILY MEASURES, V3, P319, DOI DOI 10.1177/0192513X09357555; ROBINSON CC, 1995, PSYCHOL REP, V77, P819, DOI 10.2466/pr0.1995.77.3.819; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; TEASDALE G, 1974, LANCET, V2, P81; Todis B, 2011, J HEAD TRAUMA REHAB, V26, P138, DOI 10.1097/HTR.0b013e3181e5a87a; Totsika Vasiliki, 2004, Child Adolesc Ment Health, V9, P25, DOI 10.1046/j.1475-357X.2003.00073.x; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Woods DT, 2011, DEV NEUROREHABIL, V14, P274, DOI 10.3109/17518423.2011.586371; Woods DT, 2013, SOCIAL CARE NEURODIS, V4, P94, DOI DOI 10.1108/SCN-01-2013-0003; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	43	45	45	2	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	APR	2016	170	4					343	349		10.1001/jamapediatrics.2015.4485			7	Pediatrics	Pediatrics	DI3EI	WOS:000373380800014	26902662	Green Accepted, Bronze			2021-06-18	
J	Koerte, IK; Hufschmidt, J; Muehlmann, M; Tripodis, Y; Stamm, JM; Pasternak, O; Giwerc, MY; Coleman, MJ; Baugh, CM; Fritts, NG; Heinen, F; Lin, A; Stern, RA; Shenton, ME				Koerte, Inga K.; Hufschmidt, Jakob; Muehlmann, Marc; Tripodis, Yorghos; Stamm, Julie M.; Pasternak, Ofer; Giwerc, Michelle Y.; Coleman, Michael J.; Baugh, Christine M.; Fritts, Nathan G.; Heinen, Florian; Lin, Alexander; Stern, Robert A.; Shenton, Martha E.			Cavum Septi Pellucidi in Symptomatic Former Professional Football Players	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; head trauma; MRI; neurodegenerative disorders; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; REPETITIVE BRAIN TRAUMA; MRI FINDINGS; SCHIZOPHRENIA; INJURY; DEMENTIA; DISORDER; DISEASE; BOXERS; IMPACT	Post-mortem studies reveal a high rate of cavum septi pellucidi (CSP) in chronic traumatic encephalopathy (CTE). It remains, however, to be determined whether or not the presence of CSP may be a potential in vivo imaging marker in populations at high risk to develop CTE. The aim of this study was to evaluate CSP in former professional American football players presenting with cognitive and behavioral symptoms compared with noncontact sports athletes. Seventy-two symptomatic former professional football players (mean age 54.53 years, standard deviation [SD] 7.97) as well as 14 former professional noncontact sports athletes (mean age 57.14 years, SD 7.35) underwent high-resolution structural 3T magnetic resonance imaging. Two raters independently evaluated the CSP, and interrater reliability was calculated. Within National Football League players, an association of CSP measures with cognitive and behavioral functioning was evaluated using a multivariate mixed effects model. The measurements of the two raters were highly correlated (CSP length: rho=0.98; Intraclass Correlation Coefficient [ICC] 0.99; p<0.0001; septum length: rho=0.93; ICC 0.96; p<0.0001). For presence versus absence of CSP, there was high agreement (Cohen kappa=0.83, p<0.0001). A higher rate of CSP, a greater length of CSP, as well as a greater ratio of CSP length to septum length was found in symptomatic former professional football players compared with athlete controls. In addition, a greater length of CSP was associated with decreased performance on a list learning task (Neuropsychological Assessment Battery List A Immediate Recall, p=0.04) and decreased test scores on a measure of estimate verbal intelligence (Wide Range Achievement Test Fourth Edition Reading Test, p=0.02). Given the high prevalence of CSP in neuropathologically confirmed CTE in addition to the results of this study, CSP may serve as a potential early in vivo imaging marker to identify those at high risk for CTE. Future research is needed to investigate the pathomechanism underlying the development of CSP after repetitive head impacts, and its potential association with neuropathologically confirmed CTE.	[Koerte, Inga K.; Hufschmidt, Jakob; Muehlmann, Marc; Stamm, Julie M.; Pasternak, Ofer; Giwerc, Michelle Y.; Coleman, Michael J.; Lin, Alexander; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Psychiat Neuroimaging Lab,Dept Psychiat, Boston, MA 02115 USA; [Koerte, Inga K.; Muehlmann, Marc] Univ Munich, Dept Child & Adolescent Psychiat Psychosomat & Ps, Munich, Germany; [Hufschmidt, Jakob; Heinen, Florian] Univ Munich, Dr von Hauner Childrens Hosp, Dept Pediat Neurol, Munich, Germany; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Tripodis, Yorghos; Stamm, Julie M.; Baugh, Christine M.; Fritts, Nathan G.; Stern, Robert A.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA; [Tripodis, Yorghos; Stern, Robert A.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Stamm, Julie M.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Lin, Alexander; Shenton, Martha E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Lin, Alexander] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Clin Spect,Dept Radiol, Boston, MA 02115 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton Div, Brockton, MA USA	Koerte, IK (corresponding author), Brigham & Womens Hosp, Psychiat Neuroimaging Lab, 1249 Boylston St, Boston, MA 02215 USA.	ikoerte@bwh.harvard.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020; Heinen, Florian/B-6594-2015; Shenton, Martha/V-8780-2019	Baugh, Christine/0000-0002-9340-6338; Heinen, Florian/0000-0002-3872-6136; Tripodis, Yorghos/0000-0003-2190-7608	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS081957, R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1-TR000157] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG013846, P30 AG13846] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019733] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31 NS 081957, R01 NS078337] Funding Source: Medline		Areza-Fegyveres R, 2007, ARQ NEURO-PSIQUIAT, V65, P830, DOI 10.1590/S0004-282X2007000500019; Aviv RI, 2010, CAN ASSOC RADIOL J, V61, P29, DOI 10.1016/j.carj.2009.09.002; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Beaton EA, 2010, PSYCHIAT RES-NEUROIM, V181, P108, DOI 10.1016/j.pscychresns.2009.10.009; BOGDANOFF B, 1989, NEUROLOGY, V39, P991, DOI 10.1212/WNL.39.7.991; Born CM, 2004, EUR ARCH PSY CLIN N, V254, P295, DOI 10.1007/s00406-004-0496-z; Brent BK, 2013, CHILD ADOL PSYCH CL, V22, P689, DOI 10.1016/j.chc.2013.06.003; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Filipovic B, 2004, EUR ARCH PSY CLIN N, V254, P228, DOI 10.1007/s00406-004-0483-4; Flashman LA, 2007, PSYCHIAT RES-NEUROIM, V154, P147, DOI 10.1016/j.pscychresns.2006.09.001; Gardner R. C., 2015, J NEUROTRAUMA; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gur RE, 2013, AM J NEURORADIOL, V34, P2021, DOI 10.3174/ajnr.A3525; Hagino H, 2001, AM J PSYCHIAT, V158, P1717, DOI 10.1176/appi.ajp.158.10.1717; Handratta V, 2010, NEUROCASE, V16, P125, DOI 10.1080/13554790903329166; Hasiloglu ZI, 2011, AM J NEURORADIOL, V32, P99, DOI 10.3174/ajnr.A2250; Koerte IK, 2015, BRAIN PATHOL, V25, P318, DOI 10.1111/bpa.12249; Kwon JS, 1998, AM J PSYCHIAT, V155, P509, DOI 10.1176/ajp.155.4.509; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCarley RW, 1999, BIOL PSYCHIAT, V45, P1099, DOI 10.1016/S0006-3223(99)00018-9; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Ng TSC, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt239; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Pittella JEH, 2005, SURG NEUROL, V63, P30, DOI 10.1016/j.surneu.2004.09.012; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Shenton ME, 2001, SCHIZOPHR RES, V49, P1, DOI 10.1016/S0920-9964(01)00163-3; Silk T, 2013, PSYCHIAT RES-NEUROIM, V213, P186, DOI 10.1016/j.pscychresns.2013.03.001; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stamm J. M., 2015, J NEUROTRAUMA; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Winter TC, 2010, J ULTRAS MED, V29, P427, DOI 10.7863/jum.2010.29.3.427	39	45	45	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2016	33	4					346	353		10.1089/neu.2015.3880			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DD2NH	WOS:000369758800004	26414478	Green Published			2021-06-18	
J	Meier, TB; Bergamino, M; Bellgowan, PSF; Teague, TK; Ling, JM; Jeromin, A; Mayer, AR				Meier, Timothy B.; Bergamino, Maurizio; Bellgowan, Patrick S. F.; Teague, T. K.; Ling, Josef M.; Jeromin, Andreas; Mayer, Andrew R.			Longitudinal Assessment of White Matter Abnormalities Following Sports-Related Concussion	HUMAN BRAIN MAPPING			English	Article						diffusion tensor imaging; mTBI; fractional anisotropy; tau	TRAUMATIC BRAIN-INJURY; TENSOR IMAGING FINDINGS; COLLEGIATE FOOTBALL PLAYERS; CEREBROSPINAL-FLUID; NCAA CONCUSSION; NERVOUS-SYSTEM; DIFFUSION; BIOMARKERS; RECOVERY; ADOLESCENTS	There is great interest in developing physiological-based biomarkers such as diffusion tensor imaging to aid in the management of concussion, which is currently entirely dependent on clinical judgment. However, the time course for recovery of white matter abnormalities following sportsrelated concussion (SRC) is unknown. We collected diffusion tensor imaging and behavioral data in forty concussed collegiate athletes on average 1.64 days (T1; n = 33), 8.33 days (T2; n = 30), and 32.15 days post-concussion (T3; n = 26), with healthy collegiate contact-sport athletes (HA) serving as controls (n = 46). We hypothesized that fractional anisotropy (FA) would be increased acutely and partially recovered by one month post-concussion. Mood symptoms were assessed using structured interviews. FA differences were assessed using both traditional and subject-specific analyses. An exploratory analysis of tau plasma levels was conducted in a subset of participants. Results indicated that mood symptoms improved over time post-concussion, but remained elevated at T3 relative to HA. Across both group and subject-specific analyses, concussed athletes exhibited increased FA in several white matter tracts at each visit post-concussion with no longitudinal evidence of recovery. Increased FA at T1 and T3 was significantly associated with an independent, real-world outcome measure for return-to-play. Finally, we observed a nonsignificant trend for reduced tau in plasma of concussed athletes at T1 relative to HA, with tau significantly increasing by T2. These results suggest white matter abnormalities following SRC may persist beyond one month and have potential as an objective biomarker for concussion outcome. (C) 2015 Wiley Periodicals, Inc.	[Meier, Timothy B.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Meier, Timothy B.; Ling, Josef M.; Mayer, Andrew R.] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM USA; [Meier, Timothy B.; Bergamino, Maurizio] Laureate Inst Brain Res, Tulsa, OK USA; [Bellgowan, Patrick S. F.] NINDS, NIH, North Bethesda, MD USA; [Teague, T. K.] Univ Oklahoma, Coll Med, Dept Surg, Tulsa, OK USA; [Teague, T. K.] Univ Oklahoma, Coll Med, Dept Psychiat, Tulsa, OK USA; [Teague, T. K.] Univ Oklahoma, Coll Pharm, Dept Pharmaceut Sci, Tulsa, OK USA; [Teague, T. K.] Oklahoma State Univ, Ctr Hlth Sci, Dept Biochem & Microbiol, Tulsa, OK USA; [Jeromin, Andreas] Quanterix Corp, Lexington, MA USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Meier, Timothy B.; Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA	Meier, TB (corresponding author), Neurosci Res Ctr, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	tmeier@mcw.edu	Teague, T. Kent/A-2527-2008	Teague, T. Kent/0000-0002-4680-5440	Laureate Institute for Brain Research	Contract grant sponsor: Laureate Institute for Brain Research	Arun P, 2013, NEUROSCI LETT, V552, P87, DOI 10.1016/j.neulet.2013.07.047; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Borich M, 2013, J NEUROTRAUM, V30, P1243, DOI 10.1089/neu.2012.2818; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chen G, 2013, NEUROIMAGE, V73, P176, DOI 10.1016/j.neuroimage.2013.01.047; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Dodd AB, 2014, J NEUROTRAUM, V31, P1235, DOI 10.1089/neu.2014.3337; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones TB, 2010, NEUROIMAGE, V49, P401, DOI 10.1016/j.neuroimage.2009.07.051; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2014, HUM BRAIN MAPP, V35, P5457, DOI 10.1002/hbm.22563; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mori S, 2007, AM J PSYCHIAT, V164, P1005, DOI 10.1176/appi.ajp.164.7.1005; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Roebuck-Spencer TM, 2013, ARCH CLIN NEUROPSYCH, V28, P700, DOI 10.1093/arclin/act055; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Singh R, 2015, J NEUROL NE IN PRESS; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Talairach J., 1988, COPLANAR STEREOTAXIC; Thorne DR, 2006, BEHAV RES METHODS, V38, P569; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Turken And U, 2009, BMC Med Imaging, V9, P20, DOI 10.1186/1471-2342-9-20; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu S, 2011, J NEUROTRAUM, V28, P2091, DOI 10.1089/neu.2010.1739; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	54	45	45	0	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	FEB	2016	37	2					833	845		10.1002/hbm.23072			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	DD9KB	WOS:000370243000030	26663463	Green Published			2021-06-18	
S	Gardner, AJ; Zafonte, R		Rosano, C; Ikram, MA; Ganguli, M		Gardner, A. J.; Zafonte, R.			Neuroepidemiology of traumatic brain injury	NEUROEPIDEMIOLOGY	Handbook of Clinical Neurology		English	Article; Book Chapter							GLASGOW COMA SCALE; WESTMEAD PTA SCALE; SEVERE HEAD-INJURY; AXONAL INJURY; POSTTRAUMATIC AMNESIA; CORTICOSPINAL NEURONS; TRANSFORMING RESEARCH; COGNITIVE IMPAIRMENT; OUTCOME PREDICTION; CLINICAL KNOWLEDGE	Traumatic brain injury (TBI) is a significant public-health concern. TBI is defined as an acute brain injury resulting from mechanical energy to the head from external physical forces. Some of the leading causes of TBI include falls, assaults, motor vehicle or traffic accidents, and sport-related concussion. Two of the most common identified risk factors are sex (males are nearly three times more likely to suffer a TBI than females); and a bimodal age pattern (persons 65 years and older, and children under 14 years old). It is estimated that approximately 1.5-2 million Americans suffer from TBI annually. TBIs account for around 1.4 million emergency room visits, 275 000 hospital admissions, and 52 000 deaths in the USA each year. TBI contributes to approximately 30% of all deaths in the USA annually. In Australia, it is estimated that approximately 338 700 individuals (1.9% of the population) suffer from a disability related to TBI. Of these, 160 200 were severely or profoundly affected by acquired brain injury, requiring daily support. In the UK, TBI accounted for 3.4% of all emergency department attendances annually. An overall rate of 453 per 100 000 was found for all TBI severities, of which 40 per 100 000 (10.9%) were moderate to severe. TBI often results in residual symptoms that affect an individual's cognition, movement, sensation, and/or emotional functioning. Recovery and rehabilitation from TBI may require considerable resources and may take years. Some individuals never fully recover, and some require lifetime ongoing care and support. TBI has an enormous social and financial cost, with estimates of the annual financial burden associated with TBI ranging between 9 and 10 billion US dollars.	[Gardner, A. J.] Hunter New England Local Hlth Dist Sports Concuss, Callaghan, NSW, Australia; [Gardner, A. J.] Univ Newcastle, Sch Med & Publ Hlth, Prior Res Ctr Stroke & Brain Injury, Callaghan, NSW, Australia; [Zafonte, R.] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [Zafonte, R.] Brigham & Womens Hosp, MassGen Hosp Children, Sport Concuss Program, Boston, MA USA; [Zafonte, R.] Brigham & Womens Hosp, Red Sox Fdn, 75 Francis St, Boston, MA 02115 USA; [Zafonte, R.] Brigham & Womens Hosp, Massachusetts Gen Hosp, Home Base Program, 75 Francis St, Boston, MA 02115 USA	Gardner, AJ (corresponding author), Calvary Mater Hosp, Ctr Translat Neurosci & Mental Hlth, Level 5,McCauley Bldg, Waratah, NSW 2298, Australia.	andrew.gardner@neurogard.com.au					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Austin CA, 2013, BRAIN INJURY, V27, P1056, DOI 10.3109/02699052.2013.794964; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; Bowen A, 1999, BRAIN INJURY, V13, P547; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Briggs R, 2015, DEV MED CHILD NEUROL, V57, P618, DOI 10.1111/dmcn.12674; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; Davis KC, 2016, J HEAD TRAUMA REHAB, V31, pE39, DOI 10.1097/HTR.0000000000000159; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; Evans R., 2006, NEUROLOGY AND TRAUMA; Farquharson S, 2013, J NEUROSURG, V118, P1367, DOI 10.3171/2013.2.JNS121294; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Giehl KM, 1997, EUR J NEUROSCI, V9, P2479, DOI 10.1111/j.1460-9568.1997.tb01665.x; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Graham DI, 1991, GREENFIELDS NEUROPAT, P823; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Haring RS, 2015, J SURG RES, V195, P1, DOI 10.1016/j.jss.2015.01.017; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Injury Prevention and Control, INJ PREV CONTR TRAUM; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1975, LANCET, V1, P480; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson VE, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2014.241; Katz D.I., 2007, BRAIN INJURY MED PRI, P3; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lehmann C, 2009, BRAIN RES, V1297, P1, DOI 10.1016/j.brainres.2009.08.070; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; McMillan TM, 2015, INT ENCY SOCIAL BEHA, P636; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Meares S, 2011, BRAIN INJURY, V25, P1198, DOI 10.3109/02699052.2011.608213; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Novack T, 2000, THE ORIENTATION LOG; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ranaivo HR, 2011, J NEUROTRAUM, V28, P1757, DOI 10.1089/neu.2011.1799; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Ribot T-A., 1881, MALADIES MEMOIRE; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Schootman M, 2000, BRAIN INJURY, V14, P373; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith DH, 1999, J NEUROSCI, V19, P4263; Staal JA, 2007, DEV NEUROBIOL, V67, P1831, DOI 10.1002/dneu.20552; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Stein DG, 2015, HDB CLIN NEUROLOGY; Syed A T, 2007, Int J Health Sci (Qassim), V1, P131; Tate RL, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.074989; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Tseng WC, 2011, J TRAUMA, V71, P1611, DOI 10.1097/TA.0b013e31823a8a60; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256	106	45	48	2	7	ELSEVIER SCIENCE BV	AMSTERDAM	SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0072-9752		9780-1-28-02990-9; 9780-1-28-02973-2	HAND CLINIC			2016	138						207	223		10.1016/B978-0-12-802973-2.00012-4			17	Clinical Neurology	Neurosciences & Neurology	BI3EQ	WOS:000410828400014	27637960				2021-06-18	
J	Azabou, E; Magalhaes, E; Braconnier, A; Yahiaoui, L; Moneger, G; Heming, N; Annane, D; Mantz, J; Chretien, F; Durand, MC; Lofaso, F; Porcher, R; Sharshar, T				Azabou, Eric; Magalhaes, Eric; Braconnier, Antoine; Yahiaoui, Lyria; Moneger, Guy; Heming, Nicholas; Annane, Djillali; Mantz, Jean; Chretien, Fabrice; Durand, Marie-Christine; Lofaso, Frederic; Porcher, Raphael; Sharshar, Tarek		GENER	Early Standard Electroencephalogram Abnormalities Predict Mortality in Septic Intensive Care Unit Patients	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; PERIODIC EPILEPTIFORM DISCHARGES; MECHANICALLY VENTILATED PATIENTS; TRAUMATIC BRAIN-INJURY; ELECTROGRAPHIC SEIZURES; ACUTE PHYSIOLOGY; SEPSIS; EEG; ENCEPHALOPATHY; GUIDELINES	Introduction Sepsis is associated with increased mortality, delirium and long-term cognitive impairment in intensive care unit (ICU) patients. Electroencephalogram (EEG) abnormalities occurring at the acute stage of sepsis may correlate with severity of brain dysfunction. Predictive value of early standard EEG abnormalities for mortality in ICU septic patients remains to be assessed. Methods In this prospective, single center, observational study, standard EEG was performed, analyzed and classified according to both Synek and Young EEG scales, in consecutive patients acutely admitted in ICU for sepsis. Delirium, coma and the level of sedation were assessed at the time of EEG recording; and duration of sedation, occurrence of in-ICU delirium or death were assessed during follow-up. Adjusted analyses were carried out using multiple logistic regression. Results One hundred ten patients were included, mean age 63.8 (+/- 18.1) years, median SAPS-II score 38 (29-55). At the time of EEG recording, 46 patients (42%) were sedated and 22 (20%) suffered from delirium. Overall, 54 patients (49%) developed delirium, of which 32 29%) in the days after EEG recording. 23 (21%) patients died in the ICU. Absence of EEG reactivity was observed in 27 patients (25%), periodic discharges (PDs) in 21 (19%) and electrographic seizures (ESZ) in 17 (15%). ICU mortality was independently associated with a delta-predominant background (OR: 3.36; 95% CI [1.08 to 10.4]), absence of EEG reactivity (OR: 4.44; 95% CI [1.37-14.3], PDs (OR: 3.24; 95% CI [1.03 to 10.2]), Synek grade >= 3 (OR: 5.35; 95% CI [1.66-17.2]) and Young grade > 1 (OR: 3.44; 95% CI [1.09-10.8]) after adjustment to Simplified Acute Physiology Score (SAPS-II) at admission and level of sedation. Delirium at the time of EEG was associated with ESZ in non-sedated patients (32% vs 10%, p = 0.037); with Synek grade >= 3 (36% vs 7%, p< 0.05) and Young grade > 1 (36% vs 17%, p< 0.001). Occurrence of delirium in the days after EEG was associated with a delta-predominant background (48% vs 15%, p = 0.001); absence of reactivity (39% vs 10%, p = 0.003), Synek grade >= 3 (42% vs 17%, p = 0.001) and Young grade > 1 (58% vs 17%, p = 0.0001). Conclusions In this prospective cohort of 110 septic ICU patients, early standard EEG was significantly disturbed. Absence of EEG reactivity, a delta-predominant background, PDs, Synek grade >= 3 and Young grade > 1 at day 1 to 3 following admission were independent predictors of ICU mortality and were associated with occurence of delirium. ESZ and PDs, found in about 20% of our patients. Their prevalence could have been higher, with a still higher predictive value, if they had been diagnosed more thoroughly using continuous EEG.	[Azabou, Eric; Durand, Marie-Christine; Lofaso, Frederic] Univ Versailles St Quentin En Yvelines Garches, Dept Physiol, Assistance Publ Hop Paris, Raymond Poincare Hosp,U1179,INSERM, Versailles, France; [Azabou, Eric; Magalhaes, Eric; Braconnier, Antoine; Yahiaoui, Lyria; Moneger, Guy; Heming, Nicholas; Annane, Djillali; Sharshar, Tarek] Univ Versailles St Quentin En Yvelines Garches, Gen Intens Care Med, Assistance Publ Hop Paris, Raymond Poincare Hosp,U1173,INSERM, Versailles, France; [Mantz, Jean] Paris Descartes Univ, Dept Anesthesiol & Intens Care Med, European Hosp Georges Pompidou, Paris, France; [Chretien, Fabrice] Inst Pasteur, Lab Human Histopathol & Anim Models, Paris, France; [Porcher, Raphael] Univ Paris 05, Hotel Dieu Hosp, Assistance Publ Hop Paris, Dept Stat, Paris, France	Sharshar, T (corresponding author), Univ Versailles St Quentin En Yvelines Garches, Gen Intens Care Med, Assistance Publ Hop Paris, Raymond Poincare Hosp,U1173,INSERM, Versailles, France.	tarek.sharshar@rpc.aphp.fr	WEISS, Nicolas/Q-2394-2019; Annane, Djillali/R-7947-2019; Rohaut, Benjamin/O-9250-2017; Verdonk, Franck/AAG-8997-2021; Lofaso, Frederic/R-6100-2018; Chretien, fabrice B/D-4035-2018; Sonneville, Romain/AAE-7039-2020; Gaillard, Raphael/J-6527-2015	WEISS, Nicolas/0000-0001-5155-196X; Rohaut, Benjamin/0000-0001-6752-8756; Verdonk, Franck/0000-0001-7061-5594; Chretien, fabrice B/0000-0002-2794-1383; Sonneville, Romain/0000-0003-0245-309X; Porcher, Raphael/0000-0002-5277-4679; Adam, Nicolas/0000-0002-0933-7705; naccache, lionel/0000-0002-2874-1009; Gaillard, Raphael/0000-0002-1297-4369; Navarro, Vincent/0000-0003-0077-8114			Adam N, 2013, EXPERT REV ANTI-INFE, V11, P211, DOI [10.1586/ERI.12.159, 10.1586/eri.12.159]; Akman CI, 2013, EPILEPSY RES, V106, P378, DOI 10.1016/j.eplepsyres.2013.06.019; Akman CI, 2011, J CLIN NEUROPHYSIOL, V28, P366, DOI 10.1097/WNP.0b013e3182273486; ANDERSEN P, 1967, J PHYSIOL-LONDON, V192, P283, DOI 10.1113/jphysiol.1967.sp008300; Andre-Obadia N, 2014, NEUROPHYSIOL CLIN, V44, P515, DOI 10.1016/j.neucli.2014.10.001; Andresen JM, 2014, CRIT CARE MED, V42, P2244, DOI 10.1097/CCM.0000000000000522; Annane D, 2015, LANCET RESP MED, V3, P61, DOI 10.1016/S2213-2600(14)70246-2; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; Coulon P, 2009, CELL CALCIUM, V46, P333, DOI 10.1016/j.ceca.2009.09.005; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Foreman B, 2012, NEUROLOGY, V79, P1951, DOI 10.1212/WNL.0b013e3182735cd7; Formisano R, 2007, BRAIN INJURY, V21, P499, DOI 10.1080/02699050701310994; Gigout S, 2013, BRAIN RES, V1525, P39, DOI 10.1016/j.brainres.2013.05.044; Gilmore EJ, 2015, INTENSIVE CARE MED; Guerit J M, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P117; Guerit JM, 2009, NEUROPHYSIOL CLIN, V39, P71, DOI 10.1016/j.neucli.2009.03.002; JACKSON GG, 1962, ARCH INTERN MED, V110, P663, DOI 10.1001/archinte.1962.03620230109016; JENNETT B, 1975, LANCET, V1, P480; Kaplan PW, 2004, J CLIN NEUROPHYSIOL, V21, P307; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Kurtz P, 2014, INTENS CARE MED, V40, P228, DOI 10.1007/s00134-013-3149-8; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; OLDENHOF H, 1988, CLIN PHARMACOL THER, V43, P263, DOI 10.1038/clpt.1988.31; Polito A, 2013, CRIT CARE, V17, DOI 10.1186/cc12899; Riazi K, 2008, P NATL ACAD SCI USA, V105, P17151, DOI 10.1073/pnas.0806682105; Rossetti AO, 2010, CRIT CARE, V14, DOI 10.1186/cc9276; Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sharshar T, 2014, LANCET NEUROL, V13, P534, DOI 10.1016/S1474-4422(14)70064-X; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Sutter R, 2014, EUR J NEUROL, V21, P1268, DOI 10.1111/ene.12436; Sutter R, 2015, NEUROCRIT CARE; SYNEK VM, 1988, J CLIN NEUROPHYSIOL, V5, P161, DOI 10.1097/00004691-198804000-00003; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; von Elm E, 2014, INT J SURG, V12, P1495, DOI 10.1016/j.ijsu.2014.07.013; WIJDICKS EFM, 1993, NEUROLOGY, V43, P1042, DOI 10.1212/WNL.43.5.1042; YOUNG GB, 1992, J CLIN NEUROPHYSIOL, V9, P145, DOI 10.1097/00004691-199201000-00016; Zauner C, 2002, CRIT CARE MED, V30, P1136, DOI 10.1097/00003246-200205000-00030	46	45	50	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2015	10	10							e0139969	10.1371/journal.pone.0139969			18	Multidisciplinary Sciences	Science & Technology - Other Topics	CT0TW	WOS:000362511000073	26447697	DOAJ Gold, Green Published			2021-06-18	
J	Escudero, D; Valentin, MO; Escalante, JL; Sanmartin, A; Perez-Basterrechea, M; de Gea, J; Martin, M; Velasco, J; Pont, T; Masnou, N; de la Calle, B; Marcelo, B; Lebron, M; Perez, JM; Burgos, M; Gimeno, R; Kot, P; Yus, S; Sancho, I; Zabalegui, A; Arroyo, M; Minambres, E; Elizalde, J; Montejo, JC; Dominguez-Gil, B; Matesanz, R				Escudero, D.; Valentin, M. O.; Escalante, J. L.; Sanmartin, A.; Perez-Basterrechea, M.; de Gea, J.; Martin, M.; Velasco, J.; Pont, T.; Masnou, N.; de la Calle, B.; Marcelo, B.; Lebron, M.; Perez, J. M.; Burgos, M.; Gimeno, R.; Kot, P.; Yus, S.; Sancho, I.; Zabalegui, A.; Arroyo, M.; Minambres, E.; Elizalde, J.; Montejo, J. C.; Dominguez-Gil, B.; Matesanz, R.			Intensive care practices in brain death diagnosis and organ donation	ANAESTHESIA			English	Article							DONORS; VARIABILITY; PERFORMANCE; HEMORRHAGE; MANAGEMENT; STROKE; SCALE; SCORE; TIME	We conducted a multicentre study of 1844 patients from 42 Spanish intensive care units, and analysed the clinical characteristics of brain death, the use of ancillary testing, and the clinical decisions taken after the diagnosis of brain death. The main cause of brain death was intracerebral haemorrhage (769/1844, 42%), followed by traumatic brain injury (343/1844, 19%) and subarachnoid haemorrhage (257/1844, 14%). The diagnosis of brain death was made rapidly (50% in the first 24 h). Of those patients who went on to die, the Glasgow Coma Scale on admission was >= 8/15 in 1146/1261 (91%) of patients with intracerebral haemorrhage, traumatic brain injury or anoxic encephalopathy; the Hunt and Hess Scale was 4-5 in 207/251 (83%) of patients following subarachnoid haemorrhage; and the National Institutes of Health Stroke Scale was >= 15 in 114/129 (89%) of patients with strokes. Brain death was diagnosed exclusively by clinical examination in 92/1844 (5%) of cases. Electroencephalography was the most frequently used ancillary test (1303/1752, 70.7%), followed by transcranial Doppler (652/1752, 37%). Organ donation took place in 70% of patients (1291/1844), with medical unsuitability (267/553, 48%) and family refusal (244/553, 13%) the main reasons for loss of potential donors. All life-sustaining measures were withdrawn in 413/553 of non-donors (75%).	[Escudero, D.] Cent Univ Hosp Asturias, Dept, Oviedo, Spain; [Martin, M.] Cent Univ Hosp Asturias, Intens Care Unit, Oviedo, Spain; [Perez-Basterrechea, M.] Cent Univ Hosp Asturias, Unit Transplants Cell Therapy & Regenerat Med, Oviedo, Spain; [Valentin, M. O.; Dominguez-Gil, B.; Matesanz, R.] Spanish Natl Transplant Org ONT, Madrid, Spain; [Escalante, J. L.] Gregorio Maran Univ Hosp, Hosp Transplant Program, Madrid, Spain; [de la Calle, B.] Gregorio Maran Univ Hosp, Intens Care Unit, Madrid, Spain; [Sanmartin, A.; de Gea, J.] Virgen Arrixaca Hosp, Intens Care Unit, Murcia, Spain; [Velasco, J.] Son Espases Univ Hosp, Intens Care Unit, Palma de Mallorca, Spain; [Pont, T.; Masnou, N.] Vall Hebron Hosp, Intens Care Unit, Barcelona, Spain; [Marcelo, B.] Infanta Cristina Univ Hosp, Intens Care Unit, Badajoz, Spain; [Lebron, M.] Carlos Haya Hosp, Intens Care Unit, Malaga, Spain; [Perez, J. M.; Burgos, M.] Virgen Nieves Univ Hosp, Intens Care Unit, Granada, Spain; [Gimeno, R.] La Fe Univ Hosp, Intens Care Unit, Valencia, Spain; [Kot, P.; Yus, S.] La Paz Univ Hosp, Intens Care Unit, Madrid, Spain; [Sancho, I.] Miguel Servet Univ Hosp, Intens Care Unit, Zaragoza, Spain; [Zabalegui, A.; Arroyo, M.] Gen Yague Hosp, Intens Care Unit, Burgos, Spain; [Minambres, E.] Marques Valdecilla Univ Hosp, Intens Care Unit, Santander, Spain; [Elizalde, J.] Asistential Complex Navarra, Intens Care Unit, Pamplona, Spain; [Montejo, J. C.] 12 Octubre Univ Hosp, Intens Care Unit, Dept, Madrid, Spain	Escudero, D (corresponding author), Cent Univ Hosp Asturias, Dept, Oviedo, Spain.	lolaescudero@telefonica.net	Minambres, Eduardo/H-7761-2019; VALENTIN, MARIA O/AAW-1865-2020; Basterrechea, Marcos Perez/L-9052-2014; de Gea Garcia, Jose Higinio/H-8451-2016	VALENTIN, MARIA O/0000-0003-4381-1332; Basterrechea, Marcos Perez/0000-0002-8242-5365; Dominguez-Gil, Beatriz/0000-0002-5695-8993; Pont, Teresa/0000-0003-4409-1189; de Gea Garcia, Jose Higinio/0000-0003-2460-5074; Escudero, Dolores/0000-0002-9037-3411	SEMICYUC	We acknowledge ONT, with special thanks to Mr. L. Gallardo, for providing all the informatics support needed for the development of the study, as well as SEMICYUC for its dedicated support. We also thank Dr. J. Escudero (Department of English Philology, University of Oviedo) for her review of the manuscript, as well as all those investigators who have participated in case collection (Appendix 1).	Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; [Anonymous], PEOPL KILL ROAD ACC; [Anonymous], 1968, JAMA-J AM MED ASSOC, V205, P85; [Anonymous], 1995, NEUROLOGY, V45, P1012, DOI DOI 10.1212/WNL.45.5.1012; Barber K, 2006, BMJ-BRIT MED J, V332, P1124, DOI 10.1136/bmj.38804.658183.55; Bell MDD, 2004, BRIT J ANAESTH, V92, P633, DOI 10.1093/bja/aeh108; Bernat JL, 2008, NEUROLOGY, V70, P252, DOI 10.1212/01.wnl.0000298089.91799.b5; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; de Groot YJ, 2010, INTENS CARE MED, V36, P1488, DOI 10.1007/s00134-010-1848-y; de la Rosa G, 2012, AM J TRANSPLANT, V12, P2507, DOI 10.1111/j.1600-6143.2012.04138.x; Escalante JL, 1998, REV PORTUGUESA MED I, V7, P127; Escalante JL, 1998, REV PORTUGUESA MED I, V7, P107; Escudero D, 2009, MED INTENSIVA, V33, P450, DOI 10.1016/j.medin.2009.06.004; Escudero D, 2009, MED INTENSIVA, V33, P415, DOI 10.1016/j.medin.2009.07.011; Escudero D, 2007, Med. Intensiva, V31, P335; Escudero D, 2009, MED INTENSIVA, V33, P185, DOI 10.1016/S0210-5691(09)71215-X; Escudero D, 2009, NEUROCRIT CARE, V11, P261, DOI 10.1007/s12028-009-9243-7; GOLDSTEIN LB, 1989, ARCH NEUROL-CHICAGO, V46, P660, DOI 10.1001/archneur.1989.00520420080026; Greer DM, 2008, NEUROLOGY, V70, P284, DOI 10.1212/01.wnl.0000296278.59487.c2; Haupt WF, 1999, J NEUROL, V246, P432, DOI 10.1007/s004150050378; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Jaffe J, 2009, NEUROSURGERY, V64, P436, DOI 10.1227/01.NEU.0000330402.20883.1B; Jansen NE, 2012, TRANSPL INT, V25, P830, DOI 10.1111/j.1432-2277.2012.01505.x; Jansen NE, 2010, NEPHROL DIAL TRANSPL, V25, P1992, DOI 10.1093/ndt/gfp705; JENNETT B, 1975, LANCET, V1, P480; Kompanje EJO, 2011, TRANSPLANTATION, V91, P1177, DOI 10.1097/TP.0b013e3182180567; Laureys S, 2008, NEUROLOGY, V70, P14; Martin-Lefevre L, 2011, REV NEUROL-FRANCE, V167, P463, DOI 10.1016/j.neurol.2011.01.004; Matesanz R, 2011, TRANSPL INT, V24, P333, DOI 10.1111/j.1432-2277.2010.01204.x; Moller C, 2009, TRANSPL P, V41, P729, DOI 10.1016/j.transproceed.2009.01.076; Munari M, 2005, CRIT CARE MED, V33, P2068, DOI 10.1097/01.CCM.0000179143.19233.6A; NOVOA S FERNANDO, 2007, Rev. chil. pediatr., V78, P355; Palacios JM, 2003, REV CHIL CIR, V55, P244; Powner DJ, 2004, CRIT CARE MED, V32, P1284, DOI 10.1097/01.ccm.0000127265.62431.0d; Schnitzler MA, 2005, AM J TRANSPLANT, V5, P2289, DOI 10.1111/j.1600-6143.2005.01021.x; Sharma D, 2011, NEUROCRIT CARE, V14, P370, DOI 10.1007/s12028-010-9415-5; Sheehy E, 2003, NEW ENGL J MED, V349, P667, DOI 10.1056/NEJMsa021271; Sheerani Mughis, 2008, J Pak Med Assoc, V58, P352; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Swinburn JMA, 1999, BRIT MED J, V318, P1753; Vincent A, 2012, BRIT J ANAESTH, V108, pI80, DOI 10.1093/bja/aer353; Wijdicks EFM, 2010, NEUROLOGY, V74, P1911, DOI 10.1212/WNL.0b013e3181e242a8; Wijdicks EFM, 2005, MAYO CLIN PROC, V80, P550, DOI 10.4065/80.4.550; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20	45	45	46	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	OCT	2015	70	10					1130	1139		10.1111/anae.13065			10	Anesthesiology	Anesthesiology	CT2WY	WOS:000362667400005	26040194	Bronze			2021-06-18	
J	Kang, M; Min, K; Jang, J; Kim, SC; Kang, MS; Jang, SJ; Lee, JY; Kim, SH; Kim, MK; An, SA; Kim, M				Kang, Mino; Min, Kyunghoon; Jang, Joonyoung; Kim, Seung Chan; Kang, Myung Seo; Jang, Su Jin; Lee, Ji Young; Kim, Sang Heum; Kim, Moon Kyu; An, SeongSoo A.; Kim, MinYoung			Involvement of Immune Responses in the Efficacy of Cord Blood Cell Therapy for Cerebral Palsy	STEM CELLS AND DEVELOPMENT			English	Article							LONG PENTRAXIN PTX3; ACUTE MYOCARDIAL-INFARCTION; TRAUMATIC BRAIN-INJURY; TOLL-LIKE RECEPTORS; MONONUCLEAR-CELLS; INNATE IMMUNITY; INFLAMMATION; TRANSPLANTATION; RATS; MECHANISMS	This study evaluated the efficacy of umbilical cord blood (UCB) cell for patients with cerebral palsy (CP) in a randomized, placebo-controlled, double-blind trial and also assessed factors and mechanisms related to the efficacy. Thirty-six children (ages 6 months to 20 years old) with CP were enrolled and treated with UCB or a placebo. Muscle strength and gross motor function were evaluated at baseline and 1, 3, and 6 months after treatment. Along with function measurements, each subject underwent F-18-fluorodeoxyglucose positron emission tomography at baseline and 2 weeks after treatment. Cytokine and receptor levels were quantitated in serial blood samples. The UCB group showed greater improvements in muscle strength than the controls at 1 (0.94 vs. -0.35, respectively) and 3 months (2.71 vs. 0.65) after treatment (Ps<0.05). The UCB group also showed greater improvements in gross motor performance than the control group at 6 months (8.54 vs. 2.60) after treatment (P<0.01). Additionally, positron emission tomography scans revealed decreased periventricular inflammation in patients administered UCB, compared with those treated with a placebo. Correlating with enhanced gross motor function, elevations in plasma pentraxin 3 and interleukin-8 levels were observed for up to 12 days after treatment in the UCB group. Meanwhile, increases in blood cells expressing Toll-like receptor 4 were noted at 1 day after treatment in the UCB group, and they were correlated with increased muscle strength at 3 months post-treatment. In this trial, treatment with UCB alone improved motor outcomes and induced systemic immune reactions and anti-inflammatory changes in the brain. Generally, motor outcomes were positively correlated with the number of UCB cells administered: a higher number of cells resulted in better outcomes. Nevertheless, future trials are needed to confirm the long-term efficacy of UCB therapy, as the follow-up duration of the present trial was short.	[Kang, Mino; Kim, Seung Chan; An, SeongSoo A.] Gachon Univ, Dept Bionanotechnol, Gachon Med Res Inst, Songnam 461701, Gyeonggi Do, South Korea; [Min, Kyunghoon; Jang, Joonyoung; Kim, MinYoung] CHA Univ, Dept Rehabil Med, CHA Bundang Med Ctr, Songnam 463712, Gyeonggi Do, South Korea; [Kang, Myung Seo] CHA Univ, Dept Lab Med, CHA Bundang Med Ctr, Songnam 463712, Gyeonggi Do, South Korea; [Kang, Myung Seo] CHA Med Ctr Cord Blood Bank, Songnam, South Korea; [Jang, Su Jin; Lee, Ji Young] CHA Univ, Dept Nucl Med, CHA Bundang Med Ctr, Songnam 463712, Gyeonggi Do, South Korea; [Kim, Sang Heum] CHA Univ, Dept Radiol, CHA Bundang Med Ctr, Songnam 463712, Gyeonggi Do, South Korea; [Kim, Moon Kyu] CHA Univ, CHA Bundang Med Ctr, Div Hematol Oncol, Dept Pediat, Songnam 463712, Gyeonggi Do, South Korea	An, SA (corresponding author), Gachon Univ, Dept Bionanotechnol, Gachon Med Res Inst, 65 San, Songnam 461701, Gyeonggi Do, South Korea.	kmin@cha.ac.kr; seongaan@gachon.ac.kr		Moon Kyu, Kim/0000-0001-6186-3991	CHA Bundang Medical Center; Korean Health Industry Development Institute [HI3C1204]; HSLee Welfare Foundation; Gachon University Gil Medical Center [2013-52]	UCB units used in this study were provided by "CHA Medical Center Cord Blood Bank." This study was supported by CHA Bundang Medical Center, a grant of the Korean Health Industry Development Institute (HI3C1204), HSLee Welfare Foundation, and Gachon University Gil Medical Center (grant number: 2013-52). We appreciate Sunhee Lee R.N. for devoted assistance for conduction of the study and Anthony Thomas Milliken for his help with the editing of this article.	Ballen KK, 2013, BLOOD, V122, P491, DOI 10.1182/blood-2013-02-453175; Bax M, 2005, DEV MED CHILD NEUROL, V47, P571, DOI 10.1017/S001216220500112X; Bayley N., 2006, BAYLEY SCALES INFANT; Bottazzi B, 2006, J LEUKOCYTE BIOL, V79, P909, DOI 10.1189/jlb.1005557; Bozza S, 2006, BLOOD, V108, P3387, DOI 10.1182/blood-2006-03-009266; Brain, 2000, AIDS EX PER NERV SYS; Deban L, 2010, NAT IMMUNOL, V11, P328, DOI 10.1038/ni.1854; Entok E, 2014, MOL BIOL REP, V41, P2827, DOI 10.1007/s11033-014-3137-2; Fleiss B, 2012, LANCET NEUROL, V11, P556, DOI 10.1016/S1474-4422(12)70058-3; Haley S.M., 1992, PEDIAT EVALUATION DI; Han B, 2011, INTENS CARE MED, V37, P334, DOI 10.1007/s00134-010-2067-2; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Inforzato A, 2011, TISSUE ANTIGENS, V77, P271, DOI 10.1111/j.1399-0039.2011.01645.x; Jeon H, 2010, J NEUROIMMUNOL, V229, P63, DOI 10.1016/j.jneuroim.2010.07.001; Kalluri Hari Varun, 2012, World J Transplant, V2, P51, DOI 10.5500/wjt.v2.i4.51; Kamiya N, 2008, LIFE SCI, V83, P433, DOI 10.1016/j.lfs.2008.07.018; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Ko J, 2012, ANN REHABIL MED-ARM, V36, P233, DOI 10.5535/arm.2012.36.2.233; Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163; Kunes P, 2013, PERFUSION-UK, V28, P377, DOI 10.1177/0267659113483799; Latini R, 2004, CIRCULATION, V110, P2349, DOI 10.1161/01.CIR.0000145167.30987.2E; Lee JH, 2013, ANN REHABIL MED-ARM, V37, P167, DOI 10.5535/arm.2013.37.2.167; Lin CY, 2010, ANN NEUROL, V68, P204, DOI 10.1002/ana.22049; Lulic D, 2011, NEUROSURGERY, V68, P1172, DOI 10.1227/NEU.0b013e31820c6cdc; Mantovani A, 2003, VACCINE, V21, pS43, DOI 10.1016/S0264-410X(03)00199-3; Meier C, 2006, PEDIATR RES, V59, P244, DOI 10.1203/01.pdr.0000197309.08852.f5; Min K, 2013, STEM CELLS, V31, P581, DOI 10.1002/stem.1304; Moalli F, 2011, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2011/830421; Neuhoff S, 2007, EXP HEMATOL, V35, P1119, DOI 10.1016/j.exphem.2007.03.019; Norata GD, 2009, CIRCULATION, V120, P699, DOI 10.1161/CIRCULATIONAHA.108.806547; Norrby K, 1996, CELL PROLIFERAT, V29, P315, DOI 10.1111/j.1365-2184.1996.tb01583.x; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Ravizza T, 2001, NEUROSCIENCE, V105, P43, DOI 10.1016/S0306-4522(01)00177-4; Rolls A, 2007, NAT CELL BIOL, V9, P1081, DOI 10.1038/ncb1629; Salio M, 2008, CIRCULATION, V117, P1055, DOI 10.1161/CIRCULATIONAHA.107.749234; Schmitz F, 2008, EUR J IMMUNOL, V38, P2981, DOI 10.1002/eji.200838761; Shichita T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00132; Uniform Data System for Medical Rehabilitation, 2006, WEEFIMII CLIN GUID V; Vexler ZS, 2009, DEV NEUROSCI-BASEL, V31, P378, DOI 10.1159/000232556; Volpe JJ, 2001, PEDIATR RES, V50, P553, DOI 10.1203/00006450-200111000-00003; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wu CX, 2013, THERANOSTICS, V3, P448, DOI 10.7150/thno.6592; Yuen CM, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-141; Zhu HF, 2014, TRANSPL INT, V27, P87, DOI 10.1111/tri.12197	46	45	46	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	OCT 1	2015	24	19					2259	2268		10.1089/scd.2015.0074			10	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	CR5PP	WOS:000361395900004	25977995				2021-06-18	
J	Folkerson, LE; Sloan, D; Cotton, BA; Holcomb, JB; Tomasek, JS; Wade, CE				Folkerson, Lindley E.; Sloan, Duncan; Cotton, Bryan A.; Holcomb, John B.; Tomasek, Jeffrey S.; Wade, Charles E.			Predicting progressive hemorrhagic injury from isolated traumatic brain injury and coagulation	SURGERY			English	Article							RECOMBINANT FACTOR VIIA; CLINICAL-TRIAL; COAGULOPATHY; PROGESTERONE; THROMBELASTOGRAPHY; METAANALYSIS; TESTS	Background. Progressive hemorrhagic injury (PHI) in traumatic brain injury (TBI) patients is associated with poor outcomes. Early prediction of PHI is difficult yet vital. We hypothesize that TBI subtype and coagulation would be predictors of PHI. Methods. This was a retrospective analysis of highest level activation adult trauma patients with evidence of TBI (head Abbreviated Injury Scale >= 3). Coagulopathy was determined using rapid thrombelastography (r-TEG), complete blood counts, and conventional coagulation tests obtained on arrival. Patients were dichotomized into PHI and stable groups based on head computerized CT Subtypes of TBI included subdural hematoma, intraparenchymal contusions (IPC), subarachnoid hemorrhage, epidural hematoma, and combined. Data are reported as median values with interquartile range (IQR). Multivariate logistic regression was used to assess the effect of subtype and coagulation on PHI. Results. We included 279 isolated TBI patients who met study criteria. There were 157 patients (56%) who experienced PHI; 122 (44%) were stable on repeat CT Patients with PHI were older, had fewer hospital-free days, and higher mortality (all P < .001). No differences were noted in r-TEG parameters between groups; however, coagulopathy and age were independent predictors of progression in all subtypes (odds ratio [OR], 1.81; 95% CI, 1.09-3.01 [P = .021]; OR, 1.02, 95% CI, 1.01-1.04 [P = .006]). Controlling for age, Glasgow Coma Scale score, and coagulopathy, patients with IPC were more likely to experience PHI (OA 4.49; 95% CI, 2.24-8.98; P < .0001). Conclusion. This study demonstrates that older patients with coagulation abnormalities and IPC on admission are more likely to experience PHI, identifying a target population for earlier therapies.	[Folkerson, Lindley E.; Sloan, Duncan; Cotton, Bryan A.; Holcomb, John B.; Tomasek, Jeffrey S.; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res, Houston, TX 77030 USA; [Folkerson, Lindley E.; Sloan, Duncan; Cotton, Bryan A.; Holcomb, John B.; Tomasek, Jeffrey S.; Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA	Folkerson, LE (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Surg, Ctr Translat Injury Res, 6431 Fannin St,MSB 5-212, Houston, TX 77030 USA.	Lindley.E.Folkerson@uth.tmc.edu		holcomb, john/0000-0001-8312-9157	State of Texas Emerging Technology Fund; University of Texas Health Science Center's Center for Translational Injury Research	Support for this work was provided by The State of Texas Emerging Technology Fund and The University of Texas Health Science Center's Center for Translational Injury Research.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Brohi K, 2007, CURR OPIN CRIT CARE, V13, P680, DOI 10.1097/MCC.0b013e3282f1e78f; Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17; Clifton GL, 2012, J NEUROSURG, V117, P714, DOI 10.3171/2012.6.JNS111690; ClinicalTrials.gov, 2013, NCT01990768 CLINICAL; ClinicalTrials.gov, 2011, NCT01402882 CLINICAL; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Manoel ALD, 2015, NEUROCRIT CARE, V22, P34, DOI 10.1007/s12028-014-0026-4; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Imam A, 2015, J NEUROTRAUM, V32, P307, DOI 10.1089/neu.2014.3535; Joseph B, 2014, AM SURGEON, V80, P335; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; Lee TH, 2014, J TRAUMA ACUTE CARE, V77, P67, DOI 10.1097/TA.0000000000000255; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Post A, 2015, NEUROSURGERY, V76, P81, DOI 10.1227/NEU.0000000000000554; Sixta SL, 2012, INT J BURNS TRAUMA, V2, P158; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tong WS, 2011, NEURORADIOLOGY, V53, P305, DOI 10.1007/s00234-010-0659-8; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Windelov NA, 2011, BLOOD COAGUL FIBRIN, V22, P416, DOI 10.1097/MBC.0b013e3283464f53; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Yuan Q, 2015, J CRIT CARE, V30, P116, DOI 10.1016/j.jcrc.2014.07.009; Yutthakasemsunt S, 2013, BMC EMERG MED, V13, DOI 10.1186/1471-227X-13-20; Zehtabchi S, 2014, AM J EMERG MED, V32, P1503, DOI 10.1016/j.ajem.2014.09.023	32	45	52	1	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	SEP	2015	158	3					655	661		10.1016/j.surg.2015.02.029			7	Surgery	Surgery	CP3CS	WOS:000359755000010	26067457				2021-06-18	
J	Choi, HJ; Sun, D; Jakobs, TC				Choi, Hee Joo; Sun, Daniel; Jakobs, Tatjana C.			Astrocytes in the optic nerve head express putative mechanosensitive channels	MOLECULAR VISION			English	Article							RETINAL GANGLION-CELLS; ELEVATED HYDROSTATIC-PRESSURE; RETROGRADE AXOPLASMIC-TRANSPORT; STRETCH-ACTIVATED CHANNELS; POLYCYSTIC KIDNEY-DISEASE; EPIDERMAL MERKEL CELLS; TUMOR-NECROSIS-FACTOR; INTRAOCULAR-PRESSURE; GENE-EXPRESSION; EPITHELIAL-CELLS	Purpose: To establish whether optic nerve head astrocytes express candidate molecules to sense tissue stretch. Methods: We used conventional PCR, quantitative PCR, and single-cell reverse transcription PCR (RT-PCR) to assess the expression of various members of the transient receptor potential (TRP) channel family and of the recently characterized mechanosensitive channels Piezo1 and 2 in optic nerve head tissue and in single, isolated astrocytes. Results: Most TRP subfamilies (TRPC, TRPM, TRPV, TRPA, and TRPP) and Piezo1 and 2 were expressed in the optic nerve head of the mouse. Quantitative real-time PCR analysis showed that TRPC1, TRPM7, TRPV2, TRPP2, and Piezo1 are the dominant isoforms in each subfamily. Single-cell RT-PCR revealed that many TRP isoforms, TRPC1-2, TRPC6, TRPV2, TRPV4, TRPM2, TRPM4, TRPM6-7, TRPP1-2, and Piezo1-2, are expressed in astrocytes of the optic nerve head, and that most astrocytes express TRPC1 and TRPP1-2. Comparisons of the TRPP and Piezo expression levels between different tissue regions showed that Piezo2 expression was higher in the optic nerve head and the optic nerve proper than in the brain and the corpus callosum. TRPP2 also showed higher expression in the optic nerve head. Conclusions: Astrocytes in the optic nerve head express multiple putative mechanosensitive channels, in particular the recently identified channels Piezo1 and 2. The expression of putative mechanosensitive channels in these cells may contribute to their responsiveness to traumatic or glaucomatous injury.	[Choi, Hee Joo; Sun, Daniel; Jakobs, Tatjana C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol, Boston, MA USA	Jakobs, TC (corresponding author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	Tatjana_Jakobs@meei.harvard.edu		Jakobs, Tatjana/0000-0002-8104-9206	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01EY019703, R01EY022092]; Lefler Foundation; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY022092, R01EY019703] Funding Source: NIH RePORTER	This work was supported by NIH grants R01EY019703 and R01EY022092, and the Lefler Foundation. The authors wish to thank Dr. Richard Masland for critically reading the manuscript, and Rong Guo, MS, for advice on statistical tests.	Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Arnadottir J, 2010, ANNU REV BIOPHYS, V39, P111, DOI 10.1146/annurev.biophys.37.032807.125836; Bai CX, 2008, EMBO REP, V9, P472, DOI 10.1038/embor.2008.29; Balaratnasingam C, 2007, INVEST OPHTH VIS SCI, V48, P3632, DOI 10.1167/iovs.06-1002; Bao L, 2004, FEBS LETT, V572, P65, DOI 10.1016/j.febslet.2004.07.009; Beckel JM, 2014, GLIA, V62, P1486, DOI 10.1002/glia.22695; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Bron R, 2014, J COMP NEUROL, V522, P2967, DOI 10.1002/cne.23560; Chauhan BC, 2008, CAN J OPHTHALMOL, V43, P356, DOI 10.3129/i08-060; Chauhan BC, 2004, INVEST OPHTH VIS SCI, V45, P144, DOI 10.1167/iovs.03-0687; Choi HJ, 2015, EXP EYE RES IN PRESS; Christensen AP, 2007, NAT REV NEUROSCI, V8, P510, DOI 10.1038/nrn2149; Coste B, 2012, NATURE, V483, P176, DOI 10.1038/nature10812; Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270; Davis MJ, 1999, PHYSIOL REV, V79, P387; Dietrich A, 2007, PFLUG ARCH EUR J PHY, V455, P465, DOI 10.1007/s00424-007-0314-3; Djenoune L, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00026; Dvoriantchikova G, 2006, FEBS LETT, V580, P2178, DOI 10.1016/j.febslet.2006.03.026; Faucherre A, 2013, J NEUROSCI, V 33, P17089, DOI 10.1523/JNEUROSCI.0522-13.2013; Gees M, 2010, COLD SPRING HARB PER, V2; Gilliam JC, 2011, VISION RES, V51, P2440, DOI 10.1016/j.visres.2011.10.009; Gottlieb P, 2008, PFLUG ARCH EUR J PHY, V455, P1097, DOI 10.1007/s00424-007-0359-3; Guo L, 2000, GENOMICS, V64, P241, DOI 10.1006/geno.2000.6131; Hernandez MR, 2000, GLIA, V32, P122, DOI 10.1002/1098-1136(200011)32:2<122::AID-GLIA20>3.0.CO;2-J; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; Ho KW, 2014, GLIA, V62, P1435, DOI 10.1002/glia.22691; Ho Karen W, 2012, Am J Neurodegener Dis, V1, P1; Ho KW, 2011, ARVO ANN M; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Howell GR, 2012, J CLIN INVEST, V122, P1246, DOI 10.1172/JCI61135; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Hu HL, 2010, EXP EYE RES, V91, P425, DOI 10.1016/j.exer.2010.06.017; Ikeda R, 2014, NEUROSCI LETT, V583, P210, DOI 10.1016/j.neulet.2014.05.055; Ikeda R, 2014, CELL, V157, P664, DOI 10.1016/j.cell.2014.02.026; Jakobs TC, 2007, MOL VIS, V13, P933; Jakobs TC, 2005, J CELL BIOL, V171, P313, DOI 10.1083/jcb.200506099; Jakobs TC, 2003, J COMP NEUROL, V465, P361, DOI 10.1002/cne.10845; JOHANSSON JO, 1983, INVEST OPHTH VIS SCI, V24, P1552; JOHANSSON JO, 1988, EXP EYE RES, V46, P223, DOI 10.1016/S0014-4835(88)80079-4; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Johnson EC, 2011, INVEST OPHTH VIS SCI, V52, P504, DOI 10.1167/iovs.10-5317; Kaja S, 2012, NEUROSCIENCE, V202, P99, DOI 10.1016/j.neuroscience.2011.11.047; Kalapesi FB, 2005, CLIN EXP OPHTHALMOL, V33, P210, DOI 10.1111/j.1442-9071.2005.00981.x; Kobori T, 2009, J BIOL CHEM, V284, P35507, DOI 10.1074/jbc.M109.060228; Kottgen M, 2007, BBA-MOL BASIS DIS, V1772, P836, DOI 10.1016/j.bbadis.2007.01.003; Krizaj D, 2014, CURR EYE RES, V39, P105, DOI 10.3109/02713683.2013.836541; Kunert-Keil C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-159; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Lambertsen KL, 2001, BRAIN RES PROTOC, V7, P175, DOI 10.1016/S1385-299X(01)00062-9; Leonelli M, 2013, CELL MOL NEUROBIOL, V33, P379, DOI 10.1007/s10571-012-9904-5; Leonelli M, 2009, INT J DEV NEUROSCI, V27, P709, DOI 10.1016/j.ijdevneu.2009.07.003; Libby RT, 2005, VISUAL NEUROSCI, V22, P637, DOI 10.1017/S0952523805225130; Lye-Barthel M, 2013, INVEST OPHTH VIS SCI, V54, P909, DOI 10.1167/iovs.12-10109; Ma X, 2011, CELL CALCIUM, V50, P502, DOI 10.1016/j.ceca.2011.08.006; Maksimovic S, 2014, NATURE, V509, P617, DOI 10.1038/nature13250; Malin SA, 2007, NAT PROTOC, V2, P152, DOI 10.1038/nprot.2006.461; Malone P, 2007, GLIA, V55, P1085, DOI 10.1002/glia.20527; Mandal A, 2010, INVEST OPHTH VIS SCI, V51, P3129, DOI 10.1167/iovs.09-4614; Mandal A, 2009, AM J PHYSIOL-CELL PH, V297, pC111, DOI 10.1152/ajpcell.00539.2008; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; May CA, 2002, INVEST OPHTH VIS SCI, V43, P2206; McHugh BJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040346; McHugh BJ, 2010, J CELL SCI, V123, P51, DOI 10.1242/jcs.056424; Morcos Y, 2000, J NEUROCYTOL, V29, P665, DOI 10.1023/A:1010835404754; Morgans CW, 2009, P NATL ACAD SCI USA, V106, P19174, DOI 10.1073/pnas.0908711106; Nakatani M, 2015, PFLUG ARCH EUR J PHY, V467, P101, DOI 10.1007/s00424-014-1569-0; Niggel J, 2000, J MEMBRANE BIOL, V174, P121, DOI 10.1007/s002320001037; Nilius B, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-218; Nomura H, 1998, J BIOL CHEM, V273, P25967, DOI 10.1074/jbc.273.40.25967; Numata T, 2007, AM J PHYSIOL-CELL PH, V292, pC460, DOI 10.1152/ajpcell.00367.2006; Numata T, 2007, CELL PHYSIOL BIOCHEM, V19, P1, DOI 10.1159/000099187; Oancea E, 2006, CIRC RES, V98, P245, DOI 10.1161/01.RES.0000200179.29375.cc; Ostrow LW, 2011, BIOCHEM BIOPH RES CO, V410, P81, DOI 10.1016/j.bbrc.2011.05.109; Peyronnet R, 2013, EMBO REP, V14, P1143, DOI 10.1038/embor.2013.170; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Poole K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4520; Qu J, 2013, PLOS ONE, V8; QUIGLEY HA, 1980, INVEST OPHTH VIS SCI, V19, P137; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009; Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7; Ranade SS, 2014, P NATL ACAD SCI USA, V111, P10347, DOI 10.1073/pnas.1409233111; Reigada D, 2008, NEUROSCIENCE, V157, P396, DOI 10.1016/j.neuroscience.2008.08.036; Resta V, 2007, EUR J NEUROSCI, V25, P2741, DOI 10.1111/j.1460-9568.2007.05528.x; Reyes JP, 2009, BIOCHEM BIOPH RES CO, V380, P50, DOI 10.1016/j.bbrc.2009.01.021; Rogers R, 2012, INVEST OPHTH VIS SCI, V53, P3806, DOI 10.1167/iovs.11-8480; Rogers RS, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012302; Roy B, 2014, INTEGR BIOL-UK, V6, P289, DOI [10.1039/c3ib40174j, 10.1039/C3IB40174J]; Ryskamp Daniel A, 2014, Cells, V3, P914, DOI 10.3390/cells3030914; Ryskamp DA, 2011, J NEUROSCI, V31, P7089, DOI 10.1523/JNEUROSCI.0359-11.2011; Salvador-Silva M, 2001, J NEUROSCI RES, V66, P59, DOI 10.1002/jnr.1197; Sappington RM, 2008, INVEST OPHTH VIS SCI, V49, P3004, DOI 10.1167/iovs.07-1355; Sappington RM, 2009, INVEST OPHTH VIS SCI, V50, P717, DOI 10.1167/iovs.08-2321; Seminario-Vidal L, 2009, J BIOL CHEM, V284, P20638, DOI 10.1074/jbc.M109.004762; Shen Y, 2009, J NEUROSCI, V29, P6088, DOI 10.1523/JNEUROSCI.0132-09.2009; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Storch U, 2012, J BIOL CHEM, V287, P3530, DOI 10.1074/jbc.M111.283218; Sun D, 2013, GLIA, V61, P1218, DOI 10.1002/glia.22507; Sun D, 2010, J NEUROSCI, V30, P14008, DOI 10.1523/JNEUROSCI.3605-10.2010; Sun D, 2009, J COMP NEUROL, V516, P1, DOI 10.1002/cne.22058; Takumida M, 2010, ACTA OTO-LARYNGOL, V130, P196, DOI 10.3109/00016480903013593; Verkhratsky A, 2014, REV PHYSIOL BIOCH P, V166, P1, DOI 10.1007/112_2013_15; Volkers L, 2015, PFLUG ARCH EUR J PHY, V467, P95, DOI 10.1007/s00424-014-1578-z; Volonte C, 2012, CNS NEUROL DISORD-DR, V11, P705, DOI 10.2174/187152712803581137; Ward NJ, 2014, J NEUROSCI, V34, P3161, DOI 10.1523/JNEUROSCI.4089-13.2014; Weitlauf C, 2014, J NEUROSCI, V34, P15369, DOI 10.1523/JNEUROSCI.3424-14.2014; Wheeler-Schilling TH, 2001, MOL BRAIN RES, V92, P177, DOI 10.1016/S0169-328X(01)00160-7; Woo SH, 2014, NATURE, V509, P622, DOI 10.1038/nature13251; Xia JS, 2012, J PHYSIOL-LONDON, V590, P2285, DOI 10.1113/jphysiol.2012.227983; Yang P, 2004, PHYSIOL GENOMICS, V17, P157, DOI 10.1152/physiolgenomics.00182.2003; Yang XN, 2014, DIGEST DIS SCI, V59, P1428, DOI 10.1007/s10620-014-3044-3; Zhang XL, 2005, INVEST OPHTH VIS SCI, V46, P2183, DOI 10.1167/iovs.05-0052; Zimov S, 2004, J NEUROCYTOL, V33, P441, DOI 10.1023/B:NEUR.0000046574.72380.e8; Zimov S, 2007, VISUAL NEUROSCI, V24, P581, DOI 10.1017/S095252380707054X	113	45	45	1	6	MOLECULAR VISION	ATLANTA	C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E, ATLANTA, GA 30322 USA	1090-0535			MOL VIS	Mol. Vis.	JUL 14	2015	21												18	Biochemistry & Molecular Biology; Ophthalmology	Biochemistry & Molecular Biology; Ophthalmology	CO2VR	WOS:000359015400001	26236150	DOAJ Gold			2021-06-18	
J	Nigrovic, LE; Stack, AM; Mannix, RC; Lyons, TW; Samnaliev, M; Bachur, RG; Proctor, MR				Nigrovic, Lise E.; Stack, Anne M.; Mannix, Rebekah C.; Lyons, Todd W.; Samnaliev, Mihail; Bachur, Richard G.; Proctor, Mark R.			Quality Improvement Effort to Reduce Cranial CTs for Children With Minor Blunt Head Trauma	PEDIATRICS			English	Article							COMPUTED-TOMOGRAPHY UTILIZATION; CLINICAL DECISION-SUPPORT; EMERGENCY-DEPARTMENT; UNITED-STATES; ADHERENCE; TRENDS; MODEL	OBJECTIVE: Blunt head trauma is a common injury in children, although it rarely requires surgical intervention. Cranial computed tomography (CT) is the reference standard for the diagnosis of traumatic brain injury but has been associated with increased lifetime malignancy risk. We implemented a multifaceted quality improvement initiative to decrease the use of cranial CT for children with minor head injuries. METHODS: We designed and implemented a quality improvement effort that included an evidence-based guideline as well as individual feedback for children aged 0 to 21 years who present to the emergency department (ED) for evaluation of minor blunt head trauma. Our primary outcome was cranial CT rate, and our balancing measure was any return to the ED within 72 hours that required hospitalization. We used statistical process control methodology to measure cranial CT rates over time. RESULTS: We included 6851 ED visits of which 4242 (62%) occurred in the post-guideline implementation period. From a baseline CT rate of 21%, we observed an absolute reduction of 6% in cranial CT rate (95% confidence interval 3% to 9%) after initial guideline implementation and an additional absolute reduction of 6% (95% confidence interval 4% to 8%) after initiation of individual provider feedback. No children discharged from the ED required admission within 72 hours of initial evaluation. CONCLUSIONS: An ED quality improvement effort that included an evidence-based guideline as well as individual provider feedback was associated with a reduction in cranial CT rates without an increase in missed significant head injuries.	[Nigrovic, Lise E.; Stack, Anne M.; Mannix, Rebekah C.; Lyons, Todd W.; Bachur, Richard G.] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Samnaliev, Mihail] Boston Childrens Hosp, Clin Res Ctr, Boston, MA 02115 USA; [Proctor, Mark R.] Boston Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA	Nigrovic, LE (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	Lise.nigrovic@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020	Bachur, Richard/0000-0001-8831-014X; Nigrovic, Lise/0000-0002-6369-3997; Lyons, Todd/0000-0002-7033-1070	Provider Payor Quality Initiative foundation (Boston, MA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	This project was supported by a grant from the Provider Payor Quality Initiative foundation (Boston, MA).	American Academy of Pediatrics, CHOOS WIS; [Anonymous], 2012, PASW STAT 21 COMUTER; [Anonymous], 2013, CHARTRUNNER LEAN COM; Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72; Back SE, 2011, ACAD PSYCHIATR, V35, P40, DOI 10.1176/appi.ap.35.1.40; Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458; Bischoff K, 2013, BMJ QUAL SAF, V22, P768, DOI 10.1136/bmjqs-2012-001671; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Bourgeois FT, 2014, PEDIATRICS, V134, P539, DOI 10.1542/peds.2014-1278; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Chumpitazi CE, 2011, CLIN PEDIATR EMERG M, V12, P113, DOI 10.1016/j.cpem.2011.05.001; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Ferguson J, 2014, BMC MED EDUC, V14, DOI 10.1186/1472-6920-14-76; Forrest CB, 2013, PEDIATRICS, V131, pE1071, DOI 10.1542/peds.2012-1988; Frush DP, 2008, NEW ENGL J MED, V358, P851; Gagliardi AR, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-26; Institute of Medicine of the National Academies, 2007, EM CAR CHILDR GROW P; Jamtvedt G, 2006, QUAL SAF HEALTH CARE, V15, P433, DOI 10.1136/qshc.2006.018549; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Menoch MJA, 2012, PEDIATRICS, V129, pE690, DOI 10.1542/peds.2011-2548; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Pathman DE, 1996, MED CARE, V34, P873, DOI 10.1097/00005650-199609000-00002; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Schonfeld D, 2013, ANN EMERG MED, V62, P597, DOI 10.1016/j.annemergmed.2013.06.020; Sheehan B, 2013, J BIOMED INFORM, V46, P905, DOI 10.1016/j.jbi.2013.07.005	28	45	46	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2015	136	1					E227	E233		10.1542/peds.2014-3588			7	Pediatrics	Pediatrics	CL9KB	WOS:000357296000026	26101363	Green Accepted			2021-06-18	
J	Juengst, SB; Kumar, RG; Failla, MD; Goyal, A; Wagner, AK				Juengst, Shannon B.; Kumar, Raj G.; Failla, Michelle D.; Goyal, Akash; Wagner, Amy Kathleen			Acute Inflammatory Biomarker Profiles Predict Depression Risk Following Moderate to Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cytokines; depression; inflammation; interleukins; intracellular adhesion molecule-1; vascular cell adhesion molecule-1	WHITE-MATTER; MAJOR DEPRESSION; LIFE; CYTOKINES; FLUID; HYPERINTENSITIES; ANTIDEPRESSANTS; INDIVIDUALS; SYMPTOMS; VALIDITY	Objective: To examine whether acute inflammation profiles predict posttraumatic depression (PTD) risk 6 and 12 months after traumatic brain injury. Setting: University-affiliated level 1 trauma center and community. Participants: Adults with moderate to severe traumatic brain injury (acute serum levels: n = 50; acute cerebrospinal fluid (CSF) levels: n = 41). Design: Prospective cohort study. Main Measures: Patient Health Questionnaire; inflammatory biomarkers (interleukin [IL]-1 beta, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, tumor necrosis factor alpha, soluble vascular adhesion molecule [sVCAM-1], soluble intracellular adhesion molecule [sICAM-1], soluble Fas [sFAS]). Results: Higher levels of acute CSF cytokine surface markers (sVCAM-1, sICAM-1, and sFAS) in an inflammatory biomarker risk (IBR) score were associated with a 3.920-fold increase in the odds of developing PTD at 6 months (95% confidence interval: 1.163-8.672). Having sICAM-1, sVCAM-1, or sFAS above the 75th percentile had a positive predictive value of 85.7% for PTD risk at 6 months. An IBR score including inflammatory biomarkers IL-7 and IL-8 showed a trending association with 12-month PTD risk (odds ratio = 3.166, 95% confidence interval: 0.936-10.708). Conclusion: Acute CSF IBR scores show promise for identifying individuals at risk for PTD. Further research should assess acute CSF inflammatory biomarkers' relationships to chronic inflammation as a mechanism of PTD and should explore anti-inflammatory treatments for PTD, as well as prevention and screening protocols, and link inflammatory biomarkers to symptom tracking.	[Juengst, Shannon B.; Kumar, Raj G.; Failla, Michelle D.; Goyal, Akash; Wagner, Amy Kathleen] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Failla, Michelle D.; Wagner, Amy Kathleen] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Wagner, Amy Kathleen] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, Dept Phys Med & Rehabil, 3471 Fifth Ave,Ste 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Juengst, Shannon B/AAC-5891-2019; Failla, Michelle/AAI-3788-2021	Failla, Michelle/0000-0001-9734-3373; Juengst, Shannon/0000-0003-4709-545X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR 323155, W81XWH-071-0701] Funding Source: Medline		Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Capuron L, 2003, BIOL PSYCHIAT, V54, P906, DOI 10.1016/S0006-3223(03)00173-2; Cattaneo A, 2013, NEUROPSYCHOPHARMACOL, V38, P377, DOI 10.1038/npp.2012.191; Cone JB, 2001, AM J SURG, V182, P558, DOI 10.1016/S0002-9610(01)00822-4; Dantzer R, 2006, NEUROL CLIN, V24, P441, DOI 10.1016/j.ncl.2006.03.003; Depino A, 2005, J NEUROIMMUNOL, V168, P96, DOI 10.1016/j.jneuroim.2005.07.009; Dimopoulos N, 2006, INT J GERIATR PSYCH, V21, P965, DOI 10.1002/gps.1592; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Easton AS, 2013, INT IMMUNOPHARMACOL, V17, P1218, DOI 10.1016/j.intimp.2013.06.015; Failla MD, 2013, BRAIN INJURY, V27, P696, DOI 10.3109/02699052.2013.775481; Fann Jesse, 2013, Arch Phys Med Rehabil, V94, P801, DOI 10.1016/j.apmr.2012.04.001; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Felger JC, 2013, NEUROSCIENCE, V246, P199, DOI 10.1016/j.neuroscience.2013.04.060; Firbank MJ, 2012, BRIT J PSYCHIAT, V201, P40, DOI 10.1192/bjp.bp.111.098897; Fischer A, 2012, PSYCHONEUROENDOCRINO, V37, P1712, DOI 10.1016/j.psyneuen.2012.03.001; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; Futosi K, 2013, INT IMMUNOPHARMACOL, V17, P638, DOI 10.1016/j.intimp.2013.06.034; GILLIAM FG, 2005, DEPRESSION BRAIN DYS; Gold SM, 2009, IMMUNOL ALLERGY CLIN, V29, P309, DOI 10.1016/j.iac.2009.02.008; Hallberg L, 2010, J AFFECT DISORDERS, V126, P262, DOI 10.1016/j.jad.2010.02.133; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Isingrini E, 2011, AM J GERIAT PSYCHIAT, V19, P335, DOI 10.1097/JGP.0b013e318202bc42; Jones I, 2001, ANN MED, V33, P248, DOI 10.3109/07853890108998753; Jorm AF, 2005, AM J PSYCHIAT, V162, P699, DOI 10.1176/appi.ajp.162.4.699; Jovanova-Nesic Katica, 2012, Curr Aging Sci, V5, P209; Kamppa N, 2013, EXP GERONTOL, V48, P1167, DOI 10.1016/j.exger.2013.07.009; Karson A, 2013, BASIC CLIN PHARMACOL, V112, P335, DOI 10.1111/bcpt.12037; Khajehnasiri F, 2013, J CLIN BIOCHEM NUTR, V53, P36, DOI 10.3164/jcbn.12-98; Kim YK, 2007, PROG NEURO-PSYCHOPH, V31, P1044, DOI 10.1016/j.pnpbp.2007.03.004; Kohler S, 2010, BRIT J PSYCHIAT, V196, P143, DOI 10.1192/bjp.bp.109.071399; Kraus MR, 2007, GASTROENTEROLOGY, V132, P1279, DOI 10.1053/j.gastro.2007.02.053; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kushner I, 1998, CYTOKINE GROWTH F R, V9, P191, DOI 10.1016/S1359-6101(98)00016-1; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Leal MC, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00053; Lehto SM, 2010, PROG NEURO-PSYCHOPH, V34, P846, DOI 10.1016/j.pnpbp.2010.03.033; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lettieri JR, 2013, J NEUROTRAUM, V30, pA75; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Littrell JL, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00297; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Luberto CM, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0391-2; Maes M, 1997, CYTOKINE, V9, P853, DOI 10.1006/cyto.1997.0238; Maes M, 2011, NEUROENDOCRINOL LETT, V32, P7; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Orr SK, 2013, PROSTAG LEUKOTR ESS, V88, P97, DOI 10.1016/j.plefa.2012.05.008; Ownsworth T, 2011, J INT NEUROPSYCH SOC, V17, P112, DOI 10.1017/S1355617710001311; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pineda EA, 2012, NEUROTHERAPEUTICS, V9, P477, DOI 10.1007/s13311-012-0110-4; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Qureshi NA, 2013, NEUROPSYCH DIS TREAT, V9, P639, DOI 10.2147/NDT.S43419; Raison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Schiepers OJG, 2005, PROG NEURO-PSYCHOPH, V29, P201, DOI 10.1016/j.pnpbp.2004.11.003; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Sheline YI, 2008, AM J PSYCHIAT, V165, P524, DOI 10.1176/appi.ajp.2007.07010175; Sluzewska A, 1997, NEUROPSYCHOBIOLOGY, V35, P123, DOI 10.1159/000119332; Smith AK, 2012, MOL PSYCHIATR, V17, P781, DOI 10.1038/mp.2011.67; Soo C, 1996, COCHRANE DATABASE SY; TEASDALE G, 1974, LANCET, V2, P81; Thomas AJ, 2003, INT J GERIATR PSYCH, V18, P7, DOI 10.1002/gps.720; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wise EK, 2012, ARCH PHYS MED REHAB, V93, P1319, DOI 10.1016/j.apmr.2012.05.009; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549	78	45	45	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2015	30	3					207	218		10.1097/HTR.0000000000000031			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CH8PJ	WOS:000354298100133	24590155				2021-06-18	
J	Julio-Amilpas, A; Montiel, T; Soto-Tinoco, E; Geronimo-Olvera, C; Massieu, L				Julio-Amilpas, Alberto; Montiel, Teresa; Soto-Tinoco, Eva; Geronimo-Olvera, Cristian; Massieu, Lourdes			Protection of hypoglycemia-induced neuronal death by beta-hydroxybutyrate involves the preservation of energy levels and decreased production of reactive oxygen species	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						energy failure; hypoglycemia; ketone bodies; neuronal death; oxidative stress	FUNCTION IMPROVING AGENT; KETONE-BODY UTILIZATION; TRAUMATIC BRAIN-INJURY; KETOGENIC DIET; RAT-BRAIN; GLYCOLYSIS INHIBITION; COGNITIVE IMPAIRMENT; HIPPOCAMPAL-NEURONS; CEREBRAL-ISCHEMIA; IN-VIVO	Glucose is the main energy substrate in brain but in certain circumstances such as prolonged fasting and the suckling period alternative substrates can be used such as the ketone bodies (KB), beta-hydroxybutyrate (BHB), and acetoacetate. It has been shown that KB prevent neuronal death induced during energy limiting conditions and excitotoxicity. The protective effect of KB has been mainly attributed to the improvement of mitochondrial function. In the present study, we have investigated the protective effect of D-BHB against neuronal death induced by severe noncoma hypoglycemia in the rat in vivo and by glucose deprivation (GD) in cortical cultures. Results show that systemic administration of D-BHB reduces reactive oxygen species (ROS) production in distinct cortical areas and subregions of the hippocampus and efficiently prevents neuronal death in the cortex of hypoglycemic animals. In vitro results show that D-BHB stimulates ATP production and reduces ROS levels, while the nonphysiologic isomer of BHB, L-BHB, has no effect on energy production but reduces ROS levels. Data suggest that protection by BHB, not only results from its metabolic action but is also related to its capability to reduce ROS, rendering this KB as a suitable candidate for the treatment of ischemic and traumatic injury.	[Julio-Amilpas, Alberto; Montiel, Teresa; Soto-Tinoco, Eva; Geronimo-Olvera, Cristian; Massieu, Lourdes] Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neuropatol Mol, Div Neurociencias, Mexico City 04510, DF, Mexico	Massieu, L (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Neuropatol Mol, Div Neurociencias, AP 70-253, Mexico City 04510, DF, Mexico.	lmassieu@ifc.unam.mx		Soto-Tinoco, Eva/0000-0001-8482-2076	CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [S112179]; PAPIIT (UNAM)Programa de Apoyo a Proyectos de Investigacion e Innovacion Tecnologica (PAPIIT)Universidad Nacional Autonoma de Mexico [IN204213]	This work was supported by CONACYT S112179 and PAPIIT (UNAM) IN204213 grants to LM.	Amador-Alvarado L, 2014, METAB BRAIN DIS, V29, P711, DOI 10.1007/s11011-014-9508-5; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Choi BY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081523; Ennis K, 2008, BRAIN RES, V1224, P119, DOI 10.1016/j.brainres.2008.06.003; Gibson CL, 2012, J NEUROCHEM, V123, P52, DOI 10.1111/j.1471-4159.2012.07943.x; Haces ML, 2010, NEUROSCIENCE, V165, P28, DOI 10.1016/j.neuroscience.2009.10.003; Haces ML, 2008, EXP NEUROL, V211, P85, DOI 10.1016/j.expneurol.2007.12.029; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Juge N, 2010, NEURON, V68, P99, DOI 10.1016/j.neuron.2010.09.002; LaManna JC, 2009, ADV EXP MED BIOL, V645, P301, DOI 10.1007/978-0-387-85998-9_45; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma WY, 2007, J NEUROSCI, V27, P3618, DOI 10.1523/JNEUROSCI.0132-07.2007; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; Masuda R, 2005, J NEUROSCI RES, V80, P501, DOI 10.1002/jnr.20464; Mejia-Toiber J, 2006, NEUROCHEM RES, V31, P1399, DOI 10.1007/s11064-006-9189-5; Neal EG, 2009, EPILEPSIA, V50, P1109, DOI 10.1111/j.1528-1167.2008.01870.x; NEHLIG A, 1993, PROG NEUROBIOL, V40, P163, DOI 10.1016/0301-0082(93)90022-K; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; Nordli DR, 2001, PEDIATRICS, V108, P129, DOI 10.1542/peds.108.1.129; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; Paramo B, 2010, NEUROSCIENCE, V167, P1057, DOI 10.1016/j.neuroscience.2010.02.074; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; SANDBERG M, 1986, J NEUROCHEM, V47, P178; Schutz PW, 2011, EXP NEUROL, V227, P180, DOI 10.1016/j.expneurol.2010.10.013; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2003, J NEUROSCI, V23, P10681; Suzuki M, 2002, JPN J PHARMACOL, V89, P36, DOI 10.1254/jjp.89.36; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Tai KK, 2008, J NEURAL TRANSM, V115, P1011, DOI 10.1007/s00702-008-0050-7; Tanner GR, 2011, J NEUROSCI, V31, P8689, DOI 10.1523/JNEUROSCI.5951-10.2011; Tkacs NC, 2005, J CEREBR BLOOD F MET, V25, P1645, DOI 10.1038/sj.jcbfm.9600152; Won SJ, 2012, J CEREBR BLOOD F MET, V32, P1086, DOI 10.1038/jcbfm.2012.30; Yamada KA, 2005, NEUROSCI LETT, V385, P210, DOI 10.1016/j.neulet.2005.05.038; Yudkoff M, 2001, J NEUROSCI RES, V66, P931, DOI 10.1002/jnr.10083; Zhang JY, 2013, BIOMATERIALS, V34, P7552, DOI 10.1016/j.biomaterials.2013.06.043; Zhang YF, 2013, J CEREBR BLOOD F MET, V33, P1307, DOI 10.1038/jcbfm.2013.87; Zhou D, 2012, EUR J PEDIATR, V171, P103, DOI 10.1007/s00431-011-1489-3	44	45	46	0	24	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2015	35	5					851	860		10.1038/jcbfm.2015.1			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CH1GK	WOS:000353769100020	25649993	Green Published, Bronze			2021-06-18	
J	Heinemann, AW; Magasi, S; Hammel, J; Carlozzi, NE; Garcia, SF; Hahn, EA; Lai, JS; Tulsky, D; Gray, DB; Hollingsworth, H; Jerousek, S				Heinemann, Allen W.; Magasi, Susan; Hammel, Joy; Carlozzi, Noelle E.; Garcia, Sofia F.; Hahn, Elizabeth A.; Lai, Jin-Shei; Tulsky, David; Gray, David B.; Hollingsworth, Holly; Jerousek, Sara			Environmental Factors Item Development for Persons With Stroke, Traumatic Brain Injury, and Spinal Cord Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Environment; Qualitative research; Questionnaires; Rehabilitation	INTERNATIONAL CLASSIFICATION; OUTCOMES ASSESSMENT; PARTICIPATION; HEALTH; PEOPLE; DISABILITIES; IMPAIRMENTS; ISSUES; PROMIS	Objectives: To describe methods used in operationalizing environmental factors; to describe the results of a research project to develop measures of environmental factors that affect participation; and to define an initial item set of facilitators and barriers to participation after stroke, traumatic brain injury, and spinal cord injury. Design: Instrument development included an extensive literature review, item classification and selection, item writing, and cognitive testing following the approach of the Patient-Reported Outcomes Measurement Information System. Setting: Community. Participants: Content area and outcome measurement experts (n=10) contributed to instrument development; individuals (n=200) with the target conditions participated in focus groups and in cognitive testing (n=15). Interventions: None. Main Outcome Measures: Environmental factor items were categorized in 6 domains: assistive technology; built and natural environment; social environment; services, systems, and policies; access to information and technology; and economic quality of life. Results: We binned 2273 items across the 6 domains, winnowed this pool to 291 items for cognitive testing, and recommended 274 items for pilot data collection. Conclusions: Five of the 6 domains correspond closely to the International Classification of Functioning, Disability and Health taxonomy of environmental factors; the sixth domain, economic quality of life, reflects an important construct that reflects financial resources that affect participation. Testing with a new and larger sample is underway to evaluate reliability, validity, and sensitivity. (C) 2015 by the American Congress of Rehabilitation Medicine	[Heinemann, Allen W.; Jerousek, Sara] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA; [Heinemann, Allen W.] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Magasi, Susan; Hammel, Joy] Univ Illinois, Dept Occupat Therapy, Chicago, IL USA; [Hammel, Joy] Univ Illinois, Dept Disabil & Human Dev, Chicago, IL USA; [Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Garcia, Sofia F.] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA; [Garcia, Sofia F.; Hahn, Elizabeth A.; Lai, Jin-Shei] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA; [Tulsky, David] NYU, Ctr Ambulatory Care, Langone Med Ctr, Dept Rehabil Med, New York, NY USA; [Tulsky, David] NYU, Ctr Ambulatory Care, Langone Med Ctr, Dept Orthoped Surg, New York, NY USA; [Tulsky, David] NYU, Ctr Ambulatory Care, Langone Med Ctr, Dept Gen Med, New York, NY USA; [Tulsky, David] Kessler Fdn, W Orange, NJ USA; [Gray, David B.; Hollingsworth, Holly] Washington Univ, Program Occupat Therapy, St Louis, MO USA	Heinemann, AW (corresponding author), Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, 345 E Super St, Chicago, IL 60611 USA.	a-heinemann@northwestern.edu	Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W./0000-0003-2782-7326; Tulsky, David/0000-0002-4335-4509	National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant [H133B090024]; National Center for Complementary and Alternative MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U54AR0579510]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U54AR057951] Funding Source: NIH RePORTER	Supported by the National Institute on Disability and Rehabilitation Research through a Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes grant (no. H133B090024) awarded to the Rehabilitation Institute of Chicago; and a portion of Garcia's time was supported by the National Center for Complementary and Alternative Medicine and the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (award no. U54AR0579510).	Alvarelhao J, 2012, J REHABIL MED, V44, P1, DOI 10.2340/16501977-0905; Badley EM, 2008, SOC SCI MED, V66, P2335, DOI 10.1016/j.socscimed.2008.01.026; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; DeWalt DA, 2007, MED CARE, V45, pS12, DOI 10.1097/01.mlr.0000254567.79743.e2; Escorpizo Reuben, 2011, Am J Phys Med Rehabil, V90, pS66, DOI 10.1097/PHM.0b013e318230fbf9; Field Marilyn J., 2007, FUTURE DISABILITY AM; Garcia SF, 2007, J CLIN ONCOL, V25, P5106, DOI 10.1200/JCO.2007.12.2341; Garcia SF, 2015, ARCH PHYS MED REHAB, V96, P596, DOI 10.1016/j.apmr.2014.06.019; Gray DB, 2006, ARCH PHYS MED REHAB, V87, P189, DOI 10.1016/j.apmr.2005.09.014; Hahn EA, 2003, ARCH PHYS MED REHAB, V84, pS35, DOI 10.1053/apmr.2003.50245; Hammel J, 2008, DISABIL REHABIL, V30, P1445, DOI 10.1080/09638280701625534; Hammel J, 2015, ARCH PHYS MED REHAB, V96, P578, DOI 10.1016/j.apmr.2014.12.008; Heinemann AW, 2013, ARCH PHYS MED REHAB, V94, P2157, DOI 10.1016/j.apmr.2013.05.017; Hollingsworth H, 2010, ARCH PHYS MED REHAB, V91, P1174, DOI 10.1016/j.apmr.2010.04.019; Magasi S, 2015, ARCH PHYS MED REHAB, V96, P569, DOI 10.1016/j.apmr.2014.12.002; Magasi S, 2009, J REHABIL MED, V41, P936, DOI 10.2340/16501977-0450; Mallinson T, 2010, ARCH PHYS MED REHAB, V91, pS29, DOI 10.1016/j.apmr.2010.04.027; National Institute of Health, 2012, PROMIS INSTR DEV PSY; Noreau L, 2010, ARCH PHYS MED REHAB, V91, pS44, DOI 10.1016/j.apmr.2009.10.037; Rao D, 2009, QUAL LIFE RES, V18, P585, DOI 10.1007/s11136-009-9475-1; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Reinhardt JD, 2010, TOPICS SPINAL CORD I, V15, P26, DOI DOI 10.1310/SCI1504-26; Stenner A., 1998, THE LEXILE FRAMEWORK; Strauss A., 1998, BASICS QUALITATIVE R; Tulsky DS, 2015, ARCH PHYS MED REHAB, V96, P604, DOI 10.1016/j.apmr.2014.02.030; Tulsky DS, 2011, ARCH PHYS MED REHAB, V92, pS44, DOI 10.1016/j.apmr.2011.04.024; Whiteneck G, 2009, ARCH PHYS MED REHAB, V90, pS22, DOI 10.1016/j.apmr.2009.06.009; World Health Organization, 2001, INT CLASS FUNCT DIS	28	45	47	0	25	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2015	96	4					589	595		10.1016/j.apmr.2013.11.024			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CE9RC	WOS:000352180100003	24378804	Green Accepted			2021-06-18	
J	Lu, W; Lakonishok, M; Gelfand, VI				Lu, Wen; Lakonishok, Margot; Gelfand, Vladimir I.			Kinesin-1-powered microtubule sliding initiates axonal regeneration in Drosophila cultured neurons	MOLECULAR BIOLOGY OF THE CELL			English	Article							KINESIN HEAVY-CHAIN; NEURITE OUTGROWTH; CARGO TRANSPORT; LOCUS ELAV; CALCIUM; GROWTH; EXPRESSION; INJURY; DYNEIN; GENE	Understanding the mechanism underlying axon regeneration is of great practical importance for developing therapeutic treatment for traumatic brain and spinal cord injuries. Dramatic cytoskeleton reorganization occurs at the injury site, and microtubules have been implicated in the regeneration process. Previously we demonstrated that microtubule sliding by conventional kinesin (kinesin-1) is required for initiation of neurite outgrowth in Drosophila embryonic neurons and that sliding is developmentally down-regulated when neurite outgrowth is completed. Here we report that mechanical axotomy of Drosophila neurons in culture triggers axonal regeneration and regrowth. Regenerating neurons contain actively sliding microtubules; this sliding, like sliding during initial neurite outgrowth, is driven by kinesin-1 and is required for axonal regeneration. The injury induces a fast spike of calcium, depolymerization of microtubules near the injury site, and subsequent formation of local new microtubule arrays with mixed polarity. These events are required for reactivation of microtubule sliding at the initial stages of regeneration. Furthermore, the c-Jun N-terminal kinase pathway promotes regeneration by enhancing microtubule sliding in injured mature neurons.	[Lu, Wen; Lakonishok, Margot; Gelfand, Vladimir I.] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA	Gelfand, VI (corresponding author), Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA.	vgelfand@northwestern.edu	Gelfand, Vladimir/M-1974-2019; Gelfand, Vladimir I/D-2545-2013; Lu, Wen/I-5799-2013	Gelfand, Vladimir/0000-0002-6361-2798; Gelfand, Vladimir I/0000-0002-6361-2798; 	National Institute of General Medical Science/National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM052111]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM052111] Funding Source: NIH RePORTER	We acknowledge the Bloomington Drosophila Stock Center, the Yale GFP Protein Trap Database, Chris Q. Doe, Isabel M. Palacios, Stephen L. Rogers, and Aaron DiAntonio for fly stocks. We thank Matt Pecot (Department of Neuroscience, Harvard University) and Liming Tan from Larry Zipursky's lab (UCLA) for sharing the larval brain dissociation protocol. Special thanks go to Kari Barlan (University of Chicago) and Michael Winding (Northwestern University) for critical reading of the manuscript. We also thank the Gelfand lab members for support and discussions. Research reported here was supported by National Institute of General Medical Science/National Institutes of Health Award R01 GM052111.	Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Ally S, 2009, J CELL BIOL, V187, P1071, DOI 10.1083/jcb.200908075; Barlan K, 2013, CURR BIOL, V23, P317, DOI 10.1016/j.cub.2013.01.008; Barnat M, 2010, J NEUROSCI, V30, P7804, DOI 10.1523/JNEUROSCI.0372-10.2010; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; Brendza RP, 2000, SCIENCE, V289, P2120, DOI 10.1126/science.289.5487.2120; CAMPOS AR, 1987, EMBO J, V6, P425, DOI 10.1002/j.1460-2075.1987.tb04772.x; Chen L, 2012, P NATL ACAD SCI USA, V109, P11842, DOI 10.1073/pnas.1121180109; Cho Y, 2013, CELL, V155, P894, DOI 10.1016/j.cell.2013.10.004; Cho Y, 2012, EMBO J, V31, P3063, DOI 10.1038/emboj.2012.160; del Castillo U, 2015, CURR BIOL, V25, P200, DOI 10.1016/j.cub.2014.11.008; DONADY JJ, 1975, DIFFERENTIATION, V4, P9; Egger B, 2013, NAT PROTOC, V8, P958, DOI 10.1038/nprot.2013.052; Firestone AJ, 2012, NATURE, V484, P125, DOI 10.1038/nature10936; Ghannad-Rezaie M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029869; Ghosh-Roy A, 2012, DEV CELL, V23, P716, DOI 10.1016/j.devcel.2012.08.010; Ghosh-Roy A, 2010, J NEUROSCI, V30, P3175, DOI 10.1523/JNEUROSCI.5464-09.2010; Gitler D, 1998, NEURON, V20, P1123, DOI 10.1016/S0896-6273(00)80494-8; GOLDBERG DJ, 1992, J NEUROSCI, V12, P4800; Gross SP, 2002, J CELL BIOL, V156, P715, DOI 10.1083/jcb.200109047; Gumy LF, 2013, J NEUROSCI, V33, P11329, DOI 10.1523/JNEUROSCI.5221-12.2013; Hackney DD, 2000, NAT CELL BIOL, V2, P257, DOI 10.1038/35010525; Hammarlund M, 2009, SCIENCE, V323, P802, DOI 10.1126/science.1165527; Hancock WO, 2014, NAT REV MOL CELL BIO, V15, P615, DOI 10.1038/nrm3853; Hurd DD, 1996, GENETICS, V144, P1075; Itoh A, 2009, BIOCHEM BIOPH RES CO, V383, P258, DOI 10.1016/j.bbrc.2009.04.009; Jolly AL, 2010, P NATL ACAD SCI USA, V107, P12151, DOI 10.1073/pnas.1004736107; Kamber D, 2009, EXP NEUROL, V219, P112, DOI 10.1016/j.expneurol.2009.05.004; Karpova N, 2006, CELL MOTIL CYTOSKEL, V63, P301, DOI 10.1002/cm.20124; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; Keshishian H, 1996, ANNU REV NEUROSCI, V19, P545, DOI 10.1146/annurev.ne.19.030196.002553; Klinedinst S, 2013, J NEUROSCI, V33, P12764, DOI 10.1523/JNEUROSCI.5160-12.2013; Kural C, 2005, SCIENCE, V308, P1469, DOI 10.1126/science.1108408; Ling SC, 2004, P NATL ACAD SCI USA, V101, P17428, DOI 10.1073/pnas.0408114101; Liu K, 2011, ANNU REV NEUROSCI, V34, P131, DOI 10.1146/annurev-neuro-061010-113723; Lu W, 2013, JOVE-J VIS EXP, DOI 10.3791/50838; Lu W, 2013, CURR BIOL, V23, P1018, DOI 10.1016/j.cub.2013.04.050; Lu W, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001357; Mandolesi G, 2004, FASEB J, V18, P1934, DOI 10.1096/fj.04-1805fje; MARCUM JM, 1978, P NATL ACAD SCI USA, V75, P3771, DOI 10.1073/pnas.75.8.3771; Martin M, 1999, MOL BIOL CELL, V10, P3717, DOI 10.1091/mbc.10.11.3717; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Nicholson L, 2008, GENETICS, V178, P215, DOI 10.1534/genetics.107.081968; Nicolai LJJ, 2010, P NATL ACAD SCI USA, V107, P20553, DOI 10.1073/pnas.1010198107; Nix P, 2011, P NATL ACAD SCI USA, V108, P10738, DOI 10.1073/pnas.1104830108; OBrien ET, 1997, CELL MOTIL CYTOSKEL, V36, P125, DOI 10.1002/(SICI)1097-0169(1997)36:2<125::AID-CM3>3.0.CO;2-8; Osterwalder T, 2001, P NATL ACAD SCI USA, V98, P12596, DOI 10.1073/pnas.221303298; Pilling AD, 2006, MOL BIOL CELL, V17, P2057, DOI 10.1091/mbc.E05-06-0526; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Sainath R, 2015, DEV NEUROBIOL, V75, P757, DOI 10.1002/dneu.22246; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; Seeger MA, 2010, J BIOL CHEM, V285, P8155, DOI 10.1074/jbc.M109.068247; Serbus LR, 2005, DEVELOPMENT, V132, P3743, DOI 10.1242/dev.01956; Shimada Y, 2006, DEV CELL, V10, P209, DOI 10.1016/j.devcel.2005.11.016; Shubeita GT, 2008, CELL, V135, P1098, DOI 10.1016/j.cell.2008.10.021; Song YQ, 2012, GENE DEV, V26, P1612, DOI 10.1101/gad.193243.112; Stone MC, 2008, MOL BIOL CELL, V19, P4122, DOI 10.1091/mbc.E07-10-1079; Stone MC, 2012, CELL REP, V2, P1340, DOI 10.1016/j.celrep.2012.09.032; Stone MC, 2010, MOL BIOL CELL, V21, P767, DOI 10.1091/mbc.E09-11-0967; Tian L, 2009, NAT METHODS, V6, P875, DOI 10.1038/nmeth.1398; Uchida A, 2009, MOL BIOL CELL, V20, P4997, DOI 10.1091/mbc.E09-04-0304; Waetzig V, 2006, PROG NEUROBIOL, V80, P84, DOI 10.1016/j.pneurobio.2006.08.002; Weber U, 2000, DEVELOPMENT, V127, P3619; Xiong X, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001440; Xiong X, 2012, J NEUROSCI, V32, P610, DOI 10.1523/JNEUROSCI.3586-11.2012; Xiong X, 2010, J CELL BIOL, V191, P211, DOI 10.1083/jcb.201006039; Zhang YQ, 2002, GENESIS, V34, P142, DOI 10.1002/gene.10144; Ziv NE, 1997, J NEUROSCI, V17, P3568; Ziv NE, 1995, J NEUROPHYSIOL, V74, P2625	72	45	45	0	14	AMER SOC CELL BIOLOGY	BETHESDA	8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA	1059-1524	1939-4586		MOL BIOL CELL	Mol. Biol. Cell	APR 1	2015	26	7					1296	1307		10.1091/mbc.E14-10-1423			12	Cell Biology	Cell Biology	CE6KU	WOS:000351946100009	25657321	Green Published, Other Gold			2021-06-18	
J	Lin, AP; Ramadan, S; Stern, RA; Box, HC; Nowinski, CJ; Ross, BD; Mountford, CE				Lin, Alexander P.; Ramadan, Saadallah; Stern, Robert A.; Box, Hayden C.; Nowinski, Christopher J.; Ross, Brian D.; Mountford, Carolyn E.			Changes in the neurochemistry of athletes with repetitive brain trauma: preliminary results using localized correlated spectroscopy	ALZHEIMERS RESEARCH & THERAPY			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; MR SPECTROSCOPY; ALZHEIMERS-DISEASE; HEAD-INJURY; ENCEPHALOPATHY; ABNORMALITIES; PHENYLALANINE; INFLAMMATION; ACTIVATION; SYMPTOMS	Introduction: The goal was to identify which neurochemicals differ in professional athletes with repetitive brain trauma (RBT) when compared to healthy controls using a relatively new technology, in vivo Localized COrrelated SpectroscopY (L-COSY). Methods: To achieve this, L-COSY was used to examine five former professional male athletes with 11 to 28 years of exposure to contact sports. Each athlete who had had multiple symptomatic concussions and repetitive sub concussive trauma during their career was assessed by an experienced neuropsychologist. All athletes had clinical symptoms including headaches, memory loss, confusion, impaired judgment, impulse control problems, aggression, and depression. Five healthy men, age and weight matched to the athlete cohort and with no history of brain trauma, were recruited as controls. Data were collected from the posterior cingulate gyrus using a 3 T clinical magnetic resonance scanner equipped with a 32 channel head coil. Results: The variation of the method was calculated by repeated examination of a healthy control and phantom and found to be 10% and 5%, respectively, or less. The L-COSY measured large and statistically significant differences (P <= 0.05), between healthy controls and those athletes with RBT. Men with RBT showed higher levels of glutamine/glutamate (31%), choline (65%), fucosylated molecules (60%) and phenylalanine (46%). The results were evaluated and the sample size of five found to achieve a significance level P=0.05 and a power of 90%. Differences in N-acetyl aspartate and myo-inositol between RBT and controls were small and were not statistically significance. Conclusions: A study of a small cohort of professional athletes, with a history of RBT and symptoms of chronic traumatic encephalopathy when compared with healthy controls using 2D L-COSY, showed elevations in brain glutamate/glutamine and choline as recorded previously for early traumatic brain injury. For the first time increases in phenylalanine and fucose are recorded in the brains of athletes with RBT. Larger studies utilizing the L-COSY method may offer an in-life method of diagnosis and personalized approach for monitoring the acute effects of mild traumatic brain injury and the chronic effects of RBT.	[Lin, Alexander P.; Ramadan, Saadallah; Box, Hayden C.; Ross, Brian D.; Mountford, Carolyn E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Clin Spect,Dept Radiol, Boston, MA 02115 USA; [Ramadan, Saadallah; Mountford, Carolyn E.] Univ Newcastle, Sch Hlth Sci, Ctr MR Hlth, Newcastle, NSW 2308, Australia; [Stern, Robert A.; Nowinski, Christopher J.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Stern, Robert A.] Boston Univ, Sch Med, BU Alzheimers Dis Ctr, Boston, MA 02118 USA; [Ross, Brian D.] Huntington Med Res Inst, Clin Spect, Pasadena, CA 91105 USA; [Nowinski, Christopher J.] Sports Legacy Inst, Waltham, MA 02451 USA	Lin, AP (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Clin Spect,Dept Radiol, 4 Blackfan St HIM-820, Boston, MA 02115 USA.	aplin@partners.org	, Bob/ABA-8507-2020; Mountford, Carolyn E/N-2007-2013; Ramadan, Saadallah/AAE-4885-2019	Mountford, Carolyn E/0000-0002-3870-4658; Ramadan, Saadallah/0000-0003-3874-7866; Stern, Robert/0000-0002-5008-077X	Harvard Catalyst, The Harvard Clinical and Translational Science Center; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 UL1 RR 025758-02, P30-AG13846, R01-NS078337]; Department of Defense Congressionally Directed Medical Research Programs in Psychological Health/Traumatic Brain Injury [W81XWH-10-1-0835]; Australian Research CouncilAustralian Research Council [DP0663987]; National Operating Committee; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This research was conducted with the support of a grant from a pilot grant from Harvard Catalyst, The Harvard Clinical and Translational Science Center; NIH Grant # 1 UL1 RR 025758-02; and financial contributions from participating institutions as well as the Department of Defense Congressionally Directed Medical Research Programs in Psychological Health/Traumatic Brain Injury (W81XWH-10-1-0835). Early aspects of this work were supported by the Australian Research Council (DP0663987). Additional support for the BU Center for the Study of Traumatic Encephalopathy has been received from the National Operating Committee on Standards for Athletic Equipment, as well as NIH Grants P30-AG13846 and R01-NS078337, and an unrestricted gift was received from the USA National Football League.	Altman DG, 1998, STAT MED, V17, P2661, DOI 10.1002/(SICI)1097-0258(19981215)17:23<2661::AID-SIM33>3.0.CO;2-B; [Anonymous], MATLAB STAT TOOLB RE; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; BAGCHI SP, 1977, J NEURAL TRANSM, V41, P101, DOI 10.1007/BF01670275; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; DEGRAAF TW, 1993, J EXP MED, V177, P657, DOI 10.1084/jem.177.3.657; DELIKATNY EJ, 1991, J MAGN RESON, V94, P563, DOI 10.1016/0022-2364(91)90143-H; Ferrerosa L, 2013, BUSM MED STUD SUMM R; Gavett BE, 2011, CURR OPIN NEUROL, V24, P525, DOI 10.1097/WCO.0b013e32834cd477; Govindaraju V, 2000, NMR BIOMED, V13, P129, DOI 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoeche N, 2010, FENS FOR 2010, P1057; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Jansen JFA, 2006, RADIOLOGY, V240, P318, DOI 10.1148/radiol.2402050314; Kaiser LG, 2010, J MAGN RESON, V202, P259, DOI 10.1016/j.jmr.2009.11.013; Kierans AS, 2014, NEUROLOGY, V82, P521, DOI 10.1212/WNL.0000000000000105; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; LEAN CL, 1992, BIOCHEMISTRY-US, V31, P11095, DOI 10.1021/bi00160a020; LEAN CL, 1991, MAGN RESON MED, V20, P306, DOI 10.1002/mrm.1910200213; Lee M, 2013, CURR PROTEIN PEPT SC, V14, P21, DOI 10.2174/1389203711314010005; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lowe JB, 2003, CURR OPIN CELL BIOL, V15, P531, DOI 10.1016/j.ceb.2003.08.002; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mountford CE, 2010, CHEM REV, V110, P3060, DOI 10.1021/cr900250y; Murrey HE, 2009, BIOCHEMISTRY-US, V48, P7261, DOI 10.1021/bi900640x; Nagarajan R, 2012, INT J HEPATOL, V2012, DOI 10.1155/2012/179365; OGG RJ, 1994, J MAGN RESON SER B, V104, P1, DOI 10.1006/jmrb.1994.1048; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ramadan S, 2010, P INT SOC MAGN RES M, P1478; Ramadan S, 2011, RADIOLOGY, V259, P540, DOI 10.1148/radiol.11101123; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sharman R, 2012, GENE, V504, P288, DOI 10.1016/j.gene.2012.05.007; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Smalla KH, 1998, NEUROREPORT, V9, P813, DOI 10.1097/00001756-199803300-00009; Snyder J, 2010, J MAGN RESON, V203, P66, DOI 10.1016/j.jmr.2009.12.002; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Thomas MA, 2001, MAGNET RESON MED, V46, P58, DOI 10.1002/mrm.1160; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Valentine GW, 2009, BIOCHEM PHARMACOL, V78, P431, DOI 10.1016/j.bcp.2009.04.008; Velan SS, 2007, J MAGN RESON IMAGING, V26, P405, DOI 10.1002/jmri.20968; Yuksel C, 2010, BIOL PSYCHIAT, V68, P785, DOI 10.1016/j.biopsych.2010.06.016	49	45	45	1	34	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1758-9193			ALZHEIMERS RES THER	Alzheimers Res. Ther.	MAR 15	2015	7								13	10.1186/s13195-015-0094-5			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CD8KO	WOS:000351343900001	25780390	DOAJ Gold, Green Published			2021-06-18	
J	Kirk, S; Fallon, D; Fraser, C; Robinson, G; Vassallo, G				Kirk, S.; Fallon, D.; Fraser, C.; Robinson, G.; Vassallo, G.			Supporting parents following childhood traumatic brain injury: a qualitative study to examine information and emotional support needs across key care transitions	CHILD CARE HEALTH AND DEVELOPMENT			English	Article						adolescents; children; co-ordination; information; support; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; OF-LIFE; CHILDREN; SCHOOL; OUTCOMES; ADOLESCENTS; IMPACT; REHABILITATION; PARTICIPATION	IntroductionTraumatic brain injury (TBI) is the leading cause of death and acquired disability in childhood. Research has demonstrated that TBI can lead to long-term physical, cognitive, emotional and behavioural difficulties for children and parental stress. Less is known about how parents experience a childhood brain injury and their information and support needs. This study aimed to examine parents' experiences and support needs following a childhood TBI from the time of the accident to their child's discharge home. MethodsQualitative semi-structured interviews were conducted with 29 parents/carers of children who had experienced a severe TBI. Participants were recruited from one children's tertiary centre in the UK. Data were analysed using the Framework approach. ResultsParents had unmet information and emotional support needs across the care trajectory from the time of the accident to their child's return home. Information needs related to the impact of the TBI on their child; current and future treatment/rehabilitation plans; helping their child and managing their behaviour; accessing services/support. They lacked information and support for care transitions. In different settings parents faced particular barriers to having their information needs met. Parents' felt they needed emotional support in coming to terms with witnessing the accident and the loss of their former child. Lack of community support related not only to service availability but to a general lack of understanding of the impact of TBI on children, particularly when this was invisible. Overall parents felt unsupported in coping with children's behavioural and psychological difficulties. DiscussionTaking a holistic approach to examining parents' experiences and support needs has enabled their changing needs to be highlighted across key care transitions within hospital and community settings and the service implications identified. Improvements in care co-ordination across care transitions are needed to ensure continuity of care and integration of support.	[Kirk, S.; Fallon, D.; Fraser, C.] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England; [Robinson, G.; Vassallo, G.] Royal Manchester Childrens Hosp, Paediat Neurol Dept, Manchester M27 1HA, Lancs, England	Kirk, S (corresponding author), Univ Manchester, Sch Nursing Midwifery & Social Work, Jean McFarlane Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.	sue.kirk@manchester.ac.uk	Fallon, Debbie/AAA-4553-2019; Fraser, Claire/O-9023-2014	Fraser, Claire/0000-0003-3684-3168; Kirk, Susan/0000-0002-1485-8804			Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Aitken ME, 2004, ARCH PHYS MED REHAB, V85, P567, DOI 10.1016/j.apmr.2003.06.018; Anaby D, 2012, DEV MED CHILD NEUROL, V54, P339, DOI 10.1111/j.1469-8749.2011.04204.x; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Armstrong Kira, 2002, Pediatr Rehabil, V5, P149, DOI 10.1080/1363849021000039353; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Brown FL, 2013, BRAIN INJURY, V27, P1570, DOI 10.3109/02699052.2013.841996; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Clark Alex, 2008, Clin Child Psychol Psychiatry, V13, P565, DOI 10.1177/1359104508090607; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Gfroerer SD, 2008, BRAIN INJURY, V22, P649, DOI 10.1080/02699050802227162; Glang A, 2008, NEUROREHABILITATION, V23, P477; Guerriere D, 1997, J Soc Pediatr Nurs, V2, P105, DOI 10.1111/j.1744-6155.1997.tb00067.x; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Jordan J, 2013, BRAIN INJURY, V27, P1063, DOI 10.3109/02699052.2013.794962; Kenardy J, 2012, J CLIN CHILD ADOLESC, V41, P5, DOI 10.1080/15374416.2012.632348; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Latour JM, 2011, INTENS CARE MED, V37, P319, DOI 10.1007/s00134-010-2074-3; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Mealings M, 2012, BRAIN INJURY, V26, P1165, DOI 10.3109/02699052.2012.672785; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Roscigno CI, 2011, QUAL HEALTH RES, V21, P1413, DOI 10.1177/1049732311410988; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sloper P, 2006, CHILD CARE HLTH DEV, V32, P147, DOI 10.1111/j.1365-2214.2006.00592.x; Spencer L., 2003, QUALITATIVE RES PRAC, P199; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; Tasker RC, 2011, BRIT J NEUROSURG, V25, P68, DOI 10.3109/02688697.2010.538770; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Tomlin P, 2002, DEV MED CHILD NEUROL, V44, P828; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Van Houdt S, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-296; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Williams H., 2011, REPAIRING SHATTERED	45	45	45	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1862	1365-2214		CHILD CARE HLTH DEV	Child Care Health Dev.	MAR	2015	41	2					303	313		10.1111/cch.12173			11	Psychology, Developmental; Pediatrics	Psychology; Pediatrics	CB6XU	WOS:000349771100014	25039833				2021-06-18	
J	Blaya, MO; Tsoulfas, P; Bramlett, HM; Dietrich, WD				Blaya, Meghan O.; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton			Neural progenitor cell transplantation promotes neuroprotection, enhances hippocampal neurogenesis, and improves cognitive outcomes after traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neural progenitor cell transplantation; Multineurotrophin; Hippocampal neurogenesis; Neuroprotection; Spatial memory	ADULT NEUROGENESIS; DENTATE GYRUS; NEURONS; DIFFERENTIATION; NEUROTROPHINS; ACTIVATION; RECEPTORS; SURVIVAL; POINT	Transplantation of neural progenitor cells (NPCs) may be a potential treatment strategy for traumatic brain injury (TBI) due to their intrinsic advantages, including the secretion of neurotrophins. Neurotrophins are critical for neuronal survival and repair, but their clinical use is limited. In this study, we hypothesized that pericontusional transplantation of NPCs genetically modified to secrete a synthetic, human multineurotrophin (MNTS1) would overcome some of the limitations of traditional neurotrophin therapy. MNTS1 is a multifunctional neurotrophin that binds all three tropomyosin-related kinase (Trk) receptors, recapitulating the prosurvival activity of 3 endogenous mature neurotrophins. NPCs obtained from rat fetuses at E15 were transduced with lentiviral vectors containing MNTS1 and GFP constructs (MNTS1-NPCs) or fluorescent constructs alone (control GFP-NPCs). Adult rats received fluid percussion-induced TBI or sham surgery. Animals were transplanted 1 week later with control GFP-NPCs, MNTS1-NPCs, or injected with saline (vehicle). At five weeks, animals were evaluated for hippocampal-dependent spatial memory. Six weeks post-surgery, we observed significant survival and neuronal differentiation of MNTS1-NPCs and injury-activated tropism toward contused regions. NPCs displayed processes that extended into several remote structures, including the hippocampus and contralateral cortex. Both GFP- and MNTS1-NPCs conferred significant preservation of pericontusional host tissues and enhanced hippocampal neurogenesis. NPC transplantation improved spatial memory capacity on the Morris water maze (MWM) task. Transplant recipients exhibited escape latencies approximately half that of injured vehicle controls. While we observed greater transplant survival and neuronal differentiation of MNTS1-NPCs, our collective findings suggest that MNTS1 may be superfluous in terms of preserving the cytoarchitecture and rescuing behavioral deficits given the lack of significant difference between MNTS1- and GFP-control transplanted groups. Nevertheless, our overall findings support the potential of syngeneic NPC transplantation to enhance endogenous neuroreparative responses and may therefore be an effective treatment for TBI. (C) 2014 Elsevier Inc. All rights reserved.	[Blaya, Meghan O.; Tsoulfas, Pantelis; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL 33125 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	Moconnell2@med.miami.edu; Ptsoulfa@med.miami.edu; Hbramlett@med.miami.edu; Ddietrich@miami.edu		Tsoulfas, Pantelis/0000-0003-1974-6366	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, W81XWH-06-1-0187]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER	The studies were supported by NIH NS030291 to WDD and W81XWH-06-1-0187 awarded to WDD. The authors wish to thank Mrs. Ofelia Furones-Alonso, Mr. Pingping Jia and Mrs. Yunfang Wang for their technical contributions to this study, and to Dr. Coleen Atkins for proofreading the manuscript.	Alonso M, 2004, LEARN MEMORY, V11, P172, DOI 10.1101/lm.67804; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Cossetti C, 2012, CELL TISSUE RES, V349, P321, DOI 10.1007/s00441-012-1341-8; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Follenzi A, 2002, METHOD ENZYMOL, V346, P454; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Kumagai G, 2013, EXP NEUROL, V248, P369, DOI 10.1016/j.expneurol.2013.06.028; Lessmann V, 2003, PROG NEUROBIOL, V69, P341, DOI 10.1016/S0301-0082(03)00019-4; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Walker PA, 2012, J NEUROINFLAMM, V9, P1742; Wu Y., 2012, TRANSL NEURODEGENER, V1, P2047; Xu Q, 2007, CLIN EXP PHARMACOL P, V34, P624, DOI 10.1111/j.1440-1681.2007.04619.x; Yoshimura S, 2001, P NATL ACAD SCI USA, V98, P5874, DOI 10.1073/pnas.101034998; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011	37	45	45	0	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2015	264						67	81		10.1016/j.expneurol.2014.11.014			15	Neurosciences	Neurosciences & Neurology	CB4IC	WOS:000349590400008	25483396	Green Accepted			2021-06-18	
J	Finley, EP; Bollinger, M; Noel, PH; Amuan, ME; Copeland, LA; Pugh, JA; Dassori, A; Palmer, R; Bryan, C; Pugh, MJV				Finley, Erin P.; Bollinger, Mary; Noel, Polly H.; Amuan, Megan E.; Copeland, Laurel A.; Pugh, Jacqueline A.; Dassori, Albana; Palmer, Raymond; Bryan, Craig; Pugh, Mary Jo V.			A National Cohort Study of the Association Between the Polytrauma Clinical Triad and Suicide-Related Behavior Among US Veterans Who Served in Iraq and Afghanistan	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH DIAGNOSES; SUBSTANCE USE DISORDERS; DEPLOYED MILITARY PERSONNEL; PSYCHIATRIC DIAGNOSES; COMMUNITY SAMPLE; WAR VETERANS; RISK; IDEATION	Objectives. We examined the association of posttraumatic stress disorder (PTSD), traumatic brain injury, and chronic pain-the polytrauma clinical triad (PCT)-independently and with other conditions, with suicide-related behavior (SRB) risk among Operation Enduring Freedom (OEF; Afghanistan) and Operation Iraqi Freedom (OIF) veterans. Methods. We used Department of Veterans Affairs (VA) administrative data to identify OEF and OIF veterans receiving VA care in fiscal years 2009-2011; we used International Classification of Diseases, Ninth Revision, Clinical Modification codes to characterize 211 652 cohort members. Descriptive statistics were followed by multinomial logistic regression analyses predicting SRB. Results. Co-occurrence of PCT conditions was associated with significant increase in suicide ideation risk (odds ratio [OR] = 1.9; 95% confidence interval [CI] = 1.5, 2.4) or attempt and ideation (OR = 2.6; 95% CI = 1.5, 4.6), but did not exceed increased risk with PTSD alone (ideation: OR = 2.3; 95% CI = 2.0, 2.6; attempt: OR = 2.0; 95% CI = 1.4, 2.9; ideation and attempt: OR = 1.8; 95% CI = 1.2, 2.8). Ideation risk was significantly elevated when PTSD was comorbid with depression (OR = 4.2; 95% CI = 3.6, 4.8) or substance abuse (OR = 4.7; 95% CI = 3.9, 5.6). Conclusions. Although PCT was a moderate SRB predictor, interactions among PCT conditions, particularly PTSD, and depression or substance abuse had larger risk increases.	[Finley, Erin P.; Bollinger, Mary; Noel, Polly H.; Pugh, Jacqueline A.; Dassori, Albana; Pugh, Mary Jo V.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; [Palmer, Raymond] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Amuan, Megan E.] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA; [Copeland, Laurel A.] Hlth Care Syst, Cent Texas Vet, Ctr Appl Hlth Res, Temple, TX USA; [Copeland, Laurel A.] Scott & White Healthcare Syst, Temple, TX USA; [Bryan, Craig] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT USA; [Bryan, Craig] Univ Utah, Dept Psychol, Salt Lake City, UT 84112 USA	Finley, EP (corresponding author), South Texas Vet Hlth Care Syst, Audie L Murphy Mem Vet Hosp, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	finleye@uthscsa.edu	Pugh, Mary Jo/K-5336-2019; Copeland, Laurel A/C-3763-2017; Pugh, Jacqueline/I-6199-2013	Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel A/0000-0002-9478-0209; Pugh, Jacqueline/0000-0003-4933-141X; Finley, Erin/0000-0003-4497-7721; Noel, Polly/0000-0002-1519-7489; palmer, ray/0000-0001-6621-9038; Bryan, Craig/0000-0002-9714-0733	Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; South Texas Veterans Health Care System; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25 MH080916-01A2]; Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R25MH080916] Funding Source: NIH RePORTER	This study was funded by Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). J. A. Pugh's and A. Dassori's salaries were funded by the South Texas Veterans Health Care System. E. P. Finley is an investigator with the Implementation Research Institute, at the George Warren Brown School of Social Work, Washington University in St Louis, through an award from the National Institute of Mental Health (R25 MH080916-01A2) and the Department of Veterans Affairs, Health Services Research and Development Service, Quality Enhancement Research Initiative.	Allison PD., 2001, LOGISTIC REGRESSION; [Anonymous], 2013, VA DOD CLIN PRACT GU; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Bell NS, 2010, SUICIDE LIFE-THREAT, V40, P407, DOI 10.1521/suli.2010.40.4.407; Bonn-Miller MO, 2012, MIL MED, V177, P786, DOI 10.7205/MILMED-D-12-00052; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Britton PC, 2012, AM J PUBLIC HEALTH, V102, pS125, DOI 10.2105/AJPH.2011.300415; Brotman DJ, 2007, LANCET, V370, P1089, DOI 10.1016/S0140-6736(07)61305-1; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Bryan CJ, 2011, PSYCHOL SERV, V8, P94, DOI 10.1037/a0023451; Buck CJ, 2012, 2012 ICD 9 CM PHYS 2, V1; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; Defense Casualty Analysis System, 2012, ACT DUT MIL DEATHS Y; Department of Defense, DEP DEF ICD 9 COD GU; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; FONTANA A, 1995, AM J PSYCHIAT, V152, P102; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Grossman LS, 1997, PSYCHIAT SERV, V48, P393; Guerra VS, 2011, J ANXIETY DISORD, V25, P12, DOI 10.1016/j.janxdis.2010.06.025; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holtzheimer PE, 2005, AM J PSYCHIAT, V162, P970, DOI 10.1176/appi.ajp.162.5.970; Ilgen MA, 2008, GEN HOSP PSYCHIAT, V30, P521, DOI 10.1016/j.genhosppsych.2008.09.003; Ilgen MA, 2012, J CONSULT CLIN PSYCH, V80, P323, DOI 10.1037/a0028266; Ilgen MA, 2012, AM J PUBLIC HEALTH, V102, pS88, DOI 10.2105/AJPH.2011.300392; Ilgen MA, 2010, SUICIDE LIFE-THREAT, V40, P597, DOI 10.1521/suli.2010.40.6.597; Ilgen MA, 2010, ARCH GEN PSYCHIAT, V67, P1152, DOI 10.1001/archgenpsychiatry.2010.129; Jakupcak M, 2011, J NERV MENT DIS, V199, P272, DOI 10.1097/NMD.0b013e3182124604; Jakupcak M, 2009, J TRAUMA STRESS, V22, P303, DOI 10.1002/jts.20423; Kang HK, 2008, JAMA-J AM MED ASSOC, V300, P652, DOI 10.1001/jama.300.6.652; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Kaplan MS, 2012, AM J PUBLIC HEALTH, V102, pS131, DOI 10.2105/AJPH.2011.300445; Katz IR, 2012, AM J PUBLIC HEALTH, V102, pS105, DOI 10.2105/AJPH.2011.300503; Kemp J, 2012, SUICIDE DATA REPORT; Kim HM, 2012, J CLIN PSYCHIAT, V73, pE1269, DOI 10.4088/JCP.12m07658; Kim HM, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-18; Lemaire CM, 2011, J AFFECT DISORDERS, V130, P231, DOI 10.1016/j.jad.2010.10.021; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; MacGregor AJ, 2013, J HEAD TRAUMA REHAB, V28, P59, DOI 10.1097/HTR.0b013e3182596382; MacLean A, 2010, ARMED FORCES SOC, V36, P765, DOI 10.1177/0095327X09356166; Magruder KM, 2012, AM J PUBLIC HEALTH, V102, pS118, DOI 10.2105/AJPH.2011.300451; Mattocks KM, 2012, SOC SCI MED, V74, P537, DOI 10.1016/j.socscimed.2011.10.039; Olson-Madden JH, 2012, J HEAD TRAUMA REHAB, V27, P370, DOI 10.1097/HTR.0b013e318268d496; Owens D, 2002, BRIT J PSYCHIAT, V181, P193, DOI 10.1192/bjp.181.3.193; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; Skopp Nancy A, 2012, MSMR, V19, P7; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Weiner J, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-374; Wells TS, 2010, AM J PUBLIC HEALTH, V100, P90, DOI 10.2105/AJPH.2008.155432; WICKENS T. D., 1989, MULTIWAY CONTINGENCY; Wilcox HC, 2009, ARCH GEN PSYCHIAT, V66, P305, DOI 10.1001/archgenpsychiatry.2008.557; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	59	45	45	0	21	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	FEB	2015	105	2					380	387		10.2105/AJPH.2014.301957			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CE6CD	WOS:000351922500046	25033126	Green Published			2021-06-18	
J	Abdullah, L; Evans, JE; Ferguson, S; Mouzon, B; Montague, H; Reed, J; Crynen, G; Emmerich, T; Crocker, M; Pelot, R; Mullan, M; Crawford, F				Abdullah, Laila; Evans, James E.; Ferguson, Scott; Mouzon, Benoit; Montague, Hannah; Reed, Jon; Crynen, Gogce; Emmerich, Tanja; Crocker, Madison; Pelot, Robert; Mullan, Michael; Crawford, Fiona			Lipidomic analyses identify injury-specific phospholipid changes 3 mo after traumatic brain injury	FASEB JOURNAL			English	Article						controlled cortical impact; mass spectrometry; phosphatidylcholine; phosphatidylethanolamine; phosphatidylinositol; sphingomyelin	CORTICAL IMPACT INJURY; FREE FATTY-ACIDS; SIGNAL-TRANSDUCTION; MEMORY DEFICITS; SPATIAL MEMORY; AXONAL INJURY; RAT-BRAIN; MEDIATORS; LIPOPROTEINS; ACTIVATION	Phospholipid (PL) abnormalities are observed in the cerebrospinal fluid of patients with traumatic brain injury (TBI), suggesting their role in TBI pathology. Therefore, PL levels were examined in a TBI mouse model that received 1.8 mm deep controlled cortical impact injury or craniectomy only (control). The rotarod and Barnes maze acquisition and probe tests were performed within 2 wk after injury, with another probe test performed 3 mo postinjury. Liquid chromatography/mass spectrometry analyses were performed on lipid extracts from several brain regions and plasma from injured and control mice collected at 3 mo postinjury. Compared to controls, injured mice with sensorimotor and learning deficits had decreased levels of cortical and cerebellar phosphatidylcholine (PC) and phosphatidylethanolamine (PE) levels, while hippocampal PC, sphingomyelin and PE levels were elevated. Ether PE levels were lower in the cortices and plasma of injured animals. Polyunsaturated fatty acid-containing PC and PE species, particularly ratios of docosahexaenoic acid (DHA) to arachidonic acid, were lower in the hippocampi and cortices and plasma of injured mice. Given the importance of DHA in maintaining neuronal function and resolving inflammation and of peroxisomes in synthesis of ether PLs, normalizing these PLs may be a useful strategy for treating the chronic pathology of TBI.	[Abdullah, Laila; Evans, James E.; Ferguson, Scott; Mouzon, Benoit; Montague, Hannah; Reed, Jon; Crynen, Gogce; Emmerich, Tanja; Crocker, Madison; Pelot, Robert; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Sarasota, FL 34243 USA; [Abdullah, Laila; Evans, James E.; Ferguson, Scott; Mouzon, Benoit; Reed, Jon; Crynen, Gogce; Emmerich, Tanja; Pelot, Robert; Crawford, Fiona] James A Haley Vet Affairs Hosp, Tampa, FL USA	Abdullah, L (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	labdullah@rfdn.org		Emmerich, Tanja/0000-0001-5064-7150	Congressionally Directed Medical Research Program award [W81XWH-10-1-0759]; U.S. Department of Veterans Affairs Merit awardUS Department of Veterans Affairs	This work is made possible through a Congressionally Directed Medical Research Program award (W81XWH-10-1-0759) and a U.S. Department of Veterans Affairs Merit award to F.C. The authors also thank Ariel Gonzalez for his contribution to lipidomic analyses. The contents do not represent the views of the Department of Veterans Affairs or the U.S. Government.	Abdullah L, 2012, NEUROMOL MED, V14, P349, DOI 10.1007/s12017-012-8192-z; Ando S, 2005, MASS SPECTROM REV, V24, P865, DOI 10.1002/mas.20045; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Brauer AU, 2003, NAT NEUROSCI, V6, P572, DOI 10.1038/nn1052; Braverman NE, 2012, BBA-MOL BASIS DIS, V1822, P1442, DOI 10.1016/j.bbadis.2012.05.008; Crawford F, 2012, J NEUROTRAUM, V29, P246, DOI 10.1089/neu.2011.1789; da Silva TF, 2012, BBA-MOL BASIS DIS, V1822, P1501, DOI 10.1016/j.bbadis.2012.05.014; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Driskell JA, 2007, SPORTS NUTR FATS PRO; Erdman J., 2011, NUTR TRAUMATIC BRAIN; FADEN AI, 1992, AM J PHYSIOL, V263, pR909; Farias SE, 2011, J TRAUMA, V71, P1211, DOI 10.1097/TA.0b013e3182092c62; Farooqui AA, 2001, NEUROSCIENTIST, V7, P232, DOI 10.1177/107385840100700308; Farooqui AA, 2007, J NEUROSCI RES, V85, P1834, DOI 10.1002/jnr.21268; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Ferguson S, 2010, NEUROSCIENCE, V168, P811, DOI 10.1016/j.neuroscience.2010.01.031; Finkelstein EA., 2006, INCIDENCE EC BURDEN; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frisardi V, 2011, PROG LIPID RES, V50, P313, DOI 10.1016/j.plipres.2011.06.001; Fujimoto S, 2004, HEART VESSELS, V19, P19, DOI 10.1007/s00380-003-0725-9; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hamilton JA, 2007, J MOL NEUROSCI, V33, P2, DOI 10.1007/s12031-007-0060-1; Hankin JA, 2011, J AM SOC MASS SPECTR, V22, P1014, DOI 10.1007/s13361-011-0122-z; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Hunt RF, 2012, EPILEPSY RES, V99, P167, DOI 10.1016/j.eplepsyres.2011.10.011; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; King JA, 2004, NEUROPSYCHOLOGY, V18, P405, DOI 10.1037/0894-4105.18.3.405; Lin YH, 2007, J LIPID RES, V48, P2709, DOI 10.1194/jlr.M700369-JLR200; Liu F, 2006, FEBS LETT, V580, P6269, DOI 10.1016/j.febslet.2006.10.033; Lohner K, 1996, CHEM PHYS LIPIDS, V81, P167, DOI 10.1016/0009-3084(96)02580-7; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Meyer U, 2010, PSYCHOPHARMACOLOGY, V208, P531, DOI 10.1007/s00213-009-1754-6; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Nguyen LN, 2014, NATURE, V509, P503, DOI 10.1038/nature13241; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Patil SS, 2009, BEHAV BRAIN RES, V198, P58, DOI 10.1016/j.bbr.2008.10.029; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Polozova A, 2007, J MOL NEUROSCI, V33, P56, DOI 10.1007/s12031-007-0039-y; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Purdon AD, 2002, NEUROCHEM RES, V27, P1641, DOI 10.1023/A:1021635027211; Russell KL, 2013, PROSTAG LEUKOTR ESS, V89, P97, DOI 10.1016/j.plefa.2013.05.004; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sawada Masato, 2013, Keio Journal of Medicine, V62, P13, DOI 10.2302/kjm.2012-0005-RE; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI 10.1146/annurev.pathmechdis.3.121806.151409; Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c; Sierra A, 2015, BRAIN STRUCT FUNCT, V220, P781, DOI 10.1007/s00429-013-0683-7; Spector AA, 2001, J MOL NEUROSCI, V16, P159, DOI 10.1385/JMN:16:2-3:159; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; Taber KH, 2010, PTSD RES Q, V21, P1; U.S. Centers for Disease Control and Prevention National Institutes of Health Department of Defense and Department of Veterans Affairs Leadership Panel, 2013, REP C TRAUM BRAIN IN; Vance DE, 2008, N COMP BIOC, P1; VANCE JE, 1994, J NEUROCHEM, V62, P329; Wallace D, 2012, J MIL VETERANS HEALT, V20, P10; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yu GF, 2013, CLIN CHIM ACTA, V421, P7, DOI 10.1016/j.cca.2013.02.030; Zhou ZG, 2011, LIPIDS, V46, P879, DOI 10.1007/s11745-011-3575-8	69	45	46	0	22	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2014	28	12					5311	5321		10.1096/fj.14-258228			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	AU9EN	WOS:000345894500025	25208845				2021-06-18	
J	Stepniak, B; Papiol, S; Hammer, C; Ramin, A; Everts, S; Hennig, L; Begemann, M; Ehrenreich, H				Stepniak, Beata; Papiol, Sergi; Hammer, Christian; Ramin, Anna; Everts, Sarah; Hennig, Lena; Begemann, Martin; Ehrenreich, Hannelore			Accumulated environmental risk determining age at schizophrenia onset: a deep phenotyping-based study	LANCET PSYCHIATRY			English	Article							GENOME-WIDE ASSOCIATION; WHITE-MATTER VOLUME; CANNABIS USE; CHILDHOOD TRAUMA; LIFE STRESS; PSYCHOSIS; METAANALYSIS; SAMPLE; BRAIN; BIRTH	Background Schizophrenia is caused by a combination of genetic and environmental factors, as first evidenced by twin studies. Extensive efforts have been made to identify the genetic roots of schizophrenia, including large genome-wide association studies, but these yielded very small effect sizes for individual markers. In this study, we aimed to assess the relative contribution of genome-wide association study-derived genetic versus environmental risk factors to crucial determinants of schizophrenia severity: disease onset, disease severity, and socioeconomic measures. Methods In this parallel analysis, we studied 750 male patients from the Gottingen Research Association for Schizophrenia (GRAS) dataset (Germany) with schizophrenia for whom both genome-wide coverage of single-nucleotide polymorphisms and deep clinical phenotyping data were available. Specifically, we investigated the potential effect of schizophrenia risk alleles as identified in the most recent large genome-wide association study versus the effects of environmental hazards (ie, perinatal brain insults, cannabis use, neurotrauma, psychotrauma, urbanicity, and migration), alone and upon accumulation, on age at disease onset, age at prodrome, symptom expression, and socioeconomic parameters. Findings In this study, we could show that frequent environmental factors become a major risk for early schizophrenia onset when accumulated (prodrome begins up to 9 years earlier; p=2.9x10(-10)). In particular, cannabis use-an avoidable environmental risk factor-is highly significantly associated with earlier age at prodrome (p=3.8x10(-2)0). By contrast, polygenic genome-wide association study risk scores did not have any detectable effects on schizophrenia phenotypes. Interpretation These findings should be translated to preventive measures to reduce environmental risk factors, since age at onset of schizophrenia is a crucial determinant of an affected individual's fate and the total socioeconomic cost of the illness.	[Stepniak, Beata; Papiol, Sergi; Hammer, Christian; Ramin, Anna; Everts, Sarah; Hennig, Lena; Begemann, Martin; Ehrenreich, Hannelore] Max Planck Inst Expt Med, D-37075 Gottingen, Germany; [Papiol, Sergi; Ehrenreich, Hannelore] DFG Res Ctr Nanoscale Microscopy & Mol Physiol Br, Gottingen, Germany	Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Hammer, Christian/C-5827-2014	Hammer, Christian/0000-0003-4548-7548; Ehrenreich, Hannelore/0000-0001-8371-5711; Papiol, Sergi/0000-0001-9366-8728	Max Planck SocietyMax Planck Society; Max Planck ForderstiftungMax Planck Society; German Research Foundation (Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain); EXTRABRAIN EU-FP7; ERA-Net NEURON [01EW1106]	This work was supported by the Max Planck Society, Max Planck Forderstiftung, the German Research Foundation (Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain), EXTRABRAIN EU-FP7, and ERA-Net NEURON (grant no. 01EW1106). We thank all Gottingen Research Association for Schizophrenia (GRAS) patients for participating in the study, and all the many colleagues who have contributed to the GRAS data collection during the past 10 years.	Abel KM, 2010, INT REV PSYCHIATR, V22, P417, DOI 10.3109/09540261.2010.515205; Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632; ANDREASSON S, 1987, LANCET, V2, P1483, DOI 10.1016/s0140-6736(87)92620-1; Beards S, 2013, SCHIZOPHRENIA BULL, V39, P740, DOI 10.1093/schbul/sbt065; Begemann M, 2010, ARCH GEN PSYCHIAT, V67, P879, DOI 10.1001/archgenpsychiatry.2010.107; Brown AS, 2011, PROG NEUROBIOL, V93, P23, DOI 10.1016/j.pneurobio.2010.09.003; Cardno AG, 2000, AM J MED GENET, V97, P12, DOI 10.1002/(SICI)1096-8628(200021)97:1<12::AID-AJMG3>3.3.CO;2-L; Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307; Di Forti M, 2007, CURR OPIN PSYCHIATR, V20, P228; Ehrenreich H, 1999, PSYCHOPHARMACOLOGY, V142, P295, DOI 10.1007/s002130050892; Ehrenreich H, 2014, GENES-BASEL, V5, P97, DOI 10.3390/genes5010097; Fanous AH, 2012, AM J PSYCHIAT, V169, P1309, DOI 10.1176/appi.ajp.2012.12020218; Giusti-Rodriguez P, 2013, J CLIN INVEST, V123, P4557, DOI 10.1172/JCI66031; Glaser JP, 2006, J PSYCHOSOM RES, V61, P229, DOI 10.1016/j.jpsychores.2006.04.014; HAFNER H, 2003, SCHIZOPHRENIA, P101; Hammer C, 2014, MOL PSYCHIATR, V19, P1143, DOI 10.1038/mp.2013.110; Hare E, 2010, AM J MED GENET B, V153B, P298, DOI 10.1002/ajmg.b.30959; Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529; Korosi A, 2012, BEHAV BRAIN RES, V227, P400, DOI 10.1016/j.bbr.2011.07.037; Large M, 2011, ARCH GEN PSYCHIAT, V68, P555, DOI 10.1001/archgenpsychiatry.2011.5; Lederbogen F, 2011, NATURE, V474, P498, DOI 10.1038/nature10190; Malone DT, 2010, BRIT J PHARMACOL, V160, P511, DOI 10.1111/j.1476-5381.2010.00721.x; McDonald C, 2000, BRAIN RES REV, V31, P130, DOI 10.1016/S0165-0173(99)00030-2; Messias E, 2004, ARCH GEN PSYCHIAT, V61, P985, DOI 10.1001/archpsyc.61.10.985; Miller B, 2011, SCHIZOPHRENIA BULL, V37, P1039, DOI 10.1093/schbul/sbq011; Monshouwer K, 2005, ADDICTION, V100, P963, DOI 10.1111/j.1360-0443.2005.01088.x; Mortensen PB, 1999, NEW ENGL J MED, V340, P603, DOI 10.1056/NEJM199902253400803; Papiol S, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2013.126; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Read J, 2005, ACTA PSYCHIAT SCAND, V112, P330, DOI 10.1111/j.1600-0447.2005.00634.x; Ribbe K, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-91; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Romeo RD, 2010, DEV PSYCHOBIOL, V52, P244, DOI 10.1002/dev.20437; Schneider M, 2008, ADDICT BIOL, V13, P253, DOI 10.1111/j.1369-1600.2008.00110.x; Semple DM, 2005, J PSYCHOPHARMACOL, V19, P187, DOI 10.1177/0269881105049040; Sturman DA, 2011, NEUROSCI BIOBEHAV R, V35, P1704, DOI 10.1016/j.neubiorev.2011.04.003; van Os J, 2010, NATURE, V468, P203, DOI 10.1038/nature09563; van Scheltinga AFT, 2013, BIOL PSYCHIAT, V73, P525, DOI 10.1016/j.biopsych.2012.08.017; Verdoux H, 1997, AM J PSYCHIAT, V154, P1220	40	45	45	1	22	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2215-0374			LANCET PSYCHIAT	Lancet Psychiatry	NOV	2014	1	6					444	453		10.1016/S2215-0366(14)70379-7			10	Psychiatry	Psychiatry	AU5GP	WOS:000345635400025	26361199				2021-06-18	
J	Baugh, CM; Kroshus, E; Bourlas, AP; Perry, KI				Baugh, Christine M.; Kroshus, Emily; Bourlas, Alexandra P.; Perry, Kaitlyn I.			Requiring Athletes to Acknowledge Receipt of Concussion-Related Information and Responsibility to Report Symptoms: A Study of the Prevalence, Variation, and Possible Improvements	JOURNAL OF LAW MEDICINE & ETHICS			English	Article							TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; HIGH-SCHOOL FOOTBALL; RECURRENT CONCUSSION; ASSOCIATION; EPIDEMIOLOGY; IMPAIRMENT; EDUCATION; COLLEGE; DISEASE	State concussion laws and sport-league policies are important tools for protecting public health, but also present implementation challenges. Both state laws and league policies often require athletes provide written acknowledgement of having received concussion-related information and/or of their responsibility to report concussion-related symptoms. This paper examines these requirements in two ways: an analysis of the variation in state laws and sport-league policies and a study of their effects in a cohort of collegiate football players.	[Baugh, Christine M.; Bourlas, Alexandra P.] Boston Univ, Chron Traumat Encephalopathy Ctr, Boston, MA 02215 USA; [Baugh, Christine M.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Baugh, Christine M.] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA; [Bourlas, Alexandra P.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA; [Perry, Kaitlyn I.] Univ Kansas, Lawrence, KS 66045 USA	Baugh, CM (corresponding author), Boston Univ, Chron Traumat Encephalopathy Ctr, Boston, MA 02215 USA.		Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338			Allen E, 2013, BOSTON GLOBE; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Bazarian J. J., 2013, MAGNETIC RESONANCE I, V30, P171; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Horton D, 2003, UCLA LAW REV, V51, P339; Kettle KL, 2011, J CONSUM RES, V38, P474, DOI 10.1086/659753; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Krauss SE, 2005, QUAL REP, V10, P758; Kroshus E., 2014, CONCUSSION IN PRESS; Kroshus E., 2014, NORMS ATHLE IN PRESS; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCabe DL, 2002, RES HIGH EDUC, V43, P357, DOI 10.1023/A:1014893102151; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; NCAA, 2013, 2013 2014 NCAA SPORT, P56; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; ROGERS RW, 1988, J APPL BEHAV ANAL, V21, P263, DOI 10.1901/jaba.1988.21-263; Saldana J., 2012, CODING MANUAL QUALIT; Sarris CE, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.7.FOCUS12224; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stevens MM, 2002, PEDIATRICS, V109, P490, DOI 10.1542/peds.109.3.490; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; White JS, 2013, AM J PREV MED, V45, P533, DOI 10.1016/j.amepre.2013.06.020; Williams BR, 2005, TOP GERIATR REHABIL, V21, P332	51	45	45	1	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1105	1748-720X		J LAW MED ETHICS	J. Law Med. Ethics	FAL	2014	42	3			SI		297	313		10.1111/jlme.12147			17	Ethics; Law; Medical Ethics; Medicine, Legal	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	AQ4ED	WOS:000342745000005	25264088				2021-06-18	
J	Nakayama, Y; Covassin, T; Schatz, P; Nogle, S; Kovan, J				Nakayama, Yusuke; Covassin, Tracey; Schatz, Philip; Nogle, Sally; Kovan, Jeff			Examination of the Test-Retest Reliability of a Computerized Neurocognitive Test Battery	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; neurocognitive testing; test-retest reliability	HIGH-SCHOOL; CONSTRUCT-VALIDITY; ONLINE VERSION; IMPACT; SPORT; SENSITIVITY; CONCUSSION; INDIVIDUALS; SPECIFICITY; PERFORMANCE	Background: Test-retest reliability is a critical issue in the utility of computer-based neurocognitive assessment paradigms employing baseline and postconcussion tests. Researchers have reported low test-retest reliability for the Immediate Post Concussion Assessment and Cognitive Testing (ImPACT) across an interval of 45 and 50 days. Purpose: To re-examine the test-retest reliability of the ImPACT between baseline, 45 days, and 50 days. Study Design: Descriptive laboratory study. Methods: Eighty-five physically active college students (51 male, 34 female) volunteered for this study. Participants completed the ImPACT as well as a 15-item memory test at baseline, 45 days, and 50 days. Intraclass correlation coefficients (ICCs) were calculated for ImPACT composite scores, and change scores were calculated using reliable change indices (RCIs) and regression-based methods (RBMs) at 80% and 95% confidence intervals (CIs). Results: The respective ICCs for baseline to day 45, day 45 to day 50, baseline to day 50, and overall were as follows: verbal memory (0.76, 0.69, 0.65, and 0.78), visual memory (0.72, 0.66, 0.60, and 0.74), visual motor (processing) speed (0.87, 0.88, 0.85, and 0.91), and reaction time (0.67, 0.81, 0.71, and 0.80). All ICCs exceeded the threshold value of 0.60 for acceptable test-retest reliability. All cases fell well within the 80% CI for both the RCI and RBM, while 1% to 5% of cases fell outside the 95% CI for the RCI and 1% for the RBM. Conclusion: Results suggest that the ImPACT is a reliable neurocognitive test battery at 45 and 50 days after the baseline assessment. The current findings agree with those of other reliability studies that have reported acceptable ICCs across 30-day to 1-year testing intervals, and they support the utility of the ImPACT for the multidisciplinary approach to concussion management.	[Nakayama, Yusuke; Covassin, Tracey; Schatz, Philip; Nogle, Sally; Kovan, Jeff] Michigan State Univ, E Lansing, MI 48824 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 308 W Circle Dr, E Lansing, MI 48824 USA.	Covassin@msu.edu			International Brain Research Foundation; Sports Concussion Center of New Jersey; ImPACT Applications Inc.	One or more of the authors has declared the following potential conflict of interest or source of funding: P.S. has received funding to study the effect of concussions in high school and college athletes from the International Brain Research Foundation, the Sports Concussion Center of New Jersey, and ImPACT Applications Inc. However, ImPACT Applications Inc had no role in the conceptualization of the current study, the collection or analysis of data, the writing of the article, or the decision to submit for publication.	Anastasi A., 1998, PSYCHOL TESTING; BARR WB, 2002, CNS SPECTRUMS, V7, P304; Barr William B, 2002, CNS Spectr, V7, P300; Baumgartner T.A., 2001, MEAS PHYS EDUC EXERC, V5, P179, DOI [10.1207/S15327841MPEE0503_4, DOI 10.1207/S15327841MPEE0503_4]; BERNARD LC, 1990, J CLIN PSYCHOL, V46, P432, DOI 10.1002/1097-4679(199007)46:4<432::AID-JCLP2270460410>3.0.CO;2-0; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; CHINN S, 1991, THORAX, V46, P454, DOI 10.1136/thx.46.6.454; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Crawford JR, 2006, NEUROPSYCHOLOGY, V20, P259, DOI 10.1037/0894-4105.20.3.259; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb; GOLDBERG JO, 1986, J CLIN PSYCHOL, V42, P792, DOI 10.1002/1097-4679(198609)42:5<792::AID-JCLP2270420519>3.0.CO;2-8; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2001, LUPUS, V10, P266, DOI 10.1191/096120301680416959; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maerlender A, 2013, CLIN NEUROPSYCHOL, V27, P290, DOI 10.1080/13854046.2012.744098; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Randolph C, 2005, J ATHL TRAINING, V40, P139; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1	35	45	45	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	AUG	2014	42	8					2000	2005		10.1177/0363546514535901			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	AO8WC	WOS:000341634900032	24907286				2021-06-18	
J	Covassin, T; Crutcher, B; Bleecker, A; Heiden, EO; Dailey, A; Yang, JZ				Covassin, Tracey; Crutcher, Bryan; Bleecker, Alisha; Heiden, Erin O.; Dailey, Alexander; Yang, Jingzhen			Postinjury Anxiety and Social Support Among Collegiate Athletes: A Comparison Between Orthopaedic Injuries and Concussions	JOURNAL OF ATHLETIC TRAINING			English	Article						psychology; state anxiety; trait anxiety; return to play	SPORT-INJURY; PRECOMPETITION ANXIETY; PERFORMANCE; PATTERNS; TRACK; LEVEL; ZONE	Context: When an athlete is injured, the primary focus of the sports medicine team is to treat the physical effects of the injury. However, many injured athletes experience negative psychological responses, including anxiety, regarding their injury. Objective: To compare the anxiety and social support of athletes with concussions and a matched group of athletes with orthopaedic injuries. Design: Cross-sectional study. Setting: Athletic training room. Patients or Other Participants: A total of 525 injuries among athletes from 2 Big Ten universities were observed. Of these, 63 concussion injuries were matched with 63 orthopaedic injuries for the athlete's sex, sport, and time loss due to injury. Main Outcome Measure(s): Clinical measures included the State-Trait Anxiety Inventory (which measures both state and trait anxiety) and the modified 6-item Social Support Questionnaire. Results: The group with concussions relied on their family for social support 89% of the time, followed by friends (78%), teammates (65%), athletic trainers (48%), coaches (47%), and physicians (35%). The group with orthopaedic injuries relied on their family for social support 87% of the time, followed by friends (84%), teammates (65%), athletic trainers (57%), coaches (51%), and physicians (36%). We found no differences for the State-Trait Anxiety Inventory (t = -1.38, P = .193) between the concussed and orthopaedic-injury groups. Social Support Questionnaire scores were significant predictors for postinjury state anxiety. Specifically, increased scores were associated with decreased postinjury state anxiety (beta = -4.21, P = .0001). Conclusions: Both the concussed athletes and those with orthopaedic injuries experienced similar state and trait anxiety and relied on similar sources of social support postinjury. However, athletes with orthopaedic injuries reported greater satisfaction with support from all sources compared with concussed athletes. In contrast, concussed athletes showed more significant predictor models of social support on state anxiety at return to play.	[Covassin, Tracey; Crutcher, Bryan; Bleecker, Alisha; Dailey, Alexander] Michigan State Univ, E Lansing, MI 48824 USA; [Heiden, Erin O.] Univ Iowa, Iowa City, IA USA; [Yang, Jingzhen] Kent State Univ, Kent, OH USA	Covassin, T (corresponding author), Michigan State Univ, 105 IM Sports Circle, E Lansing, MI 48824 USA.	covassin@msu.edu	Yang, Jingzhen/N-4786-2014		University of Iowa Injury Prevention Research Center - Centers for Disease Control and Prevention National Center for Injury Prevention and Control [R49 CD001167-01]	This research was supported by the University of Iowa Injury Prevention Research Center, funded by grant #R49 CD001167-01 of the Centers for Disease Control and Prevention National Center for Injury Prevention and Control. We thank the University of Iowa Sports Medicine Research Center, the Department of Athletics at the University of Iowa, and the Department of Athletics at the Michigan State University. We acknowledge the invaluable contributions of the coaches, athletic trainers, and student-athletes who were involved in this research project.	Albright JP, 2004, AM J SPORT MED, V32, P1394, DOI 10.1177/0363546504264159; Asci FH, 2009, INT J PSYCHOL, V44, P313, DOI 10.1080/00207590802325903; Barefield S, 1997, J ATHL TRAINING, V32, P333; Bianco T, 2001, RES Q EXERCISE SPORT, V72, P376, DOI 10.1080/02701367.2001.10608974; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Cassidy CM, 2006, ATHLET THER TODAY, V11, P57; Clement D, 2011, J SPORT REHABIL, V20, P457, DOI 10.1123/jsr.20.4.457; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; Corbillon F., 2008, J SPORT BEHAV, V31, P93; Flint F, 2007, PSYCHOL BASES SPORT; Gould D, 1997, SPORT PSYCHOL, V11, P379, DOI 10.1123/tsp.11.4.379; Green SL, 2001, J APPL SPORT PSYCHOL, V13, P40, DOI 10.1080/10413200109339003; Hootman JM, 2007, J ATHL TRAINING, V42, P311; IMLAY GJ, 1995, INT J SPORT PSYCHOL, V26, P295; Johnston LH, 1998, J SPORT REHABIL, V7, P267, DOI 10.1123/jsr.7.4.267; Kvist J, 2005, KNEE SURG SPORT TR A, V13, P393, DOI 10.1007/s00167-004-0591-8; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Magyar TM, 2000, SPORT PSYCHOL, V14, P372, DOI 10.1123/tsp.14.4.372; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; NEWCOMBE PA, 1995, INT J SPORT PSYCHOL, V26, P277; Podlog L, 2011, PHYS THER SPORT, V12, P36, DOI 10.1016/j.ptsp.2010.07.005; Putukian M, 2003, CLIN SPORT MED, V22, P617, DOI 10.1016/S0278-5919(02)00100-X; RAGLIN JS, 1993, PERS INDIV DIFFER, V14, P163, DOI 10.1016/0191-8869(93)90186-7; Robbins J.E, 2001, Journal of Sport Behavior, V24, P277; Sarason B, 1990, SOCIAL SUPPORTS INTE; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; Spielberger CD, 1970, STATE TRAIT ANXIETY; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Turner PE, 1996, MED SCI SPORT EXER, V28, P378, DOI 10.1097/00005768-199603000-00014; Udry E, 1997, J SPORT EXERCISE PSY, V19, P368, DOI 10.1123/jsep.19.4.368; Weinberg R.S., 2007, FDN SPORT EXERCISE P; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; Wilson GS, 2002, PERS INDIV DIFFER, V32, P893, DOI 10.1016/S0191-8869(01)00094-0; Yang JZ, 2010, J ATHL TRAINING, V45, P372, DOI 10.4085/1062-6050-45.4.372	36	45	46	1	30	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2014	49	4					462	468		10.4085/1062-6059-49.2.03			7	Sport Sciences	Sport Sciences	AQ4LO	WOS:000342768700005	24673237	Bronze, Green Published			2021-06-18	
J	Tulsky, DS; Carlozzi, N; Chiaravalloti, ND; Beaumont, JL; Kisala, PA; Mungas, D; Conway, K; Gershon, R				Tulsky, David S.; Carlozzi, Noelle; Chiaravalloti, Nancy D.; Beaumont, Jennifer L.; Kisala, Pamela A.; Mungas, Dan; Conway, Kevin; Gershon, Richard			NIH Toolbox Cognition Battery (NIHTB-CB): List Sorting Test to Measure Working Memory	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognition; Working memory; Memory; Short-term; Neuropsychological tests; Executive function; Adult	TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; EXECUTIVE FUNCTION; PREFRONTAL CORTEX; COMPLEX SPAN; SHORT-TERM; PERFORMANCE; INFORMATION; CAPACITY; ACTIVATION	The List Sorting Working Memory Test was designed to assess working memory (WM) as part of the NIH Toolbox Cognition Battery. List Sorting is a sequencing task requiring children and adults to sort and sequence stimuli that are presented visually and auditorily. Validation data are presented for 268 participants ages 20 to 85 years. A subset of participants (N = 89) was retested 7 to 21 days later. As expected, the List Sorting Test had moderately high correlations with other measures of working memory and executive functioning (convergent validity) but a low correlation with a test of receptive vocabulary (discriminant validity). Furthermore, List Sorting demonstrates expected changes over the age span and has excellent test-retest reliability. Collectively, these results provide initial support for the construct validity of the List Sorting Working Memory Measure as a measure of working memory. However, the relationship between the List Sorting Test and general executive function has yet to be determined.	[Tulsky, David S.] NYU, Rusk Inst, Dept Rehabil Med, Dept Orthoped Surg,Dept Gen Med,Langone Med Ctr, New York, NY 10016 USA; [Tulsky, David S.; Chiaravalloti, Nancy D.] Kessler Fdn, Spinal Cord Injury Lab, Neuropsychol & Neurosci Lab, West Orange, NJ USA; [Carlozzi, Noelle] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Beaumont, Jennifer L.; Gershon, Richard] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Tulsky, David S.; Kisala, Pamela A.] NYU, Rusk Inst, Dept Rehabil Med, Langone Med Ctr, New York, NY 10016 USA; [Mungas, Dan] Univ Calif Davis, Dept Neurol, Davis, CA 95616 USA; [Conway, Kevin] NIDA, Rockville, MD USA	Tulsky, DS (corresponding author), NYU, Rusk Inst, Dept Rehabil Med, Langone Med Ctr, Ambulatory Care Ctr 240 E 38th St,17th Floor, New York, NY 10016 USA.	david.tulsky@nyumc.org	Beaumont, Jennifer/AAA-2825-2020	Beaumont, Jennifer/0000-0002-1484-260X; Conway, Kevin/0000-0002-7638-339X; Tulsky, David/0000-0002-4335-4509; Chiaravalloti, Nancy/0000-0003-2943-7567	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [N01AG60007]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010129, R01AG010220] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [N44AA002006] Funding Source: NIH RePORTER	Funding for this research was provided by contract number N01AG60007 from the National Institutes of Health. The authors have nothing to disclose.	Alloway TP, 2006, CHILD DEV, V77, P1698, DOI 10.1111/j.1467-8624.2006.00968.x; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A., 1987, WORKING MEMORY, V11; Baddeley A. D., 1986, WORKING MEMORY; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; Baddeley AD, 2002, EUR PSYCHOL, V7, P85, DOI 10.1027//1016-9040.7.2.85; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Beatty WW, 1996, J CLIN EXP NEUROPSYC, V18, P56, DOI 10.1080/01688639608408262; Belger A, 1998, HUM BRAIN MAPP, V6, P14, DOI 10.1002/(SICI)1097-0193(1998)6:1<14::AID-HBM2>3.0.CO;2-O; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Chiaravalloti ND, 2005, J CLIN EXP NEUROPSYC, V27, P33, DOI 10.1080/138033990513609; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Conlin JA, 2005, J EXP CHILD PSYCHOL, V90, P303, DOI 10.1016/j.jecp.2004.12.001; Conway ARA, 2005, PSYCHON B REV, V12, P769, DOI 10.3758/BF03196772; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957; Crone EA, 2006, P NATL ACAD SCI USA, V103, P9315, DOI 10.1073/pnas.0510088103; Crosson B, 1999, NEUROPSYCHOLOGY, V13, P171, DOI 10.1037/0894-4105.13.2.171; Crowe SF, 2000, ASSESSMENT, V7, P113, DOI 10.1177/107319110000700202; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; de Jong PF, 1998, J EXP CHILD PSYCHOL, V70, P75, DOI 10.1006/jecp.1998.2451; de Jong PF, 2004, J EXP CHILD PSYCHOL, V88, P254, DOI 10.1016/j.jecp.2004.03.007; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; DEMPSTER FN, 1981, PSYCHOL BULL, V89, P63, DOI 10.1037/0033-2909.89.1.63; DEsposito M, 1996, NEUROPSYCHOLOGY, V10, P51, DOI 10.1037/0894-4105.10.1.51; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Dunn L., 2007, PEABODY PICTURE VOCA, V4th ed.; Edin F, 2007, J COGNITIVE NEUROSCI, V19, P750, DOI 10.1162/jocn.2007.19.5.750; Edin F, 2009, P NATL ACAD SCI USA, V106, P6802, DOI 10.1073/pnas.0901894106; ENGLE Randall W, 1996, WORKING MEMORY HUMAN, P89, DOI [DOI 10.1093/ACPROF:OSO/9780195100990.003.0004, 10.1093/acprof:oso/9780195100990.003.0004]; Fuster J, 1989, PREFRONTAL CORTEX; Gathercole SE, 2004, DEV PSYCHOL, V40, P177, DOI 10.1037/0012-1649.40.2.177; Gershon RC, 2013, NEUROLOGY, V80, pS2, DOI 10.1212/WNL.0b013e3182872e5f; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; GRIGSBY J, 1994, J NEUROL, V241, P125; GRIGSBY J, 1994, ARCH CLIN NEUROPSYCH, V9, P134; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GROSSMAN M, 1994, NEUROPSY NEUROPSY BE, V7, P194; HASHER L, 1991, J EXP PSYCHOL LEARN, V17, P163, DOI 10.1037/0278-7393.17.1.163; Haut M W, 2000, Appl Neuropsychol, V7, P237, DOI 10.1207/S15324826AN0704_5; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heaton R. K., 2003, CLIN INTERPRETATION, P181, DOI [DOI 10.1016/B978-012703570-3/50010-9, 10.1016/B978-012703570-3/50010-9]; Hitch GJ, 2001, J EXP PSYCHOL GEN, V130, P184, DOI 10.1037//0096-3445.130.2.184; Hodes RJ, 2013, NEUROLOGY, V80, pS1, DOI 10.1212/WNL.0b013e3182872e90; Hofmann W, 2012, TRENDS COGN SCI, V16, P174, DOI 10.1016/j.tics.2012.01.006; Jacobsen CF, 1935, ARCH NEURO PSYCHIATR, V33, P558, DOI 10.1001/archneurpsyc.1935.02250150108009; Jonides J., 1995, INVITATION COGNITIVE, V3, P215; Kirasic KC, 1996, PSYCHOL AGING, V11, P658, DOI 10.1037/0882-7974.11.4.658; Klingberg T, 1996, EUR J NEUROSCI, V8, P1965, DOI 10.1111/j.1460-9568.1996.tb01340.x; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Kongs SK, 2000, WISCONSIN CARD SORTI; Kwon H, 2002, P NATL ACAD SCI USA, V99, P13336, DOI 10.1073/pnas.162486399; KYLLONEN PC, 1990, INTELLIGENCE, V14, P389, DOI 10.1016/S0160-2896(05)80012-1; Lehto JH, 1996, Q J EXP PSYCHOL-A, V49, P29, DOI 10.1080/027249896392793; Linden DEJ, 2007, NEUROSCIENTIST, V13, P257, DOI 10.1177/1073858406298480; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P281, DOI 10.1001/archneur.1988.00520270059021; LOGIE RH, 1996, WORKING MEMORY HUMAN, P31; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McAuley T, 2011, J EXP CHILD PSYCHOL, V108, P453, DOI 10.1016/j.jecp.2010.08.009; McCabe DP, 2010, NEUROPSYCHOLOGY, V24, P222, DOI 10.1037/a0017619; MESSICK S, 1980, AM PSYCHOL, V35, P1012, DOI 10.1037/0003-066X.35.11.1012; MESSICK S, 1991, ENCY ED RES; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/0033-295X.101.2.343; Milner B, 1964, FRONTAL GRANULAR COR, P313; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Miyake A., 1999, MODELS WORKING MEMOR; Mungas D, 2000, NEUROPSYCHOLOGY, V14, P209, DOI 10.1037//0894-4105.14.2.209; Newell A, 1972, HUMAN PROBLEM SOLVIN, V104; Newell A, 1973, VISUAL INFORMATION P, P463; Orellana Gricel, 2013, Front Psychiatry, V4, P35, DOI 10.3389/fpsyt.2013.00035; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Pelphrey KA, 2003, ADV CHILD DEV BEHAV, V31, P173; Rao S.M., 1993, NEUROPSYCHOLOGY, V7, P364, DOI [10.1037/0894-4105.7.3.364, DOI 10.1037/0894-4105.7.3.364]; Repovs G, 2006, NEUROSCIENCE, V139, P1, DOI 10.1016/j.neuroscience.2005.12.007; Riggs KJ, 2006, J EXP CHILD PSYCHOL, V95, P18, DOI 10.1016/j.jecp.2006.03.009; Salmon E, 1996, BRAIN, V119, P1617, DOI 10.1093/brain/119.5.1617; Salthouse T.A., 1994, NEUROPSYCHOLOGY, V8, P535, DOI [DOI 10.1037/0894-4105.8.4.535, 10.1037/0894-4105.8.4.535]; SALTHOUSE TA, 1989, J EXP PSYCHOL LEARN, V15, P507, DOI 10.1037/0278-7393.15.3.507; Scherf KS, 2006, J COGNITIVE NEUROSCI, V18, P1045, DOI 10.1162/jocn.2006.18.7.1045; Schmiedek F, 2009, J EXP PSYCHOL LEARN, V35, P1089, DOI 10.1037/a0015730; Seidman LJ, 1998, NEUROPSYCHOLOGY, V12, P505, DOI 10.1037/0894-4105.12.4.505; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tulsky D., 2003, CLIN INTERPRETATION, P43, DOI 10.1016/B978-012703570-3/50006-7; Tulsky DS, 2013, MONOGR SOC RES CHILD, V78, P70, DOI 10.1111/mono.12035; Van Snellenberg JX, 2009, PSYCHIAT RES-NEUROIM, V174, P89, DOI 10.1016/j.pscychresns.2009.04.001; Vugs B, 2014, RES DEV DISABIL, V35, P62, DOI 10.1016/j.ridd.2013.10.022; Wechsler D., 1997, WAIS 3 ADM SCORING M; WECHSLER D, 1952, RANGE HUMAN CAPACITI; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Weintraub S, 2013, NEUROLOGY, V80, pS54, DOI 10.1212/WNL.0b013e3182872ded; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Woods SP, 2009, NEUROPSYCHOL REV, V19, P152, DOI 10.1007/s11065-009-9102-5; You SC, 2014, MOVEMENT DISORD, V29, P405, DOI 10.1002/mds.25762; Zelazo PD, 2013, MONOGR SOC RES CHILD, V78, P16, DOI 10.1111/mono.12032	104	45	45	0	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2014	20	6					599	610		10.1017/S135561771400040X			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AL7PH	WOS:000339326300004	24959983	Green Accepted			2021-06-18	
J	Lange, RT; Brickell, TA; Kennedy, JE; Bailie, JM; Sills, C; Asmussen, S; Amador, R; Dilay, A; Ivins, B; French, LM				Lange, Rael T.; Brickell, Tracey A.; Kennedy, Jan E.; Bailie, Jason M.; Sills, Cheryl; Asmussen, Sarah; Amador, Ricardo; Dilay, Angelica; Ivins, Brian; French, Louis M.			Factors Influencing Postconcussion and Posttraumatic Stress Symptom Reporting Following Military-Related Concurrent Polytrauma and Traumatic Brain Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Postconcussion; Posttraumatic stress; Depression; Traumatic brain injury; Military	MILD HEAD-INJURY; MENTAL-HEALTH PROBLEMS; POST-CONCUSSION SYNDROME; GOOD OLD DAYS; SERVICE MEMBERS; COMPENSATION-SEEKING; RISK-FACTORS; BASE RATES; EARLY INTERVENTION; TEST-PERFORMANCE	The purpose of this study was to identify factors that are predictive of, or associated with, high endorsement of postconcussion and posttraumatic stress symptoms following military-related traumatic brain injury (TBI). Participantswere 1,600 U. S. service members (age: M = 27.1, SD = 7.1; 95.4% male) who had sustained a mild-to-moderateTBI and who had been evaluated by the Defense and Veterans Brain Injury Center at one of six military medical centers. Twenty-two factors were examined that included demographic, injury circumstances/severity, treatment/evaluation, and psychological/physical variables. Four factors were statistically and meaningfully associated with clinically elevated postconcussion symptoms: (i) low bodily injury severity, (ii) posttraumatic stress, (iii) depression, and (iv) military operation where wounded (p<.001, 43.2% variance). The combination of depression and posttraumatic stress symptoms accounted for the vast majority of unique variance (41.5%) and were strongly associated with, and predictive of, clinically elevated postconcussion symptoms [range: odds ratios (OR) 4.24-7.75; relative risk (RR) 2.28-2.51]. Five factors were statistically and meaningfully associated with clinically elevated posttraumatic stress symptoms: (i) low bodily injury severity, (ii) depression, (iii) a longer time from injury to evaluation, (iv) military operation where wounded, and (v) current auditory deficits (p<.001; 65.6% variance accounted for). Depression alone accounted for the vast majority of unique variance (60.0%) and was strongly associated with, and predictive of, clinically elevated posttraumatic stress symptoms (OR=38.78; RR=4.63). There was a very clear, strong, and clinically meaningful association between depression, posttraumatic stress, and postconcussion symptoms in this sample. Brain injury severity, however, was not associated with symptom reporting following TBI.	[Lange, Rael T.; Brickell, Tracey A.; Kennedy, Jan E.; Bailie, Jason M.; Sills, Cheryl; Asmussen, Sarah; Amador, Ricardo; Dilay, Angelica; Ivins, Brian; French, Louis M.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.; Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Kennedy, Jan E.; Sills, Cheryl; Amador, Ricardo] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA; [Bailie, Jason M.; Dilay, Angelica] Naval Med Ctr San Diego, San Diego, CA USA; [Asmussen, Sarah] 33 Area Branch Clin Camp Pendleton, Camp Pendleton, CA USA	Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, 8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.t.lange@us.army.mil	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brickell T. A., J NEUROTRAU IN PRESS; Bryant RA, 2003, BEHAV RES THER, V41, P489, DOI 10.1016/S0005-7967(02)00179-1; Bryant RA, 2008, ARCH GEN PSYCHIAT, V65, P659, DOI 10.1001/archpsyc.65.6.659; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Ciorba A, 2012, CLIN INTERV AGING, V7, P159, DOI 10.2147/CIA.S26059; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Defense and Veterans Brain Injury Center D, 2012, DOD NUMB TRAUM BRAIN; Department of Defense, 2013, OP IR FREED OP END F; DeViva JC, 2003, J TRAUMA STRESS, V16, P503, DOI 10.1023/A:1025766713188; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gold PB, 1999, J NERV MENT DIS, V187, P680, DOI 10.1097/00005053-199911000-00005; Goodwin L, 2012, J NERV MENT DIS, V200, P429, DOI 10.1097/NMD.0b013e31825322fe; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Horesh D, 2013, PSYCHIAT RES, V208, P265, DOI 10.1016/j.psychres.2012.12.004; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2012, BRAIN INJURY MED PRI; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keane T., 1994, PTSD CHECKLIST CIVIL; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sareen J, 2007, ARCH GEN PSYCHIAT, V64, P843, DOI 10.1001/archpsyc.64.7.843; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Smith DW, 1996, PSYCHOL ASSESSMENT, V8, P3, DOI 10.1037/1040-3590.8.1.3; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J., 2007, INT NEUR SOC 35 ANN; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Vasterling JJ, 2010, J TRAUMA STRESS, V23, P41, DOI 10.1002/jts.20487; Veterans for Common Sense, 2012, IR AFGH IMP REP; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 INT STAT CLAS; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593	100	45	45	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2014	29	4					329	347		10.1093/arclin/acu013			19	Psychology, Clinical; Psychology	Psychology	AM6BY	WOS:000339947100003	24723461	Bronze			2021-06-18	
J	Stoller, J; Carson, JD; Garel, A; Libfeld, P; Snow, CL; Law, M; Fremont, P				Stoller, Jacqueline; Carson, James D.; Garel, Alisha; Libfeld, Paula; Snow, Catherine L.; Law, Marcus; Fremont, Pierre			Do family physicians, emergency department physicians, and pediatricians give consistent sport-related concussion management advice?	CANADIAN FAMILY PHYSICIAN			English	Article							INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; ZURICH; CHILD	Objective To identify differences and gaps in recommendations to patients for the management of sport-related concussion among FPs, emergency department physicians (EDPs), and pediatricians. Design A self-administered, multiple-choice survey was e-mailed to FPs, EDPs, and pediatricians. The survey had been assessed for content validity. Setting Two community teaching hospitals in the greater Toronto area in Ontario. Participants Two hundred seventy physicians, including FPs, EDPs, and pediatricians, were invited to participate. Main outcome measures Identification of sources of concussion management information, usefulness of concussion diagnosis strategies, and whether physicians use common terminology when explaining cognitive rest strategies to patients after sport-related concussions. Results The response rate was 43.7%. Surveys were completed by 70 FPs, 23 EDPs, and 11 pediatricians. In total, 49% of FP, 52% of EDP, and 27% of pediatrician respondents reported no knowledge of any consensus statements on concussion in sport, and 54% of FPs, 86% of EDPs, and 78% of pediatricians never used the Sport Concussion Assessment Tool, version 2. Only 49% of FPs, 57% of EDPs, and 36% of pediatricians always advised cognitive rest. Conclusion This study identified large gaps in the knowledge of concussion guidelines and implementation of recommendations for treating patients with sport-related concussions. Although some physicians recommended physical and cognitive rest, a large proportion failed to consistently advise this strategy. Better knowledge transfer efforts should target all 3 groups of physicians.	[Carson, James D.; Law, Marcus] Univ Toronto, Dept Family & Community Med, 255 Main St, Unionville, ON L3R 2H3, Canada; [Garel, Alisha] Med Univ Amer, Nevis, St Kitts & Nevi; [Libfeld, Paula] Univ Kings Coll, Halifax, NS, Canada; [Snow, Catherine L.] York Univ, N York, ON M3J 1P3, Canada; [Fremont, Pierre] Univ Laval, Dept Rehabil, Quebec City, PQ, Canada; [Fremont, Pierre] Univ Laval, Dept Family Med, Quebec City, PQ, Canada	Carson, JD (corresponding author), Univ Toronto, Dept Family & Community Med, 255 Main St, Unionville, ON L3R 2H3, Canada.	james.carson@utoronto.ca		Law, Marcus/0000-0001-9746-6381; Fremont, Pierre/0000-0003-2810-8382			Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Carson J, 2006, CAN FAM PHYSICIAN, V52, P756; Carson J, 2013, BRIT J SPORT MED, V47, pe1, DOI [10.1136/bjsports-2012-092101.22, DOI 10.1136/BJSPORTS-2012-092101.22]; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Dillman D.A., 2009, INTERNET MAIL MIXED; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Parachute [website], THINKFIRST CAN IS NO; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Statistics Canada [website], TYP MOST SER INJ PEO	13	45	46	0	7	COLL FAMILY PHYSICIANS CANADA	MISSISSAUGA	2630 SKYMARK AVE, MISSISSAUGA, ONTARIO L4W 5A4, CANADA	0008-350X	1715-5258		CAN FAM PHYSICIAN	Can. Fam. Phys.	JUN	2014	60	6					548	552					5	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	AK2GG	WOS:000338236500018	24925947				2021-06-18	
J	Shultz, SR; Tan, XL; Wright, DK; Liu, SJJ; Semple, BD; Johnston, L; Jones, NC; Cook, AD; Hamilton, JA; O'Brien, TJ				Shultz, Sandy R.; Tan, Xin L.; Wright, David K.; Liu, Shijie J.; Semple, Bridgette D.; Johnston, Leigh; Jones, Nigel C.; Cook, Andrew D.; Hamilton, John A.; O'Brien, Terence J.			Granulocyte-Macrophage Colony-Stimulating Factor Is Neuroprotective in Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						models of injury; traumatic brain injury; MRI; animal studies; cytokine; inflammation	FLUID PERCUSSION INJURY; GM-CSF; SPINAL-CORD; ANIMAL-MODEL; NEUROINFLAMMATION; DISINHIBITION; INFLAMMATION; ARTHRITIS; TISSUE; MICE	Traumatic brain injury (TBI) is an international health concern with a complex pathogenesis resulting in major long-term neurological, neurocognitive, and neuropsychiatric outcomes. Although neuroinflammation has been identified as an important pathophysiological process resulting from TBI, the function of specific inflammatory mediators in the aftermath of TBI remains poorly understood. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an inflammatory cytokine that has been reported to have neuroprotective effects in various animal models of neurodegenerative disease that share pathological similarities with TBI. The importance of GM-CSF in TBI has yet to be studied, however. We examined the role of GM-CSF in TBI by comparing the effects of a lateral fluid percussion (LFP) injury or sham injury in GM-CSF gene deficient (GM-CSF-/-) versus wild-type (WT) mice. After a 3-month recovery interval, mice were assessed using neuroimaging and behavioral outcomes. All mice given a LFP injury displayed significant brain atrophy and behavioral impairments compared with those given sham-injuries; however, this was significantly worse in the GM-CSF-/- mice compared with the WT mice. GM-CSF-/- mice given LFP injury also had reduced astrogliosis compared with their WT counterparts. These novel findings indicate that the inflammatory mediator, GM-CSF, may have significant protective properties in the chronic sequelae of experimental TBI and suggest that further research investigating GM-CSF and its potential benefits in the injured brain is warranted.	[Shultz, Sandy R.; Tan, Xin L.; Wright, David K.; Liu, Shijie J.; Semple, Bridgette D.; Jones, Nigel C.; Cook, Andrew D.; Hamilton, John A.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Melbourne Brain Ctr, Parkville, Vic 3050, Australia; [Shultz, Sandy R.; Wright, David K.; Johnston, Leigh] Florey Neurosci Inst, Small Anim MRI Facil, Parkville, Vic, Australia; [Semple, Bridgette D.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA	Shultz, SR (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Dept Med, 4th Floor Clin Sci Bldg, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au	Johnston, Leigh A/D-7102-2014	Johnston, Leigh A/0000-0002-5032-4674; Cook, Andrew/0000-0002-7314-924X; Shultz, Sandy/0000-0002-2525-8775; Hamilton, John A/0000-0002-9493-9224; O'Brien, Terence/0000-0002-7198-8621; Wright, David/0000-0002-7535-8651; Jones, Nigel/0000-0002-1080-8439	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1006077]; Victorian Transport Accident Commission (Victorian Neurotrauma Initiative Grant) [DNP13]; Royal Melbourne Hospital Neuroscience Foundation; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); NHMRCNational Health and Medical Research Council of Australia	We would like to thank Thanh Nguyen for assistance with immunofluorescence experiments. This study was funded by grants to T.O.B. from the National Health and Medical Research Council (NHMRC #1006077), the Victorian Transport Accident Commission (Victorian Neurotrauma Initiative Grant #DNP13), and the Royal Melbourne Hospital Neuroscience Foundation, a fellowship from the Canadian Institute of Health Research to S. S., and a Senior Principal Research Fellowship from NHMRC to J.A.H..	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Armitage JO, 1998, BLOOD, V92, P4491, DOI 10.1182/blood.V92.12.4491; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bortolato M, 2009, NEUROPSYCHOPHARMACOL, V34, P2746, DOI 10.1038/npp.2009.118; Bouhy D, 2006, FASEB J, V20, P1239, DOI 10.1096/fj.05-4382fje; Boyd TD, 2010, J ALZHEIMERS DIS, V21, P507, DOI 10.3233/JAD-2010-091471; Campbell IK, 1998, J IMMUNOL, V161, P3639; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; Cook AD, 2004, J IMMUNOL, V173, P4643, DOI 10.4049/jimmunol.173.7.4643; Franzen R, 2004, NEUROSCI LETT, V361, P76, DOI 10.1016/j.neulet.2003.12.018; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Guillemin G, 1996, GLIA, V16, P71, DOI 10.1002/(SICI)1098-1136(199601)16:1<71::AID-GLIA8>3.0.CO;2-E; Ha Y, 2005, J NEUROSURG-SPINE, V2, P55, DOI 10.3171/spi.2005.2.1.0055; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Hamilton JA, 2012, CYTOKINE, V57, P30, DOI 10.1016/j.cyto.2011.10.021; Hayashi K, 2009, NEUROSCI RES, V64, P96, DOI 10.1016/j.neures.2009.01.018; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Kim E, 2002, NEUROREHABILITATION, V17, P297; Krieger M, 2012, SCI REP-UK, V2, DOI 10.1038/srep00697; Krueger C, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-88; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Mangano EN, 2011, NEUROBIOL DIS, V43, P99, DOI 10.1016/j.nbd.2011.02.011; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McLay RN, 1997, BRAIN, V120, P2083, DOI 10.1093/brain/120.11.2083; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Nishihara T, 2011, EXP NEUROL, V229, P507, DOI 10.1016/j.expneurol.2011.04.006; Schabitz WR, 2008, J CEREBR BLOOD F MET, V28, P29, DOI 10.1038/sj.jcbfm.9600496; Schneider UC, 2007, STROKE, V38, P1320, DOI 10.1161/01.STR.0000259707.43496.71; Shelbani N., 2004, CRIT CARE MED, V32, P2274; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Takeuchi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021050; Thyagarajan T, 2003, CRIT REV ORAL BIOL M, V14, P154, DOI 10.1177/154411130301400302; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	48	45	45	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 15	2014	31	10					976	983		10.1089/neu.2013.3106			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AH1ES	WOS:000335863200009	24392832	Green Published			2021-06-18	
J	Chang, JO; Levy, SS; Seay, SW; Goble, DJ				Chang, Jasper O.; Levy, Susan S.; Seay, Seth W.; Goble, Daniel J.			An Alternative to the Balance Error Scoring System: Using a Low-Cost Balance Board to Improve the Validity/Reliability of Sports-Related Concussion Balance Testing	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; mild traumatic brain injury; postural control; assessment; force plate	MILD HEAD-INJURY; POSTURAL STABILITY; INTRACLASS CORRELATIONS; RELIABILITY; YOUNG; MANAGEMENT; ASYMMETRY; STATEMENT; SYMPTOMS; RECOVERY	Objective:Recent guidelines advocate sports medicine professionals to use balance tests to assess sensorimotor status in the management of concussions. The present study sought to determine whether a low-cost balance board could provide a valid, reliable, and objective means of performing this balance testing.Design:Criterion validity testing relative to a gold standard and 7 day test-retest reliability.Setting:University biomechanics laboratory.Participants:Thirty healthy young adults.Assessment of Risk Factors:Balance ability was assessed on 2 days separated by 1 week using (1) a gold standard measure (ie, scientific grade force plate), (2) a low-cost Nintendo Wii Balance Board (WBB), and (3) the Balance Error Scoring System (BESS).Main Outcome Measures:Validity of the WBB center of pressure path length and BESS scores were determined relative to the force plate data. Test-retest reliability was established based on intraclass correlation coefficients.Results:Composite scores for the WBB had excellent validity (r = 0.99) and test-retest reliability (R = 0.88). Both the validity (r = 0.10-0.52) and test-retest reliability (r = 0.61-0.78) were lower for the BESS.Conclusions:These findings demonstrate that a low-cost balance board can provide improved balance testing accuracy/reliability compared with the BESS.Clinical Relevance:This approach provides a potentially more valid/reliable, yet affordable, means of assessing sports-related concussion compared with current methods.	[Chang, Jasper O.; Levy, Susan S.; Seay, Seth W.; Goble, Daniel J.] San Diego State Univ, Coll Hlth & Human Serv, Sch Exercise & Nutr Sci, San Diego, CA 92182 USA	Goble, DJ (corresponding author), San Diego State Univ, Coll Hlth & Human Serv, 5500 Campanile Dr, San Diego, CA 92182 USA.	dgoble@mail.sdsu.edu	Goble, Daniel/A-1317-2007	Goble, Daniel/0000-0002-8027-6722			Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bonett DG, 2002, STAT MED, V21, P1331, DOI 10.1002/sim.1108; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Chisholm D.M., 1975, B C MED J, V17, P375; Cicchetti DV, 2001, J CLIN EXP NEUROPSYC, V23, P695, DOI 10.1076/jcen.23.5.695.1249; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Clark RA, 2010, GAIT POSTURE, V31, P307, DOI 10.1016/j.gaitpost.2009.11.012; Clark RA, 2011, GAIT POSTURE, V34, P288, DOI 10.1016/j.gaitpost.2011.04.010; Doros G., 2010, AM J BIOSTATISTICS, V1, P1, DOI DOI 10.3844/AMJBSP.2010.1.8; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Goble DJ, 2014, J DEV PHYS DISABIL, V26, P145, DOI 10.1007/s10882-013-9350-4; Goble DJ, 2011, J NEUROSCI, V31, P16344, DOI 10.1523/JNEUROSCI.4159-11.2011; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Holmes JD, 2013, CLIN REHABIL, V27, P361, DOI 10.1177/0269215512458684; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Huurnink A, 2013, J BIOMECH, V46, P1392, DOI 10.1016/j.jbiomech.2013.02.018; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McGough R, 2012, J STRENGTH COND RES, V26, P47, DOI 10.1519/JSC.0b013e318220b515; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Tabachnick BG, 2007, USING MULTIVARIATE S; Valovich TC, 2003, J ATHL TRAINING, V38, P51	37	45	45	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2014	24	3					256	262		10.1097/JSM.0000000000000016			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	AG4KS	WOS:000335389100011	24284947				2021-06-18	
J	Zatzick, D; Donovan, DM; Jurkovich, G; Gentilello, L; Dunn, C; Russo, J; Wang, J; Zatzick, CD; Love, J; McFadden, C; Rivara, FP				Zatzick, Douglas; Donovan, Dennis M.; Jurkovich, Gregory; Gentilello, Larry; Dunn, Chris; Russo, Joan; Wang, Jin; Zatzick, Christopher D.; Love, Jeff; McFadden, Collin; Rivara, Frederick P.			Disseminating alcohol screening and brief intervention at trauma centers: a policy-relevant cluster randomized effectiveness trial	ADDICTION			English	Article						Alcohol; policy mandate; motivational interviewing; dissemination and implementation research; traumatic brain injury; American College of Surgeons; screening and brief intervention	POSTTRAUMATIC-STRESS-DISORDER; EMERGENCY-DEPARTMENTS; SUBSTANCE USE; PRIMARY-CARE; INJURY; DRINKING; HEALTH; RISK; ADULTS	Background and Aims In 2005 the American College of Surgeons passed a mandate requiring that level I trauma centers have mechanisms to identify and intervene with problem drinkers. The aim of this investigation was to determine if a multi-level trauma center intervention targeting both providers and patients would lead to higher-quality alcohol screening and brief intervention (SBI) when compared with trauma center mandate compliance without implementation enhancements. Design Cluster randomized trial in which intervention site (site n = 10, patient n = 409) providers received 1-day workshop training on evidence-based motivational interviewing (MI) alcohol interventions and four 30-minute feedback and coaching sessions; control sites (site n = 10, patient n = 469) implemented the mandate without study team training enhancements. Setting Trauma centers in the United States of America. Participants A total of 878 blood alcohol-positive in-patients with and without traumatic brain injury (TBI). Measurements MI skills of providers were assessed with fidelity coded standardized patient interviews. All patients were interviewed at baseline and 6- and 12-months post-injury with the Alcohol Use Disorders Identification Test (AUDIT). Findings Intervention site providers consistently demonstrated enhanced MI skills compared with control providers. Intervention patients demonstrated an 8% reduction in AUDIT hazardous drinking relative to controls over the course of the year after injury (relative risk = 0.88, 95%, confidence interval = 0.79, 0.98). Intervention patients were more likely to demonstrate improvements in alcohol use problems in the absence of traumatic brain injury (TBI) (P = 0.002). Conclusion Trauma center providers can be trained to deliver higher-quality alcohol screening and brief intervention (SBI) than untrained providers, which is associated with modest reductions in alcohol use problems, particularly among patients without TBI.	[Zatzick, Douglas; Gentilello, Larry; Wang, Jin] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Donovan, Dennis M.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Alcohol & Drug Abuse Inst, Seattle, WA 98195 USA; [Jurkovich, Gregory] Denver Hlth Care Colorado, Dept Surg, Denver, CO USA; [Dunn, Chris; Russo, Joan; Love, Jeff; McFadden, Collin] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Zatzick, Christopher D.] Simon Fraser Univ, Business Adm, Burnaby, BC V5A 1S6, Canada; [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA	Zatzick, D (corresponding author), Dept Psychiat & Behav Sci, 325 Ninth Ave Box 359960, Seattle, WA 98104 USA.	dzatzick@u.washington.edu		Donovan, Dennis/0000-0003-2237-4292	National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01/AA016102]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24/MH086814]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH086814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA016102] Funding Source: NIH RePORTER	Thisworkwas supported by National Institute on Alcohol Abuse and Alcoholism R01/AA016102 and National Institute of Mental Health K24/MH086814 grants to Dr Zatzick. The investigators would like to acknowledge the contribution of Roselyn Peterson BA for her contribution to the preparation of the references and proofreading the submission. She received no additional compensation for her work on the manuscript. The investigators also wish to acknowledge participating trauma centers and trauma surgical champions, including: William 'Bill' Charash MD (Fletcher Allen Healthcare, Burlington, VT); Frederic 'Ric' Cole MD (Legacy Emanuel Hospital and Health Center, Portland, OR); John Griswold MD (Texas Tech University Health Sciences Center, Lubbock, TX); Rajan Gupta MD (Dartmouth-Hitchcock Medical Center, Lebanon, NH); Charles Hu MD (Scottsdale Healthcare, Scottsdale, AZ); Toan Huynh MD (Carolina's Medical Center, Charlotte, NC); Michael E. Lekawa MD (University of California, Irvine, Orange, CA); David Livingston MD (New Jersey Trauma Center, University Hospital, Newark, NJ); Michael Moncure MD(University of Kansas Hospital, Kansas City, KS); Ernest Moore MD (Denver Health, Denver, CO); Lena M. Napolitano MD (University of Michigan, Ann Arbor, MI); Joseph Nold MD (Via Christi Regional Medical Center, Wichita, KS); Steven E. Ross MD (Cooper University Hospital, Camden, NJ); Scott Sagraves, MD (Vidant Medical Center, Greenville, NC); John Sherck MD (Santa Clara Valley Medical Center, San Jose, CA); Steven Steinberg MD (Ohio State University Medical System, Columbus, OH); Ronald Stewart MD (University Health System, San Antonio, TX); Fresca Swaniker MD (Borgess Medical Center, Kalamazoo, MI); Gail T. Tominaga MD (Scripps Memorial Hospital, La Jolla, CA, Trauma Services); and Robert Winchell MD (Maine Medical Center, Portland, ME).	Adams RS, 2012, J SOC WORK PRACT ADD, V12, P28, DOI 10.1080/1533256X.2012.647580; Allen Donner, 2000, DESIGN ANAL CLUSTER; American College of Surgeons Committee on Trauma, 2006, RES OPT CAR INJ PAT; American College of Surgeons US Department of Health and Human Services Department of Transportation, 2010, ALC SCREEN BRIEF INT; Babor TF, 1989, ALCOHOL USE DISORDER; Bergen GS, 2008, INJURY US 2007 CHART; Bernstein JA, 2010, DRUG ALCOHOL REV, V29, P498, DOI 10.1111/j.1465-3362.2010.00174.x; Bonnie R.J., 1999, REDUCING BURDEN INJU; Bray JW, 2011, MED CARE, V49, P287, DOI 10.1097/MLR.0b013e318203624f; Civil I.D., 1985, ABBREVIATED INJURY S; Corrigan JD, 2013, AM J PSYCHIAT, V170, P351, DOI 10.1176/appi.ajp.2012.12121602; Cunningham RM, 2009, ACAD EMERG MED, V16, P1078, DOI 10.1111/j.1553-2712.2009.00552.x; D'Onofrio G, 2012, ANN EMERG MED, V60, P181, DOI 10.1016/j.annemergmed.2012.02.006; D'Onofrio G, 2010, ANN EMERG MED, V56, P551, DOI 10.1016/j.annemergmed.2010.06.562; Donovan DM, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-16; Dunn Chris, 2003, Semin Clin Neuropsychiatry, V8, P188, DOI 10.1016/S1084-3612(03)00025-X; Field CA, 2010, ALCOHOL CLIN EXP RES, V34, P2004, DOI 10.1111/j.1530-0277.2010.01297.x; Field CA, 2010, ADDICTION, V105, P62, DOI 10.1111/j.1360-0443.2009.02737.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gentilello LM, 2005, ANN SURG, V241, P541, DOI 10.1097/01.sla.0000157133.80396.1c; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gibbons RD, 2010, ANNU REV CLIN PSYCHO, V6, P79, DOI 10.1146/annurev.clinpsy.032408.153550; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; Havard A, 2008, ADDICTION, V103, P368, DOI 10.1111/j.1360-0443.2007.02072.x; Institute of Medicine (US) Committee on Quality of Health Care in America ebrary Inc, 2012, SUBST US DIS US ARM; *J HOPK HLTH SERV, 1989, DET INJ SEV HOSP DIS; Jonas DE, 2012, ANN INTERN MED, V157, P645, DOI 10.7326/0003-4819-157-9-201211060-00544; Koepsell TD, 2011, AM J PREV MED, V40, P191, DOI 10.1016/j.amepre.2010.10.022; Madras BK, 2009, DRUG ALCOHOL DEPEN, V99, P280, DOI 10.1016/j.drugalcdep.2008.08.003; McGlynn EA, 2003, NEW ENGL J MED, V349, P1867; Miller W., 1996, FORM 90 STRUCTURED A; Miller WR, 1995, DRINKER INVENTORY CO; Moyers TB, 2005, J SUBST ABUSE TREAT, V28, P19, DOI 10.1016/j.jsat.2004.11.001; Murray, 1998, DESIGN ANAL GROUP RA; National Center for Injury Prevention, 2012, CDC 2012; National Institute on Alcohol Abuse Alcoholism, MOD BING DRINK; Neumann T, 2004, ALCOHOL CLIN EXP RES, V28, P1693, DOI 10.1097/01.ALC.0000145696.58084.08; Nilsen P, 2008, J SUBST ABUSE TREAT, V35, P184, DOI 10.1016/j.jsat.2007.09.008; Oliver I, 2012, IEEE IC COMP COM NET; Perl HI, 2011, ADDICT BEHAV, V36, P590, DOI 10.1016/j.addbeh.2011.01.027; Raghavan R., 2012, DISSEMINATION IMPLEM, P94; Rehm J, 2009, LANCET, V373, P2223, DOI 10.1016/S0140-6736(09)60746-7; Rogers E. M., 2010, DIFFUSION INNOVATION; Room R, 2005, LANCET, V365, P519, DOI 10.1016/S0140-6736(05)70276-2; Rose G., 1992, STRATEGY PREVENTIVE; Roudsari B, 2006, INJURY, V37, P614, DOI 10.1016/j.injury.2006.02.010; Sander AM, 2012, J HEAD TRAUMA REHAB, V27, P319, DOI 10.1097/HTR.0b013e318269838c; Schermer CR, 2006, J TRAUMA, V60, P29, DOI 10.1097/01.ta.0000199420.12322.5d; Sobell L. C., 2003, ASSESSING ALCOHOL PR, P75; Soderstrom CA, 1997, JAMA-J AM MED ASSOC, V277, P1769, DOI 10.1001/jama.277.22.1769; Soderstrom CA, 2007, J TRAUMA, V62, P1102, DOI 10.1097/TA.0b013e31804bdb26; Sommers MS, 2006, J TRAUMA, V61, P523, DOI 10.1097/01.ta.0000221756.67126.91; Sommers MS, 2000, ALCOHOL CLIN EXP RES, V24, P1406, DOI 10.1111/j.1530-0277.2000.tb02110.x; TEASDALE G, 1974, LANCET, V2, P81; Terrell F, 2008, J AM COLL SURGEONS, V207, P630, DOI 10.1016/j.jamcollsurg.2008.05.021; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Whitlock EP, 2004, ANN INTERN MED, V140, P557, DOI 10.7326/0003-4819-140-7-200404060-00017; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313; Zatzick D, 2012, J SUBST ABUSE TREAT, V43, P410, DOI 10.1016/j.jsat.2012.08.009; Zatzick DF, 2013, GEN HOSP PSYCHIAT, V35, P174, DOI 10.1016/j.genhosppsych.2012.11.012; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	64	45	45	0	18	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	MAY	2014	109	5					754	765		10.1111/add.12492			12	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	AE4XO	WOS:000333990500014	24450612	Green Accepted			2021-06-18	
J	Zuckerbraun, NS; Atabaki, S; Collins, MW; Thomas, D; Gioia, GA				Zuckerbraun, Noel S.; Atabaki, Shireen; Collins, Michael W.; Thomas, Danny; Gioia, Gerard A.			Use of Modified Acute Concussion Evaluation Tools in the Emergency Department	PEDIATRICS			English	Article						brain concussion; mild traumatic brain injury; pediatrics; emergency medicine	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; FOOTBALL PLAYERS; HEAD-INJURIES; HIGH-SCHOOL; MANAGEMENT; CHILDREN; EPIDEMIOLOGY; ADOLESCENTS; IMPACT	OBJECTIVES:Accurate recognition of pediatric concussion in the emergency department (ED) is important to ensure appropriate management for safe recovery. The study objective was to determine whether the Centers for Disease Control and Prevention's Acute Concussion Evaluation (ACE) tools, modified for ED use, improved patient follow-up and post-injury behaviors.METHODS:The original ACE tools (ACE, ACE Care Plan) were modified for ED use via Delphi methodology with an expert panel and implemented in 2 urban pediatric EDs for patients aged 5 to 21 years evaluated within 24 hours of a head injury. Pre- (February 2009 to July 2009) and post- (December 2009 to June 2010) implementation, patient phone surveys were conducted 1, 2, and 4 weeks after ED discharge. Reported rates of patient follow-up and recovery measures were analyzed. ED clinician adherence was assessed.RESULTS:During the study, 164 patients were enrolled pre-implementation and 190 post-implementation. The mean patient age was 10.6 years (SD, 3.7); 65% were males, 49% were African American, and 46% were Caucasian. Post-implementation, 58% of patients received the modified ACE diagnostic tool and 84% received the modified ACE discharge instructions. Follow-up was improved at all time points (32% vs 61% at week 4; P < .001; odds ratio, 3.4; 95% confidence interval, 2.1-5.4). Post-implementation, parental recall of discharge instructions was significantly increased, patient's mean total post-concussion symptom score was significantly higher, and report of return to normal activity was significantly longer.CONCLUSIONS:The ACE tools, modified for ED use, were successfully implemented in the pediatric ED. Post-implementation, increased patient follow-up and improved recall of and adherence to ED discharge recommendations was demonstrated.	[Zuckerbraun, Noel S.] Univ Pittsburgh, Sch Med, Dept Pediat, Div Pediat Emergency Med, Pittsburgh, PA 15224 USA; [Collins, Michael W.] Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA; [Atabaki, Shireen] George Washington Univ, Sch Med, Dept Pediat, Div Pediat Emergency Med, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Psychiat & Behav Sci, Washington, DC USA; [Thomas, Danny] Med Coll Wisconsin, Dept Pediat, Div Pediat Emergency Med, Milwaukee, WI 53226 USA	Zuckerbraun, NS (corresponding author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh, Dept Pediat,Div Pediat Emergency Med,UPMC, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	zuckns@chp.edu	Thomas, Danny G/C-8314-2014	Thomas, Danny/0000-0002-7470-9835	NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U49CE001385] Funding Source: NIH RePORTER; NCIPC CDC HHS [5 U49 CE001385-02] Funding Source: Medline		Atabaki SGG, 2010, INT BRAIN INJ ASS 8, p[24, 355]; Benedetti F, 2007, NEUROSCIENCE, V147, P260, DOI 10.1016/j.neuroscience.2007.02.020; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; (CDC). National Center for Injury Prevention and Control, 2007, HEADS BRAIN INJ YOUR; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colloca L, 2011, PSYCHOSOM MED, V73, P598, DOI 10.1097/PSY.0b013e3182294a50; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Fowles J, 1978, HDB FUTURES RES; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Giebel S, 2011, J EMERG MED, V41, P649, DOI 10.1016/j.jemermed.2011.03.021; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2012, PEDIATR ANN, V41, P198, DOI 10.3928/00904481-20120426-10; Griesbach GS, 2011, PM&R, V3, pS64, DOI 10.1016/j.pmrj.2011.02.008; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Langlois J. A., 2010, HEADS FACTS PHYS MIL; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5	33	45	45	0	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2014	133	4					635	642		10.1542/peds.2013-2600			8	Pediatrics	Pediatrics	AG3TU	WOS:000335343500010	24616361				2021-06-18	
J	Wong, RH; Wong, AK; Bailes, JE				Wong, Ricky H.; Wong, Andrew K.; Bailes, Julian E.			Frequency, magnitude, and distribution of head impacts in Pop Warner football: The cumulative burden	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Chronic traumatic encephalopathy; Head impact; Pop Warner football; Traumatic brain injury; Youth football	CHRONIC TRAUMATIC ENCEPHALOPATHY; RECURRENT CONCUSSION; LEAGUE	Background: A growing body of research suggests that subconcussive head impacts or repetitive mild Traumatic Brain Injury (mTBI) can have cumulative and deleterious effects. Several studies have investigated head impacts in football at the professional, collegiate, and high school levels, in an attempt to elucidate the biomechanics of head impacts among football players. Youth football players, generally from 7 to 14 years of age, constitute 70% of all football players, yet burden of, and susceptibility to, head injury in this population is not well known. Methods: A novel impact sensor utilizing binary force switches (Shockbox (R)) was used to follow an entire Pop Warner football team consisting of twenty-two players for six games and five practices. The impact sensor was designed to record impacts with linear accelerations over 30g. In addition, video recording of games and practices were used to further characterize the head impacts by type of position (skilled versus unskilled), field location of impact (open field versus line of scrimmage), type of hit (tackling, tackled, or hold/push), and whether the impact was a head-to-head impact or not. Results: We recorded a total of 480 head impacts. An average of 21.8 head impacts occurred per practice, while 61.8 occurred per game. Players had an average of 3.7 head impacts per game and 1.5 impacts per practice (p < 0.001). The number of high magnitude head impacts (>80g) was 11. Two concussions were diagnosed over the course of the season. However, due to technical reasons the biomechanics of those hits resulting in concussions were not captured. Conclusion: Despite smaller players and slower play when compared to high school, collegiate or professional players, those involved in youth football sustain a moderate number of head impacts per season with several high magnitude impacts. Our results suggest that players involved in open-field, tackling plays that have head-to-head contact sustain impacts with the highest linear accelerations. Our data supports previously published data that suggests changes to the rules of play during practice can reduce the burden of hits. (C) 2013 Elsevier B.V. All rights reserved.	[Wong, Ricky H.] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA; [Wong, Andrew K.; Bailes, Julian E.] North Shore Univ Hlth Syst, Dept Neurosurg, Evanston, IL 60201 USA	Wong, RH (corresponding author), Univ Chicago, Neurosurg Sect, 5841 S Maryland Ave MC3026, Chicago, IL 60637 USA.	wong.ricky@gmail.com					[Anonymous], 2012, RULE CHANGES REGARDI; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Casson IR, 2013, SPORTS HEALTH, V2, P471; Casson IR, 2009, PHYS MED REH CLIN N, V20, P195, DOI 10.1016/j.pmr.2008.10.006; Casson IR, 2009, ARCH NEUROL-CHICAGO, V66, P419, DOI 10.1001/archneurol.2008.592; Cobb BR, 2013, ANN BIOMED ENG; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Crisco JJ, 2013, J BIOMECH, V44, P2673; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Foreman S., 2013, ASTM S MECH CONC SPO; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parkinson D, 2003, NEUROSURGERY, V53, P247, DOI 10.1227/01.NEU.0000072307.16102.F4; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12	24	45	45	0	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	MAR	2014	118						1	4		10.1016/j.clineuro.2013.11.036			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AD0JM	WOS:000332920300001	24529219				2021-06-18	
J	Sillesen, M; Rasmussen, LS; Jin, G; Jepsen, CH; Imam, A; Hwabejire, JO; Halaweish, I; DeMoya, M; Velmahos, G; Johansson, PI; Alam, HB				Sillesen, Martin; Rasmussen, Lars S.; Jin, Guang; Jepsen, Cecilie H.; Imam, Ayesha; Hwabejire, John O.; Halaweish, Ihab; DeMoya, Marc; Velmahos, George; Johansson, Par I.; Alam, Hasan B.			Assessment of coagulopathy, endothelial injury, and inflammation after traumatic brain injury and hemorrhage in a porcine model	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Coagulopathy; brain; injury; shock; inflammation; porcine	LARGE-ANIMAL-MODEL; UNCONTROLLED HEMORRHAGE; GLYCOCALYX DEGRADATION; COMPLEMENT ACTIVATION; COAGULATION TESTS; NERVOUS-SYSTEM; PROTEIN-C; DYSFUNCTION; RESUSCITATION; TISSUE	BACKGROUND: Traumatic brain injury (TBI) and hemorrhagic shock (HS) can be associated with coagulopathy and inflammation, but the mechanisms are poorly understood. We hypothesized that a combination of TBI and HS would disturb coagulation, damage the endothelium, and activate inflammatory and complement systems. METHODS: A total of 33 swine were allocated to either TBI + HS (n = 27, TBI and volume-controlled 40% blood loss) or controls (n = 6, anesthesia and instrumentation). TBI + HS animals were left hypotensive (mean arterial pressure, 30-35 mm Hg) for 2 hours. Blood samples were drawn at baseline, 3 minutes and 15 minutes after injury, as well as following 2 hours of hypotension. Markers of coagulation, anticoagulation, endothelial activation/glycocalyx shedding, inflammation, complement, and sympathoadrenal function were measured. RESULTS: The TBI + HS group demonstrated an immediate (3 minutes after injury) activation of coagulation (prothrombin fragment 1 + 2, 289 ng/mL vs. 232 ng/mL, p = 0.03) and complement (C5a, 2.83 ng/mL vs. 2.05 ng/mL, p = 0.05). Shedding of the endothelial glycocalyx (syndecan 1) was evident 15 minutes after injury (851.0 ng/ml vs. 715.5 ng/ml, p = 0.03) while inflammation (tumor necrosis factor alpha [ TNF-alpha], 81.1 pg/mL vs. 50.8 pg/mL, p = 0.03) and activation of the protein C system (activated protein C, 56.7 ng/mL vs. 26.1 ng/mL, p = 0.01) were evident following the 2-hour hypotension phase. CONCLUSION: The combination of TBI and shock results in an immediate activation of coagulation and complement systems with subsequent endothelial shedding, protein C activation, and inflammation. (Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Sillesen, Martin; Jepsen, Cecilie H.; Imam, Ayesha; Hwabejire, John O.; DeMoya, Marc; Velmahos, George] Harvard Univ, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Dept Surg,Massachusetts Gen Hos, Boston, MA 02115 USA; [Jin, Guang; Halaweish, Ihab; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Johansson, Par I.] Univ Texas Med Sch, Dept Surg, Houston, TX USA; [Sillesen, Martin; Rasmussen, Lars S.] Rigshosp, Copenhagen Univ Hosp, Dept Anesthesia, Copenhagen, Denmark; [Jepsen, Cecilie H.; Johansson, Par I.] Rigshosp, Copenhagen Univ Hosp, Ctr Head & Orthoped, Copenhagen, Denmark; [Jepsen, Cecilie H.; Johansson, Par I.] Rigshosp, Copenhagen Univ Hosp, Capital Reg Blood Bank, Copenhagen, Denmark	Alam, HB (corresponding author), Univ Michigan Hosp, Taubman Ctr 2920, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu	Johansson, Par I/P-9283-2015	Johansson, Par I/0000-0001-9778-5964; Rasmussen, Lars/0000-0002-7480-3004; Sillesen, Martin/0000-0001-9494-5475	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [GRANTT00521959]; Copenhagen University Hospital, Rigshospitalet (Denmark); Laerdal Foundation (Norway); Aase and Ejnar Danielsen Foundation (Denmark); Olof Norlander Foundation (Sweden); Maersk Foundation (Denmark); Tryg Foundation (Denmark); Lundbeck Foundation (Denmark)Lundbeckfonden	The study was funded by a grant from the US Army Medical Research and Materiel Command (GRANTT00521959) to H. B. A. and grants from Copenhagen University Hospital, Rigshospitalet (Denmark), The Laerdal Foundation (Norway), The Aase and Ejnar Danielsen Foundation (Denmark), The Olof Norlander Foundation (Sweden), and The Maersk Foundation (Denmark) to M. S.; L. S. R. has received funding from the Tryg Foundation (Denmark).; P.I.J. received funding from the Lundbeck Foundation (Denmark).	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Barklin A, 2009, ANESTHESIOLOGY, V110, P1287, DOI 10.1097/ALN.0b013e3181a10352; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Esmon CT, 2005, BRIT J HAEMATOL, V131, P417, DOI 10.1111/j.1365-2141.2005.05753.x; Esmon CT, 2004, TRENDS IMMUNOL, V25, P536, DOI 10.1016/j.it.2004.08.003; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fuchs TA, 2010, P NATL ACAD SCI USA, V107, P15880, DOI 10.1073/pnas.1005743107; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; Giesen PLA, 2000, SEMIN THROMB HEMOST, V26, P379, DOI 10.1055/s-2000-8456; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Grenegard M, 2008, J BIOL CHEM, V283, P18493, DOI 10.1074/jbc.M800358200; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Johansson PI, 2011, ANN SURG, V254, P194, DOI 10.1097/SLA.0b013e318226113d; Johansson PI, 2012, J TRAUMA ACUTE CARE, V72, P428, DOI 10.1097/TA.0b013e31821e0f93; Kanse SM, 2012, J IMMUNOL, V188, P2858, DOI 10.4049/jimmunol.1103029; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; MAKHMUDOV RM, 1985, COR VASA, V27, P456; Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006; Molina PE, 2005, SHOCK, V24, P3, DOI 10.1097/01.shk.0000167112.18871.5c; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Neate SL, 2013, BLOOD COAGUL FIBRIN, V24, P581, DOI 10.1097/MBC.0b013e32835fad68; Nieuwdorp M, 2006, DIABETES, V55, P480, DOI 10.2337/diabetes.55.02.06.db05-1103; Ostrowski SR, 2012, J TRAUMA ACUTE CARE, V73, P60, DOI 10.1097/TA.0b013e31825b5c10; Ostrowski SR, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-64; Prevost TP, 2011, ACTA BIOMATER, V7, P4090, DOI 10.1016/j.actbio.2011.06.032; Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Schrieber M, 2007, J TRAUMA, V63, P1261; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; SIMS PJ, 1988, J BIOL CHEM, V263, P18205; Teranishi K, 2012, INJURY, V43, P585, DOI 10.1016/j.injury.2010.09.042; van der Poll T, 2012, CURR VASC PHARMACOL, V10, P632, DOI 10.2174/157016112801784549; White NJ, 2013, SHOCK, V39, P210, DOI 10.1097/SHK.0b013e31827fd62b; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	44	45	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2014	76	1					12	19		10.1097/TA.0b013e3182aaa675			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AH8JN	WOS:000336384200004	24368352				2021-06-18	
J	Thiagarajan, P; Ciuffreda, KJ; Capo-Aponte, JE; Ludlam, DP; Kapoor, N				Thiagarajan, Preethi; Ciuffreda, Kenneth J.; Capo-Aponte, Jose E.; Ludlam, Diana P.; Kapoor, Neera			Oculomotor neurorehabilitation for reading in mild traumatic brain injury (mTBI): An integrative approach	NEUROREHABILITATION			English	Article						Traumatic brain injury; mTBI; reading dysfunction; oculomotor deficiency; nearvision symptoms; oculomotor rehabilitation; neuroplasticity; oculomotor learning; eye movements	SUSTAINED-ATTENTION; VISUAL FUNCTION; REHABILITATION; ACCOMMODATION; VERGENCE; MILITARY; VETERANS; BEHAVIOR; DEFICITS; MODEL	BACKGROUND: Considering the extensive neural network of the oculomotor subsystems, traumatic brain injury (TBI) could affect oculomotor control and related reading dysfunction. OBJECTIVE: To evaluate comprehensively the effect of oculomotor-based vision rehabilitation (OBVR) in individuals with mTBI. METHODS: Twelve subjects with mTBI participated in a cross-over, interventional study involving oculomotor training (OMT) and sham training (ST). Each training was performed for 6 weeks, 2 sessions a week. During each training session, all three oculomotor subsystems (vergence/accommodation/version) were trained in a randomized order across sessions. All laboratory and clinical parameters were determined before and after OMT and ST. In addition, nearvision-related symptoms using the Convergence Insufficiency Symptom Survey (CISS) scale and subjective visual attention using the Visual Search and Attention Test (VSAT) were assessed. RESULTS: Following the OMT, over 80% of the abnormal parameters significantly improved. Reading rate, along with the amplitudes of vergence and accommodation, improved markedly. Saccadic eye movements demonstrated enhanced rhythmicity and accuracy. The improved reading-related oculomotor behaviorwas reflected in reduced symptoms and increased visual attention. None of the parameters changed with ST. CONCLUSIONS: OBVR had a strong positive effect on oculomotor control, reading rate, and overall reading ability. This oculomotor learning effect suggests considerable residual neuroplasticity following mTBI.	[Thiagarajan, Preethi; Ciuffreda, Kenneth J.; Ludlam, Diana P.] SUNY State Coll Optometry, Dept Biol & Vis Sci, New York, NY USA; [Capo-Aponte, Jose E.] Womack Army Med Ctr, Optometry Serv, Ft Bragg, NC USA; [Kapoor, Neera] SUNY State Coll Optometry, Dept Clin Sci, New York, NY USA	Thiagarajan, P (corresponding author), Retina Fdn Southwest, 9600 N Cent Expy,Suite 200, Dallas, TX 75231 USA.	pthiagarajan@retinafoundation.org			US Army, DoDUnited States Department of Defense [W81XWH-10- 1-1041, W81XWH12-1-0240]; College of Optometrists in Vision Development (COVD); SUNY Graduate Program	This research was funded by the US Army, DoD, Award # s: W81XWH-10- 1-1041 and W81XWH12-1-0240, the College of Optometrists in Vision Development (COVD), and the SUNY Graduate Program.	ABERNETHY B., 1997, BIOPHYSICAL FDN HUMA; ABRAMS SG, 1972, READ RES QUART, V8, P40, DOI 10.2307/746979; Alvarez TL, 2010, OPTOMETRY VISION SCI, V87, P985, DOI 10.1097/OPX.0b013e3181fef1aa; BAKER RS, 1991, SURV OPHTHALMOL, V35, P245, DOI 10.1016/0039-6257(91)90046-I; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Borish I. M., 2006, CLIN REFRACTION; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bulson R, 2012, J REHABIL RES DEV, V49, P1075, DOI 10.1682/JRRD.2011.02.0017; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chen HW, 2010, PM&R, V2, pS306, DOI 10.1016/j.pmrj.2010.10.006; Chiu YC, 2009, J NEUROSCI, V29, P3930, DOI 10.1523/JNEUROSCI.5737-08.2009; Ciuffreda K, 1983, VERGENCE EYE MOVEMEN, P101; Ciuffreda K. J., 2007, OPTOMETRY, V78, P55; Ciuffreda K. J., 2005, BRAIN INJURY PROFESS, V2, P16; Ciuffreda K. J., 1996, J BEHAV OPTOM, V7, P31; Ciuffreda K. J., 1994, EYE MOVEMENTS READIN, P163; Ciuffreda KJ, 2006, NEUROREHABILITATION, V21, P9; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Ciuffreda KJ, 1995, EYE MOVEMENT BASICS; Ciuffreda MA, 2003, J BEHAV OPTOM, V14, P60; Clark B, 1935, J EDUC PSYCHOL, V26, P530, DOI 10.1037/h0053899; Cuiffreda K., 1992, J BEHAV OPTOM, V3, P3; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Green W, 2010, OPTOMETRY, V81, P129, DOI 10.1016/j.optm.2009.07.015; Green W, 2010, J REHABIL RES DEV, V47, P183, DOI 10.1682/JRRD.2009.04.0041; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griffin JR, 2002, BINOCULAR ANOMALIES; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Hatch S. W., 1998, OPHTHALMIC RES EPIDE, P97; Hibbard M. R., 2001, VISUAL VESTIBULAR CO, P32; Hung GK, 1996, OPHTHAL PHYSL OPT, V16, P31, DOI 10.1016/0275-5408(95)00110-7; HUNG GK, 1986, IEEE T BIO-MED ENG, V33, P1021, DOI 10.1109/TBME.1986.325868; HUNG GK, 1988, OPHTHAL PHYSL OPT, V8, P327, DOI 10.1111/j.1475-1313.1988.tb01062.x; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Khan AA, 2005, DIGITAL SIGNAL PROCE; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; KOTULAK JC, 1987, VISION RES, V27, P1797, DOI 10.1016/0042-6989(87)90108-8; Leigh R. J., 2006, NEUROLOGY EYE MOVEME; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Nag S, 1999, NEUROL INDIA, V47, P32; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pashler HE., 1998, PSYCHOL ATTENTION; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Rabbetts R.B., 2007, BENNETT RABBETTS CLI, V4th ed.; Reichle E. D., 2002, MODELS VISUAL SYSTEM, P565; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Scheiman M., 2008, CLIN MANAGEMENT BINO, V3rd; Solan HA, 2003, J LEARN DISABIL-US, V36, P556, DOI 10.1177/00222194030360060601; Stark Lawrence, 1968, NEUROLOGICAL CONTROL; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suchoff IB, 2001, VISUAL VESTIBULAR CO; Szymanowicz D, 2012, J REHABIL RES DEV, V49, P1083, DOI 10.1682/JRRD.2010.07.0129; Taylor EA., 1966, FUNDAMENTAL READING; Thiagarajan P, J REHABILIT IN PRESS; Thiagarajan P., 2012, THESIS SUNY COLLEGE; Trenerry M. R., 1989, VISUAL SEARCH ATTENT; Warraich Z, 2010, PM&R, V2, pS208, DOI 10.1016/j.pmrj.2010.10.016; Xu J. J., 2009, J BEHAV OPTOMETRY, V20, P67	62	45	45	0	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2014	34	1					129	146		10.3233/NRE-131025			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AA4JN	WOS:000331062000015	24284470				2021-06-18	
J	Tillou, A; Kelley-Quon, L; Burruss, S; Morley, E; Cryer, H; Cohen, M; Min, L				Tillou, Areti; Kelley-Quon, Lorraine; Burruss, Sigrid; Morley, Eric; Cryer, Henry; Cohen, Marilyn; Min, Lillian			Long-term Postinjury Functional Recovery Outcomes of Geriatric Consultation	JAMA SURGERY			English	Article							VULNERABLE ELDERS SURVEY; TRAUMATIC BRAIN-INJURY; ACUTE MEDICAL ILLNESS; HIP FRACTURE; RESOURCE USE; CARE; MORTALITY; DECLINE; HOSPITALIZATION; MANAGEMENT	IMPORTANCE Functional recovery is an important outcome following injury. Functional impairment is persistent in the year following injury for older trauma patients. OBJECTIVE To measure the impact of routine geriatric consultation on functional outcomes in older trauma patients. DESIGN, SETTING, AND PARTICIPANTS In this pretest-posttest study, the pretest control group (n = 37) was retrospectively identified (December 2006-November 2007). The posttest geriatric consultation (GC) group (n = 85) was prospectively enrolled (December 2007-June 2010). We then followed up both groups for 1 year after enrollment. This study was conducted at an academic level 1 trauma center with adults 65 years of age and older admitted as an activated code trauma. INTERVENTION Routine GC. MAIN OUTCOMES AND MEASURES The Short Functional Status survey of 5 activities of daily living (ADLs) at hospital admission and 3, 6, and 12 months postinjury. RESULTS The unadjusted Short Functional Status score (GC group only) declined from 4.6 preinjury to 3.7 at 12 months postinjury, a decline of nearly 1 full ADL (P < .05). The ability to shop for personal items was the specific ADL more commonly retained by the GC group compared with the control group. The GC group had a better recovery of function in the year following injury than the GC group, controlling for age, sex, race/ethnicity, length of stay, comorbidity, injury severity, postdischarge rehabilitation, complication, and whether surgery was performed (P < .01), a difference of 0.67 ADL abilities retained by the GC group compared with the control group (95% CI, 0.06-1.4). CONCLUSIONS AND RELEVANCE Functional recovery for older adults following injury may be improved by GC. Early introduction of multidisciplinary care in geriatric trauma patients warrants further investigation.	[Tillou, Areti; Kelley-Quon, Lorraine; Burruss, Sigrid; Cryer, Henry; Cohen, Marilyn] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA; [Morley, Eric] Boston Univ, Sch Med, Boston, MA 02118 USA; [Min, Lillian] Univ Michigan, Sch Med, Div Geriatr, Ann Arbor, MI 48109 USA	Min, L (corresponding author), Univ Michigan, Sch Med, Div Geriatr, 300 N Ingalls, Ann Arbor, MI 48109 USA.	lmin@med.umich.edu			American Geriatrics Society Jahnigen Award; K12 University of California, Los Angeles Mentored Clinical Scientist Development Program in Geriatrics (National Institute on Aging); Research Career Development Core grant from the University of Michigan Pepper Center (National Institute on Aging); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG024824] Funding Source: NIH RePORTER	Dr Tillou was supported by an American Geriatrics Society Jahnigen Award (2009-11). Drs Tillou and Min were supported by the K12 University of California, Los Angeles Mentored Clinical Scientist Development Program in Geriatrics (National Institute on Aging). Dr Min is supported by a Research Career Development Core grant from the University of Michigan Pepper Center (National Institute on Aging).	Agostini JV, 2001, AHRQ PUBLICATION, V01-E058; American College of Surgeons, 2007, NAT TRAUM DAT BANK R; Bachmann S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1718; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Campbell PR, 1996, POPULATION PROJECTIO; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; COVINGTON DL, 1993, J AM GERIATR SOC, V41, P847, DOI 10.1111/j.1532-5415.1993.tb06182.x; DEMARIA EJ, 1988, J TRAUMA, V28, P1244, DOI 10.1097/00005373-198808000-00018; Demetriades D, 2002, BRIT J SURG, V89, P1319, DOI 10.1046/j.1365-2168.2002.02210.x; Deschodt M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-48; Dudgeon BJ, 2008, ARCH PHYS MED REHAB, V89, P1256, DOI 10.1016/j.apmr.2007.11.038; Fallon WF, 2006, J TRAUMA, V61, P1040, DOI 10.1097/01.ta.0000238652.48008.59; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; Givens JL, 2008, J AM GERIATR SOC, V56, P1075, DOI 10.1111/j.1532-5415.2008.01711.x; Glance LG, 2004, J TRAUMA, V56, P682, DOI 10.1097/01.TA.0000053469.92142.40; Glance LG, 2004, J TRAUMA, V56, P165, DOI 10.1097/01.TA.0000047808.77902.83; Jacobs DG, 2003, J TRAUMA, V54, P391, DOI 10.1097/01.TA.0000042015.54022.BE; Kelley-Quon L, 2010, AM SURGEON, V76, P1055; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; KENNIE DC, 1988, BRIT MED J, V297, P1083, DOI 10.1136/bmj.297.6656.1083; KNUDSON MM, 1994, ARCH SURG-CHICAGO, V129, P448; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Malani PN, 2009, JAMA-J AM MED ASSOC, V302, P1582, DOI 10.1001/jama.2009.1453; Marcantonio ER, 2001, J AM GERIATR SOC, V49, P516, DOI 10.1046/j.1532-5415.2001.49108.x; Marcantonio ER, 2000, J AM GERIATR SOC, V48, P618, DOI 10.1111/j.1532-5415.2000.tb04718.x; McCusker J, 2002, J GERONTOL A-BIOL, V57, pM569, DOI 10.1093/gerona/57.9.M569; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; McGwin G, 2000, J TRAUMA, V49, P470, DOI 10.1097/00005373-200009000-00014; McKevitt EC, 2003, CAN J SURG, V46, P211; Min LC, 2006, J AM GERIATR SOC, V54, P507, DOI 10.1111/j.1532-5415.2005.00615.x; Min L, 2009, J AM GERIATR SOC, V57, P2070, DOI 10.1111/j.1532-5415.2009.02497.x; Min LC, 2008, J AM GERIATR SOC, V56, P1932, DOI 10.1111/j.1532-5415.2008.01921.x; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; ROSS N, 1989, SOUTHERN MED J, V82, P857, DOI 10.1097/00007611-198907000-00016; Rudolph JL, 2010, ACTA ANAESTH SCAND, V54, P663, DOI 10.1111/j.1399-6576.2010.02236.x; Ruhm CJ, 2005, INT J EPIDEMIOL, V34, P1206, DOI 10.1093/ije/dyi143; Rzepka SG, 2001, J CLIN EPIDEMIOL, V54, P627, DOI 10.1016/S0895-4356(00)00337-1; Sager MA, 1996, ARCH INTERN MED, V156, P645, DOI 10.1001/archinte.156.6.645; Sager MA, 1996, J AM GERIATR SOC, V44, P251, DOI 10.1111/j.1532-5415.1996.tb00910.x; Saliba D, 2000, J GERONTOL A-BIOL, V55, pM750, DOI 10.1093/gerona/55.12.M750; Saliba D, 2001, J AM GERIATR SOC, V49, P1691, DOI 10.1046/j.1532-5415.2001.49281.x; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; SHABOT MM, 1995, J TRAUMA, V39, P254, DOI 10.1097/00005373-199508000-00011; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; VANAALST JA, 1991, J TRAUMA, V31, P1096; vanderSluis CK, 1996, J TRAUMA, V40, P78, DOI 10.1097/00005373-199601000-00015; Wu HY, 2006, ANN ACAD MED SINGAP, V35, P17	52	45	45	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	JAN	2014	149	1					83	89		10.1001/jamasurg.2013.4244			7	Surgery	Surgery	295LJ	WOS:000330117300016	24284836	Green Accepted, Bronze			2021-06-18	
J	Schwulst, SJ; Trahanas, DM; Saber, R; Perlman, H				Schwulst, Steven J.; Trahanas, Diane M.; Saber, Rana; Perlman, Harris			Traumatic brain injury-induced alterations in peripheral immunity	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	72nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma / Clinical Congress of Acute Care Surgery	SEP 18-23, 2013	San Francisco, CA	Amer Assoc Surg Trauma		Traumatic brain injury; immunosuppression; peripheral immunity; innate immunity; mice	SPINAL-CORD-INJURY; BETA-BLOCKER EXPOSURE; HEAD-INJURY; IMPROVED SURVIVAL; ACTIVATION; STROKE; DISEASE; CELLS; MODEL	BACKGROUND: The complex alterations that occur in peripheral immunity after traumatic brain injury (TBI) have been poorly characterized to date. The purpose of this study was to determine the temporal changes in the peripheral immune response after TBI in a murine model of closed head injury. METHODS: C57Bl/6 mice underwent closed head injury via a weight drop technique (n = 5) versus sham injury (n = 3) per time point. Blood, spleen, and thymus were collected, and immune phenotype, cytokine expression, and antibody production were determined via flow cytometry and multiplex immunoassays at 1, 3, 7, 14, 30, and 60 days after injury. RESULTS: TBI results in acute and chronic changes in both the innate and adaptive immune response. TBI resulted in a striking loss of thymocytes as early as 3 days after injury (2.1 x 10(7) TBI vs. 5.6 x 10(7) sham, p = 0.001). Similarly, blood monocyte counts were markedly diminished as early as 24 hours after TBI (372 per deciliter TBI vs. 1359 per deciliter sham, p = 0.002) and remained suppressed throughout the first month after injury. At 60 days after injury, monocytes were polarized toward an anti-inflammatory (M2) phenotype. TBI also resulted in diminished interleukin 12 expression from Day 14 after injury throughout the remainder of the observation period. CONCLUSION: TBI results in temporal changes in both the peripheral and the central immune systems culminating in an overall immune suppressed phenotype and anti-inflammatory milieu. (J Trauma Acute Care Surg. 2013;75:780-788. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Schwulst, Steven J.; Trahanas, Diane M.] Northwestern Univ, Dept Surg, Div Trauma, Chicago, IL 60611 USA; [Schwulst, Steven J.; Trahanas, Diane M.] Northwestern Univ, Dept Surg, Div Crit Care, Chicago, IL 60611 USA; [Saber, Rana; Perlman, Harris] Northwestern Univ, Dept Med, Div Rheumatol, Chicago, IL 60611 USA	Schwulst, SJ (corresponding author), Northwestern Univ, Dept Surg, 676 N St Clair St Suite 650, Chicago, IL 60611 USA.	sschwuls@nmh.org			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL108795, P01 HL108795] Funding Source: Medline; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21 AI092490, AI092490] Funding Source: Medline; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR050250, AR054796, AR050250, R01 AR054796] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL108795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI092490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR050250, R01AR054796] Funding Source: NIH RePORTER		Barker RN, 1999, PATHOBIOLOGY, V67, P302, DOI 10.1159/000028085; Becher B, 2000, GLIA, V29, P293; Boomer JS, 2012, CRIT CARE, V16, DOI 10.1186/cc11404; Campagnolo DI, 1997, AM J PHYS MED REHAB, V76, P276, DOI 10.1097/00002060-199707000-00005; Cassetta L, 2011, THESCIENTIFICWORLDJO, V11, P2391, DOI 10.1100/2011/213962; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; CZLONKOWSKA A, 1979, J NEUROL SCI, V43, P455, DOI 10.1016/0022-510X(79)90024-8; Enderson BL, 2007, J TRAUMA, V62, P33; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FELTEN DL, 1987, IMMUNOL REV, V100, P225, DOI 10.1111/j.1600-065X.1987.tb00534.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gui T, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/693083; Harms H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002158; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; Huschak G, 2003, CLIN EXP IMMUNOL, V134, P491, DOI 10.1111/j.1365-2249.2003.02302.x; Imhoff M, 1990, Ann Ital Chir, V61, P525; Imhoff M, 1990, ANN ITAL CHIR, V61, P529; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Lech M, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/951390; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Lucin KM, 2009, J NEUROCHEM, V110, P1409, DOI 10.1111/j.1471-4159.2009.06232.x; Matzinger P, 2011, NAT REV IMMUNOL, V11, P221, DOI 10.1038/nri2940; MEERT KL, 1995, CRIT CARE MED, V23, P822, DOI 10.1097/00003246-199505000-00008; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Mrakovcic-Sutic I, 2010, SCAND J IMMUNOL, V72, P57, DOI 10.1111/j.1365-3083.2010.02407.x; Pearson WS, 2012, WEST J EMERG MED, V13, P289, DOI 10.5811/westjem.2012.3.11559; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; QUATTROCCHI K B, 1991, Neurological Research, V13, P13; Rehm KE, 2012, NEUROIMMUNOMODULAT, V19, P220, DOI 10.1159/000334711; Rose S, 2012, CYTOM PART A, V81A, P343, DOI 10.1002/cyto.a.22012; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Vega JL, 2003, J NEUROPATH EXP NEUR, V62, P848, DOI 10.1093/jnen/62.8.848; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006	41	45	45	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	NOV	2013	75	5					780	788		10.1097/TA.0b013e318299616a			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300IP	WOS:000330457900005	24158195	Green Accepted			2021-06-18	
J	Wiseman-Hakes, C; Murray, B; Moineddin, R; Rochon, E; Cullen, N; Gargaro, J; Colantonio, A				Wiseman-Hakes, Catherine; Murray, Brian; Moineddin, Rahim; Rochon, Elizabeth; Cullen, Nora; Gargaro, Judith; Colantonio, Angela			Evaluating the impact of treatment for sleep/wake disorders on recovery of cognition and communication in adults with chronic TBI	BRAIN INJURY			English	Article						Cognition; communication; mood; outcomes; sleep disorders; traumatic brain injury	TRAUMATIC BRAIN-INJURY; INSOMNIA; RELIABILITY; DISTURBANCE; NEUROGENESIS; CONSEQUENCES; HIPPOCAMPUS; SLEEPINESS; INVENTORY; VALIDITY	Objective: To longitudinally examine objective and self-reported outcomes for recovery of cognition, communication, mood and participation in adults with traumatic brain injury (TBI) and co-morbid post-traumatic sleep/wake disorders. Design: Prospective, longitudinal, single blind outcome study. Setting: Community-based. Participants: Ten adults with moderate-severe TBI and two adults with mild TBI and persistent symptoms aged 18-58 years. Six males and six females, who were 1-22 years post-injury and presented with self-reported sleep/wake disturbances with onset post-injury. Interventions: Individualized treatments for sleep/wake disorders that included sleep hygiene recommendations, pharmacological interventions and/or treatments for sleep apnea with follow-up. Main outcome measures: Insomnia Severity Index, Beck Depression and Anxiety Inventories, Latrobe Communication Questionnaire, Speed and Capacity of Language Processing, Test of Everyday Attention, Repeatable Battery for the Assessment of Neuropsychological Status, Daily Cognitive-Communication and Sleep Profile. Results: Group analysis revealed positive trends in change for each measure and across sub-tests of all measures. Statistically significant changes were noted in insomnia severity, p = 0.0003; depression severity, p = 0.03; language, p = 0.01; speed of language processing, p = 0.007. Conclusions: These results add to a small but growing body of evidence that sleep/wake disorders associated with TBI exacerbate trauma-related cognitive, communication and mood impairments. Treatment for sleep/wake disorders may optimize recovery and outcomes.	[Wiseman-Hakes, Catherine] Univ Toronto, Dept Rehabil Sci, Toronto, ON, Canada; [Wiseman-Hakes, Catherine; Rochon, Elizabeth; Cullen, Nora; Colantonio, Angela] Toronto Rehabil Inst, Toronto, ON, Canada; [Murray, Brian] Univ Toronto, Dept Med, Sunnybrook Hlth Sci Ctr, Div Neurol, Toronto, ON, Canada; [Moineddin, Rahim] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada; [Rochon, Elizabeth] Univ Toronto, Dept Speech Language Pathol, Toronto, ON, Canada; [Cullen, Nora; Gargaro, Judith] West Pk Hlth Care Ctr, Toronto, ON, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Therapy & Occupat Sci, Toronto, ON, Canada	Wiseman-Hakes, C (corresponding author), 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	catherinewh@utoronto.ca	Wiseman-Hakes, Catherine/AAC-8303-2021; Lang, Steven/AAE-8102-2021; Murray, Brian/E-6786-2016	Wiseman-Hakes, Catherine/0000-0001-8441-884X; Lang, Steven/0000-0003-1669-9146; Murray, Brian/0000-0001-5085-0909; Rochon, Elizabeth/0000-0001-5521-0513; Cullen, Nora/0000-0001-6359-9418; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); University of Toronto Open FellowshipUniversity of Toronto; Ontario Ministry of Long Term Care; Ontario Work Study Program	The authors report no conflicts of interest. The study was funded through a fellowship in Clinical Research from the Canadian Institutes for Health Research and a University of Toronto Open Fellowship. Other support came from the Toronto Rehabilitation Institute who receives funding through the Ontario Ministry of Long Term Care. Support was also provided through the Ontario Work Study Program.	*AASM, 2005, INT 57 CLASS SLEEP D; [Anonymous], 2007, MAN SCOR SLEEP ASS E; Backhaus J, 2006, BIOL PSYCHIAT, V60, P1324, DOI 10.1016/j.biopsych.2006.03.051; Baddeley A.D., 1992, SPEED CAPACITY LANGU; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Coelho FMS, 2011, CURR OPIN PULM MED, V17, P406, DOI 10.1097/MCP.0b013e32834b7e04; Doghramji K, 1997, ELECTROEN CLIN NEURO, V103, P554, DOI 10.1016/S0013-4694(97)00010-2; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Fung C., 2011, SLEEP MED S1, V12, pS127; Gosselin N, 2010, J NEUROL NEUROSUR PS, V81, P1297, DOI 10.1136/jnnp.2010.222471; Guzman-Marin R, 2005, EUR J NEUROSCI, V22, P2111, DOI 10.1111/j.1460-9568.2005.04376.x; Guzman-Marin R, 2008, SLEEP, V31, P167, DOI 10.1093/sleep/31.2.167; Hagen C, 1973, RANCHO LEVELS COGNIT; Iber C, 2007, AASM MANUAL SCORING; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MacDonald S, 2010, BRAIN INJURY, V24, P486, DOI 10.3109/02699050903518118; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Mirescu C, 2006, P NATL ACAD SCI USA, V103, P19170, DOI 10.1073/pnas.0608644103; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Morrell MJ, 2003, SLEEP MED, V4, P451, DOI 10.1016/S1389-9457(03)00159-X; Novati A, 2011, NEUROSCIENCE, V190, P145, DOI 10.1016/j.neuroscience.2011.06.027; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Orban P, 2006, P NATL ACAD SCI USA, V103, P7124, DOI 10.1073/pnas.0510198103; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, ARCH PHYS MED REHAB, V85, P1298, DOI 10.1016/j.apmr.2003.11.036; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Peigneux P, 2004, NEURON, V44, P535, DOI 10.1016/j.neuron.2004.10.007; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Randolph C, 1998, REPEATABLE BATTERY A; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Riemann D, 2007, SLEEP, V30, P955, DOI 10.1093/sleep/30.8.955; ROBERTSON H, 1994, TEST EVERYDAY ATTENT; SAS Institute Inc, 2008, SAS SYST WIND V9 2; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; TEASDALE G, 1974, LANCET, V2, P81; Walker MP, 2005, NEUROSCIENCE, V133, P911, DOI 10.1016/j.neuroscience.2005.04.007; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Wiseman-Hakes C, 2009, CRIT REV PHYS REHABI, V21, P317, DOI DOI 10.1615/CRITREVPHYSREHABILMED.V21.I3-4.70; Wiseman-Hakes C, 2011, BRAIN INJURY, V25, P1256, DOI 10.3109/02699052.2011.608215; World Health Organization, 2001, INT CLASS FUNCT DIS, P299; Zollman FS, 2012, J HEAD TRAUMA REHAB, V27, P135, DOI 10.1097/HTR.0b013e3182051397	60	45	45	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2013	27	12					1364	1376		10.3109/02699052.2013.823663			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	235UF	WOS:000325745500005	24070180	Green Published, Bronze			2021-06-18	
J	Forslund, MV; Roe, C; Sigurdardottir, S; Andelic, N				Forslund, M. V.; Roe, C.; Sigurdardottir, S.; Andelic, N.			Predicting health-related quality of life 2years after moderate-to-severe traumatic brain injury	ACTA NEUROLOGICA SCANDINAVICA			English	Article						traumatic brain injury; health-related quality of life; patient-reported outcome; SF-36; depression	BECK DEPRESSION INVENTORY; HEAD-INJURY; COMMUNITY INTEGRATION; PRACTICAL SCALE; SF-36; POPULATION; QUESTIONNAIRE; INDIVIDUALS; VALIDITY; OUTCOMES	Aims - To describe health-related quality of life (HRQL) 2years after moderate-to-severe traumatic brain injury (TBI) and to assess predictors of HRQL. Materials and methods - A prospective cohort study of 91 patients, aged 16-55years, admitted with moderate-to-severe TBI to a trauma referral centre between 2005 and 2007, with follow-up at 1 and 2years. Mean age was 31.1 (SD=11.3) years, and 77% were men. Injury severity was evaluated by the Glasgow Coma Scale (GCS), head CT scan (using a modified Marshall Classification), Injury Severity Score (ISS) and post-traumatic amnesia (PTA). The Functional Independence Measure (FIM), Community Integration Questionnaire (CIQ), Beck Depression Inventory (BDI) and Medical Outcomes 36-item Short Form Health Survey (SF-36) were administered at follow-up visits. The main outcome measures were the Physical Component Summary (PCS) and Mental Component Summary (MCS) of the SF-36. Results - HRQL appears to be relatively stable between 1 and 2years after injury. In the multivariate linear regression, younger age (=-0.20, P=0.032), more severe TBI (=0.28, P=0.016), more severe overall trauma (=0.22, P=0.026), higher levels of community integration (=0.36, P=0.019) and higher positive change in PCS scores from 1 to 2years (=0.41, P<0.001) predicted better self-reported physical health 2years post-TBI. Lower scores for depression (=-0.70, P<0.001) and a higher positive change in MCS scores (=0.62, P<0.001) predicted better self-reported mental health. Conclusions -Future interventions should focus on aspects related to HRQL that are more easily modified, such as physical functioning, home and social integration, productivity, and mental and emotional status.	[Forslund, M. V.; Roe, C.; Andelic, N.] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0424 Oslo, Norway; [Forslund, M. V.; Roe, C.] Univ Oslo, Fac Med, Oslo, Norway; [Sigurdardottir, S.] Sunnaas Rehabil Hosp Trust, Akershus, Norway	Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, PB 4950 Nydalen, N-0424 Oslo, Norway.	nandelic@online.no		Andelic, Nada/0000-0002-3719-4406	Norwegian Health South-East Authority; Research Council of NorwayResearch Council of Norway	The authors would like to thank all the subjects for their participation. Special thanks to Morten Hestnes for the extraction of trauma scores from the Trauma Register, and Tone Jerstad, neuroradiologist, for the CT assessments. This study was funded by grants from the Norwegian Health South-East Authority and The Research Council of Norway.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Archer T, 2012, ACTA NEUROL SCAND, V125, P293, DOI 10.1111/j.1600-0404.2011.01638.x; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beck A T, 1974, Mod Probl Pharmacopsychiatry, V7, P151; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Friedman B, 2005, J AM GERIATR SOC, V53, P1978, DOI 10.1111/j.1532-5415.2005.00469.x; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Harris IA, 2008, J TRAUMA, V64, P969, DOI 10.1097/01.ta.0000245972.83948.1a; Hu XB, 2012, BRAIN INJURY, V26, P183, DOI 10.3109/02699052.2011.648707; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lasa L, 2000, J AFFECT DISORDERS, V57, P261, DOI 10.1016/S0165-0327(99)00088-9; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Loge JH, 1998, SCAND J SOC MED, V26, P250; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Puljula J, 2013, ACTA NEUROL SCAND, V127, P192, DOI 10.1111/j.1600-0404.2012.01697.x; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TEASDALE G, 1974, LANCET, V2, P81; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Uniform Data System for Medical Rehabilitation, 1996, GUID UN DAT SET MED; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Watson WL, 2007, INJURY PREV, V13, P45, DOI 10.1136/ip.2005.010157; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	37	45	45	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	OCT	2013	128	4					220	227		10.1111/ane.12130			8	Clinical Neurology	Neurosciences & Neurology	213WR	WOS:000324091700003	23621298	Bronze			2021-06-18	
J	Whyte, J; Nordenbo, AM; Kalmar, K; Merges, B; Bagiella, E; Chang, H; Yablon, S; Cho, S; Hammond, F; Khademi, A; Giacino, J				Whyte, John; Nordenbo, Annette M.; Kalmar, Kathleen; Merges, Barbara; Bagiella, Emilia; Chang, Helena; Yablon, Stuart; Cho, Sooja; Hammond, Flora; Khademi, Allen; Giacino, Joseph			Medical Complications During Inpatient Rehabilitation Among Patients With Traumatic Disorders of Consciousness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Autonomic nervous system diseases; Brain injuries; Consciousness disorders; Dyssomnias; Hydrocephalus; Muscle hypertonia; Persistent vegetative state; Pneumonia; Rehabilitation; Urinary tract infections	BRAIN-INJURY; UNAWARENESS; MORTALITY	Objective: To assess the incidence of medical complications in patients with recent traumatic disorders of consciousness (DOCs). Design: Data on adverse events in a placebo controlled trial of amantadine hydrochloride revealed no group difference, which allowed these events to be reanalyzed descriptively as medical complications experienced by the 2 groups collectively. Setting: Eleven clinical facilities in the United States, Denmark, and Germany with specialty rehabilitation programs for patients with DOCs. Participants: Patients (N=184) with nonpenetrating traumatic brain injury enrolled from acute inpatient rehabilitation programs between 4 and 16 weeks postinjury. Interventions: Participants were randomized to receive 200 to 400mg of amantadine hydrochloride or placebo daily for 4 weeks, and followed for an additional 2 weeks. Adverse events were recorded and categorized with respect to their nature, timing, and severity. Main Outcome Measure: Number, type, and severity of medical complications occurring during the 6-week study interval. Results: A total of 468 medical complications were documented among the patients (.40 events per week per patient). More than 80% of patients experienced at least 1 medical complication, and 41 of these were defined as serious adverse events. New medical complications declined over time in rehabilitation and were not dependent on time since injury. Hypertonia, agitation/aggression, urinary tract infection, and sleep disturbance were the most commonly reported problems. Hydrocephalus, pneumonia, gastrointestinal problems, and paroxysmal sympathetic hyperactivity were the most likely to be severe. Conclusions: Patients with DOCs have a high rate of medical complications early after injury. Many of these complications require brain injury expertise for optimal management. Active medical management appears to contribute to the reduction in new complications. An optimal system of care for DOC patients must provide expert medical management in the early weeks after injury. (c) 2013 by the American Congress of Rehabilitation Medicine	[Whyte, John; Cho, Sooja] Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Whyte, John; Cho, Sooja] MossRehab, Elkins Pk, PA 19027 USA; [Nordenbo, Annette M.] Copenhagen Univ Hosp, Traumat Brain Injury Unit, Dept Neurorehabil, Glostrup, Denmark; [Kalmar, Kathleen; Khademi, Allen; Giacino, Joseph] JFK Johnson Rehabil Inst, Edison, NJ USA; [Merges, Barbara] Bryn Mawr Rehab Hosp, Malvern, PA USA; [Bagiella, Emilia; Chang, Helena] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, Ctr Biostat, New York, NY USA; [Yablon, Stuart] Univ Alberta, Div Phys Med & Rehabil, Edmonton, AB, Canada; [Yablon, Stuart] Glenrose Rehabil Hosp, Edmonton, AB, Canada; [Hammond, Flora] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Hammond, Flora] Carolinas Rehabil, Charlotte, NC USA; [Khademi, Allen] Good Shepherd Rehabil Network, Allentown, PA USA; [Giacino, Joseph] Spaulding Rehabil Hosp, Boston, MA USA; [Giacino, Joseph] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	jwhyte@einstein.edu	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698; Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research, United States Department of EducationUS Department of Education [H133A031713]	Supported in part by the National Institute on Disability and Rehabilitation Research (grant no. H133A031713), United States Department of Education.	Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; Denes Z, 2011, INT J REHABIL RES, V34, P222, DOI 10.1097/MRR.0b013e328346e87d; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Giacino JT, 2005, REHABILITATION TRAUM, P305; Gokkaya NKO, 2005, J REHABIL MED, V37, P123, DOI 10.1080/16501970410001096; Hansen TS, 2008, ARCH PHYS MED REHAB, V89, P2114, DOI 10.1016/j.apmr.2008.04.013; Mukand J, 1999, Med Health R I, V82, P19; National Institute of Neurological Disorders and Stroke, 2013, NINDS GLOSS CLIN RES; O'Dell MW, 1998, ARCH PHYS MED REHAB, V79, pS10, DOI 10.1016/S0003-9993(98)90114-9; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Sayer NA, 2009, ARCH PHYS MED REHAB, V89, P163; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SAZBON L, 1991, ACTA NEUROCHIR, V112, P110, DOI 10.1007/BF01405137; SAZBON L, 1991, Brain Injury, V5, P3, DOI 10.3109/02699059108998505; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; U.S. Food and Drug Administration, 2013, MEDWATCH FDA SAF INF	18	45	50	1	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1877	1883		10.1016/j.apmr.2012.12.027			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100005	23735519				2021-06-18	
J	Radford, K; Phillips, J; Drummond, A; Sach, T; Walker, M; Tyerman, A; Haboubi, N; Jones, T				Radford, Kate; Phillips, Julie; Drummond, Avril; Sach, Tracey; Walker, Marion; Tyerman, Andy; Haboubi, Naseer; Jones, Trevor			Return to work after traumatic brain injury: Cohort comparison and economic evaluation	BRAIN INJURY			English	Article						Work; vocational rehabilitation; traumatic brain injury; job retention; community-based rehabilitation; occupational therapy; employment; activities of daily living	VOCATIONAL-REHABILITATION CLIENTS; QUALITY-OF-LIFE; SUPPORTED EMPLOYMENT; HOSPITAL ANXIETY; HEAD-INJURY; FOLLOW-UP; OUTCOMES; MODEL; DISABILITY; PROGRAM	Background: Returning to work (RTW) in the UK is problematic following TBI. Vocational rehabilitation (VR) is limited and efficacy or costs seldom reported. This study aimed to determine whether a TBI specialist VR intervention (TBI VR) was more effective at work return and retention 12 months after injury than usual care (UC). Secondary aims were to explore the feasibility of collecting economic data to inform a definitive trial. Method: Work outcomes of TBI-VR were compared to UC. Ninety-four participants (40 TBI-VR) with TBI resulting in hospitalization >= 48 hours, who were working at injury were followed up by postal questionnaire at 3, 6 and 12 months posthospital discharge. Primary outcome was RTW. Secondary outcomes were functional ability, mood and quality-of-life. Health resource use was measured by self-report. Results: At 12 months, 15% more TBI-VR participants (27% more with moderate/severe TBI) were working than UC (27/36, 75% vs. 27/45, 60%). Mean TBI-VR health costs per person (consultant, GP, therapy, medication) were only 75 pound greater at 1 year. Secondary outcomes showed no significant baseline differences between groups. Discussion: More TBI-VR participants returned to work than UC. People with moderate/severe TBI benefitted most. This positive trend was achieved without greatly increased health costs, suggesting cost-effectiveness. This study justifies the need for and can inform a definitive Randomized Controlled Trial (RCT).	[Radford, Kate; Drummond, Avril; Walker, Marion] Univ Nottingham, Nottingham NG7 2RD, England; [Phillips, Julie] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Sach, Tracey] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England; [Tyerman, Andy] Cambourne Ctr, Aylesbury, Bucks, England; [Haboubi, Naseer] Univ Hosp NHS Trust, Nottingham, England; [Jones, Trevor] Serv User Representat, Nottingham, England	Radford, K (corresponding author), Queens Med Ctr, Div Rehabil & Ageing, Sch Med, B102, Nottingham NG7 2UH, England.	kate.radford@nottingham.ac.uk	Radford, Kate A/F-8571-2013	Radford, Kate A/0000-0001-6246-3180; Sach, Tracey/0000-0002-8098-9220; Walker, Marion/0000-0002-3534-591X; Drummond, Avril/0000-0003-1220-8354	College of Occupational Therapists; Nottingham Traumatic Brain Injury Service; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10092] Funding Source: researchfish	This project was funded by the College of Occupational Therapists. The authors wish to acknowledge the support of the Nottingham Traumatic Brain Injury Service, Professor Nadina Lincoln, Professor of Clinical Psychology and Dr Graham Warren, Medical Statistician for their advice, members of the steering group and principally the participants.	Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; [Anonymous], 2007, BRIT NAT FORM V54; Association of Personal Injury Lawyers, 2008, THINK REH BEST PRACT; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Black DC, 2008, WORKING HLTH TOMORRO; Brazier J, 2004, HEALTH ECON, V13, P873, DOI 10.1002/hec.866; Briggs AH, 1999, HLTH TECHNOLOGY ASSE, V3, P1, DOI DOI 10.3310/hta3020; British Society of Rehabilitation Medicine, 2003, REH FOLL ACQ BRAIN I; Catalano D, 2006, NEUROREHABILITATION, V21, P279; Chamberlain MA, 2007, CLIN MED, V7, P603, DOI 10.7861/clinmedicine.7-6-603; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Department of Health, 2009, NHS REF COSTS 2007 0; Department of Health, 2010, NHS OUTC FRAM 2011 1; Deshpande P, 2004, VOCATIONAL ASSESSMEN; Deutsch PM, 2006, NEUROREHABILITATION, V21, P305; Dolan P., 1995, SOCIAL TARIFF EUROQO; Drummond MF., 1997, METHODS EC EVALUATIO, V2nd; Drummond MF, 2005, METHODS EC EVALUATIO; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Frank AO, 2006, INT J THER REHABIL, V13, P126, DOI 10.12968/ijtr.2006.13.3.21364; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gibson AM, 2011, CLIN REHABIL, V25, P956; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P824, DOI 10.1080/09602010902995945; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Johnstone B, 2006, NEUROREHABILITATION, V21, P335; Kendall E, 2006, J VOCAT REHABIL, V25, P149; Kind P, 1999, 172 U YORK CTR HLTH; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; Malec JF, 2006, BRAIN INJURY, V20, P227, DOI 10.1080/02699050500488124; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; Marsh JM, 2010, CLIN REHABIL, V24, P281; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; Muirhead L., 2008, COMMUNICATION; Murphy L, 2006, BRAIN INJURY, V20, P1119, DOI 10.1080/02699050600664335; National Institute for Health and Clinical Excellence, 2009, GUID MAN; O'Brien L, 2007, BRAIN INJURY, V21, P465, DOI 10.1080/02699050701315134; Office for National Statistics, 2007, ANN SURV HOURS EARN; Office for National Statistics, 2008, STAND OCC CLASS 2000; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paniak C, 2000, BRAIN INJURY, V14, P219; Personal Social Services Research Unit, 2007, UNIT COSTS HLTH SOCI; Phillips J, 2010, BRIT J OCCUP THER, V73, P422, DOI 10.4276/030802210X12839367526138; Playford E., 2011, MAPPING VOCATIONAL R; Possl O, 2001, BRAIN INJURY, V15, P15; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1295, DOI 10.1080/02699050701721802; Relyea-Chew A, 2009, ARCH PHYS MED REHAB, V90, P413, DOI 10.1016/j.apmr.2008.07.031; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; Thompson S, 2001, ANNOTATED COST QUEST; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Turner-Stokes L, 2005, COCHRANE DB SYST REV, V20; Tyerman A, 2004, VOCATIONAL ASSESSMEN; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; van Velzen JM, 2011, DISABIL REHABIL, V33, P2237, DOI 10.3109/09638288.2011.563821; Waddell G., 2008, VOCATIONAL REHABILIT; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	71	45	46	0	41	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2013	27	5					507	520		10.3109/02699052.2013.766929			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	124UK	WOS:000317493000001	23473058				2021-06-18	
J	Hahl, P; Davis, T; Washburn, C; Rogers, JT; Smith, A				Hahl, Peter; Davis, Taron; Washburn, Cecilia; Rogers, Jack T.; Smith, Ann			Mechanisms of neuroprotection by hemopexin: modeling the control of heme and iron homeostasis in brain neurons in inflammatory states	JOURNAL OF NEUROCHEMISTRY			English	Article						APP; heme; hemopexin; iron; neuroprotection; stroke	AMYLOID PRECURSOR PROTEIN; HUMAN-SERUM-ALBUMIN; HYDROGEN-PEROXIDE; 5'-UNTRANSLATED REGION; HYPOCHLOROUS ACID; BINDING PROTEINS; OXYGENASE-1; HEMOGLOBIN; EXPRESSION; TRANSPORT	Hemopexin provides neuroprotection in mouse models of stroke and intracerebral hemorrhage and protects neurons in vitro against heme or reactive oxygen species (ROS) toxicity via heme oxygenase-1 (HO1) activity. To model human brain neurons experiencing hemorrhages and inflammation, we used human neuroblastoma cells, hemehemopexin complexes, and physiologically relevant ROS, for example, H2O2 and HOCl, to provide novel insights into the underlying mechanism whereby hemopexin safely maintains heme and iron homeostasis. Human amyloid precursor protein (hAPP), needed for iron export from neurons, is induced similar to twofold after hemehemopexin endocytosis by iron from heme catabolism via the iron-regulatory element of hAPP mRNA. Hemehemopexin is relatively resistant to damage by ROS and retains its ability to induce the cytoprotective HO1 after exposure to tert-butylhydroperoxide, although induction is impaired, but not eliminated, by exposure to high concentrations of H2O2 in vitro. Apo-hemopexin, which predominates in non-hemolytic states, resists damage by H2O2 and HOCl, except for the highest concentrations likely in vivo. Hemealbumin and albumin are preferential targets for ROS; thus, albumin protects hemopexin in biological fluids like CSF and plasma where it is abundant. These observations provide strong evidence that hemopexin will be neuroprotective after traumatic brain injury, with heme release in the CNS, and during the ensuing inflammation. Hemopexin sequesters heme, thus preventing unregulated heme uptake that leads to toxicity; it safely delivers heme to neuronal cells; and it activates the induction of proteins including HO1 and hAPP that keep heme and iron at safe levels in neurons.	[Hahl, Peter; Davis, Taron; Smith, Ann] Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA; [Washburn, Cecilia; Rogers, Jack T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp East, Neurochem Lab,Dept Psychiat Neurosci, Charlestown, MA USA	Smith, A (corresponding author), Univ Missouri KC, Sch Biol Sci, Div Mol Biol & Biochem, 5007 Rockhill Rd, Kansas City, MO 64110 USA.	smithan@umkc.edu		Rogers, Jack/0000-0003-1262-8578	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH R21DK64363]; University of Missouri Research Board; University of Missouri Kansas City RIF; Alzheimer's Association Zenith AwardAlzheimer's Association; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R21DK064363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS077079] Funding Source: NIH RePORTER	The authors state that there is no conflict of interest. We wish to thank Dr. Clare Hawkins (Heart Research Institute, Newtown, Australia) and Dr. John Dawson (Univ. of South Carolina) for helpful discussions, and Mr. Lee Likins and Dr. S. Simons (UMKC) for their advice with the statistical analyses used. Vinusha Tummala (Department of Psychiatry-Neuroscience, Massachusetts General Hospital) is thanked for her technical help in the initial stages of the APP-IRE regulation studies. The illustration for the "in this issue" is by Joe Moran (UMKC-School of Medicine) and the neuron image is courtesy of the National Institute on Aging/National Institutes of Health. This work was partially supported by the National Institute of Health Grant NIH R21DK64363, the University of Missouri Research Board, and University of Missouri Kansas City RIF (all to A.S.) and an Alzheimer's Association Zenith Award (J.T.R.).	ALAM J, 1989, J BIOL CHEM, V264, P17637; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; Bandyopadhyay S, 2006, J BIOMOL SCREEN, V11, P469, DOI 10.1177/1087057106287271; Bartzokis G, 2000, ARCH GEN PSYCHIAT, V57, P47, DOI 10.1001/archpsyc.57.1.47; BEAVEN GH, 1974, EUR J BIOCHEM, V41, P539, DOI 10.1111/j.1432-1033.1974.tb03295.x; Brenner SR, 2008, NEUROLOGY, V70, P243, DOI 10.1212/01.wnl.0000299721.10189.fe; Buehler PW, 2009, BLOOD, V113, P2578, DOI 10.1182/blood-2008-08-174466; Chen J, 2004, BIOCHEM BIOPH RES CO, V318, P88, DOI 10.1016/j.bbrc.2004.03.187; Chen LF, 2011, J NEUROSURG, V114, P1159, DOI 10.3171/2010.10.JNS10861; Cho HH, 2010, J BIOL CHEM, V285, P31217, DOI 10.1074/jbc.M110.149161; Cordonnier C, 2011, BRAIN, V134, P335, DOI 10.1093/brain/awq321; DAVIES DM, 1979, BIOCHEM BIOPH RES CO, V91, P1504, DOI 10.1016/0006-291X(79)91235-X; Duce JA, 2010, CELL, V142, P857, DOI 10.1016/j.cell.2010.08.014; Eskew JD, 1999, J BIOL CHEM, V274, P638, DOI 10.1074/jbc.274.2.638; Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200; Flaherty MM, 2008, BIOMETALS, V21, P239, DOI 10.1007/s10534-007-9112-9; FLISS H, 1988, MOL CELL BIOCHEM, V84, P177, DOI 10.1007/BF00421053; Gebicka L, 2012, TOXICOL IN VITRO, V26, P924, DOI 10.1016/j.tiv.2012.04.010; Gottlieb Y, 2012, HAEMATOL-HEMATOL J, V97, P1489, DOI 10.3324/haematol.2012.063651; Grinberg LN, 1999, FREE RADICAL BIO MED, V27, P214, DOI 10.1016/S0891-5849(99)00082-9; GUO Y, 1995, J APPL PHYSIOL, V78, P1330; Gupta Shilpi, 2011, Adv Hematol, V2011, P389854, DOI 10.1155/2011/389854; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; Hershko C, 2007, FOOD NUTR BULL, V28, pS500, DOI 10.1177/15648265070284S403; HRKAL Z, 1974, EUR J BIOCHEM, V43, P73, DOI 10.1111/j.1432-1033.1974.tb03386.x; Hunt RC, 1996, J CELL PHYSIOL, V168, P71, DOI 10.1002/(SICI)1097-4652(199607)168:1<71::AID-JCP9>3.0.CO;2-5; Hunt RC, 1996, J CELL PHYSIOL, V168, P81, DOI 10.1002/(SICI)1097-4652(199607)168:1<81::AID-JCP10>3.0.CO;2-S; HUNTER MJ, 1959, J AM CHEM SOC, V81, P1400, DOI 10.1021/ja01515a030; JIANG ZY, 1990, FEBS LETT, V268, P69, DOI 10.1016/0014-5793(90)80974-N; KETTLE AJ, 1994, METHOD ENZYMOL, V233, P502; Larsen R, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001118; Li B, 2012, TOHOKU J EXP MED, V228, P27, DOI 10.1620/tjem.228.27; Li RC, 2009, J CEREBR BLOOD F MET, V29, P953, DOI 10.1038/jcbfm.2009.19; Liang XY, 2009, J LEUKOCYTE BIOL, V86, P229, DOI 10.1189/jlb.1208742; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Lin T, 2012, J IMMUNOL, V189, P2017, DOI 10.4049/jimmunol.1103623; Liu XP, 2001, FREE RADICAL BIO MED, V31, P894, DOI 10.1016/S0891-5849(01)00665-7; McCall MR, 2001, ARTERIOSCL THROM VAS, V21, P1040, DOI 10.1161/01.ATV.21.6.1040; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; MCLACHLAN DRC, 1991, LANCET, V337, P1304, DOI 10.1016/0140-6736(91)92978-B; MORGAN WT, 1976, BIOCHIM BIOPHYS ACTA, V444, P435, DOI 10.1016/0304-4165(76)90387-1; Morgan WT, 2001, ADV INORG CHEM, V51, P205; MORGAN WT, 1972, J BIOL CHEM, V247, P7181; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; Otterbein LE, 2011, P NATL ACAD SCI USA, V108, P14491, DOI 10.1073/pnas.1102295108; PASTERNACK RF, 1983, BIOCHEMISTRY-US, V22, P1753, DOI 10.1021/bi00277a002; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799; Rish KR, 2007, BBA-BIOENERGETICS, V1767, P1107, DOI 10.1016/j.bbabio.2007.06.003; Rogers JT, 2002, J BIOL CHEM, V277, P45518, DOI 10.1074/jbc.M207435200; Schipper HM, 2004, ANN NY ACAD SCI, V1012, P84, DOI 10.1196/annals.1306.007; Schipper HM, 2009, CURR ALZHEIMER RES, V6, P424, DOI 10.2174/156720509789207985; Schipper HM, 2009, J NEUROCHEM, V110, P469, DOI 10.1111/j.1471-4159.2009.06160.x; Schobel S, 2006, INT J DEV NEUROSCI, V24, P141, DOI 10.1016/j.ijdevneu.2005.11.003; Schroder E, 2008, CURR OPIN PHARMACOL, V8, P153, DOI 10.1016/j.coph.2007.12.012; Siesjo BK, 1996, ADV NEUROL, V71, P209; SMITH A, 1979, BIOCHEM J, V182, P47, DOI 10.1042/bj1820047; Smith A, 2011, HANDB PORPHYR SCI, V15, P217; Song W, 2006, J CELL PHYSIOL, V206, P655, DOI 10.1002/jcp.20509; Song W, 2012, J NEUROSCI, V32, P10841, DOI 10.1523/JNEUROSCI.6469-11.2012; Sung L., 2000, IRON CHELATORS NEW D, P67; Takahashi M, 2000, NEURON, V28, P461, DOI 10.1016/S0896-6273(00)00125-2; TEST ST, 1984, J BIOL CHEM, V259, P399; TIMMINS GS, 1995, FREE RADICAL RES, V23, P559, DOI 10.3109/10715769509065277; Tong XK, 2005, J NEUROSCI, V25, P11165, DOI 10.1523/JNEUROSCI.4031-05.2005; Vanacore RM, 2000, ANTIOXID REDOX SIGN, V2, P739, DOI 10.1089/ars.2000.2.4-739; VINCENT SH, 1988, ARCH BIOCHEM BIOPHYS, V265, P539, DOI 10.1016/0003-9861(88)90159-2; WALLEVIK K, 1973, J BIOL CHEM, V248, P2650; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Windsant ICV, 2012, CRIT CARE, V16, DOI 10.1186/cc11359; YOSHINAGA T, 1982, J BIOL CHEM, V257, P7786; Zheng W, 2009, FASEB J, V23, P4207, DOI 10.1096/fj.09-135749	73	45	46	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2013	125	1					89	101		10.1111/jnc.12165			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	112YR	WOS:000316631900010	23350672	Green Accepted			2021-06-18	
J	Wang, X; Dong, Y; Han, X; Qi, XQ; Huang, CG; Hou, LJ				Wang, Xiang; Dong, Yan; Han, Xi; Qi, Xiang-Qian; Huang, Cheng-Guang; Hou, Li-Jun			Nutritional Support for Patients Sustaining Traumatic Brain Injury: A Systematic Review and Meta-Analysis of Prospective Studies	PLOS ONE			English	Article							TOTAL PARENTERAL-NUTRITION; EARLY ENTERAL NUTRITION; IMMUNE-ENHANCING DIET; CONTROLLED-TRIAL; HEAD; HYPERALIMENTATION; SUPPLEMENTATION; GLUTAMINE; BENEFITS; MODERATE	Background: In traumatic brain injury (TBI), the appropriate timing and route of feeding, and the efficacy of immune-enhancing formulae have not been well established. We performed this meta-analysis aiming to compare the effects of different nutritional support modalities on clinical outcomes of TBI patients. Methods: We systematically searched Pubmed, Embase, and the Cochrane Library until October, 2012. All randomized controlled trials (RCTs) and non-randomized prospective studies (NPSs) that compared the effects of different routes, timings, or formulae of feeding on outcomes in TBI patients were selected. The primary outcomes included mortality and poor outcome. The secondary outcomes included the length of hospital stay, the length of ventilation days, and the rate of infectious or feeding-related complications. Findings: 13 RCTs and 3 NPSs were included. The pooled data demonstrated that, compared with delayed feeding, early feeding was associated with a significant reduction in the rate of mortality (relative risk [RR] = 0.35; 95% CI, 0.24-0.50), poor outcome (RR = 0.70; 95% CI, 0.54-0.91), and infectious complications (RR = 0.77; 95% CI, 0.59-0.99). Compared with enteral nutrition, parenteral nutrition showed a slight trend of reduction in the rate of mortality (RR = 0.61; 95% CI, 0.34-1.09), poor outcome (RR = 0.73; 95% CI, 0.51-1.04), and infectious complications (RR = 0.89; 95% CI, 0.66-1.22), whereas without statistical significances. The immune-enhancing formula was associated with a significant reduction in infection rate compared with the standard formula (RR = 0.54; 95% CI, 0.35-0.82). Small-bowel feeding was found to be with a decreasing rate of pneumonia compared with nasogastric feeding (RR = 0.41; 95% CI, 0.22-0.76). Conclusion: After TBI, early initiation of nutrition is recommended. It appears that parenteral nutrition is superior to enteral nutrition in improving outcomes. Our results lend support to the use of small-bowel feeding and immune-enhancing formulae in reducing infectious complications.	[Wang, Xiang; Dong, Yan; Qi, Xiang-Qian; Huang, Cheng-Guang; Hou, Li-Jun] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Dong, Yan] Second Mil Med Univ, Changzheng Hosp, Ctr Neurosci, Shanghai, Peoples R China; [Han, Xi] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200433, Peoples R China	Huang, CG (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.	huang64@163.com; lj_hou@hotmail.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171130/H0908]; Natural Science Foundation from Science and Technology Commission of Shanghai Municipality [11ZR1448700]	This study was supported by Natural Science Foundation of China (81171130/H0908) and Natural Science Foundation from Science and Technology Commission of Shanghai Municipality (11ZR1448700). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta-Escribano J, 2010, INTENS CARE MED, V36, P1532, DOI 10.1007/s00134-010-1908-3; Berg A, 2008, CLIN NUTR, V27, P816, DOI 10.1016/j.clnu.2008.06.006; Bistrian BR, 2011, JPEN-PARENTER ENTER, V35, P556, DOI 10.1177/0148607111416122; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Boselli M, 2012, NUTR CLIN PRACT, V27, P99, DOI 10.1177/0884533611431068; Briassoulis G, 2006, PEDIATR CRIT CARE ME, V7, P56, DOI 10.1097/01.PCC.0000192339.44871.26; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CALON B, 1990, INFUSIONSTHERAPIE, V17, P246; Casaer MP, 2011, NEW ENGL J MED, V365, P506, DOI 10.1056/NEJMoa1102662; Chiang YH, 2012, J NEUROTRAUM, V29, P75, DOI 10.1089/neu.2011.1801; Chourdakis M, 2012, JPEN-PARENTER ENTER, V36, P108, DOI 10.1177/0148607110397878; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; Cook AM, 2008, NUTR CLIN PRACT, V23, P608, DOI 10.1177/0884533608326060; de Arruda ISF, 2004, CLIN SCI, V106, P287, DOI 10.1042/CS20030251; Dhandapani Sivashanmugam, 2012, Surg Neurol Int, V3, P31, DOI 10.4103/2152-7806.93858; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Foley N, 2008, J NEUROTRAUM, V25, P1415, DOI 10.1089/neu.2008.0628; GADISSEUX P, 1984, J NEUROSURG, V60, P219, DOI 10.3171/jns.1984.60.2.0219; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; Griffiths RD, 2006, LANCET, V368, P1868, DOI 10.1016/S0140-6736(06)69771-7; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; HAUSMANN D, 1985, INTENS CARE MED, V11, P80; Heidegger CP, 2013, LANCET, V381, P385, DOI 10.1016/S0140-6736(12)61351-8; Higgins JP, 2008, COCHRANE HDB SYSTEMA; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Meirelles CMJ, 2011, NUTR HOSP, V26, P1120, DOI [10.3305/nh.2011.26.5.5133, 10.1590/S0212-16112011000500030]; Khorana Jiraporn, 2009, Journal of the Medical Association of Thailand, V92, P188; Kostadima E, 2005, EUR RESPIR J, V26, P106, DOI 10.1183/09031936.05.00096104; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Maurya I, 2011, SAUDI J ANAESTH, V5, P195, DOI 10.4103/1658-354X.82800; Minard G, 2000, JPEN-PARENTER ENTER, V24, P145, DOI 10.1177/0148607100024003145; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Nataloni S, 1999, CLIN NUTR, V18, P247, DOI 10.1016/S0261-5614(99)80077-6; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; Suchner U, 1996, NUTRITION, V12, P13, DOI 10.1016/0899-9007(95)00016-X; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; TWYMAN D, 1985, JPEN-PARENTER ENTER, V9, P679, DOI 10.1177/0148607185009006679; Vincent JL, 2013, LANCET, V381, P354, DOI 10.1016/S0140-6736(12)61893-5; Vizzini A, 2011, NUTRITION, V27, P129, DOI 10.1016/j.nut.2010.05.004; Wells G, 2009, NEWCASTLE OTTAWA SCA; Worthington ML, 2011, NUTR CLIN PRACT, V26, P650, DOI 10.1177/0884533611425799; YOUNG B, 1987, J NEUROSURG, V67, P76, DOI 10.3171/jns.1987.67.1.0076; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668; Zaloga GP, 2006, LANCET, V367, P1101, DOI 10.1016/S0140-6736(06)68307-4; Ziegler TR, 2009, NEW ENGL J MED, V361, P1088, DOI 10.1056/NEJMct0806956	51	45	56	0	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2013	8	3							e58838	10.1371/journal.pone.0058838			14	Multidisciplinary Sciences	Science & Technology - Other Topics	125SR	WOS:000317562100050	23527035	DOAJ Gold, Green Published			2021-06-18	
J	Kim, JH; Jang, BG; Choi, BY; Kim, HS; Sohn, M; Chung, TN; Choi, HC; Song, HK; Suh, SW				Kim, Jin Hee; Jang, Bong Geom; Choi, Bo Young; Kim, Hyeong Seop; Sohn, Min; Chung, Tae Nyoung; Choi, Hui Chul; Song, Hong Ki; Suh, Sang Won			Post-treatment of an NADPH oxidase inhibitor prevents seizure-induced neuronal death	BRAIN RESEARCH			English	Article						Temporal lobe epilepsy; Seizure; NADPH oxidase; Reactive oxygen species; Blood brain barrier; Neurodegeneration; Microglia; Neurotrophil infiltration	TEMPORAL-LOBE EPILEPSY; PILOCARPINE-INDUCED SEIZURES; OXIDATIVE STRESS; STATUS EPILEPTICUS; MICROGLIAL ACTIVATION; CEREBRAL-ISCHEMIA; NITRIC-OXIDE; CELL-DEATH; RATS; SUPEROXIDE	The present study sought to evaluate the neuroprotective effects of apocynin, an NADPH oxidase assembly inhibitor, on seizure-induced neuronal death. Apocynin, also known as acetovanillone, is a natural organic compound isolated from the root of Canadian hemp (Apocynum cannabium). It has been extensively studied to determine its disease-fighting capabilities and application in several brain insults, such as traumatic brain injury and stroke. Here we tested the hypothesis that post-treatment of apocynin may prevent seizure-induced neuronal death by suppression of NADPH oxidase-mediated superoxide production. Temporal lobe epilepsy (TLE) was induced by intraperitoneal injection of pilocarpine (25 mg/kg) in male rats. Apocynin (30 mg/kg, i.p.) was injected into the intraperitoneal space two hours after seizure onset. A second injection was performed 24 h after seizure. To test whether apocynin inhibits NADPH oxidase activation-induced reactive oxygen species (ROS) production, dihydroethidium (dHEt, 5 mg/kg, i.p.) was injected before onset of seizure and ROS production was detected five hours after seizure onset. Neuronal oxidative injury (4HNE), neuronal death (Fluoro Jade-B), blood brain barrier (BBB) disruption (IgG leak), neurotrophil infiltration (MPO) and microglia activation (CD11b) in the hippocampus was evaluated at three days after status epilepticus (SE). Pilocarpine-induced seizure increased p47 immunofluorescence in the plasma membrane of hippocampal neurons at 12 h post-insult and apocynin treatment prevented this increase. The present study found that apocynin post-treatment decreased ROS production and lipid peroxidation after seizure and decreased the number of degenerating hippocampal neurons. Apocynin also reduced seizure-induced BBB disruption, neurotrophil infiltration and microglial activation. Taken together, the present results suggest that inhibition of NADPH oxidase by apocynin may have a high therapeutic potential to reduce seizure-induced neuronal dysfunction. (C) 2013 Elsevier B.V. All rights reserved.	[Kim, Jin Hee; Jang, Bong Geom; Choi, Bo Young; Kim, Hyeong Seop; Suh, Sang Won] Hallym Univ, Coll Med, Dept Physiol, Chunchon 200702, South Korea; [Sohn, Min] Inha Univ, Dept Nursing, Inchon, South Korea; [Chung, Tae Nyoung] CHA Univ, Sch Med, CHA Bundang Med Ctr, Gyeonggi Do, South Korea; [Choi, Hui Chul; Song, Hong Ki] Hallym Univ, Hallym Inst Epelepsy Res, Chunchon 200702, South Korea	Song, HK (corresponding author), Hallym Univ, Hallym Inst Epelepsy Res, Chunchon 200702, South Korea.	hksong0@paran.com; swsuh@hallym.ac.kr	Chung, Tae Nyoung/AAN-7886-2020	Chung, Tae Nyoung/0000-0003-3537-4136; SOHN, MIN/0000-0003-4021-2051; Choi, Bo Young/0000-0002-9579-3503	Hallym University Specialization Fund [HRF-S-41]	This study was supported by a grant from the Hallym University Specialization Fund (HRF-S-41). The authors thank Aaron M. Hamby, University of California, Berkeley, for help with preparing the manuscript.	Ashrafi MR, 2007, EPILEPSIA, V48, P1750, DOI 10.1111/j.1528-1167.2007.01143.x; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Cai AL, 2006, EUR J NEUROSCI, V24, P2169, DOI 10.1111/j.1460-9568.2006.05110.x; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Chang YC, 2003, ANN NEUROL, V54, P706, DOI 10.1002/ana.10789; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Dodd-O JM, 2000, AM J PHYSIOL-HEART C, V279, pH303; Frantseva MV, 2000, NEUROSCIENCE, V97, P431, DOI 10.1016/S0306-4522(00)00041-5; Freitas RM, 2005, FEBS J, V272, P1307, DOI 10.1111/j.1742-4658.2004.04537.x; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Holmes GL, 1998, ANN NEUROL, V44, P845, DOI 10.1002/ana.410440602; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Inamasu J, 2000, ACT NEUR S, V76, P525; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Liu JZ, 2010, SEIZURE-EUR J EPILEP, V19, P165, DOI 10.1016/j.seizure.2010.01.010; de Freitas RLM, 2010, BRAIN RES BULL, V81, P505, DOI 10.1016/j.brainresbull.2009.09.014; Muller CJ, 2009, EUR J PHARMACOL, V619, P15, DOI 10.1016/j.ejphar.2009.07.020; Murakami K, 1998, J NEUROSCI, V18, P205; Nairismagi J, 2006, EPILEPSIA, V47, P479, DOI 10.1111/j.1528-1167.2006.00455.x; Olney J W, 1986, Adv Neurol, V44, P857; Patel M, 2005, J NEUROCHEM, V92, P123, DOI 10.1111/j.1471-4159.2004.02838.x; PERSINGER MA, 1988, PHYSIOL BEHAV, V44, P27, DOI 10.1016/0031-9384(88)90342-3; Pestana RRF, 2010, NEUROSCI LETT, V484, P187, DOI 10.1016/j.neulet.2010.08.049; RACINE RJ, 1972, BRAIN RES, V47, P262, DOI 10.1016/0006-8993(72)90268-5; Ravizza T, 2008, NEUROBIOL DIS, V29, P142, DOI 10.1016/j.nbd.2007.08.012; Rigau V, 2007, BRAIN, V130, P1942, DOI 10.1093/brain/awm118; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; ROGERS SW, 1994, SCIENCE, V265, P648, DOI 10.1126/science.8036512; RUTH RE, 1988, ACTA NEUROPATHOL, V76, P380, DOI 10.1007/BF00686975; Shapiro LA, 2008, EPILEPSIA, V49, P33, DOI 10.1111/j.1528-1167.2008.01491.x; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; STOLK J, 1994, AM J RESP CELL MOL, V11, P95, DOI 10.1165/ajrcmb.11.1.8018341; Suh SW, 2008, J CEREBR BLOOD F MET, V28, P1697, DOI 10.1038/jcbfm.2008.61; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511; Tang XN, 2008, NEUROSCIENCE, V154, P556, DOI 10.1016/j.neuroscience.2008.03.090; Tejada-Simon MV, 2005, MOL CELL NEUROSCI, V29, P97, DOI 10.1016/j.mcn.2005.01.007; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5	43	45	45	0	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 7	2013	1499						163	172		10.1016/j.brainres.2013.01.007			10	Neurosciences	Neurosciences & Neurology	113ZX	WOS:000316710300016	23313582				2021-06-18	
J	Anglin, CO; Spence, JS; Warner, MA; Paliotta, C; Harper, C; Moore, C; Sarode, R; Madden, C; Diaz-Arrastia, R				Anglin, Catherine O.; Spence, Jeffrey S.; Warner, Matthew A.; Paliotta, Christopher; Harper, Caryn; Moore, Carol; Sarode, Ravi; Madden, Christopher; Diaz-Arrastia, Ramon			Effects of platelet and plasma transfusion on outcome in traumatic brain injury patients with moderate bleeding diatheses	JOURNAL OF NEUROSURGERY			English	Article						transfusion; traumatic brain injury; platelet; fresh frozen plasma; Glasgow Outcome Scale-Extended	FRESH-FROZEN PLASMA; FUNCTIONAL STATUS EXAMINATION; CLOSED-HEAD INJURY; INTRAVASCULAR COAGULATION; COAGULOPATHY; ANEMIA; MORTALITY; SCALE	Object. Coagulopathy and thrombocytopenia are common after traumatic brain injury (TBI), yet transfusion thresholds for mildly to moderately abnormal ranges of international normalized ratio and platelet count remain controversial. This study evaluates associations between fresh frozen plasma (FFP) and platelet transfusions with long-term functional outcome and survival in TBI patients with moderate hemostatic laboratory abnormalities. Methods. This study is a retrospective review of prospectively collected data of patients with mild to severe TBI. Data include patient demographics, several initial injury severity metrics, daily laboratory values, Glasgow Outcome Score-Extended (GOSE) scores, Functional Status Examination (FSE) scores, and survival to 6 months. Correlations were evaluated between these variables and transfusion of FIT, platelets, packed red blood cells (RBCs), cryoprecipitate, recombinant factor VIIa, and albumin. Ordinal regression was performed to account for potential confounding variables to further define relationships between transfusion status and long-term outcome. By analyzing collected data, mild to moderate coagulopathy was defined as an international normalized ratio 1.4-2.0, moderate thrombocytopenia as platelet count 50 x 10(9)/L to 107 x 10(9)/L, and moderate anemia as 21%-30% hematocrit. Results. In patients with mild to moderate laboratory hematological abnormalities, univariate analysis shows significant correlations between poor outcome scores and FFP, platelet, or packed RBC transfusion; the volume of FFP or packed RBCs transfused also correlated with poor outcome. Several measures of initial injury and laboratory abnormalities also correlated with poor outcome. Patient age, initial Glasgow Coma Scale score, and highest recorded serum sodium were included in the ordinal regression model using backward variable selection. In the moderate coagulopathy subgroup, patients transfused with FIT were more likely to have a lower GOSE score relative to those who did not receive a transfusion (OR 5.20 [95% CI 1.72-15.73]). Patients with moderate coagulopathy who received FFP and packed RBCs were even more likely to be have a lower GOSE score (OR 7.17 [95% CI 2.12-24.12]). Moderately anemic patients who received packed RBCs alone were more likely to have a worse long-term functional outcome as determined by GOSE and FSE scores (GOSE: OR 2.41 [95% CI 1.51-3.85]; and FSE: OR 3.27 [95% CI 2.00-5.35]). No transfusion types or combinations were noted to significantly correlate with the 6-month mortality in ordinal regression. Conclusions. In TBI patients with moderate coagulopathy, FFP transfusions alone or a combination of FFP and packed RBCs were associated with poorer long-term functional outcomes as measured by the GOSE. Red blood cell transfusions were associated with poor long-term functional outcome in TBI patients with moderate anemia. Platelet transfusion in patients with moderate thrombocytopenia was not significantly associated with outcome. Although transfusion is beneficial to many patients with severe hematological abnormalities, it is not without risk, and the indications for transfusion should be carefully considered in patients with moderate hematological abnormalities. (http://thejns.org/doi/abs/10.3171/2012.11.JNS12622)	[Anglin, Catherine O.; Warner, Matthew A.; Paliotta, Christopher; Harper, Caryn; Moore, Carol; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Neurol, Dallas, TX 75390 USA; [Spence, Jeffrey S.] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Clin Sci & Internal Med, Dallas, TX 75390 USA; [Madden, Christopher] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Neurol Surg, Dallas, TX 75390 USA; [Sarode, Ravi] Univ Texas SW Med Ctr Dallas, Parkland Mem Hosp, Dept Pathol, Dallas, TX 75390 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Diaz-Arrastia, R (corresponding author), Uniformed Serv Univ Hlth Sci, 12725 Twinbrook Pkwy, Rockville, MD 20851 USA.	Ramon.Diaz-Arrastia@USUHS.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	Clinical Research Fellowship through the Doris Duke Charitable Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD48179, U01 HD42652]; National Institute on Disability and Rehabilitation Research (NIDRR) [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	This study was supported by a Clinical Research Fellowship through the Doris Duke Charitable Foundation to Ms Anglin and Dr. Warner, and by support from the NIH (Grant Nos. R01 HD48179, U01 HD42652) and the National Institute on Disability and Rehabilitation Research (NIDRR) (Grant No. H133 A020526) to Dr. Diaz-Arrastia.	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Bostrom K, 1986, Acta Neurochir Suppl (Wien), V36, P51; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Duane TM, 2008, J SURG RES, V147, P163, DOI 10.1016/j.jss.2008.02.044; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; George ME, 2008, NEUROCRIT CARE, V8, P337, DOI 10.1007/s12028-008-9066-y; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Ozier Y, 2008, TRANSFUS CLIN BIOL, V15, P240, DOI 10.1016/j.tracli.2008.09.010; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Shariff MM, 2007, JCPSP-J COLL PHYSICI, V17, P207; Stainsby D, 2006, TRANSFUS MED REV, V20, P273, DOI 10.1016/j.tmrv.2006.05.002; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Triulzi DJ, 2009, ANESTH ANALG, V108, P770, DOI 10.1213/ane.0b013e31819029b2; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	26	45	47	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	2013	118	3					676	686		10.3171/2012.11.JNS12622			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	094DW	WOS:000315244200032	23259827				2021-06-18	
J	Davis, JJ; Walter, KH; Chard, KM; Parkinson, RB; Houston, WS				Davis, Jeremy J.; Walter, Kristen H.; Chard, Kathleen M.; Parkinson, R. Bruce; Houston, Wes S.			Treatment Adherence in Cognitive Processing Therapy for Combat-Related PTSD With History of Mild TBI	REHABILITATION PSYCHOLOGY			English	Article						posttraumatic stress disorder; mild traumatic brain injury; cognitive processing therapy; veterans	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SELF-REPORTED SYMPTOMS; POSTCONCUSSIVE SYMPTOMS; VETERANS; REHABILITATION; AFGHANISTAN; DIAGNOSIS; FOOTBALL; EXPOSURE	Objective: This retrospective study examined treatment adherence in Cognitive Processing Therapy (CPT) for combat-related posttraumatic stress disorder (PTSD) in Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF) with and without history of mild traumatic brain injury (mTBI). Method: Medical record review of consecutive referrals to an outpatient PTSD clinic identified veterans diagnosed with combat-related PTSD who began treatment with CPT. The sample (N = 136) was grouped according to positive (n = 44) and negative (n = 92) mTBI history. Groups were compared in terms of presenting symptoms and treatment adherence. Results: The groups were not different on a pretreatment measure of depression, but self-reported and clinician-rated PTSD symptoms were higher in veterans with history of mTBI. The treatment completion rate was greater than 61% in both groups. The number of sessions attended averaged 9.6 for the PTSD group and 7.9 for the mTBI/PTSD group (p = .05). Implications: Given the lack of marked group differences in treatment adherence, these initial findings suggest that standard CPT for PTSD may be a tolerable treatment for OEF/OIF veterans with a history of PTSD and mTBI as well as veterans with PTSD alone.	[Davis, Jeremy J.; Parkinson, R. Bruce; Houston, Wes S.] Cincinnati VA Med Ctr, Mental Hlth Care Line, Cincinnati, OH USA; [Davis, Jeremy J.] Univ Utah, Sch Med, Div Phys Med & Rehabil, Salt Lake City, UT 84112 USA; [Walter, Kristen H.] Cincinnati VA Med Ctr, Trauma Recovery Ctr, Cincinnati, OH USA; [Chard, Kathleen M.] Univ Cincinnati, Sch Med, Cincinnati VA Med Ctr, Trauma Recovery Ctr, Cincinnati, OH 45221 USA; [Chard, Kathleen M.] Univ Cincinnati, Sch Med, Dept Psychiat, Cincinnati, OH 45221 USA	Chard, KM (corresponding author), 3200 Vine St, Cincinnati, OH 45220 USA.	kathleen.chard@va.gov	Walter, Kristen H/S-1827-2019				American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLANCHARD EB, 1995, BEHAV RES THER, V33, P471, DOI 10.1016/0005-7967(94)00064-Q; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chard KM, 2011, J TRAUMA STRESS, V24, P347, DOI 10.1002/jts.20644; Chard KM, 2010, J TRAUMA STRESS, V23, P25, DOI 10.1002/jts.20500; Chard KM, 2005, J CONSULT CLIN PSYCH, V73, P965, DOI 10.1037/0022-006X.73.5.965; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Department of Defence Task Force on Mental Health, 2007, ACH VIS REP DEP DEF; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Foa E.B., 2008, EFFECTIVE TREATMENTS; Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Garden N, 2010, NEUROPSYCHOLOGY, V24, P168, DOI 10.1037/a0017431; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meyers JE, 2004, ARCH CLIN NEUROPSYCH, V19, P637, DOI 10.1016/j.acn.2003.08.007; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Resick P. A, 2007, COGNITIVE PROCESSING; Resick PA, 2002, J CONSULT CLIN PSYCH, V70, P867, DOI 10.1037//0022-006X.70.4.867; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Soo C, 2007, COCHRANE DB SYST REV, V3; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; *VET HLTH ADM DEP, 2004, VA DOD CLIN PRACT GU; Veterans Health Administration, 2007, SCREEN EV POSS TRAUM; Veterans Health Administration, 2005, IMPL NAT CLIN REM AF; Veterans Health Administration & Department of Defense, 2009, VA DOD CLIN PRACT GU; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Williams W H, 2003, Cogn Neuropsychiatry, V8, P1, DOI 10.1080/713752238	63	45	45	0	23	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	FEB	2013	58	1					36	42		10.1037/a0031525			7	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	095VA	WOS:000315361900005	23437998				2021-06-18	
J	Maggio, N; Cavaliere, C; Papa, M; Blatt, I; Chapman, J; Segal, M				Maggio, Nicola; Cavaliere, Carlo; Papa, Michele; Blatt, Ilan; Chapman, Joab; Segal, Menahem			Thrombin regulation of synaptic transmission: Implications for seizure onset	NEUROBIOLOGY OF DISEASE			English	Article						Thrombin; Seizures; Epilepsy; Inhibition; Hemorrhage; Hippocampus	PROTEASE-ACTIVATED RECEPTOR-1; CORTICOSTEROID MODULATION; STATUS EPILEPTICUS; MESSENGER-RNA; CELL-DEATH; EXPRESSION; BRAIN; PROTHROMBIN; EPILEPSY; NEURODEGENERATION	Seizures are a common outcome of cerebrovascular events as well as of traumatic brain injuries. Thrombin, a protease-activated receptor (PAR) agonist, has been implicated in the onset of seizures in these settings, yet its mode of action is not entirely clear. In this study, the effect of thrombin and a PAR-1 agonist on neuronal excitability and synaptic currents was assessed by whole cell-patch recordings of pyramidal neurons in rat hippocampal slices. In addition, PAR-1 distribution in different hippocampal regions was assessed using immunohistochemistry. We found that thrombin caused an increase in spontaneous action potential discharges of CA3 but not of CA1 pyramidal neurons. When excitatory synaptic activity was blocked, thrombin caused a marked reduction in spontaneous IPSCs in CA3 neurons and a marked increase in the frequency of IPSCs in CA1 neurons. These effects are likely to be local, as they were reproduced in TTX-treated slices. In parallel, thrombin increased both the frequency and the amplitude of mEPSCs only in CA3 neurons. These effects were blocked by a selective PAR-1 antagonist. The higher expression of PAR-1 in stratum lucidum of CA3 is correlated with the effects of thrombin in this region. These results suggest that thrombin triggers the generation of epileptic seizures by reducing the inhibitory and increasing the excitatory tone in CA3 neurons, providing a novel insight to the pathophysiology of seizures following cerebrovascular events and present new avenues for therapeutic intervention. (C) 2012 Elsevier Inc. All rights reserved.	[Maggio, Nicola] Chaim Sheba Med Ctr, Talpiot Med Leadership Program, IL-52621 Tel Hashomer, Israel; [Maggio, Nicola; Blatt, Ilan; Chapman, Joab] Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel; [Maggio, Nicola; Blatt, Ilan; Chapman, Joab] Chaim Sheba Med Ctr, Joseph Sagol Neurosci Ctr, IL-52621 Tel Hashomer, Israel; [Maggio, Nicola; Segal, Menahem] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; [Cavaliere, Carlo; Papa, Michele] Univ Naples 2, Dipartimento Med Pubbl Clin & Preventiva, Lab Morphol Neuronal Networks, I-80138 Naples, Italy; [Chapman, Joab] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; [Blatt, Ilan; Chapman, Joab] Tel Aviv Univ, Sackler Fac Med, Dept Neurol, IL-69978 Tel Aviv, Israel	Maggio, N (corresponding author), Chaim Sheba Med Ctr, Dept Neurol, IL-52621 Tel Hashomer, Israel.	nicola.maggio@sheba.health.gov.il	Papa, Michele/A-7228-2017; Chapman, Joab/E-4598-2010; Cavaliere, Carlo/AAA-7116-2021; Papa, Michele/AAB-1759-2021; Cavaliere, Carlo/K-6544-2016; SEGAL, MENAHEM/K-1577-2012	Papa, Michele/0000-0003-4834-7970; Cavaliere, Carlo/0000-0002-3297-2213; Papa, Michele/0000-0002-6609-7453; Cavaliere, Carlo/0000-0002-3297-2213; Maggio, Nicola/0000-0001-5041-2108	Sheba Medical Center	NM is the recipient of a Talpiot Fellowship at the Sheba Medical Center. The funding agency did not have a role in study design: collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Arai T, 2006, J NEUROPATH EXP NEUR, V65, P19, DOI 10.1097/01.jnen.0000196133.74087.cb; Atkinson L, 2004, NEUROSCIENCE, V123, P761, DOI 10.1016/j.neuroscience.2003.08.065; Camilo O, 2004, STROKE, V35, P1769, DOI 10.1161/01.STR.0000130989.17100.96; Cavaliere C, 2007, NEURON GLIA BIOL, V3, P141, DOI 10.1017/S1740925X07000695; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2007, NEUROSURGERY, V61, P60, DOI 10.1227/01.neu.0000279724.05898.e7; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; FRENCH CR, 1990, J GEN PHYSIOL, V95, P1139, DOI 10.1085/jgp.95.6.1139; Gilmore E, 2010, NEUROLOGIST, V16, P165, DOI 10.1097/NRL.0b013e3181c7cd0b; Gingrich MB, 2000, J NEUROSCI, V20, P4582, DOI 10.1523/JNEUROSCI.20-12-04582.2000; Hashimotodani Y, 2011, J NEUROSCI, V31, P3104, DOI 10.1523/JNEUROSCI.6000-10.2011; Heinemann U, 2004, CURR OPIN NEUROL, V17, P155, DOI 10.1097/00019052-200404000-00012; Heinemann U, 2002, PROG BRAIN RES, V135, P197; Isaeva E, 2012, ANN NEUROL; Junge CE, 2004, EXP NEUROL, V188, P94, DOI 10.1016/j.expneurol.2004.02.018; Lee CJ, 2007, J PHYSIOL-LONDON, V581, P1057, DOI 10.1113/jphysiol.2007.130377; Lee DY, 2006, BIOCHEM BIOPH RES CO, V346, P727, DOI 10.1016/j.bbrc.2006.05.174; Lee KR, 1997, J NEUROSURG, V87, P73, DOI 10.3171/jns.1997.87.1.0073; Lossius MI, 2005, EPILEPSIA, V46, P1246, DOI 10.1111/j.1528-1167.2005.57904.x; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Luo W, 2007, BRAIN RES REV, V56, P331, DOI 10.1016/j.brainresrev.2007.08.002; Maggio N, 2008, J NEUROSCI, V28, P732, DOI 10.1523/JNEUROSCI.3665-07.2008; Maggio N, 2012, EXP NEUROL, V234, P200, DOI 10.1016/j.expneurol.2011.12.035; Maggio N, 2009, J NEUROSCI, V29, P2857, DOI 10.1523/JNEUROSCI.4399-08.2009; Olsen T S, 2001, Curr Atheroscler Rep, V3, P340, DOI 10.1007/s11883-001-0029-4; Papa M, 2003, J COMP NEUROL, V466, P119, DOI 10.1002/cne.10886; Shavit E, 2011, J NEUROCHEM, V119, P460, DOI 10.1111/j.1471-4159.2011.07436.x; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Wang YF, 2006, J NEUROCHEM, V98, P1046, DOI 10.1111/j.1471-4159.2006.03950.x; WEINSTEIN JR, 1995, J NEUROSCI, V15, P2906; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257	32	45	45	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2013	50						171	178		10.1016/j.nbd.2012.10.017			8	Neurosciences	Neurosciences & Neurology	073QR	WOS:000313758100019	23103417				2021-06-18	
J	Lee, DJ; Gurkoff, GG; Izadi, A; Berman, RF; Ekstrom, AD; Muizelaar, JP; Lyeth, BG; Shahlaie, K				Lee, Darrin J.; Gurkoff, Gene G.; Izadi, Ali; Berman, Robert F.; Ekstrom, Arne D.; Muizelaar, J. Paul; Lyeth, Bruce G.; Shahlaie, Kiarash			Medial Septal Nucleus Theta Frequency Deep Brain Stimulation Improves Spatial Working Memory after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						deep brain stimulation; hippocampus; medial septal nucleus; TBI; theta oscillations	LATERAL FLUID-PERCUSSION; GAMMA OSCILLATIONS; IN-VIVO; HIPPOCAMPAL; RHYTHM; RAT; DYSFUNCTION; MODERATE; NEURONS; MILD	More than 5,000,000 survivors of traumatic brain injury (TBI) live with persistent cognitive deficits, some of which likely derive from hippocampal dysfunction. Oscillatory activity in the hippocampus is critical for normal learning and memory functions, and can be modulated using deep brain stimulation techniques. In this pre-clinical study, we demonstrate that lateral fluid percussion TBI results in the attenuation of hippocampal theta oscillations in the first 6 days after injury, which correlate with deficits in the Barnes maze spatial working memory task. Theta band stimulation of the medial septal nucleus (MSN) results in a transient increase in hippocampal theta activity, and when delivered 1 min prior to training in the Barnes maze, it significantly improves spatial working memory. These results suggest that MSN theta stimulation may be an effective neuromodulatory technique for treatment of persistent learning and memory deficits after TBI.	[Lee, Darrin J.; Gurkoff, Gene G.; Izadi, Ali; Berman, Robert F.; Muizelaar, J. Paul; Lyeth, Bruce G.; Shahlaie, Kiarash] UC Davis Sch Med, Dept Neurol Surg, Sacramento, CA 95817 USA; [Ekstrom, Arne D.] Univ Calif Davis, Davis Sch Med, Dept Psychol, Sacramento, CA 95817 USA	Shahlaie, K (corresponding author), UC Davis Sch Med, Dept Neurol Surg, 4860 Y 0St,Suite 3740, Sacramento, CA 95817 USA.	kiarash.shahlaie@ucdmc.ucdavis.edu	Ekstrom, Arne/A-1329-2013	Ekstrom, Arne/0000-0002-6812-2368; Lyeth, Bruce/0000-0003-4811-1474	Bronte Epilepsy Research Foundation; UC Davis Health System National Board of Advisors	This project was supported by the Bronte Epilepsy Research Foundation, and a "Vision Grant" from the UC Davis Health System National Board of Advisors. We thank Angela Echeverri, Mikhail Melnik, Rebecca Wong, and Heather McConnell for their expert technical assistance.	Addante RJ, 2011, P NATL ACAD SCI USA, V108, P10702, DOI 10.1073/pnas.1014528108; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Belluscio MA, 2012, J NEUROSCI, V32, P423, DOI 10.1523/JNEUROSCI.4122-11.2012; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; COLOM LV, 1988, BRAIN RES, V460, P329, DOI 10.1016/0006-8993(88)90377-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Darling RD, 2011, J NEUROPHYSIOL, V105, P2213, DOI 10.1152/jn.00801.2010; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eakin K, 2012, J NEUROTRAUM, V29, P1180, DOI 10.1089/neu.2011.2192; Ekstrom AD, 2005, HIPPOCAMPUS, V15, P881, DOI 10.1002/hipo.20109; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GREEN JD, 1954, J NEUROPHYSIOL, V17, P533; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Igarashi J, 2007, COGN NEURODYNAMICS, V1, P169, DOI 10.1007/s11571-006-9003-8; Jacobs J, 2009, J NEUROSCI, V29, P10203, DOI 10.1523/JNEUROSCI.2187-09.2009; Jensen O, 1996, LEARN MEMORY, V3, P279, DOI 10.1101/lm.3.2-3.279; Kocsis B, 1997, HIPPOCAMPUS, V7, P204, DOI 10.1002/(SICI)1098-1063(1997)7:2<204::AID-HIPO7>3.0.CO;2-M; LANDFIELD PW, 1972, SCIENCE, V175, P87, DOI 10.1126/science.175.4017.87; LAWSON VH, 1993, EXP NEUROL, V120, P132, DOI 10.1006/exnr.1993.1047; Laxton AW, 2010, ANN NEUROL, V68, P521, DOI 10.1002/ana.22089; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lundqvist M, 2011, J COGNITIVE NEUROSCI, V23, P3008, DOI 10.1162/jocn_a_00029; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCNAUGHTON BL, 1977, J COMP NEUROL, V175, P439, DOI 10.1002/cne.901750404; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; MIZUMORI SJY, 1990, BRAIN RES, V528, P12, DOI 10.1016/0006-8993(90)90188-H; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nyhus E, 2010, NEUROSCI BIOBEHAV R, V34, P1023, DOI 10.1016/j.neubiorev.2009.12.014; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Raghavachari S, 2001, J NEUROSCI, V21, P3175, DOI 10.1523/JNEUROSCI.21-09-03175.2001; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Sederberg PB, 2003, J NEUROSCI, V23, P10809; Shin SS, 2011, BRAIN RES, V1369, P208, DOI 10.1016/j.brainres.2010.10.096; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Suthana N, 2012, NEW ENGL J MED, V366, P502, DOI 10.1056/NEJMoa1107212; Takahashi M, 2009, COGN NEURODYNAMICS, V3, P165, DOI 10.1007/s11571-009-9081-5; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; Vertes RP, 2005, HIPPOCAMPUS, V15, P923, DOI 10.1002/hipo.20118; Vertes RP, 2001, NEUROSCIENCE, V104, P619, DOI 10.1016/S0306-4522(01)00131-2; Vertes RP, 1997, NEUROSCIENCE, V81, P893; Wang XJ, 2002, J NEUROPHYSIOL, V87, P889, DOI 10.1152/jn.00135.2001; WINSON J, 1974, ELECTROEN CLIN NEURO, V36, P291, DOI 10.1016/0013-4694(74)90171-0; Yamamoto T, 2005, ACTA NEUROCHIR SUPPL, V93, P101; Yamamoto T, 2005, NEUROPSYCHOL REHABIL, V15, P406, DOI 10.1080/09602010443000353	56	45	45	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					131	139		10.1089/neu.2012.2646			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000008	23016534				2021-06-18	
J	Kamnaksh, A; Kwon, SK; Kovesdi, E; Ahmed, F; Barry, ES; Grunberg, NE; Long, J; Agoston, D				Kamnaksh, Alaa; Kwon, Sook-Kyung; Kovesdi, Erzsebet; Ahmed, Farid; Barry, Erin S.; Grunberg, Neil E.; Long, Joseph; Agoston, Denes			Neurobehavioral, cellular, and molecular consequences of single and multiple mild blast exposure	ELECTROPHORESIS			English	Article						Blast; Cumulative effect; Neurobehavior; Protein biomarkers; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; ENDOTHELIAL GROWTH-FACTOR; COMBAT VETERANS; NEUROGENESIS; HIPPOCAMPUS; EXPRESSION; CELLS; MODEL; RAT	Mild traumatic brain injury, caused by the exposure to single or repeated blast overpressure, is a principal concern due to its pathological complexity and neurobehavioral similarities with posttraumatic stress disorder. In this study, we exposed rats to a single or multiple (five total; administered on consecutive days) mild blasts, assessed their behavior at 1 and 16 days postinjury) and performed histological and protein analyses of brains and plasma at an early (2 h) and a late (22 days) termination time point. One day postinjury, multiple-injured (MI) rats showed the least general locomotion and the most depression- and anxiety-related behaviors among the experimental groups; there were no such differences at 16 days. However, at the later time point, both injured groups displayed elevated levels of select protein biomarkers. Histology showed significantly increased numbers of TUNEL+ (terminal-deoxy-transferase-mediated dUTP nick-end labeling)-positive cells in the dorsal and ventral hippocampus (DHC and VHC) of both injured groups as early as 2 h after injury. At 22 days, the increase was limited to the VHC of MI animals. Our findings suggest that the exposure to mild blast overpressure triggers early hippocampal cell death as well as neuronal, glial, and vascular damage that likely contribute to significant, albeit transient increases in depression- and anxiety-related behaviors. However, the severity of the observed pathological changes in MI rats failed to support the hypothesized cumulative effect of repeated injury. We infer that at this blast frequency, a potential conditioning phenomenon counteracts with and reduces the extent of subsequent damage in MI rats.	[Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Sch Med, Bethesda, MD 20814 USA; [Kamnaksh, Alaa; Kwon, Sook-Kyung; Ahmed, Farid; Barry, Erin S.; Grunberg, Neil E.; Agoston, Denes] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA; [Barry, Erin S.; Grunberg, Neil E.] Walter Reed Army Inst Res, Dept Med & Clin Psychol, Silver Spring, MD USA; [Long, Joseph] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA	Agoston, D (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu		Barry, Erin/0000-0003-0788-7153	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G1703F]	We thank the Neurotrauma Team at the Walter Reed Army Institute of Research for their technical help during the exposures. This work was supported by the Center for Neuroscience and Regenerative Medicine grant number G1703F. The views, opinions, and/or findings contained herein are those of the authors and should not be construed as an official position, policy, or decision of the Department of the Army or the Department of Defense. Animal handling and treatments were conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations related to animals and experiments involving animals, and adhered to principles stated in the Guide to the Care and Use of Laboratory Animals, National Research Council. The facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.	Aarabi B, 2009, CURR OPIN CRIT CARE, V15, P548, DOI 10.1097/MCC.0b013e32833190da; Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Andrew Richard J., 2002, P157, DOI 10.1017/CBO9780511546372.007; Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; Barr TL, 2011, BIOL RES NURS, V13, P140, DOI 10.1177/1099800410385671; Bay Esther H, 2009, Res Theory Nurs Pract, V23, P42; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Engin E, 2007, BEHAV PHARMACOL, V18, P365, DOI 10.1097/FBP.0b013e3282de7929; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Gu XL, 2003, INVEST OPHTH VIS SCI, V44, P3219, DOI 10.1167/ivos.02-0852; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hailer NP, 2001, EUR J NEUROSCI, V14, P315, DOI 10.1046/j.0953-816x.2001.01649.x; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Jaffee CMS, 2009, CLIN NEUROPSYCHOL, V23, P1291, DOI 10.1080/13854040903307250; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kempermann G, 2002, E SCHERING RES FDN W, V35, P17; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2000, NOVART FDN SYMP, V231, P235; Kempermann G., 2000, NOVART FDN SYMP, V231, P302; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kwon S. K. C., 2011, FRONT NEUROL, V2, P1; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Moser MB, 1998, HIPPOCAMPUS, V8, P608, DOI 10.1002/(SICI)1098-1063(1998)8:6<608::AID-HIPO3>3.0.CO;2-7; Mota BC, 2012, NEUROTOX RES, V21, P175, DOI 10.1007/s12640-011-9257-8; Nag S, 2002, J NEUROPATH EXP NEUR, V61, P778, DOI 10.1093/jnen/61.9.778; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Pun P, 2011, FRONT NEUROL, V2, P1; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Ren CH, 2011, NEUROL RES, V33, P514, DOI 10.1179/016164111X13007856084241; Robinson R. G., 1985, CEREBRAL LATERALIZAT, P135; Rosenfeld JV, 2010, INJURY, V41, P437, DOI 10.1016/j.injury.2009.11.018; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Tan G, 2009, PAIN MED, V10, P1237, DOI 10.1111/j.1526-4637.2009.00712.x; Thompson JM, 2008, CAN FAM PHYSICIAN, V54, P1549; Tischler L, 2006, ANN NY ACAD SCI, V1071, P405, DOI 10.1196/annals.1364.031; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Zhao H, 2009, J CEREBR BLOOD F MET, V29, P873, DOI 10.1038/jcbfm.2009.13	68	45	46	0	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	DEC	2012	33	24			SI		3680	3692		10.1002/elps.201200319			13	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	057FT	WOS:000312548900011	23161523				2021-06-18	
J	Lovstad, M; Funderud, I; Endestad, T; Due-Tonnessen, P; Meling, TR; Lindgren, M; Knight, RT; Solbakk, AK				Lovstad, M.; Funderud, I.; Endestad, T.; Due-Tonnessen, P.; Meling, T. R.; Lindgren, M.; Knight, R. T.; Solbakk, A. K.			Executive functions after orbital or lateral prefrontal lesions: Neuropsychological profiles and self-reported executive functions in everyday living	BRAIN INJURY			English	Article						Executive functioning; frontal lobe; neuropsychological; assessment; cognition	TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; GLASGOW OUTCOME SCALE; VERBAL-LEARNING TEST; FRONTAL LESIONS; PERFORMANCE; CORTEX; MEMORY; CHILDREN; REHABILITATION	Objective: This study examined the effects of chronic focal lesions to the lateral prefrontal cortex (LPFC) or orbitofrontal cortex (OFC) on neuropsychological test performance and self-reported executive functioning in everyday living. Methods: Fourteen adults with OFC lesions were compared to 10 patients with LPFC injuries and 21 healthy controls. Neuropsychological tests with emphasis on measures of cognitive executive function were administered along with the Behavior Rating Inventory of Executive Functions (BRIEF-A) and a psychiatric screening instrument. Results: The LPFC group differed from healthy controls on neuropsychological tests of sustained mental effort, response inhibition, working memory and mental switching, while the BRIEF-A provided more clinically important information on deficits in everyday life in the OFC group compared to the LPFC group. Correlations between neuropsychological test results and BRIEF-A were weak, while the BRIEF-A correlated strongly with emotional distress. Conclusions: It was demonstrated that LPFC damage is particularly prone to cause cognitive executive deficit, while OFC injury is more strongly associated with self-reported dysexecutive symptoms in everyday living. The study illustrates the challenge of identifying executive deficit in individual patients and the lack of strong anatomical specificity of the currently employed methods. There is a need for an integrative methodological approach where standard testing batteries are supplemented with neuropsychiatric and frontal-specific rating scales.	[Lovstad, M.] Sunnaas Rehabil Hosp, N-1450 Nesoddtangen, Norway; [Funderud, I.; Endestad, T.; Lindgren, M.; Solbakk, A. K.] Natl Hosp Norway, Oslo Univ Hosp, Dept Neuropsychiat & Psychosomat Med, Oslo, Norway; [Endestad, T.] Univ Oslo, Dept Psychol, N-0316 Oslo, Norway; [Due-Tonnessen, P.] Natl Hosp Norway, Oslo Univ Hosp, Dept Radiol, Oslo, Norway; [Meling, T. R.] Natl Hosp Norway, Oslo Univ Hosp, Dept Neurosurg, Oslo, Norway; [Lindgren, M.] Lund Univ, Dept Psychol, S-22100 Lund, Sweden; [Knight, R. T.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Knight, R. T.] Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA	Lovstad, M (corresponding author), Sunnaas Rehabil Hosp, Bjornemyrvn 11, N-1450 Nesoddtangen, Norway.	marianne.lovstad@sunnaas.no	Meling, Torstein/Q-2568-2019	Meling, Torstein/0000-0001-6595-0873; Due-Tonnessen, Paulina/0000-0002-3615-1914	South-Eastern Norway Regional Health Authority [SUN-001-SS, 2008047]; Research Council of NorwayResearch Council of Norway [186504/V50]; National Institute of Neurological Disorders (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21135]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS021135, R01NS021135, R56NS021135] Funding Source: NIH RePORTER	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This research is supported by the South-Eastern Norway Regional Health Authority (grants SUN-001-SS and 2008047) and the Research Council of Norway (grant no. 186504/V50 to author AKS) as well as the National Institute of Neurological Disorders (NINDS; grant NS21135 to author RTK). The work forms part of a doctoral thesis to be submitted to the Department of Psychology, University of Oslo, Norway.	Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Anderson V, 2005, J INT NEUROPSYCH SOC, V11, P817, DOI 10.1017/S1355617705051052; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Baldo JV, 2002, J INT NEUROPSYCH SOC, V8, P539, DOI 10.1017/S135561770281428X; Benedict R., 1997, BRIEF VISUOSPATIAL M; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 2001, EXAMINERS MANUAL DEL; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Fernandez-Duque D, 2000, CONSCIOUS COGN, V9, P288, DOI 10.1006/ccog.2000.0447; Garlinghouse MA, 2010, SCHIZOPHR RES, V120, P71, DOI 10.1016/j.schres.2010.02.1067; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Kaplan CP, 1998, BRAIN INJURY, V12, P199, DOI 10.1080/026990598122674; Kliegel M, 2008, DEV PSYCHOL, V44, P612, DOI 10.1037/0012-1649.44.2.612; Koenigs M., 2006, ORBITOFRONTAL CORTEX, P597; Krueger CE, 2011, NEUROPSYCHOLOGY, V25, P249, DOI 10.1037/a0021681; Lovstad M, 2012, J COGNITIVE NEUROSCI, V24, P378, DOI 10.1162/jocn_a_00099; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Matheson L, 2010, WORK, V36, P413, DOI 10.3233/WOR-2010-1043; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Pearson Education Inc, 2000, CALIFORNIA VERBAL LE; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Roth R.M., 2005, BEHAV RATING INVENTO; Royall DR, 2002, J NEUROPSYCH CLIN N, V14, P377, DOI 10.1176/appi.neuropsych.14.4.377; Shimamura AP, 1995, ANN NY ACAD SCI, V769, P151, DOI 10.1111/j.1749-6632.1995.tb38136.x; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; STUSS DT, 2007, HUMAN FRONTAL LOBES, P292; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tranel D, 2008, CLIN NEUROPSYCHOL, V22, P242, DOI 10.1080/13854040701218410; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yochim B, 2007, J INT NEUROPSYCH SOC, V13, P704, DOI 10.1017/S1355617707070907; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	44	45	46	2	32	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1586	1598		10.3109/02699052.2012.698787			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700005	22731818	Green Accepted			2021-06-18	
J	Boone, DR; Sell, SL; Micci, MA; Crookshanks, JM; Parsley, M; Uchida, T; Prough, DS; DeWitt, DS; Hellmich, HL				Boone, Deborah R.; Sell, Stacy L.; Micci, Maria-Adelaide; Crookshanks, Jeanna M.; Parsley, Margaret; Uchida, Tatsuo; Prough, Donald S.; DeWitt, Douglas S.; Hellmich, Helen L.			Traumatic Brain Injury-Induced Dysregulation of the Circadian Clock	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; SUPRACHIASMATIC NUCLEUS; ALZHEIMERS-DISEASE; RAT HIPPOCAMPUS; GENE-EXPRESSION; HEAD TRAUMA; RHYTHMS; MEMORY; NEURONS; OSCILLATION	Circadian rhythm disturbances are frequently reported in patients recovering from traumatic brain injury (TBI). Since circadian clock output is mediated by some of the same molecular signaling cascades that regulate memory formation (cAMP/MAPK/CREB), cognitive problems reported by TBI survivors may be related to injury-induced dysregulation of the circadian clock. In laboratory animals, aberrant circadian rhythms in the hippocampus have been linked to cognitive and memory dysfunction. Here, we addressed the hypothesis that circadian rhythm disruption after TBI is mediated by changes in expression of clock genes in the suprachiasmatic nuclei (SCN) and hippocampus. After fluid-percussion TBI or sham surgery, male Sprague-Dawley rats were euthanized at 4 h intervals, over a 48 h period for tissue collection. Expression of circadian clock genes was measured using quantitative real-time PCR in the SCN and hippocampus obtained by laser capture and manual microdissection respectively. Immunofluorescence and Western blot analysis were used to correlate TBI-induced changes in circadian gene expression with changes in protein expression. In separate groups of rats, locomotor activity was monitored for 48 h. TBI altered circadian gene expression patterns in both the SCN and the hippocampus. Dysregulated expression of key circadian clock genes, such as Bmal1 and Cry1, was detected, suggesting perturbation of transcriptional-translational feedback loops that are central to circadian timing. In fact, disruption of circadian locomotor activity rhythms in injured animals occurred concurrently. These results provide an explanation for how TBI causes disruption of circadian rhythms as well as a rationale for the consideration of drugs with chronobiotic properties as part of a treatment strategy for TBI.	[Boone, Deborah R.; Sell, Stacy L.; Micci, Maria-Adelaide; Crookshanks, Jeanna M.; Parsley, Margaret; Uchida, Tatsuo; Prough, Donald S.; DeWitt, Douglas S.; Hellmich, Helen L.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX USA	Hellmich, HL (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX USA.	hhellmic@utmb.edu	Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	Moody Foundation/Mission Connect; Department of Anesthesiology	This study was supported in part by the Moody Foundation/Mission Connect and in part by the Department of Anesthesiology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe M, 2000, NEUROREPORT, V11, P3261, DOI 10.1097/00001756-200009280-00042; Akashi M, 2008, J NEUROSCI, V28, P4619, DOI 10.1523/JNEUROSCI.3410-07.2008; Alamili M, 2010, DAN MED BULL, V57; Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; BARNES CA, 1977, SCIENCE, V197, P91, DOI 10.1126/science.194313; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Bechtold DA, 2010, TRENDS PHARMACOL SCI, V31, P191, DOI 10.1016/j.tips.2010.01.002; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Benca R, 2009, BRAIN RES REV, V62, P57, DOI 10.1016/j.brainresrev.2009.09.005; Boyce P, 2010, AUST FAM PHYSICIAN, V39, P307; Brambrink AM, 2010, ANESTHESIOLOGY, V112, P834, DOI 10.1097/ALN.0b013e3181d049cd; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chaudhury D, 2005, J BIOL RHYTHM, V20, P225, DOI 10.1177/0748730405276352; Cheeseman JF, 2012, P NATL ACAD SCI USA, V109, P7061, DOI 10.1073/pnas.1201734109; Chen G, 2000, J NEUROCHEM, V75, P1729, DOI 10.1046/j.1471-4159.2000.0751729.x; Chen Z, 2007, CELL CYCLE, V6, P2906, DOI 10.4161/cc.6.23.5041; Craig LA, 2008, BRAIN RES BULL, V76, P141, DOI 10.1016/j.brainresbull.2008.02.013; Dawson D, 1996, PHARMACOL THERAPEUT, V69, P15, DOI 10.1016/0163-7258(95)02020-9; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Eckel-Mahan KL, 2008, NAT NEUROSCI, V11, P1074, DOI 10.1038/nn.2174; Eckel-Mahan KL, 2009, EMBO REP, V10, P584, DOI 10.1038/embor.2009.123; Gamsby JJ, 2009, J BIOL RHYTHM, V24, P193, DOI 10.1177/0748730409334748; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Gerstner JR, 2009, J NEUROSCI, V29, P12824, DOI 10.1523/JNEUROSCI.3353-09.2009; Gerstner JR, 2012, FRONTIERS MOL NEUROS, V5, P1; Golombek DA, 2010, PHYSIOL REV, V90, P1063, DOI 10.1152/physrev.00009.2009; Gouin JP, 2010, J AFFECT DISORDERS, V126, P161, DOI 10.1016/j.jad.2010.04.002; Halberg Franz, 2003, J Circadian Rhythms, V1, P2, DOI 10.1186/1740-3391-1-2; Hardeland R, 2003, CHRONOBIOL INT, V20, P921, DOI 10.1081/CBI-120025245; Honma S, 1998, BIOCHEM BIOPH RES CO, V250, P83, DOI 10.1006/bbrc.1998.9275; Iitaka C, 2005, J BIOL CHEM, V280, P29397, DOI 10.1074/jbc.M503526200; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kang TH, 2009, P NATL ACAD SCI USA, V106, P2864, DOI 10.1073/pnas.0812638106; LeSauter J, 1999, J NEUROSCI, V19, P5574; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meerlo P, 2009, SLEEP MED REV, V13, P187, DOI 10.1016/j.smrv.2008.07.004; Mendlewicz J, 2009, CNS DRUGS, V23, P15, DOI 10.2165/11318630-000000000-00000; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; Phan TH, 2011, J NEUROSCI, V31, P10640, DOI 10.1523/JNEUROSCI.6535-10.2011; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Rawashdeh O, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00027; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rojo DR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023111; Ruby NF, 2008, P NATL ACAD SCI USA, V105, P15593, DOI 10.1073/pnas.0808259105; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; *SAS I INC, 2004, SAS STAT US GUID VER; Sassone-Corsi P, 2010, MOL ENDOCRINOL, V24, P2081, DOI 10.1210/me.2010-0359; Schaaf MJM, 2000, MOL BRAIN RES, V75, P342, DOI 10.1016/S0169-328X(99)00314-9; Shieh KR, 2003, NEUROSCIENCE, V118, P831, DOI 10.1016/S0306-4522(03)00004-6; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Sprouse J, 2006, BIOL PSYCHIAT, V60, P896, DOI 10.1016/j.biopsych.2006.03.003; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Ukai-Tadenuma M, 2011, CELL, V144, P268, DOI 10.1016/j.cell.2010.12.019; Uz T, 2005, NEUROSCIENCE, V134, P1309, DOI 10.1016/j.neuroscience.2005.05.003; Volicer L, 2001, AM J PSYCHIAT, V158, P704, DOI 10.1176/appi.ajp.158.5.704; Wang NN, 2008, CELL METAB, V8, P482, DOI 10.1016/j.cmet.2008.10.009; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yin L, 2006, SCIENCE, V311, P1002, DOI 10.1126/science.1121613; Zhang EE, 2009, CELL, V139, P199, DOI 10.1016/j.cell.2009.08.031	68	45	48	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 3	2012	7	10							e46204	10.1371/journal.pone.0046204			9	Multidisciplinary Sciences	Science & Technology - Other Topics	015NU	WOS:000309454000025	23056261	DOAJ Gold, Green Published			2021-06-18	
J	Auxemery, Y				Auxemery, Y.			Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context	ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE			French	Article						Posttraumatic stress disorder; Psychic trauma; Acute stress disorder; Debriefing; Comorbidites; Gene-by-environment interaction; Psychopathology; Anthropology; Prevention; Treatment	TRAUMA EXPOSURE; ENVIRONMENTAL-INFLUENCES; RISK-FACTORS; LIFE EVENTS; DRD2 GENE; POLYMORPHISM; DEPRESSION; SYMPTOMS; TWIN; ASSOCIATION	Introduction. - Why are some individuals more likely than others to develop a posttraumatic stress disorder (PTSD) in the face of similar levels of trauma exposure? Monitoring the traumatic process combining the antecedents, the determinants of the psychic trauma and the acute symptoms can clarify the causes of the final onset of a chronic repetition syndrome. Epidemiologic research has clarified risk factors that increase the likelihood of PTSD after exposure to a potentially traumatic event. PTSD is an interaction between a subject, a traumatogenic factor and a social context. With each epidemiological, psychopathological and more particularly neurogenetic study, we will expand on the impact of these interactions on the therapeutic treatment of psycho-traumatised persons. Literature findings. - Most studies have shown that unrelated to the traumatic event, additional risk factors for developing PTSD include younger age at the time of the trauma, female gender, lower social economic statuts, lack of social support, premorbid personality characteristics and preexisting anxiety or depressive disorders increase the risk of PTSD. The psychic trauma is firmly attached to the repetition and the previous traumas are as many risks of developing a subsequent PTSD in the wake of a new trauma: PTSD in adults may represent a prolonged symptomatic reaction to prior traumatic assault, child abuse and childhood adversities. Related to the traumatic event, the organic pain, the traumatic brain injury, but also the sight of blood can lead to a trauma being considered as more serious or more harmful to life. It is useful to recognize the acute reactions of exhaustion stress as they can guide both the pharmacotherapeutic and the psychotherapeutic treatment thanks to debriefings. Even though the majority of people with acute stress disorder subsequently develop PTSD, the current data indicate that too many people can develop PTSD without initially displaying acute stress disorder. Though peritraumatic dissociation and peritraumatic distress have emerged as the strongest predictors for PTSD and have to be treated as soon as possible with the debriefing or the pharmacology; initial evidence suggests the potential benefits of early intervention, shortly after the trauma, and psychological debriefing has received increasing interest from the scientific community. However the Anglo-Saxon techniques (such as Critical Incident Stress Debriefing also known as the Mitchell model) are in total contrast with the French approach. In the first case the emotional response is controlled to ensure the pursuit of the group action, whilst in the second case the debriefing concerns patients with acute symptoms in order to prevent the development of a PTSD structuring of the latter. The facts, emotions and thoughts are not partitioned but inter-linked, thus enabling a fragmentation of the traumatic experience. In the face of the annihilation experienced, speech production by the subject is restored linking the person to the human community, once abandoned. However, debate continues on the efficacy of single session debriefing in the prevention of PTSD. At the time of the acute stress reactions, benzodiazepines are contraindicated at this stage as they promote dissociation and ulterior revivals. On the other hand, treatment with propranolol could be proposed: a two or three week course of propranolol begun in the aftermath of a traumatic event can reduce subsequent PTSD symptoms. Discussion. - A genetic polymorphism is evidently at work in the development of a PTSD via the regulation of the expression of genes of interest to the serotoninergic system and the adrenocorticotropic axis. The 5-HTTLPR (promoter region of SLC6A4 witch encodes the serotonin transporter) constitutes a genetic candidate region that may modulate emotional responses to traumatic events. The interaction between variation at the 5HTTLPR and stressful life events could predict depression and PTSD. Considering the dopaminergic pathway, the A1 allele coding the type 2 dopaminergic receptor is associated with a severe comorbidity of PTSD with the presence of somatic disorders, anxiety, social change and depression. For noradrenergic neuromodulation, an interaction between the polymorphism of gene GABRA2 and the occurrence of PTSD is described whereas an interaction between the number of traumatic events and Val(158)Met polymorphism of the gene coding for catecholamine-O-methyltransferase has also been found. The role of polymorphisms in FKBP5 (a co-chaperone of hsp 90 which binds to the glucocorticoid receptor) in predicting PTSD too, with a gene-by-environment point of view. These gene-by-environment studies are needed to focus more on distinct endophenotypes and influences from environmental factors. If several candidate genes are involved, a weighting of susceptibility to such and such a neurological regulation system will imply various endophenotypes. According to the monoamine predominantly incriminated, PTSD can take on a more hyper-vegetative clinical expression linked with noradrenergic overuse. Differently, avoidance behaviour and the depressive aspect invoke more a modification of the serotoninergic modulation whilst posttraumatic psychotic reactions question the role of dopaminergic pathways. Neuroscientific discoveries interesting the biological support of PTSD can thus modify our view of the conception of the disorder in relation to different therapeutic prospects. Conclusion. - Chronic PTSD can manifest itself in different clinical forms. The repetition syndrome can appear a long time after the traumatic event, following a paucisymptomatic latency period, which can last several years or even decades. The absence of complaints from the patient is common, the latter suffering in silence. Often other comorbid disorders and other complaints arise sooner than the clinical picture. Thus a depressive episode characterised as drug-seeking behaviour is frequently encountered. The therapeutic accompaniment traditionally combines a pharmacological and a psychotherapeutic treatment even if recommendations are rare. A posttraumatic stress disorder is never just a coincidence. The different stages of the evolution and the establishment of a PTSD are the expression of an interaction between the outside and the inner self. Despite a known progression of the posttraumatic stress disorder, this deleterious evolution is far from being a foregone conclusion. On the contrary, several levels of prevention are possible at each stage of its structuration to propose treatments to subjects who are vulnerable and/or present symptoms. No neurobiological study has yet found a biological marker, which would apparently and inevitably destine a subject to structure, a posttraumatic stress disorder in reaction to a stress. Conversely, the psychopathological study finds afterwards that a particular subject has necessarily built a traumatic repetition syndrome according to the concordance of significant data relative to his/her history. The event strikes a repression or an anterior biographical deadlock and of which the thematic questions the fundamentals of human culture in its emancipation with nature, like the question of death and its consequences: bereavement, parentality, transgenerational transmission and organicity often linked to the illness. A therapeutic proposal constitutes an environmental factor par excellence which can be either protective or deleterious. If the traumatic repetition syndrome has been known since Antiquity, the birth of PTSD has followed the chronology of the DSM according to the sociopolitical contexts encountered. A PTSD does not occur by chance: the conditions of possibility of the trauma are established by genetic and psychological determinants interactively integrated at the heart of a social context. After the increase in a psychotraumatic interest in international publications since the 1980s, a fight against over-victimisation seems to be setting in. The advances in genetic and neuroimaging techniques are in the process of superseding psychometric studies in terms of reliability and validity; maybe we should see in this social evolution the changes of tomorrow concerning the clinical of PTSD and its treatment. The healing of the psycho-traumatised subject cannot just be established on the passive status of victim, which would be detrimental to reflection and ultimately reconstruction: the rebirth of the subject will require active commitment, which could distract from the deadly repetition. Whilst the confrontation with death resembled nonsense, the subject will question the psychotraumatic determinants of his/her life history to reinstate this tragic event within a search for meaning. Such restructuring is built on the intersubjectivity of the clinical relationship, which occurs within a social context. PTSD is a pathology which interacts with the societal context: on the one hand the trauma is established on the brutal reconsideration of social values which seem immutable and on the other hand, the clinical and nosographical concept of PTSD is changing with the evolution of society. (C) L'Encephale, Paris, 2011.	[Auxemery, Y.] Hop Instruct Armees Legouest, Psychiat Serv, F-57077 Metz 3, France; [Auxemery, Y.] Hop Instruct Armees Legouest, Psychol Clin, F-57077 Metz 3, France; [Auxemery, Y.] Univ Paris 07, Ctr Rech Psychanal Med & Soc, UFR Sci Humaines Clin, F-75480 Paris 10, France	Auxemery, Y (corresponding author), Hop Instruct Armees Legouest, Psychiat Serv, 27 Ave Plantieres,BP 90001, F-57077 Metz 3, France.	yann.auxemery@hotmail.fr					Afifi TO, 2010, CLIN PSYCHOL REV, V30, P101, DOI 10.1016/j.cpr.2009.10.002; Amstadter AB, 2009, J ANXIETY DISORD, V23, P369, DOI 10.1016/j.janxdis.2008.12.005; [Anonymous], 2004, AM J PSYCHIAT, V161, P1321; Auxemery Y, 2011, ENCEPHALE, V37, P433, DOI 10.1016/j.encep.2010.12.001; Binder EB, 2008, JAMA-J AM MED ASSOC, V299, P1291, DOI 10.1001/jama.299.11.1291; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Drury SS, 2009, J TRAUMA STRESS, V22, P534, DOI 10.1002/jts.20475; Ducrocq F, 2005, ENCEPHALE, V31, P212; Grabe HJ, 2009, AM J PSYCHIAT, V166, P926, DOI 10.1176/appi.ajp.2009.08101542; Hetrick SE, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007316.pub2; Kendler KS, 2005, ARCH GEN PSYCHIAT, V62, P529, DOI 10.1001/archpsyc.62.5.529; Kilpatrick DG, 2007, AM J PSYCHIAT, V164, P1693, DOI 10.1176/appi.ajp.2007.06122007; Koenen KC, 2003, TWIN RES, V6, P218, DOI 10.1375/twin.6.3.218; Koenen KC, 2002, J NERV MENT DIS, V190, P209, DOI 10.1097/00005053-200204000-00001; Kolassa IT, 2010, J CLIN PSYCHIAT, V71, P543, DOI 10.4088/JCP.08m04787blu; Kolassa IT, 2010, BIOL PSYCHIAT, V67, P304, DOI 10.1016/j.biopsych.2009.10.009; Lapp KG, 2005, MIL MED, V170, P787, DOI 10.7205/MILMED.170.9.787; Lawford BR, 2006, EUR PSYCHIAT, V21, P180, DOI 10.1016/j.eurpsy.2005.01.006; Lee HJ, 2005, DEPRESS ANXIETY, V21, P135, DOI 10.1002/da.20064; Nelson EC, 2009, MOL PSYCHIATR, V14, P234, DOI 10.1038/mp.2008.81; Olff M, 2005, PSYCHONEUROENDOCRINO, V30, P974, DOI 10.1016/j.psyneuen.2005.04.009; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Rose S., 2003, PSYCHOL DEBRIEFING P; Southwick SM, 1997, ARCH GEN PSYCHIAT, V54, P749; Stein MB, 2002, AM J PSYCHIAT, V159, P1675, DOI 10.1176/appi.ajp.159.10.1675; TRUE WR, 1993, ARCH GEN PSYCHIAT, V50, P257, DOI 10.1001/archpsyc.1993.01820160019002; Voisey J, 2009, DEPRESS ANXIETY, V26, P28, DOI 10.1002/da.20517; Xian H, 2000, DRUG ALCOHOL DEPEN, V61, P95, DOI 10.1016/S0376-8716(00)00127-7; Xie P, 2010, NEUROPSYCHOPHARMACOL, V35, P1684, DOI 10.1038/npp.2010.37; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153; Young A., 1995, HARMONY ILLUSIONS IN	32	45	48	3	162	MASSON EDITEUR	MOULINEAUX CEDEX 9	21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE	0013-7006			ENCEPHALE	Enceph.-Rev. Psychiatr. Clin. Biol. Ther.	OCT	2012	38	5					373	380		10.1016/j.encep.2011.12.003			8	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	055PG	WOS:000312428300002	23062450				2021-06-18	
J	Rivara, FP; Vavilala, MS; Durbin, D; Temkin, N; Wang, J; O'Connor, SS; Koepsell, TD; Dorsch, A; Jaffe, KM				Rivara, Frederick P.; Vavilala, Monica S.; Durbin, Dennis; Temkin, Nancy; Wang, Jin; O'Connor, Stephen S.; Koepsell, Thomas D.; Dorsch, Andrea; Jaffe, Kenneth M.			Persistence of Disability 24 to 36 Months after Pediatric Traumatic Brain Injury: A Cohort Study	JOURNAL OF NEUROTRAUMA			English	Article						children and adolescents; disability; functional outcome; traumatic brain injury	QUALITY-OF-LIFE; CHILDREN; RECOVERY; RELIABILITY; SYMPTOMS; CARE	This study examined the outcome of 0- to 17-year-old children 36 months after traumatic brain injury (TBI), and ascertained if there was any improvement in function between 24 and 36 months. Controls were children treated in the emergency department for an arm injury. Functional outcome 36 months after injury was measured by the Pediatric Quality of Life Inventory (PedsQL), the self-care and communication subscales of the Adaptive Behavior Assessment Scale-2nd edition (ABAS-II), and the Child and Adolescent Scale of Participation (CASP). At 36 months after TBI, those with moderate or severe TBI continued to have PedsQL scores that were 16.1 and 17.9 points, respectively, lower than at baseline, compared to the change seen among arm injury controls. Compared to the baseline assessment, children with moderate or severe TBI had significantly poorer functioning on the ABAS-II and poorer participation in activities (CASP). There was no significant improvement in any group on any outcomes between 24 and 36 months. Post-injury interventions that decrease the impact of these deficits on function and quality of life, as well as preventive interventions that reduce the likelihood of TBI, should be developed and tested.	[Rivara, Frederick P.; Vavilala, Monica S.; Wang, Jin; Jaffe, Kenneth M.] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Rivara, Frederick P.; Koepsell, Thomas D.] Univ Washington, Dept Epidemiol, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98104 USA; [O'Connor, Stephen S.] Univ Washington, Dept Psychiat, Seattle, WA 98104 USA; [Koepsell, Thomas D.] Univ Washington, Dept Hlth Serv, Seattle, WA 98104 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Rivara, Frederick P.; Vavilala, Monica S.; Wang, Jin; O'Connor, Stephen S.; Koepsell, Thomas D.; Jaffe, Kenneth M.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Durbin, Dennis] Childrens Hosp Philadelphia, Dept Emergency Med, Philadelphia, PA 19104 USA; [Durbin, Dennis] Univ Penn, Philadelphia, PA 19104 USA; [Dorsch, Andrea] Mary Bridge Childrens Hosp, Pediat Dev Serv, Tacoma, WA USA	Rivara, FP (corresponding author), Univ Washington, Dept Pediat, Box 359960,325 9th Ave, Seattle, WA 98104 USA.	fpr@uw.edu			National Center for Injury Prevention and Control, CDCUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CE 001021]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001021] Funding Source: NIH RePORTER	This project was supported by the National Center for Injury Prevention and Control, CDC grant R49 CE 001021. The CDC had no role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript. We thank Maria Roper-Caldbeck, Eileen Houseknecht, and Andrea Miller for their work on subject recruitment, and for interviews and administrative support. We thank the many children and parents who participated in this study and the study hospitals.	Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Anderson V, 2012, PEDIATRICS, V129, pE254, DOI 10.1542/peds.2011-0311; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Anderson V, 2009, PEDIATRICS, V124, pE1064, DOI 10.1542/peds.2009-0365; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Bedell G., 2006, BRAIN INJ PROF, V3, P14; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Crowther JE, 2011, J HEAD TRAUMA REHAB, V26, P192, DOI 10.1097/HTR.0b013e318218dd22; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; Marr AL., 2004, CENTRAL NERVOUS SYST; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Rivara F. P., 2012, AM J PUBLIC IN PRESS; Rivara F. P., 2012, ARCH PHYS MED REHABI; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Seid M, 2006, J PEDIATR-US, V149, P354, DOI 10.1016/j.jpeds.2006.04.024; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	37	45	45	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2012	29	15					2499	2504		10.1089/neu.2012.2434			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	022NY	WOS:000309967300007	22757748	Green Published			2021-06-18	
J	Zhang, X; Wang, B; O'Callaghan, P; Hjertstrom, E; Jia, J; Gong, F; Zcharia, E; Nilsson, LNG; Lannfelt, L; Vlodavsky, I; Lindahl, U; Li, JP				Zhang, Xiao; Wang, Bo; O'Callaghan, Paul; Hjertstrom, Elina; Jia, Juan; Gong, Feng; Zcharia, Eyal; Nilsson, Lars N. G.; Lannfelt, Lars; Vlodavsky, Israel; Lindahl, Ulf; Li, Jin-Ping			Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-beta in murine brain	ACTA NEUROPATHOLOGICA			English	Article						Neuroinflammation; Heparan sulfate; Heparanase; Amyloid-beta; Clearance; Alzheimer's disease	CENTRAL-NERVOUS-SYSTEM; INTERCELLULAR-ADHESION MOLECULE-1; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; LEUKOCYTE ADHESION; MICROGLIAL CELLS; INTERFERON-GAMMA; SULFATE; EXPRESSION; MICE	Neuroinflammation is typically observed in neurodegenerative diseases such as Alzheimer's disease, as well as after traumatic injury and pathogen infection. Resident immune cells, microglia and astrocytes, are activated and joined by blood-borne monocytes that traverse the blood-brain barrier and convert into activated macrophages. The activated cells express various cytokines, chemokines and proteolytic enzymes. To study the role of heparan sulfate proteoglycans in neuroinflammation, we employed a transgenic mouse overexpressing heparanase, an endoglucuronidase that specifically degrades heparan sulfate side chains. Neuroinflammation was induced by systemic challenge with lipopolysaccharide, or by localized cerebral microinjection of aggregated amyloid-beta peptide, implicated in Alzheimer's disease. Lipopolysaccharide-treated control mice showed massive activation of resident microglia as well as recruitment of monocyte-derived macrophages into the brain parenchyma. Microinjection of aggregated amyloid-beta elicited a similar inflammatory response, albeit restricted to the injection site, which led to dispersion and clearance of the amyloid. In the heparanase-overexpressing mice, all aspects of immune cell recruitment and activation were significantly attenuated in both inflammation models, as was amyloid dispersion. Accordingly, an in vitro blood-brain barrier model constructed from heparanase-overexpressing cerebral vascular cells showed impaired transmigration of monocytes compared to a corresponding assembly of control cells. Our data indicate that intact heparan sulfate chains are required at multiple sites to mediate neuroinflammatory responses, and further point to heparanase as a modulator of this process, with potential implications for Alzheimer's disease.	[Wang, Bo; Hjertstrom, Elina; Jia, Juan; Gong, Feng; Lindahl, Ulf; Li, Jin-Ping] Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden; [Zhang, Xiao; O'Callaghan, Paul; Nilsson, Lars N. G.; Lannfelt, Lars] Uppsala Univ, Rudbeck Lab, Dept Publ Hlth & Caring Sci, S-75185 Uppsala, Sweden; [Wang, Bo] Inst Pharmacol & Toxicol, Dept Pharmacol, Beijing 100850, Peoples R China; [Gong, Feng] Inst Transfus Med, Dept Blood Biochem & Mol Biol, Beijing 100850, Peoples R China; [Zcharia, Eyal; Vlodavsky, Israel] Technion Israel Inst Technol, Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; [Nilsson, Lars N. G.] Univ Oslo, Fac Med, Inst Clin Med, Dept Pharmacol, Oslo, Norway; [Nilsson, Lars N. G.] Oslo Univ Hosp, Oslo, Norway	Li, JP (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Box 582,Husargatan 3, S-75123 Uppsala, Sweden.	jin-ping.li@imbim.uu.se	O'Callaghan, Paul/T-5308-2018	O'Callaghan, Paul/0000-0003-3117-5367; nilsson, lars/0000-0002-8362-1042	Swedish Research CouncilSwedish Research CouncilEuropean Commission [K2009-67X-21128-01-3, K2012-67X-21128-04-4, K2010-61X-15383-06-3, 2009-4567]; Swedish Cancer Foundation; Swedish Heart-Lung FoundationSwedish Heart-Lung Foundation [20110131]; European Commission (EURAMY)European CommissionEuropean Commission Joint Research Centre; Mizutani Foundation for Glycoscience; Polysackaridforskning AB (Uppsala); Alzheimerfonden; Stohnes Stiftelse; Stiftelsen for Gamla Tjanarinnor; Demensforbundet; Swedish Brain Foundation; Bertil Hallstens Forskningsstiftelse; Israel Science FoundationIsrael Science Foundation [549/06]; National Cancer Institute, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [RO1-CA106456]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA106456] Funding Source: NIH RePORTER	This work was supported by grants from the Swedish Research Council: K2009-67X-21128-01-3, K2012-67X-21128-04-4, K2010-61X-15383-06-3, #2009-4567, Swedish Cancer Foundation, Swedish Heart-Lung Foundation (20110131), The European Commission (EURAMY), the Mizutani Foundation for Glycoscience, Polysackaridforskning AB (Uppsala), Alzheimerfonden, Stohnes Stiftelse, Stiftelsen for Gamla Tjanarinnor, Demensforbundet, The Swedish Brain Foundation, Bertil Hallstens Forskningsstiftelse. The Israel Science Foundation (549/06), the National Cancer Institute, NIH (RO1-CA106456). I. Vlodavsky is a Research Professor of the ICRF.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; Bates KA, 2009, MOL PSYCHIATR, V14, P469, DOI 10.1038/mp.2008.96; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; de Haas AH, 2007, MOL NEUROBIOL, V36, P137, DOI 10.1007/s12035-007-0036-8; DeVries HE, 1997, PHARMACOL REV, V49, P143; DUSTIN ML, 1986, J IMMUNOL, V137, P245; El Khoury J, 2007, NAT MED, V13, P432, DOI 10.1038/nm1555; El Khoury J, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI 10.1016/j.tips.2008.08.004; Fiala M, 2002, EUR J CLIN INVEST, V32, P360, DOI 10.1046/j.1365-2362.2002.00994.x; Fiala M, 2007, J ALZHEIMERS DIS, V11, P457; FORD AL, 1995, J IMMUNOL, V154, P4309; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Galvis MLE, 2007, NAT CHEM BIOL, V3, P773, DOI 10.1038/nchembio.2007.41; Gate D, 2010, J NEURAL TRANSM, V117, P961, DOI 10.1007/s00702-010-0422-7; Giulian D, 1998, J BIOL CHEM, V273, P29719, DOI 10.1074/jbc.273.45.29719; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Hickman SE, 2010, CNS NEUROL DISORD-DR, V9, P168, DOI 10.2174/187152710791011982; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Johnston B, 2002, SEMIN IMMUNOL, V14, P83, DOI 10.1006/smim.2001.0345; Kanekiyo T, 2011, J NEUROSCI, V31, P1644, DOI 10.1523/JNEUROSCI.5491-10.2011; Long EO, 2011, J IMMUNOL, V186, P5021, DOI 10.4049/jimmunol.1100646; MAIO M, 1989, J IMMUNOL, V143, P181; Malm TM, 2005, NEUROBIOL DIS, V18, P134, DOI 10.1016/j.nbd.2004.09.009; Martins IC, 2008, EMBO J, V27, P224, DOI 10.1038/sj.emboj.7601953; Massena S, 2010, BLOOD, V116, P1924, DOI 10.1182/blood-2010-01-266072; Miners JS, 2008, BRAIN PATHOL, V18, P240, DOI 10.1111/j.1750-3639.2008.00132.x; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Morise Z, 1999, INFLAMMATION, V23, P99, DOI 10.1023/A:1020232826906; MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807; Nakanishi H, 2003, MOL NEUROBIOL, V27, P163, DOI 10.1385/MN:27:2:163; O'Callaghan P, 2008, BRAIN PATHOL, V18, P548, DOI 10.1111/j.1750-3639.2008.00152.x; Parish CR, 2005, NAT IMMUNOL, V6, P861, DOI 10.1038/ni0905-861; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Rezai-Zadeh K, 2009, J NEUROIMMUNE PHARM, V4, P462, DOI 10.1007/s11481-009-9166-2; Rogers J, 2007, INT REV NEUROBIOL, V82, P235, DOI 10.1016/S0074-7742(07)82012-5; Rummel C, 2010, MOL PSYCHIATR, V15, P523, DOI 10.1038/mp.2009.98; Sandwall E, 2010, GLYCOBIOLOGY, V20, P533, DOI 10.1093/glycob/cwp205; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Shafat I, 2006, BIOCHEM BIOPH RES CO, V341, P958, DOI 10.1016/j.bbrc.2006.01.048; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Solito E, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00014; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Steidl U, 2000, ANN HEMATOL, V79, P414, DOI 10.1007/s002770000168; Thompson WL, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-35; TONKS N K, 1988, Biochemistry, V27, P8695, DOI 10.1021/bi00424a001; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24; van Horssen J, 2003, LANCET NEUROL, V2, P482, DOI 10.1016/S1474-4422(03)00484-8; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233; WONG D, 1992, J NEUROIMMUNOL, V39, P11, DOI 10.1016/0165-5728(92)90170-P; Zcharia E, 2004, FASEB J, V18, P252, DOI 10.1096/fj.03-0572com; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	63	45	46	1	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	OCT	2012	124	4					465	478		10.1007/s00401-012-0997-1			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	008MY	WOS:000308962300002	22692572	Green Published, Other Gold			2021-06-18	
J	Payne, SC; Bartlett, CA; Harvey, AR; Dunlop, SA; Fitzgerald, M				Payne, Sophie C.; Bartlett, Carole A.; Harvey, Alan R.; Dunlop, Sarah A.; Fitzgerald, Melinda			Myelin Sheath Decompaction, Axon Swelling, and Functional Loss during Chronic Secondary Degeneration in Rat Optic Nerve	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article							SPINAL-CORD-INJURY; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; EARLY ULTRASTRUCTURAL FINDINGS; CHANNEL BLOCKER LOMERIZINE; OCULAR HYPERTENSION; PROTEOLIPID PROTEIN; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; GLAUCOMA	PURPOSE. To examine chronic changes occurring at 6 months following partial optic nerve (ON) transection, assessing optic axons, myelin, and visual function. METHODS. Dorsal ON axons were transected, leaving ventral optic axons vulnerable to secondary degeneration. At 3 and 6 months following partial transection, toluidine-blue stained sections were used to assess dimensions of the ON injury site. Transmission electron microscopy (TEM) images of ventral ON were used to quantify numbers, diameter, area, and myelin thickness of optic axons. Immunohistochemistry and fluoromyelin staining were used to assess semiquantitatively myelin protein, lipids in ventral ON, and retinal ganglion cells (RGCs) in midventral retina. Visuomotor function was assessed using optokinetic nystagmus. RESULTS. Following partial ON transection, optic axons and function remained disrupted at 6 months. Although ventral ON swelling observed at 3 months (P <= 0.05) receded to normal by 6 months, ultrastructurally, myelinated axons remained swollen (P >= 0.05), and myelin thickness increased (P <= 0.05) due to loosening of lamellae and an increase in the number of intraperiodic lines. Axons with decompacted myelin persisted and were distinguished as having large axonal calibers and thicker myelin sheaths. Nevertheless, progressive loss of myelin lipid staining with fluoromyelin was seen at 6 months. Despite no further loss of ventral optic axons between 3 and 6 months (P >= 0.05), visuomotor function progressively declined at 6 months following partial transection (P <= 0.05). CONCLUSIONS. Continued decompaction of myelin, altered myelin structure, and swelling of myelinated axons are persistent features of the chronic phases of secondary degeneration and likely contribute to progressive loss of visual function. (Invest Ophthalmol Vis Sci. 2012; 53: 6093-6101) DOI: 10.1167/iovs.12-10080	[Payne, Sophie C.; Bartlett, Carole A.; Dunlop, Sarah A.; Fitzgerald, Melinda] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Payne, Sophie C.; Bartlett, Carole A.; Dunlop, Sarah A.; Fitzgerald, Melinda] Univ Western Australia, Western Australian Inst Med Res, Crawley, WA 6009, Australia; [Harvey, Alan R.] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA 6009, Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia.	lindy.fitzgerald@uwa.edu.au	Dunlop, Sarah A/G-9357-2013; Fitzgerald, Melinda/C-4235-2011; Harvey, Alan/A-4911-2008	Fitzgerald, Melinda/0000-0002-4823-8179; Dunlop, Sarah/0000-0002-1306-3962; , Alan/0000-0002-2590-831X	Neurotrauma Research Program (Western Australia); National Health and Medical Research Council, Australia (NHMRC)National Health and Medical Research Council of Australia [572550]; NHMRCNational Health and Medical Research Council of Australia [APP1002347]; University Government; State Government; Commonwealth Government	Supported by the Neurotrauma Research Program (Western Australia) and National Health and Medical Research Council, Australia (NHMRC) Grant 572550 (MF) and from NHMRC Grant APP1002347 (SAD).; We thank Michael Archer for technical assistance with electron microscopy. The authors thank the facilities, scientific, and technical assistance of the Australian Microscopy & Microanalysis Research Facility at the Centre for Microscopy, Characterisation & Analysis, The University of Western Australia, a facility funded by the University, State, and Commonwealth Governments.	Access Economics Pty Limited for the Victorian Neurotrauma Initiative, 2009, EC COST SPIN CORD IN; Bai HQ, 2009, EUR J OPHTHALMOL, V19, P201; Baumann N, 2001, PHYSIOL REV, V81, P871; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bizzozero OA, 2001, J NEUROCHEM, V76, P1129, DOI 10.1046/j.1471-4159.2001.00116.x; Bizzozero OA, 2001, NEUROCHEM RES, V26, P1127, DOI 10.1023/A:1012370822754; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BONGARZONE ER, 1995, J NEUROSCI RES, V41, P213, DOI 10.1002/jnr.490410209; BUTT AM, 1995, GLIA, V14, P185, DOI 10.1002/glia.440140304; Casson RJ, 2006, CLIN EXP OPHTHALMOL, V34, P54, DOI 10.1111/j.1442-9071.2006.01146.x; Chabi A, 2012, AM J OPHTHALMOL, V153, P1187, DOI 10.1016/j.ajo.2011.11.008; Crish SD, 2011, NEUROSCIENCE, V176, P1, DOI 10.1016/j.neuroscience.2010.12.036; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Fechtner RD, 2004, ACTA OPHTHALMOL SCAN, V82, P42, DOI 10.1046/j.1600-0420.2004.0205.x; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Fitzgerald M, 2009, INVEST OPHTH VIS SCI, V50, P5456, DOI 10.1167/iovs.09-3717; Fitzgerald M, 2009, EXP NEUROL, V216, P219, DOI 10.1016/j.expneurol.2008.11.026; Franklin RJM, 2008, NAT REV NEUROSCI, V9, P839, DOI 10.1038/nrn2480; FRIEDE RL, 1970, BRAIN RES, V19, P165, DOI 10.1016/0006-8993(70)90432-4; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Howell GR, EXP NEUROL; HSIEH ST, 1994, J NEUROSCI, V14, P6392; James ND, 2011, J NEUROSCI, V31, P18543, DOI 10.1523/JNEUROSCI.4306-11.2011; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Karim MD, 2006, CURR EYE RES, V31, P273, DOI 10.1080/02713680500536647; Knoferle J, 2010, P NATL ACAD SCI USA, V107, P6064, DOI 10.1073/pnas.0909794107; Kursula P, 2008, AMINO ACIDS, V34, P175, DOI 10.1007/s00726-006-0479-7; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lasiene J, 2008, J NEUROSCI, V28, P3887, DOI 10.1523/JNEUROSCI.4756-07.2008; Lau A, 2010, PFLUG ARCH EUR J PHY, V460, P525, DOI 10.1007/s00424-010-0809-1; Levkovitch-Verbin H, 2001, INVEST OPHTH VIS SCI, V42, P975; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; Mellough CB, 2004, EXP NEUROL, V186, P6, DOI 10.1016/j.expneurol.2003.10.021; Monnier PP, 2011, J NEUROSCI, V31, P10494, DOI 10.1523/JNEUROSCI.0148-11.2011; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Payne SC, 2011, J NEUROTRAUM, V28, P1077, DOI 10.1089/neu.2010.1665; Quek DTL, 2011, AM J OPHTHALMOL, V152, P463, DOI 10.1016/j.ajo.2011.02.023; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P635, DOI 10.1001/archopht.1981.03930010635009; Raineteau O, 2001, NAT REV NEUROSCI, V2, P263, DOI 10.1038/35067570; Sanli AM, 2012, TURK NEUROSURG, V22, P189, DOI 10.5137/1019-5149.JTN.5193-11.1; Selt M, 2010, BRAIN RES BULL, V81, P467, DOI 10.1016/j.brainresbull.2009.11.004; Sousa AD, 2007, NEURON GLIA BIOL, V3, P169, DOI 10.1017/S1740925X07000415; Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Tripathi R, 2007, GLIA, V55, P698, DOI 10.1002/glia.20491; Vrabec JP, 2007, EYE, V21, pS11, DOI 10.1038/sj.eye.6702880; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124; Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004; Wrathall JR, 1996, EXP NEUROL, V137, P119, DOI 10.1006/exnr.1996.0012; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906	60	45	48	1	10	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404	1552-5783		INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	SEP	2012	53	10					6093	6101		10.1167/iovs.12-10080			9	Ophthalmology	Ophthalmology	016NQ	WOS:000309526200014	22879411				2021-06-18	
J	Michetti, CP; Fakhry, SM; Ferguson, PL; Cook, A; Moore, FO; Gross, R				Michetti, Christopher P.; Fakhry, Samir M.; Ferguson, Pamela L.; Cook, Alan; Moore, Forrest O.; Gross, Ronald		AAST Ventilator-Associated Pneumon	Ventilator-associated pneumonia rates at major trauma centers compared with a national benchmark: A multi-institutional study of the AAST	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 14-17, 2011	Chicago, IL	Amer Assoc Surg Trauma		Ventilator-associated pneumonia; trauma; ventilator-associated pneumonia rates; trauma centers; multi-institutional study	NETWORK NHSN REPORT; RISK-FACTORS; INFECTION; TRACHEOBRONCHITIS; DIAGNOSIS; OUTCOMES; COMMON	BACKGROUND: Ventilator-associated pneumonia (VAP) rates reported by the National Healthcare Safety Network (NHSN) are used as a benchmark and quality measure, yet different rates are reported from many trauma centers. This multi-institutional study was undertaken to elucidate VAP rates at major trauma centers. METHODS: VAP rate/1,000 ventilator days, diagnostic methods, institutional, and aggregate patient data were collected retrospectively from a convenience sample of trauma centers for 2008 and 2009 and analyzed with descriptive statistics. RESULTS: At 47 participating Level I and II centers, the pooled mean VAP rate was 17.2 versus 8.1 for NHSN (2006-2008). Hospitals' rates were highly variable (range, 1.8-57.6), with 72.3% being above NHSN's mean. Rates differed based on who determined the rate (trauma service, 27.5; infection control or quality or epidemiology, 11.9; or collaborative effort, 19.9) and the frequency with which VAP was excluded based on aspiration or diagnosis before hospital day 5. In 2008 and 2009, blunt trauma patients had higher VAP rates (17.3 and 17.6, respectively) than penetrating patients (11.0 and 10.9, respectively). More centers used a clinical diagnostic strategy (57%) than a bacteriologic strategy (43%). Patients with VAP had a mean Injury Severity Score of 28.7, mean Intensive Care Unit length of stay of 20.8 days, and a 12.2% mortality rate. 50.5% of VAP patients had a traumatic brain injury. CONCLUSIONS: VAP rates at major trauma centers are markedly higher than those reported by NHSN and vary significantly among centers. Available data are insufficient to set benchmarks, because it is questionable whether any one data set is truly representative of most trauma centers. Application of a single benchmark to all centers may be inappropriate, and reliable diagnostic and reporting standards are needed. Prospective analysis of a larger data set is warranted, with attention to injury severity, risk factors specific to trauma patients, diagnostic method used, VAP definitions and exclusions, and reporting guidelines. (J Trauma. 2012; 72: 1165-1173. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Michetti, Christopher P.] Inova Reg Trauma Ctr, Dept Surg, Falls Church, VA 22042 USA; Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA	Michetti, CP (corresponding author), Inova Reg Trauma Ctr, Dept Surg, 3300 Gallows Rd, Falls Church, VA 22042 USA.	christopher.michetti@inova.org		Michetti, Christopher/0000-0002-3744-0603			Bregeon F, 2000, EUR RESPIR J, V16, P969, DOI 10.1183/09031936.00.16596900; Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001; Cocanour Christine S, 2005, Surg Infect (Larchmt), V6, P65, DOI 10.1089/sur.2005.6.65; Cook A, 2010, J TRAUMA, V69, P1083, DOI 10.1097/TA.0b013e3181f9fb51; Cook DJ, 1998, JAMA-J AM MED ASSOC, V279, P1605, DOI 10.1001/jama.279.20.1605; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Croce MA, 2001, AM SURGEON, V67, P105; Croce MA, 1998, ANN SURG, V227, P743, DOI 10.1097/00000658-199805000-00015; Dallas J, 2011, CHEST, V139, P513, DOI 10.1378/chest.10-1336; Edwards JR, 2008, AM J INFECT CONTROL, V36, P609, DOI 10.1016/j.ajic.2008.08.001; Edwards JR, 2007, AM J INFECT CONTROL, V35, P290, DOI 10.1016/j.ajic.2007.04.001; Edwards JR, 2009, AM J INFECT CONTROL, V37, P783, DOI 10.1016/j.ajic.2009.10.001; Fabregas N, 1999, THORAX, V54, P867, DOI 10.1136/thx.54.10.867; Fagon JY, 2000, ANN INTERN MED, V132, P621, DOI 10.7326/0003-4819-132-8-200004180-00004; Hedrick TL, 2008, J TRAUMA, V64, P714, DOI 10.1097/TA.0b013e31811ec18e; Heyland D, 2006, NEW ENGL J MED, V355, P2619, DOI 10.1056/NEJMoa052904; Klompas M, 2007, ANN INTERN MED, V147, P803, DOI 10.7326/0003-4819-147-11-200712040-00013; McKibben L, 2005, AM J INFECT CONTROL, V33, P217, DOI 10.1016/j.ajic.2005.04.001; MEDURI GU, 1994, CHEST, V106, P221, DOI 10.1378/chest.106.1.221; Miller PR, 2006, J TRAUMA, V60, P98, DOI 10.1097/01.ta.0000196379.74305.e4; Napolitano LM, 2003, AM J SURG, V186, p4S, DOI 10.1016/j.amjsurg.2003.10.002; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; Sawyer RG, 2010, CRIT CARE MED, V38, pS483, DOI 10.1097/CCM.0b013e3181ec68c9; Thomas BW, 2011, AM SURGEON, V77, P998; Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754; Wunderink RC, 2011, CHEST, V139, P485, DOI 10.1378/chest.10-2641	26	45	45	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2012	72	5					1165	1172		10.1097/TA.0b013e31824d10fa			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	944JD	WOS:000304195100009	22673241				2021-06-18	
J	Bulger, EM; Guffey, D; Guyette, FX; MacDonald, RD; Brasel, K; Kerby, JD; Minei, JP; Warden, C; Rizoli, S; Morrison, LJ; Nichol, G				Bulger, Eileen M.; Guffey, Danielle; Guyette, Francis X.; MacDonald, Russell D.; Brasel, Karen; Kerby, Jeffery D.; Minei, Joseph P.; Warden, Craig; Rizoli, Sandro; Morrison, Laurie J.; Nichol, Graham		Resuscitation Outcomes Consortium	Impact of prehospital mode of transport after severe injury: A multicenter evaluation from the Resuscitation Outcomes Consortium	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	70th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST) / Clinical Congress of Acute Care Surgery	SEP 14-17, 2011	Chicago, IL	Amer Assoc Surg Trauma		Air medical; emergency medical services; transport: hypovolemic shock; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HYPERTONIC RESUSCITATION; GROUND TRANSPORT; HELICOPTER; MORTALITY; PATIENT; SYSTEM; AIR	BACKGROUND: There is ongoing controversy about the relative effectiveness of air medical versus ground transportation for severely injured patients. In some systems, air medical crews may provide a higher level of care but may require longer transport times. We sought to evaluate the impact of mode of transport on outcome based on analysis of data from two randomized trials of prehospital hypertonic resuscitation. METHODS: Injured patients were enrolled based on prehospital evidence of hypovolemic shock (systolic blood pressure <= 70 mm Hg or systolic blood pressure =71-90 mm Hg with heart rate >= 108 bpm) or severe traumatic brain injury (TBI; Glasgow Coma Scale score <= 8). Patient demographics, injury severity, and physiology were compared based on mode of transport. Multivariate logistic regression was used to determine the impact of mode of transport on 24-hour and 28-day survival for all patients and 6-month extended Glasgow Outcome Scale for patients with TBI, adjusting for differences in injury severity. RESULTS: Included were 2,049 patients, of which 703 (34%) were transported by air. Patients transported by air were more severely injured (mean Injury Severity Score, 30.3 vs. 22.8; p < 0.001), more likely to be in the TBI cohort (70% vs. 55.4%; p < 0.001), and more likely blunt mechanism (94.0% vs. 78.1%; p < 0.001). Patients transported by air had higher rates of prehospital intubation (81% vs. 36%; p < 0.001), received more intravenous fluids (mean 1.3 L vs. 0.8 L; p < 0.001), and had longer prehospital times (mean 76.1 minutes vs. 43.5 minutes; p < 0.001). Adjusted analysis revealed no significant impact of mode of transport on survival or 6-month neurologic outcome (air transport-28-day survival: odds ratio, 1.11; 95% confidence interval, 0.82-1.51; 6-month extended Glasgow Outcome Scale score <= 4: odds ratio, 0.94; 95% confidence interval, 0.68-1.31). CONCLUSION: There was no difference in the adjusted clinical outcome according to mode of transport. However, air medical transported more severely injured patients with more advanced life support procedures and longer prehospital time. (J Trauma. 2012; 72: 567-575. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Bulger, Eileen M.] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Guffey, Danielle] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Nichol, Graham] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Guyette, Francis X.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [MacDonald, Russell D.; Morrison, Laurie J.] Univ Toronto, Div Emergency Med, Toronto, ON, Canada; [Rizoli, Sandro] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Brasel, Karen] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Kerby, Jeffery D.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; [Minei, Joseph P.] Univ Texas SW, Dept Surg, Dallas, TX USA; [Warden, Craig] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR USA	Bulger, EM (corresponding author), Box 359796 Harborview Med Ctr,325 9th Ave, Seattle, WA 98005 USA.	ebulger@u.washington.edu	morrison, laurie J/A-6325-2012; Nichol, Graham/Z-4996-2019	morrison, laurie J/0000-0001-8369-9774; Guffey, Danielle/0000-0003-3721-614X; Guyette, Francis/0000-0002-9151-4896	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL077881, HL077908, U01 HL077871, U01 HL077887, U01 HL077885, U01 HL077865, U01 HL077863, U01 HL077908, HL077867, HL077872, HL077866, U01 HL077873, 5U01 HL077863, HL077887, U01 HL077881, U01 HL077867, HL077885, HL077873, HL077865, U01 HL077872, HL077871, U01 HL077866] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077865, U01HL077887, U01HL077867, U01HL077863, U01HL077885, U01HL077872, U01HL077881, U01HL077866, U01HL077871, U01HL077908, U01HL077873] Funding Source: NIH RePORTER		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Bledsoe BE, 2006, J TRAUMA, V60, P1257, DOI 10.1097/01.ta.0000196489.19928.c0; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Brown JB, 2010, J TRAUMA, V69, P1030, DOI 10.1097/TA.0b013e3181f6f450; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Butler DP, 2010, EMERG MED J, V27, P692, DOI 10.1136/emj.2009.087486; Carr BG, 2006, PREHOSP EMERG CARE, V10, P198, DOI 10.1080/10903120500541324; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Diaz MA, 2005, J TRAUMA, V58, P148, DOI 10.1097/01.TA.0000124264.43941.41; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Jacobs L M, 1999, Conn Med, V63, P677; James DN, 2009, RESUSCITATION, V80, P650, DOI 10.1016/j.resuscitation.2009.02.020; Kerr W A, 1999, Prehosp Disaster Med, V14, P159; Koury S I, 1998, Prehosp Emerg Care, V2, P289, DOI 10.1080/10903129808958882; Lerner EB, 1999, ACAD EMERG MED, V6, P1127, DOI 10.1111/j.1553-2712.1999.tb00115.x; Mcvey J, 2010, PREHOSP EMERG CARE, V14, P45, DOI 10.3109/10903120903349788; Mitchell AD, 2007, CAN J SURG, V50, P129; Newgard CD, 2009, ACAD EMERG MED, V16, P1269, DOI 10.1111/j.1553-2712.2009.00604.x; Talving P, 2009, WORLD J SURG, V33, P2469, DOI 10.1007/s00268-009-0185-1; Taylor CB, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2009.09.030; Thomas SH, 2002, J TRAUMA, V52, P136, DOI 10.1097/00005373-200201000-00023; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	25	45	45	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2012	72	3					567	573		10.1097/TA.0b013e31824baddf			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	906TR	WOS:000301371100010	22491538	Green Accepted			2021-06-18	
J	Jamora, CW; Young, A; Ruff, RM				Jamora, Christina Weyer; Young, Ashley; Ruff, Ronald M.			Comparison of subjective cognitive complaints with neuropsychological tests in individuals with mild vs more severe traumatic brain injuries	BRAIN INJURY			English	Article						Neuropsychology; traumatic brain injury; self-report; cognition; post-traumatic stress disorder	STRESS-DISORDER SYMPTOMS; CLOSED-HEAD INJURY; MEMORY PERFORMANCE; CHRONIC PAIN; DEPRESSION	Primary objective: The aim of this study was to examine the complex inter-relationship between subjective reports of cognitive impairments and neuropsychological performances in compensation-seeking individuals with traumatic brain injury (TBI) of differing severities. Specifically, this study examined: (a) the participants' neuropsychological test scores and self-reported ratings according to TBI severity; (b) whether there was a predictive relationship between self-report and cognitive test scores; and (c) the influence of emotional functioning on self-reported cognitive functioning. Research design: A multi-group comparative research design was employed. Methods and procedure: An outpatient sample of 61 patients with TBIs using neuropsychological testing, RNBI (Ruff Neurobehavioral Inventory) and clinical interviews. Main outcomes and results: The mild TBI group exhibited greater attentional impairments, while the moderate-to-severe group exhibited greater memory and learning impairments on neuropsychological tests. The mild group reported more cognitive symptoms than their more severely damaged counterparts. The mild TBI participants reported significantly more symptoms of post-traumatic stress disorder (PTSD). Conclusions: Individuals with moderate-to-severe TBI were more accurate when reporting their memory and learning difficulties, whereas individuals with mild TBI were more accurate when reporting attentional difficulties. It is likely that the occurrence of PTSD worsens the outcome of a mild TBI. There likely is a cumulative effect between the PTSD symptoms and the emotional residuals in the mild TBI population.	[Jamora, Christina Weyer; Ruff, Ronald M.] Univ Calif San Francisco, San Francisco, CA 94143 USA	Jamora, CW (corresponding author), 909 Hyde St,Suite 620, San Francisco, CA 94109 USA.	christina.weyerjamora@ucsf.edu			RNBI	Dr. Ruff receives royalties from the RNBI. All of the other authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Bailey CM, 2006, FOUNDATIONS OF SPORT-RELATED BRAIN INJURIES, P171, DOI 10.1007/0-387-32565-4_8; Bailey CM, 2009, J HEAD TRAUMA REHAB, V24, P123, DOI 10.1097/HTR.0b013e31819c1caa; Beck AT, 2002, CLINICAL ADVANCES IN COGNITIVE PSYCHOTHERAPY: THEORY AND APPLICATION, P29; Benton A., 1994, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Buitenhuis J, 2006, J PSYCHOSOM RES, V61, P681, DOI 10.1016/j.jpsychores.2006.07.008; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; *C REH MED AM, 1993, J HEAD TRAUMA REHAB, V8, P86; *CDCP, 1996, TRAUM BRAIN INJ US E; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; Fargo JD, 2004, EPILEPSY BEHAV, V5, P143, DOI 10.1016/j.yebeh.2003.11.023; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; GASS CS, 1990, PSYCHOL ASSESSMENT J, V2, P175, DOI DOI 10.1037//1040-3590.2.2.175; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Greiffenstein MF, 2008, ARCH CLIN NEUROPSYCH, V23, P801, DOI 10.1016/j.acn.2008.07.005; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Heaton R., 1993, WISCONSIN CARD SORTI; Hoffman R. G., 1999, J FORENSIC NEUROPSYC, V1, P3, DOI DOI 10.1300/J151V01N02_02; IVERSON G, 2001, J FORENSIC NEUROPSYC, V6, P371; Johansson SH, 2008, BRAIN INJURY, V22, P999, DOI 10.1080/02699050802530573; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; King NS, 2003, HDB CLIN NEUROPSYCHO, P487; Kizilbash AH, 2002, ARCH CLIN NEUROPSYCH, V17, P57, DOI 10.1016/S0887-6177(00)00101-3; KRAUS JF, 1996, NEUROTRAUMA, P12; Larrabee G, 2005, FORENSIC NEUROPSYCHO, P209; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; LEESHALEY P, 1996, ARCH CLIN NEUROPSYCH, V8, P203; Meyers J., 1995, REY COMPLEX FIGURE T; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Mueller J., 2007, NEUROPSYCHIATRIC PRO; Nicholson K, 2001, NEUROREHABILITATION, V16, P225; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prudic J, 2000, J ECT, V16, P121, DOI 10.1097/00124509-200006000-00004; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; Roth RS, 2005, ARCH PHYS MED REHAB, V86, P1147, DOI 10.1016/j.apmr.2004.10.041; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruff R. M., 1999, RUFF LIGHT TRAIL LEA; Ruff R.M., 1996, RUFF 2 7 SELECTIVE A; Ruff R. M., 1996, RUFF FIGURAL FLUENCY; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Taber Katherine H, 2009, J Neuropsychiatry Clin Neurosci, V21, P1, DOI 10.1176/appi.neuropsych.21.1.iv; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	57	45	45	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2012	26	1					36	47		10.3109/02699052.2011.635352			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	858HY	WOS:000297787900004	22149443				2021-06-18	
J	Kigerl, KA; Ankeny, DP; Garg, SK; Wei, P; Guan, Z; Lai, WM; McTigue, DM; Banerjee, R; Popovich, PG				Kigerl, Kristina A.; Ankeny, Daniel P.; Garg, Sanjay K.; Wei, Ping; Guan, Zhen; Lai, Wenmin; McTigue, Dana M.; Banerjee, Ruma; Popovich, Phillip G.			System x(c)(-) regulates microglia and macrophage glutamate excitotoxicity in vivo	EXPERIMENTAL NEUROLOGY			English	Article						System x(c)(-); Redox; Neuroinflammation; Spinal cord injury; Glutamate	SPINAL-CORD-INJURY; CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; CYSTINE TRANSPORT; ALZHEIMERS-DISEASE; PLASMA-MEMBRANE; PROTEIN-KINASE; BLOOD-BRAIN; CELL-DEATH; IFN-GAMMA; NEUROTOXICITY	It is widely believed that microglia and monocyte-derived macrophages (collectively referred to as central nervous system (CNS) macrophages) cause excitotoxicity in the diseased or injured CNS. This view has evolved mostly from in vitro studies showing that neurotoxic concentrations of glutamate are released from CNS macrophages stimulated with lipopolysaccharide ([PS), a potent inflammogen. We hypothesized that excitotoxic killing by CNS macrophages is more rigorously controlled in vivo, requiring both the activation of the glutamate/cystine antiporter (system x(c)(-)) and an increase in extracellular cystine, the substrate that drives glutamate release. Here, we show that non-traumatic microinjection of low-dose LPS into spinal cord gray matter activates CNS macrophages but without causing overt neuropathology. In contrast, neurotoxic inflammation occurs when LPS and cystine are co-injected. Simultaneous injection of NBQX, an antagonist of AMPA glutamate receptors, reduces the neurotoxic effects of LPS + cystine, implicating glutamate as a mediator of neuronal cell death in this model. Surprisingly, neither LPS nor LPS + cystine adversely affects survival of oligodendrocytes or oligodendrocyte progenitor cells. Ex vivo analyses show that redox balance in microglia and macrophages is controlled by induction of system x(c)(-) and that high GSH:GSSG ratios predict the neurotoxic potential of these cells. Together, these data indicate that modulation of redox balance in CNS macrophages, perhaps through regulating system x(c)(-), could be a novel approach for attenuating injurious neuroinflammatory cascades. (C) 2011 Elsevier Inc. All rights reserved.	[Kigerl, Kristina A.; Ankeny, Daniel P.; Wei, Ping; Guan, Zhen; Lai, Wenmin; McTigue, Dana M.; Popovich, Phillip G.] Ohio State Univ, Coll Med, Ctr Brain & Spinal Cord Repair, Columbus, OH 43210 USA; [Kigerl, Kristina A.; Wei, Ping; Guan, Zhen; Lai, Wenmin; McTigue, Dana M.; Popovich, Phillip G.] Ohio State Univ, Coll Med, Dept Neurosci, Columbus, OH 43210 USA; [Garg, Sanjay K.; Banerjee, Ruma] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA	Popovich, PG (corresponding author), Ohio State Univ, Coll Med, Ctr Brain & Spinal Cord Repair, 786 Biomed Res Tower,460 W 12th Ave, Columbus, OH 43210 USA.	phillip.popovich@osumc.edu		Kigerl, Kristina/0000-0002-1652-0882	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS37846, NS059776, DK64959, P30-NS045758]; Craig H. Neilsen Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK064959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037846, R01NS047175, P30NS045758, R01NS059776] Funding Source: NIH RePORTER	This work was supported in part by grants NIH-NS37846 (PGP), NS059776 (DMM) and DK64959 (RB), P30-NS045758, and Craig H. Neilsen Foundation (PGP).	ANDERSON ME, 1989, FASEB J, V3, P2527; Baker DA, 2003, NAT NEUROSCI, V6, P743, DOI 10.1038/nn1069; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Burdo J, 2006, J HISTOCHEM CYTOCHEM, V54, P549, DOI 10.1369/jhc.5A6840.2006; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P197, DOI 10.2174/1567202054368317; Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005; Dobashi K, 2001, CLIN EXP IMMUNOL, V124, P290, DOI 10.1046/j.1365-2249.2001.01535.x; Domercq M, 2007, J IMMUNOL, V178, P6549, DOI 10.4049/jimmunol.178.10.6549; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; DROGE W, 1991, AM J MED, V91, pS140, DOI 10.1016/0002-9343(91)90297-B; Farso MC, 2009, NEUROCHEM RES, V34, P1721, DOI 10.1007/s11064-009-9999-3; Fogal B, 2007, J NEUROSCI, V27, P10094, DOI 10.1523/JNEUROSCI.2459-07.2007; Gan HT, 2005, J GASTROEN HEPATOL, V20, P1016, DOI 10.1111/j.1440-1746.2005.03862.x; Garg S, 2006, J BIOL CHEM, V281, P38712, DOI 10.1074/jbc.M606235200; Garg SK, 2008, J IMMUNOL, V180, P3866, DOI 10.4049/jimmunol.180.6.3866; Gensel JC, 2009, J NEUROSCI, V29, P3956, DOI 10.1523/JNEUROSCI.3992-08.2009; Glezer I, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000310; Hauss-Wegrzyniak B, 1998, BRAIN RES, V780, P294, DOI 10.1016/S0006-8993(97)01215-8; Hermann GE, 2001, NEUROBIOL DIS, V8, P590, DOI 10.1006/nbdi.2001.0414; Hosoya K, 2001, MICROVASC RES, V62, P136, DOI 10.1006/mvre.2001.2328; Johnson JM, 2008, CLIN CHIM ACTA, V396, P43, DOI 10.1016/j.cca.2008.06.020; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kigerl KA, 2007, J NEUROCHEM, V102, P37, DOI 10.1111/j.1471-4159.2007.04524.x; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Longbrake EE, 2007, J NEUROCHEM, V102, P1083, DOI 10.1111/j.1471-4159.2007.04617.x; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; McMillian MK, 1997, J NEUROPATH EXP NEUR, V56, P301, DOI 10.1097/00005072-199703000-00009; Miller BA, 2005, NEUROCHEM RES, V30, P867, DOI 10.1007/s11064-005-6880-x; Murata Y, 2002, EUR J IMMUNOL, V32, P2866, DOI 10.1002/1521-4141(2002010)32:10<2866::AID-IMMU2866>3.0.CO;2-V; Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029; Noh JH, 2006, NEUROPHARMACOLOGY, V50, P1, DOI 10.1016/j.neuropharm.2005.07.020; OKA A, 1993, J NEUROSCI, V13, P1441; OLNEY JW, 1994, J NEURAL TRANSM-SUPP, P47; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; PIANI D, 1994, J IMMUNOL, V152, P3578; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Qin S, 2006, J NEUROSCI, V26, P3345, DOI 10.1523/JNEUROSCI.5186-05.2006; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; SATO H, 1995, BIOCHEM J, V310, P547, DOI 10.1042/bj3100547; Sato H, 2002, J NEUROSCI, V22, P8028; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Schonberg D.L, 2007, J NEUROPATHOL EXP NE, V66; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; WADE LA, 1981, J NEUROCHEM, V37, P730; Wang JY, 2003, J NEUROSCI RES, V72, P508, DOI 10.1002/jnr.10597; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029; Ye ZC, 1999, J NEUROSCI, V19, P10767	59	45	47	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2012	233	1					333	341		10.1016/j.expneurol.2011.10.025			9	Neurosciences	Neurosciences & Neurology	890CY	WOS:000300123900037	22079587	Green Accepted			2021-06-18	
J	Shigemori, M; Abe, T; Aruga, T; Ogawa, T; Okudera, H; Ono, J; Onuma, T; Katayama, Y; Kawai, N; Kawamata, T; Kohmura, E; Sakaki, T; Sakamoto, T; Sasaki, T; Sato, A; Shiogai, T; Shima, K; Sugiura, K; Takasato, Y; Tokutomi, T; Tomita, H; Toyoda, I; Nagao, S; Nakamura, H; Park, YS; Matsumae, M; Miki, T; Miyake, Y; Murai, H; Murakami, S; Yamaura, A; Yamaki, T; Yamada, K; Yoshimine, T				Shigemori, Minoru; Abe, Toshiaki; Aruga, Tohru; Ogawa, Takeki; Okudera, Hiroshi; Ono, Junichi; Onuma, Takehide; Katayama, Yoichi; Kawai, Nobuyuki; Kawamata, Tatsuro; Kohmura, Eiji; Sakaki, Toshisuke; Sakamoto, Tetsuya; Sasaki, Tatsuya; Sato, Akira; Shiogai, Toshiyuki; Shima, Katsuji; Sugiura, Kazuo; Takasato, Yoshio; Tokutomi, Takashi; Tomita, Hiroki; Toyoda, Izumi; Nagao, Seig; Nakamura, Hiroshi; Park, Young-soo; Matsumae, Mitsunori; Miki, Tamotsu; Miyake, Yasushi; Murai, Hisayuki; Murakami, Shigeyuki; Yamaura, Akira; Yamaki, Tarumi; Yamada, Kazuo; Yoshimine, Toshiki			Guidelines for the Management of Severe Head Injury, 2nd Edition Guidelines from the Guidelines Committee on the Management of Severe Head Injury, the Japan Society of Neurotraumatology The guidelines are officially approved by the Japan Neurosurgical Society	NEUROLOGIA MEDICO-CHIRURGICA			English	Article						head injury; traumatic brain injury; neurotrauma; guidelines; management	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; VENOUS OXYGEN-SATURATION; INTRACRANIAL-PRESSURE; DECOMPRESSIVE CRANIECTOMY; BLOOD-FLOW; ENERGY-EXPENDITURE; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; COMPUTED-TOMOGRAPHY	In 1998, the Guidelines Committee on the Management of Severe Head Injury was established by the Japan Society of Neurotraumatology, and performed a critical review of national and international studies published over the past 10 years. The guidelines were first published in 2000 based on the results of this literature review and the Committee consensus, and the 2nd revised edition was published in 2006. This English version of the 2nd edition of the guidelines is intended to promote its concepts and use worldwide.	[Shigemori, Minoru] Jikei Univ, Sch Med, Dept Neurosurg, Secretariat Japan Soc Neurotraumatol,Minato Ku, Tokyo 1058461, Japan	Shigemori, M (corresponding author), Jikei Univ, Sch Med, Dept Neurosurg, Secretariat Japan Soc Neurotraumatol,Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	neurotrauma@jikei.ac.jp		Okudera, Hiroshi/0000-0003-0153-6352			Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Albanese J, 1997, ANESTHESIOLOGY, V87, P1328, DOI 10.1097/00000542-199712000-00011; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; American Association for the Surgery of Trauma, 2003, J Trauma, V54, pS235; Anand Vijay K., 1995, Rhinology (Utrecht), V33, P212; ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; ASPEN Board of Directors and the Clinical Guidelines Task Force, 2002, JPEN J Parenter Enteral Nutr, V26, p1SA; BALDWIN HZ, 1992, PEDIATR NEUROSURG, V17, P115, DOI 10.1159/000120579; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; BARKER FG, 1994, NEUROSURGERY, V35, P484, DOI 10.1227/00006123-199409000-00017; Bazarian JJ, 2002, ANN EMERG MED, V40, P515, DOI 10.1067/mem.2002.128780; Becker DP, 1989, TXB HEAD INJURY, P350; Biffl WL, 1999, CURR PROB SURG, V36, P510; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Bok AP, 1986, J TRAUMA, V40, P986; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; Brawanski A, 2002, J CEREBR BLOOD F MET, V22, P605, DOI 10.1097/00004647-200205000-00012; Brodie HA, 1997, ARCH OTOLARYNGOL, V123, P749; BRUDER N, 1991, CRIT CARE MED, V19, P43, DOI 10.1097/00003246-199101000-00013; Bula W I, 1994, Neuroimaging Clin N Am, V4, P753; Bullock MR, 1996, J NEUROTRAUM, V13, P643; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Burger R, 1998, ACT NEUR S, V71, P157; Burnstine MA, 2002, OPHTHALMOLOGY, V109, P1207, DOI 10.1016/S0161-6420(02)01057-6; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Centers for Disease Control and Prevention, 2000, B AM COLL SURG, V85, P23; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; Cooper PR, 1979, J NEUROSURG, V64, P81; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Cruz J, 1996, J NEUROSURG, V85, P758, DOI 10.3171/jns.1996.85.5.0758; Cruz J, 1998, CRIT CARE MED, V26, P344, DOI 10.1097/00003246-199802000-00039; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Edwards P, 2005, LANCET, V365, P1957; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Fabregas N, 2004, ANESTHESIOLOGY, V101, P43, DOI 10.1097/00000542-200407000-00009; FANCONI S, 1988, INTENS CARE MED, V14, P163; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Friedman JA, 2001, WORLD J SURG, V25, P1062, DOI 10.1007/s00268-001-0059-7; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GRAHM TW, 1989, NEUROSURGERY, V25, P729, DOI 10.1227/00006123-198911000-00007; Gruszkiewicz J, 1973, Surg Neurol, V1, P197; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Guyot LL, 2001, NEUROL RES, V23, P291, DOI 10.1179/016164101101198442; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ishikawa E, 2000, NEUROL MED-CHIR, V40, P458, DOI 10.2176/nmc.40.458; Ito M, 2001, J CLIN NEUROSCI, V8, P261, DOI 10.1054/jocn.1999.0733; Iwase M, 1999, NEUROSURGICAL EMERGE, V4, P27; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; Jensen RL, 1997, SURG NEUROL, V47, P16, DOI 10.1016/S0090-3019(96)00276-5; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KASOFF SS, 1988, PEDIATR NEUROSCI, V14, P241, DOI 10.1159/000120397; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kitakami A, 1999, NEUROL MED-CHIR, V39, P150, DOI 10.2176/nmc.39.150; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lang E W, 1995, New Horiz, V3, P400; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lannoo E, 1998, INTENS CARE MED, V24, P236, DOI 10.1007/s001340050556; LEVY DI, 1995, J NEUROSURG, V83, P453, DOI 10.3171/jns.1995.83.3.0453; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 1996, J NEUROSURG, V84, P731; Matsumae M, 2001, ACTA NEUROCHIR, V143, P1229, DOI 10.1007/s007010100019; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; McCall M, 2003, JPEN-PARENTER ENTER, V27, P27, DOI 10.1177/014860710302700127; MCGUIRT WF, 1995, LARYNGOSCOPE, V105, P359, DOI 10.1288/00005537-199504000-00003; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; McKinely BA, 1999, J TRAUMA, V46, P271, DOI 10.1097/00005373-199902000-00013; Meier U, 2003, ACTA NEUROCHIR SUPPL, V86, P367; Meixensberger J, 1997, NEUROL RES, V19, P249, DOI 10.1080/01616412.1997.11740808; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; Mendizabal G R, 1992, Rev Laryngol Otol Rhinol (Bord), V113, P423; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; Mine S, 1999, ACTA NEUROCHIR, V141, P27, DOI 10.1007/s007010050262; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; Moro-Sutherland DM, 2000, ACAD EMERG MED, V7, P1370, DOI 10.1111/j.1553-2712.2000.tb00494.x; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; National Collaborate Centre for Acute Care: NICE Clinical Guidelines CG56: Head injury: triage assessment investigation and early management of head injury in infants children and adults, 2003, NICE CLIN GUID CG56; NEW PFJ, 1976, RADIOLOGY, V121, P635, DOI 10.1148/121.3.635; Ng M, 1998, ARCH OTOLARYNGOL, V124, P1125, DOI 10.1001/archotol.124.10.1125; Nirula R, 2004, J TRAUMA, V57, P37, DOI 10.1097/01.TA.0000128236.45043.6A; NORDBY HK, 1984, ACTA NEUROCHIR, V72, P157, DOI 10.1007/BF01406868; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; Ohata H, 1999, ANESTH ANALG, V89, P370, DOI 10.1097/00000539-199908000-00023; OTSUKA S-I, 1990, Neurologia Medico-Chirurgica, V30, P24, DOI 10.2176/nmc.30.24; Ott L, 1999, J NEUROTRAUM, V16, P233, DOI 10.1089/neu.1999.16.233; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Pittman JE, 1997, ANESTHESIOLOGY, V87, P1139, DOI 10.1097/00000542-199711000-00018; PITTMAN T, 1989, PEDIATR NEUROSCI, V15, P13, DOI 10.1159/000120433; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Poon WS, 2002, ACT NEUR S, V81, P335; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; RAURICH JM, 1994, JPEN-PARENTER ENTER, V18, P521, DOI 10.1177/0148607194018006521; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rhodes Jonathan K J, 2003, Curr Opin Crit Care, V9, P86; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; SATO M, 1989, RESUSCITATION, V17, P233, DOI 10.1016/0300-9572(89)90039-7; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHETTINI A, 1982, J NEUROSURG, V56, P679, DOI 10.3171/jns.1982.56.5.0679; Schneider GH, 2002, ACT NEUR S, V81, P77; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SEELIG JM, 1981, J NEUROSURG, V55, P516, DOI 10.3171/jns.1981.55.4.0516; Segatore M, 1999, J Neurosci Nurs, V31, P239; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Sethi D. S., 1996, Annals Academy of Medicine Singapore, V25, P724; SHACKFORD SR, 1988, SURGERY, V104, P553; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Shiogai T, 1998, ACT NEUR S, V71, P94; Shiogai T, 1999, ACT NEUR S, V75, P49; Shiozaki T, 2003, J NEUROSURG, V99, P47, DOI 10.3171/jns.2003.99.1.0047; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Sires BS, 1998, ARCH OPHTHALMOL-CHIC, V116, P955; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; SMITH HP, 1986, J NEUROSURG, V65, P820, DOI 10.3171/jns.1986.65.6.0820; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Suchner U, 1996, NUTRITION, V12, P13, DOI 10.1016/0899-9007(95)00016-X; SUGIURA K, 1992, NEUROSURGERY, V31, P1023, DOI 10.1227/00006123-199212000-00006; Takanashi Y, 2002, J Neurosurg Sci, V46, P25; Talke P, 1996, ANESTHESIOLOGY, V85, P551, DOI 10.1097/00000542-199609000-00014; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; TORNHEIM PA, 1979, NEUROSURGERY, V4, P48, DOI 10.1227/00006123-197901000-00009; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vernon DD, 2000, CRIT CARE MED, V28, P1569, DOI 10.1097/00003246-200005000-00051; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Villalobos T, 1998, CLIN INFECT DIS, V27, P364, DOI 10.1086/514666; Vriens JPM, 1995, J CRANIO MAXILL SURG, V23, P363, DOI 10.1016/S1010-5182(05)80131-3; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Winkelman C, 2000, Am J Crit Care, V9, P373; Wintermark M, 2004, CRIT CARE MED, V32, P1579, DOI 10.1097/01.CCM.0000130171.08842.72; Yokota H, 2000, CRIT CARE MED, V28, P3275, DOI 10.1097/00003246-200009000-00025; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; ZACHARIADES N, 1990, J CRANIO MAXILL SURG, V18, P315, DOI 10.1016/S1010-5182(05)80539-6; Zafonte RD, 2001, NEUROL RES, V23, P219, DOI 10.1179/016164101101198370; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937; 2001, J TRAUMA, V51, pS3	194	45	47	0	7	JAPAN NEUROSURGICAL SOC	TOKYO	5-25-16 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105	1349-8029		NEUROL MED-CHIR	Neurol. Med.-Chir.	JAN	2012	52	1					1	30					30	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	879SE	WOS:000299351700001	22278024				2021-06-18	
J	Stanley, RM; Bonsu, BK; Zhao, WY; Ehrlich, PF; Rogers, AJ; Xiang, HY				Stanley, Rachel M.; Bonsu, Bema K.; Zhao, Weiyan; Ehrlich, Peter F.; Rogers, Alexander J.; Xiang, Huiyun			US Estimates of Hospitalized Children With Severe Traumatic Brain Injury: Implications for Clinical Trials	PEDIATRICS			English	Article						severe traumatic brain injury; clinical trials; children	UNIQUE CHALLENGES	OBJECTIVES: To estimate sample sizes available for clinical trials of severe traumatic brain injury (TBI) in children, we described the patient demographics and hospital characteristics associated with children hospitalized with severe TBI in the United States. METHODS: We analyzed the 2006 Kids' Inpatient Database. Severe TBI hospitalizations were defined as children discharged with TBI who required mechanical ventilation or intubation. Types of high-volume severe TBI hospitals were categorized based on the numbers of discharged patients with severe TBI in 2006. National estimates of demographics and hospital characteristics were calculated for pediatric severe TBI. Simulation analyses were performed to assess the potential number of severe TBI cases from randomly selected hospitals for inclusion in future clinical trials. RESULTS: The majority of children with severe TBI were discharged from either a children's unit in general hospitals (41%) or a nonchildren's hospital (34%). Less than 5% of all hospitals were high-volume TBI hospitals, which discharged >78% of severe TBI cases and were more likely to be a children's unit in a general hospital or a children's hospital. Simulation analyses indicate that there is a saturation point after which the benefit of adding additional recruitment sites decreases significantly. CONCLUSIONS: Children with severe TBI are infrequent at any one hospital in the United States, and few hospitals treat large numbers of children with severe TBI. To effectively plan trials of therapies for severe TBI, much attention has to be paid to selecting the right types of centers to maximize enrollment efficiency. Pediatrics 2012; 129: e24-e30	[Stanley, Rachel M.; Rogers, Alexander J.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48105 USA; [Ehrlich, Peter F.] Univ Michigan, Dept Surg, Ann Arbor, MI 48105 USA; [Stanley, Rachel M.; Ehrlich, Peter F.] Univ Michigan, Injury Ctr, Ann Arbor, MI 48105 USA; [Bonsu, Bema K.; Xiang, Huiyun] Ohio State Univ, Dept Pediat, Nationwide Childrens Hosp, Columbus, OH 43210 USA; [Zhao, Weiyan; Xiang, Huiyun] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH USA	Stanley, RM (corresponding author), Univ Michigan, Dept Emergency Med, 24 Frank Lloyd Wright,Suite H-3200,POB 443, Ann Arbor, MI 48105 USA.	stanleyr@umich.edu	Xiang, Huiyun/E-4335-2011		National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE001172-01]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172] Funding Source: NIH RePORTER	Efforts by Drs Xiang and Zhao at the Center for Injury Research and Policy, The Research Institute at Nationwide Children's Hospital, were supported in part by National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, grant R49/CE001172-01.	Alexander D, 2003, PEDIATR EMERG CARE, V19, P185; Brain Trauma Foundation American Association of Neurological Surgeons Congress of Neurological Surgeons, 2007, J NEUROTRAUM, V24, pS45, DOI DOI 10.1089/NEU.2007.9989; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, 2006, HEALTHC COST UT PROJ; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Medicine PE, MED PE; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT CTR INJ PREV, 2006, TRAUM BRAIN INJ US A; Natale JE, 2007, PEDIATR CRIT CARE ME, V8, P1, DOI 10.1097/01.pcc.0000256620.55512.5f; Natale JE, 2006, DEV NEUROSCI-BASEL, V28, P276, DOI 10.1159/000094154; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; The National Institute of Neurological Disorders and Stroke (NINDS), COOLKIDS TRIAL; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5	21	45	45	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2012	129	1					E24	E30		10.1542/peds.2011-2074			7	Pediatrics	Pediatrics	870BT	WOS:000298644800004	22184643				2021-06-18	
J	Irimia, A; Chambers, MC; Alger, JR; Filippou, M; Prastawa, MW; Wang, B; Hovda, DA; Gerig, G; Toga, AW; Kikinis, R; Vespa, PM; Van Horn, JD				Irimia, Andrei; Chambers, Micah C.; Alger, Jeffry R.; Filippou, Maria; Prastawa, Marcel W.; Wang, Bo; Hovda, David A.; Gerig, Guido; Toga, Arthur W.; Kikinis, Ron; Vespa, Paul M.; Van Horn, John D.			Comparison of Acute and Chronic Traumatic Brain Injury Using Semi-Automatic Multimodal Segmentation of MR Volumes	JOURNAL OF NEUROTRAUMA			English	Article						magnetic resonance imaging; segmentation; TBI; visualization	DIFFUSE AXONAL INJURY; HEAD-INJURY; CLINICAL-APPLICATIONS; COMPUTED-TOMOGRAPHY; TUMOR SEGMENTATION; CEREBRAL ATROPHY; AXIAL TOMOGRAPHY; CHILDREN; LESIONS; STROKE	Although neuroimaging is essential for prompt and proper management of traumatic brain injury (TBI), there is a regrettable and acute lack of robust methods for the visualization and assessment of TBI pathophysiology, especially for of the purpose of improving clinical outcome metrics. Until now, the application of automatic segmentation algorithms to TBI in a clinical setting has remained an elusive goal because existing methods have, for the most part, been insufficiently robust to faithfully capture TBI-related changes in brain anatomy. This article introduces and illustrates the combined use of multimodal TBI segmentation and time point comparison using 3D Slicer, a widely-used software environment whose TBI data processing solutions are openly available. For three representative TBI cases, semi-automatic tissue classification and 3D model generation are performed to perform intra-patient time point comparison of TBI using multimodal volumetrics and clinical atrophy measures. Identification and quantitative assessment of extra-and intra-cortical bleeding, lesions, edema, and diffuse axonal injury are demonstrated. The proposed tools allow cross-correlation of multimodal metrics from structural imaging (e. g., structural volume, atrophy measurements) with clinical outcome variables and other potential factors predictive of recovery. In addition, the workflows described are suitable for TBI clinical practice and patient monitoring, particularly for assessing damage extent and for the measurement of neuroanatomical change over time. With knowledge of general location, extent, and degree of change, such metrics can be associated with clinical measures and subsequently used to suggest viable treatment options.	[Irimia, Andrei; Chambers, Micah C.; Toga, Arthur W.; Van Horn, John D.] Univ Calif Los Angeles, Lab Neuro Imaging, Dept Neurol, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Toga, Arthur W.] Univ Calif Los Angeles, Brain Res Inst, Dept Neurol, Los Angeles, CA 90095 USA; [Chambers, Micah C.] Univ Calif Los Angeles, Henri Samueli Sch Engn & Appl Sci, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Hovda, David A.] Univ Calif Los Angeles, Dept Radiol Sci, Los Angeles, CA 90095 USA; [Alger, Jeffry R.; Toga, Arthur W.] Univ Calif Los Angeles, Div Brain Mapping, Inst Neuropsychiat, Los Angeles, CA 90095 USA; [Filippou, Maria; Vespa, Paul M.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurosurg, Los Angeles, CA 90095 USA; [Filippou, Maria; Vespa, Paul M.] Univ Calif Los Angeles, Brain Injury Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA; [Prastawa, Marcel W.; Wang, Bo; Gerig, Guido] Univ Utah, Sci Comp & Imaging Inst, Salt Lake City, UT USA; [Prastawa, Marcel W.; Wang, Bo; Gerig, Guido] Univ Utah, Sch Comp, Salt Lake City, UT USA; [Kikinis, Ron] Harvard Univ, Sch Med, Dept Radiol, Surg Planning Lab, Boston, MA 02115 USA	Irimia, A (corresponding author), Univ Calif Los Angeles, Lab Neuro Imaging, Dept Neurol, Los Angeles, CA 90095 USA.	andrei.irimia@loni.ucla.edu	Irimia, Andrei/B-8275-2008; Prastawa, Marcel W/G-6335-2012	Irimia, Andrei/0000-0002-9254-9388; Gerig, Guido/0000-0002-9547-6233; Van Horn, John/0000-0003-1537-0816; Filippou-Frye, Maria/0000-0001-5516-0384; Wang, Bo/0000-0002-0127-2281; Prastawa, Marcel/0000-0002-0278-9637	National Alliance for Medical Image Computing (NA-MIC) under National Institutes of Health Roadmap Initiative [2U54EB005149]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [U54EB005149] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS082086, P01NS058489] Funding Source: NIH RePORTER	We acknowledge the assistance of David McArthur, Maria Etcheparre, Silvain Gouttard, Steve Pieper, Stephen Aylward, Sonja Pujol, and the staff of the Laboratory of Neuro Imaging at UCLA. 3D Slicer is a multi-platform, free, and open source software package for visualization and medical image computing available from www.slicer.org. This work was supported by the National Alliance for Medical Image Computing (NA-MIC; www.na-mic.org), under National Institutes of Health Roadmap Initiative grant 2U54EB005149 to R. K. and sub-award to J. D. V. H., and by the NINDS, grant P01NS058489 to P. M. V.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Chesnut RM, 1998, SURG NEUROL, V50, P187, DOI 10.1016/S0090-3019(98)00075-5; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DECOENE B, 1992, AM J NEURORADIOL, V13, P1555; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Dubroff JG, 2008, SEMIN NEUROL, V28, P548, DOI 10.1055/s-0028-1083698; EARNEST MP, 1979, NEUROLOGY, V29, P1138, DOI 10.1212/WNL.29.8.1138; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Filippi M, 1998, NEUROLOGY, V50, P238, DOI 10.1212/WNL.50.1.238; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; GYLDENSTED C, 1977, NEURORADIOLOGY, V14, P183, DOI 10.1007/BF00496982; HAHN FJY, 1976, NEURORADIOLOGY, V12, P137, DOI 10.1007/BF00341858; HUCKMAN MS, 1975, RADIOLOGY, V116, P85, DOI 10.1148/116.1.85; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Itti L, 2001, J NEUROIMAGING, V11, P412, DOI 10.1111/j.1552-6569.2001.tb00071.x; JONES KM, 1992, AM J ROENTGENOL, V158, P1313, DOI 10.2214/ajr.158.6.1590133; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lee Bruce, 2005, NeuroRx, V2, P372; Lehmann M, 2010, NEUROIMAGE, V49, P2264, DOI 10.1016/j.neuroimage.2009.10.056; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maes F, 1997, IEEE T MED IMAGING, V16, P187, DOI 10.1109/42.563664; MUGLER JP, 1990, MAGNET RESON MED, V15, P152, DOI 10.1002/mrm.1910150117; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Pohl KM, 2007, IEEE T MED IMAGING, V26, P1201, DOI 10.1109/TMI.2007.901433; Prastawa M, 2004, MED IMAGE ANAL, V8, P275, DOI 10.1016/j.media.2004.06.007; Prastawa M, 2003, ACAD RADIOL, V10, P1341, DOI 10.1016/S1076-6332(03)00506-3; Prastawa M, 2009, MED IMAGE ANAL, V13, P297, DOI 10.1016/j.media.2008.11.002; Prastawa M, 2008, LECT NOTES COMPUT SC, V5358, P562, DOI 10.1007/978-3-540-89639-5_54; ROBB RA, 1989, COMPUT MED IMAG GRAP, V13, P433, DOI 10.1016/0895-6111(89)90285-1; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Strangman GE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00182; SYNEK V, 1976, NEUROLOGY, V26, P231, DOI 10.1212/WNL.26.3.231; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Van Leemput K, 1999, IEEE T MED IMAGING, V18, P897, DOI 10.1109/42.811270; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; Zollei L, 2007, P MED IM COMP COMP A, P39	56	45	46	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2287	2306		10.1089/neu.2011.1920			20	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600008	21787171	Green Published			2021-06-18	
J	Das, M; Leonardo, CC; Rangooni, S; Mohapatra, SS; Mohapatra, S; Pennypacker, KR				Das, Mahasweta; Leonardo, Christopher C.; Rangooni, Saniya; Mohapatra, Shyam S.; Mohapatra, Subhra; Pennypacker, Keith R.			Lateral fluid percussion injury of the brain induces CCL20 inflammatory chemokine expression in rats	JOURNAL OF NEUROINFLAMMATION			English	Article						TBI; LFPI; CCL20; inflammation; neural damage; spleen; cortex; hippocampus	FLUORO-JADE; RHEUMATOID-ARTHRITIS; IRAQI FREEDOM; HEAD-INJURY; ASTROCYTES; ACTIVATION; CYTOKINES; CELLS; MODEL; NEURODEGENERATION	Background: Traumatic brain injury (TBI) evokes a systemic immune response including leukocyte migration into the brain and release of pro-inflammatory cytokines; however, the mechanisms underlying TBI pathogenesis and protection are poorly understood. Due to the high incidence of head trauma in the sports field, battlefield and automobile accidents identification of the molecular signals involved in TBI progression is critical for the development of novel therapeutics. Methods: In this report, we used a rat lateral fluid percussion impact (LFPI) model of TBI to characterize neurodegeneration, apoptosis and alterations in pro-inflammatory mediators at two time points within the secondary injury phase. Brain histopathology was evaluated by fluoro-jade (FJ) staining and terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay, polymerase chain reaction (qRT PCR), enzyme linked immunosorbent assay (ELISA) and immunohistochemistry were employed to evaluate the CCL20 gene expression in different tissues. Results: Histological analysis of neurodegeneration by FJ staining showed mild injury in the cerebral cortex, hippocampus and thalamus. TUNEL staining confirmed the presence of apoptotic cells and CD11b(+) microglia indicated initiation of an inflammatory reaction leading to secondary damage in these areas. Analysis of spleen mRNA by PCR microarray of an inflammation panel led to the identification of CCL20 as an important pro-inflammatory signal upregulated 24 h after TBI. Although, CCL20 expression was observed in spleen and thymus after 24h of TBI, it was not expressed in degenerating cortex or hippocampal neurons until 48 h after insult. Splenectomy partially but significantly decreased the CCL20 expression in brain tissues. Conclusion: These results demonstrate that the systemic inflammatory reaction to TBI starts earlier than the local brain response and suggest that spleen- and/ or thymus-derived CCL20 might play a role in promoting neuronal injury and central nervous system inflammation in response to mild TBI.	[Das, Mahasweta; Rangooni, Saniya; Mohapatra, Shyam S.] Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; [Leonardo, Christopher C.; Pennypacker, Keith R.] Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33612 USA; [Mohapatra, Subhra] Univ S Florida, Coll Med, Dept Mol Med, Tampa, FL 33612 USA; [Mohapatra, Shyam S.; Mohapatra, Subhra] JAH VA Hosp, Tampa, FL 33612 USA	Mohapatra, SS (corresponding author), Univ S Florida, Coll Med, Dept Internal Med, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	smohapat@health.usf.edu; smohapa2@health.usf.edu; kpennypa@health.usf.edu	Pennypacker, Keith/I-5092-2012; Mohapatra, Shyam/C-2500-2012		VA career scientist award; USF [5R21NS060907]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS060907] Funding Source: NIH RePORTER	This work is supported by a VA career scientist award to Shyam Mohapatra, a USF Health development grant to Subhra Mohapatra and 5R21NS060907 to Keith Pennypacker. We would like to acknowledge Xiaoyuan Kong, Jordan Heft and Sowndharya Rajavel for technical assistance and James Musso (III) for assistance in initial experiments.	Ajmo CT, 2008, J NEUROSCI RES, V86, P2227, DOI 10.1002/jnr.21661; Ambrosini E, 2003, GLIA, V41, P290, DOI 10.1002/glia.10193; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chabaud M, 2001, J IMMUNOL, V167, P6015, DOI 10.4049/jimmunol.167.10.6015; Comerford I, 2010, BIOESSAYS, V32, P1067, DOI 10.1002/bies.201000063; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Duckworth EAM, 2005, BRAIN RES, V1042, P29, DOI 10.1016/j.brainres.2005.02.021; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; FERNAUDESPINOSA I, 1993, GLIA, V8, P277, DOI 10.1002/glia.440080408; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Hellmich HL, 2007, BRAIN RES, V1127, P119, DOI 10.1016/j.brainres.2006.09.094; HELMY A, 2010, J CEREB BLOOD FLOW M; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Li M, 2011, J TRAUMA; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lunemann A, 2006, GLIA, V53, P412, DOI 10.1002/glia.20301; MACGREGOR AJ, 2010, J HEAD TRAUMA REHABI; Matsui T, 2001, CLIN EXP IMMUNOL, V125, P155, DOI 10.1046/j.1365-2249.2001.01542.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKimmie CS, 2010, BIOCHEM BIOPH RES CO, V394, P1006, DOI 10.1016/j.bbrc.2010.03.111; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; Okuaki Y, 1996, LIVER, V16, P188; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; REID DM, 1993, NEUROSCIENCE, V56, P529, DOI 10.1016/0306-4522(93)90353-H; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stewart IB, 2002, SPORTS MED, V32, P361, DOI 10.2165/00007256-200232060-00002; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Villares R, 2009, EUR J IMMUNOL, V39, P1671, DOI 10.1002/eji.200839123; Walker PA, 2010, REGEN MED, V5, P65, DOI 10.2217/RME.09.73	39	45	47	0	14	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 31	2011	8								148	10.1186/1742-2094-8-148			16	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	857NK	WOS:000297725100001	22040257	DOAJ Gold, Green Published			2021-06-18	
J	Doonan, F; O'Driscoll, C; Kenna, P; Cotter, TG				Doonan, Francesca; O'Driscoll, Carolyn; Kenna, Paul; Cotter, Thomas G.			Enhancing survival of photoreceptor cells in vivo using the synthetic progestin Norgestrel	JOURNAL OF NEUROCHEMISTRY			English	Article						bFGF; neuroprotection; Norgestrel; photoreceptor; progestin; retinal degeneration	FIBROBLAST-GROWTH-FACTOR; CILIARY NEUROTROPHIC FACTOR; INDUCED RETINAL DEGENERATION; TRAUMATIC BRAIN-INJURY; FACTOR MESSENGER-RNA; RETINITIS-PIGMENTOSA; GENE-EXPRESSION; UP-REGULATION; MOUSE RETINA; LIGHT DAMAGE	Retinal degenerations such as Retinitis Pigmentosa remain difficult to treat given the diverse array of genes responsible for their aetiology. Rather than concentrate on specific genes, our focus is on identifying therapeutic avenues for the treatment of retinal disease that target general survival mechanisms or pathways. Norgestrel is a synthetic progestin commonly used in hormonal contraception. Here, we report a novel anti-apoptotic role for Norgestrel in diseased mouse retinas in vivo. Dosing with Norgestrel protects photoreceptor cells from undergoing apoptosis in two distinct models of retinal degeneration; the light damage model and the Pde6b(rd10) model. Photoreceptor rescue was assessed by analysis of cell number, structural integrity and function. Improvements in cell survival of up to 70% were achieved in both disease models, indicating that apoptosis had been halted or at least delayed. A speculative mechanism of action for Norgestrel involves activation of survival pathways in the retina. Indeed, Norgestrel increases the expression of basic fibroblast growth factor which is known to both promote cell survival and inhibit apoptosis. In summary, our results demonstrate significant protection of photoreceptor cells which may be attributed to Norgestrel mediated activation of endogenous survival pathways within the retina.	[Doonan, Francesca; O'Driscoll, Carolyn; Cotter, Thomas G.] Univ Coll Cork, Dept Biochem, Biosci Res Inst, Cell Dev & Dis Lab, Cork, Ireland; [Kenna, Paul] Trinity Coll Dublin, Dept Genet, Smurfit Inst Genet, Dublin, Ireland	Cotter, TG (corresponding author), Univ Coll Cork, Dept Biochem, Biosci Res Inst, Cell Dev & Dis Lab, Cork, Ireland.	t.cotter@ucc.ie		Cotter, Thomas/0000-0003-4626-5613	Enterprise Ireland (EI); European Regional Development FundEuropean Commission; Science Foundation IrelandScience Foundation IrelandEuropean Commission	The authors gratefully acknowledge all members of the Biological Services Unit (BSU) for technical assistance. This work was supported by Enterprise Ireland (EI) the European Regional Development Fund and Science Foundation Ireland (SFI).	Aramant RB, 2004, PROG RETIN EYE RES, V23, P475, DOI 10.1016/j.preteyeres.2004.05.003; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001; Berson EL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1306, DOI 10.1001/archopht.122.9.1306; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176; BOUGHMAN JA, 1980, AM J HUM GENET, V32, P223; Cao W, 1997, EXP EYE RES, V65, P241, DOI 10.1006/exer.1997.0328; Cayouette M, 1998, J NEUROSCI, V18, P9282; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Cheung AKH, 2005, DIABETES, V54, P3119, DOI 10.2337/diabetes.54.11.3119; Corrochano S, 2008, INVEST OPHTH VIS SCI, V49, P4188, DOI 10.1167/iovs.08-2182; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Doonan F, 2003, J NEUROSCI, V23, P5723; Doonan F, 2009, J NEUROCHEM, V109, P631, DOI 10.1111/j.1471-4159.2009.05995.x; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fayard B, 2005, J NEUROSCI RES, V80, P18, DOI 10.1002/jnr.20432; Fontaine V, 1998, J NEUROSCI, V18, P9662; Frasson M, 1999, NAT MED, V5, P1183; Friberg PA, 2009, BIOL REPROD, V80, P1160, DOI 10.1095/biolreprod.108.073932; Frye CA, 2009, AGE, V31, P143, DOI 10.1007/s11357-009-9091-6; GAO H, 1995, DEV BIOL, V169, P168, DOI 10.1006/dbio.1995.1135; Gao H, 1996, EXP EYE RES, V62, P181, DOI 10.1006/exer.1996.0022; Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144; Geller SF, 2001, INVEST OPHTH VIS SCI, V42, P1363; Gibbs RB, 1999, BRAIN RES, V844, P20, DOI 10.1016/S0006-8993(99)01880-6; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Gonzalez SL, 2009, CELL MOL NEUROBIOL, V29, P27, DOI 10.1007/s10571-008-9291-0; Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723; Grimm C, 2000, MOL VIS, V6, P252; GUARNERI P, 1994, J NEUROCHEM, V63, P86; Hackett SF, 1997, EXP EYE RES, V64, P865, DOI 10.1006/exer.1996.0256; Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8; Kaldi I, 2004, EUR J OPHTHALMOL, V14, P306, DOI 10.5301/EJO.2008.1363; Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152; Lange CA, 2008, J STEROID BIOCHEM, V108, P203, DOI 10.1016/j.jsbmb.2007.09.019; LANTHIER A, 1988, BRAIN RES, V463, P403, DOI 10.1016/0006-8993(88)90419-2; Lee SY, 2011, J CELL PHYSIOL, V226, P1843, DOI 10.1002/jcp.22508; Liu CD, 1998, J NEUROSCI, V18, P1337; Lu Na, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P2026; Makrigiannakis A, 2000, ANN NY ACAD SCI, V900, P16; Moorthy K, 2005, EXP GERONTOL, V40, P295, DOI 10.1016/j.exger.2005.01.004; Nakazawa T, 2006, BRAIN RES, V1093, P141, DOI 10.1016/j.brainres.2006.03.084; Nutu M, 2007, MOL REPROD DEV, V74, P843, DOI 10.1002/mrd.20685; O'Driscoll C, 2008, J NEUROCHEM, V105, P524, DOI 10.1111/j.1471-4159.2007.05189.x; O'Driscoll C, 2007, J NEUROCHEM, V103, P860, DOI 10.1111/j.1471-4159.2007.04827.x; O'Reilly M, 2007, AM J HUM GENET, V81, P127, DOI 10.1086/519025; Olive DL, 2001, NEW ENGL J MED, V345, P266, DOI 10.1056/NEJM200107263450407; OSTEEN WK, 1977, EXP EYE RES, V25, P361, DOI 10.1016/0014-4835(77)90103-8; Pang JJ, 2008, INVEST OPHTH VIS SCI, V49, P4278, DOI 10.1167/iovs.07-1622; Pawlyk BS, 2002, INVEST OPHTH VIS SCI, V43, P1912; Peluso JJ, 1999, BIOL REPROD, V60, P290, DOI 10.1095/biolreprod60.2.290; Peluso JJ, 2009, J CLIN ENDOCR METAB, V94, P2644, DOI 10.1210/jc.2009-0147; Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027; Rider V, 1997, J ENDOCRINOL, V154, P75, DOI 10.1677/joe.0.1540075; RIDER V, 1994, J ENDOCRINOL, V140, P239, DOI 10.1677/joe.0.1400239; Roopa BA, 2003, HUM REPROD, V18, P1809, DOI 10.1093/humrep/deg329; Schuettauf F, 2004, CURR EYE RES, V29, P379, DOI 10.1080/02713680490517872; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103; Singh M, 2001, ENDOCRINE, V14, P407, DOI 10.1385/ENDO:14:3:407; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Sun X, 2010, GENE THER, V17, P117, DOI 10.1038/gt.2009.104; Svensson EC, 2000, BIOL REPROD, V63, P1457, DOI 10.1095/biolreprod63.5.1457; Swiatek-De Lange M, 2007, GLIA, V55, P1061, DOI 10.1002/glia.20523; UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P907; Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47; Wahlin KJ, 2000, INVEST OPHTH VIS SCI, V41, P927; Wickham LA, 2000, ACTA OPHTHALMOL SCAN, V78, P146, DOI 10.1034/j.1600-0420.2000.078002146.x; WONG F, 1993, ARCH OPHTHALMOL-CHIC, V111, P754, DOI 10.1001/archopht.1993.01090060042020	73	45	46	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042			J NEUROCHEM	J. Neurochem.	SEP	2011	118	5					915	927		10.1111/j.1471-4159.2011.07354.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	806HT	WOS:000293797600021	21689103	Bronze			2021-06-18	
J	Meyns, P; Van Gestel, L; Massaad, F; Desloovere, K; Molenaers, G; Duysens, J				Meyns, Pieter; Van Gestel, Leen; Massaad, Firas; Desloovere, Kaat; Molenaers, Guy; Duysens, Jacques			Arm swing during walking at different speeds in children with Cerebral Palsy and typically developing children	RESEARCH IN DEVELOPMENTAL DISABILITIES			English	Article						CP; Gait; Arm movement; Rehabilitation; Walking speed; Speed increment	TRAUMATIC BRAIN-INJURY; GAIT; STROKE; MOVEMENTS; HEALTHY; COORDINATION; INDIVIDUALS; PATTERNS; ADULTS	Children with Cerebral Palsy (CP) have difficulties walking at a normal or high speed. It is known that arm movements play an important role to achieve higher walking speeds in healthy subjects. However, the role played by arm movements while walking at different speeds has received no attention in children with CP. Therefore we investigated the use of arm movements at two walking speeds for children with diplegia (DI) and hemiplegia (HE) as compared to typically developing (TD) children. Arm and leg swing lengths were determined in 11 HE children and 15 DI children and compared to 24 TD children using 3D gait analysis at their preferred and "as fast as possible" walking speeds. We found that TD children increased walking speed more than both CP groups. HE children showed larger arm swings on the non-hemiplegic compared to the hemiplegic side for both walking speeds. In contrast to TD or DI children, the HE group did not show an increase in arm swing length with increasing walking speed. Their leg swing length was larger on the non-hemiplegic than on the hemiplegic side but only at the preferred walking speed. The DI children exhibited smaller leg swings at both walking speeds. Since arm swing is used both by DI (to increase speed) and by HE children (to compensate for the reduced movement on the affected side) it is argued that these movements are important and should be allowed (or even encouraged) in gait training procedures (such as treadmill training). (C) 2011 Elsevier Ltd. All rights reserved.	[Meyns, Pieter; Massaad, Firas; Duysens, Jacques] Katholieke Univ Leuven, Dept Biomed Kinesiol, Fac Kinesiol & Rehabil Sci, B-3001 Heverlee, Belgium; [Van Gestel, Leen; Desloovere, Kaat] Katholieke Univ Leuven, Dept Rehabil Sci, Fac Kinesiol & Rehabil Sci, B-3001 Heverlee, Belgium; [Desloovere, Kaat; Molenaers, Guy] Univ Hosp Leuven, CERM, Clin Mot Anal Lab, Louvain, Belgium; [Duysens, Jacques] Sint Maartensklin, Dept Res Dev & Educ, Nijmegen, Netherlands	Meyns, P (corresponding author), Katholieke Univ Leuven, Dept Biomed Kinesiol, Fac Kinesiol & Rehabil Sci, Tervuursevest 101 Box 1501, B-3001 Heverlee, Belgium.	Pieter.meyns@faber.kuleuven	Desloovere, Kaat/F-3240-2014	Desloovere, Kaat/0000-0002-8507-5276; Duysens, Jacques/0000-0002-0043-8817; Meyns, Pieter/0000-0003-2218-187X			Abel MF, 1996, J PEDIATR ORTHOPED, V16, P753, DOI 10.1097/01241398-199611000-00010; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Dabney Kirk W., 1997, Current Opinion in Pediatrics, V9, P81, DOI 10.1097/00008480-199702000-00017; Doorenbosch CAM, 2003, J REHABIL RES DEV, V40, P147; Eke-Okoro ST, 1997, CLIN BIOMECH, V12, P516, DOI 10.1016/S0268-0033(97)00050-8; Esquenazi A, 2008, AM J PHYS MED REHAB, V87, P305, DOI 10.1097/PHM.0b013e318168d36c; Ford MP, 2007, GAIT POSTURE, V26, P150, DOI 10.1016/j.gaitpost.2006.08.007; Ford MP, 2007, GAIT POSTURE, V26, P135, DOI 10.1016/j.gaitpost.2006.08.008; Ford Matthew P, 2007, J Neurol Phys Ther, V31, P85; FORSSBERG H, 1992, DEV MED CHILD NEUROL, V34, P920; Hirsch MA, 2005, MOVEMENT DISORD, V20, P1014, DOI 10.1002/mds.20499; Hof A., 1996, GAIT POSTURE, V4, P222, DOI 10.1016/0966-6362(95)01057-2; Huang YP, 2011, EUR SPINE J, V20, P491, DOI 10.1007/s00586-010-1639-8; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Meyer-Heim A, 2007, DEV MED CHILD NEUROL, V49, P900, DOI 10.1111/j.1469-8749.2007.00900.x; Milosevic M, 2011, GAIT POSTURE, V33, P507, DOI 10.1016/j.gaitpost.2010.12.005; Neptune RR, 2008, GAIT POSTURE, V28, P135, DOI 10.1016/j.gaitpost.2007.11.004; Perry J, 1992, GAIT ANAL NORMAL PAT; Roerdink M, 2007, PHYS THER, V87, P1009, DOI 10.2522/ptj.20050394; Romkes J, 2007, J PEDIATR ORTHOP B, V16, P175, DOI 10.1097/BPB.0b013e32801405bf; Stephenson JL, 2010, GAIT POSTURE, V31, P109, DOI 10.1016/j.gaitpost.2009.09.008; Stephenson JL, 2009, GAIT POSTURE, V29, P11, DOI 10.1016/j.gaitpost.2008.05.013; WAGENAAR RC, 1994, HUM MOVEMENT SCI, V13, P441, DOI 10.1016/0167-9457(94)90049-3; Williams G, 2010, NEUROREHAB NEURAL RE, V24, P550, DOI 10.1177/1545968309357925; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	25	45	45	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0891-4222			RES DEV DISABIL	Res. Dev. Disabil.	SEP-OCT	2011	32	5					1957	1964		10.1016/j.ridd.2011.03.029			8	Education, Special; Rehabilitation	Education & Educational Research; Rehabilitation	799UC	WOS:000293310600065	21531534				2021-06-18	
J	Huang, MI; O'Riordan, MA; Fitzenrider, E; McDavid, L; Cohen, AR; Robinson, S				Huang, Mary I.; O'Riordan, Mary Ann; Fitzenrider, Ellen; McDavid, Lolita; Cohen, Alan R.; Robinson, Shenandoah			Increased incidence of nonaccidental head trauma in infants associated with the economic recession Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						nonaccidental head trauma; economic recession; trauma; unemployment; Glasgow Coma Scale	INJURY; CHILDREN	Object. Nonaccidental head trauma (NAHT) is a major cause of death in infants. During the current economic recession, the authors noticed an anecdotal increase in infants with NAHT without an increase in the overall number of infants admitted with traumatic injuries. An analysis was performed to determine whether there was an association between economic recession and NAHT. Methods. With Institutional Review Board approval, the trauma database was searched for NAHT in infants 0-2 years old during nonrecession (December 2001 to November 2007) and recession (December 2007 to June 2010) periods. Incidence is reported as infants with NAHT per month summarized over time periods. Continuous variables were compared using Mann-Whitney U-tests, and proportions were compared using the Fisher exact test. Results. Six hundred thirty-nine infant traumas were observed during the study time period. From the nonrecession to the recession period, there was an 8.2% reduction in all traumas (458 in 72 months [6.4 /month] vs 181 in 31 months [5.8/month]) and a 3.5% reduction in accidental head traumas (142 in 72 months [2.0/month] vs 59 in 31 months [1.9/month]). Nonaccidental head trauma accounted for 14.6% of all traumas (93/639). The median patient age was 4.0 months and 52% were boys. There were no significant differences in the representative counties of referral or demographics between nonrecession and recession populations (all p > 0.05). The monthly incidence rates of NAHT doubled from nonrecession to recession periods (50 in 72 months [0.7/month] vs 43 in 31 months [1.4/month]; p = 0.01). During this recession, at least 1 NAHT was reported in 68% of the months compared with 44% of the months during the nonrecession period (p = 0.03). The severity of NAHTs also increased, with a greater proportion of deaths (11.6% vs 4%, respectively; p = 0.16) and severe brain injury (Glasgow Coma Scale score <= 8: 19.5% vs 4%, respectively; p = 0.06) during the recession. Conclusions. In the context of an overall reduction in head trauma, the significant increase in the incidence of NAHT appears coincident with economic recession. Although the cause is likely multifactorial, a full analysis of the basis of this increase is beyond the scope of this study. This study highlights the need to protect vulnerable infants during challenging economic times. (DOI: 10.3171/2011.5.PEDS1139)	[Huang, Mary I.; Cohen, Alan R.; Robinson, Shenandoah] Case Western Reserve Univ, Univ Hosp Rainbow Babies & Childrens Hosp, Div Pediat Neurol Surg, Neurol Inst,Sch Med, Cleveland, OH USA; [O'Riordan, Mary Ann; McDavid, Lolita] Case Western Reserve Univ, Dept Pediat, Univ Hosp Rainbow Babies & Childrens Hosp, Neurol Inst,Sch Med, Cleveland, OH 44106 USA; [Fitzenrider, Ellen; Cohen, Alan R.; Robinson, Shenandoah] Case Western Reserve Univ, Univ Hosp Rainbow Babies & Childrens Hosp, Pediat Trauma Ctr, Neurol Inst,Sch Med, Cleveland, OH USA	Huang, MI (corresponding author), Univ Hosp Case Med Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA.	maryihuang@gmail.com					Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Graupman P, 2006, J NEUROSURG, V104, P245, DOI 10.3171/ped.2006.104.4.245; Johnson N, UPDATE STATE BUDGET; Minns RA, 2008, AM J PREV MED, V34, pS126, DOI 10.1016/j.amepre.2008.01.016; Mok JYQ, 2010, J EPIDEMIOL COMMUN H, V64, P1049, DOI 10.1136/jech.2009.090217; National Bureau of Economic Research, US BUS CYCL EXP CONT; Stoodley N, 2002, LANCET, V360, P271, DOI 10.1016/S0140-6736(02)09563-6; Tucker IB, 2008, SURVEY EC, P243; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130	10	45	46	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2011	8	2					171	176		10.3171/2011.5.PEDS1139			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	797RI	WOS:000293144900011	21806359				2021-06-18	
J	Luoma, JI; Kelley, BG; Mermelstein, PG				Luoma, Jessie I.; Kelley, Brooke G.; Mermelstein, Paul G.			Progesterone inhibition of voltage-gated calcium channels is a potential neuroprotective mechanism against excitotoxicity	STEROIDS			English	Article						Brain injury; Calcium; Excitotoxicity; Ion channels; Neuroprotection; Glutamate	ESTROGEN-RECEPTOR-ALPHA; TRAUMATIC BRAIN-INJURY; SELECTIVE VULNERABILITY; NERVOUS-SYSTEM; NEURONS; ACTIVATION; BINDING; NFAT; APOPTOSIS; ESTRADIOL	The therapeutic use of progesterone following traumatic brain injury has recently entered phase III clinical trials as a means of neuroprotection. Although it has been hypothesized that progesterone protects against calcium overload following excitotoxic shock, the exact mechanisms underlying the beneficial effects of progesterone have yet to be determined. We found that therapeutic concentrations of progesterone to be neuroprotective against depolarization-induced excitotoxicity in cultured stria tal neurons. Through use of calcium imaging, electrophysiology and the measurement of changes in activity-dependent gene expression, progesterone was found to block calcium entry through voltage-gated calcium channels, leading to alterations in the signaling of the activity-dependent transcription factors NFAT and CREB. The effects of progesterone were highly specific to this steroid hormone, although they did not appear to be receptor mediated. In addition, progesterone did not inhibit AMPA or NMDA receptor signaling. This analysis regarding the effect of progesterone on calcium signaling provides both a putative mechanism by which progesterone acts as a neuroprotectant, as well as affords a greater appreciation for its potential far-reaching effects on cellular function. (C) 2011 Elsevier Inc. All rights reserved.	[Luoma, Jessie I.; Kelley, Brooke G.; Mermelstein, Paul G.] Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA	Mermelstein, PG (corresponding author), Univ Minnesota, Dept Neurosci, 6-145 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	luom0025@umn.edu; kell0530@umn.edu; pmerm@umn.edu	Tuluc, Petronel/C-2527-2011		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS41302]; IRACDA Post-Doctoral Fellowship [GM074628]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K12GM074628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041302] Funding Source: NIH RePORTER	This research was supported by the National Institutes of Health [Grant NS41302] (PGM); the IRACDA Post-Doctoral Fellowship [Grant GM074628] (BGK).	Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; BARGAS J, 1994, J NEUROSCI, V14, P6667; Barlow C, 2006, AM J RESP CELL MOL, V34, P7, DOI 10.1165/rcmb.2005-0153OC; BENDER C, 2009, NEUROSCIENCE; Bielefeldt K, 1996, AM J PHYSIOL-GASTR L, V271, pG370; Boulware MI, 2005, J NEUROSCI, V25, P5066, DOI 10.1523/JNEUROSCI.1427-05.2005; Bryant DN, 2010, NEUROSCIENCE, V170, P1261, DOI 10.1016/j.neuroscience.2010.08.019; Candelario-Jalil E, 2001, J APPL TOXICOL, V21, P403, DOI 10.1002/jat.768; CHOI DW, 1985, NEUROSCI LETT, V58, P293, DOI 10.1016/0304-3940(85)90069-2; Deisseroth K, 2003, CURR OPIN NEUROBIOL, V13, P354, DOI 10.1016/S0959-4388(03)00076-X; FFRENCHMULLEN JMH, 1994, J NEUROSCI, V14, P1963; Flockhart RJ, 2008, FASEB J, V22, P4218, DOI 10.1096/fj.08-113076; Furman JL, 2010, NEUROSCI LETT, V469, P365, DOI 10.1016/j.neulet.2009.12.029; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Groth RD, 2008, EUR J NEUROSCI, V27, P31, DOI 10.1111/j.1460-9568.2007.05980.x; Grove-Strawser D, 2010, NEUROSCIENCE, V170, P1045, DOI 10.1016/j.neuroscience.2010.08.012; HURD C, 1988, BIOCHEMISTRY-US, V27, P3618, DOI 10.1021/bi00410a014; Jayanthi S, 2005, P NATL ACAD SCI USA, V102, P868, DOI 10.1073/pnas.0404990102; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029; Kim MS, 2009, J NEUROSCI, V29, P12101, DOI 10.1523/JNEUROSCI.3384-09.2009; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; KOKATE TG, 1994, J PHARMACOL EXP THER, V270, P1223; Kondo E, 2003, EUR J IMMUNOL, V33, P1, DOI 10.1002/immu.200390000; Lebesgue D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008642; Lebesgue D, 2009, STEROIDS, V74, P555, DOI 10.1016/j.steroids.2009.01.003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luoma JI, 2008, J NEUROSCI, V28, P3159, DOI 10.1523/JNEUROSCI.5227-07.2008; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Mermelstein PG, 2009, J NEUROENDOCRINOL, V21, P257, DOI 10.1111/j.1365-2826.2009.01838.x; Mermelstein PG, 1996, J NEUROSCI, V16, P595; Mermelstein PG, 2000, J NEUROSCI, V20, P266, DOI 10.1523/JNEUROSCI.20-01-00266.2000; Micevych PE, 2007, ENDOCRINOLOGY, V148, P782, DOI 10.1210/en.2006-0774; Miller NR, 2005, ENDOCRINOLOGY, V146, P3070, DOI 10.1210/en.2004-1515; Miyazaki H, 1999, LIFE SCI, V64, P869, DOI 10.1016/S0024-3205(99)00011-9; Ozacmak VH, 2009, PHYSIOL RES, V58, P909, DOI 10.33549/physiolres.931647; Quadros PS, 2007, J COMP NEUROL, V504, P42, DOI 10.1002/cne.21427; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Saeki K, 1999, BIOCHEM J, V343, P249, DOI 10.1042/0264-6021:3430249; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Schauwecker PE, 2010, EXP NEUROL, V224, P207, DOI 10.1016/j.expneurol.2010.03.013; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Schumacher M, 2004, GROWTH HORM IGF RES, V14, pS18, DOI 10.1016/j.ghir.2004.03.007; Sinchak K, 2003, DEV NEUROSCI-BASEL, V25, P343, DOI 10.1159/000073511; Sleiter N, 2009, ENDOCRINOLOGY, V150, P3833, DOI 10.1210/en.2008-0774; Sribnick EA, 2009, BRAIN RES, V1276, P159, DOI 10.1016/j.brainres.2009.04.022; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Thomas P, 2004, STEROIDS, V69, P567, DOI 10.1016/j.steroids.2004.05.004; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Vallazza-Deschamps G, 2005, DOC OPHTHALMOL, V110, P25, DOI 10.1007/s10633-005-7341-1; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Wang XK, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00012; Watson CS, 2010, TOXICOL SCI, V115, P1, DOI 10.1093/toxsci/kfp288; Weick JP, 2003, J NEUROSCI, V23, P3446; WEICK JPK, 2005, CELLSCIENCE, V1; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu J, 2009, J NEUROSCI, V29, P9330, DOI 10.1523/JNEUROSCI.2212-09.2009; ZIRPEL L, 1995, J NEUROSCI, V15, P214	64	45	47	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0039-128X	1878-5867		STEROIDS	Steroids	AUG	2011	76	9			SI		845	855		10.1016/j.steroids.2011.02.013			11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	799YH	WOS:000293322200006	21371490	Green Accepted			2021-06-18	
J	Blumcke, I; Muhlebner, A				Bluemcke, I.; Muehlebner, A.			Neuropathological work-up of focal cortical dysplasias using the new ILAE consensus classification system - practical guideline article invited by the Euro-CNS Research Committee	CLINICAL NEUROPATHOLOGY			English	Article						epilepsy; seizures; hippocampal sclerosis; tumors; cortical dysplasia; dysmorphic	TEMPORAL-LOBE EPILEPSY; TUBEROUS SCLEROSIS COMPLEX; HIPPOCAMPAL SCLEROSIS; DUAL PATHOLOGY; MALFORMATIONS; CHILDREN; FEATURES; CELL; RECORDINGS; EXPRESSION	FCDs are increasingly recognized in patients with drug-resistant epilepsies, and many patients benefit from tailored resection strategies. Yet, postsurgical seizure control cannot be sufficiently predicted and specification of FCD variants remains difficult during presurgical monitoring. The International League against Epilepsy (ILAE) has published a new consensus classification system for focal cortical dysplasias (FCDs). Based on a review of imaging data, electro-clinical features and postsurgical seizure control correlation with neuropathological findings specify three clinico-pathological FCD subtypes: FCD Type I is characterized by aberrant radial (FCD Type Ia) or tangential lamination of the neocortex (FCD Type Ib) affecting one or multiple lobes. FCD Type II is characterized by cortical dyslamination and dysmorphic neurons without (Type IIa) or with balloon cells (Type IIb). It is important to note, that these types should not be associated with any other structural brain lesion (isolated FCD). In contrast, a new FCD Type III is introduced, which occurs in combination with hippocampal sclerosis (FCD Type IIIa), or with epilepsy-associated tumors (FCD Type IIIb). FCD Type IIIc is found adjacent to vascular malformations, whereas FCD Type IIId can be diagnosed in association with other epileptogenic lesions obtained in early life (i.e., traumatic injury, ischemic injury or encephalitis). Histopathological features are very similar to those observed in FCD Type I, but likely present postnatal development and maturation failures acquired by the principal lesion. This first international consensus classification may encourage neuropathologists to focus their attention onto this important histopathological group. Addressing more precisely defined clinico-pathological entities will also help to clarify underlying pathomechanisms and, thereby, improve treatment strategies for patients with difficult-to-treat epilepsies.	[Bluemcke, I.; Muehlebner, A.] Univ Hosp Erlangen, Dept Neuropathol, D-91054 Erlangen, Germany	Muhlebner, A (corresponding author), Univ Hosp Erlangen, Dept Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany.	angelika.muehlebner@uk-erlangen.de	Muhlebner, Angelika/L-3734-2019; Blumcke, Ingmar/D-4705-2018	Muhlebner, Angelika/0000-0001-9102-7353; Blumcke, Ingmar/0000-0001-8676-0788			Andres M, 2005, CEREB CORTEX, V15, P194, DOI 10.1093/cercor/bhh122; Battaglia G, 2009, EPILEPTIC DISORD, V11, P206, DOI 10.1684/epd.2009.0273; Blumcke I, 2007, ACTA NEUROPATHOL, V113, P235, DOI 10.1007/s00401-006-0187-0; Blumcke I, 2011, EPILEPSIA, V52, P158, DOI 10.1111/j.1528-1167.2010.02777.x; Blumcke I, 2011, LANCET NEUROL, V10, P26, DOI 10.1016/S1474-4422(10)70225-8; Blumcke I, 2010, EPILEPTIC DISORD, V12, P172, DOI 10.1684/epd.2010.0321; Blumcke I, 2009, EPILEPTIC DISORD, V11, P181, DOI 10.1684/epd.2009.0261; Blumcke I, 2009, EPILEPSY BEHAV, V15, P34, DOI 10.1016/j.yebeh.2009.02.033; Blumcke I, 2004, ACTA NEUROPATHOL, V108, P89, DOI 10.1007/s00401-004-0873-8; Blumcke I, 1999, ACTA NEUROPATHOL, V97, P481, DOI 10.1007/s004010051017; CENDES F, 1995, NEUROLOGY, V45, P2058, DOI 10.1212/WNL.45.11.2058; Cepeda C, 2006, EPILEPSY BEHAV, V9, P219, DOI 10.1016/j.yebeh.2006.05.012; Chamberlain WA, 2009, EPILEPSIA, V50, P2593, DOI 10.1111/j.1528-1167.2009.02344.x; Chandra PS, 2007, NEUROLOGY, V68, P438, DOI 10.1212/01.wnl.0000252952.62543.20; Colombo N, 2009, EPILEPTIC DISORD, V11, P194, DOI 10.1684/epd.2009.0262; CROME L, 1957, J NEUROL NEUROSUR PS, V20, P117, DOI 10.1136/jnnp.20.2.117; Ding SL, 2009, J COMP NEUROL, V514, P595, DOI 10.1002/cne.22053; Fauser S, 2006, BRAIN, V129, P82, DOI 10.1093/brain/awh687; Fauser S, 2009, BRAIN, V132, P2079, DOI 10.1093/brain/awp145; Ferrier CH, 2007, J NEUROSURG, V107, P495, DOI 10.3171/JNS-07/09/0495; Garbelli R, 1999, BRAIN PATHOL, V9, P445, DOI 10.1111/j.1750-3639.1999.tb00534.x; Garbelli R, 2006, EPILEPSIA, V47, P1074, DOI 10.1111/j.1528-1167.2006.00577.x; Hildebrandt M, 2005, ACTA NEUROPATHOL, V110, P1, DOI 10.1007/s00401-005-1016-6; Kahane P, 2010, EPILEPSIA, V51, P59, DOI 10.1111/j.1528-1167.2009.02448.x; Kloosterhof NK, 2011, LANCET ONCOL, V12, P83, DOI 10.1016/S1470-2045(10)70053-X; Krsek P, 2008, ANN NEUROL, V63, P758, DOI 10.1002/ana.21398; Krsek P, 2009, EPILEPSIA, V50, P125, DOI 10.1111/j.1528-1167.2008.01682.x; Lombroso CT, 2000, EPILEPSIA, V41, P245, DOI 10.1111/j.1528-1157.2000.tb00148.x; Marin-Padilla M, 2002, ACTA NEUROPATHOL, V103, P321, DOI 10.1007/s00401-001-0470-z; Martinian L, 2009, NEUROPATH APPL NEURO, V35, P394, DOI [10.1111/j.1365-2990.2008.00996.x, 10.1111/j.1365-2990.2009.00996.x]; Meroni A, 2009, EPILEPSIA, V50, P116, DOI 10.1111/j.1528-1167.2008.01717.x; Palmini A, 2004, NEUROLOGY, V62, pS2, DOI 10.1212/01.WNL.0000114507.30388.7E; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; Talos DM, 2008, ANN NEUROL, V63, P454, DOI 10.1002/ana.21342; Tassi L, 2010, EPILEPTIC DISORD, V12, P181, DOI 10.1684/epd.2010.0327; TAYLOR DC, 1971, J NEUROL NEUROSUR PS, V34, P369, DOI 10.1136/jnnp.34.4.369; Thom M, 2009, J NEUROPATH EXP NEUR, V68, P928, DOI 10.1097/NEN.0b013e3181b05d67; Urbach H, 2002, EPILEPSIA, V43, P33, DOI 10.1046/j.1528-1157.2002.38201.x; WOLF HK, 1993, BRAIN PATHOL, V3, P371, DOI 10.1111/j.1750-3639.1993.tb00765.x; Yasin SA, 2010, ACTA NEUROPATHOL, V120, P85, DOI 10.1007/s00401-010-0677-y	40	45	53	0	8	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	JUL-AUG	2011	30	4					164	177		10.5414/NP300398			14	Clinical Neurology; Pathology	Neurosciences & Neurology; Pathology	797CM	WOS:000293101700002	21726501				2021-06-18	
J	Eckner, JT; Kutcher, JS; Richardson, JK				Eckner, James T.; Kutcher, Jeffrey S.; Richardson, James K.			Between-Seasons Test-Retest Reliability of Clinically Measured Reaction Time in National Collegiate Athletic Association Division I Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						intraclass correlation coefficient; concussions; traumatic brain injuries; assessment	SPORT-RELATED CONCUSSION; FOOTBALL PLAYERS; REPRODUCIBILITY; MANAGEMENT; STATEMENT; IMPACT; LONG	Context: Reaction time is typically impaired after concussion. A clinical test of reaction time (RT(clin)) that does not require a computer to administer may be a valuable tool to assist in concussion diagnosis and management. Objective: To determine the test-retest reliability of RT(clin) measured over successive seasons in competitive collegiate athletes and to compare these results with a computerized measure of reaction time (RT(comp)). Design: Case series with repeated measures. Setting: Preparticipation physical examinations for the football, women's soccer, and wrestling teams at a single university. Patients or Other Participants: 102 National Collegiate Athletic Association Division I athletes. Intervention(s): The RT(clin) was measured using a measuring stick embedded in a weighted rubber disk that was released and caught as quickly as possible. The RT(comp) was measured using the simple reaction time component of CogState Sport. Main Outcome Measure(s): Data were collected at 2 time points, 1 season apart, during preparticipation physical examinations. Outcomes were mean simple RT(clin) and RT(comp). Results: The intraclass correlation coefficient estimates from season 1 to season 2 were 0.645 for RT(clin), (n=102, entire sample) and 0.512 for RT(comp) (n=62 athletes who had 2 consecutive valid baseline CogState Sport test sessions). Conclusions: The test-retest reliability of RT(clin) over consecutive seasons compared favorably with that of a concurrently tested computerized measure of reaction time and with literature-based estimates of computerized reaction time measures. This finding supports the potential use of RT(clin) as part of a multifaceted concussion assessment battery. Further prospective study is warranted.	[Eckner, James T.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48108 USA	Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 100A, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			University of MichiganUniversity of Michigan System [UL1RR024986]; Foundation for Physical Medicine and Rehabilitation (Chicago, IL); University of Michigan Bone & Joint Injury Prevention & Rehabilitation Center (Ann Arbor, MI); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024986] Funding Source: NIH RePORTER	We thank Dr. David Darby, chief medical officer for CogState Ltd, for his advice and assistance relating to the CogState Sport program and Mr. Steve Nordwall and his athletic training staff for their support in organizing and conducting this project. We also thank Katherine Bohard, James Burke, Sri Krishna Chandran, Heather Eckner, Burton Engel, Shawn Heiler, Jennifer Kendall, Michael Louwers, Raman Malhotra, Stephen Oh, and Devon Shuchman for their assistance with data collection and management. We thank the University of Michigan Biostatistics Core (UL1RR024986 Clinical & Translational Science Award funded) for its statistical advice. We acknowledge the support of our sponsors, the Foundation for Physical Medicine and Rehabilitation (Chicago, IL; awarded to J.T.E.) and the University of Michigan Bone & Joint Injury Prevention & Rehabilitation Center (Ann Arbor, MI; awarded to J.T.E. and J.K.R.).	Anastasi A., 1998, PSYCHOL TESTING; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Eckner JT, 2011, PM&R, V3, P212, DOI 10.1016/j.pmrj.2010.12.003; Eckner JT, 2011, MED SCI SPORT EXER, V43, P382, DOI 10.1249/MSS.0b013e3181f1cc51; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; TAMMEMAGI MC, 1995, J CLIN EPIDEMIOL, V48, P1123, DOI 10.1016/0895-4356(94)00243-J; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	27	45	46	0	21	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2011	46	4					409	414					6	Sport Sciences	Sport Sciences	808NA	WOS:000293983200011	21944073				2021-06-18	
J	Sun, YR; Wang, JQ; Wu, X; Xi, CH; Gai, YT; Liu, H; Yuan, Q; Wang, ES; Gao, L; Hu, J; Zhou, LF				Sun, Yirui; Wang, Jianqing; Wu, Xing; Xi, Caihua; Gai, Yanting; Liu, Hua; Yuan, Qiang; Wang, Ersong; Gao, Liang; Hu, Jin; Zhou, Liangfu			Validating the incidence of coagulopathy and disseminated intravascular coagulation in patients with traumatic brain injury - analysis of 242 cases	BRITISH JOURNAL OF NEUROSURGERY			English	Article						Traumatic brain injury (TBI); head injury; coagulopathy; disseminated intravascular coagulation (DIC); neurological outcome	ACTIVATED FACTOR-VII; HEAD TRAUMA; MORTALITY PREDICTION; SOLUBLE FIBRIN; CONSEQUENCES; SCORE	Objectives: To estimate the incidence of coagulopathy and disseminated intravascular coagulation (DIC) in patients with traumatic brain injury (TBI) and to investigate its relationship to patient outcome. Design: A prospective observational study. Measurements and main results. From January 2007 to June 2009, 242 consecutive adult patients with TBI seen in three independent hospitals were recruited. Glasgow Coma Score (GCS) on admission, platelet counts (PLT), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), D-dimer (D-DT) and DIC scores were recorded for each case on admission. Clinical outcome was measured according to the Glasgow Outcome Scale (GOS) at 3 months after injury. Statistical analysis was carried using Student's t-test, one-way analysis of variance (ANOVA), and Tudey test. Coagulation abnormalities were present in approximately 50% of patients with TBI. Prolonged PT and increased D-DT and FIB levels occurred in patients with more severe brain injury and poorer outcome, and these findings were statistically significant. Conclusions: Coagulation changes, particularly the incidence of DIC, may occur within 6 h after TBI and are more pronounced in patients with severe injuries and poor outcome. PT, D-DT levels and more comprehensively a DIC scores may be useful prognostic indicators in patients with TBI.	[Sun, Yirui; Wu, Xing; Gao, Liang; Hu, Jin; Zhou, Liangfu] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai 200032, Peoples R China; [Sun, Yirui; Xi, Caihua; Liu, Hua; Yuan, Qiang] Jiao Tong Univ, Shanghai Hosp 6, Dept Neurosurg, Shanghai, Peoples R China; [Wang, Jianqing; Gai, Yanting] Shanghai Ruijin Hosp, Dept Neurosurg, Grp Minhang Dist Cent Hosp, Shanghai, Peoples R China	Hu, J (corresponding author), Fudan Univ, Huashan Hosp, Dept Neurosurg, 12 Wulumuqi Rd, Shanghai 200032, Peoples R China.	yriui.sun@live.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81000518, 30770824]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [201003237]; Scientific Research Foundation for the Returned Overseas Chinese Scholars, Ministry of Education of ChinaScientific Research Foundation for the Returned Overseas Chinese ScholarsMinistry of Education, China; Shanghai Pujiang ProgramShanghai Pujiang Program [09PJ1408300]; Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [10JC1402300]	The study is funded by The National Natural Science Foundation of China (81000518, 30770824); China Postdoctoral Science Foundation funded project (201003237); the Scientific Research Foundation for the Returned Overseas Chinese Scholars, Ministry of Education of China; Shanghai Pujiang Program (09PJ1408300); The Science and Technology Commission of Shanghai Municipality project (10JC1402300). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors report no conflicts of interest. The authors thank Hengli Tian, Haijun Yao, Yong Liu, Yi Jin, Xuehai Wu for supporting this study.	Aibiki M, 2005, RESUSCITATION, V65, P115, DOI 10.1016/j.resuscitation.2004.09.013; Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Armand R, 2003, TRANSFUS MED REV, V17, P223, DOI 10.1016/S0887-7963(03)00022-1; Barker DE, 1996, J TRAUMA, V40, P927; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; ENDERSON BL, 1991, J TRAUMA, V31, P1240, DOI 10.1097/00005373-199109000-00007; FARINGER PD, 1993, J TRAUMA, V34, P481, DOI 10.1097/00005373-199304000-00002; Gando S, 1999, ANN SURG, V229, P121, DOI 10.1097/00000658-199901000-00016; Garrison JR, 1996, J TRAUMA, V40, P923, DOI 10.1097/00005373-199606000-00010; Gennarelli TA, 2005, ABBREVIATED INJURY S; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Grenander A, 2001, J NEUROSURG ANESTH, V13, P49, DOI 10.1097/00008506-200101000-00010; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Hoots WK, 1997, SEMIN THROMB HEMOST, V23, P3; Horan JT, 2001, SEMIN THROMB HEMOST, V27, P657, DOI 10.1055/s-2001-18870; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; Keller M S, 2001, Semin Pediatr Surg, V10, P12, DOI 10.1053/spsu.2001.19381; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; May AK, 1997, AM SURGEON, V63, P233; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MINER ME, 1982, J PEDIATR-US, V100, P687, DOI 10.1016/S0022-3476(82)80565-9; Morenski JD, 2003, J NEUROSURG, V98, P611, DOI 10.3171/jns.2003.98.3.0611; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; RUBIN RN, 1992, DRUGS, V44, P963, DOI 10.2165/00003495-199244060-00005; Saggar V, 2009, J NEUROTRAUM, V26, P1665, DOI 10.1089/neu.2008.0799; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327; Tieu BH, 2007, WORLD J SURG, V31, P1055, DOI 10.1007/s00268-006-0653-9; UEDA S, 1985, J NEUROL NEUROSUR PS, V48, P58, DOI 10.1136/jnnp.48.1.58; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; VECHT CJ, 1975, J NEUROL NEUROSUR PS, V38, P567, DOI 10.1136/jnnp.38.6.567; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	41	45	54	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	2011	25	3					363	368		10.3109/02688697.2011.552650			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	769QR	WOS:000291033800017	21355766				2021-06-18	
J	Cekic, M; Cutler, SM; VanLandingham, JW; Stein, DG				Cekic, Milos; Cutler, Sarah M.; VanLandingham, Jacob W.; Stein, Donald G.			Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats	NEUROBIOLOGY OF AGING			English	Article						Aging; Inflammation; Progesterone; 1,25-Dihydroxyvitamin D-3; Traumatic brain injury; Vitamin D deficiency	1,25-DIHYDROXYVITAMIN D-3; HYPOVITAMINOSIS-D; AUTOIMMUNE ENCEPHALOMYELITIS; BREAST-CANCER; D INADEQUACY; BONE HEALTH; EXPRESSION; 25-HYDROXYVITAMIN-D; NEUROPROTECTION; PREVALENCE	Administration of the neurosteroid progesterone (PROG) has been shown to be beneficial in a number of brain injury models and in two recent clinical trials. Given widespread vitamin D deficiency and increasing traumatic brain injuries (TBIs) in the elderly, we investigated the interaction of vitamin D deficiency and PROG with cortical contusion injury in aged rats. Vitamin D deficient (VitD-deficient) animals showed elevated inflammatory proteins (TNF alpha, IL-1 beta, IL-6, NF kappa B p65) in the brain even without injury. VitD-deficient rats with TBI, whether given PROG or vehicle, showed increased inflammation and greater open-field behavioral deficits compared to VitD-normal animals. Although PROG was beneficial in injured VitD-normal animals, in VitD-deficient subjects neurosteroid treatment conferred no improvement over vehicle. A supplemental dose of 1,25-dihydroxyvitamin D-3 (VDH) given with the first PROG treatment dramatically improved results in VitD-deficient rats, but treatment with VDH alone did not. Our results suggest that VitD-deficiency can increase baseline brain inflammation, exacerbate the effects of TBI, and attenuate the benefits of PROG treatment; these effects may be reversed if the deficiency is corrected. (C) 2009 Elsevier Inc. All rights reserved.	[Stein, Donald G.] Emory Clin, Emergency Med Brain Res Lab, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Clin, Emergency Med Brain Res Lab, Sch Med, Dept Emergency Med, Suite 5100,1365B Clifton Rd NE, Atlanta, GA 30322 USA.	dstei04@emory.edu	Cekic, Milos/AAR-8250-2020; Stein, Donald/AAJ-5139-2020		BHR; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1RO1N540825, 1RO1N538664]; Emory University Graduate School of Arts and Sciences; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664, R01NS040825, R01NS048451] Funding Source: NIH RePORTER	Dr. Donald Stein is entitled to royalty derived from BHR Pharmaceuticals's sale of products related to the research described in this paper and may receive research funding from BHR, which is developing products related to this research. In addition, the author serves as consultant to BHR and receives compensation for these services. The terms of this agreement have been reviewed and approved by Emory University in accordance with its conflict of interest policies.; The authors would like to thank Sarah Johnson, John Eicken, and Dr. Stuart Hoffman for their contributions to this project and Leslie McCann for invaluable editorial assistance. This research was supported by funding from NIH grants #1RO1N540825 and #1RO1N538664 and the Emory University Graduate School of Arts and Sciences.	Asakura H, 2001, THROMB HAEMOSTASIS, V85, P287; Banerjee P, 2003, MOL CELL BIOCHEM, V253, P247, DOI 10.1023/A:1026072118217; Barrera D, 2007, J STEROID BIOCHEM, V103, P529, DOI 10.1016/j.jsbmb.2006.12.097; Bauer B, 2004, MOL PHARMACOL, V66, P413; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Cantorna MT, 2005, J RHEUMATOL, V32, P11; CDC, 2004, TRAUM BRAIN INJ TBI; Charalampopoulos I, 2006, ANN NY ACAD SCI, V1088, P139, DOI 10.1196/annals.1366.003; Chatfield SM, 2007, INTERN MED J, V37, P377, DOI 10.1111/j.1445-5994.2007.01339.x; Chen KB, 2003, ANN NY ACAD SCI, V993, P313, DOI 10.1111/j.1749-6632.2003.tb07539.x; Corino A, 2007, CALCIFIED TISSUE INT, V80, P76, DOI 10.1007/s00223-006-0189-x; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Diamond TH, 2005, MED J AUSTRALIA, V183, P10, DOI 10.5694/j.1326-5377.2005.tb06879.x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Elmadfa I, 2008, ANN NUTR METAB, V52, P1, DOI 10.1159/000115338; Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1; Garcion E, 2003, ACTA NEUROPATHOL, V105, P438, DOI 10.1007/s00401-002-0663-0; Gaugris S, 2005, QJM-INT J MED, V98, P667, DOI 10.1093/qjmed/hci096; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Giulietti A, 2004, DIABETOLOGIA, V47, P451, DOI 10.1007/s00125-004-1329-3; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grant WB, 2006, PROG BIOPHYS MOL BIO, V92, P65, DOI 10.1016/j.pbiomolbio.2006.02.013; Grant WB, 2005, ALTERN MED REV, V10, P94; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Gupta R, 2007, J INVEST DERMATOL, V127, P707, DOI 10.1038/sj.jid.5700597; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Hayes CE, 2003, CELL MOL BIOL, V49, P277; Hayes CE, 1997, P SOC EXP BIOL MED, V216, P21, DOI 10.3181/00379727-216-44153A; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Heaney RP, 2004, AM J CLIN NUTR, V80, p1706S, DOI 10.1093/ajcn/80.6.1706S; Holick MF, 2004, AM J CLIN NUTR, V80, p1678S, DOI 10.1093/ajcn/80.6.1678S; Holick MF, 2005, J NUTR, V135, p2726S; Holick MF, 2005, SOUTH MED J, V98, P1024, DOI 10.1097/01.SMJ.0000140865.32054.DB; Holick MF, 2005, J CLIN ENDOCR METAB, V90, P3215, DOI 10.1210/jc.2004-2364; Holick MF, 2008, AM J CLIN NUTR, V87, p1080S; Kalueff AV, 2004, NEUROREPORT, V15, P1271, DOI 10.1097/01.wnr.0000129370.04248.92; Kalueff AV, 2004, BRAIN RES BULL, V64, P25, DOI 10.1016/j.brainresbull.2004.04.015; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Khazai Natasha, 2008, Curr Rheumatol Rep, V10, P110, DOI 10.1007/s11926-008-0020-y; Kutuzova GD, 2004, ARCH BIOCHEM BIOPHYS, V432, P152, DOI 10.1016/j.abb.2004.09.004; Langmade SJ, 2006, P NATL ACAD SCI USA, V103, P13807, DOI 10.1073/pnas.0606218103; Larrosa M, 2001, MED CLIN-BARCELONA, V117, P611, DOI 10.1016/S0025-7753(01)72195-1; Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]; Lin AMY, 2003, FREE RADICAL BIO MED, V34, P1416, DOI 10.1016/S0891-5849(03)00105-9; Lipsitz Lewis A, 2004, Sci Aging Knowledge Environ, V2004, ppe16; Losem-Heinrichs E, 2005, ARCH BIOCHEM BIOPHYS, V439, P70, DOI 10.1016/j.abb.2005.04.021; Lowe LC, 2005, EUR J CANCER, V41, P1164, DOI 10.1016/j.ejca.2005.01.017; MacFarlane GD, 2004, J STEROID BIOCHEM, V89-90, P621, DOI 10.1016/j.jsbmb.2004.03.042; Markle-Reid M, 2003, J ADV NURS, V44, P58, DOI 10.1046/j.1365-2648.2003.02767.x; Martins D, 2007, ARCH INTERN MED, V167, P1159, DOI 10.1001/archinte.167.11.1159; McCarty MF, 2005, MED HYPOTHESES, V64, P1022, DOI 10.1016/j.mehy.2004.03.041; Melamed ML, 2008, ARTERIOSCL THROM VAS, V28, P1179, DOI 10.1161/ATVBAHA.108.165886; Michos ED, 2008, CURR OPIN CLIN NUTR, V11, P7, DOI 10.1097/MCO.0b013e3282f2f4dd; Moore M, 2007, SYNAPSE, V61, P851, DOI 10.1002/syn.20433; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; Narayanan R, 2004, BONE, V35, P134, DOI 10.1016/j.bone.2004.02.014; Offer H, 2002, CARCINOGENESIS, V23, P1025, DOI 10.1093/carcin/23.6.1025; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Pascussi JM, 2005, J CLIN INVEST, V115, P177, DOI 10.1172/JCI200521867; Peterlik M, 2005, EUR J CLIN INVEST, V35, P290, DOI 10.1111/j.1365-2362.2005.01487.x; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pfeifer M, 2002, OSTEOPOROSIS INT, V13, P187, DOI 10.1007/s001980200012; Polek TC, 2003, ENDOCRINOLOGY, V144, P50, DOI 10.1210/en.2001-210109; Rajakumar K, 2008, OBESITY, V16, P90, DOI 10.1038/oby.2007.23; RAMMOS G, 2008, INT UROL NEPHROL; Riaz SS, 2000, MOL BRAIN RES, V85, P179; Robsahm TE, 2004, CANCER CAUSE CONTROL, V15, P149, DOI 10.1023/B:CACO.0000019494.34403.09; ROJANASATHIT S, 1977, ENDOCRINOLOGY, V100, P642, DOI 10.1210/endo-100-3-642; Sanchez B, 2002, MOL BRAIN RES, V108, P143, DOI 10.1016/S0169-328X(02)00545-4; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shinpo K, 2000, J NEUROSCI RES, V62, P374, DOI 10.1002/1097-4547(20001101)62:3<374::AID-JNR7>3.0.CO;2-7; Singh M, 2008, FRONT BIOSCI-LANDMRK, V13, P1083, DOI 10.2741/2746; Spach KM, 2005, J IMMUNOL, V175, P4119, DOI 10.4049/jimmunol.175.6.4119; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Tangpricha V, 2004, AM J CLIN NUTR, V80, P1645; Thien R, 2005, J ALLERGY CLIN IMMUN, V116, P683, DOI 10.1016/j.jaci.2005.05.013; Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201; Topinkova E, 2008, ANN NUTR METAB, V52, P6, DOI 10.1159/000115340; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Vieth R, 2006, AM J CLIN NUTR, V83, P731; Wang JY, 2001, BRAIN RES, V904, P67, DOI 10.1016/S0006-8993(01)02450-7; Wang TJ, 2008, CIRCULATION, V117, P503, DOI 10.1161/CIRCULATIONAHA.107.706127; Wang Y, 2000, NEUROPHARMACOLOGY, V39, P873, DOI 10.1016/S0028-3908(99)00255-5; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu Y, 2006, MOL PHARMACOL, V69, P56, DOI 10.1124/mol.105.017392; Zasloff M, 2006, NAT MED, V12, P388, DOI 10.1038/nm0406-388; Zhu Y, 2005, EUR J IMMUNOL, V35, P217, DOI 10.1002/eji.200425491; Zygun D, 2005, CURR OPIN CRIT CARE, V11, P139, DOI 10.1097/01.ccx.0000155356.86241.c0	93	45	45	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	MAY	2011	32	5					864	874		10.1016/j.neurobiolaging.2009.04.017			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	755SP	WOS:000289957000011	19482377	Green Accepted			2021-06-18	
J	Kelleher, MA; Palliser, HK; Walker, DW; Hirst, JJ				Kelleher, Meredith A.; Palliser, Hannah K.; Walker, David W.; Hirst, Jonathan J.			Sex-dependent effect of a low neurosteroid environment and intrauterine growth restriction on foetal guinea pig brain development	JOURNAL OF ENDOCRINOLOGY			English	Article							NEUROACTIVE STEROIDS; SLICE CULTURES; NERVOUS-SYSTEM; LATE-GESTATION; CELL-DEATH; PROGESTERONE; ALLOPREGNANOLONE; PREGNANCY; INJURY; SHEEP	Progesterone and its neuroactive metabolite, allopregnanolone, are present in high concentrations during pregnancy, but drop significantly following birth. Allopregnanolone influences foetal arousal and enhances cognitive and behavioural recovery following traumatic brain injury. Inhibition of allopregnanolone synthesis increases cell death in foetal animal brains with experimental hypoxia. We hypothesised that complications during pregnancy, such as early or preterm loss of placental steroids and intrauterine growth restriction (IUGR), would disrupt the foetal neurosteroid system, contributing to poor neurodevelopmental outcomes. This study aimed to investigate the effects of chronic inhibition of allopregnanolone synthesis before term and IUGR on developmental processes in the foetal brain. Guinea pig foetuses were experimentally growth restricted at mid-gestation and treated with finasteride, an inhibitor of allopregnanolone synthesis. Finasteride treatment reduced foetal brain allopregnanolone concentrations by up to 75% and was associated with a reduction in myelin basic protein (MBP) (P=0.001) and an increase in glial fibrillary acidic protein expression in the subcortical white matter brain region (P < 0.001). IUGR resulted in decreased MBP expression (P < 0.01) and was associated with a reduction in the expression of steroidogenic enzyme 5 alpha-reductase (5 alpha R) type 2 in the foetal brain (P=0.061). Brain levels of 5 alpha R1 were higher in male foetuses (P=0.008). Both IUGR and reduced foetal brain concentrations of allopregnanolone were associated with altered expression of myelination and glial cell markers within the developing foetal brain. The potential role of neurosteroids in protecting and regulating neurodevelopmental processes in the foetal brain may provide new directions for treatment of neurodevelopmental disorders in infants who are exposed to perinatal insults and pathologies. Journal of Endocrinology (2011) 208, 301-309	[Kelleher, Meredith A.; Palliser, Hannah K.; Hirst, Jonathan J.] Univ Newcastle, Mothers & Babies Res Ctr, John Hunter Hosp, Newcastle, NSW 2310, Australia; [Kelleher, Meredith A.; Palliser, Hannah K.; Hirst, Jonathan J.] Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2310, Australia; [Walker, David W.] Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia	Kelleher, MA (corresponding author), Univ Newcastle, Mothers & Babies Res Ctr, John Hunter Hosp, Newcastle, NSW 2310, Australia.	meredith.kelleher@uon.edu.au	Kelleher, Meredith Anne/L-2317-2019; Hirst, Jonathan/G-7822-2013	Kelleher, Meredith Anne/0000-0002-5313-004X; Hirst, Jonathan/0000-0002-9362-5303	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [455527]	This work was supported by the National Health and Medical Research Council of Australia (project grant ID#455527).	Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Di Renzo GC, 2007, GENDER MED, V4, P19, DOI 10.1016/S1550-8579(07)80004-0; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; Evans SEG, 2005, GYNECOL ENDOCRINOL, V21, P268, DOI 10.1080/09513590500361747; Faturi CD, 2006, PHARMACOL BIOCHEM BE, V85, P569, DOI 10.1016/j.pbb.2006.10.011; Ghoumari AM, 2005, NEUROSCIENCE, V135, P47, DOI 10.1016/j.neuroscience.2005.05.023; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hirst JJ, 2006, NEUROENDOCRINOLOGY, V84, P264, DOI 10.1159/000097990; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; Lackman F, 2001, AM J OBSTET GYNECOL, V184, P946, DOI 10.1067/mob.2001.111719; Larroque B, 2001, PEDIATRICS, V108, P111, DOI 10.1542/peds.108.1.111; Mallard C, 2000, NEUROSCIENCE, V100, P327, DOI 10.1016/S0306-4522(00)00271-2; McKendry AA, 2010, J NEUROENDOCRINOL, V22, P166, DOI 10.1111/j.1365-2826.2009.01949.x; Mitchell BF, 2009, AM J PHYSIOL-REG I, V297, pR525, DOI 10.1152/ajpregu.00153.2009; Nguyen PN, 2004, J PHYSIOL-LONDON, V560, P593, DOI 10.1113/jphysiol.2004.069336; Nguyen PN, 2003, PEDIATR RES, V54, P840, DOI 10.1203/01.PDR.0000088066.47755.36; Nicol MB, 1997, J ENDOCRINOL, V152, P379, DOI 10.1677/joe.0.1520379; NITSOS I, 1990, INT J DEV NEUROSCI, V8, P233, DOI 10.1016/0736-5748(90)90029-2; PAUL SM, 1992, FASEB J, V6, P2311; Poletti A, 1998, STEROIDS, V63, P246, DOI 10.1016/S0039-128X(98)00018-X; Rees S, 1998, COMP BIOCHEM PHYS A, V119, P653, DOI 10.1016/S1095-6433(98)01001-0; Saigal S, 2008, LANCET, V371, P261, DOI 10.1016/S0140-6736(08)60136-1; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Kruse MS, 2009, BRAIN RES, V1303, P1, DOI 10.1016/j.brainres.2009.09.078; Turner AJ, 2009, PLACENTA, V30, P236, DOI 10.1016/j.placenta.2008.11.023; Yawno T, 2007, NEUROSCIENCE, V146, P1726, DOI 10.1016/j.neuroscience.2007.03.023; Yawno T, 2009, NEUROSCIENCE, V163, P838, DOI 10.1016/j.neuroscience.2009.07.009	31	45	47	1	6	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0022-0795			J ENDOCRINOL	J. Endocrinol.	MAR	2011	208	3					301	309		10.1677/JOE-10-0248			9	Endocrinology & Metabolism	Endocrinology & Metabolism	720TF	WOS:000287304000012	21149437	Bronze			2021-06-18	
J	Ozen, LJ; Fernandes, MA				Ozen, Lana J.; Fernandes, Myra A.			Effects of "Diagnosis Threat" on Cognitive and Affective Functioning Long After Mild Head Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injuries; Mild concussion; Neuropsychological test; Attentions; Memory; Affects	TRAUMATIC BRAIN-INJURY; GOOD-OLD-DAYS; POSTTRAUMATIC-STRESS-DISORDER; DEPRESSION FOLLOWING MILD; POSTCONCUSSION-SYNDROME; WORKING-MEMORY; ATTENTION DEFICITS; PERFORMANCE; ACTIVATION; SYMPTOMS	Persistent cognitive complaints are common following a mild head injury (MHI), but deficits are rarely detected on neuropsychological tests. Our objective was to examine the effect of symptom expectation on self-report and cognitive performance measures in MHI individuals. Prior research suggests that when MHI participants are informed they may experience cognitive difficulties, they perform worse on neuropsychological tests compared to MHI participants who are uninformed. In this study, undergraduate students with and without a prior MHI were either informed that the study's purpose was to investigate the effects of MHI on cognitive functioning ("diagnosis threat" condition) or merely informed that their cognitive functioning was being examined, with no mention of status ("neutral" condition). "Diagnosis threat" MHIs self-reported more attention failures compared to "diagnosis threat" controls and "neutral" MHIs, and more memory failures compared to "diagnosis threat" controls. In the "neutral" condition, MHIs reported higher anxiety levels compared to controls and compared to "diagnosis threat" MHIs. Regardless of condition, MHIs performed worse on only one neuropsychological test of attention span. "Diagnosis threat" may contribute to the prevalence and persistence of cognitive complaints made by MHI individuals found in the literature, but may not have as strong of an effect on neuropsychological measures. (JINS, 2011, 17, 219-229)	[Ozen, Lana J.; Fernandes, Myra A.] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada	Ozen, LJ (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	lozen@uwaterloo.ca			National Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); NSERCNatural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by a Discovery grant from the National Sciences and Engineering Research Council of Canada (NSERC) awarded to Dr. M.A. Fernandes and post-graduate scholarships from NSERC awarded to L.J. Ozen.	Beck A.T., 1996, MANUAL BECK DEPRESSI; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Davis CH, 2002, AM J PHYS MED REHAB, V81, P609, DOI 10.1097/00002060-200208000-00009; Delis DC, 1987, CALIFORNIA VERBAL LE; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; EDNA TH, 1987, ACTA NEUROCHIR, V85, P40, DOI 10.1007/BF01402368; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Halstead WC, 1985, HALSTEAD REITAN NEUR; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Messe A., 2010, HUMAN BRAIN MAPPING; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; REASON JT, 1982, ABSENT MINDED PSYCHO; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spencer SJ, 1999, J EXP SOC PSYCHOL, V35, P4, DOI 10.1006/jesp.1998.1373; Spiegel H, 1997, PREV MED, V26, P616, DOI 10.1006/pmed.1997.0229; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Thurman DJ, 2001, HEAD TRAUMA, P327; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wechsler D, 1997, WAIS 3 ADM SCORING M; Westcott MC, 2005, BRAIN INJURY, V19, P1261, DOI 10.1080/02699050500150104; Wheeler SC, 2001, PSYCHOL BULL, V127, P797, DOI 10.1037//0033-2909.127.6.797; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	53	45	45	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2011	17	2					219	229		10.1017/S135561771000144X			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	738DY	WOS:000288620900002	21138607				2021-06-18	
J	Sastre, M; Richardson, JC; Gentleman, SM; Brooks, DJ				Sastre, M.; Richardson, J. C.; Gentleman, S. M.; Brooks, D. J.			Inflammatory Risk Factors and Pathologies Associated with Alzheimer's Disease	CURRENT ALZHEIMER RESEARCH			English	Article						Alzheimer's disease; diabetes; imaging; infection; inflammation; microglia; stroke; trauma	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MILD COGNITIVE IMPAIRMENT; MICROGLIAL ACTIVATION; PLAQUE DEPOSITION; HEAD-INJURY; INDUCED-NEUROINFLAMMATION; INSULIN-RESISTANCE; GENE POLYMORPHISM	The importance of inflammatory processes in Alzheimer's disease ( AD) progression has been confirmed during the past decade by the intensive investigation of inflammatory mediators in the brain of AD patients as well as by the genetic and drug manipulation of animal models of AD. Imaging studies have revealed that the activation of microglia occurs in early stages of the disease, even before plaque and tangle formation, and is correlated with early cognitive deficits. In this review, we analyze how different risk factors, such as trauma, stroke, infection, and metabolic diseases can lead to an acceleration of the inflammatory response in the AD brain and to an increased risk of developing this disorder. The use of imaging techniques for early detection of glial activation which offer the advantage of investigating how potential anti-inflammatory therapies may influence disease progression and levels of cognition is also discussed.	[Richardson, J. C.] GlaxoSmithKline, Neurosci CEDD, Harlow, Essex, England; [Sastre, M.; Gentleman, S. M.; Brooks, D. J.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, Ctr Neurosci, London W12 0NN, England	Sastre, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Neurosci, Div Expt Med, Du Cane Rd, London W12 0NN, England.	m.sastre@imperial.ac.uk		Brooks, David/0000-0003-2602-2518	Alzheimer's Research Trust [ART/PG2009/5, ART/PPG2009B/10]; Alzheimers Research UKAlzheimer's Research UK (ARUK) [ART-PG2011-12] Funding Source: Researchfish	We would like to thank the Alzheimer's Research Trust for their support ( grants ART/PG2009/5 and ART/PPG2009B/10).	Allen B, 2002, J NEUROSCI, V22, P9340; Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Anderson AN, 2007, NEUROIMAGE, V36, P28, DOI 10.1016/j.neuroimage.2007.02.017; Anthony IC, 2006, ACTA NEUROPATHOL, V111, P529, DOI 10.1007/s00401-006-0037-0; Archer HA, 2006, ANN NEUROL, V60, P145, DOI 10.1002/ana.20889; Arnaud L, 2006, NEURODEGENER DIS, V3, P313, DOI 10.1159/000095638; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; BALES KR, 2010, NEUROPHARMACOLOGY; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; BANATI RB, 1997, J CEREB BLOOD FLOW M, V17, pS435; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Barroso I, 1999, NATURE, V402, P880; Batarseh A, 2010, MOL CELL ENDOCRINOL, V327, P1, DOI 10.1016/j.mce.2010.06.013; Bellelli G, 2009, J AM GERIATR SOC, V57, P178, DOI 10.1111/j.1532-5415.2009.02067.x; Bellucci A, 2004, AM J PATHOL, V165, P1643, DOI 10.1016/S0002-9440(10)63421-9; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Boche D, 2010, ACTA NEUROPATHOL, V120, P13, DOI 10.1007/s00401-010-0705-y; Breitner JCS, 2009, NEUROLOGY, V72, P1899, DOI 10.1212/WNL.0b013e3181a18691; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Britschgi M, 2009, ARCH NEUROL-CHICAGO, V66, P161, DOI 10.1001/archneurol.2008.530; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Brown AK, 2007, J NUCL MED, V48, P2072, DOI 10.2967/jnumed.107.044842; Cagnin A, 2001, BRAIN, V124, P2014, DOI 10.1093/brain/124.10.2014; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Capurso C, 2004, EXP GERONTOL, V39, P1567, DOI 10.1016/j.exger.2004.07.006; Chakrabarty P, 2010, J IMMUNOL, V184, P5333, DOI 10.4049/jimmunol.0903382; Chakrabarty P, 2010, FASEB J, V24, P548, DOI 10.1096/fj.09-141754; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2008, J ALZHEIMERS DIS, V15, P571; Craft S, 1999, ARCH GEN PSYCHIAT, V56, P1135, DOI 10.1001/archpsyc.56.12.1135; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; DICKSON DW, 1993, GLIA, V7, P75, DOI 10.1002/glia.440070113; Edison P, 2007, NEUROLOGY, V68, P501, DOI 10.1212/01.wnl.0000244749.20056.d4; Edison P, 2008, NEUROBIOL DIS, V32, P412, DOI 10.1016/j.nbd.2008.08.001; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Engler H, 2006, BRAIN, V129, P2856, DOI 10.1093/brain/awl178; Fagan AM, 2006, ANN NEUROL, V59, P512, DOI 10.1002/ana.20730; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gerard HC, 2006, FEMS IMMUNOL MED MIC, V48, P355, DOI 10.1111/j.1574-695X.2006.00154.x; Gerhard A, 2005, NEUROIMAGE, V24, P591, DOI 10.1016/j.neuroimage.2004.09.034; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; Gold M, 2010, DEMENT GERIATR COGN, V30, P131, DOI 10.1159/000318845; Gouin JP, 2008, NEUROIMMUNOMODULAT, V15, P251, DOI 10.1159/000156468; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; He P, 2007, J CELL BIOL, V178, P829, DOI 10.1083/jcb.200705042; Heneka MT, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-22; Heneka MT, 2005, BRAIN, V128, P1442, DOI 10.1093/brain/awh452; Heneka MT, 2001, J NEUROPATH EXP NEUR, V60, P906, DOI 10.1093/jnen/60.9.906; HENEKA MT, 2006, GLIA INIFLAMMATION N, P117; Herber DL, 2004, EXP NEUROL, V190, P245, DOI 10.1016/j.expneurol.2004.07.007; Hevener AL, 2003, NAT MED, V9, P1491, DOI 10.1038/nm956; Hickman SE, 2008, J NEUROSCI, V28, P8354, DOI 10.1523/JNEUROSCI.0616-08.2008; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Honjo K, 2009, ALZHEIMERS DEMENT, V5, P348, DOI 10.1016/j.jalz.2008.12.001; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Jaeger LB, 2009, BRAIN BEHAV IMMUN, V23, P507, DOI 10.1016/j.bbi.2009.01.017; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Jolivalt CG, 2008, J NEUROSCI RES, V86, P3265, DOI 10.1002/jnr.21787; JOLIVALT CG, 2009, EXP NEUROL; Kaddai V, 2009, DIABETOLOGIA, V52, P932, DOI 10.1007/s00125-009-1273-3; KAMBOH MI, 1995, NAT GENET, V10, P486, DOI 10.1038/ng0895-486; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Klunk WE, 2003, J NEUROSCI, V23, P2086; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Koistinaho M, 2005, BRAIN RES REV, V48, P240, DOI 10.1016/j.brainresrev.2004.12.014; Koivisto AM, 2006, DEMENT GERIATR COGN, V22, P449, DOI 10.1159/000095857; Kriz J, 2009, ACTA NEUROPATHOL, V117, P497, DOI 10.1007/s00401-009-0496-1; Kukar T, 2005, NAT MED, V11, P545, DOI 10.1038/nm1235; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Lee JW, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-37; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Maier M, 2008, J NEUROSCI, V28, P6333, DOI 10.1523/JNEUROSCI.0829-08.2008; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; McCusker SM, 2001, LANCET, V357, P436, DOI 10.1016/S0140-6736(00)04008-3; Miklossy J, 2008, J ALZHEIMERS DIS, V13, P381; Mintun MA, 2005, CNS SPECTRUMS, V10, P13, DOI 10.1017/S1092852900014188; Nicoll JAR, 2003, TRENDS MOL MED, V9, P281, DOI 10.1016/S1471-4914(03)00109-6; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.3.CO;2-7; Okello A, 2009, NEUROLOGY, V72, P56, DOI 10.1212/01.wnl.0000338622.27876.0d; Papadopoulos V, 2006, TRENDS PHARMACOL SCI, V27, P402, DOI 10.1016/j.tips.2006.06.005; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Petersen R C, 2000, Neurologia, V15, P93; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rasgon N, 2004, J GERONTOL A-BIOL, V59, P178; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Roberts JC, 2009, EXP NEUROL, V216, P459, DOI 10.1016/j.expneurol.2009.01.002; ROGERS JT, 1999, J BIOL CHEM, V274, P6231; Rossner S, 2005, J NEUROCHEM, V92, P226, DOI 10.1111/j.1471-4159.2004.02857.x; Sastre M, 2003, J NEUROSCI, V23, P9796; Sastre M, 2006, INT J DEV NEUROSCI, V24, P167, DOI 10.1016/j.ijdevneu.2005.11.014; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; SASTRE M, 2010, NEUROSCIENCE, V2, P20; Sastre M, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-25; Sauder S, 2005, J NEURAL TRANSM, V112, P1381, DOI 10.1007/s00702-004-0267-z; Shaftel SS, 2007, J CLIN INVEST, V117, P1595, DOI 10.1172/JCI31450; Sheng JG, 2003, NEUROBIOL DIS, V14, P133, DOI 10.1016/S0969-9961(03)00069-X; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Szekely CA, 2008, NEUROLOGY, V70, P2291, DOI 10.1212/01.wnl.0000313933.17796.f6; Tai YF, 2007, BRAIN, V130, P1759, DOI 10.1093/brain/awm044; Takeda S, 2010, P NATL ACAD SCI USA, V107, P7036, DOI 10.1073/pnas.1000645107; Thirumangalakudi L, 2008, J NEUROCHEM, V106, P475, DOI 10.1111/j.1471-4159.2008.05415.x; Tobinick Edward, 2006, MedGenMed, V8, P25; Turner MR, 2004, NEUROBIOL DIS, V15, P601, DOI 10.1016/j.nbd.2003.12.012; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Verhoeff NPLG, 2004, AM J GERIAT PSYCHIAT, V12, P584, DOI 10.1176/appi.ajgp.12.6.584; Verma NK, 2004, BRIT J PHARMACOL, V143, P1006, DOI 10.1038/sj.bjp.0706002; Verreault R, 2001, CAN MED ASSOC J, V165, P1495; Vlad SC, 2008, NEUROLOGY, V70, P1672, DOI 10.1212/01.wnl.0000311269.57716.63; Wellen KE, 2005, J CLIN INVEST, V115, P1111, DOI 10.1172/JCI200525102; Whitehead SN, 2007, STROKE, V38, P3245, DOI 10.1161/STROKEAHA.107.492660; Wozniak MA, 2009, J PATHOL, V217, P131, DOI 10.1002/path.2449; WOZNIAK MA, 2010, THERAPEUTIC ADV NEUR; Wozniak MA, 2007, NEUROSCI LETT, V429, P95, DOI 10.1016/j.neulet.2007.09.077; Wyss-Coray T, 2003, NAT MED, V9, P453, DOI 10.1038/nm838; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xu F, 2007, STROKE, V38, P2598, DOI 10.1161/STROKEAHA.106.480103; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	132	45	47	0	15	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2050	1875-5828		CURR ALZHEIMER RES	Curr. Alzheimer Res.	MAR	2011	8	2					132	141		10.2174/156720511795256062			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	744TV	WOS:000289118300003	21345169				2021-06-18	
J	Faux, S; Sheedy, J; Delaney, R; Riopelle, R				Faux, Steven; Sheedy, Jo; Delaney, R.; Riopelle, Richard			Emergency department prediction of post-concussive syndrome following mild traumatic brain injury-an international cross-validation study	BRAIN INJURY			English	Article						Mild traumatic brain injury; concussion; post-concussive syndrome; mild head injury; prognosis	BLOOD-ALCOHOL CONCENTRATIONS; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RAPID SCREEN; CHRONIC PAIN; ADULTS; TRIAL; CARE	Background: Between 20-50% of those suffering a mild traumatic brain injury (MTBI) will suffer symptoms beyond 3 months or post-concussive disorder (PCD). Researchers in Sydney conducted a prospective controlled study which identified that bedside recordings of memory impairment together with recordings of moderate or severe pain could predict those who would suffer PCS with 80% sensitivity and specificity of 76%. Primary objective: This study is a cross-validation study of the Sydney predictive model conducted at Montreal General Hospital, Montreal, Canada. Methods: One hundred and seven patients were assessed in the Emergency Department following a MTBI and followed up by phone at 3 months. The Rivermead Post-Concussive Questionnaire was the main outcome measure. Results: Regression analysis showed that immediate verbal recall and quantitative recording of headache was able to predict PCD with a sensitivity of 71.4% and a specificity of 63.3%. In the combined MTBI groups from Sydney and Montreal the sensitivity was 70.2% and the specificity was 64.2%. Conclusion: This is the first study to compare populations from different countries with diverse language groups using a predictive model for identifying PCD following MTBI. The model may be able to identify an 'at risk' population to whom pre-emptive treatment can be offered.	[Faux, Steven] St Vincents Hosp, Sydney, NSW 2010, Australia; [Delaney, R.] McGill Univ, Montreal Gen Hosp, Med Ctr, Dept Emergency Med, Montreal, PQ H3G 1A4, Canada; [Riopelle, Richard] McGill Univ, Montreal Gen Hosp, Med Ctr, Dept Neurol Neurosurg, Montreal, PQ H3G 1A4, Canada	Faux, S (corresponding author), St Vincents Hosp, 170 Darlinghurst Rd, Sydney, NSW 2010, Australia.	sfaux@stvincents.com.au	Faux, Steven/Y-3409-2019	Faux, Steven/0000-0001-8846-216X	Stroke Society of Australia; Australian Faculty of Rehabilitation Medicine Ipsen Research FellowshipIpsen	Dr Faux's travel to Canada was supported by two grants; (1) Short Traveling Grant from the Stroke Society of Australia and (2) Australian Faculty of Rehabilitation Medicine Ipsen Research Fellowship. There was no direct funding of this research. The assistance, kind advice and cooperation of Dr R. Primavesi, Director of Emergency Medicine at Montreal General Hospital/Hopital General de Montreal, Canada is acknowledged.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; *AUSTR AC MUSC PAI, 2004, EV BAS MAN AC MUSC P; *AUSTR BUR STAT, 2004, CENS; *COLL MED QUEB, 2005, OR MIN TRAUM CRAN CE; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; COPES WS, 1997, P 33 ANN M ASS ADV A, P205; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; De Monte VE, 2004, J CLIN EXP NEUROPSYC, V26, P628, DOI 10.1080/13803390490504443; Hillier SL, 1997, BRAIN INJURY, V11, P649; *I STAT QUEB, 2001, CENS; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JONES AW, 1991, FORENSIC SCI PROGR, V5, P31; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Noble B, 2005, J PAIN SYMPTOM MANAG, V29, P14, DOI 10.1016/j.jpainsymman.2004.08.007; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Paniak C, 2000, BRAIN INJURY, V14, P219; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; *STAT CAN, 2001, CENS; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stowell AR, 1998, J FORENSIC SCI, V43, P14, DOI 10.1520/JFS16083J; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; WATSON PE, 1981, J STUD ALCOHOL, V42, P547, DOI 10.15288/jsa.1981.42.547; Weschler D., 1981, MANUAL WECHSLER ADUL	46	45	48	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2011	25	1					14	22		10.3109/02699052.2010.531686			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731JI	WOS:000288101700003	21142827				2021-06-18	
J	Putukian, M				Putukian, Margot			The Acute Symptoms of Sport-Related Concussion: Diagnosis and On-field Management	CLINICS IN SPORTS MEDICINE			English	Article						Sport-related concussion; Sideline management; Concussion protocol; Symptoms; Diagnosis; Mild traumatic brain injury; Head injury; Sports	MILD HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; NEUROPSYCHOLOGICAL ASSESSMENT; INTERNATIONAL-CONFERENCE; CEREBRAL CONCUSSION; POSTURAL STABILITY; STATEMENT; RETURN; RELIABILITY; VALIDATION	Sport-related concussion is a common injury that occurs in a variety of sports. In recent years, more attention has been focused on the importance of this injury as well as the long-term complications of unrecognized, repetitive, and/or severe injury. The acute presentation of concussion as well as the diagnosis of concussion is often straightforward and obvious, but it can also be subtle and difficult to discern. Most injuries are short lived with complete recovery within a couple of weeks, with a small minority taking several months to resolve. Unfortunately, it is difficult to predict which injuries will linger. This article discusses the on-field presentation, diagnosis, and management of sport-related concussion. It is important to have a concussion protocol for high-risk sports, including a preseason and postinjury assessment, and an individualized yet comprehensive approach that includes evaluating symptoms, and a neurologic examination that includes cognitive function and balance testing. A multifaceted approach to the evaluation and diagnosis of concussion is endorsed for the optimal management of this injury.	[Putukian, Margot] Univ Med & Dent New Jersey, New Brunswick, NJ 08901 USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA	Putukian, M (corresponding author), Univ Med & Dent New Jersey, 125 Paterson St, New Brunswick, NJ 08901 USA.	putukian@princeton.edu					Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; [Anonymous], 2009, BRIT J SPORT MED, V43, pi85; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J ATHL TRAINING, V36, P297; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Barth JT., 1989, MILD HEAD INJURY, P257; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Bruce JM, 2004, NEUROLOGY, V63, P1516; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Colorado Medical Society School and Sports Medicine Committee, 1990, COLO MED, V87, P4; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hecht S, 2004, CLIN J SPORT MED, V14, P310; HERRING S, 2001, MED SCI SPORTS EXERC, V33, P846; HERRING SA, 2005, MED SCI SPORTS EXERC, V37, P2012; JENNETT B, 1975, LANCET, V1, P480; Kelly JP, 1997, NEUROLOGY, V48, P581; LECLERC S, 2004, ASSESSMENT CONCUSSIO; Lovell M. R., 2007, IMMEDIATE POSTCONCUS; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; *NAT FED HIGH SCH, 2009 NFHS CONS BROCH; *NCAA HLTH SAF, NCAA REQ CONC MAN PL; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Piland SG, 2003, J ATHL TRAINING, V38, P104; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Randolph C, 2005, J ATHL TRAINING, V40, P139; RANDOLPH C, CONCUSSION SYMPTOM I; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rubin Aaron L, 2004, Curr Sports Med Rep, V3, P141; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; VALVOLICHMCLEOD TC, 2006, J ATHL TRAINING, V41, P399; Van Kampen D., 2006, AM J SPORTS MED, V34, P1	62	45	45	0	23	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					49	+		10.1016/j.csm.2010.09.005			14	Sport Sciences	Sport Sciences	691XR	WOS:000285114800006	21074081				2021-06-18	
J	Reinhardt, JD; Li, JA; Gosney, J; Rathore, FA; Haig, AJ; Marx, M; DeLisa, JA				Reinhardt, Jan D.; Li, Jianan; Gosney, James; Rathore, Farooq A.; Haig, Andrew J.; Marx, Michael; DeLisa, Joel A.		Int Soc Phys Rehabil Med	Disability and health-related rehabilitation in international disaster relief	GLOBAL HEALTH ACTION			English	Article							SPINAL-CORD INJURIES; 2008 WENCHUAN EARTHQUAKE; SUB-SAHARAN AFRICA; GREAT HANSHIN EARTHQUAKE; PHYSICAL MEDICINE; WHITE PAPER; BLACK MARK; CONCEPTUAL DESCRIPTION; NORTHERN PAKISTAN; UNIFYING MODEL	Background: Natural disasters result in significant numbers of disabling impairments. Paradoxically, however, the traditional health system response to natural disasters largely neglects health-related rehabilitation as a strategic intervention. Objectives: To examine the role of health-related rehabilitation in natural disaster relief along three lines of inquiry: (1) epidemiology of injury and disability, (2) impact on health and rehabilitation systems, and (3) the assessment and measurement of disability. Design: Qualitative literature review and secondary data analysis. Results: Absolute numbers of injuries as well as injury to death ratios in natural disasters have increased significantly over the last 40 years. Major impairments requiring health-related rehabilitation include amputations, traumatic brain injuries, spinal cord injuries (SCI), and long bone fractures. Studies show that persons with pre-existing disabilities are more likely to die in a natural disaster. Lack of health-related rehabilitation in natural disaster relief may result in additional burdening of the health system capacity, exacerbating baseline weak rehabilitation and health system infrastructure. Little scientific evidence on the effectiveness of health-related rehabilitation interventions following natural disaster exists, however. Although systematic assessment and measurement of disability after a natural disaster is currently lacking, new approaches have been suggested. Conclusion: Health-related rehabilitation potentially results in decreased morbidity due to disabling injuries sustained during a natural disaster and is, therefore, an essential component of the medical response by the host and international communities. Significant systematic challenges to effective delivery of rehabilitation interventions during disaster include a lack of trained responders as well as a lack of medical recordkeeping, data collection, and established outcome measures. Additional development of health-related rehabilitation following natural disaster is urgently required.	[Reinhardt, Jan D.] Swiss Parapleg Res, CH-6207 Nottwil, Switzerland; [Reinhardt, Jan D.; Li, Jianan; Gosney, James; Rathore, Farooq A.; Haig, Andrew J.; DeLisa, Joel A.] Rehabil Disaster Relief Comm, ISPRM, Ghent, Belgium; [Reinhardt, Jan D.] Univ Lucerne, Dept Hlth Sci & Hlth Policy, Luzern, Switzerland; [Li, Jianan] Nanjing Med Univ, Affiliated Hosp 1, Dept Rehabil Med, Nanjing, Peoples R China; [Li, Jianan; Gosney, James; Rathore, Farooq A.; Haig, Andrew J.] Int Rehabil Forum Emergency Rehabil Work Grp, Ann Arbor, MI USA; [Rathore, Farooq A.] Combined Mil Hosp, Dept Rehabil Med, Sindh, Pakistan; [Haig, Andrew J.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Marx, Michael] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany; [DeLisa, Joel A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; [DeLisa, Joel A.] Univ Hosp, Newark, NJ USA	Reinhardt, JD (corresponding author), Swiss Parapleg Res, Guido A Zach Str 4, CH-6207 Nottwil, Switzerland.	jan.reinhardt@paranet.ch	Rathore, Farooq Azam/B-8232-2008	Rathore, Farooq Azam/0000-0002-4759-0453			[Anonymous], 1980, WHO CHRON, V34, P96; Anonymous, 2011, Morbidity and Mortality Weekly Report, V59, P1673; Armenian HK, 2000, ACTA PSYCHIAT SCAND, V102, P58, DOI 10.1034/j.1600-0447.2000.102001058.x; Armenian HK, 1998, AM J EPIDEMIOL, V148, P1077, DOI 10.1093/oxfordjournals.aje.a009585; Armenian HK, 1997, INT J EPIDEMIOL, V26, P806, DOI 10.1093/ije/26.4.806; Bai XD, 2009, CHIN J TRAUMATOL, V12, P122, DOI 10.3760/cma.j.issn.1008-1275.2009.02.012; Centre for Research on the Epidemiology of Disasters (CRED), 2011, EM DAT INT DIS DAT; Chan E Y Y, 2007, Asia Pac J Public Health, V19 Spec No, P45; Chan EYY, 2009, PREHOSPITAL DISASTER, V24, P365, DOI 10.1017/S1049023X00007159; Chiou-Tan FY, 2007, AM J PHYS MED REHAB, V86, P762, DOI 10.1097/PHM.0b013e31813e61cc; Chou YJ, 2004, AM J EPIDEMIOL, V160, P688, DOI 10.1093/aje/kwh270; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; de Goyet CD, 2007, PREHOSP DISASTER MED, V22, P152, DOI 10.1017/S1049023X00004556; DUNNETT CW, 1980, J AM STAT ASSOC, V75, P796, DOI 10.2307/2287161; Eldar R, 1997, DISABIL REHABIL, V19, P547, DOI 10.3109/09638289709166048; Fan F, 2011, J TRAUMA STRESS, V24, P44, DOI 10.1002/jts.20599; Gosney JE, 2010, DISASTER MED PUBLIC, V4, P110, DOI 10.1001/dmphp.4.2.110; Gosselin RA, 2009, INT ORTHOP, V33, P1445, DOI 10.1007/s00264-009-0798-x; Grosse SD, 2009, PUBLIC HEALTH REP, V124, P197, DOI 10.1177/003335490912400206; Guha-Sapir D., 2011, HUMAN CASUALTIES EAR, P13; Haig AJ, 2009, EUR J PHYS REHAB MED, V45, P185; Haig AJ, 2009, CHINESE J REHABILITA, V24, P385; Haig AJ, 2009, PM&R, V1, P421, DOI 10.1016/j.pmrj.2008.12.012; Haig AJ, 2009, DISABIL REHABIL, V31, P1031, DOI 10.1080/09638280902803765; Haig AJ, 2009, J REHABIL MED, V41, P401, DOI 10.2340/16501977-0367; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Huang Ming-jin, 2010, Zhonghua Liu Xing Bing Xue Za Zhi, V31, P167; Iezzoni LI, 2010, ANN INTERN MED, V152, P812, DOI 10.7326/0003-4819-152-12-201006150-00234; Ingstad Benedict., 1995, DISABILITY CULTURE; Ke X, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-573; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelen GD, 2006, LANCET, V368, P1984, DOI 10.1016/S0140-6736(06)69808-5; King JC, 2005, PHYS MED REHABILITAT, P1051; LECHAT MF, 1979, B WORLD HEALTH ORGAN, V57, P11; Li S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004964; Li WF, 2009, CRIT CARE, V13, DOI 10.1186/cc8160; Loar J, 2011, DISABIL REHABIL, V33, P319, DOI 10.3109/09638288.2010.490870; Majchrzak A, 2007, ORGAN SCI, V18, P147, DOI 10.1287/orsc.1060.0228; MICRODIS, 2007, MICRODIS INT S HLTH; Mont D, 2007, LANCET, V369, P1658, DOI 10.1016/S0140-6736(07)60752-1; Mori Kikuko, 2007, Disaster Manag Response, V5, P8, DOI 10.1016/j.dmr.2006.11.002; MURRAY CJL, 1990, GLOBAL BURDEN DIS CO, V1; Nufer KE, 2006, J EMERG MED, V30, P183, DOI 10.1016/j.jemermed.2005.03.020; OCHA ROMENACA, 2010, HUM RESP HAIT; Osaki Y, 1999, Nihon Koshu Eisei Zasshi, V46, P175; Phalkey R, 2011, INJURY EPIDEMIOLOGY; Priestley M, 2007, J SOC WORK DISABIL R, V5, P23, DOI 10.1300/J198v05n03_02; Qiu J, 2010, CHIN J TRAUMATOL, V13, P297, DOI 10.3760/cma.j.issn.1008-1275.2010.05.009; Raissi GR, 2007, AM J PHYS MED REHAB, V86, P912, DOI 10.1097/PHM.0b013e3181583abc; Raissi GR, 2007, J SPINAL CORD MED, V30, P369, DOI 10.1080/10790268.2007.11753954; Rathore FA, 2008, ARCH PHYS MED REHAB, V89, P579, DOI 10.1016/j.apmr.2007.09.027; Rathore FA, 2011, ARCH PHYS MED REHAB, V92, P161, DOI 10.1016/j.apmr.2010.10.004; Rathore MFA, 2008, SPINAL CORD, V46, P461, DOI 10.1038/sj.sc.3102162; Rathore MFA, 2007, SPINAL CORD, V45, P658, DOI 10.1038/sj.sc.3102023; Rathore MFA, 2008, J SPINAL CORD MED, V31, P118; Redmond AD, 2011, EMERG MED J, V28, P516, DOI 10.1136/emj.2009.089920; Smith K., 2009, ENV HAZARDS ASSESSIN; Stucki G, 2007, J REHABIL MED, V39, P279, DOI 10.2340/16501977-0041; Stucki G, 2007, J REHABIL MED, V39, P286, DOI 10.2340/16501977-0044; Takahashi A, 1997, J INTELL DISABIL RES, V41, P193, DOI 10.1111/j.1365-2788.1997.tb00695.x; Tanida N, 1996, BRIT MED J, V313, P1133, DOI 10.1136/bmj.313.7065.1133; Tauqir SF, 2007, J SPINAL CORD MED, V30, P373, DOI 10.1080/10790268.2007.11753955; Teal GE, 1965, TRAINING REQUIREMENT; Tinney MJ, 2007, DISABIL REHABIL, V29, P921, DOI 10.1080/09638280701240482; United Nations ESCAP, 2010, STAT YB AS PAC 2009; WHO, 2009, WHODAS 2 0 WHO DIS A; Wisner B., 2003, ENV HLTH EMERGENCIES; World Health Organisation, 2005, DIS DIS REH; World Health Organization, 2008, GUID PROV MAN WHEELC; World Health Organization, 2001, INT CLASS FUNCT DIS; Yang C, 2009, INJURY, V40, P488, DOI 10.1016/j.injury.2009.01.102; Yun K, 2010, NEW ENGL J MED, V363, P1193, DOI 10.1056/NEJMp1008304; Zhang LL, 2011, EMERG MED J, V28, P618, DOI 10.1136/emj.2009.087296	73	45	46	1	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1654-9880			GLOBAL HEALTH ACTION	Glob. Health Action		2011	4				SI				7191	10.3402/gha.v4i0.7191			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	875EH	WOS:000299012700052	21866223	DOAJ Gold, Green Published			2021-06-18	
J	Lv, LQ; Hou, LJ; Yu, MK; Qi, XQ; Chen, HR; Chen, JX; Hu, GH; Luo, C; Lu, YC				Lv, Li-Quan; Hou, Li-Jun; Yu, Ming-Kun; Qi, Xiang-Qian; Chen, Huai-Rui; Chen, Ju-Xiang; Hu, Guo-Han; Luo, Chun; Lu, Yi-Cheng			Prognostic Influence and Magnetic Resonance Imaging Findings in Paroxysmal Sympathetic Hyperactivity after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						magnetic resonance imaging; outcome; paroxysmal sympathetic hyperactivity; traumatic brain injury	DIFFUSE AXONAL INJURY; SEVERE HEAD-INJURY; COMPUTED-TOMOGRAPHY; DYSAUTONOMIA; STEM; CLASSIFICATION	Paroxysmal sympathetic hyperactivity (PSH) is a clinical syndrome affecting a subgroup of survivors of severe brain injury. In this study, the prevalence, magnetic resonance imaging (MRI) presentation, influence on the clinical course in the intensive care unit (ICU), and effect on neurological recovery of PSH were prospectively surveyed in 87 patients with severe traumatic brain injury (TBI). Cranial MRI was performed during the first 30 days after injury. The outcome was assessed according to the Glasgow Outcome Scale (GOS). PSH occurred in 18.4% of patients, with a greater incidence among younger patients and those with lower Glasgow Coma Scale (GCS) scores. Patients with PSH had more deep lesions as shown on cranial MRI, significantly longer ICU stays, and worse outcomes. PSH was shown to be common among patients with severe TBI who also had deep intraparenchymal lesions. The mechanism by which PSH influences patient outcomes has yet to be defined, but we believe that it may be mediated by diencephalic-mesencephalic dysfunction or disconnection.	[Lv, Li-Quan; Hou, Li-Jun; Yu, Ming-Kun; Qi, Xiang-Qian; Chen, Huai-Rui; Chen, Ju-Xiang; Hu, Guo-Han; Luo, Chun; Lu, Yi-Cheng] Shanghai Changzheng Hosp, Dept Neurosurg, Shanghai Inst Neurosurg, Shanghai 200003, Peoples R China	Lu, YC (corresponding author), Shanghai Changzheng Hosp, Dept Neurosurg, Shanghai Inst Neurosurg, 415 Feng Yang Rd, Shanghai 200003, Peoples R China.	neuro_lycheng@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30600635]	This research was supported by National Natural Science Foundation of China grant 30600635.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Baguley IJ, 1999, MAYO CLIN PROC, V74, P105, DOI 10.4065/74.1.105; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; DOLCE G, 2008, J NEUROTRAUMA; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071; Sahuquillo J, 2002, ADV TECH STAND NEUR, V27, P23; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z	22	45	50	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2010	27	11					1945	1950		10.1089/neu.2010.1391			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	682BZ	WOS:000284375500001	21028988				2021-06-18	
J	Abeare, CA; Cohen, JL; Axelrod, BN; Leisen, JCC; Mosley-Williams, A; Lumley, MA				Abeare, Christopher A.; Cohen, Jay L.; Axelrod, Bradley N.; Leisen, James C. C.; Mosley-Williams, Angelia; Lumley, Mark A.			Pain, Executive Functioning, and Affect in Patients With Rheumatoid Arthritis	CLINICAL JOURNAL OF PAIN			English	Article						pain; executive functioning; negative affect; positive affect; rheumatoid arthritis	TRAUMATIC BRAIN-INJURY; POSITIVE AFFECT; INDUCED MOOD; ATTENTION; FIBROMYALGIA; CATEGORIZATION; INTEGRATION; DEPRESSION; COGNITION; DEFICITS	Objectives: Rheumatoid arthritis (RA) is a chronic inflammatory disease resulting in substantial pain. The physical and emotional effects of RA are well known, but little attention has been given to the potential cognitive effects of RA pain, although intact executive functioning in patients with chronic illness is crucial for the successful completion of many daily activities. We examined the relationship between pain and executive functioning in patients with RA, and also considered the influence of positive and negative affect in the relationship between pain and executive functioning. Methods: A sample of 157 adults with RA completed measures of pain and positive and negative affect and were tested for working memory and selective attention using the Letter Number Sequencing subtest from the Wechsler Adult Intelligence Scale-Third Edition and the Stroop Color Word Test tests, respectively. Results: Consistent with prior research, pain was inversely related to executive functioning, with higher pain levels associated with poorer performance on executive functioning tasks. This relationship was not moderated or mediated by negative affect; however, positive affect moderated the relationship between pain and executive functioning. For patients high in positive affect there was a significant inverse relationship between pain and executive functioning, whereas there was no such relationship for patients low in positive affect. Discussion: These findings are discussed in the context of cognitive research on the effects of positive affect on executive functioning and functional neuroanatomical research suggesting neurocognitive mechanisms for such moderation.	[Abeare, Christopher A.] Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; [Cohen, Jay L.; Axelrod, Bradley N.] John D Dingell VAMC, Rheumatol Sect, Mental Hlth Serv, Psychol Sect, Detroit, MI USA; [Cohen, Jay L.; Lumley, Mark A.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Leisen, James C. C.] Henry Ford Hlth Syst, Dept Med, Div Rheumatol, Detroit, MI USA; [Mosley-Williams, Angelia] John D Dingell Vet Affairs Med Ctr, Med Sect, Detroit, MI USA; [Mosley-Williams, Angelia] Wayne State Univ, Dept Internal Med, Div Rheumatol, Detroit, MI 48202 USA	Abeare, CA (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	cabeare@uwindsor.ca		Abeare, Christopher/0000-0002-7163-7434	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR049059] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01 AR049059-01A1, R01 AR049059] Funding Source: Medline		Aiken L.S., 1991, MULTIPLE REGRESSION; Ashby FG, 1999, PSYCHOL REV, V106, P529, DOI 10.1037/0033-295X.106.3.529; Brown SC, 2002, PAIN, V96, P279, DOI 10.1016/S0304-3959(01)00457-2; Connelly M, 2007, PAIN, V131, P162, DOI 10.1016/j.pain.2007.01.002; COTE KA, 1997, J RHEUMATOL, V24, P14; Coull JT, 1998, J NEUROSCI, V18, P7426; Davis MC, 2004, J PERS, V72, P1133, DOI 10.1111/j.1467-6494.2004.00293.x; de Wied M, 2001, PAIN, V90, P163, DOI 10.1016/S0304-3959(00)00400-0; Dixon KE, 2007, HEALTH PSYCHOL, V26, P241, DOI 10.1037/0278-6133.26.3.241; Dreisbach G, 2004, J EXP PSYCHOL LEARN, V30, P343, DOI 10.1037/0278-7393.30.2.343; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; Finan PH, 2009, PSYCHOSOM MED, V71, P474, DOI 10.1097/PSY.0b013e31819e0a8b; Gimse R, 1997, J CLIN EXP NEUROPSYC, V19, P838, DOI 10.1080/01688639708403764; Grace GM, 1999, J CLIN EXP NEUROPSYC, V21, P477, DOI 10.1076/jcen.21.4.477.876; Hamilton NA, 2005, ANN BEHAV MED, V29, P216, DOI 10.1207/s15324796abm2903_8; Hampshire A, 2006, CEREB CORTEX, V16, P1679, DOI 10.1093/cercor/bhj116; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; ISEN AM, 1984, J PERS SOC PSYCHOL, V47, P1206, DOI 10.1037/0022-3514.47.6.1206; ISEN AM, 1992, MOTIV EMOTION, V16, P65, DOI 10.1007/BF00996487; Kreitler S, 2007, PAIN, V15, P1; KREITLER S, 2007, HDB CHRONIC PAIN, P299; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Labouvie-Vief G, 2003, CURR DIR PSYCHOL SCI, V12, P201, DOI 10.1046/j.0963-7214.2003.01262.x; Meagher MW, 2001, PSYCHOSOM MED, V63, P79, DOI 10.1097/00006842-200101000-00010; MEENAN RF, 2005, ARTHRITIS RHEUM, V35, P1; Mitchell RLC, 2007, NEUROPSYCHOLOGIA, V45, P617, DOI 10.1016/j.neuropsychologia.2006.06.030; Mitchell RLC, 2005, BRAIN COGNITION, V59, P23, DOI 10.1016/j.bandc.2005.04.001; Nes LS, 2009, ANN BEHAV MED, V37, P173, DOI 10.1007/s12160-009-9096-5; Peyron R, 1999, BRAIN, V122, P1765, DOI 10.1093/brain/122.9.1765; Phillips LH, 2002, EMOTION, V2, P12, DOI 10.1037/1528-3542.2.1.12; Pincus T, 1998, BRIT J CLIN PSYCHOL, V37, P49, DOI 10.1111/j.2044-8260.1998.tb01278.x; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; RADANOV BP, 1992, ACTA NEUROL SCAND, V85, P358; Rowe G, 2007, P NATL ACAD SCI USA, V104, P383, DOI 10.1073/pnas.0605198104; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; SLETVOLD H, 1995, J RHEUMATOL, V22, P137; Strand EB, 2007, PAIN, V127, P204, DOI 10.1016/j.pain.2006.08.015; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; TRENNERY MR, 1989, STROOP NEUROPSYCHOLO; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Watson D., 1994, PANAS X MANUAL POSIT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weinberger D. A., 1990, REPRESSION DISSOCIAT, P337; Weisenberg M, 1998, PAIN, V76, P365, DOI 10.1016/S0304-3959(98)00069-4; Zautra A, 2001, J CONSULT CLIN PSYCH, V69, P786, DOI 10.1037//0022-006X.69.5.786; ZELMAN DC, 1991, PAIN, V46, P105, DOI 10.1016/0304-3959(91)90040-5	48	45	45	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-8047			CLIN J PAIN	Clin. J. Pain	OCT	2010	26	8					683	689		10.1097/AJP.0b013e3181ed1762			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	650AJ	WOS:000281818200005	20862788				2021-06-18	
J	Wise, EK; Mathews-Dalton, C; Dikmen, S; Temkin, N; Machamer, J; Bell, K; Powell, JM				Wise, Elizabeth K.; Mathews-Dalton, Christine; Dikmen, Sureyya; Temkin, Nancy; Machamer, Joan; Bell, Kathleen; Powell, Janet M.			Impact of Traumatic Brain Injury on Participation in Leisure Activities	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Conference on American-Occupational-Therapy-Associatioin	APR 10-13, 2008	Long Beach, CA	Amer Occupat Therapy Assoc, Univ Washington Traumatic Brain Injury Model Syst		Brain injuries; Recreation; Rehabilitation; Treatment outcome	QUALITY-OF-LIFE; FUNCTIONAL STATUS EXAMINATION; PHYSICAL-DISABILITIES; OCCUPATIONAL GAPS; EVERYDAY LIFE; ADULTS; SATISFACTION; REHABILITATION; INDIVIDUALS; SYSTEMS	Wise EK, Mathews-Dalton C. Dikmen S, Temkin N, Machamer J, Bell K, Powell JM. Impact of traumatic brain injury on participation in leisure activities. Arch Phys Med Rehabil 2010;91:1357-62. Objective: To determine how participation in leisure activities for people with traumatic brain injury (TBI) changes from before injury to 1 year after injury. Design: Prospective evaluation of leisure participation at 1 year after TBI. Setting: Level I trauma center. Participants: Rehabilitation inpatients (mean age, 35.3 years; 77% male; 77% white) with moderate to severe TBI (N=160). Interventions: Not applicable. Main Outcome Measure: Functional Status Examination. Results: At 1 year after injury, 81% had not returned to preinjury levels of leisure participation. Activities most frequently discontinued included partying, drug and alcohol use, and various sports. The activity most often reported as new after injury was watching television. Of the small fraction who returned to preinjury levels, 70% did so within 4 months of injury. Sixty percent of those who did not return to preinjury levels were moderately to severely bothered by the changes. Conclusions: At 1 year after injury, many TBI survivors engage in a reduced number of leisure activities, which are more sedentary and less social, with a substantial fraction dissatisfied with these changes. While discontinuing some activities may be viewed as a positive change, there are few new ones to replace them.	[Wise, Elizabeth K.] Univ Washington, Harborview Med Ctr, Seattle, WA 98104 USA; [Dikmen, Sureyya; Temkin, Nancy; Machamer, Joan; Bell, Kathleen; Powell, Janet M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Dikmen, Sureyya; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Mathews-Dalton, Christine] Shoreline Sch Dist, Shoreline, WA USA	Wise, EK (corresponding author), Univ Washington, Harborview Med Ctr, Box 359819,325 9th Ave, Seattle, WA 98104 USA.	bwise@u.washington.edu		Bell, Kathleen/0000-0002-0928-2046			ALLEN LR, 1982, J LEISURE RES, V14, P307; Bier N, 2009, J HEAD TRAUMA REHAB, V24, P187, DOI 10.1097/HTR.0b013e3181a0b15a; *CDCP, 2004, INJ PREV CONTR TRAUM; Chevan J, 2008, J STRENGTH COND RES, V22, P553, DOI 10.1519/JSC.0b013e3181636bee; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; Eriksson G, 2009, J REHABIL MED, V41, P187, DOI 10.2340/16501977-0307; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; *I MED, 2009, GULF WAR HLTH, V7, P301; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Kleiber DA, 2008, NEUROREHABILITATION, V23, P321; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kruger J., 2006, Morbidity and Mortality Weekly Report, V55, P769; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Malley D, 2008, NEUROREHABILITATION, V23, P329; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NIEMI ML, 1988, STROKE, V19, P1101, DOI 10.1161/01.STR.19.9.1101; Reynolds, 1997, BRIT J OCCUPATIONAL, V60, DOI [10.1177/030802269706000806, DOI 10.1177/030802269706000806]; RIDDICK CC, 1986, J LEISURE RES, V18, P259; Specht J, 2002, AM J OCCUP THER, V56, P436, DOI 10.5014/ajot.56.4.436; SPREITZER E, 1987, J LEISURE RES, V19, P49; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Taylor LPS, 1996, AM J OCCUP THER, V50, P39, DOI 10.5014/ajot.50.1.39; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; TINSLEY HEA, 1984, J LEISURE RES, V16, P234; UDD E, 1990, LEISURE CHALLENGES B; Viemero V, 1998, PSYCHOTHER PSYCHOSOM, V67, P317, DOI 10.1159/000012297; Wilson BA, 2008, ANNU REV CLIN PSYCHO, V4, P141, DOI 10.1146/annurev.clinpsy.4.022007.141212; 2003, DICT COMS 21 CENTURY	35	45	45	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	2010	91	9					1357	1362		10.1016/j.apmr.2010.06.009			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	651IM	WOS:000281921400007	20801252				2021-06-18	
J	Chrzaszcz, M; Venkatesan, C; Dragisic, T; Watterson, DM; Wainwright, MS				Chrzaszcz, MaryAnn; Venkatesan, Charu; Dragisic, Tina; Watterson, D. Martin; Wainwright, Mark S.			Minozac Treatment Prevents Increased Seizure Susceptibility in a Mouse "Two-Hit'' Model of Closed Skull Traumatic Brain Injury and Electroconvulsive Shock-Induced Seizures	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; electroconvulsive shock; microglia; seizure; traumatic brain injury	INDUCED STATUS EPILEPTICUS; FLUID PERCUSSION INJURY; PROINFLAMMATORY CYTOKINE; POSTTRAUMATIC EPILEPSY; HEAD INJURY; FUNCTIONAL RECOVERY; GENE-EXPRESSION; UP-REGULATION; METALLOTHIONEIN; INFLAMMATION	The mechanisms linking traumatic brain injury (TBI) to post-traumatic epilepsy (PTE) are not known and no therapy for prevention of PTE is available. We used a mouse closed-skull midline impact model to test the hypotheses that TBI increases susceptibility to seizures in a "two-hit'' injury model, and that suppression of cytokine upregulation after the first hit will attenuate the increased susceptibility to the second neurological insult. Adult male CD-1 mice underwent midline closed skull pneumatic impact. At 3 and 6 h after impact or sham procedure, the mice were injected IP with either Minozac (Mzc), a suppressor of proinflammatory cytokine upregulation, or vehicle (saline). On day 7 after sham operation or TBI, seizures were induced using electroconvulsive shock (ECS), and susceptibility to seizures was measured by the current required for seizure induction. Activation of glia, neuronal injury, and metallothionein-immunoreactive cells were quantified in the hippocampus by immunohistochemical methods. Neurobehavioral function over 14-day recovery was quantified using the Barnes maze. Following TBI there was a significant increase in susceptibility to seizures induced by ECS, and this susceptibility was prevented by suppression of cytokine upregulation with Mzc. Astrocyte activation, metallothionein expression, and neurobehavioral impairment were also increased in the two-hit group subjected to combined TBI and ECS. These enhanced responses in the two-hit group were also prevented by suppression of proinflammatory cytokine upregulation with Mzc. These data implicate glial activation in the mechanisms of epileptogenesis after TBI, and identify a potential therapeutic approach to attenuate the delayed neurological sequelae of TBI.	[Chrzaszcz, MaryAnn; Venkatesan, Charu; Dragisic, Tina; Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Div Neurol, Chicago, IL 60611 USA; [Chrzaszcz, MaryAnn; Venkatesan, Charu; Dragisic, Tina; Wainwright, Mark S.] Northwestern Univ, Feinberg Sch Med, Ctr Interdisciplinary Res Pediat Crit Illness & I, Chicago, IL 60611 USA; [Watterson, D. Martin; Wainwright, Mark S.] Northwestern Univ, Feinberg Sch Med, Ctr Mol Innovat & Drug Discovery, Chicago, IL 60611 USA	Wainwright, MS (corresponding author), Childrens Mem Hosp, Div Neurol 51, 2300 Childrens Plaza, Chicago, IL 60614 USA.	m-wainwright@northwestern.edu	venkatesan, charu/ABE-7369-2020; Venkatesan, Charu/D-5944-2016	Watterson, Daniel/0000-0001-7605-5866	Medical Research Junior Board Foundation; Lyndsey Whittingham Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12 HD052902, R01 NS056051, KO8 NS044998]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD052902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056051, K08NS044998] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031311] Funding Source: NIH RePORTER	This work was supported by the Medical Research Junior Board Foundation (M.S.W.), the Lyndsey Whittingham Foundation (M.S.W.), and by NIH grants K12 HD052902 (C.V.), R01 NS056051 (D.M.W.), and KO8 NS044998 (M.S.W.).	Altar CA, 2004, J NEUROSCI, V24, P2667, DOI 10.1523/JNEUROSCI.5377-03.2004; Ambjorn M, 2008, J NEUROCHEM, V104, P21, DOI 10.1111/j.1471-4159.2007.05036.x; Balosso S, 2008, BRAIN, V131, P3256, DOI 10.1093/brain/awn271; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chung RS, 2008, J BIOL CHEM, V283, P15349, DOI 10.1074/jbc.M708446200; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Ferraro TN, 1999, J NEUROSCI, V19, P6733, DOI 10.1523/JNEUROSCI.19-16-06733.1999; Ferraro TN, 2002, BRAIN RES, V936, P82, DOI 10.1016/S0006-8993(02)02565-9; Ferraro TN, 1998, BRAIN RES, V813, P207, DOI 10.1016/S0006-8993(98)01013-0; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Frankel WN, 2001, GENOMICS, V74, P306, DOI 10.1006/geno.2001.6564; Galic MA, 2008, J NEUROSCI, V28, P6904, DOI 10.1523/JNEUROSCI.1901-08.2008; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Golarai G, 2001, J NEUROSCI, V21, P8523; Heida JG, 2005, EPILEPSIA, V46, P1906, DOI 10.1111/j.1528-1167.2005.00294.x; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Hu BR, 2004, J CEREBR BLOOD F MET, V24, P934, DOI 10.1097/01.WCB.0000125888.56462.A1; Hu WH, 2007, BIOORG MED CHEM LETT, V17, P414, DOI 10.1016/j.bmcl.2006.10.028; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Quintana A, 2007, J NEUROSCI RES, V85, P2668, DOI 10.1002/jnr.21126; Ravizza T, 2005, EPILEPSIA, V46, P113, DOI 10.1111/j.1528-1167.2005.01006.x; Ravizza T, 2008, NEUROBIOL DIS, V29, P142, DOI 10.1016/j.nbd.2007.08.012; Rizzi M, 2003, NEUROBIOL DIS, V14, P494, DOI 10.1016/j.nbd.2003.08.001; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shibley H, 2002, EPILEPSY RES, V49, P109, DOI 10.1016/S0920-1211(02)00012-8; Smith BN, 2002, J NEUROPHYSIOL, V87, P1655, DOI 10.1152/jn.00581.2001; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Somera-Molina KC, 2009, BRAIN RES, V1282, P162, DOI 10.1016/j.brainres.2009.05.073; Sosin DM, 1996, BRAIN INJURY, V10, P47; Statler KD, 2009, EPILEPSY RES, V86, P221, DOI 10.1016/j.eplepsyres.2009.05.006; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Teasell R, 2007, BRAIN INJURY, V21, P201, DOI 10.1080/02699050701201854; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vezzani Annamaria, 2007, Epilepsy Curr, V7, P45, DOI 10.1111/j.1535-7511.2007.00165.x; Wainwright MS, 2003, P NATL ACAD SCI USA, V100, P6233, DOI 10.1073/pnas.1031595100; Wang H, 2007, NEUROSCIENCE, V144, P1324, DOI 10.1016/j.neuroscience.2006.11.017; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484	60	45	46	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1283	1295		10.1089/neu.2009.1227			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100013	20486807	Green Published			2021-06-18	
J	Arango-Lasprilla, JC; Kreutzer, JS				Arango-Lasprilla, Juan Carlos; Kreutzer, Jeffrey S.			Racial and Ethnic Disparities in Functional, Psychosocial, and Neurobehavioral Outcomes After Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; health status disparities; minority health; outcomes assessment	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; QUALITY-OF-LIFE; COMMUNITY INTEGRATION; AFRICAN-AMERICANS; MINORITY STATUS; RISK-FACTORS; REHABILITATION; DEPRESSION; HISPANICS; MODERATE	Because of the growing minority population in the past 3 decades in the United States and the increasing numbers of individuals who sustain a traumatic brain injury (TBI), researchers and clinicians have started to pay more attention to the role of race and ethnicity in outcomes after TBI, with the goal of better serving this population. The aim of this article is to review the literature on the influence of race/ethnicity on functional, psychosocial, and neurobehavioral outcomes after TBI. Specifically, the following 8 areas of outcomes will be examined: (1) treatment outcomes, (2) neuropsychological outcomes, (3) employment/productivity, (4) functional outcomes, (5) community integration, (6) marital status, (7) quality of life/life satisfaction, and (8) emotional/neurobehavioral outcomes. To conclude this review, suggestions for improvements in professional competency, research, systems of care, and training are proposed.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA 23219 USA	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Theater Row Bldg,4th Floor,Room 4230A,730 E Broad, Richmond, VA 23219 USA.	jcarangolasp@vcu.edu			National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of EducationUS Department of Education [H133A070036]	This study was supported in part by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grant H133A070036).	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2008, BRAIN INJURY, V22, P565, DOI 10.1080/02699050802172004; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arango-Lasprilla JC, 2009, PM&R, V1, P41, DOI 10.1016/j.pmrj.2008.07.001; Arango-Lasprilla JC, 2009, NEUROREHABILITATION, V24, P5, DOI 10.3233/NRE-2009-0449; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Bethel JW, 2005, AM J PREV MED, V29, P143, DOI 10.1016/j.amepre.2005.04.014; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Burnett DM, 2000, BRAIN INJURY, V14, P713; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; *CDCP, TRAUM BRAIN INJ US; Chang PFJ, 2008, ARCH PHYS MED REHAB, V89, P231, DOI 10.1016/j.apmr.2007.08.143; Clark R, 1999, AM PSYCHOL, V54, P805, DOI 10.1037/0003-066X.54.10.805; COOPER KD, 1983, NEUROEPIDEMIOLOGY, V2, P70; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; Howard I, 2005, ETHNIC DIS, V15, pS51; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kennepohl S, 2004, J INT NEUROPSYCH SOC, V10, P566, DOI 10.1017/S1355617704104128; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI 10.1146/annurev.publhealth.26.021304.144615; Marin G., 1991, RES HISPANIC POPULAT, V23; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Mascialino G, 2009, NEUROREHABILITATION, V24, P29, DOI 10.3233/NRE-2009-0451; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Prieto LR, 2001, COUNS PSYCHOL, V29, P18, DOI 10.1177/0011000001291002; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rutland-Brown W, 2005, J HEAD TRAUMA REHAB, V20, P205, DOI 10.1097/00001199-200505000-00004; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Shafi S, 2008, ARCH SURG-CHICAGO, V143, P1057, DOI 10.1001/archsurg.143.11.1057; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Simoni Jane M, 2003, Cultur Divers Ethnic Minor Psychol, V9, P3, DOI 10.1037/1099-9809.9.1.3; SMART JF, 1992, J REHABIL, V58, P29; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whaley AL, 2002, J CLIN PSYCHOL, V58, P383, DOI 10.1002/jclp.1150; WHITFIELD KE, 2003, HDB PSYCHOL, P545; WILLIAMS K, 2009, BRAIN INJURY, V23, P775	55	45	45	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					128	136		10.1097/HTR.0b013e3181d36ca3			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000008	20234227				2021-06-18	
J	Filanovsky, Y; Miller, P; Kao, J				Filanovsky, Yevgeny; Miller, Philip; Kao, Jesse			Myth: Ketamine should not be used as an induction agent for intubation in patients with head injury	CANADIAN JOURNAL OF EMERGENCY MEDICINE			English	Article						ketamine; head injury; intracranial pressure; rapid sequence intubation	CEREBRAL-BLOOD-FLOW; CEREBROSPINAL-FLUID PRESSURE; TRAUMATIC BRAIN INJURY; PERFUSION-PRESSURE; ANESTHESIA; ISCHEMIA; VOLUME; CONTUSIONS; S(+)-KETAMINE; HEMODYNAMICS		[Filanovsky, Yevgeny] Nanaimo Gen Reg Hosp, Emergency Dept, Nanaimo, BC V9S 2B7, Canada; [Miller, Philip] Univ Toronto, Dept Emergency Med, Toronto, ON, Canada; [Kao, Jesse] Univ British Columbia, Dept Emergency Med, Vancouver, BC V5Z 1M9, Canada	Filanovsky, Y (corresponding author), Nanaimo Gen Reg Hosp, Emergency Dept, 1200 Dufferin Cres, Nanaimo, BC V9S 2B7, Canada.	yfilanov@mac.com					BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bourgoin A, 2005, CRIT CARE MED, V33, P1109, DOI 10.1097/01.CCM.0000162491.26292.98; Bourgoin A, 2003, CRIT CARE MED, V31, P711, DOI 10.1097/01.CCM.0000044505.24727.16; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P361; Chieregato A, 2007, NEUROSURGERY, V60, P115, DOI 10.1227/01.NEU.0000249194.76527.28; den Brinker M, 2005, J CLIN ENDOCR METAB, V90, P5110, DOI 10.1210/jc.2005-1107; GARDNER AE, 1971, ANESTHESIOLOGY, V35, P226, DOI 10.1097/00000542-197108000-00029; GARDNER AE, 1972, ANESTH ANAL CURR RES, V51, P741; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; HOFFMAN WE, 1992, ANESTHESIOLOGY, V76, P755, DOI 10.1097/00000542-199205000-00014; Jackson WL, 2005, CHEST, V127, P1031, DOI 10.1378/chest.127.3.1031; Kolenda H, 1996, ACTA NEUROCHIR, V138, P1193, DOI 10.1007/BF01809750; LIST WF, 1972, ANESTHESIOLOGY, V36, P98, DOI 10.1097/00000542-197201000-00023; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; MILLER RD, 2005, MILLERS ANESTHESIA, P346; Nagels W, 2004, ANESTH ANALG, V98, P1595; Schmittner MD, 2007, J NEUROSURG ANESTH, V19, P257, DOI 10.1097/ANA.0b013e31811f3feb; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schroder ML, 1998, ACT NEUR S, V71, P127; Sehdev Rajesh S, 2006, Emerg Med Australas, V18, P37; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; Sivilotti Marco L A, 2006, CJEM, V8, P351; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; TINTINALLI J, 2004, EMERGEN MED, P113; TINTINALLI J, 2004, EMERGEN MED, P114; TINTINALLI J, 2004, EMERGEN MED, P279; Walls RM, 2008, ANN EMERG MED, V52, P13, DOI [10.1016/j.annemergmed.2008.01.344, 10.1016/j.annemergmed.2008.01.001]; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021	35	45	48	0	3	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1481-8035	1481-8043		CAN J EMERG MED	Can. J. Emerg. Med.	MAR	2010	12	2					154	157					4	Emergency Medicine	Emergency Medicine	573UV	WOS:000275941600009	20219164				2021-06-18	
J	Novack, TA; Labbe, D; Grote, M; Carlson, N; Sherer, M; Arango-Lasprilla, JC; Bushnik, T; Cifu, D; Powell, JM; Ripley, D; Seel, RT				Novack, Thomas A.; Labbe, Don; Grote, Miranda; Carlson, Nichole; Sherer, Mark; Arango-Lasprilla, Juan Carlos; Bushnik, Tamara; Cifu, David; Powell, Janet M.; Ripley, David; Seel, Ronald T.			Return to driving within 5 years of moderate-severe traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; driving; outcome	COMMUNITY INTEGRATION; DEPRESSIVE SYMPTOMS; OUTCOMES; SCALE; LIFE; SATISFACTION; COMA	Primary objective: To examine return to driving and variables associated with that activity in a longitudinal database. Research design: Retrospective analysis of a large, national database. Methods and procedures: The sample was comprised of people with predominantly moderate severe traumatic brain injury (TBI) enrolled in the TBI Model System national database at 16 centres and followed at 1 (n = 5942), 2 (n = 4628) and 5 (n = 2324) years after injury. Main outcomes and results: Respondents were classified as driving or not driving at each follow-up interval. Five years after injury, half the sample had returned to driving. Those with less severe injuries were quicker to return to driving, but, by 5 years, severity was not a factor. Those who were driving expressed a higher life satisfaction. Functional status at rehabilitation discharge, age at injury, race, pre-injury residence, pre-injury employment status and education level were associated with the odds of a person driving. Conclusions: Half of those with a moderate severe TBI return to driving within 5 years and most of those within 1 year of injury. Driving is associated with increased life satisfaction. There are multiple factors that contribute to return to driving that do not relate to actual driving ability.	[Novack, Thomas A.; Labbe, Don] Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA; [Grote, Miranda; Carlson, Nichole] Univ Colorado Denver, Denver, CO USA; [Sherer, Mark] Baylor Coll Med, TIRR Mem Hermann, Houston, TX 77030 USA; [Arango-Lasprilla, Juan Carlos; Cifu, David] Virginia Commonwealth Univ, Richmond, VA USA; [Bushnik, Tamara] Santa Clara Valley Hlth & Hosp Syst, Rehabil Res Ctr, San Jose, CA USA; [Powell, Janet M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Ripley, David] Craig Hosp, Englewood, CO USA; [Seel, Ronald T.] Shepherd Ctr, Atlanta, GA USA	Novack, TA (corresponding author), Univ Alabama, Dept Phys Med & Rehabil, SRC 530,619 19th St S, Birmingham, AL 35249 USA.	novack@uab.edu		Ripley, David/0000-0002-5349-1830; Cifu, David/0000-0003-1600-9387	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133A020509, H133A070043, H133A070032, H133A070036, H133A070038, H133A070022]	This study was supported by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. H133A020509, H133A070043, H133A070032, H133A070036, H133A070038, H133A070022).	Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Fisk GD, 1998, BRAIN INJURY, V12, P683; Fonda SJ, 2001, J GERONTOL B-PSYCHOL, V56, pS343, DOI 10.1093/geronb/56.6.S343; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Kleinbaum D., 1998, APPL REGRESSION ANAL; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Pietrapiana P, 2005, BRAIN INJURY, V19, P197, DOI 10.1080/02699050400017197; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; Rapport LJ, 2008, ARCH PHYS MED REHAB, V89, P922, DOI 10.1016/j.apmr.2008.01.009; Rudman DL, 2006, CAN J AGING, V25, P65, DOI 10.1353/cja.2006.0031; TEASDALE G, 1974, LANCET, V2, P81; *US BUR TRANSP STA, 2003, NHTS 2001 HIGHLIGHTS; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Windsor TD, 2007, GERONTOLOGIST, V47, P215, DOI 10.1093/geront/47.2.215; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	20	45	46	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2010	24	3					464	471		10.3109/02699051003601713			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800002	20184403				2021-06-18	
J	Bao, YH; Liang, YM; Gao, GY; Pan, YH; Luo, QZ; Jiang, JY				Bao, Ying-hui; Liang, Yu-min; Gao, Guo-yi; Pan, Yao-hua; Luo, Qi-zhong; Jiang, Ji-yao			Bilateral Decompressive Craniectomy for Patients with Malignant Diffuse Brain Swelling after Severe Traumatic Brain Injury: A 37-Case Study	JOURNAL OF NEUROTRAUMA			English	Article						brain swelling; decompressive craniectomy; intracranial hypertension; traumatic brain injury	INTRACRANIAL HYPERTENSION; HEAD-INJURY; CEREBRAL EDEMA; MANAGEMENT; CRANIOTOMY; PRESSURE; CHILDREN; ICP	In this study we retrospectively analyzed the outcome of bilateral decompressive craniectomy (BDC) for 37 patients with bilateral malignant diffuse brain swelling following severe traumatic brain injury (TBI). Our 37 patients (Glasgow Coma Scale [GCS] score <= 8) were retrospectively analyzed from September 2005 through September 2008. All patients underwent bilateral frontotemporoparietal decompressive craniectomy followed by duraplasty. The intracranial pressure (ICP) and cerebral perfusion pressure (CPP) were measured before and after BDC, and Glasgow Outcome Scale (GOS) scores were measured after >6 months of follow-up. The mean ICP was 37.7 +/- 6.4mm Hg, and the mean CPP was 57.6 +/- 7.5mm Hg before BDC. The ICP significantly decreased to 27.4 +/- 7.2mm Hg (p<0.05) after bone removal, and the CPP significantly increased to 63.3 +/- 8.4mm Hg (p<0.05). The ICP had a larger decrease, to 11.2 +/- 7.1mm Hg (p<0.05), after opening and enlargement of the dura mater (p<0.05) compared to the levels seen after bone removal, and CPP significantly increased to 77.8 +/- 8.3mm Hg (p<0.05). After surgery, the ICP was elevated, but remained lower than the initial ICP (p<0.05), and was easily controlled by routine medical treatment in the ensuing days, and the CPP remained above the optimal threshold of 70mm Hg. The mean follow-up time was 9.4 +/- 3.2 months. In total, 20 patients (54.1%) had favorable outcomes, including 12 patients (32.5%; GOS 4) with moderate deficits, and 8 patients (21.6%; GOS 5) showed good recovery and social reintegration. Also, 17 patients (45.9%) had unfavorable outcomes, including 7 patients (18.9%; GOS 1) who died, 4 patients (10.8%; GOS 2) remained in a vegetative state, and 6 patients (16.2%; GOS 3) had severe deficits. The most common complication was hydrocephalus (7 patients, 18.9%). Our data show that BDC offers immediate reductions in intracranial hypertension, and perhaps contributes to satisfactory outcomes in patients with bilateral diffuse brain swelling following severe TBI.	[Bao, Ying-hui; Liang, Yu-min; Gao, Guo-yi; Pan, Yao-hua; Luo, Qi-zhong; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China.	jiyaojiang@126.com			National Key Basic Research ProjectNational Basic Research Program of China [2005CB522604]; National Health Science [200802093]; Science and Technology Committee of ShanghaiShanghai Science & Technology Committee [07JC14038, 08411951900, 0852nm04900]; Program for Shanghai Outstanding Medical Academic Leaders	This work was supported by grants from the National Key Basic Research Project (no. 2005CB522604), National Health Science Grant (no. 200802093), the Science and Technology Committee of Shanghai (no. 07JC14038, 08411951900, and 0852nm04900), and the Program for Shanghai Outstanding Medical Academic Leaders. We also want to give our heartfelt thanks to professor W. Dalton Dietrich for his revisions and valuable editorial comments.	Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; American Association of Neurological Surgeons, 1996, J NEUROTRAUM, V13, P639; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; El-Watidy S, 2005, PEDIATR NEUROSURG, V41, P151, DOI 10.1159/000085874; Elwatidy S, 2006, SAUDI MED J, V27, P1547; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Hieu PD, 1996, CHILD NERV SYST, V12, P270; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kocher T, 1901, HIRNERSCHUTTERUNG HI; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; Miyazaki Y, 1966, Shujutsu, V20, P845; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; Mussack T, 2005, J TRAUMA, V58, P1061, DOI 10.1097/01.TA.0000171989.63817.8c; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Ong YK, 2002, CHILD NERV SYST, V18, P340, DOI 10.1007/s00381-002-0597-9; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Reithmeier T, 2005, CHILD NERV SYST, V21, P249, DOI 10.1007/s00381-004-1044-x; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; RINALDI A, 1990, ACT NEUR S, V51, P394; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schneider GH, 2002, ACT NEUR S, V81, P77; Scozzafava J, 2007, NEUROCRIT CARE, V6, P49, DOI 10.1385/NCC:6:1:49; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	43	45	68	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					341	347		10.1089/neu.2009.1040			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800007	19715392				2021-06-18	
J	Cappuccino, A; Bisson, LJ; Carpenter, B; Marzo, J; Dietrich, WD; Cappuccino, H				Cappuccino, Andrew; Bisson, Leslie J.; Carpenter, Bud; Marzo, John; Dietrich, W. Dalton, III; Cappuccino, Helen			The Use of Systemic Hypothermia for the Treatment of an Acute Cervical Spinal Cord Injury in a Professional Football Player	SPINE			English	Article						spinal cord injuries; hypothermia; cervical; football	TRAUMATIC BRAIN-INJURY; COMPRESSION INJURY; BLOOD-FLOW; MILD HYPOTHERMIA; RAT; DAMAGE; PATHOPHYSIOLOGY; TEMPERATURE; PROTECTION; RELEASE	Study Design. Case Report. Objective. We will describe the injury and clinical course of an NFL Football player who sustained a complete spinal cord injury and was treated with conventional care in addition to modest systemic hypothermia. Summary of Background Data. Systemically induced moderate hypothermia is a potentially neuroprotective intervention in acute spinal cord injury. However, case descriptions of human patients receiving systemic hypothermia after spinal cord injuries are lacking in the literature. Methods. Here, we present the case of a National Football League player who sustained a complete (ASIA A) spinal cord injury from a C3/4 fracture dislocation. Moderate systemic hypothermia was instituted immediately after his injury, in addition to standard medical/surgical treatment, including, surgical decompression and intravenous methylprednisolone. Results. The patient experienced significant and rapid neurologic improvement, and within weeks of his injury was walking with harness assistance. Since that time, the patient has continued to make significant progress in his rehabilitation (now ASIA D). Conclusion. The extent to which this hypothermia contributed to his neurologic recovery is difficult to determine. It is hoped that this case will draw attention to the need for further preclinical and clinical studies to elucidate the role of hypothermia in acute spinal cord injury. Until these studies are completed, it is impossible to advocate for systemic hypothermia as a standard of care.	[Cappuccino, Andrew] Buffalo Spine Surg, Lockport, NY USA; [Cappuccino, Andrew; Bisson, Leslie J.; Carpenter, Bud; Marzo, John] Team Orthoped Surgeon Buffalo Bills, Buffalo, NY USA; [Bisson, Leslie J.; Marzo, John] SUNY Buffalo, Dept Orthoped, Buffalo, NY 14260 USA; [Bisson, Leslie J.] Team Buffalo Sabres, Buffalo, NY USA; [Dietrich, W. Dalton, III] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Cappuccino, Helen] SUNY Buffalo, Roswell Pk Canc Inst, Sch Med & Biomed Sci, Buffalo, NY 14260 USA	Cappuccino, H (corresponding author), 46 Davison Ct, Lockport, NY 14094 USA.	helencapp@aol.com					Abou-Chebl A, 2004, NEUROCRIT CARE, V1, P131, DOI 10.1385/NCC:1:2:131; Adams H, 2005, STROKE, V36, P916, DOI 10.1161/01.STR.0000163257.66207.2d; ALAN S, 2008, NY TIMES        0115; ALLEN BT, 1994, J VASC SURG, V19, P332, DOI 10.1016/S0741-5214(94)70108-3; ALLEN BT, 1996, J VASC SURG, V19, P339; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Arrica M, 2007, SEMIN CARDIOTHORAC V, V11, P6, DOI 10.1177/1089253206297409; Aslam AF, 2006, AM J MED, V119, P297, DOI 10.1016/j.amjmed.2005.09.062; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Black James H, 2003, Semin Thorac Cardiovasc Surg, V15, P345, DOI 10.1053/S1043-0679(03)00086-8; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Cambria R P, 2000, Semin Vasc Surg, V13, P315; Casas CE, 2005, J NEUROSURG-SPINE, V2, P308, DOI 10.3171/spi.2005.2.3.0308; Chatzipanteli K, 2000, J NEUROTRAUM, V17, P321, DOI 10.1089/neu.2000.17.321; CHEN GY, 2000, J NEUROSURG, V93, P85; Cheung Ka Wai, 2006, CJEM, V8, P329; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Coleman William P, 2004, Spine J, V4, P373, DOI 10.1016/j.spinee.2003.12.006; Conrad MF, 2007, ANN THORAC SURG, V83, pS856, DOI 10.1016/j.athoracsur.2006.10.096; Dietrich WD, 1996, ADV NEUROL, V71, P177; DIETRICH WD, 2006, 34 ANN M CERV SPIN R; DIETRICH WD, 1996, ADV NEUROL, V71, P194; Dimar JR, 2000, SPINE, V25, P2294, DOI 10.1097/00007632-200009150-00006; Farooque M, 1997, J NEUROTRAUM, V14, P63, DOI 10.1089/neu.1997.14.63; Fehlings MG, 2005, INJURY, V36, P13, DOI 10.1016/j.injury.2005.06.011; Frelinger AL, 2003, AM J CARDIOL, V92, P1099, DOI 10.1016/j.amjcard.2003.06.007; Gebauer CM, 2006, PEDIATRICS, V117, P843, DOI 10.1542/peds.2004-1587; GIBBONS KJ, 2008, CNSQ SPRING, P45; GOLDSTEIN J, LOWERING BODY TEMPER; HANSEBOUT RR, 1984, SPINE, V9, P508, DOI 10.1097/00007632-198407000-00020; HANSEBOUT RR, 1985, CAN J NEUROL SCI, V12, P83, DOI 10.1017/S0317167100046758; Hartemink KJ, 2004, CRIT CARE, V8, pR343, DOI 10.1186/cc2928; Heier T, 2006, ANESTHESIOLOGY, V104, P1070, DOI 10.1097/00000542-200605000-00025; Holzer M, 2002, NEW ENGL J MED, V346, P549; HORODYSKI MB, 2008, AM ORTH SOC SPORTS M, P87; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jou IM, 2000, SPINE, V25, P1878, DOI 10.1097/00007632-200008010-00004; KEVIN G, 2008, SPORTS ILLUSTRA 0114; Kleiner DM, 2001, PREHOSPITAL CARE SPI; Kouchoukos NT, 1999, ANN THORAC SURG, V67, P1940, DOI 10.1016/S0003-4975(99)00442-7; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Kwon BK, 2008, SPINE J, V8, P859, DOI 10.1016/j.spinee.2007.12.006; Marion D, 2009, J NEUROTRAUM, V26, P455, DOI 10.1089/neu.2008.0582; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSALA M, 1993, J SURG RES, V55, P21, DOI 10.1006/jsre.1993.1103; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; METZLER M, CURR SURG, V1, P38; *NAT CTR CAT SPORT, 2005, 12 NAT CTR CAT SPORT; PETER A, 2007, ANN ACAD MED SINGAP, V36, P49; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROKKAS CK, 1995, J THORAC CARDIOV SUR, V110, P27, DOI 10.1016/S0022-5223(05)80006-6; SAKAMOTO T, 1990, AM J PHYSIOL, V259, pH1649; SAKAMOTO T, 1989, J NEUROSURG, V70, P780, DOI 10.3171/jns.1989.70.5.0780; SCHWAB MS, 2000, STROKE, V29, P2461; Scivoletto G, 2004, ARCH PHYS MED REHAB, V85, P485, DOI 10.1016/S0003-9993(03)00766-4; Shibuya S, 2004, SPINAL CORD, V42, P29, DOI 10.1038/sj.sc.3101516; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Torg JS, 2002, J BONE JOINT SURG AM, V84A, P112, DOI 10.2106/00004623-200201000-00017; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VALE FL, J NEUROSURG, V2, P239; Waters R L, 1998, J Spinal Cord Med, V21, P195; Westergren H, 2000, ACTA NEUROCHIR, V142, P567, DOI 10.1007/s007010050471; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 2001, SPINAL CORD, V39, P74, DOI 10.1038/sj.sc.3101127; Yamamoto K, 1998, NEUROREPORT, V9, P1655, DOI 10.1097/00001756-199805110-00072; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 1999, NEUROPATHOLOGY, V19, P172, DOI 10.1046/j.1440-1789.1999.00227.x; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206	72	45	49	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JAN 15	2010	35	2					E57	E62		10.1097/BRS.0b013e3181b9dc28			6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	551WY	WOS:000274245300025	20081503				2021-06-18	
J	Lepelletier, D; Roquilly, A; Latte, DDD; Mahe, PJ; Loutrel, O; Champin, P; Corvec, S; Naux, E; Pinaud, M; Lejus, C; Asehnoune, K				Lepelletier, Didier; Roquilly, Antoine; Latte, Dominique Demeure Dit; Mahe, Pierre Joachim; Loutrel, Olivier; Champin, Philippe; Corvec, Stephane; Naux, Edouard; Pinaud, Michel; Lejus, Corinne; Asehnoune, Karim			Retrospective Analysis of the Risk Factors and Pathogens Associated With Early-onset Ventilator-associated Pneumonia in Surgical-ICU Head-trauma Patients	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						pneumonia; head-trauma; risk factors	EARLY ENTERAL NUTRITION; INTENSIVE-CARE-UNIT; NOSOCOMIAL PNEUMONIA; RESPIRATORY-TRACT; COLONIZATION; INFECTIONS; MANAGEMENT	Background: Early-onset ventilator associated pneumonia (EOVAP) are frequent in head-trauma patients, but specific risk factors are poorly studied in this Population. Methods: We conducted a retrospective cohort study in a Surgical intensive care unit. Consecutive severe head-trauma patients admitted from January 2000 to December 2002 were studied. Microorganisms, and risks factors for EOVAP were analyzed. Results: During the 3-year period, 161 patients were studied;, 21.1% of them developed all EOVAP. Oil univariate analysis 6 variables were associated with EOVAP: early enteral feeding, barbiturate use, immunosuppression, mean Simplified Acute Physiology Score 2, acute respiratory distress syndrome, an initial neurosurgery procedures. Oil multivariate analysis, enteral feeding > 2000 Kcal before day 5 [odds ratio (OR): 0.33, 95% confidence interval (Q: 0.21-0.85] and initial neurosurgical procedure (OR: 0.36, 95% Cl: 0.15-0.89) remained protective factors for EOVAP, whereas irnmunosuppression (OR: 7.15, 95% Cl: 1.66-30.73) and barbiturate use (OR: 2.68, 95% C. 1.06-6.80) remained risk factors for EOVAP. EOVAP was also significantly associated with a longer duration of mechanical ventilation (14.0 vs. 11.0d, P=0.024), and a longer sedation duration (8.3 vs. 5.8 d P = 0.005). Methicillin-susceptible Staphylococcus aureus was the most common pathogen involved in EOVAP (46%). Conclusions: We demonstrate for the first time that early enteral feeding is a protective factor for EOVAP, and this result could have clinical implications for the prevention of EOVAP after traumatic brain Injury. This Study also confirms that barbiturate use is an important risk factor of EOVAP whereas Methicillin-susceptible S. aureus was found to be the main pathogen involved in EOVAP.	[Roquilly, Antoine; Latte, Dominique Demeure Dit; Mahe, Pierre Joachim; Loutrel, Olivier; Champin, Philippe; Naux, Edouard; Pinaud, Michel; Lejus, Corinne; Asehnoune, Karim] CHU Nantes, Serv Anesthesie Reanim, F-44093 Nantes 1, France; [Lepelletier, Didier; Corvec, Stephane; Asehnoune, Karim] Univ Nantes, Fac Med, Lab UPRES EA 3826, Nantes, France; [Lepelletier, Didier; Corvec, Stephane] CHU Nantes, Serv Bacteriol Hyg, F-44093 Nantes 1, France	Asehnoune, K (corresponding author), CHU Nantes, Serv Anesthesie Reanim, 1 Pl Alexis Ricordeau, F-44093 Nantes 1, France.	karim.asehnoune@chu-nantes.fr	Roquilly, Antoine/P-9826-2017				Agbaht K, 2007, INTENS CARE MED, V33, P1387, DOI 10.1007/s00134-007-0729-5; Akca O, 2000, ANESTHESIOLOGY, V93, P638, DOI 10.1097/00000542-200009000-00011; Allouch H, 1999, PRESSE MED, V28, P799; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; Artinian V, 2006, CHEST, V129, P960, DOI 10.1378/chest.129.4.960; Baker AM, 1996, AM J RESP CRIT CARE, V153, P343, DOI 10.1164/ajrccm.153.1.8542141; Bonten MJM, 1996, AM J RESP CRIT CARE, V154, P1339, DOI 10.1164/ajrccm.154.5.8912745; Boulard G, 1999, PRESSE MED, V28, P793; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; *FRENCH SOC AN RES, 1999, CHIRURGIE, V124, P441; *FRENCH SOC AN RES, 1999, ANN FR ANESTH, V18, P123; Ibrahim EH, 2002, JPEN-PARENTER ENTER, V26, P174, DOI 10.1177/0148607102026003174; Kallel H, 2005, J TRAUMA, V59, P705, DOI 10.1097/01.ta.0000177749.09844.c6; Marik PE, 2001, CRIT CARE MED, V29, P2264, DOI 10.1097/00003246-200112000-00005; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Nadal P, 1995, Eur J Emerg Med, V2, P14, DOI 10.1097/00063110-199503000-00004; Reignier J, 2004, CRIT CARE MED, V32, P94, DOI 10.1097/01.CCM.0000104208.23542.A8; Rello J, 1999, AM J RESP CRIT CARE, V160, P608, DOI 10.1164/ajrccm.160.2.9812034; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Sirvent JM, 2000, INTENS CARE MED, V26, P1369, DOI 10.1007/s001340000611; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Wallace WC, 1999, AM SURGEON, V65, P987	32	45	48	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2010	22	1					32	37		10.1097/ANA.0b013e3181bdf52f			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	540FH	WOS:000273316200006	20027012				2021-06-18	
J	Leung, YKJ; Pankhurst, M; Dunlop, SA; Ray, S; Dittmann, J; Eaton, ED; Palumaa, P; Sillard, R; Chuah, MI; West, AK; Chung, RS				Leung, Y. K. J.; Pankhurst, M.; Dunlop, S. A.; Ray, S.; Dittmann, J.; Eaton, E. D.; Palumaa, P.; Sillard, R.; Chuah, M. I.; West, A. K.; Chung, R. S.			Metallothionein induces a regenerative reactive astrocyte phenotype via JAK/STAT and RhoA signalling pathways	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Astrogliosis; Regeneration	FOCAL CEREBRAL-ISCHEMIA; II-DEFICIENT MICE; FACTOR OLEIC-ACID; BRAIN-INJURY; NEURONAL DIFFERENTIATION; PROTECTIVE ROLE; PLUS II; CNS; EXPRESSION; DEGENERATION	Following central nervous system injury, astrocytes rapidly respond by undergoing a stereotypical pattern of molecular and morphological alterations termed "reactive" astrogliosis. We have reported previously that metallothioneins (MTs) are rapidly expressed by reactive astrocytes and that their secretion and subsequent interaction with injured neurons leads to improved neuroregeneration. We now demonstrate that exogenous MT induces a reactive morphology and elevated GFAP expression in cultured astrocytes. Furthermore, these astrogliotic hallmarks were mediated via JAK/STAT and RhoA signalling pathways. However, rather than being inhibitory, MT induced a form of astrogliosis that was permissive to neurite outgrowth and which was associated with decreased chondroitin sulphate proteoglycan (CSPG) expression. The results suggest that MT has an important role in mediating permissive astrocytic responses to traumatic brain injury. Crown Copyright (C) 2009 Published by Elsevier Inc. All rights reserved.	[Leung, Y. K. J.; Pankhurst, M.; Ray, S.; Dittmann, J.; Eaton, E. D.; Chuah, M. I.; West, A. K.; Chung, R. S.] Univ Tasmania, Menzies Res Inst, Hobart, Tas 7001, Australia; [Dunlop, S. A.] Univ Western Australia, Sch Anim Biol, Nedlands, WA 6907, Australia; [Palumaa, P.; Sillard, R.] Tallinn Univ Technol, Dept Gene Technol, EE-12618 Tallinn, Estonia	Chung, RS (corresponding author), Univ Tasmania, Menzies Res Inst, Private Bag 58, Hobart, Tas 7001, Australia.	rschung@utas.edu.au	Chung, Roger/ABF-8395-2020; Dunlop, Sarah A/G-9357-2013; Pankhurst, Michael/F-2585-2017; Chuah, Meng Inn/J-7671-2014; Palumaa, Peep/B-4668-2019	Pankhurst, Michael/0000-0002-0976-5742; Palumaa, Peep/0000-0002-3505-3466; Chung, Roger/0000-0002-9286-947X; Dunlop, Sarah/0000-0002-1306-3962	Australian Research CouncilAustralian Research Council [LP0774820]; Bestenbalt LLC (Estonia); Discovery project grants [DP0556630, DP0984673]; Jack & Ethel Goldin Foundation; National Health & Medical Research CouncilNational Health and Medical Research Council of Australia [254670, 352623]	This research was supported by the Australian Research Council through a Linkage (LP0774820) project grant in partnership with Bestenbalt LLC (Estonia), and Discovery (DP0556630, DP0984673) project grants. It was also supported by an Alzheimer's Australia grant (Jack & Ethel Goldin Foundation). SAD holds a National Health & Medical Research Council Senior Research Fellowship (ID: 254670). RSC holds a National Health & Medical Research Council Peter Doherty Fellowship (ID: 352623).	Ambjorn M, 2008, J NEUROCHEM, V104, P21, DOI 10.1111/j.1471-4159.2007.05036.x; Asher R A, 2001, Prog Brain Res, V132, P611; Asmussen JW, 2009, J NEUROSCI RES, V87, P2926, DOI 10.1002/jnr.22118; Bento-Abreu A, 2008, J NEUROCHEM, V106, P1149, DOI 10.1111/j.1471-4159.2008.05462.x; Bento-Abreu A, 2009, J NEUROCHEM, V111, P49, DOI 10.1111/j.1471-4159.2009.06304.x; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Chung RS, 2007, CELL MOL LIFE SCI, V64, P2716, DOI 10.1007/s00018-007-7267-8; Chung RS, 2008, J BIOL CHEM, V283, P15349, DOI 10.1074/jbc.M708446200; Chung RS, 2004, J NEUROCHEM, V88, P454, DOI 10.1046/j.1471-4159.2003.02193.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Chung RS, 2002, EXP NEUROL, V178, P1, DOI 10.1006/exnr.2002.8017; Chung RS, 2002, BIOCHEM J, V365, P323, DOI 10.1042/BJ20011751; Damiani CL, 2007, J NEUROCHEM, V100, P720, DOI 10.1111/j.1471-4159.2006.04321.x; Degryse B, 2004, J BIOL CHEM, V279, P22595, DOI 10.1074/jbc.M313004200; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Kohler LB, 2003, BRAIN RES, V992, P128, DOI 10.1016/j.brainres.2003.08.049; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MICHALSKA AE, 1993, P NATL ACAD SCI USA, V90, P8088, DOI 10.1073/pnas.90.17.8088; Natale JE, 2004, J NEUROSCI RES, V78, P303, DOI 10.1002/jnr.20265; O'Toole DA, 2007, CELL MOL LIFE SCI, V64, P1303, DOI 10.1007/s00018-007-7106-y; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Penkowa M, 2005, J NEUROSCI RES, V79, P522, DOI 10.1002/jnr.20387; Penkowa M, 2002, J COMP NEUROL, V444, P174, DOI 10.1002/cne.10149; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2006, J NEUROSCI RES, V84, P1452, DOI 10.1002/jnr.21043; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; West AK, 2004, REV NEUROSCIENCE, V15, P157; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956	34	45	50	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2010	221	1					98	106		10.1016/j.expneurol.2009.10.006			9	Neurosciences	Neurosciences & Neurology	546RH	WOS:000273827500012	19837066				2021-06-18	
J	Ownsworth, T; Quinn, H; Fleming, J; Kendall, M; Shum, D				Ownsworth, Tamara; Quinn, Hayley; Fleming, Jennifer; Kendall, Melissa; Shum, David			Error self-regulation following traumatic brain injury: A single case study evaluation of metacognitive skills training and behavioural practice interventions	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Metacognitive skills training; Error self-regulation; Rehabilitation; Behavioural observation; Traumatic brain injury	PSYCHOSOCIAL ADJUSTMENT; AWARENESS; INDIVIDUALS; FEEDBACK; TRIAL	The objective of the study was to evaluate the effects of metacognitive skills training (MST) and behavioural practice on error self-regulation during a naturalistic task after traumatic brain injury (TBI). A single-case study design was used and three participants (two males, one female) aged 26-43 years with severe TBI were included in the study. In the first study, after a four-session baseline of behavioural practice, two participants received eight MST sessions followed by four maintenance sessions. In the second study, a third participant received 16 sessions of behavioural practice to assess the extent to which error self-regulation improves through long-term task practice and therapist corrections. Participants prepared two different meals with a novel meal introduced later to examine skills generalisation. Behavioural outcomes included error frequency, checking and self-corrections. Data analysis involved a combination of visual analysis and two standard deviation (2-SD) band analysis. In the MST study, the two participants demonstrated a 38% and 76% reduction in error frequency (p .05), a significant decrease in checks (p .05), and a significant increase in self-corrections (p .05) relative to baseline. In the behavioural practice study, the participant demonstrated reduced errors (25%), although this was not statistically significant, and a significant increase in checks (p .05), but self-corrections did not significantly change (p .05). This exploratory research suggests that, firstly, by targeting error self-regulation MST can potentially promote independence on complex everyday tasks; and secondly, although behavioural practice alone may facilitate some functional gains, it fails to promote more independent self-regulatory behaviours.	[Ownsworth, Tamara; Quinn, Hayley; Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Ownsworth, Tamara; Quinn, Hayley; Shum, David] Griffith Univ, Appl Cognit Neurosci Res Ctr, Brisbane, Qld 4111, Australia; [Fleming, Jennifer] Univ Queensland, Sch Hlth & Rehabil Sci, St Lucia, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Dept Occupat Therapy, Brisbane, Qld 4102, Australia; [Kendall, Melissa] Princess Alexandra Hosp, Acquired Brain Injury Outreach Serv, Buranda, Qld, Australia; [Kendall, Melissa] Griffith Univ, Sch Human Serv, Nathan, Qld 4111, Australia	Ownsworth, T (corresponding author), Griffith Univ, Sch Psychol, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Fleming, Jennifer M/B-4436-2011; Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262; Ownsworth, Tamara/0000-0003-1835-7094	Griffith UniversityGriffith University	The authors would like to thank the participants and their families. We also extend our gratitude to Narina Jenkinson, for her skills and expertise in the project, and staff from the Acquired Brain Injury Outreach Service. A grant from Griffith University supported the project.	Bieman-Copland S, 2000, BRAIN COGNITION, V44, P1; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; CICERONE KD, 1991, NEUROPSYCHOLOGY EVER, P271; Domholdt E., 2005, REHABILITATION RES P; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Fleming JM, 2006, NEUROPSYCHOL REHABIL, V16, P474, DOI 10.1080/09602010500505518; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Katz N, 1998, COGNITION AND OCCUPATION IN REHABILITATION, P323; Kazdin A. E., 1982, SINGLE CASE RES DESI; Landa-Gonzalez BELKIS, 2001, Occup Ther Int, V8, P49, DOI 10.1002/oti.131; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McGraw-Hunter M, 2006, BRAIN INJURY, V20, P1061, DOI 10.1080/02699050600912163; MCNAUGHTON SS, 1987, PAUSE PROMPT PRAISE; NOURBAKHSH MR, 1994, PHYS THER, V74, P768, DOI 10.1093/ptj/74.8.768; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2008, J REHABIL MED, V40, P81, DOI 10.2340/16501977-0124; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Schlund MW, 1999, BRAIN INJURY, V13, P889; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Wilson BA, 2003, NEUROPSYCHOLOG REHAB, P1	30	45	45	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	1					59	80	PII 912451940	10.1080/09602010902949223			22	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	530SB	WOS:000272611500004	19533497				2021-06-18	
J	Petraglia, AL; Marky, AH; Walker, C; Thiyagarajan, M; Zlokovic, BV				Petraglia, Anthony L.; Marky, Andrew H.; Walker, Corey; Thiyagarajan, Meenakshisundaram; Zlokovic, Berislav V.			Activated Protein C Is Neuroprotective and Mediates New Blood Vessel Formation and Neurogenesis After Controlled Cortical Impact	NEUROSURGERY			English	Article						Activated protein C; Angiogenesis; Controlled cortical impact; Neurogenesis; Neuroprotection; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; TISSUE-PLASMINOGEN ACTIVATOR; ERYTHROPOIETIN ENHANCES NEUROGENESIS; SUBVENTRICULAR ZONE; FUNCTIONAL RECOVERY; ISCHEMIC BRAIN; STROKE; RATS; ANGIOGENESIS; SYNAPTOGENESIS	OBJECTIVE: Activated protein C (APC) is neuroprotective in stroke models and promotes postischemic neovascularization and neurogenesis. We used a controlled cortical impact (CCI) in mice to determine the effects of APC on neuroprotection and angiogenesis and neurogenesis after traumatic brain injury (TBI). METHODS: Mice were given (1) single-dose APC (0.8 mg/kg intraperitoneally) 15 minutes after injury, (2) multidose APC (0.8 mg/kg intraperitoneally) 15 minutes and 6 to 48 hours after injury, or (3) vehicle. We then assessed the effects of APC on posttraumatic motor function with the rotarod and wire grip and beam balance tasks, and we determined the lesion volumes and studied the formation of new blood vessels and markers of neurogenesis. RESULTS: Mice treated with single-dose or multiclose APC, compared with vehicle, showed significantly improved motor function on all tests. In the single-dose and multiclose APC treatment groups, at 7 days after treatment, lesion volume was significantly decreased by 30% and 50%, respectively. Multidose APC, but not single-dose APC, increased new blood vessel formation as shown by CD105(+)/Ki-67(+) double immunostaining by nearly 2-fold at 7 days. Multidose APC also promoted posttraumatic proliferation of neuroblasts in the subventricular zone (SVZ) and their migration from the SVZ to the perilesional area. CONCLUSION: Activated protein C improves functional outcome and is neuroprotective after TBI. It also promotes angiogenesis and survival and migration of neuroblasts from the SVZ to the perilesional area, but the exact role of these brain repair mechanisms remains to be determined. The present findings suggest that APC therapy may hold a significant therapeutic potential for TBI.	[Petraglia, Anthony L.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA; [Marky, Andrew H.; Walker, Corey; Thiyagarajan, Meenakshisundaram; Zlokovic, Berislav V.] Univ Rochester, Med Ctr, Ctr Neurodegenerat & Vasc Brain Disorders, Rochester, NY 14642 USA	Zlokovic, BV (corresponding author), Univ Rochester, Med Ctr, Ctr Neurodegenerat & Vasc Brain Disorders, Arthur Kornberg Med Res Bldg,Room G-9613,601 Elmw, Rochester, NY 14642 USA.	berislav_zlokovic@urmc.rochester.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL63290, HL081528, TLI RR024135]; Socratech LLC; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR024135] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL063290, R01HL081528] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health grants HL63290, HL081528 (to B.V.Z), and TLI RR024135 (to A.H.M.). B.V.Z. is a scientific founder of Socratech LLC. a startup biotech company with a mission to develop new treatments for the aging brain, stroke, and Alzheimers disease. B.V.Z is an inventor on pending parents related to APC.	Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cheng T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hirose K, 2000, ANN SURG, V232, P272, DOI 10.1097/00000658-200008000-00018; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Liu D, 2004, NAT MED, V10, P1379, DOI 10.1038/nm1122; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shibata M, 2001, CIRCULATION, V103, P1799, DOI 10.1161/01.CIR.103.13.1799; Thiyagarajan M, 2008, J NEUROSCI, V28, P12788, DOI 10.1523/JNEUROSCI.3485-08.2008; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 1997, J CEREBR BLOOD F MET, V17, P136, DOI 10.1097/00004647-199702000-00002; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Yamashita T, 2006, J NEUROSCI, V26, P6627, DOI 10.1523/JNEUROSCI.0149-06.2006; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zlokovic BV, 2005, ANN NEUROL, V58, P474, DOI 10.1002/ana.20602	31	45	50	1	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2010	66	1					165	171		10.1227/01.NEU.0000363148.49779.68			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	535KP	WOS:000272967400031	20023547	Green Accepted			2021-06-18	
J	Derrett, S; Langley, J; Hokowhitu, B; Ameratunga, S; Hansen, P; Davie, G; Wyeth, E; Lilley, R				Derrett, S.; Langley, J.; Hokowhitu, B.; Ameratunga, S.; Hansen, P.; Davie, G.; Wyeth, E.; Lilley, R.			Prospective outcomes of injury study	INJURY PREVENTION			English	Article							QUALITY-OF-LIFE; TRAUMATIC BRAIN-INJURY; RACIAL-DISCRIMINATION; MAJOR TRAUMA; NEW-ZEALAND; DISABILITY; WORK; HEALTH; DETERMINANTS; IMPACT	Background: In New Zealand (NZ), 20% of adults report a disability, of which one-third is caused by injury. No prospective epidemiological studies of predictors of disability following all-cause injury among New Zealanders have been undertaken. Internationally, studies have focused on a limited range of predictors or specific injuries. Although these studies provide useful insights, applicability to NZ is limited given the importance of NZ's unique macro-social factors, such as NZ's no-fault accident compensation and rehabilitation scheme, the Accident Compensation Corporation (ACC). Objectives: (1) To quantitatively determine the injury, rehabilitation, personal, social and economic factors leading to disability outcomes following injury in NZ. (2) To qualitatively explore experiences and perceptions of injury-related outcomes in face-to-face interviews with 15 Maori and 15 other New Zealanders, 6 and 12 months after injury. Setting: Four geographical regions within NZ. Design: Prospective cohort study with telephone interviews 1, 4 and 12 months after injury. Participants: 2500 people (including 460 Maori), aged 18-64 years, randomly selected from ACC's entitlement claims register (people likely to be off work for at least 1 week or equivalent). Data: Telephone interviews, electronic hospital and ACC injury data. Exposures include demographic, social, economic, work-related, health status, participation and/or environmental factors. Outcome measures: Primary: disability (including WHODAS II) and health-related quality of life (including EQ-5D). Secondary: participation (paid and unpaid activities), life satisfaction and costs. Analysis: Separate regression models will be developed for each of the outcomes. Repeated measures outcomes will be modelled using general estimating equation models and generalised linear mixed models.	[Derrett, S.; Langley, J.; Davie, G.; Lilley, R.] Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin Sch Med, Dunedin, New Zealand; [Hokowhitu, B.] Univ Otago, Te Tumu Sch Maori Pacific & Indigenous Studies, Dunedin, New Zealand; [Ameratunga, S.] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Auckland 1, New Zealand; [Hansen, P.] Univ Otago, Dept Econ, Dunedin, New Zealand; [Wyeth, E.] Univ Otago, Dept Prevent & Social Med, Ngai Tahu Maori Hlth Res Unit, Dunedin Sch Med, Dunedin, New Zealand	Langley, J (corresponding author), Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin Sch Med, Dunedin, New Zealand.	john.langley@ipru.otago.ac.nz		Davie, Gabrielle/0000-0001-5466-5364; Wyeth, Emma/0000-0002-6869-5190; Derrett, Sarah/0000-0003-2867-0498; Ameratunga, Shanthi/0000-0001-8042-2251	Health Research Council of New ZealandHealth Research Council of New Zealand; Accident Compensation Corporation, Wellington, New Zealand	This study is funded by the Health Research Council of New Zealand and the Accident Compensation Corporation, Wellington, New Zealand.	*ACC COMP CORP, 2006, ENT CLAIM AG 18 65 Y; *ACC COMP CORP, 2006, PERS COMM RES TEAM; *ACC COMP CORP, 2005, ACC INJ STAT; Adams M., 2002, AFTERMATH SOCIAL EC; AMERATUNGA S, ANN EMERGEN IN PRESS; Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS1, DOI 10.1053/apmr.2000.20614; Badia X, 2001, INTENS CARE MED, V27, P1901, DOI 10.1007/s00134-001-1137-x; Bishop R., 1997, ED RES PERSPECTIVES, V24, P28; Bishop R., 1996, COLLABORATIVE RES ST; BISHOP R, 1994, NZ J ED STUDIES, V29, P1; BISMARCK M, 2006, MAUR OR MAOR HLTH S; BRAY A, 2002, SAFE LIVES PEOPLE IN; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Broughton J, 2000, NEW ZEAL MED J, V113, P511; Brych SB, 2001, J BURN CARE REHABIL, V22, P401, DOI 10.1097/00004630-200111000-00010; CLANDININ D, 1991, NARRATIVE STORY PRAC; Cole DC, 2002, CAN MED ASSOC J, V166, P749; Creswell J., 2003, RES DESIGN QUALITATI, V2nd edn; CRICHTON S, 2005, 1857 IZA DP I STUD L; Devlin N, 2000, 180 U YORK; Dionne CE, 2005, CAN MED ASSOC J, V172, P1559, DOI 10.1503/cmaj.1041159; Frank AW, 1997, WOUNDED STORYTELLER; Harris R, 2006, SOC SCI MED, V63, P1428, DOI 10.1016/j.socscimed.2006.04.009; Harris R, 2006, LANCET, V367, P2005, DOI 10.1016/S0140-6736(06)68890-9; Hendrie Delia, 2004, Aust Health Rev, V28, P363; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Hurst R, 2003, DISABIL REHABIL, V25, P572, DOI 10.1080/0963828031000137072; JENSEN J, 2005, SOC POLICY J N Z, P134; JENSEN J, 2005, DISABILITY WORK PART; King A., 2000, NZ HLTH STRATEGY; Kingi J., 2000, MAORI CONCEPTS DISAB; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; KUIJER W, 2005, DISABILITY REHABILIT, P379; Langley J, 2006, INJURY PREV, V12, P58, DOI 10.1136/ip.2005.010173; Langley J, 2000, NEW ZEAL MED J, V113, P508; LANGLEY J, 1998, NGA TATAURANGA INJUR; Lather P., 1991, GETTING SMART FEMINI; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Lydell M, 2005, J REHABIL MED, V37, P281, DOI 10.1080/16501970510030255; MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MAPSTONE J, 2006, STRATEGIES IMPROVE R; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; *MIN HLTH, 2004, LIV DIS NZ; Ministry of Health, 2001, PRIOR MAOR PAC HLTH; Nilsen Per, 2006, Int J Inj Contr Saf Promot, V13, P7, DOI 10.1080/17457300500167651; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; *OFF DIS ISS, 2005, INCL DIS PERSP TOOLK; Oliver M., 1996, UNDERSTANDING DISABI; Ottosson C, 2005, J TRAUMA, V58, P553, DOI 10.1097/01.TA.0000152634.66513.AF; Peden M, 2002, INJURY CHART BOOK GR; Post MWM, 1999, CLIN REHABIL, V13, P5, DOI 10.1191/026921599701532072; Priestley M., 2003, DISABILITY LIFE COUR; Richardson G, 2005, INT J TECHNOL ASSESS, V21, P423, DOI 10.1017/S0266462305050592; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Shakespeare Tom, 2001, EXPLORING THEORIES E, V2; STAMM TA, 2005, AUSTR OCCUPATIONAL T, P1; *STAT NZ TAT AOT, 2002, DIS COUNTS 2001; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; SULLIVAN M, 1996, PARAPLEGIC BODIES SE; TRIPP DH, 1983, INTERCHANGE, V14, P32, DOI 10.1007/BF01810469; Ueda S, 2003, DISABIL REHABIL, V25, P596, DOI 10.1080/0963828031000137108; Uppal S, 2006, SOC SCI MED, V63, P525, DOI 10.1016/j.socscimed.2006.01.016; Ustun TB, 2003, DISABIL REHABIL, V25, P565, DOI 10.1080/0963828031000137063; VANBEECK E, 2005, DRAFT GUIDELINES CON, P1; Vangel SJ, 2005, AM J PHYS MED REHAB, V84, P153, DOI 10.1097/01.PHM.0000154896.55045.E7; Ville I, 2006, DISABIL REHABIL, V28, P423, DOI 10.1080/09638280500192561; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Wade DT, 2000, BMJ-BRIT MED J, V320, P1385, DOI 10.1136/bmj.320.7246.1385; Wang PP, 2006, DISABIL REHABIL, V28, P135, DOI 10.1080/09638280500167761; *WHO, 2001, ICF INT CLASS FUNCT; Wolcott H. F., 1994, TRANSFORMING QUALITA; World Health Organization, 2002, WHO TRAD MED STRAT 2, P1	74	45	45	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	OCT	2009	15	5								10.1136/ip.2009.022558			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	502UJ	WOS:000270485400019	19805606				2021-06-18	
J	Franschman, G; Peerdeman, SM; Greuters, S; Vieveen, J; Brinkman, ACM; Christiaans, HMT; Toor, EJ; Jukema, GN; Loer, SA; Boer, C				Franschman, G.; Peerdeman, S. M.; Greuters, S.; Vieveen, J.; Brinkman, A. C. M.; Christiaans, H. M. T.; Toor, E. J.; Jukema, G. N.; Loer, S. A.; Boer, C.		ALARM-TBI Investigators	Prehospital endotracheal intubation in patients with severe traumatic brain injury: Guidelines versus reality	RESUSCITATION			English	Article						Brain injury; Prehospital; Emergency medical service; Airway management; Guideline adherence	SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; CEREBRAL-ISCHEMIA; HYPERVENTILATION; MANAGEMENT; OUTCOMES; HYPERGLYCEMIA; PREDICTORS; PHYSICIANS; HYPOXEMIA	The international Brain Trauma Foundation guidelines recommend prehospital endotracheal intubation in all patients with traumatic brain injury (TBI) and a Glasgow Coma Scale (GCS) <= 8. Close adherence to these guidelines is associated with improved outcome, but not all severely injured TBI patients receive adequate prehospital airway support. Here we hypothesized that guideline adherence varies when skills are involved that rely on training and expertise, such as endotracheal intubation. We retrospectively studied the medical records of CT-confirmed TBI patients with a GCS <= 8 who were referred to a level 1 trauma centre in Amsterdam (n = 127). Records were analyzed for demographic parameters, prehospital treatment modalities, involvement of an emergency medical service (EMS) and respiratory and metabolic parameters Upon arrival at the hospital. Patients were mostly male, aged 45 +/- 21 years with a median injury severity score (ISS) of 26. Of all patients for whom guidelines recommend endotracheal intubation, only 56% were intubated. In 21 out of 106 severe cases an EMS was not called for, suggesting low guideline adherence. Especially those TBI patients treated by paramedics tended to develop higher levels of stress markets like glucose and lactate. We observed a low degree of adherence to intubation guidelines in a Dutch urban area. Main reasons for low adherence were the unavailability of specialized care, scoop and run strategies and absence of a specialist physician in cases where intubation was recommended. The discrepancy between guidelines and reality warrants changing practice to improve guideline compliance and optimize outcome in TBI patients. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Franschman, G.; Greuters, S.; Vieveen, J.; Brinkman, A. C. M.; Christiaans, H. M. T.; Loer, S. A.; Boer, C.] Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, NL-1081 HV Amsterdam, Netherlands; [Peerdeman, S. M.] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands; [Toor, E. J.; Jukema, G. N.] Vrije Univ Amsterdam, Med Ctr, Dept Traumatol, NL-1081 HV Amsterdam, Netherlands	Franschman, G (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	g.franschman@vumc.nl		Boer, Christa/0000-0002-7781-6951			Ausina A, 1998, ACT NEUR S, V71, P1; Bouamra O, 2006, J TRAUMA, V61, P701, DOI 10.1097/01.ta.0000197175.91116.10; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DF, 2008, CURR OPIN CRIT CARE, V14, P142, DOI 10.1097/MCC.0b013e3282f63c40; Davis DP, 2008, RESUSCITATION, V76, P333, DOI 10.1016/j.resuscitation.2007.08.004; Davis DP, 2007, RESUSCITATION, V73, P354, DOI 10.1016/j.resuscitation.2006.09.015; Davis DP, 2005, J TRAUMA, V59, P794; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; *FDN NAT AMB EM RO, 2007, LAND PROT AMB LPA7; FLORES EA, 1990, METABOLISM, V39, P738, DOI 10.1016/0026-0495(90)90110-X; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; HILL M, 1991, J CLIN INVEST, V88, P811, DOI 10.1172/JCI115381; Huizenga JE, 2002, ACAD EMERG MED, V9, P806, DOI 10.1197/aemj.9.8.806; Khani S, 2001, CLIN SCI, V101, P739, DOI [10.1042/CS20010180, 10.1042/cs1010739]; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Neumann JO, 2008, INTENS CARE MED, V34, P1676, DOI 10.1007/s00134-008-1123-7; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Parr M, 2008, RESUSCITATION, V76, P321, DOI 10.1016/j.resuscitation.2008.01.001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; STRINGER WA, 1993, AM J NEURORADIOL, V14, P475; Timmermann A, 2008, CURR OPIN ANESTHESIO, V21, P222, DOI 10.1097/ACO.0b013e3282f5f4f7; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Watt MJ, 2001, J PHYSIOL-LONDON, V534, P269, DOI 10.1111/j.1469-7793.2001.t01-1-00269.x; Watts Dorraine D, 2004, Prehosp Emerg Care, V8, P254; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	36	45	46	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	OCT	2009	80	10					1147	1151		10.1016/j.resuscitation.2009.06.029			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	513PX	WOS:000271336400013	19632024				2021-06-18	
J	Garcia-Capdevila, S; Portell-Cortes, I; Torras-Garcia, M; Coll-Andreu, M; Costa-Miserachs, D				Garcia-Capdevila, Silvia; Portell-Cortes, Isabel; Torras-Garcia, Meritxell; Coll-Andreu, Margalida; Costa-Miserachs, David			Effects of long-term voluntary exercise on learning and memory processes: dependency of the task and level of exercise	BEHAVIOURAL BRAIN RESEARCH			English	Article						Running wheel exercise; Learning and memory; Object recognition; Two-way active avoidance; Anxiety-like behaviour	OXIDATIVE STRESS MARKERS; TRAUMATIC BRAIN-INJURY; GROWTH-FACTOR-I; NEUROTROPHIC FACTOR; SYNAPTIC PLASTICITY; OBJECT RECOGNITION; PHYSICAL-EXERCISE; COGNITIVE FUNCTION; FORCED EXERCISE; GENE-EXPRESSION	The effect of long-term voluntary exercise (running wheel) on anxiety-like behaviour (plus maze and open field) and learning and memory processes (object recognition and two-way active avoidance) was examined on Wistarrats. Because major individual differences in running wheel behaviour were observed, the data were analysed considering the exercising animals both as a whole and grouped according to the time spent in the running wheel (low, high, and very-high running). Although some variables related to anxiety-like behaviour seem to reflect an anxiogenic compatible effect, the view of the complete set of variables could be interpreted as an enhancement of defensive and risk assessment behaviours in exercised animals, without major differences depending on the exercise level. Effects on learning and memory processes were dependent on task and level of exercise. Two-way avoidance was not affected either in the acquisition or in the retention session, while the retention of object recognition task was affected. In this latter task, an enhancement in low running subjects and impairment in high and very-high running animals were observed. (C) 2009 Elsevier B.V. All rights reserved.	[Garcia-Capdevila, Silvia; Portell-Cortes, Isabel; Torras-Garcia, Meritxell; Coll-Andreu, Margalida; Costa-Miserachs, David] Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Inst Neurociencies, Bellaterra 08193, Spain	Costa-Miserachs, D (corresponding author), Univ Autonoma Barcelona, Dept Psicobiol & Metodol Ciencies Salut, Inst Neurociencies, Bellaterra 08193, Spain.	David.Costa@uab.cat	Costa-Miserachs, David/E-1318-2011; Portell-Cortes, Isabel/C-5991-2011; Costa-Miserachs, David/N-2794-2019; Coll-Andreu, Margalida/C-9119-2011; Torras-Garcia, Meritxell/K-9068-2014	Costa-Miserachs, David/0000-0001-5781-0774; Portell-Cortes, Isabel/0000-0002-7710-0101; Costa-Miserachs, David/0000-0001-5781-0774; Coll-Andreu, Margalida/0000-0003-4106-2606; Torras-Garcia, Meritxell/0000-0003-2511-8788	Generalitat de CatalunyaGeneralitat de Catalunya [2006FIC 00231]; Ministerio de Educacion y CienciaSpanish GovernmentEuropean Commission [SEJ2006-14226/PSIC]	S.G.-C. was supported by predoctoral fellowship from the Generalitat de Catalunya (2006FIC 00231). The research was funded by the Ministerio de Educacion y Ciencia (SEJ2006-14226/PSIC).	Afonso VM, 2003, PHYSIOL BEHAV, V80, P19, DOI 10.1016/S0031-9384(03)00216-6; Aggleton JP, 2005, Q J EXP PSYCHOL-B, V58, P218, DOI 10.1080/02724990444000131; Alaei H, 2006, EUR J PHARMACOL, V536, P138, DOI 10.1016/j.ejphar.2006.02.025; Ang ET, 2006, BRAIN RES, V1113, P186, DOI 10.1016/j.brainres.2006.07.023; Arida RM, 2004, NEUROSCI LETT, V364, P135, DOI 10.1016/j.neulet.2004.03.086; Barker GRI, 2007, J NEUROSCI, V27, P2948, DOI 10.1523/JNEUROSCI.5289-06.2007; BARNES CA, 1991, NEUROBIOL AGING, V12, P47, DOI 10.1016/0197-4580(91)90038-L; Baruch DE, 2004, BEHAV NEUROSCI, V118, P1123, DOI 10.1037/0735-7044.118.5.1123; Binder E, 2004, BEHAV BRAIN RES, V155, P197, DOI 10.1016/j.bbr.2004.04.017; Blustein JE, 2006, PHYSIOL BEHAV, V89, P582, DOI 10.1016/j.physbeh.2006.07.017; Boguszewski P, 2002, BEHAV BRAIN RES, V133, P323, DOI 10.1016/S0166-4328(02)00018-9; Braszko JJ, 2001, NEUROSCI RES, V39, P79, DOI 10.1016/S0168-0102(00)00207-8; Burghardt PR, 2006, PHARMACOL BIOCHEM BE, V84, P306, DOI 10.1016/j.pbb.2006.05.015; Burghardt PR, 2004, BRAIN RES, V1019, P84, DOI 10.1016/j.brainres.2004.05.086; Callaghan P, 2004, J Psychiatr Ment Health Nurs, V11, P476, DOI 10.1111/j.1365-2850.2004.00751.x; Carter PA, 2000, BEHAV GENET, V30, P85, DOI 10.1023/A:1001967019229; CHAOULOFF F, 1994, NEUROSCI LETT, V176, P226, DOI 10.1016/0304-3940(94)90088-4; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Da Cunha C, 2002, CELL MOL NEUROBIOL, V22, P227, DOI 10.1023/A:1020736131907; de Lima MN, 2006, NEUROSCI LETT, V405, P142, DOI 10.1016/j.neulet.2006.06.044; Dere E, 2007, NEUROSCI BIOBEHAV R, V31, P673, DOI 10.1016/j.neubiorev.2007.01.005; Ding Q, 2006, NEUROSCIENCE, V140, P823, DOI 10.1016/j.neuroscience.2006.02.084; Ding Y, 2004, NEUROSCIENCE, V124, P583, DOI 10.1016/j.neuroscience.2003.12.029; Dishman RK, 1997, BRAIN RES BULL, V42, P399, DOI 10.1016/S0361-9230(96)00329-2; Dishman RK, 1996, PHYSIOL BEHAV, V60, P699; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; Dunn AL, 2001, MED SCI SPORT EXER, V33, pS587, DOI 10.1097/00005768-200106001-00027; ElMassioui N, 1997, NEUROSCI RES COMMUN, V21, P103; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; Etnier JL, 2007, MED SCI SPORT EXER, V39, P199, DOI 10.1249/01.mss.0000239399.85955.5e; Farmer J, 2004, NEUROSCIENCE, V124, P71, DOI 10.1016/j.neuroscience.2003.09.029; Fulk LJ, 2004, INT J SPORTS MED, V25, P78; Gobbo OL, 2005, BRAIN RES, V1046, P224, DOI 10.1016/j.brainres.2005.03.046; Greenwood BN, 2003, J NEUROSCI, V23, P2889; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gwag BJ, 1995, NEUROREPORT, V7, P93, DOI 10.1097/00001756-199512000-00022; Hansalik M, 2006, EXP GERONTOL, V41, P169, DOI 10.1016/j.exger.2005.11.002; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; HINELINE PN, 1978, J EXP ANAL BEHAV, V29, P87, DOI 10.1901/jeab.1978.29-87; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Koteja P, 1999, PHYSIOL BIOCHEM ZOOL, V72, P238, DOI 10.1086/316653; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Larun L, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004691.PUB2; Leasure JL, 2008, NEUROSCIENCE, V156, P456, DOI 10.1016/j.neuroscience.2008.07.041; Llorens-Martin M, 2006, HIPPOCAMPUS, V16, P480, DOI 10.1002/hipo.20175; MARTINICOLOVIUS M, 1988, PHYSIOL BEHAV, V43, P93, DOI 10.1016/0031-9384(88)90103-5; McCloskey DP, 2001, BRAIN RES, V891, P168, DOI 10.1016/S0006-8993(00)03200-5; Morishima M, 2006, NEUROPSYCHOPHARMACOL, V31, P2627, DOI 10.1038/sj.npp.1301028; Mostafa RM, 2002, PHYSIOL BEHAV, V76, P589, DOI 10.1016/S0031-9384(02)00730-8; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/0006-8993(96)00273-9; O'Callaghan RM, 2007, BEHAV BRAIN RES, V176, P362, DOI 10.1016/j.bbr.2006.10.018; Ogonovszky H, 2005, NEUROCHEM INT, V46, P635, DOI 10.1016/j.neuint.2005.02.009; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; Peluso Marco Aurélio Monteiro, 2005, Clinics, V60, P61, DOI 10.1590/S1807-59322005000100012; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Petzinger GM, 2007, J NEUROSCI, V27, P5291, DOI 10.1523/JNEUROSCI.1069-07.2007; Ploughman M, 2005, NEUROSCIENCE, V136, P991, DOI 10.1016/j.neuroscience.2005.08.037; Ploughman M, 2007, BRAIN RES, V1150, P207, DOI 10.1016/j.brainres.2007.02.065; Radak Z, 2001, NEUROCHEM INT, V38, P17, DOI 10.1016/S0197-0186(00)00063-2; Radak Z, 2006, NEUROCHEM INT, V49, P387, DOI 10.1016/j.neuint.2006.02.004; Ramsden M, 2003, BRAIN RES, V971, P239, DOI 10.1016/S0006-8993(03)02365-5; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Rudge JS, 1998, EXP NEUROL, V149, P398, DOI 10.1006/exnr.1997.6737; Salam JN, 2009, BEHAV BRAIN RES, V197, P31, DOI 10.1016/j.bbr.2008.07.036; Samdani AF, 1997, J NEUROSCI, V17, P4633; SAMORAJSKI T, 1985, NEUROBIOL AGING, V6, P17, DOI 10.1016/0197-4580(85)90066-1; Schweitzer NB, 2006, NEUROCHEM INT, V48, P9, DOI 10.1016/j.neuint.2005.08.006; Sherwin CM, 1998, ANIM BEHAV, V56, P11, DOI 10.1006/anbe.1998.0836; Squire LR, 2007, NAT REV NEUROSCI, V8, P872, DOI 10.1038/nrn2154; Stranahan AM, 2006, NAT NEUROSCI, V9, P526, DOI 10.1038/nn1668; THARP GD, 1975, MED SCI SPORT EXER, V7, P123; Torras-Garcia M, 2005, EXP BRAIN RES, V164, P177, DOI 10.1007/s00221-005-2240-y; Torres JB, 2006, EXP BRAIN RES, V175, P292, DOI 10.1007/s00221-006-0549-9; Tou JCL, 2002, EXP BIOL MED, V227, P587; Uysal N, 2005, NEUROSCI LETT, V383, P241, DOI 10.1016/j.neulet.2005.04.054; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Wall PM, 2001, NEUROSCI BIOBEHAV R, V25, P275, DOI 10.1016/S0149-7634(01)00013-6; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008	86	45	45	0	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	SEP 14	2009	202	2					162	170		10.1016/j.bbr.2009.03.020			9	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	458HK	WOS:000267006300003	19463697				2021-06-18	
J	Carrico, KM; Vaishnav, R; Hall, ED				Carrico, Kimberly M.; Vaishnav, Radhika; Hall, Edward D.			Temporal and Spatial Dynamics of Peroxynitrite-Induced Oxidative Damage after Spinal Cord Contusion Injury	JOURNAL OF NEUROTRAUMA			English	Article						4-hydroxynonenal; lipid peroxidation; peroxynitrite; protein nitration; spinal cord injury; 3-nitrotyrosine	TRAUMATIC BRAIN-INJURY; PROTEIN-TYROSINE NITRATION; NITRIC-OXIDE; LIPID-PEROXIDATION; MOUSE MODEL; SUPEROXIDE; MITOCHONDRIA; INFLAMMATION; ACTIVATION; EXPRESSION	The reactive nitrogen species peroxynitrite (PN) has been suggested to be an important mediator of the secondary oxidative damage that occurs following acute spinal cord injury (SCI). The PN decomposition products nitrogen dioxide (center dot NO2), hydroxyl radical (center dot OH), and carbonate radical (center dot CO3) are highly reactive with cellular lipids and proteins. In this immunohistochemical study, we examined the temporal (3, 24, and 72 h, and 1 and 2 weeks) and spatial relationships of PN-mediated oxidative damage in the contusion-injured rat thoracic spinal cord (IH device, 200 kdyn, T10) using 3-nitrotyrosine (3-NT), a marker for protein nitration by PN-derived center dot NO2 and 4-hydroxynonenal (4-HNE), an indicator of lipid peroxidation (LP) initiated by any of the PN radicals. Minimal 3-NT or 4-HNE immunostaining was seen in sham, non-injured spinal cords. In contrast, both markers showed a substantial increase at 3 h post-injury at the epicenter, that extended throughout the gray matter and into the surrounding white matter. At 24 and 72 h, the oxidative damage expanded circumferentially to involve all but a small rim of white matter tissue at the injury site, and longitudinally as much as 6-9 mm in the rostral and caudal directions. The staining was observed in neuronal soma, axons, and microvessels. At all time points except 3 h, there was no significant difference in the mean rostral or caudal extent of 3-NT and 4-HNE staining. By 1, and more so at 2 weeks, the longitudinal extent of the oxidative damage staining was greatly decreased. The spatial and temporal overlap of 3-NT and 4-HNE staining supports the concept that PN is involved in both damage produced by lipid peroxidation and protein nitration, and that antioxidant agents that target PN or PN-derived radicals should be effective neuroprotectants for acute SCI if administered during the first post-injury hours.	[Carrico, Kimberly M.; Vaishnav, Radhika; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013; Vaishnav, Radhika/AAN-4556-2021		Kentucky Spinal Cord & Head Injury Research Trust [5P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220] Funding Source: NIH RePORTER	This work was supported by a grant from the Kentucky Spinal Cord & Head Injury Research Trust (5P30 NS051220).	Aksenova M, 2002, J NEUROTRAUM, V19, P491, DOI 10.1089/08977150252932433; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Conti A, 2007, BRAIN RES REV, V54, P205, DOI 10.1016/j.brainresrev.2007.01.013; Deen WM, 2002, FASEB J, V16, P1144; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Genovese T, 2007, FREE RADICAL BIO MED, V43, P763, DOI 10.1016/j.freeradbiomed.2007.05.012; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Halliwell B, 2007, FREE RADICALS BIOL M, V4th; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Liu DX, 2000, J NEUROCHEM, V75, P2144, DOI 10.1046/j.1471-4159.2000.0752144.x; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Scott GS, 2004, J NEUROTRAUM, V21, P1255, DOI 10.1089/neu.2004.21.1255; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2003, GLIA, V41, P105, DOI 10.1002/glia.10137; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Springer JE, 1997, J NEUROCHEM, V68, P2469; Squadrito GL, 2002, CHEM RES TOXICOL, V15, P885, DOI 10.1021/tx020004c; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323	38	45	47	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1369	1378		10.1089/neu.2008.0870			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900020	19419247	Green Accepted			2021-06-18	
J	Iverson, GL; Brooks, BL; Ashton, VL; Johnson, LG; Gualtieri, CT				Iverson, Grant L.; Brooks, Brian L.; Ashton, V. Lynn; Johnson, Lynda G.; Gualtieri, C. Thomas			Does familiarity with computers affect computerized neuropsychological test performance?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	115th Annual Convention of the American-Psychological-Association	AUG 17-20, 2007	San Francisco, CA	Amer Psychol Assoc		Neurocognitive testing; Computerized testing; Demographic variables	COGNITIVE IMPAIRMENT; BRAIN-INJURY; CONCUSSION; BATTERY; CANTAB; DEPRESSION; EXPERIENCE; VALIDITY; BIPOLAR	The purpose of this study was to determine whether self-reported computer familiarity is related to performance on computerized neurocognitive testing. Participants were 130 healthy adults who self-reported whether their computer use was "some" (n = 65) or "frequent" (n = 65). The two groups were individually matched on age, education, sex, and race. All completed the CNS Vital Signs (Gualtieri & Johnson, 2006b) computerized neurocognitive battery. There were significant differences on 6 of the 23 scores, including scores derived from the Symbol-Digit Coding Test, Stroop Test, and the Shifting Attention Test. The two groups were also significantly different on the Psychomotor Speed (Cohen's d = 0.37), Reaction Time (d = 0.68), Complex Attention (d = 0.40), and Cognitive Flexibility (d = 0.64) domain scores. People with "frequent" computer use performed better than people with "some" computer use on some tests requiring rapid visual scanning and keyboard work.	[Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.; Brooks, Brian L.; Ashton, V. Lynn] British Columbia Mental Hlth & Addict Serv, Coquitlam, BC, Canada; [Johnson, Lynda G.; Gualtieri, C. Thomas] N Carolina Neuropsychiat Clin, Chapel Hill, NC USA; [Johnson, Lynda G.; Gualtieri, C. Thomas] N Carolina Neuropsychiat Clin, Charlotte, NC USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			Barker MJ, 2004, CNS DRUGS, V18, P37, DOI 10.2165/00023210-200418010-00004; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Day JC, 2005, CURRENT POPULATION R; De Luca CR, 2003, J CLIN EXP NEUROPSYC, V25, P242, DOI 10.1076/jcen.25.2.242.13639; Di Sclafani V, 2002, DRUG ALCOHOL DEPEN, V66, P161, DOI 10.1016/S0376-8716(01)00197-1; Doniger Glen M, 2006, Am J Alzheimers Dis Other Demen, V21, P28; Dorion AA, 2002, NEUROPSYCHOLOGIA, V40, P946, DOI 10.1016/S0028-3932(01)00150-6; Dwolatzky T, 2004, J MOL NEUROSCI, V24, P33, DOI 10.1385/JMN:24:1:033; Goldberg AL, 2002, EDUC PSYCHOL MEAS, V62, P1053, DOI 10.1177/0013164402238092; Grant I, 2003, J INT NEUROPSYCH SOC, V9, P679, DOI 10.1017/S1355617703950016; Grant MM, 2001, BIOL PSYCHIAT, V50, P35, DOI 10.1016/S0006-3223(00)01072-6; Gualtieri C Thomas, 2006, J Atten Disord, V9, P534, DOI 10.1177/1087054705283758; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gualtieri CT, 2006, J NEUROPSYCH CLIN N, V18, P217, DOI 10.1176/appi.neuropsych.18.2.217; Gualtieri C Thomas, 2005, Am J Alzheimers Dis Other Demen, V20, P359; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; KOMINSKI R, 1988, CURRENT POPULATI P23, V155; LEE JA, 1986, EDUC PSYCHOL MEAS, V46, P727, DOI 10.1177/0013164486463030; Lopez SJ, 2001, PSYCHOL REP, V88, P183, DOI 10.2466/PR0.88.1.183-188; Louis WJ, 1999, J HYPERTENS, V17, P1813, DOI 10.1097/00004872-199917121-00005; Luciana M, 2002, DEV NEUROPSYCHOL, V22, P595, DOI 10.1207/S15326942DN2203_3; Moore JL, 2002, EPILEPSY BEHAV, V3, P92, DOI 10.1006/ebeh.2001.0313; Nielen MMA, 2003, PSYCHOL MED, V33, P917, DOI 10.1017/S0033291703007682; Pavuluri MN, 2006, AM J PSYCHIAT, V163, P286, DOI 10.1176/appi.ajp.163.2.286; Potosky D, 1998, COMPUT HUM BEHAV, V14, P337, DOI 10.1016/S0747-5632(98)00011-9; Purcell R, 1997, PSYCHOL MED, V27, P1277, DOI 10.1017/S0033291797005448; Raymond PD, 2006, EUR J CARDIO-THORAC, V29, P82, DOI 10.1016/j.ejcts.2005.10.016; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schubert G, 2006, UROL RES, V34, P146, DOI 10.1007/s00240-005-0028-y; SIEGEL PM, 1991, CURRENT POPULATI P23, V171; Sweeney JA, 2000, BIOL PSYCHIAT, V48, P674, DOI 10.1016/S0006-3223(00)00910-0; Taylor C, 1999, LANG LEARN, V49, P219, DOI 10.1111/0023-8333.00088	37	45	45	2	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	2009	31	5					594	604		10.1080/13803390802372125			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	473YT	WOS:000268249200009	18972312				2021-06-18	
J	Eckner, JT; Whitacre, RD; Kirsch, NL; Richardson, JK				Eckner, James T.; Whitacre, Ross D.; Kirsch, Ned L.; Richardson, James K.			EVALUATING A CLINICAL MEASURE OF REACTION TIME: AN OBSERVATIONAL STUDY	PERCEPTUAL AND MOTOR SKILLS			English	Article							TRAUMATIC BRAIN-INJURY; TASK; CONVERSATIONS	The present study was an initial evaluation into the reliability and validity of a novel clinical measure of reaction time that consists of a vertical cylinder that is released and caught as quickly as possible. 65 healthy adults performed clinical and Computerized reaction time tasks (RT(clin) and RT(comp)) under simple and dual-task conditions. RT(clin) demonstrated excellent test-retest and interrater reliabilities and was significantly correlated with the criterion standard RT(comp). RT(clin) increased with increasing age and when tested under dual-task conditions. These preliminary results suggest that RT(clin) is a reliable and valid measure of reaction time.	[Eckner, James T.; Whitacre, Ross D.; Kirsch, Ned L.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA	Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 100, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu					ALM H, 1995, ACCIDENT ANAL PREV, V27, P707, DOI 10.1016/0001-4575(95)00026-V; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Der G, 2006, PSYCHOL AGING, V21, P62, DOI 10.1037/0882-7974.21.1.62; Irwin M, 2000, PERCEPT MOTOR SKILL, V90, P1130, DOI 10.2466/PMS.90.3.1130-1134; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Strayer DL, 2004, HUM FACTORS, V46, P640, DOI 10.1518/hfes.46.4.640.56806	7	45	45	0	4	AMMONS SCIENTIFIC, LTD	MISSOULA	PO BOX 9229, MISSOULA, MT 59807-9229 USA	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	JUN	2009	108	3					717	720		10.2466/PMS.108.3.717-720			4	Psychology, Experimental	Psychology	479XO	WOS:000268695700007	19725308				2021-06-18	
J	Bier, N; Dutil, E; Couture, M				Bier, Nathalie; Dutil, Elisabeth; Couture, Melanie			Factors Affecting Leisure Participation After a Traumatic Brain Injury: An Exploratory Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						explanatory model; head trauma; leisure participation; motor impairments; trauma severity; social obstacles	LIFE-STYLE; DISABILITIES; IMPAIRMENTS; ADJUSTMENT; COMMUNITY; AWARENESS; MODERATE; PLAY; SELF	Objective: To explore leisure participation by people with traumatic brain injury (TBI) and reasons underlying changes after the trauma. Participants: Twenty-six individuals with mild to severe TBI. Main Measure: Leisure Profile, a semi-structured questionnaire measuring involvement in leisure activities before and after TBI (frequency of activities, degree of interest, and desire to modify one's leisure activities), attitudes toward leisure, and difficulties that might influence leisure activities (impairments and environmental obstacles). Results: Leisure participation was greatly disrupted after TBI, with 92% of the participants reporting a reduction posttrauma. Less severe Injuries, more time since the injury, and the presence of social obstacles in the environment were positively correlated with leisure participation. Motor impairments had a negative impact on leisure participation. Conclusion: TBI has a significant negative effect on leisure participation. Leisure activities should be evaluated and included in a therapy program designed to promote reintegration into society and work.	[Bier, Nathalie] Univ Sherbrooke, Sch Rehabil, Dept Occupat Therapy, Sherbrooke, PQ J1H 5N4, Canada; [Dutil, Elisabeth] Univ Montreal, Sch Rehabil, Dept Occupat Therapy, Quebec City, PQ, Canada; [Dutil, Elisabeth] Montreal Rehabil Inst, Ctr Interdisciplinary Res Rehabil Metropolitan Mo, Quebec City, PQ, Canada	Bier, N (corresponding author), Univ Sherbrooke, Sch Rehabil, Dept Occupat Therapy, 3001 12E Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Nathalie.Bier@USherbrooke.ca		Couture, Melanie/0000-0002-4919-573X; Bier, Nathalie/0000-0002-2940-694X			Anke AGW, 2003, CLIN REHABIL, V17, P431, DOI 10.1191/0269215503cr629oa; BREWIN J, 2001, BR J THER REHABIL, V8, P224; BROOKS C, 1992, J AM STUD, V26, P126, DOI 10.1017/S002187580003053X; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; BUNDY AC, 1993, AM J OCCUP THER, V47, P217, DOI 10.5014/ajot.47.3.217; CALDWELL LL, 1988, CAN J PUBLIC HEALTH, V79, pS44; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; COUTURE M, 2000, ETUDE FIDELITE INTER; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dumazedier Joffre, 1962, VERS CIVILISATION LO; DUTIL E, 1991, PROFIL LOISIR VERSIO; Dutil E., 1995, EXPERIENCES ERGOTHER, P52; Dutil Elisabeth, 2007, Can J Occup Ther, V74, P326; Fougeyrollas P, 1998, INT J REHABIL RES, V21, P127, DOI 10.1097/00004356-199806000-00002; Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7; GAGNE J, 1995, 14 C AEGSF U MONTR Q; HAGGARD LM, 1992, J LEISURE RES, V24, P1; Jennette B, 1981, MANAGEMENT HEAD INJU; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; Lefebvre H, 2004, PARTICIPATION SOCIAL; LEZAK MD, 1988, J LEARN DISABIL, V21, P456, DOI 10.1177/002221948802100802; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lyons R. F., 1993, CANADIAN J REHABILIT, V6, P256; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; NIEMI ML, 1988, STROKE, V19, P1101, DOI 10.1161/01.STR.19.9.1101; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; Patterson I, 1996, INT J AGING HUM DEV, V42, P123, DOI 10.2190/TG1M-75CB-PL27-R6G3; PIERA JB, 1982, J READAPT MED, V2, P149; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; Quintard B., 2002, Annales de Readaptation et de Medecine Physique, V45, P456, DOI 10.1016/S0168-6054(02)00296-9; ROGGENBUCK JW, 1990, J LEISURE RES, V22, P112; Scarmeas N, 2003, J CLIN EXP NEUROPSYC, V25, P625, DOI 10.1076/jcen.25.5.625.14576; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Suto M., 1998, CANADIAN J OCCUPATIO, V65, P271, DOI DOI 10.1177/000841749806500504; Turner H, 2000, Occup Ther Health Care, V12, P73, DOI 10.1080/J003v12n02_05; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540	41	45	45	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2009	24	3					187	194		10.1097/HTR.0b013e3181a0b15a			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	448HD	WOS:000266252800005	19461366				2021-06-18	
J	Cadosch, D; Gautschi, OP; Thyer, M; Song, S; Skirving, AP; Filgueira, L; Zellweger, R				Cadosch, Dieter; Gautschi, Oliver P.; Thyer, Matthew; Song, Swithin; Skirving, Allan P.; Filgueira, Luis; Zellweger, Rene			Humoral Factors Enhance Fracture-Healing and Callus Formation in Patients with Traumatic Brain Injury	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							HEAD-INJURY; HETEROTOPIC OSSIFICATION; SPINAL-CORD	Background: Scientific evidence is mounting for an association between traumatic brain injury and enhanced osteogenesis. The aim of this study was to correlate the in vitro osteoinductive potential of serum with the features of fracture-healing and the extent of brain damage in patients with severe traumatic brain injury and bone fracture. Methods: Patients with a long-bone fracture and a traumatic brain injury (seventeen patients) or without a brain injury (twenty-four patients) were recruited. The Glasgow Coma Scale score was determined on admission. Radiographs of the fracture were made before surgery, at six weeks, and at three, six, and twelve months after surgery. The time to union was estimated clinically and radiographically, and the callus ratio to, shaft diameter was calculated. Serum samples were collected at six, twenty-four, seventy-two, and 168 hours after injury, and their osteogenic potential was determined by measurement of the in vitro proliferation rate of the human fetal osteoblastic cell line hFOB1.19. Results: Patients with a traumatic brain injury had a twofold shorter time to union (p = 0.01), a 37% to 50% increased callus ratio (p < 0.01), and their sera induced a higher proliferation rate in hFOB cells (p < 0.05). A linear relationship was revealed between hFOB cell proliferation rates and the amount of callus formed (p < 0.05). The Glasgow Coma Scale score was correlated with the callus ratio on both radiographic projections (p < 0.05), time to union (p = 0.04), and the proliferation rate of hFOB cells at six hours after injury (p = 0.03). Conclusions: Patients with a severe brain injury release unknown humoral factors into the blood circulation that enhance and accelerate fracture-healing.	[Cadosch, Dieter; Gautschi, Oliver P.; Thyer, Matthew; Song, Swithin; Skirving, Allan P.; Filgueira, Luis; Zellweger, Rene] Royal Perth Hosp, Perth, WA, Australia	Cadosch, D (corresponding author), Univ Western Australia, Sch Anat & Human Biol, 35 Stirling Highway, Crawley, WA 6009, Australia.	dcadosch@anhb.uwa.edu.au	Filgueira, Luis/B-6492-2008	Filgueira, Luis/0000-0002-2266-6650			*ASS ADV AUT MED, 1998, ABBR INJ SCOR; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; COLLICOTT PE, 1980, JAMA-J AM MED ASSOC, V243, P1156; GARLAND DE, 1980, CLIN ORTHOP RELAT R, P198; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Gautschi OP, 2006, J AM COLL SURGEONS, V203, pS37, DOI 10.1016/j.jamcollsurg.2006.05.094; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Giannoudis PV, 2007, INJURY, V38, P1224; Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635-200403000-00007; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259; TEASDALE G, 1974, LANCET, V2, P81; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628; Waters KM, 2001, J CELL BIOCHEM, V83, P448, DOI 10.1002/jcb.1242; WHARTON GW, 1970, J BONE JOINT SURG AM, VA 52, P105, DOI 10.2106/00004623-197052010-00010	24	45	55	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	FEB	2009	91A	2					282	288		10.2106/JBJS.G.01613			7	Orthopedics; Surgery	Orthopedics; Surgery	403LA	WOS:000263082900004	19181971				2021-06-18	
J	Draper, K; Ponsford, J				Draper, Kristy; Ponsford, Jennie			Long-term outcome following traumatic brain injury: A comparison of subjective reports by those injured and their relatives	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Outcome measurement; TBI versus close-other report	SEVERE HEAD-INJURY; SELF-AWARENESS; COGNITIVE DEFICITS; IMPAIRED AWARENESS; CLOSE RELATIVES; ADULTS; REHABILITATION; MODERATE; VALIDATION; DEPRESSION	Many long-term outcome studies have documented changes following injury using subjective reports from TBI patients and close others. It is known that factors such as self-awareness and emotional adjustment can influence subjective reports, but there has been limited research comparing reports by those injured with those of their close others at longer periods post-injury. The aims of the present study were to compare TBI participants' and close others' subjective reports of cognitive and behavioural problems 10 years following TBI and to investigate the relationship between subjective reports of cognitive impairments and TBI participants' performances on cognitive tests. Fifty-four participants who had sustained mild to very severe TBI were followed up a mean of 10 years post-injury and 54 close others also participated. Measures included the Neurobehavioural Functioning Inventory (NFI), the Hospital Anxiety and Depression Scale (HADS), and cognitive measures of attention, memory and executive function. TBI participants and close others showed strong agreement in their reporting of problems on the NFI. However, there was no strong relationship between subjective reports of cognitive problems and test performances. Much stronger relationships were found between subjective reports of cognitive change and emotional state. This study highlights the importance of assessing emotional state when utilising subjective report data, as well as the need to use objective measures of cognitive impairment.	[Ponsford, Jennie] Monash Univ, Sch Psychol Psychiat & Psychol Med, Monash Epworth Rehabil Res Ctr, Epworth Hosp,Natl Trauma Res Inst, Melbourne, Vic 3004, Australia	Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN, P59; Baddeley A, 1994, DOORS PEOPLE; BERGNER M, 1976, MED CARE, V14, P57, DOI 10.1097/00005650-197601000-00006; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dixon R.A., 1999, COGNITIVE NEUROREHAB, P59; ELSASS L, 1991, THESIS TROBE U MELBO; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Hoofien D, 2001, BRAIN INJURY, V15, P189; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; LEZAK MD, 2004, NEUROPSYCHOL ASSESSM; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Markova IS, 2005, AGING MENT HEALTH, V9, P386, DOI 10.1080/13607860500142945; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rey A., 1958, LEXAMEN CLINIQUE PSY; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Shallice, 1997, HAYLING BRIXTON TEST; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P239, DOI 10.1016/j.acn.2005.12.004; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	67	45	45	0	11	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	5					645	661		10.1080/17405620802613935			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	539EK	WOS:000273236200002	19629849				2021-06-18	
J	Hart, T				Hart, Tessa			Treatment definition in complex rehabilitation interventions	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Rehabilitation; Clinical trials; Treatment fidelity; Complex intervention; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; COGNITIVE-BEHAVIORAL-THERAPY; RANDOMIZED CONTROLLED-TRIAL; HEALTH-SERVICES RESEARCH; FOLLOW-UP; TREATMENT FIDELITY; ANGER MANAGEMENT; STROKE REHABILITATION; CAREGIVER BURDEN; IMPROVE HEALTH	Rehabilitation research is challenged to improve its evidence base, which requires more precise and more consistent conceptualisation and measurement of treatment ingredients. This paper presents the steps in defining and specifying treatments towards the construction of a therapy manual for experimental interventions, or a coding system for observational treatment research. Specifying the active ingredients, identifying the behavioural operations that are aligned with each, and developing procedural details and materials are discussed and illustrated using two on-going trials for treatment of traumatic brain injury. The process of assessing treatment fidelity, that is, the extent to which interventions are delivered, received and used as intended, is also discussed.	Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 60 E Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD050836] Funding Source: Medline		Addis ME, 1999, CLIN PSYCHOL-SCI PR, V6, P430, DOI 10.1093/clipsy/6.4.430; Beck R, 1998, COGNITIVE THER RES, V22, P63, DOI 10.1023/A:1018763902991; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; Bellg AJ, 2004, HEALTH PSYCHOL, V23, P443, DOI 10.1037/0278-6133.23.5.443; Bostrom J, 1996, APPL NURS RES, V9, P47, DOI 10.1016/S0897-1897(96)80402-2; Bradley F, 1999, BMJ-BRIT MED J, V318, P711; BURNS DD, 1992, J CONSULT CLIN PSYCH, V60, P441, DOI 10.1037/0022-006X.60.3.441; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Dayus B, 2000, NEUROPSYCHOL REHABIL, V10, P415, DOI 10.1080/096020100411998; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEFFENBACHER JL, 1992, J COUNS PSYCHOL, V39, P158, DOI 10.1037/0022-0167.39.2.158; Deffenbacher JL, 2002, COUNS PSYCHOL, V30, P262, DOI 10.1177/0011000002302004; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; EAMES P, 2001, NEUROBEHAVIORAL DISA; Eames P., 1990, NEUROBEHAVIORAL SEQU, P410; Estrada AU, 1999, J SEX MARITAL THER, V25, P151, DOI 10.1080/00926239908403989; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HART T, 2007, TREATMENT DEFINITION; HART T, 2009, DESIGNING IMPLEMENTI; Hart T, 1993, J HEAD TRAUMA REHAB, V8, P1; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hawe P, 2004, J EPIDEMIOL COMMUN H, V58, P788, DOI 10.1136/jech.2003.014415; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Howard, 1987, J INTEGRATIVE ECLECT, V6, P6; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; Kolden GG, 2006, J CONSULT CLIN PSYCH, V74, P327, DOI 10.1037/0022-006X.74.2.327; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Litt MD, 2005, J CONSULT CLIN PSYCH, V73, P1015, DOI 10.1037/0022-006X.73.6.1015; LONG C, 1995, NEUROPSYCHOLOGICAL A; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Marshall WL, 2003, AGGRESS VIOLENT BEH, V8, P205, DOI 10.1016/S1359-1789(01)00065-9; Mateer C A, 1999, Semin Clin Neuropsychiatry, V4, P50; *MED RES COUNC, 2000, FRAM DEV EV RCTS COM; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Miller SJ, 2002, PSYCHOTHERAPY, V39, P184, DOI 10.1037/0033-3204.39.2.184; Moos RH, 2007, DRUG ALCOHOL DEPEN, V88, P109, DOI 10.1016/j.drugalcdep.2006.10.010; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Oakley A, 2006, BRIT MED J, V332, P413, DOI 10.1136/bmj.332.7538.413; Pantalon MV, 2004, AM J DRUG ALCOHOL AB, V30, P353, DOI 10.1081/ADA-120037382; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; Silver J, 2007, BRAIN INJURY MED PRI, P963; Spillane V, 2007, J ADV NURS, V60, P343, DOI 10.1111/j.1365-2648.2007.04386.x; Strasser DC, 2008, ARCH PHYS MED REHAB, V89, P10, DOI 10.1016/j.apmr.2007.08.127; Strasser DC, 2005, ARCH PHYS MED REHAB, V86, P403, DOI 10.1016/j.apmr.2004.04.046; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D	63	45	45	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	6					824	840		10.1080/09602010902995945			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	539EL	WOS:000273236300004	19544183				2021-06-18	
J	Maillard-Wermelinger, A; Yeates, KO; Taylor, HG; Rusin, J; Bangert, B; Dietrich, A; Nuss, K; Wright, M				Maillard-Wermelinger, Anne; Yeates, Keith Owen; Taylor, H. Gerry; Rusin, Jerome; Bangert, Barbara; Dietrich, Ann; Nuss, Kathryn; Wright, Martha			Mild traumatic brain injury and executive functions in school-aged children	DEVELOPMENTAL NEUROREHABILITATION			English	Article						traumatic barin injury; executive functions; children; concussion	WORKING-MEMORY; HEAD-INJURY; YOUNG-CHILDREN; SHORT-TERM; OUTCOMES; VALIDITY; BEHAVIOR	Objective: This study sought to examine the effects of mild traumatic brain injury (TBI) on executive functions in school-aged children. Participants and method: The prospective, longitudinal study involved 8-15 year old children, 186 with mild TBI and 99 with mild orthopaedic injuries (OI). They were administered the Stockings of Cambridge and Spatial Working Memory sub-tests from the Cambridge Neuropsychological Testing Automated Battery (CANTAB) similar to 10 days, 3 months and 12 months post-injury. Parents completed the Behavior Rating Inventory of Executive Functions (BRIEF) on each occasion, with ratings at the initial assessment intended to assess pre-morbid functioning retrospectively. Results: On the CANTAB, the groups did not differ on the Stockings of Cambridge and the mild TBI group unexpectedly performed better than the OI group on Spatial Working Memory. On the BRIEF, children with mild TBI showed a marginally significant trend toward more problems than the OI group on the Metacognition Index composite. The only BRIEF sub-scale on which they demonstrated significantly more problems was Organization of Materials. The presence of intracranial abnormalities on MRI was associated with more problems on the BRIEF Organization of Materials sub-scale at 3 months, but other findings were not consistent with hypothesized effects of TBI severity. The CANTAB sub-tests were significant predictors of later ratings on the BRIEF, but accounted for modest variance. Discussion: Children with mild TBI show limited evidence of deficits in executive functions, either cognitively or behaviourally, irrespective of injury characteristics. Cognitive tests of executive functions are modest predictors of ratings of executive functions in everyday life, for children both with and without mild TBI.	[Maillard-Wermelinger, Anne] Childrens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Yeates, Keith Owen; Dietrich, Ann; Nuss, Kathryn] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; [Taylor, H. Gerry; Wright, Martha] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry; Wright, Martha] Univ Hosp Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Rusin, Jerome] Nationwide Childrens Hosp, Dept Radiol, Columbus, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Radiol, Cleveland, OH USA; [Bangert, Barbara] Univ Hosp Hlth Syst, Dept Neurosurg, Cleveland, OH USA; [Dietrich, Ann; Nuss, Kathryn] Nationwide Childrens Hosp, Dept Emergency Med, Columbus, OH USA	Yeates, KO (corresponding author), Nationwide Childrens Hosp, Dept Psychol, Res Inst, Ctr Biobehav Hlth, 700 Childrens Dr, Columbus, OH 43205 USA.	keith.yeates@nationwidechildrens.org	Maillard, Anne/N-4779-2017; Yeates, Keith/AAJ-4223-2020	Maillard, Anne/0000-0002-4811-0693; Nuss, Kathryn/0000-0003-2185-7364; Yeates, Keith/0000-0001-7680-2892	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD44099, HD39834]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER	This work was supported by grants HD44099 and HD39834 from the National Institutes of Health to the second author (KOY).	*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; *CAMBR COGN, 2005, CAMBR NEUR TEST AUT; Catale C, 2009, J CLIN EXP NEUROPSYC, V31, P331, DOI 10.1080/13803390802134616; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Luciana M, 2000, FDN FUTURE FUNCTIONA; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Stuss D.T., 1986, FRONTAL LOBES; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Wechsler D., 1999, ABBREVIATED SCALE IN; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, pXVII; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	43	45	45	2	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	5					330	341		10.3109/17518420903087251			12	Clinical Neurology; Pediatrics; Rehabilitation	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FS	WOS:000207788500008	20477562	Green Accepted			2021-06-18	
J	Struhkamp, R; Mol, A; Swierstra, T				Struhkamp, Rita; Mol, Annemarie; Swierstra, Tsjalling			Dealing with In/dependence Doctoring in Physical Rehabilitation Practice	SCIENCE TECHNOLOGY & HUMAN VALUES			English	Article						physical rehabilitation; clinical trials; independence; care; daily life	TRAUMATIC BRAIN-INJURY; THERAPY INTENSITY; CARE; SCIENCE; COORDINATION; TECHNOLOGY; DISABILITY	By now, the laboratory tradition, crafting transportable knowledge that allows for comparison, has been amply studied. However, other knowledge traditions, notably that of the clinic, deserve further articulation. The authors contribute to this by unraveling some specificities of rehabilitation practice. How do laboratory and clinical traditions in rehabilitation relate to independence? The first seeks to quantify people's independence; the latter attends to qualitatively different ways of being independent. While measuring independence is a matter of aggregating scores on a priori established dimensions, clinical rehabilitation concerns coordinating different ways of being independent. While independence scales map a linear development in time, rehabilitation participants juggle with time, including uncertain futures in their present. In clinical practice, then, independence is neither a single, coherent, fact nor a clear-cut, stable goal. Instead, professionals as well as patients work by creatively doctoring with the large variety of elements that are relevant to daily life with long-term disabilities.	[Struhkamp, Rita] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Res Policy, Rotterdam, Netherlands; [Swierstra, Tsjalling] Univ Twente, Dept Philosophy, Enschede, Netherlands	Struhkamp, R (corresponding author), Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Res Policy, Rotterdam, Netherlands.						Akrich M, 2000, THEOR MED BIOETH, V21, P63, DOI 10.1023/A:1009943017769; Barnes M, 2000, TXB REHABILITATION M; BERG M, 1998, DIFFERENCES MED PRAC; Bowker G., 1999, SORTING THINGS OUT C; Canguilhem Georges, 1989, NORMAL PATHOLOGICAL; CASPER MJ, 1995, SCI TECHNOL HUM VAL, V20, P395, DOI 10.1177/016224399502000401; Charmaz K., 1991, GOOD DAYS BAD DAYS S; Chen CC, 2002, ARCH PHYS MED REHAB, V83, P1514, DOI 10.1053/apmr.2002.35107; CHRISTIANSEN CH, 1998, REHABILITATION MED P, P137; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; DEJONG G, 1979, ARCH PHYS MED REHAB, V60, P435; GRANGER CV, 1996, PHYSICAL MED REHABIL, P239; Haraway DonnaJ., 1991, SIMIANS CYBORGS WOME; Harbers H, 2002, THEOR CULT SOC, V19, P207, DOI 10.1177/026327602761899228; Healy David, 2002, CREATION PSYCHOPHARM; KEITH RA, 1993, IMPROVING ASSESSMENT IN REHABILITATION AND HEALTH, P33; KELLYHAYES M, 1996, REHABILITATION NURSI, P144; Lettinga A, 1999, THEOR MED BIOETH, V20, P517, DOI 10.1023/A:1009947524766; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Mahoney FI, 1965, MD STATE MED J, V14, P56; Marks Harry, 1997, PROGR EXPT SCI THERA; Mol A, 2006, QUAL HEALTH RES, V16, P405, DOI 10.1177/1049732305285856; Mol A, 2006, LOGICA ZORGEN ACTIEV; Mol A., 2002, BODY MULTIPLE ONTOLO; Moreira T, 2006, SOC STUD SCI, V36, P69, DOI 10.1177/0306312705053051; MORETTO MB, 2004, NEUROCHEM RES, V10, P1; Moser I., 2000, SCI CULTURE, V9, P201, DOI [DOI 10.1080/713695234, 10.1080/713695234]; Moser I, 2006, SCI TECHNOL HUM VAL, V31, P537, DOI 10.1177/0162243906289611; Moser I, 2003, DIGITAL MEDIA REVISITED: THEORETICAL AND CONCEPTUAL INNOVATIONS IN DIGITAL DOMAINS, P491; NELIS A, 2000, CONTESTED FUTURES SO, P209; Patti F, 2003, J NEUROL, V250, P861, DOI 10.1007/s00415-003-1097-x; Pols J, 2006, SCI TECHNOL HUM VAL, V31, P409, DOI 10.1177/0162243906287544; Rajan K.S., 2006, BIOCAPITAL CONSTITUT; Rapp R, 1998, SCI TECHNOL HUM VAL, V23, P45, DOI 10.1177/016224399802300103; Schlich T, 2007, SCI TECHNOL HUM VAL, V32, P65, DOI 10.1177/0162243906293886; SINGLETON V, 1993, SOC STUD SCI, V23, P227, DOI 10.1177/030631293023002001; Struhkamp R, 2005, CULT STUD, V19, P701, DOI 10.1080/09502380500365655; Struhkamp R, 2004, HEALTH CARE ANAL, V12, P131, DOI 10.1023/B:HCAN.0000041187.93819.17; Timmermans S., 2003, GOLD STANDARD CHALLE; van Dijk AJ, 2001, REHABILITATION MED T; Vos R, 2000, THEOR MED BIOETH, V21, P1, DOI 10.1023/A:1009903321229; WADE DT, 1997, NEUROLOGICAL REHABIL, P147; Williams PM, 2000, AM J OTOLARYNG, V21, P38, DOI 10.1016/S0196-0709(00)80122-2; Winance M, 2006, SCI TECHNOL HUM VAL, V31, P52, DOI 10.1177/0162243905280023; World Health Organization, 2001, INT CLASS FUNCT DIS	45	45	46	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0162-2439			SCI TECHNOL HUM VAL	Sci. Technol. Hum. Values	JAN	2009	34	1					55	76		10.1177/0162243907312954			22	Social Issues	Social Issues	383YD	WOS:000261709400004					2021-06-18	
J	Wells, R; Minnes, P; Phillips, M				Wells, Rebecca; Minnes, Patricia; Phillips, Marjory			Predicting social and functional outcomes for individuals sustaining paediatric traumatic brain injury	DEVELOPMENTAL NEUROREHABILITATION			English	Article						Traumatic brain injury; paediatrics; clinicians; quality of life; severity; outcomes	MILD HEAD-INJURY; GLASGOW COMA SCALE; CHILDREN; ADOLESCENTS; REHABILITATION; PERFORMANCE; BEHAVIOR; FAMILY; PARTICIPATION; MEMORY	Objective: To determine the efficacy of models employing the classification of severity of injury, based on either GCS scores or clinical findings using standardized test scores for Occupational Therapy, Physiotherapy and Psychology in predicting outcomes associated with paediatric traumatic brain injury (TBI). Method: Medical records were reviewed to obtain GCS scores and standardized tests used in the clinically based classification of severity of injury for 30 individuals who sustained a paediatric TBI and were patients of a brain injury treatment programme. Interviews were conducted with parents to obtain current data on social participation, cognitive functioning and environmental factors. Results: Three variables emerged as significant predictors of outcome: age at injury, clinical ratings of injury severity and environmental factors. Conclusion: Findings offer preliminary support for the idea that a combination of factors, including age at injury, clinical expertise and the environment, provide the best estimate of long-term outcome.	[Wells, Rebecca] Univ Waterloo, Waterloo, ON N2L 3G1, Canada; [Minnes, Patricia] Queens Univ, Kingston, ON, Canada; [Phillips, Marjory] Integra Fdn, Toronto, ON, Canada	Wells, R (corresponding author), Univ Waterloo, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	remwells@uwaterloo.ca					ALVAREZ A, ONT ASS DEV DIS C 20; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Apa Pesidential Task Force, 2006, AM PSYCHOL, V61, P271, DOI 10.1037/0003-066X.61.4.271; Arroyos-Jurado E, 2000, J SCHOOL PSYCHOL, V38, P571, DOI 10.1016/S0022-4405(00)00053-4; BEAULIEU CL, 2002, SURG CLIN N AM, V82, P1; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; BEERY K, 1997, BEERY DEV TEST VISUA; BIJUR PE, 1990, PEDIATRICS, V86, P337; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brooks BM, 2003, DISABIL REHABIL, V25, P51, DOI 10.1080/09638280210151987; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUININKS RH, 1978, BRUININKSOSERETKSY T; BUTTERBAUGH G, 1993, ASSESSING ADOLESCENT, P293; CASEY R, 1986, PEDIATRICS, V78, P497; Cassidy LD, 2003, J PEDIATR SURG, V38, P482, DOI 10.1053/jpsu.2003.50084; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; Cohen M.J., 1997, CHILDRENS MEMORY SCA; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Gil AM, 2003, J SCHOOL PSYCHOL, V41, P337, DOI 10.1016/S0022-4405(03)00085-2; GREWAL M, 1991, J PEDIATR SURG, V26, P1161, DOI 10.1016/0022-3468(91)90323-L; GUPTA A, 1996, INDIAN J CLIN PSYCHO, V23, P170; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Horowitz I, 1983, Int Rehabil Med, V5, P32; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; LEAHY LF, 1987, J CLIN EXP NEUROPSYC, V9, P55; LEVIN HS, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P89; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Minnes P, 2001, NEUROREHABILITATION, V16, P3; Nelson LD, 1997, PSYCHOL ASSESSMENT, V9, P368; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Solish A., 2003, J DEV DISABILITIES, V10, P115; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; VILELA T, 5 INTERURBAN BRAIN I; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Watt S, 1999, NEUROPSYCHOLOGY, V13, P338, DOI 10.1037/0894-4105.13.3.338; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	52	45	45	0	20	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1751-8423	1751-8431		DEV NEUROREHABIL	Dev. Neurorehabil.		2009	12	1					12	23		10.1080/17518420902773109			12	Clinical Neurology; Pediatrics; Rehabilitation	Neurosciences & Neurology; Pediatrics; Rehabilitation	V15FJ	WOS:000207787600003	19283530				2021-06-18	
J	Diestel, A; Roessler, J; Berger, F; Schmitt, KRL				Diestel, Antje; Roessler, Joerg; Berger, Felix; Schmitt, Katharina R. L.			Hypothermia downregulates inflammation but enhances IL-6 secretion by stimulated endothelial cells	CRYOBIOLOGY			English	Article						Hypothermia; Endothelial cells; IL-6; ERK 1/2; Bcl-2; I kappa B-alpha; Inflammation	NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; CARDIAC-ARREST; APOPTOSIS; KINASE; ACTIVATION; EXPRESSION	Hypothermia is a standard method for organ protection during cardiac surgery in children. However, the mechanisms of hypothermia-induced cell protection have not yet been clearly established. Therefore, the aim of our studies was to elucidate molecular effects of clinically relevant mild and deep hypothermia on endothelial cells. The endothelium plays a pivotal role in the interaction between blood cells and actively participates in complex inflammatory events. We isolated primary human umbilical vein endothelial cells (HUVEC) and investigated cell viability, proliferation and inflammatory characteristics after TNF-alpha stimulation under mild (32 degrees C) and deep (17 degrees C) hypothermia in comparison to normothermia (37 degrees C). As a protective mechanism of endothelial cells kept under hypothermic conditions we found a significant upregulation of the antiapoptotic protein Bcl-2, resulting in the same cell viability under hypothermic conditions. Unexpectedly we demonstrated significantly higher IL-6 release after 6 h of mild hypothermia. In contrast, hypothermia diminished inflammatory chemokines such as IL-8, MCP-1 and COX-2 protein expression which could lead to reduced leukocyte recruitment under hypothermia. Underlying mechanisms of this downregulation were found to be reduced ERK 1/2 phosphorylation and incomplete I kappa B-alpha degradation resulting in reduced NF kappa B-dependent proinflammatory gene expression. The upregulation of BcI-2 protein and the higher IL-6 release after 6 h of mild hypothermia are new and interesting cellular mechanisms of hypothermia in endothelial cell biology. Both factors may play a major role as cell protective mechanisms in hypothermia. (C) 2008 Elsevier Inc. All rights reserved.	[Roessler, Joerg; Berger, Felix; Schmitt, Katharina R. L.] Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis Paediat Cardiol, D-13353 Berlin, Germany; [Diestel, Antje; Berger, Felix] Charite, Dept Pediat Cardiol, D-13353 Berlin, Germany	Schmitt, KRL (corresponding author), Deutsch Herzzentrum Berlin, Dept Congenital Heart Dis Paediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	katharina.schmitt@charite.de		Berger, Felix/0000-0001-7881-1557	Fordergemeinschaft Deutsche Kinderherzzentren Bonn, Germany	Statement of funding: The is supported by Fordergemeinschaft Deutsche Kinderherzzentren Bonn, Germany.	[Anonymous], 2002, N ENGL J MED, V346, P549; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Boutilier RG, 2001, J EXP BIOL, V204, P3171; Cines DB, 1998, BLOOD, V91, P3527; Dinarello CA, 1996, INFECT DIS CLIN N AM, V10, P433, DOI 10.1016/S0891-5520(05)70306-8; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Fairchild KD, 2005, AM J PHYSIOL-CELL PH, V289, pC1114, DOI 10.1152/ajpcell.00152.2005; Fairchild KD, 2004, AM J PHYSIOL-CELL PH, V287, pC422, DOI 10.1152/ajpcell.00507.2003; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; HANSEN TN, 1994, CRYOBIOLOGY, V31, P101, DOI 10.1006/cryo.1994.1013; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; Jonas Richard A, 2002, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V5, P76, DOI 10.1053/pcsu.2002.31493; Kawaguchi AT, 1998, CIRCULATION, V98, pII385; Lee HS, 2002, NEUROSCI LETT, V329, P53, DOI 10.1016/S0304-3940(02)00591-8; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MENASCHE P, 1995, CIRCULATION, V92, P334, DOI 10.1161/01.CIR.92.9.334; Murphy AN, 1999, ANN NY ACAD SCI, V893, P19, DOI 10.1111/j.1749-6632.1999.tb07815.x; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nyhlen K, 2000, CYTOKINE, V12, P355, DOI 10.1006/cyto.1999.0557; Olsen TS, 2003, LANCET NEUROL, V2, P410, DOI 10.1016/S1474-4422(03)00436-8; Rasband W. S, 2012, IMAGEJ; Roberts JR, 2002, CRYOBIOLOGY, V44, P161, DOI 10.1016/S0011-2240(02)00018-4; Sahuquillo J, 2004, CURR PHARM DESIGN, V10, P2193, DOI 10.2174/1381612043384051; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; Schmitt KRL, 2007, NEUROSCI RES, V59, P68, DOI 10.1016/j.neures.2007.05.011; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Teague TK, 1997, J IMMUNOL, V158, P5791; TILG H, 1994, BLOOD, V83, P113; Waxman AB, 2003, AM J RESP CELL MOL, V29, P513, DOI 10.1165/rcmb.2002-0044OC; Yumoto H, 2007, ORAL MICROBIOL IMMUN, V22, P36, DOI 10.1111/j.1399-302X.2007.00320.x; Zhu LP, 2001, J MOL CELL CARDIOL, V33, P2135, DOI 10.1006/jmcc.2001.1476	36	45	45	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0011-2240			CRYOBIOLOGY	Cryobiology	DEC	2008	57	3					216	222		10.1016/j.cryobiol.2008.08.005			7	Biology; Physiology	Life Sciences & Biomedicine - Other Topics; Physiology	383HU	WOS:000261665500005	18790695				2021-06-18	
J	Esposito, E; Genovese, T; Caminiti, R; Bramanti, P; Meli, R; Cuzzocrea, S				Esposito, Emanuela; Genovese, Tiziana; Caminiti, Rocco; Bramanti, Placido; Meli, Rosaria; Cuzzocrea, Salvatore			Melatonin regulates matrix metalloproteinases after traumatic experimental spinal cord injury	JOURNAL OF PINEAL RESEARCH			English	Article						free radicals; inflammation; metalloproteinase; spinal cord damage; spinal cord injury	BLOOD-BRAIN-BARRIER; FOCAL CEREBRAL-ISCHEMIA; INDUCED GASTRIC-ULCER; NECROSIS-FACTOR-ALPHA; TNF-ALPHA; INFLAMMATORY RESPONSE; FUNCTIONAL RECOVERY; RADICAL SCAVENGER; BASEMENT-MEMBRANE; OXIDATIVE DAMAGE	The matrix metalloproteinases (MMPs) are important enzymes that regulate developmental processes, maintain normal physiology in adulthood and have reparative roles at specific stages after an insult to the nervous system. MMPs, particularly MMP-9/gelatinase B, promote early inflammation and barrier disruption after spinal cord injury (SCI). Recently, we have reported that the pineal secretory product melatonin exerts important anti-inflammatory effects in an experimental model of SCI induced by the application of vascular clips (force of 24 g) to the dura after a four-level T5-T8 laminectomy. However, no reports are available on the relationship between the activity of MMPs and melatonin's anti-inflammatory effects. The aim of the present study was to evaluate whether the protective effect of melatonin observed in SCI is related to the regulation of MMP-9 and MMP-2 in mice. Biochemical and zymographic methods were used to analyze MMP-9 and -2 expression and activities in spinal cord tissue from SCI-treated mice at 24 hr after the trauma. Our studies reveal that melatonin reduced SCI and lipid peroxidation in spinal cord at 24 hr after SCI. Melatonin also diminished proMMP-9 and -2 activities that were induced in the spinal cord tissues at 24 hr after SCI. The reduced activities of MMP-9 and -2 were associated with depressed expression of TNF-alpha. We propose that melatonin's ability to reduce SCI in mice is also related to a reduction in MMP-9 and MMP-2 activity and expression.	[Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, I-98100 Messina, Italy; [Esposito, Emanuela; Meli, Rosaria] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; [Esposito, Emanuela; Genovese, Tiziana; Bramanti, Placido; Cuzzocrea, Salvatore] IRCCS Ctr Neurolesi Bonino Pulejo, Messina, Italy; [Caminiti, Rocco] Univ Messina, Sch Med, Dept Human Pathol, I-98100 Messina, Italy	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Policlin Univ Via C, I-98100 Messina, Italy.	salvator@unime.it	Bramanti, Placido/K-5117-2016	GENOVESE, Tiziana/0000-0002-3335-7327; Meli, Rosaria/0000-0002-6246-6813			Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bao F, 2003, J NEUROSCI RES, V71, P220, DOI 10.1002/jnr.10481; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bilici D, 2002, DIGEST DIS SCI, V47, P856, DOI 10.1023/A:1014764705864; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Buss A, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-17; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Castaneda FE, 2005, GASTROENTEROLOGY, V129, P1991, DOI 10.1053/j.gastro.2005.09.017; Chen HY, 2006, J PINEAL RES, V41, P175, DOI 10.1111/j.1600-079X.2006.00351.x; Crocker SJ, 2006, AM J PATHOL, V169, P2104, DOI 10.2353/ajpath.2006.060626; Cuzzocrea S, 1999, FASEB J, V13, P1930; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; Cuzzocrea S, 2006, J PHARMACOL EXP THER, V319, P127, DOI 10.1124/jpet.106.108076; de Castro R, 2000, NEUROREPORT, V11, P3551, DOI 10.1097/00001756-200011090-00029; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; Duchossoy Y, 2001, CLIN CHEM LAB MED, V39, P362, DOI 10.1515/CCLM.2001.057; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; English JL, 2006, J BIOL CHEM, V281, P10337, DOI 10.1074/jbc.M512009200; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Ganguly K, 2005, J PINEAL RES, V39, P307, DOI 10.1111/j.1600-079X.2005.00250.x; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Genovese T, 2005, J NEUROIMMUNOL, V166, P55, DOI 10.1016/j.jneuroim.2005.05.009; Genovese T, 2008, SHOCK, V29, P32, DOI 10.1097/shk.0b013e318059053a; Genovese T, 2007, J PINEAL RES, V43, P140, DOI 10.1111/j.1600-079X.2007.00454.x; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; Glaser J, 2006, J NEUROSCI RES, V84, P724, DOI 10.1002/jnr.20982; Hardeland R, 2007, J PINEAL RES, V43, P382, DOI 10.1111/j.1600-079X.2007.00489.x; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOLTZ A, 1989, ACTA NEUROL SCAND, V79, P460, DOI 10.1111/j.1600-0404.1989.tb03815.x; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; Jiang XF, 2001, NEUROSCI LETT, V305, P41, DOI 10.1016/S0304-3940(01)01800-6; Kalkan E, 2007, SPINAL CORD, V45, P722, DOI 10.1038/sj.sc.3102035; LaFleur M, 1996, J EXP MED, V184, P2311; Lempinen M, 2000, EUR SURG RES, V32, P169, DOI 10.1159/000008759; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Leon J, 2006, J NEUROCHEM, V98, P2023, DOI 10.1111/j.1471-4159.2006.04029.x; Liu DX, 2005, J NEUROTRAUM, V22, P1123, DOI 10.1089/neu.2005.22.1123; Liu JB, 2004, CHINESE MED J-PEKING, V117, P571; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Manda K, 2007, J PINEAL RES, V42, P386, DOI 10.1111/j.1600-079X.2007.00432.x; Mori N, 2003, GASTROENTEROLOGY, V124, P983, DOI 10.1053/gast.2003.50152; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Mullane K, 1989, Prog Clin Biol Res, V301, P39; Noble LJ, 2002, J NEUROSCI, V22, P7526; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Onuki J, 2005, J PINEAL RES, V38, P107, DOI 10.1111/j.1600-079X.2004.00180.x; Ousman SS, 2001, J NEUROSCI, V21, P4649, DOI 10.1523/JNEUROSCI.21-13-04649.2001; Pearse DD, 2004, EUR J NEUROSCI, V20, P3387, DOI 10.1111/j.1460-9568.2004.03799.x; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; REITER RJ, 1994, ANN NY ACAD SCI, V719, P1, DOI 10.1111/j.1749-6632.1994.tb56817.x; Rosen J, 2006, J PINEAL RES, V41, P374, DOI 10.1111/j.1600-079X.2006.00379.x; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; ROSENBERG GA, 1994, LAB INVEST, V71, P417; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; SHAFITZAGARDO B, 1993, INT J DEV NEUROSCI, V11, P189, DOI 10.1016/0736-5748(93)90078-R; SHAPIRO SD, 2000, J CELL SCI 19, V113, P3355; Sharma HS, 2003, ACT NEUR S, V86, P407; Shubayev VI, 2000, BRAIN RES, V855, P83, DOI 10.1016/S0006-8993(99)02321-5; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Swarnakar S, 2007, J PINEAL RES, V43, P56, DOI 10.1111/j.1600-079X.2007.00443.x; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TATOR CH, 1991, NEUROCHIRURGIE, V37, P291; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Vaillant C, 1999, J NEUROSCI, V19, P4994; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571	77	45	47	1	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3098	1600-079X		J PINEAL RES	J. Pineal Res.	SEP	2008	45	2					149	156		10.1111/j.1600-079X.2008.00569.x			8	Endocrinology & Metabolism; Neurosciences; Physiology	Endocrinology & Metabolism; Neurosciences & Neurology; Physiology	336QT	WOS:000258380400005	18298463				2021-06-18	
J	Tanriverdi, F; Taheri, S; Ulutabanca, H; Caglayan, AO; Ozkul, Y; Dundar, M; Selcuklu, A; Unluhizarci, K; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Taheri, Serpil; Ulutabanca, Halil; Caglayan, Ahmet Okay; Ozkul, Yusuf; Dundar, Munis; Selcuklu, Ahmet; Unluhizarci, Kursad; Casanueva, Felipe F.; Kelestimur, Fahrettin			Apolipoprotein E3/E3 Genotype Decreases the Risk of Pituitary Dysfunction after Traumatic Brain Injury due to Various Causes: Preliminary Data	JOURNAL OF NEUROTRAUMA			English	Article						APO E; hypopituitarism; polymorphism; pituitary; traumatic brain injury	E POLYMORPHISM; HEAD-INJURY; APOE GENOTYPE; HYPOPITUITARISM; DISEASE; INSUFFICIENCY; HEMORRHAGE; SEIZURES; PROTEIN; ALLELE	Traumatic brain injury (TBI) is a devastating public health problem which may result in hypopituitarism. However, the mechanisms and the risk factors responsible for hypothalamo-pituitary dysfunction due to TBI are still unclear. Although APO E is one of the most abundant protein in hypothalamo-pituitary region, there is no study investigating the relation between APO E polymorphism and TBI-induced hypopituitarism. This study was undertaken to determine whether APO E genotypes modulate the pituitary dysfunction risk after TBI due to various causes, including traffic accident, boxing, and kickboxing. Ninety-three patients with TBI (mean age, 30.61 +/- 1.25 years) and 27 healthy controls (mean age, 29.03 +/- 1.70 years) were included in the study. Pituitary functions were evaluated, and APO E genotypes (E2/E2; E3/E3; E4/E4; E2/E3; E2/E4; E3/E4) were screened. Twenty-four of 93 subjects (25.8%) had pituitary dysfunction after TBI. The ratio of pituitary dysfunction was significantly lower in subjects with APO E3/E3 (17.7%) than the subjects without APO E3/E3 genotype (41.9%; p = 0.01), and the corresponding odds ratio was 0.29 (95% confidence interval [CI], 0.11-0.78). In conclusion, this study provides strong evidence for the first time that APO E polymorphism is associated with the development of TBI-induced pituitary dysfunction. Present data demonstrated that APO E3/E3 genotype decreases the risk of hypopituitarism after TBI. The demonstration of the association between the APO E polymorphism and TBI may provide a new point of view in this field and promote further studies.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; [Taheri, Serpil; Caglayan, Ahmet Okay; Ozkul, Yusuf; Dundar, Munis] Erciyes Univ, Sch Med, Dept Genet, TR-38039 Kayseri, Turkey; [Ulutabanca, Halil; Selcuklu, Ahmet] Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; [Casanueva, Felipe F.] Univ Santiago, Sch Med, Dept Med, Santiago De Compostela, Spain; [Casanueva, Felipe F.] Univ Santiago, Complejo Hosp, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	Dundar, Munis/B-3150-2011; Caglayan, Ahmet O/D-1066-2012; Taheri, Serpil/AAL-8870-2021	Dundar, Munis/0000-0003-0969-4611; Caglayan, Ahmet O/0000-0002-2332-322X; 	Scientific and Technical Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [SBAG-3017]	This study was funded by the Scientific and Technical Research Council of Turkey (TUBITAK, project no. SBAG-3017).	Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Ballerini S, 2002, CLIN CHIM ACTA, V317, P71, DOI 10.1016/S0009-8981(01)00769-0; Barger SW, 1997, J NEUROCHEM, V69, P60; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; COUDERC R, 1993, STROKE, V24, P661, DOI 10.1161/01.STR.24.5.661; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Lamberts SWJ, 1998, LANCET, V352, P127; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Nishida Y, 2005, GENE, V344, P133, DOI 10.1016/j.gene.2004.09.007; Schauwecker PE, 1998, EXP NEUROL, V149, P87, DOI 10.1006/exnr.1997.6679; Schiefermeier M, 2000, BRAIN, V123, P585, DOI 10.1093/brain/123.3.585; Schmidt R, 1997, STROKE, V28, P951, DOI 10.1161/01.STR.28.5.951; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; WelshBohmer KA, 1997, ANN NEUROL, V42, P319, DOI 10.1002/ana.410420308; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	38	45	46	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1071	1077		10.1089/neu.2007.0456			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900003	18707245				2021-06-18	
J	Fan, Y; Kong, H; Shi, XR; Sun, XL; Ding, JH; Wu, J; Hu, G				Fan, Yi; Kong, Hui; Shi, Xueru; Sun, Xiulan; Ding, Jianhua; Wu, Jie; Hu, Gang			Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrah.ydropyrindine and astrocytic modulation	NEUROBIOLOGY OF AGING			English	Article						aquaporin 4; Parkinson's disease; astrocyte; neurodegeneration; neuroprotection	GDNF GENE-EXPRESSION; NEUROTROPHIC FACTOR; MESSENGER-RNA; PARKINSONS-DISEASE; WATER TRANSPORT; REACTIVE ASTROCYTES; SUBSTANTIA-NIGRA; DOPAMINE NEURONS; GLIAL-CELLS; BRAIN	Aquaporm 4 (AQP4) is a predominant water channel protein in mammalian brains, which is localized in the astrocyte plasma membrane. AQP4 has gained much attraction due to its involvement in the physiopathology of cerebral disorders including stroke, tumor, infection, hydrocephalus, epilepsy, and traumatic brain injury. But there is almost no evidence whether abnormal AQP4 levels are associated with degenerative diseases, such as Parkinson's disease (PD). In our studies, we established PD animal models by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to test the hypothesis that abnormal AQP4 expression is involved in the pathophysiology of this disease. We show that mutant mice lacking AQP4 were significantly more prone to MPTP-induced neurotoxicity than their wild-type littermates. Furthermore, after administration of MPTP, astroglial proliferation and GDNF protein synthesis were inhibited by AQP4 deficiency. This study demonstrates that AQP4 is important in the MPTP neurotoxic process and indicates that the therapeutic strategy targeted to astrocytic modulation with AQP4 may offer a great potential for the development of new treatment for PD. 0 2007 Elsevier Inc. All rights reserved.	[Fan, Yi; Kong, Hui; Shi, Xueru; Sun, Xiulan; Ding, Jianhua; Hu, Gang] Nanjing Med Univ, Neuropharmacol Lab, Dept Anat Histol & Pharmacol, Jiangsu 210029, Peoples R China; [Wu, Jie] St Josephs Hosp, Neurophysiol Lab, Barrow Neurol Inst, Phoenix, AZ 85013 USA	Hu, G (corresponding author), Nanjing Med Univ, Neuropharmacol Lab, Dept Anat Histol & Pharmacol, 140 Hanzhong Rd, Jiangsu 210029, Peoples R China.	ghu@njmu.edu.cn	Wu, Jie/E-8906-2010; Fan, Yi/AAQ-1874-2021; Fan, Yi/Q-9252-2018	Fan, Yi/0000-0003-1783-3220; Fan, Yi/0000-0003-1783-3220			Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Airavaara M, 2004, EUR J NEUROSCI, V20, P2336, DOI 10.1111/j.1460-9568.2004.03700.x; Asai S, 1996, NEUROREPORT, V7, P1092, DOI 10.1097/00001756-199604100-00028; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; Burke RE, 1998, J NEUROCHEM, V71, P517; Carey JR, 2002, ARCH PHYS MED REHAB, V83, P972, DOI 10.1053/apmr.2002.33026; Chen LW, 2005, CURR DRUG TARGETS, V6, P821, DOI 10.2174/138945005774574506; Dolman D, 2005, J NEUROCHEM, V93, P825, DOI 10.1111/j.1471-4159.2005.03111.x; Dringen R, 1999, J NEUROSCI, V19, P562, DOI 10.1523/jneurosci.19-02-00562.1999; Drukarch B, 1998, FREE RADICAL BIO MED, V25, P217, DOI 10.1016/S0891-5849(98)00050-1; DUWU C, 2002, J NEUROVIROL, V8, P551; Eberhardt O, 2000, J NEUROSCI, V20, P9126; Fahn S, 2000, MERRITTS NEUROLOGY, P679; FAHN S, 1989, HDB EXPT PHARM, P386; Fan Y, 2005, J NEUROSCI RES, V82, P458, DOI 10.1002/jnr.20664; Fernagut PO, 2004, EXP NEUROL, V185, P47, DOI 10.1016/j.expneurol.2003.09.014; FORNO LS, 1992, PROG BRAIN RES, V94, P429; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; GIOVANNI A, 1991, J PHARMACOL EXP THER, V257, P691; GRUNDL W, 1991, ACTA MED HUNG, V48, P127; Hatakeyama S, 1996, TOXICOL LETT, V89, P231, DOI 10.1016/S0378-4274(96)03825-8; HO A, 1995, NEUROREPORT, V6, P1454, DOI 10.1097/00001756-199507100-00023; HUMPEL C, 1994, NEUROSCIENCE, V59, P791, DOI 10.1016/0306-4522(94)90284-4; Hunot S, 1996, J NEURAL TRANSM, V103, P1043, DOI 10.1007/BF01291789; Inoue T, 1999, BRAIN RES, V826, P306, DOI 10.1016/S0006-8993(99)01254-8; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Liberatore GT, 1999, NAT MED, V5, P1403; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Mena MA, 2002, MOL NEUROBIOL, V25, P245, DOI 10.1385/MN:25:3:245; MUDO G, 1993, NEUROSCIENCE, V57, P901, DOI 10.1016/0306-4522(93)90036-F; MUTHANE U, 1994, EXP NEUROL, V126, P195, DOI 10.1006/exnr.1994.1058; Nakajima K, 2001, BRAIN RES, V916, P76, DOI 10.1016/S0006-8993(01)02866-9; Nielsen S, 1997, J NEUROSCI, V17, P171; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; PAKKENBERG B, 1991, J NEUROL NEUROSUR PS, V54, P30, DOI 10.1136/jnnp.54.1.30; Przedborski S, 2001, J NEUROCHEM, V76, P1265, DOI 10.1046/j.1471-4159.2001.00183.x; RANSOM BR, 1987, NEUROSCI LETT, V75, P323, DOI 10.1016/0304-3940(87)90543-X; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; SCHMIDTKASTNER R, 1994, MOL BRAIN RES, V26, P325, DOI 10.1016/0169-328X(94)90106-6; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Smeyne M, 2005, GLIA, V52, P144, DOI 10.1002/glia.20233; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; STROMBERG I, 1993, EXP NEUROL, V124, P401, DOI 10.1006/exnr.1993.1214; Teismann P, 2004, CELL TISSUE RES, V318, P149, DOI 10.1007/s00441-004-0944-0; Teismann P, 2003, MOVEMENT DISORD, V18, P121, DOI 10.1002/mds.10332; Tokumine J, 2003, ACT NEUR S, V86, P231; Volterra A, 2005, NAT REV NEUROSCI, V6, P626, DOI 10.1038/nrn1722; Wang S, 2005, NEUROPHARMACOLOGY, V48, P984, DOI 10.1016/j.neuropharm.2005.01.009; Wang XF, 2000, J NEUROCHEM, V74, P1434, DOI 10.1046/j.1471-4159.2000.0741434.x; Wen H, 1999, EUR J NEUROSCI, V11, P935, DOI 10.1046/j.1460-9568.1999.00502.x; WEST RW, 1993, CARCINOGENESIS, V14, P285, DOI 10.1093/carcin/14.2.285	55	45	48	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	AUG	2008	29	8					1226	1236		10.1016/j.neurobiolaging.2007.02.015			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	321KF	WOS:000257302900013	17353068				2021-06-18	
J	Kang, YJ; Ku, J; Han, K; Kim, SI; Yu, TW; Lee, JH; Park, CI				Kang, Youn Joo; Ku, Jeonghun; Han, Kiwan; Kim, Sun I.; Yu, Tae Won; Lee, Jang Han; Park, Chang Il			Development and clinical trial of virtual reality-based cognitive assessment in people with stroke: Preliminary study	CYBERPSYCHOLOGY & BEHAVIOR			English	Article							BRAIN-INJURY; REHABILITATION; ENVIRONMENTS; TECHNOLOGY; TELEREHABILITATION; PERFORMANCE; IMPAIRMENTS; ATTENTION; EXPOSURE; SYSTEM	Stroke and traumatic brain injury affect an increasing number of people, many of whom retain permanent damage in cognitive functions. Conventionally, cognitive function has been assessed by a paper-based neuropsychological evaluation. However these test environments differ substantially from everyday life. This problem can be overcome by using virtual reality (VR) to objectively evaluate behaviors and cognitive function in simulated daily activities. With our virtual shopping simulation, we compared people who had undergone a stroke with control participants in an immersive VR program that used a head-mounted display (HMD). We evaluated user satisfaction with the tests, complications, and the user interface. Significant differences were consistently found between the stroke group and the control group for the following tasks: stage 1 performance index, interaction error; stage 2 delayed recognition memory score, attention index; and stage 3 executive index (p < 0.001). Perceptive dysfunction, visuospatial dysfunction, level of computer experience, and level of education affected the performance of the stroke group. The frequency of complications in the stroke group, calculated using the cut-off score for the Simulator Sickness Questionnaire, was 9.6% for nausea, 41.9% for oculomotor complications, and 25.8% for disorientation. The frequency of complications between the stroke and control groups was not significantly different. Thirtyfive percent of participants in the stroke group and 13% in the control group reported difficulties with using the joystick. This computer-generated VR-based cognitive test shows promise in assessing cognitive function in patients with stroke. More refinements are needed in the user interface and the projection methods.	[Ku, Jeonghun] Hanyang Univ, Dept Biomed Engn, Neuromech Virtual Environm Lab, Seoul 133605, South Korea; [Kang, Youn Joo] Myongi Hosp, Dept Phys Med & Rehabil, Seoul, South Korea; [Yu, Tae Won] Sol Hosp, Med & Rehabil Ctr, Seoul, South Korea; [Lee, Jang Han] Chung Ang Univ, Dept Psychol, Seoul 156756, South Korea; [Park, Chang Il] Yonsei Univ, Coll Med, Dept Phys Med & Rehabil, Seoul 120749, South Korea	Ku, J (corresponding author), Hanyang Univ, Dept Biomed Engn, Neuromech Virtual Environm Lab, POB 55, Seoul 133605, South Korea.	kujh@bme.hanyang.ac.kr		Kang, Youn Joo/0000-0002-9938-5435			Burdea G, 2000, IEEE T REHABIL ENG, V8, P430, DOI 10.1109/86.867886; Calarusso RP, 1972, MOTOR FREE VISUAL PE; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Cunningham D, 1999, ST HEAL T, V62, P90; Cutmore TRH, 2000, INT J HUM-COMPUT ST, V53, P223, DOI 10.1006/ijhc.2000.0389; Davies R. C., 1999, International Journal of Virtual Reality, V4, P3; Di Girolamo S, 2001, ACTA OTO-LARYNGOL, V121, P211; Girone M, 2000, Stud Health Technol Inform, V70, P89; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; HETTINGER LJ, 1992, PRESENCE-TELEOP VIRT, V1, P306; Kennedy R. S., 1993, Int'l. J. Aviat. Psychol., V3, P203, DOI [DOI 10.1207/S15327108IJAP0303_3, 10.1207/s15327108ijap0303_3]; Kesztyues TI, 2000, CYBERPSYCHOL BEHAV, V3, P343, DOI 10.1089/10949310050078788; Kim H.K., 2001, KIMS FRONTAL EXECUTI; KIM HK, 1999, MEMORY TEST; KIM HK, 2001, P ANN M KOR PSYCH AS, P670; Kim Y.H., 2001, J KOREAN ACAD REHABI, V25, P209; Lackner J. R., 1992, PRESENCE-TELEOP VIRT, V1, P319; Lee JH, 2003, CYBERPSYCHOL BEHAV, V6, P383, DOI 10.1089/109493103322278763; Lengenfelder J, 2002, J HEAD TRAUMA REHAB, V17, P26, DOI 10.1097/00001199-200202000-00005; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Pugnetti L., 1998, CYBERPSYCHOL BEHAV, V1, P151; REGAN EC, 1994, AVIAT SPACE ENVIR MD, V65, P527; Reinkensmeyer DJ, 2002, IEEE T NEUR SYS REH, V10, P102, DOI 10.1109/TNSRE.2002.1031978; Riva G, 1999, Cyberpsychol Behav, V2, P577, DOI 10.1089/cpb.1999.2.577; Rizzo A.A., 1998, CYBERPSYCHOLOGY BEHA, V1, P59, DOI [10.1089/cpb.1998.1.59, DOI 10.1089/CPB.1998.1.59]; Rizzo AA, 1997, ST HEAL T, V44, P123; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rose FD, 1999, DISABIL REHABIL, V21, P548; Rose FD, 1996, CURR OPIN NEUROL, V9, P461, DOI 10.1097/00019052-199612000-00012; ROTHBAUM BO, 1995, AM J PSYCHIAT, V152, P626; Seymour NE, 2002, ANN SURG, V236, P458, DOI 10.1097/00000658-200210000-00008; Trepagnier CG, 1999, NEUROREHABILITATION, V12, P63; Wilson PN, 1997, DISABIL REHABIL, V19, P213, DOI 10.3109/09638289709166530; Zhang L, 2001, AM J PHYS MED REHAB, V80, P597, DOI 10.1097/00002060-200108000-00010	34	45	47	2	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1094-9313			CYBERPSYCHOL BEHAV	CyberPsychol. Behav.	JUN	2008	11	3					329	339		10.1089/cpb.2007.0116			11	Communication; Psychology, Applied	Communication; Psychology	321PV	WOS:000257319900011	18537503				2021-06-18	
J	McLeod, TCV; Bay, RC; Heil, J; McVeigh, SD				Valovich McLeod, Tamara C.; Bay, R. Curtis; Heil, John; McVeigh, Scott D.			Identification of sport and recreational activity concussion history through the preparticipation screening and a symptom survey in young athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						mild brain injury; preparticipation examination; children; adolescent	COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; NCAA CONCUSSION; SCHOOL; PREVENTION; YOUTH	Objective: To evaluate the concussion history of young athletes using three questions on the preparticipation screening (PPS) and a concussion symptom survey (CSS). Design: Descriptive survey. Setting: Mass high school PPS. Patients or Other Participants: Five hundred twenty young athletes. Interventions: Athletes were asked about their concussion history using three different questions on the PPS. The CSS, a list of concussion-related symptoms, was also given to assess the history of concussion-related symptoms associated with a previous injury to the head. Main Outcome Measures: Positive concussion history was determined as a positive response on one of the three PPS questions or any one of the CSS responses and reported as frequencies and percentages. Kappa coefficients were used to evaluate the agreement between the responses on the three PPS questions. Results: There was little agreement among the three PPS questions, with kappa coefficients ranging from K = -0.018 to 0.342. Analysis of the CSS revealed that 286 athletes (55.0%) reported having at least one concussion symptom after a head injury. Of those reporting symptoms, 86.4% did not report a concussion history in sport, and 92.7% did not report a concussion history in recreational activities. Conclusions: The identification of concussion history may depend on the phrasing of questions on the PPS. Simply asking an athlete whether they had a concussion may not adequately identify athletes with concussion histories. Although recommendations have been made to avoid the terminology of ding and bell rung, it seems these terms may be needed to ensure adequate reporting of previous concussions in young athletes.	[Valovich McLeod, Tamara C.] AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, Mesa, AZ 85206 USA; [Bay, R. Curtis] AT Still Univ, Arizona Sch Hlth Sci, Dept Interdisciplinary Hlth Sci, Mesa, AZ 85206 USA; [McVeigh, Scott D.] DGR Management Inc, Wyomissing, PA USA	McLeod, TCV (corresponding author), AT Still Univ, Arizona Sch Hlth Sci, Athlet Training Program, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmelcod@atsu.edu	McLeod, Tamara/AAU-9435-2020	Bay, Ralph/0000-0003-3525-9269			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; KOESTER MC, 2003, CONT PEDIAT, V20, P85; LaBotz M, 2005, CLIN J SPORT MED, V15, P73, DOI 10.1097/01.jsm.0000157649.99867.fc; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory Paul, 2005, Clin J Sport Med, V15, P48; *PREP PHYS EV WORK, 2005, PREP PHYS EV; RISSER WL, 1985, TEX MED, V81, P35; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	20	45	45	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2008	18	3					235	240					6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	298SG	WOS:000255706800003	18469564				2021-06-18	
J	Brown, AW; Elovic, EP; Kothari, S; Flanagan, SR; Kwasnica, C				Brown, Allen W.; Elovic, Elie P.; Kothari, Sunil; Flanagan, Steven R.; Kwasnica, Christina			Congenital and acquired brain injury. 1. Epidemiology, pathophysiology, prognostication, innovative treatments, and prevention	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						diffuse axonal injury; economics; guidelines [publication type]; mortality; preventive measures; rehabilitation	PEDIATRIC TRAUMA; UNITED-STATES; HEAD-INJURY; MORTALITY; MANAGEMENT; TRENDS; DEATH; MODEL	This self-directed learning module reviews the cur-rent epidemiology of traumatic brain injury (TBI), its pathophysiology, prognostication after injury, currently available innovative early approaches to diagnosis and treatment, and effective methods of prevention. It is intended to provide the rehabilitation clinician with current knowledge to accurately inform patients, families, significant others, referring physicians, and payers and to aid in clinical decision making while caring for patients after TBI. Overall Article Objective: To describe current knowledge in traumatic brain injury epidemiology, pathophysiology, prognostication, acute treatment, and prevention.	[Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN 55905 USA; [Elovic, Elie P.] Kessler Med Rehabil Res & Educ Ctr, W Orange, NJ USA; [Kothari, Sunil] Inst Rehabil & Res, Houston, TX USA; [Flanagan, Steven R.] Mt Sinai Hosp, New York, NY 10029 USA; [Kwasnica, Christina] Barrow Neurol Inst, Phoenix, AZ 85013 USA	Brown, AW (corresponding author), Mayo Clin, Dept Phys Med & Rehabil, 200 1st SW, Rochester, MN 55905 USA.	brown.allen@mayo.edu		Flanagan, Steven/0000-0001-9005-5897; Brown, Allen W./0000-0001-7228-3351			Anderson CV, 1996, J NEUROTRAUM, V13, P59, DOI 10.1089/neu.1996.13.59; Benoit R, 2000, J TRAUMA, V49, P477, DOI 10.1097/00005373-200009000-00015; *BRAIN TRAUM FDN, 2003, GUID MAN SEV TRAUM B; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Everett SA, 2001, J ADOLESCENT HEALTH, V28, P228, DOI 10.1016/S1054-139X(00)00177-4; Finkelstein EA., 2006, INCIDENCE EC BURDEN; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Kim DH, 2006, NEUROCRIT CARE, V4, P83, DOI 10.1385/NCC:4:1:083; KOCHANEK PM, 2007, BRAIN INJURY MED PRI, P81; Kothari S., 2007, BRAIN INJURY MED PRI, P169; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Napolitano E, 2007, BRAIN INJURY MED PRI, P57; *NHTSA, 1996, 3 REP C EFF OCC PROT; Plautz B, 1996, AM J PREV MED, V12, P33; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; STYLIANOS S, 1993, PEDIATR CLIN N AM, V40, P1359; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Vitaz TW, 2001, J TRAUMA, V51, P369, DOI 10.1097/00005373-200108000-00025; Winter CD, 2005, SURG-J R COLL SURG E, V3, P329, DOI 10.1016/S1479-666X(05)80112-X	31	45	48	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2008	89	3		1			S3	S8		10.1016/j.apmr.2007.12.001			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	276TX	WOS:000254167100002	18295647				2021-06-18	
J	Stein, DM; Dutton, RP; Kramer, ME; Handley, C; Scalea, TM				Stein, Deborah M.; Dutton, Richard P.; Kramer, Mary E.; Handley, Christopher; Scalea, Thomas M.			Recombinant factor VIIa: Decreasing time to intervention in coagulopathic patients with severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	66th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 27-29, 2007	Las Vegas, NV	Amer Assoc Surg Trauma		trauma; traumatic brain injury; coagulopathy; rFVIIa	ACTIVATED FACTOR-VII; CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; WARFARIN; REVERSAL; THERAPY; ANTICOAGULATION; MANAGEMENT; MORTALITY; NOVOSEVEN	Background: Treatment of coagulopathy is often needed before neurosurgical intervention in patients with traumatic brain injury (TBI). Typically, this is accomplished with administration of plasma. We hypothesized that the off-label use of recombinant factor VIIa (rFVIIa) to normalize the coagulation profile would allow for earlier intervention than conventional therapy. Methods: The trauma registry was used to identify patients with severe TBI who were admitted during a 4-year period and were coagulopathic at admission (international normalized ratio, INR >= 1.4) and required a neurosurgical procedure. Severe TBI was defined as head abbreviated injury scale (AIS) >3 and admission Glasgow coma score (GCS) <9. Demographics, injury, blood bank and laboratory data, time of intervention, rFVIIa use, and complications were abstracted. Characteristics of the group who received rFVIIa were compared against those treated with plasma alone with a Student's t test and chi(2) analysis, as well as nonparametric methods for comparison of medians. Results: Of 681 patients with severe TBI, 63 were coagulopathic at admission and needed an emergent neurosurgical procedure. Twenty-nine patients who received rFVIIa were compared against 34 patients who were treated with only plasma. Mean age, injury severity score (ISS), and admission GCS and INR were not different between the two groups. Time to neurosurgical intervention was less in the rFVIIa group (median = 144 vs. 446 minutes, p = 0.0003) as were the number of units of plasma administered before intervention (median = 2 vs. 6, p = 0.0006). The rate of thromboembolic complications was not different between groups. In patients with isolated TBI, mortality was 33.3% in the rFVIIa group and 52.9% in controls (p 0.24). Conclusions: rFVIIa rapidly and effectively reversed coagulopathy in patients with severe TBI. rFVIIa decreased the time to intervention and decreased the use of blood products without increasing the rate of thromboembolic complications.	[Stein, Deborah M.; Dutton, Richard P.; Kramer, Mary E.; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Natl Study Ctr Trauma & Emergency Med Syst, Baltimore, MD 21201 USA	Stein, DM (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Cortiana M, 1986, J Neurosurg Sci, V30, P133; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Freeman WD, 2004, MAYO CLIN PROC, V79, P1495, DOI 10.4065/79.12.1495; Harrison TD, 2005, J TRAUMA, V59, P150, DOI 10.1097/01.TA.0000171470.39742.8E; Hedner U, 2006, SEMIN THROMB HEMOST, V32, P77, DOI 10.1055/s-2006-939557; Henzler D, 2007, CRIT CARE MED, V35, P1027, DOI 10.1097/01.CCM.0000259526.45894.08; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Karadimov D, 2003, J NEUROSURG ANESTH, V15, P330, DOI 10.1097/00008506-200310000-00008; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Lu J, 2005, ACT NEUR S, V95, P281; May AK, 1997, AM SURGEON, V63, P233; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; MOHR JP, 2007, 16 EUR STROK C GLASG; Park P, 2003, NEUROSURGERY, V53, P34, DOI 10.1227/01.NEU.0000068830.54968.A8; Perkins JG, 2007, J TRAUMA, V62, P1095, DOI 10.1097/TA.0b013e31804798a4; Powner DJ, 2005, NEUROSURGERY, V57, P823, DOI 10.1227/01.NEU.0000179915.74429.b2; Rizoli SB, 2006, J TRAUMA, V61, P1419, DOI 10.1097/01.ta.0000243045.56579.74; Roitberg B, 2005, NEUROSURGERY, V57, P832, DOI 10.1227/01.NEU.0000180816.80626.C2; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Sorensen B, 2003, BLOOD COAGUL FIBRIN, V14, P469, DOI 10.1097/00001721-200307000-00007; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; TAWIL S, IN PRESS J TRAUMA; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; VALADKA AB, 2000, TRAUMA, P377; White Christopher E, 2006, Curr Surg, V63, P310, DOI 10.1016/j.cursur.2006.04.013; Yusim Y, 2006, J CLIN ANESTH, V18, P545, DOI 10.1016/j.jclinane.2006.02.012; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	44	45	48	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2008	64	3					620	627		10.1097/TA.0b013e3181650fc7			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	274JE	WOS:000253996800013	18332801				2021-06-18	
J	Bay, E; Donders, J				Bay, Esther; Donders, Jacobus			Risk factors for depressive symptoms after mild-to-moderate traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; stress; depressive symptoms; allostatic load; pain	POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; HEAD-INJURY; MAJOR DEPRESSION; POSTCONCUSSIVE SYMPTOMS; CORTISOL RESPONSES; CHRONIC PAIN; MANAGEMENT; DISABILITY; ADULTS	Primary objective: To determine the extent to which pre-injury psychosocial factors, injury-related variables and post-injury litigation, perceived stress, fatigue, pain and information processing speed contributed to depressive symptoms after traumatic brain injury (TBI). Research design: Cross-sectional outpatient follow-up at 1-36 months post-injury. Methods and procedures: Eighty-four adults recruited from outpatient clinics completed measures of depressive symptoms, measured with the Neurobehavioural Functioning Inventory, chronic stress and other symptoms. Hierarchial linear regression analysis was used to identify statistically significant covariates. Logistic regression analysis determined classification accuracy of these variables with regard to the presence or absence of borderline depression levels. Main outcomes: Perceived stress, pain and litigation status made independent contributions to the level of depressive symptoms, with perceived stress explaining the bulk of the variance and mediating the effect of milder injury severity. These variables had a classification accuracy of 77% with regard to post-injury depressive symptoms, with a sensitivity of 84% and a specificity of 69%. Conclusions: Perceived stress, one indicator of allostatic load, explains a considerable amount of the variance in depressive symptoms after mild-moderate TBI. The findings suggest a need for earlier identification of, as well as preventative education with, those who are stress-vulnerable.	[Bay, Esther] Michigan State Univ, E Lansing, MI 48824 USA; [Donders, Jacobus] Mary Fee Bed Rehabil Hosp, Grand Rapids, MI USA	Bay, E (corresponding author), Ctr Nursing Res, A417 W Fee, E Lansing, MI 48824 USA.	baye@msu.edu					Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Anstey KJ, 2004, J CLIN EPIDEMIOL, V57, P1202, DOI 10.1016/j.jclinepi.2003.11.011; Antoni MH, 2001, HEALTH PSYCHOL, V20, P20, DOI 10.1037/0278-6133.20.1.20; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; BAY E, 2004, INT J, V18, P213; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Blumenthal JA, 2005, JAMA-J AM MED ASSOC, V293, P1626, DOI 10.1001/jama.293.13.1626; Borgaro SR, 2004, BRAIN INJURY, V18, P685, DOI 10.1080/02699050310001646080; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; BRESLAU N, 1986, ARCH GEN PSYCHIAT, V43, P309; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chamberlain DJ, 2006, J ADV NURS, V54, P407, DOI 10.1111/j.1365-2648.2006.03840.x; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; Davis SR, 1997, CURR OPIN OBSTET GYN, V9, P177; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Gaab J, 2006, PSYCHONEUROENDOCRINO, V31, P428, DOI 10.1016/j.psyneuen.2005.10.005; Gaab J, 2003, PSYCHONEUROENDOCRINO, V28, P767, DOI 10.1016/S0306-4530(02)00069-0; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GUALTIERI CT, 2001, J NEUROPSYCHIATRY CL, V18, P217; Heim C, 2001, BIOL PSYCHIAT, V49, P1023, DOI 10.1016/S0006-3223(01)01157-X; Heim Christine, 2002, Semin Clin Neuropsychiatry, V7, P147, DOI 10.1053/scnp.2002.33127; HIBBARD MR, 2004, ARCHIVES PHYSL M S85, pS43; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Hughes RB, 2005, WOMEN HEALTH ISS, V15, P14, DOI 10.1016/j.whi.2004.09.001; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kreutzer J, 1999, NEUROBEHAVIORAL FUNC, P1; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; LOVELL M, 2002, IMMEDIATE POST CONCU, P1; LOVELL M, 2002, BEST APPROACH CONCUS, P1; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lutgendorf SK, 2002, J UROLOGY, V167, P1338, DOI 10.1016/S0022-5347(05)65295-0; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McEwen B, 2002, END STRESS WE KNOW I, P1; McEwen BS, 2003, BIOL PSYCHIAT, V54, P200, DOI 10.1016/S0006-3223(03)00177-X; McEwen BS, 2001, ANN NY ACAD SCI, V933, P265, DOI 10.1111/j.1749-6632.2001.tb05830.x; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Millis SR., 2001, J FORENSIC NEUROPSYC, V2, P1, DOI [10.1300/J151v02n01_01, DOI 10.1300/J151V02N01_]; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MONROE SM, 1991, PSYCHOL BULL, V110, P406, DOI 10.1037/0033-2909.110.3.406; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; *NATL MULT SCLER S, 1997, CONS MULT SCLE R CTR, V2007; Nemeroff CB, 1998, SCI AM, V278, P42, DOI 10.1038/scientificamerican0698-42; NEMEROFF CB, 2005, J CLIN PSYCHIAT S7, V66, pS5; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Pruessner JC, 1999, PSYCHOSOM MED, V61, P197, DOI 10.1097/00006842-199903000-00012; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Raskin SA, 1997, BRAIN INJURY, V11, P587, DOI 10.1080/026990597123287; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHRETIEN DJ, 2003, INT REV PSYCHIAT MED, V15, P341; Silver JM, 1997, J NEUROPSYCH CLIN N, V9, P102; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Szanton SL, 2005, BIOL RES NURS, V7, P7, DOI 10.1177/1099800405278216; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TURNER RJ, 1990, J NERV MENT DIS, V178, P343, DOI 10.1097/00005053-199006000-00001; Wessa M, 2006, PSYCHONEUROENDOCRINO, V31, P209, DOI 10.1016/j.psyneuen.2005.06.010; Williams RA, 2000, J PSYCHIAT RES, V34, P227, DOI 10.1016/S0022-3956(00)00012-1; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Young E A, 1997, Depress Anxiety, V5, P66, DOI 10.1002/(SICI)1520-6394(1997)5:2<66::AID-DA2>3.0.CO;2-3	97	45	48	0	42	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					233	241		10.1080/02699050801953073			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500004	18297595				2021-06-18	
J	Cole, WR; Gerring, JP; Gray, RM; Vasa, RA; Salorio, CF; Grados, M; Christensen, JR; Slomine, BS				Cole, Wesley R.; Gerring, Joan P.; Gray, Robert M.; Vasa, Roma A.; Salorio, Cynthia F.; Grados, Marco; Christensen, James R.; Slomine, Beth S.			Prevalence of aggressive behaviour after severe paediatric traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; aggression; predictors of aggression; overt aggression scale	OVERT AGGRESSION; RELATIONAL AGGRESSION; PHYSICAL AGGRESSION; CHILDREN; SCALE; ADOLESCENTS; PREDICTORS; DISORDERS; ANXIETY; FAMILY	Objective: The goals of this study were to explore the prevalence of aggressive behaviours after severe paediatric traumatic brain injury (TBI) and identify predictors of aggressive behaviours 1 year post-injury. Methods: A cohort of 97 children aged 4-19 years at time of severe TBI (GCS 3-8) were prospectively followed for 1 year. Pre-injury psychiatric status was obtained retrospectively at enrolment and post-injury behavioural and functional concerns were assessed at 1 year. Aggression was measured with a modified version of the Overt Aggression Scale (OAS). Results: Results revealed aggressive behaviour increased from pre-injury to post-injury. Pre-injury factors including aggression, attention problems and anxiety were associated with increased post-injury aggressive behaviour. Children with greater disability after injury were also at increased risk for aggressive behaviours. Conclusions: Aggression is a prevalent symptom after paediatric TBI and can significantly impede rehabilitation. Awareness of these predictors can aid in early identification of children at risk in order to help appropriately design rehabilitation programmes.	[Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21202 USA; [Cole, Wesley R.; Gerring, Joan P.; Vasa, Roma A.; Salorio, Cynthia F.; Grados, Marco; Christensen, James R.; Slomine, Beth S.] Johns Hopkins Sch Med, Baltimore, MD USA; [Gray, Robert M.] Univ Calif San Diego, San Diego, CA 92103 USA	Slomine, BS (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 707 N Broadway, Baltimore, MD 21202 USA.	slomine@kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH00997]; NIH-NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD07414]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997, K23MH071567] Funding Source: NIH RePORTER	This work was supported by NIMH grant K20 MH00997 and NIH-NICHD grant T32-HD07414.	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Beyers JM, 2001, J ABNORM CHILD PSYCH, V29, P369, DOI 10.1023/A:1010491218273; Bittner A, 2007, J CHILD PSYCHOL PSYC, V48, P1174, DOI 10.1111/j.1469-7610.2007.01812.x; Blum RW, 2000, AM J PUBLIC HEALTH, V90, P1879, DOI 10.2105/AJPH.90.12.1879; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Capaldi D M, 1994, Prog Exp Pers Psychopathol Res, P165; Crick NR, 2006, J ABNORM CHILD PSYCH, V34, P131, DOI 10.1007/s10802-005-9009-4; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Farrington D P, 1989, Violence Vict, V4, P79; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; GRAY JA, 1990, COGNITION EMOTION, V4, P269, DOI 10.1080/02699939008410799; Guttmann-Steinmetz S, 2006, J AM ACAD CHILD PSY, V45, P440, DOI 10.1097/01.chi.0000196422.42599.63; Halperin JM, 2003, J AM ACAD CHILD PSY, V42, P965, DOI 10.1097/01.CHI.0000046899.27264.EB; Herrenkohl TI, 2007, J INTERPERS VIOLENCE, V22, P386, DOI 10.1177/0886260506296986; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kempes M, 2005, EUR CHILD ADOLES PSY, V14, P11, DOI 10.1007/s00787-005-0432-4; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, BRAIN INJURY, V12, P41; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; Nagin DS, 2001, ARCH GEN PSYCHIAT, V58, P389, DOI 10.1001/archpsyc.58.4.389; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Recklitis CJ, 2004, CHILD PSYCHIAT HUM D, V34, P341; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Rojahn J, 2001, J AUTISM DEV DISORD, V31, P577, DOI 10.1023/A:1013299028321; SCHATZ DB, 1996, J ATTEN DISORD, V10, P141; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Swaim Randall C, 2006, J Prim Prev, V27, P229, DOI 10.1007/s10935-006-0031-2; Swan L, 2004, BRAIN INJURY, V18, P143, DOI 10.1080/02699050310001596923; SZARTMARI P, 1994, INT J METH PSYCH RES, V4, P231; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tremblay RE, 2004, PEDIATRICS, V114, pE43, DOI 10.1542/peds.114.1.e43; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; WALKER JL, 1991, J AM ACAD CHILD PSY, V30, P187, DOI 10.1097/00004583-199103000-00004; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	44	45	45	1	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	12					932	939	PII 905454051	10.1080/02699050802454808			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RV	WOS:000260849900004	19005885	Green Accepted			2021-06-18	
J	Lachapelle, J; Bolduc-Teasdale, J; Ptito, A; Mckerral, M				Lachapelle, Julie; Bolduc-Teasdale, Julie; Ptito, Alain; Mckerral, Michelle			Deficits in complex visual information processing after mild TBI: Electrophysiological markers and vocational outcome prognosis	BRAIN INJURY			English	Article; Proceedings Paper	2nd International Conference on Vocational Outcomes in Traumatic Brain Injury	MAY 24-26, 2007	Vancouver, CANADA			mild traumatic brain injury; electrophysiology; vision; cognition intervention; return to work	TRAUMATIC BRAIN-INJURY; TEXTURE SEGREGATION; EVOKED-POTENTIALS; COGNITIVE DEFICITS; MOTION; HEAD; CONCUSSION; PERCEPTION; PATHOPHYSIOLOGY; ABNORMALITIES	Primary objective: To evaluate low-level to complex information processing using visual electrophysiology and to examine the latter's prognostic value in regards to vocational outcome in persons having sustained a mild traumatic brain injury (mTBI). Research design/methods: Event-related potentials (ERPs) were recorded to pattern-reversal, simple motion, texture segregation and cognitive oddball paradigms from 17 participants with symptomatic mTBI at onset of specialized clinical intervention and from 15 normal controls. The relationship between abnormal electrophysiology and post-intervention return to work status was also examined. Main outcomes and results: Participants with mTBI showed a statistically significant (p 0.05) amplitude reduction for cognitive ERPs and delayed latencies for texture (p 0.05) and cognitive paradigms (p 0.005) compared to controls. Furthermore, participants with mTBI presenting texture or cognitive ERP latency delays upon admission were at significantly (p 0.01) greater risk of negative vocational outcome than mTBI participants with normal electrophysiology. Conclusions: The findings suggest that individuals with symptomatic mTBI can present selective deficits in complex visual information processing that could interfere with vocational outcome. ERP paradigms such as those employed in this study thus show potential for evaluating outcome prognosis and merit further study.	[Bolduc-Teasdale, Julie; Mckerral, Michelle] Univ Montreal, Dept Psychol, Montreal, PQ H2H 2N8, Canada; [Lachapelle, Julie; Ptito, Alain] McGill Univ, Dept Neurol Neurosurg, Montreal, PQ, Canada; [Lachapelle, Julie; Bolduc-Teasdale, Julie; Ptito, Alain; Mckerral, Michelle] CRLB, CRIR, Montreal, PQ, Canada	Mckerral, M (corresponding author), Univ Montreal, Dept Psychol, 2275 Laurier Ave E, Montreal, PQ H2H 2N8, Canada.	michelle.mckerral@umontreal.ca			Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [42843] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Armitage P, 2002, STAT METHODS MED RES; Bach M, 2000, VISION RES, V40, P3559, DOI 10.1016/S0042-6989(00)00195-4; Bach M, 1997, VISION RES, V37, P1409, DOI 10.1016/S0042-6989(96)00322-7; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bertone A, 2003, J COGNITIVE NEUROSCI, V15, P218, DOI 10.1162/089892903321208150; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Caputo G, 1999, VISION RES, V39, P1597, DOI 10.1016/S0042-6989(98)00270-3; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; CHEN JK, 2007, J NEUROLOGY NEUROSUR; Drake AI, 2000, J HEAD TRAUMA REHAB, V15, P1103, DOI 10.1097/00001199-200010000-00004; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; FORGET R, 2007, PHYSIOTHERAPY, V93, pS402; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gagnon I, 2004, J HEAD TRAUMA REHAB, V19, P391, DOI 10.1097/00001199-200409000-00004; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; GUERIN F, 2005, CRIF PUBLICATIONS IN, P145; Guerin F, 2006, NEUROREHABILITATION, V21, P295; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holbourn AHS, 1943, LANCET, V2, P438; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; KAY T, 1993, REHABILITATION POST; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; KUBA M, 1992, DOC OPHTHALMOL, V80, P83, DOI 10.1007/BF00161234; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; LAMME VAF, 1992, VISION RES, V32, P797, DOI 10.1016/0042-6989(92)90022-B; LAMME VAF, 1993, VISUAL NEUROSCI, V10, P781, DOI 10.1017/S0952523800006039; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Luck S.J., 2005, **DROPPED REF**; MARCOTTE AC, 2005, ORIENTATIONS MINISTE; Marion DW, 1998, NEUROL CLIN, V16, P485, DOI 10.1016/S0733-8619(05)70073-6; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MCCRORY P, 2005, J SPORTS MED, V39, P78; McKerral M, 2001, VISION RES, V41, P1085, DOI 10.1016/S0042-6989(01)00037-2; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; *NIH, 1998, REH PERS TRAUM BRAIN, V16, P1; Odom JV, 2004, DOC OPHTHALMOL, V108, P115, DOI 10.1023/B:DOOP.0000036790.67234.22; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Prins ML, 2003, DEV BRAIN RES, V140, P93, DOI 10.1016/S0165-3806(02)00588-6; Regan D., 1989, HUMAN BRAIN ELECTROP; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; SELZER ME, 1995, J NEUROL REHABIL, V9, P55; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; STULEMEIJER M, 2006, J NEUROTRAUM, V23, P1450; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Vaina LM, 1996, P ROY SOC B-BIOL SCI, V263, P1225, DOI 10.1098/rspb.1996.0180; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	73	45	45	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	3					265	274		10.1080/02699050801938983			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	267LW	WOS:000253511500007	18297598				2021-06-18	
J	Meier, R; Bechir, M; Ludwig, S; Sommerfeld, J; Keel, M; Steiger, P; Stocker, R; Stover, JF				Meier, Regula; Bechir, Markus; Ludwig, Silke; Sommerfeld, Jutta; Keel, Marius; Steiger, Peter; Stocker, Reto; Stover, John F.			Differential temporal profile of lowered blood glucose levels (3.5 to 6.5 mmol/l versus 5 to 8 mmol/l) in patients with severe traumatic brain injury	CRITICAL CARE			English	Article							INTENSIVE-CARE-UNIT; INSULIN THERAPY; PERIINFARCT DEPOLARIZATIONS; HEAD-INJURY; HYPERGLYCEMIA; MICRODIALYSIS; PROTOCOL; METABOLISM; MANAGEMENT; LACTATE	Introduction Hyperglycaemia is detrimental, but maintaining low blood glucose levels within tight limits is controversial in patients with severe traumatic brain injury, because decreased blood glucose levels can induce and aggravate underlying brain injury. Methods In 228 propensity matched patients (age, sex and injury severity) treated in our intensive care unit (ICU) from 2000 to 2004, we retrospectively evaluated the influence of different predefined blood glucose targets (3.5 to 6.5 versus 5 to 8 mmol/l) on frequency of hypoglycaemic and hyperglycaemic episodes, insulin and norepinephrine requirement, changes in intracranial pressure and cerebral perfusion pressure, mortality and length of stay on the ICU. Results Mortality and length of ICU stay were similar in both blood glucose target groups. Blood glucose values below and above the predefined levels were significantly increased in the 3.5 to 6.5 mmol/l group, predominantly during the first week. Insulin and norepinephrine requirements were markedly increased in this group. During the second week, the incidences of intracranial pressure exceeding 20 mmHg and infectious complications were significantly decreased in the 3.5 to 6.5 mmol/l group. Conclusion Maintaining blood glucose within 5 to 8 mmol/l appears to yield greater benefit during the first week. During the second week, 3.5 to 6.5 mmol/l is associated with beneficial effects in terms of reduced intracranial hypertension and decreased rate of pneumonia, bacteraemia and urinary tract infections. It remains to be determined whether patients might profit from temporally adapted blood glucose limits, inducing lower values during the second week, and whether concomitant glucose infusion to prevent hypoglycaemia is safe in patients with post-traumatic oedema.	[Keel, Marius; Stover, John F.] Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland	Stover, JF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Trauma Surg, Raemistr 100, CH-8091 Zurich, Switzerland.	john.stover@access.unizh.ch					Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; BILOTTA F, 2008, NEUROCRIT C IN PRESS; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Clayton SB, 2006, CRIT CARE MED, V34, P2974, DOI 10.1097/01.CCM.0000248906.10399.CF; Cochran A, 2008, J BURN CARE RES, V29, P187, DOI 10.1097/BCR.0b013e318160d066; De Ciuceis C, 2008, J VASC RES, V45, P512, DOI 10.1159/000128604; de Courten-Myers GM, 2000, J CEREBR BLOOD F MET, V20, P82, DOI 10.1097/00004647-200001000-00012; Erol A, 2007, BIOESSAYS, V29, P811, DOI 10.1002/bies.20618; Gale SC, 2007, AM SURGEON, V73, P454; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Garg R, 2006, STROKE, V37, P267, DOI 10.1161/01.STR.0000195175.29487.30; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Grey Neil J, 2004, Endocr Pract, V10 Suppl 2, P46; Hattori N, 2004, J NUCL MED, V45, P775; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hui L, 2005, BRAIN RES, V1052, P1, DOI 10.1016/j.brainres.2005.05.043; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kanji S, 2004, INTENS CARE MED, V30, P804, DOI 10.1007/s00134-004-2252-2; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; KELLEHER JA, 1993, STROKE, V24, P855, DOI 10.1161/01.STR.24.6.855; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; Malliopoulou V, 2006, MOL CELL BIOCHEM, V284, P87, DOI 10.1007/s11010-005-9018-1; McMullin J, 2007, J CRIT CARE, V22, P112, DOI 10.1016/j.jcrc.2006.08.002; Nelson DW, 2004, CRIT CARE MED, V32, P2428, DOI 10.1097/01.CCM.0000147688.08813.9C; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Oldenborg PA, 1999, BIOSCIENCE REP, V19, P511, DOI 10.1023/A:1020286010551; Quinn JA, 2006, PHARMACOTHERAPY, V26, P1410, DOI 10.1592/phco.26.10.1410; Shi HL, 2006, NEUROSCI LETT, V410, P57, DOI 10.1016/j.neulet.2006.09.066; Strong AJ, 2000, STROKE, V31, P214, DOI 10.1161/01.STR.31.1.214; Strong AJ, 2007, CURR OPIN CRIT CARE, V13, P126, DOI 10.1097/MCC.0b013e32807faffb; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Thomson GA, 1997, ACTA DIABETOL, V34, P253, DOI 10.1007/s005920050084; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Van den Berghe G, 2005, NEUROLOGY, V64, P1348, DOI 10.1212/01.WNL.0000158442.08857.FC; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanhorebeek I, 2007, CRIT CARE MED, V35, pS496, DOI 10.1097/01.CCM.0000278051.48643.91; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vriesendorp TM, 2006, CRIT CARE MED, V34, P96, DOI 10.1097/01.CCM.0000194536.89694.06; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613	44	45	45	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	4							R98	10.1186/cc6974			13	Critical Care Medicine	General & Internal Medicine	360UF	WOS:000260082700014	18680584	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Harch, PG; Kriedt, C; Van Meter, KW; Sutherland, RJ				Harch, Paul G.; Kriedt, Christopher; Van Meter, Keith W.; Sutherland, Robert James			Hyperbaric oxygen therapy improves spatial learning and memory in a rat model of chronic traumatic brain injury	BRAIN RESEARCH			English	Article						hyperbaric oxygen; chronic traumatic brain injury	DECOMPRESSION ILLNESS; TEXTURE ANALYSIS; NEURONAL DEATH; BLOOD-FLOW; DIVERS; RESPONSES; METABOLISM; APOPTOSIS; ISCHEMIA; HISTORY	In the present experiment we use a rat model of traumatic brain injury to evaluate the ability of low-pressure hyperbaric oxygen therapy (HBOT) to improve behavioral and neurobiological outcomes. The study employed an adaptation of the focal cortical contusion model. 64 Male Long-Evans rats received unilateral cortical contusion and were tested in the Morris Water Task (MWT) 31-33 days post injury. Rats were divided into three groups: an untreated control group (N=22), an HBOT treatment group (N=19) and a sham-treated normobaric air group (N = 23). The HBOT group received 80 bid, 7 days/week 1.5 ATA/90-min HBOTs and the sham-treated normobaric air group the identical schedule of air treatments using a sham hyperbaric pressurization. All rats were subsequently retested in the MWT. After testing all rats were euthanized. Blood vessel density was measured bilaterally in hippocampus using a diaminobenzadine stain and was correlated with MWT performance. HBOT caused an increase in vascular density in the injured hippocampus (p < 0.001) and an associated improvement in spatial learning (p < 0.001) compared to the control groups. The increased vascular density and improved MWT in the HBOT group were highly correlated (p < 0.001). In conclusion, a 40-day series of 80 low-pressure HBOTs caused an increase in contused hippocampus vascular density and an associated improvement in cognitive function. These findings reaffirm the clinical experience of HBOT-treated patients with chronic traumatic brain injury. (c) 2007 Elsevier B.V. All rights reserved.	LSU Hlth Sci Ctr New Orleans, Dept Med, Sect Emergency Med, Harvey, LA 70058 USA; Baromed Res Inst, New Orleans, LA USA; Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; LSU Hlth Sci Ctr New Orleans, Neurosci Ctr Excellence, Harvey, LA 70058 USA; Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada; Univ Lethbridge, Dept Psychol & Neurosci, Lethbridge, AB T1K 3M4, Canada	Harch, PG (corresponding author), LSU Hlth Sci Ctr New Orleans, Dept Med, Sect Emergency Med, 1816 Ind Blvd, Harvey, LA 70058 USA.	paulharchmd@aol.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bonomo SR, 1998, UNDERSEA HYPERBAR M, V25, P211; Calvert JW, 2003, J APPL PHYSIOL, V95, P2072, DOI 10.1152/japplphysiol.00630.2003; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; GALL C, 1980, J COMP NEUROL, V193, P1047, DOI 10.1002/cne.901930416; GELDERD JB, 1980, UNDERSEA BIOMED RES, V7, P305; Ginaldi L., 1991, J HYPERBARIC MED, V6, P25; Golarai G, 2001, J NEUROSCI, V21, P8523; Golden ZL, 2002, INT J NEUROSCI, V112, P119, DOI 10.1080/00207450212027; HAAMPANIEMI T, 1998, EXP NEUROL, V149, P433; Harch P. G., 2004, TXB HYPERBARIC MED, P471; Harch PG, 1996, TXB HYPERBARIC MED, P480; Harch PG, 2004, TXB HYPERBARIC MED, P223; Harch PG, 1996, UNDERSEA HYPERB ME S, V23, P48; Harch PG, 1999, TXB HYPERBARIC MED, P318; Harch PG, 1996, TREATMENT DECOMPRESS, P203; Hehenberger Karin, 1997, Wound Repair and Regeneration, V5, P147, DOI 10.1046/j.1524-475X.1997.50206.x; HOSSMANN KA, 1993, PROG BRAIN RES, V96, P161; Houston AS, 1998, J NUCL MED, V39, P425; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; INAMOTO Y, 1991, BIOCHEM BIOPH RES CO, V179, P886, DOI 10.1016/0006-291X(91)91901-N; Ishii Y, 1999, TISSUE ENG, V5, P279, DOI 10.1089/ten.1999.5.279; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; Ketchum S.A., 1970, P 4 INT C HYP MED SA, P388; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kondo A, 1996, NEUROPATH APPL NEURO, V22, P350, DOI 10.1111/j.1365-2990.1996.tb01114.x; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Macleod MA, 1996, NUCL MED COMMUN, V17, P795, DOI 10.1097/00006231-199609000-00010; MANSON PN, 1980, SURG FORUM, V31, P565; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; Marx RE, 1988, PROBLEM WOUNDS ROLE, P65; NEUBAUER RA, 1992, CLIN NUCL MED, V17, P477, DOI 10.1097/00003072-199206000-00010; Neubauer RA, 1998, NEUROL RES, V20, pS33; NEUBAUER RA, 1994, SOUTHERN MED J, V87, P933, DOI 10.1097/00007611-199409000-00015; Neubauer V, 2004, TXB HYPERBARIC MED, P287; PALMER AC, 1992, NEUROPATH APPL NEURO, V18, P113, DOI 10.1111/j.1365-2990.1992.tb00773.x; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; POLKINGHORNE PJ, 1988, LANCET, V2, P1381; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAICHLE ME, 1976, ARCH NEUROL-CHICAGO, V33, P523, DOI 10.1001/archneur.1976.00500080001001; Reivich M, 1974, Res Publ Assoc Res Nerv Ment Dis, V53, P125; RIEDER MJ, 1995, MICROVASC RES, V49, P180, DOI 10.1006/mvre.1995.1014; Rosenthal RE, 2003, STROKE, V34, P1311, DOI 10.1161/01.STR.0000066868.95807.91; Rossignol DA, 2006, MED HYPOTHESES, V67, P216, DOI 10.1016/j.mehy.2006.02.009; SAITO K, 1991, CLIN EXP IMMUNOL, V86, P322; SCHOLZ KH, 1990, ORG SYNTH, V7, P4; Sheikh AY, 2000, ARCH SURG-CHICAGO, V135, P1293, DOI 10.1001/archsurg.135.11.1293; SHERMAN DM, 1985, STAIN TECHNOL, V60, P89, DOI 10.3109/10520298509113897; Shields TG, 1997, OCCUP ENVIRON MED, V54, P247, DOI 10.1136/oem.54.4.247; Siddiqui A, 1997, PLAST RECONSTR SURG, V99, P148, DOI 10.1097/00006534-199701000-00023; Staff RT, 1996, J NUCL MED, V37, P1154; STAFF RT, 1995, NUCL MED COMMUN, V16, P438, DOI 10.1097/00006231-199506000-00003; Stoller KP, 2005, PEDIATRICS, V116, pE586, DOI 10.1542/peds.2004-2851; SUTHERLAND RJ, 1993, J NEUROTRAUMA, V10, pS162; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Thurman DJ, 2001, HEAD TRAUMA THERAPEU; Vila JF, 2005, UNDERSEA HYPERBAR M, V32, P341; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Weisz G, 1997, J CLIN IMMUNOL, V17, P154, DOI 10.1023/A:1027378532003; WU LC, 1995, GROWTH FACTORS, V12, P29, DOI 10.3109/08977199509003211; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	65	45	47	2	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 12	2007	1174						120	129		10.1016/j.brainres.2007.06.105			10	Neurosciences	Neurosciences & Neurology	226TU	WOS:000250612200013	17869230				2021-06-18	
J	Linder-Lucht, M; Othmer, V; Walther, M; Vry, J; Michaelis, U; Stein, S; Weissenmayer, H; Korinthenberg, R; Mall, V				Linder-Lucht, Michaela; Othmer, Verena; Walther, Michael; Vry, Julia; Michaelis, Ulla; Stein, Sabine; Weissenmayer, Heike; Korinthenberg, Rudolf; Mall, Volker		Gross Motor Function Measure-Traum	Validation of the gross motor function measure for use in children and adolescents with traumatic brain injuries	PEDIATRICS			English	Article						GMFM-88; GMFM-66; GMFM; traumatic brain injury; children; adolescents; evaluation; motor function; validity; rehabilitation	RECOVERY; REHABILITATION; EPIDEMIOLOGY; VALIDITY; MOBILITY; TRENDS	OBJECTIVES. Motor function recovery is a key goal during rehabilitation of children and adolescents with traumatic brain injury. To evaluate how well treatment strategies improve motor function, we need validated outcome measures that are responsive to change in pediatric patients with traumatic brain injury. The Gross Motor Function Measure has demonstrated excellent psychometric properties in children with cerebral palsy and Down syndrome, yet its responsiveness in patients with pediatric traumatic brain injury has not been proven irrefutably. Our aim was to validate the Gross Motor Function Measure for this patient group. METHODS. Seventy-three patients ( mean age: 11.4 years; range: 0.8 - 18.9 years) with moderate-to-severe traumatic brain injury were recruited in 12 rehabilitation centers and assessed twice with the Gross Motor Function Measure-88 over 4 to 6 weeks. As an external standard, we used judgements of change made independently by parents, physiotherapists, and 2 video assessors who were not familiar with the patients. We formulated and statistically investigated a priori hypotheses of how Gross Motor Function Measure change scores would correlate with those judgements of change. Both Gross Motor Function Measure versions, the original Gross Motor Function Measure-88 and the more recently developed Gross Motor Function Measure-66, were evaluated. RESULTS. Both Gross Motor Function Measure change scores correlated significantly with all of the clinical judgements of change. The degree of correlation that we postulated, that the Gross Motor Function Measure change score would correlate highest with the video rating followed by physiotherapists and parents, was fully confirmed by the Gross Motor Function Measure-88 and largely confirmed by the Gross Motor Function Measure-66. Both Gross Motor Function Measure versions revealed convincing discriminative capability. Test-retest reliability was excellent. CONCLUSIONS. We demonstrate convincing evidence of responsiveness and validity to support the use of both Gross Motor Function Measure versions as evaluative measures of gross motor function in children and adolescents with traumatic brain injury.	Univ Hosp Freiburg, Dept Pediat & Adolescent Med, Div Neuropediat & Muscular Disorders, D-79106 Freiburg, Germany	Linder-Lucht, M (corresponding author), Univ Hosp Freiburg, Dept Pediat & Adolescent Med, Div Neuropediat & Muscular Disorders, Mathildenstr 1, D-79106 Freiburg, Germany.	michaela.linder@uniklinik-freiburg.de	Korinthenberg, Rudolf/A-9796-2009	Korinthenberg, Rudolf/0000-0002-4638-3460			Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Avery LM, 2003, ARCH PHYS MED REHAB, V84, P697, DOI 10.1016/S0003-9993(03)04896-7; Bedell GM, 2002, BRAIN INJURY, V16, P659, DOI 10.1080/02699050210128924; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Dumas Helene M., 2002, Physical & Occupational Therapy in Pediatrics, V22, P73, DOI 10.1300/J006v22n03_06; Emanuelson I, 1996, CHILD NERV SYST, V12, P460, DOI 10.1007/BF00261625; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; Gemus Maryan, 2001, Physical and Occupational Therapy in Pediatrics, V21, P69; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Long A F, 1996, J Eval Clin Pract, V2, P71, DOI 10.1111/j.1365-2753.1996.tb00029.x; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; Nelson L, 2006, NEUROMUSCULAR DISORD, V16, P374, DOI 10.1016/j.nmd.2006.03.005; Russell D, 1998, DEV MED CHILD NEUROL, V40, P693; RUSSELL D, 2006, GMFM GMFCS MESSUNG K; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Russell DJ, 2000, PHYS THER, V80, P873, DOI 10.1093/ptj/80.9.873; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Thomas-Stonell N, 2006, Pediatr Rehabil, V9, P14, DOI 10.1080/13638490500050097; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8	25	45	46	0	8	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2007	120	4					880	886		10.1542/peds.2006-2258			7	Pediatrics	Pediatrics	216HV	WOS:000249870000064					2021-06-18	
J	Fijalkowski, RJ; Stemper, BD; Pintar, FA; Yoganandan, N; Crowe, MJ; Gennarelli, TA				Fijalkowski, Ronald J.; Stemper, Brian D.; Pintar, Frank A.; Yoganandan, Narayan; Crowe, Maria J.; Gennarelli, Thomas A.			New rat model for diffuse brain injury using coronal plane angular acceleration	JOURNAL OF NEUROTRAUMA			English	Article						concussion; craniocerebral trauma; diffuse brain injury; experimental rat model; mild traumatic brain injury	CLOSED-HEAD INJURY; AXONAL INJURY; CEREBRAL CONCUSSION; IMPACT; PATHOPHYSIOLOGY; MEDETOMIDINE; ATIPAMEZOLE; DAMAGE; MECHANICS; REVERSAL	A new experimental model was developed to induce diffuse brain injury (DBI) in rats through pure coronal plane angular acceleration. An impactor was propelled down a guide tube toward the lateral extension of the helmet fixture. Upon impactor-helmet contact, helmet and head were constrained to rotate in the coronal plane. In the present experimental series, the model was optimized to generate rotational kinematics necessary for concussion. Twenty-six rats were subjected to peak angular accelerations of 368 +/- 30 krad/sec(2) ( mean +/- standard deviation) with 2.1 +/- 0.5-msec durations. Following rotational loading, unconsciousness was defined as time between reversal agent administration and return of corneal reflex. All experimental rats demonstrated transient unconsciousness lasting 8.8 +/- 3.7 min that was significantly longer than control rats. Macroscopic damage was noted in 51% of experimental animals: 38% subarachnoid hemorrhage, and 15% intraparenchymal lesion. Microscopic analysis indicated no evidence of axonal swellings at sacrifice times of 24, 48, 72, and 96 h. All rats survived rotational loading without skull fracture. Injuries were classified as concussion based on transient unconsciousness, scaled biomechanics, limited macroscopic damage, and minimal histological abnormalities. The experimental methodology remains adjustable, permitting investigation of increasing DBI severities through modulation of model parameters, and inclusion of further functional and histological outcome measures.	Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA	Pintar, FA (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	fpintar@mcw.edu	Stemper, Brian/AAX-7611-2020				ABEL JM, 1978, 22 STAPP CAR CRASH C; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Buki A, 2000, J NEUROSCI, V20, P2825; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ellingson Benjamin M., 2005, V41, P86; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Furukawa T, 2003, J NEUROTRAUM, V20, P269, DOI 10.1089/089771503321532851; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1987, 31 STAPP CAR CRASH C; Gennarelli TA, 2003, ANN P ASS ADV AUTOMO, P624; GENNARELLI TA, 1982, NATO AGARD C; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hahn N, 2005, LAB ANIMAL, V34, P48, DOI 10.1038/laban0205-48; Hirsch A.E., 1968, TOLERANCE SUBHUMAN P; Holbourn AHS, 1943, LANCET, V2, P438; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARGULIES SS, 1985, STUDY SCALING HEAD I; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; NEWMAN J, 2000, NEW BIOMECHANICAL AS; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1967, 11 STAPP CAR CRASH C; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; PINCEMAILLE Y, 1989, 33 STAPP CAR CRASH C; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Sleeman JM, 2000, J ZOO WILDLIFE MED, V31, P28, DOI 10.1638/1042-7260(2000)031[0028:SACEOM]2.0.CO;2; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; STRICH SJ, 1961, LANCET, V2, P443; Sun FJ, 2003, CONTEMP TOP LAB ANIM, V42, P32; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Yamashita K, 1996, J VET MED SCI, V58, P1049, DOI 10.1292/jvms.58.10_1049	61	45	46	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1387	1398		10.1089/neu.2007.0268			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500010	17711400				2021-06-18	
J	Verhaeghe, STL; van Zuuren, FJ; Defloor, T; Duijnstee, MSH; Grypdonck, MHF				Verhaeghe, Sofie T. L.; van Zuuren, Florence J.; Defloor, Tom; Duijnstee, Mia S. H.; Grypdonck, Mieke H. F.			How does information influence hope in family members of traumatic coma patients in intensive care unit?	JOURNAL OF CLINICAL NURSING			English	Article						coma; family members; hope; information; intensive care unit; nursing	CRITICALLY ILL PATIENTS; OF-THE-LITERATURE; PERCEIVED NEEDS; ADULT PATIENTS; BRAIN INJURY; RELATIVES; NURSES; PERCEPTIONS; EXPERIENCES	Aims. To assess the interplay between hope and the information provided by health care professionals. Background. Earlier research learned that hope is crucial for relatives of traumatic coma patients. Also it has been reported that the need for information is extremely important for relatives of critically ill patients. Design. A qualitative approach according to the 'grounded theory' method with constant comparison was used. Method. We held 24 in-depth interviews with 22 family members of 16 patients with traumatic coma. Data processing and data analysis took place in a cyclic process wherein the induction of themes was alternated by confrontation with new material. Results. Family members of traumatic coma patients want information that is as accurate as possible, provided by doctors and nurses in an understandable manner and leaving room for hope. At first, family members can do no more than passively absorb the information they receive. After some time, they actively start working with information and learn what to build their hope on. In this way, concrete hope evolves and seems to be strongly determined by information. Information that is more positive than warranted is not appreciated at all. It leads to false hope and once its real nature becomes apparent, to increased distress and loss of trust in the professionals. Conclusion. The process of hope is crucial in coping with traumatic coma and information can facilitate this process. Relevance to clinical practice. If professionals, especially nurses, keep the process in mind that family members go through in handling information, they can not only facilitate this process but also help them to establish realistic hope.	Univ Ghent, B-9000 Ghent, Belgium; Univ Amsterdam, Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Utrecht, Netherlands; Univ Ghent, B-9000 Ghent, Belgium	Verhaeghe, STL (corresponding author), Univ Ghent, UZ Blok A2o De Pintelaan 185, B-9000 Ghent, Belgium.	sofie.verhaeghe@ugent.be		Verhaeghe, Sofie/0000-0002-2063-5033; Beeckman, Dimitri/0000-0003-3080-8716			Azoulay E, 2004, CRIT CARE MED, V32, P2323, DOI 10.1097/01.CCM.0000145950.57614.04; Bijttebier P, 2001, INTENS CARE MED, V27, P160, DOI 10.1007/s001340000750; Bijttebier P, 2000, HEART LUNG, V29, P278, DOI 10.1067/mhl.2000.107918; Burr G, 1997, Aust Crit Care, V10, P124, DOI 10.1016/S1036-7314(97)70415-6; Campbell C H, 1988, Rehabil Nurs, V13, P320; COULTER M, 1989, INTENSIVE CARE NURSI, V5, P5; DALEY L, 1984, HEART LUNG, V13, P231; DAVISMARTIN S, 1994, HEART LUNG, V23, P515; DOCKTER B, 1988, PATIENT EDUC COUNS, V12, P29, DOI 10.1016/0738-3991(88)90035-3; Engli M, 1993, J Neurosci Nurs, V25, P78; Engstrom Asa, 2004, Intensive Crit Care Nurs, V20, P299; FORRESTER DA, 1990, HEART LUNG, V19, P655; FREICHELS T A, 1991, Critical Care Nursing Quarterly, V14, P16; Fulbrook P, 1999, Nurs Crit Care, V4, P138; GELLING I, 2002, NURSING CRITICAL CAR, V7, P271; Gelling L., 1999, NURSING CRITICAL CAR, V4, P214; Glaser B. G., 1967, DISCOVERY GROUNDED T; HAMPE SO, 1975, NURS RES, V24, P113; HICKEY M, 1990, HEART LUNG, V19, P401; JACONO J, 1990, HEART LUNG, V19, P72; Jamerson PA, 1996, HEART LUNG, V25, P467, DOI 10.1016/S0147-9563(96)80049-5; Johnson L H, 1996, J Trauma Nurs, V3, P72; Johnson L H, 1996, J Neurosci Nurs, V28, P259; Johnson S K, 1995, Image J Nurs Sch, V27, P238, DOI 10.1111/j.1547-5069.1995.tb00866.x; Kleiber C, 1994, Am J Crit Care, V3, P70; Kleinpell R M, 1992, Appl Nurs Res, V5, P2; Koller P A, 1991, AACN Clin Issues Crit Care Nurs, V2, P338; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kuyper MB, 1998, QUAL HEALTH RES, V8, P237, DOI 10.1177/104973239800800207; LESKE JS, 1986, HEART LUNG, V15, P189; LYNNMCHALE DJ, 1988, HEART LUNG, V17, P447; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mendonca D, 1998, Crit Care Nurs Q, V21, P58; Miller J F, 1991, AACN Clin Issues Crit Care Nurs, V2, P307; Miller J F, 1989, Appl Nurs Res, V2, P23; MOLTER NC, 1979, HEART LUNG, V8, P332; Morse J. M., 1996, NURSING RES APPL QUA; MORSE JM, 1995, J ADV NURS, V21, P886, DOI 10.1046/j.1365-2648.1995.21050886.x; MURPHY PA, 1992, HEART LUNG, V21, P25; Neabel B, 2000, HEART LUNG, V29, P196, DOI 10.1067/mhl.2000.106938; NORRIS LO, 1986, HEART LUNG, V15, P194; OMALLEY P, 1991, HEART LUNG, V20, P189; Plowfield L A, 1999, J Neurosci Nurs, V31, P231; PRICE DM, 1991, HEART LUNG, V20, P183; RUKHOLM E, 1991, J ADV NURS, V16, P920, DOI 10.1111/j.1365-2648.1991.tb01796.x; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Spatt L, 1986, QRB Qual Rev Bull, V12, P16; STILLWELL SB, 1984, HEART LUNG, V13, P238; Takman Christina A S, 2004, Intensive Crit Care Nurs, V20, P22, DOI 10.1016/j.iccn.2003.09.003; Testani-Dufour L, 1992, J Neurosci Nurs, V24, P317; Verhaeghe S, 2005, J CLIN NURS, V14, P501, DOI 10.1111/j.1365-2702.2004.01081.x; Verhaeghe STL, 2007, QUAL HEALTH RES, V17, P730, DOI 10.1177/1049732307303242; Warren N A, 1993, Crit Care Nurs Q, V16, P56; WERTZ FJ, 1987, ADV QUALITATIVE PSYC, P1; Wester F., 1987, STRATEGIEEN KWALITAT	55	45	45	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	AUG	2007	16	8					1488	1497		10.1111/j.1365-2702.2006.01807.x			10	Nursing	Nursing	196LM	WOS:000248483000013	17655537				2021-06-18	
J	Simosa, HF; Petersen, DJ; Agarwal, SK; Burke, PA; Hirsch, EF				Simosa, Hector F.; Petersen, Dustin J.; Agarwal, Suresh K.; Burke, Peter A.; Hirsch, Erwin F.			Increased risk of deep venous thrombosis with endovascular cooling in patients with traumatic head injury	AMERICAN SURGEON			English	Article							BRAIN-INJURY; INDUCED HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; CARDIAC-ARREST; HEMORRHAGE; EFFICACY; STROKE; FEVER	Endovascular therapeutic hypothermia has been shown to preserve neurological function and improve outcomes; however, its use and potential complications have not been fully described in patients with traumatic head injuries. We believe that the use of endovascular cooling leads to deep venous thrombosis (DVT) in this high-risk population. We performed a retrospective review of 11 patients with severe head injuries admitted to our Level I trauma center surgical intensive care unit who underwent intravascular cooling. Duplex sonograms were obtained after 4 days at catheter removal or with clinical symptoms that were suspicious for DVT. Patients had a mean age of 23.2 (range, 16-42) years and an Injury Severity Score of 31.9 (range, 25-43). The overall incidence of DVT was 50 per cent. The DVT rate was 33 per cent if catheters were removed in 4 days or less and 75 per cent if removed after 4 days (risk ratio = 2.25; odds ratio = 6; P = ns). An elevated international normalized ratio upon admission was protective against DVT (no DVT = 1.26 vs DVT = 1.09; P = 0.02). Inferior vena cava filters were placed in most patients with DVT. The use of endovascular cooling catheters is associated with increased risk of DVT in patients with traumatic head injuries. Therefore, we discourage the use of endovascular cooling devices in this patient population.	Boston Univ, Dept Gen Surg Trauma & Crit Care, Boston Med Ctr, Boston, MA 02215 USA	Hirsch, EF (corresponding author), Boston Med Ctr, 850 Harrison Ave,Dowling 2, S Boston, MA 02118 USA.			Burke, Peter/0000-0002-0329-5436			Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Dohi K, 2006, ACTA NEUROCHIR SUPPL, V96, P409; FAY T, 1945, RES PUBL ASS NERV ME, V24, P611; Fay T, 1940, NY STATE J MED, V40, P1351; Georgiadis D, 2001, STROKE, V32, P2550, DOI 10.1161/hs1101.097382; Holzer M, 2002, NEW ENGL J MED, V346, P549; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Lindenblatt N, 2005, AM J PHYSIOL-HEART C, V289, pH2680, DOI 10.1152/ajpheart.00425.2005; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Polderman KH, 2004, CRIT CARE MED, V32, P2558, DOI 10.1097/01.CCM.0000148087.41418.0A; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Wijdicks EFM, 1997, NEUROLOGY, V49, P1342, DOI 10.1212/WNL.49.5.1342	19	45	49	0	1	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	MAY	2007	73	5					461	464					4	Surgery	Surgery	163VP	WOS:000246191600008	17520999				2021-06-18	
J	Howard, AL; Neu, A; Morgan, RJ; Echegoyen, JC; Soltesz, I				Howard, Allyson L.; Neu, Axel; Morgan, Robert J.; Echegoyen, Julio C.; Soltesz, Ivan			Opposing modifications in intrinsic currents and synaptic inputs in post-traumatic mossy cells: Evidence for single-cell homeostasis in a hyperexcitable network	JOURNAL OF NEUROPHYSIOLOGY			English	Article							RAT DENTATE GYRUS; DEPOLARIZATION-INDUCED SUPPRESSION; ACTIVATED PACEMAKER CHANNELS; HIPPOCAMPAL PYRAMIDAL CELLS; TEMPORAL-LOBE EPILEPSY; LONG-TERM PLASTICITY; FEBRILE SEIZURES; NEOCORTICAL SYNAPSES; STATUS EPILEPTICUS; BRAIN-INJURY	Recent experimental and modeling results demonstrated that surviving mossy cells in the dentate gyrus play key roles in the generation of network hyperexcitability. Here we examined if mossy cells exhibit long-term plasticity in the posttraumatic, hyperexcitable dentate gyrus. Mossy cells 1 wk after fluid percussion head injury did not show alterations in their current-firing frequency (I-F) and current-membrane voltage (I-V) relationships. In spite of the unchanged I-F and I-V curves, mossy cells showed extensive modifications in Na+, K+ and h-currents, indicating the coordinated nature of these opposing modifications. Computational experiments in a realistic large-scale model of the dentate gyrus demonstrated that individually, these perturbations could significantly affect network activity. Synaptic inputs also displayed systematic, opposing modifications. Miniature excitatory postsynaptic current (EPSC) amplitudes were decreased, whereas miniature inhibitory postsynaptic current (IPSC) amplitudes were increased as expected from a homeostatic response to network hyperexcitability. In addition, opposing alterations in miniature and spontaneous synaptic event frequencies and amplitudes were observed for both EPSCs and IPSCs. Despite extensive changes in synaptic inputs, cannabinoid-mediated depolarization-induced suppression of inhibition was not altered in posttraumatic mossy cells. These data demonstrate that many intrinsic and synaptic properties of mossy cells undergo highly specific, long-term alterations after traumatic brain injury. The systematic nature of such extensive and opposing alterations suggests that single-cell properties are significantly influenced by homeostatic mechanisms in hyperexcitable circuits.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	Howard, AL (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	ahoward@uci.edu		Neu, Axel/0000-0001-7045-7194	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS035915, R01NS035915, R37NS035915] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-35915] Funding Source: Medline		Acsady L, 2000, J NEUROSCI, V20, P6907, DOI 10.1523/JNEUROSCI.20-18-06907.2000; Atherton JF, 2005, J NEUROSCI, V25, P8272, DOI 10.1523/JNEUROSCI.1475-05.2005; Beaumont V, 2000, NAT NEUROSCI, V3, P133, DOI 10.1038/72072; Bernard C, 2005, P NATL ACAD SCI USA, V102, P9388, DOI 10.1073/pnas.0409641102; Blair RE, 2006, J PHARMACOL EXP THER, V317, P1072, DOI 10.1124/jpet.105.100354; BlascoIbanez JM, 1997, HIPPOCAMPUS, V7, P307, DOI 10.1002/(SICI)1098-1063(1997)7:3<307::AID-HIPO6>3.0.CO;2-H; Blumcke I, 2000, EPILEPSIA, V41, pS174, DOI 10.1111/j.1528-1157.2000.tb01577.x; Bollmann JH, 2005, NAT NEUROSCI, V8, P426, DOI 10.1038/nn1417; Borst JGG, 1999, PHILOS T R SOC B, V354, P347, DOI 10.1098/rstb.1999.0386; Buckmaster PS, 1996, J COMP NEUROL, V366, P270, DOI 10.1002/(SICI)1096-9861(19960304)366:2<270::AID-CNE7>3.0.CO;2-2; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; Chen K, 2003, NEURON, V39, P599, DOI 10.1016/S0896-6273(03)00499-9; Cooper DC, 2003, J NEUROSCI, V23, P9937; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; Desai NS, 2002, NAT NEUROSCI, V5, P783, DOI 10.1038/nn878; Desai NS, 1999, NAT NEUROSCI, V2, P515; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dyhrfjeld-Johnsen J, 2007, J NEUROPHYSIOL, V97, P1566, DOI 10.1152/jn.00950.2006; ECHEGOYEN JC, 2005, SOC NEUR ABSTR; FROTSCHER M, 1991, J COMP NEUROL, V312, P145, DOI 10.1002/cne.903120111; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Geiger JRP, 2000, NEURON, V28, P927, DOI 10.1016/S0896-6273(00)00164-1; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Henze DA, 2001, NEUROSCIENCE, V105, P121, DOI 10.1016/S0306-4522(01)00167-1; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Hofmann ME, 2006, J NEUROPHYSIOL, V96, P2501, DOI 10.1152/jn.00310.2006; Kamal A, 2006, EUR J NEUROSCI, V23, P2230, DOI 10.1111/j.1460-9568.2006.04732.x; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kreitzer AC, 2001, J NEUROSCI, V21, part. no.; Leranth C, 1996, NEUROSCIENCE, V70, P631, DOI 10.1016/S0306-4522(96)83003-X; Lisman JE, 1999, NEURON, V22, P233, DOI 10.1016/S0896-6273(00)81085-5; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luther JA, 2003, J NEUROPHYSIOL, V90, P2720, DOI 10.1152/jn.00370.2003; Maccaferri G, 1996, J PHYSIOL-LONDON, V497, P119, DOI 10.1113/jphysiol.1996.sp021754; MacLean JN, 2005, J NEUROPHYSIOL, V94, P3601, DOI 10.1152/jn.00281.2005; MacLean JN, 2003, NEURON, V37, P109, DOI 10.1016/S0896-6273(02)01104-2; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; Marder E, 2003, NEURON, V37, P2, DOI 10.1016/S0896-6273(02)01173-X; Marder E, 2006, NAT REV NEUROSCI, V7, P563, DOI 10.1038/nrn1949; Marsicano G, 2003, SCIENCE, V302, P84, DOI 10.1126/science.1088208; Martina M, 1997, J PHYSIOL-LONDON, V505, P593, DOI 10.1111/j.1469-7793.1997.593ba.x; Metz AE, 2005, J NEUROSCI, V25, P5763, DOI 10.1523/JNEUROSCI.0624-05.2005; Mizrahi A, 2001, J NEUROSCI, V21, P7331, DOI 10.1523/JNEUROSCI.21-18-07331.2001; Niven JE, 2003, NATURE, V421, P630, DOI 10.1038/nature01384; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Ohno-Shosaku T, 2001, NEURON, V29, P729, DOI 10.1016/S0896-6273(01)00247-1; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PITLER TA, 1992, J NEUROSCI, V12, P4122; Pulver SR, 2005, J NEUROBIOL, V62, P47, DOI 10.1002/neu.20066; Ratzliff ADH, 2004, J NEUROSCI, V24, P2259, DOI 10.1523/JNEUROSCI.5191-03.2004; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; RIBAK CE, 1985, J NEUROCYTOL, V14, P835, DOI 10.1007/BF01170832; Ross ST, 2001, P NATL ACAD SCI USA, V98, P8874, DOI 10.1073/pnas.141042398; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Santhakumar V, 2005, J NEUROPHYSIOL, V93, P437, DOI 10.1152/jn.00777.2004; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; SCHARFMAN HE, 1994, J NEUROPHYSIOL, V72, P2167; Schulz DJ, 2006, NAT NEUROSCI, V9, P356, DOI 10.1038/nn1639; Sekerli M, 2004, IEEE T BIO-MED ENG, V51, P1665, DOI 10.1109/TBME.2004.827531; Shafaroodi H, 2004, NEUROPHARMACOLOGY, V47, P390, DOI 10.1016/j.neuropharm.2004.04.011; Shah MM, 2004, NEURON, V44, P495, DOI 10.1016/j.neuron.2004.10.011; Siegelbaum SA, 2000, NAT NEUROSCI, V3, P101, DOI 10.1038/72038; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SOLTESZ I, 1993, NEUROSCIENCE, V57, P555, DOI 10.1016/0306-4522(93)90005-Z; Spampanato J, 2004, J NEUROPHYSIOL, V91, P2040, DOI 10.1152/jn.00982.2003; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; Sutula TP, 2003, CURR OPIN NEUROL, V16, P189, DOI 10.1097/00019052-200304000-00012; Toth Z, 1997, J NEUROSCI, V17, P8106; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Watt AJ, 2000, NEURON, V26, P659, DOI 10.1016/S0896-6273(00)81202-7; Wenzel HJ, 1997, HIPPOCAMPUS, V7, P559; Wierenga CJ, 2005, J NEUROSCI, V25, P2895, DOI 10.1523/JNEUROSCI.5217-04.2005; Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076	83	45	46	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	MAR	2007	97	3					2394	2409		10.1152/jn.00509.2006			16	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	145KW	WOS:000244864900051	16943315	Green Published			2021-06-18	
J	McHugh, GS; Butcher, I; Steyerberg, EW; Lu, J; Mushkudiani, N; Marmarou, A; Maas, AIR; Murray, GD				McHugh, Gillian S.; Butcher, Isabella; Steyerberg, Ewout W.; Lu, Juan; Mushkudiani, Nino; Marmarou, Anthony; Maas, Andrew I. R.; Murray, Gordon D.			Statistical approaches to the univariate prognostic analysis of the IMPACT database on traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						forest plots; GOS; ordinal data; proportional odds model; traumatic brain injury	MODELS	The univariate prognostic analysis of the IMPACT database on traumatic brain injury (TBI) poses the formidable challenge of how best to summarize a highly complex set of data in a way which is accessible without being overly simplistic. In this paper, we describe and illustrate the battery of statistical methods that have been used. Boxplots, histograms, tabulations, and splines were Used for initial data checking and in identifying appropriate transformations for more formal statistical modeling. Imputation techniques were used to minimize the problems associated with the analysis of incomplete data due to missing values. The associations between covariates and outcome (Glasgow Outcome Scale [GOS] assessed at 6 months) were expressed as odds ratios with supporting confidence intervals when the GOS was collapsed to a dichotomous scale. This was extended to use common odds ratios from proportional odds models to express associations over the full range of the GOS. Forest plots were used to illustrate the consistency of results from study to study within the IMPACT database. The overall prognostic strength of the prognostic factors was expressed as the proportion of variance explained (Nagelkerke's R-2 statistic). Many of our approaches are based on simple graphical displays of the data, but, where appropriate, we have also used methods that although established in the statistical literature are relatively novel in their application to TBI.	Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Erasmus MC, Ctr Clin Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA	McHugh, GS (corresponding author), Univ Edinburgh, Sch Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Gillian.McHugh@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Murray, Gordon/0000-0001-9866-4734; Lu, Juan/0000-0002-5389-7603	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		Agresti A., 1996, INTRO CATEGORICAL DA; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Harrell FE, 2001, INT J TECHNOL ASSESS, V17, P17, DOI 10.1017/S0266462301104034; Harrell Frank E., 2001, REGRESSION MODELING; JENNETT B, 1975, LANCET, V1, P480; Little RJA, 1987, STAT ANAL MISSING DA; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Royston P, 2000, STAT MED, V19, P1831, DOI 10.1002/1097-0258(20000730)19:14<1831::AID-SIM502>3.0.CO;2-1; Stone CJ, 1986, STAT SCI, V1, P312, DOI DOI 10.1214/ss/1177013607; STONE CJ, 1985, P STAT COMPUTING SEC; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Whitehead A., 2002, METAANALYSIS CONTROL	16	45	46	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					251	258		10.1089/neu.2006.0026			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900004	17375989				2021-06-18	
J	Gianotti, S; Hume, PA				Gianotti, Simon; Hume, Patria A.			Concussion sideline management intervention for rugby union leads to reduced concussion claims	NEUROREHABILITATION			English	Article						concussion; injury prevention intervention; concussion management; community; rugby; return on investment; education	SPORT; STATEMENT	The effectiveness of a concussion management education programme (CMEP) in rugby in reducing the number and cost of concussion/brain injury (CBI) moderate to serious claims (MSC) was assessed. A RugbySmart (TM) educational video and a sideline concussion check (SCC) tool comprised the CMEP. Over 30,000 SCC, providing information on management of suspected concussion among community level rugby players prior to seeking medical treatment, were distributed from July 2003 to June 2005. Each year approximately 10,000 coaches and 2,000 referees participated in RugbySmart (TM). From 2003 to 2005 new rugby CBI MSC reduced by 10.7% (actual) and 58.2% (forecast). Rugby player numbers, new non-sport CBI MSC and new sport MSC all increased by 13.6%, 16.9% and 24.6% respectively in the same period. The median number of days between CBI injury and the player seeking medical treatment decreased from six days to four days. Cost savings after CMEP were $USD690,690 (actual) to $USD3,354,780 (forecast). The two-year cost of CMEP was $USD54,810 returning $USD12.60 (actual) and $USD61.21 (forecast) for every $USD1 invested (ROI). CMEP provided community coaches and managers with education on minimum best practice for managing suspected concussion, contributed towards ROI and savings for CBI MSC in rugby.	Accid Compensat Corp, Wellington, New Zealand; Auckland Univ Technol, Inst Sport & Recreat Res New Zealand, Div Sch Sport & Recreat, Fac Hlth & Environm Sci, Auckland, New Zealand	Gianotti, S (corresponding author), Accid Compensat Corp, POB 242, Wellington, New Zealand.	simon.gianotti@acc.co.nz	Hume, Patria/AAN-5514-2021	Hume, Patria/0000-0003-1847-8128			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; CAMBELL D, 2004, RUGBY NEWS, P11; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; COLLINS MW, 2004, COMMUNICATION; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; GIANOTTI S, 2007, IN PRESS J SCI MED S; GIANOTTI S, 2003, DEV OFFICER RUGBYSMA; GILKSON T, 2004, COMMUNICATION; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; HARTE D, 2004, MODELLING WORK RELAT, P65; HARTE D, 2004, MODELLING ACC CLAIM, P44; JEGATHEESON P, 2002, INJURY PREVENTION RE; KUNTER K, 1998, NATL ACAD NEUROPSYCH, V14, P19; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; MCCRORY P, 2002, BRIT J SPORT MED, V36, P315; *NZ RUGB FOOTB UN, 2004, RUGB PLAY NUMB SURG; *NZ RUGB FOOTB UN, 2001, COMP RUGBYSMART COAC, P1	21	45	45	0	27	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					181	189					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800004	17917168				2021-06-18	
J	Nekludov, M; Antovic, J; Bredbacka, S; Blomback, M				Nekludov, Michael; Antovic, Jovan; Bredbacka, Sixten; Blomback, Margareta			Coagulation abnormalities associated with severe isolated traumatic brain injury: Cerebral arterio-venous differences in coagulation and inflammatory markers	JOURNAL OF NEUROTRAUMA			English	Article						coagulopathy; inflammation; jugular bulb catheter; transcranial gradient; traumatic brain injury (TBI)	MEMBRANE ATTACK COMPLEX; HEAD TRAUMA; PROCOAGULANT ACTIVITY; COAGULOPATHY; DYSFUNCTION; ACTIVATION; CYTOKINES; TIME	Although coagulopathy is known to be the major contributor to a poor outcome of traumatic brain injury (TBI), the mechanisms that trigger coagulation abnormalities have not been studied in detail. We undertook a prospective observational study at a neurosurgical ICU (NICU) in a university hospital. We examined 11 patients with severe isolated TBI, at admittance to the hospital and during the next 3 days. We collected cerebrovenous blood samples from a jugular bulb catheter, arterial blood, and cerebrospinal fluid (CSF) samples. We measured concentrations of thombin-antithrombin complex (TAT), fibrin D-dimer (DD), prothrombin fragment 1+2 (F1+2), interleukin-6 (IL-6), and complement complex (C5b-9). All patients had some degree of consumption coagulopathy at the study start and a tendency to thrombocytopenia during the next few days. Levels of DD (3.6 +/- 2.7 mg/L), TAT (86 +/- 72 mu g/L) and F1+2 (5.9 +/- 6.8 nmol/L) were significantly increased shortly after the trauma compared to reference values, with considerable transcranial gradients for TAT (49 mu g/L) and F1+2 (3.2 nmol/L). Compared to controls, IL-6 levels were increased more than a hundredfold in both blood (283 +/- 192 ng/L) and CSF (424 +/- 355 ng/L) samples, with a transcranial gradient at the study start (107 ng/L). C5b-9 levels were moderately increased in blood samples, 270 114 mu g/L, versus controls, 184 39 (p < 0.05). We conclude that activation of the coagulation system takes place during the passage of blood through the damaged brain, and is already evident hours after the trauma. IL-6 and activation of the complement system (C5b-9) co-vary with hemostatic parameters in TBI patients.	Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden; Karolinska Inst, S-10401 Stockholm, Sweden; St Goran Hosp, Dept Anesthesiol, Stockholm, Sweden	Nekludov, M (corresponding author), Karolinska Univ Hosp, Dept Anesthesiol & Intens Care, S-17176 Stockholm, Sweden.	michael.nekludov@karolinska.se		Nekludov, Michael/0000-0001-9916-7086			BELL A, 1958, AM J MED TECHNOL, P264; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Esmon CT, 2005, BRIT J HAEMATOL, V131, P417, DOI 10.1111/j.1365-2141.2005.05753.x; Esmon CT, 1999, BEST PRACT RES CL HA, V12, P343, DOI 10.1053/beha.1999.0029; Gando S, 2002, THROMB HAEMOSTASIS, V88, P943; Grignani G, 2000, HAEMATOLOGICA, V85, P967; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MATTA BF, 2000, TXB NEUROANAESTHESIA; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; SIMS PJ, 1995, SEMIN CELL BIOL, V6, P275, DOI 10.1006/scel.1995.0037; Singer AJ, 2003, AM J EMERG MED, V21, P441, DOI 10.1016/S0735-6757(03)00100-1; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Ungerstedt JS, 2003, J NEUROSURG ANESTH, V15, P13, DOI 10.1097/00008506-200301000-00003	21	45	49	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					174	180		10.1089/neu.2006.0173			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100017	17263681				2021-06-18	
J	Cremer, OL; Moons, KGM; van Dijk, GW; van Balen, P; Kalkman, CJ				Cremer, Olaf L.; Moons, Karel G. M.; van Dijk, Gert W.; van Balen, Peter; Kalkman, Cor J.			Prognosis following severe head injury: Development and validation of a model for prediction of death, disability, and functional recovery	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						head injuries, closed; outcome prediction; ordinal logistic regression analysis; prognosis	TRAUMATIC BRAIN-INJURY; GLASGOW OUTCOME SCALE; STRUCTURED INTERVIEWS; CLINICAL-TRIALS; MORTALITY; MANAGEMENT; SURVIVAL; PATIENT; DETERMINANTS; GUIDELINES	Background: A prognostic model for head trauma patients is useful only if it predicts clinically relevant outcomes accurately on new subjects in various settings. Most existing models consider only dichotomous outcome and have not been tested externally. We developed and validated a rule for prediction of three functional outcome states after severe head injury, using information from day 1. Methods: The model was developed in a cohort of 304 adults who were admitted to a Dutch trauma center and had survived and remained comatose for > 24 hours following severe head injury. We used ordinal logistic regression analysis to predict the extended Glasgow Outcome Scale after 2:12 months, merged into three categories. We preselected five known predictors of outcome and used bootstrapping techniques to avoid statistical overfitting. The performance of the model was subsequently tested in a cohort of 122 patients from an unrelated hospital. Results: The model contained age (p < 0.0001), best motor response on day 1 (p = 0.002), pupil response after resuscitation (p = 0.005), computed tomography findings (p = 0.004), and presence of arterial hypotension (p = 0.37) as predictor variables. In the external validation cohort the model showed adequate agreement between observed and predicted outcome probabilities (calibration). The model had a good ability to discriminate patients with different outcomes (c-statistic 0.808). The predictive accuracy was 66% when the model was used to classify patients across the three outcome categories. Conclusions: We have developed a practical model for predicting the probability of death, survival with major disability, and functional recovery in patients who are comatose 24 hours after severe head injury. The model performed well in an external setting, indicating that measures to avoid statistical overfitting were successful.	Univ Utrecht, Med Ctr, Div Perioperat Care & Emergency Med, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Neurol, Utrecht, Netherlands	Cremer, OL (corresponding author), Acad Med Ctr C3, Dept Intens Care 423, POB 22660, NL-1100 DD Amsterdam, Netherlands.	o.l.cremer@amc.uva.nl	Kalkman, Cor/O-3215-2019; Cremer, Olaf L/G-3855-2016	Kalkman, Cor/0000-0002-8372-6960; Cremer, Olaf L/0000-0003-4264-1108			Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; GIBSON RM, 1989, LANCET, V2, P369; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; Harrell FE, 1998, STAT MED, V17, P909, DOI 10.1002/(SICI)1097-0258(19980430)17:8<909::AID-SIM753>3.0.CO;2-O; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Maas AIR, 2004, ACT NEUR S, V89, P113; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	39	45	47	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2006	61	6					1484	1491		10.1097/01.ta.0000195981.63776.ba			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	119CI	WOS:000242989400038	16983303				2021-06-18	
J	Uzan, M; Erman, H; Tanriverdi, T; Sanus, GZ; Kafadar, A; Uzun, H				Uzan, M.; Erman, H.; Tanriverdi, T.; Sanus, G. Z.; Kafadar, A.; Uzun, H.			Evaluation of apoptosis in cerebrospinal fluid of patients with severe head injury	ACTA NEUROCHIRURGICA			English	Article						apoptosis; bcl-2; caspase-3; sFas; programmed cell death	TRAUMATIC BRAIN-INJURY; PROGRAMMED CELL-DEATH; FAS LIGAND; DNA FRAGMENTATION; PRACTICAL SCALE; BCL-2; EXPRESSION; CASPASE-3; RATS; ACTIVATION	Objective. To determine whether sFas, caspase-3, proteins which propagate apoptosis, and bcl-2, a protein which inhibits apoptosis, would be increased in cerebrospinal fluid (CSF) in patients with severe traumatic brain injury (TBI) and to examine the correlation of sFas, caspase-3, and bcl-2 with each other and with clinical variables. Methods. sFas, caspase-3, and bcl-2 were measured in CSF of 14 patients with severe TBI on days 1, 2, 3, 5, 7, and 10 post-trauma. The results were compared with CSF samples from control patients who had no brain and spinal pathology and had undergone spinal anesthesia for some other reason. Soluble Fas and bcl-2 were measured by ELISA while caspase-3 was measured enzymatically. Results. No sFas, caspase-3, and bcl-2 activities were found in CSF of controls, but activities significantly increased in CSF of patients at all time points post-trauma (p < 0.01). Caspase-3 significantly correlated to intracranial pressure (p = 0.01) and cerebral perfusion pressure (p = 0.04). Soluble Fas and caspase-3 peaks coincided on day 5 post-trauma and there was significant association between sFas and caspase-3 increase (p = 0.01). Conclusion. This study indicates a prolonged activation of pro-apoptotic (sFas, caspase-3) and anti-apoptotic (bcl-2) proteins after severe TBI in humans. The degree of activation of particularly caspase-3 may be related to the severity of the injury. Parallel increases of these three molecules may indicate a pivotal role of apoptosis in the pathophysiology of post-traumatic brain oedema, secondary cell destruction and chronic cell loss following severe TBI and may open new targets for post-traumatic therapeutic interventions.	Istanbul Univ, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey; Istanbul Univ, Cerrahpasa Med Fac, Dept Biochem, Istanbul, Turkey	Uzan, M (corresponding author), POB 5, TR-34301 Istanbul, Turkey.	uzan@istanbul.edu.tr	Uzun, Hafize/D-4811-2019; Tanriverdi, Taner/C-9003-2019; Uzan, Mustafa/D-6571-2019; Kafadar, Ali/AAH-9387-2019; Sanus, Galip Zihni/D-6715-2019	Uzun, Hafize/0000-0002-1347-8498; Kafadar, Ali/0000-0002-3312-3192; Uzan, Mustafa/0000-0001-7214-380X			Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; JENNETT B, 1975, LANCET, V1, P480; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; Lazebnik YA, 1995, J CELL SCI, P41; LEZLINGER PM, 2002, J NEUROIMMUNOL, V122, P167; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Lu J, 2000, NEUROSCI LETT, V290, P89, DOI 10.1016/S0304-3940(00)01307-0; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Ng I, 2000, NEUROSURGERY, V46, P949, DOI 10.1097/00006123-200004000-00034; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	35	45	46	0	6	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2006	148	11					1157	1164		10.1007/s00701-006-0887-1			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	105EU	WOS:000242013600010	16964558				2021-06-18	
J	Tran, LD; Lifshitz, J; Witgen, BM; Schwarzbach, E; Cohen, AS; Grady, MS				Tran, Lorriann D.; Lifshitz, Jonathan; Witgen, Brent M.; Schwarzbach, Elizabeth; Cohen, Akiva S.; Grady, M. Sean			Response of the contralateral hippocampus to lateral fluid percussion brain injury	JOURNAL OF NEUROTRAUMA			English	Article						electrophysiology; fluoro-jade; mouse; stereology; traumatic brain injury	FLUORO-JADE-B; NEURONAL DEGENERATION; CELL LOSS; STEREOLOGICAL ESTIMATION; OPTICAL FRACTIONATOR; ARBITRARY PARTICLES; BEHAVIORAL DEFICITS; TOTAL NUMBER; HEAD-INJURY; RAT	Traumatic brain injury is a leading cause of death and disability in the United States. Pathological examinations of humans and animal models after brain injury demonstrate hippocampal neuronal damage, which may contribute to cognitive impairments. Data from our laboratories have shown that, at 1 week after brain injury, mice possess significantly fewer neurons in all ipsilateral hippocampal subregions and a cognitive impairment. Since cognitive function is distributed across both cerebral hemispheres, the present paper explores the morphological and physiological response of the contralateral hippocampus to lateral brain injury. We analyzed the contralateral hippocampus using design-based stereology, Fluoro-Jade (FJ) histochemistry, and extracellular field recordings in mice at 7 and 30 days after lateral fluid percussion injury (FPI). At 7 days, all contralateral hippocampal subregions possess significantly fewer healthy neurons compared to sham-injured animals and demonstrate FJ-positive neuronal damage, but not at 30 days. Both the ipsilateral and contralateral dentate gyri demonstrate significantly increased excitability at 7 days post-injury, but only ipsilateral dentate gyrus hyperexcitability persists at 30 days compared to sham. In the contralateral hippocampus, the transient decrease in the number of healthy neurons, concomitant with FJ damage, and electrophysiological alterations establish a stunned period of cellular and circuit dysfunction. The return of healthy neuron number, absence of FJ damage, and sham level of excitability in the contralateral hippocampus suggest recovery of structure and function by 30 days after injury. The cognitive recovery observed after human traumatic brain injury may stem from a differential injury exposure and time course of recovery between homologous regions of the two hemispheres.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Div Neurol, Philadelphia, PA 19104 USA	Grady, MS (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3 Silverstein Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	gradys@uphs.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD059288] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD049343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045975, R01NS050598] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD059288-06, R01 HD059288, F32 HD-049343] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS-050598, R01 NS-45975] Funding Source: Medline		Anderson KJ, 2003, J NEUROTRAUM, V20, P1223, DOI 10.1089/089771503770802899; ATKINS CM, 2006, IN PRESS J CEREB BLO; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Calhoun ME, 1998, NEUROBIOL AGING, V19, P599, DOI 10.1016/S0197-4580(98)00098-0; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cohen AS, 1996, J NEUROPHYSIOL, V76, P953; Colombo JA, 2002, J HISTOCHEM CYTOCHEM, V50, P1135, DOI 10.1177/002215540205000815; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hardman R, 1997, BRAIN RES, V758, P187, DOI 10.1016/S0006-8993(97)00223-0; Hartman RE, 2002, J NEUROSCI, V22, P10083; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; KERR DIB, 1994, EUR J PHARMACOL, V262, P189, DOI 10.1016/0014-2999(94)90046-9; Li HB, 1999, BRAIN RES BULL, V48, P113, DOI 10.1016/S0361-9230(98)00157-9; Lifshitz J, 2004, J NEUROTRAUM, V21, P1287; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Poe GR, 2000, BEHAV NEUROSCI, V114, P940, DOI 10.1037//0735-7044.114.5.940; Poirier JL, 2000, NEUROSCIENCE, V97, P59, DOI 10.1016/S0306-4522(00)00026-9; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Squire L R, 1991, Hippocampus, V1, P269, DOI 10.1002/hipo.450010313; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Toth Z, 1997, J NEUROSCI, V17, P8106; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; West MJ, 1999, TRENDS NEUROSCI, V22, P51, DOI 10.1016/S0166-2236(98)01362-9; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320	54	45	47	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2006	23	9					1330	1342		10.1089/neu.2006.23.1330			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	085LP	WOS:000240605900005	16958585				2021-06-18	
J	Sheedy, J; Geffen, G; Donnelly, J; Faux, S				Sheedy, Joanne; Geffen, Gina; Donnelly, James; Faux, Steven			Emergency department assessment of mild traumatic brain injury and prediction of post-concussion symptoms at one month post injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							RAPID SCREEN; HEAD-INJURY; SEVERITY; RECOVERY; MODERATE; STRESS	Mild traumatic brain injury (mTBI) is a common injury and a significant proportion of those affected report chronic symptoms. This study investigated prediction of post-concussion symptoms using an Emergency Department (ED) assessment that examined neuropsychological and balance deficits and pain severity of 29 concussed individuals. Thirty participants with minor orthopedic injuries and 30 ED visitors were recruited as control subjects. Concussed and orthopedically injured participants were followed up by telephone at one month to assess symptom severity. In the ED, concussed subjects performed worse on some neuropsychological tests and had impaired balance compared to controls. They also reported significantly more post-concussive symptoms at follow-up. Neurocognitive impairment, pain and balance deficits were all significantly correlated with severity of post-concussion symptoms. The findings suggest that a combination of variables assessable in the ED may be useful in predicting which individuals will suffer persistent post-concussion problems.	St Vincents Hosp, Darlinghurst, NSW 2010, Australia; Univ Queensland, Sch Psychol, Cognit Psychophysiol Lab, Brisbane, Qld, Australia; Univ New England, Sch Psychol, Armidale, NSW, Australia	Sheedy, J (corresponding author), St Vincents Hosp, Victoria St, Darlinghurst, NSW 2010, Australia.	jsheedy@stvincents.com.au	Faux, Steven/Y-3409-2019; Donnelly, James F/P-5932-2015	Faux, Steven/0000-0001-8846-216X; Donnelly, James F/0000-0002-2052-7948			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BIGLER ED, 2000, UNPUB LESIONS TRAUMA; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; De Monte VE, 2004, J CLIN EXP NEUROPSYC, V26, P628, DOI 10.1080/13803390490504443; DEMONTE V, IN PRESS J CLIN EXPT; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HINTONBAYRE AD, 1997, SPORT HLTH, V15, P4; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Malec JF, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P15; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; *NAT HLTH MED RES, 1992, IS THER SAF LEV DAIL; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RADANOV BP, 1991, LANCET, V338, P712, DOI 10.1016/0140-6736(91)91441-V; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; RUBIN AM, 1995, AM J OTOL, V16, P216; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Uzzell BP, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P1; Wasserberg J, 2002, BMJ-BRIT MED J, V325, P454, DOI 10.1136/bmj.325.7362.454; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wrisley DM, 2000, J ORTHOP SPORT PHYS, V30, P755, DOI 10.2519/jospt.2000.30.12.755	37	45	45	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	2006	28	5					755	772		10.1080/13803390591000864			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	046AS	WOS:000237784400011	16723323				2021-06-18	
J	Armin, SS; Colohan, ART; Zhang, JH				Armin, Sean S.; Colohan, Austin R. T.; Zhang, John H.			Traumatic subarachnoid hemorrhage: our current understanding and its evolution over the past half century	NEUROLOGICAL RESEARCH			English	Article						traumatic subarachnoid hemorrhage; vasospasm; secondary injury	SEVERE HEAD-INJURY; TRANSCRANIAL DOPPLER ULTRASOUND; CEREBRAL ARTERIAL SPASM; ISCHEMIC BRAIN-DAMAGE; COMPUTERIZED-TOMOGRAPHY; FLOW VELOCITIES; INTRAVENOUS NIMODIPINE; PROGNOSTIC VALUE; DOUBLE-BLIND; BLOOD-FLOW	Traumatic brain injury (TBI) is a common cause of morbidity and mortality in the US, especially among the young. Primary injury in TBI is preventable, whereas secondary injury is treatable. As a result, considerable research efforts have been focused on elucidating the pathophysiology of secondary injury and determining various prognosticators in the hopes of improving final outcome by minimizing secondary injury. One such variable, traumatic subarachnoid hemorrhage (tSAH), has been the focus of many discussions over the past half century as numerous clinical studies have shown tSAH to be associated with adverse outcome. Whether the relationship of tSAH with poorer outcome in TBI is merely an epiphenomenon or a result of direct cause and effect is unclear. Some investigators believe that tSAH is merely a marker of severer TBI, while others argue that it directly causes deleterious effects such as vasospasm and ischemia. At the present time, no proven treatment regimen aimed specifically at decreasing the detrimental effects of tSAH exists, although calcium channel blockers traditionally thought to target vasospasm have shown some promises. Given that tSAH may primarily be an early indicator of associated and evolving brain injury, vigilant diagnostic surveillance including serial head CT and prevention of secondary brain damage owing to hypotension, hypoxia and intracranial hypertension may be more cost-effective than attempting to treat potential adverse sequelae associated with tSAH.	Loma Linda Univ, Med Ctr, Div Neurosurg, Loma Linda, CA 92354 USA	Colohan, ART (corresponding author), 11234 Anderson St, Loma Linda, CA 92354 USA.	acolohan@ahs.llumc.edu					Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; AUER LM, 1981, DRUG RES, V31, P1423; Barker FG, 1996, J NEUROSURG, V84, P405, DOI 10.3171/jns.1996.84.3.0405; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BROWN ST, 1990, ANNU REV PUBL HEALTH, V11, P251; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; Chen Guangxin, 2002, Chin J Traumatol, V5, P169; CHESTNUT RM, 1993, P 8 INT S INTR PRESS, P503; Chhabra R, 2001, NEUROL INDIA, V49, P138; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Collier BR, 2004, J NEUROSURG ANESTH, V16, P196, DOI 10.1097/00008506-200407000-00003; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; COOPER PR, 1982, HEAD INJURY, P321; COURVILLE CB, 1950, PATHOLOGY CENTRAL NE, P112; DALE J, 1983, AM HEART J, V105, P103, DOI 10.1016/0002-8703(83)90285-5; DEMIRCIVI F, 1993, ACTA NEUROCHIR, V122, P45, DOI 10.1007/BF01446985; DOWLING G, 1988, AM J FOREN MED PATH, V9, P23, DOI 10.1097/00000433-198803000-00007; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FORD R, 1956, J FORENSIC SCI, V1, P117; FREYTAG E, 1963, ARCH PATHOL, V75, P402; Fukuda T, 1998, NEUROSURGERY, V43, P1040, DOI 10.1097/00006123-199811000-00022; GAETANI P, 1995, J NEUROL NEUROSUR PS, V59, P635, DOI 10.1136/jnnp.59.6.635; GENTLEMAN D, 1990, INJURY, V21, P305, DOI 10.1016/0020-1383(90)90047-X; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Grcevic N, 1983, Acta Neurochir Suppl (Wien), V32, P79; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Greene KA, 1996, J TRAUMA, V41, P964, DOI 10.1097/00005373-199612000-00004; Grunsfeld Alexander, 2005, Curr Neurol Neurosci Rep, V5, P488, DOI 10.1007/s11910-005-0039-7; Hanlon RE, 2005, BRAIN INJURY, V19, P257, DOI 10.1080/02699050400004955; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; JAN M, 1988, NEUROSURGERY, V23, P154, DOI 10.1227/00006123-198808000-00004; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; KAKARIEKA A, 1994, J NEURAL TRANSM-SUPP, P13; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KAOUTZANIS M, 1993, J NEUROSCI METH, V50, P301, DOI 10.1016/0165-0270(93)90037-R; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Langham J., 2003, COCHRANE DB SYST REV, V4, DOI [10.1002/14651858.CD000565, DOI 10.1002/14651858.CD000565]; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LEEDS NE, 1966, ACTA RADIOL DIAGN, V5, P320, DOI 10.1177/02841851660050P135; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Megyesi JF, 2000, NEUROSURGERY, V46, P448, DOI 10.1097/00006123-200002000-00035; Miller J D, 1979, Acta Neurochir Suppl (Wien), V28, P86; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Morris GF, 1997, ACTA NEUROCHIR S, V71, P382; NEIL-DWYER G, 1987, European Heart Journal, V8, P41; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; OHMAN J, 1988, J NEUROSURG, V69, P683, DOI 10.3171/jns.1988.69.5.0683; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Patel HC, 1999, HOSP MED, V60, P497, DOI 10.12968/hosp.1999.60.7.1155; PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505; PHILIPPON J, 1986, ACTA NEUROCHIR, V82, P110, DOI 10.1007/BF01456369; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Radhakrishnan D, 1997, ANAESTHESIA, V52, P489, DOI 10.1111/j.1365-2044.1997.112-az0105.x; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROBINSON MJ, 1990, CEREBROVAS BRAIN MET, V2, P205; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; Sahuquillo J, 2000, REV NEUROLOGIA, V30, P401, DOI 10.33588/rn.3005.99063; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; Schmieder K, 1996, ACTA NEUROL SCAND, V93, P123, DOI 10.1111/j.1600-0404.1996.tb00573.x; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SHIGEMORI M, 1990, Neurologia Medico-Chirurgica, V30, P396, DOI 10.2176/nmc.30.396; SIMONSEN J, 1963, J Forensic Sci, V8, P97; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Suarez JI, 2002, CRIT CARE MED, V30, P1348, DOI 10.1097/00003246-200206000-00035; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1967, J NEUROL NEUROSUR PS, V30, P497, DOI 10.1136/jnnp.30.6.497; TAKIZAWA T, 1984, Neurologia Medico-Chirurgica, V24, P390, DOI 10.2176/nmc.24.390; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; TEASDALE G, 1974, LANCET, V2, P81; Thomas S, 1998, ACT NEUR S, V71, P135; Thomas S, 2000, ACTA NEUROCHIR SUPPL, V76, P203; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WADWORTH AN, 1992, DRUG AGING, V2, P262, DOI 10.2165/00002512-199202040-00002; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	94	45	55	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2006	28	4					445	452		10.1179/016164106X115053			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	058HR	WOS:000238656600009	16759448				2021-06-18	
J	Sojka, P; Stalnacke, BM; Bjornstig, U; Karlsson, K				Sojka, Peter; Stalnacke, Britt-Marie; Bjornstig, Ulf; Karlsson, Kurt			One-year follow-up of patients with mild traumatic brain injury: Occurrence of post-traumatic stress-related symptoms at follow-up and serum levels of cortisol, S-100B and neuron-specific enolase in acute phase	BRAIN INJURY			English	Article						traumatic brain injury; head trauma; brain concussion; post-concussion symptoms biochemical marker; S100 proteins; cortisol; post-traumatic stress disorder	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; PLASMA-CORTISOL; EVENT SCALE; DISORDER; PROTEIN; CATECHOLAMINES; INTOXICATION; SEVERITY	Objective: To investigate serum levels of cortisol ( a biochemical marker of stress), S-100B and neuron-specific enolase ( two biochemical markers of brain tissue injury), in acute phase in mild traumatic brain injury patients and the occurrence of post-traumatic stress-related symptoms 1 year after the trauma. Methods: Blood samples were taken in patients (n = 88) on admission and similar to 7 hours later for analysis. Occurrence of post-traumatic stress-related symptoms was assessed for 69 patients using items from the Impact of Event Scale questionnaire (IES) at follow-up at 15 +/- 4 months after the injury. Results: Serum levels of cortisol were more increased in the first sample (cortisol/1, 628.9 +/- 308.9 nmol L-1) than in the second blood sample (cortisol/2, 398.2 +/- 219.4 nmol L-1). The difference between these samples was statistically significant (p < 0.001). Altogether 12 patients (17%) showed post-traumatic stress related symptoms at the time of the follow-up. Stepwise forward logistic regression analysis of symptoms and serum concentrations of markers revealed that only S-100B in the second sample was statistically significantly (p < 0.05) associated to symptoms ( three symptoms of the avoidance sub-set of IES). Conclusion: A major increase in serum concentrations of cortisol indicates that high stress levels were reached by the patients, in particular shortly (similar to 3 hours) after the trauma. The association between the occurrence of post-traumatic stress related symptoms and serum levels of S-100B (generally considered as a biochemical marker of brain injury) seem to reflect the complexity of interactions between brain tissue injury and the ensemble of stress reactions.	Umea Univ Hosp, Dept Community Med & Rehabil, S-90185 Umea, Sweden; Umea Univ Hosp, Dept Surg & Peri Operat Sci, S-90185 Umea, Sweden; Umea Univ Hosp, Dept Med Biosci, S-90185 Umea, Sweden	Sojka, P (corresponding author), Umea Univ Hosp, Dept Community Med & Rehabil, Bldg 9A, S-90185 Umea, Sweden.	peter.sojka@clinphys.umu.se					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BAUM A, 1995, MEASURING STRESS GUI, P175; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Cernak I, 1999, BRAIN INJURY, V13, P1005; Deb S, 1999, AM J PSYCHIAT, V156, P374; Delahanty DL, 2000, BIOL PSYCHIAT, V48, P940, DOI 10.1016/S0006-3223(00)00896-9; Frias J, 2000, LIFE SCI, V67, P1081, DOI 10.1016/S0024-3205(00)00702-5; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; KATO K, 1983, J BIOCHEM-TOKYO, V94, P1009, DOI 10.1093/oxfordjournals.jbchem.a134397; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McFarlane AC, 1997, ANN NY ACAD SCI, V821, P437, DOI 10.1111/j.1749-6632.1997.tb48299.x; MIDDELBOE T, 1991, Acta Neurologica Scandinavica, V85, P5; Morgan CA, 2000, BIOL PSYCHIAT, V47, P891, DOI 10.1016/S0006-3223(99)00307-8; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; SUZUKI F, 1983, J BIOCHEM-TOKYO, V94, P1707; SUZUKI F, 1984, J NEUROCHEM, V42, P130, DOI 10.1111/j.1471-4159.1984.tb09708.x; SUZUKI F, 1986, BIOCHIM BIOPHYS ACTA, V889, P84, DOI 10.1016/0167-4889(86)90011-X; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; VanCauter E, 1996, J CLIN ENDOCR METAB, V81, P2468, DOI 10.1210/jc.81.7.2468; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Yehuda R, 1998, BIOL PSYCHIAT, V44, P1305, DOI 10.1016/S0006-3223(98)00276-5; Yehuda R, 1997, NATO ADV SCI I A-LIF, V291, P221	37	45	46	0	11	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	6					613	620		10.1080/02699050600676982			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	062LU	WOS:000238947100006	16754286				2021-06-18	
J	Nelson, TJ; Wall, DB; Stedje-Larsen, ET; Clark, RT; Chambers, LW; Bohman, HR				Nelson, TJ; Wall, DB; Stedje-Larsen, ET; Clark, RT; Chambers, LW; Bohman, HR			Predictors of mortality in close proximity blast injuries during operation Iraqi freedom	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							SUICIDE BOMBING ATTACKS; SYSTEM	BACKGROUND: Blast injury is an increasingly common problem faced by military surgeons in the field. Because of urban terrorism worldwide, blast injury is becoming more common in the civilian sector as well. Blast injuries are often devastating and can overwhelm medical resources. We sought to determine whether simple factors easily obtained from the clinical history and primary survey could be used to triage patients more effectively. STUDY DESIGN: A retrospective review of 18 consecutive close-proximity blast injury patients presenting to a forward deployed surgical unit in Iraq was performed. Patients' injuries and outcomes were recorded. We compared the presence of sustained hypotension, penetrating head injury, multiple (three or more) long-bone fractures, and associated fatalities (whether another patient involved in the same explosion died) between nonsurvivors and survivors using Fisher's exact test. RESULTS: All patients who presented alive but exhibited sustained hypotension (n = 5) died, versus 0% who did not exhibit sustained hypotension (n = 9, p < 0.01). There was no marked increase in mortality with presence of multiple long-bone fractures, penetrating head injury, or associated fatalities individually. Having two or more of these factors was associated with a mortality of 86% (6 of 7) versus 20% (2 of 10, p = 0.015) in those who had less than two factors. CONCLUSIONS: Blast injury can overwhelm military and civilian trauma systems alike. Sustained hypotension and presence of two or more easily determined factors, including three or more long-bone fractures, penetrating head injury, and associated fatalities, are associated with increased mortality and can potentially help triage patients and allocate scarce resources more efficiently.	USN, Hosp Camp Pendleton, Dept Surg, Camp Pendleton, CA 92055 USA; USN, San Diego Med Ctr, San Diego, CA 92152 USA; 1st Battal, 7th Marines, Twenty Nine Palms, CA USA; 1st Force Serv Support Grp, 1st Med Battal, Camp Pendleton, CA USA	Nelson, TJ (corresponding author), USN, Hosp Camp Pendleton, Dept Surg, Marine Corps Base, Camp Pendleton, CA 92055 USA.	tom.nelson2120@sbcglobal.net					Almogy G, 2005, ARCH SURG-CHICAGO, V140, P390, DOI 10.1001/archsurg.140.4.390; Almogy G, 2004, ANN SURG, V239, P295, DOI 10.1097/01.sla.0000114014.63423.55; Bellamy RF, 1995, ANESTHESIA PERIOPERA, P1; Bohman HR, 2005, MIL MED, V170, P297, DOI 10.7205/MILMED.170.4.297; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chambers LW, 2005, ARCH SURG-CHICAGO, V140, P26, DOI 10.1001/archsurg.140.1.26; CHAMBERS LW, 2005, AM ASS SURG TRAUM SE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Gutierrez de Ceballos J Peral, 2005, Crit Care Med, V33, pS107; Kluger Y, 2004, J AM COLL SURGEONS, V199, P875, DOI 10.1016/j.jamcollsurg.2004.09.003; Mallonee S, 1996, JAMA-J AM MED ASSOC, V276, P382, DOI 10.1001/jama.276.5.382; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Rodoplu Ulkumen, 2004, Prehosp Disaster Med, V19, P133; Ryan J, 2005, NEW ENGL J MED, V353, P543, DOI 10.1056/NEJMp058177; Singer Pierre, 2005, Crit Care Med, V33, pS61, DOI 10.1097/01.CCM.0000151068.33935.3E; 2004, NATO EMERGENCY WAR S	16	45	46	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	MAR	2006	202	3					418	422		10.1016/j.jamcollsurg.2005.11.011			5	Surgery	Surgery	024YZ	WOS:000236233800006	16500245				2021-06-18	
J	Gaulke, LJ; Horner, PJ; Fink, AJ; McNamara, CL; Hicks, RR				Gaulke, LJ; Horner, PJ; Fink, AJ; McNamara, CL; Hicks, RR			Environmental enrichment increases progenitor cell survival in the dentate gyrus following lateral fluid percussion injury	MOLECULAR BRAIN RESEARCH			English	Article						astrogenesis; bromodeoxyuridine; neurogenesis; hippocampus; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ADULT HIPPOCAMPAL NEUROGENESIS; STATUS EPILEPTICUS; NEURONAL DEGENERATION; COGNITIVE DEFICITS; PHYSICAL-EXERCISE; GRANULE CELLS; FLUORO-JADE; HEAD-INJURY; RAT	Neurons in the hilus of the dentate gyrus are lost following a lateral fluid percussion injury. Environmental enrichment is known to increase neurogenesis in the dentate in intact rats, suggesting that it might also do so following fluid percussion injury, and potentially provide replacements for lost neurons. We report that I h of daily environmental enrichment for 3 weeks increased the number of progenitor cells in the dentate following fluid percussion injury, but only on the ipsilesional side. In the dentate granule cell layer, but not the hilus, most progenitors had a neuronal phenotype. The rate of on going cell proliferation was similar across groups. Collectively, these results suggest that the beneficial effects of environmental enrichment on behavioral recovery following FP injury are not attributable to neuronal replacement in the hilus but may be related to increased neurogenesis in the granule cell layer. (c) 2005 Elsevier B.V. All rights reserved.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA	Hicks, RR (corresponding author), Univ Washington, Dept Rehabil Med, 1959 NE Pacific St, Seattle, WA 98195 USA.	rhicks@u.washington.edu	Horner, Philip J./AAF-7012-2021		NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD002274] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS046792-01A1, R01 NS046792] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046792] Funding Source: NIH RePORTER		Ambrogini P, 2000, NEUROSCI LETT, V286, P21, DOI 10.1016/S0304-3940(00)01074-0; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Baldwin SA, 1996, GLIA, V16, P266; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Briones Teresita L, 2005, Biol Res Nurs, V6, P167, DOI 10.1177/1099800404271328; Brown J, 2003, EUR J NEUROSCI, V17, P2042, DOI 10.1046/j.1460-9568.2003.02647.x; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cheng YH, 2002, EUR J NEUROSCI, V15, P3, DOI 10.1046/j.0953-816x.2001.01832.x; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Diamond MC, 2001, AN ACAD BRAS CIENC, V73, P211, DOI 10.1590/S0001-37652001000200006; Dobkin BH, 2000, CURR OPIN NEUROL, V13, P655, DOI 10.1097/00019052-200012000-00007; Doetsch F, 2001, BRAIN BEHAV EVOLUT, V58, P306, DOI 10.1159/000057572; Ehninger D, 2003, CEREB CORTEX, V13, P845, DOI 10.1093/cercor/13.8.845; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; GomezPinilla F, 1997, BRAIN RES, V764, P1, DOI 10.1016/S0006-8993(97)00375-2; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GREENFIELD JG, 2002, GREENFIELDS NEUROPAT; Gustafsson E, 2003, STROKE, V34, P2710, DOI 10.1161/01.STR.0000096025.35225.36; Hachem S, 2005, GLIA, V51, P81, DOI 10.1002/glia.20184; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hastings NB, 2003, NAT MED, V9, P264, DOI 10.1038/nm0303-264; Hastings NB, 1999, J COMP NEUROL, V413, P146, DOI 10.1002/(SICI)1096-9861(19991011)413:1<146::AID-CNE10>3.0.CO;2-B; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Hicks RR, 1998, RESTOR NEUROL NEUROS, V12, P41; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kee N, 2002, J NEUROSCI METH, V115, P97, DOI 10.1016/S0165-0270(02)00007-9; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kuan CY, 2004, J NEUROSCI, V24, P10763, DOI 10.1523/JNEUROSCI.3883-04.2004; Kuhn HG, 2001, EUR ARCH PSY CLIN N, V251, P152, DOI 10.1007/s004060170035; Liu JL, 1998, J NEUROSCI, V18, P7768; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Markakis EA, 1999, J COMP NEUROL, V406, P449; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mohapel P, 2004, NEUROBIOL DIS, V15, P196, DOI 10.1016/j.nbd.2003.11.010; MOUTON PR, 2002, PRINCIPLES PRACTICES; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 1999, J NEUROSCI, V19, P4508; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Payne BR, 2001, NAT REV NEUROSCI, V2, P911, DOI 10.1038/35104085; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; Rosenthal M, 1987, REHABIL PSYCHOL, P37; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Steiner B, 2004, GLIA, V46, P41, DOI 10.1002/glia.10337; SUN L, 1995, SCAND J STAT, V22, P105; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wang S, 2005, EXP BRAIN RES, V165, P250, DOI 10.1007/s00221-005-2296-8; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; York GK, 1995, NEUROLOGY, V45, P2297, DOI 10.1212/WNL.45.12.2297; Young D, 1999, NAT MED, V5, P448	81	45	46	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	NOV 30	2005	141	2					138	150		10.1016/j.molbrainres.2005.08.011			13	Neurosciences	Neurosciences & Neurology	990ZV	WOS:000233782800003	16171896	Green Accepted			2021-06-18	
J	Duncan, CC; Kosmidis, MH; Mirsky, AF				Duncan, CC; Kosmidis, MH; Mirsky, AF			Closed head injury-related information processing deficits: An event-related potential analysis	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article; Proceedings Paper	12th World Congress of Psychophysiology of the International-Organization-of-Psychophysiology	SEP 18-23, 2004	Thessaloniki, GREECE	Int Org Psychophysiol		closed head injury; event-related brain potentials; ERP; P300; N200; N100; information processing; attention; reaction tinie; CPT	TRAUMATIC BRAIN-INJURY; AUDITORY-EVOKED-POTENTIALS; DIFFUSE AXONAL INJURY; RETROGRADE-AMNESIA; ODDBALL TASK; ELECTROPHYSIOLOGICAL EVIDENCE; POSTTRAUMATIC AMNESIA; MISMATCH NEGATIVITY; CEREBRAL CONCUSSION; NOVELTY DETECTION	Event-related potentials (ERPs) can elucidate aspects of sensory and cognitive processing that have been compromised due to closed head injury. We present the results of two investigations, one previously unreported, in which we used ERPs to evaluate information processing in head-injury survivors. In the first study, We used visual and auditory reaction time tasks differing in attentional demands to assess processing after head trauma. We found numerous changes in auditory processing in survivors: longer reaction times (but normal accuracy), longer N200 and P300 latencies, and reduced N100 and N200 amplitudes. In contrast, on visual tasks, only reduced N200 amplitude distinguished survivors and controls. To increase attentional demands, in a second study, we administered the continuous performance test (CPT). Survivors performed with lower accuracy than controls on Visual and auditory tasks, and their ERPs were characterized by smaller Visual and auditory N200s and P300s and smaller auditory N100s. We also present a synthesis, derived from a review of the literature, of closed head-injury effects on ERPs. Our own findings are in agreement with that synthesis. Namely, cognitive ERP components are more sensitive than sensory components to the effects of trauma. Specifically, in survivors, the amplitudes of N200 and P300 are often reduced, and their latencies prolonged. In general, as compared with visual ERPs, auditory ERPs may be more Susceptible to the effects of closed head injury, suggesting that the auditory processing system is more Vulnerable than the visual system. We conclude by discussing the potential use Of ERPs to monitor clinical course and recovery in survivors of closed head injury. (c) 2005 Elsevier B.V. All rights reserved.	NIMH, SCEN, NIH, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Psychiat, Clin Psychophysiol & Psychopharmacol, Bethesda, MD 20814 USA; Aristotle Univ Thessaloniki, Dept Psychol, GR-54006 Thessaloniki, Greece	Duncan, CC (corresponding author), NIMH, SCEN, NIH, 5415 W Cedar Lane,Suite 203-B,MSC 2615, Bethesda, MD 20892 USA.	connieduncan@mail.nih.gov	Kosmidis, Mary H/AAN-2104-2021	Kosmidis, Mary/0000-0001-8790-1220	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [Z01MH000509] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA Funding Source: Medline		Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; CAMPBELL K, 1986, CEREBRAL PSYCHOPHYSI, V38, P486; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; CAMPBELL KB, 1990, NEW TRENDS ADV TEC S, V41, P202; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; COLES MGH, 1995, OX PSYCH S, P1; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; CURRY SH, 1996, FUNCTIONAL NEUROSC S, V46, P283; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; DEACON D, 1991, CLIN NEUROPHYSIOL, V78, P131; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Duncan CC, 2003, PSYCHOPHYSIOLOGY, V40, P45, DOI 10.1111/1469-8986.00006; DUNCAN CC, 2003, ANN M SOC PSYCH RES; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; DUNCANJOHNSON CC, 1977, PSYCHOPHYSIOLOGY, V14, P456, DOI 10.1111/j.1469-8986.1977.tb01312.x; DUNCANJOHNSON CC, 1981, SCIENCE, V214, P938, DOI 10.1126/science.7302571; DUNCANJOHNSON CC, 1982, BIOL PSYCHOL, V14, P1, DOI 10.1016/0301-0511(82)90016-3; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellwanger J, 1997, CLIN NEUROPSYCHOL, V11, P428, DOI 10.1080/13854049708400473; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gron G, 1996, J CLIN EXP NEUROPSYC, V18, P406, DOI 10.1080/01688639608408997; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; GROSSI D, 1988, CORTEX, V24, P457, DOI 10.1016/S0010-9452(88)80009-1; Gurdjian ES, 1958, HEAD INJURIES MECH D; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holbourn AHS, 1943, LANCET, V2, P438; ICHISE M, 1994, J NUCL MED, V35, P217; ISREAL JB, 1980, PSYCHOPHYSIOLOGY, V17, P259, DOI 10.1111/j.1469-8986.1980.tb00146.x; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kane NM, 2000, AUDIOL NEURO-OTOL, V5, P186, DOI 10.1159/000013879; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Keren O, 1998, J HEAD TRAUMA REHAB, V13, P15; KETY SS, 1962, FRONTIERS BRAIN RES, P97; Knight RT, 1998, J CLIN NEUROPHYSIOL, V15, P3, DOI 10.1097/00004691-199801000-00003; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; LAIACONA M, 1993, CORTEX, V29, P727, DOI 10.1016/S0010-9452(13)80293-6; Landau WM, 1955, T AM NEUROL ASSOC, V80, P125; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEETSMA JE, 1988, FORENSIC NEUROPATHOL; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mazzini L, 2001, ARCH PHYS MED REHAB, V82, P57, DOI 10.1053/apmr.2001.18076; Mazzini Letizia, 2004, Phys Med Rehabil Clin N Am, V15, P163, DOI 10.1016/S1047-9651(03)00101-3; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MIRSKY AF, 1979, DEV PSYCHOBIOL, V12, P369, DOI 10.1002/dev.420120411; Muller SV, 2002, ARCH PHYS MED REHAB, V83, P115, DOI 10.1053/apmr.2002.27472; MYERS RE, 1972, AM J OBSTET GYNECOL, V112, P246, DOI 10.1016/0002-9378(72)90124-X; Naatanen R, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P169; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; Naatanen R, 2004, COGNITIVE NEUROSCIEN, P194; Naatanen R., 1992, ATTENTION BRAIN FUNC; Nauta W. J. H., 1986, FUNDAMENTAL NEUROANA; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Nieuwenhuis S, 2005, PSYCHOL BULL, V131, P510, DOI 10.1037/0033-2909.131.4.510; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ONOFRJ M, 1991, ACTA NEUROL SCAND, V83, P273, DOI 10.1111/j.1600-0404.1991.tb04700.x; Packard RC, 1996, HEADACHE Q-CURR TREA, V7, P218; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PAPO I, 1982, ACTA NEUROCHIR, V62, P47, DOI 10.1007/BF01402210; Picton TW, 2000, PSYCHOPHYSIOLOGY, V37, P127, DOI 10.1017/S0048577200000305; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Polo MD, 2002, NEUROPSYCHOLOGIA, V40, P2350, DOI 10.1016/S0028-3932(02)00127-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1987, NEUROBEHAVIORAL RECO, P390; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Potter DD, 1999, J PSYCHOPHYSIOL, V13, P173, DOI 10.1027//0269-8803.13.3.173; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Regan D., 1989, HUMAN BRAIN ELECTROP; Reinvang I, 1999, NEUROPSYCHOL REV, V9, P231, DOI 10.1023/A:1021638723486; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; RIZZO M, 1996, HEAD INJURY POSTCONC; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; Solbakk AK, 2002, CLIN ELECTROENCEPHAL, V33, P102, DOI 10.1177/155005940203300306; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spikman JM, 2004, J INT NEUROPSYCH SOC, V10, P851, DOI 10.1017/S1355617704106061; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spitzer R.L., 1975, SCHEDULE AFFECTIVE D; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; STRICH SJ, 1961, LANCET, V2, P443; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Suresh S, 2003, ALCOHOL CLIN EXP RES, V27, P1064, DOI 10.1097/01.ALC.0000075549.49800.A0; Symonds CP, 1943, LANCET, V1, P7; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Torner James C., 1996, P19; Umile EM, 1998, BRAIN INJURY, V12, P577; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VANZOMEREN AH, 1981, THESIS STATE U GRONI; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; WANG CC, 1986, ARCH NEUROL-CHICAGO, V43, P570, DOI 10.1001/archneur.1986.00520060034013; Watt S, 1999, NEUROPSYCHOLOGY, V13, P338, DOI 10.1037/0894-4105.13.3.338; WERNER RA, 1991, ARCH PHYS MED REHAB, V72, P31; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207	150	45	48	0	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	NOV-DEC	2005	58	2-3					133	157		10.1016/j.ijpsycho.2005.05.011			25	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	985MW	WOS:000233383000006	16203052				2021-06-18	
J	Brown, TH; Mount, J; Rouland, BL; Kautz, KA; Barnes, RM; Kim, J				Brown, TH; Mount, J; Rouland, BL; Kautz, KA; Barnes, RM; Kim, J			Body weight-supported treadmill training versus conventional gait training for people with chronic traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						body weight support; gait training; head injury; physical therapy; rehabilitation; traumatic brain injury; treadmill	LOCOMOTION; RELIABILITY; RECOVERY	Objectives: To compare body weight support treadmill training (BWSTT) to conventional over-ground gait training (COGT). Design: Randomized controlled trial. Setting: Residential rehabilitation center. Participants: Twenty subjects with chronic traumatic brain injury (TBI). Intervention: The BWSTT or COGT for 15 minutes plus 30 minutes of exercise 2 days per week, for 3 months. Main Outcome Measures: Functional Ambulation Category (FAC), Functional Reach (FR), Timed Up and Go; gait velocity, step width (BOS) and step length differential using instrumented gait mat. Results: Step width approached the norm Without between-group differences. Step length differential improved significantly more for the COGT Conclusions: Physical therapy can improve gait for patients more than 6 years post-TBL. The COGT is more effective than the BWSTT for improving gait symmetry during overground walking.	Beechwood Rehabil Serv, Dept Phys Therapy, Langhorne, PA 19047 USA; Thomas Jefferson Univ, Coll Hlth Profess, Dept Phys Therapy, Philadelphia, PA 19107 USA	Brown, TH (corresponding author), Beechwood Rehabil Serv, Dept Phys Therapy, Langhorne, PA 19047 USA.						BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; DUNCAN PW, 1990, J GERONTOL, V45, pM192, DOI 10.1093/geronj/45.6.M192; Gardner MB, 1998, PHYS THER, V78, P361, DOI 10.1093/ptj/78.4.361; Grillner S, 1979, Prog Brain Res, V50, P227; Hassid E, 1997, J NEUROL REHABIL, V11, P21; HEITMANN DK, 1989, PHYS THER, V69, P923, DOI 10.1093/ptj/69.11.923; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; HESSE S, 1994, ARCH PHYS MED REHAB, V75, P1087, DOI 10.1016/0003-9993(94)90083-3; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P339, DOI 10.1016/0003-9993(92)90007-J; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; McDonough AL, 2001, ARCH PHYS MED REHAB, V82, P419, DOI 10.1053/apmr.2001.19778; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Miller EW, 2002, PHYS THER, V82, P53, DOI 10.1093/ptj/82.1.53; Miyai I, 2000, ARCH PHYS MED REHAB, V81, P849, DOI 10.1053/apmr.2000.4439; Moseley A. M., 2003, COCHRANE DB SYST REV; Murray M P, 1970, Arch Phys Med Rehabil, V51, P637; MURRAY MP, 1964, J BONE JOINT SURG AM, V46, P335, DOI 10.2106/00004623-196446020-00009; Nymark J, 1998, J NEUROL REHABIL, V12, P119; Ochi F, 1999, J HEAD TRAUMA REHAB, V14, P105, DOI 10.1097/00001199-199904000-00002; OSULLIVAN S, 1994, PHYS REHABILITATION, P454; Perry J, 1992, GAIT ANAL NORMAL PAT, P432; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; ROVNER BW, 1987, HOSP PRACT, V22, P99; Schindl MR, 2000, ARCH PHYS MED REHAB, V81, P301, DOI 10.1053/apmr.2000.0810301; Seif-Naraghi AH, 1999, J HEAD TRAUMA REHAB, V14, P146, DOI 10.1097/00001199-199904000-00005; SHUMWAYCOOK A, 1995, MOTOR CONTROL THEORY, P198; Stolze H, 2002, J NEUROL NEUROSUR PS, V73, P310, DOI 10.1136/jnnp.73.3.310; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; VISINTIN M, 1994, PARAPLEGIA, V32, P540, DOI 10.1038/sc.1994.86; VISINTIN M, 1989, CAN J NEUROL SCI, V16, P315, DOI 10.1017/S0317167100029152; WERNIG A, 1995, EUR J NEUROSCI, V7, P823, DOI 10.1111/j.1460-9568.1995.tb00686.x; Wilson DJ, 2002, BRAIN INJURY, V16, P259, DOI 10.1080/02699050110103922	36	45	47	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2005	20	5					402	415		10.1097/00001199-200509000-00002			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	965NO	WOS:000231957600003	16170249				2021-06-18	
J	Soustiel, JF; Glenn, TC; Shik, V; Boscardin, J; Mahamid, E; Zaaroor, M				Soustiel, JF; Glenn, TC; Shik, V; Boscardin, J; Mahamid, E; Zaaroor, M			Monitoring of cerebral blood flow and metabolism in traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; glucose; lactate; oxidative metabolism; traumatic brain injury	INTERNAL CAROTID-ARTERY; ACUTE HEAD-INJURY; GLUCOSE-UTILIZATION; VERTEBRAL ARTERIES; HEALTHY-ADULTS; VOLUME; LACTATE; DYSFUNCTION; ASTROCYTES; SONOGRAPHY	The aim of the present study was to investigate the course of cerebral blood flow (CBF) and metabolism in traumatic brain injury (TBI) patients and to specifically characterize the changes in lactate and glucose indices in the acute post-traumatic period with regard to neurological condition and functional outcome. For this purpose, 55 consecutive TBI patients (mean age 37 +/- 17 years, mean GCS 6.8 +/- 3.2) were prospectively and daily evaluated. Global CBF, cerebral metabolic rates of oxygen (CMRO2), glucose (CMRGlc), and lactate (CMRLct) were calculated using arterial jugular differences. In all patients, CBF was moderately decreased during the first 24 h in comparison with normal subjects although this relative oligemia was more pronounced in patients with poor outcome (p = 0.0007). Both CMRO2 and CMRGlc were significantly depressed and correlated to outcome (p < 0.0001, p = 0.0088). CMRLct analysis revealed positive values (lactate uptake) during the first 48 h, especially in patients with favorable outcome. Both CMRO2 and CMRLct correlated with GCS (p = 0.0001, p = 0.0205). CMRLct levels showed an opposite correlation with CBF in patients with favorable and poor outcome. In the former group, correlation analysis exhibited a negative slope with evidence for increasing lactate uptake associated with lower CBF values (r = -0.1940, p = 0.0242). On the contrary, in patients with adverse outcome, CMRLct values demonstrated a weak though opposite correlation with CBF (r = 0.0942,p = 0.2733). The present data emphasize the clinical significance of monitoring of cerebral blood flow and metabolism in TBI and provide evidence for metabolic coupling between astrocytes and neurons.	Technion Israel Inst Technol, Rambam Med Ctr, Dept Neurosurg, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Acute Brain Injury Res Lab, IL-31096 Haifa, Israel; Univ Calif Los Angeles, Cerebral Blood Flow Lab, Div Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, Med Ctr, Dept Biostat, Los Angeles, CA 90024 USA	Soustiel, JF (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Dept Neurosurg, POB 9602, IL-31096 Haifa, Israel.	j_soustieI@rambarn.health.gov.il		Glenn, Thomas/0000-0003-4273-3408			Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bouzier-Sore AK, 2003, J CEREBR BLOOD F MET, V23, P1298, DOI 10.1097/01.WCB.0000091761.61714.25; Clarke DD, 1989, BASIC NEUROCHEMISTRY, P565; Debernardi R, 2003, J NEUROSCI RES, V73, P141, DOI 10.1002/jnr.10660; Dorfler P, 2000, J CEREBR BLOOD F MET, V20, P269; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Hattori N, 2003, J NUCL MED, V44, P1709; Ho SSY, 2002, AM J ROENTGENOL, V178, P551, DOI 10.2214/ajr.178.3.1780551; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Rothoerl RD, 2003, ACTA NEUROCHIR, V145, P943, DOI 10.1007/s00701-003-0108-0; Scheel P, 2000, STROKE, V31, P147, DOI 10.1161/01.STR.31.1.147; SCHONING M, 1994, STROKE, V25, P17, DOI 10.1161/01.STR.25.1.17; Soustiel JF, 2003, STROKE, V34, P1876, DOI 10.1161/01.STR.0000080942.32331.39; Soustiel JF, 2002, J ULTRAS MED, V21, P1405, DOI 10.7863/jum.2002.21.12.1405; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; TASCOPOULOS M, 1996, J NEUROSCI, V16, P877; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamaki T, 1996, J NUCL MED, V37, P1166; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	34	45	46	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					955	965		10.1089/neu.2005.22.955			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600003	16156711				2021-06-18	
J	Schreihofer, DA; Do, KD; Schreihofer, AM				Schreihofer, DA; Do, KD; Schreihofer, AM			High-soy diet decreases infarct size after permanent middle cerebral artery occlusion in female rats	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						phytoestrogen; isoflavone	ESTROGEN-RECEPTOR-BETA; TRAUMATIC BRAIN INJURY; REPLACEMENT THERAPY; HIPPOCAMPAL CA1; MEDIATED NEUROPROTECTION; EXPERIMENTAL STROKE; GLOBAL-ISCHEMIA; FOCAL ISCHEMIA; FRONTAL-CORTEX; ER-ALPHA	Estrogen is a powerful neuroprotective agent in rodent models of ischemic stroke. However, in humans, estrogen treatment can increase risk of stroke. Health risks associated with hormone replacement have led many women to consider alternative therapies including high-soy diets or supplements containing soy isoflavones, which act as estrogen receptor ligands to selectively mimic some of estrogen's actions. We hypothesized that a high-soy diet would share the neuroprotective actions of estrogen in focal cerebral ischemia. Female Sprague-Dawley rats were ovariectomized and divided into three groups: isoflavone-free diet + placebo (IF-P), isoflavone-free diet + estradiol (IF-E), or high-soy diet + placebo (S-P). Two weeks after being placed on diets, rats underwent left permanent middle cerebral artery occlusion (MCAO). Reductions in ipsilateral cerebral blood flow were equivalent across groups (similar to 50%). Twenty-four hours later neurological deficit was determined, and brains were collected for assay of cerebral infarct by TTC staining. In the IF-P rats MCAO produced a 50 +/- 4% cerebral infarct. Estrogen and high-soy diet both significantly reduced the size of the infarcts to 26 +/- 5% in IF-E rats and to 37 +/- 5% in S-P rats. Analysis at five rostro-caudal levels revealed that estrogen treatment was slightly more effective at reducing infarct size than high soy diet. Overall neurological deficit scores at 24 h correlated with infarct size; however, there were no statistically significant differences among the treatment groups. These data show that 2 wk of a high-soy diet is an effective prophylactic strategy for reducing stroke size in a rat model of focal cerebral ischemia.	Med Coll Georgia, Dept Physiol, Augusta, GA 30912 USA	Schreihofer, DA (corresponding author), Med Coll Georgia, Dept Physiol, 1120 15th St,CA-3145, Augusta, GA 30912 USA.	dschreihofer@mail.mcg.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [R01AT001882] Funding Source: NIH RePORTER; NCCIH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine [1R01AT001882-01] Funding Source: Medline		An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Beck V, 2003, J STEROID BIOCHEM, V84, P259, DOI 10.1016/S0960-0760(03)00034-7; BIXO M, 1986, ACTA PHYSIOL SCAND, V128, P241, DOI 10.1111/j.1748-1716.1986.tb07972.x; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Carswell HVO, 2004, AM J PHYSIOL-HEART C, V287, pH1501, DOI 10.1152/ajpheart.00227.2004; Carswell HVO, 2000, J CEREBR BLOOD F MET, V20, P931, DOI 10.1097/00004647-200006000-00005; DeVries AC, 2001, NEUROSCI BIOBEHAV R, V25, P325, DOI 10.1016/S0149-7634(01)00017-3; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Fitzpatrick JL, 2002, J NEUROCHEM, V82, P674, DOI 10.1046/j.1471-4159.2002.01000.x; Fukuda K, 2000, STROKE, V31, P155, DOI 10.1161/01.STR.31.1.155; Glazier MG, 2001, ARCH INTERN MED, V161, P1161, DOI 10.1001/archinte.161.9.1161; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Hall JM, 2002, J BIOL CHEM, V277, P44455, DOI 10.1074/jbc.M200849200; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Harris HA, 2002, ENDOCRINOLOGY, V143, P4172, DOI 10.1210/en.2002-220403; HATFIELD RH, 1991, NEUROPATH APPL NEURO, V17, P61, DOI 10.1111/j.1365-2990.1991.tb00694.x; He Z, 2002, J NEUROL SCI, V193, P79, DOI 10.1016/S0022-510X(01)00648-7; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Kondo Y, 1997, NEUROSCI LETT, V238, P45, DOI 10.1016/S0304-3940(97)00847-1; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lephart ED, 2002, NEUROTOXICOL TERATOL, V24, P5, DOI 10.1016/S0892-0362(01)00197-0; Lephart ED, 2000, BRAIN RES, V859, P123, DOI 10.1016/S0006-8993(00)01968-5; Li XL, 2004, EXP NEUROL, V187, P94, DOI 10.1016/j.expneurol.2004.01.004; Linford NJ, 2002, STEROIDS, V67, P1029, DOI 10.1016/S0039-128X(02)00062-4; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lund TD, 2004, BIOL REPROD, V70, P1188, DOI 10.1095/biolreprod.103.023713; Lund TD, 2001, BRAIN RES, V914, P92, DOI 10.1016/S0006-8993(01)02779-2; Lund TD, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-20; McCullough LD, 2003, TRENDS ENDOCRIN MET, V14, P228, DOI 10.1016/S1043-2760(03)00076-6; Newton KM, 2002, OBSTET GYNECOL, V100, P18, DOI 10.1016/S0029-7844(02)02005-7; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P2842, DOI 10.1073/pnas.0438041100; Pan YL, 1999, P SOC EXP BIOL MED, V221, P118, DOI 10.1046/j.1525-1373.1999.d01-64.x; Pan YL, 1999, NEUROSCI LETT, V261, P17, DOI 10.1016/S0304-3940(98)00994-X; Rossberg MI, 2000, STROKE, V31, P3041, DOI 10.1161/01.STR.31.12.3041; Routledge EJ, 2000, J BIOL CHEM, V275, P35986, DOI 10.1074/jbc.M006777200; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Sampei K, 2000, STROKE, V31, P738, DOI 10.1161/01.STR.31.3.738; Sawada H, 2000, FASEB J, V14, P1202; Scallet AC, 2003, TOXICOL SCI, V72, P296, DOI 10.1093/toxsci/kfg029; Setchell KDR, 2001, J AM COLL NUTR, V20, p354S, DOI 10.1080/07315724.2001.10719168; Shi J, 2001, STROKE, V32, P987, DOI 10.1161/01.STR.32.4.987; Shughrue PJ, 2001, J COMP NEUROL, V436, P64; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Trieu VN, 1999, BIOCHEM BIOPH RES CO, V258, P685, DOI 10.1006/bbrc.1999.0577; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Wilson ME, 2002, MOL BRAIN RES, V102, P48, DOI 10.1016/S0169-328X(02)00181-X; Wise PM, 2001, ENDOCRINOLOGY, V142, P969, DOI 10.1210/en.142.3.969; Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322; Zhao LX, 2002, EXP BIOL MED, V227, P509	59	45	48	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	JUL	2005	289	1					R103	R108		10.1152/ajpregu.00642.2004			6	Physiology	Physiology	935PI	WOS:000229793800015	15956759				2021-06-18	
J	Rice, SA; Blackman, JA; Braun, S; Linn, RT; Granger, CV; Wagner, DP				Rice, SA; Blackman, JA; Braun, S; Linn, RT; Granger, CV; Wagner, DP			Rehabilitation of children with traumatic brain injury: Descriptive analysis of a nationwide sample using the WeeFIM	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; disabled children; rehabilitation; treatment outcome	FUNCTIONAL INDEPENDENCE MEASURE; DEVELOPMENTAL-DISABILITIES; STABILITY	Objective: To describe functional capability at admission and discharge of children with traumatic brain injury (TBI) in rehabilitation settings. Design: Descriptive analysis. Setting: Inpatient pediatric rehabilitation hospitals in the United States. Participants: Children (N = 3815) in 56 pediatric inpatient rehabilitation facilities who were discharged during 1999 to 2001. Interventions: Not applicable. Main Outcome Measures: Admission and discharge WeeFIM scores. Results: Admission and discharge WeeFIM scores correlated positively with age at admission, time from injury to rehabilitation admission, and length of stay (LOS). Higher admission WeeFIM scores correlated with shorter LOS, shorter time from injury to admission to rehabilitation, and higher discharge WeeFIM scores. Conclusions: Children with TBI demonstrated significant improvement in functional measures during rehabilitation. Discharge function and LOS correlated with admission severity, with children who had higher functional status and shorter time between injury and rehabilitation care having higher discharge function and shorter LOS. (c) 2005 by American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA; Univ Arizona, Dept Hlth Evaluat Sci, Tucson, AZ 85724 USA; Univ Virginia, Charlottesville, VA USA; SUNY Buffalo, Dept Rehabil Med, Buffalo, NY USA	Rice, SA (corresponding author), Univ Arizona, Dept Pediat, 1501 N Campbell, Tucson, AZ 85724 USA.	srice@peds.arizona.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD040756] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [T32HL007956] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5 T32 HL 7956-4] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1 F32 HD40756-01A1] Funding Source: Medline		[Anonymous], 2000, WEEFIM SYST CLIN GUI; Azaula M, 2000, ARCH PHYS MED REHAB, V81, P307, DOI 10.1053/apmr.2000.0810307; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; *MATHS, 1999, S PLUS 2000 US GUID; Msall ME, 1993, PHYS MED REHAB CLIN, V4, P517; Ottenbacher KJ, 1996, DEV MED CHILD NEUROL, V38, P907; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; Ottenbacher KJ, 2000, AM J PHYS MED REHAB, V79, P114, DOI 10.1097/00002060-200003000-00002; Ottenbacher KJ, 2000, ARCH PHYS MED REHAB, V81, P1317, DOI 10.1053/apmr.2000.9387; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91, DOI 10.1080/J006v21n02_08	10	45	46	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2005	86	4					834	836		10.1016/j.apmr.2004.11.006			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	914ON	WOS:000228237300034	15827941				2021-06-18	
J	Furlan, JC; Krassioukov, AV; Fehlings, MG				Furlan, JC; Krassioukov, AV; Fehlings, MG			The effects of gender on clinical and neurological outcomes after acute cervical spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						clinical outcome; gender; neurological outcome; neurotrauma; sex; spinal cord injury	TRAUMATIC BRAIN-INJURY; DEEP-VEIN THROMBOSIS; ACUTE REHABILITATION UNIT; LONG-TERM SURVIVAL; NOSOCOMIAL INFECTION; FUNCTIONAL OUTCOMES; SEX-DIFFERENCES; CELL-DEATH; RECOVERY; RATS	The potential clinical relevance of gender on clinical and neurological outcome after spinal cord injury (SCI) has received little attention. In order to address this issue, we examined all consecutive cases of acute traumatic cervical SCI admitted to our institution from 1998 to 2000. There were 38 males (ages 17-89 years, mean of 51.6) and 17 females (ages 18-84 years, mean of 63.2). Both groups were comparable regarding level (CI to C7) and severity of SCI (ASIA A to D) at admission. Age differences between the groups approached significance (p = 0.057), and thus this factor was treated as a covariate in the analysis. Co-morbidities were as frequent in men (86.8%) as in women (76.5%). The therapeutic approaches, length-of-stay in the acute care unit, mortality, and discharge disposition were similar in men and women. During hospitalization, 44.7% of men and 52.9% of women developed post-SCI secondary complications without any significant gender-related differences. Both groups showed a similar incidence of infections, cardiovascular complications, thromboembolism, and pressure sores. Univariate analysis revealed a trend for higher incidence of psychiatric complications (p = 0.054) and deep venous thrombosis (p = 0.092) in women, which was confirmed by multivariate analysis. Neurological outcome was not correlated with gender. A similar number of males and females (42.1%, 47.1%) showed evidence of neurological recovery as revealed by an improvement in ASIA scores. Moreover, 18.4% of males and 29.4% of females recovered to ASIA E status. Our data suggest a shift in the demographics of acute SCI with an increasing incidence in elderly women. Although neurological outcomes were not significantly related to gender, we observed a trend for higher rates of reactive depression and deep venous thrombosis in women. These issues may be of key clinical importance in developing improved management protocols for SCI so as to maximize functional recovery and quality-of-life.	Univ Toronto, Div Neurosurg, Dept Surg, Toronto Western Hosp, Toronto, ON, Canada; Univ Toronto, Hlth Network, Toronto Western Hosp, Spinal Program,Krembil Neurosci Ctr, Toronto, ON, Canada	Fehlings, MG (corresponding author), Univ Toronto, Div Neurosurg, Dept Surg, Toronto Western Hosp, 399 Bathurst St 4W449, Toronto, ON, Canada.	Michael.Fehlings@uhn.on.ca	Krassioukov, Andrei V/K-3131-2017; Furlan, Julio/Q-8290-2018	Fehlings, Michael/0000-0002-5722-6364; Furlan, Julio/0000-0002-2038-0018			ACTON PA, 1993, ARCH PHYS MED REHAB, V74, P1035, DOI 10.1016/0003-9993(93)90058-I; Aito S, 2003, SPINAL CORD, V41, P629, DOI 10.1038/sj.sc.3101513; Akiyama H, 1997, J NEUROL SCI, V152, P39, DOI 10.1016/S0022-510X(97)00141-X; Anderson FA, 2003, CIRCULATION, V107, pI9, DOI 10.1161/01.CIR.0000078469.07362.E6; Attia J, 2001, ARCH INTERN MED, V161, P1268, DOI 10.1001/archinte.161.10.1268; Barbeau H, 1998, ANN NY ACAD SCI, V860, P377, DOI 10.1111/j.1749-6632.1998.tb09063.x; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bilello JF, 2003, ARCH SURG-CHICAGO, V138, P1127, DOI 10.1001/archsurg.138.10.1127; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKETT TO, 1984, JAMA-J AM MED ASSOC, V252, P793; Brown TJ, 1999, RESTOR NEUROL NEUROS, V15, P289; Budh CN, 2003, SPINAL CORD, V41, P122, DOI 10.1038/sj.sc.3101407; Burns AS, 2001, SPINE, V26, pS137, DOI 10.1097/00007632-200112151-00023; Catz A, 2002, SPINAL CORD, V40, P595, DOI 10.1038/sj.sc.3101391; CHARLES ED, 1978, PARAPLEGIA, V15, P302, DOI 10.1038/sc.1977.46; Chen D, 1999, ARCH PHYS MED REHAB, V80, P1397, DOI 10.1016/S0003-9993(99)90250-2; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P733, DOI 10.1016/S0003-9993(99)90219-8; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1989, ARCH INTERN MED, V149, P1761, DOI 10.1001/archinte.149.8.1761; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P424; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P785, DOI 10.1016/S0003-9993(99)90228-9; Dryden DM, 2003, CAN J NEUROL SCI, V30, P113, DOI 10.1017/S0317167100053373; Eastwood EA, 1999, ARCH PHYS MED REHAB, V80, P1457, DOI 10.1016/S0003-9993(99)90258-7; Falconer EM, 2003, BRAIN RES, V975, P22, DOI 10.1016/S0006-8993(03)02542-3; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FINE PR, 1987, INQUIRY-J HEALTH CAR, V24, P147; FRANKEL H, 1969, TETRAPLEGIA, V1, P7; Frankel HL, 1998, SPINAL CORD, V36, P266, DOI 10.1038/sj.sc.3100638; FUHRER MJ, 1993, ARCH PHYS MED REHAB, V74, P255; Galea LAM, 2000, HORM BEHAV, V37, P86, DOI 10.1006/hbeh.1999.1560; GERHART KA, 1991, J TRAUMA, V31, P1529, DOI 10.1097/00005373-199111000-00012; Glance LG, 2004, J TRAUMA, V56, P165, DOI 10.1097/01.TA.0000047808.77902.83; Green D, 2003, AM J PHYS MED REHAB, V82, P950, DOI 10.1097/01.PHM.0000098043.88979.BA; Greenwald BD, 2001, ARCH PHYS MED REHAB, V82, P1181, DOI 10.1053/apmr.2001.24891; Gregory CM, 2003, SPINAL CORD, V41, P23, DOI 10.1038/sj.sc.3101370; GRIFFIN MR, 1985, AM J EPIDEMIOL, V121, P884, DOI 10.1093/oxfordjournals.aje.a114058; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gunnarsson T, 2003, CURR OPIN NEUROL, V16, P717, DOI 10.1097/00019052-200312000-00012; Harrop JS, 2001, SPINE, V26, P340, DOI 10.1097/00007632-200102150-00008; Imai K, 1996, J CLIN EPIDEMIOL, V49, P505, DOI 10.1016/0895-4356(95)00576-5; *INF CIHI, 2001, NAT TRAUM REG REP HO; KELLEY DB, 1986, TRENDS NEUROSCI, V9, P499, DOI 10.1016/0166-2236(86)90158-X; Krassioukov AV, 2003, J NEUROTRAUM, V20, P707, DOI 10.1089/089771503767869944; Krassioukov AV, 2003, J NEUROTRAUM, V20, P391, DOI 10.1089/089771503765172345; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; Krause JS, 1999, ARCH PHYS MED REHAB, V80, P1492; LYONS JS, 1988, GEN HOSP PSYCHIAT, V10, P292, DOI 10.1016/0163-8343(88)90038-2; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; McKinley William O, 2002, J Spinal Cord Med, V25, P88; MERLI GJ, 1993, ARCH PHYS MED REHAB, V74, P1199; Mohta M, 2003, INJURY, V34, P17, DOI 10.1016/S0020-1383(02)00377-7; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Mylotte JM, 2000, CLIN INFECT DIS, V30, P425, DOI 10.1086/313708; Mylotte JM, 2001, INFECT CONT HOSP EP, V22, P83, DOI 10.1086/501868; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; North NT, 1999, SPINAL CORD, V37, P671, DOI 10.1038/sj.sc.3100913; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; OSEBOLD WR, 1981, SPINE, V6, P13, DOI 10.1097/00007632-198101000-00004; Pires JGP, 2003, BRAZ J MED BIOL RES, V36, P239, DOI 10.1590/S0100-879X2003000200012; Pleym H, 2003, ACTA ANAESTH SCAND, V47, P241, DOI 10.1034/j.1399-6576.2003.00036.x; Pollard ME, 2003, SPINE, V28, P33, DOI 10.1097/00007632-200301010-00009; Poynton AR, 1997, INJURY, V28, P545, DOI 10.1016/S0020-1383(97)00090-9; PRICE C, 1994, AM J EPIDEMIOL, V139, P37, DOI 10.1093/oxfordjournals.aje.a116933; Regan RF, 1997, BRAIN RES, V764, P133, DOI 10.1016/S0006-8993(97)00437-X; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rossignol S, 2002, BRAIN RES REV, V40, P257, DOI 10.1016/S0165-0173(02)00208-4; ROTH EJ, 1992, PARAPLEGIA, V30, P520, DOI 10.1038/sc.1992.109; Safarinejad MR, 2001, UROLOGY, V58, P671, DOI 10.1016/S0090-4295(01)01353-X; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; SCHNEIDER RC, 1955, J NEUROSURG, V12, P95, DOI 10.3171/jns.1955.12.2.0095; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Surkin J, 1998, J TRAUMA, V45, P502, DOI 10.1097/00005373-199809000-00012; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; TATOR CH, 1993, SURG NEUROL, V40, P207, DOI 10.1016/0090-3019(93)90069-D; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; THURMAN DJ, 1994, PARAPLEGIA, V32, P665, DOI 10.1038/sc.1994.107; Wade WE, 2000, AM J PHYS MED REHAB, V79, P504, DOI 10.1097/00002060-200011000-00003; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; WANG YH, 1992, AM J PHYS MED REHAB, V71, P328, DOI 10.1097/00002060-199212000-00004; Warren S, 1995, Alaska Med, V37, P11; YAO JST, 1992, CHEST, V102, pS645, DOI 10.1378/chest.102.6.645S; YEKUTIEL M, 1989, PARAPLEGIA, V27, P58, DOI 10.1038/sc.1989.9; YOUNG JS, 1978, PARAPLEGIA, V16, P39, DOI 10.1038/sc.1978.6; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; 2002, NEUROSURGERY, V52, pS73	93	45	53	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2005	22	3					368	381		10.1089/neu.2005.22.368			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	911QM	WOS:000228019500004	15785232				2021-06-18	
J	Masedo, AI; Hanley, M; Jensen, MP; Ehde, D; Cardenas, DD				Masedo, AI; Hanley, M; Jensen, MP; Ehde, D; Cardenas, DD			Reliability and validity of a self-report FIMTM(FIM-SR) in persons with amputation or spinal cord injury and chronic pain	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						FIMTM (TM)instrument; reliability; validity; amputation; spinal cord injury	FUNCTIONAL INDEPENDENCE MEASURE; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; COGNITIVE DYSFUNCTION; IMPAIRMENT; DISABILITY; AMITRIPTYLINE; PERFORMANCE; HANDICAP; OUTCOMES	Objective: To evaluate the reliability and validity of a self-report FIM(TM) (FIM-SR) in two samples of adults with disabilities. Design: Participants in a clinical trial of amitriptyline for pain (n = 84 with spinal cord injury [SCI], n = 38 with amputation) provided responses to the study measures via telephone interview. Reliability was estimated using Cronbach's alpha and test-retest correlation coefficients, and validity was examined by comparing FIM-SR scores with the Craig Handicap Assessment and Reporting Technique (CHART) by comparing the CHART scores between the participants with SCI and amputation, and by comparing CHART scores between subjects with different levels of SCI. Results: In the SCI sample, the FIM-SR demonstrated adequate reliability, and correlational analyses supported the validity of the FIM-SR motor scales. In addition, the FIM-SR motor scales discriminated subjects with different diagnoses (SCI vs. amputation) and injury levels (paraplegia vs. tetraplegia). The psychometric properties of the entire FIM-SR in the amputation sample and of the FIM-SR cognitive scales in the SCI sample were difficult to determine due to a ceiling effect in which these scale scores were skewed toward the top end of the range. Conclusions: The FIM-SR motor scales and total FIM-SR score are reliable and valid measures of perceived functional independence in individuals with SCI. However, all of the FIM-SR scales in the amputation sample, and the FIM-SR cognitive scales in the SCI sample, seem to be less useful measures of functioning due to subjects reporting high levels of independence. The FIM-SR should be retested in amputation samples with more variable levels of functioning.	Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98105 USA; Univ Washington, Med Ctr, Ctr Multidisciplinary Pain, Seattle, WA 98105 USA	Jensen, MP (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, 1959 NE Pacific St,Box 356490, Seattle, WA 98105 USA.		Ehde, Dawn/K-1883-2016	Masedo Gutierrez, Ana Isabel/0000-0003-3495-6265; Ehde, Dawn/0000-0002-9555-2347	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD033988] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000037] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR-0037] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1P01-HD/NS-33988] Funding Source: Medline		Alarcon GS, 2002, ARTHRIT RHEUM-ARTHR, V47, P310, DOI 10.1002/art.10457; Brewer NT, 2004, MED CARE, V42, P875, DOI 10.1097/01.mlr.0000135817.31355.6b; Cardenas DD, 2002, PAIN, V96, P365, DOI 10.1016/S0304-3959(01)00483-3; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Cotter EM, 2002, CLIN REHABIL, V16, P36, DOI 10.1191/0269215502cr465oa; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; Ehde DM, 2003, CLIN J PAIN, V19, P3, DOI 10.1097/00002508-200301000-00002; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Garber MC, 2004, MED CARE, V42, P649, DOI 10.1097/01.mlr.0000129496.05898.02; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GREY N, 1993, PARAPLEGIA, V31, P457, DOI 10.1038/sc.1993.74; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; Hinkin CH, 1996, J CLIN EXP NEUROPSYC, V18, P431, DOI 10.1080/01688639608408999; Hoenig H, 1999, SPINE, V24, P539, DOI 10.1097/00007632-199903150-00007; Hoenig H, 1998, ARCH PHYS MED REHAB, V79, P378, DOI 10.1016/S0003-9993(98)90137-X; Hoenig H, 2001, ARCH PHYS MED REHAB, V82, P613, DOI 10.1053/apmr.2001.20832; Iezzoni LI, 2000, MED CARE, V38, P1051, DOI 10.1097/00005650-200010000-00009; Jensen MP, 2005, ARCH PHYS MED REHAB, V86, P116, DOI 10.1016/j.apmr.2004.01.040; Liu C, 2003, J NEUROL, V250, P1214, DOI 10.1007/s00415-003-0187-0; Magaziner J, 1997, AM J EPIDEMIOL, V146, P418, DOI 10.1093/oxfordjournals.aje.a009295; Marshall HM, 2002, ARCH PHYS MED REHAB, V83, P1116, DOI 10.1053/apmr.2002.33121; Mendelsohn ME, 2003, AM J PHYS MED REHAB, V82, P766, DOI 10.1097/00002060-200310000-00005; MUECKE L, 1992, ARCH PHYS MED REHAB, V73, P851; ODELL MW, 1991, AM J PHYS MED REHAB, V70, P91, DOI 10.1097/00002060-199104000-00008; OTOOLE DM, 1991, WESTERN J MED, V155, P384; REUBEN DB, 1995, J AM GERIATR SOC, V43, P17, DOI 10.1111/j.1532-5415.1995.tb06236.x; Robinson LR, 2004, ARCH PHYS MED REHAB, V85, P1, DOI 10.1016/S0003-9993(03)00476-3; Simondson JA, 2003, CLIN REHABIL, V17, P558, DOI 10.1191/0269215503cr650oa; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILSON DB, 1991, WESTERN J MED, V154, P587	32	45	45	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR	2005	84	3					167	176		10.1097/01.PHM.0000154898.25609.4A			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	898TE	WOS:000227098300004	15725790				2021-06-18	
J	Loy, DN; Sroufe, AE; Pelt, JL; Burke, DA; Cao, QL; Talbott, JF; Whittemore, SR				Loy, DN; Sroufe, AE; Pelt, JL; Burke, DA; Cao, QL; Talbott, JF; Whittemore, SR			Serum biomarkers for experimental acute spinal CORD injury: Rapid elevation ofneuron-specific enolase and S-100 beta	NEUROSURGERY			English	Article						adult rat; biomarkers; neuron-specific enolase; S-100 beta; spinal cord injury	NEURON-SPECIFIC ENOLASE; SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; ACUTE STROKE; ADULT-RAT; NEUROBIOCHEMICAL MARKERS; CARDIOPULMONARY BYPASS; EVOKED-POTENTIALS; DAMAGE MARKERS; PROTEIN	OBJECTIVE: We evaluated whether serum levels of neuron-specific enolase (NSE) and S-100beta protein are biomarkers for traumatic injury in an animal model of spinal cord injury (SCI). METHODS: Enzyme-linked immunosorbent assay serum measurements of NSE and S-100beta and assays of serum protein were compared at 6 and 24 hours after a graded contusive SCI (150 or 200 kdyn IH impactor injury (Infinite Horizons, L.L.C., Lexington, KY) or sham laminectomy at T9 in 30 female Sprague-Dawley rats. Serum from control animals was also analyzed. RESULTS: Increases in serum levels of NSE were observed for 200-kdyn (3.1 -fold,:P <0.001) and 150-kdyn (2.3-fold, P < 0.001) injury groups at 6 hours after injury, which decreased by 73.7%, (P < 0.001). and 65.2% (P < 0.001) at 24 hours after SCI, respectively; the levels were still greater than in sham animals (P < 0.001, P,= 0.001)., The 200- and 150-kdyn injury groups were not different at either time point. S-100beta serum levels increased at 6 hours-in the 200-kdyn injury group (P <0.05), and no differences from sham levels, were seen at 24 hours. No differences in total protein concentrations were observed between the injury and control groups. CONCLUSION: Present data suggest that NSE and S-100beta serum,levels may, be useful, experimental tools for the acute measurement of tissue loss after SCI. Despite significant shortcomings, NSE and S-100beta serum measurements in acute, SCI patients with clinically defined functional deficits should allow, comparisons, with well-characterized SCI animal models. Future efforts to develop biomarkers that predict functional outcomes in the acute phase should focus on axon-specific proteins as markers of secondary axonal loss and regeneration.	Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA; Univ Louisville, Sch Med, MD PhD Program, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA	Whittemore, SR (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	swhittemore@louisville.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U54NS039405, P01NS038665] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR-15576] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-38665, NS-39405] Funding Source: Medline		Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; BALENTINE JD, 1977, ANN NEUROL, V2, P520, DOI 10.1002/ana.410020612; Bilgen M, 2000, MAGN RESON MED, V43, P594; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Burns AS, 2003, J NEUROTRAUM, V20, P477, DOI 10.1089/089771503765355540; Butterworth RJ, 1998, STROKE, V29, P730, DOI 10.1161/01.STR.29.3.730; Butterworth RJ, 1996, STROKE, V27, P2064, DOI 10.1161/01.STR.27.11.2064; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; CAO QL, IN PRESS EXP NEUROL; CHABOT R, 1985, J NEUROSURG, V63, P544, DOI 10.3171/jns.1985.63.4.0544; Cunningham RT, 1996, EUR J CLIN INVEST, V26, P298, DOI 10.1046/j.1365-2362.1996.129282.x; de Vries J, 2003, MINIM INVAS NEUROSUR, V46, P33, DOI 10.1055/s-2003-37963; de Vries J, 2001, J NEUROL NEUROSUR PS, V71, P671, DOI 10.1136/jnnp.71.5.671; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Ditunno J., 2002, SPINAL CORD MED, P108; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Fan M, 2001, CELL MOL NEUROBIOL, V21, P497, DOI 10.1023/A:1013867306555; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Grossman SD, 2000, J NEUROCHEM, V75, P174, DOI 10.1046/j.1471-4159.2000.0750174.x; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Hauben E, 2003, TRENDS PHARMACOL SCI, V24, P7, DOI 10.1016/S0165-6147(02)00013-5; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Hulsebosch CE, 2002, ADV PHYSIOL EDUC, V26, P238, DOI 10.1152/advan.00039.2002; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jonsson H, 1998, ANN THORAC SURG, V65, P1639, DOI 10.1016/S0003-4975(98)00229-X; KATZ RT, 1991, SPINE, V16, P730, DOI 10.1097/00007632-199107000-00007; KURIHARA M, 1985, J NEUROSURG, V62, P743, DOI 10.3171/jns.1985.62.5.0743; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liu Cheng-long, 2003, Chin J Traumatol, V6, P18; Loy DN, 2002, EXP NEUROL, V177, P575, DOI 10.1006/exnr.2002.7959; Loy DN, 2002, J COMP NEUROL, V445, P308, DOI 10.1002/cne.10168; Loy DN, 2002, J NEUROSCI, V22, P315, DOI 10.1523/JNEUROSCI.22-01-00315.2002; Ma JJ, 2001, SCAND J PLAST RECONS, V35, P355; Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016; Marangos P J, 1980, Essays Neurochem Neuropharmacol, V4, P211; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; Oh SH, 2002, YONSEI MED J, V43, P357, DOI 10.3349/ymj.2002.43.3.357; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; RIVLIN AS, 1978, J NEUROSURG, V49, P844, DOI 10.3171/jns.1978.49.6.0844; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Shepard MJ, 1999, SPINAL CORD, V37, P833, DOI 10.1038/sj.sc.3100927; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Toupalik P, 2001, Soud Lek, V46, P34; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	66	45	53	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2005	56	2					391	396		10.1227/01.NEU.0000148906.83616.D2			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	895UO	WOS:000226889400041	15670387				2021-06-18	
S	Barbee, KA		Lee, RC; Despa, F; Hamann, KJ		Barbee, Kenneth A.			Mechanical cell injury	CELL INJURY: MECHANISMS, RESPONSES, AND REPAIR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	Conference on Cell Injury - Responses and Repair	MAR 31-JUN 02, 2004	Univ Chicago, Chicago, IL		Univ Chicago	neurotrauma; angioplasty; mechanoporation; poloxamer	FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; IN-VITRO MODEL; ERYTHROCYTE MEMBRANE GHOSTS; SPINAL-CORD-INJURY; AXONAL INJURY; NEURAL TRAUMA; STRAIN-RATE; STRETCH; PROLIFERATION	The tissues of the body are continually subjected to mechanical stimulation by external forces, such as gravity, and internally generated forces, such as the pumping of blood or muscle contraction. Within a physiological range, the forces elicit adaptive responses acutely (to rapidly alter function) and chronically (to remodel tissue structure to optimize load-bearing capabilities). When the forces exceed certain thresholds, injury results. To understand the mechanisms of mechanical injury at the cellular level, we must analyze the structural response of the cell to various modes of deformation and examine the biological consequences of the structural alterations caused by the trauma. This chapter reviews the mechanics of cell membrane deformation and failure. Evidence for the strain-rate-dependent, transient disruption of cell membranes, or mechanoporation, is presented for a variety of cell types. The complex interactions between the structural damage and the biological sequelae are illustrated using clinically relevant forms of cell injury. Finally, novel therapeutic approaches targeting membrane integrity are described.	Drexel Univ, Sch Biomed Engn, Sci & Hlth Syst, Philadelphia, PA 19104 USA	Barbee, KA (corresponding author), Drexel Univ, Sch Biomed Engn, Sci & Hlth Syst, 3141 Chestnut St, Philadelphia, PA 19104 USA.	barbee@drexel.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR316574-01-3] Funding Source: Medline		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; *AM HEART ASS, 2000, 2001 HEART STROK STA; BARBEE KA, 1995, AM J PHYSIOL-HEART C, V268, pH1765; BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; Blackman BR, 2000, ANN BIOMED ENG, V28, P363, DOI 10.1114/1.286; Blackshear PL, 1972, BIOMECHANICS, P501; Boal D, 2002, MECH CELL; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; Borgens RB, 2002, J EXP BIOL, V205, P1; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; Cheng GC, 1997, CIRC RES, V80, P28, DOI 10.1161/01.RES.80.1.28; CHOI DW, 1987, J NEUROSCI, V7, P369; CLARKE MSF, 1992, J CELL SCI, V102, P533; CLARKE MSF, 1995, CIRC RES, V76, P927, DOI 10.1161/01.RES.76.6.927; Clarke MSF, 1996, FASEB J, V10, P502; CLARKE MSF, 1993, J CELL SCI, V106, P121; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; CLOWES AW, 1986, LAB INVEST, V54, P295; DARTSCH PC, 1989, BASIC RES CARDIOL, V84, P268, DOI 10.1007/BF01907974; DEWITZ TS, 1977, J LAB CLIN MED, V90, P728; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Evans DV, 1979, APPL OCEAN RES, V1, P3, DOI [10.1016/0141-1187(79)90003-8., DOI 10.1016/0141-1187(79)90003-8, DOI 10.1016/0141-1187(79)90003-8)]; EVANS EA, 1979, CRC CR REV BIOM ENG, V3, P331; EVANS EA, 1976, BIOPHYS J, V16, P585, DOI 10.1016/S0006-3495(76)85713-X; EVANS EA, 1978, CURR TOP MEMBR TRANS, V10, P1; FECHHEIMER M, 1987, P NATL ACAD SCI USA, V84, P8463, DOI 10.1073/pnas.84.23.8463; FINGERLE J, 1990, ARTERIOSCLEROSIS, V10, P1082, DOI 10.1161/01.ATV.10.6.1082; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; GILBERT JA, 1994, J BIOMECH, V27, P1169, DOI 10.1016/0021-9290(94)90057-4; Hannig J, 2000, RADIAT RES, V154, P171, DOI 10.1667/0033-7587(2000)154[0171:SSOMPB]2.0.CO;2; HERRMANN HC, 1993, ARTERIOSCLER THROMB, V13, P924, DOI 10.1161/01.ATV.13.6.924; HOCHMUTH RM, 1973, BIOPHYS J, V13, P747, DOI 10.1016/S0006-3495(73)86021-7; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P424, DOI 10.1113/jphysiol.1952.sp004716; HUNG CT, 1994, J BIOMECH, V27, P227, DOI 10.1016/0021-9290(94)90212-7; JAWIEN A, 1992, J CLIN INVEST, V89, P507, DOI 10.1172/JCI115613; KHAW BA, 1995, NAT MED, V1, P1195, DOI 10.1038/nm1195-1195; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; LaPlaca MC, 1997, ANN BIOMED ENG, V25, P665, DOI 10.1007/BF02684844; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; LEE RC, 1992, P NATL ACAD SCI USA, V89, P4524, DOI 10.1073/pnas.89.10.4524; LEUNG DYM, 1977, EXP CELL RES, V109, P285, DOI 10.1016/0014-4827(77)90008-8; LIEBER MR, 1982, J BIOL CHEM, V257, P1651; LIEBER MR, 1982, J BIOL CHEM, V257, P1660; LINDNER V, 1991, P NATL ACAD SCI USA, V88, P3739, DOI 10.1073/pnas.88.9.3739; LINDNER V, 1993, CIRC RES, V73, P589, DOI 10.1161/01.RES.73.3.589; Liu SQ, 2000, J BIOMECH ENG-T ASME, V122, P31, DOI 10.1115/1.429625; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Maskarinec SA, 2002, BIOPHYS J, V82, P1453, DOI 10.1016/S0006-3495(02)75499-4; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; Merchant FA, 1998, J SURG RES, V74, P131, DOI 10.1006/jsre.1997.5252; Morrison B, 1998, ANN BIOMED ENG, V26, P381, DOI 10.1114/1.61; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; ONEILL ME, 1968, CHEM ENG SCI, V23, P1293, DOI 10.1016/0009-2509(68)89039-6; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RAND RP, 1963, J CELL COMPAR PHYSL, V61, P245, DOI 10.1002/jcp.1030610306; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SCHAFFER JL, 1994, J ORTHOP RES, V12, P709, DOI 10.1002/jor.1100120514; Serbest G, 2005, J NEUROTRAUM, V22, P119, DOI 10.1089/neu.2005.22.119; SERBEST G, 2005, IN PRESS FASEB J; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Smith DH, 1999, J NEUROSCI, V19, P4263; WILLIAMS JL, 1992, J BIOMECH ENG-T ASME, V114, P377, DOI 10.1115/1.2891398; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	74	45	47	0	18	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-616-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2005	1066						67	84		10.1196/annals.1363.006			18	Cell Biology; Multidisciplinary Sciences	Cell Biology; Science & Technology - Other Topics	BEE77	WOS:000236999100005	16533919				2021-06-18	
J	Platz, T; Kim, IH; Engel, U; Pinkowski, C; Eickhof, C; Kutzner, M				Platz, T; Kim, IH; Engel, U; Pinkowski, C; Eickhof, C; Kutzner, M			Amphetamine fails to facilitate motor performance and to enhance recovery among stroke patients with mild arm paresis: Interim analysis and termination of a double blind, randomised, placedo-controlled trial	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						arm; stroke; rehabilitation; training; recovery; amphetamine; clinical trial	KINEMATIC MOTION ANALYSIS; TRAUMATIC BRAIN INJURY; PROGNOSTIC-FACTORS; PHYSIOTHERAPY	Purpose. To assess the effects of d-amphetamine on motor facilitation and recovery in stroke patients with mild arm paresis receiving the Arm Ability training. Methods. Thirty-one stroke patients with mild arm paresis were randomly assigned to either (a.) receiving placebo or (b.) d-amphetamine twice a week 2 hours before Arm Ability training sessions for three weeks. Main outcome measure: time needed to perform TEMPA tasks, a measure of upper extremity performance reflecting everyday life tasks. Secondary measures: aimed movements, tapping, and a 10 in walkway as well as motor performance during training sessions. Results: The interim efficacy analysis of 26 stroke patients who completed the study intervention showed overall ann motor recovery both from pre to post test after 3 weeks of training and from pre test to follow-up 1 year later. No superior effect of d-amphetamine over placebo could be substantiated for either motor facilitation during training or motor recovery (post training or long-term). D-amphetamine exerted mild effects on blood pressure. Serious adverse events were not observed. Conclusions. d-Amphetamine failed to facilitate motor performance during training sessions, to promote skill acquisition with training tasks, and most importantly to enhance motor recovery among patients with mild arm paresis after stroke.	Klin Berlin, Dept Neurol Rehabil, D-14089 Berlin, Germany; Segeberger Klin, Neurol Zentrum, Bad Segeberg, Germany	Platz, T (corresponding author), Klin Berlin, Dept Neurol Rehabil, Kladower Damm 223, D-14089 Berlin, Germany.	tplatz@zedat.fu-berlin.de		Platz, Thomas/0000-0003-2629-9744			BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Desrosiers J, 1993, CAN J OCCUP THER, V60, P9, DOI DOI 10.1177/000841749306000104; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gladstone DJ, 2004, STROKE, V35, P239; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P318; Hankey GJ, 2002, STROKE, V33, P1034, DOI 10.1161/01.STR.0000012515.66889.24; Martinsson L, 2003, CEREBROVASC DIS, V16, P338, DOI 10.1159/000072555; MARTINSSON L, 2004, COCHRANE LIB; Meijer R, 2003, CLIN REHABIL, V17, P119, DOI 10.1191/0269215503cr585oa; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P394, DOI 10.1016/0003-9993(94)90161-9; PLATZ T, 1994, NEUROPSYCHOLOGIA, V32, P1209, DOI 10.1016/0028-3932(94)90103-1; Platz T, 2004, RESTOR NEUROL NEUROS, V22, P301; Platz T, 2001, NEUROPSYCHOLOGIA, V39, P687, DOI 10.1016/S0028-3932(01)00005-7; Platz T, 2002, RESTOR NEUROL NEUROS, V20, P37; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; Platz T, 1999, ARCH PHYS MED REHAB, V80, P270, DOI 10.1016/S0003-9993(99)90137-5; Schmidt R.A., 1999, MOTOR CONTROL LEARNI, V3rd ed; Sonde L, 2001, CEREBROVASC DIS, V12, P253, DOI 10.1159/000047712; Treig T, 2003, CLIN REHABIL, V17, P590, DOI 10.1191/0269215503cr653oa; Unnebrink K, 2001, STAT MED, V20, P3931, DOI 10.1002/sim.1149.abs; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; WADE DT, 1992, MEASUREMENT NEUROLOG, P53; WALKERBATSON D, 1995, STROKE, V26, P2254, DOI 10.1161/01.STR.26.12.2254	25	45	46	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2005	23	5-6					271	280					10	Neurosciences	Neurosciences & Neurology	007HS	WOS:000234960200002	16477089				2021-06-18	
J	Lee, LL; Galo, E; Lyeth, BG; Muizelaar, JP; Berman, RF				Lee, LL; Galo, E; Lyeth, BG; Muizelaar, JP; Berman, RF			Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker	EXPERIMENTAL NEUROLOGY			English	Article						lateral fluid percussion; voltage-gated calcium channels; SNX185; traumatic brain injury; fluoro-jade; hippocampus; Morris water maze; beam walk test	ZICONOTIDE; ISCHEMIA; RELEASE; LOCALIZATION; ANTAGONISTS; POTASSIUM; PROTECTS; NEURONS; INFLUX	Overload of intracellular calcium ([Ca2+](i)) following traumatic brain injury (TBI) has been implicated in the pathogenesis of neuronal injury and death. Voltage-gated calcium channels (VGCCs) provide one of the major sources of Ca2+ entry into cells. Therefore, the potential neuroprotective activity of SNX-185, a specific N-type VGCC blocker, was tested in rats using the lateral fluid percussion (LFP) model of TBI. SNX-185 (50, 100, or 200 pmol) or vehicle was injected 5 min after injury into the CA2-3 subregion of the hippocampus ipsilateral to TBI. Acute neuronal degeneration was visualized in brain sections 24 h postinjury using the histofluorescent marker Fluoro-Jade (FJ), and the number of surviving neurons in the CA2-3 subregion of the hippocampus 42 days after injury was determined stereologically. Behavioral outcome after TBI and drug treatment was assessed in the beam walk test and Morris water maze. Direct injection of SNX-185 into the CA2-3 region of the hippocampus reduced neuronal injury 24 h after TBI and increased neuronal survival at 42 days at each of the three drug concentrations. Behavioral outcome in both the beam walk and Morris water maze were also improved by SNX-185, with 100 and 200 pmol, but not 50 pmol SNX-185 providing neuroprotection. These data support previous studies demonstrating substantial neuroprotection after TBI by treatment with N-type VGCC blockers. (C) 2004 Elsevier Inc. All rights reserved.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA	Berman, RF (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95616 USA.	rfberman@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039090] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39090] Funding Source: Medline		Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; BOWERSOX SS, 1992, J CARDIOVASC PHARM, V20, P756, DOI 10.1097/00005344-199211000-00011; Bowersox SS, 1997, BRAIN RES, V747, P343; Brose WG, 1997, CLIN J PAIN, V13, P256, DOI 10.1097/00002508-199709000-00012; BUCHAN AM, 1994, J CEREBR BLOOD F MET, V14, P903, DOI 10.1038/jcbfm.1994.121; CHOI DW, 1994, ANN NY ACAD SCI, V747, P162; Conti AC, 1998, J NEUROSCI, V18, P5663; Craig PJ, 1998, J COMP NEUROL, V397, P251; Currie KPM, 1997, J NEUROSCI, V17, P4570; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; HOVDA DA, 1994, ACTA NEUROCHIR, P521; Hu LY, 1999, BIOORG MED CHEM LETT, V9, P1121, DOI 10.1016/S0960-894X(99)00160-2; Hu LY, 1999, BIOORG MED CHEM LETT, V9, P2151, DOI 10.1016/S0960-894X(99)00359-5; JONES OT, 1989, SCIENCE, V244, P1189, DOI 10.1126/science.2543080; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Latour I, 2003, GLIA, V41, P347, DOI 10.1002/glia.10162; Lee A, 2000, J NEUROSCI, V20, P6830, DOI 10.1523/JNEUROSCI.20-18-06830.2000; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; McGuire D, 1997, J CARDIOVASC PHARM, V30, P400, DOI 10.1097/00005344-199709000-00019; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILJANICH GP, 1995, ANNU REV PHARMACOL, V35, P707, DOI 10.1146/annurev.pa.35.040195.003423; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Newcomb R, 2000, PEPTIDES, V21, P491, DOI 10.1016/S0196-9781(00)00175-3; Nicholls DG, 2000, PHYSIOL REV, V80, P315; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.biochem.63.1.823; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Randall A, 1999, MOL CELL NEUROSCI, V14, P255, DOI 10.1006/mcne.1999.0795; Ryder TR, 1999, BIOORG MED CHEM LETT, V9, P1813, DOI 10.1016/S0960-894X(99)00284-X; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Staats PS, 2004, JAMA-J AM MED ASSOC, V291, P63, DOI 10.1001/jama.291.1.63; TAKIZAWA S, 1995, J CEREBR BLOOD F MET, V15, P611, DOI 10.1038/jcbfm.1995.75; TSIEN RW, 1999, CALCIUM CELLULAR REG, P95; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; WANG YX, 1998, NAUNYNSCHMIEDEBERGS, V357; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wu LG, 1997, TRENDS NEUROSCI, V20, P204, DOI 10.1016/S0166-2236(96)01015-6; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1996, NEUROTRAUMA, P1421; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V150, P459, DOI 10.1111/j.1748-1716.1994.tb09713.x	54	45	46	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	NOV	2004	190	1					70	78		10.1016/j.expneurol.2004.07.003			9	Neurosciences	Neurosciences & Neurology	867DJ	WOS:000224822100006	15473981				2021-06-18	
J	Carlesimo, GA; Casadio, P; Caltagirone, C				Carlesimo, GA; Casadio, P; Caltagirone, C			Prospective and retrospective components in the memory for actions to be performed in patients with severe closed-head injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						prospective memory; retrospective memory; closed-head injury; time monitoring; executive functions	RETRIEVAL; DAMAGE; EVENT	This study investigated the basic mechanisms of the impairment of memory for actions to be performed in a group of 16 chronic survivors of severe closed-head injury (CHI). The experimental paradigm allowed discrimination between the deficit in spontaneously remembering the intention at the appropriate moment (prospective component of the task) and the deficit in remembering the specific actions to perform (retrospective component). The experimental procedure also contrasted a condition in which the time expiration was marked by the ringing of a timer (event-based condition) and one in which the time expiration was not marked by any event and the patient had to monitor the passing of time and completely self-activate the recall of the intention (time-based condition). Two other experimental manipulations were concerned with the duration of the delay interval from the examiner's instructions to the time expiration ( 10 vs. 45 min) and the fact that the three actions to be performed could be functionally related or not. With respect to a group of 16 normal controls. the patients with CHI were impaired in both the prospective and retrospective components of the memory for actions. Although an impairment of episodic memory is a plausible explanation for the poor retrieval of specific actions to perform, it is unlikely that this deficit played a major role in the CHI patients' reduced accuracy in spontaneously recalling the intention when the event occurred or the time expired. Instead, reduced frequency and less strategic utilization of time monitoring and/or self-reminding likely played a significant role in this sense.	IRCCS, Fdn S Lucia, I-00179 Rome, Italy; Univ Roma Tor Vergata, Neurol Clin, Rome, Italy	Carlesimo, GA (corresponding author), IRCCS, Fdn S Lucia, V Ardeatina 306, I-00179 Rome, Italy.	memolab@hsantalucia.it	Caltagirone, Carlo/B-4930-2013				BISIACCHI PS, 1995, TRAUMA CRANICO CONSE, P92; BISIACCHI PS, 1992, RIV PSICOLOGIA SOCIA, V17, P77; BRANDIMONTE MA, 1994, Q J EXP PSYCHOL-A, V47, P565, DOI 10.1080/14640749408401128; BRNADIMONTE MA, 1996, PROSPECTIVE MEMORY T; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burgess P. W., 1997, COGNITIVE MODELS MEM, P247; Burgess PW, 2003, NEUROPSYCHOLOGIA, V41, P906, DOI 10.1016/S0028-3932(02)00327-5; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Carlesimo G.A., 2002, NUOVA RIV NEUROLOGIA, V12, P1, DOI DOI 10.1080/17408989.2016.1268591; Carlesimo GA, 1997, CORTEX, V33, P131, DOI 10.1016/S0010-9452(97)80009-3; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Guynn MJ, 1998, MEM COGNITION, V26, P287, DOI 10.3758/BF03201140; HUPPERT FA, 1993, J CLIN EXP NEUROPSYC, V15, P805, DOI 10.1080/01688639308402597; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KVAVILASHVILI L, 1987, BRIT J PSYCHOL, V78, P507, DOI 10.1111/j.2044-8295.1987.tb02265.x; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Leynes PA, 2003, CONSCIOUS COGN, V12, P1, DOI 10.1016/S1053-8100(02)00002-8; Marsh RL, 1998, MEM COGNITION, V26, P633, DOI 10.3758/BF03211383; Otani H, 1997, MEMORY, V5, P343, DOI 10.1080/741941393; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SPINNLER H, 1987, ITALIAN J NEUROLOG S, V6, P44	28	45	45	0	4	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2004	10	5					679	688		10.1017/S1355617704105079			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	848XZ	WOS:000223502700004	15327715				2021-06-18	
J	Yoshino, O; Matsuno, H; Nakamura, H; Yudoh, K; Abe, Y; Sawai, T; Uzuki, M; Yonehara, S; Kimura, T				Yoshino, O; Matsuno, H; Nakamura, H; Yudoh, K; Abe, Y; Sawai, T; Uzuki, M; Yonehara, S; Kimura, T			The role of Fas-mediated apoptosis after traumatic spinal cord injury	SPINE			English	Article						apoptosis; Fas antigen; Fas ligand; lpr mice; secondary injury; spinal cord injury	PROGRAMMED CELL-DEATH; RHEUMATOID SYNOVIUM; DNA FRAGMENTATION; MOLECULAR-CLONING; LEUKEMIA-CELLS; MOUSE MODEL; IN-SITU; INDUCTION; EXPRESSION; ANTIGEN	Study Design. Functional recovery and histopathological change after spinal cord injury in the Fas-deficient mice and the wild-type mice were investigated. Objectives. To investigate the role of the Fas/Fas ligand ( FasL) system as a signal transduction pathway leading to apoptosis after spinal cord injury. Summary of Background Date. Apoptosis observed after spinal cord injury has recently gained widespread interest as a cause of collateral damage after the initial injury. Apoptosis mediated by the Fas antigen in the post-ischemic brain or spinal cord was reported. Recently, the upregulation of Fas after spinal cord injury was also reported. However, the influence of Fas-mediated apoptosis on the extent of the secondary spinal cord injury has not yet been clarified. Methods. We investigated Fas-mediated apoptosis after spinal cord injury and examined the behavioral changes and the histopathological changes after spinal cord injury using MRL/Mp-lpr/lpr (MRL/lpr) mice, which were Fas-deficient mutant mice, and MRL/Mp-+/+ (MRL/+) mice, which were Fas-positive wild-type mice. Results. Locomotor recovery after spinal cord injury in MRL/lpr mice was superior to that observed in MRL/+ mice. In addition, the damaged area in MRL/lpr mice was significantly smaller than that seen in MRL/+ mice. Further, the frequency of apoptotic cells in the injured spinal cord of MRL/lpr mice was significantly less than that in MRL/+ mice. Conclusion. We demonstrated the appearance of Fas-mediated apoptosis in the spinal cord after spinal cord injury. In addition, we elucidated for the first time that Fas-mediated apoptosis following spinal cord injury played an important role in the spinal cord damage and the ultimate neurologic injury.	Toyama Med & Pharmaceut Univ, Dept Orthopaed Surg, Toyama 9300194, Japan; Toin Yokohama Univ, Dept Biomed Engn, Yokohama, Kanagawa, Japan; St Marianna Univ, Inst Med Sci, Yokohama, Kanagawa, Japan; Iwate Med Univ, Sch Med, Dept Pathol, Morioka, Iwate 020, Japan; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Lab Tumor Biogenesis, Kyoto 606, Japan	Yoshino, O (corresponding author), Toyama Med & Pharmaceut Univ, Dept Orthopaed Surg, 2630 Sugitani, Toyama 9300194, Japan.	g7410006@ms.toyama-mpu.ac.jp					Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BEILHARZ EJ, 1995, MOL BRAIN RES, V29, P1; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GELBARD HA, 1995, NEUROPATH APPL NEURO, V21, P208, DOI 10.1111/j.1365-2990.1995.tb01052.x; GUNJI H, 1991, CANCER RES, V51, P741; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HAMBURGER V, 1975, J COMP NEUROL, V160, P535, DOI 10.1002/cne.901600408; Henderson CE, 1996, NEURON, V17, P579, DOI 10.1016/S0896-6273(00)80191-9; HILL IE, 1995, BRAIN RES, V676, P398, DOI 10.1016/0006-8993(95)00145-G; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Katoh K, 1996, NEUROSCI LETT, V216, P9; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; LI Y, 1995, AM J PATHOL, V146, P1045; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; MATSUNO H, 1999, MECH LOADING BONE JO, P215; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; Morita I, 1998, INT J TISSUE REACT, V20, P37; Murphy E. D., 1978, Genetic control of autoimmune disease. Proceedings of the workshop on the genetic control of autoimmune disease held in Bloomfield Hills, Michigan, USA, on July 10-12, 1978., P207; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Okamoto K, 1998, GENE THER, V5, P331, DOI 10.1038/sj.gt.3300597; Park CH, 1998, BIOCHEM BIOPH RES CO, V252, P623, DOI 10.1006/bbrc.1998.9572; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; Sakai K, 1998, ARTHRITIS RHEUM, V41, P1251, DOI 10.1002/1529-0131(199807)41:7<1251::AID-ART16>3.0.CO;2-B; Sakurai M, 1998, BRAIN RES, V797, P23, DOI 10.1016/S0006-8993(98)00290-X; SASANO H, 1995, J CLIN ENDOCR METAB, V80, P2378, DOI 10.1210/jc.80.8.2378; Sasano H, 1997, J BONE MINER RES, V12, P1416, DOI 10.1359/jbmr.1997.12.9.1416; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHIN RW, 1991, LAB INVEST, V64, P693; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Walczak H, 1999, NAT MED, V5, P157; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	54	45	48	8	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JUL 1	2004	29	13					1394	1404		10.1097/01.BRS.0000129894.34550.48			11	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	835DT	WOS:000222461200004	15223929				2021-06-18	
J	Alexander, S; Kerr, ME; Yonas, H; Marion, DW				Alexander, S; Kerr, ME; Yonas, H; Marion, DW			The effects of admission alcohol level on cerebral blood flow and outcomes after severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; cerebral blood flow; outcomes; traumatic brain injury	HEAD-INJURY; ETHANOL INTOXICATION; CONSCIOUS LEVEL; MANAGEMENT; DEFICITS; ABUSE; RATS	This study examined the relationship between admission serum alcohol level (ETOH) and cerebral blood flow (CBF) and outcomes in the adult traumatic brain injured (TBI) population. We hypothesized that individuals with ETOH > 100 mg/dL will have decreased blood flow on admission and poorer outcomes. Eighty subjects, age 16-65, with severe TBI (Glasgow Coma Score [GCS] less than or equal to 8) were entered into the study. Correlational analysis assessed the relationship between ETOH and admission severity of injury scores as measured by Marshall and APACHE III scores, CBF, and outcomes. Comparison of CBF and outcomes between groups based on admission serum ETOH level was conducted with analysis of variance and post hoe Scheffe analyses as well as regression analysis. There was a significant relationship between serum ETOH level and GCS (P = 0.02), but not APACHE III scores (p = 0.12) or Marshall scores (p = 0.27). There was a significant correlation between global CBF and serum ETOH level (p = 0.02). There was no statistically significant association between serum ETOH level and GOS at 3 (p = 0.97), 6 (p = 0.56), or 12 (p = 0.73) months after injury. The data indicated that serum ETOH levels > 100 mg/dL at the time of admission after a TBI were associated with a decrease in global CBF. Elevated serum ETOH level at time of injury did not, however, impact outcomes.	Univ Pittsburgh, Sch Nursing, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Med Ctr, Ctr Stroke Inst, Dept Neurol Surg, Pittsburgh, PA 15261 USA; Boston Univ, Boston Med Ctr, Dept Neurol Surg, Boston, MA 02215 USA	Alexander, S (corresponding author), Univ Pittsburgh, Sch Nursing, Dept Neurosurg, 360 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA.	salexand@pitt.edu	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P50NS30318] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R01 40801] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		ALTURA BM, 1995, ALCOHOL, V12, P433, DOI 10.1016/0741-8329(95)00026-N; Bastos M L, 1976, J Forensic Sci, V21, P176; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Biros MH, 1999, ACAD EMERG MED, V6, P1088, DOI 10.1111/j.1553-2712.1999.tb00109.x; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BULLOCK MR, 1996, J NEUROTRAUM, V13, P638; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Fabbri A, 2001, J TRAUMA, V50, P521, DOI 10.1097/00005373-200103000-00018; Field CA, 2001, J TRAUMA, V50, P13, DOI 10.1097/00005373-200101000-00002; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALBRAITH S, 1975, BRIT J SURG, V62, P152; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Marshall SB, 1991, J NEUROSURG S, V75, P14; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; POIRES SE, 1992, J TRAUMA, V32, P60; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; SANO M, 1993, J STUD ALCOHOL, V54, P367; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; STEINBOK P, 1978, NEUROSURGERY, V3, P9, DOI 10.1227/00006123-197807000-00002; SUN H, 2001, CLIN EXP RES, V26, P663; Tate PS, 1999, BRAIN INJURY, V13, P767; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	32	45	46	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					575	583		10.1089/089771504774129900			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900008	15165365				2021-06-18	
J	Geffroy, A; Bronchard, R; Merckx, P; Seince, PF; Faillot, T; Albaladejo, P; Marty, J				Geffroy, A; Bronchard, R; Merckx, P; Seince, PF; Faillot, T; Albaladejo, P; Marty, J			Severe traumatic head injury in adults: Which patients are at risk of early hyperthermia?	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; hyperthermia; leukocytosis; diabetes insipidus; outcome	INTENSIVE-CARE-UNIT; BRAIN-INJURY; SUBARACHNOID HEMORRHAGE; NEURONAL DAMAGE; ACUTE STROKE; FEVER; TEMPERATURE; HYPOTHERMIA; ISCHEMIA; RATS	Objective. Prevention of secondary insults, such as hyperthermia, is a major goal after traumatic brain injury. The aim of our study was to identify risk factors for early hyperthermia in severe head-injured patients. Design. Retrospective cohort study. Setting. A 17-bed multidisciplinary ICU of a 700-bed teaching hospital. Patients. A total of 101 adult patients admitted from January 1999 to December 2001 requiring continuous monitoring of intracranial pressure according to international guidelines. Measurement and results. Forty-four patients experienced early hyperthermia (at least one episode of body temperature >38.5degreesC within the first 2 days). On univariate analysis five variables were associated with early hyperthermia: sex; body temperature; white blood cell count on admission; prophylactic use of acetaminophen; and diabetes insipidus within 2 days. On multivariate analysis, white blood cell count >14.5x10(9)/l on admission (odds ratio, 7.1; 95% confidence interval, 2.4-20.5; p=0.001) and a body temperature on admission >36degreesC (odds ratio, 6.7; 95% confidence interval, 2.3-20.1) were strong risk factors of early hyperthermia. Prophylactic use of acetaminophen was negatively associated with early hyperthermia (odds ratio, 0.1; 95% confidence interval, 0.02-0.4). Patients who experienced early hyperthermia were less prone to have good recovery (GOS=5; p=0.03). More patients with severe or moderate disability (GOS=3 or 4) experienced early hyperthermia (p=0.01). Conclusion. We identified a subgroup of patients at high risk of early hyperthermia, which is common in severe head-injured patients. These results could have clinical implications for prevention of hyperthermia after traumatic brain injury in adults.	Univ Paris 07, Beaujon Hosp, Dept Anesthesiol & Crit Care, Assistance Publ Hop Paris, F-92118 Clichy, France; Univ Paris 07, Beaujon Hosp, Dept Neurosurg, Assistance Publ Hop Paris, Clichy, France	Geffroy, A (corresponding author), Univ Paris 07, Beaujon Hosp, Dept Anesthesiol & Crit Care, Assistance Publ Hop Paris, 100 Bvd Gen Leclerc, F-92118 Clichy, France.	arnaud.geffroy@bjn.ap-hop-paris.fr	albaladejo, pierre/M-6901-2014				AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARPENTER MB, 1983, HUMAN ANATOMY, P552; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078; Circiumaru B, 1999, INTENS CARE MED, V25, P668, DOI 10.1007/s001340050928; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; FAN L, 1995, MOL BRAIN RES, V30, P125; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Jorgensen HS, 1999, STROKE, V30, P2008, DOI 10.1161/01.STR.30.10.2008; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kim Y, 1996, STROKE, V27, P2274, DOI 10.1161/01.STR.27.12.2274; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Peng RY, 1999, J AM COLL SURGEONS, V188, P685, DOI 10.1016/S1072-7515(99)00035-6; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Thompson HJ, 2003, J NEUROL NEUROSUR PS, V74, P614, DOI 10.1136/jnnp.74.5.614; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; 1999, ANN FR ANESTH REANIM, V18, P5	38	45	46	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2004	30	5					785	790		10.1007/s00134-004-2280-y			6	Critical Care Medicine	General & Internal Medicine	817BW	WOS:000221154000009	15052388				2021-06-18	
J	Kotani, N; Kudo, R; Sakurai, Y; Sawamura, D; Sessler, DI; Okada, H; Nakayama, H; Yamagata, T; Yasujima, M; Matsuki, A				Kotani, N; Kudo, R; Sakurai, Y; Sawamura, D; Sessler, DI; Okada, H; Nakayama, H; Yamagata, T; Yasujima, M; Matsuki, A			Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia	AMERICAN JOURNAL OF MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; HERPES-ZOSTER; RISK; PAIN; METHYLPREDNISOLONE; PREVENTION; INFECTION; SEQUELAE; CHILDREN	PURPOSE: Other than age, the risk factors for postherpetic neuralgia are not well established. We studied whether the concentration of interleukin 8 in the cerebrospinal fluid is associated with the risk of postherpetic neuralgia. METHODS: We enrolled 170 patients more than 50 years old who had a typical painful and nontrigeminal herpetic rash. Patients were treated with acyclovir; no corticosteroids were given. Cerebrospinal fluid was taken for analysis of interleukin 8 during and at full crusting of the herpetic rash. Age, sex, comorbid conditions, prodromal pain, localization and severity of herpetic rash, number of skin lesions, and degree of pain were recorded. We used multivariate logistic regression modeling to identify significant predictive factors. Receiver operating characteristic (ROC) curves were evaluated to determine the contribution of each factor. RESULTS: Six months after healing, 31 patients (18%) had postherpetic neuralgia; 27 patients still had it after 1 year. Only three variables-age (odds ratio [OR] = 2.7 per 10-year increase; 95% confidence interval [Cl]: 1.2 to 6.2), acute pain (OR = 1.8 per unit increase in visual analog scale; 95% CI: 1.2 to 2.8), and interleukin 8 concentration in the cerebrospinal fluid at full crusting of the herpetic rash (OR = 1.6 per 20-mug/L increase; 95% Cl: 1.3 to 2.0)-were significant predictors of postherpetic neuralgia at I year. Interleukin 8 concentration also had the highest area under the ROC curve at these evaluation points (P <0.001). CONCLUSION: Our results suggest that interleukin 8 concentration in the cerebrospinal fluid at full crusting of herpetic rash may be useful for identifying patients who are likely to develop intractable postherpetic neuralgia. (C) 2004 by Excerpta Medica Inc.	Yamagata Univ, Sch Med, Dept Anesthesiol, Outcomes Res Grp, Yamagata 9909585, Japan; Hirosaki Univ, Dept Anesthesiol, Hirosaki, Aomori, Japan; Hirosaki Univ, Dept Lab Med, Hirosaki, Aomori, Japan; Natl Def Med Coll, Dept Hyg, Tokorozawa, Saitama 359, Japan; Hokkaido Univ, Dept Dermatol, Sapporo, Hokkaido, Japan; Univ Louisville, Dept Anesthesiol, Louisville, KY 40292 USA; Iwate Med Univ, Dept Anesthesiol, Morioka, Iwate 020, Japan; Tohoku Chem Co Ltd, Hirosaki, Aomori, Japan	Kotani, N (corresponding author), Yamagata Univ, Sch Med, Dept Anesthesiol, Outcomes Res Grp, Yamagata 9909585, Japan.	kotani@med.id.yamagata-u.ac.jp	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM061655-01A2, R01 GM058273-04, GM061655, GM58273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM058273, R01GM061655] Funding Source: NIH RePORTER		ARAUJO DM, 1993, BRAIN RES, V600, P49, DOI 10.1016/0006-8993(93)90400-H; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Choo PW, 1997, ARCH INTERN MED, V157, P1217, DOI 10.1001/archinte.157.11.1217; DWORKIN RH, 1992, J ABNORM PSYCHOL, V101, P200, DOI 10.1037/0021-843X.101.1.200; Dworkin RH, 1998, J INFECT DIS, V178, pS76, DOI 10.1086/514260; Galil K, 1997, ARCH INTERN MED, V157, P1209, DOI 10.1001/archinte.157.11.1209; Haanpaa M, 1998, NEUROLOGY, V51, P1405, DOI 10.1212/WNL.51.5.1405; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Higa K, 1997, PAIN, V69, P245, DOI 10.1016/S0304-3959(96)03229-0; Jiang N, 1998, BRAIN RES, V788, P25, DOI 10.1016/S0006-8993(97)01503-5; Kikuchi A, 1999, REGION ANESTH PAIN M, V24, P287, DOI 10.1016/S1098-7339(99)90101-3; KIKUCHI T, 1995, NEUROL RES, V17, P106, DOI 10.1080/01616412.1995.11740296; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kost RG, 1997, ARCH INTERN MED, V157, P1166, DOI 10.1001/archinte.157.11.1166; Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107; Kotani N, 2000, NEW ENGL J MED, V343, P1514, DOI 10.1056/NEJM200011233432102; Lopez-Cortes LF, 2000, CRIT CARE MED, V28, P215, DOI 10.1097/00003246-200001000-00035; Matsumoto T, 1997, LAB INVEST, V77, P119; Meister W, 1998, INFECTION, V26, P359, DOI 10.1007/BF02770836; Ostergaard C, 1999, INFECT IMMUN, V67, P3430; RAGOZZINO MW, 1982, MEDICINE, V61, P310, DOI 10.1097/00005792-198209000-00003; SCHMIDBAUER M, 1992, BRAIN, V115, P383, DOI 10.1093/brain/115.2.383; Sherwood ER, 2000, CRIT CARE MED, V28, P1221, DOI 10.1097/00003246-200004000-00054; WATSON CPN, 1991, PAIN, V44, P105, DOI 10.1016/0304-3959(91)90124-G; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whitley RJ, 1999, J INFECT DIS, V179, P9, DOI 10.1086/314562; Whitley RJ, 1998, J INFECT DIS, V178, pS71, DOI 10.1086/514274; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; Xia MQ, 1997, AM J PATHOL, V150, P1267	30	45	50	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	MAR 1	2004	116	5					318	324		10.1016/j.amjmed.2003.10.027			7	Medicine, General & Internal	General & Internal Medicine	777RL	WOS:000189191300005	14984817				2021-06-18	
J	Tureci, E; Dashti, R; Tanriverdi, T; Sanus, GZ; Oz, B; Uzan, M				Tureci, E; Dashti, R; Tanriverdi, T; Sanus, GZ; Oz, B; Uzan, M			Acute ethanol intoxication in a model of traumatic brain injury: The protective role of moderate doses demonstrated by immunoreactivity of synaptophysin in hippocampal neurons	NEUROLOGICAL RESEARCH			English	Article						ethanol; neuroprotection; synaptophysin; traumatic brain injury	MICROTUBULE-ASSOCIATED PROTEIN-2; SYNAPTIC VESICLE MEMBRANE; EXPERIMENTAL HEAD TRAUMA; CEREBRAL INFARCT VOLUME; FOREBRAIN ISCHEMIA; ADULT-RAT; ALCOHOL; POTENTIATION; SYNAPTOGENESIS; IDENTIFICATION	Although ethanol intoxication is reported to be a complicating factor in traumatic brain injury, some recent studies are indicating its possible protective role especially at lower doses. Ethanol inhibition of NMDA-mediated excitotoxicity which predominates at lower doses is believed to be responsible for this protection. The aim of this study was to demonstrate this neuroprotective role of alcohol using immunoreactivity for synaptophysin as an indirect marker for severity of injury. Acute ethanol intoxication at moderate doses was performed 2 h prior to trauma. Severe traumatic brain injury was administrated using an impact acceleration model in Sprague-Dawley rats. At post-traumatic 48th hour, immunorectivity for synapthophysin in the rat hippocampi was evaluated under light microscopy. According to our results there were slight increases in immunoreactivity for synaptophysin in the stratum oriens and striatum radiatum of CA1 subfield of hippocampus when ethanol was administered prior to trauma comparing to moderate increase in the trauma-only group. On the other hand vacuolar degeneration and red neuron formation was more prominent in the pyramidal cell layer of CA1 and CA3 when ethanol was not administered. Ethanol may have a neuroprotective role when administered at moderate doses prior to traumatic brain injury. This effect of ethanol may primarily be due to inhibition of NMDA receptors.	Univ Istanbul, Cerrahpasa Med Sch, Dept Anesthesiol, Istanbul, Turkey; Univ Istanbul, Cerrahpasa Med Sch, Dept Neurosurg, Istanbul, Turkey; Univ Istanbul, Cerrahpasa Med Sch, Dept Pathol, Istanbul, Turkey	Uzan, M (corresponding author), POB 5, TR-34303 Cerrahpasa, Turkey.	uzan@istanbul.edu.tr	Sanus, Galip Zihni/D-6715-2019; Dashti, Reza/B-1368-2013; Uzan, Mustafa/D-6571-2019; Tanriverdi, Taner/C-9003-2019; Oz, Buge/AAH-6542-2019	Dashti, Reza/0000-0002-2257-262X; Sanus, Galip Zihni/0000-0001-6539-7254; Uzan, Mustafa/0000-0001-7214-380X			ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; BAUGHMAN VL, 1990, J NEUROSURG ANESTH, V2, P290, DOI 10.1097/00008506-199012000-00007; Bergmann M, 1997, EXP BRAIN RES, V117, P80, DOI 10.1007/s002210050201; BRODNER RA, 1981, J TRAUMA, V21, P124, DOI 10.1097/00005373-198102000-00005; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DILDY JE, 1989, BRAIN RES, V499, P383, DOI 10.1016/0006-8993(89)90789-0; ELMER O, 1984, HAEMOSTASIS, V14, P223; Ferrer I, 1998, J COMP NEUROL, V394, P416; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; Hinz B, 2001, EUR J CELL BIOL, V80, P615, DOI 10.1078/0171-9335-00196; HOFSTEDE DJ, 1995, J NEUROTRAUM, V12, P974; Hou XE, 2000, NEUROCHEM RES, V25, P1275, DOI 10.1023/A:1007600313865; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; INGLIS FM, 1990, ACT NEUR S, V51, P277; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Kraus JF, 1993, HEAD INJURY, P1; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; MIYAZAWA T, 1993, ACTA NEUROPATHOL, V85, P526; MODELL JG, 1990, NEW ENGL J MED, V323, P455, DOI 10.1056/NEJM199008163230706; MONTASSER A, 1994, J NEUROSURG, V80, P301; MOORE JW, 1964, J GEN PHYSIOL, V48, P279, DOI 10.1085/jgp.48.2.279; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PIKAAR NA, 1987, METABOLISM, V36, P538, DOI 10.1016/0026-0495(87)90163-6; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SHAPIRA Y, 1994, STROKE, V25, P1637, DOI 10.1161/01.STR.25.8.1637; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAKADERA T, 1997, BRAIN RES, V53, P109; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; WALAAS SI, 1988, SYNAPSE, V2, P516, DOI 10.1002/syn.890020507; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; ZINC BJ, 1995, J NEUROSURGF, V82, P822; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	59	45	48	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JAN	2004	26	1					108	112		10.1179/016164104225013699			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	773FF	WOS:000188886500017	14977068				2021-06-18	
J	Underhill, AT; Lobello, SG; Stroud, TP; Terry, KS; Devivo, MJ; Fine, PR				Underhill, AT; Lobello, SG; Stroud, TP; Terry, KS; Devivo, MJ; Fine, PR			Depression and life satisfaction in patients with traumatic brain injury: a longitudinal study	BRAIN INJURY			English	Article							INDEX	Primary objective: To assess the relationship between depression and life satisfaction among survivors of traumatic brain injury (TBI) over a 3-year period after injury. It was hypothesized that survivors of TBI with depression would have decreased life satisfaction. Research design: Two groups ( depression vs no depression) longitudinal design. Methods and procedures: Interviewed survivors of TBI (n = 324) by telephone at 24, 48 and 60 months after hospitalization. At the 24-month interview, 90 (27.8%) respondents reported a post-injury diagnosis of depression and 234 (72.2%) reported no diagnosis. Respondents then completed the Life Satisfaction Index I-A, which was repeated at the 48- and 60-month interviews. Main outcomes and results: The depression group had significantly lower life satisfaction than the no depression group at 24-, 48- and 60-month interviews. Conclusions: Depression and diminished life satisfaction among survivors of TBI are persistent problems that require the close attention of medical and rehabilitation professionals.	Univ Alabama, Sch Med, Injury Control Res Ctr, Birmingham, AL 35294 USA; UAB, Spain Rehabil Ctr, Dept Phys Med & Rehabil, Birmingham, AL USA; Auburn Univ, Montgomery, AL 36117 USA	Underhill, AT (corresponding author), Univ Alabama, Sch Med, Injury Control Res Ctr, 403 Community Hlth Serv Bldg,933 19th St S, Birmingham, AL 35294 USA.				ODCDC CDC HHS [R49 CCR403641] Funding Source: Medline		ADAMS DL, 1969, J GERONTOL, V24, P470, DOI 10.1093/geronj/24.4.470; *AM ASS AUT MED CO, 1985, ABBR INJ SCAL; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Garthe E, 1999, J TRAUMA, V47, P309, DOI 10.1097/00005373-199908000-00016; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Lecrubier Y, 2001, J CLIN PSYCHIAT, V62, P4; Lecrubier Y, 2000, EUR NEUROPSYCHOPHARM, V10, pS439, DOI 10.1016/S0924-977X(00)00111-5; LOHMANN N, 1977, J GERONTOL, V32, P73, DOI 10.1093/geronj/32.1.73; Maciejewski PK, 2001, PSYCHOL MED, V31, P593, DOI 10.1017/S0033291701003877; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Miranda J., 1994, MENTAL DISORDERS PRI; *NAT I MENT HLTH, 1996, PUBL NAT I MENT HLTH; *NAT I MENT HLTH, 2001, PUBL NAT I MENT HLTH; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; RAO V N, 1981, International Journal of Aging and Human Development, V14, P55, DOI 10.2190/DWM4-E05K-CNTD-XNAA; ROBINS LN, 1990, PSYCHIAT DISORDERS A; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; Wallace KA, 2002, EDUC PSYCHOL MEAS, V62, P674, DOI 10.1177/0013164402062004009	23	45	46	0	12	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2003	17	11					973	982		10.1080/0269905031000110418			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	725GE	WOS:000185534800004	14514448				2021-06-18	
J	Bedi, A; Murray, JM; Dingley, J; Stevenson, MA; Fee, JPH				Bedi, A; Murray, JM; Dingley, J; Stevenson, MA; Fee, JPH			Use of xenon as a sedative for patients receiving critical care	CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	2000	SAN FRANCISCO, CALIFORNIA	Amer Soc Anesthesiologists		noble gases; sedatives; critical care	CLOSED-CIRCUIT ANESTHESIA; NITROUS-OXIDE; STABLE XENON; SUBANAESTHETIC CONCENTRATIONS; INTRACRANIAL-PRESSURE; PROPOFOL INFUSION; DELIVERY SYSTEM; HEAD-INJURY; ACCUMULATION; BLOOD	Objective. Many sedative regimens are used in the intensive care setting, but none are wholly without adverse effect. Xenon is a noble gas with sedative and analgesic properties. It has been used successfully as a general anesthetic and has many desirable properties, not least of which is a minimal effect on the myocardium. In theory, xenon may provide sedation without adverse effect for certain groups of critically ill patients. The objective of this study was to assess the feasibility of using xenon as an intensive care sedative. Design: Double-blind, randomized study. Setting. Tertiary-level intensive care unit. Subjects. Twenty-one patients admitted to an intensive care unit following elective thoracic surgery. Interventions. A standard intensive care sedation regimen (intravenous propofol at 0-5 mg(.)kg(-1.)hr(-1) and alfentanil 30 mug(.)kg(-1.)hr(-1)) was compared with a xenon sedation regimen delivered using a novel bellows-in-bottle delivery system. Measurements and Main Results., Each sedative regimen was continued for 8 hrs. The hemodynamic effects, additional analgesic requirements, recovery from sedation, and effect on hematological and biochemical variables were compared for the two sedation regimens. All patients were successfully sedated during the xenon regimen. The mean +/- SD end-tidal xenon concentration required to provide sedation throughout the duration of the study was 28 +/- 9.0% (range, 9-62%). Arterial systolic, diastolic, and mean pressures showed a greater tendency for negative gradients in patients receiving the propofol regimen (p < .05, p < .1, and p < .01, respectively). Recovery following xenon was significantly faster than from the standard sedation regimen (p < .0001). Hematological and biochemical laboratory markers were within normal clinical limits in both groups. Conclusions. Xenon provided satisfactory sedation in our group of patients. It was well tolerated with minimal hemodynamic effect. Recovery from this agent is extremely rapid. We have demonstrated the feasibility of using xenon within the critical care setting, without adverse effect.	Royal Grp Hosp, Belfast, Antrim, North Ireland; Queens Univ Belfast, Dept Anaesthet & Intens Care Med, Belfast, Antrim, North Ireland; Morriston Hosp, Swansea, W Glam, Wales; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast, Antrim, North Ireland	Bedi, A (corresponding author), Royal Grp Hosp, Belfast, Antrim, North Ireland.						Bedi A, 2002, ANAESTHESIA, V57, P233, DOI 10.1046/j.0003-2409.2001.02455.x; BOOMSMA F, 1990, ANAESTHESIA, V45, P273, DOI 10.1111/j.1365-2044.1990.tb14731.x; BUROV NE, 1993, ANESTEZIOL REANIMAT, V5, P57; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; DARBY JM, 1989, SURG NEUROL, V32, P343, DOI 10.1016/0090-3019(89)90136-5; Dingley J, 1999, CRIT CARE MED, V27, P2435, DOI 10.1097/00003246-199911000-00019; Dingley J, 2001, ANESTHESIOLOGY, V94, P173, DOI 10.1097/00000542-200101000-00034; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; Goto T, 1997, BRIT J ANAESTH, V79, P595; Goto T, 1998, BRIT J ANAESTH, V80, P255, DOI 10.1093/bja/80.2.255; Goto T, 2000, BRIT J ANAESTH, V85, P359, DOI 10.1093/bja/85.3.359; LACHMANN B, 1990, LANCET, V335, P1413; LUTTROPP HH, 1993, ANAESTHESIA, V48, P1045; MARION DW, 1991, J CEREBR BLOOD F MET, V11, P347, DOI 10.1038/jcbfm.1991.69; Marx T, 1997, BRIT J ANAESTH, V78, P326; MORITA S, 1985, ANESTH ANALG, V64, P343; Murdoch S, 2000, INTENS CARE MED, V26, P922, DOI 10.1007/s001340051282; Nakata Y, 1999, J CLIN ANESTH, V11, P477, DOI 10.1016/S0952-8180(99)00087-2; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Petersen-Felix S, 1998, BRIT J ANAESTH, V81, P742, DOI 10.1093/bja/81.5.742; Petzelt C, 1999, PFLUG ARCH EUR J PHY, V437, P737, DOI 10.1007/s004240050840; Petzelt C, 1999, LIFE SCI, V65, P901, DOI 10.1016/S0024-3205(99)00320-3; PHILLIPS AS, 1993, ANAESTHESIA, V48, P661, DOI 10.1111/j.1365-2044.1993.tb07173.x; PLOUGMANN J, 1994, J NEUROSURG, V81, P822, DOI 10.3171/jns.1994.81.6.0822; PUNTILLO KA, 1990, HEART LUNG, V19, P526; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; REVELL S, 1988, ANAESTHESIA, V43, P477, DOI 10.1111/j.1365-2044.1988.tb06636.x; ROLLY G, 1994, ANESTH ANALG, V79, P545; SCHOENBORN BP, 1965, NATURE, V208, P760, DOI 10.1038/208760a0; STRAUSS JM, 1993, BRIT J ANAESTH, V70, P363, DOI 10.1093/bja/70.3.363; Suzuki A, 2000, EUR J ANAESTH, V17, P359, DOI 10.1046/j.1365-2346.2000.00697.x; Trudell JR, 1998, ANESTH ANALG, V87, P411, DOI 10.1097/00000539-199808000-00034; Versichelen L, 1996, BRIT J ANAESTH, V76, P668; WILLATTS SM, 1994, ANAESTHESIA, V49, P422; YAGI M, 1995, BRIT J ANAESTH, V74, P670, DOI 10.1093/bja/74.6.670	35	45	47	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	OCT	2003	31	10					2470	2477		10.1097/01.CCM.0000089934.66049.76			8	Critical Care Medicine	General & Internal Medicine	733LZ	WOS:000186003100008	14530753				2021-06-18	
J	Lendon, CL; Harris, JM; Pritchard, AL; Nicoll, JAR; Teasdale, GM; Murray, G				Lendon, CL; Harris, JM; Pritchard, AL; Nicoll, JAR; Teasdale, GM; Murray, G			Genetic variation of the APOE promoter and outcome after head injury	NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; APOLIPOPROTEIN-E GENE; ALZHEIMERS-DISEASE; POLYMORPHISMS	The APOE-epsilon4 allele is associated with risk for Alzheimer's disease (AD) and poorer outcome after head injury. Several studies show that polymorphisms in the promoter that influence APOE expression also increase risk for AD. The authors' data from a study of 92 patients are consistent with a possible influence of the G-219T promoter polymorphism on outcome after head injury. The group with unfavorable outcome had a genotype frequency distribution similar to that found in AD.	Univ Birmingham, Dept Psychiat, Birmingham, W Midlands, England; Univ Birmingham, Dept Neurosci, Birmingham, W Midlands, England; Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Southampton, Div Clin Neurosci, Southampton SO9 5NH, Hants, England; Univ Glasgow, So Gen Hosp, Dept Neurosurg, Glasgow G12 8QQ, Lanark, Scotland	Lendon, CL (corresponding author), Univ Birmingham, Dept Psychiat, Birmingham, W Midlands, England.		Pritchard, Antonia L/F-4288-2010; Nicoll, James/I-9253-2017	Pritchard, Antonia L/0000-0001-5336-0454; Nicoll, James/0000-0002-9444-7246; Murray, Gordon/0000-0001-9866-4734			Artiga MJ, 1998, FEBS LETT, V421, P105, DOI 10.1016/S0014-5793(97)01543-3; Barnes MP, 1999, BRIT MED BULL, V55, P927, DOI 10.1258/0007142991902727; Bullido MJ, 2000, MICROSC RES TECHNIQ, V50, P261, DOI 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO;2-B; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Lambert JC, 2002, NEUROLOGY, V59, P59, DOI 10.1212/WNL.59.1.59; Lambert JC, 2001, LANCET, V357, P608, DOI 10.1016/S0140-6736(00)04063-0; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3	10	45	53	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	SEP 9	2003	61	5					683	685		10.1212/01.WNL.0000078033.81925.80			3	Clinical Neurology	Neurosciences & Neurology	719CX	WOS:000185187000019	12963763				2021-06-18	
J	Soustiel, JF; Glenn, TC; Vespa, P; Rinsky, B; Hanuscin, C; Martin, NA				Soustiel, JF; Glenn, TC; Vespa, P; Rinsky, B; Hanuscin, C; Martin, NA			Assessment of cerebral blood flow by means of blood-flow-volume measurement in the internal carotid artery - Comparative study with a (133)xenon clearance technique	STROKE			English	Article						cerebral blood flow; hemodynamics; ultrasonography, Doppler	POSITRON-EMISSION-TOMOGRAPHY; COLOR DUPLEX MEASUREMENT; ACUTE HEAD-INJURY; VERTEBRAL ARTERIES; HEALTHY-ADULTS; STROKE; INHALATION; METABOLISM; VASOSPASM; REPRODUCIBILITY	Background and Purpose-We sought to evaluate a new, angle-independent ultrasonic device for assessment of blood flow volume (BFV) in the internal carotid artery (ICA). Methods-Nineteen patients and 4 healthy volunteers were enrolled in a comparative study conducted in the Care Unit of the Division of Neurosurgery at UCLA Medical Center. All patients had been admitted because of severe brain injury: 15 patients with severe head trauma (Glasgow Coma Scale scoreless than or equal to8) and 4 patients with subarachnoid hemorrhage due to aneurysm rupture. In all patients and subjects, cerebral blood flow (CBF) values obtained with the (133)xenon-clearance technique were compared with BFV measurements in the ipsilateral ICA. Results-Hemispheric CBF values showed a close and linear correlation with BFV measurements (r=0.76, P<0.0001). Global CBF values showed a higher correlation with the total BFV value obtained from both ICAs (r=0.84, P<0.0001). With 37 mL . min(-1) . 100 g(-1) as a cutoff value for the ischemic range, a BFV value of 220 mL/min would yield a positive predictive value of 91.7% and a negative predictive value of 82.6% ( sensitivity 73.3%, specificity 95%). Conversely, BFV sensitivity and specificity were 60% and 96%, respectively, for the hyperemic range defined by a CBF value >55 mL . min(-1) . 100 g(-1) (positive predictive value of 85.7% and negative prediction value of 85.7%). Conclusions-BFV measurements with this new technology proved to accurately correlate with CBF values evaluated by the (133)xenon-clearance technique. These results support the implementation of this technique for bedside assessment of cerebral hemodynamics in critically ill neurosurgical patients.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rambam Med Ctr, Dept Neurosurg, IL-31096 Haifa, Israel	Martin, NA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA.			Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408			Ascher E, 2002, J VASC SURG, V35, P439, DOI 10.1067/mva.2002.120044; Blizhevsky A, 1997, MED ENG PHYS, V19, P352, DOI 10.1016/S1350-4533(96)00048-3; DOBERSTEIN C, 1996, NEUROLOGICAL SURG, V1; Dorfler P, 2000, J CEREBR BLOOD F MET, V20, P269; Eicke B M, 1995, J Neuroimaging, V5, P115; GILL RW, 1985, ULTRASOUND MED BIOL, V11, P625, DOI 10.1016/0301-5629(85)90035-3; Ho SSY, 2002, AM J ROENTGENOL, V178, P551, DOI 10.2214/ajr.178.3.1780551; Ho SSY, 2000, STROKE, V31, P1342, DOI 10.1161/01.STR.31.6.1342; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; KETY SS, 1945, AM J PHYSIOL, V143, P53; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LENZI GL, 1981, EUR NEUROL, V20, P285, DOI 10.1159/000115248; Licht PB, 1999, EUR J VASC ENDOVASC, V17, P219, DOI 10.1053/ejvs.1998.0741; MADSEN PL, 1993, J CEREBR BLOOD F MET, V13, P646, DOI 10.1038/jcbfm.1993.83; Martin N A, 1994, Neurosurg Clin N Am, V5, P607; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1967, CIRC RES, V20, P124, DOI 10.1161/01.RES.20.1.124; PERLMUTTER JS, 1987, J CEREBR BLOOD F MET, V7, P64, DOI 10.1038/jcbfm.1987.9; PODREKA I, 1989, STROKE, V20, P183, DOI 10.1161/01.STR.20.2.183; Sakoh M, 2000, STROKE, V31, P1958, DOI 10.1161/01.STR.31.8.1958; Sakoh M, 2000, J NEUROSURG, V93, P647, DOI 10.3171/jns.2000.93.4.0647; Scheel P, 2000, STROKE, V31, P147, DOI 10.1161/01.STR.31.1.147; SCHONING M, 1994, STROKE, V25, P17, DOI 10.1161/01.STR.25.1.17; Schoning M, 1996, J CEREBR BLOOD F MET, V16, P523, DOI 10.1097/00004647-199605000-00020; SHIRAHATA N, 1985, J COMPUT ASSIST TOMO, V9, P861, DOI 10.1097/00004728-198509000-00004; Sorensen AG, 1999, RADIOLOGY, V210, P519, DOI 10.1148/radiology.210.2.r99fe06519; Soustiel JF, 2002, J ULTRAS MED, V21, P1405, DOI 10.7863/jum.2002.21.12.1405; Soustiel JF, 2001, STROKE, V32, P629, DOI 10.1161/01.STR.32.3.629; Steinman AH, 2001, ULTRASOUND MED BIOL, V27, P655, DOI 10.1016/S0301-5629(01)00352-0; Tan TY, 2002, J NEUROIMAGING, V12, P144, DOI 10.1111/j.1552-6569.2002.tb00111.x; ZIERLER BK, 1992, J VASC SURG, V16, P520, DOI 10.1016/0741-5214(92)90159-6	32	45	48	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	AUG	2003	34	8					1876	1880		10.1161/01.STR.0000080942.32331.39			5	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	706YF	WOS:000184482100014	12843349	Bronze			2021-06-18	
J	Mills, JD; Stone, JR; Rubin, DG; Melon, DE; Okonkwo, DO; Periasamy, A; Helm, GA				Mills, JD; Stone, JR; Rubin, DG; Melon, DE; Okonkwo, DO; Periasamy, A; Helm, GA			Illuminating protein interactions in tissue using confocal and two-photon excitation fluorescent resonance energy transfer microscopy	JOURNAL OF BIOMEDICAL OPTICS			English	Article						fluorescent resonance energy transfer; confocal and two-photon fluorescent resonance energy transfer; BAD; Bcl-xL; traumatic axonal injury; tissue fluorescent; resonance energy transfer	TRAUMATIC BRAIN-INJURY; FRET MICROSCOPY; LIVING CELLS; APOPTOSIS; DEPHOSPHORYLATION; VISUALIZATION; ACTIVATION; ASSAY; BAD	Traumatic brain injury (TBI) remains the most common cause of death in persons under age 45 in the Western world. One of the principal determinants of morbidity and mortality following TBI is traumatic axonal injury (TAI). Current hypotheses on the pathogenesis of TAI involve activation of apoptotic cascades secondary to TBI. While a number of studies have demonstrated direct evidence for the activation of apoptotic cascades in TAI, the precise pathway by which these cascades are initiated remains a subject of intense investigation. As axolemmal disruption with the subsequent intra-axonal influx of large molecular weight species has been demonstrated to occur in relation to local axonal breakdown, attention has focused on cascades that may occur as a result of loss of ionic homeostasis. One proposed pathway by which this has been hypothesized to occur is the Ca2+-mediated activation of calmodulin and subsequent activation of the phosphatase calcineurin with dephosphorylation of a protein known as BAD, leading to a proapoptotic interaction between BAD and the mitochondrial protein Bcl-xL. While this pathway is an intriguing route for traumatic axonal pathogenesis, neither conventional irnmunocytochemical/histochemical nor ultrastructural approaches have had the capacity to shed insight on whether BAD and Bcl-xL interact in TAI in vivo. We describe the implementation of confocal and two-photon excitation fluorescence resonance energy transfer (FRET) microscopy techniques through which we demonstrate interaction between the proapoptotic protein BAD and the prosurvival protein Bcl-xL within TAI following TBI. Further, we report on a method to reliably detect protein interactions within aldehyde fixed tissue sections through conventional immunohistochemical approaches. (C) 2003 society of Photo-Optical Instrumentation Engineers.	Univ Virginia, Hlth Sci Ctr, Dept Neurosurg, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Neurosci, Charlottesville, VA 22908 USA; Univ Virginia, WM Keck Ctr Cellular Imaging, Charlottesville, VA 22904 USA; Univ Virginia, Dept Biol, Charlottesville, VA 22904 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22904 USA	Mills, JD (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Neurosurg, Charlottesville, VA 22908 USA.		Periasamy, Ammasi/B-1279-2010				Bai YL, 2003, MOL ENDOCRINOL, V17, P589, DOI 10.1210/me.2002-0351; Bruno JG, 2001, BIOCHEM BIOPH RES CO, V287, P875, DOI 10.1006/bbrc.2001.5669; Buki A, 2000, J NEUROSCI, V20, P2825; Day RN, 1998, MOL ENDOCRINOL, V12, P1410, DOI 10.1210/me.12.9.1410; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Elangovan M, 2003, METHODS, V29, P58, DOI 10.1016/S1046-2023(02)00283-9; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Everett H, 2002, J EXP MED, V196, P1127, DOI 10.1084/jem.20011247; Forster T, 1965, MODERN QUANTUM CHEMI, P93; Janetopoulos C, 2001, SCIENCE, V291, P2408, DOI 10.1126/science.1055835; Jones J, 2000, J BIOMOL SCREEN, V5, P307, DOI 10.1177/108705710000500502; KAM Z, 1995, J CELL SCI, V108, P1051; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; KOKSCH M, 1995, J IMMUNOL METHODS, V187, P53, DOI 10.1016/0022-1759(95)00166-8; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Periasamy A, 1999, MICROSC RES TECHNIQ, V47, P172, DOI 10.1002/(SICI)1097-0029(19991101)47:3<172::AID-JEMT3>3.3.CO;2-1; Periasamy A, 2001, J BIOMED OPT, V6, P287, DOI 10.1117/1.1383063; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sekar RB, 2003, J CELL BIOL, V160, P629, DOI 10.1083/jcb.200210140; Sharma N, 2001, AM J PATHOL, V159, P339, DOI 10.1016/S0002-9440(10)61700-2; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Springer JE, 2000, J NEUROSCI, V20, P7246; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509	29	45	46	0	5	SPIE-INT SOCIETY OPTICAL ENGINEERING	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668			J BIOMED OPT	J. Biomed. Opt.	JUL	2003	8	3					347	356		10.1117/1.1584443			10	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	709CD	WOS:000184606400004	12880338				2021-06-18	
J	Wagner, AK; Fabio, T; Zafonte, RD; Goldberg, G; Marion, DW; Peitzman, AB				Wagner, AK; Fabio, T; Zafonte, RD; Goldberg, G; Marion, DW; Peitzman, AB			Physical medicine and rehabilitation consultation - Relationships with acute functional outcome, length of stay, and discharge planning after traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						physiatry; consultation; traumatic brain injury; rehabilitation; outcome; health care	VARIABLES; SEVERITY	Objective: Patients hospitalized with traumatic brain injury comprise a large portion of the population treated at trauma centers, and physiatry consultants evaluate many traumatic brain injury patients in this setting. The purpose of this study was to delineate relationships between physical medicine and rehabilitation consultation in this population and acute functional outcome, length of stay, and discharge planning. Design: Data were obtained for 1866 adult patients hospitalized with non-fatal traumatic brain injury. Functional outcome was determined using a modification of the FIM(TM). Descriptive and regression analyses were used to determine the relationship of physical medicine and rehabilitation consultation to acute discharge FIM score, length of stay, and discharge disposition. Results: Patients receiving physical medicine and rehabilitation consultation had more severe injuries, lower acute discharge FIM scores, and longer length of stay. However, multivariate analysis showed that earlier (<48 hr after admission) physical medicine and rehabilitation consultation resulted in significantly better FIM scores with transfers (odds ratio, 2.61; 95% confidence interval, 1.06-6.40) and locomotion (odds ratio, 3.54; 95% confidence interval, 1.34-9.32) and a significantly shorter acute length of stay (P = 0.001). Conclusions: Early physical medicine and rehabilitation consultation may positively impact functional status and length of stay for patients with traumatic brain injury during acute hospitalization. Additional work is needed to determine how physical medicine and rehabilitation consultation impacts rehabilitation-specific medical issues, long-term functional outcome, and healthcare costs.	Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurol Surg, Ctr Injury Res & Control, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Sect Trauma, Dept Surg, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	ODCDC CDC HHS [CCR310285-07] Funding Source: Medline		GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; LEHMAN LB, 1988, POSTGRAD MED, V83, P140; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MACKAY LE, 1994, J HEAD TRAUMA REHAB, V9, P11; MAZZUCCHI A, 1992, J NEUROL, V239, P256; Melchiorre PJ, 1998, ARCH PHYS MED REHAB, V79, P62, DOI 10.1016/S0003-9993(98)90210-6; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; Taheri PA, 1997, J TRAUMA, V43, P565, DOI 10.1097/00005373-199710000-00001; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; UNICO J, 2001, J NEUROTRAUM, V18, P1177; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198	15	45	48	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUL	2003	82	7					526	536		10.1097/00002060-200307000-00006			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	694DC	WOS:000183757700006	12819540				2021-06-18	
J	Reynolds, S; Paniak, C; Toller-Lobe, G; Nagy, J				Reynolds, S; Paniak, C; Toller-Lobe, G; Nagy, J			A longitudinal study of compensation-seeking and return to work in a treated mild traumatic brain injury sample	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						financial compensation; mild traumatic brain injury; return to work	CLOSED-HEAD-INJURY; RANDOMIZED TRIAL	Objective: In patients with mild traumatic brain injury (MTBI), to assess: (1) changes in financial compensation-seeking status over time and (2) the relationship between compensation-seeking and return to work. Design: Longitudinal evaluation of financial compensation-seeking status (i.e., at intake, 3 months postinjury, and 12 months postinjury) and relationship of such status to return to work. Setting: Outpatient rehabilitation clinic. Subjects: Ninety-seven patients with MTBI Main outcome measures: Compensation-seeking status at 3 and 12 months and days taken to return to preinjury vocational activity. Results: Those in litigation at intake generally continued to be in litigation at 3 and 12 months postinjury. Those seeking or receiving compensation via administrative means (e.g., sick pay or workers' compensation) at intake were generally not seeking or receiving compensation by 3 months or later, as was the case for most of those not seeking any financial compensation at intake. Patients seeking or receiving financial compensation via litigation and/or administrative means at intake took longer to return to work than did people who were not seeking or receiving compensation at intake. Conclusions: present study design does not allow for determination of the reasons for the strong relationship between financial compensation-seeking soon post-MTBI and a slow return to work. However, the strength of the present findings indicates that the presence or absence of financial compensation-seeking soon post-MTBI should be routinely evaluated when return to work is an issue.	Glenrose Rehabil Hosp, Psychol Serv, Edmonton, AB T5G 0B7, Canada; Glenrose Rehabil Hosp, Phys Therapy Serv, Edmonton, AB T5G 0B7, Canada; Glenrose Rehabil Hosp, Med Serv, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada	Paniak, C (corresponding author), Glenrose Rehabil Hosp, Psychol Serv, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.						*AM MED ASS, 1995, AMA DRUG EV; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; DUSH DM, 1994, J PERS ASSESS, V62, P299, DOI 10.1207/s15327752jpa6202_10; Evans R. W., 1994, AM J FORENSIC PSYCH, V4, P19; Greiffenstein M. F., 2000, BRAIN INJ SOURCE, V4, P26; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	14	45	45	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					139	147		10.1097/00001199-200303000-00005			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600005	12802223				2021-06-18	
J	Williams, WH				Williams, WH			Brain injury and emotion: An overview to a special issue on biopsychosocial approaches in neurorehabilitation	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY	Survivors of acquired brain injury (ABI) are at risk of a range of neuropsychiatric and behavioural disorders. Emotional disturbance, with reactive elements of mood disorder, such as depression and anxiety, appear particularly common. Specific anxiety disorders, such as post-traumatic stress disorder (PTSD) have also been identified. Pain syndromes are also common-particularly in those who have suffered Traumatic Brain Injuries (TBI). Survivors of ABI are often at risk of substance misuse and of irritability states. Their relationships may suffer from the stresses triggered by the aftermath of injury. Intimate, in particular, sexual relationships may be particularly affected. These effects are not, necessarily, only consequent of severe injuries, as mild TBI can also have, for some, significant neuropsychiatric effects. Assessment and management of such conditions are compromised by survivors of injury often having a limited insight into the sequelae of their injuries. Interventions for such disorders and forms of distress are increasingly available. This paper introduces the special issue of Neuropsychological Rehabilitation on biopsychosocial approaches in neurorehabilitation. A range of papers provide overviews for assessing and managing such neuropsychiatric, mood and behavioural (health and habit) disorders.	Univ Exeter, Sch Psychol, Exeter EX4 4QG, Devon, England; Oliver Zangwill Ctr, Ely, Cambs, England	Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Exeter EX4 4QG, Devon, England.			williams, huw/0000-0003-0670-2620			Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; HARRIS DP, 1997, J OUTCOMES MEASUREME, V1, P23; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Lewis G, 2001, J NEUROL NEUROSUR PS, V71, P431, DOI 10.1136/jnnp.71.4.431; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P11; Lishman WA, 1998, ORGANIC PSYCHIAT; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; Oddy M, 2001, NEUROBEHAVIOURAL DIS; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; WILLIAMS WH, 2003, STUDIES NEUROPSYCHOL; WILSON B, 1989, MODELS BRAIN INJURY, P117; Wood RL, 2001, NEUROBEHAVIOURAL DIS; World Health Organization, 2001, INT CLASS FUNCT DIS; Zeman A, 2001, BRAIN, V124, P1263, DOI 10.1093/brain/124.7.1263	22	45	45	0	16	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		1	11		10.1080/09602010244000444			11	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500001	22004099				2021-06-18	
J	Williams, WH; Evans, JJ; Fleminger, S				Williams, WH; Evans, JJ; Fleminger, S			Neurorehabilitation and cognitive-behaviour therapy of anxiety disorders after brain injury: An overview and a case illustration of obsessive-compulsive disorder	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							OUTCOME MEASURES	Survivors of acquired and traumatic brain injuries may often experience anxiety states. Psychological reactions to neurological trauma may be caused by a complex interaction of a host of factors. We explore how anxiety states may be understood in terms of a biopsychosocial formulation of such factors. We also review the current evidence for the presence of specific anxiety disorders after brain injury. We then describe how cognitive-behaviour therapy (CBT), a treatment of choice for many anxiety disorders, may be integrated with cognitive rehabilitation (CR), for the management of anxiety disorders in brain injury. We illustrate how CBT and CR may be delivered with a case of a survivor of traumatic brain injury (TBI) who had developed obsessive compulsive disorder and health anxiety. We show how CBT plus CR allows a biopsychosocial formulation to be developed of the survivor's concerns for guiding a goal-based intervention. The survivor made significant gains from intervention in terms of goals achieved and changes on clinical measures. We argue that large-scale research is needed for developing an evidence base for managing emotional disorders in brain injury.	Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter, Devon, England; Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, England; Maudsley Hosp & Inst Psychiat, Lishman Brain Injury Unit, London SE5 8AZ, England	Williams, WH (corresponding author), Univ Exeter, Sch Psychol, Washington Singer Labs, Exeter, Devon, England.			williams, huw/0000-0003-0670-2620			*AM PSYCH ASS, 1994, DIAGN STAT MAN, V4; *AM PSYCH ASS, 2000, DIAGN STAT MAN, V4; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Bond M. R., 1990, REHABILITATION ADULT, P179; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bradshaw J.L., 2001, DEV DISORDERS FRONTO; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; DAVEY GL, 1994, NEW WORRYING PERSPEC; Eells T. D., 1997, HDB PSYCHOTHERAPY CA; Fonagy, 1996, WHAT WORKS WHOM CRIT; HARRIS DP, 1997, J OUTCOMES MEASUREME, V1, P23; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HODGSON RJ, 1977, BEHAV RES THER, V15, P389, DOI 10.1016/0005-7967(77)90042-0; Holzer JC, 1998, J NEUROPSYCH CLIN N, V10, P113, DOI 10.1176/jnp.10.1.113; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lishman WA, 1998, ORGANIC PSYCHIAT; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MANCHESTER D, 2001, NEUROBEHAVIOURAL DIS; MARCH JS, 1994, J AM ACAD CHILD PSY, V33, P333, DOI 10.1097/00004583-199403000-00006; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; Pender N, 1999, NEUROPSYCHOL REHABIL, V9, P345, DOI 10.1080/096020199389428; PONSFORD J, 1998, TRAUMATIC BRAIN INJU; Rauch SL, 1997, BIOL PSYCHIAT, V42, P446, DOI 10.1016/S0006-3223(97)00145-5; SALKOVSKIS PM, 2001, HYPOCHONDRIASIS MODE; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; Spinella M, 2002, BRAIN INJURY, V16, P359, DOI 10.1080/02699050110103319; Tallis F, 1997, BRIT J CLIN PSYCHOL, V36, P3, DOI 10.1111/j.2044-8260.1997.tb01226.x; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; WILLIAMS WH, 1997, COGNITIVE THERAPY PE; WILLIAMS WH, IN PRESS STUDIES NEU; WILLIAMS WH, IN PRESS BRAIN INJUR; Wise M G, 1999, Semin Clin Neuropsychiatry, V4, P98; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zitterl W, 2001, PSYCHOPATHOLOGY, V34, P113, DOI 10.1159/000049292	37	45	46	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		133	148		10.1080/09602010244000417			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500008	21854331				2021-06-18	
J	Nakahara, S; Yone, K; Setoguchi, T; Yamaura, I; Arishima, Y; Yoshino, S; Komiya, S				Nakahara, S; Yone, K; Setoguchi, T; Yamaura, I; Arishima, Y; Yoshino, S; Komiya, S			Changes in nitric oxide and expression of nitric oxide synthase in spinal cord after acute traumatic injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						microdialysis; nitric oxide; nitric oxide synthase; spinal cord injury	METHYL-D-ASPARTATE; FOCAL CEREBRAL-ISCHEMIA; BRAIN; APOPTOSIS; NEUROTOXICITY; MECHANISMS; NOS; INHIBITION; CULTURES; NEURONS	The aim of this study was to observe the time course of NO production and NOS expression in the spinal cord following acute traumatic injury. Rat spinal cord was injured by extradural static weight-compression, which resulted in an incomplete transverse spinal cord lesion with paralysis of, the lower extremities. Using this model, measurement of NO by microdialysis and Griess reaction and histological and immunohistochemical examinations using polyclonal antibodies to nNOS and iNOS were performed from immediately to 14 days after injury. In injured cord, the amount of, NO markedly increased immediately after injury and gradually decreased between 1 and 12 h after injury. A second wave of increase in NO level was observed at 24 h and 3 days after injury. Histologically, hematomas and necrotic changes were observed after injury and demyelination of nerve fibers increased with time in the compressed segment. Immunohistochemically, the number of cells with expression of nNOS was increased immediately to 12 h after injury. Expression of iNOS was observed from 12 h to 3 days after injury. These findings suggested that the initial maximal increase of NO production might be caused mainly by nNOS and that the second wave of increase in NO might be due mainly to iNOS.	Kagoshima Univ, Fac Med, Dept Orthopaed Surg, Kagoshima 8908520, Japan	Yone, K (corresponding author), Kagoshima Univ, Fac Med, Dept Orthopaed Surg, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.						AKIRA T, 1994, BRAIN RES, V645, P285, DOI 10.1016/0006-8993(94)91662-4; Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; ANDERSON DK, 1980, J NEUROSURG, V52, P387, DOI 10.3171/jns.1980.52.3.0387; BLACK P, 1986, NEUROSURGERY, V19, P752, DOI 10.1227/00006123-198611000-00006; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brunetti L, 1994, Clin Ter, V144, P147; BUISSON A, 1993, J NEUROCHEM, V61, P690; CHI OZ, 1994, PHARMACOLOGY, V48, P367, DOI 10.1159/000139202; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEMEDIUK P, 1989, J NEUROCHEM, V52, P1529, DOI 10.1111/j.1471-4159.1989.tb09204.x; Esch F, 1998, J NEUROSCI, V18, P4083; Estevez AG, 1998, J NEUROSCI, V18, P923; FAIRHOLM DJ, 1971, J NEUROSURG, V35, P277, DOI 10.3171/jns.1971.35.3.0277; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GRIFFITHS IR, 1975, J NEUROSURG, V42, P155, DOI 10.3171/jns.1975.42.2.0155; Guizar-Sahagun G, 1998, NEUROREPORT, V9, P2899, DOI 10.1097/00001756-199808240-00040; Hamada Y, 1996, FREE RADICAL BIO MED, V20, P1, DOI 10.1016/0891-5849(95)02017-9; Hamada Y, 1996, J NEUROCHEM, V66, P1525; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; LI P, 1994, BRAIN RES, V637, P287, DOI 10.1016/0006-8993(94)91246-7; NAGAFUJI T, 1993, EUR J PHARM-ENVIRON, V248, P325; NOVIKOV L, 1995, NEUROSCI LETT, V200, P45, DOI 10.1016/0304-3940(95)12078-I; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; RUDA MA, 1994, ANN NY ACAD SCI, V738, P181; Satake K, 2000, MOL BRAIN RES, V85, P114, DOI 10.1016/S0169-328X(00)00253-9; SAXON DW, 1994, NEUROREPORT, V5, P809, DOI 10.1097/00001756-199403000-00018; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SELGERSTAHL K, 1985, NEUROCHEM RES, V10, P563; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; Suzuki T, 2001, N-S ARCH PHARMACOL, V363, P94, DOI 10.1007/s002100000317; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P271, DOI 10.1001/archneurpsyc.1954.02320390001001; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WU W, 1994, NEUROSCIENCE, V61, P719, DOI 10.1016/0306-4522(94)90394-8; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; Xu J, 2001, J NEUROTRAUM, V18, P523, DOI 10.1089/089771501300227323; Yamada K, 1997, J NEUROCHEM, V68, P1234; YANASE M, 1995, J NEUROSURG, V83, P884, DOI 10.3171/jns.1995.83.5.0884; Yick LW, 1998, NEUROSCI LETT, V241, P155; Yoshino S, 1998, J Orthop Sci, V3, P54, DOI 10.1007/s007760050021; Young W, 1985, Cent Nerv Syst Trauma, V2, P109; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	49	45	47	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1467	1474		10.1089/089771502320914697			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500007	12490011				2021-06-18	
J	Lea, PM; Custer, SJ; Vicini, S; Faden, AI				Lea, PM; Custer, SJ; Vicini, S; Faden, AI			Neuronal and glial mGluR5 modulation prevents stretch-induced enhancement of NMDA receptor current	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						glutamate receptor; excitotoxicity; stretch injury; head trauma; cortical neurons; neuronal-glial interaction	METABOTROPIC GLUTAMATE RECEPTORS; D-ASPARTATE RECEPTORS; TRAUMATIC BRAIN INJURY; SPINAL-CORD MOTONEURONS; RAT HIPPOCAMPAL SLICES; PROTEIN-KINASE-C; CORTICAL-NEURONS; IN-VITRO; INTRACELLULAR CALCIUM; AMPA RESPONSES	Neuronal stretching in culture has been used to model diffuse axonal injury caused by head trauma, and activation of N-methyl-D-aspartate receptors (NMDARs) has been implicated in the pathophysiology of such injury. Here we report the effects of modulating injury severity and the metabotropic glutamate receptor subtype 5 (mGluR5) on NMDAR activity after stretch injury. Following mild stretch, cortical neurons plated upon a confluent layer of astrocytes (NG) exhibited both increased maximal current (I-NMDA) and reduction in the voltage-dependent Mg2+ block. In contrast, neurons grown without an astrocyte monolayer (PN) only exhibited increased INMDA. In NG, surprisingly, pretreatment with either the mGluR5 agonist CHPG or the mGluR5 antagonist MPEP decreased the enhancement of I-NMDA. In contrast, in PN, MPEP similarly limited INMDA Changes, but CHPG was without effect. In both culture conditions, MPEP, but not CHPG, limited the stretch-reduced Mg2+ block. Severe stretch had,no effect on INMDA or the Mg2+ block in either culture condition, despite a correlation between injury severity and the release of lactose dehydrogenase measured postinjury. Neither CHPG nor MPEP had any direct effects upon the NMDA receptor. We conclude that mGIuR5 regulates NMDAR activity during mild stretch injury, but not severe injury, by modulating both the Mg2+ block and INMDA. (C) 2002 Elsevier Science Inc. All rights reserved.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Physiol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Faden, AI (corresponding author), EP-04 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.			Vicini, Stefano/0000-0001-8671-5194			Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Alagarsamy S, 1999, NAT NEUROSCI, V2, P234; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Angenstein F, 1999, HIPPOCAMPUS, V9, P173, DOI 10.1002/(SICI)1098-1063(1999)9:2<173::AID-HIPO8>3.0.CO;2-K; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; Awad H, 2000, J NEUROSCI, V20, P7871; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; BORTOLOTTO ZA, 1995, NEUROPHARMACOLOGY, V34, P1003, DOI 10.1016/0028-3908(95)00054-A; Bruno V, 1998, PROG BRAIN RES, V116, P209, DOI 10.1016/S0079-6123(08)60439-2; Bruno V, 1999, NEUROPHARMACOLOGY, V38, P199, DOI 10.1016/S0028-3908(98)00159-2; BRUNO V, 1995, NEUROPHARMACOLOGY, V34, P1089, DOI 10.1016/0028-3908(95)00077-J; Bruno V, 2001, EUR J NEUROSCI, V13, P1469, DOI 10.1046/j.0953-816x.2001.01541.x; Bruno V, 1996, ADV NEUROL, V71, P47; Chen NS, 1999, J NEUROSCI, V19, P6844, DOI 10.1523/JNEUROSCI.19-16-06844.1999; Colwell CS, 1996, P NATL ACAD SCI USA, V93, P1200, DOI 10.1073/pnas.93.3.1200; CONDORELLI DF, 1993, J NEUROCHEM, V61, P2133, DOI 10.1111/j.1471-4159.1993.tb07451.x; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Contractor A, 1998, P NATL ACAD SCI USA, V95, P8969, DOI 10.1073/pnas.95.15.8969; Corsi L, 1998, J NEUROCHEM, V70, P1898; Daniels M, 2001, J BIOL CHEM, V276, P22446, DOI 10.1074/jbc.M101740200; Dingledine R, 1999, PHARMACOL REV, V51, P7; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gereau RW, 1998, NEURON, V20, P143, DOI 10.1016/S0896-6273(00)80442-0; GILL R, 1994, CEREBROVAS BRAIN MET, V6, P225; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Hampson AJ, 1998, J NEUROCHEM, V70, P671; Hisatsune C, 1997, J BIOL CHEM, V272, P20805, DOI 10.1074/jbc.272.33.20805; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; Holohean AM, 1999, BRIT J PHARMACOL, V126, P333, DOI 10.1038/sj.bjp.0702263; Kawabata S, 1998, J BIOL CHEM, V273, P17381, DOI 10.1074/jbc.273.28.17381; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; KINNEY GA, 1993, J NEUROPHYSIOL, V69, P585; Kreutz MR, 1998, J NEUROSCI, V18, P8278; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LIPTON SA, 1994, NEUROPHARMACOLOGY, V33, P1229, DOI 10.1016/0028-3908(94)90021-3; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1997, NEUROREPORT, V8, P2561, DOI 10.1097/00001756-199707280-00028; Nicoletti F, 1999, NEUROPHARMACOLOGY, V38, P1477, DOI 10.1016/S0028-3908(99)00102-1; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Skeberdis VA, 2001, NEUROPHARMACOLOGY, V40, P856, DOI 10.1016/S0028-3908(01)00005-3; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Temple MD, 2001, HEAD TRAUMA, P87; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Ugolini A, 1999, NEUROPHARMACOLOGY, V38, P1569, DOI 10.1016/S0028-3908(99)00095-7; Ugolini A, 1997, NEUROPHARMACOLOGY, V36, P1047, DOI 10.1016/S0028-3908(97)00103-2; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Yu SP, 1997, J PHYSIOL-LONDON, V499, P721, DOI 10.1113/jphysiol.1997.sp021964; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; ZHONG J, 1994, MOL PHARMACOL, V45, P846	66	45	45	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2002	73	2					287	298	PII S0091-3057(02)0082500	10.1016/S0091-3057(02)00825-0			12	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	585AT	WOS:000177501500002	12117582				2021-06-18	
J	Baker, AJ; Phan, N; Moulton, RJ; Fehlings, MG; Yucel, Y; Zhao, M; Liu, E; Tian, GF				Baker, AJ; Phan, N; Moulton, RJ; Fehlings, MG; Yucel, Y; Zhao, M; Liu, E; Tian, GF			Attenuation of the electrophysiological function of the corpus callosum after fluid percussion injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						corpus callosum; electrophysiology; fluid percussion injury model; traumatic brain injury; white matter injury	TRAUMATIC BRAIN INJURY; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; SPINAL-CORD INJURY; WHITE-MATTER INJURY; PIG OPTIC-NERVE; HEAD-INJURY; GLUTAMATE RECEPTORS; BLOOD-FLOW; IN-VITRO	This study describes a new method used to evaluate axonal physiological dysfunction following fluid percussion induced traumatic brain injury (TBI) that may facilitate the study of the mechanisms and novel therapeutic strategies of posttraumatic diffuse axonal injury (DAI). Stimulated compound action potentials (CAP) were recorded extracellularly in the corpus callosum of superfused brain slices at 3 h, and 1, 3, and 7 days following central fluid percussion injury and demonstrated a temporal pattern of functional deterioration. The maximal CAP amplitude (CAPA) covaried with the intensity of impact 1 day following sham, mild (1.0-1.2 atm), and moderate (1.8-2.0 atm) injury (p < 0.05; 1.11 +/- 0.10, 0.82 +/- 0.11, and 0.49 +/- 0.08 mV, respectively). The CAPA in sham animals were approximately 1.1 mV and did not vary with survival interval (3 h, and 1, 3, and 7 days); however, they were significantly decreased at each time point following moderate injury (p < 0.05; 0.51 +/- 0.11, 0.49 +/- 0.08, 0.46 +/- 0.10, and 0.75 +/- 0.13 mV, respectively). The CAPA at 7 days in the injured group were higher than at 3 h, and 1 and 3 days. H&E and amyloid precursor protein (APP) light microscopic analysis confirmed previously reported trauma-induced axonal injury in the corpus callosum seen after fluid percussion injury. Increased APP expression was confirmed using Western blotting showing significant accumulation at 1 day (IOD 913.0 +/- 252.7; n = 3; p = 0.05), 3 days (IOD 753.1 +/- 159.1; n = 3; p = 0.03), and at 7 days (IOD 1093.8 +/- 105.0; n = 3; p = 0.001) compared to shams (IOD 217.6 +/- 20.4; n = 3). Thus, we report the characterization of white matter axonal dysfunction in the corpus callosum following TBI. This novel method was easily applied, and the results were consistent and reproducible. The electrophysiological changes were sensitive to the early effects of impact intensity, as well as to delayed changes occurring several days following injury. They also indicated a greater degree of attenuation than predicted by APP expression changes alone.	Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Ophthalmol, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON, Canada	Baker, AJ (corresponding author), Univ Toronto, Dept Anaesthesia, Toronto, ON, Canada.			Fehlings, Michael/0000-0002-5722-6364			AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Agrawal SK, 1998, J NEUROTRAUM, V15, P929, DOI 10.1089/neu.1998.15.929; Agrawal SK, 1996, J NEUROSCI, V16, P545; Agrawal SK, 1997, J NEUROSCI, V17, P1055; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Koszyca B, 1998, J NEUROTRAUM, V15, P675, DOI 10.1089/neu.1998.15.675; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; Li S, 1999, J NEUROSCI, V19, P1; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; Marmarou A, 1990, Adv Neurol, V52, P233; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; PETERSEN G, 1977, ANAL BIOCHEM, V3, P346; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; RANSOM BR, 1992, J CEREBR BLOOD F MET, V12, P593, DOI 10.1038/jcbfm.1992.83; Rosenberg LJ, 1997, J NEUROTRAUM, V14, P823, DOI 10.1089/neu.1997.14.823; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STYS PK, 1995, J CEREBR BLOOD F MET, V15, P425, DOI 10.1038/jcbfm.1995.53; Swanson TH, 1998, BRAIN RES, V784, P188, DOI 10.1016/S0006-8993(97)01323-1; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Tian GF, 2000, J NEUROPHYSIOL, V83, P1830; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; Wilkinson AE, 1999, ACTA NEUROPATHOL, V98, P197, DOI 10.1007/s004010051069; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613	65	45	46	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					587	599		10.1089/089771502753754064			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900004	12042094				2021-06-18	
J	Maxwell, RA; Chavarria-Aguilar, M; Cockerham, WT; Lewis, PL; Barker, DE; Durham, RM; Ciraulo, DL; Richart, CM				Maxwell, RA; Chavarria-Aguilar, M; Cockerham, WT; Lewis, PL; Barker, DE; Durham, RM; Ciraulo, DL; Richart, CM			Routine prophylactic vena cava filtration is not indicated after acute spinal cord injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	31st Annual Meeting of the Western-Trauma-Association	FEB 24-MAR 01, 2001	BIG SKY, MONTANA	Western Trauma Assoc		acute spinal cord injury; deep venous thrombosis prophylaxis; pulmonary embolism prophylaxis	DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; CALF COMPRESSION; FILTER INSERTION; DOSE HEPARIN; PREVENTION; TRAUMA	Background. Acute spinal cord injury (SCI) is a devastating problem, with over 10,000 new cases annually. Pulmonary embolism (PE) is a well-recognized risk in SCI patients, although no clear recommendations for prophylaxis exist. We therefore evaluated whether routine placement of prophylactic inferior vena cava filters is indicated in SCI patients. Methods. The trauma registry of a regional trauma center was used to identify patients sustaining acute SCI resulting in tetraplegia or paraplegia after blunt or penetrating trauma for a 5-year period beginning in January 1995. Patients were analyzed for demographics, mechanism of injury, Injury Severity Score, associated long bone or pelvic fracture, severe closed-head injury, type of deep venous thrombosis (DVT) prophylaxis, level of SCI, and incidence of DVT and PE. DVT prophylaxis was performed in all patients with sequential compression devices (SCDs') when extremity fracture status permitted. Data are expressed as mean +/- SD and analyzed using Fishers exact test. Results: There were 8,269 admissions during the study period, with an overall incidence of DVT and PE of 11.8% and 0.9%, respectively. There were Ill (1.3%) patients who sustained SCI, with an incidence of DVT and PE of 9.0% and 1.8%, respectively, and no deaths. Of these 111 patients, 41.4% were paraplegics and 58.6% were tetraplegics, and 17.1% of patients had severe closed-head injury. Mean hospital length of stay was 23 +/- 20 days for SCI patients. Surveillance duplex ultrasound was performed an average of 2.3 +/- 2.1 times during each hospitalization. Mean Injury Severity Score was 30.0 +/- 12.2. The incidence of DVT and PE in those patients with SCDs alone was 7.1% and 2.3%; for SCDs plus subcutaneous heparin, the incidence was 11.1% and 2.8%; and for SCDs plus low-molecular-weight heparin, the incidence was 7.4% and 0%, respectively, with no statistical difference between groups. The incidence of DVT in SCI patients with long bone fractures was 37.5%, which was significantly greater than the total SCI population (p < 0.021). Conclusion: The incidence of DVT and PE in SCI patients was similar to that of the overall trauma population when appropriate DVT prophylaxis was used. Subgroup analysis demonstrated that SCI associated with long bone fracture significantly increases the incidence of DVT. On the basis of the low incidence of PE in the present study, routine placement of prophylactic caval filters does not appear warranted in all SCI patients. However, SCI patients with long bone fractures, patients with DVT formation despite prophylactic anticoagulation, or patients with contraindications to anticoagulation may be appropriate candidates for prophylactic caval filtration.	Univ Tennessee, Coll Med, Dept Surg, Chattanooga Unit, Chattanooga, TN 37403 USA; Univ S Florida, Tampa Gen Hosp, Coll Med, Dept Surg, Tampa, FL USA	Maxwell, RA (corresponding author), Univ Tennessee, Coll Med, Dept Surg, Chattanooga Unit, 979 E 3rd St,Suite 401, Chattanooga, TN 37403 USA.						BORS E, 1954, SURG GYNECOL OBSTET, V99, P451; BRACH BB, 1977, J TRAUMA, V17, P289, DOI 10.1097/00005373-197704000-00005; Devivo Michael J., 1995, P289; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GREEN D, 1990, ANN INTERN MED, V113, P571, DOI 10.7326/0003-4819-113-8-571; GREEN D, 1982, PARAPLEGIA, V20, P227, DOI 10.1038/sc.1982.41; GREEN D, 1988, JAMA-J AM MED ASSOC, V260, P1255, DOI 10.1001/jama.260.9.1255; GREEN D, 1994, ARCH PHYS MED REHAB, V75, P290, DOI 10.1016/0003-9993(94)90031-0; GREENBERG DS, 1997, P SC97 HIGH PERF NET, P1; GUNDUZ S, 1993, PARAPLEGIA, V31, P606; Harris S, 1996, AM J PHYS MED REHAB, V75, P326, DOI 10.1097/00002060-199609000-00002; MERLI GJ, 1988, ARCH PHYS MED REHAB, V69, P661; MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013; PETAJA J, 1989, ACTA CHIR SCAND, V155, P241; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; ROSSI EC, 1980, BRIT J HAEMATOL, V45, P143, DOI 10.1111/j.1365-2141.1980.tb03819.x; SALZMAN EW, 1987, ANN SURG, V206, P636; Silver J R, 1974, Paraplegia, V12, P188; STOVER SL, 1986, SPINAL CORD INJURY F, P1; TRIBE C R, 1963, Paraplegia, V1, P19; Velmahos GC, 2000, J TRAUMA, V49, P1059, DOI 10.1097/00005373-200012000-00014; WILSON JT, 1994, NEUROSURGERY, V35, P234, DOI 10.1227/00006123-199408000-00008; Winemiller M H, 1999, J Spinal Cord Med, V22, P182; YELNIK A, 1991, PARAPLEGIA, V29, P253, DOI 10.1038/sc.1991.36	24	45	47	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2002	52	5					902	906		10.1097/00005373-200205000-00013			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	552DM	WOS:000175603600023	11988656				2021-06-18	
J	Sanz, O; Acarin, L; Gonzalez, B; Castellano, B				Sanz, O; Acarin, L; Gonzalez, B; Castellano, B			NF-kappa B and I kappa B alpha expression following traumatic brain injury to the immature rat brain	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						astrocyte; microglia; glial response; developing brain; transcription factor; inflammation	THALAMIC GLIAL RESPONSE; INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; HIPPOCAMPAL-NEURONS; CYTOKINE EXPRESSION; EXCITOTOXIC LESION; YOUNG BRAIN; ACTIVATION; PROTEINS; SUPPRESSION	NF-kappaB is one of the most important modulators of stress and inflammatory gene expression in the nervous system. In the adult brain, NF-kappaB upregulation has been demonstrated in neurons and glial cells in response to experimental injury and neuropathological disorders, where it has been related to both neurodegenerative and neuroprotective activities. Accordingly, the aim of this study was to evaluate the cellular and temporal patterns of NF-kappaB activation and the expression of its endogenous inhibitor IkappaBalpha following traumatic brain injury (TBI) during the early postnatal weeks, when the brain presents elevated levels of plasticity and neuroprotection. Our results showed that cortical trauma to the 9-day-old rat brain induced a very fast upregulation of NF-kappaB, which was maximal within the first 24 hours after injury. NF-kappaB was mainly observed in neuronal cells of the degenerating cortex as well as in astrocytes located in the corpus callosum adjacent to the injury, where a pulse-like pattern of microglial NF-kappaB activation was also found. In addition, astrocytes of the corpus callosum, and microglial cells to a lower extent, also showed de novo expression Of IkappaBalpha within the time of NF-kappaB activation. This study suggests an important role of NF-kappaB activation in the early mechanisms of neuronal death or survival, as well as in the development of the glial and inflammatory responses following traumatic injury to the immature rat brain. (C) 2002 Wiley-Liss, Inc.	Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Fac Med, Unit Histol, Bellaterra 08193, Spain	Acarin, L (corresponding author), Autonomous Univ Barcelona, Dept Cell Biol Physiol & Immunol, Fac Med, Unit Histol, Bellaterra 08193, Spain.	laia.acarin@uab.es	Acarin, Laia/G-2620-2010; Castellano, Bernardo/G-1428-2010; Gonzalez, Berta/G-6250-2010; Gonzalez, Berta/G-1428-2010	Castellano, Bernardo/0000-0003-1976-971X; Gonzalez, Berta/0000-0002-1860-3980			Acarin L, 1999, NEUROSCIENCE, V89, P549, DOI 10.1016/S0306-4522(98)00331-5; Acarin L, 1999, NEUROSCIENCE, V92, P827, DOI 10.1016/S0306-4522(99)00022-6; Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Acarin L, 1998, NEUROREPORT, V9, P2869, DOI 10.1097/00001756-199808240-00035; Acarin L, 1997, EXP NEUROL, V147, P410, DOI 10.1006/exnr.1997.6593; Acarin L, 2001, STROKE, V32, P2394, DOI 10.1161/hs1001.097243; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Bancroft J., 1996, THEORY PRACTICE HIST, P735; Bethea JR, 1998, J NEUROSCI, V18, P3251; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Dalmau I, 1997, J COMP NEUROL, V377, P70; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; Kolb B, 1996, BEHAV BRAIN RES, V79, P1, DOI 10.1016/0166-4328(95)00254-5; KOLB B, 1994, BRAIN RES, V645, P85, DOI 10.1016/0006-8993(94)91641-1; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 1998, INT REV NEUROBIOL, V42, P103, DOI 10.1016/S0074-7742(08)60609-1; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Qin ZH, 1998, MOL PHARMACOL, V53, P33; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sanz O, 2001, GLIA, V36, P259, DOI 10.1002/glia.1114; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Warr W.B., 1981, NEUROANATOMICAL TRAC, P207; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	38	45	49	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	MAR 15	2002	67	6					772	780		10.1002/jnr.10140			9	Neurosciences	Neurosciences & Neurology	526ZC	WOS:000174158700009	11891791				2021-06-18	
J	Downs, DS; Abwender, D				Downs, DS; Abwender, D			Neuropsychological impairment in soccer athletes	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article; Proceedings Paper	107th Annual Convention of the American-Psychological-Association	JUN, 1999	Denver, CO	Amer Psychol Assoc		soccer; swimming; neurophysiology; brain	BRAIN-INJURY; BALL	Background. Soccer reportedly places participants at risk for neuropsychological. impairment, although it is unknown if the risk is associated primarily with concussion, subconcussive blows from heading the ball, or some combination thereof. Moreover, the extent to which younger versus older athletes are at risk for soccer-related cognitive impairment is unclear. We hypothesized that soccer athletes, especially older ones, would show poorer neuropsychological test performance than comparable swimmers. Methods. Thirty-two soccer (26 college and 6 professional) and 29 swimmers (22 college and 7 masters level), all involved for at least 4 years in their sport at collegiate or national levels, participated. In a 2 X 2 (sport X age category) factorial design, all participants underwent 4 neuropsychological tests with 11 outcome measures assessing motor speed, attention, concentration, reaction time, and conceptual thinking. Results. Soccer athletes performed worse than swimmers on measures of conceptual thinking. The older soccer group in particular performed poorly on measures of conceptual thinking, reaction time, and concentration. Among non-goaltender soccer athletes, estimates of career exposure to brain trauma (based on length of career and level of play) predicted significantly poorer test performance on 6 of 11 measures, even after statistically controlling for age. Conclusions. Results provide additional evidence that participation in soccer may be associated with poorer neuropsychological performance, although the observed pattern of findings does not specifically implicate heading as the cause. Although deficits were most apparent among older soccer players, serial neuropsychological testing for early detection of impairment is recommended for younger players as well.	Univ Florida, Dept Exercise & Sport Sci, Gainesville, FL 32611 USA; SUNY Coll Brockport, Dept Psychol, Brockport, NY USA	Downs, DS (corresponding author), Univ Florida, Dept Exercise & Sport Sci, POB 118205,Room 110 Florida Gym, Gainesville, FL 32611 USA.	symons@ufl.edu	Abwender, David/AAG-1837-2021				Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Gean A, 1994, IMAGING HEAD TRAUMA; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GRONWALL D, 1975, LANCET, V2, P995; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Levin HS, 1989, MILD HEAD INJURY; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	15	45	45	1	9	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707	1827-1928		J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	MAR	2002	42	1					103	107					5	Sport Sciences	Sport Sciences	541KG	WOS:000174983300017	11832883				2021-06-18	
J	Thompson, JS; Brown, SA; Khurdayan, V; Zeynalzadedan, A; Sullivan, PG; Scheff, SW				Thompson, JS; Brown, SA; Khurdayan, V; Zeynalzadedan, A; Sullivan, PG; Scheff, SW			Early effects of tribromoethanol, ketamine/xylazine, pentobarbitol, and isoflurane anesthesia on hepatic and lymphoid tissue in ICR mice	COMPARATIVE MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; TOXICITY; XYLAZINE; AVERTIN; RATS	We investigated the effects of various anesthetic agents on hepatic and splenic injury in mice. Three and six hours after intraperitoneal injection of TBE, intramuscular injection of ketamine/xylazine combination (K/X), intraperitoneal injection of pentobarbital (PB), and inhalation of isoflurane (IF), or intraperitoneal and intramuscular injection of control saline, mice were exsanguinated and serum was obtained for measurement of hepatic aspartate transaminase (AST), alanine transaminase (ALT) and gamma-glutamyltransferase (GGT). The spleen and liver also were obtained, and sections were examined by use of routine light microscopy for pathologic changes and for apoptosis, as determined by use of the in situ terminal deoxynucleotidyl transferase-mediated dUPT nick-end-labeling (TUNEL) histochemical analysis. Three hours after TBE or K/X administration, AST activity increased three- to fourfold above that in untreated and saline-injected control animals, and remained high at six hours. Administration of PB did not effect AST activity at three hours, but there was a significant increase at six hours. Activity of ALT was non-significantly increased three hours after TBE and K/X, but not PB administration. Administration of IF had no effect on hepatic enzyme activities, and GGT was not increased after administration of any of the agents. Markedly increased apoptosis was observed in splenic follicles and in hepatic Kupffer and endothelial cells at three hours after TBE and K/X administration, but apoptosis decreased to control levels by six hours. Increased apoptosis was not observed after IF administration. Administration of TBE and K/X causes injury to lymphocytes and to hepatic Kupffer and endothelial cells within three hours, and PB administration induces changes within six hours. Thus, use of these anesthetic agents should be avoided when experiments are being designed to test short-term effects of an experimental intervention on the spleen and possibly on all lymphoid tissues. In addition, they also should be avoided in experiments testing effects on hepatic tissue.	Univ Kentucky, Dept Internal Med, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Thompson, JS (corresponding author), Univ Kentucky, Dept Internal Med, Room MN644A, Lexington, KY 40536 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39828] Funding Source: Medline		CHANGTSUI YYH, 1980, CLIN TOXICOL, V16, P41, DOI 10.3109/15563658008989922; CLEMENT JG, 1983, BIOCHEM PHARMACOL, V32, P1411, DOI 10.1016/0006-2952(83)90455-0; ERHARDT W, 1984, RES EXP MED, V184, P159, DOI 10.1007/BF01852390; GARDNER DJ, 1995, LAB ANIM SCI, V45, P199; Kimbro JR, 2000, ANESTHESIOLOGY, V92, P806, DOI 10.1097/00000542-200003000-00024; NIEDERWIESER D, 1990, TRANSPLANTATION, V50, P620, DOI 10.1097/00007890-199010000-00019; RAPER SE, 1987, ANAT RECORD, V218, P116, DOI 10.1002/ar.1092180204; Reid WC, 1999, LAB ANIM SCI, V49, P665; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TAKEDA T, 1987, Journal of Toxicological Sciences, V12, P57; Weiss J, 1999, LAB ANIM, V33, P192, DOI 10.1258/002367799780578417; WIXSON SK, 1987, LAB ANIM SCI, V37, P743; Zeller W, 1998, LAB ANIM, V32, P407, DOI 10.1258/002367798780599811	14	45	45	0	2	AMER ASSOC LABORATORY ANIMAL SCIENCE	MEMPHIS	9190 CRESTWYN HILLS DR, MEMPHIS, TN 38125 USA	1532-0820			COMPARATIVE MED	Comparative Med.	FEB	2002	52	1					63	67					5	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	527PH	WOS:000174194200009	11900415				2021-06-18	
J	Spikman, JM; Kiers, HAL; Deelman, BG; van Zomeren, AH				Spikman, JM; Kiers, HAL; Deelman, BG; van Zomeren, AH			Construct validity of concepts of attention in healthy controls and patients with CHI	BRAIN AND COGNITION			English	Article							CLOSED-HEAD-INJURY; REACTION-TIME; INTELLIGENCE; DEFICITS; RECOVERY	The present study aimed to examine the construct validity of three aspects of attention, namely focused, divided, and supervisory control of attention. Factor-analytic techniques were applied to scores of healthy subjects on a series of neuropsychological tests tapping these aspects of attention. The two components found did not match the hypothesized aspects and were labeled as Memory-driven Action and Stimulus-driven Reaction. The second question was whether the same components could be found in a group of patients with CHI. The pattern of attentional functions found in healthy subjects had changed qualitatively in patients with CHI. A possible explanation for this result in terms of a shift from automatic to controlled processing is discussed. (C) 2001 Elsevier Science.	Groningen State Univ, Dept Neuropsychol, Groningen, Netherlands; Acad Hosp Groningen, Dept Neuropsychol, NL-9713 EZ Groningen, Netherlands; Groningen State Univ, Heymans Inst Psychol, Groningen, Netherlands	Spikman, JM (corresponding author), Acad Hosp Groningen, Dept Neuropsychol, Poortweg 4,Hanzeplein 1, NL-9713 EZ Groningen, Netherlands.		Kiers, Henk/D-2900-2012	Spikman, Jacoba/0000-0002-6477-0763; Kiers, Henk/0000-0002-4995-9349			BROUWER WH, 1985, LIMITATIONS ATTENTIO; Cohen R. A., 1993, NEUROPSYCHOLOGY ATTE; COOK DT, 1979, QUASI EXPT DESIGN AN; DAVIES DR, 1983, PHYSL CORRELATED HUM; Deelman B. G., 1980, NEUROPSYCHOLOGIE NED, P253; DEJONG PF, 1991, THESIS FREE U AMST N; DELAND N, 1995, THESIS U MONTREAL; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; HOCKEY GRJ, 1979, HUMAN STRESS COGNITI; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KIERS HAL, 1989, PSYCHOMETRIKA, V54, P467, DOI 10.1007/BF02294629; KIERS HAL, 1990, USERS MANUAL SCA PRO; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Leonberger F. T., 1992, NEUROPSYCHOLOGY, V6, P239, DOI DOI 10.1037/0894-4105.6.3.239; Mesulam M., 1985, PRINCIPLES BEHAV NEU; Miller E, 1970, Cortex, V6, P121; MILLSAP RE, 1988, PSYCHOMETRIKA, V53, P123, DOI 10.1007/BF02294198; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; POGGE DL, 1994, J CLIN EXP NEUROPSYC, V16, P344, DOI 10.1080/01688639408402645; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P182; PRIBRAM KH, 1975, PSYCHOL REV, V82, P116, DOI 10.1037/h0076780; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHUM DHK, 1990, CLIN NEUROPSYCHOL, V4, P163; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STANKOV L, 1988, PSYCHOL AGING, V3, P59, DOI 10.1037/0882-7974.3.1.59; STANOV L, 1983, J EDUC PSYCHOL, V4, P471; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T., 1989, CLIN NEUROPSYCHOL, V3, P145, DOI DOI 10.1080/13854048908403287; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TANBERGE JMF, 1986, MULTIVARIATE BEHAV R, V21, P41; TENBERGE JMF, 1986, MULTIVAR BEHAV RES, V21, P262; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VELTMAN JC, 1996, NEUROPSYCHOLOGY, V10, P1; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Walsh K. W, 1991, UNDERSTANDING BRAIN	45	45	46	0	3	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	DEC	2001	47	3					446	460		10.1006/brcg.2001.1320			15	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	502BG	WOS:000172723400006	11748900				2021-06-18	
J	Schoppen, T; Boonstra, A; Groothoff, JW; van Sonderen, E; Goeken, LN; Eisma, WH				Schoppen, T; Boonstra, A; Groothoff, JW; van Sonderen, E; Goeken, LN; Eisma, WH			Factors related to successful job reintegration of people with a lower limb amputation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amputees; employment; Netherlands; prosthesis; rehabilitation; reintegration	TRAUMATIC BRAIN INJURY; VOCATIONAL-REHABILITATION; NORTHERN SWEDEN; EMPLOYMENT; WORK; AMPUTEES; RETURN; DISABILITY; ARTHRITIS; IMPACT	Objective: To study demographically, amputation-, and employment-related factors that show a relationship to successful job reintegration of patients after lower limb amputation. Design: Cross-sectional study. Setting: University hospital. Patients: Subjects had an acquired unilateral major amputation of the lower limb at least 2 years before, were aged 18 to 60 years (mean, 46yr), and were living in the Netherlands. All 322 patients were working at the time of amputation and were recruited from orthopedic workshops. Intervention: Questionnaires sent to subjects to self-report (1) demographic and amputation information and (2) job characteristics and readjustment postamputation. Questionnaire sent to rehabilitation specialists to assess physical work load. Main Outcome Measures: Demographically related (age, gender); amputation-related (comorbidity; reason and level; problems with stump, pain, prosthesis use and problems, mobility, rehabilitation); and employment-related (education, physical workload) information about the success of job reintegration. Results: Job reintegration was successful in 79% and unsuccessful in 21% of the amputees. Age at the time of amputation, wearing comfort of the prosthesis, and education level were significant indicators of successful job reintegration. Subjects with physically demanding jobs who changed type of job before and after the amputation more often successfully returned to work than subjects who tried to stay at the same type of job. Conclusions: Older patients with a low education level and problems with the wearing comfort of the prosthesis are a population at risk who require special attention during the rehabilitation process in order to return to work. Lowering the physical workload by changing to another type of work enhances the chance of successful reintegration.	Univ Groningen Hosp, Dept Rehabil Med, NL-9700 RB Groningen, Netherlands; Rehabil Ctr Revalidatie Friesland, Groningen, Netherlands; Univ Groningen, No Ctr Hlth Care Res, Groningen, Netherlands; Univ Groningen, Inst Movement Sci, Groningen, Netherlands	Schoppen, T (corresponding author), Univ Groningen Hosp, Dept Rehabil Med, POB 30-001, NL-9700 RB Groningen, Netherlands.						ANDRIES F, 1998, WERKEN MET VOORZIENI; ANDRIES F, 1996, WERKEN MET NEUROMUSC; ANDRIES F, 1993, SOCICAL MAANDBLAD AR, V48, P350; Branholm I, 1991, J REHABIL SCI, V4, P29; EKLUND M, 1991, SCAND J REHABIL MED, V23, P73; FUGLMEYER AR, 1991, SCAND J REHABIL MED, V23, P83; GERHARDS F, 1984, INT J REHABIL RES, V7, P379, DOI 10.1097/00004356-198412000-00001; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; HOWARD G, 1985, JAMA-J AM MED ASSOC, V253, P226, DOI 10.1001/jama.253.2.226; Krause JS, 1998, ARCH PHYS MED REHAB, V79, P615, DOI 10.1016/S0003-9993(98)90033-8; LIVINGSTON DH, 1994, J TRAUMA, V37, P495, DOI 10.1097/00005373-199409000-00027; MILLSTEIN S, 1985, PROSTHET ORTHOT INT, V9, P69; MITCHELL JM, 1991, MED CARE, V29, P362, DOI 10.1097/00005650-199104000-00005; NARANG IC, 1984, PROSTHET ORTHOT INT, V8, P43; NIJBOER ID, 1990, JOB QUALITY HANDICAP; NIJBOER ID, 1989, JOB PERSPECTIVES YOU; PURRY NA, 1989, INJURY, V20, P32, DOI 10.1016/0020-1383(89)90041-7; Rozin R, 1982, Int Rehabil Med, V4, P75; SCHMIDT SH, 1995, ARCH PHYS MED REHAB, V76, P950, DOI 10.1016/S0003-9993(95)80073-5; Schoppen T, 2001, ARCH PHYS MED REHAB, V82, P239, DOI 10.1053/apmr.2001.18231; SHEIKH K, 1985, J SOC OCCUP MED, V35, P114; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; Wevers C W, 1993, Disabil Rehabil, V15, P24; YELIN E, 1980, ANN INTERN MED, V93, P551, DOI 10.7326/0003-4819-93-4-551	25	45	47	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2001	82	10					1425	1431		10.1053/apmr.2001.26074			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	479NQ	WOS:000171410800014	11588749				2021-06-18	
J	Chan, RCK				Chan, RCK			A further study on the sustained attention response to task (SART): the effect of age, gender and education	BRAIN INJURY			English	Article							CLOSED-HEAD INJURY; CHILDREN; DISABILITIES	The present study aimed to investigate the potential effect of age, gender and education upon the theoretically sound measure of sustained attention-Sustained Attention Response to Task (SART)-amongst a control sample and patients with traumatic brain injury (TBI). The SART is a simple and brief computer-assisted programme for assessing sustained attention over a short period of time. Two further studies on the use of the SART among the Hong Kong Chinese were conducted. In particular, experiment 1 recruited a control group to study the potential impact of age, education, and gender upon the performance of the SART. Experiment 2 was aimed to establish the discriminative validity of the SART upon the attentional slip in a larger sample of patients with TBI and the normal controls. The potential impact of age, gender, and education upon the SART performance was found to be minimal. In keeping with previous studies, the present findings demonstrate that SART is able to discriminate the patients with TBI from normal controls.	Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China	Chan, RCK (corresponding author), Queen Mary Hosp, Dept Psychiat, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.		Chan, Raymond CK/B-6717-2009	Chan, Raymond CK/0000-0002-3414-450X			Brand EFJM, 1996, CHILD NEUROPSYCHOL, V2, P109, DOI 10.1080/09297049608401356; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Davies D.R., 1982, PSYCHOL VIGILANCE; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Lee TMC, 1999, ARCH CLIN NEUROPSYCH, V14, P730; Lee TMC, 2000, J CLIN EXP NEUROPSYC, V22, P465, DOI 10.1076/1380-3395(200008)22:4;1-0;FT465; LOEB M, 1963, J ACOUST SOC AM, V35, P884, DOI 10.1121/1.1918621; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; LONG GM, 1981, HUM FACTORS, V23, P285; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; MANLY T, 1997, METHODOLOGY FRONTAL, P135; MCKAY K, 1994, DEV NEUROPSYCHOL, V10, P221; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; PARASURAMAN R, 1984, SUSTAINED ATTENTION, P62; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUCKERT L, 1996, NEUROPSYCHOLOGIA, V34, P953; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SMILEY AM, 1990, ACCIDENT ANAL PREV, V22, P443, DOI 10.1016/0001-4575(90)90039-N; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Warm J. S., 1993, WORKLOAD TRANSITION, P139; Wechsler D., 1981, WAIS R MANUAL WECHSL; Westling DL, 1999, EDUC TRAIN MENT RET, V34, P43; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	28	45	50	0	20	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					819	829		10.1080/02699050119721			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400007	11516350				2021-06-18	
J	Kirkendall, DT; Garrett, WE				Kirkendall, DT; Garrett, WE			Heading in soccer: Integral skill or grounds for cognitive dysfunction?	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; mild traumatic brain injury	TRAUMATIC BRAIN INJURY; FOOTBALL PLAYERS; CONCUSSION; DAMAGE	Objective: To critically review the literature concerning the effect of purposeful heading of a soccer ball and head injuries on reported cognitive dysfunction in soccer players. Data Sources: We searched MEDLINE (1965-2001) and SPORTDiscus (1975-2001) for refereed articles in English combining key words for soccer (eg, soccer, football, association football) with key words for head injuries (eg, concussion, head injury). In addition, literature on cognition and head injuries was obtained. We reviewed reference lists of current literature for pertinent citations that might not have been found in the search procedures. Data Synthesis: The fact that soccer players (and other athletes) have selected cognitive deficits is not questioned, and the popular press is quick to publicize results of questionable validity. The reasons for such deficits are many. Much of the early data implied that heading was the culprit; however, subsequent research has suggested that other interpretations and factors may be potential explanations for these deficits. The current focus is on concussions, a known factor in cognitive dysfunction and a common head injury in soccer. Conclusions/Recommendations: It is difficult to blame purposeful heading for the reported cognitive deficits when actual heading exposure and details of the nature of head-ball impact are unknown. Concussions are a common head injury in soccer (mostly from head-head or head-ground impact) and a factor in cognitive deficits and are probably the mechanism of the reported dysfunction.	Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; US Soccer Federat, Chicago, IL USA	Kirkendall, DT (corresponding author), Univ N Carolina, Dept Orthopaed, CB 7055, Chapel Hill, NC 27599 USA.						ARMSTRONG C, 1994, SCI FOOTBALL, P493; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BEERS SR, 1994, J LEARN DISABIL, V27, P315, DOI 10.1177/002221949402700508; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Frith U, 1998, SCAND J PSYCHOL, V39, P191, DOI 10.1111/1467-9450.393078; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOLBOURN AHS, 1943, LANCET, P438; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Lees K., 1988, SCI FOOTBALL, P385; Lohnes JH, 1994, SPORTS INJURIES MECH, P603; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Luhtanen P., 1994, FOOTBALL SOCCER HDB, P59; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; Neiman J, 1998, ALCOHOL CLIN EXP RES, V22, p346S, DOI 10.1111/j.1530-0277.1998.tb04389.x; Nigg JT, 1998, J ABNORM PSYCHOL, V107, P468, DOI 10.1037/0021-843X.107.3.468; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Reilly T., 1976, J HUMAN MOVEMENT STU, V2, P87; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P258; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; VICTOR M, 1989, WERNICKEKORSAKOFF S; 2001, SITE FOOTBALL ALGERI	36	45	45	0	4	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					328	333					6	Sport Sciences	Sport Sciences	557NC	WOS:000175913800019					2021-06-18	
J	Matsushita, Y; Bramlett, HM; Kuluz, JW; Alonso, O; Dietrich, WD				Matsushita, Y; Bramlett, HM; Kuluz, JW; Alonso, O; Dietrich, WD			Delayed hemorrhagic hypotension exacerbates the hemodynamic and histopathologic consequences of traumatic brain injury in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						autoregulation; fluid-percussion injury; hypoxia; pathology; rat; regional cerebral blood flow	CEREBRAL BLOOD-FLOW; CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; OXYGEN DELIVERY; METABOLISM; ISCHEMIA; MILD; CONTUSION; RESPONSES; CATS	Alterations in cerebral autoregulation and cerebrovascular reactivity after traumatic brain injury (TBI) may increase the susceptibility of the brain to secondary insults, including arterial hypotension. The purpose of this study was to evaluate the consequences of mild hemorrhagic hypotension on hemodynamic and histopathologic outcome after TBI. Intubated, anesthetized male rats were subjected to moderate (1.94 to 2.18 atm) parasagittal fluid-percussion (FP) brain injury. After TBI, animals were exposed to either normotension (group 1: TBI alone, n = 6) or hypotension (group 2: TBI + hypotension, n = 6). Moderate hypotension (60 mm Hg/30 min) was induced 5 minutes after TBI or sham procedures by hemorrhage. Sham-operated controls (group 3, n = 7) underwent an induced hypotensive period, whereas normotensive controls (group 4, n = 4) did not. For measuring regional cerebral blood flow (rCBF), radiolabeled microspheres were injected before, 20 minutes after, and 60 minutes after TBI (n = 23). For quantitative histopathologic evaluation, separate groups of animals were perfusion-fixed 3 days after TBI (n = 22). At 20 minutes after TBI, rCBF was bilaterally reduced by 57% + 6% and 48% +/- 11%; in cortical and subcortical brain regions, re spectively, under normotensive conditions. Compared with normotensive TBI rats, hemodynamic depression was significantly greater with induced hypotension in the histopathologically vulnerable (P1) posterior parietal cortex (P < 0.01). Secondary hypotension also increased contusion area at specific bregma levels compared with normotensive TBI rats (P < 0.05), as well as overall contusion volume (0.96 +/- 0.46 mm(3) vs. 2.02 +/- 0.51 mm(3), mean +/- SD, P < 0.05). These findings demonstrate that mild hemorrhagic hypotension after FP injury worsens local histopathologic outcome, possibly through vascular mechanisms.	Univ Miami, Sch Med, Miami Project Cure Paralysis, Lois Pope LIFE Ctr, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Pediat, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurotrauma Res Ctr, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Miami Project Cure Paralysis, Lois Pope LIFE Ctr, 1095 NW 14 Ter,R48, Miami, FL 33136 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1998, J NEUROTRAUM, V15, P721, DOI 10.1089/neu.1998.15.721; ARMSTEAD WM, 1999, AM J PHYSIOL, pH1884; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; BOLANDER HG, 1989, STROKE, V20, P930, DOI 10.1161/01.STR.20.7.930; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Davis KL, 1998, J NEUROTRAUM, V15, P615, DOI 10.1089/neu.1998.15.615; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DEWITT DS, 1995, NEW HORIZONS, P3376; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1994, J NEUROTRAUM, P11289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MALIK AB, 1976, J APPL PHYSIOL, V40, P472; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; SCHMOKER JD, 1992, J TRAUMA, V32, P714, DOI 10.1097/00005373-199206000-00007; TYSON GW, 1984, ANN NEUROL, V15, P559, DOI 10.1002/ana.410150608; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	58	45	47	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2001	21	7					847	856		10.1097/00004647-200107000-00010			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	448WV	WOS:000169653700010	11435797	Bronze			2021-06-18	
J	Reid, SR; Roesler, JS; Gaichas, AM; Tsai, AK				Reid, SR; Roesler, JS; Gaichas, AM; Tsai, AK			The epidemiology of pediatric traumatic brain injury in Minnesota	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article; Proceedings Paper	Annual Congress of the American-Academy-of-Pediatrics	OCT 16-19, 1998	SAN FRANCISCO, CALIFORNIA	Amer Acad Pediat			HEAD-INJURY; POPULATION; TRENDS; COMMUNITY; CHILDREN; COUNTY; URBAN	Objectives: To determine the epidemiology of pediatric traumatic brain injury (TBI) in a midwestern state and to examine differences between metropolitan and nonmetropolitan residents. Design: Population-based case series. Participants: Patients aged 0-19 years sustaining TBI in 1993 that resulted in hospitalization or death. Interventions: None. Main Outcome Measures: Incidence, mortality and case-fatality rates, length of hospital stay, discharge status, and Glasgow Outcome Scale score. Results: Nine hundred seventy-seven patients met inclusion criteria. Incidence, mortality, and case-fatality rates were 73.5 per 100 000, 9.3 per 100 000, and 12.8 per 100, respectively. Higher median household incomes and percentages of adult high-school graduates in a patient's census block group correlated with lower incidence. Median length of stay was 2 days. Of those included in the study, 720 patients (74%) were discharged home with self-care. Three hundred fifty-seven patients met criteria for severe TBI; 346 (97%) were assigned Glasgow Outcome Scale scores, of which 161 (47%) had disabilities or died. Severe TBI was associated with nonmetropolitan residence, higher median household income, and certain injury mechanisms. Incidence was similar for metropolitan and nonmetropolitan residents. Median head-region Abbreviated Injury Score, Injury Severity Score, and mortality and case-fatality rates were higher for nonmetropolitan residents. Conclusions: This study reports the lowest incidence of pediatric TBI that results in death or hospitalization to date. One half of severely injured patients suffered poor outcomes. A greater proportion of nonmetropolitan than metropolitan residents suffered severe TBI and had higher mortality and case-fatality rates.	Childrens Hosp & Clin, Dept Emergency Med, St Paul, MN 55102 USA; Univ Minnesota, Dept Hlth, St Paul, MN 55108 USA; Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA	Reid, SR (corresponding author), Childrens Hosp & Clin, Dept Emergency Med, 245 N Smith Ave, St Paul, MN 55102 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BROWN DSO, 1991, SOC SCI MED, V33, P283, DOI 10.1016/0277-9536(91)90362-G; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; *CTR HLTH PROM, 1995, OV TRAUM BRAIN SPIN, P27; *CTR HLTH STAT, 1994, 1993 MINN HLTH STAT, P107; DUNN KA, 1999, REP NIH CONS DEV C R, pB1; Edna T H, 1987, J Oslo City Hosp, V37, P101; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; GABELLA B, 1997, MMWR-MORBID MORTAL W, V46, P8; GAICHAS A, 2000, P NAT C HLTH STAT WA, P29; GOLDSMITH HF, 1993, IMPROVING OPERATIONA, P1; HOROWITZ I, 1982, INT REHABIL MED, V5, P32; Hwang H C, 1997, Inj Prev, V3, P35, DOI 10.1136/ip.3.1.35; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KALSBEEK WD, 1980, J NEUROSURG, V53, P519; KING WD, 1994, PEDIATR EMERG CARE, V10, P34, DOI 10.1097/00006565-199402000-00010; KLAUBER MR, 1981, NEUROSURGERY, V9, P236, DOI 10.1227/00006123-198109000-00003; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LAPORTE RE, 1995, AM J EPIDEMIOL, V142, P1069, DOI 10.1093/oxfordjournals.aje.a117560; MacKenzie E J, 1989, Md Med J, V38, P725; MICHAUD LJ, 1993, PEDIATR CLIN N AM, V40, P553; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; *OFF TRAFF SAF, 1999, MINN MOT VEH CRASH F, P1; SINGH GK, 1996, MON VITAL STAT REP, V45, P75; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ., 1995, GUIDELINES SURVEILLA; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; YIP PSF, 1995, AM J EPIDEMIOL, V142, P1059, DOI 10.1093/oxfordjournals.aje.a117559; YIP PSF, 1995, AM J EPIDEMIOL, V142, P1047	38	45	45	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2001	155	7					784	789		10.1001/archpedi.155.7.784			6	Pediatrics	Pediatrics	450WF	WOS:000169767300006	11434844	Bronze			2021-06-18	
J	Varney, NR; Pinkston, JB; Wu, JC				Varney, NR; Pinkston, JB; Wu, JC			Quantitative PET findings in patients with posttraumatic anosmia	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						positron emission tomography; posttraumatic anosmia; single photon emission computed tomography	CLOSED HEAD-INJURY; TRAUMATIC BRAIN INJURY; SPECT	Objective: To investigate quantitative positron emission tomography (PET) findings, particularly from orbitofrontal cortex. in patients with posttraumatic anosmia. Setting: Neuropsychology outpatient clinic and university brain imaging center. Subjects: Eleven patients with head injury resulting in severe anosmia and 11 controls matched for age. All 11 head-injured patients had their head injuries at least 2 years before involvement in the study Measures: Regional cerebral glucose metabolism was measured with PET. Results: Quantitative evaluation of PET findings fur anosmic patients as a group showed orbitofrontal hypometabolism compared with controls. Decreased activity was also noted in mesial temporal lobe. Activity in subcortical white matter was essentially identical between groups. Conclusions: Findings strongly suggest that posttraumatic anosmia is closely associated with hypometabolism in the orbitofrontal cortex and the medial prefrontal cortex. The results also underscore the importance of posttraumatic anosmia as a clinical sign of orbitofrontal damage, as has been shown previously with neuroSPECT (single photon emission computed tomography).	VA Med Ctr, Psychiat Serv 116B, Iowa City, IA 52246 USA; Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Oklahoma City, OK 73190 USA; Univ Calif Irvine, Brain Imaging Ctr, Irvine, CA USA	Varney, NR (corresponding author), VA Med Ctr, Psychiat Serv 116B, Iowa City, IA 52246 USA.						American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Medical Association, 1993, GUID EV PERM IMP; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GRAY BG, 1992, J NUCL MED, V33, P52; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; Newberg AB, 1996, J HEAD TRAUMA REHAB, V11, P65, DOI 10.1097/00001199-199612000-00009; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Ogawa T, 1999, ACTA OTO-LARYNGOL, P50; Pinkston JB, 2000, ARCH CLIN NEUROPSYCH, V15, P545, DOI 10.1016/S0887-6177(99)00051-7; SUMNER D, 1976, HDN CLIN NEUROLOGY, V2; Varney N R, 1998, Appl Neuropsychol, V5, P100, DOI 10.1207/s15324826an0502_6; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; VARNEY NR, 1988, J CLIN EXP NEUROPSYC, V10, P250, DOI 10.1080/01688638808408239; Varney NR, 1998, J HEAD TRAUMA REHAB, V13, P63; Wu J, 1999, AM J PSYCHIAT, V156, P1149; ZUSHO H, 1982, ARCH OTOLARYNGOL, V108, P90	22	45	45	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2001	16	3					253	259		10.1097/00001199-200106000-00004			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	442YY	WOS:000169313600004	11346447				2021-06-18	
J	Floyd, CL; Rzigalinski, BA; Weber, JT; Sitterding, HA; Willoughby, KA; Ellis, EF				Floyd, CL; Rzigalinski, BA; Weber, JT; Sitterding, HA; Willoughby, KA; Ellis, EF			Traumatic injury of cultured astrocytes alters inositol (1,4,5) trisphosphate-mediated signaling	GLIA			English	Article						calcium signaling; glutamate; tACPD; neomycin; U73122	CAPACITATIVE CALCIUM-ENTRY; EXPERIMENTAL BRAIN INJURY; STRETCH-INDUCED INJURY; PHOSPHOLIPASE-C; 1,4,5-TRISPHOSPHATE RECEPTOR; COGNITIVE IMPAIRMENT; GLUTAMATE RECEPTORS; CORTICAL-NEURONS; PLASMA-MEMBRANE; GAP-JUNCTIONS	Our previous studies using an in vitro model of traumatic injury have shown that stretch injury of astrocytes causes a rapid elevation in intracellular free calcium ([Ca2+](i)), which returns to near normal by 15 min postinjury. We have also shown that after injury astrocyte intracellular calcium stores are no longer able to release Ca2+ in response to signal transduction events mediated by the second messenger inositol (1,4,5)-trisphosphate (IP3, Rzigalinski et al., 1998). Therefore, we tested the hypothesis that in vitro injury perturbs astrocyte IP3 levels. Astrocytes grown on Silastic membranes were labeled with [H-3]-myo-inositol and stretch-injured. Cells and media were acid-extracted and inositol phosphates isolated using anion-exchange columns. Alter injury, inositol polyphosphate (IP3) levels increased up to 10-fold over uninjured controls. Significant injury-induced increases were seen at 5, 15, and 30 min and at 24 and 48 h postinjury. Injury-induced increases in IPx were equivalent to the maximal glutamate and trans-(1S,3R)-1-amino-1,3-cyclopentanedicarboxylic acid-stimulated IPx production, however injury-induced increases in IPx were sustained through 24 and 48 h postinjury. Injury-induced increases in IPx were attenuated by pretreatment with the phospholipase C inhibitors neomycin (100 muM) or U73122 (1.0 muM). Since we have previously shown that astrocyte [Ca2+](i) returns to near basal levels by 15 min postinjury, the current results suggest that IP3-mediated signaling is uncoupled from its target, the intracellular Ca2+ store. Uncoupling of IP3-mediated signaling may contribute to the pathological alterations seen after traumatic brain injury. GLIA 33:12-23, 2001. (C) 2001 Wiley-Liss, Inc.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychol, Richmond, VA 23298 USA	Rzigalinski, BA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, POB 980613, Richmond, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27214, NS 07288] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER		Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Cotrina ML, 1998, J NEUROSCI, V18, P2520; CUNNINGHAM AM, 1993, NEUROSCIENCE, V57, P339, DOI 10.1016/0306-4522(93)90067-P; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; Delahunty TM, 1995, J NEUROTRAUM, V12, P1045, DOI 10.1089/neu.1995.12.1045; DI X, 1999, IN PRESS BRAIN EDEMA; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAROOQUI AA, 1994, J NEUROSCI RES, V38, P6, DOI 10.1002/jnr.490380103; Fisher Stpehen K., 1999, P415; GINSBERG MD, 1993, RES P ARNMD, V71, P207; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; HUGHES AR, 1990, ENVIRON HEALTH PERSP, V84, P141, DOI 10.2307/3430715; IMAZAWA M, 1989, JPN J PSYCHIAT NEUR, V43, P465; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LEVITZKI A, 1987, FEBS LETT, V211, P113, DOI 10.1016/0014-5793(87)81419-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Marmarou A, 1997, ACT NEUR S, V70, P68; McIntosh TK, 1996, LAB INVEST, V74, P315; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; NEDERGAARD M, 1995, J NEUROBIOL, V28, P433, DOI 10.1002/neu.480280404; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OCONNOR ER, 1993, J NEUROSCI, V13, P2638; OLIVER JM, 1978, AM J PATHOL, V93, P221; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Parsons JT, 1997, J NEUROCHEM, V68, P1124; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RHEE SG, 1992, J BIOL CHEM, V267, P12393; Roberts RE, 1997, J NEUROCHEM, V69, P1291; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHREIBER D, 1995, P 1995 INT RES C BIO; SHAO Y, 1995, CELL CALCIUM, V17, P187, DOI 10.1016/0143-4160(95)90033-0; Smith RJ, 1996, J PHARMACOL EXP THER, V278, P320; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Wang JP, 1996, J BIOL CHEM, V271, P8387, DOI 10.1074/jbc.271.14.8387; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WU DQ, 1992, J BIOL CHEM, V267, P25798; Young W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	71	45	47	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	JAN	2001	33	1					12	23		10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V			12	Neurosciences	Neurosciences & Neurology	389MY	WOS:000166243200002	11169788				2021-06-18	
J	Hodgkinson, A; Veerabangsa, A; Drane, D; McCluskey, A				Hodgkinson, A; Veerabangsa, A; Drane, D; McCluskey, A			Service utilization following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						follow-up; psychosocial disability; service utilization; traumatic brain injury	BLUNT HEAD-INJURY	Objectives: To document service utilization by people with a traumatic brain injury at different times postinjury and to identify factors that predict service use. Design: Cross-sectional study design. Four groups of subjects were randomly selected from a regional database, according to their time postinjury: 6-18 months; 2-4 years; 6-9 years; and 10-17 years. Subjects: A total of 119 adults with a traumatic brain injury (TBI) Setting: Hospital and community-based clients in Sydney Australia. Outcome measures: Glasgow Outcome Scale, Disability Rating Scale; Functional Independence Measure; Lidcombe Psychosocial Disability Scale; number, type, and frequency of services used in the previous 12 months. Results: Subjects in all four groups used a variety of services. The mean number of services used was 4.2, and there was only a moderate decline in service use over time. The use of medical and allied health services remained high in all four groups. Severity of injury, physical and cognitive disability, and psychosocial disability were all predictors of service utilization. Psychosocial disability was strongly associated with ongoing service utilization. Conclusion: In this study, people with TBI used services well beyond the early stage of recovery Psychosocial disability may be a better predictor of service use than physical and cognitive disability alone.	Liverpool Hlth Serv, Brain Injury Rehabil Med, Liverpool, NSW, Australia; Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL USA; Univ Western Sydney Macarthur, Fac Hlth, Div Occupat Therapy, Campbelltown, NSW 2560, Australia	Hodgkinson, A (corresponding author), Liverpool Hlth Serv, Brain Injury Rehabil Med, Liverpool, NSW, Australia.						BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Fricke J., 1993, AUST OCCUP THER J, V40, P7; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hamilton B., 1987, REHABILITATION OUTCO; HIGHTOWER CM, 1995, SPE DRILL COMPLETION, V10, P4, DOI 10.2118/26335-PA; JENNETT B, 1975, LANCET, V1, P480; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	16	45	46	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2000	15	6					1208	1226		10.1097/00001199-200012000-00003			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	378ZX	WOS:000165617400003	11056404				2021-06-18	
J	Warden, DL; Salazar, AM; Martin, EM; Schwab, KA; Coyle, M; Walter, J				Warden, DL; Salazar, AM; Martin, EM; Schwab, KA; Coyle, M; Walter, J		DVHIP Study Grp	A home program of rehabilitation for moderately severe traumatic brain injury patients	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; home activities; home rehabilitation; outcome; telephone monitoring	COMMUNITY-BASED REHABILITATION	We have recently reported the results of a prospective controlled randomized trial comparing home versus inpatient cognitive rehabilitation for patients with model-ate to severe head injury. That study showed no overall difference in outcomes between the two groups.(1) In this article, we provide further details of the home program arm of the study ALI patients in the home program received medical treatment as needed. a multidisciplinary in-hospital evaluation, and TBI counseling before entering the eight-week home program, which then included guidance on home activities, as well as weekly telephone calls from a psychiatric nurse.	Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Walter Reed AMC, Def & Vet Head Injury Program, Washington, DC USA; Walter Reed AMC, Neurosurg Serv, Washington, DC USA	Warden, DL (corresponding author), Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA.						BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Braverman SE, 1999, BRAIN INJURY, V13, P405; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; CHESTNUT R, 1999, 9E0006 AHCPR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Freeman EA, 1997, BRAIN INJURY, V11, P143, DOI 10.1080/026990597123746; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Pace GM, 1999, BRAIN INJURY, V13, P535; Portnow J, 1991, Clin Geriatr Med, V7, P695; PRIGATANO G, 1984, J NEUROL NEUROSRUG P, V47, P503; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Sargent M, 1993, Rehabil Nurs, V18, P380; Sartorius N, 1974, MEASUREMENT CLASSIFI; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Stonnington HH, 1997, BRAIN INJURY, V11, P155, DOI 10.1080/026990597123755; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9	17	45	45	0	9	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1092	1102		10.1097/00001199-200010000-00003			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800003	10970930				2021-06-18	
J	Butler, PV				Butler, PV			Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury	AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY			English	Article						Capgras syndrome; content-specific delusions; Cotard's syndrome; delusional misidentification; depersonalisation; derealisation	MISIDENTIFICATION; IDENTITY	Objective: The aim of this paper is to document regular nocturnal intensification of delusional nihilistic and persecutory ideas (Cotard delusion) linked with extreme depersonalisation and hypervivid dreaming. Clinical Picture: A 17-year-old man presented with Cotard and Capgras delusions after sustaining multiple cognitive impairments secondary to traumatic brain injury. Treatment and outcome: Delusional ideation fully resolved within 14 days of commencement of olanzapine 5 mg daily. Conclusion: This patient's experience of perceptual abnormalities and impairments in meta-abilities related to self-monitoring and critical inferencing lends support to multicomponent sensory processing accounts of brain injury related, content-specific delusional syndromes.	Royal Rehabil Ctr, Ryde, NSW 2112, Australia	Butler, PV (corresponding author), Royal Rehabil Ctr, Ryde, NSW 2112, Australia.						BANOV MD, 1993, COMPR PSYCHIAT, V34, P414, DOI 10.1016/0010-440X(93)90068-F; BERSON RJ, 1983, AM J PSYCHIAT, V140, P969; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Cotard J., 1882, ARCH NEUROL-PARIS, V4, P282; Cotard J., 1882, ARCH NEUROL-PARIS, V4, P152; *CTR FUNCT ASS RES, 1990, AUSTR GUID US UN DAT; Edelstyn NMJ, 1999, INT J GERIATR PSYCH, V14, P48, DOI 10.1002/(SICI)1099-1166(199901)14:1<48::AID-GPS891>3.3.CO;2-S; ELLIS HD, 1990, BRIT J PSYCHIAT, V157, P239, DOI 10.1192/bjp.157.2.239; ENOCH MD, 1979, UNCOMMON PSYCHIAT SY, P1; ENOCH MD, 1979, UNCOMMON PSYCHIAT SY, P116; FLEMINGER S, 1994, PSYCHOPATHOLOGY, V27, P161, DOI 10.1159/000284865; Hirstein W, 1997, P ROY SOC B-BIOL SCI, V264, P437, DOI 10.1098/rspb.1997.0062; MALLOY PF, 1994, J NEUROPSYCH CLIN N, V6, P455; MILLER L, 1994, J COGNITIVE REHABILI, V12, P12; RAMACHANDRAN VS, 1999, PHANTOMS BRAIN, P158; SCHNAPER N, 1975, J TRAUMA, V15, P94, DOI 10.1097/00005373-197502000-00002; TEASDALE G, 1974, LANCET, V2, P81; WEINSTEIN E, 1996, METHOD MADNESS, P13; WRIGHT S, 1993, BRIT J CLIN PSYCHOL, V32, P345, DOI 10.1111/j.2044-8260.1993.tb01065.x; YOUNG AW, 1996, METHOD MADNESS CASE, P147	20	45	46	0	14	BLACKWELL SCIENCE ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0004-8674			AUST NZ J PSYCHIAT	Aust. N. Z. J. Psych.	AUG	2000	34	4					684	687		10.1046/j.1440-1614.2000.00758.x			4	Psychiatry	Psychiatry	339AG	WOS:000088455000018	10954402				2021-06-18	
J	Di Stefano, G; Bachevalier, J; Levin, HS; Song, JX; Scheibel, RS; Fletcher, JM				Di Stefano, G; Bachevalier, J; Levin, HS; Song, JX; Scheibel, RS; Fletcher, JM			Volume of focal brain lesions and hippocampal formation in relation to memory function after closed head injury in children	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; magnetic resonance imaging; verbal learning and memory; frontal lobe; hippocampus	DIFFUSE AXONAL INJURY; POSTNATAL-DEVELOPMENT; FRONTAL-CORTEX; DENTATE GYRUS; MOSSY CELLS; LOBE; ADOLESCENTS; DEFICIT; MONKEYS; HUMANS	Objectives-(1) A study of verbal learning and memory in children who had sustained a closed head injury (CHI) at least 3 months earlier. (2) To relate memory function to focal brain lesion and hippocampal formation volumes using morphometric analysis of MRI. Methods-A group of 245 children who had been admitted to hospital for CHI graded by the Glasgow coma scale (GCS), including 161 patients with severe and 84 with mild CHI completed the California verbal learning test (CVLT) and underwent MRI which was analysed for focal brain lesion volume independently of memory test data. Brain MRI with 1.5 mm coronal slices obtained in subsets of 25 patients with severe and 25 patients with mild CHI were analysed for hippocampal formation volume. Interoperator reliability in morphometry was satisfactory. Results-Severity of CHI and age at study significantly affected memory performance. Regression analysis showed that bifrontal, left frontal, and right frontal lesion volumes incremented prediction of various learning and memory indices after entering the GCS score and age into the model. Extrafrontal lesion volume did not contribute to predicting memory performance. Conclusions-Prefrontal lesions contribute to residual impairment of learning and memory after severe CHI in children. Although effects of CHI on hippocampal formation volume might be difficult to demonstrate in non-fatal paediatric CHI, further investigation using functional brain imaging could potentially demonstrate hippocampal dysfunction.	Baylor Coll Med, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Neurobiol & Anat, Houston, TX USA; Univ Houston, Hlth Sci Ctr, Dept Pediat, Houston, TX USA	Di Stefano, G (corresponding author), Univ Bern, Inselspital, Dept Psychiat, Murtenstr 21, CH-3010 Bern, Switzerland.	giuseppe.distefano@papk.unibe.ch	fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BENES FM, 1994, ARCH GEN PSYCHIAT, V51, P477; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Chugani H T, 1999, Adv Neurol, V79, P883; Cohen N.J., 1993, MEMORY AMNESIA HIPPO; DELIS D, 1986, CALIFORNIA VERBAL LE; DIAMOND A, 1990, P394; FREE SL, 1995, AM J NEURORADIOL, V16, P637; FUSTER JM, 1989, PREFRONTAL CORTEX AN; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giedd JN, 1996, J COMP NEUROL, V366, P223, DOI 10.1002/(SICI)1096-9861(19960304)366:2<223::AID-CNE3>3.0.CO;2-7; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; GRASBY PM, 1993, BRAIN, V116, P1, DOI 10.1093/brain/116.1.1; HILLMAN GR, 1991, J COMPUT ASSIST TOMO, V15, P640, DOI 10.1097/00004728-199107000-00021; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; JETTER W, 1986, CORTEX, V22, P229, DOI 10.1016/S0010-9452(86)80047-8; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; PETRIDES M, 1995, P NATL ACAD SCI USA, V92, P5803, DOI 10.1073/pnas.92.13.5803; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; Schacter DL, 1996, NEUROREPORT, V7, P1165, DOI 10.1097/00001756-199604260-00014; SERESS L, 1995, J COMP NEUROL, V355, P93, DOI 10.1002/cne.903550111; SERESS L, 1992, HIPPOCAMPUS, V2, P127, DOI 10.1002/hipo.450020205; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Stern CE, 1996, P NATL ACAD SCI USA, V93, P8660, DOI 10.1073/pnas.93.16.8660; STRICH SJ, 1961, LANCET, V2, P443; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	41	45	45	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2000	69	2					210	216		10.1136/jnnp.69.2.210			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	338XM	WOS:000088448600014	10896695	Bronze, Green Published			2021-06-18	
J	Raju, U; Gumin, GJ; Tofilon, PJ				Raju, U; Gumin, GJ; Tofilon, PJ			Radiation-induced transcription factor activation in the rat cerebral cortex	INTERNATIONAL JOURNAL OF RADIATION BIOLOGY			English	Article							NF-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR EXPRESSION; TRAUMATIC BRAIN INJURY; GENE-EXPRESSION; MESSENGER-RNA; IONIZING-RADIATION; IN-VIVO; C-FOS; DEPENDENT ACTIVATION	Purpose: To determine the effects of ionising radiation on the DNA-binding activity of the injury-related transcription factors AP-1, Sp-1, p53 and NF kappa B in the rat brain. Materials and methods: Male Sprague-Dawley rats were irradiated with Cs-137 gamma-rays at 3.8 Gy/min and the cerebral cortex was isolated at intervals up to 24 h . Nuclear protein extract of the cerebral cortex was analysed by electrophoretic mobility shift assay for DNA-binding activity of AP-1, Sp-1, p53 and NF kappa B. In addition, total RNA was extracted from the cerebral cortex and subjected to northern analysis. Results: The DNA-binding activity of each of the transcription factors increased in a time- and dose-dependent manner after irradiation. Maximum increase in the activity of AP-1, Sp-1, and p53 DNA binding was seen after exposure to 10 Gy and then decreased after higher doses. In contrast, NF kappa B DNA-binding activity continued to increase out to at least 30 Gy. The levels of bFGF and p21(WAF-1) mRNA increased after irradiation, suggesting an increase in the transactivating activity of AP-1, Sp-1, and p53. Conclusions: These data indicate that the response of the CNS to irradiation includes the activation of a similar set of transcription factors as previously observed after other types of insults.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	Tofilon, PJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd,Box 66, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA072156, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 72156, CA 16672] Funding Source: Medline		Azuma Y, 1996, NEUROCHEM INT, V29, P323, DOI 10.1016/0197-0186(95)00147-6; Barger SW, 1996, MOL BRAIN RES, V40, P116; Chiang CS, 1997, INT J RADIAT BIOL, V72, P45; DANIELSON PE, 1988, DNA CELL BIOL, V7, P920; DIEHL JA, 1995, J BIOL CHEM, V270, P2703, DOI 10.1074/jbc.270.6.2703; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Feng ZH, 1999, MOL BRAIN RES, V69, P144, DOI 10.1016/S0169-328X(99)00099-6; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; HERDEGEN T, 1995, J COMP NEUROL, V354, P39, DOI 10.1002/cne.903540105; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Hong JH, 1997, MOL BRAIN RES, V48, P223, DOI 10.1016/S0169-328X(97)00095-8; HONG JH, 1995, INT J RADIAT ONCOL, V33, P619, DOI 10.1016/0360-3016(95)00279-8; Hughes PE, 1996, NEUROSCIENCE, V74, P1143, DOI 10.1016/S0306-4522(96)00174-1; IJICHI A, 1995, GLIA, V14, P87, DOI 10.1002/glia.440140203; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Keyeux A, 1997, RADIAT RES, V147, P621, DOI 10.2307/3579629; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; Lezoualc'h F, 1998, MOL PSYCHIATR, V3, P15, DOI 10.1038/sj.mp.4000295; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; Li YQ, 1996, CANCER RES, V56, P5417; Liu W, 1999, MOL BRAIN RES, V63, P248, DOI 10.1016/S0169-328X(98)00285-X; MacCallum DE, 1996, ONCOGENE, V13, P2575; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; MYERS R, 1986, BRIT J CANCER, V53, P221; Nakagomi T, 1996, NEUROL RES, V18, P559; Noel F, 1997, RADIAT RES, V147, P484, DOI 10.2307/3579506; Pennypacker K, 1997, HISTOL HISTOPATHOL, V12, P1125; Raju U, 1997, J BIOL CHEM, V272, P24624, DOI 10.1074/jbc.272.39.24624; Raju U, 1999, RADIAT ONCOL INVESTI, V7, P145, DOI 10.1002/(SICI)1520-6823(1999)7:3<145::AID-ROI2>3.0.CO;2-R; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Schneider A, 1999, NAT MED, V5, P554; SCHULTHEISS TE, 1992, BRIT J RADIOL, V65, P737, DOI 10.1259/0007-1285-65-777-737; SCHULTHEISS TE, 1995, INT J RADIAT ONCOL, V31, P1093, DOI 10.1016/0360-3016(94)00655-5; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tomasevic G, 1999, NEUROSCIENCE, V90, P781, DOI 10.1016/S0306-4522(98)00484-9; VALK PE, 1991, AM J ROENTGENOL, V156, P689; VANDERKOGEL AJ, 1986, BRIT J CANCER, V53, P207; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; Woo RA, 1998, NATURE, V394, P700; WOOD KA, 1995, J NEUROSCI, V15, P5851; Xiang H, 1998, J NEUROSCI, V18, P1363; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Zhou DH, 1999, RADIAT RES, V151, P703, DOI 10.2307/3580209	52	45	48	0	2	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0955-3002			INT J RADIAT BIOL	Int. J. Radiat. Biol.	AUG	2000	76	8					1045	1053					9	Biology; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	Life Sciences & Biomedicine - Other Topics; Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical Imaging	344EY	WOS:000088747300003	10947117				2021-06-18	
J	Godfrey, HPD; Shum, D				Godfrey, HPD; Shum, D			Executive functioning and the application of social skills following traumatic brain injury	APHASIOLOGY			English	Article							CLOSED-HEAD-INJURY; ADJUSTMENT; IMPAIRMENT; REHABILITATION; COMMUNICATION; CONVERSATION; DYSFUNCTION	Many adults with a traumatic brain injury (TBI) are less competent conversationalists following their injury. Reduced conversational competency is a clinically significant problem. It is associated with a variety of adverse psychosocial outcomes following TBI. Unfortunately, direct attempts to improve the conversational competency of adults with TBI using social skills training has had limited success. This article applies McFall's (1982) social skills model to conversational competency following TBI. This social skills model is based on two critical assumptions. First, in order to be judged socially competent, a person needs to possess the social skills required in a given social context. Second, that social competence requires the ability to apply social skills flexibly according to the rules of social interaction. It is argued that the inability to flexibly apply behaviour according to rules (executive dysfunction) could account for many characteristics of conversation following TBI. This argument is illustrated through the detailed application of Norman and Shallice's (1986) theory of executive functioning to research on conversational behaviour following TBI. It is concluded that fostering appropriate social environments, and providing support are more likely to be effective than remedial social skills training.	Univ Otago, Dept Psychol, Dunedin, New Zealand; Griffith Univ, Sch Appl Psychol, Brisbane, Qld, Australia	Godfrey, HPD (corresponding author), Univ Otago, Dept Psychol, POB 56, Dunedin, New Zealand.		Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			ALEXANDER MP, 1987, NEUROBEHAVIOURAL REC; Argyle M., 1969, SOCIAL INTERACTION; ARGYLE M, ANATOMY RELATIONSHIP; BARCH D, 1994, J ABNORM PSYCHOL, V103, P241, DOI 10.1037/0021-843X.103.2.241; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; DERLEGA VJ, 1986, FRIENDSHIP SOCIAL IN; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Godfraind T, 1996, NAT MED, V2, P2; GODFREY H P D, 1991, Brain Injury, V5, P207, DOI 10.3109/02699059109008091; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; GODFREY HPD, 1988, ARCH PHYS MED REHAB, V69, P458; HALFORD WK, 1991, CLIN PSYCHOL REV, V11, P23, DOI 10.1016/0272-7358(91)90136-I; Heaton R., 1981, MANUAL WISCONSIN CAR; HORNER RH, 1990, J ASSOC PERS SEVERE, V15, P125; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Linscott RJ, 1996, BRAIN INJURY, V10, P397, DOI 10.1080/026990596124269; Mandler J.M., 1984, STORIES SCRIPTS SCEN; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MCFALL RM, 1982, BEHAV ASSESS, V4, P1; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; Norman D, 1986, CONSCIOUSNESS SELF R, VIV; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; REASON J, 1982, ABSENTMINDED PSYCHOL; RIPICH DN, 1994, ALZ DIS ASSOC DIS, V8, P95, DOI 10.1097/00002093-199424004-00011; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHALLICE T, 1991, FRONTAL LOBE FUNCTIO; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Smith L.M., 1995, FAMILY SUPPORT PROGR; SPENCE SE, 1993, BRIT J CLIN PSYCHOL, V32, P309, DOI 10.1111/j.2044-8260.1993.tb01061.x; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trower P., 1978, SOCIAL SKILLS MENTAL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Williamson JG, 1996, NEUROPSYCHOLOGY CLIN	48	45	47	0	15	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	APR	2000	14	4					433	444		10.1080/026870300401441			12	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	315AV	WOS:000087091200006					2021-06-18	
J	Li, YC; Liu, L; Chiu, WT; Jian, WS				Li, YC; Liu, L; Chiu, WT; Jian, WS			Neural network modeling for surgical decisions on traumatic brain injury patients	INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS			English	Article						medical decision support system; computer-assisted medical decision; decision theory; intracranial hematoma; traumatic brain injury; logistic regression; neural networks	MYOCARDIAL-INFARCTION; DIAGNOSIS; PREDICTION; CURVES	Computerized medical decision support systems have been a major research topic in recent years. Intelligent computer programs were implemented to aid physicians and other medical professionals in making difficult medical decisions. This report compares three different mathematical models for building a traumatic brain injury (TBI) medical decision support system (MDSS). These models were developed based on a large TBI patient database. This MDSS accepts a set of patient data such as the types of skull fracture, Glasgow Coma Scale (GCS), episode of convulsion and return the chance that a neurosurgeon would recommend an open-skull surgery for this patient. The three mathematical models described in this report including a logistic regression model, a multi-layer perceptron (MLP) neural network and a radial-basis-function (RBF) neural network. From the 12 640 patients selected from the database. A randomly drawn 9480 cases were used as the training group to develop/train our models. The other 3160 cases were in the validation group which we used to evaluate the performance of these models. We used sensitivity, specificity, areas under receiver-operating characteristics (ROC) curve and calibration curves as the indicator of how accurate these models are in predicting a neurosurgeon's decision on open-skull surgery. The results showed that, assuming equal importance of sensitivity and specificity, the logistic regression model had a (sensitivity, specificity) of (73%, 68%), compared to (80%, 80%) from the RBF model and (88%, 80%) from the MLP model. The resultant areas under ROC curve for logistic regression, RBF and MLP neural networks are 0.761, 0.880 and 0.897, respectively (P < 0.05). Among these models, the logistic regression has noticeably poorer calibration. This study demonstrated the feasibility of applying neural networks as the mechanism for TBI decision support systems based on clinical databases. The results also suggest that neural networks may be a better solution for complex, non-linear medical decision support systems than conventional statistical techniques such as logistic regression. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Taipei Med Coll, Grad Inst Med Informat, Taipei 110, Taiwan; Taipei Med Coll, Ctr Biomed Informat, Taipei, Taiwan; Taipei Med Coll, Dept Med, Taipei, Taiwan; Wanfang Hosp, Taipei, Taiwan; Taipei Med Coll, Sch Healthcare Adm, Taipei, Taiwan	Li, YC (corresponding author), Taipei Med Coll, Grad Inst Med Informat, 250 Wu Hsin Rd, Taipei 110, Taiwan.		Li, Yu-Chuan/E-9476-2011	Jian, Wen-Shan/0000-0002-1739-4398; Li, Yu-Chuan (Jack)/0000-0001-6497-4232			Barreto J M, 1993, Artif Intell Med, V5, P515, DOI 10.1016/0933-3657(93)90041-Z; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1994, CANCER LETT, V77, P85, DOI 10.1016/0304-3835(94)90090-6; BAXT WG, 1991, ANN INTERN MED, V115, P843, DOI 10.7326/0003-4819-115-11-843; BERGERON BP, 1994, COMPUT BIOL MED, V24, P157, DOI 10.1016/0010-4825(94)90073-6; BUCHMAN TG, 1994, CRIT CARE MED, V22, P750, DOI 10.1097/00003246-199405000-00008; Chang PL, 1996, COMPUT MED IMAG GRAP, V20, P43, DOI 10.1016/0895-6111(96)00029-8; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; CHIU WT, 1993, J TRAUMA, V35, P206, DOI 10.1097/00005373-199308000-00006; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; DEDOMBAL FT, 1990, BAILLIERE CLIN OB GY, V4, P841, DOI 10.1016/S0950-3552(05)80347-5; DYBOWSKI R, 1995, LANCET, V346, P1203, DOI 10.1016/S0140-6736(95)92904-5; EVANS RS, 1994, ADV EXP MED BIOL, V349, P87; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; Li Y C, 1993, Proc Annu Symp Comput Appl Med Care, P471; LI YC, 1993, AM MED INF ASS SPR C, P95; MCNEIL BJ, 1984, MED DECIS MAKING, V4, P137, DOI 10.1177/0272989X8400400203; NIELEN M, 1995, J DAIRY SCI, V78, P1050, DOI 10.3168/jds.S0022-0302(95)76721-2; SAHASAKUL Y, 1990, BRIT HEART J, V64, P182; SELKER HP, 1995, J INVEST MED, V43, P468; WU YZ, 1993, RADIOLOGY, V187, P81, DOI 10.1148/radiology.187.1.8451441; WYATT J, 1995, LANCET, V346, P1175, DOI 10.1016/S0140-6736(95)92893-6; YATES JF, 1982, ORGAN BEHAV HUM PERF, V30, P132, DOI 10.1016/0030-5073(82)90237-9	25	45	47	0	9	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1386-5056			INT J MED INFORM	Int. J. Med. Inform.	JAN	2000	57	1					1	9		10.1016/S1386-5056(99)00054-4			9	Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics	Computer Science; Health Care Sciences & Services; Medical Informatics	283HZ	WOS:000085271500001	10708251				2021-06-18	
J	Saatman, KE; Zhang, C; Bartus, RT; McIntosh, TK				Saatman, KE; Zhang, C; Bartus, RT; McIntosh, TK			Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						calcium-activated protease; cytoskeleton; histology; rat; traumatic brain injury	TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; CELL-DEATH; RAT; CYTOSKELETAL; ACTIVATION; BREAKDOWN; RECOVERY	Administration of the selective calpain inhibitor AK295 has been shown to attenuate motor and cognitive dysfunction after brain trauma in rats. To explore mechanisms underlying the behavioral efficacy of posttraumatic calpain inhibition, we investigated histologic consequences of AK295 administration. Anesthetized Sprague-Dawley rats received lateral fluid percussion brain injury of moderate severity (2.2 to 2.4 arm) or served as uninjured controls. At 15 minutes after injury, animals were randomly assigned to receive a 48-hour infusion of either 2 mmol/L AK295 (120 to 140 mg/kg) or saline via the carotid artery. At 48 hours and 1 week after injury, spectrin fragments generated specifically by calpain were detected by Western blotting and immunohistochemistry, respectively, in saline-treated, brain-injured animals. Interestingly, equivalent spectrin breakdown was observed in AK295-treated animals when cortical and hippocampal regions were evaluated. Similarly. administration of the calpain inhibitor did not attenuate cortical lesion size or the numbers of apoptotic cells in the cortex, subcortical white matter, or hippocampus, as verified by terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick-end labeling and morphology, at 48 hours after injury. These data suggest that an overt reduction in spectrin proteolysis, cortical lesion, or apoptotic cell death at 48 hours or 1 week is not required for behavioral improvements associated with calpain inhibition by AK295 after experimental brain injury in rats.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Alkermes Inc, Cambridge, MA USA	Saatman, KE (corresponding author), Univ Penn, Dept Neurosurg, 120 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P50-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803] Funding Source: NIH RePORTER		ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BARTH W, 1993, MATH ANN, V295, P25, DOI 10.1007/BF01444875; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; BEHRENS MM, 1995, CELL GROWTH DIFFER, V6, P1375; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brown SB, 1997, BIOCHEM J, V323, P233, DOI 10.1042/bj3230233; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Gressner AM, 1997, BIOCHEM BIOPH RES CO, V231, P457, DOI 10.1006/bbrc.1996.5777; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HIRAMATSU K, 1993, STROKE, V24, P1725, DOI 10.1161/01.STR.24.11.1725; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.3.CO;2-#; Jordan J, 1997, J NEUROCHEM, V68, P1612; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEWCOMB JK, 1997, J NEUROTRAUM, V14, P369; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sabel BA, 1997, NEUROSCIENTIST, V3, P366, DOI 10.1177/107385849700300609; SAIDO TC, 1994, FASEB J, V8, P814; Shoeman RL, 1990, INTRACELLULAR CALCIU, P191; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; WANG KKW, 1995, TRENDS PHARMACOL SCI, V15, P412; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	44	45	46	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2000	20	1					66	73		10.1097/00004647-200001000-00010			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	281PJ	WOS:000085169600010	10616794	Bronze			2021-06-18	
J	Golding, EM; Steenberg, ML; Contant, CF; Krishnappa, I; Robertson, CS; Bryan, RM				Golding, EM; Steenberg, ML; Contant, CF; Krishnappa, I; Robertson, CS; Bryan, RM			Cerebrovascular reactivity to CO2 and hypotension after mild cortical impact injury	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						autoregulation; carbon dioxide reactivity; rat; secondary injury; traumatic brain injury	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; MYOGENIC RESPONSE; COMATOSE PATIENTS; CARBON-DIOXIDE; RATS; AUTOREGULATION; METABOLISM; CIRCULATION	Cerebrovascular reactivity to CO2 or hypotension was studied in vivo and in vitro [pressurized arteries (similar to 82 mu m) and arterioles (similar to 30 mu m)] at 1 h after mild controlled cortical impact (CCI) injury in rats. The cortical perfusion response [assessed using laser-Doppler flowmetry (LDF)] to altered CO2 was diminished (up to 81%) after mild CCI injury. The responses to CO2 alterations in arteries and arterioles isolated from the injured cortex were similar to responses in vessels isolated from sham-injured animals. After mild CCI injury, the autoregulatory response to hypotension (measured using LDF) was maintained or even enhanced, depending on the method used to measure the response. Vessels isolated from the injury site showed a response to changes in pressure similar to that in vessels isolated from sham-injured rats. We conclude that mild CCI injury produces complicated alterations in cerebrovascular control. Whereas the autoregulatory response to hypotension was maintained or even enhanced, the in vivo vascular response to CO2 was severely compromised. The altered response to CO2 was not caused by an intrinsic vascular perturbation but rather an altered milieu alter mild CCI injury.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA	Golding, EM (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,Suite 944, Houston, TX 77030 USA.	egolding@bcm.tmc.edu					ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Brian JE, 1996, CLIN EXP PHARMACOL P, V23, P449, DOI 10.1111/j.1440-1681.1996.tb02760.x; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BRYAN RM, 1988, BRAIN RES, V475, P397, DOI 10.1016/0006-8993(88)90634-8; BRYAN RM, 1995, AM J PHYSIOL-HEART C, V269, pH1171; CHEN RYZ, 1984, STROKE, V15, P343, DOI 10.1161/01.STR.15.2.343; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt D S, 1995, New Horiz, V3, P376; DIRNAGL U, 1993, NEUROL RES, V15, P128; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Golding EM, 1998, J NEUROTRAUM, V15, P973, DOI 10.1089/neu.1998.15.973; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Golding EM, 1998, J NEUROTRAUM, V15, P635, DOI 10.1089/neu.1998.15.635; Golding EM, 1998, BRAIN RES, V785, P293, DOI 10.1016/S0006-8993(97)01419-4; GRUBB RL, 1982, ANESTHESIOLOGY, V56, P3, DOI 10.1097/00000542-198201000-00002; HARPER SL, 1984, HYPERTENSION, V6, P408, DOI 10.1161/01.HYP.6.3.408; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; Jones SC, 1999, AM J PHYSIOL-HEART C, V276, pH1253; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KJALLQUIST A, 1969, ACTA PHYSIOL SCAND, V76, P485; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MEININGER GA, 1992, AM J PHYSIOL, V263, pH647; MILLER JD, 1975, J NEUROL NEUROSUR PS, V38, P657, DOI 10.1136/jnnp.38.7.657; MIRRO R, 1992, STROKE, V23, P1613, DOI 10.1161/01.STR.23.11.1613; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; WAHL M, 1970, PFLUG ARCH EUR J PHY, V316, P152, DOI 10.1007/BF00586483; WANG Q, 1992, J CEREBR BLOOD F MET, V12, P947, DOI 10.1038/jcbfm.1992.131; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	39	45	45	0	5	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	OCT	1999	277	4					H1457	H1466					10	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	259XN	WOS:000083919400025					2021-06-18	
J	Mattsson, P; Meijer, B; Svensson, M				Mattsson, P; Meijer, B; Svensson, M			Extensive neuronal cell death following intracranial transection of the facial nerve in the adult rat	BRAIN RESEARCH BULLETIN			English	Article						proximal nerve transection; microglia; astroglia; oligodendroglia; nerve cell death	HYPOGLOSSAL NUCLEUS; NEUROTROPHIC FACTOR; MOTOR-NEURONS; NITRIC-OXIDE; MOTONEURON DEATH; GLIAL REACTION; TOXIC RICIN; AXOTOMY; INJURY; SURVIVAL	The aim of the present study is to examine the neuronal degeneration and the glial response following intracranial transection of the facial nerve close to the brainstem and furthermore to compare the results with a distal nerve injury, The facial nerve was cut either intracranially in the posterior cranial fossa or further distally, where it passes the parotid gland, in adult rats. Intracranial axotomy caused a massive loss of neuronal profiles, Only 26.8 +/- 11.3% of facial motor neuronal profiles were found ipsilateral to the nerve injury when compared to the contralateral side, following intracranial axotomy, This was statistically significant in comparison to the distal injury (72.4 +/- 9.5%), 4 weeks post-lesion, Reactive microglial cells expressed ED1 immunoreactivity following the intracranial axotomy but not following the distal nerve injury. In conclusion, there was a large discrepancy in neuronal degeneration as well as presence of phagocytic (ED1 positive) microglia between the two lesions. The intracranial lesion model used in the present study generates a massive neuronal cell death and should therefore be a useful tool for studies on proximal cranial nerve injuries and in particular mechanisms causing cell death, which may occur following, for example, head trauma. (C) 1999 Elsevier Science Inc.	Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden	Mattsson, P (corresponding author), Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden.		Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003			ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ALDSKOGIUS H, 1980, J COMP NEUROL, V193, P165, DOI 10.1002/cne.901930111; ALDSKOGIUS H, 1993, ADV STRUCTURAL BIOL, V2, P191; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Cajal Y, 1928, DEGENERATION REGENER; COLTON CA, 1993, ADV NEUROL, V59, P321; CRAGG BG, 1970, BRAIN RES, V23, P1, DOI 10.1016/0006-8993(70)90345-8; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; DAVIES DC, 1977, J ANAT, V127, P43; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FERNANDEZ HL, 1981, NEUROSCI LETT, V25, P7, DOI 10.1016/0304-3940(81)90092-6; FUNKOSHI H, 1993, J CELL BIOL, V123; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; HARDY DG, 1997, BRIT J NEUROSURG, V11, P455; Kishino A, 1997, EXP NEUROL, V144, P273, DOI 10.1006/exnr.1996.6367; KOLIATSOS VE, 1994, J COMP NEUROL, V342, P35, DOI 10.1002/cne.903420105; Kreutzberg GW, 1997, BRAIN PATHOL, V7, P1231; KREUTZBERG GW, 1989, METAB BRAIN DIS, V4, P81, DOI 10.1007/BF00999498; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI LX, 1995, P NATL ACAD SCI USA, V92, P9771, DOI 10.1073/pnas.92.21.9771; LI LX, 1994, J NEUROBIOL, V25, P759, DOI 10.1002/neu.480250702; Lieberman A.R., 1974, ESSAYS NERVOUS SYSTE, P71; LINDA H, 1993, STUDIES SPINAL MOTON; LUNN ER, 1990, NEUROSCIENCE, V35, P157, DOI 10.1016/0306-4522(90)90130-V; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; POLLIN MM, 1991, DEVELOPMENT, V112, P83; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; RUAN RS, 1995, BRAIN RES, V698, P163, DOI 10.1016/0006-8993(95)00887-V; RUAN RS, 1994, ACTA OTO-LARYNGOL, V114, P271, DOI 10.3109/00016489409126055; SCHMALBRUCH H, 1984, J COMP NEUROL, V224, P252, DOI 10.1002/cne.902240206; SINGER PA, 1982, J NEUROSCI, V2, P1299; SJOSTRAND J, 1971, EXP NEUROL, V30, P178, DOI 10.1016/0014-4886(71)90232-9; SNIDER WD, 1992, J NEUROBIOL, V23, P1231, DOI 10.1002/neu.480230913; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; SVENSSON M, 1993, BRAIN RES BULL, V30, P499, DOI 10.1016/0361-9230(93)90284-I; SVENSSON M, 1993, EUR J NEUROSCI, V5, P85, DOI 10.1111/j.1460-9568.1993.tb00208.x; SVENSSON M, 1993, GLIA, V7, P286, DOI 10.1002/glia.440070404; SVENSSON M, 1992, J NEUROIMMUNOL, V40, P99, DOI 10.1016/0165-5728(92)90217-9; SVENSSON M, 1994, J ANAT, V185, P537; SWETT JE, 1991, J COMP NEUROL, V304, P234, DOI 10.1002/cne.903040207; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; THOENEN H, 1980, PHYSL REV, V60; Tornquist E, 1997, NEUROSCI RES, V28, P167, DOI 10.1016/S0168-0102(97)00040-0; TORNQVIST E, 1994, J NEUROSCI RES, V39, P159, DOI 10.1002/jnr.490390206; TORVIK A, 1975, BRAIN RES, V95, P519, DOI 10.1016/0006-8993(75)90125-0; VACA K, 1992, EXP NEUROL, V118, P62, DOI 10.1016/0014-4886(92)90023-J; Wu W., 1995, Society for Neuroscience Abstracts, V21, P279; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YU WHA, 1988, EXP NEUROL, V102, P230, DOI 10.1016/0014-4886(88)90098-2	54	45	49	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	JUL 15	1999	49	5					333	341		10.1016/S0361-9230(98)00178-6			9	Neurosciences	Neurosciences & Neurology	222DU	WOS:000081768800004	10452353				2021-06-18	
J	Aronowski, J; Cho, KH; Strong, R; Grotta, JC				Aronowski, J; Cho, KH; Strong, R; Grotta, JC			Neurofilament proteolysis after focal ischemia; When do cells die after experimental stroke?	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						neurofilament proteolysis; focal ischemia; reperfusion injury; infarct maturation	CEREBRAL-ARTERY OCCLUSION; CALCIUM-ACTIVATED PROTEOLYSIS; TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN INJURY; CYTOSKELETAL DERANGEMENTS; NEURONAL NECROSIS; INFARCT VOLUME; RATS; DEGRADATION; TRANSPORT	To determine the occurrence and time-course of presumably irreversible subcellular damage after moderate focal ischemia, rats were subjected to 1, 3, 6, 9, or 24 hours of permanent unilateral middle cerebral and common carotid occlusion or 3 hours of reversible occlusion followed by 3, 6, or 21 hours of reperfusion. The topography and the extent of damage were analyzed with tetrazolium staining and immunoblot using an antibody capable of detecting breakdown of neurofilament. Neurofilament proteolysis began after 3 hours in the infarct core but was still incomplete in penumbral regions up to 9 hours. Similarly, tetrazolium-staining abnormalities were observed in the core of 50% of animals after 3 hours of ischemia. At 6 hours of permanent ischemia, infarct volume was maximal, and further prolongation of occlusion to 9 or 24 hours did nor increase abnormal tetrazolium staining. In contrast to permanent ischemia and in agreement with the authors' previous demonstration of "reperfusion injury" in this model, prolongation of reperfusion from 3 hours to 6 and 21 hours after 3 hours of reversible occlusion gradually augmented infarct volume by 203% and 324%, respectively. Neurofilament proteolysis initiated approximately 3 hours after ischemia was quantitatively greatest in the core and extended during reperfusion to incorporate penumbra with a similar time course to that of tetrazolium abnormalities. These data demonstrate that, at least as measured by neurofilament breakdown and mitochondrial failure, extensive cellular damage is not present in penumbral regions for up to 9 hours, suggesting the potential for rescuing these regions by appropriate and timely neuroprotective strategies.	Univ Texas, Sch Med, Dept Neurol, Houston, TX 77030 USA; Chonnam Univ, Sch Med, Dept Neurol, Kwangju, South Korea	Grotta, JC (corresponding author), Univ Texas, Sch Med, Dept Neurol, 6431 Fannin,Rm 7-044, Houston, TX 77030 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS23979] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS023979] Funding Source: NIH RePORTER		ARONOWSKI J, 1992, J NEUROCHEM, V58, P1743, DOI 10.1111/j.1471-4159.1992.tb10049.x; Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; BANIK NL, 1982, NEUROCHEM RES, V7, P1465, DOI 10.1007/BF00965089; BARTUS RT, 1995, J CEREBR BLOOD F MET, V15, P969, DOI 10.1038/jcbfm.1995.123; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; GARCIA JH, 1993, AM J PATHOL, V142, P623; GARCIA JH, 1995, STROKE, V26, P636, DOI 10.1161/01.STR.26.4.636; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167; GRIFFIN JW, 1988, ANN NEUROL, V23, P3, DOI 10.1002/ana.410230103; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; MORRIS JR, 1982, J CELL BIOL, V92, P192, DOI 10.1083/jcb.92.1.192; NAKAMURA M, 1992, EXP BRAIN RES, V89, P31; OGATA N, 1989, J NEUROSURG, V70, P103, DOI 10.3171/jns.1989.70.1.0103; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; SCHLAEPFER WW, 1985, J NEUROCHEM, V44, P502, DOI 10.1111/j.1471-4159.1985.tb05442.x; SHAW G, 1986, EUR J CELL BIOL, V42, P1; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; YANG GY, 1994, STROKE, V25, P1658, DOI 10.1161/01.STR.25.8.1658; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x	28	45	46	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	1999	19	6					652	660		10.1097/00004647-199906000-00008			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	277TB	WOS:000084948700008	10366195	Bronze			2021-06-18	
J	Bell, MJ; Kochanek, PM; Heyes, MP; Wisniewski, SR; Sinz, EH; Clark, RSB; Blight, AR; Marion, DW; Adelson, PD				Bell, MJ; Kochanek, PM; Heyes, MP; Wisniewski, SR; Sinz, EH; Clark, RSB; Blight, AR; Marion, DW; Adelson, PD			Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head injury; inflammation; shaken infant syndrome; neurotoxin; child abuse; macrophage; quinolinic acid; NMDA; head trauma; excitotoxicity	INTRAVENTRICULAR INFUSION; NEUROLOGICAL DISEASE; L-TRYPTOPHAN; SPINAL-CORD; AMINO-ACIDS; HEAD-INJURY; RAT; MODEL; EXCITOTOXICITY; ACCUMULATION	Objective: To measure quinolinic acid, a macrophage-derived neurotoxin, in the cerebrospinal fluid (CSF) of children after traumatic brain injury (TBI) and to correlate CSF quinolinic acid concentrations to clinically important variables. Design: A prospective, observational study. Setting: The pediatric intensive care unit in Children's Hospital of Pittsburgh, a tertiary care, university based children's hospital. Patients: Seventeen critically ill children following severe TBI (Glasgow Coma Scale score <8) whose care required the place ment of an intraventricular catheter for continuous drainage of CSF, interventions: None, Measurements and Main Results: Patients ranged in age from 2 mos to 16 yrs (mean 6.0 yrs), CSF was collected immediately on placement of the ventricular catheter and daily thereafter, Quinolinic acid concentration was measured by gas chromatography/mass spectroscopy in 69 samples (4.0 +/- 0.4 [SEM] samples per patient), CSF quinolinic acid concentration progressively increased after injury (p = .034, multivariate analysis) and was increased in nonsurvivors vs, survivors (p = .002, multivariate analysis). CSF quinolinic acid concentration was not associated with age. Although overall CSF quinolinic acid concentration was not associated with shaken injury (p = .16, multivariate analysis), infants suffering with shaken infant syndrome had increased admission CSF quinolinic acid concentrations compared with children with accidental mechanisms of injury (p = .027, Mann-Whitney Rank Sum test), Conclusions: A large and progressive increase in the macrophage-derived neurotoxin quinolinic acid is seen following severe TBI in children, The increase is strongly associated with increased mortality, Increased CSF quinolinic acid concentration on admission in children with shaken infant syndrome could reflect a delay in presentation to medical attention or age-related differences in quinolinic acid production, These findings raise the possibility that quinolinic acid may play a role in secondary injury after TBI in children and suggest an interaction between inflammatory and excitotoxic mechanisms of injury following TBI.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA USA; Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA USA; Childrens Natl Med Ctr, Dept Pediat & Crit Care Med, Washington, DC 20010 USA; Univ N Carolina, Dept Neurol Surg, Chapel Hill, NC USA; NIMH, Lab Neurotoxicol, Bethesda, MD 20892 USA	Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Adelson, David/W-2083-2019; Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Sinz, Elizabeth/0000-0001-7129-6193; Wisniewski, Stephen/0000-0002-3877-9860	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline		BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GIULIAN D, 1993, J NEUROSCI, V13, P29; HEYES MP, 1995, J NEUROL SCI, V133, P112, DOI 10.1016/0022-510X(95)00164-W; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HEYES MP, 1988, ANAL BIOCHEM, V174, P349, DOI 10.1016/0003-2697(88)90556-8; HEYES MP, 1993, BRAIN, V116, P1425, DOI 10.1093/brain/116.6.1425; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LAPIN IP, 1982, NEUROPHARMACOLOGY, V21, P1227, DOI 10.1016/0028-3908(82)90125-3; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Misztal M, 1996, NEUROPHARMACOLOGY, V35, P449, DOI 10.1016/0028-3908(96)00005-6; Misztal M, 1996, EUR J PHARMACOL, V296, P1, DOI 10.1016/0014-2999(95)00682-6; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; SAITO K, 1993, J NEUROCHEM, V61, P2061, DOI 10.1111/j.1471-4159.1993.tb07443.x; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; SUSEL Z, 1991, NEUROSCI LETT, V121, P234, DOI 10.1016/0304-3940(91)90693-N; THOMAS SR, 1994, J BIOL CHEM, V269, P14457; WALKER ML, 1984, CHILD BRAIN, V11, P387; WHETSELL WO, 1989, NEUROSCI LETT, V97, P271, DOI 10.1016/0304-3940(89)90609-5	24	45	47	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	1999	27	3					493	497		10.1097/00003246-199903000-00023			5	Critical Care Medicine	General & Internal Medicine	182LH	WOS:000079500100022	10199527				2021-06-18	
J	Uysal, S; Hibbard, MR; Robillard, D; Pappadopulos, E; Jaffe, M				Uysal, S; Hibbard, MR; Robillard, D; Pappadopulos, E; Jaffe, M			The effect of parental traumatic brain injury on parenting and child behavior	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							BLUNT HEAD-INJURY; DEPRESSED MOTHERS; SOCIAL SUPPORT; FAMILY; PERCEPTIONS; RELATIVES; PSYCHOPATHOLOGY; INVENTORY; DISORDER; SPOUSES	Objectives: To examine (1) the parenting skills of individuals with traumatic brain injury (TBI) and their spouses, (2) the effects of parental TBI on children, and (3) the effects of parental TBI on levels of depression for all family members. Design: Independent two-tailed t tests and Pearson chi-square analyses were utilized to compare parents with TBI versus parents without TBI, spouses of parents with TBI versus spouses of parents without TBI, and children of parents with TBI versus children of parents without TBI. Setting: Urban, suburban, and rural New York State. Participants: 32 families participated in the study; in 16 families one parent had a TBI and in the remaining 16 families, no parent had a TBI. Eighteen children from families with parental TBI and 26 children from families without TBI were interviewed. On average, parents with TBI were 9 years post-onset of injury at the time of interview. Main Outcome Measures: The parents' battery explored parents' perspectives of their own parenting skills (Parent Behavior Form, Parent Practices Questionnaire, Parenting Dimensions Inventory), their mood (Beck Depression Inventory), and the behaviors of their children (Children's Problem Checklist, Behavior Rating Profile). The child's battery tapped the children's perspective of their own behaviors (Behavior Rating Profile), their mood (Children's Depression Inventory), and the parental abilities of both parents (Parent Behavior Form, Parent Practices Questionnaire). Results: Although parents with TBI and their spouses were similar to their comparison group in many parenting skills, parents with TBI reported less goal setting, less encouragement of skill development, less emphasis on obedience to rules and orderliness, less promotion of work values, less nurturing, and lower levels of active involvement with their children. Spouses of individuals with TBI, compared to their counterparts, reported less feelings of warmth, love, and acceptance toward their children. Children from families in which a parent had a TBI perceived both parents as more lax in their discipline, with the parent without TBI perceived as less actively involved in parenting roles. No differences in the frequency of behavioral problems were found between children of parents with TBI and children of parents without TBI. Parents with TBI and their children experienced more symptoms of depression relative to their respective comparison groups. Conclusion: Parental TBI has select consequences for all family members: individuals with TBI, their spouses, and their children. Prospective clinical evaluations of family members and proactive interventions to maximize family adjustment and minimize affective distress are indicated.	Mt Sinai Med Ctr, New York, NY 10029 USA; CUNY Hunter Coll, Educ Fdn Program, New York, NY 10021 USA; CUNY Hunter Coll, Counseling Program, New York, NY 10021 USA; Long Isl Jewish Med Ctr, Hillside Hosp, Glen Oaks, NY 11004 USA	Hibbard, MR (corresponding author), Mt Sinai Med Ctr, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.						BEARDSLEE WR, 1983, AM J PSYCHIAT, V140, P825; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1984, CLOSED HEAD INJURY P; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brown L, 1990, BEHAV RATING PROFILE; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CUMMINGS EM, 1995, DEV PSYCHOL, V31, P425, DOI 10.1037/0012-1649.31.3.425; DEPOMPEI R, 1989, TOP LANG DISORD, V9, P78, DOI 10.1097/00011363-198903000-00008; DODGE KA, 1990, DEV PSYCHOL, V26, P3, DOI 10.1037/0012-1649.26.1.3; FRANKEL F, 1983, J PEDIAT NURS, V8, P177; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GELFAND DM, 1990, CLIN PSYCHOL REV, V10, P329, DOI 10.1016/0272-7358(90)90065-I; GILBERT LA, 1983, J MARRIAGE FAM, V45, P203, DOI 10.2307/351309; GOODMAN SH, 1990, DEV PSYCHOL, V26, P31, DOI 10.1037/0012-1649.26.1.31; HAMILTON EB, 1993, FAM PROCESS, V32, P329, DOI 10.1111/j.1545-5300.1993.00329.x; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HU XH, 1993, CAN MED ASSOC J, V149, P421; KASHANI JH, 1985, CHILD PSYCHIAT HUM D, V15, P234, DOI 10.1007/BF00706367; KOVACS M, 1985, PSYCHOPHARMACOL BULL, V21, P995; Kovacs M., 1992, CHILDRENS DEPRESSION; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUTTER M, 1984, PSYCHOL MED, V14, P853, DOI 10.1017/S0033291700019838; Scherer DG, 1996, J CLIN CHILD PSYCHOL, V25, P156, DOI 10.1207/s15374424jccp2502_4; SCHINCKA JA, 1985, CHILDRENS PROBLEMS C; Slater M. A., 1987, ADV FAMILY INTERVENT; STRAYHORN JM, 1988, J AM ACAD CHILD PSY, V27, P613, DOI 10.1097/00004583-198809000-00016; Urbach J R, 1989, Psychiatr Med, V7, P17; URBACH JR, 1991, PSYCHOSOMATICS, V32, P24, DOI 10.1016/S0033-3182(91)72108-7; WEISSMAN MM, 1984, J AM ACAD CHILD PSY, V23, P78, DOI 10.1097/00004583-198401000-00011; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WORELL J, COMMUNICATION; ZEIGLER EA, 1987, J REHABIL, V53, P50	42	45	46	0	10	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1998	13	6					57	71		10.1097/00001199-199812000-00007			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141KF	WOS:000077142300007	9885318				2021-06-18	
J	Sato, M; Noble, LJ				Sato, M; Noble, LJ			Involvement of the endothelin receptor subtype A in neuronal pathogenesis after traumatic brain injury	BRAIN RESEARCH			English	Article						traumatic brain injury; endothelin-1; Ro 61-1790; heat shock protein; microglia	CEREBRAL BLOOD-FLOW; ANEURYSMAL SUBARACHNOID HEMORRHAGE; SPINAL CORD BARRIER; CEREBROSPINAL-FLUID; ET(A) RECEPTORS; TIME COURSE; RAT; VASOSPASM; RESPONSES; BREAKDOWN	Endothelin-1 (ET-1) is a 21 amino acid peptide that has been closely linked to cerebral vasospasm and more recently to oxidative stress after traumatic brain injury. In this study, we have examined the effects of the endothelin receptor subtype A antagonist, Ro 61-1790, on acute cortical neuronal injury and delayed neuronal death in the cerebellum after mild traumatic brain injury. Rats were administered Ro 61-1790 or vehicle for 24 h after injury and euthanized at 1 day, 3 days, or 7 days. Heat shock protein70 (HSP70), a marker of neuronal stress/injury, was immunolocalized in the cortex. Induction of heme oxygenase-1 (HO-1) and enhanced immunoexpression of the complement C3bi receptor, both of which are indicators of cerebellar glial reactivity, and Purkinje cell loss were evaluated in the cerebellum. There was maximal induction of HSP70 in cortical neurons at 24 h postinjury in all animals. Drug treated animals showed significantly fewer HSP70 labeled cortical neurons at this time point. There were fewer reactive glia in the cerebellum of drug treated animals as compared to vehicle controls at 3 days postinjury. However, at 7 days postinjury glial reactivity and Purkinje cell loss were similar in both groups. These findings demonstrate that Ro 61-1790, when administered for the first 24 h postinjury, limits acute neuronal injury in the cortex, transiently influences glial reactivity in the cerebellum, and does not attenuate delayed Purkinje cell death. The latter finding may reflect the duration of infusion of the drug. (C) 1998 Elsevier Science B.V. All rights reserved.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Noble, LJ (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 521 Parnassus Ave,Room C224, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		Armstead WM, 1996, J NEUROSURG, V85, P901, DOI 10.3171/jns.1996.85.5.0901; ASANO T, 1989, BIOCHEM BIOPH RES CO, V159, P1345, DOI 10.1016/0006-291X(89)92258-4; CLOZEL M, 1993, LIFE SCI, V52, P825, DOI 10.1016/0024-3205(93)90081-D; COSENTINO F, 1994, STROKE, V25, P904, DOI 10.1161/01.STR.25.4.904; DEOLIVEIRA AM, 1995, PEPTIDES, V16, P139, DOI 10.1016/0196-9781(94)00169-7; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; FILEP JG, 1993, BRIT J PHARMACOL, V109, P880, DOI 10.1111/j.1476-5381.1993.tb13657.x; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GREENBERG DA, 1992, NEUROLOGY, V42, P25, DOI 10.1212/WNL.42.1.25; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; KARNE S, 1993, J BIOL CHEM, V268, P19126; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; Kurokawa K, 1997, J COMP NEUROL, V389, P348, DOI 10.1002/(SICI)1096-9861(19971215)389:2<348::AID-CNE11>3.0.CO;2-H; LYSKO PG, 1995, DEV BRAIN RES, V88, P96, DOI 10.1016/0165-3806(95)00087-T; MACCUMBER MW, 1990, P NATL ACAD SCI USA, V87, P2359, DOI 10.1073/pnas.87.6.2359; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; MAINES MD, 1988, FASEB J, V2, P2557; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; McIntosh T K, 1986, NIDA Res Monogr, V75, P527; MCKENZIE AL, 1995, J NEUROTRAUM, V12, P257, DOI 10.1089/neu.1995.12.257; MUGNAINI E, 1987, ARCH ITAL BIOL, V126, P41; Nakagomi T, 1989, Neurol Med Chir (Tokyo), V29, P967, DOI 10.2176/nmc.29.967; Nayler W G, 1990, Trends Pharmacol Sci, V11, P96, DOI 10.1016/0165-6147(90)90188-E; Nilsson T, 1997, NEUROSURGERY, V40, P346, DOI 10.1097/00006123-199702000-00023; OKIYAMA K, 1994, J NEUROTRAUM, V11, P83, DOI 10.1089/neu.1994.11.83; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; POHL U, 1989, J CARDIOVASC PHAR S5, V13, P188; ROBINSON MJ, 1990, J CEREBR BLOOD F MET, V10, P285, DOI 10.1038/jcbfm.1990.46; Roux S, 1997, J PHARMACOL EXP THER, V283, P1110; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; SHIBATA M, 1993, J NEUROSURG, V79, P696, DOI 10.3171/jns.1993.79.5.0696; SHIRAKAMI G, 1994, ACTA ANAESTH SCAND, V38, P457, DOI 10.1111/j.1399-6576.1994.tb03929.x; STANIMIROVIC DB, 1994, J NEUROCHEM, V62, P592; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VIGNE P, 1993, EUR J PHARM-MOLEC PH, V245, P229, DOI 10.1016/0922-4106(93)90101-E; WESTMARK R, 1995, NEUROSCI LETT, V192, P173, DOI 10.1016/0304-3940(95)11638-D; YAMADA G, 1995, J CARDIOVASC PHARM, V26, pS486; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YAMASHITA K, 1993, CELL MOL NEUROBIOL, V13, P15, DOI 10.1007/BF00712986; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	48	45	48	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	OCT 26	1998	809	1					39	49		10.1016/S0006-8993(98)00817-8			11	Neurosciences	Neurosciences & Neurology	134BJ	WOS:000076722700006	9795123				2021-06-18	
J	Sarapatta, M; Herrmann, D; Johnson, T; Aycock, R				Sarapatta, M; Herrmann, D; Johnson, T; Aycock, R			The role of head injury in cognitive functioning, emotional adjustment and criminal behaviour	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; VIOLENCE	In two investigations, 50% of non-violent convicted felons, who avoided incarceration by participating in a day reporting progranune, reported a prior history of head injury and current problems in cognitive and emotional functioning. Only 5% of a college sample in the first investigation and 15% of a community sample in the second investigation reported prior head injury. In a third investigation, 83% of felons who had reported a history of head injury also reported a date for their head injury that preceded the dale of their first encounter with law enforcement. Some participants reported no trouble with the law until after experiencing a head injury that occurred in their late thirties. Considering the research reported here and elsewhere in the literature, it appears that many serious crimes follow a head injury. One implication of the findings reported here is that many crimes might not occur if people with head injury were given prompt and comprehensive treatment after the injury.	Indiana State Univ, Terre Haute, IN 47809 USA; Vigo Cty Community Correct, Terre Haute, IN USA	Sarapatta, M (corresponding author), 7940 Greenwood Court, Terre Haute, IN 47802 USA.						Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; CLUM MS, 1981, J NEUROSURGICAL NURS, V13, P165; DUNWAY G, 1991, CRIME DELINQUENCY, P536; EYSENCK HJ, 1964, CRIME PERSONALITY; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HERRMANN D, 1996, RETRAINING COGNITION; HODGINS S, BIOL CONTRIBUTIONS C, P161; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; Langevin R., 1987, BEHAVIORAL SCI LAW, V5, P77; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; MCGUE M, BEHAV GENETICS, P607; Modestin J, 1996, SCHIZOPHRENIA BULL, V22, P69, DOI 10.1093/schbul/22.1.69; NESTOR PG, 1995, B AM ACAD PSYCH LAW, V23, P331; PINCUS JH, 1991, SEMIN NEUROL, V11, P146, DOI 10.1055/s-2008-1041216; ROSENBAUM M, 1986, AM J PSYCHIAT, V143, P267; SCHEPANK H, 1974, MONOGRAPHIEN GESAMTG; Winer B.J., 1962, STAT PRINCIPLES EXPT; YEUDALL LT, 1977, CAN MENT HEALTH, V25, P7	20	45	45	0	15	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1998	12	10					821	842		10.1080/026990598122061			22	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	121FR	WOS:000076003100003	9783082				2021-06-18	
J	Regan, RF; Guo, YP				Regan, RF; Guo, YP			Toxic effect of hemoglobin on spinal cord neurons in culture	JOURNAL OF NEUROTRAUMA			English	Article						free radical; hemorrhage; iron; lipid peroxidation; spinal cord injury; traumatic brain injury	CORTICAL CELL-CULTURE; ACUTE SUBDURAL-HEMATOMA; LIPID-PEROXIDATION; SUPEROXIDE-DISMUTASE; EXCITOTOXIC INJURY; NERVOUS-SYSTEM; FREE-RADICALS; RAT-BRAIN; IRON; GLUTATHIONE	The vulnerability of spinal cord neurons to hemoglobin was quantitatively assessed in primary cultures derived from fetal mice. Exposure to hemoglobin for 28 h in a serum-free medium resulted in concentration-dependent neuronal death, with an EC50 of 0.9 mu M; glia were not injured, Neuronal death was decreased by the ferric iron chelator deferoxamine, the a-tocopherol analogue Trolox C, ascorbate, and exogenous catalase, but was potentiated by superoxide dismutase, Neuronal death was also increased by depletion of cellular glutathione with the gamma-glutamylcysteine synthetase inhibitor buthionine sulfoxamine; inhibition of endogenous catalase with 3-amino-1,2,4-triazole had no significant effect. These results suggest that hemoglobin is toxic to spinal neurons via an iron-dependent, oxidative mechanism involving a hydrogen peroxide intermediate, and support the hypothesis that hemoglobin release may contribute to neuronal loss after spinal cord trauma.	Thomas Jefferson Univ, Div Emergency Med, Philadelphia, PA 19107 USA	Regan, RF (corresponding author), Thomas Jefferson Univ, Div Emergency Med, 1020 Sansom St, Philadelphia, PA 19107 USA.						BARROWS LJ, 1955, BRAIN, V78, P59, DOI 10.1093/brain/78.1.59; BUCKMAN TD, 1993, J NEUROCHEM, V60, P2046, DOI 10.1111/j.1471-4159.1993.tb03489.x; CHRISTENSEN SM, 1988, J BIOCHEM BIOPH METH, V17, P143, DOI 10.1016/0165-022X(88)90045-0; DARGEL R, 1992, EXP TOXICOL PATHOL, V44, P169, DOI 10.1016/S0940-2993(11)80202-2; DEGIROLAMI U, 1997, GREENFIELDS NEUROPAT, P1111; DICKINSON TK, 1995, J COMP NEUROL, V355, P67, DOI 10.1002/cne.903550109; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; GUTTERIDGE JMC, 1985, BIOCHIM BIOPHYS ACTA, V834, P144, DOI 10.1016/0005-2760(85)90149-3; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Halliwell B, 1989, FREE RADICALS BIOL M; KAJIKAWA H, 1979, Neurologia Medico-Chirurgica, V19, P61, DOI 10.2176/nmc.19.61; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LAZAROW PB, 1987, J INHERIT METAB DIS, V10, P11, DOI 10.1007/BF01812843; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; MAVELLI I, 1982, BIOCHEM J, V204, P535, DOI 10.1042/bj2040535; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MISRA HP, 1972, J BIOL CHEM, V247, P6960; NELSON SK, 1994, FREE RADICAL BIO MED, V16, P195, DOI 10.1016/0891-5849(94)90143-0; PIETRONIGRO DD, 1983, J NEUROCHEM, V41, P1072, DOI 10.1111/j.1471-4159.1983.tb09053.x; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; Regan RF, 1996, NEUROSCI LETT, V213, P9, DOI 10.1016/0304-3940(96)12823-8; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; REGAN RF, 1995, BRAIN RES, V682, P144, DOI 10.1016/0006-8993(95)00330-S; REGAN RF, 1997, SOC NEUR ABSTR, V23, P2193; REHNCRONA S, 1980, J NEUROCHEM, V34, P477, DOI 10.1111/j.1471-4159.1980.tb11170.x; ROSEN AD, 1979, EXP NEUROL, V66, P277, DOI 10.1016/0014-4886(79)90080-3; RUBINSTEIN JD, 1992, FREE RADICAL BIO MED, V13, P627, DOI 10.1016/0891-5849(92)90037-H; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SATO PH, 1992, J NEUROCHEM, V58, P2263, DOI 10.1111/j.1471-4159.1992.tb10972.x; SCHAICH KM, 1992, LIPIDS, V27, P209, DOI 10.1007/BF02536181; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; WILLMORE LJ, 1991, INT J DEV NEUROSCI, V9, P175, DOI 10.1016/0736-5748(91)90009-B; WINSLOW RM, 1992, BIOMATER ARTIF CELLS, V20, P413; WINTERBOURN CC, 1979, BIOCHEM J, V182, P625, DOI 10.1042/bj1820625; Yip S, 1996, BRAIN RES, V713, P134, DOI 10.1016/0006-8993(95)01499-3; Zhang JR, 1996, J NEUROCHEM, V66, P355	39	45	52	2	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1998	15	8					645	653		10.1089/neu.1998.15.645			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	111KP	WOS:000075436500008	9726263				2021-06-18	
J	Ciallella, JR; Yan, HQ; Ma, XC; Wolfson, BM; Marion, DW; DeKosky, ST; Dixon, CE				Ciallella, JR; Yan, HQ; Ma, XC; Wolfson, BM; Marion, DW; DeKosky, ST; Dixon, CE			Chronic effects of traumatic brain injury on hippocampal vesicular acetylcholine transporter and M-2 muscarinic receptor protein in rats	EXPERIMENTAL NEUROLOGY			English	Article						cortical impact; cholinergic; VAChT; M-2 muscarinic; rat	CONTROLLED CORTICAL IMPACT; FLUID-PERCUSSION INJURY; CHOLINE-ACETYLTRANSFERASE; NEUTROPHIL ACCUMULATION; COGNITIVE IMPAIRMENT; EXPRESSION; ACTIVATION; DEFICITS; NECROSIS; RELEASE	Experimental traumatic brain injury (TBI) produces cholinergic neurotransmission deficits that may contribute to chronic spatial memory deficits. Cholinergic neurotransmission deficits may be due to presynaptic alterations in the storage and release of acetylcholine (ACh) or from changes in the receptors for ACh. The vesicular ACh transporter (VAChT) mediates accumulation of ACh into secretory vesicles, and M-2 receptors can modulate cholinergic neurotransmission via a presynaptic inhibitory feedback mechanism. We examined the effects of controlled cortical impact (CCI) injury on hippocampal VAChT and M-2 muscarinic subtype receptor protein levels at four time points: 1 day, 1 week, 2 weeks, and 4 weeks following injury. Rats were anesthetized and surgically prepared for controlled cortical impact injury (4 m/s, 2.5- to 2.9-mm depth) and sham surgery. Animals were sacrificed and coronal sections (35 mu m thick) were cut through the dorsal hippocampus for VAChT and M-2 immunohistochemistry. Semiquantitative measurements of VAChT and M-2 protein in hippocampal homogenates from injured and sham rats were assessed using Western blot analysis. Immunohistochemistry showed no obvious changes in VAChT and M-2 immunoreactivity at 1 day and 1 week postinjury. At 2 and 4 weeks postinjury, an increase in hippocampal VAChT protein and a corresponding loss of hippocampal M-2 protein was observed compared to sham controls. Consistent with these results, Western blot analyses at 4 weeks postinjury demonstrated a 40-50% increase in VAChT and a 25-30% decrease in M-2. These changes may represent a compensatory response of cholinergic neurons to increase the efficiency of ACh neurotransmission chronically after TBI, by upregulating the storage capacity and subsequent release of ACh and downregulating presynaptic inhibitory receptors. (C) 1998 Academic Press.	Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Dept Neurol, Pittsburgh, PA 15260 USA	Ciallella, JR (corresponding author), Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA.		Marion, Donald/AAR-5749-2021	DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS30313] Funding Source: Medline		Barnes PJ, 1997, LIFE SCI, V60, P1015, DOI 10.1016/S0024-3205(97)00042-8; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BLASCOIBANEZ JM, 1995, EUR J NEUROSCI, V7, P2170, DOI 10.1111/j.1460-9568.1995.tb00638.x; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; DASH PK, 1995, J NEUROSCI, V15, P2030; Dixon C. E., 1995, CENTRAL NERVOUS SYST, P255; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gilmor ML, 1996, J NEUROSCI, V16, P2179; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes R. L., 1992, J HEAD TRAUMA REHAB, V7, P16; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVEY AI, 1995, J NEUROSCI, V15, P4077; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; POSMANTUR R, 1996, J NEUROPATHOL EXP NE, V55, P65; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	44	45	47	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JUL	1998	152	1					11	19		10.1006/exnr.1998.6831			9	Neurosciences	Neurosciences & Neurology	106KC	WOS:000075127600002	9682008				2021-06-18	
J	Klonoff, PS; Lamb, DG; Henderson, SW; Shepherd, SW				Klonoff, PS; Lamb, DG; Henderson, SW; Shepherd, SW			Outcome assessment after milieu-oriented rehabilitation: New considerations	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	16th Annual Meeting of the National-Academy-of-Neuropsychology	OCT 30-NOV 02, 1996	NEW ORLEANS, LA	Natl Acad Neuropsychol			TRAUMATIC BRAIN INJURY; WORK; PREDICTORS; RETURN	Objective: This study incorporated level of functional impairment ratings at program admission into rehabilitation outcome (return to work/school) at the time of program discharge. Hypotheses: (1) Patients and families with better working alliance ratings will show better adjusted outcome; (2) patients seeking compensation will have poorer outcome than those not seeking compensation or receiving benefits; (3) speed of information processing and memory will relate to the level of adjusted outcome. Design: Consecutive neurorehabilitation admissions from March 1992 to May 1996. Setting: Outpatient milieu-based interdisciplinary day treatment program. Subjects: Sixty-four patients with heterogeneous brain injury etiologies. Main Outcome Measures: Adjusted outcome, defined as level of discharge productivity adjusted by staff ratings of functional severity of impairment at program admission; work readiness and work eagerness, based on average staff ratings. Results: At discharge, 89.5% of patients showed fair or good adjusted outcome; 62% were gainfully employed/full-time students; 15.6% resumed preinjury status. Better working alliance predicted better adjusted outcome. Patients seeking compensation showed significantly lower work eagerness ratings. Poorer outcome was associated with better neuropsychological status. Conclusions: Efficacy of neurorehabilitation was demonstrated for patients with better working alliance who were not seeking compensation. Adjusted outcome demonstrated greater sensitivity and utility by incorporating the variable of functional severity of impairment at program admission, Inclusion of "process" variables addressing working alliance, motivation, and capacity to work provide important contributions to understanding rehabilitation outcome. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	St Josephs Hosp, Barrow Neurol Inst, Adult Day Hosp Neurol Rehabil, Phoenix, AZ 85013 USA; Med Ctr, Phoenix, AZ USA	Klonoff, PS (corresponding author), 222 W Thomas Rd,Suite 115, Phoenix, AZ 85013 USA.						BENYISHAY Y, 1970, J ABNORM PSYCHOL, V75, P248, DOI 10.1037/h0029368; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Delis DC, 1987, CALIFORNIA VERBAL LE; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; KLONOFF PS, 1997, CLIN NEUROPSYCHOLOGY, P219; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; Reitan RM., 1985, HALSTEAD REITAN NEUR; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355	24	45	46	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1998	79	6					684	690		10.1016/S0003-9993(98)90045-4			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZT554	WOS:000074099500015	9630150				2021-06-18	
J	Yam, PS; Dewar, D; McCulloch, J				Yam, PS; Dewar, D; McCulloch, J			Axonal injury caused by focal cerebral ischemia in the rat	JOURNAL OF NEUROTRAUMA			English	Article						cytoskeleton; focal ischemia; MAPS; NF68kD; rats; SNAP25	AMYLOID PRECURSOR PROTEIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN; HEAD-INJURY; OPTIC-NERVE; CALPAIN INHIBITOR; ANOXIC INJURY; BRAIN INJURY; WHITE-MATTER; NEUROFILAMENT SUBUNITS; EXTRACELLULAR CALCIUM	The susceptibility of axons to blunt head injury is well established. However, axonal injury following cerebral ischemia has attracted less attention than damage in gray matter. We have employed immunocytochemical methods to assess the vulnerability of axons to cerebral ischemia in vivo. Immunocytochemistry was performed using antibodies to a synaptosomal-associated protein of 25 kDa (SNAP25), which is transported by fast anterograde transport; the 68-kDa neurofilament subunit (NF68kD); and microtubule-associated protein 5 (MAPS) on sections from rats subjected to 30 min and 1, 2, and 4 h of ischemia induced by permanent middle cerebral artery (MCA) occlusion. After 4 h of occlusion, there was increased SNAP25 immunoreactivity, which was bulbous in appearance, reminiscent of the axonal swellings that occur following blunt head injury. Increased SNAP25 immunoreactivity was present in circumscribed zones in the subcortical white matter and in the axonal tracts at the border of infarction, a pattern similar to that previously described for amyloid precursor protein. Although less marked, similar changes in immunoreactivity in axons were evident following 2 h of ischemia. MAPS and NF68kD had striking changes in immunoreactivity in axonal tracts permeating the caudate nucleus within the MCA territory at 4 h. The appearance was roughened and disorganized compared with the smooth regular staining in axons within the nonischemic areas. Profiles reminiscent of axonal bulbs were evident in MAPS-stained sections. The changes seen with NF68kD and MAP5 were also evident at 2 h but were more subtle at 1 h. There were no changes in axonal immunoreactivity with SNAP25 or NF68kD at 30 min after MCA occlusion. Altered immunoreactivity following ischemia using SNAP25, MAPS, and NF68kD provides further evidence for the progressive breakdown of the axonal cytoskeleton following an ischemic insult. NF68kD and MAP5 appear to be sensitive markers of the structural disruption of the cytoskeleton, which precedes the subsequent accumulation of SNAP25 within the damaged axons. Axonal cytoskeletal breakdown and disruption of fast axonal transport, which are well-recognized features of traumatic brain injury, are also sequalae of an ischemic insult.	Univ Glasgow, Wellcome Surg Inst, Glasgow, Lanark, Scotland; Univ Glasgow, Hugh Fraser Neurosci Labs, Glasgow G61 1QH, Lanark, Scotland	Yam, PS (corresponding author), Univ Glasgow, Wellcome Surg Inst, Garscube Estate, Glasgow, Lanark, Scotland.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARTUS RT, 1994, STROKE, V25, P2265, DOI 10.1161/01.STR.25.11.2265; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; Dewar D, 1997, ACTA NEUROPATHOL, V93, P71, DOI 10.1007/s004010050584; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; HESS DT, 1992, J NEUROSCI, V12, P4634; HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LUDIN B, 1993, HIPPOCAMPUS, V3, P61; Maxwell W. L., 1995, Journal of Neurotrauma, V12, P363; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCKENZIE KJ, 1996, ACTA NEUROPATHOL, V92, P609; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; OCHS S, 1972, J PHYSIOL-LONDON, V227, P627, DOI 10.1113/jphysiol.1972.sp010051; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Povlishock John T., 1995, P504; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SCHLAEPFER WW, 1987, J NEUROPATH EXP NEUR, V46, P117, DOI 10.1097/00005072-198703000-00001; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; SHIGENO T, 1985, SURG NEUROL, V24, P47, DOI 10.1016/0090-3019(85)90063-1; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; STYS PK, 1990, P NATL ACAD SCI USA, V87, P4212, DOI 10.1073/pnas.87.11.4212; SUENAGA T, 1994, ACTA NEUROPATHOL, V87, P450; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; WAXMAN SG, 1992, BRAIN RES, V574, P105, DOI 10.1016/0006-8993(92)90806-K; WAXMAN SG, 1994, BRAIN RES, V644, P197, DOI 10.1016/0006-8993(94)91680-2; WAXMAN SG, 1993, BRAIN RES, V614, P137, DOI 10.1016/0006-8993(93)91027-P; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610	55	45	45	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1998	15	6					441	450		10.1089/neu.1998.15.441			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZR931	WOS:000074030700006	9624629				2021-06-18	
J	Farmer, JE; Johnson-Gerard, M				Farmer, JE; Johnson-Gerard, M			Misconceptions about traumatic brain injury among educators and rehabilitation staff: A comparative study	REHABILITATION PSYCHOLOGY			English	Article							SCHOOL REENTRY; CHILDREN	This study compared the responses of 184 educators and 111 rehabilitation specialists on a measure of knowledge about childhood traumatic brain injury (TBI). Educators displayed more misconceptions about TBI overall compared to rehabilitation staff. They underestimated the effect of TBI on cognition, behavior, and continued development. More specifically, educators showed more misconceptions than the rehabilitation staff in the following areas: coma, memory and new learning, anger management, and factors affecting recovery. An important task for rehabilitation staff members is to clarify educator misconceptions about TBI as children transition to school. Information provided should increase the level of teacher preparation and help to maximize children's academic success and adaptation following TBI.	Ctr Innovat Special Educ, Columbia, MO USA; Univ Missouri, Sch Med, Columbia, MO 65211 USA	Farmer, JE (corresponding author), Rusk Rehabil Ctr, Dept Phys Med & Rehabil, 501, Columbia, MO 65212 USA.						ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BLOSSER J, 1994, PEDIAT TRAUMATIC BRA; BRYAN MR, 1995, ED MANUAL WHAT ED NE, P117; DEPOMPEI R, 1993, STAFF DEV CLIN INTER, P229; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; GOLDBERG A, 1996, ACQUIRED BRAIN INJUR; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; HANSON SL, 1992, PHYSICAL MED REHABIL, P483; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Lash M, 1993, NeuroRehabilitation, V3, P13, DOI 10.3233/NRE-1993-3304; Lash M., 1995, ED MANUAL WHAT ED NE, P41; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wolcott G. F, 1995, ED MANUAL WHAT ED NE; YLVISAKER M, 1995, J HEAD TRAUMA REHAB, V10, P25, DOI 10.1097/00001199-199512000-00006	23	45	45	0	3	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	WIN	1997	42	4					273	286					14	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	ZC599	WOS:000072597600002					2021-06-18	
J	Coplin, WM; OKeefe, GE; Grady, MS; Grant, GA; March, KS; Winn, HR; Lam, AM				Coplin, WM; OKeefe, GE; Grady, MS; Grant, GA; March, KS; Winn, HR; Lam, AM			Thrombotic, infectious, and procedural complications of the jugular bulb catheter in the intensive care unit	NEUROSURGERY			English	Article						complications; critical care; head injury; jugular vein; monitoring; venous thromboembolism	DEEP VENOUS THROMBOSIS; SUBCLAVIAN VEIN-THROMBOSIS; COLOR DOPPLER ULTRASOUND; LARGE-BORE CATHETERS; ACUTE BRAIN INJURY; UPPER-EXTREMITY; CEREBRAL OXYGENATION; PULMONARY-EMBOLISM; HEAD-INJURY; DIAGNOSIS	OBJECTIVE: An assessment of the thrombotic infectious, and technical complications of continuous jugular bulb catheter monitoring in the intensive care unit (ICU) was made. METHODS: Over a 1-year period, 44 patients suffering from traumatic brain injury, subarachnoid hemorrhage, or stroke received jugular bulb catheter monitoring in the ICU. They were followed for catheter insertion complications and the development of bacteremia. In 20 patients chosen randomly, an ultrasonographic evaluation was performed after removal of the catheter for an assessment of internal jugular vein thrombosis. RESULTS: Of the 44 patients, 1 became bacteremic; the source was identified as a thoracostomy site. Among the complications related to the 44 catheter insertions, there were 2 instances of carotid artery puncture (4.5%), 1 misplaced catheter (thoracic placement), and 1 clinically insignificant hematoma. Of the 20 patients investigated with ultrasonography, 8 (40%) had nonobstructive, subclinical internal jugular vein thrombi after jugular bulb catheter monitoring (95% confidence interval, 19-61%). The median monitoring duration was 3 days (range, 1-6 d). No clinical factor was identified to be associated with thrombus formation. CONCLUSION: We conclude the following: 1) the risk of bacteremia related to the jugular bulb catheter was negligible; 2) complications related to catheter insertion were rare and clinically insignificant; and 3) the incidence of subclinical internal jugular vein thrombosis after jugular bulb catheter monitoring is considerable. Although it is worthy to note this complication, no patient with a thrombus became symptomatic in the present series. The risk-benefit assessment of this monitoring technique must include consideration of subclinical thrombosis.	UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL SURG,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT ANESTHESIOL,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT SURG,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NURSING EDUC,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DIV PULM & CRIT CARE MED,SEATTLE,WA 98104					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30305] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030305] Funding Source: NIH RePORTER		Agraharkar M, 1995, ASAIO J, V41, P169; ANDREWS PJD, 1991, BRIT J ANAESTH, V67, P553, DOI 10.1093/bja/67.5.553; Bambauer R, 1992, ASAIO J, V38, P96, DOI 10.1097/00002480-199204000-00006; BAMBAUER R, 1994, ARTIF ORGANS, V18, P318, DOI 10.1111/j.1525-1594.1994.tb02204.x; BAXTER GM, 1991, BRIT J RADIOL, V64, P777, DOI 10.1259/0007-1285-64-765-777; BLACK MD, 1993, CHEST, V103, P1887, DOI 10.1378/chest.103.6.1887; CAMPBELL CB, 1977, SURGERY, V82, P816; CORONA ML, 1990, MAYO CLIN PROC, V65, P979, DOI 10.1016/S0025-6196(12)65159-3; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1993, CRIT CARE MED, V21, P1242, DOI 10.1097/00003246-199308000-00027; DIEBOLD J, 1991, PATHOL RES PRACT, V187, P260; DONAYRE CE, 1986, AM J SURG, V152, P179, DOI 10.1016/0002-9610(86)90238-2; DORFMAN GS, 1989, RADIOLOGY, V173, P159, DOI 10.1148/radiology.173.1.2675182; FUMAGALLI P, 1995, BRIT J ANAESTH, V74, P345, DOI 10.1093/bja/74.3.345; GIBBS EL, 1945, AM J PSYCHIAT, V102, P184, DOI 10.1176/ajp.102.2.184; GOETTING MG, 1991, INTENS CARE MED, V17, P195, DOI 10.1007/BF01709876; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; HAHN U, 1995, J CLIN APHERESIS, V10, P12, DOI 10.1002/jca.2920100104; HAIRE WD, 1991, J VASC SURG, V13, P391, DOI 10.1067/mva.1991.25130; HAIRE WD, 1991, J ULTRAS MED, V10, P493, DOI 10.7863/jum.1991.10.9.493; HIRSCH DR, 1995, JAMA-J AM MED ASSOC, V274, P335, DOI 10.1001/jama.274.4.335; HORATTAS MC, 1988, SURGERY, V104, P561; JAKOBSEN M, 1989, J CEREBR BLOOD F MET, V9, P717, DOI 10.1038/jcbfm.1989.101; KARNIK R, 1993, CLIN CARDIOL, V16, P26, DOI 10.1002/clc.4960160106; KOKSOY C, 1995, CLIN RADIOL, V50, P687, DOI 10.1016/S0009-9260(05)83313-6; MATTA BF, 1994, ANESTH ANALG, V79, P745; MONREAL M, 1991, CHEST, V99, P280, DOI 10.1378/chest.99.2.280; NAKAJIMA T, 1993, ANESTH ANALG, V77, P1111; OLSEN KS, 1994, J NEUROSURG ANESTH, V6, P233; PRESCOTT SM, 1979, CIRCULATION, V59, P350, DOI 10.1161/01.CIR.59.2.350; PRINCE SR, 1976, ANESTHESIOLOGY, V44, P170, DOI 10.1097/00000542-197602000-00022; ROBERTSON C, 1993, ACTA NEUROCHIR SUPP, V59, P98; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROSS AHM, 1982, JPEN-PARENTER ENTER, V6, P61, DOI 10.1177/014860718200600161; RYAN JA, 1974, NEW ENGL J MED, V290, P757, DOI 10.1056/NEJM197404042901401; SCHOLZ KH, 1990, THORAC CARDIOV SURG, V38, P69, DOI 10.1055/s-2007-1013996; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SNYDER RH, 1988, ANN SURG, V208, P651, DOI 10.1097/00000658-198811000-00018; SWINTON NW, 1968, CIRCULATION, V38, P737, DOI 10.1161/01.CIR.38.4.737	41	45	47	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUL	1997	41	1					101	107		10.1097/00006123-199707000-00022			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XH585	WOS:A1997XH58500055	9218301				2021-06-18	
J	Emanuelson, I; vonWendt, L				Emanuelson, I; vonWendt, L			Epidemiology of traumatic brain injury in children and adolescents in south-western Sweden	ACTA PAEDIATRICA			English	Article						brain injury; children; epidemiology	UNITED-STATES; HEAD-INJURY; DEATHS; AGE	The objectives of this study were to outline the incidence, gender distribution, external causes, severity and early outcome of traumatic brain injury (TBI). The subjects were children and adolescents in the southwestern Swedish health care region, aged 0-17 y in 1987-1991 and fulfilling the criteria for TBI. Identification was made from the discharge registers of the hospitals in the region admitting patients with TBI, and outcome data were obtained from medical records. The mean incidence rate was 12/100 000 for TBI. The dominant external cause was traffic (60%), followed by falls (22%). At discharge, 49% of these surviving were healthy, 48% suffered from one functional impairment and 52% suffered from two or more impairments. In conclusion, although the incidence rate of TBI is low in Sweden, the condition causes permanent functional impairment in 6/100 000 cases every year.	UNIV HELSINKI,DEPT PEDIAT NEUROL,HELSINKI,FINLAND	Emanuelson, I (corresponding author), BRACKE OSTERGARD REG PEDIAT REHABIL CTR,PL-21062,S-41804 GOTHENBURG,SWEDEN.						ARNARSON EO, 1995, ACTA PAEDIATR, V84, P96, DOI 10.1111/j.1651-2227.1995.tb13496.x; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR; BERNEY J, 1994, CHILD NERV SYST, V10, P509, DOI 10.1007/BF00335073; BERNEY J, 1995, CHILD NERV SYST, V11, P256, DOI 10.1007/BF00301755; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; ENGBERG A, 1995, ACTA NEUR SCAND S164, V92, P48; GELLES RJ, 1986, CHILD ABUSE NEGLECT, V10, P501, DOI 10.1016/0145-2134(86)90055-4; HAGBERG B, 1989, ACTA PAEDIATR SCAND, V78, P283, DOI 10.1111/j.1651-2227.1989.tb11071.x; Hansen T B, 1991, Ugeskr Laeger, V153, P2944; HENRY CP, 1992, J NEUROSCI NURS, V24, P311; JENNETT B, 1975, LANCET, V1, P480; KLEINMAN JC, 1990, PEDIATRICS, V86, P1091; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Kramhoft M, 1986, Ugeskr Laeger, V148, P738; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1995, TRAUMATIC HEAD INJUR; LOHMANN M, 1990, UGESKRIFT LAEGER, V150, P1591; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; RANTAKALLIO P, 1985, J EPIDEMIOL COMMUN H, V39, P353, DOI 10.1136/jech.39.4.353; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; *SWED EQ FED, 1995, RIDSP VERK; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; *WHO, 1995, WORLD HLTH STAT ANN; World Health Organization, 1977, INT CLASS DIS	27	45	47	0	0	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0803-5253			ACTA PAEDIATR	Acta Paediatr.	JUL	1997	86	7					730	735		10.1111/j.1651-2227.1997.tb08576.x			6	Pediatrics	Pediatrics	XM187	WOS:A1997XM18700011	9240881				2021-06-18	
J	Otte, A; Weiner, SM; Peter, HH; MuellerBrand, J; Goetze, M; Moser, E; Gutfleisch, J; Hoegerle, S; Juengling, FD; Nitzsche, EU				Otte, A; Weiner, SM; Peter, HH; MuellerBrand, J; Goetze, M; Moser, E; Gutfleisch, J; Hoegerle, S; Juengling, FD; Nitzsche, EU			Brain glucose utilization in systemic lupus erythematosus with neuropsychiatric symptoms: a controlled positron emission tomography study	EUROPEAN JOURNAL OF NUCLEAR MEDICINE			English	Article						neuropsychiatric systemic lupus erythematosus; positron emission tomography; fluorine-18 fluorodeoxyglucose; parieto-occipital brain hypometabolism	CLOSED-HEAD-INJURY; CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; TECHNETIUM-99M-HMPAO SPECT; CT; MRI; PATHOGENESIS; DIAGNOSIS; PET	In contrast to morphological imaging [such as magnetic resonance imaging (MRI) or computed tomography], functional imaging may be of advantage in the detection of brain abnormalities in cases of neuropsychiatric systemic lupus erythematosus (SLE). Therefore, we studied 13 patients (aged 40+/-14 years, 11 female, 2 male) with neuropsychiatric SLE who met four of the American Rheumatism Association criteria for the classification of SLE. Ten clinically and neurologically healthy volunteers served as controls (aged 40+/-12 years, 5 female, 5 male). Both groups were investigated using fluorine-18-labelled fluorodeoxyglucose brain positron emission tomography (PET) and cranial MRI. The normal controls and 11 of the 13 patients showed normal MRI scans. However, PET scan was abnormal in all 13 SLE patients. Significant group-to-group differences in the glucose metabolic index (GMI=region of interest uptake/global uptake at the level of the basal ganglia and thalamus) were found in the parieto-occipital region on both sides: the GMI of the parieto-occipital region on the right side was 0.922+/-0.045 in patients and 1.066+/-0.081 in controls (P<0.0001, Mann Whitney U test), while on the left side it was 0.892+/-0.060 in patients and 1.034+/-0.051 in controls (P=0.0002). Parietooccipital hypometabolism is a conspicuous finding in mainly MRI-negative neuropsychiatric SLE. As the parieto-occipital region is located at the boundary of blood supply of all three major arteries, it could be the most vulnerable zone of the cerebrum and may be affected at an early stage of the cerebrovascular disease.	UNIV FREIBURG KLINIKUM,DEPT RHEUMATOL & IMMUNOL,FREIBURG,GERMANY; UNIV FREIBURG KLINIKUM,DEPT NUCL MED,FREIBURG,GERMANY	Otte, A (corresponding author), UNIV BASEL HOSP,SCH MED,INST NUCL MED,DEPT RADIOL SCI,PETERSGRABEN 4,CH-4031 BASEL,SWITZERLAND.		Juengling, Freimut/L-8071-2016; Nitzsche, Egbert U./A-1243-2011	Juengling, Freimut/0000-0002-2538-3074; Otte, Andreas/0000-0002-6290-6786			BAUM KA, 1993, CLIN NEUROL NEUROSUR, V95, P29, DOI 10.1016/0303-8467(93)90088-X; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; BRUYN GAW, 1995, ANN RHEUM DIS, V54, P159, DOI 10.1136/ard.54.3.159; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; FRIBERG L, 1991, J NEUROL, V238, pS12, DOI 10.1007/BF01642900; GonzalezCrespo MR, 1995, BRIT J RHEUMATOL, V34, P1055; GRAHAM DG, 1984, NEUROPATHOLOGY, P125; GRAY BG, 1992, J NUCL MED, V33, P52; GRUNWALD F, 1995, EUR J NUCL MED, V22, P1073, DOI 10.1007/BF00808421; HAMACHER K, 1986, J NUCL MED, V27, P235; HOW A, 1985, ARTHRITIS RHEUM, V28, P789, DOI 10.1002/art.1780280710; HUANG SC, 1981, J NUCL MED, V22, P627; ISSHI K, 1994, J RHEUMATOL, V21, P1758; KOVACS JAJ, 1995, J RHEUMATOL, V22, P1247; Masdeu J C, 1994, J Neuroimaging, V4, P177; MCINNES PM, 1994, ARTHRITIS RHEUM, V37, P1000, DOI 10.1002/art.1780370704; MILLER BL, 1990, DEMENTIA, V1, P41; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; OTTE A, 1995, LANCET, V345, P1513, DOI 10.1016/S0140-6736(95)91075-1; Otte A, 1997, J VASC INVEST, V3, P1; PRAYER L, 1993, ACTA RADIOL, V34, P593; ROPER SN, 1991, J NUCL MED, V32, P1684; SIBBITT WL, 1993, RHEUM DIS CLIN N AM, V19, P851; STOPPE G, 1989, NUKLEARMED-NUCL MED, V28, P187; SZER IS, 1993, J RHEUMATOL, V20, P2143; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VANDAM AP, 1991, RHEUMATOL INT, V11, P1; WALDEMAR G, 1994, J NEUROL NEUROSUR PS, V57, P285, DOI 10.1136/jnnp.57.3.285; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7	31	45	46	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0340-6997			EUR J NUCL MED	Eur. J. Nucl. Med.	JUL	1997	24	7					787	791					5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	XP344	WOS:A1997XP34400013	9211766				2021-06-18	
J	Emshoff, R; Schoning, H; Rothler, G; Waldhart, E				Emshoff, R; Schoning, H; Rothler, G; Waldhart, E			Trends in the incidence and cause of sport-related mandibular fractures: A retrospective analysis	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							FACIAL FRACTURES; ETIOLOGY	Purpose: This study assessed changes in the incidence and causes of mandibular fractures occurring in Innsbruck, Austria between 1984 and 1993. Patients and Methods: Records from 712 patients sustaining 982 mandibular fractures were reviewed and analyzed according to age, sex, date of fracture, place of trauma, cause, anatomic site of fracture, and associated orofacial and craniocerebral injuries. Results: Sports were the most common cause of mandibular fractures, accounting for 31.5% of the entire sample, followed by road traffic accidents (27.2%) and falls (20.8%). The yearly distribution of sport-related mandibular fractures showed an increase from 28.6% in 1984 to 1988 to 34.5% in 1989 to 1993. The major causative factor in sports-related mandibular fractures was skiing (55.3%), whereas cycling and soccer accounted for 25.4% and 8.9%, respectively. Significant changes in the occurrence of cycling-related mandibular fractures were observed, with an increase of 19.3% from 1984 to 1988 to 1989 to 1993, whereas skiing-related mandibular fractures showed a decrease of similar magnitude (19.5%). Sex distribution showed a male-to-female ratio of 2.5:1, with the percentage of females involved increasing, In cases of cycling-related accidents, there was a considerable prevalence of associated injuries (133.3 injuries per 100 mandibular fractures), with significantly higher rates of facial lacerations (73.2), tooth fractures (39), tooth luxations (24.4), and orbital fractures (3.7) than in the case of skiing-related injuries, whereas in patients sustaining mandibular fractures caused by soccer, mucosal lacerations, tooth luxations, and cerebral concussions were the only associated injuries found. Conclusions: The results of this study indicate a considerable change in the cause of mandibular fractures, showing that sporting injuries are becoming increasingly common. The high incidence of associated maxillofacial injuries in patients involved in skiing and cycling accidents may suggest an increasing need for preventive and protective measures.	UNIV INNSBRUCK, DEPT ORAL & MAXILLOFACIAL SURG, A-6020 INNSBRUCK, AUSTRIA			Emshoff, Rudiger/AAW-4773-2020	Emshoff, Rudiger/0000-0002-1527-1458			AFZELIUS LE, 1982, INT J ORAL SURG, V9, P252; BROOK IM, 1983, INT J ORAL MAXILLOF, V12, P293, DOI 10.1016/S0300-9785(83)80016-7; ELLIS E, 1985, ORAL SURG ORAL MED O, V59, P120, DOI 10.1016/0030-4220(85)90002-7; HILL CM, 1984, J MAXILLOFAC SURG, V12, P267, DOI 10.1016/S0301-0503(84)80257-X; LINDQVIST C, 1986, INT J ORAL MAX SURG, V15, P12, DOI 10.1016/S0300-9785(86)80005-9; LINN EW, 1986, J MAXILLOFAC SURG, V14, P83, DOI 10.1016/S0301-0503(86)80266-1; MELMED EP, 1975, PLAST RECONSTR SURG, V56, P323, DOI 10.1097/00006534-197509000-00011; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; VOSS R, 1982, J MAXILLOFAC SURG, V10, P146, DOI 10.1016/S0301-0503(82)80031-3	9	45	49	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391			J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	JUN	1997	55	6					585	592		10.1016/S0278-2391(97)90490-0			8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	XD372	WOS:A1997XD37200014	9191640				2021-06-18	
J	Katoh, H; Sima, K; Nawashiro, H; Wada, K; Chigasaki, H				Katoh, H; Sima, K; Nawashiro, H; Wada, K; Chigasaki, H			The effect of MK-801 on extracellular neuroactive amino acids in hippocampus after closed head injury followed by hypoxia in rats	BRAIN RESEARCH			English	Article						closed head injury; hypoxia; vulnerability; hippocampus; glutamate; GABA; microdialysis	TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; GLUTAMATE RELEASE; FOREBRAIN ISCHEMIA; SELECTIVE VULNERABILITY; SPREADING DEPRESSION; GLOBAL-ISCHEMIA; MICRODIALYSIS; ASPARTATE; ANTAGONISTS	Increased neuronal vulnerability to ischemia or hypoxia has been demonstrated following traumatic brain injury but not explained. Animal data suggest that neuronal damage after traumatic brain injury is caused mainly by massive glutamate release that activates N-methyl-D-aspartate (NMDA) receptors. Using rat models with controlled closed head injury (CHI) followed by hypoxia, we investigated extracellular concentrations of neuroactive amino acids in the hippocampus by in vivo microdialysis. CHI alone produced an immediate increase of glutamate and taurine; hypoxia alone did not alter amino acid concentrations. CHI followed by hypoxia produced a biphasic increase in extracellular glutamate and taurine, with an immediate peak after CHI and a prolonged plateau after hypoxia. Though changes in gamma-aminobutylic acid (GABA) concentration is also prolonged by combined traumatic and hypoxic insults, it showed less alteration than glutamate. Pre-treatment with dizocilpine maleate (MK-801), a non-competitive NMDA antagonist, did not affect the immediate peak of glutamate after CHI but significantly diminished the prolonged plateau after hypoxia. These findings suggest that traumatic brain injury may increase hypoxic release of glutamate, contributing to increased vulnerability to hypoxia. Our data suggest that MK-801 may be beneficial in preventing secondary neuronal damages by hypoxia.		Katoh, H (corresponding author), NATL DEF MED COLL, DEPT NEUROSURG, 3-2 NAMIKI, TOKOROZAWA, SAITAMA 359, JAPAN.						ADAMSON P, 1990, J NEUROCHEM, V55, P1850, DOI 10.1111/j.1471-4159.1990.tb05767.x; BECKER DP, 1986, MECH SECONDARY BRAIN, P47; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; CONNICK JH, 1988, BRIT J PHARMACOL, V93, P863, DOI 10.1111/j.1476-5381.1988.tb11473.x; DELPINO MMS, 1995, J BIOL CHEM, V270, P14913, DOI 10.1074/jbc.270.25.14913; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GEMBA T, 1992, NEUROSCI LETT, V135, P184, DOI 10.1016/0304-3940(92)90432-7; GHRIBI O, 1995, FUNDAM CLIN PHARM, V9, P141, DOI 10.1111/j.1472-8206.1995.tb00273.x; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P39, DOI 10.1016/0304-3940(91)90889-2; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAHARA N, 1995, NEUROL RES, V17, P9, DOI 10.1080/01616412.1995.11740281; KITA H, 1994, ACTA NEUROCHIR, P452; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; LEKIEFFRE D, 1992, NEUROSCI LETT, V137, P78, DOI 10.1016/0304-3940(92)90303-O; LIN BW, 1992, J NEUROCHEM, V59, P2213; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARTIN D, 1991, J NEUROCHEM, V56, P1647, DOI 10.1111/j.1471-4159.1991.tb02063.x; MATSUMOTO M, 1992, ANESTHESIOLOGY, V77, P764, DOI 10.1097/00000542-199210000-00022; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MITANI A, 1990, J NEUROCHEM, V54, P709, DOI 10.1111/j.1471-4159.1990.tb01930.x; MIYASHITA K, 1992, NEUROCHEM RES, V17, P147, DOI 10.1007/BF00966792; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; SEGAL MB, 1990, BLOOD BRAIN BARRIER, P31; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHIBANOKI S, 1993, J NEUROCHEM, V61, P1698, DOI 10.1111/j.1471-4159.1993.tb09806.x; SHIMA K, 1993, ADV NEUROTRAUMA RES, V5, P53; SHIMA K, 1990, ADV EXPT NEUROTRAUMA, V2, P53; SZERB JC, 1991, BRAIN RES, V542, P259, DOI 10.1016/0006-8993(91)91576-M; Tan WKM, 1996, PEDIATR RES, V39, P791, DOI 10.1203/00006450-199605000-00008	40	45	47	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 30	1997	758	1-2					153	162		10.1016/S0006-8993(97)00213-8			10	Neurosciences	Neurosciences & Neurology	XE606	WOS:A1997XE60600019	9203544				2021-06-18	
J	Busto, R; Dietrich, WD; Globus, MYT; Alonso, O; Ginsberg, MD				Busto, R; Dietrich, WD; Globus, MYT; Alonso, O; Ginsberg, MD			Extracellular release of serotonin following fluid-percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; serotonin; microdialysis	CEREBRAL BLOOD-FLOW; EXPERIMENTAL SPINAL TRAUMA; MODERATE HYPOTHERMIA; NEWBORN PIGS; CORD INJURY; AMINO-ACIDS; HEAD-INJURY; 5-HYDROXYTRYPTAMINE; DAMAGE; MODEL	Serotonin has been implicated in the pathobiology of central nervous system trauma. Using microdialysis techniques, we performed measurements of extracellular serotonin release within the traumatized cerebral cortex of rats subjected to moderate fluid-percussion (F-P) brain injury. Twenty-four hours prior to TBI, a F-P interface was positioned parasagitally over the right cerebral cortex. On the second day, fasted rats were anesthetized with 70% nitrous oxide, 1% halothane, and 30% oxygen. Under controlled physiological conditions and normothermic brain temperature (37-37.5 degrees C), rats were injured (n = 6) with a F-P pulse ranging from 1.8 to 2.0 atm. Following trauma, brain temperature was maintained for 4 h at 37 degrees C. Sham trauma animals (n = 7) were treated in an identical manner. Brain trauma induced acute elevations in the extracellular levels of serotonin (p < 0.01, ANOVA) compared to sham-operated controls. For example, serotonin levels increased from 18.85 +/- 7.12 pm/mL (mean +/- SD) in baseline samples to 65.78 +/- 11.36 in the first 10 min after trauma. The levels of serotonin remained significantly higher than control for the first 90-min sampling period. In parallel to the increase in serotonin levels after TBI, a significant 71.1% decrease (i.e., 182.29 +/- 30.08 vs 52.75 +/- 16.92) in extracellular 5-hydroxyindoleacetic acid (5-HIAA) levels was observed during the first 10 min after TBI. These data indicate that TBI is followed by a prompt increase in the extracellular levels of serotonin in cortical regions adjacent to the impact site. These neurochemical findings indicate that serotonin may play a significant role in the pathophysiology of TBI.		Busto, R (corresponding author), UNIV MIAMI,SCH MED,DEPT NEUROL D4 5,NEUROTRAUMA RES CTR,POB 016960,MIAMI,FL 33101, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30291] Funding Source: Medline		ALAFACI C, 1990, ACTA PHYSIOL SCAND, V138, P317, DOI 10.1111/j.1748-1716.1990.tb08852.x; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORTEZ SC, 1989, BRAIN RES, V482, P272; DAPRADA M, 1979, BRIT J PHARMACOL, V65, P653; DELALANDE JS, 1989, PERIPHERAL ACTION 5, P123; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIETRICH WD, 1989, J CEREBR BLOOD F MET, V9, P812, DOI 10.1038/jcbfm.1989.115; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EDVINSSON L, 1977, NEUROLOGY, V27, P878, DOI 10.1212/WNL.27.9.878; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1988, BRAIN RES, V450, P94, DOI 10.1016/0006-8993(88)91548-X; FENIUK W, 1989, PERIPHERAL ACTIONS 5, P100; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GINSBERG MD, 1995, J CEREB BLOOD FLOW S, V15, pS31; GLOBUS MYT, 1992, STROKE, V23, P1595, DOI 10.1161/01.STR.23.11.1595; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HOLMSEN H, 1985, SEROTONIN CARDIOVASC, P75; IVERSEN LL, 1974, BIOCHEM PHARMACOL, V23, P1927, DOI 10.1016/0006-2952(74)90250-0; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMBELBERG HK, 1985, SCIENCE, V228, P889; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LIU D, 1990, Journal of Neurotrauma, V7, P219, DOI 10.1089/neu.1990.7.219; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOHANTY S, 1978, INDIAN J MED RES, V67, P1029; NAYAK AK, 1980, J NEUROL SCI, V47, P211, DOI 10.1016/0022-510X(80)90005-2; NEDERGAARD S, 1987, CELL MOL NEUROBIOL, V7, P367, DOI 10.1007/BF00733789; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OSBORNE NN, 1982, BIOL SEROTONERGIC TR, P1; OSTERHOLM JL, 1969, J NEUROSURG, V31, P408, DOI 10.3171/jns.1969.31.4.0408; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; PARFENOVA H, 1993, STROKE, V24, P1729, DOI 10.1161/01.STR.24.11.1729; Peroutka S. J., 1991, SEROTONIN RECEPTOR S, P65; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; REYNOLDS JN, 1988, BRAIN RES, V456, P286, DOI 10.1016/0006-8993(88)90230-2; Salzman S K, 1987, Cent Nerv Syst Trauma, V4, P181; SALZMAN SK, 1991, ANN NEUROL, V30, P533, DOI 10.1002/ana.410300405; SALZMAN SK, 1987, J NEUROSURG, V66, P431, DOI 10.3171/jns.1987.66.3.0431; SALZMAN SK, 1994, NEUROBIOLOGY CENTRAL, P182; Salzman SK, 1991, J NEUROTRAUM, V8, P45, DOI 10.1089/neu.1991.8.45; SHARMA HS, 1989, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1988, P317; SHARMA HS, 1990, ACTA NEUROPATHOL, V80, P12, DOI 10.1007/BF00294216; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; SINGH S, 1986, J EXP BIOL, V24, P503; SMITH D R, 1969, Journal of Neurosurgery, V30, P664, DOI 10.3171/jns.1969.30.6.0664; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VANHOUTTE PM, 1985, CIRCULATION, V72, P728, DOI 10.1161/01.CIR.72.4.728; VANNUETEN JM, 1985, SEROTONIN CARDIOVASC, P95; WESTER P, 1992, STROKE, V23, P870, DOI 10.1161/01.STR.23.6.870; YAKUBU MA, 1994, PEDIATR RES, V36, P589, DOI 10.1203/00006450-199411000-00009; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG BC, 1992, AM J PHYSIOL, V262, pH931; YOUNG HA, 1986, NEUROSURGERY, V19, P502, DOI 10.1227/00006123-198610000-00003; ZILLES L, 1985, CORTEX RAT STEREOTAX; ZIVIN JA, 1976, NEUROLOGY, V26, P99, DOI 10.1212/WNL.26.2.99; ZIVIN JA, 1985, NEUROLOGY, V35, P584, DOI 10.1212/WNL.35.4.584; ZIVIN JA, 1984, NEUROLOGY, V34, P469, DOI 10.1212/WNL.34.4.469	69	45	45	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1997	14	1					35	42		10.1089/neu.1997.14.35			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WK032	WOS:A1997WK03200004	9048309				2021-06-18	
J	Bernard, LC; McGrath, MJ; Houston, W				Bernard, LC; McGrath, MJ; Houston, W			The differential effects of simulating malingering, closed head injury, and other CNS pathology on the Wisconsin Card Sorting Test: Support for the ''pattern of performance'' hypothesis	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							AGE	We investigated the effects of faking bad on the Wisconsin Card Sorting Test, comparing the performance of simulating malingerers (M; n = 24) to controls (C; n = 21), closed head-injured patients (CHI; n = 70), and patients with mired CNS pathology other than CHI alone (CNS; n = 89). Stepwise discriminant functions achieved good accuracy (91-96%), sensitivity (58-100%), and specificity (92-100%) in differentiating simulating malingerers from these groups. The Categories score was a consistent significant independent discriminating variable. Categories alone could differentiate between the M and C groups. However; in discriminating between simulating malingerers and both CHI or CNS patients, more complex patterns of performance emerged, consisting of relatively poorer performance ratios on Categories compared to Perseverative Errors. This supported the Fatten of Performance theory of the effects of simulating malingering on neuropsychological tests, which holds that people simulating malingering do more poorly on obvious vs. subtle tasks compared to people with verified brain damage. Due to the difficulty of tracking one's performance on several different indices simultaneously, known patterns of performance for patients with verified brain dysfunction should be very difficult to fake, even with coaching.	ROYAL C JOHNSON VET MEM HOSP,SIOUX FALLS,SD	Bernard, LC (corresponding author), LOYOLA MARYMOUNT UNIV,DEPT PSYCHOL,LOYOLA BLVD & W 80TH ST,LOS ANGELES,CA 90045, USA.						ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Axelrod B., 1992, CLIN NEUROPSYCHOL, V6, P16; AXELROD BN, 1992, CLIN NEUROPSYCHOLOGI, V6, P142; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; BERNARD LC, 1993, ARCH CLIN NEUROPSYCH, V8, P539, DOI 10.1016/0887-6177(93)90054-5; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; BERNARD LC, 1993, J CLIN PSYCHOL, V49, P45, DOI 10.1002/1097-4679(199301)49:1<45::AID-JCLP2270490107>3.0.CO;2-7; BOONE KB, 1993, J CLIN PSYCHOL, V49, P54, DOI 10.1002/1097-4679(199301)49:1<54::AID-JCLP2270490108>3.0.CO;2-6; DAIGNEAULT S, 1992, DEV NEUROPSYCHOL, V8, P99, DOI 10.1080/87565649209540518; DANNENBAUM SE, 1993, J PERS ASSESS, V61, P501, DOI 10.1207/s15327752jpa6103_6; DUSH DM, 1994, J PERS ASSESS, V62, P299, DOI 10.1207/s15327752jpa6202_10; Flashman LA., 1991, CLIN NEUROPSYCHOL, V5, P190, DOI [10.1080/13854049108403303, DOI 10.1080/13854049108403303]; GOLDSTEIN H, 1945, PSYCHOL BULL, V42, P104, DOI 10.1037/h0056446; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.8.1120-1122; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Harris M. E., 1990, WISCONSIN CARD SORTI; Heaton R. K, 1981, WISCONSIN CARD SORTI; HEATON RK, 1993, COMPREHENSIVE NORMS; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; Powell K. H., 1991, THESIS U S CAROLINA; Reitan RM, 1988, TRAUMATIC BRAIN INJU, VII; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; ROGERS R, 1988, CLIN ASSESSMENT MALI, P293; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; Spreen O., 1991, COMPENDIUM NEUROPSYC; Tabachnick B.G., 1989, USING MULTIVARIATE S; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wolfson D., 1993, HALSTEAD REITAN NEUR	30	45	47	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1996	11	3					231	245		10.1016/0887-6177(95)00025-9			15	Psychology, Clinical; Psychology	Psychology	UB662	WOS:A1996UB66200007	14588927				2021-06-18	
J	DIRUSSO, SM; NELSON, LD; SAFCSAK, K; MILLER, RS				DIRUSSO, SM; NELSON, LD; SAFCSAK, K; MILLER, RS			SURVIVAL IN PATIENTS WITH SEVERE ADULT-RESPIRATORY-DISTRESS-SYNDROME TREATED WITH HIGH-LEVEL POSITIVE END-EXPIRATORY PRESSURE	CRITICAL CARE MEDICINE			English	Article						ADULT RESPIRATORY DISTRESS SYNDROME; OXYGENATION; VENTILATION; OXYGEN; HYPOXEMIA; HYPOXIA; MECHANICAL VENTILATION; POSITIVE END-EXPIRATORY PRESSURE; PULMONARY EMERGENCIES; LUNG INJURY	MECHANICAL VENTILATION; AIRWAY PRESSURE; FAILURE; PEEP; PROGNOSIS; MORTALITY; OXYGEN; RISK	Objective: To assess the mortality rate and complications in a population of surgical patients with severe adult respiratory distress syndrome (ARDS) treated with positive end-expiratory pressure (PEEP) of >15 cm H2O in an attempt to reduce intrapulmonary shunt to similar to 0.20 and reduce FIO2 to <0.50. Design: Retrospective review of patients treated by a standardized ventilatory support protocol at the time of their illness. Setting: A 24-bed surgical intensive care unit in a university medical center. Patients: All patients admitted to the surgical intensive care unit during a 34-month period who met the criteria for severe ARDS (PaO2 of less than or equal to 70 torr [less than or equal to 9.3 kPa] on an FIO2 of greater than or equal to 0.50, diffuse interstitial and/or alveolar infiltrates on chest radiograph, decreased lung compliance, no evidence of congestive heart failure, and a likely predisposing etiology) were evaluated. Patients treated with PEEP of >15 cm H2O were selected for this review. Interventions: Patients were treated by a protocol to achieve oxygenation end points, which consisted of maintaining arterial oxyhemoglobin saturation (as determined by pulse oximetry of greater than or equal to 0.92), while reducing FIO2 to <0.50 and decreasing intrapulmonary shunt fraction to less than or equal to 0.20 by adding PEEP. With the exception of patients with suspected intracranial hypertension related to closed-head injury, low-rate intermittent mandatory ventilation was the primary mode of ventilation. Pressure-support ventilation was added, when needed, to improve patient comfort, enhance spontaneous tidal volume, or improve CO2 excretion. Measurements and Main Results: Eighty-six patients with severe ARDS were treated with a PEEP of >15 cm H2O. Nineteen of these patients died early of severe closed-head injury or massive uncontrollable hemorrhage and were excluded from the evaluation. The remaining 67 patients had a mean Lung Injury Score of 3.3 during their treatment with high PEEP. Twenty (30%) of 67 patients died. Eight of the deaths occurred after decrease of ventilatory support and with acceptable blood gases. The other 12 patients who died had continued oxygenation deficits and received increased levels of ventilatory support at the time of death. Twenty-six (39%) of 67 patients had radiographic manifestations of barotrauma (pneumothorax, subcutaneous emphysema, etc.) related to their primary injuries or to complications related to central venous catheter placement. Seven (17%) of 41 patients developed clinical or radiographic signs of barotrauma while receiving high-level PEEP. The hemodynamic effects of increased airway pressure were managed with fluids and inotropic agents, when necessary, and did not limit the application of PEEP to reach the defined end point of treatment. Conclusions: This subset of patients with severe ARDS treated with high-level PEEP had a mortality rate lower than those rates previously reported by other researchers using more conventional ventilatory support and resuscitation techniques. FIO2 may be significantly reduced and PaO2 may be maintained at acceptable values by decreasing intrapulmonary shunt fraction using high-level PEEP.	VANDERBILT UNIV,SCH MED,DEPT SURG,SURG CRIT CARE SERV,NASHVILLE,TN 37212							ASHBAUGH DG, 1967, LANCET, V2, P319; ASHBAUGH DG, 1969, J THORAC CARDIOV SUR, V57, P31, DOI 10.1016/S0022-5223(19)42760-8; BARTLETT RH, 1986, CHEST, V89, P684, DOI 10.1378/chest.89.5.684; BAUMANN WR, 1986, CRIT CARE MED, V14, P1, DOI 10.1097/00003246-198601000-00001; BERNARD GR, 1983, CHEST, V89, P594; BOLIN R W, 1986, Critical Care Clinics, V2, P585; BONE RC, 1980, ARCH INTERN MED, V140, P85, DOI 10.1001/archinte.140.1.85; CHEATHAM ML, 1993, CRIT CARE MED, V21, pS244; CIVETTA JM, 1976, SOUTH MED J, V69, P749, DOI 10.1097/00007611-197606000-00026; CULLEN DJ, 1979, ANESTHESIOLOGY, V50, P185, DOI 10.1097/00000542-197903000-00003; DENKE SM, 1980, NEW ENGL J MED, V303, P76; DOUGLAS ME, 1977, CHEST, V71, P18, DOI 10.1378/chest.71.1.18; DREYFUSS D, 1985, AM REV RESPIR DIS, V132, P880; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; FEIN AM, 1983, CHEST, V83, P40, DOI 10.1378/chest.83.1.40; FOWLER AA, 1985, AM REV RESPIR DIS, V132, P472; GALLAGHER TJ, 1978, CRIT CARE MED, V6, P323, DOI 10.1097/00003246-197809000-00005; JARDIN F, 1981, INTENS CARE MED, V7, P171, DOI 10.1007/BF01724837; JARDIN F, 1981, NEW ENGL J MED, V304, P387, DOI 10.1056/NEJM198102123040703; KAPLAN RL, 1979, ARCH INTERN MED, V139, P867, DOI 10.1001/archinte.139.8.867; KIRBY RR, 1975, CHEST, V67, P156, DOI 10.1378/chest.67.2.156; Kumar A, 1973, Crit Care Med, V1, P181, DOI 10.1097/00003246-197307000-00001; LAURENZI GA, 1968, NEW ENGL J MED, V279, P333, DOI 10.1056/NEJM196808152790701; MANNING HL, 1994, CHEST, V105, P242, DOI 10.1378/chest.105.1.242; MAUNDER R J, 1989, American Review of Respiratory Disease, V139, pA220; MEYRICK B, 1986, Critical Care Clinics, V2, P405; MILLER RS, 1992, J TRAUMA, V33, P284, DOI 10.1097/00005373-199208000-00020; MONTGOMERY AB, 1985, AM REV RESPIR DIS, V132, P485; MORAN JF, 1981, SURGERY, V89, P575; MURRAY JF, 1978, AM REV RESPIR DIS, V138, P720; NELSON LD, 1987, CRIT CARE MED, V15, P14, DOI 10.1097/00003246-198701000-00003; NORWOOD SH, 1986, CRIT CARE MED, V14, P376; PEPE PE, 1984, NEW ENGL J MED, V311, P281, DOI 10.1056/NEJM198408023110502; PEPE PE, 1982, AM J SURG, V144, P124, DOI 10.1016/0002-9610(82)90612-2; PERSCHAU RA, 1979, CIRCULATION, V59, P1312, DOI 10.1161/01.CIR.59.6.1312; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; PRATT PC, 1974, AM REV RESPIR DIS, V110, P51; RALPH DD, 1985, AM REV RESPIR DIS, V131, P54; RAPPAPORT SH, 1994, CRIT CARE MED, V22, P22, DOI 10.1097/00003246-199401000-00009; REGISTER SD, 1987, CRIT CARE MED, V15, P598, DOI 10.1097/00003246-198706000-00012; SHAPIRO BA, 1980, CHEST, V77, P138, DOI 10.1378/chest.77.2.138; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; SMITH PK, 1982, ANN SURG, V195, P121, DOI 10.1097/00000658-198202000-00001; SNIDER MT, 1990, CRIT CARE CLIN, V6, P103; STEVENS PM, 1985, ANN NY ACAD SCI, V384, P477; SUCHYTA MR, 1992, CHEST, V101, P1074, DOI 10.1378/chest.101.4.1074; TOUNG TJK, 1978, SURG GYNECOL OBSTET, V147, P518; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; WINTER PM, 1972, ANESTHESIOLOGY, V37, P210, DOI 10.1097/00000542-197208000-00010; WOLF WG, 1979, ANN SURG, V188, P530; WOLFE WG, 1972, SURGERY, V72, P246; WOODRING JH, 1985, CRIT CARE MED, V13, P786, DOI 10.1097/00003246-198510000-00003; ZWILLICH CW, 1974, AM J MED, V57, P161, DOI 10.1016/0002-9343(74)90440-9	53	45	47	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	SEP	1995	23	9					1485	1496		10.1097/00003246-199509000-00008			12	Critical Care Medicine	General & Internal Medicine	RU202	WOS:A1995RU20200008	7664550				2021-06-18	
J	SNOW, P; DOUGLAS, J; PONSFORD, J				SNOW, P; DOUGLAS, J; PONSFORD, J			DISCOURSE ASSESSMENT FOLLOWING TRAUMATIC BRAIN INJURY - A PILOT-STUDY EXAMINING SOME DEMOGRAPHIC AND METHODOLOGICAL ISSUES	APHASIOLOGY			English	Article							CLOSED-HEAD-INJURY; ADULTS; DEFICITS; APPRAISAL; LANGUAGE	With the shift away from evaluation of isolated aspects of linguistic performance, discourse assessment has become an important tool in assessing the communication skills of individuals who have sustained traumatic brain injury (TBI). Given the substantial evidence that the brain-injured represent a largely preselected population, it would seem relevant that speech pathologists acquire a greater understanding of the role of premorbid sociolinguistic and demographic characteristics in determining the clinical presentation of these patients. This demands that close consideration be given to the selection of control subjects for research with this population. Further, there needs to be clarification about which discourse tasks (by virtue of their cognitive/linguistic demands) are sensitive to brain injury. The pilot study described here compared the discourse skills of three TBI subjects with those of three non-TBI orthopaedic patients, on a range of discourse tasks thought to make differing cognitive and/or linguistic demands on the speaker. The results appear to confirm the need to examine discourse skills within a sociolinguistic context. The importance of examining different discourse parameters is also borne out. Finally, the results suggest that there is some merit in tapping sources other than direct discourse analysis in order to determine how verbal skills have altered as a consequence of brain injury.	BETHESDA HOSP,MELBOURNE,AUSTRALIA	SNOW, P (corresponding author), LA TROBE UNIV,FAC HLTH SCI,SCH COMMUN DISORDERS,BUNDOORA,VIC 3083,AUSTRALIA.		Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Snow, Pamela/0000-0002-2426-8349			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; BENJAMIN L, 1989, THEORY FUNCTION BRID; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; CAMPBELL TF, 1992, TOP LANG DISORD, V12, P42, DOI 10.1097/00011363-199202000-00006; CANNITO M P, 1988, Seminars in Speech and Language, V9, P117, DOI 10.1055/s-0028-1082459; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COEHLO CA, 1991, ARCH PHYSICAL MED RE, V72, P465; COEHLO CA, 1990, J PSYCHOLINGUISTIC R, V19, P405; COEHLO CA, 1991, J HEAD TRAUMA REHAB, V6, P92; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Damico JS, 1985, COMMUNICATION SKILLS, P165; DILLER L, 1981, J CONSULT CLIN PSYCH, V49, P822, DOI 10.1037/0022-006X.49.6.822; Ehrlich J, 1989, Brain Inj, V3, P193, DOI 10.3109/02699058909004552; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; GILLIES S, 1990, UNPUB PERCEPTIONS CO; Goldstein H, 1990, TREATMENT EFFICACY R, P91; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HAGEN C, 1981, TOPICS LANGUAGE  SEP, P73; HARTLEY L, 1989, J SPEECH LANGUAGE PA, V13, P51; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hartley L. L., 1990, NEUROPSYCHOLOGY EVER, P125; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HUNT KW, 1970, MONOGR SOC RES CHILD, V35, P1; Jennett B, 1981, MANAGEMENT HEAD INJU; JORDAN F, 1990, AUSTR J HUMAN COMMUN, V19, P69; KEARNS KJ, 1990, TREATMENT EFFICACY R, P79; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LOBAN WD, 1963, NATIONAL COUNCIL TEA; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milton S. B., 1986, CLIN NEUROPSYCHOLOGY, P223, DOI [10.1007/978-1-4613-2291-7_11, DOI 10.1007/978-1-4613-2291-7_11]; MISLER EG, 1979, HARVARD EDUC REV, V49, P1; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; Penn C, 1985, S Afr J Commun Disord, V32, P18; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POOLE ME, 1976, SOCIAL CLASS LANGUAG; Prigatano G., 1986, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Rimel RW, 1990, REHABILITATION ADULT, P8; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SARNO MT, 1984, FUNCTIONAL ASSESSMEN, P210; SLOAN S, 1989, THEORY FUNCTION BRID, P36; SNOW P, 1987, BRAIN IMPAIRMENT P 1, P87; STUBBS M, 1983, DISCOURSE ANAL; Suls Jerry M., 1983, HDB HUMOR RES BASIC, V1, P39, DOI DOI 10.1007/978-1-4612-5572-7_3; SWINDELL CS, 1982, CLIN APHASIOLOGY C P, P50; TRUDGILL P, 1983, INTRO LANGUAGE SOC; ULTATOWSKA HK, 1988, NEUROPSYCHOLOGIAL ST, P108; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WILSON, 1989, BOUNDARIES CONVERSAT; YLVISAKER M, 1985, CLIN MANAGEMENT NEUR, P243	61	45	47	0	3	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0268-7038			APHASIOLOGY	Aphasiology	JUL-AUG	1995	9	4					365	380		10.1080/02687039508248210			16	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	RE390	WOS:A1995RE39000004					2021-06-18	
J	EDDY, VA; VITSKY, JL; RUTHERFORD, EJ; MORRIS, JA				EDDY, VA; VITSKY, JL; RUTHERFORD, EJ; MORRIS, JA			AGGRESSIVE USE OF ICP MONITORING IS SAFE AND ALTERS PATIENT-CARE	AMERICAN SURGEON			English	Article; Proceedings Paper	62nd Annual Scientific Meeting of the Southeastern Surgical Conference	FEB 06-10, 1994	LAKE BUENA VISTA, FL				CEREBRAL PERFUSION-PRESSURE; INTRA-CRANICAL PRESSURE; INTRACRANIAL-PRESSURE; CLINICAL-EVALUATION; FIBEROPTIC DEVICE; RISK-FACTORS; HEAD-INJURY; COMA; COMPLICATIONS; LESIONS	Objective: To identify complications and interventions resulting from fiberoptic ICP monitoring in a large series of patients with closed head injury (CHI). Setting/Design: Level I trauma center/Consecutive case series. Methods: Of 11,962 consecutive trauma admissions from 1984-1991, 279 patients underwent fiberoptic ICP monitoring for CHI. We identified the last 100 consecutive blunt trauma patients who had received ICP monitoring. Ninety-eight of these patients had charts available and constitute the study group. We examined mortality, Glasgow Coma Score (GCS), and admission CT findings for the group. Indications, interventions, and complications (bleeding, meningitis, and wound infections) associated with ICP monitoring were identified. Results: Mortality for the group was 24%. Reasons for ICP monitoring included GCS less than or equal to 8 and/or abnormal CT findings; 83% had GCS less than or equal to 8. Admission CT findings included subarachnoid hemorrhage (48%), intracerebral hemorrhage (47%), edema (31%), intraventricular hemorrhage (20%), subdural hematoma (18%), and epidural hematoma (9%). Eighty-one per cent of patients had interventions based on ICP monitoring: osmolar therapy (81%), emergency CT (22%), surgical decompression (3%), or pentobarbital coma (2%). No complications resulted from ICP monitoring. Mean duration of monitoring was 4 days (maximum 13 days). Twenty patients (20%) required two or more monitors. Reasons for placing a second monitor included duration >5 days (50%), questionable accuracy (20%), and accidental removal of the first monitor (10%). Conclusions: 1) Fiberoptic intracranial pressure monitoring leads to specific interventions in the majority of patients. 2) The procedure is safe. 3) Prospective studies are needed to determine the impact of coagulopathy on the safety of fiberoptic intracranial pressure monitoring and to define those factors responsible for the low infection rate.		EDDY, VA (corresponding author), VANDERBILT UNIV,SCH MED,DEPT SURG,DIV TRAUMA,243 MED CTR S,2100 PIERCE AVE,NASHVILLE,TN 37212, USA.						ARTRU F, 1992, ANN FR ANESTH, V11, P424, DOI 10.1016/S0750-7658(05)80342-9; AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; CHAMBERS IR, 1990, NEUROSURGERY, V26, P421, DOI 10.1227/00006123-199003000-00007; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CLARK WC, 1989, NEUROSURGERY, V25, P20; CRUTCHFIELD JS, 1990, J NEUROSURG, V72, P482, DOI 10.3171/jns.1990.72.3.0482; DOYLE J, 1992, J CLIN MONITOR, V8, P81, DOI 10.1007/BF01618093; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; HICKMAN KM, 1990, HEART LUNG, V19, P84; HOLLINGSWORTHFR.P, 1988, HEART LUNG, V17, P111; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NORTH B, 1986, NEUROSURGERY, V18, P730, DOI 10.1227/00006123-198606000-00009; OSTRUP RC, 1987, J NEUROSURG, V67, P26; ROSENWASSER RH, 1992, TRAUUMA Q, V8, P30; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; TASKER RC, 1991, NEUROPEDIATRICS, V22, P47, DOI 10.1055/s-2008-1071416; TEASDALE G, 1974, LANCET, V2, P81; TRUNKEY D, 1985, TRAUMA CENTRAL NERVO, P9; WEAVER DD, 1982, J NEUROSURG, V56, P660, DOI 10.3171/jns.1982.56.5.0660; WEINSTABL C, 1992, J CLIN MONITOR, V8, P116, DOI 10.1007/BF01617429; YALON JS, 1993, J CLIN MONITOR, V9, P71; YANO M, 1987, NEUROSURGERY, V21, P688, DOI 10.1227/00006123-198711000-00015	24	45	46	0	2	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	JAN	1995	61	1					24	29					6	Surgery	Surgery	QC078	WOS:A1995QC07800006	7832377				2021-06-18	
J	Lee, ST; Lui, TN; Wong, CW; Yeh, YS; Tzaan, WC				Lee, ST; Lui, TN; Wong, CW; Yeh, YS; Tzaan, WC			Early seizures after moderate closed head injury	ACTA NEUROCHIRURGICA			English	Article						seizures; head injury; posttraumatic seizures	EPILEPSY; TRAUMA; MILD	The incidence and clinical significance was studied in 2574 closed head injury patients, each of them having a Glasgow Coma Scale (GCS) 9 to 12 after trauma. All patients underwent computerized tomography (CT) after being admitted to the emergency service. One hundred and six patients (4.1%) experienced seizures within 1 week after head injury; 46 of these (1.8% of the series) had seizures within 24 hours after trauma. There was no statistically significant difference between the early seizure and seizure free group of patients in gender, age and GCS with the exception of cause of injury (p < 0.01). The incidence of intracerebral parenchymal damage was found to be higher with seizures developing between day 2 and day 7 (80%) than those with seizures developing within 24 hours (54.3%). Analysing the data revealed that early posttraumatic seizures were not related to the presence of intra cerebral parenchymal damage on CT scan. The occurrence of early seizures did not affect the mortality and outcome of moderate closed head injury patients.	CHANG GUNG & MED & ENGN COLL,TAYUAN,TAIWAN	Lee, ST (corresponding author), CHANG GUNG MEM HOSP,DEPT NEUROSURG,5 FU SHING ST,TAYUAN 333,TAIWAN.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BAILEY BN, TXB HEAD INJURY, P308; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; EISENBERG HM, 1989, MILD MODERATE HEAD I, P95; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT B, 1981, MANAGEMENT HEAD INJU, P301; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MILLER JD, 1986, NEUROSURG REV, V9, P135, DOI 10.1007/BF01743065; MILLER JD, 1989, MILD MODERATE HEAD I, P117; PITTS LH, 1989, MILD MODERATE HEAD I, P107; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	20	45	46	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	137	3-4					151	154		10.1007/BF02187187			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TL370	WOS:A1995TL37000011	8789655				2021-06-18	
J	PHILLIPS, LL; LYETH, BG; HAMM, RJ; POVLISHOCK, JT				PHILLIPS, LL; LYETH, BG; HAMM, RJ; POVLISHOCK, JT			COMBINED FLUID PERCUSSION BRAIN INJURY AND ENTORHINAL CORTICAL LESION - A MODEL FOR ASSESSING THE INTERACTION BETWEEN NEUROEXCITATION AND DEAFFERENTATION	JOURNAL OF NEUROTRAUMA			English	Article							DENTATE GYRUS; HIPPOCAMPAL FORMATION; CORTEX LESIONS; ADULT-RAT; EXTRACELLULAR POTASSIUM; REACTIVE SYNAPTOGENESIS; REINNERVATION; DENERVATION; RECOVERY; SYNAPTOPHYSIN	Laboratory studies suggest that excessive neuroexcitation and deafferentation contribute to long-term morbidity following human head injury. Because no current animal model of traumatic brain injury (TBI) has been shown to combine excessive neuroexcitation and significant levels of deafferentation, we developed a rat model combining the neuroexcitation of fluid percussion TBI with subsequent entorhinal cortical (EC) deafferentation. In this paradigm, moderate fluid percussion TBI was induced in each rat, followed 24 h later by bilateral EC lesion (BEG). Six conditions were examined: (1) fluid percussion TBI followed 24 h later by bilateral EC lesion (TBEC), (2) fluid percussion TBI (TBI), (3) bilateral EC lesion (BEG), (4) sham fluid percussion TBI (SHAM), (5) TBI followed 24 h later by unilateral EC lesion (TUEC), and (6) unilateral EC lesion (UEC). The first four groups were assessed for motor (with beam-balance and beam-walk testing) and cognitive deficits (with the Morris water maze) and hippocampal morphology (with immunocytochemistry and electron microscopy). The TUEC and UEC groups were assessed for cognitive deficits alone. Motor deficits were greater in the TBEC injury than in TBI or sham alone; however, no significant difference was observed between the TBEC and BEC conditions in motor performance. Cognitive deficits were of a greater magnitude in the combined TBEC injury model relative to each individual insult. These cognitive deficits appeared to be additive for the two experimental injuries, BEC deafferentation producing deficits intermediate between TBI and TBEC insults. Morphologic analysis of the dentate gyrus molecular layer at 15 days after TBEC showed that the distribution of synaptophysin-positive presynaptic terminals was distinct from that observed after either TBI or BEC alone. Specifically, the laminar pattern of presynaptic rearrangement induced by BEC lesion did not occur after TBEC injury. The present results show that axonal injury and its attendant deafferentation, when coupled with traumatically induced neuroexcitation, produce an enhancement of the morbidity associated with TBI. Moreover, they indicate that this model can effectively be used to study the interaction between neuroexcitation and synaptic plasticity.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284	PHILLIPS, LL (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 693,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 20193] Funding Source: Medline		CALBAKA LM, 1992, NEUROBIOL AGING, V13, P283; COTMAN CW, 1978, NEURONAL PLASTICITY, P227; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GRADY MS, 1989, J NEUROSURG, V71, P534, DOI 10.3171/jns.1989.71.4.0534; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hamm RJ, 1993, BRAIN RES COGN BRAIN, V1, P223, DOI [10.1016/0926-6410(93)90006-Q, DOI 10.1016/0926-6410(93)90006-Q]; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HOVDA DA, 1990, ACT NEUR S, V51, P331; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1990, Society for Neuroscience Abstracts, V16, P778; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH G, 1976, BRAIN RES, V110, P57, DOI 10.1016/0006-8993(76)90208-0; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, J NEUROCHEM, V55, P1170; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Nagahara A. H., 1992, Society for Neuroscience Abstracts, V18, P1421; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; PHILLIPS LL, 1993, SOC NEUR ABSTR, V19, P1993; PKA MJ, 1992, ACTA NEUROPATHOL BER, V83, P530; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; REEVES TM, 1987, BEHAV NEUROSCI, V101, P179; REEVES TM, 1988, EXP NEUROL, V102, P37, DOI 10.1016/0014-4886(88)90076-3; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; SMITH D H, 1990, Society for Neuroscience Abstracts, V16, P779; STEWARD O, 1988, J COMP NEUROL, V267, P203, DOI 10.1002/cne.902670205; STEWARD O, 1977, BRAIN RES BULL, V2, P41, DOI 10.1016/0361-9230(77)90023-5; STEWARD O, 1983, J COMP NEUROL, V214, P370, DOI 10.1002/cne.902140403; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; STORMMAT.J, 1974, BRAIN RES, V80, P181, DOI 10.1016/0006-8993(74)90683-0; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; VES TM, 1986, EXP BRAIN RES, V102, P167; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	48	45	45	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1994	11	6					641	656		10.1089/neu.1994.11.641			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	QD215	WOS:A1994QD21500002	7723064				2021-06-18	
J	DEANGELIS, MM; HAYES, RL; LYETH, BG				DEANGELIS, MM; HAYES, RL; LYETH, BG			TRAUMATIC BRAIN INJURY CAUSES A DECREASE IN M2 MUSCARINIC CHOLINERGIC RECEPTOR-BINDING IN THE RAT-BRAIN	BRAIN RESEARCH			English	Article						FLUID PERCUSSION; AFDX384; ACETYLCHOLINE; PIRENZIPINE; AUTORADIOGRAPHY; HIPPOCAMPUS; TRAUMATIC BRAIN INJURY; RECEPTOR BINDING	AMINO-ACIDS; DEFICITS; BEHAVIOR; RELEASE; M1	Numerous studies indicate that an acute, excessive activation of muscarinic acetylcholine receptors (mAChR) contributes to the pathophysiological sequela of TBI. The present study examined the effect of moderate fluid percussion traumatic brain injury (TBI) on binding to M1 and M2 mAChR subtypes in the hippocampal formation and adjacent cortex using quantitative autoradiography. Injured animals along with concurrent controls were sacrificed by in situ freezing at 3 h or 24 h following TBI. Slide-mounted tissue sections were incubated in either [H-3]pirenzipine (23 nM) for M1 or [H-3]AFDX384 (9 nM) for M2 mAChR subtype labeling. Binding of [H-3]pirenzipine to the M1 mAChR subtype was not significantly altered by TBI when compared to sham-injured animals. [H-3]AFDX384 binding to the M2 mAChR subtype was significantly decreased at 24 h in hippocampal CA2-3 region and dorsal blade of the dentate gyrus (P < 0.05). The differences observed between M1 and M2 subtypes suggests that these muscarinic subtypes may differentially contribute to the pathophysiology of TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT SURG,DIV NEUROSURG,RICHMOND,VA 23298; UNIV TEXAS,SCH MED,DEPT SURG,DIV NEUROSURG,HOUSTON,TX 77030			DeAngelis, e/J-7863-2015	Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587, R01 NS21458, R01 NS29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, R01NS021458, P50NS012587, P01NS012587] Funding Source: NIH RePORTER		AUBERT I, 1992, EUR J PHARMACOL, V217, P173, DOI 10.1016/0014-2999(92)90843-S; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DELAHUNTY TM, 1992, 10TH P ANN NUEUR SOC; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAYES RL, 1992, J NEUROTRAUM, V9, P5173; HEPPNER F, 1958, Monatsschr Unfallheilkd Versicherungsmed, V61, P257; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LAPCHAK PA, 1989, BRAIN RES, V496, P285, DOI 10.1016/0006-8993(89)91075-5; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYETH BG, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P253; MAKIYAMA Y, 1990, 8TH P ANN M SOC NEUR; MASH DC, 1986, NEUROSCIENCE, V19, P551, DOI 10.1016/0306-4522(86)90280-0; MASH DC, 1985, SCIENCE, V228, P1115, DOI 10.1126/science.3992249; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERRY DC, 1992, MOL CHEM NEUROPATHOL, V16, P95, DOI 10.1007/BF03159963; POTTER LT, 1984, TRENDS PHARM SCI S, V5, P22; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; TONNAER JAD, 1990, EUR J PHARMACOL, V207, P183; WAMSLEY JK, 1984, LIFE SCI, V34, P1375; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398	32	45	47	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 8	1994	653	1-2					39	44		10.1016/0006-8993(94)90369-7			6	Neurosciences	Neurosciences & Neurology	PA036	WOS:A1994PA03600006	7982073				2021-06-18	
J	CHESNUT, RM; GAUTILLE, T; BLUNT, BA; KLAUBER, MR; MARSHALL, LE				CHESNUT, RM; GAUTILLE, T; BLUNT, BA; KLAUBER, MR; MARSHALL, LE			THE LOCALIZING VALUE OF ASYMMETRY IN PUPILLARY SIZE IN SEVERE HEAD-INJURY - RELATION TO LESION TYPE AND LOCATION	NEUROSURGERY			English	Article						AGE; ANISOCORIA; BRAIN INJURIES; EPIDURAL HEMATOMA; HEAD INJURIES; MECHANISM OF INJURY; PREDICTION; SUBDURAL HEMATOMA	TENTORIAL HERNIATION; SUBDURAL-HEMATOMA; MORTALITY; MANAGEMENT	RELIABLE ASSESSMENT OF the probability that a head injury patient harbors a surgical intracranial lesion is critical to both triage and treatment. The authors analyzed data from 608 patients with severe head injuries (Glasgow Coma Scale score, less than or equal to 8) in the Traumatic Coma Data Bank to assess the reliability of pupillary asymmetry in predicting the presence and location of an intracranial mass lesion. Of 210 patients with pupillary asymmetry of greater than or equal to 1 mm, 63 (30%) had intracranial mass lesions, 52 (25%) of which were extra-axial in location, 38 (73%) of these located ipsilateral to the larger pupil. Of 51 patients with asymmetry of greater than or equal to 3 mm, 22 (43%) had intracranial mass lesions, 18 (35%) of which were extra-axial in location, 14 (64%) of these located ipsilateral to the larger pupil. For both asymmetry categories, strong interactions were found with age and mechanism of injury, the highest incidence of extra-axial lesions occurring in older patients injured other than as occupants of motor vehicles. The authors developed regression equations that provide a graphic means to predict the presence of an intracranial hematoma using data on pupillary asymmetry, age, and mechanism of injury. This predictive model, interpreted in a hospital- and patient-specific fashion, should be of significant use in directing triage, activating diagnostic and therapeutic resources, and evaluating the utility of exploratory trephination.	UNIV CALIF SAN DIEGO,MED CTR,DEPT FAMILY & COMMUNITY MED,SAN DIEGO,CA 92103; SAN DIEGO VET ADM HOSP,DIV NEUROL SURG,LA JOLLA,CA; UNIV CALIF SAN FRANCISCO,MED CTR,DEPT RADIOL,SAN FRANCISCO,CA 94143	CHESNUT, RM (corresponding author), UNIV CALIF SAN DIEGO,MED CTR,DEPT SURG,DIV NEUROSURG,200 W ARBOR ST,SAN DIEGO,CA 92103, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032340, N01NS032341, N01NS032339] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS-3-2340, N01-NS-3-2339, N01-NS-3-2341] Funding Source: Medline		ANDREWS BT, 1986, NEUROSURGERY, V19, P408, DOI 10.1227/00006123-198609000-00012; BAXT WG, 1987, J TRAUMA, V27, P602, DOI 10.1097/00005373-198706000-00003; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOWERS SA, 1980, NEUROSURGERY, V6, P237; Burton C, 1965, J Trauma, V5, P643, DOI 10.1097/00005373-196509000-00008; Finney LA, 1962, TRANSTENTORIAL HERNI; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; HOFF JT, 1978, WESTERN J MED, V128, P112; Hosmer D. W., 1989, APPLIED LOGISTIC REG; JENNETT B, 1975, LANCET, V1, P480; JOHNSON RT, 1956, ACTA RADIOL, V46, P242, DOI 10.3109/00016925609170833; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KLUGE DN, 1960, AM J SURG, V99, P707, DOI 10.1016/0002-9610(60)90018-0; MAHONEY BD, 1981, NEUROSURGERY, V8, P551, DOI 10.1227/00006123-198105000-00006; RAND BO, 1966, J NEUROSURG, V25, P410, DOI 10.3171/jns.1966.25.4.0410; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SEELIG JM, 1981, J NEUROSURG, V55, P516, DOI 10.3171/jns.1981.55.4.0516; TEASDALE G, 1974, LANCET, V2, P81	19	45	46	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1994	34	5					840	845		10.1227/00006123-199405000-00008			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NH386	WOS:A1994NH38600022	8052380				2021-06-18	
J	AHUJA, A; GLASAUER, FE; ALKER, GJ; KLEIN, DM				AHUJA, A; GLASAUER, FE; ALKER, GJ; KLEIN, DM			RADIOLOGY IN SURVIVORS OF TRAUMATIC ATLANTOOCCIPITAL DISLOCATION	SURGICAL NEUROLOGY			English	Article						ATLANTOOCCIPITAL DISLOCATION; DIAGNOSIS; RADIOLOGY; TRAUMATIC	ATLANTOOCCIPITAL DISLOCATION; INJURIES; JUNCTION; CHILDREN; ANATOMY	Traumatic atlanto-occipital dislocation is fatal, but survivals are reported. Six cases of survival after atlanto-occipital dislocation are presented. Lateral cervical spine radiographs demonstrated retropharyngeal swelling in all patients, and Powers' ratio was abnormal in five of six patients. Reformatted computed tomography (CT) images or three-dimensional CT were useful in confirming the diagnosis. Initial treatment consisted of immobilization with halo or collar, and, in one patient, Crutchfield tongs. Reduction of the dislocation was associated with decreasing Powers' ratio in five long-term survivors. Residual neurologic deficits, however, were seen in these patients. Atlanto-occipital dislocation should be suspected in trauma patients with findings of brain stem injury-especially agonal respirations, irregular heart rate, lower cranial nerve abnormality, and asymmetrical motor deficits.		AHUJA, A (corresponding author), SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT NEUROSURG,3 GATES CIRCLE,BUFFALO,NY 14209, USA.						ALKER GJ, 1978, ORTHOP CLIN N AM, V9, P1003; BELZBERG AJ, 1991, J NEUROSURG, V75, P478, DOI 10.3171/jns.1991.75.3.0478; Blackwood NJ, 1908, ANN SURG, V47, P654, DOI 10.1097/00000658-190805000-00003; BOOLS JC, 1986, AM J NEURORADIOL, V7, P901; BUCHOLZ RW, 1979, J BONE JOINT SURG AM, V61, P248, DOI 10.2106/00004623-197961020-00014; COLLALTO PM, 1986, J BONE JOINT SURG AM, V68A, P1106, DOI 10.2106/00004623-198668070-00024; DAVIS D, 1971, J NEUROSURG, V34, P603, DOI 10.3171/jns.1971.34.5.0603; DIBENEDETTO T, 1990, SPINE, V15, P595, DOI 10.1097/00007632-199006000-00031; DUBLIN AB, 1980, J NEUROSURG, V52, P541, DOI 10.3171/jns.1980.52.4.0541; DVORAK J, 1987, SPINE, V12, P183, DOI 10.1097/00007632-198703000-00016; EISMONT FJ, 1978, J BONE JOINT SURG AM, V60, P397, DOI 10.2106/00004623-197860030-00024; EVARTS CM, 1970, J BONE JOINT SURG AM, VA 52, P1653, DOI 10.2106/00004623-197052080-00017; FRUIN AH, 1977, J NEUROSURG, V46, P663, DOI 10.3171/jns.1977.46.5.0663; GERLOCK AJ, 1983, NEUROSURGERY, V13, P316, DOI 10.1227/00006123-198309000-00019; GOLDBERG AL, 1991, J COMPUT ASSIST TOMO, V15, P174, DOI 10.1097/00004728-199101000-00034; JEVTICH V, 1989, SPINE, V14, P123, DOI 10.1097/00007632-198901000-00027; KAUFMAN RA, 1987, AM J NEURORADIOL, V8, P995; KAUFMAN RA, 1982, AM J NEURORADIOL, V3, P415; LEE C, 1991, J TRAUMA, V31, P401, DOI 10.1097/00005373-199103000-00017; LEE C, 1987, AM J NEURORADIOL, V8, P19; LEVINE AM, 1989, CLIN ORTHOP RELAT R, V239, P53; MONTANE I, 1991, SPINE, V16, P112, DOI 10.1097/00007632-199102000-00002; PAGE CP, 1973, J NEUROSURG, V39, P394, DOI 10.3171/jns.1973.39.3.0394; PANG D, 1980, NEUROSURGERY, V7, P503, DOI 10.1227/00006123-198011000-00017; PAPADOPOULOS SM, 1991, NEUROSURGERY, V28, P574, DOI 10.1227/00006123-199104000-00015; POWERS B, 1979, NEUROSURGERY, V4, P12, DOI 10.1097/00006123-197901000-00004; PUTNAM WE, 1986, J AM OSTEOPATH ASSOC, V86, P798; RASOOL MN, 1987, S AFR MED J, V72, P295; ROCKSWOLD GL, 1979, MINN MED, V62, P151; SCHNEIDER R, 1961, J NEUROSURG, V18, P348, DOI 10.3171/jns.1961.18.3.0348; TRAYNELIS VC, 1986, J NEUROSURG, V65, P863, DOI 10.3171/jns.1986.65.6.0863; WATRIDGE CB, 1985, NEUROSURGERY, V17, P345, DOI 10.1227/00006123-198508000-00021; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WHITE AA, 1978, ORTHOP CLIN N AM, V9, P867; WHOLEY MH, 1958, RADIOLOGY, V71, P350, DOI 10.1148/71.3.350; WOODRING JH, 1981, AM J NEURORADIOL, V2, P251	36	45	48	0	1	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0090-3019			SURG NEUROL	Surg. Neurol.	FEB	1994	41	2					112	118		10.1016/0090-3019(94)90107-4			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NL663	WOS:A1994NL66300005	8115947				2021-06-18	
J	MCDONALD, S; VANSOMMERS, P				MCDONALD, S; VANSOMMERS, P			PRAGMATIC LANGUAGE-SKILLS AFTER CLOSED-HEAD INJURY - ABILITY TO NEGOTIATE REQUESTS	COGNITIVE NEUROPSYCHOLOGY			English	Article							DEFICITS	Closed head injuries (CHI) frequently result in a constellation of frontal lobe deficits such as poor abstraction, poor regulation of behaviour, and disinhibition. These deficits have ramifications for communication abilities despite intact primary language processes. This study focused on the ability of 2 CHI subjects to make requests in social contexts compared to 12 non-brain-damaged controls. The CHI subjects were found to retain a sensitivity to the various social factors influencing the form a request takes and to use these normally when the request was simple, conventional, and straightforward. They had difficulty, however, formulating their request indirectly in the form of a hint. Their attempts reflected a failure to appreciate logically related aspects of the request context and to use these in their request formulation. Alternatively, if they managed to formulate an indirect hint, they were unable to avoid completing the argument to the point of stating their requests baldly. These features were discussed in relationship to their known frontal lobe deficits.	MACQUARIE UNIV,N RYDE,NSW 2113,AUSTRALIA	MCDONALD, S (corresponding author), UNIV NEW S WALES,DEPT PSYCHOL,POB 1,KENSINGTON,NSW 2033,AUSTRALIA.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; BOWDEN S, 1992, CLIN NEUROPSYCHOLOGI, V6, P45; Brown Penelope, 1987, POLITENESS SOME UNIV, DOI [10.1017/CBO9780511813085, DOI 10.2307/3587263]; CLARK HH, 1979, COGNITIVE PSYCHOL, V11, P430, DOI 10.1016/0010-0285(79)90020-3; CLARK HH, 1975, J VERB LEARN VERB BE, V14, P56, DOI 10.1016/S0022-5371(75)80006-5; CLARK HH, 1980, COGNITION, V8, P111, DOI 10.1016/0010-0277(80)90009-8; Courville CB, 1945, PATHOLOGY NERVOUS SY; Cronbach L.J., 1972, DEPENDABILITY BEHAVI; CROWE SF, 1992, J CLIN EXP NEUROPSYC, V14, P327, DOI 10.1080/01688639208402832; EDGINGTON ES, 1980, RANDOMIZATION TESTS, V31; FRANCIK EP, 1985, J MEM LANG, V24, P560, DOI 10.1016/0749-596X(85)90046-4; Halliday MAK, 1985, LANGUAGE CONTEXT TEX; Holbourn AHS, 1943, LANCET, V2, P438; Kertesz A, 1979, W APHASIA BATTERY; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria A. R., 1976, BASIC PROBLEMS NEURO; LURIA AR, 1976, HIGHER CORTICAL FUNC; Milner B., 1964, FRONTAL GRANULAR COR; Milton S. B., 1984, CLIN APHASIOLOGY, V14, P114; PILLON B, 1981, NEUROPSYCHOLOGIA, V19, P375, DOI 10.1016/0028-3932(81)90067-1; SEIGEL S, 1988, NONPARAMETRIC STATIS; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T., 1988, NEUROPSYCHOLOGY MENT; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sperber D., 1986, RELEVANCE COMMUNICAT; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stuss D.T., 1986, FRONTAL LOBES; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TATE RL, 1992, UNPUB DATA 40 NORMAL; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WALSH K, 1978, NEUROPSYCHOLOGY CLIN; Walsh K. W., 1985, UNDERSTANDING BRAIN	34	45	50	0	3	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.	AUG	1993	10	4					297	315		10.1080/02643299308253466			19	Psychology; Psychology, Experimental	Psychology	LT369	WOS:A1993LT36900001					2021-06-18	
J	KITCHENER, PD; VANDERZEE, CEEM; DIAMOND, J				KITCHENER, PD; VANDERZEE, CEEM; DIAMOND, J			LESION-INDUCED NADPH-DIAPHORASE REACTIVITY IN NEOCORTICAL PYRAMIDAL NEURONS	NEUROREPORT			English	Article						BRAIN INJURY; NEURONAL PLASTICITY; NEOCORTEX; NITRIC OXIDE SYNTHASE	LONG-TERM POTENTIATION; NITRIC-OXIDE; MESSENGER	PYRAMIDAL neurones of the rat neocortex do not normally express NADPH-diaphorase reactivity. However, after stab lesions which extended through the entire depth of the neocortex, strong NADPH-diaphorase reactivity was observed in pyramidal neurones at 7 and 14 days post-lesion. At 3 and 21 days post-lesion fewer and less reactive pyramidal neurones were observed, and no reactive pyramidal neurones were seen at 2 and 26 days post-lesion. The great majority of reactive pyramidal neurones were in layers V and VI and most were situated medial to the lesion. The induction of NADPH-diaphorase implies that the capability to synthesize nitric oxide may be a component of the pyramidal neurones' response to traumatic injury.	MCMASTER UNIV,DEPT BIOMED SCI,DIV NEUROSCI,HAMILTON L8N 3Z5,ONTARIO,CANADA	KITCHENER, PD (corresponding author), UNIV QUEENSLAND,DEPT ANAT SCI,CEREBRAL SENSORY FUNCT UNIT,BRISBANE,QLD 4072,AUSTRALIA.		Van der Zee, Catharina E.E.M./L-4773-2015	Kitchener, Peter/0000-0003-4324-5270			BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; BROWN IR, 1990, J NEUROSCI RES, V27, P47; CHAPMAN PF, 1992, NEUROREPORT, V3, P567, DOI 10.1097/00001756-199207000-00005; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; FERRIERO DM, 1988, ANN NEUROL, V24, P670, DOI 10.1002/ana.410240512; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GOADSBY PJ, 1992, BRAIN RES, V595, P167, DOI 10.1016/0006-8993(92)91470-Y; GONZALEZ MF, 1987, BRAIN RES BULL, V18, P417, DOI 10.1016/0361-9230(87)90016-5; HOPE BT, 1992, TRENDS NEUROSCI, V15, P108; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Jones EG, 1984, CEREB CORTEX, V1, P521; KITCHENER PD, 1993, IN PRESS NEUROSCI; KITCHENER PD, 1991, P AUST PHYSL PHARM S, V22, pP186; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POW DV, 1992, J NEUROENDOCRINOL, V4, P377, DOI 10.1111/j.1365-2826.1992.tb00183.x; SAGAR SM, 1987, BRAIN RES, V400, P348, DOI 10.1016/0006-8993(87)90633-0; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SIMMONS ML, 1992, J NEUROCHEM, V59, P897, DOI 10.1111/j.1471-4159.1992.tb08328.x; SOLODKIN A, 1992, NEUROSCIENCE, V51, P495, DOI 10.1016/0306-4522(92)90290-I; TITMUS MJ, 1990, PROG NEUROBIOL, V35, P1, DOI 10.1016/0301-0082(90)90039-J; WALLACE MN, 1992, NEUROREPORT, V3, P953, DOI 10.1097/00001756-199211000-00001; WALLIS RA, 1992, NEUROREPORT, V3, P645, DOI 10.1097/00001756-199207000-00026	25	45	49	0	0	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	0959-4965			NEUROREPORT	Neuroreport	MAY	1993	4	5					487	490		10.1097/00001756-199305000-00006			4	Neurosciences	Neurosciences & Neurology	LB076	WOS:A1993LB07600006	8513123				2021-06-18	
J	PRASAD, MR; TZIGARET, CM; SMITH, D; SOARES, H; MCINTOSH, TK				PRASAD, MR; TZIGARET, CM; SMITH, D; SOARES, H; MCINTOSH, TK			DECREASED ALPHA-1-ADRENERGIC RECEPTORS AFTER EXPERIMENTAL BRAIN INJURY	JOURNAL OF NEUROTRAUMA			English	Article							INCREASED PROSTAGLANDIN SYNTHESIS; RAT-BRAIN; HEAD-INJURY; RECOVERY; RELEASE; NORADRENALINE; BINDING; CORTEX; NEUROTRANSMITTER; NOREPINEPHRINE	The magnitude of neuronal damage in central nervous system (CNS) injury may be related, in part, to alterations in the balance between excitatory and inhibitory neurotransmitters. Previous studies have implicated a role of central inhibitory noradrenergic mechanisms in the pathophysiologic sequelae of traumatic brain injury. In the present study, we examined alpha1-adrenergic receptor binding after parasaggital lateral fluid percussion (FP) brain injury of moderate severity (2.3 atm) in the rat. At 30 min following injury, the specific binding of [H-3]prazosin to membranes isolated from left cortex (injury site) was reduced by 37 % in brain-injured animals when compared to sham-operated noninjured animals (p < 0.05). However, there were no significant differences in [H-3]prazosin binding to membranes of either contralateral (right) cortex or left and right hippocampi between brain-injured and sham-operated animals. Conversely, at 24 h posttrauma, specific binding to membranes of left cortex, cortex adjacent to injury site, contralateral (right) cortex, and left hippocampus was reduced by 25 %, 16 %, 27 %, and 24 %, respectively (all p < 0. 05). Scatchard analysis revealed that a reduction of [H-3]prazosin binding to membranes of injured animals resulted from a decrease in alpha1-receptor binding density (B-max) but not from changes in ligand affinity. Histopathologic assessment of neuronal damage at 24 h postinjury revealed neuronal loss within injury site cortex and left hippocampus but no clearly discernible cell loss in contralateral right cortex, suggesting that the decrease in B-max might be a consequence of early pathophysiology of trauma rather than of neuronal cell loss. We suggest that alterations in alpha1-adrenergic receptors after brain injury may result in decreased inhibitory neurotransmitter action of norepinephrine and may thus contribute to the pathophysiology of traumatic brain injury.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104; UNIV CONNECTICUT,CTR HLTH,DEPT SURG,SURG RES CTR,CNS INJURY LAB,FARMINGTON,CT 06032	PRASAD, MR (corresponding author), UNIV KENTUCKY,SCH MED,MED CTR,DEPT SURG,LEXINGTON,KY 40536, USA.		smith, douglas/A-1321-2007	Tigaret, Cezar/0000-0001-5848-6697	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, R01NS026818] Funding Source: NIH RePORTER		ARAKI T, 1989, ACTA NEUROL SCAND, V80, P451, DOI 10.1111/j.1600-0404.1989.tb03908.x; BATTAGLIA G, 1983, J NEUROCHEM, V41, P538, DOI 10.1111/j.1471-4159.1983.tb04772.x; BLENDY JA, 1990, J NEUROSCI, V10, P2580; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BUCHWEITZ E, 1982, J PHARMACOL EXP THER, V223, P322; Cooper P.R., 1985, CENTRAL NERVOUS SYST; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROWDER JM, 1987, EUR J PHARMACOL, V143, P343, DOI 10.1016/0014-2999(87)90458-4; DELANGEN CDJ, 1980, BRAIN RES, V185, P399; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DISBREY DB, 1970, HISTOLOGICAL LABORAT, P230; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FELDSTEIN JB, 1986, AM J PHYSIOL, V251, pC230; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOBAYASHI H, 1985, EXPERIENTIA, V41, P427, DOI 10.1007/BF01966140; KOBAYASHI H, 1985, CIRC RES, V56, P402, DOI 10.1161/01.RES.56.3.402; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5661; LOWRY OH, 1951, J BIOL CHEM, V261, P7710; LYNCH MA, 1986, NEUROPHARMACOLOGY, V25, P493, DOI 10.1016/0028-3908(86)90173-5; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; NISHINO K, 1989, J CEREBR BLOOD F MET, V9, P358, DOI 10.1038/jcbfm.1989.54; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; Palkovits M., 1988, MAPS GUIDE MICRODISS; PAPPIUS HM, 1991, NEUROCHEM RES, V16, P941, DOI 10.1007/BF00965837; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TAFT W C, 1991, Society for Neuroscience Abstracts, V17, P164; VINK R, 1988, J BIOL CHEM, V263, P757; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WEISS HR, 1988, EUR J PHARMACOL, V148, P107, DOI 10.1016/0014-2999(88)90459-1	44	45	49	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	FAL	1992	9	3					269	279		10.1089/neu.1992.9.269			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	JW451	WOS:A1992JW45100007	1335519				2021-06-18	
J	BROOKE, MM; QUESTAD, KA; PATTERSON, DR; VALOIS, TA				BROOKE, MM; QUESTAD, KA; PATTERSON, DR; VALOIS, TA			DRIVING EVALUATION AFTER TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						AUTOMOBILE DRIVING; BRAIN INJURY; PSYCHOMOTOR PERFORMANCE	DAMAGE	Traumatic closed head injury results in a variety of cognitive and behavioral deficits that may be difficult to assess fully. Adequately evaluating driving safety is a common and important problem for health care professionals. The purpose of this study was to examine the relationship between standardized measures of cognitive function and measures of driving performance in patients with closed head injuries and in their age-matched relative or friend cohorts. Thirteen patients were evaluated. They had each sustained a closed head injury (followed by more than 1 h of coma) 3 to 6 months before testing. Their scores were analyzed along with those of seven cohorts. Assessments of cognitive function and behind-the-wheel driving performance were conducted by examiners blinded to subjects' group membership and medical condition. There was a significant relationship (r = 0.44) between the sum of rated scores of the Tactual Performance Test and Trail Making Test and the global pass/fail ratings of the behind-the-wheel driving test, but it was not related to the driving performance score. The difference between the verbal and performance IQs, and the difference between the block design and other performance tests of the Wechsler Adult Intelligence Scale-Revised were also not significantly related to driving performance. These results suggest that tests of cognitive function alone are not adequate to predict driving performance, and should be used along with standardized driving performance evaluations before recommendations are made.	UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,SEATTLE,WA 98195	BROOKE, MM (corresponding author), TUFTS UNIV,SCH MED,DEPT REHABIL MED,136 HARRISON AVE,BOSTON,MA 02111, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR002570-03] Funding Source: Medline		COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; GALSKI T, 1990, AM J OCCUP THER, V44, P709, DOI 10.5014/ajot.44.8.709; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Halstead WC, 1985, HALSTEAD REITAN NEUR; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; SULLIVAN RA, 1975, PREDRIVING EVALUATIO; VANZOMEREN AH, 1988, ARCH PHYS MED REHAB, V69, P90; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	8	45	45	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	1992	71	3					177	182		10.1097/00002060-199206000-00009			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HY972	WOS:A1992HY97200009	1627283				2021-06-18	
J	RISLING, M; FRIED, K; LINDA, H; CULLHEIM, S; MEIER, M				RISLING, M; FRIED, K; LINDA, H; CULLHEIM, S; MEIER, M			CHANGES IN NERVE GROWTH-FACTOR RECEPTOR-LIKE IMMUNOREACTIVITY IN THE SPINAL-CORD AFTER VENTRAL FUNICULUS LESION IN ADULT CATS	JOURNAL OF NEUROCYTOLOGY			English	Article							ELECTRON-MICROSCOPIC OBSERVATIONS; HYALURONATE-BINDING PROTEIN; MOTOR-NEURON INJURY; SENSORY NEURONS; NEUROTROPHIC FACTOR; NGF-RECEPTOR; AXONAL REGENERATION; OPTIC-NERVE; RAT-BRAIN; PERIVASCULAR CELLS	Spinal motoneurons have a capability to regenerate CNS-type axons after intramedullary lesions in the adult cat. Regrowing axons have been traced through CNS-type scar tissue in the ventral funiculus of the spinal cord and into adjacent ventral root fascicles. This scar tissue, which appears to support and sustain regenerating axons, has been shown to have a persistent defect in the blood-brain barrier. It has been suggested that the blood-brain barrier may play a vital role in CNS regeneration by regulating the access of blood-borne trophic factors to the lesion area. In the present study, the binding of antibodies to the human nerve growth factor receptor in the cat spinal cord was examined with immunohistochemical methods 2 days to 8 weeks after a ventral funiculus lesion. The results show that, while no neurons in the ventral horn of the control material contained nerve growth factor receptor-like immunoreactivity as revealed by fluorescence microscopy, affected motoneurons expressed nerve growth factor receptor after ventral funiculus lesion. Nerve growth factor receptor-like immunoreactivity associated to both capillaries and interstitium was present in the scar tissue. Electron microscopic examination of sections labelled with the immunogold-silver method showed that perivascular nerve growth factor receptor-like immunoreactivity was located exclusively to non-pericytic perivascular cells. These cells were abundant in the expanded capillary perivascular spaces adjacent to the traumatic lesion. Similar cells, with or without relation to blood vessels, were observed in the scar tissue and in the pia mater. In a separate set of specimens it was observed that a ventral funiculus lesion combined with ventral root avulsion, which removes denervated PNS tissue, resulted in an expression of nerve growth factor receptor-like immunoreactivity which was similar to the one observed after ventral funiculus lesion only. The results of the present study show that affected motoneurons and cells in the scar tissue express nerve growth factor receptor after ventral funiculus lesion which implies that neurotrophic factors related to nerve growth factor may be of importance for the regenerative response.		RISLING, M (corresponding author), KAROLINSKA INST, DEPT ANAT, POB 60400, S-10401 STOCKHOLM 60, SWEDEN.						ALDERSON RF, 1990, NEURON, V5, P297, DOI 10.1016/0896-6273(90)90166-D; ALETTA JM, 1988, J CELL BIOL, V106, P1573, DOI 10.1083/jcb.106.5.1573; ALLEN SJ, 1989, J COMP NEUROL, V289, P626, DOI 10.1002/cne.902890408; BABA M, 1988, N-S ARCH PHARMACOL, V337, P423; BALIN BJ, 1986, J COMP NEUROL, V251, P260, DOI 10.1002/cne.902510209; BASBAUM AI, 1989, J HISTOCHEM CYTOCHEM, V37, P1811, DOI 10.1177/37.12.2479673; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BERRY M, 1988, BRAIN RES BULL, V20, P223, DOI 10.1016/0361-9230(88)90182-7; BIGNAMI A, 1988, EXP NEUROL, V100, P253, DOI 10.1016/0014-4886(88)90218-X; BROWN MC, 1991, NEURON, V6, P359, DOI 10.1016/0896-6273(91)90245-U; CARLSTEDT T, 1977, ACTA PHYSIOL SCAND, P5; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; CAVICCHIOLI L, 1989, EUR J NEUROSCI, V1, P258, DOI 10.1111/j.1460-9568.1989.tb00793.x; CULLHEIM S, 1989, NEUROSCIENCE, V29, P725, DOI 10.1016/0306-4522(89)90144-9; D'MELLO SR, 1990, J NEUROCHEM, V55, P718, DOI 10.1111/j.1471-4159.1990.tb04192.x; DAVID S, 1984, J NEUROCYTOL, V13, P961, DOI 10.1007/BF01148596; DAVID S, 1988, J NEUROCYTOL, V17, P131, DOI 10.1007/BF01735385; DISTEFANO PS, 1988, P NATL ACAD SCI USA, V85, P270, DOI 10.1073/pnas.85.1.270; DUNCAN D, 1948, TEX REP BIOL MED, V6, P461; ECKENSTEIN F, 1988, BRAIN RES, V446, P149, DOI 10.1016/0006-8993(88)91305-4; ERNFORS P, 1989, NEURON, V2, P1605, DOI 10.1016/0896-6273(89)90049-4; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; EVELETH DD, 1988, NEURON, V1, P929, DOI 10.1016/0896-6273(88)90150-X; FRANSON P, 1985, J COMP NEUROL, V231, P490, DOI 10.1002/cne.902310407; FRIED K, 1991, CELL TISSUE RES, V264, P321, DOI 10.1007/BF00313969; FRIED K, 1990, BRAIN RES, V536, P321, DOI 10.1016/0006-8993(90)90043-B; GAGE FH, 1988, EXP NEUROL, V102, P2, DOI 10.1016/0014-4886(88)90073-8; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GRAEBER MB, 1989, J NEUROSCI RES, V22, P103, DOI 10.1002/jnr.490220114; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HAGG T, 1991, EXP NEUROL, V112, P79, DOI 10.1016/0014-4886(91)90116-T; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1989, RECENT PROG HORM RES, V45, P441; HILDEBRAND C, 1985, J NEUROCYTOL, V14, P597, DOI 10.1007/BF01200800; HILDEBRAND C, 1976, J COMP NEUROL, V170, P191, DOI 10.1002/cne.901700205; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; JOHNSON EM, 1989, BRAIN RES, V478, P166, DOI 10.1016/0006-8993(89)91491-1; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; KIERNAN JA, 1979, BIOL REV, V54, P155, DOI 10.1111/j.1469-185X.1979.tb00871.x; KIERNAN JA, 1980, ACTA NEUROPATHOL, V51, P39, DOI 10.1007/BF00688848; KIERNAN JA, 1985, J ANAT, V141, P139; KOLIATSOS VE, 1991, BRAIN RES, V541, P121, DOI 10.1016/0006-8993(91)91084-E; KOLIATSOS VE, 1991, BRAIN RES, V549, P297, DOI 10.1016/0006-8993(91)90471-7; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534; LIESI P, 1988, DEV BIOL, V130, P774, DOI 10.1016/0012-1606(88)90366-1; LINDA H, 1990, BRAIN RES, V534, P352, DOI 10.1016/0006-8993(90)90157-7; LINDA H, 1985, BRAIN RES, V358, P329, DOI 10.1016/0006-8993(85)90978-3; LINDHOLM D, 1990, EUR J NEUROSCI, V2, P795, DOI 10.1111/j.1460-9568.1990.tb00471.x; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; LINDSAY RM, 1990, EUR J NEUROSCI, V2, P389, DOI 10.1111/j.1460-9568.1990.tb00431.x; LINDSAY RM, 1989, NEUROSCIENCE, V33, P53, DOI 10.1016/0306-4522(89)90310-2; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; MANNEN T, 1977, J NEUROL NEUROSUR PS, V40, P464, DOI 10.1136/jnnp.40.5.464; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MANTHORPE M, 1983, J CELL BIOL, V97, P1882, DOI 10.1083/jcb.97.6.1882; MARCHETTI D, 1990, J NEUROSCI RES, V27, P211, DOI 10.1002/jnr.490270211; MORGAN B, 1989, J NEUROSCI RES, V23, P41, DOI 10.1002/jnr.490230106; Peters A., 1976, FINE STRUCTURE NERVO; PIORO EP, 1990, NEUROSCIENCE, V34, P89, DOI 10.1016/0306-4522(90)90305-N; Priestley JV, 1984, IMMUNOLABELLING ELEC, P37; RAGSDALE C, 1991, NATURE, V350, P660, DOI 10.1038/350660a0; RAIVICH G, 1985, EMBO J, V4, P637, DOI 10.1002/j.1460-2075.1985.tb03677.x; Ramon y Cajal S, 1959, DEGENERATION REGENER; RICH KM, 1987, J NEUROCYTOL, V16, P261, DOI 10.1007/BF01795309; RISLING M, 1983, BRAIN RES, V280, P15, DOI 10.1016/0006-8993(83)91169-1; RISLING M, 1989, BRAIN RES, V494, P13, DOI 10.1016/0006-8993(89)90138-8; RISLING M, 1990, FERNS FOUND SERIES, V14, P555; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; SAIKA T, 1991, MOL BRAIN RES, V9, P157, DOI 10.1016/0169-328X(91)90142-K; SCHWAB ME, 1990, EXP NEUROL, V109, P2, DOI 10.1016/S0014-4886(05)80003-2; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SJOGREN A, 1991, BRAIN RES, V559, P276, DOI 10.1016/0006-8993(91)90012-K; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; STEPHANI U, 1987, J NEUROSCI RES, V17, P25, DOI 10.1002/jnr.490170105; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; THOMSON TM, 1988, EXP CELL RES, V174, P533, DOI 10.1016/0014-4827(88)90323-0; TSUDA T, 1990, INT ARCH ALLER A IMM, V91, P15, DOI 10.1159/000235083; VARNDELL IM, 1986, IMMUNOCYTOCHEMISTRY, P147; WADDELL WR, 1972, LANCET, V1, P1365; WOOD SJ, 1990, EUR J NEUROSCI, V2, P650, DOI 10.1111/j.1460-9568.1990.tb00454.x; YAN Q, 1989, J COMP NEUROL, V290, P585, DOI 10.1002/cne.902900411; YAN Q, 1988, NEURON, V1, P335; YAN Q, 1988, J NEUROSCI, V8, P3481; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUPAN AA, 1989, J BIOL CHEM, V264, P11714	90	45	45	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0300-4864			J NEUROCYTOL	J. Neurocytol.	FEB	1992	21	2					79	93		10.1007/BF01189007			15	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	HE544	WOS:A1992HE54400001	1313859				2021-06-18	
J	COELHO, CA; LILES, BZ; DUFFY, RJ				COELHO, CA; LILES, BZ; DUFFY, RJ			DISCOURSE ANALYSES WITH CLOSED HEAD INJURED ADULTS - EVIDENCE FOR DIFFERING PATTERNS OF DEFICITS	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						COMMUNICATIVE DISORDERS; HEAD INJURIES; LINGUISTICS; SPEECH DISORDERS; VERBAL BEHAVIOR		To better characterize the verbal impairments of higher level closed head injured (CHI) adults, we used narrative stories to longitudinally sample their discourse abilities. Stories were analyzed at the levels of intersentential cohesion and story grammar. Two differing patterns of deficits that emerged are described. In the first, a CHI subject demonstrated excessive verbalization characterized by poorly organized, but task-appropriate, content. In the second, a CHI subject demonstrated fair to good organization but little appropriate content. Prognostically, the presence of appropriate, although disorganized, content was an early indication that the subject was able to appreciate potential relationships of characters in the stimulus picture. The second pattern represented a more severe cognitive dysfunction. This subject's attempts at stories, although well organized, were merely elaborate descriptions of the picture. Discourse analyses appear to be well suited for the assessment of CHI adults.	UNIV CONNECTICUT,DEPT COMMUN SCI,STORRS,CT 06268	COELHO, CA (corresponding author), GAYLORD HOSP,DEPT COMMUN DISORDERS,POB 400,WALLINGFORD,CT 06492, USA.						COELHO CA, 1990, J PSYCHOLINGUIST RES, V19, P405, DOI 10.1007/BF01068887; HAGEN C, 1980, REHABILITATION HEAD, P8; Hunt K., 1970, MONOGRAPHS SOC RES C, V35; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53	7	45	46	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1991	72	7					465	468					4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FP702	WOS:A1991FP70200004	2059117				2021-06-18	
J	REHRER, NJ; MEIJER, GA				REHRER, NJ; MEIJER, GA			BIOMECHANICAL VIBRATION OF THE ABDOMINAL REGION DURING RUNNING AND BICYCLING	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article						GASTROINTESTINAL DISTRESS; RUNNING; BICYCLING		The incidence of gastrointestinal (GI) distress reported among long distance runners and not in practitioners of other sports with more gliding movements, such as bicycling, leads one to speculate that there is a difference in concussions and vibration of the GI region and that this may possibly be associated with the disparity in GI disorders. The present experiment was conducted to quantify the difference in vibration (accelerations/decelerations) of the GI region during running as compared to bicycling. An actometer was used which included a piezoelectric sensor. The sensor was placed on the abdomen of six subjects during identical trials of bicycling and running. Movement in three planes was detected by the sensor and recorded. The accelerometer output (AO) is an integral of these measurements. AO was used in making comparisons of the two types of movement, expressed as counts per minute. Mean AO was more than doubled in running, 859.5 +/- 130.1 (SD), versus bicycling, 425.8 +/- 149.5 (SD) (p < .0001). The common assumption that running results in more body vibrations than bicycling has been substantiated and quantified. Although the differences are large, it can only be speculated that these differences explain the high frequency of GI symptoms among runners.		REHRER, NJ (corresponding author), STATE UNIV LIMBURG,DEPT HUMAN BIOL,POB 616,6200 MD MAASTRICHT,NETHERLANDS.							0	45	45	0	6	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707			J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	JUN	1991	31	2					231	234					4	Sport Sciences	Sport Sciences	GH444	WOS:A1991GH44400018	1753730				2021-06-18	
J	PECHADRE, JC; LAUXEROIS, M; COLNET, G; COMMUN, C; DIMICOLI, C; BONNARD, M; GIBERT, J; CHABANNES, J				PECHADRE, JC; LAUXEROIS, M; COLNET, G; COMMUN, C; DIMICOLI, C; BONNARD, M; GIBERT, J; CHABANNES, J			PREVENTION OF LATE POSTTRAUMATIC EPILEPSY BY PHENYTOIN IN SEVERE BRAIN INJURIES - 2 YEARS FOLLOW-UP	PRESSE MEDICALE			French	Article						PHENYTOIN; EPILEPSY	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; PHARMACOLOGICAL PROPHYLAXIS; INTRAVENOUS PHENYTOIN; SEIZURES; CAT	The high incidence rate and the invalidating nature of post-traumatic epilepsy after severe brain injury have encouraged the authors to review the prophylactic treatment of this type of epilepsy. Thirty-four out of 86 randomised patients with brain injuries admitted into a neurotraumatology intensive care unit were treated prophylactically, immediately after the injury, with an intravenous hydantoin injection in a dose sufficient to provide stable and effective blood levels. This was followed by dose-adjusted oral administration maintained for a minimum period of 3 months. After a 2 years' follow-up, there was a significant difference between treated and untreated patients, since only 6 per cent of the patients treated suffered from post-traumatic epilepsy, as against 42 percent in the untreated group.	CTR HOSP REG & UNIV CLERMONT FERRAND HOTEL DIEU,SERV NEUROTRAUMATOL,F-63003 CLERMONT FERRAND,FRANCE; CTR HOSP REG & UNIV CLERMONT FERRAND,HOTEL DIEU,SERV ANESTHESIE REANIMAT,F-69003 CLERMONT FERRAND,FRANCE	PECHADRE, JC (corresponding author), CTR HOSP REG & UNIV CLERMONT FERRAND,HOTEL DIEU,SERV EXPLORAT FONCT SYST NERVEUX,BP 69,F-63003 CLERMONT FERRAND,FRANCE.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BRICOLO E, 1974, IL FRACASTORO, V67, P225; BUCHTHAL F, 1972, ANTIEPILEPTIC DRUGS, P193; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; COURJON J, 1966, CAH MED LYON, V42, P1343; CRANFORD RE, 1978, NEUROLOGY, V28, P874, DOI 10.1212/WNL.28.9.874; De Santis A, 1979, J Neurosurg Sci, V23, P207; EARNEST MP, 1983, JAMA-J AM MED ASSOC, V249, P762, DOI 10.1001/jama.249.6.762; GLAZKO AJ, 1972, ANTIEPILEPTIC DRUGS, P103; HAGEL KH, 1983, UNFALLHEILKUNDE, V86, P331; JANZ D, 1982, NERVENARZT, V53, P238; Jennett W. B., 1969, LATE EFFECTS HEAD IN, P201; KARBOWSKI K, 1981, SCHWEIZ RUNDSCH MED, V70, P1546; KUTT H, 1972, ANTIEPILEPTIC DRUGS, P211; LAUXEROIS M, 1990, EPILEPSIES, V2, P5; LAUXEROIS M, 1983, NEUROCHIRURGIE, V30, P241; LOCKARD JS, 1976, EPILEPSIA, V17, P37, DOI 10.1111/j.1528-1157.1976.tb03380.x; MAUGUIERE F, 1979, REV EEG NEUROPHYSIOL, V9, P149, DOI 10.1016/S0370-4475(79)80069-6; Mauguiere F, 1984, Rev Electroencephalogr Neurophysiol Clin, V14, P207, DOI 10.1016/S0370-4475(84)80006-4; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; MEIROWSKY AM, 1982, MIL MED, V147, P632; RAPPORT RL, 1975, ARCH NEUROL-CHICAGO, V32, P539, DOI 10.1001/archneur.1975.00490500059007; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SERVIT Z, 1972, 4TH P EUR C NEUR AMS; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; TURNER IM, 1977, ANN NEUROL, V2, P221, DOI 10.1002/ana.410020307; VANDERVELDE GA, 1972, CHEM PHYS LETT, V13, P409, DOI 10.1016/0009-2614(72)80112-X; WADA JA, 1976, ARCH NEUROL-CHICAGO, V33, P426, DOI 10.1001/archneur.1976.00500060032008; WOHNS RNW, 1979, J NEUROSURG, V51, P507, DOI 10.3171/jns.1979.51.4.0507; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1979, EPILEPSIA, V20, P671, DOI 10.1111/j.1528-1157.1979.tb04851.x	32	45	48	1	2	MASSON EDITEUR	PARIS 06	120 BLVD SAINT-GERMAIN, 75280 PARIS 06, FRANCE	0755-4982			PRESSE MED	Presse Med.	MAY 11	1991	20	18					841	845					5	Medicine, General & Internal	General & Internal Medicine	FM026	WOS:A1991FM02600006	1829177				2021-06-18	
J	SPETTELL, CM; ELLIS, DW; ROSS, SE; SANDEL, ME; OMALLEY, KF; STEIN, SC; SPIVACK, G; HURLEY, KE				SPETTELL, CM; ELLIS, DW; ROSS, SE; SANDEL, ME; OMALLEY, KF; STEIN, SC; SPIVACK, G; HURLEY, KE			TIME OF REHABILITATION ADMISSION AND SEVERITY OF TRAUMA - EFFECT ON BRAIN INJURY OUTCOME	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; GLASGOW OUTCOME SCALE; HEAD INJURIES; HOSPITALIZATION; MULTIPLE TRAUMA; REHABILITATION	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; PROGNOSIS	Outcome after traumatic brain injury, defined by the Glasgow Outcome Scale (GOS) and length of stay in acute rehabilitation, was measured in 59 patients admitted to an intensive rehabilitation program to examine the effects of severity of the initial brain injury, severity of multiple trauma, and length of stay in the acute care hospital. Severity of initial brain injury, best measured by length of coma, was the most significant predictor of GOS outcome. Length of acute hospitalization was a small, but significant, predictor of GOS. Severity of initial brain injury, length of acute hospitalization, and gender emerged as predictors of length of rehabilitation hospital stay. Although length of acute hospitalization is apparently affected by severity of brain injury, it adds significantly - more than severity of brain injury - to the prediction of length of rehabilitation.	COOPER HOSP UNIV MED CTR,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ	SPETTELL, CM (corresponding author), MEDIPLEX REHAB CAMDEN,INST BRAIN INJURY RES & TRAINING,2 COOPER PLAZA,CAMDEN,NJ 08103, USA.						ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; BERGMAN TA, 1987, MINN MED, V70, P397; BLACK P, 1975, OUTCOME SEVERE DAMAG, P65; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; EDWARDS AL, 1972, EXPT PSYCHOL RES; EISENBERG HM, 1987, NEUROBEHAVIORAL RECO, P13; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; GIANNOTTA SL, 1987, HEAD INJURY, P464; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Jones C, 1981, J Neurosurg Nurs, V13, P178; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; KRAUS JF, 1987, HEAD INJURY, P1; Levin H., 1987, HEAD INJURY, P442; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MAYER T, 1981, CHILD BRAIN, V8, P189; OVERGAARD J, 1973, LANCET, V2, P631; PAZZAGLIA D, 1975, J NEUROL NEUROSUR PS, V38, P149; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rosenzwelg M., 1980, RECOVERY FUNCTION TH, P127; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STEIN DG, 1974, PLASTICITY RECOVERY, P373; TEASDALE G, 1974, LANCET, V2, P81; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; YU J, 1976, ARCH PHYS MED REHAB, V57, P38; 1985, ABBREVIATED INJURY S	37	45	46	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1991	72	5					320	325					6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FF342	WOS:A1991FF34200011	2009049				2021-06-18	
J	ERB, DE; POVLISHOCK, JT				ERB, DE; POVLISHOCK, JT			NEUROPLASTICITY FOLLOWING TRAUMATIC BRAIN INJURY - A STUDY OF GABAERGIC TERMINAL LOSS AND RECOVERY IN THE CAT DORSAL LATERAL VESTIBULAR NUCLEUS	EXPERIMENTAL BRAIN RESEARCH			English	Article						BRAIN TRAUMA; DEGENERATION; NEUROPLASTICITY; GABAERGIC SYNAPSES; CAT	FLUID-PERCUSSION INJURY; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; DENTATE GYRUS; SPINAL-CORD; ENTORHINAL LESIONS; RAT-BRAIN; REINNERVATION; DAMAGE; DECARBOXYLASE	Terminal loss and recovery were assessed in the cat dorsal lateral vestibular nucleus (dLVN) following diffuse axonal damage caused by experimental traumatic brain injury. Using sterile technique, anesthetized adult cats received a moderate fluid-percussion traumatic brain injury. After predetermined survival periods of 7-368 days, the animals were perfused and the dLVN prepared for the immunocytochemical visualization of GABAergic puncta/terminals at the light (LM) and electron (EM) microscopic levels. In controls, the Deiters' neuronal somata within the dLVN were encompassed by numerous GABA-immunoreactive puncta/terminals. Within 7 days of injury, axonal damage was seen scattered throughout the dLVN, and associated with this, some neuronal somata demonstrated a dramatic loss of perisomatic GABA-immunoreactive puncta, while other somata appeared unchanged. Ultrastructural examination demonstrated that the loss of immunoreactive puncta observed with LM was directly correlated with the presence of degenerating GABAergic terminals. Overall, these neuronal somata showed a reduction of perisomatic puncta/terminals to values approximately 25% of controls. Over a thirty day posttraumatic course, this pattern of scattered perisomatic puncta/terminal loss persisted, with some puncta/terminal return by 60 days postinjury. During the next six months, a recovery of the immunoreactive puncta/terminals was observed in relation to the deafferented somata, with perisomatic terminal numbers now reaching 75% of control values. Over the 7 to 12 month postinjury period, recovery continued, with virtually complete recovery observed in the later phases of this period. Importantly, throughout this recovery period, there was a consistent correlation between the light and electron microscopic findings. The observed diffuse pattern of terminal loss, followed a prolonged adaptive recovery process, suggests that traumatic injury with its attendant diffuse axonal injury and related diffuse deafferentation creates a unique environment for rather complete and adaptive synaptic recovery. As diffuse axonal injury is a common feature of human traumatic brain injury, we believe that these studies, performed in cat, help explain some of the initial morbidity as well as some of the partial recovery seen in head-injured man.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,BOX 709,MCV STN,RICHMOND,VA 23298					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-07288, NS-20193] Funding Source: Medline		ADAMS J, 1980, J CLIN PATHOL, V33, P2231; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BERNSTEIN JJ, 1973, BRAIN BEHAV EVOLUT, V8, P135, DOI 10.1159/000124351; BREGMAN BS, 1982, SCIENCE, V217, P553, DOI 10.1126/science.7089581; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FONNUM F, 1970, BRAIN RES, V20, P259, DOI 10.1016/0006-8993(70)90293-3; GAGE FH, 1983, BRAIN RES, V268, P27, DOI 10.1016/0006-8993(83)90387-6; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HOUSER CR, 1984, NEUROSCI LETT, V47, P213, DOI 10.1016/0304-3940(84)90516-0; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; KATSUMARU H, 1986, J NEUROSCI, V6, P2864; LEVIN H, 1986, J NEUROSURG, V74, P132; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LYNCH G, 1972, BRAIN RES, V42, P311, DOI 10.1016/0006-8993(72)90533-1; Marmarou A, 1990, Adv Neurol, V52, P233; MATTHEWS DA, 1976, BRAIN RES, V115, P23, DOI 10.1016/0006-8993(76)90820-9; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; NYGREN LG, 1974, BRAIN RES, V78, P377, DOI 10.1016/0006-8993(74)90922-6; OTTERSEN OP, 1984, J COMP NEUROL, V229, P374, DOI 10.1002/cne.902290308; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PICKEL VM, 1973, BRAIN RES, V59, P169, DOI 10.1016/0006-8993(73)90258-8; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; POVLISHOCK JT, 1982, NEURAL TRAUMA SEMINA, P15; RAISMAN G, 1973, BRAIN RES, V50, P241, DOI 10.1016/0006-8993(73)90729-4; RAISMAN G, 1969, BRAIN RES, V14, P25, DOI 10.1016/0006-8993(69)90029-8; STEWARD O, 1976, BRAIN RES, V114, P181, DOI 10.1016/0006-8993(76)90665-X; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; STEWARD O, 1976, SCIENCE, V194, P426, DOI 10.1126/science.982024; STORMMATHISEN J, 1976, GABA NERVOUS SYSTEM, P149; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WALBERG F, 1961, EXP NEUROL, V3, P32, DOI 10.1016/0014-4886(61)90005-X; WALBERG F, 1990, EXP BRAIN RES, V79, P547; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	48	45	46	0	1	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0014-4819			EXP BRAIN RES	Exp. Brain Res.		1991	83	2					253	267					15	Neurosciences	Neurosciences & Neurology	EV505	WOS:A1991EV50500002	2022238				2021-06-18	
J	JENSEN, OK; NIELSEN, FF				JENSEN, OK; NIELSEN, FF			THE INFLUENCE OF SEX AND PRE-TRAUMATIC HEADACHE ON THE INCIDENCE AND SEVERITY OF HEADACHE AFTER HEAD-INJURY	CEPHALALGIA			English	Article							CONCUSSION	Pre- and post-traumatic headache of 168 individuals aged 18-60 years was registered 9-12 months after a head trauma. Headache before the trauma was reported by 39.9%, women being in the majority. After the trauma 64.3% were suffering from headache. Post-traumatic headache was reported by 64 patients (38.1%), of whom 22 patients experienced an increase of already existing headache and 42 patients complained of new headache. Patients suffering from headache before the trauma were not more at risk of having post-traumatic headache than patients who did not suffer from headache before the trauma. Patients who experienced an increase of already-existing pre-traumatic headache used more analgesics than patients first suffering from headache after the trauma. Post-traumatic headache was reported by more women than men (p < 0.02), the corresponding relative risk being 1.6. Both the use of analgesics and the frequency of headache showed a significant increase for patients with post-traumatic headache when compared with a "control group" of 41 patients with unchanged headache and when compared with all patients with headache before the trauma. There was no significant difference in the location of pain between the groups analysed.	AARHUS UNIV, CTY HOSP, DEPT ORTHOPAED SURG, DK-8000 AARHUS, DENMARK; AARHUS UNIV, CTY HOSP, DEPT RHEUMATOL, DK-8000 AARHUS, DENMARK			Jensen, Ole Kudsk/R-8957-2019	Jensen, Ole Kudsk/0000-0001-8196-5661			Cartlidge N E, 1981, HEAD INJURY; Dalsgaard-Nielsen T, 1970, Headache, V10, P14, DOI 10.1111/j.1526-4610.1970.hed1001014.x; FRIEDMAN AP, 1969, LATE EFFECTS HEAD IN, P55; JENSEN OK, IN PRESS OPEN STUDY; JENSEN OK, IN PRESS RELATION PO; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Peatfield R, 1986, HEADACHE; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; WILKINSON M, 1980, UPSALA J MED SCI, P48	10	45	45	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	DEC	1990	10	6					285	293		10.1046/j.1468-2982.1990.1006285.x			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EU540	WOS:A1990EU54000003	2289229				2021-06-18	
J	WISNER, D; BUSCHE, F; STURM, J; GAAB, M; MEYER, H				WISNER, D; BUSCHE, F; STURM, J; GAAB, M; MEYER, H			TRAUMATIC SHOCK AND HEAD-INJURY - EFFECTS OF FLUID RESUSCITATION ON THE BRAIN	JOURNAL OF SURGICAL RESEARCH			English	Article									HANOVER UNIV MED,DEPT NEUROSURG,D-3000 HANOVER 61,FED REP GER; HANOVER UNIV MED,DEPT TRAUMA SURG,D-3000 HANOVER 61,FED REP GER	WISNER, D (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT SURG,SACRAMENTO,CA 95817, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007860] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5T32 GM07860-05] Funding Source: Medline		ALBRIGHT AL, 1984, J NEUROSURG, V60, P481, DOI 10.3171/jns.1984.60.3.0481; ALBRIGHT AL, 1982, ACTA NEUROCHIR, V60, P257, DOI 10.1007/BF01406311; ARTURSON G, 1961, Acta Chir Scand Suppl, VSuppl 274, P1; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BLASBERG RG, 1976, DYNAMICS BRAIN EDEMA, P98; DELOSREYES RA, 1980, CLIN NEUROSURG, V28, P98; Fenstermacher J, 1976, DYNAMICS BRAIN EDEMA, P87; FENSTERMACHER JD, 1966, AM J PHYSIOL, V211, P341; GARBOW JD, 1984, AM J PUBLIC HEALTH, V74, P710; GARDNER AE, 1971, ANESTHESIOLOGY, V35, P226, DOI 10.1097/00000542-197108000-00029; GO KG, 1981, BRAIN EDEMA, P3; GORIS RJA, 1982, J TRAUMA, V22, P141, DOI 10.1097/00005373-198202000-00011; GURDJIAN ES, 1978, SURG GYNECOL OBSTET, V146, P805; GUYTON AC, 1982, HUMAN PHYSL MECHANIS, P30; JUPAMARCINKOWSK.V, 1981, BRAIN EDEMA, P155; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KLATZO I, 1972, STEROIDS BRAIN EDEMA, P1; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KNOBLICH OE, 1979, EXP NEUROL, V66, P30, DOI 10.1016/0014-4886(79)90060-8; KWAPINSKI JB, 1965, METHODS SEROLOGICAL, P168; Lentner C, 1984, GEIGY SCI TABLES, V3, P78; LEVISON M, 1982, SURG CLIN N AM, V62, P9; MARTYN JAJ, 1979, CHEST, V76, P374, DOI 10.1378/chest.76.4.374; Meeh K., 1879, Z BIOL, V15, P425; ODOM GL, 1981, DAVISCHRISTOPHER TXB, P1484; PAPPIUS HM, 1965, ARCH NEUROL-CHICAGO, V13, P395, DOI 10.1001/archneur.1965.00470040061010; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PRUITT BA, 1978, SURG CLIN N AM, V58, P1291; REULEN HJ, 1981, BRAIN EDEMA, P31; SCHMIDT K, 1972, HIRNKREISLAUF, P715; SHAPIRO HM, 1973, BRIT J ANAESTH, V45, P1057, DOI 10.1093/bja/45.10.1057; SHIRES GT, 1985, PRINCIPLES TRAUMA CA, P3; SMITH AL, 1977, ANESTHESIOLOGY, V47, P285, DOI 10.1097/00000542-197709000-00010; SMITH SD, 1982, J TRAUMA, V22, P588, DOI 10.1097/00005373-198207000-00011; SNEDECOR GW, 1967, STATISTICAL METHODS, P91; STURM JA, 1985, TRAUMATISCHER SCHOCK, P32; TOMMASINO C, 1982, Anesthesiology (Hagerstown), V57, pA109, DOI 10.1097/00000542-198209001-00109; TRANBAUGH RF, 1984, SURG GYNECOL OBSTET, V158, P193; TRUNKEY DD, 1983, SCI AM, V249, P20; WARD RE, 1981, RADIOL CLIN N AM, V19, P3; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021; YOUNG EG, 1963, COMPREHENSIVE BIOCH, P1; 1977, STANDARD MED ALMANAC, P488	44	45	46	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0022-4804			J SURG RES	J. Surg. Res.	JAN	1989	46	1					49	59		10.1016/0022-4804(89)90181-9			11	Surgery	Surgery	R9450	WOS:A1989R945000009	2915535				2021-06-18	
J	Shin, J; Liu, ZH; Bai, WB; Liu, YH; Yan, Y; Xue, YG; Kandela, I; Pezhouh, M; MacEwan, MR; Huang, YG; Ray, WZ; Zhou, WD; Rogers, JA				Shin, Jiho; Liu, Zhonghe; Bai, Wubin; Liu, Yonghao; Yan, Ying; Xue, Yeguang; Kandela, Irawati; Pezhouh, Maryam; MacEwan, Matthew R.; Huang, Yonggang; Ray, Wilson Z.; Zhou, Weidong; Rogers, John A.			Bioresorbable optical sensor systems for monitoring of intracranial pressure and temperature	SCIENCE ADVANCES			English	Article							SILICON NANOMEMBRANES; FIBER; ELECTRONICS; DISSOLUTION; CHALLENGES; LAYERS	Continuous measurements of pressure and temperature within the intracranial, intraocular, and intravascular spaces provide essential diagnostic information for the treatment of traumatic brain injury, glaucoma, and cardiovascular diseases, respectively. Optical sensors are attractive because of their inherent compatibility with magnetic resonance imaging (MRI). Existing implantable optical components use permanent, nonresorbable materials that must be surgically extracted after use. Bioresorbable alternatives, introduced here, bypass this requirement, thereby eliminating the costs and risks of surgeries. Here, millimeter-scale bioresorbable Fabry-Perot interferometers and two dimensional photonic crystal structures enable precise, continuous measurements of pressure and temperature. Combined mechanical and optical simulations reveal the fundamental sensing mechanisms. In vitro studies and histopathological evaluations quantify the measurement accuracies, operational lifetimes, and biocompatibility of these systems. In vivo demonstrations establish clinically relevant performance attributes. The materials, device designs, and fabrication approaches outlined here establish broad foundational capabilities for diverse classes of bioresorbable optical sensors.	[Shin, Jiho] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA; [Shin, Jiho] Univ Illinois, Frederick Seitz Mat Res Lab, Urbana, IL 61801 USA; [Liu, Zhonghe; Liu, Yonghao; Zhou, Weidong] Univ Texas Arlington, Dept Elect Engn, Arlington, TX 76019 USA; [Bai, Wubin; Xue, Yeguang; Huang, Yonggang; Rogers, John A.] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA; [Bai, Wubin; Rogers, John A.] Northwestern Univ, Ctr Biointegrated Elect, Evanston, IL 60208 USA; [Yan, Ying; MacEwan, Matthew R.; Ray, Wilson Z.] Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; [Xue, Yeguang; Huang, Yonggang] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA; [Xue, Yeguang; Huang, Yonggang] Northwestern Univ, Dept Civil & Environm Engn, Evanston, IL 60208 USA; [Kandela, Irawati] Northwestern Univ, Dev Therapeut Core, Evanston, IL 60208 USA; [Pezhouh, Maryam] Northwestern Univ, Feinberg Sch Med, Northwestern Med, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Biomed Engn, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Chem, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Mech Engn Elect Engn & Comp Sci, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Neurol Surg, Evanston, IL 60208 USA; [Rogers, John A.] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA	Zhou, WD (corresponding author), Univ Texas Arlington, Dept Elect Engn, Arlington, TX 76019 USA.; Rogers, JA (corresponding author), Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Ctr Biointegrated Elect, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Biomed Engn, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Chem, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Mech Engn Elect Engn & Comp Sci, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, McCormick Sch Engn, Simpson Querrey Inst Nano Biotechnol, Dept Neurol Surg, Evanston, IL 60208 USA.; Rogers, JA (corresponding author), Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA.	wzhou@uta.edu; jrogers@northwestern.edu	Huang, Yonggang/B-6998-2009; Xue, Yeguang/B-8696-2015; Rogers, John/L-2798-2016; Bai, Wubin/AAG-2382-2020	Xue, Yeguang/0000-0002-1968-5092; Bai, Wubin/0000-0003-2872-5559; Liu, Zhonghe/0000-0002-9629-110X; Kandela, Irawati/0000-0002-8646-9357	Ryan Fellowship; Northwestern University International Institute for Nanotechnology; Cancer Center Support grant (National Cancer Institute) [P30 CA060553]; NSFNational Science Foundation (NSF) [1635443]; NSF PFI programNational Science Foundation (NSF)NSF - Directorate for Engineering (ENG) [IIP-1827693]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA060553] Funding Source: NIH RePORTER	Y.X. acknowledges support from the Ryan Fellowship and the Northwestern University International Institute for Nanotechnology. I.K. acknowledges support from Cancer Center Support grant no. P30 CA060553 (National Cancer Institute) awarded to the Robert H. Lurie Comprehensive Cancer Center. Y.H. acknowledges support from the NSF (grant no. 1635443). W.Z. and J.A.R. acknowledge support from the NSF PFI program (grant no. IIP-1827693).	Annese VF, 2014, IEEE I C ELECT CIRC, P598, DOI 10.1109/ICECS.2014.7050056; Bai WB, 2018, ADV MATER, V30, DOI 10.1002/adma.201801584; Bhat YM, 2013, GASTROINTEST ENDOSC, V78, P209, DOI 10.1016/j.gie.2013.04.166; Boutry CM, 2018, NAT ELECTRON, V1, P314, DOI 10.1038/s41928-018-0071-7; Boutry CM, 2015, ADV MATER, V27, P6954, DOI 10.1002/adma.201502535; Boutry CM, 2012, PHILOS T R SOC A, V370, P2418, DOI 10.1098/rsta.2011.0439; Chamis AL, 2001, CIRCULATION, V104, P1029, DOI 10.1161/hc3401.095097; Choi M, 2015, ADV MATER, V27, P4081, DOI 10.1002/adma.201501603; Fang H, 2016, P NATL ACAD SCI USA, V113, P11682, DOI 10.1073/pnas.1605269113; Franta D, 2018, J APPL PHYS, V123, DOI 10.1063/1.5026195; Fu RX, 2018, ADV OPT MATER, V6, DOI 10.1002/adom.201700941; Ge YX, 2013, OPTIK, V124, P6946, DOI 10.1016/j.ijleo.2013.05.156; Gentile P, 2014, INT J MOL SCI, V15, P3640, DOI 10.3390/ijms15033640; Hall-Stoodley L, 2004, NAT REV MICROBIOL, V2, P95, DOI 10.1038/nrmicro821; Hecht E., 2002, OPTICS; Hwang SW, 2015, NANO LETT, V15, P2801, DOI 10.1021/nl503997m; Hwang SW, 2014, ADV MATER, V26, P3905, DOI 10.1002/adma.201306050; Hwang SW, 2012, SCIENCE, V337, P1640, DOI 10.1126/science.1226325; Jiang GQ, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/neuro.20.002.2010; Joannopoulos John, 2002, PHOTONIC CRYSTALS RO; Jung IW, 2009, IEEE LEOS ANN MTG, P761, DOI 10.1109/LEOS.2009.5343346; Kang SK, 2016, NATURE, V530, P71, DOI 10.1038/nature16492; Kang SK, 2015, ADV FUNCT MATER, V25, P1789, DOI 10.1002/adfm.201403469; Kang SK, 2014, ADV FUNCT MATER, V24, P4427, DOI 10.1002/adfm.201304293; Karrock T, 2015, BIOMED OPT EXPRESS, V6, P4901, DOI 10.1364/BOE.6.004901; Lee G, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201700157; Lee YK, 2017, ACS NANO, V11, P12562, DOI 10.1021/acsnano.7b06697; Leviton D. B., 2006, SPIE ASTRONOMICAL TE, V6273, P11; Li M, 2006, OPT EXPRESS, V14, P1497, DOI 10.1364/OE.14.001497; Liu V, 2012, COMPUT PHYS COMMUN, V183, P2233, DOI 10.1016/j.cpc.2012.04.026; Liu YH, 2017, OPT EXPRESS, V25, P10536, DOI 10.1364/OE.25.010536; Lu YR, 2011, PROC IEEE MICR ELECT, P621, DOI 10.1109/MEMSYS.2011.5734501; Luo MD, 2014, J MICROELECTROMECH S, V23, P4, DOI 10.1109/JMEMS.2013.2290111; Newcombe VFJ, 2008, J NEUROSURG, V109, P159, DOI 10.3171/JNS/2008/109/7/0159; Nizamoglu S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10374; Park B, 2011, IEEE SENS J, V11, P2643, DOI 10.1109/JSEN.2011.2153844; Phang I, 2016, SPINE, V41, pE605, DOI 10.1097/BRS.0000000000001334; Poeggel S, 2015, SENSORS-BASEL, V15, P17115, DOI 10.3390/s150717115; Rodriguez DAA, 2015, MED ENG PHYS, V37, P100, DOI 10.1016/j.medengphy.2014.11.004; Roguin A, 2008, EUROPACE, V10, P334, DOI 10.1093/europace/eun021; Shan DY, 2017, BIOMATERIALS, V143, P142, DOI 10.1016/j.biomaterials.2017.08.003; Shin JH, 2019, NAT BIOMED ENG, V3, P37, DOI 10.1038/s41551-018-0300-4; Sit AJ, 2009, J GLAUCOMA, V18, P272, DOI 10.1097/IJG.0b013e3181862490; Taffoni F, 2013, SENSORS-BASEL, V13, P14105, DOI 10.3390/s131014105; Vanhoestenberghe A, 2009, SENSOR REV, V29, P345, DOI 10.1108/02602280910986593; Watanabe H, 2004, INT J THERMOPHYS, V25, P221, DOI 10.1023/B:IJOT.0000022336.83719.43; Williams EJ, 1999, J NEUROSURG, V91, P706, DOI 10.3171/jns.1999.91.4.0706; Wu X, 2015, J MICROELECTROMECH S, V24, P968, DOI 10.1109/JMEMS.2014.2360859; Yin L, 2015, ADV MATER, V27, P1857, DOI 10.1002/adma.201404579; Yu KJ, 2016, NAT MATER, V15, P782, DOI [10.1038/NMAT4624, 10.1038/nmat4624]; Yu L, 2014, SENSORS-BASEL, V14, P20620, DOI 10.3390/s141120620; Zhou WD, 2014, PROG QUANT ELECTRON, V38, P1, DOI 10.1016/j.pquantelec.2014.01.001	52	44	46	17	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	2375-2548			SCI ADV	Sci. Adv.	JUL	2019	5	7							eaaw1899	10.1126/sciadv.aaw1899			12	Multidisciplinary Sciences	Science & Technology - Other Topics	IN6EO	WOS:000478770400055	31281889	DOAJ Gold, Green Published			2021-06-18	
J	Williams, AM; Dennahy, IS; Bhatti, UF; Halaweish, I; Xiong, Y; Chang, PP; Nikolian, VC; Chtraklin, K; Brown, J; Zhang, YL; Zhang, ZG; Chopp, M; Buller, B; Alam, HB				Williams, Aaron M.; Dennahy, Isabel S.; Bhatti, Umar F.; Halaweish, Ihab; Xiong, Ye; Chang, Panpan; Nikolian, Vahagn C.; Chtraklin, Kiril; Brown, Jordana; Zhang, Yanlu; Zhang, Zheng Gang; Chopp, Michael; Buller, Benjamin; Alam, Hasan B.			Mesenchymal Stem Cell-Derived Exosomes Provide Neuroprotection and Improve Long-Term Neurologic Outcomes in a Swine Model of Traumatic Brain Injury and Hemorrhagic Shock	JOURNAL OF NEUROTRAUMA			English	Article						exosomes; hemorrhagic shock; mesenchymal stem cells; traumatic brain injury	MARROW STROMAL CELLS; NEUROVASCULAR PLASTICITY; EXTRACELLULAR VESICLES; FUNCTIONAL RECOVERY; VALPROIC ACID; RATS; MICROVESICLES; DELIVERY; BENEFIT	Combined traumatic brain injury (TBI) and hemorrhagic shock (HS) remains a leading cause of preventable death worldwide. Mesenchymal stem cell-derived exosomes have demonstrated promise in small animal models of neurologic injury. To investigate the effects of exosome treatment in a clinically realistic large animal model, Yorkshire swine underwent TBI and HS. Animals were maintained in shock for 2 h before resuscitation with normal saline (NS). Animals were then resuscitated either with NS (3 x volume of shed blood) or with the same volume of NS with delayed exosome administration (1 x 10(13) particles/4 mL) (n = 5/cohort). Exosomes were administered 9 h post-injury, and on post-injury days (PID) 1, 5, 9, and 13. Neurologic severity scores (NSS) were assessed for 30 days, and neurocognitive functions were objectively measured. Exosome-treated animals had significantly lower NSS (p < 0.05) during the first five days of recovery. Exosome-treated animals also had a significantly shorter time to complete neurologic recovery (NSS = 0) compared with animals given NS alone (days to recovery: NS = 16.8 +/- 10.6; NS + exosomes = 5.6 +/- 2.8; p = 0.03). Animals treated with exosomes initiated neurocognitive testing earlier (days to initiation: NS = 9.6 +/- 0.5 vs. NS + exosomes = 4.2 +/- 0.8; p = 0.008); however, no difference was seen in time to mastery of tasks. In conclusion, treatment with exosomes attenuates the severity of neurologic injury and allows for faster neurologic recovery in a clinically realistic large animal model of TBI and HS.	[Williams, Aaron M.; Dennahy, Isabel S.; Bhatti, Umar F.; Halaweish, Ihab; Chang, Panpan; Nikolian, Vahagn C.; Chtraklin, Kiril; Brown, Jordana; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Xiong, Ye; Zhang, Yanlu] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael; Buller, Benjamin] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Alam, HB (corresponding author), Univ Michigan Hosp, Dept Surg, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Xiong, Ye/0000-0001-9770-6031			Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Chaput N, 2011, SEMIN IMMUNOPATHOL, V33, P419, DOI 10.1007/s00281-010-0233-9; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Dorayappan KDP, 2016, GYNECOL ONCOL, V142, P199, DOI 10.1016/j.ygyno.2016.03.036; Faul M XL, 2010, TRAUMATIC BRAIN INJU; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Kalani A, 2014, MOL NEUROBIOL, V49, P590, DOI 10.1007/s12035-013-8544-1; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Lee C, 2012, CIRCULATION, V126, P2601, DOI 10.1161/CIRCULATIONAHA.112.114173; Lener T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.30087; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Nikolian VC, 2017, J TRAUMA ACUTE CARE, V83, P1066, DOI 10.1097/TA.0000000000001612; Ohno S, 2013, ADV DRUG DELIVER REV, V65, P398, DOI 10.1016/j.addr.2012.07.019; Phinney DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9472; Pischiutta F, 2014, NEUROPHARMACOLOGY, V79, P119, DOI 10.1016/j.neuropharm.2013.11.001; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Sun DM, 2010, MOL THER, V18, P1606, DOI 10.1038/mt.2010.105; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yang YX, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00055; Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001; Zhang B, 2014, STEM CELLS DEV, V23, P1233, DOI 10.1089/scd.2013.0479; Zhang L, 2013, CELL TRANSPLANT, V22, P1569, DOI 10.3727/096368912X658674; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhu W, 2012, CANCER LETT, V315, P28, DOI 10.1016/j.canlet.2011.10.002	39	44	45	5	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2019	36	1					54	60		10.1089/neu.2018.5711			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HF0PB	WOS:000453863000005	29690826	Bronze	Y	N	2021-06-18	
J	Seabury, SA; Gaudette, E; Goldman, DR; Markowitz, AJ; Brooks, J; McCrea, MA; Okonkwo, DO; Manley, GT				Seabury, Seth A.; Gaudette, Etienne; Goldman, Dana R.; Markowitz, Amy J.; Brooks, Jordan; McCrea, Michael A.; Okonkwo, David O.; Manley, Geoffrey T.		TRACK-TBI Investigators	Assessment of Follow-up Care After Emergency Department Presentation for Mild Traumatic Brain Injury and Concussion Results From the TRACK-TBI Study	JAMA NETWORK OPEN			English	Article							HEAD COMPUTED-TOMOGRAPHY; EARLY INTERVENTION; UNITED-STATES; UTILITY; HOSPITALIZATION; KNOWLEDGE; OUTCOMES; DEATHS; VISITS; IMPACT	IMPORTANCE Mild traumatic brain injury (mTBI) affects millions of Americans each year. Lack of consistent clinical practice raises concern that many patients with mTBI may not receive adequate follow-up care. OBJECTIVE To characterize the provision of follow-up care to patients with mTBI during the first 3 months after injury. DESIGN, SETTING, AND PARTICIPANTS This cohort study used data on patients with mTBI enrolled in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study between February 26, 2014, and August 25, 2016. We examined site-specific variations in follow-up care, the types of clinicians seen by patients receiving follow-up care, and patient and injury characteristics associated with a higher likelihood of receiving follow-up care. The TRACK-TBI study is a prospective, multicenter, longitudinal observational study of patients with TBI presenting to the emergency department of 1 of 11 level I US trauma centers. Study data included patients with head trauma who underwent a computed tomography (CT) scan within 24 hours of injury, had a Glasgow Coma Scale score of 13 to 15, were aged 17 years or older, and completed follow-up care surveys at 2 weeks and 3 months after injury (N = 831). MAIN OUTCOMES AND MEASURES Follow-up care was defined as hospitals providing TBI educational material at discharge, hospitals calling patients to follow up, and patients seeing a physician or other medical practitioner within 3 months after the injury. Unfavorable outcomes were assessed with the Rivermead Post Concussion Symptoms Questionnaire. RESULTS Of 831 patients (289 [35%) female; 483 [58%) non-Hispanic white; mean [SD] age, 40.3 [16.9] years), less than half self-reported receiving TBI educational material at discharge (353 patients [42%]) or seeing a physician or other health care practitioner within 3 months after injury (367 patients [44%)). Follow-up care varied by study site: adjusting for patient characteristics, the provision of educational material varied from 19% to 72% across sites. Of 236 patients with a positive finding on a CT scan, 92 (39%) had not seen a medical practitioner 3 months after the injury. Adjusting for injury severity and demographics, patient admission to the hospital ward or intensive care unit, patient income, and insurance status were not associated with the probability of seeing a medical practitioner. Among the patients with 3 or more moderate to severe postconcussive symptoms, only 145 of 279 (52%) reported having seen a medical practitioner by 3 months. CONCLUSIONS AND RELEVANCE There are gaps in follow-up care for patients with mTBI after hospital discharge, even those with a positive finding on CT or who continue to experience postconcussive symptoms.	[Seabury, Seth A.] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA; [Seabury, Seth A.] Univ Southern Calif, Keck Sch Med, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90089 USA; [Gaudette, Etienne; Goldman, Dana R.] Univ Southern Calif, Sch Pharm, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90089 USA; [Goldman, Dana R.] Univ Southern Calif, Leonard D Schaeffer Ctr Hlth Policy & Econ, Price Sch Publ Policy, Los Angeles, CA 90089 USA; [Markowitz, Amy J.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Brooks, Jordan; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA	Seabury, SA (corresponding author), Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA.; Seabury, SA (corresponding author), Univ Southern Calif, Keck Sch Med, Leonard D Schaeffer Ctr Hlth Policy & Econ, Los Angeles, CA 90089 USA.	seabury@usc.edu	Yue, John K/P-1348-2015; Goldman, Dana P/E-7667-2013	Yue, John K/0000-0001-9694-7722; Goldman, Dana P/0000-0001-8498-6396; Markowitz, Amy/0000-0001-9314-2814; Wang, Kevin/0000-0002-9343-6473; Hemphill, Claude/0000-0003-4019-7525; Bodien, Yelena/0000-0003-4858-2903	National Institute of Neurological Disorders and Stroke, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5U01NS086090-02]; Research to Prevent Blindness, New York, New YorkResearch to Prevent Blindness (RPB); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS047996] Funding Source: NIH RePORTER	This study was supported by grant 5U01NS086090-02 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health. Funding was also provided by Research to Prevent Blindness, New York, New York.	af Geijerstam JL, 2005, EMERG MED J, V22, P103, DOI 10.1136/emj.2004.015396; Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Hansen LO, 2011, ANN INTERN MED, V155, P520, DOI 10.7326/0003-4819-155-8-201110180-00008; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Huynh T, 2006, AM SURGEON, V72, P1162; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lin CY, 2011, J AM GERIATR SOC, V59, P1947, DOI 10.1111/j.1532-5415.2011.03572.x; Mackelprang JL, 2014, AM J PUBLIC HEALTH, V104, P1986, DOI 10.2105/AJPH.2014.302087; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; McIsaac Kathryn E, 2016, CMAJ Open, V4, pE746, DOI 10.9778/cmajo.20160072; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Topolovec-Vranic Jane, 2014, CMAJ Open, V2, pE69, DOI 10.9778/cmajo.20130046; Toth M, 2017, HEALTH SERV RES, V52, P1473, DOI 10.1111/1475-6773.12543; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	30	44	44	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	MAY	2018	1	1							e180210	10.1001/jamanetworkopen.2018.0210			13	Medicine, General & Internal	General & Internal Medicine	HD4PB	WOS:000452508700013	30646055	DOAJ Gold, Green Published			2021-06-18	
J	Master, CL; Master, SR; Wiebe, DJ; Storey, EP; Lockyer, JE; Podolak, OE; Grady, MF				Master, Christina L.; Master, Stephen R.; Wiebe, Douglas J.; Storey, Eileen P.; Lockyer, Julia E.; Podolak, Olivia E.; Grady, Matthew F.			Vision and Vestibular System Dysfunction Predicts Prolonged Concussion Recovery in Children	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; pediatric; vision; accommodative amplitude; near point of convergence; vestibular	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; FRONTAL EYE-FIELD; HIGH-SCHOOL; ACTIVE REHABILITATION; STIMULATION; BALANCE; ADOLESCENTS; DISORDERS; SCORES	Objective: Up to one-third of children with concussion have prolonged symptoms lasting beyond 4 weeks. Vision and vestibular dysfunction is common after concussion. It is unknown whether such dysfunction predicts prolonged recovery. We sought to determine which vision or vestibular problems predict prolonged recovery in children. Design: A retrospective cohort of pediatric patients with concussion. Setting: A subspecialty pediatric concussion program. Patients (or Participants): Four hundred thirty-two patient records were abstracted. Assessment of Risk Factors: Presence of vision or vestibular dysfunction upon presentation to the subspecialty concussion program. Main Outcome Measures: The main outcome of interest was time to clinical recovery, defined by discharge from clinical follow-up, including resolution of acute symptoms, resumption of normal physical and cognitive activity, and normalization of physical examination findings to functional levels. Results: Study subjects were 5 to 18 years (median - 14). A total of 378 of 432 subjects (88%) presented with vision or vestibular problems. A history of motion sickness was associated with vestibular dysfunction. Younger age, public insurance, and presence of headache were associated with later presentation for subspecialty concussion care. Vision and vestibular problems were associated within distinct clusters. Provocable symptoms with vestibulo-ocular reflex (VOR) and smooth pursuits and abnormal balance and accommodative amplitude (AA) predicted prolonged recovery time. Conclusions: Vision and vestibular problems predict prolonged concussion recovery in children. A history of motion sickness may be an important premorbid factor. Public insurance status may represent problems with disparities in access to concussion care. Vision assessments in concussion must include smooth pursuits, saccades, near point of convergence (NPC), and accommodative amplitude (AA). A comprehensive, multidomain assessment is essential to predict prolonged recovery time and enable active intervention with specific school accommodations and targeted rehabilitation.	[Master, Christina L.; Storey, Eileen P.; Lockyer, Julia E.; Podolak, Olivia E.; Grady, Matthew F.] Childrens Hosp Philadelphia, Div Orthopaed, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA; [Master, Christina L.; Grady, Matthew F.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Master, Stephen R.] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA; [Wiebe, Douglas J.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA	Master, CL (corresponding author), Childrens Hosp Philadelphia, Div Orthopaed, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	masterc@email.chop.edu		Master, Christina/0000-0002-6717-4270			Aligene K, 2013, NEUROREHABILITATION, V32, P543, DOI 10.3233/NRE-130876; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Blanke O, 2000, J NEUROL NEUROSUR PS, V69, P553, DOI 10.1136/jnnp.69.4.553; Blanke O, 2003, EXP BRAIN RES, V150, P174, DOI 10.1007/s00221-003-1395-7; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Custer A, 2016, J ATHL TRAINING, V51, P136, DOI 10.4085/1062-6050-51.2.12; de Waele C, 2001, EXP BRAIN RES, V141, P541, DOI 10.1007/s00221-001-0894-7; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Fasold O, 2002, NEUROIMAGE, V17, P1384, DOI 10.1006/nimg.2002.1241; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gamlin PDR, 2002, ANN NY ACAD SCI, V956, P264, DOI 10.1111/j.1749-6632.2002.tb02825.x; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Houston MN, 2016, BRAIN INJURY, V30, P891, DOI 10.3109/02699052.2016.1146960; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Li H, 2015, PLOS ONE, V10; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDougal DH, 2015, COMPR PHYSIOL, V5, P439, DOI 10.1002/cphy.c140014; Meier TB, 2017, BRAIN IMAGING BEHAV, V11, P129, DOI 10.1007/s11682-016-9520-y; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Nelson LD, 2016, J ATHL TRAINING, V51, P142, DOI 10.4085/1062-6050-51.4.04; Pardini D., 2004, BR J SPORTS MED, V38, P661; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; Petit L, 1997, J NEUROPHYSIOL, V77, P3386; Scheiman M, 2011, OPTOMETRY VISION SCI, V88, P1343, DOI 10.1097/OPX.0b013e31822f4d7c; Storey EP, 2017, OPTOMETRY VISION SCI, V94, P96, DOI 10.1097/OPX.0000000000000910; Thiagarajan P, 2014, J REHABIL RES DEV, V51, P175, DOI 10.1682/JRRD.2013.01.0027; Ventura RE, 2016, J NEUROL SCI, V361, P79, DOI 10.1016/j.jns.2015.12.010; Ventura RE, 2015, SEMIN NEUROL, V35, P599, DOI 10.1055/s-0035-1563567; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	43	44	46	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2018	28	2					139	145		10.1097/JSM.0000000000000507			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	GP1HC	WOS:000440564900009	29064869				2021-06-18	
J	Ju, MJ; Liu, BF; He, HY; Gu, ZY; Liu, YM; Su, Y; Zhu, DM; Cang, J; Luo, Z				Ju, MinJie; Liu, BoFei; He, HongYu; Gu, ZhunYong; Liu, YiMei; Su, Ying; Zhu, DuMing; Cang, Jing; Luo, Zhe			MicroRNA-27a alleviates LPS-induced acute lung injury in mice via inhibiting inFLammation and apoptosis through modulating TLR4/MyD88/NF-kappa B pathway	CELL CYCLE			English	Article						Acute lung injury; inFLammation and apoptosis; microRNA-27a; TLR4/MyD88/NF-kappa B pathway	RESPIRATORY-DISTRESS-SYNDROME; TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; DOWN-REGULATION; EXPRESSION; PROTECTS; MIR-27A; CELLS; BCL-2; DEATH	Acute lung injury (ALI) is a critical clinical condition with a high mortality rate, characterized with excessive uncontrolled inflammation and apoptosis. Recently, microRNAs (miRNAs) have been found to play crucial roles in the amelioration of various inflammation-induced diseases, including ALI. However, it remains unknown the biological function and regulatory mechanisms of miRNAs in the regulation of inFLammation and apoptosis in ALI. The aim of this study is to identify and evaluate the potential role of miRNAs in ALI and reveal the underlying molecular mechanisms of their effects. Here, we analyzed microRNA expression profiles in lung tissues from LPS-challenged mice using miRNA microarray. Because microRNA-27a (miR-27a) was one of the miRNAs being most significantly downregulated, which has an important role in regulation of inflammation, we investigated its function. Overexpression of miR-27a by agomir-27a improved lung injury, as evidenced by the reduced histopathological changes, lung wet/dry (W/D) ratio, lung microvascular permeability and apoptosis in the lung tissues, as well as ameliorative survival of ALI mice. This was accompanied by the alleviating of inflammation, such as the reduced total BALF cell and neutrophil counts, decreased levels of tumor necrosis factor alpha (TNF-alpha), interleukin-1 (IL-6) interleukin-1 beta (IL-1 beta) and myeloperoxidase (MPO) activity in BAL fluid. Toll-like receptor 4 (TLR4), an important regulator of the nuclear factor kappa-B (NF-kappa B) signaling pathway, was identified as a novel target of miR-27a in RAW264.7 cells. Furthermore, our results showed that LPS stimulation increased the expression of MyD88 and NF-kappa B p65 (p-p65), but inhibited the expression of inhibitor of nuclear factor-kappa B-alpha (I kappa B-alpha), suggesting the activation of NF-kappa B signaling pathway. Further investigations revealed that agomir-miR-27a reversed the promoting effect of LPS on NF-kappa B signaling pathway. The results here suggested that miR-27a alleviates LPS-induced ALI in mice via reducing inFLammation and apoptosis through blocking TLR4/MyD88/NF-kappa B activation.	[Ju, MinJie; He, HongYu; Gu, ZhunYong; Liu, YiMei; Su, Ying; Zhu, DuMing; Luo, Zhe] Fudan Univ, Zhongshan Hosp, Dept Critial Care Med, Shanghai, Peoples R China; [Liu, BoFei] 1st People Hosp, Dept Intens Care Med, ZhangjiaGang, Peoples R China; [Cang, Jing] Fudan Univ, Zhongshan Hosp, Dept Anesthesiol, Shanghai, Peoples R China	Luo, Z (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Critial Care Med, Shanghai, Peoples R China.; Cang, J (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Anesthesiol, Shanghai, Peoples R China.	cang.jing@zs-hospital.sh.cn; luo.zhe@zs-hospital.sh.cn					Bao YP, 2013, ASIAN PAC J CANCER P, V14, P3751, DOI 10.7314/APJCP.2013.14.6.3751; Bardales RH, 1996, AM J PATHOL, V149, P845; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291; Ben DF, 2012, J SURG RES, V174, P326, DOI 10.1016/j.jss.2010.12.005; Bhargava M, 2012, TRANSL RES, V159, P205, DOI 10.1016/j.trsl.2012.01.007; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Brandenberger C, 2018, AGING DIS, V9, P553, DOI 10.14336/AD.2017.0902; Cai Q, 2016, NEURAL REGEN RES, V11, P1285, DOI 10.4103/1673-5374.189194; Chen CS, 2016, CELL BIOL TOXICOL, V32, P169, DOI 10.1007/s10565-016-9322-4; Chen JJ, 2017, AM J CHINESE MED, V45, P137, DOI 10.1142/S0192415X17500100; Cheng YC, 2015, ADV MATER SCI ENG, V2015, DOI 10.1155/2015/947834; Chi GF, 2013, INFLAMMATION, V36, P501, DOI 10.1007/s10753-012-9571-1; Chong AJ, 2004, J THORAC CARDIOV SUR, V128, P170, DOI 10.1016/j.jtcvs.2003.11.036; Deng GM, 2017, BIOMED PHARMACOTHER, V96, P148, DOI 10.1016/j.biopha.2017.09.094; Dengler V, 2013, AM J RESP CELL MOL, V49, P1, DOI 10.1165/rcmb.2012-0472TR; DosReis GA, 2004, J CELL MOL MED, V8, P285, DOI 10.1111/j.1582-4934.2004.tb00318.x; Duan YL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-4; Eveillard M, 2010, J INFECTION, V60, P154, DOI 10.1016/j.jinf.2009.09.004; Fan HY, 2016, ONCOTARGET, V7, P39497, DOI 10.18632/oncotarget.8347; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Fang L, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/283939; Fang Y, 2017, AM J TRANSL RES, V9, P1287; Ferrari RS, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/590987; Ferruelo A, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.10; Fu XD, 2016, BIOCHEM BIOPH RES CO, V477, P167, DOI 10.1016/j.bbrc.2016.06.038; Guo ZL, 2014, IMMUNOL LETT, V162, P18, DOI 10.1016/j.imlet.2014.06.008; Herold S, 2013, AM J PHYSIOL-LUNG C, V305, pL665, DOI 10.1152/ajplung.00232.2013; Jiang KF, 2017, ONCOTARGET, V8, P71038, DOI 10.18632/oncotarget.20298; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Lee W L, 2001, Curr Opin Crit Care, V7, P1, DOI 10.1097/00075198-200102000-00001; Li WQ, 2016, BIOMED PHARMACOTHER, V84, P1375, DOI 10.1016/j.biopha.2016.10.065; Li XQ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0246-3; Lv YN, 2017, CELL MOL NEUROBIOL, V37, P195, DOI 10.1007/s10571-016-0361-4; Mac Sweeney R, 2013, SEMIN RESP CRIT CARE, V34, P487, DOI 10.1055/s-0033-1351119; Matthay MA, 2011, ANNU REV PATHOL-MECH, V6, P147, DOI 10.1146/annurev-pathol-011110-130158; Meduri GU, 2007, LANCET, V370, P384, DOI 10.1016/S0140-6736(07)61184-2; Mei SHJ, 2007, PLOS MED, V4, P1525, DOI 10.1371/journal.pmed.0040269; Mendez JL, 2005, CURR OPIN CRIT CARE, V11, P29, DOI 10.1097/00075198-200502000-00005; Neudecker V, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5360; Parsey MV, 1998, J IMMUNOL, V160, P1007; Rajasekaran S, 2016, J CELL PHYSIOL, V231, P2097, DOI 10.1002/jcp.25316; Sabirzhanov B, 2014, J NEUROSCI, V34, P10055, DOI 10.1523/JNEUROSCI.1260-14.2014; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Shi DL, 2016, MOL CELLS, V39, P611, DOI 10.14348/molcells.2016.0103; Shi Lei, 2017, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V29, P244, DOI 10.3760/cma.j.issn.2095-4352.2017.03.010; Singh N, 2007, LANCET, V370, P383, DOI 10.1016/S0140-6736(07)61183-0; Song L, 2017, INFLAMMATION, V40, P927, DOI 10.1007/s10753-017-0537-1; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; Su ZQ, 2014, INT IMMUNOPHARMACOL, V22, P371, DOI 10.1016/j.intimp.2014.06.043; Sun CC, 2015, ONCOTARGET, V6, P25533, DOI 10.18632/oncotarget.4575; Sun HY, 2017, CELL BIOL INT, V41, P739, DOI 10.1002/cbin.10768; Sun LQ, 2017, BIOCHEM BIOPH RES CO, V482, P1141, DOI 10.1016/j.bbrc.2016.12.001; Tang RR, 2016, BIOTECHNOL LETT, V38, P1277, DOI 10.1007/s10529-016-2107-2; Tian WF, 2017, CHINESE MED J-PEKING, V130, P859, DOI 10.4103/0366-6999.202735; Wu CT, 2018, INT J BIOCHEM CELL B, V101, P1, DOI 10.1016/j.biocel.2018.04.019; Xue WL, 2015, BIOCHEM BIOPH RES CO, V464, P855, DOI 10.1016/j.bbrc.2015.07.051; Yao H, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00120; Zhang TZ, 2015, TOXICOL MECH METHOD, V25, P665, DOI 10.3109/15376516.2015.1045652; Zhang TZ, 2015, INFLAMMATION, V38, P1529, DOI 10.1007/s10753-015-0127-z; Zhao G, 2017, ONCOTARGET, V8, P68153, DOI 10.18632/oncotarget.19249; Zhao JJ, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00389; Zhao XH, 2018, J CELL PHYSIOL, V233, P3048, DOI 10.1002/jcp.26053; Zhou T, 2011, TRANSL RES, V157, P180, DOI 10.1016/j.trsl.2011.01.010	64	44	48	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1538-4101	1551-4005		CELL CYCLE	Cell Cycle		2018	17	16					2001	2018		10.1080/15384101.2018.1509635			18	Cell Biology	Cell Biology	GZ6MY	WOS:000449552300006	30231673	Green Published, Bronze			2021-06-18	
J	Olesen, J				Olesen, Jes			Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition Asbtracts	CEPHALALGIA			English	Article							TENSION-TYPE HEADACHE; TRAUMATIC BRAIN-INJURY; DAILY-PERSISTENT HEADACHE; MEDICATION-OVERUSE HEADACHE; CHRONIC PAROXYSMAL HEMICRANIA; CENTRAL-NERVOUS-SYSTEM; NECK-TONGUE-SYNDROME; ICE-CREAM HEADACHE; FAMILIAL HEMIPLEGIC MIGRAINE; CHIARI-I MALFORMATION		[Olesen, Jes] Int Headache Soc, Headache Classificat Comm, London, England	Olesen, J (corresponding author), Int Headache Soc, Headache Classificat Comm, London, England.						Aaseth K, 2010, CEPHALALGIA, V30, P152, DOI 10.1111/j.1468-2982.2009.01877.x; Aaseth K, 2011, EUR J PAIN, V15, P186, DOI 10.1016/j.ejpain.2010.06.005; Abadie V, 2014, CEPHALALGIA, V34, P887, DOI 10.1177/0333102414523340; ABBOTT PJ, 1986, MED J AUSTRALIA, V145, P518, DOI 10.5694/j.1326-5377.1986.tb139455.x; Abhinav K, 2012, CLIN NEUROL NEUROSUR, V114, P361, DOI 10.1016/j.clineuro.2011.11.018; Abu-Arafeh I, 2017, ARCH DIS CHILD, V102, P210, DOI 10.1136/archdischild-2016-312137; Abu-Bakra M, 2001, J LARYNGOL OTOL, V115, P629; ABUARAFEH I, 1995, ARCH DIS CHILD, V72, P413, DOI 10.1136/adc.72.5.413; Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Afridi S, 2003, J NEUROL NEUROSUR PS, V74, P680, DOI 10.1136/jnnp.74.5.680; Aggarwal VR, 2007, J OROFAC PAIN, V21, P203; Aggarwal VR, 2006, INT J EPIDEMIOL, V35, P468, DOI 10.1093/ije/dyi265; Agrawal K, 2016, HEADACHE, V56, P1380, DOI 10.1111/head.12873; Aidi Saadia, 1999, Headache, V39, P559, DOI 10.1046/j.1526-4610.1999.3908559.x; Aiken AH, 2012, AM J NEURORADIOL, V33, P1901, DOI 10.3174/ajnr.A3068; Akhtar N D, 2001, Semin Pediatr Neurol, V8, P27, DOI 10.1053/spen.2001.23329; Akinci A, 2008, J AAPOS, V12, P290, DOI 10.1016/j.jaapos.2007.11.018; Aktan C, 2017, CEPHALALGIA, V37, P1074, DOI 10.1177/0333102416665878; Al-Twaijri WA, 2002, PEDIATR NEUROL, V26, P365, DOI 10.1016/S0887-8994(01)00416-7; ALAHURULA V, 1981, HEADACHE, V21, P240, DOI 10.1111/j.1526-4610.1981.hed2106240.x; Alberti A, 2005, ACTA NEUROL SCAND, V111, P309, DOI 10.1111/j.1600-0404.2005.00372.x; ALDRICH MS, 1990, ARCH INTERN MED, V150, P1265, DOI 10.1001/archinte.150.6.1265; Alfano DP, 2006, BRAIN COGNITION, V60, P194; Algin O, 2013, CAN ASSOC RADIOL J, V64, P56, DOI 10.1016/j.carj.2011.12.011; Allet JL, 2006, CURR OPIN PSYCHIATR, V19, P413, DOI 10.1097/01.yco.0000228764.25732.21; Alonso AA, 2006, J ENDODONT, V32, P1110, DOI 10.1016/j.joen.2006.02.033; Altura BM, 2000, J MENT SCI, V104, P972; Alvarez FK, 2007, J ORAL PATHOL MED, V36, P347, DOI 10.1111/j.1600-0714.2006.00489.x; Ambrose HE, 2011, J CLIN MICROBIOL, V49, P3576, DOI 10.1128/JCM.00862-11; Ambrosini A, 2005, NEUROLOGY, V65, P1826, DOI 10.1212/01.wnl.0000187072.71931.c0; Ambrosini A, 2001, ACTA NEUROL BELG, V101, P166; Amorim JA, 2012, CEPHALALGIA, V32, P916, DOI 10.1177/0333102412453951; AMY JR, 1987, HEADACHE, V27, P351, DOI 10.1111/j.1526-4610.1987.hed2706351.x; ANDERSSON PG, 1975, HEADACHE, V15, P118, DOI 10.1111/j.1526-4610.1975.hed1502118.x; Antonaci F, 2001, Curr Pain Headache Rep, V5, P387, DOI 10.1007/s11916-001-0030-1; Antonaci F, 2001, CEPHALALGIA, V21, P573, DOI 10.1046/j.0333-1024.2001.00207.x; Antoniazzi AL, 2003, CEPHALALGIA, V23, P146, DOI 10.1046/j.1468-2982.2003.00510.x; Antoniazzi Ana Luisa de Lima, 2007, Curr Pain Headache Rep, V11, P297; Antonini G, 2014, PAIN, V155, P1464, DOI 10.1016/j.pain.2014.04.020; Aoki Y, 2012, J NEUROL NEUROSUR PS, V83, P870, DOI 10.1136/jnnp-2012-302742; APPENZELLER O, 1972, HEADACHE, V12, P126; Arafah BM, 2000, J CLIN ENDOCR METAB, V85, P1789, DOI 10.1210/jc.85.5.1789; Arngrim N, 2014, CEPHALALGIA, V34, P1169, DOI 10.1177/0333102414534085; Arnold M, 2006, J NEUROL NEUROSUR PS, V77, P1021, DOI 10.1136/jnnp.2006.094359; Arredondo M, 2012, AIDS RES HUM RETROV, V28, P889, DOI [10.1089/aid.2011.0149, 10.1089/AID.2011.0149]; Arruda MA, 2010, CEPHALALGIA, V30, P1056, DOI 10.1177/0333102409361214; Ashina M, 1999, PAIN, V79, P201, DOI 10.1016/S0304-3959(98)00167-5; Ashina M, 1999, LANCET, V353, P287, DOI 10.1016/S0140-6736(98)01079-4; Ashina M, 2000, BRAIN, V123, P1830, DOI 10.1093/brain/123.9.1830; Ashina M, 2004, CEPHALALGIA, V24, P161, DOI 10.1111/j.1468-2982.2003.00644.x; Ashina M, 2003, CEPHALALGIA, V23, P109, DOI 10.1046/j.1468-2982.2003.00520.x; Ashina M, 2002, BRAIN, V125, P320, DOI 10.1093/brain/awf029; Ashina M, 2000, CEPHALALGIA, V20, P919, DOI 10.1046/j.1468-2982.2000.00150.x; Ashina Messoud, 2002, Expert Opin Pharmacother, V3, P395, DOI 10.1517/14656566.3.4.395; Ashina S, 2006, CEPHALALGIA, V26, P940, DOI 10.1111/j.1468-2982.2006.01150.x; Ashina S, 2005, EUR J NEUROL, V12, P543, DOI 10.1111/j.1468-1331.2005.01023.x; Ashina S, 2004, PAIN, V108, P108, DOI 10.1016/j.pain.2003.12.012; ASKMARK H, 1989, HEADACHE, V29, P441, DOI 10.1111/j.1526-4610.1989.hed2907441.x; Aurora SK, 2009, CEPHALALGIA, V29, P597, DOI 10.1111/j.1468-2982.2008.01811.x; Avery RA, 2010, NEW ENGL J MED, V363, P891, DOI 10.1056/NEJMc1004957; Azevedo LL, 2011, EUR NEUROL, V66, P133, DOI 10.1159/000330675; Bahra A, 2002, NEUROLOGY, V58, P354, DOI 10.1212/WNL.58.3.354; Bakar B, 2008, J KOREAN NEUROSURG S, V44, P285, DOI 10.3340/jkns.2008.44.5.285; Ballegaard V, 2008, CEPHALALGIA, V28, P832, DOI 10.1111/j.1468-2982.2008.01597.x; Banik R, 2006, J NEUROL SCI, V247, P71, DOI 10.1016/j.jns.2006.03.016; BARTLESON JD, 1981, NEUROLOGY, V31, P1257, DOI 10.1212/WNL.31.10.1257; Bartsch T, 2005, HEADACHE CURR, V2, P42, DOI 10.1111/j.1743-5013.2005.20201.x; BASSI P, 1991, ACTA NEUROL SCAND, V84, P277, DOI 10.1111/j.1600-0404.1991.tb04954.x; Batzdorf U, 2013, J NEUROSURG, V118, P232, DOI 10.3171/2012.10.JNS12305; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BECH RW, 1991, ARCH OPHTHALMOL-CHIC, V109, P1673, DOI 10.1001/archopht.1991.01080120057025; Beck HG, 1940, J AMER MED ASSOC, V115, P1; Beekman R, 2001, HEADACHE, V41, P410, DOI 10.1046/j.1526-4610.2001.111006410.x; Belcastro V, 2011, CEPHALALGIA, V31, P999, DOI 10.1177/0333102411410083; Belcastro V, 2011, J HEADACHE PAIN, V12, P289, DOI 10.1007/s10194-011-0318-4; Bellamio M, 2017, CEPHALALGIA, V37, P491, DOI 10.1177/0333102416652094; Beltramone M, 2014, CEPHALALGIA, V34, P633, DOI 10.1177/0333102414520763; BENDTSEN L, 1995, CEPHALALGIA, V15, P205, DOI 10.1046/j.1468-2982.1995.015003205.x; Bendtsen L, 1996, ARCH NEUROL-CHICAGO, V53, P373, DOI 10.1001/archneur.1996.00550040113021; Bendtsen L, 2000, CEPHALALGIA, V20, P603, DOI 10.1046/j.1468-2982.2000.00087.x; Bendtsen L, 2000, CEPHALALGIA, V20, P486, DOI 10.1046/j.1468-2982.2000.00070.x; Bendtsen L, 2004, NEUROLOGY, V62, P1706, DOI 10.1212/01.WNL.0000127282.90920.8C; Bendtsen L, 1996, PAIN, V65, P259, DOI 10.1016/0304-3959(95)00239-1; Bendtsen L, 2010, EUR J NEUROL, V17, P1318, DOI 10.1111/j.1468-1331.2010.03070.x; Bendtsen L, 1996, J NEUROL NEUROSUR PS, V61, P285, DOI 10.1136/jnnp.61.3.285; Bendtsen L, 2010, CEPHALALGIA, V30, P1, DOI 10.1111/j.1468-2982.2009.01948.x; Bendtsen L, 2006, CURR OPIN NEUROL, V19, P305; Benoliel R, 2005, ORAL SURG ORAL MED O, V99, P657, DOI 10.1016/j.tripleo.2004.10.014; Benoliel R, 1998, CEPHALALGIA, V18, P85, DOI 10.1046/j.1468-2982.1998.1802085.x; Benoliel R, 2012, J OROFAC PAIN, V26, P49; Benoliel R, 2009, J OROFAC PAIN, V23, P330; Bento MS, 2000, HEADACHE, V40, P52, DOI 10.1046/j.1526-4610.2000.00010.x; Beretta E, 2017, NEUROL SCI, V38, pS95, DOI 10.1007/s10072-017-2950-5; BERG MJ, 1995, NEUROLOGY, V45, P1648, DOI 10.1212/WNL.45.9.1648; Bergdahl M, 1999, J ORAL PATHOL MED, V28, P350; Berger JR, 2010, SEMIN NEUROL, V30, P66, DOI 10.1055/s-0029-1244996; Berilgen MS, 2011, CEPHALALGIA, V31, P1266, DOI 10.1177/0333102411413159; Berilgen MS, 2006, CEPHALALGIA, V26, P707, DOI 10.1111/j.1468-2982.2006.01096.x; Bezov D, 2010, HEADACHE, V50, P1144, DOI 10.1111/j.1526-4610.2010.01699.x; Bharucha DX, 2007, PEDIATR NEUROL, V37, P59, DOI 10.1016/j.pediatrneurol.2007.03.008; Bhatoe HS, 1998, BRIT J NEUROSURG, V12, P165; BICKERSTAFF ER, 1961, LANCET, V1, P15; Biehl K, 2007, CEPHALALGIA, V27, P1271, DOI 10.1111/j.1468-2982.2007.01381.x; Bigal ME, 2007, CEPHALALGIA, V27, P230, DOI 10.1111/j.1468-2982.2006.01274.x; Bigal ME, 2008, NEUROLOGY, V71, P559, DOI 10.1212/01.wnl.0000323925.29520.e7; Bigal ME, 2008, CURR PAIN HEADACHE R, V12, P292, DOI 10.1007/s11916-008-0049-7; Bigal ME, 2008, HEADACHE, V48, P7, DOI 10.1111/j.1526-4610.2007.00969.x; Bigal ME, 2004, NEUROLOGY, V63, P843, DOI 10.1212/01.WNL.0000137039.08724.18; Bigal ME, 2002, CEPHALALGIA, V22, P432, DOI 10.1046/j.1468-2982.2002.00384.x; Bigal ME, 2005, HEADACHE, V45, P582, DOI 10.1111/j.1526-4610.2005.05112.x; Bigal ME, 2004, CEPHALALGIA, V24, P483, DOI 10.1111/j.1468-2982.2004.00691.x; Bing R, 1930, NERVENARZT, V3, P506; Biousse V, 1999, NEUROLOGY, V53, P1537, DOI 10.1212/WNL.53.7.1537; BIOUSSE V, 1995, STROKE, V26, P235, DOI 10.1161/01.STR.26.2.235; BIRD N, 1992, HEADACHE, V32, P35, DOI 10.1111/j.1526-4610.1992.hed3201035.x; Birk S, 2006, CEPHALALGIA, V26, P1304, DOI 10.1111/j.1468-2982.2006.01218.x; Bisdorff A, 2009, J VESTIBUL RES-EQUIL, V19, P1, DOI 10.3233/VES-2009-0343; BLACKY RA, 1987, AM J CARDIOL, V60, P730, DOI 10.1016/0002-9149(87)90394-8; Blau JN, 2004, HEADACHE, V44, P411, DOI 10.1111/j.1526-4610.2004.04092.x; Bloudek LM, 2012, J HEADACHE PAIN, V13, P361, DOI 10.1007/s10194-012-0460-7; Blumenfeld A, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0343-x; Blumenthal HJ, 2001, HEADACHE, V41, P883, DOI 10.1046/j.1526-4610.2001.041009883.x; Boes CJ, 2005, NEUROLOGY, V64, P1093, DOI 10.1212/01.WNL.0000154470.19225.49; Boes CJ, 2003, CEPHALALGIA, V23, P24, DOI 10.1046/j.1468-2982.2003.00406.x; BOGDUK N, 1985, MED J AUSTRALIA, V143, P202, DOI 10.5694/j.1326-5377.1985.tb122915.x; BOGDUK N, 1981, J NEUROL NEUROSUR PS, V44, P202, DOI 10.1136/jnnp.44.3.202; Bogduk N, 2001, Curr Pain Headache Rep, V5, P382, DOI 10.1007/s11916-001-0029-7; Bogduk N, 2005, PHYS MED REH CLIN N, V14, P455; Bogduk N, 1997, HEADACHE, P369; Bohara Manoj, 2015, Hiroshima Journal of Medical Sciences, V64, P39; BOHR V, 1983, J INFECTION, V7, P102, DOI 10.1016/S0163-4453(83)90443-7; Bonnet G F, 1971, Sem Hop, V47, P2441; Bono G, 2006, CLIN EXP HYPERTENS, V28, P233, DOI 10.1080/10641960600549116; BORDINI C, 1991, HEADACHE, V31, P20, DOI 10.1111/j.1526-4610.1991.hed3101020.x; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Borkum JM, 2010, CURR PAIN HEADACHE R, V14, P55, DOI 10.1007/s11916-009-0084-z; Botha SS, 2010, CEPHALALGIA, V30, P1495, DOI 10.1177/0333102410370876; BOUHASSIRA D, 1994, CEPHALALGIA, V14, P168, DOI 10.1046/j.1468-2982.1994.1402168.x; Bousser MG, 2007, LANCET NEUROL, V6, P162, DOI 10.1016/S1474-4422(07)70029-7; Bousser MG, 2000, CEPHALALGIA, V20, P155, DOI 10.1046/j.1468-2982.2000.00035.x; BOWEN J, 1993, HEADACHE, V33, P238, DOI 10.1111/j.1526-4610.1993.hed3305238.x; Bowsher D, 1998, NEUROLOGY, V51, P1352, DOI 10.1212/WNL.51.5.1352; Bowsher D, 1997, J NEUROSURG, V86, P190, DOI 10.3171/jns.1997.86.2.0190; Brantberg K, 2011, ACTA OTO-LARYNGOL, V131, P722, DOI 10.3109/00016489.2011.556661; Breen JC, 1996, NEUROLOGY, V46, P175, DOI 10.1212/WNL.46.1.175; BREW BJ, 1993, NEUROLOGY, V43, P1098, DOI 10.1212/WNL.43.6.1098; BREWERTON TD, 1992, HEADACHE, V32, P217, DOI 10.1111/j.1526-4610.1992.hed3205217.x; BROESKE D, 1993, J CHILD NEUROL, V8, P235, DOI 10.1177/088307389300800305; BROOKS RG, 1986, ANN NEUROL, V20, P91, DOI 10.1002/ana.410200116; Brostigen CS, 2017, ACTA NEUROL SCAND, V135, P484, DOI 10.1111/ane.12632; Brott TG, 2016, NEW ENGL J MED, V374, P1021, DOI 10.1056/NEJMoa1505215; BRUYN GW, 1984, CEPHALALGIA, V4, P191, DOI 10.1046/j.1468-2982.1984.0403191.x; Buchgreitz L, 2008, PAIN, V137, P623, DOI 10.1016/j.pain.2007.10.023; Buchgreitz L, 2006, PAIN, V123, P19, DOI 10.1016/j.pain.2006.01.040; Buchgreitz L, 2008, BRAIN, V131, P3232, DOI 10.1093/brain/awn199; Bui SBD, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0628-7; Burkhart CG, 2006, INT J DERMATOL, V45, P1116, DOI 10.1111/j.1365-4632.2006.02790.x; Burtscher M, 2011, CEPHALALGIA, V31, P706, DOI 10.1177/0333102410394678; Buse D, 2012, HEADACHE, V52, P3, DOI 10.1111/j.1526-4610.2011.02046.x; Buse DC, 2012, HEADACHE, V52, P1456, DOI 10.1111/j.1526-4610.2012.02223.x; BUSSONE G, 1991, CEPHALALGIA, V11, P123, DOI 10.1046/j.1468-2982.1991.1103123.x; Buzzi MG, 2003, CEPHALALGIA, V23, P672; Buzzi MG, 2003, HEADACHE, V43, P404, DOI 10.1046/j.1526-4610.2003.03076.x; Byard RW, 2016, J FORENSIC SCI, V61, P1538, DOI 10.1111/1556-4029.13180; Byrum EP, 2009, AM J NEURORADIOL, V30, P1059, DOI 10.3174/ajnr.A1382; Cady RK, 2005, MAYO CLIN PROC, V80, P908, DOI 10.4065/80.7.908; Cakirer S, 2003, EUR J RADIOL, V45, P83, DOI 10.1016/S0720-048X(02)00012-8; Calabrese LH, 2007, ANN INTERN MED, V146, P34, DOI 10.7326/0003-4819-146-1-200701020-00007; Calabrese LH, 1997, ARTHRITIS RHEUM, V40, P1189, DOI 10.1002/art.2; CALABRESE LH, 1992, CLEV CLIN J MED, V59, P293, DOI 10.3949/ccjm.59.3.293; CALL GK, 1988, STROKE, V19, P1159, DOI 10.1161/01.STR.19.9.1159; Caminero AB, 1998, CEPHALALGIA, V18, P159, DOI 10.1046/j.1468-2982.1998.1803159.x; Fabri GMC, 2009, ARQ NEURO-PSIQUIAT, V67, P474, DOI 10.1590/S0004-282X2009000300018; Canestri P, 2001, CEPHALALGIA, V21, P288; Canuet L, 2008, EPILEPSY BEHAV, V13, P570, DOI 10.1016/j.yebeh.2008.05.013; Cao Y, 1999, ARCH NEUROL-CHICAGO, V56, P548, DOI 10.1001/archneur.56.5.548; Capelli E, 2010, INT J IMMUNOPATH PH, V23, P981, DOI 10.1177/039463201002300402; CAPLAN LR, 1991, NEUROLOGY, V41, P55, DOI 10.1212/WNL.41.1.55; Cariga P, 2002, SPINAL CORD, V40, P77, DOI 10.1038/sj.sc.3101259; Carney N, 2014, NEUROSURGERY, V75, pS2; Carroll D, 1970, Headache, V10, P9, DOI 10.1111/j.1526-4610.1970.hed1001009.x; CASELLI RJ, 1993, RHEUM DIS CLIN N AM, V19, P941; Cass SP, 1997, ANN OTO RHINOL LARYN, V106, P182, DOI 10.1177/000348949710600302; Castillo J, 1999, HEADACHE, V39, P190, DOI 10.1046/j.1526-4610.1999.3903190.x; Cathcart S, 2008, EUR J NEUROL, V15, P552, DOI 10.1111/j.1468-1331.2008.02124.x; Cathcart S, 2010, CEPHALALGIA, V30, P285, DOI 10.1111/j.1468-2982.2009.01917.x; Cathcart S, 2010, HEADACHE, V50, P403, DOI 10.1111/j.1526-4610.2009.01545.x; Centonze V, 2001, CEPHALALGIA, V21, P71, DOI 10.1046/j.1468-2982.2001.00152.x; Chabriat H, 1996, REV NEUROL-FRANCE, V152, P536; CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5; CHAKERES DW, 1989, RADIOL CLIN N AM, V27, P265; Chakravarty A, 2006, CEPHALALGIA, V26, P202, DOI 10.1111/j.1468-2982.2005.01027.x; Chakravarty A, 2005, CEPHALALGIA, V25, P795, DOI 10.1111/j.1468-2982.2005.00958.x; CHALSTREY S, 1991, J ROY SOC MED, V84, P193; Chang CL, 1999, BMJ-BRIT MED J, V318, P13; Chapman KM, 2003, HEADACHE, V43, P892, DOI 10.1046/j.1526-4610.2003.03168.x; Charidimou A, 2012, STROKE, V43, P2324, DOI 10.1161/STROKEAHA.112.657759; Charles A, 2009, CEPHALALGIA, V29, P1115, DOI 10.1111/j.1468-2982.2009.01983.x; Chavez A, 2014, J CLIN NEUROSCI, V21, P2201, DOI 10.1016/j.jocn.2014.06.009; Chen PK, 2009, CEPHALALGIA, V29, P1079, DOI 10.1111/j.1468-2982.2009.01844.x; Chen PK, 2011, CEPHALALGIA, V31, P829, DOI 10.1177/0333102411403635; Chen SP, 2006, NEUROLOGY, V67, P2164, DOI 10.1212/01.wnl.0000249115.63436.6d; Chen SP, 2009, CEPHALALGIA, V29, P401, DOI 10.1111/j.1468-2982.2008.01744.x; Chen SP, 2010, ANN NEUROL, V67, P648, DOI 10.1002/ana.21951; Chen SP, 2004, EUR NEUROL, V51, P221, DOI 10.1159/000078489; Chen WT, 2011, BRAIN, V134, P2387, DOI 10.1093/brain/awr157; Chen WT, 2001, HEADACHE, V41, P823, DOI 10.1046/j.1526-4610.2001.01150.x; Chen YY, 2004, CEPHALALGIA, V24, P694, DOI 10.1111/j.1468-2982.2004.00739.x; CHENG TMW, 1993, NEUROLOGY, V43, P2298, DOI 10.1212/WNL.43.11.2298; Cheshire WP, 2001, HEADACHE, V41, P235, DOI 10.1046/j.1526-4610.2001.111006235.x; Chhiber SS, 2010, NEUROL INDIA, V58, P654, DOI 10.4103/0028-3886.68698; Cho SJ, 2016, CEPHALALGIA, V36, P454, DOI 10.1177/0333102415597890; Choi JC, 2014, CEPHALALGIA, V34, P22, DOI 10.1177/0333102413497598; Choi KS, 2014, ACTA NEUROCHIR, V156, P1281, DOI 10.1007/s00701-014-2095-8; Chong CD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0485-0; Christensen MB, 2005, CEPHALALGIA, V25, P1061, DOI 10.1111/j.1468-2982.2005.00962.x; Chronicle EP, 1996, CEPHALALGIA, V16, P525, DOI 10.1046/j.1468-2982.1996.1608525.x; Chu MK, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-28; CHUN CH, 1986, MEDICINE, V65, P415, DOI 10.1097/00005792-198611000-00006; Cianchetti C, 2013, SEIZURE-EUR J EPILEP, V22, P679, DOI 10.1016/j.seizure.2013.05.017; Cittadini E, 2008, BRAIN, V131, P1142, DOI 10.1093/brain/awn010; Cittadini E, 2010, BRAIN, V133, P1973, DOI 10.1093/brain/awq137; CLARK GT, 1995, CEPHALALGIA, V15, P511, DOI 10.1046/j.1468-2982.1995.1506511.x; Clarke C, 2006, POSTGRAD MED J, V82, P748, DOI 10.1136/pgmj.2006.047662; Cleophas TJM, 1996, ANGIOLOGY, V47, P679, DOI 10.1177/000331979604700707; Close LG, 1997, SEMIN NEUROL, V17, P351, DOI 10.1055/s-2008-1040948; Cochius J I, 1989, Clin Exp Neurol, V26, P183; COFFEY RJ, 1991, SURG NEUROL, V35, P49, DOI 10.1016/0090-3019(91)90202-K; Cohen AS, 2006, BRAIN, V129, P2746, DOI 10.1093/brain/awl202; Cohen ME, 1994, BRAIN TUMORS CHILDRE; COHN DF, 1979, EUR NEUROL, V18, P373, DOI 10.1159/000115107; Colby CC, 2011, ARCH OTOLARYNGOL, V137, P248, DOI 10.1001/archoto.2011.25; Cologno D, 1998, CEPHALALGIA, V18, P690, DOI 10.1046/j.1468-2982.1998.1810690.x; CONNOR RCR, 1962, LANCET, V2, P1072; Contini C., 2008, Parassitologia (Rome), V50, P45; CORBETT JJ, 1983, NEUROLOGY, V33, P1386, DOI 10.1212/WNL.33.10.1386; Corral F, 2001, ARCH NEUROL-CHICAGO, V58, P1143, DOI 10.1001/archneur.58.7.1143; Couch JR, 2009, EUR J NEUROL, V16, DOI 10.1111/j.1468-1331.2008.02362.x; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; COUCH JR, 1983, HEADACHE, V23, P94; Couch JR, 2001, HEADACHE, V41, P559, DOI 10.1046/j.1526-4610.2001.041006559.x; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; Cruccu G, 2009, PAIN, V143, P186, DOI 10.1016/j.pain.2008.12.026; Cruccu G, 2016, NEUROLOGY, V87, P220, DOI 10.1212/WNL.0000000000002840; Cruccu G, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0248-2; CSALA B, 1994, NERVENARZT, V65, P75; Cuadrado ML, 2010, CEPHALALGIA, V30, P200, DOI 10.1111/j.1468-2982.2009.01895.x; Cuadrado ML, 2009, CEPHALALGIA, V29, P583, DOI 10.1111/j.1468-2982.2008.01815.x; Cumurciuc R, 2005, J NEUROL NEUROSUR PS, V76, P1084, DOI 10.1136/jnnp.2004.056275; Cure J, 2007, HEADACHE, V47, P1091, DOI 10.1111/j.1526-4610.2007.00878.x; Curioso EP, 1999, NEUROLOGY, V52, pA471; Curone M, 2017, NEUROL SCI, V38, pS91, DOI 10.1007/s10072-017-2915-8; CUTRER FM, 1992, HEADACHE, V32, P300, DOI 10.1111/j.1526-4610.1992.hed3206300.x; Cutrer FM, 2004, NEUROL CLIN, V22, P133, DOI 10.1016/S0733-8619(03)00092-6; Cutrer FM, 1998, ANN NEUROL, V43, P25, DOI 10.1002/ana.410430108; Da Motta LA, 1991, J NEUROSURG SCI, V43, P25; DALTON K, 1975, HEADACHE, V15, P188, DOI 10.1111/j.1526-4610.1975.hed1503188.x; DANGOND F, 1993, HEADACHE, V33, P257, DOI 10.1111/j.1526-4610.1993.hed3305257.x; Daroff RB, 1998, HEADACHE, V38, P661, DOI 10.1046/j.1526-4610.1998.3809661.x; Daum K M, 1988, J Am Optom Assoc, V59, P691; Davies PTG, 2011, J HEADACHE PAIN, V12, P287, DOI 10.1007/s10194-011-0344-2; DAVIS LE, 1983, ANN NEUROL, V13, P192, DOI 10.1002/ana.410130215; DAY JW, 1986, LANCET, V2, P1247; de Arcaya AA, 1999, HEADACHE, V39, P321; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; de Coo IF, 2016, CEPHALALGIA, V36, P547, DOI 10.1177/0333102415607856; De Fusco M, 2003, NAT GENET, V33, P192, DOI 10.1038/ng1081; de Gray LC, 2005, ANAESTHESIA, V60, P693, DOI 10.1111/j.1365-2044.2005.03997.x; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Noronha RJ, 2003, J NEUROL NEUROSUR PS, V74, P752, DOI 10.1136/jnnp.74.6.752; de Vries B, 2009, HUM GENET, V126, P115, DOI 10.1007/s00439-009-0684-z; DeBenedittis G, 1996, NEUROSURGERY, V38, P466, DOI 10.1097/00006123-199603000-00008; DeBenedittis G, 1996, CEPHALALGIA, V16, P503, DOI 10.1046/j.1468-2982.1996.1607503.x; Debette S, 2015, LANCET NEUROL, V14, P640, DOI 10.1016/S1474-4422(15)00009-5; Debette S, 2009, LANCET NEUROL, V8, P668, DOI 10.1016/S1474-4422(09)70084-5; deBruijn SFTM, 1996, LANCET, V348, P1623, DOI 10.1016/S0140-6736(96)07294-7; DEMARINIS M, 1992, CEPHALALGIA, V12, P197; DEMARINIS M, 1991, HEADACHE, V31, P159; DEMARINIS M, 1991, J NEUROL NEUROSUR PS, V54, P314, DOI 10.1136/jnnp.54.4.314; Denes E, 2010, SWISS MED WKLY, V140, DOI 10.4414/smw.2010.13107; Denier C, 2004, ANN NEUROL, V55, P213, DOI 10.1002/ana.10804; DENNING DW, 1988, BIOMED PHARMACOTHER, V42, P11; Depreitere B, 2003, ACTA NEUROCHIR, V145, P541, DOI 10.1007/s00701-003-0020-7; Desmond RA, 2006, ANTIMICROB AGENTS CH, V50, P2409, DOI 10.1128/AAC.00227-06; DEXTER JD, 1978, HEADACHE, V18, P91, DOI 10.1111/j.1526-4610.1978.hed1802091.x; DHOPESH V, 1991, HEADACHE, V31, P17, DOI 10.1111/j.1526-4610.1991.hed3101017.x; DHUNA A, 1991, J NEUROL NEUROSUR PS, V54, P803, DOI 10.1136/jnnp.54.9.803; Di Fabio R, 2012, HEADACHE, V52, P385, DOI 10.1111/j.1526-4610.2011.01994.x; Di Stefano G, 2018, CEPHALALGIA, V38, P1049, DOI 10.1177/0333102417721677; Diamond S, 2000, HEADACHE Q-CURR TREA, V11, P177; Dichgans M, 2005, LANCET, V366, P371, DOI 10.1016/S0140-6736(05)66786-4; Diener HC, 2012, NAT REV NEUROL, V8, P162, DOI 10.1038/nrneurol.2012.13; Diener Hans-Christoph, 2010, Handb Clin Neurol, V97, P547, DOI 10.1016/S0072-9752(10)97050-4; DIENER HC, 1989, J NEUROL, V236, P9, DOI 10.1007/BF00314210; Diener HC, 2006, HEADACHES, P971; Dieterich M, 1999, J NEUROL, V246, P883, DOI 10.1007/s004150050478; Dignan F, 2001, ARCH DIS CHILD, V84, P415, DOI 10.1136/adc.84.5.415; Dinwiddie SH, 2010, J ECT, V26, P116, DOI 10.1097/YCT.0b013e3181b07c0a; Diyora Batuk, 2013, Asian J Neurosurg, V8, P162, DOI 10.4103/1793-5482.121689; Dlamini N, 2011, J CHILD NEUROL, V26, P1203, DOI 10.1177/0883073811408904; Dodick DW, 2000, CEPHALALGIA, V20, P509, DOI 10.1046/j.1468-2982.2000.00073.x; Dodick DW, 2000, HEADACHE, V40, P748, DOI 10.1046/j.1526-4610.2000.00131.x; Dodick DW, 1999, CEPHALALGIA, V19, P118, DOI 10.1046/j.1468-2982.1999.019002118.x; Dodick DW, 2000, HEADACHE, V40, P830, DOI 10.1046/j.1526-4610.2000.00150.x; Dodick DW, 1998, NEUROLOGY, V50, P1510, DOI 10.1212/WNL.50.5.1510; Doepp F, 2008, CEPHALALGIA, V28, P182, DOI 10.1111/j.1468-2982.2007.01484.x; Domachowske JB, 1996, PEDIATR INFECT DIS J, V15, P871, DOI 10.1097/00006454-199610000-00008; Domingues RB, 2006, CEPHALALGIA, V26, P879, DOI 10.1111/j.1468-2982.2006.01100.x; Donnet A, 2009, CEPHALALGIA, V29, P928, DOI 10.1111/j.1468-2982.2008.01826.x; Donnet A, 2009, NEUROLOGY, V72, pA419; Doran M, 2004, J NEUROL, V251, P100, DOI 10.1007/s00415-004-0219-4; Dowman CE, 1928, ARCH NEURO PSYCHIATR, V20, P1312, DOI 10.1001/archneurpsyc.1928.02210180163008; Drake KW, 2009, NEUROLOGY, V73, P1780, DOI 10.1212/WNL.0b013e3181c34b69; Drangsholt M, 2001, J EVID-BASED DENT PR, V1, P41, DOI DOI 10.1067/med.2001.116846; Dreier JP, 2005, NEUROLOGY, V64, P2145, DOI 10.1212/01.WNL.0000176298.63840.99; DREXLER ED, 1990, POSTGRAD MED, V87, P164; Drigo P, 2000, BRAIN DEV-JPN, V22, P169, DOI 10.1016/S0387-7604(00)00099-1; Drigo P, 2001, BRAIN DEV-JPN, V23, P38, DOI 10.1016/S0387-7604(01)00175-9; Drossman Douglas A, 2006, J Gastrointestin Liver Dis, V15, P237; Drummond P D, 1984, Clin Exp Neurol, V20, P93; Du Y, 2011, J CLIN NEUROSCI, V18, P902, DOI 10.1016/j.jocn.2010.11.011; Ducros A, 2012, BMJ-BRIT MED J, V345, pe8557; Ducros A, 2007, BRAIN, V130, P3091, DOI 10.1093/brain/awm256; Ducros A, 2010, STROKE, V41, P2505, DOI 10.1161/STROKEAHA.109.572313; DUNN DW, 1976, AM J DIS CHILD, V130, P1099, DOI 10.1001/archpedi.1976.02120110061008; Dworkin RH, 1996, PAIN, V67, P241, DOI 10.1016/0304-3959(96)03122-3; Eastwood JD, 1998, AM J NEURORADIOL, V19, P1789; EDIS RH, 1988, LANCET, V1, P993; Edlow JA, 2000, NEW ENGL J MED, V342, P29, DOI 10.1056/NEJM200001063420106; Edmonds RC, 1992, DIVING SUBAQUATIVE M, P404; Egermark I, 2001, ACTA ODONTOL SCAND, V59, P40, DOI 10.1080/000163501300035788; EHNI G, 1984, J NEUROSURG, V61, P961, DOI 10.3171/jns.1984.61.5.0961; EKBOM K, 1968, ARCH NEUROL-CHICAGO, V19, P487, DOI 10.1001/archneur.1968.00480050057005; EKBOM K, 1994, CEPHALALGIA, V14, P266, DOI 10.1046/j.1468-2982.1994.1404266.x; Ekbom K, 1947, ACTA PSYCHIAT SCAND, V46, P106; Eliav E, 2007, J AM DENT ASSOC, V138, P628, DOI 10.14219/jada.archive.2007.0234; ELISEVICH K, 1984, J NEUROL NEUROSUR PS, V47, P407, DOI 10.1136/jnnp.47.4.407; ELMALLAKH RS, 1991, HEADACHE, V31, P584; ELMALLAKH RS, 1987, HEADACHE, V27, P442; Empl M, 2003, CEPHALALGIA, V23, P584; Englund M, 2003, AVIAT SPACE ENVIR MD, V74, P236; EPSTEIN MA, 1990, J CHILD NEUROL, V5, P27, DOI 10.1177/088307389000500105; EPSTEIN MT, 1975, LANCET, V1, P543, DOI 10.1016/s0140-6736(75)91558-5; Eriksen MK, 2006, HEADACHE, V46, P286, DOI 10.1111/j.1526-4610.2006.00286.x; Eriksen MK, 2005, CEPHALALGIA, V25, P801, DOI 10.1111/j.1468-2982.2005.00955.x; Eriksen MK, 2004, CEPHALALGIA, V24, P564, DOI 10.1111/j.1468-2982.2003.00718.x; Eulenberg A, 1878, LEHRBUCH NERVENKRANK; Evans Randolph W, 2003, Curr Pain Headache Rep, V7, P303, DOI 10.1007/s11916-003-0051-z; Evans RW, 2000, HEADACHE, V40, P696, DOI 10.1046/j.1526-4610.2000.040008696.x; Evans RW, 2000, HEADACHE, V40, P692, DOI 10.1046/j.1526-4610.2000.040008692.x; Evans RW, 2004, NEUROL CLIN, V22, P237, DOI 10.1016/S0733-8619(03)00097-5; Evans RW, 1996, NEUROL CLIN, V14, P1, DOI 10.1016/S0733-8619(05)70240-1; Evans RW, 2001, HEADACHE, V41, P830, DOI 10.1046/j.1526-4610.2001.01152.x; Evers S, 2000, PAIN, V85, P191, DOI 10.1016/S0304-3959(99)00266-3; Evers S, 2003, NEUROLOGY, V60, P905, DOI 10.1212/01.WNL.0000046582.21771.9C; Evers S, 1999, CLIN NEUROPHARMACOL, V22, P201; FANCIULLACCI M, 1995, PAIN, V60, P119, DOI 10.1016/0304-3959(94)00097-X; Farazmand P, 2011, INT J STD AIDS, V22, P306, DOI 10.1258/ijsa.2010.010405; FARQUHAR HG, 1956, BRIT MED J, V1, P1082, DOI 10.1136/bmj.1.4975.1082; Fasano V A, 1982, Adv Neurol, V33, P399; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fazzone HE, 2003, OPHTHALMOLOGY, V110, P1646, DOI 10.1016/S0161-6420(03)00477-9; FENICHEL GM, 1967, J PEDIATR-US, V71, P114, DOI 10.1016/S0022-3476(67)80239-7; FENICHEL NM, 1948, ANN INTERN MED, V29, P456, DOI 10.7326/0003-4819-29-3-456; Fernandez-De-Las-Penas C, 2007, CEPHALALGIA, V27, P383, DOI 10.1111/j.1468-2982.2007.01295.x; Fernandez-de-las-Penas C, 2007, CEPHALALGIA, V27, P182, DOI 10.1111/j.1468-2982.2007.01253.x; Fernandez-de-las-Penas C, 2007, CLIN J PAIN, V23, P346, DOI 10.1097/AJP.0b013e31803b3770; Fernandez-de-las-Penas C, 2007, HEADACHE, V47, P662, DOI 10.1111/j.1526-4610.2006.00632.x; Fernandez-de-las-Penas C, 2006, MANUAL THER, V11, P225, DOI 10.1016/j.math.2006.07.003; Fernandez-De-Las-Penas C, 2006, HEADACHE, V46, P1264, DOI 10.1111/j.1526-4610.2006.00440.x; Fernandaz-de-las-Penas C, 2009, CURR OPIN NEUROL, V22, P254, DOI 10.1097/WCO.0b013e32832973ce; FERRO JM, 1995, HEADACHE, V35, P544, DOI 10.1111/j.1526-4610.1995.hed3509544.x; Ferro JM, 1998, NEUROLOGY, V50, P203, DOI 10.1212/WNL.50.1.203; FERRO JM, 1995, HEADACHE, V35, P315, DOI 10.1111/j.1526-4610.1995.hed3506315.x; Find NL, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0612-2; Fisayo A, 2016, NEUROLOGY, V86, P341, DOI 10.1212/WNL.0000000000002318; Fisher C M, 1971, Clin Neurosurg, V18, P267; Fisher C M, 1968, Trans Am Neurol Assoc, V93, P211; FISHER CM, 1980, CAN J NEUROL SCI, V7, P9; FISHER CM, 1982, HEADACHE, V22, P60, DOI 10.1111/j.1526-4610.1982.hed2202060.x; Fitzek S, 2001, ANN NEUROL, V49, P493; FLEETCROFT R, 1985, J ROY SOC MED, V78, P676, DOI 10.1177/014107688507800817; Fleisher DR, 1999, J PEDIATR-US, V134, P533, DOI 10.1016/S0022-3476(99)70234-9; Forbes HS, 1924, ARCH NEURO PSYCHIATR, V11, P264, DOI 10.1001/archneurpsyc.1924.02190330014002; Forderreuther S, 2002, HEADACHE, V42, P649, DOI 10.1046/j.1526-4610.2002.02154.x; Formisano R, 2009, J HEADACHE PAIN, V10, P145, DOI 10.1007/s10194-009-0108-4; Forssell H, 2002, PAIN, V99, P41, DOI 10.1016/S0304-3959(02)00052-0; Forssell H, 2007, NEUROLOGY, V69, P1451, DOI 10.1212/01.wnl.0000277274.83301.c0; FORSYTH PA, 1993, NEUROLOGY, V43, P1678, DOI 10.1212/WNL.43.9.1678; FORTIN CJ, 1985, HEADACHE, V25, P255, DOI 10.1111/j.1526-4610.1985.hed2505255.x; FRANCKE E, 1987, POSTGRAD MED, V82, P175, DOI 10.1080/00325481.1987.11699934; Franco AL, 2010, J OROFAC PAIN, V24, P287; Fredriksen TA, 2000, CLIN EXP RHEUMATOL, V18, pS16; French H, 2014, OCHSNER J, V14, P188; Frese A, 2007, CEPHALALGIA, V27, P1265, DOI 10.1111/j.1468-2982.2007.01449.x; Frese A, 2003, NEUROLOGY, V61, P796, DOI 10.1212/01.WNL.0000083988.98336.A3; Friedenberg S, 2000, HEADACHE, V40, P487, DOI 10.1046/j.1526-4610.2000.00074.x; Friedman DI, 2017, HEADACHE, V57, P1195, DOI 10.1111/head.13153; Friedman DI, 2013, NEUROLOGY, V81, P1159, DOI 10.1212/WNL.0b013e3182a55f17; Friedman DI, 2004, J NEURO-OPHTHALMOL, V24, P138, DOI 10.1097/00041327-200406000-00009; Friedman J, 2001, NEUROL CLIN, V19, P681, DOI 10.1016/S0733-8619(05)70040-2; Fritsche G, 2010, PAIN, V151, P404, DOI 10.1016/j.pain.2010.07.032; FROMM GH, 1990, NEUROLOGY, V40, P1493, DOI 10.1212/WNL.40.10.1493; Fuentes B, 1998, CEPHALALGIA, V18, P570, DOI 10.1046/j.1468-2982.1998.1808570.x; Fuh JL, 2007, CEPHALALGIA, V27, P1005, DOI 10.1111/j.1468-2982.2007.01365.x; Fuh JL, 2003, CEPHALALGIA, V23, P977, DOI 10.1046/j.1468-2982.2003.00620.x; Fumal A, 2005, CEPHALALGIA, V25, P754, DOI 10.1111/j.1468-2982.2004.00945.x; Fumal A, 2008, LANCET NEUROL, V7, P70, DOI 10.1016/S1474-4422(07)70325-3; Furlan JC, 2011, NEUROLOGY, V77, P792, DOI 10.1212/WNL.0b013e31822afff1; Fusco C, 2003, BRAIN DEV-JPN, V25, P237, DOI 10.1016/S0387-7604(02)00216-4; Gaist D, 1998, BMJ-BRIT MED J, V316, P1352, DOI 10.1136/bmj.316.7141.1352; Gaist D, 1996, EUR J CLIN PHARMACOL, V50, P161, DOI 10.1007/s002280050086; Gambini O, 2010, NEUROL SCI, V31, P111, DOI 10.1007/s10072-010-0300-y; Garg RK, 2001, CEPHALALGIA, V21, P78, DOI 10.1046/j.1468-2982.2001.00171.x; Garza I, 2008, HEADACHE, V48, P1120, DOI 10.1111/j.1526-4610.2008.01149.x; GEDDE-DAHL T W, 1980, NIPH (National Institute of Public Health) Annals (Oslo), V3, P31; Gee JR, 2003, HEADACHE, V43, P276, DOI 10.1046/j.1526-4610.2003.03053.x; Gelfand AA, 2018, CEPHALALGIA, V38, P374, DOI 10.1177/0333102416681570; Gelfand AA, 2012, J CHILD NEUROL, V27, P759, DOI 10.1177/0883073811426502; Gelfand AA, 2010, NEUROLOGY, V75, pE16, DOI 10.1212/WNL.0b013e3181ebdd53; Gentile S, 2009, CEPHALALGIA, V29, P687, DOI 10.1111/j.1468-2982.2008.01803.x; Gerling J, 1998, NEURO-OPHTHALMOLOGY, V19, P93, DOI 10.1076/noph.19.2.93.3947; GHOSE K, 1984, NEUROPSYCHOBIOLOGY, V12, P122, DOI 10.1159/000118123; Giffin NJ, 2016, NEUROLOGY, V87, P309, DOI 10.1212/WNL.0000000000002789; Giffin NJ, 2002, DEV MED CHILD NEUROL, V44, P490; Gil-Gouveia R, 2007, J NEUROL, V254, P646, DOI 10.1007/s00415-006-0424-4; Gil-Gouveia R, 2007, J NEUROL, V254, P591, DOI 10.1007/s00415-006-0330-9; Gil-Gouveia RS, 2008, J HEADACHE PAIN, V9, P327, DOI 10.1007/s10194-008-0057-3; GINSBERG MD, 1985, J TOXICOL-CLIN TOXIC, V23, P281, DOI 10.3109/15563658508990635; Gipponi S, 2010, NEUROL SCI, V31, P171, DOI 10.1007/s10072-010-0322-5; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Glaros AG, 2007, CEPHALALGIA, V27, P542, DOI 10.1111/j.1468-2982.2007.01325.x; Goadsby PJ, 2008, HEADACHE, V48, P799, DOI 10.1111/j.1526-4610.2008.01157.x; Goadsby PJ, 1997, BRAIN, V120, P193, DOI 10.1093/brain/120.1.193; Goadsby PJ, 2006, BMJ-BRIT MED J, V332, P25, DOI 10.1136/bmj.332.7532.25; Goadsby PJ, 2005, HEADACHE, V45, pS14, DOI 10.1111/j.1526-4610.2005.4501003.x; Goadsby PJ, 2002, J NEUROL NEUROSUR PS, V72, P297, DOI 10.1136/jnnp.72.3.297; Goadsby PJ, 2002, J NEUROL NEUROSUR PS, V72, P6; Goadsby PJ, 2002, LANCET NEUROL, V1, P251, DOI 10.1016/S1474-4422(02)00104-7; Goadsby PJ, 2001, CEPHALALGIA, V21, P82, DOI 10.1046/j.1468-2982.2001.00175.x; Goadsby PJ, 2001, HEADACHE, V41, P608, DOI 10.1046/j.1526-4610.2001.041006608.x; Gobel H, 2001, PAIN, V91, P195, DOI 10.1016/S0304-3959(01)00292-5; Gobel H, 2000, HEADACHES, P899; Gobel H, 2000, HEADACHES, P891; Gobel H, 2000, HEADACHES, P905; Gobel H, 1997, MUNCHEN MED WOCHEN, V139, P456; Goksan B, 2009, CEPHALALGIA, V29, P635, DOI 10.1111/j.1468-2982.2008.01781.x; Goksel BK, 2006, HEADACHE, V46, P40, DOI 10.1111/j.1526-4610.2006.00295.x; GomezAranda F, 1997, BRAIN, V120, P1105, DOI 10.1093/brain/120.7.1105; Gonzalez-Gay MA, 2005, MEDICINE, V84, P269, DOI 10.1097/01.md.0000180042.42156.d1; Gordon GE, 2001, OPHTHAL PHYSL OPT, V21, P45; GORELICK PB, 1986, NEUROLOGY, V36, P1445, DOI 10.1212/WNL.36.11.1445; GOSSOP M, 1995, ADDICTION, V90, P607, DOI 10.1046/j.1360-0443.1995.9056072.x; GOTO Y, 1989, J NEUROL, V236, P448, DOI 10.1007/BF00328504; Gould DB, 2006, NEW ENGL J MED, V354, P1489, DOI 10.1056/NEJMoa053727; Grace A, 1997, CEPHALALGIA, V17, P195, DOI 10.1046/j.1468-2982.1997.1703195.x; Graff-Radford J, 2016, EUR J NEUROL, V23, P839, DOI 10.1111/ene.12926; Grande RB, 2011, EUR J NEUROL, V18, P129, DOI 10.1111/j.1468-1331.2010.03094.x; Grande RB, 2009, CEPHALALGIA, V29, P1149, DOI 10.1111/j.1468-2982.2009.01842.x; Grande RB, 2009, J NEUROL NEUROSUR PS, V80, P784, DOI 10.1136/jnnp.2008.168864; GRANELLA F, 1994, CEPHALALGIA, V14, P16, DOI 10.1046/j.1468-2982.1994.1401016.x; Grazzi L, 2011, NEUROL SCI, V32, P299, DOI 10.1007/s10072-011-0696-z; Green MW, 2001, MED CLIN N AM, V85, P1085, DOI 10.1016/S0025-7125(05)70361-8; Greenough Glen P, 2002, Sleep Med, V3, P361, DOI 10.1016/S1389-9457(02)00006-0; Grosberg BM, 2006, CEPHALALGIA, V26, P1275, DOI 10.1111/j.1468-2982.2006.01206.x; Grosberg Brian M, 2007, Curr Pain Headache Rep, V11, P310, DOI 10.1007/s11916-007-0209-1; Guerrero AL, 2012, CEPHALALGIA, V32, P649, DOI 10.1177/0333102412447537; Guerrero AL, 2010, HEADACHE, V50, P451, DOI 10.1111/j.1526-4610.2009.01607.x; Guey S, 2016, CEPHALALGIA, V36, P1038, DOI 10.1177/0333102415620909; Guidetti V, 1998, CEPHALALGIA, V18, P455, DOI 10.1046/j.1468-2982.1998.1807455.x; Guillon B, 1998, J NEUROL SCI, V153, P146, DOI 10.1016/S0022-510X(97)00287-6; Gunduz A, 2012, HEADACHE, V52, P544, DOI 10.1111/j.1526-4610.2012.02096.x; Gunther M, 2010, OTOL NEUROTOL, V31, P1493, DOI 10.1097/MAO.0b013e3181f0c524; Gus M, 2001, ARCH INTERN MED, V161, P252, DOI 10.1001/archinte.161.2.252; Gutierrez-Morlote J, 2002, CEPHALALGIA, V22, P765, DOI 10.1046/j.1468-2982.2002.00418.x; Haan J, 2000, NEUROLOGY, V55, P1588, DOI 10.1212/WNL.55.10.1588; Haan J, 2002, CEPHALALGIA, V22, P552, DOI 10.1046/j.1468-2982.2002.00420.x; Haanpaa M, 1998, NEUROLOGY, V51, P1405, DOI 10.1212/WNL.51.5.1405; HAAS DC, 1982, ANN NEUROL, V11, P197; HAAS DC, 1991, HEADACHE, V31, P509, DOI 10.1111/j.1526-4610.1991.hed3108509.x; Hache M, 2016, J CHILD NEUROL, V31, P899, DOI 10.1177/0883073815627882; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hajj-Ali RA, 2011, LANCET NEUROL, V10, P561, DOI 10.1016/S1474-4422(11)70081-3; Hamilton W, 2007, BRIT J GEN PRACT, V57, P695; Hannerz J, 1998, CEPHALALGIA, V18, P124, DOI 10.1046/j.1468-2982.1998.1803123-4.x; HANNERZ J, 1993, CEPHALALGIA, V13, P361, DOI 10.1046/j.1468-2982.1993.1305361.x; Hansen AP, 2015, CEPHALALGIA, V35, P399, DOI 10.1177/0333102414545894; Hansen JM, 2016, CEPHALALGIA, V36, P216, DOI 10.1177/0333102415584601; Hansen JM, 2012, NEUROLOGY, V79, P2044, DOI 10.1212/WNL.0b013e3182749eed; Hansen JM, 2011, HEADACHE, V51, P1289, DOI 10.1111/j.1526-4610.2011.01963.x; Hansen JM, 2010, NEUROLOGY, V74, P594, DOI 10.1212/WNL.0b013e3181cff79d; HARNER SG, 1993, AM J OTOL, V14, P552; HARRIS LF, 1985, SOUTH MED J, V78, P704, DOI 10.1097/00007611-198506000-00022; Harris W, 1936, BRIT MED J, V1936, P457; Carvalho MDL, 2017, CEPHALALGIA, V37, P938, DOI 10.1177/0333102416658714; Cuadrado ML, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0557-9; Cuadrado ML, 2010, J HEADACHE PAIN, V11, P75, DOI 10.1007/s10194-009-0172-9; Traumatic Brain Injury (TBI) Task Force for the US Department of the Army, 2008, REP SURG GEN; Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6; AEBELHOLTKRABBE A, 1980, PAIN, V8, P253, DOI 10.1016/0304-3959(88)90012-7; [Anonymous], 1999, CEPHALALGIA, V19, P67, DOI 10.1046/j.1468-2982.1999.1901067.x; Martins HAD, 2009, ARQ NEURO-PSIQUIAT, V67, P43; Ribeiro MDD, 2013, CEPHALALGIA, V33, P897, DOI 10.1177/0333102413479833; Lucas CD, 2007, ACTA NEUROCHIR, V149, P1249, DOI 10.1007/s00701-007-1367-y; Fernandez-De-Las-Penas C, 2006, HEADACHE, V46, P1195, DOI 10.1111/j.1526-4610.2006.00511.x; HARRIS KG, 1994, AM J NEURORADIOL, V15, P317; Haviv Y, 2016, CEPHALALGIA, V36, P730, DOI 10.1177/0333102415611405; Hayashi T, 2000, NEUROL MED-CHIR, V40, P419, DOI 10.2176/nmc.40.419; HECKERLING PS, 1987, ANN INTERN MED, V107, P174, DOI 10.7326/0003-4819-107-2-174; Heckman Bernadette Davantes, 2006, Curr Pain Headache Rep, V10, P439, DOI 10.1007/s11916-006-0075-2; Heckmann JG, 1997, HEADACHE, V37, P597; HEDGES TR, 1976, STROKE, V7, P379, DOI 10.1161/01.STR.7.4.379; Heinzen EL, 2012, NAT GENET, V44, P1030, DOI 10.1038/ng.2358; Helbok R, 2009, J NEUROL, V256, P168, DOI 10.1007/s00415-009-0122-0; HERING R, 1991, LANCET, V337, P1442, DOI 10.1016/0140-6736(91)93129-W; Hernandez A, 1998, EUR J NEUROL, V5, P499, DOI 10.1046/j.1468-1331.1998.550499.x; Herrero-Velazquez S, 2011, REV NEUROLOGIA, V53, P531, DOI 10.33588/rn.5309.2011421; Heyer GL, 2016, CEPHALALGIA, V36, P309, DOI 10.1177/0333102415590240; Hill DL, 2007, J NEURO-OPHTHALMOL, V27, P3, DOI 10.1097/WNO.0b013e3180335222; HODGES J, 1986, Q J MED, V59, P387; HOLLANDER H, 1987, AM J MED, V83, P813, DOI 10.1016/0002-9343(87)90635-8; Holle D, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0505-0; Holle D, 2011, ANN NEUROL, V69, P533, DOI 10.1002/ana.22188; Holle D, 2010, CEPHALALGIA, V30, P1435, DOI 10.1177/0333102410375727; Holle D, 2011, CEPHALALGIA, V31, P286, DOI 10.1177/0333102410381146; Holroyd KA, 2000, HEADACHE, V40, P3, DOI 10.1046/j.1526-4610.2000.00001.x; Holroyd KA, 2001, JAMA-J AM MED ASSOC, V285, P2208, DOI 10.1001/jama.285.17.2208; Hong JH, 2010, EUR NEUROL, V64, P163, DOI 10.1159/000319040; HORTON B T, 1952, J Lancet, V72, P92; Hottenga JJ, 2005, CEPHALALGIA, V25, P1168, DOI 10.1111/j.1468-2982.2005.00994.x; Hou CC, 2011, EUR J PHARMACOL, V667, P6, DOI 10.1016/j.ejphar.2011.05.075; HUBBARD DR, 1993, SPINE, V18, P1803, DOI 10.1097/00007632-199310000-00015; HUNDER GG, 1990, RHEUM DIS CLIN N AM, V16, P399; Hung CI, 2009, J AFFECT DISORDERS, V117, P108, DOI 10.1016/j.jad.2008.12.015; Iizuka T, 2012, J NEUROL NEUROSUR PS, V83, P205, DOI 10.1136/jnnp-2011-300843; ILLE O, 1995, STROKE, V26, P488, DOI 10.1161/01.STR.26.3.488; Irimia P, 2008, CEPHALALGIA, V28, P626, DOI 10.1111/j.1468-2982.2008.01565.x; Ito M, 2004, CEPHALALGIA, V24, P23, DOI 10.1111/j.1468-2982.2004.00628.x; Ito M, 2003, PSYCHIAT CLIN NEUROS, V57, P385, DOI 10.1046/j.1440-1819.2003.01136.x; Iversen H, 1987, CEPHALALGIA S7, V6, P394; IVERSEN HK, 1989, PAIN, V38, P17, DOI 10.1016/0304-3959(89)90067-5; Jaaskelainen SK, 2005, PAIN, V117, P349, DOI 10.1016/j.pain.2005.06.028; Jaaskelainen SK, 1997, PAIN, V73, P455, DOI 10.1016/S0304-3959(97)00140-1; Jacob Mary K, 2014, Middle East Afr J Ophthalmol, V21, P344, DOI 10.4103/0974-9233.142275; Jafarian S, 2007, CEPHALALGIA, V27, P899, DOI 10.1111/j.1468-2982.2007.01351.x; Jager HR, 2005, CEPHALALGIA, V25, P323, DOI 10.1111/j.1468-2982.2004.00858.x; JAMESON MD, 1990, MED CLIN N AM, V74, P945, DOI 10.1016/S0025-7125(16)30528-4; Janke EA, 2004, PAIN, V111, P230, DOI 10.1016/j.pain.2004.06.007; JENSEN K, 1986, ACTA NEUROL SCAND, V73, P359, DOI 10.1111/j.1600-0404.1986.tb03290.x; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Jensen R, 1999, CEPHALALGIA, V19, P602, DOI 10.1046/j.1468-2982.1999.019006602.x; Jensen R, 1996, PAIN, V64, P251, DOI 10.1016/0304-3959(95)00114-X; JENSEN R, 1993, PAIN, V52, P193, DOI 10.1016/0304-3959(93)90131-8; JENSEN R, 1992, PAIN, V48, P197, DOI 10.1016/0304-3959(92)90059-K; Jensen R, 1998, HEADACHE, V38, P10, DOI 10.1046/j.1526-4610.1998.3801010.x; Jensen R, 2008, LANCET NEUROL, V7, P354, DOI 10.1016/S1474-4422(08)70062-0; Jensen R, 2010, CEPHALALGIA, V30, P1214, DOI 10.1177/0333102410361403; JENSEN TS, 1982, ACTA NEUROL SCAND, V65, P182; Jensen TS, 2000, HEADACHES, P781; John S, 2016, CEPHALALGIA, V36, P387, DOI 10.1177/0333102415591507; JONES HR, 1989, BRAIN, V112, P1295; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Jurkat-Rott K, 2004, NEUROLOGY, V62, P1857, DOI 10.1212/01.WNL.0000127310.11526.FD; Kaczorowski M, 2002, BRIT MED J, V325, P1445, DOI 10.1136/bmj.325.7378.1445; Kahn EN, 2015, NEUROSURG CLIN N AM, V26, P501, DOI 10.1016/j.nec.2015.06.006; Kalita J, 2011, PAIN MED, V12, P282, DOI 10.1111/j.1526-4637.2010.01046.x; Kalladka M, 2016, OR SURG OR MED OR PA, V122, pE55, DOI 10.1016/j.oooo.2016.05.012; Kallela M, 1999, CEPHALALGIA, V19, P151, DOI 10.1046/j.1468-2982.1999.1903151.x; Kandan SR, 2010, BRIT J NEUROSURG, V24, P441, DOI 10.3109/02688697.2010.487131; Karaali-Savrun F, 2002, SEIZURE-EUR J EPILEP, V11, P67, DOI 10.1053/seiz.2001.0583; Katsarava Z, 2011, CEPHALALGIA, V31, P520, DOI 10.1177/0333102410383590; Katsarava Z, 2001, NEUROLOGY, V57, P1694, DOI 10.1212/WNL.57.9.1694; KAUBE H, 1994, BRIT MED J, V308, P1573, DOI 10.1136/bmj.308.6943.1573d; Kaur A, 2000, NEUROSURGERY, V47, P633; Kelman L, 2004, HEADACHE, V44, P865, DOI 10.1111/j.1526-4610.2004.04168.x; Kennard C, 1991, CLIN NEUROLOGY, P446; Kennedy PG, 1998, NEUROPATHOL APPL NEU, V14, P395; Kennedy PG, 1988, OJM, V86, P533; Kenny TJ, 2001, OTOLARYNG HEAD NECK, V125, P40, DOI 10.1067/mhn.2001.116779; Kernick DP, 2008, BRIT J GEN PRACT, V58, P880, DOI 10.3399/bjgp08X376203; Kertesz DP, 2015, J ECT, V31, P105, DOI 10.1097/YCT.0000000000000179; Killeen A, 2015, J CLIN NEUROSCI, V22, P133, DOI 10.1016/j.jocn.2014.06.008; Kim JG, 2015, CEPHALALGIA, V35, P516, DOI 10.1177/0333102414547135; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kirby S, 2010, CEPHALALGIA, V30, P387, DOI 10.1111/j.1468-2982.2009.02023.x; Kirchmann M, 2006, NEUROLOGY, V66, P880, DOI 10.1212/01.wnl.0000203647.48422.dd; Kirk C, 2008, DEV MED CHILD NEUROL, V50, P422, DOI 10.1111/j.1469-8749.2008.02063.x; Kirkland KE, 2012, HEADACHE, V52, P455, DOI 10.1111/j.1526-4610.2011.02025.x; Kivelev J, 2010, J NEUROSURG, V112, P140, DOI 10.3171/2009.3.JNS081693; Kjeldgaard D, 2014, CEPHALALGIA, V34, P191, DOI 10.1177/0333102413505236; KLAPPER J, 1994, HEADACHE, V34, P521, DOI 10.1111/j.1526-4610.1994.hed3409521.x; Klasser GD, 2007, J OROFAC PAIN, V21, P171; KLIMEK A, 1987, CEPHALALGIA, V7, P161, DOI 10.1046/j.1468-2982.1987.0702161.x; Klit H, 2009, LANCET NEUROL, V8, P857, DOI 10.1016/S1474-4422(09)70176-0; Klopstock T, 1996, NEUROLOGY, V46, P1735, DOI 10.1212/WNL.46.6.1735; Knackstedt H, 2010, CEPHALALGIA, V30, P1468, DOI 10.1177/0333102410368442; Koerbel A, 2005, BRIT J RADIOL, V78, P646, DOI 10.1259/bjr/60601877; Kone L, 2017, CEPHALALGIA, V37, P442, DOI 10.1177/0333102416648654; KOO B, 1993, ANN NEUROL, V34, P25, DOI 10.1002/ana.410340107; Koopman JSHA, 2009, PAIN, V147, P122, DOI 10.1016/j.pain.2009.08.023; Kraemer M, 2017, CEPHALALGIA, V37, P496, DOI 10.1177/0333102416643516; Kreiner M, 1996, J CRANIO MAXILL SURG, V24, P289, DOI 10.1016/S1010-5182(96)80061-8; Kristiansen HA, 2012, CEPHALALGIA, V32, P451, DOI 10.1177/0333102411431900; Kristiansen HA, 2011, J HEADACHE PAIN, V12, P63, DOI 10.1007/s10194-010-0265-5; Kristoffersen ES, 2016, J NEUROL, V263, P344, DOI 10.1007/s00415-015-7975-1; Kristoffersen ES, 2015, J NEUROL NEUROSUR PS, V86, P505, DOI 10.1136/jnnp-2014-308548; Kruszewski P, 2000, J HYPERTENS, V18, P437, DOI 10.1097/00004872-200018040-00013; Kruuse C, 2003, BRAIN, V126, P241, DOI 10.1093/brain/awg009; Kruuse C, 2002, J CEREBR BLOOD F MET, V22, P1124, DOI 10.1097/00004647-200209000-00010; Kruuse C, 2000, J CEREBR BLOOD F MET, V20, P1372, DOI 10.1097/00004647-200009000-00012; Krymchantowski AV, 2010, CURR PAIN HEADACHE R, V14, P321, DOI 10.1007/s11916-010-0122-x; KUDROW DB, 1989, HEADACHE, V29, P280, DOI 10.1111/j.1526-4610.1989.hed2905280.x; Kudrow L, 1980, CLUSTER HEADACHE MEC; KULALI A, 1990, ACTA NEUROCHIR, V107, P140, DOI 10.1007/BF01405793; KUMAR KL, 1993, J GEN INTERN MED, V8, P333, DOI 10.1007/BF02600150; Kumar R, 1997, J NEUROL NEUROSUR PS, V62, P649, DOI 10.1136/jnnp.62.6.649; Kung E, 2009, CEPHALALGIA, V29, P17, DOI 10.1111/j.1468-2982.2008.01647.x; Kunkle E. Charles, 1942, BULL NEW YORK ACAD MED, V18, P400; Kurtuncu M, 2013, CEPHALALGIA, V33, P123, DOI 10.1177/0333102412463494; Kwan P, 2008, EPILEPSIA, V49, P1099, DOI 10.1111/j.1528-1167.2008.01574.x; La Mantia L, 2006, CEPHALALGIA, V26, P772, DOI 10.1111/j.1468-2982.2006.01115.x; Leal PRL, 2014, J NEUROSURG, V120, P1484, DOI 10.3171/2014.2.JNS131288; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Lake AE, 2005, HEADACHE, V45, P493, DOI 10.1111/j.1526-4610.2005.05101.x; Lake AE, 2001, MED CLIN N AM, V85, P1055, DOI 10.1016/S0025-7125(05)70359-X; Lam DK, 2001, J OROFAC PAIN, V15, P146; Lam S, 2015, J PEDIATR NEUROSCI, V10, P321, DOI 10.4103/1817-1745.174443; LANCE JW, 1976, J NEUROL NEUROSUR PS, V39, P1226, DOI 10.1136/jnnp.39.12.1226; LANCE JW, 1980, J NEUROL NEUROSUR PS, V43, P97, DOI 10.1136/jnnp.43.2.97; Lance JW, 1998, HEADACHE, V38, P315, DOI 10.1046/j.1526-4610.1998.3804315.x; Lance JW, 2001, CEPHALALGIA, V21, P84, DOI 10.1046/j.1468-2982.2001.00160.x; LANCE JW, 1976, ARCH NEUROL-CHICAGO, V33, P281, DOI 10.1001/archneur.1976.00500040065011; Landtblom AM, 2002, CEPHALALGIA, V22, P354, DOI 10.1046/j.1468-2982.2002.00368.x; Lanfranconi S, 2009, J NEUROL SCI, V285, P227, DOI 10.1016/j.jns.2009.06.009; LANGEMARK M, 1993, ARCH NEUROL-CHICAGO, V50, P1061, DOI 10.1001/archneur.1993.00540100056015; LANGEMARK M, 1989, PAIN, V38, P203, DOI 10.1016/0304-3959(89)90239-X; LANGEMARK M, 1987, CEPHALALGIA, V7, P249, DOI 10.1046/j.1468-2982.1987.0704249.x; Langridge B, 2017, WORLD NEUROSURG, V104, P213, DOI 10.1016/j.wneu.2017.04.082; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; LASKA EM, 1984, JAMA-J AM MED ASSOC, V251, P1711, DOI 10.1001/jama.251.13.1711; LASSEN LH, 1995, NEUROREPORT, V6, P1475, DOI 10.1097/00001756-199507310-00003; Laurell K, 2011, EUR J NEUROL, V18, P1220, DOI 10.1111/j.1468-1331.2011.03364.x; Lauria G, 2005, PAIN, V115, P332, DOI 10.1016/j.pain.2005.03.028; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Lawrence John E, 2015, Psychiatr Danub, V27 Suppl 1, pS315; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lebedeva ER, 2018, CEPHALALGIA, V38, P561, DOI 10.1177/0333102417702121; Lee AG, 1999, J AM GERIATR SOC, V47, P1364, DOI 10.1111/j.1532-5415.1999.tb07442.x; Lee A, 2014, J NEUROSURG, V120, P1048, DOI 10.3171/2014.1.JNS131410; Lee CC, 2000, AM J EMERG MED, V18, P328, DOI 10.1016/S0735-6757(00)90130-X; Lee MJ, 2016, J HEADACHE PAIN, V17, DOI [10.1186/s10194-016-0662-5, 10.1186/s10194-016-0615-z]; LEFKOWITZ D, 1982, ARCH NEUROL-CHICAGO, V39, P130, DOI 10.1001/archneur.1982.00510140064019; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Leistad RB, 2006, CEPHALALGIA, V26, P64, DOI 10.1111/j.1468-2982.2005.00997.x; Leker RR, 1999, EUR J NEUROL, V6, P601, DOI 10.1046/j.1468-1331.1999.650601.x; Leligdowicz A, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1325-2; Lempert T, 2012, J VESTIBUL RES-EQUIL, V22, P167, DOI 10.3233/VES-2012-0453; Lempert T, 2009, ANN NY ACAD SCI, V1164, P242, DOI 10.1111/j.1749-6632.2009.03852.x; Lenaerts M, 2015, CEPHALALGIA, V35, P143; Lenaerts ME, 2008, CEPHALALGIA, V28, P12, DOI 10.1111/j.1468-2982.2008.01608.x; Lenck S, 2017, NEUROSURGERY, V80, P393, DOI 10.1227/NEU.0000000000001261; Leniger T, 2001, EPILEPSIA, V42, P1176, DOI 10.1046/j.1528-1157.2001.37500.x; Leo L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002129; LEON AS, 1989, ARCH INTERN MED, V149, P2318, DOI 10.1001/archinte.149.10.2318; Leone M, 2000, NEUROLOGY, V55, P136, DOI 10.1212/WNL.55.1.136; Leone M, 1998, PAIN, V78, P1, DOI 10.1016/S0304-3959(98)00116-X; LEONE M, 1995, HEADACHE, V35, P461, DOI 10.1111/j.1526-4610.1995.hed3508461.x; Leotta N, 2005, J PAEDIATR CHILD H, V41, P508, DOI 10.1111/j.1440-1754.2005.00693.x; Levine HL, 2000, ARCH OTOLARYNGOL, V126, P234; LEVITON A, 1975, HEADACHE, V15, P207, DOI 10.1111/j.1526-4610.1975.hed1503207.x; Levy MJ, 2005, BRAIN, V128, P1921, DOI 10.1093/brain/awh525; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lewis DW, 2003, HEADACHE, V43, P132, DOI 10.1046/j.1526-4610.2003.03032.x; Lewis J, 1998, HEADACHE, V38, P684, DOI 10.1046/j.1526-4610.1998.3809684.x; Li B U, 2001, Semin Pediatr Neurol, V8, P13, DOI 10.1053/spen.2001.23456; Li BUK, 2008, J PEDIATR GASTR NUTR, V47, P379, DOI 10.1097/MPG.0b013e318173ed39; Li D, 2002, CEPHALALGIA, V22, P66, DOI 10.1046/j.1468-2982.2002.00326.x; Li D, 2015, CEPHALALGIA, V35, P748, DOI 10.1177/0333102414559731; Liang JF, 2008, CEPHALALGIA, V28, P209, DOI 10.1111/j.1468-2982.2007.01496.x; Liang JF, 2014, CEPHALALGIA, V34, P795, DOI 10.1177/0333102414537914; Lichten EM, 1996, HEADACHE, V36, P367, DOI 10.1046/j.1526-4610.1996.3606367.x; LIE JT, 1992, HUM PATHOL, V23, P164, DOI 10.1016/0046-8177(92)90238-X; Liesegang TJ, 2008, OPHTHALMOLOGY, V115, pS3, DOI 10.1016/j.ophtha.2007.10.009; Limmroth V, 1999, LANCET, V353, P378, DOI 10.1016/S0140-6736(05)74950-3; Limmroth V, 2002, NEUROLOGY, V59, P1011, DOI 10.1212/WNL.59.7.1011; Linde M, 2017, EUR J NEUROL, V24, P1055, DOI 10.1111/ene.13334; Lindelof K, 2010, CEPHALALGIA, V30, P860, DOI 10.1177/0333102409354783; Lindelof K, 2009, CLIN NEUROPHYSIOL, V120, P1364, DOI 10.1016/j.clinph.2009.04.013; Linn FHH, 2002, NEUROLOGIST, V8, P279, DOI 10.1097/00127893-200209000-00001; LINN FHH, 1994, LANCET, V344, P590, DOI 10.1016/S0140-6736(94)91970-4; Linn FHH, 1998, J NEUROL NEUROSUR PS, V65, P791, DOI 10.1136/jnnp.65.5.791; Linn FHH, 1999, J NEUROL, V246, P946, DOI 10.1007/s004150050488; Lipton RB, 2004, NEUROLOGY, V63, P427, DOI 10.1212/01.WNL.0000133301.66364.9B; LIPTON RB, 1989, HEADACHE, V29, P225, DOI 10.1111/j.1526-4610.1989.hed22904225.x; Lipton RB, 1997, HEADACHE, V37, P392, DOI 10.1046/j.1526-4610.1997.3706392.x; Lipton RB, 1997, NEUROLOGY, V49, P813, DOI 10.1212/WNL.49.3.813; Lisotto C, 2004, CEPHALALGIA, V24, P1001, DOI 10.1111/j.1468-2982.2004.00784.x; List T, 2001, J OROFAC PAIN, V15, P218; List T, 2008, PAIN, V139, P333, DOI 10.1016/j.pain.2008.05.002; LIU GT, 1995, NEUROLOGY, V45, P664, DOI 10.1212/WNL.45.4.664; Loh KC, 1997, QJM-MON J ASSOC PHYS, V90, P51; Loh NK, 1999, ARCH INTERN MED, V159, P1765, DOI 10.1001/archinte.159.15.1765; LORD SM, 1994, J NEUROL NEUROSUR PS, V57, P1187, DOI 10.1136/jnnp.57.10.1187; Lord SM., 1996, J MUSCULOSKELET PAIN, V4, P81; Lowry JK, 1998, ARCH NEUROL-CHICAGO, V55, P922, DOI 10.1001/archneur.55.7.922; Lu SR, 2004, NEUROLOGY, V62, P1414, DOI 10.1212/01.WNL.0000120669.85649.77; Lucas S, 2014, CEPHALALGIA, V34, P93, DOI 10.1177/0333102413499645; Lucas S, 2012, CEPHALALGIA, V32, P600, DOI 10.1177/0333102412445224; Lucchesi LM, 2010, CEPHALALGIA, V30, P1477, DOI 10.1177/0333102410368440; LUDA E, 1991, HEADACHE, V31, P582, DOI 10.1111/j.1526-4610.1991.hed3109582.x; LUNDBERG PO, 1988, FRONT GYN E, P149; Lundqvist C, 2012, PAIN, V153, P682, DOI 10.1016/j.pain.2011.12.008; Lyngberg AC, 2005, EUR J EPIDEMIOL, V20, P243, DOI 10.1007/s10654-004-6519-2; Maarbjerg S, 2015, BRAIN, V138, P311, DOI 10.1093/brain/awu349; MacGowan DJL, 1997, NEUROLOGY, V49, P120, DOI 10.1212/WNL.49.1.120; MacGregor EA, 1998, BRIT J FAM PLAN, V24, P53; Mack KJ, 2009, CURR PAIN HEADACHE R, V13, P47, DOI 10.1007/s11916-009-0010-4; Mack KJ, 2004, PEDIATR NEUROL, V31, P122, DOI 10.1016/j.pediatrneurol.2004.02.006; Maggioni F, 2008, HEADACHE, V48, P1129, DOI 10.1111/j.1526-4610.2008.01091.x; Magnusson T, 2000, J OROFAC PAIN, V14, P310; MAGOS AL, 1986, BRIT J OBSTET GYNAEC, V93, P1290, DOI 10.1111/j.1471-0528.1986.tb07868.x; Mainardi F, 2012, CEPHALALGIA, V32, P592, DOI 10.1177/0333102412441720; Mainardi F, 2018, CEPHALALGIA, V38, P1119, DOI 10.1177/0333102417724154; Maizels M, 2004, HEADACHE, V44, P983, DOI 10.1111/j.1526-4610.2004.04192.x; Malek AM, 1998, NEUROIMAG CLIN N AM, V8, P445; MALOUF R, 1985, ANN NEUROL, V17, P421, DOI 10.1002/ana.410170502; Mannelli M, 1999, EUR J ENDOCRINOL, V141, P619, DOI 10.1530/eje.0.1410619; MANZONI GC, 1991, CEPHALALGIA, V11, P169, DOI 10.1046/j.1468-2982.1991.1104169.x; MANZONI GC, 1983, CEPHALALGIA, V3, P21, DOI 10.1046/j.1468-2982.1983.0301021.x; Manzoni GC, 1998, CEPHALALGIA, V18, P138, DOI 10.1046/j.1468-2982.1998.1803138.x; Manzoni GC, 2011, J HEADACHE PAIN, V12, P585, DOI 10.1007/s10194-011-0393-6; Marazziti D, 1999, INT CLIN PSYCHOPHARM, V14, P247, DOI 10.1097/00004850-199907000-00007; Marchioni E, 2006, CEPHALALGIA, V26, P1427, DOI 10.1111/j.1468-2982.2006.01213.x; MARKS DA, 1993, NEUROLOGY, V43, P2476, DOI 10.1212/WNL.43.12.2476; MARKUS HS, 1991, J NEUROL NEUROSUR PS, V54, P1117, DOI 10.1136/jnnp.54.12.1117; Martelletti Paolo, 2005, J Headache Pain, V6, P261, DOI 10.1007/s10194-005-0202-1; Martin TJ, 2001, WOLFFS HEADACHE OTHE, P459; Martinez-Salio A, 2000, HEADACHE, V40, P682, DOI 10.1046/j.1526-4610.2000.040008682.x; MARTINS IP, 1993, HEADACHE, V33, P227, DOI 10.1111/j.1526-4610.1993.hed3305227.x; MARTINS IP, 1995, HEADACHE, V35, P107, DOI 10.1111/j.1526-4610.1995.hed3502107.x; Martsen BH, 1990, J NEUROL NEUROSUR PS, V53, P1029; MAS JL, 1986, STROKE, V17, P1019, DOI 10.1161/01.STR.17.5.1019; Matharu MS, 2001, NEUROLOGY, V56, P273, DOI 10.1212/WNL.56.2.273; Mathew NT, 2006, CURR NEUROL NEUROSCI, V6, P100, DOI 10.1007/s11910-996-0031-x; MATHEW NT, 1987, HEADACHE, V27, P102, DOI 10.1111/j.1526-4610.1987.hed2702102.x; Mathias CJ, 1999, J NEUROL, V246, P893, DOI 10.1007/s004150050479; Mattsson P, 2001, CEPHALALGIA, V21, P230, DOI 10.1046/j.1468-2982.2001.00211.x; Maurino J, 2001, ARCH NEUROL-CHICAGO, V58, P629, DOI 10.1001/archneur.58.4.629; May A, 1998, LANCET, V352, P275, DOI 10.1016/S0140-6736(98)02470-2; May A, 1999, J CEREBR BLOOD F MET, V19, P115; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCabe DJH, 1999, STROKE, V30, P2483, DOI 10.1161/01.STR.30.11.2483; McCluskey PJ, 1999, OPHTHALMOLOGY, V106, P2380, DOI 10.1016/S0161-6420(99)90543-2; McCrory P, 1997, PHYSICIAN SPORTSMED, V25, P33, DOI 10.3810/psm.1997.02.1133; MCFADZEAN RM, 1991, NEUROSURGERY, V29, P669, DOI 10.1227/00006123-199111000-00005; MCINTYRE PB, 1991, MED J AUSTRALIA, V154, P653, DOI 10.5694/j.1326-5377.1991.tb121250.x; Mea E, 2009, CEPHALALGIA, V29, P418, DOI 10.1111/j.1468-2982.2008.01747.x; Mea E, 2011, NEUROL SCI, V32, P291, DOI 10.1007/s10072-011-0698-x; Meineri P, 2004, NEUROL SCI, V25, pS281, DOI 10.1007/s10072-004-0310-8; Melo TP, 1996, NEUROLOGY, V47, P494, DOI 10.1212/WNL.47.2.494; MENDEZ MF, 1993, J NEUROPSYCH CLIN N, V5, P283; Merlino G, 2007, HEADACHE, V47, P919, DOI 10.1111/j.1526-4610.2007.00829.x; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Mills RJ, 2010, BRIT J RADIOL, V83, P493, DOI 10.1259/bjr/65228893; Minagar A, 2000, NEUROLOGY, V54, P1368, DOI 10.1212/WNL.54.6.1368; Mirsattari SM, 1999, HEADACHE, V39, P3, DOI 10.1046/j.1526-4610.1999.3901003.x; Missori P, 2000, ACTA NEUROCHIR, V142, P697, DOI 10.1007/s007010070115; Mitsikostas DD, 2008, CEPHALALGIA, V28, P139, DOI 10.1111/j.1468-2982.2007.01473.x; Mitsikostas DD, 1999, CEPHALALGIA, V19, P211, DOI 10.1046/j.1468-2982.1999.019004211.x; Molina OF, 2000, CRANIO, V18, P205, DOI 10.1080/08869634.2000.11746134; Monzillo PH, 2000, ARQ NEURO-PSIQUIAT, V58, P518, DOI 10.1590/S0004-282X2000000300019; Moon J, 2010, CEPHALALGIA, V30, P1527, DOI 10.1177/0333102410368445; Moore PM, 1994, SEMIN NEUROL, V14, P313; MORALES F, 1994, CEPHALALGIA, V14, P301, DOI 10.1046/j.1468-2982.1994.1404301.x; Moreau T, 1998, CEPHALALGIA, V18, P687, DOI 10.1046/j.1468-2982.1998.1810687.x; Moris G, 2014, JAMA INTERN MED, V174, P1511, DOI 10.1001/jamainternmed.2014.2918; Mork H, 2004, CEPHALALGIA, V24, P466, DOI 10.1111/j.1468-2982.2004.00709.x; Mork H, 2003, EUR J NEUROL, V10, P249, DOI 10.1046/j.1468-1331.2003.00570.x; Morrison DG, 2003, OPHTHALMOLOGY, V110, P115, DOI 10.1016/S0161-6420(02)01444-6; MORRISON DP, 1990, CEPHALALGIA, V10, P273, DOI 10.1046/j.1468-2982.1990.1006273.x; Mortimer AM, 2013, CLIN RADIOL, V68, pE101, DOI 10.1016/j.crad.2012.08.032; MOSEK A, 1995, NEUROLOGY, V45, P1953, DOI 10.1212/WNL.45.11.1953; Mueller D, 2011, CEPHALALGIA, V31, P1542, DOI 10.1177/0333102411424619; Mukhtyar C, 2009, ANN RHEUM DIS, V68, P318, DOI 10.1136/ard.2008.088351; Mulero P, 2011, J HEADACHE PAIN, V12, P535, DOI 10.1007/s10194-011-0353-1; Mulleners WM, 1996, NEUROLOGY, V47, P302, DOI 10.1212/WNL.47.1.302; MUNARI LM, 1994, CEPHALALGIA, V14, P127, DOI 10.1046/j.1468-2982.1994.1402127.x; MURPHREE HB, 1967, FED PROC, V26, P1468; Murphy E, 2001, J Ir Dent Assoc, V47, P46; Mutton Kenneth, 2011, Infectious Disorders - Drug Targets, V11, P206; Nakatomi H, 1997, STROKE, V28, P1278, DOI 10.1161/01.STR.28.6.1278; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nappi RE, 2001, MATURITAS, V38, P157, DOI 10.1016/S0378-5122(00)00215-2; Natoli JL, 2010, CEPHALALGIA, V30, P599, DOI 10.1111/j.1468-2982.2009.01941.x; Neely ET, 2009, HEADACHE, V49, P1089, DOI 10.1111/j.1526-4610.2009.001460.x; Neff BA, 2012, OTOL NEUROTOL, V33, P1235, DOI 10.1097/MAO.0b013e31825d644a; Nesher R, 2014, ACTA NEUROL BELG, V114, P269, DOI 10.1007/s13760-014-0290-2; Nestoriuc Y, 2008, J CONSULT CLIN PSYCH, V76, P379, DOI 10.1037/0022-006X.76.3.379; Neuhauser H, 2001, NEUROLOGY, V56, P436, DOI 10.1212/WNL.56.4.436; Neuhauser HK, 2006, NEUROLOGY, V67, P1028, DOI 10.1212/01.wnl.0000237539.09942.06; NEWMAN DS, 1989, HEADACHE, V29, P82, DOI 10.1111/j.1526-4610.1989.hed2902082.x; NEWMAN LC, 1990, NEUROLOGY, V40, P1904, DOI 10.1212/WNL.40.12.1904-a; NEWMAN LC, 1994, NEUROLOGY, V44, P2111, DOI 10.1212/WNL.44.11.2111; NICHOLS FT, 1990, STROKE, V21, P555, DOI 10.1161/01.STR.21.4.555; NICHOLS FT, 1993, HEADACHE, V33, P87, DOI 10.1111/j.1526-4610.1993.hed3302087.x; Nicholson RA, 2010, CURR PAIN HEADACHE R, V14, P47, DOI 10.1007/s11916-009-0087-9; Nicolodi M, 1997, INT J CLIN PHARM RES, V17, P79; Nomura Motohiro, 2016, J Clin Med Res, V8, P342, DOI 10.14740/jocmr2489w; Norval DA, 2004, SAMJ S AFR MED J, V94, P450; Nowak DA, 2003, CEPHALALGIA, V23, P218, DOI 10.1046/j.1468-2982.2003.00507.x; O'Connor AB, 2008, PAIN, V137, P96, DOI 10.1016/j.pain.2007.08.024; Obelieniene D, 1999, J NEUROL NEUROSUR PS, V66, P279, DOI 10.1136/jnnp.66.3.279; Obermann M, 2007, NEUROLOGY, V69, P835, DOI 10.1212/01.wnl.0000269670.30045.6b; Obermann M, 2007, CEPHALALGIA, V27, P504, DOI 10.1111/j.1468-2982.2007.01316.x; Obermann M, 2010, CEPHALALGIA, V30, P528, DOI 10.1111/j.1468-2982.2009.01972.x; Obermann M, 2009, NEUROLOGY, V73, P978, DOI 10.1212/WNL.0b013e3181b8791a; Obermann M, 2011, CURR PAIN HEADACHE R, V15, P314, DOI 10.1007/s11916-011-0193-3; Obermann M, 2009, EXPERT REV NEUROTHER, V9, P1361, DOI 10.1586/ERN.09.84; Odabasi Z, 1997, CLIN NEUROL NEUROSUR, V99, P151, DOI 10.1016/S0303-8467(97)00013-9; Ogawa K, 2010, ACTA NEUROL BELG, V110, P190; OGUS H, 1978, J ROY SOC MED, V71, P748; Oh AK, 2001, AM J MED GENET, V100, P287, DOI 10.1002/ajmg.1294; Ojaimi J, 1998, CEREBROVASC DIS, V8, P102, DOI 10.1159/000015826; Oldenburg MS, 2015, OTOL NEUROTOL, V36, P1735, DOI 10.1097/MAO.0000000000000891; OLESEN J, 1990, ANN NEUROL, V28, P791, DOI 10.1002/ana.410280610; OLESEN J, 1993, BRAIN, V116, P187, DOI 10.1093/brain/116.1.187; OLESEN J, 1991, PAIN, V46, P125, DOI 10.1016/0304-3959(91)90066-7; Olesen J, 2014, CEPHALALGIA, V34, P1193, DOI 10.1177/0333102414534327; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; Onishi A, 2012, J CLIN MICROBIOL, V50, P7, DOI 10.1128/JCM.05267-11; ORRELL RW, 1994, J NEUROL NEUROSUR PS, V57, P348, DOI 10.1136/jnnp.57.3.348; Osterberg A, 2005, EUR J PAIN, V9, P531, DOI 10.1016/j.ejpain.2004.11.005; Osterberg A, 2010, EUR J PAIN, V14, P104, DOI 10.1016/j.ejpain.2009.03.003; Ostergard JR, 2000, HEADACHES, P789; Ozge Aynur, 2006, J Headache Pain, V7, P37, DOI 10.1007/s10194-006-0264-8; Ozge C, 2005, EUR J PAIN, V9, P383, DOI 10.1016/j.ejpain.2004.09.007; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PACHNER AR, 1984, YALE J BIOL MED, V57, P481; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; PACKARD RC, 1992, HEADACHE, V32, P496, DOI 10.1111/j.1526-4610.1992.hed3210496.x; Packard Russell C, 2005, Curr Pain Headache Rep, V9, P59, DOI 10.1007/s11916-005-0076-6; Pakalnis A, 2001, J CHILD NEUROL, V16, P731, DOI 10.1177/088307380101601005; Pareja JA, 2008, CEPHALALGIA, V28, P257, DOI 10.1111/j.1468-2982.2007.01515.x; Pareja JA, 2008, CEPHALALGIA, V28, P186, DOI 10.1111/j.1468-2982.2007.01490.x; Pareja JA, 2005, CEPHALALGIA, V25, P305, DOI 10.1111/j.1468-2982.2004.00864.x; Pareja JA, 2004, HEADACHE, V44, P611, DOI 10.1111/j.1526-4610.2004.446011.x; Pareja JA, 2002, NEUROLOGY, V58, P1678, DOI 10.1212/WNL.58.11.1678; Pareja JA, 1996, CEPHALALGIA, V16, P93, DOI 10.1046/j.1468-2982.1996.1602093.x; Pareja JA, 2012, CURR NEUROL NEUROSCI, V12, P118, DOI 10.1007/s11910-011-0247-2; Pareja JA, 2012, J HEADACHE PAIN, V13, P175, DOI 10.1007/s10194-011-0407-4; Parisi P, 2012, CEPHALALGIA, V32, P723, DOI 10.1177/0333102412447536; Parisi P, 2010, EPILEPSIA, V51, P932, DOI 10.1111/j.1528-1167.2009.02407.x; Parissis D, 2011, HEADACHE, V51, P1285, DOI 10.1111/j.1526-4610.2011.01884.x; Pascual J, 1996, NEUROLOGY, V46, P1520, DOI 10.1212/WNL.46.6.1520; PASCUAL J, 1993, CEPHALALGIA, V13, P205, DOI 10.1046/j.1468-2982.1993.1303205.x; Pascual J, 2008, J HEADACHE PAIN, V9, P259, DOI 10.1007/s10194-008-0063-5; Pascual Julio, 2005, Curr Pain Headache Rep, V9, P272, DOI 10.1007/s11916-005-0036-1; Pascual-Castroviejo I, 2008, CAN J NEUROL SCI, V35, P301, DOI 10.1017/S0317167100008878; Patel A, 2002, NEUROSURGERY, V50, P705, DOI 10.1097/00006123-200204000-00004; Paterson R W, 2013, Cerebrovasc Dis Extra, V3, P81, DOI 10.1159/000347114; Patil SA, 2012, J IMMUNOASS IMMUNOCH, V33, P140, DOI 10.1080/15321819.2011.606862; Patton LL, 2007, ORAL SURG ORAL MED O, V103, P1; PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409; PEARCE J, 1971, J NEUROL NEUROSUR PS, V34, P154, DOI 10.1136/jnnp.34.2.154; Pearce JMS, 1996, J NEUROL NEUROSUR PS, V61, P324, DOI 10.1136/jnnp.61.3.324; Peet MM, 1935, ANN SURG, V101, P256, DOI 10.1097/00000658-193501000-00026; Peng KP, 2011, CEPHALALGIA, V31, P1561, DOI 10.1177/0333102411424620; Pepe G, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-16; Perenboom M, 2015, CEPHALALGIA, V35, P1224; Peres MFP, 2011, CEPHALALGIA, V31, P250, DOI 10.1177/0333102410383588; Peres MFP, 2006, EXPERT OPIN INV DRUG, V15, P367, DOI 10.1517/13543784.15.4.367; Perini F, 1998, CEPHALALGIA, V18, P493, DOI 10.1046/j.1468-2982.1998.1807493.x; Perucca P, 2010, NEUROLOGY, V75, P373, DOI 10.1212/WNL.0b013e3181ea1612; PESTRONK A, 1983, NEW ENGL J MED, V308, P226; PFAFFENRATH V, 1993, CEPHALALGIA, V13, P84, DOI 10.1177/0333102493013S1218; Pfund Z, 1999, CEPHALALGIA, V19, P787, DOI 10.1046/j.1468-2982.1999.1909787.x; Phuong HL, 2004, J CLIN NEUROSCI, V11, P758, DOI 10.1016/j.jocn.2003.07.013; Pielsticker A, 2005, PAIN, V118, P215, DOI 10.1016/j.pain.2005.08.019; Pinto A, 2001, ORAL SURG ORAL MED O, V92, P180, DOI 10.1067/moe.2001.114006; Planche V, 2014, CEPHALALGIA, V34, P73, DOI 10.1177/0333102413505237; Poceta JS, 1995, HEADACHE, V35, P586, DOI 10.1111/j.1526-4610.1995.hed3510586.x; Polycarpou N, 2005, INT ENDOD J, V38, P169, DOI 10.1111/j.1365-2591.2004.00923.x; PONEPRASERT B, 1989, Southeast Asian Journal of Tropical Medicine and Public Health, V20, P599; Porcelli M. Jay, 1995, Journal of the American Osteopathic Association, V95, P718; PORTENOY RK, 1984, STROKE, V15, P1009, DOI 10.1161/01.STR.15.6.1009; Poulikakos P J, 2010, J Infect Public Health, V3, P192, DOI 10.1016/j.jiph.2010.09.006; Prakash S, 2010, J HEADACHE PAIN, V11, P59, DOI 10.1007/s10194-009-0171-x; Prandota Joseph, 2007, Am J Ther, V14, P63, DOI 10.1097/01.mjt.0000208272.42379.aa; Pulec Jack L, 2002, Ear Nose Throat J, V81, P30; Putzki N, 2009, EUR J NEUROL, V16, P262, DOI 10.1111/j.1468-1331.2008.02406.x; Queiroz LP, 2011, CEPHALALGIA, V31, P1652, DOI 10.1177/0333102411430263; Queral-Godoy E, 2006, J ORAL MAXIL SURG, V64, P402, DOI 10.1016/j.joms.2005.11.010; Radat F, 2005, CEPHALALGIA, V25, P165, DOI 10.1111/j.1468-2982.2004.00839.x; Radat F, 1999, HEADACHE, V39, P477, DOI 10.1046/j.1526-4610.1999.3907477.x; Radat F, 2000, REV NEUROL-FRANCE, V156, P62; Radat F, 2011, HEADACHE, V51, P789, DOI 10.1111/j.1526-4610.2011.01883.x; Radtke A, 2011, CEPHALALGIA, V31, P906, DOI 10.1177/0333102411405228; Rains JC, 2001, CEPHALALGIA, V21, P584, DOI 10.1046/j.1468-2982.2001.00210.x; RAMADAN NM, 1995, HEADACHE, V35, P21, DOI 10.1111/j.1526-4610.1995.hed3501021.x; RAMADAN NM, 1991, NEUROLOGY, V41, P1084, DOI 10.1212/WNL.41.7.1084; RamirezLassepas M, 1997, ARCH NEUROL-CHICAGO, V54, P1506, DOI 10.1001/archneur.1997.00550240058013; Rapoport A, 1996, HEADACHE, V36, P14, DOI 10.1046/j.1526-4610.1996.3601014.x; RAPS EC, 1993, ARCH NEUROL-CHICAGO, V50, P265, DOI 10.1001/archneur.1993.00540030031010; Rashed H, 1999, DIGEST DIS SCI, V44, p74S; RASKIN NH, 1988, HEADACHE, V28, P534, DOI 10.1111/j.1526-4610.1988.hed2808534.x; RASKIN NH, 1995, NEUROLOGY, V45, P1784, DOI 10.1212/WNL.45.9.1784; RASKIN NH, 1990, HEADACHE, V30, P550, DOI 10.1111/j.1526-4610.1990.hed30s2550.x; RASKIN NH, 1976, HEADACHE, V16, P222, DOI 10.1111/j.1526-4610.1976.hed1605222.x; RASKIN NH, 1980, NEUROLOGY, V30, P203, DOI 10.1212/WNL.30.2.203; RASMUSSEN BK, 1991, CEPHALALGIA, V11, P129, DOI 10.1046/j.1468-2982.1991.1103129.x; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; RASMUSSEN P, 1991, ACTA NEUROCHIR, V108, P100, DOI 10.1007/BF01418516; RASMUSSEN P, 1991, ACTA NEUROCHIR, V108, P53, DOI 10.1007/BF01407667; RASMUSSEN P, 1990, ACTA NEUROCHIR, V107, P121, DOI 10.1007/BF01405790; Ravnik J, 2014, BOSNIAN J BASIC MED, V14, P132, DOI 10.17305/bjbms.2014.3.38; Raza-Knight S, 2017, ARCH DIS CHILD, V102, P238, DOI 10.1136/archdischild-2016-310662; Reinstein E, 2013, EUR J HUM GENET, V21, P386, DOI 10.1038/ejhg.2012.191; Relja G, 2005, CEPHALALGIA, V25, P56, DOI 10.1111/j.1468-2982.2004.00808.x; Renton T, 2011, J OROFAC PAIN, V25, P333; Richards A, 2007, NAT GENET, V39, P1068, DOI 10.1038/ng2082; Richter M, 2000, EUR SPINE J, V9, P109, DOI 10.1007/s005860050220; Rico M, 2014, HEADACHE, V54, P545, DOI 10.1111/head.12197; Riederer F, 2010, J HEADACHE PAIN, V11, P335, DOI 10.1007/s10194-010-0207-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rinaldi R, 1997, HEADACHE, V37, P443, DOI 10.1046/j.1526-4610.1997.3707443.x; Robbins MS, 2010, NEUROLOGY, V74, P1358, DOI 10.1212/WNL.0b013e3181dad5de; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Rocha PAS, 2010, CEPHALALGIA, V30, P509, DOI 10.1111/j.1468-2982.2009.01992.x; Rocha PAS, 2008, CEPHALALGIA, V28, P41, DOI 10.1111/j.1468-2982.2007.01465.x; Rocha-Filho PAS, 2010, CEPHALALGIA, V30, P560, DOI 10.1111/j.1468-2982.2009.02010.x; Rogawski MA, 2008, ARCH NEUROL-CHICAGO, V65, P709, DOI 10.1001/archneur.65.6.709; Romberg MH, 1840, LEHRBUCH NERVENKRANK; Ronne-Engstrom E, 2015, UPSALA J MED SCI, V120, P59, DOI 10.3109/03009734.2014.988309; Rosenfield K, 2016, NEW ENGL J MED, V374, P1011, DOI [10.1056/NEJMoa1515706, 10.1016/j.jvs.2016.06.057]; Rosman NP, 2009, J CHILD NEUROL, V24, P155, DOI 10.1177/0883073808322338; ROSSI LN, 1989, CHILD NERV SYST, V5, P307, DOI 10.1007/BF00274519; Rothrock JF, 1997, NEUROLOGY, V48, P261, DOI 10.1212/WNL.48.1.261; ROTHROCK JF, 1988, ARCH NEUROL-CHICAGO, V45, P63, DOI 10.1001/archneur.1988.00520250069023; Rozen TD, 2006, CEPHALALGIA, V26, P1182, DOI 10.1111/j.1468-2982.2006.01187.x; Rozen T, 2007, HEADACHE, V47, P1050, DOI 10.1111/j.1526-4610.2006.00722.x; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Ruscheweyh R, 2010, CEPHALALGIA, V30, P249, DOI 10.1111/j.1468-2982.2009.01893.x; Russell George, 2002, Paediatr Drugs, V4, P1; Russell MB, 1996, EUR J NEUROL, V3, P424, DOI 10.1111/j.1468-1331.1996.tb00243.x; Russell MB, 1996, CEPHALALGIA, V16, P431, DOI 10.1046/j.1468-2982.1996.1606431.x; RUSSELL MB, 1995, J MED GENET, V32, P954, DOI 10.1136/jmg.32.12.954; Russell MB, 2014, CEPHALALGIA, V34, P752, DOI 10.1177/0333102414538551; Saers SJF, 2011, J LARYNGOL OTOL, V125, P520, DOI 10.1017/S0022215110002677; SAGE JI, 1985, NEUROLOGY, V35, P1470, DOI 10.1212/WNL.35.10.1470; Saiz JC, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00496; Salhofer-Polanyi S, 2012, HEADACHE, V52, P1236, DOI 10.1111/j.1526-4610.2012.02166.x; Salvarani C, 2007, ANN NEUROL, V62, P442, DOI 10.1002/ana.21226; Saman Y, 2010, J LARYNGOL OTOL, V124, P1305, DOI 10.1017/S0022215110001556; Samanci B, 2016, CEPHALALGIA, V36, P998, DOI 10.1177/0333102415620253; Rocha PAS, 2015, HEADACHE, V55, P733, DOI 10.1111/head.12563; San-Juan OD, 2007, CEPHALALGIA, V27, P456, DOI 10.1111/j.1468-2982.2007.01307.x; Sanahuja J, 2005, CEPHALALGIA, V25, P547, DOI 10.1111/j.1468-2982.2005.00882.x; Sances G, 2009, EPILEPSIA, V50, P2487, DOI 10.1111/j.1528-1167.2009.02265.x; Sandrini G, 2006, CEPHALALGIA, V26, P782, DOI 10.1111/j.1468-2982.2006.01130.x; SANTONI JR, 1993, INTERNAL MED, V32, P530, DOI 10.2169/internalmedicine.32.530; Sardella A, 2009, Minerva Stomatol, V58, P289; Sardella A, 2012, ARCH ORAL BIOL, V57, P94, DOI 10.1016/j.archoralbio.2011.07.007; SARKOZI J, 1984, ARTHRITIS RHEUM, V27, P708, DOI 10.1002/art.1780270618; Sarmento E, 2009, HEADACHE, V49, P1345, DOI 10.1111/j.1526-4610.2009.01494.x; Sauerbrei A, 2002, J CLIN VIROL, V25, pS45, DOI 10.1016/S1386-6532(02)00033-1; Savage COS, 2000, BRIT MED J, V320, P1325, DOI 10.1136/bmj.320.7245.1325; Scala A, 2003, CRIT REV ORAL BIOL M, V14, P275, DOI 10.1177/154411130301400405; SCHACHTER SC, 1995, J EPILEPSY, V8, P41, DOI 10.1016/0896-6974(94)00007-M; Schaller B, 2003, OTOLARYNG HEAD NECK, V128, P387, DOI 10.1067/mhn.2003.104; Schankin CJ, 2007, CEPHALALGIA, V27, P904, DOI 10.1111/j.1468-2982.2007.01368.x; Schankin CJ, 2014, HEADACHE, V54, P957, DOI 10.1111/head.12378; Schankin CJ, 2014, BRAIN, V137, P1419, DOI 10.1093/brain/awu050; Scher AI, 1998, HEADACHE, V38, P497, DOI 10.1046/j.1526-4610.1998.3807497.x; Scher AI, 2003, PAIN, V106, P81, DOI 10.1016/S0304-3959(03)00293-8; Scherer A, 2001, ROFO-FORTSCHR RONTG, V173, P315, DOI 10.1055/s-2001-12464; Schievink WI, 2008, AM J NEURORADIOL, V29, P853, DOI 10.3174/ajnr.A0956; Schievink WI, 2006, JAMA-J AM MED ASSOC, V295, P2286, DOI 10.1001/jama.295.19.2286; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; Schievink WI, 2011, HEADACHE, V51, P1442, DOI 10.1111/j.1526-4610.2011.01911.x; Schiffman E, 2014, J ORAL FACIAL PAIN H, V28, P6, DOI 10.11607/jop.1151; Schiffman E, 2012, CEPHALALGIA, V32, P683, DOI 10.1177/0333102412446312; SCHIFFMAN SS, 1987, NEW ENGL J MED, V317, P1181, DOI 10.1056/NEJM198711053171903; Schmidt-Hansen PT, 2007, PAIN, V129, P113, DOI 10.1016/j.pain.2006.09.037; Schmidt-Wilcke T, 2005, NEUROLOGY, V65, P1483, DOI 10.1212/01.wnl.0000183067.94400.80; SCHNIDER P, 1994, CEPHALALGIA, V14, P162, DOI 10.1046/j.1468-2982.1994.1402162.x; Schnider P, 1996, CEPHALALGIA, V16, P481, DOI 10.1046/j.1468-2982.1996.1607481.x; SCHOENEN J, 1991, CEPHALALGIA, V11, P135, DOI 10.1046/j.1468-2982.1991.1103135.x; SCHON F, 1987, J NEUROL NEUROSUR PS, V50, P1148, DOI 10.1136/jnnp.50.9.1148; Schoonman GG, 2006, CEPHALALGIA, V26, P1209, DOI 10.1111/j.1468-2982.2006.01195.x; Schoonman GG, 2006, CEPHALALGIA, V26, P816, DOI 10.1111/j.1468-2982.2006.01112.x; Schoser BGH, 1997, J NEUROL, V244, P101, DOI 10.1007/s004150050057; Melo ES, 2017, HEADACHE, V57, P161, DOI 10.1111/head.12875; Stosch RSV, 2008, CEPHALALGIA, V28, P908, DOI 10.1111/j.1468-2982.2008.01633_1.x; Jarosch-von Schweder L, 2011, J ECT, V27, P296, DOI 10.1097/YCT.0b013e31821ff3bd; LUTZ G, 1991, CEPHALALGIA, V11, P353, DOI 10.1177/0333102491011S11189; SCHOENEN J, 1991, PAIN, V47, P145, DOI 10.1016/0304-3959(91)90198-7; Schulz UG, 2009, STROKE, V40, P3740, DOI 10.1161/STROKEAHA.109.558163; Schwartz BS, 1998, JAMA-J AM MED ASSOC, V279, P381, DOI 10.1001/jama.279.5.381; Schwedt TJ, 2006, HEADACHE, V46, P520, DOI 10.1111/j.1526-4610.2006.00386_3.x; Schwedt Todd J, 2007, Curr Pain Headache Rep, V11, P56, DOI 10.1007/s11916-007-0023-9; Schwedt TJ, 2006, LANCET NEUROL, V5, P621, DOI 10.1016/S1474-4422(06)70497-5; Schytz HW, 2014, CEPHALALGIA, V34, P712, DOI 10.1177/0333102414520767; Seiden AM, 2001, OTOLARYNG CLIN N AM, V34, P227, DOI 10.1016/S0030-6665(05)70308-X; Selekler HM, 2004, CEPHALALGIA, V24, P293, DOI 10.1111/j.1468-2982.2004.00674.x; Selekler HM, 2004, EUR NEUROL, V51, P6, DOI 10.1159/000074910; Seller EM, 1998, CLIN PHARMACOL THER, V63, P121; SELLICK JA, 1989, J AM OSTEOPATH ASSOC, V89, P806; Seol HJ, 2005, J NEUROSURG, V103, P439, DOI 10.3171/ped.2005.103.5.0439; Serrano-Duenas Marcos, 2007, Expert Rev Neurother, V7, P245, DOI 10.1586/14737175.7.3.245; Seven H, 2005, EUR ARCH OTO-RHINO-L, V262, P847, DOI 10.1007/s00405-004-0903-0; SEYMOUR JJ, 1995, AM J EMERG MED, V13, P43, DOI 10.1016/0735-6757(95)90240-6; SHARIF AA, 1995, NEUROLOGY, V45, P1929, DOI 10.1212/WNL.45.10.1929; Sheedy J, 2009, J HEAD TRAUMA REHAB, V24, P333, DOI 10.1097/HTR.0b013e3181aea51f; Sheftell FD, 2007, NEUROL SCI, V28, pS203, DOI 10.1007/s10072-007-0777-1; Shin HY, 2013, CLIN NEUROPHYSIOL, V124, P598, DOI 10.1016/j.clinph.2012.08.013; Shin JH, 2007, CEPHALALGIA, V27, P1101, DOI 10.1111/j.1468-2982.2007.01395.x; Shindler KS, 2005, NEUROLOGY, V65, P757, DOI 10.1212/01.wnl.0000174435.37184.c3; Shirley MD, 2013, NEW ENGL J MED, V368, P1971, DOI 10.1056/NEJMoa1213507; Shoja MM, 2010, CHILD NERV SYST, V26, P373, DOI 10.1007/s00381-009-0965-9; SHUAIB A, 1988, ARCH NEUROL-CHICAGO, V45, P911, DOI 10.1001/archneur.1988.00520320109024; SHUAIB A, 1989, CEPHALALGIA, V9, P59, DOI 10.1046/j.1468-2982.1989.0901059.x; SICUTERI F, 1987, HEADACHE, V27, P180, DOI 10.1111/j.1526-4610.1987.hed2704180.x; Sidman R, 1996, ACAD EMERG MED, V3, P827, DOI 10.1111/j.1553-2712.1996.tb03526.x; Siegel AM, 1999, EPILEPSIA, V40, P845, DOI 10.1111/j.1528-1157.1999.tb00790.x; Silber E, 2003, NEUROLOGY, V60, P1167, DOI 10.1212/01.WNL.0000055876.26737.B9; Silberstein SD, 2004, LANCET, V363, P381, DOI 10.1016/S0140-6736(04)15440-8; Silberstein SD, 1996, NEUROLOGY, V47, P871, DOI 10.1212/WNL.47.4.871; SILBERSTEIN SD, 1994, HEADACHE, V34, P1, DOI 10.1111/j.1526-4610.1994.hed3401001.x; Silberstein SD, 2000, NEUROLOGY, V54, P219, DOI 10.1212/WNL.54.1.219; SILBERT PL, 1991, J NEUROL NEUROSUR PS, V54, P417, DOI 10.1136/jnnp.54.5.417; SILBERT PL, 1995, NEUROLOGY, V45, P1517, DOI 10.1212/WNL.45.8.1517; SILVERMAN K, 1992, NEW ENGL J MED, V327, P1109, DOI 10.1056/NEJM199210153271601; SINGER JI, 1980, J PEDIATR-US, V96, P559, DOI 10.1016/S0022-3476(80)80866-3; Singh RR, 2009, INDIAN J PEDIATR, V76, P1109, DOI 10.1007/s12098-009-0233-8; Singhal AB, 2011, ARCH NEUROL-CHICAGO, V68, P1005, DOI 10.1001/archneurol.2011.68; Sjaastad O, 1997, FUNCT NEUROL, V12, P305; Sjaastad O, 2008, ACTA NEUROL SCAND, V117, P173, DOI 10.1111/j.1600-0404.2007.00962.x; Sjaastad O, 2006, CEPHALALGIA, V26, P233, DOI 10.1111/j.1468-2982.2006.00926.x; Sjaastad O, 2005, CEPHALALGIA, V25, P581, DOI 10.1111/j.1468-2982.2005.00927.x; Sjaastad O, 2003, CEPHALALGIA, V23, P803, DOI 10.1046/j.1468-2982.2003.00588.x; Sjaastad O, 2002, CEPHALALGIA, V22, P784, DOI 10.1046/j.1468-2982.2002.00466.x; SJAASTAD O, 1974, HEADACHE, V14, P105; Sjaastad O, 2002, FUNCT NEUROL, V17, P35; SJAASTAD O, 1989, CEPHALALGIA, V9, P147, DOI 10.1046/j.1468-2982.1989.0902147.x; Sjaastad O, 2001, CEPHALALGIA, V21, P207, DOI 10.1046/j.1468-2982.2001.00189.x; Sjostrand C, 2000, CEPHALALGIA, V20, P653, DOI 10.1046/j.1468-2982.2000.00104.x; SLIVKA A, 1995, HEADACHE, V35, P1, DOI 10.1111/j.1526-4610.1995.hed3501001.x; Sliwka U, 1998, AVIAT SPACE ENVIR MD, V69, P299; Sluder G, 1910, AM J MED SCI, V140, P868, DOI 10.1097/00000441-191012000-00009; Smith JH, 2014, EUR J NEUROL, V21, P577, DOI 10.1111/ene.12312; Smith M, 2002, NEUROLOGY, V58, P1308, DOI 10.1212/WNL.58.8.1308-a; Smitherman TA, 2008, CURR PAIN HEADACHE R, V12, P305, DOI 10.1007/s11916-008-0051-0; SOLOMON S, 1985, CEPHALALGIA, V5, P83, DOI 10.1046/j.1468-2982.1985.0502083.x; SOLOMON S, 1987, J AM GERIATR SOC, V35, P163, DOI 10.1111/j.1532-5415.1987.tb01348.x; Solomon S, 2001, ARCH NEUROL-CHICAGO, V58, P661, DOI 10.1001/archneur.58.4.661; Solomon S, 2009, HEADACHE, V49, P1112, DOI 10.1111/j.1526-4610.2009.01462.x; Solomon T, 2012, J INFECTION, V64, P347, DOI 10.1016/j.jinf.2011.11.014; SOMERVIL.BW, 1972, NEUROLOGY, V22, P355, DOI 10.1212/WNL.22.4.355; SOMERVILLE BW, 1975, NEUROLOGY, V25, P239, DOI 10.1212/WNL.25.3.239; SOMERVILLE BW, 1975, NEUROLOGY, V25, P245, DOI 10.1212/WNL.25.3.245; SOMERVILLE BW, 1971, NEUROLOGY, V21, P853, DOI 10.1212/WNL.21.8.853; Soriani S, 1996, HEADACHE, V36, P565, DOI 10.1046/j.1526-4610.1996.3609565.x; Spitzer W, 1995, SPINE, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; Sprenger T, 2010, J CLIN NEUROSCI, V17, P547, DOI 10.1016/j.jocn.2009.09.030; Stam AH, 2016, BRAIN, V139, P2909, DOI 10.1093/brain/aww217; Stewart W, 2001, CEPHALALGIA, V21, P279; Stovner LJ, 2009, EUR J NEUROL, V16, pE14, DOI 10.1111/j.1468-1331.2008.02359.x; Stovner LJ, 2009, EUR J NEUROL, V16, P112, DOI 10.1111/j.1468-1331.2008.02363.x; STRAUBE A, 1993, HEADACHE, V33, P446, DOI 10.1111/j.1526-4610.1993.hed3308446.x; Sturm JW, 2000, CEPHALALGIA, V20, P132, DOI 10.1046/j.1468-2982.2000.00053.x; STURZENEGGER M, 1994, HEADACHE, V34, P187, DOI 10.1111/j.1526-4610.1994.hed3404187.x; STURZENEGGER MH, 1985, HEADACHE, V25, P408; SUWANWELA N, 1994, HEADACHE, V34, P435, DOI 10.1111/j.1526-4610.1994.hed3407435.x; Suzuki K, 2015, J HEADACHE PAIN, V16, DOI 10.1186/s10194-015-0540-6; SWANSON JW, 1978, NEUROLOGY, V28, P782, DOI 10.1212/WNL.28.8.782; Sweeney CJ, 2001, J NEUROL NEUROSUR PS, V71, P149, DOI 10.1136/jnnp.71.2.149; Syvertsen M, 2007, J HEADACHE PAIN, V8, P224, DOI 10.1007/s10194-007-0398-3; Szatmary Z, 2006, J NEUROL NEUROSUR PS, V77, P693, DOI 10.1136/jnnp.2005.082719; Takagi Kiyoshi, 2013, Acta Neurochir Suppl, V118, P293, DOI 10.1007/978-3-7091-1434-6_57; Takahashi S, 2012, J STROKE CEREBROVASC, V21, P338, DOI 10.1016/j.jstrokecerebrovasdis.2009.12.011; Takase Y, 2004, CEPHALALGIA, V24, P955, DOI 10.1111/j.1468-2982.2004.00771.x; Takeuchi S, 2010, J CLIN NEUROSCI, V17, P153, DOI 10.1016/j.jocn.2009.03.043; Tanaka BS, 2016, MOL MED, V22, P338, DOI 10.2119/molmed.2016.00131; Tanrikulu Levent, 2015, Surg Neurol Int, V6, P189, DOI 10.4103/2152-7806.172534; Tatrow K, 2003, HEADACHE, V43, P755, DOI 10.1046/j.1526-4610.2003.03133.x; ter Berg HWM, 2001, HEADACHE, V41, P326; Terwindt GM, 1998, BRAIN, V121, P303, DOI 10.1093/brain/121.2.303; TFELTHANSEN P, 1981, CEPHALALGIA, V1, P29, DOI 10.1111/j.1468-2982.1981.tb00005.x; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Theeler BJ, 2012, CEPHALALGIA, V32, P589, DOI 10.1177/0333102412445220; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Thibault M, 2007, CAN J ANAESTH, V54, P544, DOI 10.1007/BF03022318; Thielen KR, 1998, MAYO CLIN PROC, V73, P444; Thiessen Paul N, 2002, Pediatr Rev, V23, P39, DOI 10.1542/pir.23-2-39; THOMAS JE, 1966, J AMER MED ASSOC, V197, P754, DOI 10.1001/jama.197.10.754; Thomsen LL, 2007, BRAIN, V130, P346, DOI 10.1093/brain/awl334; Thomsen LL, 2003, NEUROLOGY, V60, P595, DOI 10.1212/01.WNL.0000046524.25369.7D; Thomsen LL, 2002, BRAIN, V125, P1379, DOI 10.1093/brain/awf132; Thomsen LL, 1994, EUR J NEUROL, V1, P71; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tietjen GE, 2000, NEUROEPIDEMIOLOGY, V19, P13, DOI 10.1159/000026233; Toldo I, 2014, HEADACHE, V54, P899, DOI 10.1111/head.12341; TONJUM T, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P175; Tosun F, 2000, HEADACHE, V40, P237, DOI 10.1046/j.1526-4610.2000.00034.x; TROOST BT, 1979, ANN NEUROL, V5, P199, DOI 10.1002/ana.410050216; Troost T, 2000, HEADACHES, P511; Truini A, 2008, PAIN, V140, P405, DOI 10.1016/j.pain.2008.08.018; Truini A, 2016, NEUROLOGY, V86, P2094, DOI 10.1212/WNL.0000000000002720; Truini A, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00105; Tubbs R Shane, 2013, World Neurosurg, V79, P763, DOI 10.1016/j.wneu.2012.03.023; Tuveson B, 2009, PAIN, V143, P84, DOI 10.1016/j.pain.2009.02.002; TYCHSEN L, 1984, OPHTHALMOLOGY, V91, P1075; Tzourio C, 2002, NEUROLOGY, V59, P435, DOI 10.1212/WNL.59.3.435; Tzourio C, 2000, CEPHALALGIA, V20, P190, DOI 10.1046/j.1468-2982.2000.00041.x; Ulrich V, 1999, ANN NEUROL, V45, P242, DOI 10.1002/1531-8249(199902)45:2<242::AID-ANA15>3.0.CO;2-1; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Vahedi K, 2007, NEUROLOGY, V69, P1564, DOI 10.1212/01.wnl.0000295994.46586.e7; Vahedi K, 2004, ARCH NEUROL-CHICAGO, V61, P1237, DOI 10.1001/archneur.61.8.1237; Vahedi K, 2003, NEUROLOGY, V60, P57, DOI 10.1212/WNL.60.1.57; Vail HH, 1932, ANN OTO RHINOL LARYN, V41, P837; Valcour V, 2012, J INFECT DIS, V206, P275, DOI 10.1093/infdis/jis326; Valentinis L, 2010, CEPHALALGIA, V30, P389, DOI 10.1111/j.1468-2982.2009.01970.x; van de Beek D, 2004, NEW ENGL J MED, V351, P1849, DOI 10.1056/NEJMoa040845; VANAST WJ, 1986, HEADACHE, V26, P317; VANDERWEE N, 1995, J NEUROL NEUROSUR PS, V58, P357, DOI 10.1136/jnnp.58.3.357; VANDUSSELDORP M, 1990, BRIT MED J, V300, P1558, DOI 10.1136/bmj.300.6739.1558; Vanmolkot KR, 2006, EUR J HUM GENET, V14, P555, DOI 10.1038/sj.ejhg.5201607; Vaughan CJ, 2000, LANCET, V356, P411, DOI 10.1016/S0140-6736(00)02539-3; VAZQUEZBARQUERO A, 1994, CEPHALALGIA, V14, P270, DOI 10.1046/j.1468-2982.1994.1404270.x; Vein AA, 2009, CEPHALALGIA, V29, P683, DOI 10.1111/j.1468-2982.2008.01775.x; Velioglu SK, 1999, CEPHALALGIA, V19, P797, DOI 10.1046/j.1468-2982.1999.1909797.x; Verdelho A, 2008, CEPHALALGIA, V28, P346, DOI 10.1111/j.1468-2982.2007.01514.x; VERNAY D, 1989, HEADACHE, V29, P350, DOI 10.1111/j.1526-4610.1989.hed2906350.x; Verrotti A, 2011, EPILEPSY BEHAV, V21, P52, DOI 10.1016/j.yebeh.2011.03.004; Versino M, 2003, FUNCT NEUROL, V18, P97; VERWEIJ RD, 1988, ARCH NEUROL-CHICAGO, V45, P1019, DOI 10.1001/archneur.1988.00520330109018; Vetvik KG, 2015, CEPHALALGIA, V35, P410, DOI 10.1177/0333102414545891; Vetvik KG, 2014, CEPHALALGIA, V34, P280, DOI 10.1177/0333102413507637; Vetvik KG, 2015, CEPHALALGIA, V35, P1261, DOI 10.1177/0333102415575723; Viana M, 2016, CEPHALALGIA, V36, P413, DOI 10.1177/0333102415593089; VIJAYAN N, 1995, HEADACHE, V35, P98, DOI 10.1111/j.1526-4610.1995.hed3502098.x; Voigt K, 2010, J PSYCHOSOM RES, V68, P403, DOI 10.1016/j.jpsychores.2010.01.015; Vollbracht S, 2014, HEADACHE, V54, P170, DOI 10.1111/head.12252; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; WAIND APB, 1956, BRIT MED J, V1, P901, DOI 10.1136/bmj.1.4972.901; Walker JJ, 2000, LANCET, V356, P1260, DOI 10.1016/S0140-6736(00)02800-2; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Walker WC, 2013, CEPHALALGIA, V33, P998, DOI 10.1177/0333102413482197; Wall M, 2014, JAMA NEUROL, V71, P693, DOI 10.1001/jamaneurol.2014.133; Wang SJ, 2010, CURR PAIN HEADACHE R, V14, P41, DOI 10.1007/s11916-009-0083-0; Wang YF, 2009, NEUROLOGY, V73, P1892, DOI 10.1212/WNL.0b013e3181c3fd99; Wang YF, 2008, CEPHALALGIA, V28, P1298, DOI 10.1111/j.1468-2982.2008.01679.x; Wang YF, 2015, BRAIN, V138, P1492, DOI 10.1093/brain/awv016; Wasay M, 2010, J HEADACHE PAIN, V11, P137, DOI 10.1007/s10194-010-0186-3; WATSON P, 1985, HEADACHE, V25, P123, DOI 10.1111/j.1526-4610.1985.hed2503123.x; WEBB J, 1984, J RHEUMATOL, V11, P530; Wei JH, 2008, CEPHALALGIA, V28, P892, DOI 10.1111/j.1468-2982.2008.01590.x; Wei YX, 2017, BRIT J NEUROSURG, V31, P101, DOI 10.1080/02688697.2016.1233321; WEINKE T, 1989, J NEUROL, V236, P38, DOI 10.1007/BF00314216; Weir B, 1998, SUBARACHNOID HEMORRH, P144; Weiss AH, 2004, PEDIATR NEUROL, V30, P64, DOI 10.1016/S0887-8994(03)00424-7; WEISS NS, 1972, NEW ENGL J MED, V287, P631, DOI 10.1056/NEJM197209282871303; Welch KMA, 1999, DIGEST DIS SCI, V44, p26S; West B, 2001, LARYNGOSCOPE, V111, P581, DOI 10.1097/00005537-200104000-00006; Whiteley W, 2006, NEUROLOGY, V67, P1690, DOI 10.1212/01.wnl.0000242704.60275.e9; Wig S, 2009, J RHEUMATOL, V36, P857, DOI 10.3899/jrheum.080993; WIJDICKS EFM, 1988, LANCET, V2, P1020; WIJDICKS EFM, 1988, LANCET, V2, P68; Wijman CAC, 1998, STROKE, V29, P1539, DOI 10.1161/01.STR.29.8.1539; Wilker SC, 2009, BRIT J OPHTHALMOL, V93, P1657, DOI 10.1136/bjo.2008.155150; Wilson MH, 2013, ANN NEUROL, V73, P381, DOI 10.1002/ana.23796; Wilson MH, 2009, LANCET NEUROL, V8, P175, DOI 10.1016/S1474-4422(09)70014-6; Witham TF, 2000, AM J EMERG MED, V18, P88, DOI 10.1016/S0735-6757(00)90058-5; Woda A, 1999, J OROFAC PAIN, V13, P172; Wolf ME, 2011, NEUROLOGY, V76, P1911, DOI 10.1212/WNL.0b013e31821d74d5; Wong SL, 2008, CEPHALALGIA, V28, P994, DOI 10.1111/j.1468-2982.2008.01625.x; Wu JW, 2017, BRAIN, V140, P344, DOI 10.1093/brain/aww328; Wyngaarden JB, 1992, CECILS TXB MED, P1310; Xu HM, 2016, WORLD NEUROSURG, V88, P289, DOI 10.1016/j.wneu.2015.12.028; Yadav YR, 2015, TURK NEUROSURG, V25, P362, DOI 10.5137/1019-5149.JTN.11086-14.1; Yalin OO, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0616-y; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; Yanguela J, 2004, NEUROLOGY, V62, P1134, DOI 10.1212/01.WNL.0000118841.97273.5D; Yanguela J, 2002, NEUROLOGY, V58, P802, DOI 10.1212/WNL.58.5.802; Yankovsky AE, 2005, EPILEPSIA, V46, P1241, DOI 10.1111/j.1528-1167.2005.64804.x; Yeh YC, 2010, CEPHALALGIA, V30, P1329, DOI 10.1177/0333102410364675; YEN PT, 1995, OTOLARYNG HEAD NECK, V113, P15, DOI 10.1016/S0194-5998(95)70139-7; Yildirmak Taner, 2014, Surg Neurol Int, V5, P142, DOI 10.4103/2152-7806.141891; Yip V, 2012, QJM-INT J MED, V105, P895, DOI 10.1093/qjmed/hcr141; Yoon MS, 2010, CEPHALALGIA, V30, P92, DOI 10.1111/j.1468-2982.2009.01899.x; YOUNG GB, 1983, BRAIN, V106, P537, DOI 10.1093/brain/106.3.537; Young WB, 2010, NEUROLOGY, V74, P1338, DOI 10.1212/WNL.0b013e3181de7fb9; Yri HM, 2015, CEPHALALGIA, V35, P553, DOI 10.1177/0333102414550109; Yutzy S, 2003, PSYCHIATRY, P1419; Zach V, 2010, J HEADACHE PAIN, V11, P79, DOI 10.1007/s10194-009-0181-8; Zampaglione B, 1996, HYPERTENSION, V27, P144, DOI 10.1161/01.HYP.27.1.144; Zaragoza-Casares P, 2009, HEADACHE, V49, P476, DOI 10.1111/j.1526-4610.2008.01259.x; Zasler ND, 1999, J HEAD TRAUMA REHAB, V14, P1, DOI 10.1097/00001199-199902000-00003; Zeeberg P, 2009, CEPHALALGIA, V29, P214, DOI 10.1111/j.1468-2982.2008.01710.x; Zeeberg P, 2006, NEUROLOGY, V66, P1894, DOI 10.1212/01.wnl.0000217914.30994.bd; Zhang S R, 1989, Zhonghua Nei Ke Za Zhi, V28, P202; Zhang YX, 2016, CEPHALALGIA, V36, P240, DOI 10.1177/0333102415587704; Zukerman E, 2000, NEUROLOGY, V54, P1524, DOI 10.1212/WNL.54.7.1524	1213	44	45	5	37	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0333-1024	1468-2982		CEPHALALGIA	Cephalalgia	JAN	2018	38	1					1	211					211	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FW2QP	WOS:000425149500001					2021-06-18	
J	Kovacs, GG; Andreasson, U; Liman, V; Regelsberger, G; Lutz, MI; Danics, K; Keller, E; Zetterberg, H; Blennow, K				Kovacs, G. G.; Andreasson, U.; Liman, V.; Regelsberger, G.; Lutz, M. I.; Danics, K.; Keller, E.; Zetterberg, H.; Blennow, K.			Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						Alzheimer disease; Creutzfeldt-Jakob disease; neurodegeneration; neurofilament light chain; rapidly progressive neurological syndrome; tau	CREUTZFELDT-JAKOB-DISEASE; PROTEASE-SENSITIVE PRIONOPATHY; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY PATHOLOGY; FRONTOTEMPORAL DEMENTIA; CSF BIOMARKERS; PRION PROTEIN; LIGHT PROTEIN	Background and purposeCerebrospinal fluid (CSF) tau and neurofilament light chain (NF-L) proteins have proved to be reliable biomarkers for neuronal damage; however, there is a strong need for blood-based tests. MethodsThe present study included 132 autopsy cases with rapidly progressive neurological syndromes, including Alzheimer disease (AD) (21), sporadic (65) and genetic (21) Creutzfeldt-Jakob disease (CJD), 25 cases with vascular, neoplastic and inflammatory alterations, and additionally 18 healthy control individuals. CSF tau and NF-L concentrations were measured by enzyme-linked immunosorbent assay. Plasma tau and NF-L concentrations were measured using ultra-sensitive single molecule array technology. ResultsPlasma and CSF tau (R = 0.59, P < 0.001) and NF-L (R = 0.69, P < 0.001) levels correlated significantly (Spearman test). Plasma tau and NF-L levels were significantly higher in all disease groups compared to healthy controls (P < 0.001). Receiver operating characteristic curves were used and area under the curve values for comparisons with controls were 0.82 (AD), 0.94 (sporadic CJD), 0.92 (genetic CJD) and 0.83 (other neurological disorders) for plasma tau and 0.99, 0.99, 1.00 and 0.96 for plasma NF-L, respectively. Molecular subtyping of sporadic CJD showed a strong effect (linear logistic regression) on plasma tau (P < 0.001) but not NF-L levels (P = 0.19). ConclusionPlasma tau and NF-L concentrations are strongly increased in CJD and show similar diagnostic performance to the corresponding CSF measure. Molecular subtypes of sporadic CJD show different levels of plasma tau. Although not disease-specific, these findings support the use of plasma tau and NF-L as tools to identify, or to rule out, neurodegeneration.	[Kovacs, G. G.; Regelsberger, G.; Lutz, M. I.] Med Univ Vienna, Inst Neurol, r, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria; [Kovacs, G. G.; Danics, K.; Keller, E.] Semmelweis Univ, Prion Dis & Neuropathol Reference Ctr, Budapest, Hungary; [Andreasson, U.; Liman, V.; Zetterberg, H.; Blennow, K.] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Andreasson, U.; Zetterberg, H.; Blennow, K.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Molndal, Sweden; [Danics, K.; Keller, E.] Semmelweis Univ, Dept Forens & Insurance Med, Budapest, Hungary; [Zetterberg, H.] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England	Kovacs, GG (corresponding author), Med Univ Vienna, Inst Neurol, r, AKH 4J,Wahringer Gurtel 18-20, A-1097 Vienna, Austria.; Blennow, K (corresponding author), Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden.	gabor.kovacs@meduniwien.ac.at; kaj.blennow@neuro.gu.se	Kovacs, Gabor G/A-7468-2013	Kovacs, Gabor G/0000-0003-3841-5511	VINNOVAVinnova; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Torsten Soderberg Foundation; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; European Research CouncilEuropean Research Council (ERC)European Commission; Swedish Brain Foundation; Alzheimerfonden; Frimurarestiftelsen	The study was supported by grants from VINNOVA, the Swedish Research Council, the Torsten Soderberg Foundation, the Knut and Alice Wallenberg Foundation, the European Research Council, the Swedish Brain Foundation, Alzheimerfonden and Frimurarestiftelsen.	Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Assar H, 2015, J NEUROL NEUROSUR PS, V86, P816, DOI 10.1136/jnnp-2014-309871; Bergman J, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000271; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Buchhave P, 2012, ARCH GEN PSYCHIAT, V69, P98, DOI 10.1001/archgenpsychiatry.2011.155; Dorey A, 2015, JAMA NEUROL, V72, P267, DOI 10.1001/jamaneurol.2014.4068; Dubois B, 2016, ALZHEIMERS DEMENT, V12, P292, DOI 10.1016/j.jalz.2016.02.002; Foutz A, 2017, ANN NEUROL, V81, P79, DOI 10.1002/ana.24833; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Gmitterova K, 2016, EUR J NEUROL, V23, P1126, DOI 10.1111/ene.12991; Jack CR, 2013, NEURON, V80, P1347, DOI 10.1016/j.neuron.2013.12.003; Jackson GS, 2014, JAMA NEUROL, V71, P421, DOI 10.1001/jamaneurol.2013.6001; Kovacs GG, 2015, NEUROPATH APPL NEURO, V41, P3, DOI 10.1111/nan.12208; Kovacs GG, 2010, CLIN NEUROPATHOL, V29, P271; Kovacs GG, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020189; Kovacs GG, 2010, BRAIN RES, V1323, P192, DOI 10.1016/j.brainres.2010.01.089; Kovacs GG, 2010, ACTA NEUROPATHOL, V119, P389, DOI 10.1007/s00401-010-0658-1; Ladogana A, 2009, J NEUROL, V256, P1620, DOI 10.1007/s00415-009-5163-x; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Llorens F, 2017, ALZHEIMERS DEMENT, V13, P710, DOI 10.1016/j.jalz.2016.09.013; Llorens F, 2016, PROG NEUROBIOL, V138, P36, DOI 10.1016/j.pneurobio.2016.03.003; Mattsson N, 2016, NEUROLOGY, V87, P1827, DOI 10.1212/WNL.0000000000003246; McGuire LI, 2016, ANN NEUROL, V80, P160, DOI 10.1002/ana.24679; Nelson PT, 2012, J NEUROPATH EXP NEUR, V71, P362, DOI 10.1097/NEN.0b013e31825018f7; Nielsen MS, 2016, DEMENT GER COGN D EX, V6, P465, DOI 10.1159/000449410; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/s1474-4422(16)00070-3, 10.1016/S1474-4422(16)00070-3]; Parchi P, 1999, ANN NEUROL, V46, P224, DOI 10.1002/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W; Parchi P, 2012, ACTA NEUROPATHOL, V124, P517, DOI 10.1007/s00401-012-1002-8; Rahimi J, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0082-1; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rohrer JD, 2016, NEUROLOGY, V87, P1329, DOI 10.1212/WNL.0000000000003154; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1; Shahim P, 2016, JAMA NEUROL, V73, P1308, DOI 10.1001/jamaneurol.2016.2038; Shahim P, 2016, SCI REP-UK, V6, DOI 10.1038/srep36791; Simonsen AH, 2016, BIOMARK MED, V10, P19, DOI 10.2217/BMM.14.105; Skillback T, 2014, JAMA NEUROL, V71, P476, DOI 10.1001/jamaneurol.2013.6455; Steinacker P, 2016, SCI REP-UK, V6, DOI 10.1038/srep38737; Stoeck K, 2012, BRAIN, V135, P3051, DOI 10.1093/brain/aws238; Suarez-Calvet M, 2014, J NEUROL NEUROSUR PS, V85, P684, DOI 10.1136/jnnp-2013-305972; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; van Rossum IA, 2012, NEUROLOGY, V79, P1809, DOI 10.1212/WNL.0b013e3182704056; Zetterberg H, 2017, NEUROPATH APPL NEURO, V43, P194, DOI 10.1111/nan.12378; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163; Zou WQ, 2010, ANN NEUROL, V68, P162, DOI 10.1002/ana.22094	47	44	44	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	NOV	2017	24	11					1326	+		10.1111/ene.13389			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FJ4AA	WOS:000412673700006	28816001				2021-06-18	
J	Craig, A; Guest, R; Tran, Y; Middleton, J				Craig, Ashley; Guest, Rebecca; Tran, Yvonne; Middleton, James			Cognitive Impairment and Mood States after Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; neural injury; rehabilitation; SCI	TRAUMATIC BRAIN-INJURY; LONGITUDINAL ANALYSIS; CHRONIC PAIN; DEPRESSION; FATIGUE; MODEL; INFLAMMATION; RELIABILITY; PREVALENCE; VALIDITY	Spinal cord injury (SCI) is believed to be associated with high rates of cognitive impairment, which can result in complications in recovery. This study concerned two groups of adults with SCI. The first sample involved 150 participants with SCI who were assessed once for cognitive capacity with comparisons made with 45 able-bodied adults. Sample 2 were drawn from Sample 1, and included 88 participants with SCI who were prospectively assessed for mood states (anxiety, depressive mood, and fatigue) and pain intensity at three time periods: at admission to SCI rehabilitation, at discharge, and 6 months after transition into the community. Results showed that the SCI sample had significantly lower cognitive performance than the able-bodied control group. Further, almost 29% of the adults with SCI had lowered cognitive performance believed to be indicative of cognitive impairment. The risk of an adult with SCI having cognitive impairment was almost 13 times that of someone without an SCI. Results from Sample 2 revealed that the development of negative mood states was a significant problem in those with cognitive impairment after they transitioned into the community, a time when personal resources are severely challenged. Findings suggest all adults with SCI admitted to rehabilitation should receive a cognitive screen, and that rehabilitation strategies should then be guided by the cognitive performance of the person. Special attention should also be given to improving skills of those with cognitive impairment before they transition into the community, so as to reduce risk of comorbid mental health problems.	[Craig, Ashley; Guest, Rebecca; Tran, Yvonne; Middleton, James] Univ Sydney, Sydney Med School Northern, John Walsh Ctr Rehabil Res, Kolling Inst Med Res, Sydney, NSW 2006, Australia; [Tran, Yvonne] Univ Technol Sydney, Key Univ Ctr Hlth Technol, Broadway, Sydney, NSW 2007, Australia	Craig, A (corresponding author), Univ Sydney, Royal North Shore Hosp, John Walsh Ctr Rehabil Res, Sydney Med School Norhern,Kolling Inst Med Res, St Leonards, NSW 2065, Australia.	a.craig@sydney.edu.au		Tran, Yvonne/0000-0002-1741-4205	Lifetime Care Support Authority (NSW, Australia) [LTCSA 08/209]	We acknowledge financial support in the form of a competitive grant from the Lifetime Care Support Authority (NSW, Australia): LTCSA 08/209. We also thank Dr Dianah Rodrigues, Associate Professor Kathryn Nicholson Perry, and clinical psychologists Annalisa Dezarnaulds and Catherine Ephraums for assisting in collecting NUCOG assessments.	Ankeny DP, 2009, NEUROSCIENCE, V158, P1112, DOI 10.1016/j.neuroscience.2008.07.001; Cohen J., 1988, STAT POWER SOCIAL SC; Cotter I, 2008, PSYCHOL ASPECTS ASS, P175; Craig A, 1998, AUST NZ J PSYCHIAT, V32, P112, DOI 10.1046/j.1440-1614.1998.00376.x; Craig A, 2002, ARCH PHYS MED REHAB, V83, P1455, DOI 10.1053/apmr.2002.34624; Craig A, 2009, SPINAL CORD, V47, P108, DOI 10.1038/sc.2008.115; Craig A, 2016, SCREENING COGNITIVE; Craig A, 2015, BRIT J HEALTH PSYCH, V20, P807, DOI 10.1111/bjhp.12143; Craig A, 2015, ARCH PHYS MED REHAB, V96, P1426, DOI 10.1016/j.apmr.2015.02.027; Craig A, 2013, J PAIN, V14, P911, DOI 10.1016/j.jpain.2013.03.002; Craig A, 2012, J PSYCHOSOM RES, V73, P205, DOI 10.1016/j.jpsychores.2012.07.005; Davidoff G, 1990, Arch Clin Neuropsychol, V5, P77, DOI 10.1016/0887-6177(90)90009-E; Dowler RN, 1997, J INT NEUROPSYCH SOC, V3, P464, DOI 10.1017/S1355617797004645; Faul F., 2008, G POWER 3 0 10; Hess DW, 2003, REHABIL PSYCHOL, V48, P151, DOI 10.1037/0090-5550.48.3.151; Hill-Briggs F, 2007, ARCH CLIN NEUROPSYCH, V22, P389, DOI 10.1016/j.acn.2007.01.013; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Kennedy P, 2000, ARCH PHYS MED REHAB, V81, P932, DOI 10.1053/apmr.2000.5580; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kurylo M, 2001, REHABIL PSYCHOL, V46, P247, DOI 10.1037/0090-5550.46.3.247; Luedtke K, 2014, J NEUROTRAUM, V31, P1107, DOI 10.1089/neu.2013.3204; Maldonado-Bouchard S, 2016, BRAIN BEHAV IMMUN, V51, P176, DOI 10.1016/j.bbi.2015.08.009; McDermott LM, 2009, J AFFECT DISORDERS, V119, P1, DOI 10.1016/j.jad.2009.04.022; Pollard C, 2007, BRIT J HEALTH PSYCH, V12, P347, DOI 10.1348/135910707X197046; RICHARDS JS, 1988, AM J PHYS MED REHAB, V67, P211, DOI 10.1097/00002060-198810000-00005; ROTH E, 1989, PARAPLEGIA, V27, P480, DOI 10.1038/sc.1989.75; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; Sommer M. F., 2001, SPINAL CORD INJURY F; Tabachnick B.G., 1989, USING MULTIVARIATE S; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Tun CG, 1997, REHABIL PSYCHOL, V42, P163, DOI 10.1037/0090-5550.42.3.163; Walterfang M, 2006, AUST NZ J PSYCHIAT, V40, P995, DOI 10.1111/j.1440-1614.2006.01923.x; Wijesuriya N, 2012, ARCH PHYS MED REHAB, V93, P319, DOI 10.1016/j.apmr.2011.09.008; Williams R, 2015, ARCH PHYS MED REHAB, V96, P133, DOI 10.1016/j.apmr.2014.08.016; Woolrich Rachel A, 2006, Psychol Health Med, V11, P80, DOI 10.1080/13548500500294211; Wu J., 2016, J NEUROTRAUMA; Wu JF, 2014, CELL CYCLE, V13, P2446, DOI 10.4161/cc.29420; Wu JF, 2014, J NEUROSCI, V34, P10989, DOI 10.1523/JNEUROSCI.5110-13.2014	38	44	44	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2017	34	6					1156	1163		10.1089/neu.2016.4632			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EN7ZR	WOS:000396221200004	27717295				2021-06-18	
J	Ropper, AE; Thakor, DK; Han, IB; Yu, D; Zeng, X; Anderson, JE; Aljuboori, Z; Kim, SW; Wang, HJ; Sidman, RL; Zafonte, RD; Teng, YD				Ropper, Alexander E.; Thakor, Devang K.; Han, Inbo; Yu, Dou; Zeng, Xiang; Anderson, Jamie E.; Aljuboori, Zaid; Kim, Soo-Woo; Wang, Hongjun; Sidman, Richard L.; Zafonte, Ross D.; Teng, Yang D.			Defining recovery neurobiology of injured spinal cord by synthetic matrix-assisted hMSC implantation	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						spinal cord injury; recovery neurobiology; mesenchymal stromal stem cell; PLGA; locomotion	NEURAL STEM-CELLS; HUMAN BONE-MARROW; STROMAL CELLS; FUNCTIONAL RECOVERY; TISSUE-DAMAGE; INFLAMMATION; SCAFFOLDS; DIFFERENTIATION; POLYMER; REPAIR	Mesenchymal stromal stem cells (MSCs) isolated from adult tissues offer tangible potential for regenerative medicine, given their feasibility for autologous transplantation. MSC research shows encouraging results in experimental stroke, amyotrophic lateral sclerosis, and neurotrauma models. However, further translational progress has been hampered by poor MSC graft survival, jeopardizing cellular and molecular bases for neural repair in vivo. We have devised an adult human bone marrow MSC (hMSC) delivery formula by investigating molecular events involving hMSCs incorporated in a uniquely designed poly(lactic-co-glycolic) acid scaffold, a clinically safe polymer, following inflammatory exposures in a dorsal root ganglion organotypic coculture system. Also, in rat T9-T10 hemisection spinal cord injury (SCI), we demonstrated that the tailored scaffolding maintained hMSC stemness, engraftment, and led to robust motosensory improvement, neuropathic pain and tissue damage mitigation, and myelin preservation. The scaffolded nontransdifferentiated hMSCs exerted multimodal effects of neurotrophism, angiogenesis, neurogenesis, antiautoimmunity, and antiinflammation. Hindlimb locomotion was restored by reestablished integrity of submidbrain circuits of serotonergic reticulospinal innervation at lumbar levels, the propriospinal projection network, neuromuscular junction, and central pattern generator, providing a platform for investigating molecular events underlying the repair impact of nondifferentiated hMSCs. Our approach enabled investigation of recovery neurobiology components for injured adult mammalian spinal cord that are different from those involved in normal neural function. The uncovered neural circuits and their molecular and cellular targets offer a biological underpinning for development of clinical rehabilitation therapies to treat disabilities and complications of SCI.	[Ropper, Alexander E.; Thakor, Devang K.; Han, Inbo; Yu, Dou; Zeng, Xiang; Anderson, Jamie E.; Aljuboori, Zaid; Kim, Soo-Woo; Teng, Yang D.] Vet Affairs Boston Healthcare Syst, Div SCI Res, Boston, MA 02130 USA; [Ropper, Alexander E.; Thakor, Devang K.; Han, Inbo; Yu, Dou; Zafonte, Ross D.; Teng, Yang D.] Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Charlestown, MA 02129 USA; [Ropper, Alexander E.; Thakor, Devang K.; Han, Inbo; Yu, Dou; Zeng, Xiang; Anderson, Jamie E.; Aljuboori, Zaid; Teng, Yang D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA; [Wang, Hongjun] Stevens Inst Technol, Biomed Engn Chem & Biol Sci, Hoboken, NJ 07030 USA; [Sidman, Richard L.] Harvard Med School, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Han, Inbo] CHA Bundang Med Ctr, Dept Neurosurg, Seongnam Si 13496, South Korea; [Kim, Soo-Woo] Harvard Sch Dent Med, Dept Immunol & Infect Dis, Boston, MA 02115 USA	Teng, YD (corresponding author), Vet Affairs Boston Healthcare Syst, Div SCI Res, Boston, MA 02130 USA.; Teng, YD (corresponding author), Harvard Med Sch, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Charlestown, MA 02129 USA.; Teng, YD (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Neurosurg, Boston, MA 02115 USA.; Sidman, RL (corresponding author), Harvard Med School, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	richard_sidman@hms.harvard.edu; yang_teng@hms.harvard.edu	Wang, Hongjun/AAJ-3852-2020; Zeng, Xiang/AAB-6565-2020; Aljuboori, Zaid/AAV-3251-2020	Zeng, Xiang/0000-0003-4577-749X; Aljuboori, Zaid/0000-0002-3278-4749	United States Department of Veterans Affairs Rehabilitation Research and Development Grant [1-I01-RX000308-01A1]; Center for the Advancement of Science in Space; National Aeronautics and Space Administration Grant [GA-2015-222]; Cele H. and William B. Rubin Family Fund, Inc. Grant for the Gordon Program; Veterans AffairsUS Department of Veterans Affairs [I01RX000308] Funding Source: NIH RePORTER	Support for this work was provided by United States Department of Veterans Affairs Rehabilitation Research and Development Grant 1-I01-RX000308-01A1, Center for the Advancement of Science in Space and National Aeronautics and Space Administration Grant GA-2015-222, CIMT-DoD Grant (to Y.D.T.), and a Cele H. and William B. Rubin Family Fund, Inc. Grant for the Gordon Program (to Y.D.T. and R.D.Z.).	Alexanian AR, 2010, RESTOR NEUROL NEUROS, V28, P761, DOI 10.3233/RNN-2010-0547; Angeli CA, 2014, BRAIN, V137, P1394, DOI 10.1093/brain/awu038; Assi R, 2016, REGEN MED, V11, P245, DOI 10.2217/rme-2015-0045; Bao XJ, 2011, BRAIN RES, V1367, P103, DOI 10.1016/j.brainres.2010.10.063; Cantinieaux D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069515; Chastain EML, 2012, IMMUNOL REV, V245, P227, DOI 10.1111/j.1600-065X.2011.01076.x; Committee on Care and Use of Laboratory Animals, 1996, DHHS PUBL, V85-23; Connick P, 2012, LANCET NEUROL, V11, P150, DOI 10.1016/S1474-4422(11)70305-2; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; Cusimano M, 2012, BRAIN, V135, P447, DOI 10.1093/brain/awr339; David S, 2012, INT REV NEUROBIOL, V106, P127, DOI 10.1016/B978-0-12-407178-0.00006-5; DePaul MA, 2015, SCI REP-UK, V5, DOI 10.1038/srep16795; Du Beau A, 2012, NEUROSCIENCE, V227, P67, DOI 10.1016/j.neuroscience.2012.09.037; Egusa H, 2007, TISSUE ENG, V13, P2589, DOI 10.1089/ten.2007.0080; Finnerup NB, 2014, J PAIN, V15, P40, DOI 10.1016/j.jpain.2013.09.008; Flynn JR, 2011, NEUROPHARMACOLOGY, V60, P809, DOI 10.1016/j.neuropharm.2011.01.016; Francois M, 2012, MOL THER, V20, P187, DOI 10.1038/mt.2011.189; Fukuhara K, 2013, CELL REP, V5, P748, DOI 10.1016/j.celrep.2013.10.005; Grayson ACR, 2005, BIOMATERIALS, V26, P2137, DOI 10.1016/j.biomaterials.2004.06.033; Griffin MD, 2013, STEM CELLS, V31, P2033, DOI 10.1002/stem.1452; Grillner S, 2016, CURR BIOL, V25, pR490; Haragopal H, 2015, CELL TRANSPLANT, V24, P645, DOI 10.3727/096368915X687561; Henrique D, 2015, DEVELOPMENT, V142, P2864, DOI 10.1242/dev.119768; Jaderstad J, 2010, P NATL ACAD SCI USA, V107, P5184, DOI 10.1073/pnas.0915134107; Jarocha D, 2015, CELL TRANSPLANT, V24, P661, DOI 10.3727/096368915X687796; Jarocha D, 2014, STEM CELL TRANSL MED, V3, P395, DOI 10.5966/sctm.2013-0141; Kawai R, 2015, NEURON, V86, P800, DOI 10.1016/j.neuron.2015.03.024; Kazanis I, 2010, J NEUROSCI, V30, P9771, DOI 10.1523/JNEUROSCI.0700-10.2010; Kondo S, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-27; Konya D, 2008, REGEN MED, V3, P309, DOI 10.2217/17460751.3.3.309; Kumar AA, 2009, EXP CLIN TRANSPLANT, V7, P241; Kwon BK, 2011, J NEUROTRAUM, V28, P1589, DOI 10.1089/neu.2009.1150; Lavik Erin, 2002, Methods Mol Biol, V198, P89; Lee KD, 2009, J NEUROTRAUM, V26, P2335, DOI 10.1089/neu.2008.0840; Lennon DP, 2012, STEM CELL TRANSL MED, V1, P279, DOI 10.5966/sctm.2011-0011; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Pritchard CD, 2010, J NEUROSCI METH, V188, P258, DOI 10.1016/j.jneumeth.2010.02.019; Prockop DJ, 2013, STEM CELLS, V31, P2042, DOI 10.1002/stem.1400; Quertainmont R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039500; Ren GW, 2009, STEM CELLS, V27, P1954, DOI 10.1002/stem.118; Ribeiro TB, 2015, SCI REP-UK, V5, DOI 10.1038/srep16167; Rosenberg LJ, 1999, J NEUROSCI, V19, P464; Sabelstrom H, 2013, SCIENCE, V342, P637, DOI 10.1126/science.1242576; Saito F, 2012, RESTOR NEUROL NEUROS, V30, P127, DOI 10.3233/RNN-2011-0629; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Scruggs BA, 2013, STEM CELLS, V31, P1523, DOI 10.1002/stem.1397; Snyder EY, 2012, NEW ENGL J MED, V366, P1940, DOI 10.1056/NEJMcibr1200138; Tan AM, 2012, J NEUROSCI, V32, P12896, DOI 10.1523/JNEUROSCI.6451-11.2012; Teng YD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004579; Teng YD, 2011, CURR NEUROPHARMACOL, V9, P574, DOI 10.2174/157015911798376299; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Tester NJ, 2011, SPINAL CORD, V49, P451, DOI 10.1038/sc.2010.128; Trivedi A, 2006, CLIN NEUROSCI RES, V6, P283, DOI 10.1016/j.cnr.2006.09.007; Yang C, 2014, NAT MATER, V13, P645, DOI [10.1038/nmat3889, 10.1038/NMAT3889]; Yu D, 2013, P NATL ACAD SCI USA, V110, pE746, DOI 10.1073/pnas.1300083110; Yu D, 2009, STEM CELLS, V27, P1212, DOI 10.1002/stem.26	61	44	46	2	21	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 31	2017	114	5					E820	E829		10.1073/pnas.1616340114			10	Multidisciplinary Sciences	Science & Technology - Other Topics	EJ4OI	WOS:000393196300020	28096400	Bronze, Green Published			2021-06-18	
J	An, KY; Kaploun, K; Erdodi, LA; Abeare, CA				An, Kelly Y.; Kaploun, Kristen; Erdodi, Laszlo A.; Abeare, Christopher A.			Performance validity in undergraduate research participants: a comparison of failure rates across tests and cutoffs	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance validity tests; undergraduate students; college sample; base rate of failure; test-taking effort	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; FALSE-POSITIVE RATES; FORCED-CHOICE METHOD; WORD MEMORY TEST; SYMPTOM VALIDITY; MULTIPLE PERFORMANCE; HEAD-INJURY; CLASSIFICATION ACCURACY	Objective: This study compared failure rates on performance validity tests (PVTs) across liberal and conservative cutoffs in a sample of undergraduate students participating in academic research. Method: Participants (n=120) were administered four free-standing PVTs (Test of Memory Malingering, Word Memory Test, Rey 15-Item Test, Hiscock Forced-Choice Procedure) and three embedded PVTs (Digit Span, letter and category fluency). Participants also reported their perceived level of effort during testing. Results: At liberal cutoffs, 36.7% of the sample failed 1 PVTs, 6.7% failed 2, and .8% failed 3. At conservative cutoffs, 18.3% of the sample failed 1 PVTs, 2.5% failed 2, and .8% failed 3. Participants were 3 to 5 times more likely to fail embedded (15.8-30.8%) compared to free-standing PVTs (3.3-10.0%). There was no significant difference in failure rates between native and non-native English speaking participants at either liberal or conservative cutoffs. Additionally, there was no relation between self-reported effort and PVT failure rates. Conclusions: Although PVT failure rates varied as a function of PVTs and cutoffs, between a third and a fifth of the sample failed 1 PVTs, consistent with high initial estimates of invalid performance in this population. Embedded PVTs had notably higher failure rates than free-standing PVTs. Assuming optimal effort in research using students as participants without a formal assessment of performance validity introduces a potentially significant confound in the study design.	[An, Kelly Y.; Kaploun, Kristen; Erdodi, Laszlo A.; Abeare, Christopher A.] Univ Windsor, Dept Psychol, Windsor, ON, Canada	Abeare, CA (corresponding author), Univ Windsor, Dept Psychol, Windsor, ON, Canada.	cabeare@uwindsor.ca		Abeare, Christopher/0000-0002-7163-7434			An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Boone K., 2002, DOT COUNTING TEST; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; DeRight J, 2015, CLIN NEUROPSYCHOL, V29, P101, DOI 10.1080/13854046.2014.989267; Erdodi L., 2016, APPL NEUROPSYCHOL, DOI [10.1080/23279095.2016, DOI 10.1080/23279095.2016]; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Frederick RI, 2000, ARCH CLIN NEUROPSYCH, V15, P281, DOI 10.1016/S0887-6177(99)00002-5; Green, 2004, GREENS MED SYMPTOM V; Green P., 2003, MANUAL WORD MEMORY T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton RK, 2004, REVISED COMPREHENSIV; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Johnson SC, 2012, CLIN NEUROPSYCHOL, V26, P1230, DOI 10.1080/13854046.2012.709886; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; Kazdin A. E., 2003, RES DESIGN CLIN PSYC, V4; Kulas JF, 2014, PSYCHOL INJ LAW, V7, P236, DOI 10.1007/s12207-014-9200-4; Lacy MA, 1996, CLIN NEUROPSYCHOL, V10, P305, DOI 10.1080/13854049608406692; Larrabee G. J., 2007, FORENSIC NEUROPSYCHO, P116; Larrabee GJ, 2014, CLIN NEUROPSYCHOL, V28, P1230, DOI 10.1080/13854046.2014.988754; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Loring DW, 2005, J CLIN EXP NEUROPSYC, V27, P610, DOI 10.1080/13803390490918471; Martinez-Pagan P., 2015, CLIN NEUROPSYCHOL, P1, DOI [10.3997/2214-4609.201413738, DOI 10.3997/2214-4609.201413738]; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Musso MW, 2016, J ATTEN DISORD, V20, P763, DOI 10.1177/1087054714548031; Proto DA, 2014, ARCH CLIN NEUROPSYCH, V29, P614, DOI 10.1093/arclin/acu044; Rey A, 1964, EXAMEN CLIN PSYCHOL; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ross TP, 2016, ARCH CLIN NEUROPSYCH, V31, P97, DOI 10.1093/arclin/acv062; Santos OA, 2014, ARCH CLIN NEUROPSYCH, V29, P609, DOI 10.1093/arclin/acu039; Silk-Eglit GM, 2015, APPL NEUROPSYCH-ADUL, V22, P335, DOI 10.1080/23279095.2014.938809; Silk-Eglit GM, 2014, ARCH CLIN NEUROPSYCH, V29, P415, DOI 10.1093/arclin/acu028; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stenclik JH, 2013, APPL NEUROPSYCH-ADUL, V20, P243, DOI 10.1080/09084282.2012.704603; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Tombaugh TN, 1996, TEST MEMORY MALINGER	59	44	44	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2017	31	1					193	206		10.1080/13854046.2016.1217046			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EK2VR	WOS:000393785300012	27687709				2021-06-18	
J	Kratz, AL; Sander, AM; Brickell, TA; Lange, RT; Carlozzi, NE				Kratz, Anna L.; Sander, Angelle M.; Brickell, Tracey A.; Lange, Rael T.; Carlozzi, Noelle E.			Traumatic brain injury caregivers: A qualitative analysis of spouse and parent perspectives on quality of life	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Caregiver; Quality of life	FAMILY INTERVENTION; REHABILITATION; BURDEN; INDIVIDUALS; ADJUSTMENT; OUTCOMES; HEALTH; IMPACT; NEEDS; TBI	The objective of this qualitative study was to examine how family caregivers of individuals with traumatic brain injury (TBI) describe their quality of life in the context of their caregiving role. Fifty-two caregivers of adults with moderate or severe TBI (n = 31 parents, n = 21 partners/spouses; 77% female; mean age = 57.96 years, range = 34-78 years) were recruited from three data collection sites to participate in focus groups. Thematic content analysis was used to identify two main meta-themes: Caregiver Role Demands and Changes in Person with TBI. Prominent sub-themes indicated that caregivers are (1) overburdened with responsibilities, (2) lack personal time and time for self-care, (3) feel that their life is interrupted or lost, (4) grieve the loss of the person with TBI, and (5) endorse anger, guilt, anxiety, and sadness. Caregivers identified a number of service needs. A number of sub-themes were perceived differently by partner versus parent caregivers. The day-to-day responsibilities of being a caregiver as well as the changes in the person with the TBI present a variety of challenges and sources of distress for caregivers. Although services that address instrumental as well as emotional needs of caregivers may benefit caregivers in general, the service needs of parent and partner caregivers may differ.	[Kratz, Anna L.; Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA; [Sander, Angelle M.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle M.] TIRR Mem Hermanns Brain Injury Res Ctr, Houston, TX USA; [Sander, Angelle M.] Harris Hlth Syst, Dept Phys Med & Rehabil, Houston, TX USA; [Brickell, Tracey A.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada	Kratz, AL (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	alkratz@med.umich.edu			National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [1R01-NR013658-01]; National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [1K01AR064275]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K01AR064275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	This study was funded by the National Institute of Nursing Research [grant number 1R01-NR013658-01]. During manuscript development, Dr. Kratz was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases [grant number 1K01AR064275].	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Averill JB, 2002, QUAL HEALTH RES, V12, P855, DOI 10.1177/104973230201200611; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Carson P, 1993, J Neurosci Nurs, V25, P165; Catanzaro M., 1988, NURSING RES THEORY P, P437; Chwalisz K, 1996, Appl Neuropsychol, V3, P28, DOI 10.1207/s15324826an0301_5; Chwalisz K, 2008, REHABIL PSYCHOL, V53, P387, DOI 10.1037/a0012998; Denzin N., 2003, STRATEGIES QUALITATI; Denzin N.K., 2000, HDB QUALITATIVE RES; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gill CJ, 2011, J HEAD TRAUMA REHAB, V26, P56, DOI 10.1097/HTR.0b013e3182048ee9; Glaser B. G., 1967, DISCOVERY GROUNDED T; Godwin E, 2014, BRAIN INJURY, V28, P398, DOI 10.3109/02699052.2014.880514; Graneheim UH, 2004, NURS EDUC TODAY, V24, P105, DOI 10.1016/j.nedt.2003.10.001; Hammond FM, 2011, J HEAD TRAUMA REHAB, V26, P69, DOI 10.1097/HTR.0b013e318205174d; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Johnson B P, 1995, J Neurosci Nurs, V27, P113; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Miles MB, 2014, QUALITATIVE DATA ANA; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; QSR International Pty Ltd, 2012, NVIVO QUAL DAT AN SO; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Sander A. M., 2005, BRAIN INJURY MED, P1117; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2012, ARCH PHYS MED REHAB, V93, P842, DOI 10.1016/j.apmr.2011.11.031; Smith A M, 1998, Rehabil Nurs, V23, P252; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Traumatic Brain Injury Model Systems National Data Center, 2006, TRAUM BRAIN INJ MOD; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x	47	44	44	0	30	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2017	27	1					16	37		10.1080/09602011.2015.1051056			22	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	EB0SL	WOS:000387055700003	26052805	Green Accepted			2021-06-18	
J	Chapple, LAS; Deane, AM; Heyland, DK; Lange, K; Kranz, AJ; Williams, LT; Chapman, MJ				Chapple, Lee-anne S.; Deane, Adam M.; Heyland, Daren K.; Lange, Kylie; Kranz, Amelia J.; Williams, Lauren T.; Chapman, Marianne J.			Energy and protein deficits throughout hospitalization in patients admitted with a traumatic brain injury	CLINICAL NUTRITION			English	Article						Nutrition; Oral intake; Critical care; Head injury; Traumatic brain injury	CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; ENTERAL NUTRITION; SUPPORT PRACTICES; ORAL INTAKE; SEDATION; TRIAL; MANAGEMENT; ADEQUACY	Background and aims: Patients with traumatic brain injury (TBI) experience considerable energy and protein deficits in the intensive care unit (ICU) and these are associated with adverse outcomes. However, nutrition delivery after ICU discharge during ward-based care, particularly from oral diet, has not been measured. This study aimed to quantify energy and protein delivery and deficits over the entire hospitalization for critically ill TBI patients. Methods: Consecutively admitted adult patients with a moderate-severe TBI (Glasgow Coma Scale 3-12) over 12 months were eligible. Observational data on energy and protein delivered from all routes were collected until hospital discharge or day 90 and compared to dietician prescriptions. Oral intake was quantified using weighed food records on three pre-specified days each week. Data are mean (SD) unless indicated. Cumulative deficit is the mean absolute difference between intake and estimated requirements. Results: Thirty-seven patients [45.3 (15.8) years; 87% male; median APACHE II 18 (IQR: 14-22)] were studied for 1512 days. Median duration of ICU and ward-based stay was 13.4 (IQR: 6.4-17.9) and 19.9 (9.6-32.0) days, respectively. Over the entire hospitalization patients had a cumulative deficit of 18,242 (16,642) kcal and 1315 (1028) g protein. Energy and protein intakes were less in ICU than the ward (1798 (800) vs 1980 (915) kcal/day, p = 0.015; 79 (47) vs 89 (41) g/day protein, p = 0.001). Energy deficits were almost two-fold greater in patients exclusively receiving nutrition orally than tube-fed (806 (616) vs 445 (567) kcal/day, p = 0.016) while protein deficits were similar (40 (5) vs 37 (6) g/day, p = 0.616). Primary reasons for interruptions to enteral and oral nutrition were fasting for surgery/procedures and patient related reasons, respectively. Conclusions: Patients admitted to ICU with a TBI have energy and protein deficits that persist after ICU discharge, leading to considerable shortfalls over the entire hospitalization. Patients ingesting nutrition orally are at particular risk of energy deficit. (C) 2016 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.	[Chapple, Lee-anne S.; Deane, Adam M.; Kranz, Amelia J.; Chapman, Marianne J.] Univ Adelaide, Discipline Acute Care Med, N Terrace, Adelaide, SA, Australia; [Chapple, Lee-anne S.; Deane, Adam M.; Chapman, Marianne J.] Australia Ctr Clin Res Excellence Nutr Physiol, Natl Hlth & Med Res Council, Level 6,Eleanor Harrald Bldg,North Terrace, Adelaide, SA, Australia; [Deane, Adam M.; Chapman, Marianne J.] Royal Adelaide Hosp, Intens Care Unit, Level 4,Emergency Serv Bldg,North Terrace, Adelaide, SA, Australia; [Heyland, Daren K.] Kingston Gen Hosp, Clin Evaluat Res Unit, Kingston, ON, Canada; [Lange, Kylie] Univ Adelaide, Discipline Med, N Terrace, Adelaide, SA, Australia; [Williams, Lauren T.] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld 4111, Australia	Chapple, LAS (corresponding author), Univ Adelaide, Discipline Acute Care Med, N Terrace, Adelaide, SA, Australia.	lee-anne.costello@adelaide.edu.au; adam.m.deane@gmail.com; dkh2@queensu.ca; kylie.lange@adelaide.edu.au; amelia-jk@hotmail.com; lauren.williams@griffith.edu.au; Marianne.chapman@health.sa.gov.au	Williams, Lauren T./G-6301-2013; Chapple, Lee-anne/AAN-7751-2021; Deane, Adam/AAF-7370-2020	Williams, Lauren T./0000-0002-7860-0319; Deane, Adam/0000-0002-7620-5577; chapman, marianne/0000-0003-0710-3283; Chapple, Lee-anne S/0000-0002-9818-2484	Australasian Society of Parenteral and Enteral Nutrition (AuSPEN); Neurosurgical Research Foundation; Australian Post-Graduate AwardAustralian Government; Royal Adelaide Hospital Dawes Top-Up Scholarship	This research was funded by an Australasian Society of Parenteral and Enteral Nutrition (AuSPEN) small project grant and a Neurosurgical Research Foundation grant. LSC was supported by an Australian Post-Graduate Award and Royal Adelaide Hospital Dawes Top-Up Scholarship.	Alberda C, 2009, INTENS CARE MED, V35, P1728, DOI 10.1007/s00134-009-1567-4; Alhashemi HH, 2010, NEUROSCIENCES, V15, P231; Chapple LAS, 2016, CRIT CARE, V20, DOI 10.1186/s13054-015-1177-1; Costello LAS, 2014, INJURY, V45, P1834, DOI 10.1016/j.injury.2014.06.004; De Beaux I, 2001, ANAESTH INTENS CARE, V29, P619, DOI 10.1177/0310057X0102900611; De Jonghe B, 2001, CRIT CARE MED, V29, P8, DOI 10.1097/00003246-200101000-00002; DeChicco R, 1995, J AM DENT ASSOC S, V95, pA25; Denes Z, 2004, DISABIL REHABIL, V26, P1163, DOI 10.1080/09638280412331270380; DETSKY AS, 1984, JPEN-PARENTER ENTER, V8, P153, DOI 10.1177/0148607184008002153; Dhandapani SS, 2007, INDIAN J NEUROTRAUM, V4, P35, DOI 10.1016/S0973-0508(07)80009-8; Foley N, 2006, J NUTR HEALTH AGING, V10, P171; Foley N, 2008, J NEUROTRAUM, V25, P1415, DOI 10.1089/neu.2008.0628; GARREL DR, 1995, JPEN-PARENTER ENTER, V19, P482, DOI 10.1177/0148607195019006482; Hansen TS, 2008, ARCH PHYS MED REHAB, V89, P1556, DOI 10.1016/j.apmr.2007.11.063; Hart DW, 2001, CRIT CARE MED, V29, P1318, DOI 10.1097/00003246-200107000-00004; Heyland DK, 2011, CRIT CARE, V15, DOI 10.1186/cc10546; Heyland DK, 2010, CRIT CARE, V14, DOI 10.1186/cc8991; Hiesmayr M, 2009, CLIN NUTR, V28, P484, DOI 10.1016/j.clnu.2009.05.013; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Mistraletti G, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-92; Morgan Laurie M, 2004, Nutr Clin Pract, V19, P511, DOI 10.1177/0115426504019005511; Nicolo M, 2016, JPEN-PARENTER ENTER, V40, P45, DOI 10.1177/0148607115583675; Peake SL, 2014, AM J CLIN NUTR, V100, P616, DOI 10.3945/ajcn.114.086322; Pendyala S, 2012, GASTROENTEROLOGY, V142, P1100, DOI 10.1053/j.gastro.2012.01.034; Peterson SJ, 2011, CURR OPIN CLIN NUTR, V14, P182, DOI 10.1097/MCO.0b013e3283428e65; Peterson SJ, 2010, J AM DIET ASSOC, V110, P427, DOI 10.1016/j.jada.2009.11.020; Reade MC, 2014, NEW ENGL J MED, V370, P444, DOI 10.1056/NEJMra1208705; Shehabi Y, 2013, CRIT CARE MED, V41, P1983, DOI 10.1097/CCM.0b013e31828a437d; Singer P, 2011, INTENS CARE MED, V37, P601, DOI 10.1007/s00134-011-2146-z; SUNDERLAND PM, 1992, NEUROSURGERY, V31, P246, DOI 10.1227/00006123-199208000-00009; Tan M, 2011, BRIT J NEUROSURG, V25, P2, DOI 10.3109/02688697.2010.522745; Wang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058838; Wei XJ, 2015, CRIT CARE MED, V43, P1569, DOI 10.1097/CCM.0000000000001000; Wrieden W, 2003, MON SCOTT DIET TARG; YOUNG B, 1987, J NEUROSURG, V67, P668, DOI 10.3171/jns.1987.67.5.0668	36	44	51	0	13	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0261-5614	1532-1983		CLIN NUTR	Clin. Nutr.	DEC	2016	35	6					1315	1322		10.1016/j.clnu.2016.02.009			8	Nutrition & Dietetics	Nutrition & Dietetics	EC3UI	WOS:000388051900013	26949198				2021-06-18	
J	Noy, S; Krawitz, S; Del Bigio, MR				Noy, Shawna; Krawitz, Sherry; Del Bigio, Marc R.			Chronic Traumatic Encephalopathy-Like Abnormalities in a Routine Neuropathology Service	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Autopsy; Brain injury; Chronic traumatic encephalopathy; Concussion; Contusion; Neurofibrillary tangles; Tau	BRAIN-INJURY; TAU; DISEASE; PHOSPHORYLATION; DEPOSITION; PATHOLOGY	Chronic traumatic encephalopathy (CTE) has been described mainly in professional athletes and military personnel and is characterized by deposition of hyperphosphorylated tau at the depths of cortical sulci and around blood vessels. To assess CTE-like changes in a routine neuropathology service, we prospectively examined 111 brains (age 18-60 years). The presence of tau-immunoreactive deposits was staged using guidelines described by others and was correlated with the medical history. 72/111 cases were negative for CTE-like changes; 34/111 were CTE stage <1; 3/111 were CTE stage 1; and 2/111 were CTE stage 2. The combined history of head injury and alcohol and/or drug abuse was a significant predictor of any CTE-like changes. Age was also a significant predictor; most with any CTE-like changes were >40 years old. CTE-like changes were not identified at sites of contusion. Among a separate group studied retrospectively, we identified 4 cases that met full criteria for CTE. We conclude that CTE-like findings are not confined to professional athletes; the risk factors of head injury and substance abuse are similar in the routine population. However, the significance of very small hyperphosphorylated tau deposits remains to be determined. In addition, the absence of typical CTE-like deposits near contusion sites keeps open the question of pathogenesis.	[Noy, Shawna] Univ Manitoba, Max Rady Coll Med, Dept Pathol & Postgrad Med Educ, Winnipeg, MB, Canada; [Krawitz, Sherry; Del Bigio, Marc R.] Univ Manitoba, Max Rady Coll Med, Dept Pathol, Winnipeg, MB, Canada; [Krawitz, Sherry; Del Bigio, Marc R.] Diagnost Serv Manitoba, Winnipeg, MB, Canada	Del Bigio, MR (corresponding author), Univ Manitoba, Max Rady Coll Med, Dept Pathol, Brodie Ctr 401, 715 McDermot Ave, Winnipeg, MB R3E 3P5, Canada.	marc.delbigio@umanitoba.ca					Aho L, 2009, J NEUROSCI RES, V87, P2786, DOI 10.1002/jnr.22091; Armstrong RA, 2017, NEUROPATH APPL NEURO, V43, P154, DOI 10.1111/nan.12323; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Braak H, 2011, J NEUROPATH EXP NEUR, V70, P960, DOI 10.1097/NEN.0b013e318232a379; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Castellani RJ, 2015, LAB INVEST, V95, P576, DOI 10.1038/labinvest.2015.54; Castellani RJ, 2015, J NEUROPATH EXP NEUR, V74, P493, DOI 10.1097/NEN.0000000000000193; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; CULLEN KM, 1995, NEUROPATH APPL NEURO, V21, P312, DOI 10.1111/j.1365-2990.1995.tb01065.x; Daneshvar DH, 2015, MOL CELL NEUROSCI, V66, P81, DOI 10.1016/j.mcn.2015.03.007; Doherty CP, 2016, J NEUROPATH EXP NEUR, V75, P656, DOI 10.1093/jnen/nlw036; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; Goldstein LE, 2013, US patent application, Patent No. [US 14,398,099 A1, 14398099]; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Lucke-Wold BP, 2016, J NEUROSURG, V124, P687, DOI 10.3171/2015.3.JNS141802; Lucke-Wold BP, 2014, J NEUROTRAUM, V31, P1129, DOI 10.1089/neu.2013.3303; MANLOW A, 1992, J NEUROPATH EXP NEUR, V51, P298, DOI 10.1097/00005072-199205000-00008; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Puvenna V, 2016, BRAIN RES, V1630, P225, DOI 10.1016/j.brainres.2015.11.007; Ramage SN, 2005, NEUROPATH APPL NEURO, V31, P439, DOI 10.1111/j.1365-2990.2005.00670.x; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209	36	44	44	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	DEC	2016	75	12					1145	1154		10.1093/jnen/nlw092			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	EK0CY	WOS:000393595400004	27815395	Bronze			2021-06-18	
J	McCarty, CA; Zatzick, D; Stein, E; Wang, J; Hilt, R; Rivara, FP				McCarty, Carolyn A.; Zatzick, Douglas; Stein, Elizabeth; Wang, Jin; Hilt, Robert; Rivara, Frederick P.		Seattle Sports Concussion Res	Collaborative Care for Adolescents With Persistent Postconcussive Symptoms: A Randomized Trial	PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS; PEDIATRIC POPULATION; DEPRESSIVE SYMPTOMS; CHILDREN; HEALTH; INTERVENTION; VALIDITY; OUTCOMES	BACKGROUND AND OBJECTIVES: Postconcussive and co-occurring psychological symptoms are not uncommon after sports-related concussion and are associated with functional impairment and societal costs. There is no evidence-based treatment targeting postconcussive symptoms in children and adolescents. The goal of this study was to test a collaborative care intervention model with embedded cognitive-behavioral therapy, care management, and psychopharmacological consultation. We hypothesized that patients in collaborative care would demonstrate greater reductions in postconcussive, depressive, and anxiety symptoms and improvement in functioning over the course of 6 months, compared with usual care control. METHODS: Patients aged 11 to 17 years with persistent symptoms >= 1 month after sportsrelated concussion were randomly assigned to receive collaborative care (n = 25) or care as usual (n = 24). Patients were assessed before randomization and after 1, 3, and 6 months. Groups were compared over time via linear mixed effects regression models. RESULTS: Adolescents assigned to collaborative care experienced clinically and statistically significant improvements in postconcussive symptoms in addition to functional gains at 6 months compared with controls. Six months after the baseline assessment, 13.0% of intervention patients and 41.7% of control patients reported high levels of postconcussive symptoms (P = .03), and 78% of intervention patients and 45.8% of control patients reported >= 50% reduction in depression symptoms (P = .02). No changes between groups were demonstrated in anxiety symptoms. CONCLUSIONS: Orchestrated efforts to systematically implement collaborative care treatment approaches for slow-to-recover adolescents may be useful given the reductions in postconcussive and co-occurring psychological symptoms in addition to improved quality of life.	[McCarty, Carolyn A.; Stein, Elizabeth; Rivara, Frederick P.] Seattle Childrens Hosp, Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Hilt, Robert] Seattle Childrens Hosp, Dept Psychiat & Behav Med, Seattle, WA USA; [McCarty, Carolyn A.; Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Zatzick, Douglas; Hilt, Robert] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Zatzick, Douglas; Wang, Jin; Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA	McCarty, CA (corresponding author), POB 5371,Suite 400,Mailstop CW8-5A, Seattle, WA 98145 USA.	cari.mccarty@seattlechildrens.org	Hilt, Robert/AAJ-3792-2020	Hilt, Robert/0000-0001-8153-6461; Stein, Elizabeth/0000-0002-1820-3821	Seattle Sports Concussion Research Collaborative; National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA grant [UL1TR000423]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	Supported by the Seattle Sports Concussion Research Collaborative and by the National Center for Advancing Translational Sciences of the National Institutes of Health under CTSA grant UL1TR000423. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funded by the National Institutes of Health (NIH).	Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Asarnow JR, 2015, JAMA PEDIATR, V169, P929, DOI 10.1001/jamapediatrics.2015.1141; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Cella D, 2007, MED CARE, V45, pS3, DOI 10.1097/01.mlr.0000258615.42478.55; Chrisman SPD, 2014, J ADOLESCENT HEALTH, V54, P582, DOI 10.1016/j.jadohealth.2013.10.006; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conder R, 2015, BRAIN INJURY, V29, P249, DOI 10.3109/02699052.2014.965209; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fisher E, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011118.pub2; Freed LH, 1998, J ADOLESCENT HEALTH, V22, P475, DOI 10.1016/S1054-139X(98)00002-0; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Hajek CA, 2010, BRAIN INJURY, V24, P100, DOI 10.3109/02699050903508226; Hopkins K, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h824; Institute of Medicine (IOM) and National Research Council (NRC), 2013, SPORTS RELATED CONCU; Irwin DE, 2010, QUAL LIFE RES, V19, P595, DOI 10.1007/s11136-010-9619-3; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Kaye AJ, 2010, J TRAUMA, V68, P1396, DOI 10.1097/TA.0b013e3181cf7d1b; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kurowski BG, 2013, PEDIATRICS, V132, pE158, DOI 10.1542/peds.2012-4040; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Max JE, 2014, PSYCHIAT CLIN N AM, V37, P125, DOI 10.1016/j.psc.2013.11.003; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Pangilinan PH, 2010, PM&R, V2, P1127, DOI 10.1016/j.pmrj.2010.07.007; Peterson RL, 2013, J HEAD TRAUMA REHAB, V28, pE1, DOI 10.1097/HTR.0b013e318263f5ba; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Richardson LP, 2014, JAMA-J AM MED ASSOC, V312, P809, DOI 10.1001/jama.2014.9259; Richardson LP, 2012, PEDIATRICS, V130, pE1541, DOI 10.1542/peds.2012-0450; Riley WT, 2010, QUAL LIFE RES, V19, P1311, DOI 10.1007/s11136-010-9694-5; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Vargas G, 2015, J ATHL TRAINING, V50, P250, DOI 10.4085/1062-6050-50.3.02; Varni James W, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P705, DOI 10.1586/14737167.5.6.705; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick D, 2014, JAMA PEDIATR, V168, P532, DOI 10.1001/jamapediatrics.2013.4784; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	49	44	44	0	18	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2016	138	4							e20160459	10.1542/peds.2016-0459			11	Pediatrics	Pediatrics	DX3ZT	WOS:000384317700022		Green Published, Bronze			2021-06-18	
